<SEC-DOCUMENT>0001564590-21-011758.txt : 20210309
<SEC-HEADER>0001564590-21-011758.hdr.sgml : 20210309
<ACCEPTANCE-DATETIME>20210309161647
ACCESSION NUMBER:		0001564590-21-011758
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		104
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210309
DATE AS OF CHANGE:		20210309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eiger BioPharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001305253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				361004130
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36183
		FILM NUMBER:		21726000

	BUSINESS ADDRESS:	
		STREET 1:		2155 PARK BOULEVARD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306
		BUSINESS PHONE:		650-279-9845

	MAIL ADDRESS:	
		STREET 1:		2155 PARK BOULEVARD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celladon Corp
		DATE OF NAME CHANGE:	20041005
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>eigr-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-09T20:18:07.5218948+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 867300f52dd744cb97ec68c0fc090a12 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:eigr="http://www.eigerbio.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
eigr-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001305253_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001305253_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001305253_20200101_20201231">0001305253</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001305253_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000526" name="eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20200101_20201231">P30M</ix:nonNumeric>
			<ix:nonNumeric id="F_000540" name="eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheBMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231">P24M</ix:nonNumeric>
			<ix:nonNumeric id="F_000541" name="eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231">P36M</ix:nonNumeric>
			<ix:nonNumeric id="F_000779" name="eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223">P19M</ix:nonNumeric>
			<ix:nonNumeric id="F_000781" name="eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223">P13M</ix:nonNumeric>
			<ix:nonNumeric id="F_000754" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001305253_srtStatementGeographicalAxis_stprCA_20171031">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000778" name="eigr:ProductAgreementRenewalTerm" contextRef="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20201231">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000616" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001305253_20190101_20191231">P7Y11M8D</ix:nonNumeric>
			<ix:nonNumeric id="F_000617" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001305253_20200101_20201231">P7Y6M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000618" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001305253_20200101_20201231">P6Y8M15D</ix:nonNumeric>
			<ix:nonNumeric id="F_000632" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000633" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P5Y3M7D</ix:nonNumeric>
			<ix:nonNumeric id="F_000634" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P5Y3M7D</ix:nonNumeric>
			<ix:nonNumeric id="F_000638" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20180101_20181231">P9Y8M1D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000642" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231" decimals="INF">0.7300</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000643" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20190101_20191231" decimals="INF">0.7314</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000644" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20180101_20181231" decimals="INF">0.8400</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000648" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231" decimals="INF">0.0039</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20190101_20191231" decimals="INF">0.0142</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000650" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20180101_20181231" decimals="INF">0.0167</ix:nonFraction>
			<ix:nonNumeric id="F_000635" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P6Y29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000636" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P6Y29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000637" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P6Y29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000639" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20180101_20181231">P9Y10M2D</ix:nonNumeric>
			<ix:nonNumeric id="F_000640" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20200101_20201231">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000641" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20190101_20191231">P10Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000645" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231" decimals="INF">0.7700</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000646" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20190101_20191231" decimals="INF">0.8319</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20180101_20181231" decimals="INF">0.9500</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000651" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231" decimals="INF">0.0137</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000652" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20190101_20191231" decimals="INF">0.0257</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20180101_20181231" decimals="INF">0.0268</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001305253_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001305253_20191231" xsi:nil="true"></ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="eigr-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001305253_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001305253_20210305">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-05</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001305253_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001305253_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrPOMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:POMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrPOMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:POMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:EmployeesAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_eigrSegment">
				<xbrli:measure>eigr:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001305253_us-gaapConcentrationRiskByTypeAxis_us-gaapSupplierConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_eigrSupplyChain">
				<xbrli:measure>eigr:SupplyChain</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_eigrProductCandidate">
				<xbrli:measure>eigr:ProductCandidate</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapIncomeStatementLocationAxis_eigrCommercialSalesMember_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:CommercialSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-08-11</xbrli:startDate>
					<xbrli:endDate>2018-08-11</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20180216_20180315">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:PRFCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-02-16</xbrli:startDate>
					<xbrli:endDate>2018-03-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-19</xbrli:startDate>
					<xbrli:endDate>2016-04-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_eigrPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:PurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-19</xbrli:startDate>
					<xbrli:endDate>2016-04-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_eigrPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160420">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:PurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-20</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentAndRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-19</xbrli:startDate>
					<xbrli:endDate>2016-04-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrCommercialSalesMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:CommercialSalesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-19</xbrli:startDate>
					<xbrli:endDate>2016-04-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentPhaseTwoMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentPhaseTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-19</xbrli:startDate>
					<xbrli:endDate>2016-04-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentPhaseThreeMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentPhaseThreeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-19</xbrli:startDate>
					<xbrli:endDate>2016-04-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20100930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2010-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20100901_20100930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2010-09-01</xbrli:startDate>
					<xbrli:endDate>2010-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20150501_20150531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-05-01</xbrli:startDate>
					<xbrli:endDate>2015-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20101201_20101231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2010-12-01</xbrli:startDate>
					<xbrli:endDate>2010-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20101231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2010-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtProductOrServiceAxis_eigrProductOneMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eigr:ProductOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-09-02</xbrli:startDate>
					<xbrli:endDate>2015-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20160321_20160322">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-03-21</xbrli:startDate>
					<xbrli:endDate>2016-03-22</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20160322">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-03-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">eigr:MilestoneVestedOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">eigr:MilestoneVestedOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">eigr:MilestoneVestedOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-09-02</xbrli:startDate>
					<xbrli:endDate>2015-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAbbvieAssetPurchaseAgreementMember_20201119_20201120">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AbbvieAssetPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-19</xbrli:startDate>
					<xbrli:endDate>2020-11-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAbbvieAssetPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20201119_20201120">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AbbvieAssetPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:PRFCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-19</xbrli:startDate>
					<xbrli:endDate>2020-11-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:TrancheAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanAmendmentMember_20180531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:TrancheBMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanAmendmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheCMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanAmendmentMember_20180803">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:TrancheCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanAmendmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-08-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:TrancheBMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-05</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305_20190305">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-03-05</xbrli:startDate>
					<xbrli:endDate>2019-03-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-05</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheBMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheBMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-05</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheBMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheBMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapRegulatoryAgencyAxis_eigrFoodAndDrugAdministrationMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">eigr:FoodAndDrugAdministrationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapRegulatoryAgencyAxis_eigrFoodAndDrugAdministrationMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">eigr:FoodAndDrugAdministrationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapDebtInstrumentRedemptionPeriodAxis_eigrLoanPrepaidDuringFirstTwelveMonthsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eigr:LoanPrepaidDuringFirstTwelveMonthsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapDebtInstrumentRedemptionPeriodAxis_eigrLoanPrepaidDuringThirteenToTwentyFourMonthsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eigr:LoanPrepaidDuringThirteenToTwentyFourMonthsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417_20190417">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-17</xbrli:startDate>
					<xbrli:endDate>2019-04-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-04-17</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417_20190417">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UnderwritingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-17</xbrli:startDate>
					<xbrli:endDate>2019-04-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_20191201_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20191201_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20200830_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-30</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_eigrHoldersOfTenPercentOrMoreOfVotingPowerMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eigr:HoldersOfTenPercentOrMoreOfVotingPowerMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:EmployeesAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:EmployeesAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20131231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2013-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001305253_srtStatementGeographicalAxis_stprCA_20171031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtStatementGeographicalAxis_stprCA_20171001_20171031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2017-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eigr:PatheonIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MasterManufacturingServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eigr:PatheonIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MasterManufacturingServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eigr:PatheonIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MasterManufacturingServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanFifthAmendmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-23</xbrli:startDate>
					<xbrli:endDate>2021-02-23</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001305253</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:TrancheBMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanFifthAmendmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-23</xbrli:startDate>
					<xbrli:endDate>2021-02-23</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001305253_20200101_20201231">10-K</ix:nonNumeric></p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:DocumentAnnualReport" contextRef="C_0001305253_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001305253_20200101_20201231" format="ixt:datemonthdayyearen">December&#160;31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001305253_20200101_20201231">2020</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:DocumentTransitionReport" contextRef="C_0001305253_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number <ix:nonNumeric id="F_000019" name="dei:EntityFileNumber" contextRef="C_0001305253_20200101_20201231">001-36183</ix:nonNumeric></p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001305253_20200101_20201231">Eiger BioPharmaceuticals, Inc.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:49.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001305253_20200101_20201231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:47.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001305253_20200101_20201231">33-0971591</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:49.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of<br />incorporation or organization)</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
<tr>
<td valign="middle" style="width:49.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:49.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityAddressAddressLine1" contextRef="C_0001305253_20200101_20201231">2155 Park Boulevard</ix:nonNumeric>, <ix:nonNumeric id="F_000023" name="dei:EntityAddressCityOrTown" contextRef="C_0001305253_20200101_20201231">Palo Alto</ix:nonNumeric>, <ix:nonNumeric id="F_000024" name="dei:EntityAddressStateOrProvince" contextRef="C_0001305253_20200101_20201231">CA</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:47.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressPostalZipCode" contextRef="C_0001305253_20200101_20201231">94306</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:49.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:47.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000026" name="dei:CityAreaCode" contextRef="C_0001305253_20200101_20201231">650</ix:nonNumeric>) <ix:nonNumeric id="F_000027" name="dei:LocalPhoneNumber" contextRef="C_0001305253_20200101_20201231">272 6138</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:Security12bTitle" contextRef="C_0001305253_20200101_20201231">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001305253_20200101_20201231">EIGR</ix:nonNumeric></p></td>
<td valign="top" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:SecurityExchangeName" contextRef="C_0001305253_20200101_20201231" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: None</p>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;text-align:center;margin-top:0pt;margin-left:38.46%;margin-right:38.46%;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:MS Mincho;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000009" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001305253_20200101_20201231">No</ix:nonNumeric>&#160;&#160;<span style="font-family:MS Mincho;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:MS Mincho;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000011" name="dei:EntityVoluntaryFilers" contextRef="C_0001305253_20200101_20201231">No</ix:nonNumeric>&#160;&#160;<span style="font-family:MS Mincho;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000010" name="dei:EntityCurrentReportingStatus" contextRef="C_0001305253_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:MS Mincho;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:MS Mincho;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000016" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001305253_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:MS Mincho;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:MS Mincho;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:21.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:21.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityFilerCategory" contextRef="C_0001305253_20200101_20201231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntitySmallBusiness" contextRef="C_0001305253_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:21.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001305253_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:MS Mincho;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000030" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001305253_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntityShellCompany" contextRef="C_0001305253_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:MS Mincho;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of voting and non-voting common stock held by non-affiliates of the registrant as of June 30, 2020 totaled approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="dei:EntityPublicFloat" contextRef="C_0001305253_20200630" decimals="0" format="ixt:numdotdecimal">257,943,696</ix:nonFraction> based on the closing price of $9.60 as reported by the Nasdaq Global Market. This calculation excludes 372,505 shares held by executive officers, directors and stockholders that the Registrant has concluded are affiliates of the Registrant. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the Registrant.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, as of March 5, 2021 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000032" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001305253_20210305" decimals="INF" format="ixt:numdotdecimal">33,901,386</ix:nonFraction>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000031" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001305253_20200101_20201231">Part III incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2021 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant&#8217;s fiscal year ended December 31, 2020.</ix:nonNumeric></p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form 10-K</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the Fiscal Year Ended December&#160;31, 2020</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="5" valign="top" style="width:93.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:underline;">PART I</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 1.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 1A.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 1B.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 2.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 3.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 4</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
<tr>
<td colspan="5" valign="middle" style="width:93.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="5" valign="top" style="width:93.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:underline;">PART II</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 5.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17pt;;text-indent:-17pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 6.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:underline;">Selected Financial Data</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 7.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 7A.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_1"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 8.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 9.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;9A.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 9B.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
<tr>
<td colspan="5" valign="middle" style="width:93.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="5" valign="top" style="width:93.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:underline;">PART&#160;III</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 10.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 11.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 12.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17pt;;text-indent:-17pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 13.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_PA"><span style="text-decoration:underline;">Certain Relationships and Related Party Transactions, and Director Independence</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 14.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accountant Fees and Services</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td colspan="5" valign="middle" style="width:93.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="5" valign="top" style="width:93.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:underline;">PART IV</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 15.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits and Financial Statement Schedules</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
</tr>
<tr>
<td valign="top" style="width:2.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:9.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ITEM 16.</p></td>
<td valign="bottom" style="width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:77.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_Form_10K_Summary"><span style="text-decoration:underline;">Form 10-K Summary</span></a></p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K, including the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; may contain &#8220;forward-looking statements.&#8221; We may, in some cases, use words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;color:#000000;">our ability to support the launch of </span><span style="color:#000000;">Zokinvy&#8482; (lonafarnib) </span><span style="Background-color:#FFFFFF;color:#000000;">and our commercial development for Zokinvy</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential approval of Zokinvy in jurisdictions outside of the U.S., including the European Union&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to maintain supply of our commercial and clinical trial materials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to transition into a commercial stage biopharmaceutical company&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to finance the continued advancement of our development pipeline products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our plans to research, develop and commercialize our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to attract collaborators with development, regulatory and commercialization expertise&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain favorable reimbursement and pricing and the rate and degree of market acceptance of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to manufacture product necessary to support regulatory approvals and timely meet commercial requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory developments in the U.S. and foreign countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the performance of our third-party suppliers and manufacturers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of competing therapies that are or may become available&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to attract and retain key scientific or management personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the filing date of this Annual Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail under &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1. B</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">usin</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ess</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most severe form of human viral hepatitis, for which there is currently no FDA-approved therapy. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger has reported positive proof-of-concept clinical results across all our programs, and&#160;we have received Breakthrough Therapy designation for three programs in clinical development. Our programs have several aspects in common: the disease targets represent conditions of high unmet medical need&#59; the therapeutic approaches are supported by an understanding of disease biology and mechanism as elucidated by our academic research relationships&#59; prior clinical experience with the product candidates guides an understanding of safety&#59; and the development paths leverage the experience and capabilities of our experienced, commercially-focused management team.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing two complementary treatments for HDV. Lonafarnib is a first-in-class, oral farnesylation inhibitor in a global Phase 3 trial, and the only oral therapy in development for HDV. Peginterferon lambda (lambda) is a first-in-class, well-characterized, well-tolerated type III interferon entering Phase 3.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pivotal Phase 3 D-LIVR study (N&#61;400) of lonafarnib boosted with ritonavir in HDV is ongoing with completion of enrollment planned in 2021. The study spans twenty-two countries with over one hundred sites and has potential to generate data for two distinct lonafarnib-based ritonavir-boosted regimens for approval. An all-oral arm of lonafarnib boosted with ritonavir and a combination arm of lonafarnib boosted with ritonavir combined with pegylated interferon-alfa-2a will each be compared to placebo. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA approved our first commercial product, Zokinvy (lonafarnib) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and to treat processing-deficient progeroid laminopathies, ultra-rare and rapidly fatal genetic conditions of accelerated aging in children, on November 20, 2020. Our Marketing Authorization Application (MAA) is under review with the European Medicines Agency (EMA), and we expect a decision in the second half of 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our pipeline is summarized in the table below. Prior clinical experience by our licensors with the product candidates has supported and guided our understanding of safety in advancing these products in our clinical development programs. Specifically, we licensed lonafarnib from Merck Sharp&#160;&#38; Dohme Corp (Merck) in 2010 and licensed peginterferon lambda from Bristol-Myers Squibb (BMS) in 2016. We have relied upon Merck&#8217;s and BMS&#8217; prior Phase 1/2/3 clinical data, manufacturing and experience with these two molecules to proceed directly into Phase 2 clinical trials following authorization by the FDA and will rely on that data and information to support potentially pivotal clinical trials and any filings for regulatory approvals.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000001.jpg" title="" alt="" style="width:603px;height:264px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our portfolio includes a late-stage clinical development pipeline with four clinical product candidates and one FDA-approved product.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Product Candidates</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-weight:normal;font-style:normal;color:#000000;"></span><span style="color:#000000;">Lonafarnib (LNF) in HDV</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LNF is a well-characterized, orally bioavailable, first-in-class farnesylation inhibitor in a Phase 3 clinical trial for HDV infection and is our lead program. HDV is the most severe form of viral hepatitis for which there is currently no FDA-approved therapy. Chronic HDV infection can lead to a rapid progression to liver cirrhosis, a greater likelihood of developing liver cancer, and has the highest fatality rate of all the chronic hepatitis infections.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We licensed LNF from Merck in 2010. LNF is a small molecule that blocks the production of HDV virus particles by inhibiting a key step, called farnesylation, in the virus life cycle. We have completed Phase 2 studies in 129 HDV-infected patients dosed with LNF across five international clinical trials. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Phase 2 studies have identified two lonafarnib-based regimens, which have achieved clinically meaningful composite endpoints of HDV RNA decline &#8805; 2 logs from baseline and normalized alanine aminotransferase (ALT), a key liver enzyme, at Week 24: all-oral regimen of LNF 50 mg boosted with RTV twice daily and combination regimen of LNF boosted with RTV combined with PEG IFN-alfa-2a. Predominantly grade 1 gastrointestinal (GI) adverse events (AE) were observed in Phase 2 amongst per-protocol treated patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Phase 3 registration program consists of a single, pivotal, global trial called D-LIVR that is designed to support U.S. regulatory approval. D-LIVR has the potential to generate data for two distinct lonafarnib-based ritonavir-boosted regimens for approval. An all-oral arm of LNF boosted with RTV and a combination arm of LNF boosted with RTV combined with PEG IFN-alfa-2a will each be compared to placebo in the Phase 3 D-LIVR study. We plan to complete enrollment (N&#61;400) in 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LNF for treatment of HDV infection has been granted Orphan Drug designation by the FDA and EMA, Fast Track and Breakthrough Therapy designations by FDA and PRIME designation by EMA. The potential market for HDV therapies in the United States and Western Europe is growing due to increased migration from regions where the disease is endemic, primarily from Eastern Europe, the Middle East and Asia.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-weight:normal;color:#000000;"></span><span style="font-style:italic;color:#000000;">Peginterferon Lambda (lambda) in HDV</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lambda is our second program treating HDV. Lambda is a well-characterized, late-stage, first-in-class, type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We licensed worldwide rights to lambda from BMS in April 2016. Lambda has been administered in clinical trials involving over 3,000 patients infected with the Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), and SARS-CoV-2. Lambda has not been approved for any indication. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, following End of Phase 2 and Scientific Advice meetings with regulatory agencies, we gained agreement with FDA and EMA on a single pivotal Phase 3 trial for lambda as a monotherapy for treatment of HDV, which we expect to begin in the second half of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also generated data with lambda in a combination therapy with LNF + RTV. In November 2020, we reported positive end-of-study data from the LIFT study, a Phase 2 lambda combination study with LNF boosted with RTV at the National Institutes of Health&#8217;s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 26 HDV-infected patients. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lambda for treatment of HDV infection has received Orphan Drug designation from FDA and EMA and Fast Track and Breakthrough Therapy designations from FDA.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="font-weight:normal;font-style:normal;color:#000000;"></span><span style="color:#000000;">Avexitide in Post-Bariatric Hypoglycemia (PBH)</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avexitide is a well-characterized peptide that we are developing as a treatment for PBH, a debilitating and potentially life-threatening condition for which there is currently no approved therapy. This disorder occurs often in a subset of bariatric surgeries including Roux-en-Y gastric bypass (RYGB) and Sleeve Gastrectomies (SG). PBH patients experience frequent symptomatic hypoglycemia, with blood glucose concentrations often low enough to cause seizures, altered mental status, loss of consciousness and even death. Gastric bypass procedures are widely performed and are increasing in frequency for medically complicated obesity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed four clinical studies demonstrating clinical proof of concept in 54 patients suffering from severe, refractory PBH indicating that avexitide can prevent post-prandial hypoglycemia in affected patients. Avexitide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that competes with endogenous GLP-1 and prevents the excessive post-prandial insulin release that characterizes this disorder. These Phase 2 data were generated using both intravenous and subcutaneous (SC) formulation delivery. Pharmacokinetics from these Phase 2 SC studies indicate that the SC formulation could enable once or twice a day pre-prandial dosing. We developed a proprietary SC liquid formulation and completed a Phase 1 dose-ranging pharmacokinetics trial in healthy humans. In October 2018, we reported positive topline data from PREVENT, a multi-center, placebo-controlled study investigating the safety and durability of effect of 28-day dosing of SC avexitide in post-bariatric surgical patients. The primary efficacy endpoint of improved postprandial glucose nadir during mixed meal tolerance testing (MMTT) was achieved with statistical significance with fewer participants requiring glycemic rescue during each of the active dosing regimens than during placebo dosing. The secondary endpoint of reduced postprandial insulin peak during MMTT was also statistically significant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avexitide for the treatment of hyperinsulinemic hypoglycemia has been granted Orphan Drug designation by the FDA and for the treatment of non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS) by the EMA. NIPHS describes a spectrum of acquired metabolic disorders characterized by inappropriately high insulin levels (hyperinsulinemia) and low blood glucose levels (hypoglycemia), which includes PBH. Avexitide for the treatment of PBH has also been granted Breakthrough Therapy designation by FDA. Following End of Phase 2 and Scientific Advice meetings with regulatory agencies, we have agreement on a single pivotal Phase 3 study, including study design and endpoints with the FDA and EMA.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-weight:normal;font-style:normal;color:#000000;"></span><span style="color:#000000;">Avexitide in Congenital Hyperinsulinism (CHI) </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avexitide has also demonstrated clinical proof of concept for the treatment of congenital hyperinsulinism (CHI), an ultra-rare, pediatric metabolic disorder. CHI is the most frequent cause of persistent hypoglycemia in neonates and children and is characterized by fasting and protein-induced hypoglycemia and results in permanent brain damage with neurodevelopmental deficits in up to 50% of patients. Near-total pancreatectomy is often indicated and leads to life-long insulin-dependent diabetes (IDDM). Safe and effective therapies are urgently needed to prevent brain damage, IDDM and death.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avexitide binds to the GLP-1 receptor on pancreatic beta-cells and behaves as a GLP-1 antagonist and inverse agonist, reducing fasting and amino-acid induced cAMP accumulation and thereby decreasing calcium-stimulated insulin secretion. Avexitide has been dosed in over 25 patients with congenital hyperinsulinism at Children&#8217;s Hospital of Philadelphia (CHOP).&#160;&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avexitide has been granted Orphan Drug designation by the EMA for the treatment of CHI and Orphan Drug designation by the FDA for the treatment of hyperinsulinemic hypoglycemia, which includes CHI. Avexitide has also been granted Rare Pediatric Disease designation by FDA. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Approved Product</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:bold;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-weight:normal;font-style:normal;color:#000000;"></span><span style="color:#000000;">Zokinvy (LNF) in Progeria and Processing-Deficient Progeroid Laminopathies (PL)</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we received FDA approval for Zokinvy to reduce risk of mortality in Progeria and to treat processing-deficient PL. Zokinvy is our first approved product, and the first approved therapy for these indications. There are approximately 20 identified patients in the U.S. who are eligible for treatment with Zokinvy.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, we submitted our MAA for Zokinvy to the EMA, which is currently under review. We expect a decision in the second half of 2021.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zokinvy is a disease-modifying agent that has demonstrated a statistically significant survival benefit in children and young adults with Progeria. In patients with Progeria, Zokinvy reduced the incidence of mortality by 60% (p&#61;0.0064) and increased average survival time by 2.5 years. The most commonly reported adverse reactions were gastrointestinal (vomiting, diarrhea, nausea), and most were mild or moderate (Grade 1 or 2) in severity. Many Progeria patients have received continuous Zokinvy therapy for more than 10 years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progeria is an ultra-rare and rapidly fatal genetic condition of accelerated aging in children. Progeria is caused by a point mutation in the<span style="font-style:italic;"> LMNA</span> gene, encoding the lamin A protein, yielding the farnesylated aberrant protein called progerin. Lamin A protein is part of the structural scaffolding that holds the nucleus together. Researchers now believe that progerin may make the nucleus unstable, and that cellular instability may lead to the process of premature aging in Progeria. Children with Progeria die of the same heart disease that affects millions of normally aging adults, arteriosclerosis, but at an average age of 14.5 years. Disease manifestations include severe failure to thrive, scleroderma-like skin, global lipodystrophy, alopecia, joint contractures, skeletal dysplasia, global accelerated atherosclerosis with cardiovascular decline, and debilitating strokes. It is estimated that 400 children worldwide have Progeria.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Processing-Deficient Progeroid Laminopathies are genetic conditions of accelerated aging caused by a constellation of mutations in the <span style="font-style:italic;">LMNA</span> and/or <span style="font-style:italic;">ZMPSTE24</span> genes yielding farnesylated proteins that are distinct from progerin. While non-progerin producing, these genetic mutations result in disease manifestations with phenotypes that have overlap with, but are distinct from, Progeria. Collectively, worldwide prevalence of progeroid laminopathies is believed to be approximately 200 patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we entered into an amendment to our license agreement with Merck to include, not only all uses of lonafarnib related to the treatment of Progeria, but also Progeroid Laminopathies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Model and Management Team</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our approach to clinical development enables achievement of early clinical signals of efficacy and safety in our Phase 2 programs and potentially reduces clinical risks and costs inherent in the drug discovery and development process. We have a highly experienced management team whose members have, in the course of their prior employment, participated in bringing more than 20 product candidates through regulatory approval and into commercialization. We plan to leverage our management team&#8217;s breadth and depth of experience in clinical and regulatory drug development as well as market development and commercialization to identify potentially promising product candidates to address unmet medical needs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current product candidate pipeline has been obtained by in-licensing from pharmaceutical companies and academic institutions. With our focus on rare and ultra-rare diseases, our strategy is to acquire and retain some or all commercialization rights to our products in significant territories to diversify risk, identify a rapid regulatory pathway to approval and minimize the development investment in order to maximize long-term value for our stockholders. Over time, depending upon the data and potential market opportunity, we expect to develop an integrated commercial organization, which we believe can be targeted and cost effective for selected, promising orphan disease designated programs. We plan to balance these interests with opportunities to out-license assets from our portfolio enhance stockholder value through partnerships and other strategic relationships.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to continue evaluating in-licensing opportunities in order to enhance our pipeline and leverage our business development, clinical development, regulatory and commercial expertise. We believe our management team has the capability and experience to continue to execute this model. Our management team has worked in other private and public biotechnology companies such as Prestwick Pharmaceuticals, New River Pharmaceuticals, Clinical Data Inc., CoTherix, InterMune, Salix Pharmaceuticals, Inc., Onyx Pharmaceuticals, Aimmune Therapeutics, and Questcor, each of which was acquired by a larger pharmaceutical industry company. Our management also has previous work experience, in some cases working together, at pharmaceutical companies, including The Upjohn Company, Glaxo, Glaxo Wellcome, Glaxo Smith Kline, BioDelivery Sciences, Inc., BioTime, Inc., Halozyme, Merck, Schering-Plough, Amylin, Zeneca, Jazz Pharmaceuticals, Rigel, Theravance and Amgen.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Strateg</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">y</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our strategy is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions. We currently have a diverse portfolio of well-characterized product candidates with the potential to address life-threatening diseases for which the unmet medical need is high and, primarily focused on the development of foundational therapies for HDV infection. Our goal is to be a leader in the development and commercialization of novel therapeutics for serious unmet medical needs in rare and ultra-rare diseases. Our focus to achieve this goal will be to utilize our experience and capabilities to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Advance our existing product candidates through late-stage clinical trials, generating meaningful clinical results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Work with U.S. and international regulatory authorities for expeditious, efficient development pathways toward registration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Prepare for commercialization of each program&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Use our industry relationships and experience to source, evaluate and in-license well-characterized product candidates to continue pipeline development&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Identify potential commercial or distribution partners for our products in relevant territories.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Hepatitis Delta Virus Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">About Hepatitis Delta Virus</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hepatitis delta infection is caused by HDV, a small circular ribonucleic acid (RNA) that expresses only one protein, the hepatitis delta antigen (HDAg). There are two forms of HDAg &#8211; small and large. These two forms of HDAg and the single-stranded RNA genome are surrounded by a lipid envelope, which is embedded with Hepatitis B Virus (HBV) surface antigen (HBsAg) proteins. HDV does not encode its own envelope proteins and must acquire them from HBV during the final steps of replication. Hence, natural HDV infections always occur in the presence of a co-existing HBV infection. HBsAg is the only element of HBV relied upon by HDV. HDV replication can occur independently of HBV replication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HDV is the most severe form of viral hepatitis. HDV can be acquired either by co-infection (a simultaneous co-infection with HDV and HBV) or by super-infection (HDV infection of someone already harboring a chronic HBV infection). Both co-infection and super-infection with HDV result in more severe complications compared to infection with HBV alone. These complications include a greater likelihood of experiencing liver failure in acute infections and a rapid progression to liver cirrhosis, with an increased chance of developing liver cancer in chronic infections. HDV has the highest fatality rate of all the hepatitis infections at up to 20%. Although HDV/HBV simultaneous co-infection in adults usually resolves completely, in some cases it can become fulminant hepatitis, which carries a very high mortality rate. In the case of super-infections, the predominant form of HDV, HDV super-infection leads to a more severe form of disease than chronic HBV mono-infection. In a study published in 1987 in the Journal of Infectious Diseases, histological liver deterioration was observed in 77% of HBV patients co-infected with HDV over a 15-year follow-up period, versus 30% of patients infected with HBV alone (p&#60;0.01). In a 2013 study of chronic HBV patients published in the Journal of Gastroenterology and Hepatology, cirrhosis was present in 73% of HBV patients co-infected with HDV, compared to only 22% of those infected with HBV alone. Patients co-infected with HDV are more than twice-as-likely to develop liver-related complications, cirrhosis, or require liver transplants than matched patients infected with HBV alone.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000002.jpg" title="" alt="" style="width:392px;height:199px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000003.jpg" title="" alt="" style="width:624px;height:246px;" /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HDV is generally spread through exchange of body fluids either sexually or through contact with infected blood. Globally, it is estimated that between 4.3% and 5.7% of the 240&#160;million worldwide chronic HBV population, or 10 to 14&#160;million people, are infected with HDV. The prevalence of HDV in patients infected with chronic HBV is even higher in certain regions, including certain parts of Mongolia, China, Russia, Central Asia, Pakistan, Turkey, Africa and South America, with an HDV prevalence as high as 60% being reported in HBV-infected patients in Mongolia and Pakistan. The prevalence of HDV has recently begun to increase in Western Europe and the United States due to migration from countries with high infection rates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Role of HDV Screening in Identifying Patients Who May Benefit from LNF and/or Lambda</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Active HDV infections are best detected by reverse transcriptase-polymerase chain reaction (RT-PCR) assays for genomic RNA. These assays yield a quantitative assessment of the number of viral particles, or viral load, in serum. A commercial assay for quantitative HDV RNA has been available in Europe (Robogene&#174;) since 2015. Quest Diagnostics and ARUP Laboratories offer commercial assays for quantitative HDV RNA testing in the United States. Both assays are calibrated using the World Health Organization HDV standard provided by the Paul Erhlich Institute in Germany.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial discussions with payors have indicated that they would be willing to reimburse healthcare providers for HDV RNA quantitative assays that are carried out following a positive HBsAg test for HBV. Commercially available assays will increase the number of assays performed and increase the number of identified patients who can potentially benefit from an HDV therapy such as LNF.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Current Therapy for H</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">DV</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, there is no FDA-approved therapy for hepatitis delta virus infection. Hepcludex (buleviritide) was conditionally approved in Europe in 2020 for treatment of chronic HDV. The American Association for the Study of Liver Diseases (AASLD) guidelines suggest treatment of chronic hepatitis delta infections with IFN-alfa. In clinical trials of IFN-alfa or PEG IFN-alfa, between 25% and 33% of HDV infected patients were able to achieve undetectable HDV RNA after a minimum of 48 weeks of therapy, with some requiring two years of therapy. However, long-term therapy with IFN-alfa is known to be associated with numerous adverse events and tolerability is a significant problem for some of these patients. In addition, rebound of HDV RNA occurs in greater than 50% of patients. HBV nucleoside analogs that suppress HBV DNA are ineffective against HDV since they are ineffective in suppressing the expression HBsAg. Current development programs targeting HBV functional cures are in early stages and are not expected to eliminate extra-hepatic reservoirs of HBsAg. Given that HDV only requires small amounts of HBsAg for virion assembly, functional cures, if achieved, will not eradicate HDV. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">HDV Replication and Farnesylation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After HDV enters a target cell hepatocyte, the genome is translocated to the nucleus where genome replication occurs and the two forms of HDAg small delta antigen (SHDAg) and large delta antigen (LHDAg) are produced. The newly formed HDV genome and the small and large delta antigen must acquire a lipid envelope from HBV to complete the assembly process. An important interaction between HDV and HBV proteins has been shown to depend on the presence of the last four amino acids of the large delta antigen, comprising a CXXX box motif, where C represents cysteine and X denotes any other amino acid. This amino acid sequence is required for LHDAg to be farnesylated by a host enzyme which covalently attaches a 15-carbon prenyl lipid (farnesyl-moiety) to the cysteine of the CXXX box. Farnesylation of the large delta antigen renders it more lipophilic, promotes its association with HBsAg and is essential for initiating the HDV particle formation process. Our approach involves targeting this host process called farnesylation, or protein farnesylation, which has been shown to be essential for the last steps in HDV replication, the assembly and release of new virus progeny.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the 1980s farnesyltransferase inhibitors were developed by multiple pharmaceutical companies for oncology indications. Addition of a farnesyl or prenyl lipid group to the Ras protein (Ras) a well-known and important regulator of cellular proliferation, allows for membrane association. Once membrane bound, Ras may then be activated. The importance of activated Ras in tumor development was demonstrated by sequence analyses of tumors from patients where up to 30% have mutations involving Ras. Several farnesylation inhibitors were developed in oncology and taken into the clinic and in some cases through late-stage clinical development. However, these programs did not lead to approvals, due to a lack of compelling efficacy. The class-related, dose-limiting toxicity has been gastrointestinal side effects including nausea, vomiting, diarrhea and weight loss.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Published studies demonstrate that farnesyltransferase inhibitors block HDV viral production both in cellular experiments and in HDV transgenic mice. Targeting farnesylation or farnesyl transferase, a host target, significantly reduces the likelihood of HDV developing resistance to escape effects of antiviral therapy. Viruses mutate quickly and there is a higher rate of mutations in viral replication compared to mammalian cell division. However, no matter how much HDV may mutate, these changes are unlikely to alter the host process of farnesylation which HDV requires to complete packaging. Thus, targeting a host farnesylation process provides what we believe to be a higher barrier to resistance. Identification of clinic-ready farnesylation inhibitors has allowed us to move rapidly into proof-of-concept studies in humans.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Lead HDV Opportunity: Lonafarnib </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lonafarnib (LNF) is a well-characterized, orally active inhibitor of farnesyl transferase. LNF inhibits the farnesylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. Since farnesylation is a host process, not under control of HDV, and LNF inhibits farnesylation, we believe that there is also a potentially higher barrier to resistance with LNF therapy. LNF for the treatment of HDV infection has been granted Orphan Drug designation in Europe and the United States, and LNF in combination with RTV has been granted Fast Track and Breakthrough Therapy designations from FDA for the treatment of chronic HDV infections. In the United States, we have issued patents, U.S. Patent No. 10,076,512 and 10,828,283, both entitled Treatment of Hepatitis Delta Virus Infection. The issued claims cover a broad range of RTV-boosted LNF doses and durations. The European Patent Office, the Chinese Patent Office and the Japan Patent Office have also granted patents with claims covering a broad range of lonafarnib boosted with RTV dosing regimens for the treatment of HDV infection. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LNF Phase 2 Clinical Data</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We licensed LNF from Merck in 2010, and have relied upon Merck&#8217;s prior Phase 1, 2 and 3 clinical experience with LNF in over 2,000 patients to understand safety and pharmacokinetics.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed five Phase&#160;2 trials (POC, LOWR-1, LOWR-2, LOWR-3, LOWR-4) with LNF in 129 HDV-infected patients. The Phase 2 LOWR HDV (Lonafarnib With Ritonavir in HDV) Program identified dose(s) and regimen(s) for registration.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">POC Study (Placebo-controlled LNF monotherapy) (N&#61;14)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">LOWR-1 Study (Combination: LNF with RTV or PEG IFN-alfa-2a) (N&#61;21)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">LOWR-2 Study (Dose Finding: LNF + RTV &#177; PEG IFN-alfa-2a) (N&#61;58)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">LOWR-3 Study (QD Dosing: LNF + RTV) (N&#61;21)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">LOWR-4 Study (Dose-Escalation: LNF + RTV) (N&#61;15)</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 2 NIH proof-of-concept study demonstrated statistically significant decreases in HDV RNA viral load with two LNF active groups versus placebo for 28-days. A statistically significant correlation between increasing LNF serum levels and decreasing HDV RNA viral loads was also observed, demonstrating that higher serum levels resulted in greater decline in HDV RNA.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 2 LOWR studies demonstrated benefits of twice daily RTV-boosting of LNF for up to 24 weeks of dosing. RTV is a pharmacokinetic (PK) enhancer known to inhibit the metabolism of LNF, allowing lower doses of LNF to be administered, while resulting in higher systemic concentrations of LNF. The Phase 2 LOWR HDV studies identified two LNF-based regimens that can achieve clinically meaningful composite endpoints of HDV RNA decline &#8805; 2 logs from baseline and normalized ALT at Week 24: all-oral regimen of LNF 50 mg BID boosted with RTV twice daily and combination regimen of LNF 50 or 25 mg BID boosted with RTV combined with PEG IFN-alfa-2a (see figures below). These dosing regimens were associated with predominantly grade 1 GI AEs amongst per-protocol treated patient.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000004.jpg" title="" alt="" style="width:432px;height:224px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase 3 D-LIVR Study</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-LIVR (Delta-Liver Improvement and Virologic Response in HDV) is an international, multi-center, Phase 3 study of approximately 300 LNF-treated patients (total N&#61;400 patients including controls) to evaluate an all-oral arm of LNF boosted with RTV and a combination arm of LNF boosted with RTV combined with pegylated interferon-alfa-2a (PEG IFN-alfa-2a), with each arm to be compared to a placebo arm (background HBV nucleos(t)ide only), in HDV-infected patients.&#160;A PEG IFN-alfa-2a alone arm will be dosed to demonstrate contribution of effect only. The LNF containing arms will not be required to demonstrate superiority over PEG IFN-alfa-2a alone. A combined primary endpoint of &#8805; 2 log<sub style="font-size:85%; vertical-align:bottom"> </sub>decline in HDV RNA and ALT normalization at end of 48 weeks of treatment will be used to assess activity of LNF-based regimens versus placebo in the D-LIVR study.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-LIVR is a global study, enrolling across 22 countries and over 100 site</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to complete enrollment (N&#61;400) of D-LIVR in 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000005.jpg" title="" alt="" style="width:554px;height:240px;" /></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Second HDV Therapeutic Approach: Lambda for HDV</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lambda is a well-characterized, late-stage, first in class, well-tolerated, type III interferon (IFN) that we in-licensed from Bristol-Myers Squibb in April 2016 for the treatment of HDV infection. Lambda is being developed as a well-tolerated interferon. Lambda stimulates immune responses that are critical for the development of host protection during viral infections.&#160;Lambda targets type III IFN receptors which are distinct from the type I IFN receptors targeted by IFN-alfa. These type III receptors are highly expressed on hepatocytes with limited expression on hematopoietic and central nervous system cells, which has been demonstrated to reduce the off-target effects associated with other IFNs and improve the tolerability of lambda (Chan 2016). Although lambda does not use the IFN-alfa receptor, signaling through either the IFN-lambda or IFN-alfa receptor complexes results in the activation of the same Jak-STAT signal transduction cascade. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In clinical trials of IFN-alfa or PEG IFN-alfa-2a, after 48-72 weeks of therapy, between 25% and 33% of HDV-infected patients were HDV RNA undetectable 24 weeks after stopping therapy. However, IFN-alfa is known to be associated with numerous adverse events and tolerability is a significant problem for some of these patients. We believe lambda will be a safer and better tolerated pegylated interferon compared to PEG IFN-alfa-2a. We are developing lambda as a monotherapy and in a combination therapy with LNF. In 2020, we gained agreement with FDA and EMA on study design and endpoints for a single pivotal Phase 3 of lambda as a monotherapy for treatment of HDV infection. The study, called LIMT-2, is depicted below, is a randomized, open-label, parallel-arm study and will include 150 patients randomized 2:1 to two different lambda-containing arms. The first arm is 48 weeks of treatment with lambda 180 mcg administered weekly and a 24-week off-treatment follow-up period. The second arm is 12-weeks of no therapy followed by 48 weeks of treatment with weekly lambda 180 mcg and a 24-weeks off-treatment follow-up period. The primary endpoint is a Durable Virologic Response (DVR), or HDV RNA below limit of quantitation (BLQ) or undetectable, 24-weeks post treatment of Arm 1 compared to placebo after 12-weeks of no treatment of Arm 2. All patients will be administered an anti-HBV nucleos(t)ide analog throughout the study.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><img src="gzbwht3f4aft000006.jpg" title="" alt="" style="width:559px;height:209px;" /><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lambda Clinical Data</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIMT-1 Monotherapy Phase 2 Clinical Trial</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LIMT-1 was a 1:1 randomized, open-label Phase 2 study of lambda 120 &#956;g or 180 &#956;g subcutaneous injections administered weekly for 48 weeks in 33 patients with chronic HDV. End of treatment was followed by a treatment-free 24-week observation period. The primary objective of the Phase 2 study was to evaluate the safety, tolerability, and efficacy of treatment with two dose levels of lambda in patients with chronic HDV infection. All patients were administered an anti-HBV nucleos(t)ide analog throughout the study. The trial was conducted at four international sites in New Zealand, Israel and Pakistan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Week 48 end-of-treatment data were presented in November 2018 at AASLD. At Week 48, patients in the 180 &#956;g lambda treated group experienced a 2.4 log mean decline in HDV-RNA, with 6 of 10 (60%) experiencing &#8805; 2 log decline, 4 of 10 (40%) patients were HDV-RNA negative at end of treatment. At Week 48, patients in the 120 &#956;g lambda treated group experienced a 1.5 log<sub style="font-size:85%; vertical-align:bottom"> </sub>mean decline in HDV RNA, with 6 of 14 (42.9%) experiencing &#8805; 2 log<sub style="font-size:85%; vertical-align:bottom"> </sub>decline, 2 of 14 (14.3%) patients were HDV-RNA negative at end of treatment. The most commonly reported AEs were moderate headache, pyrexia, fatigue, and myalgia. Observed ALT flares result from vigorous antiviral immunological response to treatment, not due to direct hepatotoxicity. End of 24-week follow-up data, presented in April 2019 at EASL, demonstrated that 36% of HDV infected patients were able to maintain HDV RNA below limit of quantitation (BLQ) 24-weeks post-treatment, or a Durable Virologic Response (DVR), and achieve ALT normalization. These data are illustrated below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000007.jpg" title="" alt="" style="width:519px;height:253px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LIMT-1 study did not include per-protocol liver biopsies. However pre- and post-treatment liver biopsies were collected for two patients where regression in liver fibrosis from F5 to F1 and F4 to F1 was observed. This is the first demonstration of regression in liver fibrosis with a finite lambda treatment.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000008.jpg" title="" alt="" style="width:624px;height:236px;" /></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LIFT HDV Combination of Therapy Phase 2 Clinical Trial</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LIFT (<span style="text-decoration:underline;">L</span>ambda <span style="text-decoration:underline;">I</span>nter<span style="text-decoration:underline;">f</span>eron combination <span style="text-decoration:underline;">T</span>herapy) was an open-label, Phase 2 study evaluating lambda in combination with lonafarnib boosted with ritonavir in 26 HDV-infected patients. Patients were dosed for 24 weeks and underwent off-treatment follow-up for 24 weeks. The primary endpoint was &#62;2 log decline in HDV RNA at end of 24-weeks of treatment. Secondary endpoints included histology (&#62;2-point improvement in histological activity index and no progression in fibrosis) at end of follow-up. LIFT was conducted within the National Institutes of Health (NIH) at the NIDDK. Study design and final end-of-treatment and end-of-study data were reported in November 2020 at the AASLD conference and are summarized in the pictures below. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The data demonstrated that after 24 weeks of treatment, by per protocol analysis, 77% of patients (17 of 22) achieved the primary efficacy end point of &#62;2 log decline in HDV RNA, with 50% of patients (11 of 22) were either HDV RNA BLQ or undetectable. At Week 48 (24 weeks post-treatment), 5 of 22 patients (23%) maintained HDV RNA BLOQ or were HDV RNA undetectable, 11 of 20 patients (55%) demonstrated improvement in Histology Activity Index (HAI), and 6 of 20 patients (30%) achieved the secondary endpoint of &#62; 2 point improvement in HAI.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000009.jpg" title="" alt="" style="width:486px;height:212px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000010.jpg" title="" alt="" style="width:476px;height:208px;" /></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Potential for Registration in HDV for LNF and Lambda</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current goal in developing LNF and lambda is to suppress the virus and reduce liver inflammation. Therefore, we have defined a primary endpoint for D-LIVR as a &#8805; 2 log reduction in HDV RNA and ALT normalization. Our long-term goal in developing LNF and lambda is to reduce viral load in such a manner as to achieve durable suppression of the virus to BLQ, the point where, upon withdrawal of the therapy, the infection does not return to quantifiable levels. Evidence that academic investigators have gathered suggests that combinations of LNF and lambda with other antiviral agents may hold promise for longer duration treatment and sustained, long-term reduction of viral load. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PBH Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the use of bariatric surgical procedures has increased worldwide due to rising obesity and Type 2 diabetes, a new post-surgical complication, hypoglycemia associated with bariatric surgery, has been increasingly diagnosed and reported in the procedures that involve reducing the size of the stomach with a vertical sleeve gastrectomy (SG) or by resecting and re-routing the small intestine to a small stomach pouch (Roux-en-Y gastric bypass). This disorder leads to frequent symptomatic hypoglycemia, often resulting in glucose concentrations low enough to cause seizures, altered mental status, loss of consciousness, cognitive dysfunction, disability and death. Quality of life can be severely diminished, and many patients cannot care for themselves or others, work, drive, or be left alone. There is no approved treatment for this condition. Severe cases have historically been surgically managed with near-total to total pancreatectomy, which results in insulin dependent diabetes and is associated with a greater than 6% surgical mortality risk.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research suggests that elevated GLP-1 may play an important role in mediating the glucose-lowering effect associated with bariatric surgery. Surgically altered nutrient transit, resulting from bariatric surgeries can cause early nutrient sensing by the intestinal &#8220;L&#8221; cells, leading to enhanced secretion of GLP-1 causing elevated insulin secretion. This effect may play a primary role in the early resolution of Type 2 diabetes after surgery. A number of synthetic analogs of GLP-1, or agonists, have been approved for the treatment of Type 2 diabetes including Byetta&#8482; (exenatide), Victoza&#8482; (liraglutide), and Trulicity&#8482; (dulaglutide). These drugs, all agonists, bind to the GLP-1 receptor and enhance the release of insulin in a glucose-dependent manner. In patients with PBH, excessive secretion of GLP-1 and/or exaggerated sensitivity to GLP-1 results in dysfunctional insulin release, leading to severe, debilitating hypoglycemia. GLP-1 receptor antagonists compete with endogenous GLP-1 and has the potential to prevent dysfunctional insulin release and resultant symptomatic hypoglycemia.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately 240,000 bariatric surgical procedures are performed each year in the United States, and another 900,000 are performed each year in Europe. It is estimated that PBH can impact approximately 10% of Roux-en-Y gastric bypass and 2.5% of SG patients.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Data to Date</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have demonstrated in four clinical studies in 54 patients with avexitide that pharmacologic blockade of the GLP-1 receptor can prevent hypoglycemia in affected patients and mitigate symptoms of hypoglycemia. We believe that avexitide may represent the first targeted medical treatment for patients with PBH. In the four completed studies, there were no significant adverse drug reactions attributed to avexitide.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed our most recent Phase 2 study called PREVENT in October 2018. The PREVENT study was a Phase 2, multicenter, randomized, single-blind, placebo-controlled cross-over study to assess the efficacy and safety of 28-day dosing of avexitide in patients with&#160;PBH. A total of 18 patients were enrolled and treated with two dosing regimens (once daily and twice daily) of avexitide for 28 days. All patients participated in three 14-day treatment periods, involving placebo SC injections, once-daily avexitide SC injections, and twice-daily avexitide SC injections. Patients self-administered injections in an outpatient setting. Participants underwent in-clinic MMTT provocations with concomitant blood draws and symptom assessments following each treatment period. Metabolic and clinical improvements were monitored during each patients&#8217; daily routines in the outpatient setting and assessed by electronic diary and continuous glucose monitoring (CGM). Outcomes include improvement in plasma glucose nadir levels, reduction in peak insulin concentrations, and the requirement for rescue during MMTT provocation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary efficacy endpoint of improved postprandial glucose nadir during MMTT was achieved with statistical significance with avexitide 30 mg BID and 60 mg QD, with fewer participants requiring glycemic rescue during each of the active dosing regimens than during placebo dosing. The secondary endpoint of reduced postprandial insulin peak during MMTT was also statistically significant with avexitide 30 mg BID and 60 mg QD. The primary and secondary endpoints are shown in the figure below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000011.jpg" title="" alt="" style="width:581px;height:297px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Metabolic and clinical improvements were also monitored during each patients&#8217; daily routine in the outpatient setting and assessed by electronic diary and continuous glucose monitoring (CGM). Patients experienced fewer episodes of hypoglycemia and severe hypoglycemia during both dosing regimens of avexitide as compared to placebo as shown in the table below.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000012.jpg" title="" alt="" style="width:613px;height:301px;" /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avexitide was well tolerated. There were no treatment-related serious adverse events and no participant withdrawals. Adverse events were typically mild to moderate in severity. The most common adverse events were injection site bruising, nausea, and headache, all of which occurred with lower frequency during avexitide dosing periods than during the placebo dosing period. Avexitide has been granted Breakthrough Therapy Designation by the FDA. In 2020, we received concurrence with FDA and EMA on a single Phase 3 for Avexitide for treatment of PBH.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CHI Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CHI is an ultra-rare pediatric metabolic disease. CHI presents with severe hypoglycemia in the neonatal period requiring intensive care hospitalization, administration of high rates of intravenous glucose through central lines, continuous intravenous administration of glucagon and in most instances surgical treatment by pancreatectomy during the neonatal period or during infancy. The most common and severe form of CHI is refractory to medical treatment with diazoxide and affects approximately 60% of all patients. Diazoxide unresponsive CHI arises out of inactivating mutations in the genes encoding the K<sub style="font-size:85%; vertical-align:bottom">ATP </sub>channel, resulting in focal and diffuse forms of CHI. Focal disease, occurring in approximately 50% of patients with K<sub style="font-size:85%; vertical-align:bottom">ATP </sub>CHI, resolves in 97% of cases after partial pancreatectomy. Diffuse disease persists in 41% of cases after subtotal (98%) pancreatectomy. However, by the age of 14 years old, 91% of patients undergoing subtotal pancreatectomy develop insulin-dependent diabetes, at which point hyperinsulinism is no longer present. Thus, CHI is a congenital, rare pediatric disease with life-threatening manifestations of severe hyperinsulinemic hypoglycemia occurring primarily during the neonatal period, infancy, childhood and adolescence.&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Data to Date</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, a total of 39 patients with K<sub style="font-size:85%; vertical-align:bottom">ATP </sub>CHI enrolled in 3 clinical investigations at CHOP have received avexitide administered by continuous IV infusion: 10 adolescents and adults, 16 children, and 13 neonates. Data generated across all 3 clinical investigations suggest that treatment with avexitide may effectively reduce fasting and postprandial hypoglycemia in patients with diazoxide unresponsive CHI. Avexitide treatment was well tolerated, with no serious drug-related adverse events (AEs) reported. Data from each of the three studies are presented in the figures below. Avexitide for treatment of CHI has been granted Rare Pediatric Disease designation by the FDA.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000013.jpg" title="" alt="" style="width:474px;height:225px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000014.jpg" title="" alt="" style="width:520px;height:236px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000015.jpg" title="" alt="" style="width:432px;height:200px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently contract with third parties for the manufacturing of all of our FDA-approved product, Zokinvy, and clinical product candidates and intend to do so in the future. We do not own or operate manufacturing facilities for the production of clinical trial quantities of our product candidates and have no plans to build our own clinical or commercial scale manufacturing capabilities. We believe that the use of contracted manufacturing organizations (CMOs) eliminates the need for us to directly invest in manufacturing facilities, equipment and additional staff. Although we rely on contract manufacturers, our personnel and consultants have extensive manufacturing experience overseeing our CMOs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, our third-party manufacturers have met the manufacturing requirements for the product candidates. We expect third-party manufacturers to be capable of providing sufficient quantities of our product candidates to meet anticipated full-scale commercial demands but have not assessed these capabilities beyond the supply of clinical material for certain products. We have identified or plan to identify commercial contract manufacturers as we move our product candidates to Phase 3 clinical trials. We believe there are alternate sources of manufacturing that could be identified and enabled to satisfy our clinical and commercial requirements, however, we cannot be certain that identifying and establishing alternative relationships with such sources can be successful, cost effective, or completed on a timely basis without significant delay in the development or commercialization of our product candidates. <span style="color:#000000;">All of our third-party manufacturers are subject to periodic audits to confirm compliance with applicable regulations and must pass inspection before we can manufacture our drugs for commercial sales.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have qualified and finalized or are in process of finalizing commercial supply agreements contract manufacturers for Zokinvy (lonafarnib) and have identified commercial manufacturers for lambda and plan to proceed with qualifications.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lonafarnib</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The drug product for completed lonafarnib (LNF) Phase 2 clinical studies for the treatment of HDV was manufactured by Merck. We have successfully completed the technology transfer for manufacture of the LNF drug substance and the LNF drug product to our third-party manufacturers. All future clinical trials will be conducted with product manufactured by these CMOs. These manufacturers produce our commercial supply for progeria and processing-deficient progeroid laminopathies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lambda</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are completing the technology transfer from BMS for our Peginterferon Lambda program. As part of the license agreement, sufficient inventory of drug substance and drug product was obtained to complete our Phase 2 and initiate our Phase 3 clinical trials. We have completed the first cGMP drug product manufacturing campaign in 2017 at a new Eiger designated manufacturing facility. The drug substance CMO remains the same CMO contracted by BMS and is currently under evaluation to update for the drug substance manufacturing process.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Both lonafarnib and lambda are GMP products from all CMOs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Avexitide</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical drug product for avexitide for the treatment of PBH and CHI is manufactured by a third-party CMO.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect and in-license those proprietary technologies, inventions, and improvements we believe are important to our business. We seek and maintain, where available, patent protection for our product candidates including: composition dosage, formulation, use, manufacturing process, among others. We have also licensed patents and patent applications that cover certain of our product candidates and/or their manufacture, use, or formulation. We also rely on trade secrets, know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely, or plan to rely, on regulatory exclusivity, including Orphan Drug designation and New Chemical Entity (NCE) and Biologic License Application (BLA) exclusivities, as well as trade secrets and carefully monitor our proprietary information to protect all aspects of our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to continue to expand our intellectual property portfolio by filing patent applications for our product candidates. We file and prosecute patent applications in the United States and Europe and, when appropriate, additional countries, including Japan, Korea, Canada and China.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success will depend significantly upon our ability to: (i)&#160;obtain and maintain patents and other exclusivity protections for commercially important technology, inventions and know-how related to our business&#59; (ii)&#160;prosecute our patent applications to issue as patents and defend and enforce our patents&#59; (iii)&#160;maintain our licenses to use intellectual property owned by others&#59; (iv)&#160;preserve the confidentiality of our trade secrets, and (v)&#160;operate without infringing the valid and enforceable patents and other proprietary rights of others. In addition to maintaining our existing proprietary assets, we seek to strengthen our proprietary positions when economically reasonable to do so. Our ability to augment our proprietary position relies on its: (i)&#160;know-how&#59; (ii)&#160;ability to access technological innovations, and (iii)&#160;ability to in-license technology when appropriate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of pharmaceutical/biotechnology companies like us are generally uncertain and involve complex legal, scientific, and factual issues. In addition, the scope claimed in a patent application can be significantly reduced during the patent prosecution process before any patent issues. After issuance of a patent, if the issued patent is challenged, then the courts or a patent office can redefine the scope of the patent, including by invalidating some or all of the patent claims, or rendering the patent unenforceable in its entirety. Consequently, we do not know with certainty whether patents will issue in each country in which we or our licensors file patent applications, or if those patent applications, if ever issued, will issue with claims that cover our product candidates, or, even if they do issue, whether the patent or its relevant claims will remain enforceable upon challenge. Accordingly, we cannot predict with certainty whether the patent applications we are currently pursuing will issue as patents in a particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from potential competitors to make any of our products commercially successful. Any of our patents, including already issued in-licensed patents or any patents that may issue to us or our licensors in the future, could be challenged, narrowed, circumvented, or invalidated by third parties. Newly filed patent applications in the United States Patent and Trademark Office (the USPTO) and certain other patent offices are maintained in secrecy for a minimum of 18 months, and publications of discoveries in the scientific or patent literature often lag far behind the actual discoveries themselves. For these reasons, we cannot be certain that inventions claimed in pending patent applications were not invented by another party prior to our invention or disclosed or claimed in a patent application filed before the effective filing date of our applications, in either of which case the claims may not be patentable to us. For certain applications with an effective filing date prior to March&#160;13, 2013, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. Also, while we are not currently participating in any interferences or post-grant challenge proceedings, such as patent oppositions, post-grant reexamination proceedings, inter parties review proceedings and patent litigation, that seek to invalidate claims of pending patent applications or issued patents, we may have to participate in such proceedings in the future. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the legal term of the patents in the countries where they are issued. In most countries, the standard patent term for inventions relating to human drugs and their formulation and use is 20 years from the date of filing the first non-provisional patent or international application under the Patent Cooperation Treaty of 1970 (PCT).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The PCT is an international patent law treaty that provides a single PCT application can be converted into a patent application in any of the more than 145 PCT contracting states, providing a cost-effective means for seeking patent protection in numerous regions or countries. Conversion of a PCT application into an application in any of the contracting states typically occurs about 30 months after a priority application is filed, or about 18 months after the PCT application filing date. An applicant must undertake prosecution within the allotted time in the patent offices of any, or a combination, of the contracting states or in a regional patent office it determines to undertake patent issuance in protection in such country or territory. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own or in-license a number of patents in the U.S. and foreign countries that cover our products, product candidates, and methods of their use. With respect to our owned or in-licensed issued patents in the U.S. and Europe, we may be entitled to obtain an extension of patent term to extend the patent expiration date. For example, in the U.S., this extended coverage period is known as patent term extension (PTE) and can only be obtained provided we apply for and receive a marketing authorization for a product. The period of extension may be up to five years beyond the expiration of the patent, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended. In Europe, Supplementary Protection Certificates (SPC) may also be available to patents, which would be available by applying to the member states. However, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. The exact duration of the extension depends on the time we spend in clinical studies as well as getting marketing approval from the FDA.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Protection of Our Product Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exclusivity positions for our clinical-stage product candidates as of December 31, 2020 are summarized below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">LNF<span style="font-style:normal;">.</span><span style="font-weight:normal;font-style:normal;"> We have licensed from Merck a portfolio of patents and know how covering the compound, formulations of the compound, and synthesis, but these expire before the anticipated launch date of the LNF product candidate. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, we have obtained patent protection for the use LNF in combination with RTV for the treatment of HDV infection. Eiger&#8217;s U.S. Patent Nos. 10,076,512 and 10,828,283 entitled, Treatment of Hepatitis Delta Virus Infection, includes claims covering broad range of RTV-boosted LNF doses and durations. The patents have terms that extend to 2035. Additional claims are being pursued in a continuation application. The European Patent Office, the Chinese Patent office and the Japanese Patent Office have also granted patents with claims covering a broad range of LNF boosted with RTV dosing regimens for the treatment of HDV infection. These patents will have a term that extends to 2035. In Europe, China and Japan, additional claims are being pursued in divisional applications. We have now obtained patent protection with claims covering treatment with LNF boosted with RTV in key major pharmaceutical markets including the U.S., Europe, China and Japan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corresponding patent applications claiming the use of lonafarnib boosted with ritonavir are pending in Korea and continuation applications are pending in the U.S., Europe, China and Japan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, US Patent 10,835,496 and a European Patent issued claiming particular dosage regimens for ritonavir-boosted lonafarnib for the treatment of HDV infections. These patents extend protection until at least 2036. Applications are also pending in China, Japan and Korea. Any patents that issue from these applications will expire in 2036. In addition, LNF has been granted Orphan Drug designation by the FDA and the EMA in this indication, which respectively provide seven and ten years of regulatory exclusivity. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have in-licensed from The Progeria Research Foundation patents covering the methods of treating Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria), and progeroid laminopathies. The patents provide protection until at least 2024 and an application for patent term extension (PTE) that could extend the protection for one of the patents until 2029 have been filed. We have also filed a patent application in the US related to method of treating progeria and progeroid laminopathies that if issued would provide further protection until 2039.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lambda.<span style="font-weight:normal;"> </span><span style="font-weight:normal;font-style:normal;">We have in-licensed from BMS a portfolio of patents relating to the manufacture, use, and compositions of lambda modified by polyethylene glycol derivatization (lambda). The key United States composition of matter patent in this portfolio expires in 2025, but we expect to be eligible for the full five years of patent term extension for that patent. In addition, we expect lambda to be filed under a BLA and so lambda would be eligible for 12 years reference product exclusivity (4 years in filing exclusivity&#59; 12 years for data), as well as orphan drug exclusivity for this indication. </span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also filed a PCT application relating to the use of lambda in HDV, which matured into patent applications in the United States, Europe, China, Japan and Korea. Any patents that issue from these applications will expire in</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2037. The </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States Patent and Trademark Office (the USPTO) </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and the European Patent Office (EPO) have both issued Notices of Allowance, and we expect the patent to issue in the US and Europe the first half of 2021 with claims covering the use of lambda to treat HDV.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also filed PCT applications relating to the use of lambda in HDV and to the use of lambda, lonafarnib and ritonavir to treat HDV, which will offer protection until 2039 and 2040, respectively, if issued.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Avexitide<span style="font-style:normal;">.</span><span style="font-weight:normal;font-style:normal;"> We have in-licensed from Stanford two PCT applications that claim the use of avexitide and other agents in the treatment of hypoglycemia associated with bariatric surgery, including in PBH. The USPTO issued US 10,639,354 and US 10,660,937 which will provide protection until May 2036. The applications are filed in the United States, the European Patent Office (EPO), Australia, Brazil, Canada, and Chile. Any patents that issue from these applications will expire in 2036 without extension and up to five years of patent term extension will be available in the United States. Additionally, avexitide has been granted Orphan Drug designation in this indication by the FDA and the EMA, which provides seven years and ten years of regulatory exclusivity in the United States and Europe, respectively. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We filed a PCT application for formulations of avexitide and the use of these formulations in the treatment of hypoglycemia associated with bariatric surgery. This application is still pending and the USPTO has issued a Notice of Allowance and we expect the patent to issue in the first half of 2021. Any patents that issue from this application will expire in 2037. We have also filed an additional PCT related to method of treating PBH and CHI, that if issued would provide protection until 2039.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have in-licensed patents and patent applications from the <span style="color:#000000;">Trustees of the University of Pennsylvania (UPenn) and CHOP</span>, relating to hyperinsulemic hypoglycemia. The in-licensed patents and applications relate to <span style="color:#000000;">multiple hyperinsulinemic disorders, including </span>PBH and CHI. The patents, which are issued in the US and Europe, and provide protection until 2028. There are continuation applications pending from which we are pursuing additional claim coverage.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Proprietary Rights and Processes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on trade secret protection for some of our confidential and proprietary information. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business, scientific, development or financial affairs that are either developed or made known to the individual during the course of the individual&#8217;s relationship with us are to be kept confidential and not disclosed to third parties except in specific circumstances. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets and disclose our technology. If these events happen, we may not be able to meaningfully protect our trade secrets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or based on the employee&#8217;s use of our confidential information are our exclusive property or that we have an exclusive royalty free license to use such technology.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical industry is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Given the significant unmet medical need for novel therapies to treat chronic hepatitis delta infection, post-bariatric surgery-induced hypoglycemia associated with bariatric surgery, and congenital hyperinsulinism, these conditions are where various treatments from many companies are used and where many public and private universities and research organizations are actively engaged in the discovery, research and development of product candidates. As a result, there are and will likely continue to be extensive resources invested in the discovery and development of new products to treat these unmet medical needs. We anticipate facing intense and increasing competition as new products enter the market and advanced technologies become available.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there are numerous multinational pharmaceutical companies and large biotechnology companies currently marketing or pursuing the development of products or product candidates targeting the same indications as our product candidates. Many of our competitors, either alone or with strategic partners, have or will have substantially greater financial, technical and human resources than us. Accordingly, our competitors may be more successful than us in developing or marketing products and technologies that are more effective, safer or less costly. Additionally, our competitors may obtain regulatory approval for their products more rapidly and may achieve more widespread market acceptance. Accelerated mergers and acquisitions activity in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study sites and patient registration for clinical studies and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our potential competitors and the related stage of development of their product candidates in target indications is as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HDV: Myr (being acquired by Gilead), conditional approval in Europe, Phase 3 ongoing&#59; Replicor, Inc. (Phase 2)&#59; Janssen Research &#38; Development, LLC (Phase 2)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Progeria and Progeroid Laminopathies: none</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">PBH: Xeris Pharmaceuticals (Phase 2)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">CHI: Zealand Pharmaceuticals (Phase 3)&#59; Xeris Pharmaceuticals (Phase 2)&#59; Rezolute, Inc (Phase 2)</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are other therapies that are used or may be used for our targeted indications, and these other products in clinical development or marketed for other indications may be used in competition with our product candidates if we are able to identify potential market opportunities of interest. For example, HDV has not been generally identified as a target for development compared to hepatitis B or hepatitis C, and products on the market or in development for those indications may potentially be tested in HDV as the understanding of the potential medical need for therapies in this indication become more widely understood.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety and tolerability profile, convenience in dosing, product labeling, cost-effectiveness, price, the level of generic competition and the availability of reimbursement from the government and other third-parties. Our commercial opportunity could be reduced or eliminated for any of our products if our competitors have products that are approved earlier than our product candidates or are superior compared to our product candidates or if our product candidates do not result in an improvement in condition compared to those other products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License and Asset Purchase Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreement with Merck</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2010, we entered into an exclusive license agreement with Schering Corporation, subsequently acquired by Merck, which provides us with the exclusive right to develop and commercialize lonafarnib. As consideration for such exclusive right, we issued Private Eiger convertible preferred stock with a fair value of $0.5 million when the agreement was executed in September 2010. <span style="color:#000000;">This preferred stock was converted to 27,350 shares of common stock upon the Merger. </span>In addition, we are obligated to pay Merck up to an aggregate of $27.0 million in development milestones and will be required to pay tiered royalties based on aggregate annual net sales of all licensed products ranging from mid-single to low double-digit royalties on net sales. Our obligation to pay royalties to Merck expires on a country-by-country and product-by-product basis on the later of the expiration of the last to expire patent assigned to us under the agreement on the tenth anniversary of the first commercial sale of the product. In May 2015, the first regulatory milestone was achieved, and we paid the related milestone payment of $1.0 million to Merck. No additional milestone payments were incurred during the year ended December 31, 2020.<span style="color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merck License will continue for so long as we owe royalty payments to Merck under the agreement. Each party has the right to terminate the Merck License Agreement for the other party&#8217;s uncured material breach or bankruptcy. Merck also has the right to terminate the agreement if we discontinue development and commercialization of LNF for a specified period of time. In addition, we have the right to terminate the agreement, with notice, for any reason.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 15, 2018, we entered into an amendment to the exclusive license agreement with Merck, which provides for expansion of the existing exclusively licensed field of use under the license agreement with Merck to include all uses of lonafarnib related to the treatment of Hutchinson-Gilford Progeria Syndrome in humans at no cost to us. We have the sole responsibility and the continuing obligation for the manufacture and supply of lonafarnib to The Progeria Research Foundation. Merck will not receive milestone payments in relation to lonafarnib for the treatment of progeria and progeroid laminopathies or any royalty payments for sales of lonafarnib to treat the currently estimated progeria and progeroid laminopathies patient population worldwide.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> On November 3, 2020, we entered into an amendment to the exclusive license agreement with Merck which expanded the definition of progeria to also include progeroid laminopathies.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Asset Purchase Agreement with AbbVie Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 20, 2020, we entered into an asset purchase agreement (the AbbVie Agreement) with AbbVie Inc. (AbbVie) to sell our Rare Pediatric Disease Priority Review Voucher, which was awarded the PRV on November 20, 2020 upon approval by the FDA of our new drug application for Zokinvy<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> in Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies (the PRV) to AbbVie. The AbbVie Agreement contains customary representations, warranties, covenants, and indemnification provisions subject to certain limitations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the PRV, AbbVie agreed to pay us $95.0 million. The transaction closed in January 2021. Such consideration was shared equally with The Progeria Research Foundation in accordance with the terms of our Collaboration and Supply Agreement, dated May 15, 2018, with The Progeria Research Foundation, pursuant to which we and The Progeria Research Foundation will equally share any proceeds from the sale of a priority review voucher that the Company may receive as the sponsor of a rare pediatric disease product application. We retained approximately $47.4 million of the proceeds from the sale of the PRF.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Asset Purchase Agreement with Eiger Group International, Inc.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2010, we entered into an Asset Purchase Agreement with Eiger Group International, Inc. (EGI) dated December&#160;8, 2010 (the EGI APA). Dr.&#160;Jeffrey Glenn is the sole owner of EGI.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the EGI APA, we purchased all the assets including intellectual property rights related to the use of farnesyl transferase inhibitors as anti-viral agents and methods to treat viral infection with those inhibitors. We also purchased all assets including intellectual property rights related to the use of inhibitors of prenylation, prenyl cysteine methyltransferase, and a specified protease as anti-viral agents and methods to treat viral infection with those inhibitors. We are obligated to use commercially reasonable efforts to develop and commercialize the licensed products in major markets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the EGI APA, we paid EGI an upfront payment of $0.4 million. Additionally, we are obligated to pay EGI a low single-digit royalty based on aggregate annual net sales of products developed using the intellectual property. Within the first ten years after commercialization, we may make a one-time payment of $0.5 million for each contract for the three types of product related to such intellectual property that would reduce the payment term for the three products to the tenth anniversary of the first commercial sale. The obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either when the product is no longer sold in any country or the earliest of the tenth anniversary of the first commercial sale of the product.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the EGI APA extends until expiration of all payment obligations, and we may terminate the agreement upon notice to EGI. EGI may terminate the EGI APA if we fail to use commercially reasonable efforts to develop and commercialize licensed products. In addition, each party may terminate the EGI APA for the other party&#8217;s uncured material breach or bankruptcy. In the event of any termination, other than termination by us for EGI&#8217;s breach, we will assign the purchased assets back to EGI.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2012, we entered into an agreement with EGI whereby we sold all of the assets related to the compound clemizole, including any related intellectual property. EGI is obligated to pay to us a high single-digit royalty on future aggregate annual net sales, subject to certain reductions and exceptions. EGI&#8217;s obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either expiration of the last to expire patent sold to EGI under the agreement or the earliest of the tenth anniversary of the first commercial sale of the product. As of December 31, 2020, the product has not achieved regulatory approval.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Asset Purchase Agreement with Tracey McLaughlin and Colleen Craig</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into an Asset Purchase Agreement with two individuals, Dr. Tracey McLaughlin and Dr. Colleen Craig (the Sellers) dated September&#160;25, 2015 (Exendin APA). We also entered into a consulting agreement with the Sellers as part of the agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Exendin APA, we purchased all the assets and the intellectual property rights related to the compound avexitide from the Sellers, including an assignment of a license agreement with Stanford which covered exclusive rights with respect to the compound avexitide. Under the assigned Stanford exclusive license agreement, we are obligated to pay Stanford a low, single-digit royalty on net sales after the first commercial sale of any product developed based on avexitide.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Exendin APA, we are obligated to pay development milestone payments in aggregate up to $1.0 million to each of the Sellers and a low, single-digit royalty based on aggregate annual net sales of all products developed based on avexitide subject to certain reductions and exceptions. Our obligation to pay royalties expires on the expiration of the last to expire patent assigned to us under the agreement. We also agreed to retain each of the Sellers as consultants pursuant to consulting agreements, each with a term of one year, subject to annual renewal. The consulting agreements related to the APA have expired. During the year ended December 31, 2017, upon the successful completion of the Phase 2 trials, the development milestone was achieved, and we paid the related milestone payment of $0.1 million to each of the Sellers.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreement with Bristol-Myers Squibb Company</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, we entered into a License Agreement and <span style="color:#000000;">a Common Stock Purchase Agreement </span>with Bristol-Myers Squibb Company<span style="color:#000000;">, together BMS, the BMS Purchase Agreement </span>and the BMS License Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BMS License Agreement, BMS granted us an exclusive, worldwide, license to research, develop, manufacture, and sell products containing the proprietary BMS molecule known as PEG-interferon Lambda-1a (the&#160;Licensed Product) for all therapeutic and diagnostic uses in humans and animals. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are responsible for the development and commercialization of the Licensed Product at our sole cost and expense. In April 2016, under the BMS License Agreement we paid an upfront payment of $2.0 million in cash and issued <span style="color:#000000;">157,587 shares of our common stock</span> <span style="color:#000000;">to BMS with an aggregate fair value of $3.2 million</span>. <span style="color:#000000;">The BMS Purchase Agreement grants BMS certain registration rights with respect to the shares of common stock delivered, and BMS has agreed to certain trading and other restrictions with respect to the shares purchased.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BMS License Agreement, we are obligated to make development and regulatory milestone payments totaling $61.0 million and commercial sales milestones of up to $128.0 million after the achievement of specified milestones. We are also obligated to pay BMS annual net sales royalties in the range of mid-single to mid-teens, depending on net sales levels. If we grant a sublicense, we are obligated to pay BMS a portion of the sublicensing income received. As of December 31, 2020, the product has not reached commercialization and no milestones have been paid. In the fourth quarter of 2020, we recorded a $3.0 million milestone expense that was triggered on successful demonstration of proof of concept in a Phase 2 clinical trial based on data presented from the Phase 2 LIFT trial. The next expected milestone is $5.0 million triggered on the initiation of a Phase 3 clinical trial.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreement with the Trustees of the UPenn and CHOP</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into a license agreement (the UPenn/CHOP Agreement) with the Trustees of the UPenn and the CHOP, under which we obtained an exclusive, royalty-bearing, worldwide license to develop, manufacture and sell certain GLP-1 receptor antagonist(s) products to treat all human and animal conditions. We also obtained an exclusive, royalty-bearing, sublicenseable, worldwide license to certain data developed by CHOP. <span style="Background-color:#FFFFFF;color:#000000;">We are responsible for the development and commercialization of the licensed products at our sole cost and expense.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the consideration for the rights granted to us under the UPenn/CHOP Agreement, we paid UPenn a one-time, non-refundable issue fee of $1.0 million, which is recorded in research and development expenses for the year ended December 31, 2019. In addition, we are obligated to pay UPenn a specified annual license maintenance fee, up to $2.5 million in certain regulatory milestones, and up to $18.0 million in commercial milestones. We will also </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be required to pay UPenn a flat royalty in the low-single digits on our net sales of all licensed products, subject to specified reductions and offsets, and specified minimum annual royalty payments. Our obligation to pay royalties expires on a product-by-product and country-by-country basis, on the later of: (i) the expiration of the last valid claim in the licensed patents in any country, or (ii) the tenth anniversary of the first commercial sale of the product in such country. No milestones have been achieved as of December 31, 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may terminate the UPenn/CHOP Agreement in its entirety for any reason by providing prior written notice to UPenn and CHOP. UPenn or CHOP may terminate the UPenn/CHOP Agreement, upon a written notice, for our failure to achieve the specified diligence milestones within the specified periods, subject to our extension rights.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Government Regulations and Product Approvals</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FDA Approval Process</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our current product candidates are subject to regulation in the United States by the FDA under the Federal Food, Drug, and Cosmetic Act (FDC Act) and its implementing regulations. Our lambda product candidate is additionally subject to regulation as a biologic under the Public Health Service Act. The FDA subjects drugs and biologics to extensive pre and post market regulation. Failure to comply with the FDC Act and other federal and state statutes and regulations may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal penalties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA approval is required before any new biologic, drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. The process required by the FDA before a new drug may be marketed in the United States is long, expensive, and inherently uncertain. Drug development in the United States typically involves completion of preclinical laboratory and animal tests, submission to the FDA of an IND application, which must become effective before clinical testing may commence, approval by an independent institutional review board (IRB) at each clinical site before each trial may be initiated, performance of adequate and well controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought, submission to the FDA of an NDA or BLA, satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced, and FDA review and approval of the NDA or BLA. Developing the data to satisfy FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product, disease or indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical tests include laboratory evaluation of the product&#8217;s chemistry, formulation, and toxicity, as well as animal studies to characterize and assess the potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practice (GLP) regulations. These preclinical results are submitted to the FDA as part of an IND along with other information, including information about the product&#8217;s chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term preclinical studies including reproductive toxicity and carcinogenicity may be initiated or continue after the IND is submitted.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An IND must become effective before United States clinical trials may begin. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the IND automatically becomes effective and the clinical trial proposed in the IND may begin. If the FDA raises any concerns or questions and places the clinical trial on a clinical hold, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, a submission of an IND may not result in FDA authorization to commence a clinical trial. A </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">separate submission to an existing IND must also be made for each successive clinical trial conducted during product development.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations, including good clinical practice (GCP) requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials&#59; and (ii)&#160;with protocols that detail, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to and approved by an IRB at each study site before the study commences at that site and the IRB must monitor the clinical trial until it is completed. An IRB may also require the clinical trial at that site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or if the drug candidate has been associated with unexpected serious harm to patients, or the IRB may impose other conditions. The study sponsor or the FDA may also suspend or discontinue a clinical trial at any time on various grounds, including a determination that the subjects are being exposed to an unacceptable health risk.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials to support an NDA or BLA for marketing approval are typically conducted in three sequential phases, although there is leeway to overlap or combine these phases.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Phase 1</span><span style="color:#000000;">. The drug candidate is initially introduced into healthy human subjects or patients with the target disease or condition, and is tested to assess safety, dosage tolerance, pharmacokinetics and pharmacological activity, and, when possible, to ascertain evidence of efficacy. The drug candidate may also be tested in patients with severe or life-threatening diseases to gain an early indication of its effectiveness.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Phase 2</span><span style="color:#000000;">. The trials are conducted using a limited patient population for the purposes of preliminarily determining the effectiveness of the drug in that particular indication, ascertaining dosage tolerance, discerning the optimal dosage, and identifying possible adverse effects and safety risks.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Phase 3</span><span style="color:#000000;">. If a compound demonstrates evidence of efficacy and has an acceptable safety profile in the Phase 2 clinical trials, then Phase 3 clinical trials are undertaken to obtain additional information from an expanded and diverse patient population, at multiple, geographically dispersed clinical trial sites, in randomized controlled studies often with a double-blind design to maximize the reproducibility of the study results. Typically, a minimum of two positive Phase 3 clinical trials are submitted to support the product&#8217;s marketing application. These Phase 3 clinical trials are intended to provide sufficient data demonstrating evidence of the efficacy and safety of the drug such that the FDA can evaluate the overall benefit-risk of the drug and provide adequate information for the labeling and package insert for the drug. Trials conducted outside of the United States under similar, GCP-compliant conditions in accordance with local applicable laws may also be acceptable to FDA in support of product approval.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsors of clinical trials for investigational drugs must publicly disclose certain clinical trial information, including detailed trial design. These requirements are subject to specific timelines and apply to most Phase 3 clinical trials of FDA-regulated products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, FDA may condition approval of an NDA or BLA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical trials after approval. In other cases, a sponsor may voluntarily conduct additional clinical trials post approval to gain more information about the drug. Such post approval trials are typically referred to as Phase 4 clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">access to certain data from the study. Phase 1, Phase 2, Phase 3 and Phase 4 clinical trials may not be completed successfully within any specified period, or at all.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually finalize a process for manufacturing the drug in commercial quantities in accordance with current good manufacturing practice (cGMP) requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After completion of the required clinical testing, an NDA or BLA is prepared and submitted to the FDA requesting approval to market the drug or biologic for one or more specified indications. FDA review and approval of the NDA or BLA is required before marketing of the product may begin in the United States. The NDA or BLA must include the results of all preclinical, clinical, and other testing, including negative or ambiguous results as well as positive findings, together with other detailed information including compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The application must also contain extensive manufacturing information. The FDA reviews an NDA or BLA to determine, among other things, whether a product is safe and effective for its intended use. The cost of preparing and submitting an NDA or BLA is substantial. Under federal law, the submission of most NDAs and BLAs is subject to both a substantial application user fee and annual program user fees. These fees are typically increased annually.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has 60 days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information. Once the submission is accepted for filing, the FDA begins an in-depth review.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act (PDUFA), guidelines that are currently in effect, the FDA has agreed to certain performance goals in the review of applications. Standard applications are generally reviewed within ten months of filing, or twelve months from submission. Although FDA often meets its user fee performance goals, the FDA can extend these timelines if necessary, and FDA review may not occur on a timely basis. The FDA usually refers applications for novel drugs, or drugs that present difficult questions of safety or efficacy, to an advisory committee&#8212;a panel of independent experts, typically including clinicians and other scientific experts&#8212;for review, evaluation, and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of the advisory committee, but it generally follows its recommendations. Before approving an NDA or BLA, the FDA will typically inspect one, or more, clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the product is manufactured. The FDA will not approve an application unless it verifies that compliance with cGMP requirements is satisfactory and that the manufacturing processes and facilities are adequate to assure consistent production of the product within required specifications. The FDA will not approve a product unless the application contains data showing substantial evidence that it is safe and effective in the indication studied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA evaluates the application and conducts its inspections, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies contained in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application, including potentially significant, expensive and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. Even if such data are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive, and the FDA may interpret data differently than we do. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the application, the FDA will typically issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of additional information requested. FDA approval is never guaranteed. The FDA may refuse to approve an application if applicable regulatory criteria are not satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. The approval for a drug may be significantly more limited than requested in the application, including limitations on the specific diseases and dosages or the indications for use, which could restrict the commercial value of the product. The FDA may also require that certain contraindications, warnings, or precautions be included in the product&#8217;s package insert, or labeling.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a condition of approval, the FDA may require a risk evaluation and mitigation strategy (REMS) to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guidelines, communication plans for healthcare professionals, and elements to assure safe use (ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, including dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS or use of a companion diagnostic with a drug can materially affect the potential market and profitability of the drug. Moreover, product approval may require, as a condition of approval, substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. The FDA may also condition approval on, among other things, changes to proposed labeling or development of adequate controls and specifications.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once granted, product approvals may be withdrawn if compliance with regulatory standards are not maintained or problems are identified following initial marketing. In addition, after approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. There also are continuing, annual program user fees for any marketed products, as well as new application fees for supplemental applications with clinical data.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">505(b)(2) NDA Pathway</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As an alternative path to FDA approval, an applicant may submit an NDA under Section 505(b)(2) of the Food, Drug and Cosmetic Act. A Section 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness, but where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This type of application permits reliance for such approvals on literature or on an FDA finding of safety, effectiveness or both for an approved drug product.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Orphan Drugs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant an Orphan Drug designation to products intended to treat a rare disease or condition&#8212;generally one that affects fewer than 200,000 individuals in the United States. Orphan Drug designation must be requested before submitting the NDA or BLA. After the FDA grants orphan drug designation, the FDA publicly discloses the drug&#8217;s identity and its intended orphan use. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first active moiety to be approved to treat a disease with FDA&#8217;s Orphan Drug designation is entitled to a seven-year period of marketing exclusivity in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same orphan indication, regardless of patent status, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or if the FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different chemical/biological entity for the same disease or condition. An orphan drug designation also does not preclude the same drug from being developed for a different disease or condition. Among the other benefits of Orphan Drug designation are tax credits for certain research expenses and a waiver of the application user fee.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Rare Pediatric Disease (RPD) designation by FDA enables priority review voucher (PRV) eligibility upon U.S. market approval of a designated drug for rare pediatric diseases. The RPD-PRV program is intended to encourage development of therapies to prevent and treat rare pediatric diseases. The voucher, which is awarded upon NDA or BLA approval to the sponsor of a designated RPD can be sold or transferred to another entity and used by the </span>holder to receive priority review for a future NDA or BLA submission, which reduces the FDA review time of such future submission from ten to six months.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA offers several expedited development and review programs for qualifying product candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once an NDA or BLA is submitted, the product may be eligible for priority review. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fast track</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers. PRIME designation by the EMA confers comparable benefits on qualifying drug product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation, Breakthrough Therapy designation, priority review, accelerated approval and RMAT designation do not change the standards for approval but may expedite the development or approval process. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Advertising and Promotion</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing post-approval regulatory requirements. For instance, the FDA closely regulates the post-approval marketing, labeling, advertising and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Failure to comply with these requirements can result in adverse publicity as well as significant penalties, including the issuance of warning letters directing a company to correct any deviations from the FDA&#8217;s standards. The FDA may also impose a requirement that future advertising and promotional materials be pre-cleared by the FDA, and the company may face federal and/or state civil and criminal investigations and prosecutions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new application or supplement before the change can be implemented. A supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing supplements as it does in reviewing NDAs or BLAs. Obtaining new indication is an important part of managing the life cycle of the drug.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Adverse Event Reporting and cGMP Compliance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recordkeeping, adverse event reporting and the submission of periodic reports are required following the FDA&#8217;s approval of an NDA or BLA. The FDA also may require post-marketing testing or Phase 4 clinical trials, REMS, or surveillance to monitor the effects of an approved drug. In addition, the FDA may place conditions on an approval that could restrict the distribution or use of the product. Furthermore, manufacture, packaging, labeling, storage and distribution procedures must continue to conform to cGMPs after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies to assess compliance with ongoing regulatory requirements, including cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMPs. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, require us to recall a drug from distribution or withdraw approval of the NDA for that drug. Regulatory authorities may also withdraw product approvals, request product recalls, or impose marketing restrictions through labeling changes or product removals upon discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Healthcare Laws and Compliance Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA. These other agencies include, without limitation, the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, as well as state and local governments. Such agencies enforce a variety of laws, including without limitation, anti-kickback and false claims laws, data privacy and security laws, and physician payment transparency laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to or approval by the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes any request or demand for money or property presented to the U.S. government. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-reimbursable, uses. In addition, the civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to data privacy and information security laws and regulations, including both foreign and domestic, in the locations in which we conduct our business. HIPAA and its respective implementing regulations imposes specific requirements relating to the privacy, security and transmission of individually identifiable health information and requires the adoption of administrative, physical and technical safeguards to protect such information. In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Physician Payments Sunshine Act imposes, among other things, annual reporting requirements for covered manufacturers for certain payments and &#8220;transfers of value&#8221; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Covered manufacturers must submit reports by the 90th day of each calendar year. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists, and certified nurse-midwives.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many states have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating compliance efforts. For example, states have anti-kickback and false claims laws that may be broader in scope than analogous federal laws and may apply regardless of payer. In addition, state data privacy laws that protect the security of health information may differ from each other and may not be preempted by federal law. In addition, certain states require implementation of commercial compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. Moreover, several states and local jurisdictions require the registration of sales representatives. These laws may adversely affect our sales, marketing and other activities with respect to any product candidate for which we receive approval to market in the United States by imposing administrative and compliance burdens on us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to it, we may be subject to penalties, including potentially significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">International Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales, and distribution of drugs. Whether or not we obtain FDA approval for a drug, we or our collaborators must obtain approval of the drug by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing of the drug in those countries. The approval process varies from country to country and the time to approve may be longer or shorter than that required for FDA approval. Further, to the extent that any of our products are sold in a foreign country, we may be subject to additional foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a marketing authorization application (MAA) either under the so-called centralized or national authorization procedures. The centralized procedure provides for the grant of a single marketing authorization by the European Commission following a favorable opinion by the EMA that is valid in all EU member states, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disorders or autoimmune diseases, other immune dysfunctions and viral diseases. The centralized procedure is optional for other products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health or which contain a new active substance for indications other than those specified to be compulsory.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EMA grants orphan drug designation to promote the development of products for the treatment, prevention or diagnosis of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 people in the EU. In addition, orphan drug designation can be granted if the drug is intended for a life threatening or chronically debilitating condition in the EU and without incentives it is unlikely that sales of the drug in the EU would be sufficient to justify the investment required to develop the drug. Orphan drug designation is only available if there is no other satisfactory method approved in the EU of diagnosing, preventing or treating the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients. Orphan drug designation provides opportunities for free or reduced-fee protocol assistance, fee reductions for marketing authorization applications and other post-authorization activities and ten years of market exclusivity following drug approval, which can be extended to 12 years if trials are conducted in accordance with an agreed-upon pediatric investigational plan. The exclusivity period may be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign data protection laws, including, without limitation, the European Union&#8217;s General Data Protection Regulation (GDPR) and European Union (EU) member state data protection legislation, also apply to health-related and other personal information that we process, including, without limitation, personal information relating to clinical trial participants in the EU. The GDPR imposes significant obligations on controllers and processors of personal information, including, among other things, to implement administrative, physical, technical, and organizational safeguards to protect personal information, establish an appropriate legal basis for processing personal information, comply with transparency requirements regarding the processing of personal information, honor requests from data subjects regarding their personal information, provide data breach notifications, obtain explicit consent for collection of sensitive personal information such as health data, and comply with rules and restrictions on the transfer of personal data outside of the EU including to the U.S. The GDPR also requires businesses subject to the GDPR to make contractual privacy, data protection, and data security commitments. The GDPR allows EU member states to make additional laws and regulations further limiting the processing of personal information, including genetic, biometric and health data. Failure to comply with the GDPR and related EU member state laws, where applicable, can result in the imposition of significant regulatory fines and penalties.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pharmaceutical Coverage, Pricing and Reimbursement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend in part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process for determining whether a third-party payor will provide coverage for a drug product typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover Zokinvy or any of our product candidates once approved could reduce physician utilization of such products and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service or will provide </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that 50% to 70% of patients eligible for treatment with Zokinvy will be covered by government insurance such as Medicaid, and the remaining patients will be covered by commercial insurance. We have had active engagement with payers that cover the lives of identified patients with Progeria and processing-deficient progeroid laminopathies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. Additionally, coverage policies and third&#8209;party reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more of our products, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that third-party payors will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare Reform</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (the ACA) was passed, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. There remain judicial and Congressional challenges to numerous provisions of the ACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA.&#160;While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing this case, although it is unclear when a decision will be made. It is also unclear how such litigation will impact the ACA and our business.&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products For example, the Trump administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out-of-pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers. In addition, the Trump administration&#8217;s budget proposal for fiscal year 2<span style="Background-color:#FFFFFF;">021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs</span>. On July&#160;24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to drug pricing that seeks to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from Canada. Further, on November 20, 2020, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the U.S. Department of Health and Human Services, or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HHS</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the EU and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. For example, in the United States, there have been several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.&#160;Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses were $41.6 million, $51.8 million and $37.1 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had a total of 28 full-time employees in the United States, 13 of whom were primarily engaged in manufacturing and research and development activities, and 15 of whom were engaged in general management and administration. Six of our employees have either an M.D. or a Ph.D. None of our employees are represented by a labor union or subject to a collective bargaining agreement. We have never experienced any work stoppage and consider our relations with our employees to be good.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were originally incorporated in California in December 2000 as Celladon Corporation (Celladon). In April 2012, Celladon reincorporated in Delaware and had its initial public offering in February of 2014.<span style="Background-color:#FFFFFF;color:#000000;"> </span>On March 22, 2016, Eiger BioPharmaceuticals, Inc. (Private Eiger) completed its merger (Merger) with Celladon in accordance with the terms of the Merger Agreement. Pursuant to the Merger Agreement, Celladon Merger Sub, Inc., a wholly-owned subsidiary of Celladon (Merger Sub) merged with and into Private Eiger, with Private Eiger becoming a wholly-owned subsidiary of Celladon and the surviving corporation of the Merger. Immediately following the Merger, Celladon changed its name to Eiger BioPharmaceuticals, Inc. In connection with the Merger, our common stock began trading on The Nasdaq Global Market with the ticker symbol EIGR on March 23, 2016. Our principal executive offices are located at 2155 Park Blvd in Palo Alto, California 94306, and our telephone number is 650-272-6138. Our corporate website address is www.eigerbio.com. The contents of our website are not incorporated into this Annual Report on Form 10-K and our reference to the URL for our website is intended to be an inactive textual reference only.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form&#160;10-K, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item&#160;1A. Risk Factors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should carefully consider the following risk factors, as well as the other information in this report, and in our other public filings. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factor Summary</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face.&#160;&#160;Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report.&#160;&#160;The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report as part of your evaluation of an investment in our common stock. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are a clinical development-stage biopharmaceutical company with a limited operating history. We have incurred net losses in each year since our inception. We have no drug candidates approved for commercial sale, we have never generated any revenue from product sales and we may never be profitable.&#160;&#160; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are dependent on the success of our product candidates, which are in various stages of clinical development. We cannot give any assurance that we will generate data for any of our product candidates sufficient to receive regulatory approval and without regulatory approval we will not be able to market our product candidates. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Prior to the recent approval of our new drug application (NDA) for lonafarnib for the treatment of Progeria and Progeroid Laminopathies, we had not submitted an application for approval or obtained U.S. Food and Drug Administration (FDA) approval for any product. We may not be able to obtain FDA approval of our NDA or any future NDA for our product candidates, which would impede commercialization.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our business strategy is based upon obtaining and maintaining Orphan Drug designation for our product candidates. If we are unable to obtain Orphan Drug designation or regulatory approval, our business would be substantially harmed. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We rely on clinical studies of our product candidates in order to obtain regulatory approval. We may find it difficult to enroll patients in our clinical studies given the limited number of patients who have the diseases for which our product candidates are being studied.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If clinical studies of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We rely on third parties to conduct our clinical studies, manufacture our product candidates and perform other services. Our ability to obtain regulatory approval or commercialize our product candidates and our business could be impaired if these collaborations are unsuccessful.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced or more effective than ours.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">We currently have limited marketing and sales capabilities for the commercialization of our product candidates.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Sales of our products depend substantially on the extent to which the costs of our product candidates will be paid for or reimbursed by healthcare management organizations or government authorities or third-party payors.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are currently conducting and will continue to conduct clinical trials for our product candidates outside the United States, which could expose us to risks that could have a material adverse effect on our business. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We intend to rely on a combination of exclusivity from Orphan Drug designation and our patent rights for our product candidates. If we are unable to maintain exclusivity from the combination of these approaches, then our ability to compete effectively in our markets may be harmed. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we are unable to maintain effective proprietary rights for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical to ours.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may be unsuccessful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses. If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may not be successful in any efforts to identify, license, discover, develop or commercialize additional product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Healthcare</span> legislative reform measures may have a material adverse effect on our business and results of operations. <span style="color:#000000;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The current COVID-19 pandemic has and may continue to adversely affect our financial condition and our business as well as those of third parties on which we rely on significant manufacturing, clinical or other business operations.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Financial Condition, Integration and Capital Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred losses since our inception, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical development-stage biopharmaceutical company with a limited operating history. We have incurred net losses in each year since our inception. For the years ended December 31, 2020, 2019 and 2018, we reported a net loss of $65.1 million, $70.3 million, and $52.4 million, respectively. As of December 31, 2020, we had an accumulated deficit of $306.5 million. Our prior losses, combined with expected future losses, have had and may continue to have an adverse effect on our stockholders&#8217; equity and working capital.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our currently available resources will be sufficient to fund our planned operations for at least the next 12 months following the issuance date of these audited consolidated financial statements. We will continue to require substantial additional capital to continue our clinical development, manufacturing and regulatory approval efforts and potential commercialization activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations. The amounts and timing of our future funding requirements will depend on many factors, including our ability to achieve regulatory approval and the pace and results of our clinical development efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, including manufacturing of clinical supplies, conducting clinical studies and providing general and administrative </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">support for our operations. To date, we have financed our operations primarily through the sale of equity securities and debt facilities. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect losses to increase as regulatory reviews of our MAA of lonafarnib in Progeria and Progeroid Laminopathies progress towards potential approvals and as we advance our clinical development programs in various clinical studies, particularly the D-LIVR pivotal study to support the submission of an NDA for lonafarnib for use in a hepatitis D virus indication. We may need significant additional resources in order to aggressively move lonafarnib forward successfully based on the discussions with the FDA. It may be several years, if ever, before we complete pivotal clinical studies and have a product candidate approved for commercialization. We expect to invest significant funds into our clinical candidates to advance these compounds to potential regulatory approval.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, because the potential markets in which our product candidates may ultimately receive regulatory approval could be very small, we may never become profitable despite obtaining such market share and acceptance of our products. We have also agreed with The Progeria Research Foundation to make lonafarnib available to Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies patients under an Expanded Access Program that may not result in payment to us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continue the clinical development of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in-license or acquire additional product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">undertake the manufacturing or have manufactured our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">advance our programs into larger, more expensive clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">initiate additional nonclinical, clinical, or other studies for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">identify and develop potential commercial opportunities, such as lonafarnib boosted with ritonavir, lonafarnib for the treatment of Progeria and Progeroid Laminopathies, lambda for HDV, and avexitide for PBH and CHI&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek regulatory and marketing approvals and reimbursement for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval and market ourselves&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek to identify, assess, acquire, and/or develop other product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">make milestone, royalty or other payments under third-party license agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop and educate HDV markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek to maintain, protect, and expand our intellectual property portfolio&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek to attract and retain skilled personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">experience any delays or encounter issues with the development and potential for regulatory approval of our clinical candidates such as safety issues, clinical trial accrual delays, longer follow-up for planned studies, additional major studies, or supportive studies necessary to support marketing approval.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a representative indication of our future performance. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have never generated any revenue from product sales and may never be profitable.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no products approved for commercialization and have never generated any revenue. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, one or more of our product candidates. We do not anticipate generating significant revenue from product sales for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">completing research and development of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining regulatory and marketing approvals for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that meet regulatory requirements and our supply needs in sufficient quantities to meet market demand for our product candidates, if approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">marketing, launching and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">gaining market acceptance of our product candidates as treatment options&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">addressing any competing products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">protecting and enforcing our intellectual property rights, including patents, trade secrets, and know-how&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">negotiating favorable terms in and maintaining any collaboration, licensing, or other arrangements into which we may enter&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining reimbursement or pricing for our product candidates that supports profitability&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">attracting, hiring, and retaining qualified personnel.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our current pipeline of product candidates has been in-licensed from third parties and we will have to develop or acquire manufacturing capabilities in order to continue development and potential commercialization of our product candidates. Additionally, if we are not able to generate revenue from the sale of any approved products, we may never become profitable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity, debt or other securities convertible into equity, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder such as the Loan and Security Agreement we entered into with Oxford Finance LLC (Oxford Finance) in December 2016 (the Oxford Loan). The Oxford Loan was a $25.0 million debt financing arrangement with Oxford Finance wherein we borrowed the first tranche of $15.0 million upon closing of the debt financing in December 2016. In May 2018, we entered into an amendment to the Oxford Loan and borrowed $5.0 million. In August 2018, we drew the final $5.0 million upon achievement of certain clinical milestones. In March 2019, we entered into the third amendment to the Oxford Loan to refinance our outstanding principal balance of $23.3 million. Upon refinancing, the Oxford Loan was increased to $35.0 million in aggregate commitments, of which $30.0 million in principal is outstanding. The Oxford Loan is secured by perfected first priority liens on our assets, excluding intellectual property but including a commitment by us to&#160;not allow any liens to be placed upon&#160;such intellectual property. The Oxford Loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the United States and worldwide resulting from the ongoing COVID-19 pandemic. We cannot assure you that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially affect our business, financial condition, and results of operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Covenants in the Oxford Loan restrict our business and operations in many ways and if we do not effectively comply with our covenants, our financial conditions and results of operations could be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Oxford Loan provides for up to $35.0 million in term loans due on March 1, 2024, of which $30.0 million in principal is outstanding. All of our current and future assets, except for intellectual property, secure our borrowings under the Oxford Loan. The Oxford Loan requires that we comply with certain covenants applicable to us, including among other things, covenants restricting dispositions, changes in business, management, ownership or business locations, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt, any of which could restrict our business and operations, particularly our ability to respond to changes in our business or to take specified actions to take advantage of certain business opportunities that may be presented to us. Our failure to comply with any of the covenants could result in a default under the Oxford Loan, which could permit the lenders to declare all or part of any outstanding borrowings to be immediately due and payable. If we are unable to repay those amounts, the lenders under the Oxford Loan could proceed against the collateral granted to them to secure that debt, and our inability to use or dispose of those assets would seriously harm our business. In addition, should we be unable to comply with these covenants or if we default on any portion of our outstanding borrowings, the lenders can also impose a 5.0% penalty, restrict access to additional borrowings under the loan and security agreement, and accelerate the maturity of the debt. Any default under the Oxford Loan would materially affect our liquidity and ability to fund our operations and complete our planned clinical trials and regulatory filings would be substantially impaired.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;" id="T17">If the London Inter-Bank Offered Rate, or&#160;LIBOR, is discontinued, interest payments under the Oxford Loan may be calculated using another reference rate.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="T18">In July 2017, the Chief Executive of the United Kingdom Financial Conduct Authority (FCA), which regulates&#160;LIBOR, announced that the FCA intends to phase out the use of&#160;LIBOR&#160;by the end of 2021. In addition, the U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, is considering replacing U.S. dollar&#160;LIBOR&#160;with the Secured Overnight Financing Rate, or SOFR, a new index calculated by short-term repurchase agreements, backed by Treasury securities. Although there have been certain issuances utilizing SOFR, it is unknown whether this or any other alternative reference rate will attain market acceptance as a replacement for&#160;LIBOR.&#160;LIBOR&#160;is used as a benchmark rate throughout the Oxford Loan, and our credit agreement does not provide fallback language for all circumstances in which&#160;LIBOR&#160;ceases to be published. There remains uncertainty regarding the future utilization of&#160;LIBOR&#160;and the nature of any replacement rate, and any potential effects of the transition away from&#160;LIBOR&#160;on us are not known. The transition process may involve, among other things, increased volatility and illiquidity in markets for instruments that currently rely on&#160;LIBOR&#160;and may result in increased borrowing costs, the effectiveness of related transactions such as hedges, uncertainty under applicable documentation, including the Oxford Loan, or difficult and costly processes to amend such documentation. As a result, our ability to refinance our credit agreement or other indebtedness or to hedge our exposure to floating rate instruments may be impaired, which would adversely affect the operations of our business.&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development of our Product Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are dependent on the success of our product candidates, which are in various stages of clinical development. Certain of our product candidates have produced results in academic settings to date or for other indications than those that we contemplate, and we cannot give any assurance that we will generate data for any of our product candidates sufficient to receive regulatory approval in our planned indications, which will be required before they can be commercialized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have invested substantially all of our efforts and financial resources to identify, acquire, and develop our portfolio of product candidates. Our future success is dependent on our ability to successfully further develop, obtain regulatory approval for, and commercialize one or more of these product candidates. Our NDA for lonafarnib for treatment of Progeria and Progeroid Laminopathies was approved on November 20, 2020. Our MAA is currently under standard review with the EMA as well. Through December 31, 2020, we have not generated revenue from sales of any drugs and we may never be able to develop or commercialize additional product candidates. In addition, we have a commitment to provide access to Zokinvy for patients with Progeria and processing-deficient progeroid laminopathies for no or minimal cost to those patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to potential commercial products, we currently have one product candidate that is in Phase 3 clinical development and two development programs focused on two separate indications that have we believe have completed Phase 2 and are advancing towards Phase 3. It may be years before our studies are initiated and completed, if at all. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We provide our geographically diverse clinical sites with good clinical practice protocols. We review and monitor the execution of our protocols at our various sites in an effort to understand those protocols are being followed. There can be no assurance that the data we develop for our product candidates in our planned indications will be sufficient or complete enough to obtain regulatory approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We cannot be certain that any of our product candidates will be successful in clinical studies or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical studies. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to obtain FDA approval of any future NDA for our product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing and distribution and other possible activities relating to lonafarnib, lambda, avexitide and any other product candidate that we may develop in the future are subject to extensive regulation in the United States. Prior to the recent approval of our NDA for lonafarnib for the treatment of Progeria and Progeroid Laminopathies, we had not submitted an application for approval or obtained FDA approval for any product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval of an NDA is not guaranteed, and the approval process is an expensive and uncertain process that may take several years. The FDA and foreign regulatory entities also have substantial discretion in the approval process. The number and types of preclinical studies and clinical trials that will be required for approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to target and the regulations applicable to any particular product candidate. Data are subject to varying interpretation and the FDA may not agree that our clinical data support that any of our product candidates are safe and effective for the proposed therapeutic use. Despite the time and expense associated with preclinical studies and clinical trials, failure can occur at any stage, and we could encounter problems that require us to repeat or perform additional preclinical studies or clinical trials or generate additional chemistry, manufacturing and controls data, including drug product stability data. <span style="color:#000000;">In previous studies, ECG abnormalities were observed in our lonafarnib program. We do not expect that this will impact the conduct of the D-LIVR HDV study. </span>The FDA and similar foreign authorities could delay, limit or deny approval of a product candidate, and may ultimately approve the product for narrower indications or with unfavorable labeling that would impede our commercialization of the drug. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval procedures vary among countries and can involve additional product testing and additional administrative review periods, including obtaining reimbursement and pricing approval in select markets. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks associated with FDA approval as well as additional, presently unanticipated, risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others, including the risk that our product candidates may not be approved for all indications requested and that such approval may be subject to limitations on the indicated uses for which the product may be marketed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business strategy is based upon obtaining and maintaining Orphan Drug designation for our product candidates, which is an uncertain process. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are unable to obtain Orphan Drug designation or regulatory approval for our product candidates, our business would be substantially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our approach to identifying and developing product candidates depends, in large part, on our ability to obtain and maintain Orphan Drug designation from regulatory authorities in major markets. Without the potential protection of this regulatory exclusivity upon approval, many of our product candidates would otherwise not justify investment. While we assess the potential for obtaining Orphan Drug designation at the time that we contemplate the acquisition of product candidates and we intend to timely file for such designation, there can be no assurance that we will obtain Orphan Drug designation or be able to successfully meet the regulatory requirements to maintain that designation with the planned clinical trials for our product candidates. Failure to obtain and maintain Orphan Drug designation would make our product candidates significantly less competitive and potentially not viable investments for further development. Although we currently have Orphan Drug designation for some of our product candidates in multiple targeted indications, failure to demonstrate significant benefit over existing approved drugs in pivotal clinical trials may lead to marketing approval but without qualifying for Orphan Drug protection in some regions, such as in Europe.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with the design, size or implementation of our clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from our development efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the data collected from clinical studies of our product candidates may not be sufficient or complete or meet the regulatory requirements to support the submission of a new drug application (NDA) or other submission or to obtain regulatory approval in the United States or foreign jurisdictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities may find failures in our manufacturing processes, validation procedures and specifications, or facilities of our third-party manufacturers with which we contract for clinical and commercial supplies that may delay or limit our ability to obtain regulatory approval for our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our NDA or other submission insufficient for approval.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lengthy and uncertain regulatory approval process, as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market any of our product candidates or to be significantly delayed from our expectations for potential approval, which would significantly harm our business, results of operations, and prospects.</span><span style="color:#000000;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, although we have obtained Orphan Drug designation for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">five </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development programs </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to date, there can be no assurance that the FDA will grant our similar status for our other proposed development indications or other product candidates in the future.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Although the FDA has granted Rare Pediatric Disease&#160;designation to avexitide for the treatment of congenital hyperinsulinism, NDA approval for this program may not meet the eligibility criteria for a priority review voucher.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our avexitide compound has received Rare Pediatric Disease (RPD) designation from the FDA for the treatment of Congenital Hyperinsulinism (CHI). The FDA defines a &#8220;rare pediatric disease&#8221; as a disease that affects fewer than 200,000 individuals in the United States primarily under the age of 18 years. <span style="color:#000000;">Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval. In addition, the priority review voucher is only awarded to an NCE, thus if a compound is approved first for an indication that is not a rare pediatric disease the compound may not be eligible to receive the voucher. While we obtained and sold the Priority Review Voucher issued upon approval of ZOVINKY, there can be no assurance that we will be successful in obtaining approval for avexitide for the treatment of CHI, or that a Priority Review Voucher will be issued at the time of any such approval.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Congress has only authorized the Rare Pediatric Disease Priority Review Voucher program until September 30, 2024. However, if a drug candidate receives Rare Pediatric Disease designation before September 30, 2024, it is eligible to receive a voucher if it is approved before September 30, 2026.<span style="color:#000000;"> </span>Avexitide may not be approved by that date, or at all, and, therefore, we may not be in a position to obtain a priority review voucher prior to expiration of the program, unless Congress further reauthorizes the program.<span style="color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance we will receive a Rare Pediatric Disease Priority Review Voucher. Also, although Priority Review Vouchers may be sold or transferred to third parties, there is no guarantee that we will be able to realize any value if we were to sell a Priority Review Voucher.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Although we have received Breakthrough Therapy designations, this may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood of receiving marketing approval in the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received Breakthrough Therapy designation for lonafarnib and lambda for the treatment of HDV, and for avexitide for the treatment of post-bariatric hypoglycemia. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. The Breakthrough Therapy designations we have obtained may not result in faster development processes, reviews or approvals compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, the FDA may later decide that any of our development programs no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results of larger, later-stage controlled clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer significant setbacks in subsequent clinical studies. Our clinical studies to date have been conducted on a small number of patients in limited numbers of clinical sites and in academic settings or for other indications. We will have to conduct larger, well-controlled studies in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical studies. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase 2, Phase 3, or other clinical studies we have conducted or may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to obtain regulatory approval to receive regulatory approval or market our drug candidates. For example, in 2018 we announced negative results from two of our Phase 2 clinical trials of ubenimex in two different indications and as a result we have terminated further development of ubenimex.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may find it difficult to enroll patients in our clinical studies given the limited number of patients who have the diseases for which our product candidates are being studied. Difficulty in enrolling patients could delay or prevent clinical studies of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying and qualifying patients to participate in clinical studies of our product candidates is essential to our success. The timing of our clinical studies depends in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience delays in our clinical studies if we encounter difficulties in enrollment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The eligibility criteria of our planned clinical studies may further limit the available eligible study participants as we expect to require that patients have specific characteristics that we can measure or meet the criteria to assure their conditions are appropriate for inclusion in our clinical studies. We may not be able to identify, recruit, and enroll a sufficient number of patients to complete our clinical studies in a timely manner because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical studies, and the willingness of physicians to participate in our planned clinical studies. Additionally, we may experience delays in patient enrollment for our clinical trials as a result of the evolving COVID-19 global pandemic and competition for patients at our European clinical trial sites due to the recent conditional approval of Hepcludex in Europe. For example, certain clinical study sites that were scheduled to open have been delayed in activating and other sites have suspended randomization of subjects and if this continues longer than anticipated, the D-LIVR trial may be delayed further than anticipated. If patients are unwilling to participate in our clinical studies for any reason, the timeline for conducting studies and obtaining regulatory approval of our product candidates may be delayed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in the completion of, or termination of, any clinical study of our product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical studies would likely increase our overall costs, impair product candidate development and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may harm our business, financial condition, and prospects significantly.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical studies are costly, time consuming and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical development is expensive, time consuming and involves significant risk. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of development. Events that may prevent successful or timely completion of clinical development include but are not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">inability to generate satisfactory preclinical, toxicology, or other in vivo or in vitro data or diagnostics to support the initiation or continuation of clinical studies necessary for product approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in reaching agreement on acceptable terms with contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in obtaining required Institutional Review Board (IRB) approval at each clinical study site&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to permit the conduct of a study by regulatory authorities, after review of an investigational new drug (IND) or equivalent foreign application or amendment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in recruiting qualified patients, or patients dropping out of, in our clinical studies, including as a result of the evolving COVID-19 global pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure by clinical sites or our CROs or other third parties to adhere to clinical study requirements or report complete findings&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to perform the clinical studies in accordance with the FDA&#8217;s GCP requirements, or applicable foreign regulatory guidelines&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">occurrence of adverse events associated with our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of clinical studies of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">negative or inconclusive results from our clinical trials which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon development programs in other ongoing or planned indications for a product candidate&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in reaching agreement on acceptable terms with third-party manufacturers and the time for manufacture of sufficient quantities of our product candidates for use in clinical studies.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inability to successfully complete clinical development and obtain regulatory approval could result in additional costs to us or impair our ability to generate revenue. Clinical study delays could also shorten any periods during which our products have patent protection and may allow competitors to develop and bring products to market before we do, which could impair our ability to obtain Orphan Drug designation exclusivity and to successfully commercialize our product candidates and may harm our business and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lonafarnib product candidate has been studied in thousands of oncology patients and the most common non-hematologic adverse events of any grade were gastrointestinal system disorders (nausea, anorexia, diarrhea and vomiting), weight loss, fatigue and rash. <span style="color:#000000;">Our lonafarnib product candidate for HGPS and PL has been reported to cause ECG abnormalities, but these ECG abnormalities have not resulted in a risk of mortality for these patients. There is no guarantee that additional or more severe side effects or other properties will not be identified through ongoing clinical studies by other uses of lonafarnib for other indications or our own clinical trials. Our lambda product candidate is well-characterized and has been studied in thousands of HBV and HCV patients and the most common adverse events seen are moderate headache, pyrexia, fatigue, and myalgia. ALT flares that were seen result from vigorous antiviral immunological response to treatment, not due to direct hepatotoxicity. </span>There is no guarantee </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that additional or more severe side effects will not be identified through ongoing clinical studies for other uses of lambda. Undesirable side effects, other properties, and negative results for other indications may negatively impact the development and potential for approval of our product candidates for our proposed indications. For example, the </span><span style="color:#000000;">ECG abnormalities seen with lonafarnib in HGPS and PL patients has the potential to impact the labeling for lonafarnib boosted with ritonavir for HDV. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">avexitide</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product candidate has been studied in 54 PBH patients and 39 CHI patients and the most common adverse events are injection site bruising, nausea, and headache. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no guarantee that additional or more severe side effects will not be identified through ongoing clinical studies for other uses of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">avexitide</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in clinical trials.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, even if one or more of our product candidates receives marketing approval, and we or others later may identify undesirable side effects caused by such products, potentially significant negative consequences could result, including but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may withdraw approvals of such products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may require additional warnings on the label&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to create a Risk Evaluation and Mitigation Strategy (REMS) plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we could be sued and held liable for harm caused to patients&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our reputation may suffer.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our product candidates are approved, they will be subject to ongoing regulatory requirements with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy and other post-approval information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers and manufacturers&#8217; facilities are required to continuously comply with FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices (cGMP) regulations and corresponding foreign regulatory manufacturing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA or MAA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report certain adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was obtained through an accelerated approval pathway, we could be required to conduct a successful post-marketing clinical study to confirm the clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing, or labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issue warning letters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">impose civil or criminal penalties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspend or withdraw regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspend any of our ongoing clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refuse to approve pending applications or supplements to approved applications submitted by us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require a product recall.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, prescription drugs may be promoted only for the approved indications in accordance with the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law would be expected to require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products and the value of us and our operating results would be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to conduct our clinical studies, manufacture our product candidates and perform other services. If these third parties do not successfully perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates and our business could be substantially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have relied upon and plan to continue to rely upon investigators and third-party CROs to conduct, monitor and manage our ongoing clinical programs. We rely on these parties for execution of clinical studies and manage and control only certain aspects of their activities. We remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We, our investigators, and our CROs and other vendors are required to comply all applicable laws, regulations and guidelines, including those required by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of our investigators, CROs or vendors fail to comply with applicable laws, regulations and guidelines, the results generated in our clinical studies may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional studies before approving our marketing applications. We cannot assure you that our CROs and other vendors will meet these requirements, or that upon inspection by any regulatory authority, such regulatory authority will determine that efforts, including any of our clinical studies, comply with applicable requirements. Our failure to comply with these laws, regulations and guidelines may require us to repeat clinical studies or conduct larger additional studies, which would be costly and delay the regulatory approval process.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our relationships with investigators or third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs in a timely manner or do so on commercially reasonable terms. In addition, our CROs may not prioritize our clinical studies relative to those of other customers and any turnover in personnel or delays in the allocation of CRO employees by the CRO may negatively affect our clinical studies. If investigators or CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, our clinical studies may be delayed or terminated, and we may not be able to meet our current plans with respect to our product </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates. CROs may also involve higher costs than anticipated, which could negatively affect our financial condition and operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we do not currently have, nor do we plan to establish, the capability to manufacture product candidates for use in the conduct of our clinical studies or in support of our commercialization of potential products, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale without the use of third-party manufacturers. We plan to rely on third-party manufacturers and their responsibilities will include purchasing from third-party suppliers the materials necessary to produce our product candidates for our clinical studies and regulatory approval. There are expected to be a limited number of suppliers for the active ingredients and other materials that we expect to use to manufacture our product candidates, and we may not be able to identify alternative suppliers to prevent a possible disruption of the manufacture of our product candidates for our clinical studies, and, if approved, ultimately for commercial sale. Although we generally do not expect to begin a clinical study unless we believe we have a sufficient supply of a product candidate to complete the study, any significant delay or discontinuity in the supply of a product candidate, or the active ingredient or other material components in the manufacture of the product candidate, could delay completion of our clinical studies and potential timing for regulatory approval of our product candidates, which would harm our business and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our lonafarnib program, we procured an inventory of product from Merck to supply our initial clinical study needs. In 2016, we transferred the manufacturing of drug substance and drug product to our third-party contractors. The material used for lonafarnib HDV pivotal trials, ongoing Progeria clinical studies and expanded access program, and commercial Zokinvy supply are sourced from Eiger-controlled CMOs. These same vendors are currently under development for commercial qualification. Materials used for our avexitide clinical trials are also sourced from CMOs. Our vendors have successfully made GMP batches for our clinical studies. If these CMOs are not able to provide us with sufficient quantities of drug substance and drug product for our clinical trials or in support of our commercialization of potential products on a timely basis, or at all, whether due to production shortages or other supply interruptions resulting from the ongoing COVID-19 pandemic or otherwise, our clinical trials or regulatory approval may be delayed, <span style="Background-color:#FFFFFF;color:#000000;">or could impair our ability to generate revenue from the sale of such product candidate</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, and if those third parties fail to obtain approval of government regulators, fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices our product candidates could be stopped, delayed, or made less profitable.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have nor do we plan to acquire the infrastructure or capability internally to manufacture our clinical supplies for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on outside vendors to source raw materials and manufacture our clinical supplies of our product candidates and plan to continue relying on third parties to manufacture our product candidates on a commercial scale, if approved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facilities used by our contract manufacturers to manufacture our product candidates will be subject to pre-approval inspection by the FDA that will be conducted after we submit our marketing applications to the FDA or comparable foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as cGMPs, for manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, our NDA and MAA for lonafarnib and future applications may not be approved by regulatory authorities, which would significantly delay our commercialization plans and increase our costs. We have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our product candidates, and the actual cost to manufacture our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our reliance on third-party manufacturers exposes us to the following additional risks:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may be unable to identify manufacturers on acceptable terms or at all&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our third-party manufacturers could breach or terminate their agreement with us.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of these risks could delay our clinical trials, the approval of any of our product candidates by the FDA or comparable foreign regulatory authorities or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we rely on third parties to perform release testing on our product candidates prior to delivery to patients. If these tests are not conducted appropriately and test data is not reliable, patients could be put at risk of serious harm and could result in product liability suits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing of medical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in production, particularly in scaling up and validating initial production and absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our product candidates to patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations and, even assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We focus our product development principally on treatments for rare and ultra-rare diseases. Given the small number of patients who have the diseases that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our product candidate. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. For example, for lonafarnib and lambda, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HDV is associated with hepatitis B virus infection, which is a pre-requisite for the replication of HDV. Although we believe that the data are supportive of antiviral activity against HDV, there can be no assurance that our clinical trials will successfully address this condition. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Moreover, if lonafarnib receives regulatory approval for use in Progeria and Progeroid Laminopathies, we expect that the sales of lonafarnib to patients with Progeria and Progeroid Laminopathies will have limited profits.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We are currently aware of various existing therapies that may compete with our product candidates. For example, we have competitors both in the United States and internationally, including multinational pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies. Some of the pharmaceutical and biotechnology companies we expect to compete with include Gilead Sciences, Merck, Roche, Holding AG, Actelion Pharmaceuticals US, Inc., Johnson &#38; Johnson, Replicor, Inc., Myr, Arrowhead Pharmaceuticals, Novartis International AG, Zealand Pharmaceuticals, Xeris Pharmaceuticals, and Rezolute, Inc. as well as other smaller companies or biotechnology startups and large multinational pharmaceutical companies. Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently have limited marketing and sales experience. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although certain of our employees may have marketed, launched and sold other pharmaceutical products in the past while employed at other companies, we have no recent experience selling and marketing our product candidates and we currently have no marketing or sales organization. To successfully commercialize any products that may result from our development programs, we will need to invest in and develop these capabilities, either on our own or with others, which would be expensive, difficult and time consuming. Any failure or delay in the timely development of our internal commercialization capabilities could adversely impact the potential for success of our products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, given our lack of prior experience in marketing and selling biopharmaceutical products, we may rely on future collaborators to commercialize our products. If collaborators do not commit sufficient resources to commercialize our future products and we are unable to develop the necessary marketing and sales capabilities on our own, we will be unable to generate sufficient product revenue to sustain or grow our business. We may be competing with companies that currently have extensive and well-funded marketing and sales operations, in particular in the markets our product candidates are intended to address. Without appropriate capabilities, whether directly or through third-party collaborators, we may be unable to compete successfully against these more established companies. In addition, we have established an expanded access program in order to make lonafarnib available for patients with Progeria and Progeroid Laminopathies, which requires additional resources and costs to support.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even with the approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products will depend in part on the health care providers, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and other health care providers. The degree of market acceptance of any of our products will depend on a number of factors, including without limitation:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the efficacy of the product as demonstrated in clinical studies and potential advantages over competing treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prevalence and severity of the disease and any side effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the clinical indications for which approval is granted, including any limitations or warnings contained in a product&#8217;s approved labeling&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the convenience and ease of administration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of treatment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the willingness of the patients and physicians to accept these therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the marketing, sales and distribution support for the product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the publicity concerning our products or competing products and treatments&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the pricing and availability of third-party insurance coverage and reimbursement.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product displays a favorable efficacy and safety profile upon approval, market acceptance of the product remains uncertain. Efforts to educate the medical community and third-party payors on the benefits of the products may require significant investment and resources and may never be successful. If our products fail to achieve an adequate level of acceptance by physicians, patients, third-party payors, and other health care providers, we will not be able to generate sufficient revenue to become or remain profitable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure to obtain or maintain adequate reimbursement or insurance coverage for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pricing, coverage and reimbursement of our products must be sufficient to support our commercial efforts and other development programs and the availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford expensive treatments, particularly in Orphan Drug designated indications where the eligible patient population is small. Sales of our products will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid for or reimbursed by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or government authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide products for free or we may not be able to successfully commercialize our products. For example, lonafarnib for patients with Progeria and Progeroid Laminopathies provided under an Expanded Access Program may not result in reimbursement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &#38; Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as ours and what reimbursement codes our products may receive.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process for determining whether a third-party payor will provide coverage for a drug product typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover Zokinvy or any of our product candidates once approved could reduce physician utilization of such products and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. Additionally, coverage policies and third&#8209;party reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more of our products, less favorable coverage policies and reimbursement rates may be implemented in the future. If we are unable to obtain and maintain sufficient third&#8209;party coverage and adequate reimbursement, the commercial success of our products may be greatly hindered and our financial condition and results of operations may be materially and adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of products are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the potential revenue may be insufficient to generate commercially reasonable revenue and profits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with products due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, has and is expected to continue to increase in the future. As a result, profitability of our products may be more difficult to achieve even if they receive regulatory approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We intend to rely on a combination of exclusivity from Orphan Drug designation as well as patent rights for our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity from the combination of these approaches, we may not be able to compete effectively in our markets.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business strategy is to focus on product candidates for which Orphan Drug designation may be obtained in the major markets of the world. In addition, we rely or will rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. For example, the portfolio of patents licensed from Merck expires before the anticipated launch date of lonafarnib. Our success depends in large part on our and our licensors&#8217; ability to obtain regulatory exclusivity and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may designate a product as an Orphan Drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union (the EU), the EMA&#8217;s Committee for Orphan Medicinal Products (COMP) grants Orphan Drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, Orphan Drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has Orphan Drug designation, the product is entitled to Orphan Drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. In the EU, Orphan Drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the Orphan Drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the extent and scope of patent protection for our products may in some cases be limited, Orphan Drug designation is especially important for our products for which Orphan Drug designation may be available. For eligible drugs, we plan to rely on the exclusivity period under the Orphan Drug Act to maintain a competitive position. If we do not obtain Orphan Drug exclusivity for our drug products and biologic products that do not have broad patent protection, our competitors may then sell the same drug to treat the same condition sooner than if we had obtained Orphan Drug exclusivity and our revenue will be reduced.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even though we have Orphan Drug designations for each of our development programs in the United States and Europe, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain Orphan Drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an Orphan Drug is approved, the FDA or EMA can subsequently approve the same drug with the same active moiety for the same condition if the FDA or EMA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan Drug designation neither shortens the development time or regulatory review time of a product candidate nor gives the product candidate any advantage in the regulatory review or approval process.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The patent applications that we own or in-licensed may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, independently or together with our licensors, have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have licensed a number of patents covering methods of use and certain compositions of matter, we do not have complete patent protection for our product candidates. For example, the patent coverage for the lonafarnib composition of matter expires before the anticipated launch date. Likewise, most of the patents or applications covering products that we have licensed in from Stanford have limited protection outside of the United States. Therefore, a competitor could develop the same or similar product that may compete with our product candidate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our product licenses are limited to specified indications or therapeutic areas which may result in the same compound being developed and commercialized by a third party whom we have no control over or rights against. This may result in safety data, pricing or off label uses from that third party&#8217;s product that may negatively affect the development and commercialization of our product candidates. If we cannot obtain and maintain effective protection of exclusivity from our regulatory efforts and intellectual property rights, including patent protection, for our product candidates, we may not be able to compete effectively, and our business and results of operations would be harmed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not have sufficient patent term protections for our products to effectively protect our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20 years after it is filed. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. In addition, upon issuance in the United States any patent term can be adjusted based on certain delays caused by the applicant(s) or the United States Patent and Trademark Office (USPTO). For example, a patent term can be reduced based on certain delays caused by the patent applicant during patent prosecution.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data exclusivity terms of products. With respect to lonafarnib, lambda and avexitide, a substantial portion of the potential commercial opportunity will likely rely on patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our products for an extended period after regulatory approval, which would negatively impact our business and results of operations. If we do not have sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent laws and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that it or our licensors were the first to make the invention claimed in our owned and licensed patents or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, in the United States prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act (the Leahy-Smith Act) enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. The effects of these changes are currently unclear as the USPTO must still implement various regulations, the courts have yet to address any of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. In </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we are using or exploiting their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. Even if we conduct freedom to operate analyses, we would expect to do so only with respect to certain of our product candidates as they move through development. Accordingly, there may be third-party patents that would impair our ability to commercialize product candidates and we cannot assure you that we could obtain a license, or even if available, whether such license might be obtained on commercially reasonable terms. Even in those situations where we conduct a freedom to operate analysis, there can be no assurance that we would identify all relevant or necessary patents and patent applications that may apply to the manufacture and commercialization of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe, and if patents issue with respect to any such application and we become aware of such issuance, we would have to determine its impact on our efforts to develop and commercialize our product candidates and the strategy for obtaining a license or contesting any such issued patent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, the manufacturing process of any of our product candidates, methods of use, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Such a license may not be available on commercially reasonable terms, or at all.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to obtain a license, then parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in meeting our diligence obligations under our existing license agreements necessary to maintain our product candidate licenses in effect. In addition, if required in order to commercialize our product candidates, we may be unsuccessful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have rights to the intellectual property, through licenses from third parties and under patents that we do not own, to develop and commercialize our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to maintain in effect these proprietary rights. For example, we have certain specified diligence obligations under our Stanford license agreement for lonafarnib. We may not be able to achieve the required diligence milestones in a timely manner, which may result in Stanford&#8217;s right to terminate the license agreement, and we may be unable to successfully negotiate an extension or waiver of those termination rights. Any termination of license agreements with third parties with respect to our product candidates would be expected to negatively impact our business prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to license or acquire third-party intellectual property rights that are necessary for our product candidates, there can be no assurance that they will be available on favorable terms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We collaborate with U.S. and foreign academic institutions to identify product candidates, accelerate our research and conduct development. Typically, these institutions have provided us with an option to negotiate an exclusive license to any of the institution&#8217;s rights in the patents or other intellectual property resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue a program of interest to us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to successfully obtain and maintain rights to required third-party intellectual property, we may have to abandon development of that product candidate or pay additional amounts to the third party, and our business and financial condition could suffer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may be subject to generic competition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application (ANDA) seeking approval of a generic copy of an approved innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA under section 505(b)(2) that references the FDA&#8217;s finding of safety and effectiveness of a previously approved drug. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. Innovative small molecule drugs may be eligible for certain periods of regulatory exclusivity (e.g., five years for new chemical entities, three years for changes to an approved drug requiring a new clinical study, seven years for Orphan Drugs), which preclude FDA approval (or in some circumstances, FDA filing </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and review of) an ANDA or 505(b)(2) NDA relying on the FDA&#8217;s finding of safety and effectiveness for the innovative drug. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the &#8220;Orange Book.&#8221; If there are patents listed in the Orange Book, a generic applicant that seeks to market its product before expiration of the patents must include in the ANDA or 505(b)(2) what is known as a &#8220;Paragraph IV certification,&#8221; challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the innovator, too, and if within 45 days of receiving notice the innovator sues to protect its patents, approval of the ANDA is stayed for 30 months, or as lengthened or shortened by the court.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If there are patents listed for our products in the Orange Book after approval by FDA, ANDAs and 505(b)(2) NDAs with respect to those products would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict whether any patents issuing from our pending patent applications will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be successful in securing or maintaining proprietary patent protection in the United States and/or in other countries for products and technologies we develop or license. Moreover, if any patents that are granted and listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could more immediately face generic competition and its sales would likely decline materially. Should sales decline, we may have to write off a portion or all of the intangible assets associated with the affected product and our results of operations and cash flows could be materially and adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The patent protection and patent prosecution for some of our product candidates is dependent on third parties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we normally seek and gain the right to fully prosecute the patents relating to our product candidates, there may be times when patents relating to our product candidates are controlled by our licensors. This is the case with our agreements with Stanford and Nippon Kayaku, each of whom is primarily responsible for the prosecution of patents and patent applications licensed to us under the applicable collaboration agreements. If they or any of our future licensors fail to appropriately and broadly prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, importing, and selling competing products. In addition, even where we now have the right to control patent prosecution of patents and patent applications, we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors in effect from actions prior to us assuming control over patent prosecution.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to a number of intellectual property license and supply agreements that are important to our business and expects to enter into additional license agreements in the future. Our existing agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty, purchasing, supply and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, our agreements may be subject to termination by the licensor, in which event we would not be able to develop, manufacture or market products covered by the license or subject to supply commitments.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Although we are not currently involved in any intellectual property litigation, we may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents or the patents of our licensors. Although we are not currently involved in any intellectual property litigation, if we or one of our licensing partners were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements and make every effort to ensure that our employees, consultants and independent contractors do not use the proprietary information or intellectual property rights of others in their work forums, and we are not currently subject to any claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Business Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends in part on our ability to retain our President and Chief Executive Officer and to attract, retain, and motivate other qualified personnel.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on David Cory, our President and Chief Executive Officer, the loss of whose services may adversely impact the achievement of our objectives. Mr. Cory could leave our employment at any time, as he is an &#8220;at will&#8221; employee. Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of highly qualified personnel in our industry, which is likely to continue. As a result, competition for personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in development and commercialization of our product candidates may make it more challenging to recruit and retain qualified personnel. The inability to recruit and retain qualified personnel, or the loss of the services of Mr. Cory, may impede the progress of our research, development, and commercialization objectives and would negatively impact our ability to succeed in our in-licensing strategy.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 28 full-time employees. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, manufacturing, sales, marketing, financial, legal, and other resources. Our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions (which could include civil or criminal fines or penalties), private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use or adoption, and could otherwise negatively affect our operating results and business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulation of data processing is evolving as federal, state, and foreign governments continue to adopt new, or modify existing, laws and regulations addressing data privacy and security, and the collection, processing, storage, transfer, and use of data. We and our partners may be subject to current, new, or modified federal, state, and foreign data protection laws and regulations (e.g., laws and regulations that address data privacy and data security including, without limitation, health data). These new or proposed laws and regulations are subject to differing interpretations and may be inconsistent among jurisdictions, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data. These and other requirements could require us or our partners to incur additional costs to achieve compliance, limit our competitiveness, necessitate the acceptance of more onerous obligations in our contracts, restrict our ability to use, store, transfer, and process data, impact our or our partners&#8217; ability to process or use data in order to support the provision of our products or services, affect our or our partners&#8217; ability to offer our products and services in certain locations, or cause regulators to reject, limit or disrupt our clinical trial activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, we may receive unintended health information in error from third parties (including research institutions from which we may obtain clinical trial data) that are subject to privacy and security requirements under the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH). Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use, or disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign data protection laws, including, without limitation, the EU General Data Protection Regulation (GDPR) that took effect in May 2018, and member state data protection legislation, may also apply to health-related and other personal information obtained outside of the United States. These laws impose strict obligations on businesses, including requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators, limitations on data processing, establishing a legal basis for processing personal information, notification of data processing obligations, notification of security incidents to appropriate data protection authorities or data subjects, protecting the security and confidentiality of the personal information and establishing means for data subjects to exercise rights in relation to their personal information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR generally restricts the transfer of personal information from the European Economic Area (EEA) to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. Data protection laws in the United Kingdom and Switzerland impose similar restrictions. One of the primary safeguards allowing United States companies to import personal information from Europe has been certification to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks administered by the United States Department of Commerce. However, the Court of Justice of the EU recently invalidated the EU-U.S. Privacy Shield. The same decision also raised questions about whether one of the primary alternatives to the EU-U.S. Privacy Shield, namely, the European Commission&#8217;s Standard Contractual Clauses, can lawfully be used for personal information transfers from Europe to the United States or other countries. Similarly, the Swiss Federal Data Protection and Information Commissioner recently announced that the Swiss-U.S. Privacy Shield Framework is inadequate for personal information transfers from Switzerland to the United States, and also raised questions about the viability of the Standard Contractual Clauses. At present, there are few, if any, viable alternatives to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks and the Standard Contractual Clauses. Although we rely primarily on individuals&#8217; explicit consent to transfer their personal information from Europe to the United States and other countries, in certain cases we have relied or may rely on the Standard Contractual Clauses. Authorities in the United Kingdom, whose data protection laws are similar to those of the EU, may similarly invalidate use of the EU-U.S. Privacy Shield as a mechanism for lawful personal information transfers </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the United Kingdom</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to the United States</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other countries</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As such, if we are unable to rely on explicit consent to transfer individuals&#8217; personal information from Europe, which can be revoked, or implement another valid compliance solution, we will face increased exposure to substantial fines under European data protection laws as well as injunctions against processing personal information from Europe. Inability to import personal information from the European Economic Area, United Kingdom or Switzerland may also restrict our clinical trial activities in Europe&#59; limit our ability to collaborate with CROs, service providers, contractors and other companies subject to European data protection laws&#59; and require us to increase our data processing capabilities in Europe at significant expense. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. <span style="color:#000000;">For example, Brazil recently enacted the General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais or LGPD) (Law No. 13,709/2018), which broadly regulates the processing of personal information and imposes compliance obligations and penalties comparable to those of the GDPR.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the GDPR, regulators may impose substantial fines and penalties for non-compliance. Companies that violate the GDPR can face fines of up to the greater of 20 million Euros or 4% of their worldwide annual turnover (revenue) and restrictions or prohibitions on data processing. The GDPR has increased our responsibility and liability in relation to personal data that we process, requiring us to put in place additional mechanisms to ensure compliance with the GDPR and other EU and international data protection rules.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in June 2018, California enacted the California Consumer Privacy Act (CCPA), which went into effect on January 1, 2020. The CCPA gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that may increase data breach litigation. The CCPA will be expanded substantially on January 1, 2023, when the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;) becomes fully operative. The CPRA would, among other things, give consumers the ability to limit use of information deemed to be sensitive, increase the maximum penalties for violations concerning consumers under age 16, and establish the California Privacy Protection Agency to implement and enforce the new law and impose administrative fines. Aspects of the CCPA and CPRA, and their interpretation and enforcement, remain uncertain. The potential effects of the CCPA and CPRA are far-reaching and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. Although the CCPA includes exemptions for certain clinical trials data and HIPAA protected health information, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. The CCPA has prompted a number of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties, fines or sanctions), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations related to security or privacy, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Compliance with data protection laws may be time-consuming, require additional resources and could result in increased expenses, reduce overall demand for our products and services and make it more difficult to meet expectations of or commitments to customers or partners.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these matters could materially adversely affect our business, financial condition, or operational results.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Failure in our information technology and storage systems or our security measures, including without limitation, data breaches, or inadequacy of our business continuity and disaster recovery plans and procedures, could significantly disrupt the operation of our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to execute our business plan and maintain operations depends on the continued and uninterrupted performance of our information technology (IT) systems, and the availability of data related to our products, services and operations. IT systems and data are vulnerable to risks and damages from a variety of sources, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including catastrophe or natural disaster, telecommunications or network failures, malicious human acts, breaches of security, cyber-attacks, loss of power or other natural or man-made events. Moreover, despite network security and back-up measures, some of our and our vendors&#8217; servers are potentially vulnerable to physical or electronic break-ins, computer viruses</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, software vulnerabilities, ransomware attacks</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and similar disruptive problems. If our business continuity and disaster recovery plans and procedures were disrupted, inadequate or unsuccessful in the event of a problem, we could experience a material adverse interruption of our operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, data security breaches, whether inadvertent or intentional, by employees or others, may expose proprietary information, trade secrets, personal information, clinical trial data or other sensitive data to unauthorized persons, impact the integrity, availability or confidentiality of our IT systems or data (including, but not limited to, data loss), or disrupt or interrupt our IT systems or operations. Our partners and vendors face similar risks and any security breach of their systems could adversely affect our security posture. Malicious attacks by third parties are of ever-increasing sophistication and can be made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; nation states and others. Foreign, federal, and state laws or regulations allows for the imposition of civil liability, fines and/or corrective action on entities that improperly use or disclose the personal information of individuals, including through a data security breach. Accordingly, data security breaches experienced by us, our collaborators or contractors could lead to significant fines, required corrective action, loss of trade secrets or other intellectual property, or could lead to the public exposure of personally identifiable information (including sensitive personal information) of our employees, collaborators, clinical trial patients, and others. A data security breach or privacy violation that leads to disclosure or modification of or prevents access to personal information, including personally identifiable information, patient information or protected health information, could result in civil liability, harm our reputation, compel us to comply with federal and/or state breach notification laws, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. If we are unable to prevent data security breaches or privacy violations, respond appropriately or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer civil liability to our customers or individuals, loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive patient data. In addition, these breaches and other inappropriate access events can be difficult to detect, and any delay in identifying and responding to them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures designed to protect our data security and information technology systems, no set of security measures is infallible, and these measures may not prevent such events.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite precautionary measures to prevent anticipated and unanticipated problems, including data breaches, there can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems (or that of our third-party providers). Such events could affect our IT systems, sustained or repeated system failures that interrupt our ability to generate, use and maintain data or our IT systems could adversely affect our ability to operate our business and result in increased costs or loss of revenue, other financial and reputational harm to us, theft of trade secrets and other proprietary information, legal claims or proceedings, liability under laws that protect the privacy of personal information and regulatory penalties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we maintain. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be successful in any efforts to identify, license, discover, develop or commercialize additional product candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business is also expected to depend in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development and commercialization for a number of reasons, including but not limited to the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our product candidates may not succeed in preclinical or clinical testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">competitors may develop alternatives that render our product candidates obsolete or less attractive&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the market for a product candidate may change during our program so that such a product may become unreasonable to continue to develop&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (ACA) was passed, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. There remains judicial and Congressional challenges to numerous provisions of the ACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA.&#160;While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. <span style="color:#000000;">Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing this case, although it is unclear when a decision will be made. It is also </span>unclear how such litigation will impact the ACA and our business. <span style="color:#000000;">In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax.</span><span style="color:#FF0000;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">program reimbursement methodologies for products For example</span><span style="color:#000000;">, the Trump administration</span><span style="color:#000000;"> previously</span><span style="color:#000000;"> released a &#8220;Blueprint&#8221; to lower drug prices and reduce out-of-pocket costs of drugs that </span><span style="color:#000000;">contain</span><span style="color:#000000;">ed </span><span style="color:#000000;">proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Trump administration&#8217;s budget proposal for fiscal year 2</span><span style="Background-color:#FFFFFF;">021 includes a $135.0 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to drug pricing that seeks to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the U.S. Department of Health and Human Services, or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HHS</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span><span style="color:#000000;">Any repeal and replace legislation may have the effect of limiting the amounts that government agencies will pay for healthcare products and services. Policy changes, including potential modification or repeal of all or parts of the ACA or the implementation of new health care legislation, could result in significant changes to the health care system, which may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand or lower pricing for our product candidates, or additional pricing pressures.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the EU and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. For example, in the United States, there have been several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.&#160;Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject, directly or indirectly, to foreign, federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties, sanctions or other liability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations may be subject to various foreign, federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, physician sunshine laws, the GDPR and other regulations. These laws may impact, among other things, our research, sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by foreign, federal, and state governments in which we conduct our business. The laws that may affect our ability to operate include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HIPAA and its implementing regulations impose certain requirements on certain covered entity healthcare providers, health plans, and healthcare clearinghouse and their business associates that perform certain services involving the use or disclosure of individually identifiable health information as well as their covered subcontractors, relating to the privacy, security, and transmission of individually identifiable health information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists, and certified nurse-midwives&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payors, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#59; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures&#59; state and local laws requiring the registration of pharmaceutical sales representatives&#59; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the GDPR and other EU member state data protection legislation, which require data controllers and processors, to adopt administrative, physical and technical safeguards to protect personal data, including health-related data, including mandatory contractual terms with third-party providers, requirements for establishing an appropriate legal basis for processing personal data, transparency requirements related to communications with data subjects regarding the processing their personal data, standards for obtaining consent from individuals to process their personal data, notification requirements to individuals about the processing of their personal data, an individual data rights regime, mandatory data breach notifications, limitations on the retention of personal data, increased requirements pertaining to health data, as well as strict rules and restrictions on the transfer of personal data outside of the EU, including to the United States.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply, we may be subject to penalties, including significant civil, criminal and administrative penalties, damages, disgorgement, fines, sanctions, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The withdrawal of the United Kingdom from the EU, commonly referred to as &#8220;Brexit,&#8221; may adversely impact our ability to obtain regulatory approvals of our product candidates in the EU, result in restrictions or imposition of taxes and duties for importing our product candidates into the EU, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the EU.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 23, 2016, the U.K. held a referendum in which a majority of the eligible members of the electorate voted for the U.K. to leave the EU. The U.K&#8217;s withdrawal from the EU is commonly referred to as Brexit. The U.K. and the EU agreed to a withdrawal agreement (the <span style="font-weight:bold;font-style:italic;">Withdrawal Agreement</span>) pursuant to which the U.K. formally left the EU on January 31, 2020. Under the Withdrawal Agreement, the U.K. is subject to a transition period until December </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31, 2020 (the </span><span style="font-weight:bold;font-style:italic;">Transition Period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), during which EU rules will continue to apply. Due to the current COVID-19 global pandemic, negotiations between the U.K. and the EU scheduled for March are either being postponed or occurring in a reduced forum via video conference. There is, therefore, an increased likelihood that the Transition Period may need to be extended beyond December 31, 2020 (although it remains the position of the U.K. government that it will not be extended).</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since a significant proportion of the regulatory framework in the U.K. applicable to our business and our product candidates is derived from EU directives and regulations, Brexit, following the Transition Period, could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the U.K. or the EU. For example, as a result of the uncertainty surrounding Brexit, the European Medicines Agency (EMA) relocated to Amsterdam from London. Following the Transition Period, the U.K. will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA and, unless a specific agreement is entered into, a separate process for authorization of drug products, including our product candidates, will be required in the U.K., the potential process for which is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the U.K. or the EU and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the EU, or we may incur expenses in establishing a manufacturing facility in the EU in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the U.K. or the EU for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the U.K. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraudulent conduct or other illegal activity by our employees, independent contractors, principal investigators, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, promotion, sales, marketing and certain business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of patient recruitment or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and ethics applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our product candidates harm patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use or misuse of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">impairment of our business reputation&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">initiation of investigations by regulators&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of clinical trial participants&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs due to related litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">distraction of management&#8217;s attention from our primary business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substantial monetary awards to patients or other claimants&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to commercialize our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product recalls, withdrawals or labeling, marketing or promotional restrictions&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decreased demand for our product candidates, if approved for commercial sale.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our current product liability insurance coverage is appropriate in light of our clinical programs&#59; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to increase our insurance coverage to include the sale of commercial products&#59; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claims or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our licensors and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are currently conducting and will continue to conduct clinical trials in foreign countries, which could expose us to risks that could have a material adverse effect on the success of our business and the delivery of clinical trial data.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted in the past and are currently conducting clinical trials in the United States, Canada, Australia, Turkey, Germany, Pakistan, New Zealand, Mongolia, Spain, France, Bulgaria, Romania, Taiwan, Sweden, Italy, Belgium, Switzerland, United Kingdom, Greece, Moldova, Ukraine, Russia, and Israel, and accordingly, we are subject to risks associated with doing business globally, including commercial, political, and financial risks. Emerging regions, such as Eastern Europe, Latin America, Asia, and Africa, as well as more developed markets, such as the United Kingdom, France, Germany, and Australia, provide clinical study opportunities for us. In addition, we are subject to potential disruption caused by military conflicts&#59; potentially unstable governments or legal systems&#59; civil or political upheaval or unrest&#59; local labor policies and conditions&#59; possible expropriation, nationalization, or confiscation of assets&#59; problems with repatriation of foreign earnings&#59; economic or trade sanctions&#59; closure of markets to imports&#59; anti-American sentiment&#59; terrorism or other types of violence in or outside the United States&#59; health pandemics&#59; and a significant reduction in global travel. For example, both Turkey and Pakistan are key regions for clinical activity relating to Hepatitis Delta Virus, and further outbreaks of violence and political instability in the region could disrupt our clinical operations or otherwise limit our ability to access or conduct clinical studies in those regions. Certain countries have closed their borders due to COVID-19 preventing activation of clinical sites. Our success will depend, in part, on our ability to overcome the challenges we encounter with respect to these risks and other factors affecting U.S. companies with global operations. If our global clinical trials were to experience significant disruption due to these risks or for other reasons, it could have a material adverse effect on our financial results.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We or the third parties upon whom we depend may be adversely affected by earthquakes, natural epidemics or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Earthquakes, health epidemics or other natural disasters could severely disrupt our operations and have a material adverse effect on our business. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as the manufacturing facilities of our third-party CMOs, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. For example, in December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China. Since certain starting materials of certain of our products obtained from third-party chemical suppliers are manufactured in China and Japan, an outbreak of communicable diseases in the region, or the perception that such an outbreak could occur, and the measures taken by the governments of countries affected, could adversely affect our business, financial condition or results of operations by limiting our ability to manufacture product within or outside for example China, Japan, Italy, Canada, and the United States, forcing temporary closure of facilities that we rely upon or increasing the costs associated with obtaining starting materials and then clinical supplies of our product candidates. The extent to which the coronavirus impacts our results will depend on future developments, which are highly uncertain and cannot be accurately predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In addition, our corporate headquarters is located in the San Francisco Bay Area, which has in the past experienced severe earthquakes and other natural disasters and is currently experiencing an outbreak of COVID-19. We do not carry earthquake insurance. We have limited disaster recovery and business continuity plans in place currently and our business would be impaired in the event of a serious disaster or similar event. We may incur substantial expenses to develop and implement any disaster recovery and business continuity plans, which could have a material adverse effect on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business is currently adversely affected by and could be materially adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics including the evolving effects of the COVID-19 outbreak</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> We have a significant number of clinical trial sites in countries that have been directly affected by COVID-19</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">. We </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">depend </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">manufacturing operations</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">for various stages of our supply chain in countries that have been directly affected by COVID-19. COVID-19 continues to adversely affect our business and could materially and adversely affect our operations and those of our manufacturers and other third parties with whom we conduct business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business has been adversely affected by COVID-19 and could be materially and adversely impacted by COVID-19 or other health epidemics in regions where we have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting employees, patients, community and business operations, as well as the U.S. economy and financial markets. The effects of the shelter-in-place order and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, some of our suppliers of certain materials used in the production of our drug products are located in China, Japan, Canada, Italy and the United States. While many of these materials may be obtained by more than one supplier, including suppliers outside of China, Japan, Canada, Italy and the United States, port closures and other restrictions resulting from the coronavirus outbreak in the region may disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials have been and may continue to be affected by the COVID-19 pandemic. Site initiation and patient enrollment has been delayed, due to prioritization of hospital resources toward the COVID-19 pandemic, travel restrictions imposed by governments, and the inability to access sites for initiation and monitoring. In our D-LIVR trial, the COVID-19 pandemic has delayed enrollment in our global clinical trial, some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, we may be unable to obtain blood samples for testing, and we may not be able to provide study drug to patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, as a result of the COVID-19 pandemic, the extent and length of which is uncertain, we may be required to develop and implement additional clinical study policies and procedures designed to help protect study participants from the COVID-19 virus, which may include using telemedicine visits, remote monitoring of patients and clinical sites, and measures to ensure that data from clinical studies that may be disrupted as result of the pandemic are collected pursuant to the study protocol and consistent with good clinical practices (GCPs), with any material protocol deviation reviewed and approved by the site Institutional Review Board (IRB). Missed scheduled patient appointments, any interruption in study drug supply, or other consequences that may result in incomplete data being generated during a study as a result of the pandemic must be adequately documented and justified. For example, on March 18, 2020, the FDA issued guidance on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical study report (or as a separate document) contingency measures implemented to manage the study, any disruption of the study as a result of the COVID-19 pandemic&#59; a list of all study participants by unique subject identifier and by investigational site that were affected by the COVID-19 pandemic, and a description of how the individual&#8217;s participation was altered&#59; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the FDA may continue to suspend or delay certain foreign inspections, and the EMA may also, and if there continues to be a suspension or delay in inspections, our product application reviews and potential approvals could be impacted or delayed.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we expect the COVID-19 pandemic to continue to adversely affect our business operations, the extent of the impact on our clinical development and regulatory efforts and the value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat COVID-19. In addition, to the extent the evolving effects of the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of our Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our common stock has been and may continue to be highly volatile, and you may not be able to resell some or all of your shares at a desired market price.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock has been and is likely to continue to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">results or delays in preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unanticipated serious safety concerns related to the use of any of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reports of adverse events in other gene therapy products or clinical trials of such products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">inability to obtain additional funding&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any delay in filing an IND, NDA, or MAA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of that IND or NDA&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain regulatory approvals for our product candidates, and delays or failures to obtain such approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure of any of our product candidates, if approved, to achieve commercial success&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to obtain Orphan Drug designation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to maintain our existing third-party license and supply agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure by our licensors to prosecute, maintain, or enforce our intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in laws or regulations applicable to our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any inability to obtain adequate supply of our product candidates or the inability to do so at acceptable prices&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse regulatory authority decisions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">introduction of new products, services, or technologies by our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to meet or exceed financial and development projections we may provide to the public&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to meet or exceed the financial and development projections of the investment community&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additions or departures of key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant lawsuits, including patent or stockholder litigation&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the market valuations of similar companies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general market or macroeconomic conditions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of our common stock by us or our stockholders in the future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">trading volume of our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse publicity relating to the hepatitis market generally, including with respect to other products and potential products in such markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the introduction of technological innovations or new therapies that compete with potential products of ours&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the structure of health care payment systems&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">period-to-period fluctuations in our financial results.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. These broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic, may also adversely affect the trading price of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Effective December 31, 2019, we ceased to be an &#8220;emerging growth company,&#8221; and the reduced reporting requirements applicable to &#8220;emerging growth companies&#8221; no longer apply, which has increased our costs as a result of being a public company and places additional demands on management.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective December 31, 2019, we ceased to be classified as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act (the JOBS Act).&#160;We are now considered an Accelerated Filer and a Smaller Reporting Company, which will require accelerated deadlines of periodic reports. In March 2020, the definition of an Accelerated Filer was amended to exclude Smaller Reporting Companies from the requirements of the Sarbanes-Oxley Act Section 404(b).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have previously taken advantage of the JOBS Act&#8217;s reduced disclosure requirements applicable to &#8220;emerging growth companies&#8221; regarding executive compensation and exemptions from the requirements of holding advisory say-on-pay votes on executive compensation. Since we are no longer classified as an &#8220;emerging growth company,&#8221; we are no longer eligible for such reduced disclosure requirements and exemptions and as such, we are required to hold a say-on-pay vote and a say-on-frequency vote at our 2019 annual meeting of&#160;stockholders. As a result, we expect that because we are no longer classified as an &#8220;emerging growth company,&#8221; we will require additional attention from management with respect to our disclosures and will incur increased costs, which could include higher legal fees, accounting fees, consultant fees and fees associated with investor relations activities, among others.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred and will continue to incur significant legal, accounting and other expenses associated with public company reporting requirements. We also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as rules implemented by the SEC and The Nasdaq Stock Market LLC. These rules and regulations impose significant legal and financial compliance costs and make some activities more time-consuming and costly. For example, our management team consists of certain executive officers who have not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. In addition, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers, which may adversely affect investor confidence and could cause our business or stock price to suffer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our certificate of incorporation and bylaws may delay or prevent an acquisition or a change in management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders and the ability of the board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which prohibits stockholders owning in excess of 15% of our voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not anticipate that we will pay any cash dividends in the foreseeable future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders, if any, for the foreseeable future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales of shares by existing stockholders could cause our stock price to decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions on resale lapse, the trading price of our common stock could decline. Certain of our existing stockholders, including RA Capital, Vivo Ventures Fund VI, L.P. and Adage Capital Partners, and their respective affiliated entities, own substantial ownership interest in our common stock and any decision to sell a significant number of shares may negatively impact the price of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The ownership of our common stock is highly concentrated, and it may prevent stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause our stock price to decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers, directors and 5% stockholders and their affiliates beneficially own or control a significant portion of the outstanding shares of our common stock. Accordingly, these executive officers, directors, 5% stockholders and their affiliates, acting as a group, have substantial influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transactions. These stockholders may also delay or prevent a change of control of us, even if such a change of control would benefit our other stockholders. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our net operating loss carryforwards and certain other tax attributes are now subject to limitations.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our federal and state net operating loss (NOL) carry-forwards will begin to expire, if not utilized, beginning in 2030 for federal income tax purposes and 2028 for California state income tax purposes. These NOL carry-forwards could expire unused and be unavailable to offset future income tax liabilities. Under legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), U.S. federal net operating loss carryforwards generated in tax years beginning after December 31, 2017 may be carried forward indefinitely but, in the case of tax years beginning after December 31, 2020, may only be used to offset 80% of taxable income annually. In addition, California recently enacted A.B. 85 which imposed limits on the usability of California state net operating losses and certain tax credits in tax years beginning after 2019 and before 2023. Such limitations could result in the expiration of portions of our net operating loss and tax credit carryforwards before utilization. Moreover, if a corporation undergoes an ownership change within the meaning of Section 382 of the Code (Section 382) the corporation&#8217;s NOL carryforwards and certain other tax attributes arising from before the ownership change are subject to limitations on use after the &#8220;ownership change.&#8221; In general, an ownership change occurs if there is a cumulative change in the corporation&#8217;s equity ownership by certain stockholders that exceeds fifty percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Our merger with Celladon resulted in such an ownership change and, accordingly, Celladon&#8217;s NOL carryforwards and certain other tax attributes will be subject to further limitations on their use. In addition, we assessed whether Eiger had an ownership change, as defined by Section 382 of the Code, as a result of the Merger and other stock issuances that occurred from our formation through December 31, 2020. Based upon this assessment, we have experienced ownership changes on April 20, 2016, October 18, 2018 and December 31, 2020. Due to these ownership changes, reductions were made to our NOL and tax credit carryforwards under these rules. Additional ownership changes in the future could result in additional limitations on our net operating loss and tax credit carryforwards. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our NOL carryforwards and other tax attributes, which could have a material adverse effect on cash flow and results of operations. A full valuation allowance has been provided for the entire amount of our remaining net operating losses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">ITEM&#160;1B. Unresolved Staff Comments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">ITEM&#160;2. Properties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are located at 2155 Park Blvd in Palo Alto, California 94306 in a facility we lease encompassing 8,029 square feet of office space. The lease commenced on March 1, 2018 and expires five years after the commencement date. The lease has one three-year renewal option prior to expiration and includes rent escalation clauses through the lease term.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS">ITEM&#160;3. Legal Proceedings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that in the opinion of our management, if determined adversely to us, would have a material adverse effect on our business, financial condition, operating results or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">ITEM&#160;4. Mine Safety Disclosures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">ITEM&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;22, 2016, Celladon and Private Eiger completed the Merger. Immediately prior to the Merger, Celladon completed a 15-for-1 reverse stock split. Following the Merger, we changed the name of the combined company to Eiger BioPharmaceuticals, Inc. and changed the symbol to &#8220;EIGR.&#8221; Our common stock originally began trading on The Nasdaq Global Market on January&#160;30, 2014. Prior to January&#160;30, 2014, there was no public market for our common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Record</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 5, 2021, there were approximately 25 stockholders of record of our common stock. Certain shares are held in &#8220;street&#8221; name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends, if permitted, will be made at the discretion of our board of directors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance under Equity Compensation Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our compensation plans under which our equity securities are authorized for issuance as of December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities to be</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued Upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options, Warrants and Rights</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options ($/share)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining Available</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For Issuance Under</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation Plans</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Excluding Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reflected in Column</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a))</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Plan Category</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans approved by stockholders</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,734,575</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.81</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,564,900</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans not approved by</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stockholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.82%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,734,575</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.82%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.81</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,564,900</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">The amount shown in column (a) includes 3,697,075 outstanding options and 37,500 restricted stock units.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">The weighted average exercise price in column (b) includes options only as restricted stock units do not have exercise price.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup></span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup></span><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">As of December 31, 2020, the number of securities remaining available for issuance in column (c) includes 1,021,109 share available for future issuance in the form of options or restricted stock units under our Amended and Restated 2013 Equity Incentive Plan and 543,791 shares remained available for future issuance under our 2013 Employee Stock Purchase Plan (ESPP). </p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_SELECTED_FINANCIAL_DATA">ITEM&#160;6. Selected Financial Data</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a &#8220;smaller reporting company&#8221; as defined by Rule 12b 2 of the Exchange Act, the Company is not required to provide this information.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">ITEM&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis together with our financial statements and related notes included elsewhere in this Annual Report. The following discussion contains forward-looking statements <span style="font-style:normal;">that</span> involve risks and uncertainties. Our actual results could differ materially from those expressed or implied in any forward-looking statements as a result of various factors, including those set forth under the caption &#8220;Item 1A. Risk Factors.&#8221;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Unless otherwise indicated, references to the terms the &#8220;combined company,&#8221; &#8220;Eiger,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Eiger BioPharmaceuticals, Inc. (formerly known as Celladon Corporation) and its subsidiaries after the merger described herein. The term &#8220;Private Eiger&#8221; refers to privately-held Eiger BioPharmaceuticals, Inc. prior to its merger with Celladon Merger Sub, Inc. a wholly-owned subsidiary of Celladon Corporation. The term &#8220;Celladon&#8221; refers to Celladon Corporation and its subsidiaries prior to the Merger.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="S169418040">We are a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV), the most severe form of human viral hepatitis, for which there is currently no FDA-approved therapy. We have reported positive proof-of-concept clinical results across all our programs, and have received Breakthrough Therapy designation for three programs in clinical development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our programs have several aspects in common: the disease targets represent conditions of high unmet medical need&#59; the therapeutic approaches are supported by an understanding of disease biology and mechanism as elucidated by our academic research relationships&#59; prior clinical experience with the product candidates guides an understanding of safety&#59; and the development paths leverage the experience and capabilities of our experienced, commercially-focused management team.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing two complementary treatments for HDV. Lonafarnib is a first-in-class oral farnesylation inhibitor in a global Phase 3 trial, and the only oral therapy in development for HDV. Peginterferon lambda (lambda) is a first-in-class, well characterized, well-tolerated type III interferon entering Phase 3.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pivotal Phase 3 D-LIVR study (N&#61;400) of lonafarnib boosted with ritonavir in HDV is ongoing and enrolling patients. The study spans twenty-two countries and over one hundred sites and has potential to generate data for two lonafarnib-based ritonavir-boosted regimens for approval. An all-oral arm of lonafarnib boosted with ritonavir and a combination arm of lonafarnib boosted with ritonavir combined with pegylated interferon-alfa-2a will each be compared to placebo. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lambda is our second program treating HDV and is entering Phase 3. We have agreement with the FDA and European Medicines Agency (EMA) on a single pivotal Phase 3 study design and endpoints. Lambda is a well-characterized, late-stage, first in class, type III interferon. We previously reported Phase 2 LIMT (lambda monotherapy) study results (n&#61;33) that demonstrated a 36% durable virologic response (DVR), or below the limit of quantification (BLQ), at 24 weeks post-treatment. In the Phase 2 LIFT study, HDV patients were treated with a combination of our two proprietary products, lambda and lonafarnib boosted by ritonavir. The end-of-study results based on a per-protocol analysis reported in November 2020 showed that 77% of patients achieved the primary end-point of &#62;2 log decline in HDV RNA at Week 24 and 50% of patients were HDV RNA BLQ or undetectable. Adverse events were mostly mild to moderate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA approved our first commercial product, Zokinvy (lonafarnib) to reduce risk of mortality of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and to treat processing-deficient progeroid laminopathies, ultra-rare and rapidly fatal genetic conditions of accelerated aging in children, on November 20, 2020. Our Marketing Authorization Application (MAA) is under review with the EMA, and we expect a decision in the second half of 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">avexitide</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a well-characterized peptide, as a treatment for post-bariatric hypoglycemia (PBH), a debilitating and potentially life-threatening condition for which there is currently no approved therapy. We have completed four clinical studies demonstrating proof of concept in 54 patients suffering from severe, refractory PBH, and ha</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ve</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement with</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> FDA </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and EMA </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on a single pivotal Phase 3 trial.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avexitide has also demonstrated proof of concept for treatment of congenital hyperinsulinism (CHI), an ultra-rare pediatric metabolic genetic disorder.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not generated any revenue from product sales through 2020. We have never been profitable and have incurred operating losses in each year since inception, and we do not anticipate that we will achieve profitability in the near term. Our net losses were $65.1 million, $70.3 million and $52.4 million for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, we had an accumulated deficit of $306.5 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur significant expenses and increasing operating losses for at least the next several years as we initiate and continue the clinical development of, and seek regulatory approval for, and potentially commercialize our product candidates and add personnel necessary to operate as a public company with an advanced clinical candidate pipeline of products. In addition, we will incur costs for additional personnel and upgrades to our information technology systems as we transition from an emerging growth company. We expect that our operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of clinical development programs and efforts to achieve additional regulatory approvals.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Recent Developments</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia (PBH) in Journal of Clinical Endocrinology &#38; Metabolism</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 23, 2021, we announced that positive results from the Phase 2 PREVENT study of Avexitide in patients with PBH were published in <span style="font-style:italic;">Journal of Clinical Endocrinology &#38; Metabolism</span>. The study met its primary endpoints and we previously reported topline data from this study in March 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Publication of ILIAD Study Results of Peginterferon Lambda (Lambda) in COVID-19 in Lancet Respiratory Medicine 2021</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 8, 2021, we announced that final results from the Phase 2 ILIAD (Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19) study published in <span style="font-style:italic;">Lancet Respiratory Medicine</span>. ILIAD, an investigator sponsored randomized trial of lambda in outpatients with mild to moderate COVID-19 conducted at Toronto General Hospital, University Health Network in Toronto, Canada, demonstrated a single dose of lambda accelerated clearance of SARS-CoV2 in newly diagnosed, non-hospitalized patients. We previously reported topline data from this study on October 15, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:7.69%;text-indent:-7.69%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Completion of Sale of Priority Review Voucher</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 23, 2020, we announced that we had entered into a definitive agreement to sell our Priority Review Voucher (PRV) for a lump sum payment of $95.0 million to AbbVie Inc. (AbbVie). The transaction was subject to customary closing conditions including anti-trust review. The PRV was granted to us in conjunction with the November 20, 2020 approval by the FDA of our new drug application for Zokinvy. On January 7, 2021, we announced that we had completed the sale to AbbVie following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Eiger retained 50%, or approximately $47.4 million, of the PRV proceeds under the terms of the Collaboration and Supply Agreement with the Progeria Research Foundation.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Update on Impact of COVID-19 Pandemic on Clinical Development Activities and Business Operations</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken proactive steps to ensure the safety of patients and the integrity of our HDV Phase 3 D-LIVR trial, which is expected to complete enrollment in 2021. We have adequate clinical drug product supply for the D-LIVR study and do not anticipate any interruption in availability of study drug to patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not anticipate any impact to our planned U.S. commercial launch of Zokinvy, including availability of commercial drug supply. We previously announced that the EMA review of our MAA will follow a standard review timeline.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have put into place remote operations and new policies, which are in-line with local, state and federal guidelines, to maintain the safety and well-being of our employees, while working to maintain business continuity as this unprecedented global situation continues to evolve. W<span style="color:#000000;">e continue to monitor the situation closely, including its potential effect on our clinical development plans and timelines.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses represent costs incurred to conduct research and development, such as the development of our product candidates. We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses incurred under agreements with consultants, contract research organizations and clinical trial sites that conduct research and development activities on our behalf&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">laboratory and vendor expenses related to the execution of clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">contract manufacturing expenses, primarily for the production of clinical trial supplies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">license fees associated with our license agreements&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">internal costs that are associated with activities performed by our research and development organization and generally benefit multiple programs. These costs are not separately allocated by product candidate. Unallocated internal research and development costs consist primarily of:</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">personnel costs, which include salaries, benefits and stock-based compensation expense&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">allocated facilities and other expenses, which include expenses for rent and maintenance of facilities and depreciation expense&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory expenses and technology license fees related to development activities.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The largest component of our operating expenses has historically been the investment in clinical trials, including contract manufacturing arrangements, clinical trial material related costs and other research and development activities. However, we do not allocate internal research and development costs, such as salaries, benefits, stock-based compensation expense and indirect costs to product candidates on a program-specific basis. The following table shows our research and development expenses for the years ended December 31, 2020, 2019 and 2018 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lonafarnib</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,051</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,775</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,647</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avexitide</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,891</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,834</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,009</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lambda</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,128</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,935</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,945</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ubenimex</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,116</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal research and development costs</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,520</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,247</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,374</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expense</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,590</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,791</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,091</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect research and development expenses will continue to be significant and may increase in the future as we advance our product candidates into and through later stage clinical trials and pursue regulatory approvals, which will require a significant investment in regulatory support and contract manufacturing and clinical trial material related costs. In addition, we continue to evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to license fees and/or milestone payments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely developing and achieving regulatory approval for our product candidates. The probability of success of our product candidates may be affected by numerous factors, including clinical data, competition, intellectual property rights, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. The COVID-19 pandemic presents additional risks and uncertainties associated with developing drugs, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in trial activities and patient enrollment or diversion of healthcare resources as a result of the evolving effects of the COVID-19 pandemic or otherwise&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">production shortages or other supply interruptions in clinical trial materials resulting from the evolving effects of the COVID-19 pandemic or otherwise&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to hire and retain key research and development personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope, rate of progress, results and expense of our ongoing, as well as any additional, clinical trials and other research and development activities&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and receipt of any regulatory approvals.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist of personnel costs, allocated expenses and expenses for outside professional services, including legal, audit, accounting services, insurance costs and costs associated with being a public company. Personnel costs consist of salaries, benefits and stock-based compensation. Allocated expenses consist of facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation expense and other supplies. Our expenses include costs related to compliance with the rules and regulations of the SEC and Nasdaq, insurance, investor relations, banking fees and other administrative expenses and professional services. We expect our general and administrative expenses to increase in the future due to sales and marketing activities from the commercialization of Zokinvy. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense consists of interest and amortization of the debt discount related to the Oxford Loan. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interest Income</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest earned on our investments in debt securities and cash equivalents.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">readily apparent from other sources. Actual results may differ materially from these estimates. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accrued expenses for estimated costs of research and development activities conducted by external service providers, which include the conduct of clinical research and contract formulation and manufacturing activities. We record the estimated costs of development activities based upon the estimated amount of services provided but not yet invoiced and include these costs in accrued liabilities in the consolidated balance sheets and within research and development expenses in the consolidated statements of operations. We record accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize compensation costs related to stock options and restricted stock units based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value of stock options, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. We record forfeitures when they occur.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option-pricing model includes the following assumptions:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term. <span style="font-style:normal;">Our expected term represents the period that our stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility. <span style="font-style:normal;">Since we have only been publicly traded for a short period and do not have adequate trading history for our common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle, or area of specialty. Beginning in the third quarter of 2019, as we had been publicly traded for four and a half years, we began to layer in our historical volatility in the calculation of expected volatility. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate. <span style="font-style:normal;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend. <span style="font-style:normal;">We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use the contractual term to determine the non-employee awards&#8217; fair value at the grant date. The contractual term of options granted under the Plan is 10 years. Our Board of Directors determined the fair value of each share of underlying common stock based on the closing price of our common stock as reported by the Nasdaq Global Market on the date of grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the fair value of restricted stock units based on the closing market price of our common stock on the date of grant and the resulting stock-based compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the Years Ended December&#160;31, 2020 and 2019</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes results of operations for the years ended December&#160;31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase /</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,590</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,791</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,201</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,559</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,113</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,446</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,149</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,904</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,755</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,149</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(68,904</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,755</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,594</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,406</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(188</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">704</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,073</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,369</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,051</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,252</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,201</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.68%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses decreased by $10.2 million to $41.6 million for the year ended December 31, 2020, from $51.8 million for the same period in 2019. The decrease was primarily due to a <span style="color:#000000;">$11.7 million decrease in contract manufacturing and clinical expenditures due to decrease in clinical program activities. The decrease was partially offset by an increase of $0.7 million in regulatory expenses, an increase of $0.6 million in headcount related expenses and $0.3 million in other operating expenses.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by $3.5 million to $20.6 million for the year ended December 31, 2020, from $17.1 million for the same period in 2019. The increase was primarily due to a<span style="color:#000000;"> $1.7 million increase in compensation and personnel related expenses, including stock-based compensation, due to an increase in headcount and </span>a $1.7 million increase in outside services, including consulting, advisory and accounting services. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest expense</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense increased by $0.2 million to $3.6 million for the year ended December 31, 2020, from $3.4 million for the same period in 2019. Interest expense primarily increased due to the additional funds borrowed under the Oxford Loan in 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest income </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income decreased by $1.4 million to $0.7 million for the year ended December 31, 2020, from $2.1 million for the same period in 2019. The decrease was primarily due to a decrease in interest rates on money market funds and available-for-sale securities. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sources of Liquidity</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had $128.9 million of cash, cash equivalents and investments, comprised of $28.9 million of cash and cash equivalents and $100.0 million of debt securities available-for-sale, and an accumulated deficit of $306.5 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we filed a shelf registration statement on Form S-3 (File No. 333-235655) with the Securities and Exchange Commission, which permits the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock, preferred stock, debt securities and warrants. Up to a maximum of $50.0 million of the maximum aggregate offering price of $150.0 million may be issued and sold </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursuant to an at-the-market (ATM) financing facility (2019 ATM Facility) under a sales agreement with Jefferies LLC (Jefferies).</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In August 2020, we entered into a new sales agreement with Jefferies for up to $50</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million of the remaining amount on the shelf registration statement which may be sold pursuant to an ATM financing facility (2020 ATM Facility).</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2020, we completed both the 2019 ATM Facility and the 2020 ATM Facility for a total of 9,267,760 shares resulting in $97.3 million in net proceeds, after deducting commissions. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On December 18, 2020, we filed a new shelf registration statement on Form S-3 (File No. 333-251497) with the Securities and Exchange Commission, which permits the offering, issuance and sale by us up to a maximum aggregate offering price of $200.0 million </span><span style="color:#000000;">of our common stock, preferred stock, debt securities and warrants. Up to a maximum of $50.0 million of the maximum aggregate offering price of $200.0 million may be issued and sold pursuant to a new ATM financing facility under a sales agreement with Jefferies. We have not issued any shares under this facility.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the currently available resources will be sufficient to fund our planned operations for at least the next 12 months following the issuance date of these consolidated financial statements. However, if our anticipated operating results are not achieved in future periods, we believe that planned expenditures may need to be reduced or we would be required to raise funding in order to fund our operations. Additionally, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary uses of cash are to fund operating expenses, including research and development expenditures and general and administrative expenditures. Cash used to fund operating expenses is impacted&#160;by the timing of when we pay these expenses, as reflected in the change in outstanding accounts payable and accrued expenses.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Future Funding Requirements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not generated any revenue from product sales. We expect to generate revenues from product sales of Zokinvy beginning in 2021. At the same time, we expect our expenses to increase in connection with our ongoing development and manufacturing activities, particularly as we continue the research, development, manufacture and clinical trials of, and seek regulatory approval for our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary uses of capital are, and we expect will continue to be, funding research efforts and the development of our product candidates, sales and marketing costs for commercialization of Zokinvy and other product candidates, compensation and related expenses, hiring additional staff, including clinical, scientific, operational, financial, and management personnel, and costs associated with operating as a public company.&#160;We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to continue to fund losses from operations and capital funding needs through future equity and/or debt financings, as well as potential additional collaborations or strategic partnerships with other companies. As a result of economic conditions, general global economic uncertainty, political change and other factors, including the ongoing COVID-19 pandemic, we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional capital on reasonable terms. If we are unable to raise additional capital due to the volatile global financial markets, general economic uncertainty or other factors, we may need to curtail planned development or commercialization activities. The sale of additional equity or convertible debt could result in additional dilution to our stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financing covenants that would restrict our operations. We can provide no assurance that financing will be available in the amounts we need or on terms acceptable to us, if at all. If we are not able to secure adequate additional funding we may be forced to delay, make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm our business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash Flows</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for the periods indicated (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,185</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,614</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,787</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,471</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,463</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,196</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,509</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,889</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash flows from operating activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities for the year ended December 31, 2020 was $63.2 million, which primarily consisted of a net loss of $65.1<span style="color:#000000;"> </span>million, partially offset by <span style="Background-color:#FFFFFF;color:#000000;">stock-based compensation expense of $</span>6.0<span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">million, non-cash interest expense of $</span>0.8<span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">million, amortization of operating lease right-of-use assets of $</span>0.5<span style="Background-color:#FFFFFF;color:#000000;"> million and common stock issued under Product Development Agreement of $</span>0.2<span style="Background-color:#FFFFFF;color:#000000;"> million. </span><span style="color:#000000;">Additionally, cash used in operating activities reflected changes in net operating assets of $</span>5.9<span style="color:#000000;"> million due to an </span>increase<span style="color:#000000;"> of $</span>3.6<span style="color:#000000;"> million in prepaid expenses and other current assets primarily due to the timing of payments, an </span>increase<span style="color:#000000;"> of $</span>1.4<span style="color:#000000;"> million in other assets primarily related to long term deposits with clinical research organizations, a </span>decrease<span style="color:#000000;"> of $</span>0.4<span style="color:#000000;"> million in accounts payable and accrued liabilities due to timing of payments and a </span>decrease<span style="color:#000000;"> of $</span>0.5<span style="color:#000000;"> million in operating lease liabilities. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities for the year ended December 31, 2019 was $63.6 million and primarily consisted of a net loss of $70.3 million and amortization of debt securities discounts of $0.5 million, which was partially offset by $5.7 million of stock-based compensation expense, $0.7 million of non-cash interest related to amortization of debt discount and <span style="Background-color:#FFFFFF;color:#000000;">$0.4 million of amortization of operating lease right-of-use assets. </span>Additionally, cash used in operating activities reflected changes in net operating assets due to an increase of $3.7 million in prepaid expenses and other current assets primarily due to the timing of payments and an increase of $2.1 million in other assets primarily due to an increase in long-term deposits to IQVIA, which was partially offset by an increase of $6.2 million in accounts payable and accrued liabilities primarily associated with increase in business activity.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash flows from investing activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash<span style="color:#000000;"> used in investing activities was $44.8 million for the year ended December 31, 2020, primarily consisting of $128.3 million of purchases of debt securities, partially offset by $83.8 million of proceeds from maturities of debt securities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in investing activities for the year ended December 31, 2019 was $16.5 million. The net cash decrease was primarily due to $96.3 million purchases of debt securities and $0.5 million purchases of property and equipment, which was partially offset by $80.3 million proceeds from maturities of debt securities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash flows from financing activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities for the <span style="color:#000000;">year ended December 31, 2020 was $97.5 million and primarily </span>consisted of $96.8 million of net proceeds from the issuance of common stock under our ATM Facilities and $0.7<span style="color:#000000;"> </span>million of proceeds from the issuance of common stock upon stock option exercises and ESPP purchase.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities for the year ended December 31, 2019 was $58.2 million and primarily consisted of $53.2 million of net proceeds from the issuance of common stock upon public offering, $4.0 million of&#160;&#160;proceeds from borrowings, net of repayments, in connection with the Oxford Loan, and $0.8 million of proceeds from the issuance of common stock upon stock option exercises.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Other Commitments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases and Term Loan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to Notes 7 and 12 to our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for a description of our contractual obligations at December 31, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Asset and License Agreements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are obligated to make future payments to third parties under asset purchase and license agreements, including royalties and payments that become due and payable on the achievement of certain development and commercialization milestones. We have not included these potential payment obligations in our contractual obligations table as the amount and timing of such payments are not known.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Oxford Finance Term Loan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 30, 2016, we entered into an aggregate $25.0 million loan with Oxford Finance LLC (the Oxford Loan). We borrowed $15.0 million in December 2016 (Tranche A), $5.0 million in May 2018 (Tranche B), and $5.0 million in August 2018 (Tranche C). The Oxford Loan bears interest at a floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.41% or 6.95%, with interest only payments through July 1, 2018 followed by 36 equal monthly payments of principal and interest until maturity at July 1, 2021. Upon the receipt of Tranche B in May 2018, the interest only period for borrowed funds was extended by six months until February 1, 2019, followed by 30 equal monthly payments of principal plus accrued interest. In addition, at the time of final payment of Tranche B, we were required to pay an additional exit fee of $0.1 million. On March 5, 2019, we entered into the third amendment to the Oxford Loan (the Amended Oxford Loan) to refinance the Oxford Loan. The Amended Oxford Loan increased the aggregate amount available to be borrowed to $35.0 million and extended the maturity date to March 1, 2024. On March 5, 2019, prior to entering into the Amended Oxford Loan, the outstanding balance of the Oxford Loan was $23.3 million. At the time of entering into the Amended Oxford Loan, we borrowed an additional $6.7 million in principal under the Amended Oxford Loan, which increased the total amount borrowed to $30.0 million (Amended Tranche A). The remaining $5.0 million (Amended Tranche B) will be available to us upon the latest to occur of (i) achievement of positive lonafarnib Phase 3 HDV topline data sufficient to file new drug application (Clinical Milestone) and (ii) January 1, 2021.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Amended Oxford Loan bears interest at a floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.64% or 9.15%. The Amended Oxford Loan has an interest only period until April 1, 2021, followed by 36 equal monthly payments of principal and interest. Upon the receipt of Amended Tranche B, the interest only period for borrowed funds will be extended by one year until April 1, 2022, followed by 24 equal monthly payments of principal plus accrued interest. At the time of final payment, we are required to pay an exit fee of 7.5% of the original principal balance of borrowed funds, or $2.3 million. In addition, we are required to pay an additional exit fee of $1.0 million. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 23, 2021, we entered into the fifth amendment to the Oxford Loan. The amendment extended the interest only period by 17 months until September 1, 2022, followed by 19 equal monthly payments of principal and interest. Upon the receipt of Amended Tranche B, the interest only period for borrowed funds will be extended by six months until March 1, 2023, followed by 13 equal monthly payments of principal plus accrued interest. In addition, we paid the amendment fees of $0.2 million to the lenders on the effective date of the fifth amendment.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loan is secured by perfected first priority liens on our assets, including our commitment to not allow any liens to be placed upon our intellectual property. The Oxford Loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency. As of December 31, 2021, we were in compliance with all loan terms. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing Service Agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2020, we entered into a Master Manufacturing Services Agreement (MMSA) and Product Agreement with Patheon, Inc. (Patheon) for the manufacturing of lonafarnib capsules and packaging of bottles for commercial sale. Under the terms of the agreements, we are required to provide Patheon with annual volume forecasts of capsules and Patheon will manufacture 80% of such annual forecasts. If we order less than 80% of such annual forecasts, we are required to pay 70% of purchase price for the shortfall. The initial terms of the MMSA and Product Agreement end on December 31, 2025 with automatic renewal for successive two-year terms, unless earlier terminated pursuant to the terms of each agreement, or upon either party&#8217;s notice of termination to the other.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules of the SEC and do not have any holdings in variable interest entities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to Note 2 to our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for a description of recent accounting pronouncements adopted and not yet adopted for the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_1">ITEM&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">ITEM&#160;8. Financial Statements and Supplementary Data</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Report of Independent Registered Public Accounting Firm</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and Board of Directors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.:</p>
<p style="margin-top:18pt;margin-bottom:5pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Opinion on the Consolidated Financial Statements</p>
<p style="margin-top:8pt;margin-bottom:5pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Eiger BioPharmaceuticals, Inc. and subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-top:8pt;margin-bottom:5pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-top:8pt;margin-bottom:5pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-top:8pt;margin-bottom:5pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-top:8pt;margin-bottom:5pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-top:8pt;margin-bottom:5pt;text-indent:0%;;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Critical Audit Matters</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;;font-style:normal;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;margin-right:12.82%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzbwht3f4aft000016.jpg" title="" alt="" style="width:131px;height:28px;" /></p>
<p style="margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2015.</p>
<p style="margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities, available-for-sale</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,976</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,621</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,966</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AssetsCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">137,806</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AssetsCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,384</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001305253_20201231" decimals="-3" scale="3">709</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001305253_20191231" decimals="-3" scale="3">590</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,511</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:Assets" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">143,594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:Assets" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001305253_20201231" decimals="-3" scale="3">582</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001305253_20191231" decimals="-3" scale="3">534</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,949</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term debt, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001305253_20201231" decimals="-3" scale="3">738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,320</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:Liabilities" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,559</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:Liabilities" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 12)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000064">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000065">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000078" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001305253_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000079" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001305253_20191231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001305253_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000081" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001305253_20191231" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020 and 2019&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000082" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001305253_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000084" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001305253_20201231" decimals="INF" format="ixt:numdotdecimal">33,878,486</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000083" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001305253_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000085" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001305253_20191231" decimals="INF" format="ixt:numdotdecimal">24,523,381</ix:nonFraction></ix:nonFraction> shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and outstanding as of December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:CommonStockValue" contextRef="C_0001305253_20201231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:CommonStockValue" contextRef="C_0001305253_20191231" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">401,509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">297,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive (loss) income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001305253_20201231" decimals="-3" sign="-" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001305253_20191231" decimals="-3" scale="3">42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001305253_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">306,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001305253_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">241,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">95,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">143,594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR">Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,590</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,091</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,559</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,956</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:OperatingExpenses" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">62,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:OperatingExpenses" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:OperatingExpenses" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">62,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">68,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:InterestExpense" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:InterestExpense" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,406</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:InterestExpense" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">704</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,073</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">70,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per common share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000110" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001305253_20200101_20201231" decimals="2" sign="-">2.31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000111" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001305253_20190101_20191231" decimals="2" sign="-">3.08</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000112" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001305253_20180101_20181231" decimals="2" sign="-">3.84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">28,143,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000114" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001305253_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">22,785,611</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000115" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001305253_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">13,634,152</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.38%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:8.45pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">70,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive (loss) gain:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (loss) gain on available-for-sale debt securities, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" scale="3">50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,101</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">70,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_DEF">Consolidated Statements of Stockholders&#8217; Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(In thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2017</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000125" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" format="ixt:numdotdecimal">10,526,599</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">141,320</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231" decimals="-3" sign="-" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">118,806</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon public</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; offering, net of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,357</ix:nonFraction> of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000131" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">8,510,918</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon ESPP purchase</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000135" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">17,508</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" scale="3">96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock option exercise</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">41,208</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" scale="3">310</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">310</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Product Development Agreement</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000141" name="eigr:StockIssuedDuringPeriodSharesProductDevelopmentAgreement" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">115,526</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" scale="3">428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on available-for-sale debt securities, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" sign="-" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">19,211,759</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">237,795</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" sign="-" scale="3">25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">171,197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">66,592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon public</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; offering, net of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,731</ix:nonFraction> of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000156" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">5,175,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon ESPP purchase</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000160" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">15,701</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock option exercise</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000163" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">120,921</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of common stock under</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Product Development Agreement</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on available-for-sale debt securities, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" scale="3">67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">70,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">70,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000174" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">24,523,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">297,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">241,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon offering</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; at-the-market, net of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,231</ix:nonFraction> of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000180" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">9,267,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon ESPP purchase</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000184" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">25,645</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock option exercise</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000187" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">61,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of common stock under</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Product Development Agreement</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on available-for-sale debt securities, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" scale="3">50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" scale="3">50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:NetIncomeLoss" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000198" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">33,878,486</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">401,509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" sign="-" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">306,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:StockholdersEquity" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">95,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to the consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:ProfitLoss" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:ProfitLoss" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">70,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:ProfitLoss" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">68</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">54</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt securities premiums and discounts</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">467</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:ShareBasedCompensation" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:ShareBasedCompensation" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:ShareBasedCompensation" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">804</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="eigr:OperatingLeaseRightOfUseAssetAmortization" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="eigr:OperatingLeaseRightOfUseAssetAmortization" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issued under Product Development Agreement</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,563</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,698</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,392</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,075</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,899</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">584</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,647</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,491</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="eigr:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" scale="3">534</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="eigr:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" scale="3">430</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">212</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">63,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">63,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">42,671</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of debt securities available-for-sale</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">128,295</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of debt securities available-for-sale</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">83,766</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">80,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">44,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,471</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,085</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon offering at-the-market, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon stock option exercises</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">310</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon ESPP purchase</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001305253_20180101_20181231" decimals="-3" scale="3">96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of deferred offering costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="eigr:PaymentsOfDeferredOfferingCosts" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="eigr:PaymentsOfDeferredOfferingCosts" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon public offering,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrPOMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrPOMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from borrowings in connection with term loan,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayment of accrued exit fee and second amendment fee</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="eigr:RepaymentOfAccruedExitFeeAndSecondAmendmentFee" contextRef="C_0001305253_20190101_20191231" decimals="-3" scale="3">913</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayment of term loan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:RepaymentsOfSecuredDebt" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">97,463</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">58,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,983</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001305253_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">10,509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001305253_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">21,889</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001305253_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,262</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001305253_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001305253_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,262</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest paid</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:InterestPaidNet" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:InterestPaidNet" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,638</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:InterestPaidNet" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,652</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Eiger Biopharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">Notes to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000287" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description of Business</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc. (the Company or Eiger) was incorporated in the State of Delaware on <ix:nonNumeric id="F_000335" name="dei:EntityIncorporationDateOfIncorporation" contextRef="C_0001305253_20200101_20201231" format="ixt:datemonthdayyearen">November&#160;6, 2008</ix:nonNumeric>. Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV), the most severe form of human viral hepatitis, for which there is currently no FDA-approved therapy. Eiger has reported positive proof-of-concept clinical results across all of our programs and have received Breakthrough Therapy designation for three programs in clinical development. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger&#8217;s lead clinical programs are complementary treatments for HDV. Lonafarnib is a first-in-class oral farnesylation inhibitor in a global Phase 3 trial, and the only oral therapy in development for HDV. Peginterferon lambda is a first-in-class, well characterized, well-tolerated type III interferon entering Phase 3.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA approved the Company&#8217;s first commercial product, Zokinvy (lonafarnib) for treatment of Progeria and processing-deficient progeroid laminopathies, ultra-rare and rapidly fatal genetic conditions of accelerated aging in children, November 20, 2020. Eiger&#8217;s Marketing Authorization Application (MAA) is under review with the European Medicines Agency (EMA), with a decision expected in the second half of 2021.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also developing avexitide, a well-characterized peptide, as a treatment for PBH, a debilitating and potentially life-threatening condition for which there is currently no approved therapy, and as a treatment CHI, an ultra-rare pediatric metabolic disorder.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s principal operations are based in Palo Alto, California and it operates in <ix:nonFraction unitRef="U_eigrSegment" id="F_000336" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001305253_20201231" decimals="-5" scale="6">128.9</ix:nonFraction> million of cash, cash equivalents and investments, comprised of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001305253_20201231" decimals="-5" scale="6">28.9</ix:nonFraction> million of cash and cash equivalents and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001305253_20201231" decimals="-5" scale="6">100.0</ix:nonFraction> million of debt securities available-for-sale.&#160;The Company had an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001305253_20201231" decimals="-5" sign="-" scale="6">306.5</ix:nonFraction> million and negative cash flows from operating activities as of December 31, 2020. <span style="Background-color:#FFFFFF;color:#000000;">As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, the Company will need to continue to raise additional capital</span>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management believes that the currently available resources will be sufficient to fund its operations for at least the next 12 months following the issuance date of these consolidated financial statements. However, if the Company&#8217;s anticipated operating results are not achieved in future periods, the Company believes that planned expenditures may need to be reduced or it would be required to raise funding in order to fund the operations. Additionally, the Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.</p></ix:nonNumeric><ix:nonNumeric id="F_000288" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000288_dcnt_05575172-2113-415c-ae6e-955af1d77749">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div><ix:nonNumeric id="F_000301" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation and Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, (U.S. GAAP) and following the requirements of the Securities and Exchange Commission (the SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric id="F_000302" name="us-gaap:UseOfEstimates" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000302_dcnt_8c20d02b-8012-47a8-accc-9a67c1e6b476">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000288_dcnt_05575172-2113-415c-ae6e-955af1d77749" continuedAt="F_000288_dcnt_f2a4fb83-6263-4749-b1e3-09222281da1d"><ix:continuation id="F_000302_dcnt_8c20d02b-8012-47a8-accc-9a67c1e6b476">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period. On an ongoing basis, the Company evaluates its estimates, including those related to clinical trial accrued liabilities, stock-based compensation</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operating lease liabilities</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and income taxes.&#160;The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></ix:continuation><ix:nonNumeric id="F_000303" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consists of cash, cash equivalents and investments. The Company&#8217;s cash is held by a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.</p><ix:nonNumeric id="F_000341" name="us-gaap:ConcentrationRiskSupplier" contextRef="C_0001305253_us-gaapConcentrationRiskByTypeAxis_us-gaapSupplierConcentrationRiskMember_20200101_20201231"><p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each product candidate, the Company relies on <ix:nonFraction unitRef="U_eigrSupplyChain" id="F_000342" name="eigr:NumberOfSupplyChainsForEachProductCandidate" contextRef="C_0001305253_us-gaapConcentrationRiskByTypeAxis_us-gaapSupplierConcentrationRiskMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> supply chain for each of the <ix:nonFraction unitRef="U_eigrProductCandidate" id="F_000343" name="eigr:NumberOfProductCandidates" contextRef="C_0001305253_us-gaapConcentrationRiskByTypeAxis_us-gaapSupplierConcentrationRiskMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction> product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000304" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents include all cash balances and highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consists primarily of amounts invested in money market funds held at financial institutions and corporate debt securities. The recorded carrying amount of cash equivalents approximates their fair value.&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000305" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Debt Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. All short-term securities are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The cost of available-for-sale securities sold is based on the specific-identification method<span style="Background-color:#FFFFFF;color:#000000;">. </span>Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other expense, net on the accompanying consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric id="F_000306" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. Depreciation begins at the time the asset is placed into service. Maintenance and repairs are charged to operations as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred.</p><ix:nonNumeric id="F_000318" name="eigr:EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The useful lives of the property and equipment are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000344" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20200101_20201231" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000345" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000346" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20200101_20201231" format="ixt-sec:duryear">3</ix:nonNumeric> years</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000307" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000307_dcnt_2d322ce2-1f14-4cb4-a0d0-3436b839e680">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through December&#160;31, 2020, the Company has <ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t impaired any long-lived assets.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000288_dcnt_f2a4fb83-6263-4749-b1e3-09222281da1d" continuedAt="F_000288_dcnt_3193e0d4-45a2-4caa-b310-9d3c4516562f"><ix:continuation id="F_000307_dcnt_2d322ce2-1f14-4cb4-a0d0-3436b839e680">
</ix:continuation><ix:nonNumeric id="F_000308" name="eigr:AccruedResearchAndDevelopmentCostsPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the consolidated balance sheets and within research and development expenses in the consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.</p></ix:nonNumeric><ix:nonNumeric id="F_000309" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, &#8220;Leases&#8221; (&#8220;ASC 842&#8221;) on January 1, 2019. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception. Material leases with a term greater than one year are recognized in right-of-use (&#8220;ROU&#8221;) assets and current and noncurrent lease liabilities, as applicable, in the Company&#8217;s consolidated balance sheets.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of its right-of-use assets (ROU assets) and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable&#59; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease ROU assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the consolidated statements of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in general and administrative expenses when incurred.</p></ix:nonNumeric><ix:nonNumeric id="F_000310" name="us-gaap:DebtPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Financing Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing costs incurred with securing a term debt are recorded in the Company&#8217;s consolidated balance sheets as an offset to the term debt and amortized to interest expense in the Company&#8217;s consolidated statements of operations over the contractual life of the loan using the effective interest method. </p></ix:nonNumeric><ix:nonNumeric id="F_000311" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist of payroll expenses, stock-based compensation expense, lab supplies and allocated facility costs, as well as fees paid to third parties that conduct certain research and development and manufacturing activities on the Company&#8217;s behalf. Amounts incurred in connection with license and asset purchase agreements are also included in research and development expenses. Manufacturing costs related to products undergoing regulatory approval are expensed as research and development costs until receipt of such approval. </p></ix:nonNumeric><ix:nonNumeric id="F_000312" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000312_dcnt_81681d33-3f25-4250-9a2b-2b80eb5fc01e">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based awards to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight line-basis over the </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000288_dcnt_3193e0d4-45a2-4caa-b310-9d3c4516562f" continuedAt="F_000288_dcnt_c95576f4-9449-465e-9cd1-6b86a8e33bf4"><ix:continuation id="F_000312_dcnt_81681d33-3f25-4250-9a2b-2b80eb5fc01e">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employee&#8217;s or director&#8217;s requisite service period (generally the vesting period). </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-based awards to non-employees are recorded at their fair value as of the grant date</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, using the Black-Scholes option pricing model and recognized as expense over the period in which the related services are received. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for Black-Scholes option pricing model inputs</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accounts for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forfeitures </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-based awards </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when they occur. </span></p></ix:continuation><ix:nonNumeric id="F_000313" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been <ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> interest or penalties charged in relation to unrecognized tax benefits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal Revenue Code Section 382 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In the event that the Company experiences a change of ownership, utilization of the net operating loss and tax credit carryforwards may be restricted.</p></ix:nonNumeric><ix:nonNumeric id="F_000314" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss represents all changes in stockholders' equity except those resulting from and distributions to stockholders. The Company&#8217;s unrealized gains and losses on debt securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss. </p></ix:nonNumeric><ix:nonNumeric id="F_000315" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. </p><ix:nonNumeric id="F_000319" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000350" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,697,075</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000351" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">2,767,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000352" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">1,996,211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units (unvested)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000353" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">37,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000354" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,734,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000355" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001305253_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">2,767,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000356" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001305253_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">1,996,211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000316" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000316_dcnt_d9908877-af42-492c-aeb1-d957cc103f0a">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820)</span>. The standard eliminates, modifies and adds disclosure requirements </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000288_dcnt_c95576f4-9449-465e-9cd1-6b86a8e33bf4"><ix:continuation id="F_000316_dcnt_d9908877-af42-492c-aeb1-d957cc103f0a">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for fair value measurements. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance on January 1, 2020. </span><span style="color:#000000;">The adoption did not have a material impact on the Company&#8217;s</span><span style="color:#000000;"> </span><span style="color:#000000;">consolidated financial statements.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, the FASB issued&#160;ASU No.&#160;2018-15,&#160;<span style="font-style:italic;">Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</span> <span style="font-style:italic;">(Subtopic 350-40)</span>. The standard&#160;adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The pronouncement is effective for fiscal years beginning after December&#160;15, 2019, and interim periods within those fiscal years, with early adoption permitted. The amendments in ASU No, 2018-15&#160;should be applied either using a retrospective or prospective approach. <span style="color:#000000;">The Company adopted&#160;this guidance&#160;on January 1, 2020 using the prospective approach. The adoption did not have a material impact on the Company&#8217;s consolidated financial statements.</span></p></ix:continuation><ix:nonNumeric id="F_000317" name="eigr:AccountingPronouncementsNotYetAdoptedPolicyTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Pronouncements Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13,&#160;<span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326)</span>. The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,</span> which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, <span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), </span>which provides an option <span style="color:#000000;">to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost</span>. <span style="color:#000000;">In November 2019, the FASB issued ASU No. 2019-10, </span><span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)</span>, which<span style="font-style:italic;"> </span><span style="color:#000000;">defers the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of the guidance on its consolidated financial statements. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU No. 2020-04, <span style="font-style:italic;">Reference Rate Reform (Topic 848)</span>. The standard provides optional expedients for facilitating the effects of the reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for contract modifications permitted for contracts that are modified because of the reference rate reform and meet the scope guidance. The modifications of contracts within the scope of ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as separate contracts. <span style="color:#000000;">The pronouncement is effective for all entities as of March 12, 2020 through December 31, 2022. The Company plans to adopt upon the occurrence of such contract modification, but not later than December 31, 2022. The Company engaged in early-stage discussions with its lender and will assess the impact of the adoption once the contract is modified.</span></p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000289" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000289_dcnt_ee5e801e-15e7-4bb3-8a14-f68d87ebdbab">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). At December 31, 2020 and 2019, the carrying amount of prepaid expenses and other current assets, accounts payable and accrued liabilities approximated their estimate fair value due to their relatively short maturities. Management believes the terms of its long term debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company&#8217;s debt approximated its fair value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000289_dcnt_ee5e801e-15e7-4bb3-8a14-f68d87ebdbab" continuedAt="F_000289_dcnt_f3023bd3-404b-49e0-858d-2fe8a55279e7">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;">: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date&#59;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;">: Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities&#59; and</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;">: Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s money market funds are classified as Level 1 because they are valued using quoted market prices. The Company&#8217;s debt securities consist of available-for-sale securities and are classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> assets or liabilities classified as Level&#160;3 as of December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="eigr:FairValueTransfersBetweenLevelsTransfersAmount" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="eigr:FairValueTransfersBetweenLevelsTransfersAmount" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> transfers in or out of Level 3 of the fair value hierarchy during the periods presented.</p><ix:nonNumeric id="F_000320" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury bills</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,995</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,995</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,976</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">120,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,457</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,457</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,621</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="C_0001305253_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="C_0001305253_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> financial liabilities as of December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000289_dcnt_f3023bd3-404b-49e0-858d-2fe8a55279e7">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000321" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the estimated value of the Company&#8217;s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated<span style="font-family:Calibri;">&#160;</span>Fair&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="eigr:CashEquivalentsAmortizedCost" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="eigr:CashEquivalentsAmortizedCost" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury bills</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="eigr:CashEquivalentsAmortizedCost" contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,992</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,995</ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,984</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001305253_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001305253_20201231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,976</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated<span style="font-family:Calibri;">&#160;</span>Fair&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="eigr:CashEquivalentsAmortizedCost" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="eigr:CashEquivalentsAmortizedCost" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,457</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,457</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,579</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001305253_20191231" decimals="-3" scale="3">42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,621</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the contractual maturity of the available-for-sale debt securities is less than <ix:nonNumeric id="F_000425" name="eigr:AvailableForSaleOfDebtSecuritiesContractualMaturity" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_20200101_20201231" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_000426" name="eigr:AvailableForSaleOfDebtSecuritiesContractualMaturity" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_20190101_20191231" format="ixt-sec:durwordsen">one year</ix:nonNumeric></ix:nonNumeric>. <span style="Background-color:#FFFFFF;">The Company periodically reviews the available-for-sale investments for&#160;</span>other-than-temporary<span style="Background-color:#FFFFFF;">&#160;impairment loss. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, it also considers whether (i)&#160;it is more likely&#160;</span>than&#160;n<span style="Background-color:#FFFFFF;">ot that the Company will be required to sell the debt securities before recovery of </span><span style="color:#000000;">their</span><span style="Background-color:#FFFFFF;"> amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. As of December 31, 2020, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:ImpairmentOfInvestments" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognize any&#160;</span>other-than-temporary<span style="Background-color:#FFFFFF;">&#160;impairment losses. All debt securities with unrealized losses have been in a loss position for </span>less&#160;than<span style="Background-color:#FFFFFF;">&#160;12 months.</span></p></ix:continuation><ix:nonNumeric id="F_000290" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000290_dcnt_505b0658-30d8-4e83-bd54-3a6a6f3a3c4d">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Components</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment, Net</p><ix:nonNumeric id="F_000322" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20201231" decimals="-3" scale="3">520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20191231" decimals="-3" scale="3">160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" scale="3">111</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" scale="3">111</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" scale="3">80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" scale="3">61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20201231" decimals="-3" scale="3">271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20191231" decimals="-3" scale="3">36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" scale="3">69</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" scale="3">436</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001305253_20191231" decimals="-3" scale="3">804</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001305253_20201231" decimals="-3" scale="3">342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001305253_20191231" decimals="-3" scale="3">214</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001305253_20201231" decimals="-3" scale="3">709</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001305253_20191231" decimals="-3" scale="3">590</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000290_dcnt_505b0658-30d8-4e83-bd54-3a6a6f3a3c4d">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December&#160;31, 2020, 2019 and 2018 was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:Depreciation" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal">167,000</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:Depreciation" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal">68,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:Depreciation" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal">54,000</ix:nonFraction>, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid Expenses and Other Current Assets</p><ix:nonNumeric id="F_000323" name="eigr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consist of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid contract manufacturing costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="eigr:PrepaidContractManufacturingCosts" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,126</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="eigr:PrepaidContractManufacturingCosts" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="eigr:PrepaidResearchCosts" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="eigr:PrepaidResearchCosts" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:PrepaidInsurance" contextRef="C_0001305253_20201231" decimals="-3" scale="3">448</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:PrepaidInsurance" contextRef="C_0001305253_20191231" decimals="-3" scale="3">421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="eigr:OtherPrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="eigr:OtherPrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,968</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,966</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Liabilities</p><ix:nonNumeric id="F_000324" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract research costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="eigr:AccruedContractedResearchCostsCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,062</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="eigr:AccruedContractedResearchCostsCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract manufacturing costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="eigr:ContractManufacturingCostsCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="eigr:ContractManufacturingCostsCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,510</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation and related benefits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,169</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,707</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001305253_20191231" decimals="-3" scale="3">496</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000291" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000291_dcnt_793918c3-527f-42ed-bf8d-d0a3dc677dd3">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License, Collaboration, and Product Development Agreements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreement with the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into a license agreement (the UPenn/CHOP Agreement) with the Trustees of the University of Pennsylvania (UPenn) and the Children&#8217;s Hospital of Philadelphia (CHOP), under which the Company obtained an exclusive, royalty-bearing, worldwide license to develop, manufacture and sell certain Glucagon Like Peptide-1 (GLP-1) receptor antagonist(s) products to treat all human and animal conditions. The Company also obtained an exclusive, royalty-bearing, sublicenseable, worldwide license to certain data developed by CHOP. <span style="Background-color:#FFFFFF;color:#000000;">The Company is responsible for the development and commercialization of the licensed products at its sole cost and expense.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the consideration for the rights granted to the Company under the UPenn/CHOP Agreement, the Company paid UPenn a one-time, non-refundable issue fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="eigr:NonRefundableIssueFee" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20190101_20191231" decimals="-5" scale="6">1.0</ix:nonFraction> million, which is recorded in research and development expenses for the year ended December 31, 2019. In addition, the Company is obligated to pay UPenn a specified annual license maintenance fee, up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="eigr:LicenseMaintenanceFee" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231" decimals="-5" scale="6">2.5</ix:nonFraction> million in certain regulatory milestones, and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="eigr:MilestoneObligations" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapIncomeStatementLocationAxis_eigrCommercialSalesMember_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231" decimals="-5" scale="6">18.0</ix:nonFraction> million in commercial milestones. The Company will also be required to pay UPenn a flat royalty in the low-single digits on net sales of all licensed products by the Company, subject to specified reductions and offsets, and specified minimum annual royalty payments. The Company&#8217;s obligation to pay royalties expires on a product-by-product and country-by-country basis, on the later of: (i) the expiration of the last valid claim in the licensed patents in any country, or (ii) the tenth anniversary of the first commercial sale of the product in such country. <ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="eigr:MilestoneObligations" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231" decimals="-3" format="ixt-sec:numwordsen" scale="3">No</ix:nonFraction> milestones have been achieved as of December 31, 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the UPenn/CHOP Agreement in its entirety for any reason by providing prior written notice to UPenn and CHOP. UPenn or CHOP may terminate the UPenn/CHOP Agreement, upon a written notice, for the Company&#8217;s failure to achieve the specified diligence milestones within the specified periods, subject to the Company&#8217;s extension rights.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000291_dcnt_793918c3-527f-42ed-bf8d-d0a3dc677dd3" continuedAt="F_000291_dcnt_e91e2f71-b090-42b8-affe-f43122ef71de">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product Development Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;11, 2018, the Company entered into a Product Development Agreement and a First Project Agreement (the Product Agreements) with RDD International, LLC., pursuant to which the Company will receive development program support services for its hepatitis Delta virus (HDV) program. The services are to be provided from July&#160;1, 2018 through the completion of the Phase 3 Clinical Study Reports and the subsequent new drug application (NDA) filing. As consideration, the Company has committed to pay fees of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="eigr:ProductDevelopmentFees" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811" decimals="-5" scale="6">10.0</ix:nonFraction> million in cash and stock over four years, including approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="eigr:ExpertConsultantFeesAndPassThroughCosts" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811" decimals="-5" scale="6">0.8</ix:nonFraction> million for expert consultant fees and pass through costs to vendors, plus certain incentive-based regulatory milestone fees up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="eigr:IncentiveBasedRegulatoryMilestoneFees" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811" decimals="-5" scale="6">1.0</ix:nonFraction> million. <span style="Background-color:#FFFFFF;color:#000000;">As part of the aggregate payment, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000474" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811" decimals="INF" format="ixt:numdotdecimal">115,526</ix:nonFraction> shares of common stock subject to quarterly vesting requirements related to performance of the services and achievement of budget timeline set forth in the Product Agreements. </span>The Product Agreements can be terminated by either party due to material breach or by the Company without cause with <ix:nonNumeric id="F_000475" name="eigr:ProductAgreementTerminationNoticePeriod" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811" format="ixt-sec:durday">90</ix:nonNumeric> days prior written notice. For the years ended December 31, 2020, 2019 and 2018, the Company recognized research and development expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20190101_20191231" decimals="-5" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180101_20181231" decimals="-5" scale="6">0.4</ix:nonFraction> million, respectively, related to vesting of the shares issued under the <span style="Background-color:#FFFFFF;color:#000000;">Product Agreements</span>. Additionally, as of December&#160;31, 2020, the total unrecognized compensation expense related to unvested restricted shares was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million, which the Company expects to recognize over an estimated weighted-average period of <ix:nonNumeric id="F_000480" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20200101_20201231" format="ixt-sec:duryear">1.3</ix:nonNumeric> years. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Progeria Research Foundation (PRF) Collaboration Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 15, 2018, the Company entered into a Collaboration and Supply Agreement (the PRF Collaboration Agreement) with PRF. Under the PRF Collaboration Agreement, the parties agreed to collaborate with respect to the development and pursuit of regulatory approval of lonafarnib for the treatment of progeria and progeroid laminopathies in humans. PRF granted the Company a non-exclusive, world-wide, royalty-free, sub-licensable license pertaining to all intellectual property and data controlled by PRF to prepare and file any NDA for a product containing lonafarnib for progeria and progeroid laminopathies. The Company is obligated to: (i) exclusively supply lonafarnib to PRF for use in clinical trials and non-clinical research in progeria and progeroid laminopathies at the Company&#8217;s expense, (ii) prepare and be the sponsor of any NDA submission for lonafarnib for the treatment of progeria and progeroid laminopathies to the FDA, (iii) use commercially reasonable efforts to file a NDA for progeria and progeroid laminopathies by a specified date, (iv) submit a rare pediatric disease designation and a request for expedited approval in connection with a NDA filing, (v) establish a patient support program in progeria and progeroid laminopathies, and (vi) use commercially reasonable efforts to develop a pediatric formulation of lonafarnib for use in progeria and progeroid laminopathies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the PRF Collaboration Agreement, the Company is solely responsible for any additional studies necessary for obtaining an NDA for progeria and progeroid laminopathies and is also responsible for any additional costs for such studies up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20180216_20180315" decimals="-5" scale="6">2.0</ix:nonFraction> million. The PRF Collaboration Agreement continues for an initial term of <ix:nonNumeric id="F_000482" name="eigr:CollaborationAgreementInitialTerm" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20180216_20180315" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> and automatically renews for subsequent renewal terms of <ix:nonNumeric id="F_000483" name="eigr:CollaborativeArrangementRenewalTerm" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20180216_20180315" format="ixt-sec:durwordsen">two years</ix:nonNumeric> each unless either party terminates earlier.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinigen Master Service Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 26, 2018, the Company entered into a master service agreement with Clinigen Healthcare Ltd. (Clinigen) in anticipation of its obligations under the PRF Collaboration Agreement to establish an Expanded Access Program (EAP) for children with progeria and progeroid laminopathies. On May 23, 2018, the Company entered into the first statement of work (SOW) under the agreement. Pursuant to the SOW, Clinigen became an authorized non-exclusive worldwide distributor of lonafarnib, the unlicensed pharmaceutical product (the Product). The Company is responsible for supply of the Product to Clinigen, and Clinigen is responsible for providing the Product to patients as part of the patient support program. Clinigen is also obligated to set up, manage and close-out the patient support program. The agreement will continue on a country-by-country basis until the Product is commercially available in that country. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Bristol-Meyers Squibb License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;20, 2016, the Company and Bristol-Myers Squibb Company (BMS) entered into a License Agreement (the BMS License Agreement) and a Common Stock Purchase Agreement (the BMS Purchase Agreement).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BMS License Agreement, BMS granted the Company an exclusive, worldwide, license to research, develop, manufacture, and sell products containing PEG-interferon Lambda-1a (the&#160;Licensed Product) for all therapeutic and diagnostic uses in humans and animals. The Company is responsible for the development and </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000291_dcnt_e91e2f71-b090-42b8-affe-f43122ef71de">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialization of the Licensed Product at its sole cost and expense. The Company paid BMS $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="eigr:UpfrontCashPayments" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420" decimals="-5" scale="6">2.0</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and issued </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000485" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_eigrPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420" decimals="INF" format="ixt:numdotdecimal">157,587</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of its common stock at an aggregate fair value of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:CommonStockValue" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_eigrPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160420" decimals="-5" scale="6">3.2</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in April 2016. The BMS License Agreement also includes development and regulatory milestone payments totaling $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="eigr:MilestoneObligations" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentAndRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420" decimals="-5" scale="6">61.0</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and commercial sales milestones of up to $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="eigr:MilestoneObligations" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrCommercialSalesMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420" decimals="-5" scale="6">128.0</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million. The Company is obligated to pay BMS annual net sales royalties in the range of mid-single to mid-teens, depending on net sales levels. In fourth quarter 2020, the Company recorded </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in research and development</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> expense</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="eigr:MilestoneObligations" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentPhaseTwoMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420" decimals="-5" scale="6">3.0</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million milestone, triggered on successful demonstration of proof of concept, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as defined by the BMS License Agreement, in a Phase 2 clinical trial. The next milestone is $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="eigr:IncreaseInMilestoneObligations" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentPhaseThreeMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420" decimals="-5" scale="6">5.0</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million triggered on the initiation of a Phase 3 clinical trial.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merck License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2010, the Company entered into an exclusive license agreement with Schering Corporation, subsequently acquired by Merck&#160;&#38; Co., Inc. (Merck), which provides the Company with the exclusive right to develop, manufacture, and sell products containing the compounds lonafarnib for the treatment of all human viruses except certain specified viruses such as hepatitis B and hepatitis C alone. As part of consideration, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000492" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20100930" decimals="INF" format="ixt:numdotdecimal">27,350</ix:nonFraction> shares of common stock with a fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:CommonStockValue" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20100930" decimals="-5" scale="6">0.5</ix:nonFraction> million. <ix:nonNumeric id="F_000496" name="eigr:RoyaltiesExpirationDescription" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20200101_20201231">The Company is obligated to pay Merck up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="eigr:DevelopmentMilestoneObligations" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20100901_20100930" decimals="-5" scale="6">27.0</ix:nonFraction> million in development milestones and will be required to pay tiered royalties based on aggregate annual net sales of all licensed products ranging from mid-single to low double-digit royalties on net sales.</ix:nonNumeric> In May 2015, the first regulatory milestone was achieved and the Company paid the related milestone payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="eigr:MilestonePayments" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20150501_20150531" decimals="-5" scale="6">1.0</ix:nonFraction> million to Merck. <ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="eigr:MilestonePayments" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20200101_20201231" decimals="-6" format="ixt-sec:numwordsen" scale="6">No</ix:nonFraction> additional milestones have been achieved as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 15, 2018, the Company entered into an amendment to the exclusive license agreement with Merck, which provides for expansion of the existing exclusively licensed field of use under the license agreement with Merck to include all uses of lonafarnib related to the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) in humans at no cost to the Company. On November 3, 2020, the Company entered into an amendment to the exclusive license agreement with Merck which expanded the definition of progeria to also include progeroid laminopathies. The Company has the sole responsibility and the continuing obligation for the manufacture and supply of lonafarnib to the PRF. Merck will not receive milestone payments in relation to lonafarnib for the treatment of progeria and progeroid laminopathies or any royalty payments for sales of a specified quantity of lonafarnib to treat the currently estimated progeria and progeroid laminopathies patient population worldwide.</p></ix:continuation><ix:nonNumeric id="F_000292" name="eigr:AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000292_dcnt_371a69da-ba6e-4de4-9540-e3a5d3fb31e0">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Asset Purchase Agreements and Related License Agreements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EGI Asset Purchase Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2010, the Company entered into an asset purchase agreement with Eiger Group International, Inc. (EGI). Dr. Jeffrey Glenn, a founder and director of the Company, is the sole owner of EGI. Pursuant to the agreement, the Company purchased all of the assets including the intellectual property rights related to the use of farnesyl transferase inhibitors as anti-viral agents and methods to treat viral infections with those inhibitors and inhibitors of prenylation, prenyl cysteine methyltranferase and a protease as anti-viral agents and methods to treat viral infection with those inhibitors. The Company paid EGI an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="eigr:UpfrontCashPayments" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20101201_20101231" decimals="-5" scale="6">0.4</ix:nonFraction> million when the agreement was executed in December 2010. Additionally, the Company will pay EGI a low single-digit royalty based on aggregate annual net sales of products developed using the intellectual property. <ix:nonNumeric id="F_000498" name="eigr:AssetPurchaseDescription" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20200101_20201231">Within the first ten years after commercialization, the Company may make a one-time payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="eigr:OneTimePaymentToBeMadeOnAssetPurchaseAgreement" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20101231" decimals="-5" scale="6">0.5</ix:nonFraction> million for each contract for the three types of product related to such intellectual property that would reduce the payment term for the three products to the tenth anniversary of the first commercial sale.</ix:nonNumeric> <ix:nonNumeric id="F_000500" name="eigr:RoyaltiesExpirationDescription" contextRef="C_0001305253_srtProductOrServiceAxis_eigrProductOneMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20200101_20201231">The obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either when the product is no longer sold in any country or the earliest of the tenth anniversary of the first commercial sale of the product.</ix:nonNumeric> As of December 31, 2020, the product has not achieved regulatory approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Avexitide Purchase Agreement and Related Stanford License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2015, the Company entered into an asset purchase agreement with two individuals, Dr. Tracey McLaughlin and Dr. Colleen Craig, (the Sellers), whereby the Company purchased all of the assets related to the compound avexitide (formerly known as exendin 9-39) including any related intellectual property from the Sellers (the Exendin APA). The Company also entered into a consulting agreement with the Sellers as part of the agreement. The Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000501" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930" decimals="INF" format="ixt:numdotdecimal">15,378</ix:nonFraction> shares of common stock that were valued at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930" decimals="-5" scale="6">0.2</ix:nonFraction> million and with the option to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000503" name="eigr:OptionsToPurchaseOfCommonStock" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930" decimals="INF" format="ixt:numdotdecimal">46,134</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000504" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150930" decimals="2">2.06</ix:nonFraction> per share when the agreement was executed in September 2015.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000292_dcnt_371a69da-ba6e-4de4-9540-e3a5d3fb31e0">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the 46,134 options to purchase common stock, 15,378 shares vest monthly over <ix:nonNumeric id="F_000505" name="eigr:VestingPeriodOfOptionsIssuedForCommonStockPurchase" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930" format="ixt-sec:durwordsen">four years</ix:nonNumeric> as services are provided by the Sellers and <ix:nonFraction unitRef="U_xbrlishares" id="F_000506" name="eigr:VestingOfOptionsToPurchaseCommonStock" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930" decimals="INF" format="ixt:numdotdecimal">30,756</ix:nonFraction> vest upon the earlier of the first commercial sale of the product or the approval of new drug application by the U.S. Food and Drug Administration (the milestone-vested options).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 22, 2016, immediately following the closing of the merger, the Company issued additional top-up options to the Sellers to purchase an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000507" name="eigr:OptionsToPurchaseOfCommonStock" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20160321_20160322" decimals="INF" format="ixt:numdotdecimal">48,544</ix:nonFraction> shares of common stock, pursuant to the terms of the Exendin APA, with an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000508" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20160322" decimals="2">17.25</ix:nonFraction> per share. The top-up options consist of both time-vested and milestone-vested options.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the time-vested options is recognized as stock-based compensation expense as the awards vest over time. The fair value of the milestone-vested options will be recognized as research and development expense when it is probable that the earliest milestone will be achieved at their fair value as of the ASU 2018-07 adoption date. During the years ended December 31, 2020, 2019 and 2018, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20180101_20181231" decimals="1">0.1</ix:nonFraction> million of compensation expense related to the time-vested options, respectively. <ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> expense was recognized for the milestone vested options during the years ended December 31, 2020, 2019 and 2018.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also obligated to pay development milestone payments in an aggregate amount of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="eigr:LicenseAgreementPotentialMilestonePayments" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930" decimals="-5" scale="6">1.0</ix:nonFraction> million to each Seller. Additionally, the Company is obligated to pay each Seller royalties of low single-digits based on aggregate annual net sales of all products developed based on avexitide, subject to certain reductions and exceptions. The Company&#8217;s obligation to pay royalties expires on the expiration of the last to expire patent assigned to the Company under the agreement. Additionally, the Company has assumed the license agreement the Sellers had previously entered into with the Board of Trustees of the Leland Stanford Junior University (Stanford). The Company is obligated to pay a royalty to Stanford in the low single-digits on annual net sales after the first commercial sale of any products developed based on avexitide. As of December 31, 2020, the Company has paid a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="eigr:LicenseAgreementMilestonePaymentsPaid" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million in milestone payments to each of the Sellers related to the successful completion of the Phase 2 trials.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Asset Purchase Agreement with AbbVie Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 20, 2020, the Company entered into an asset purchase agreement (AbbVie APA) with AbbVie Inc. (AbbVie) to sell its Rare Pediatric Disease Priority Review Voucher, which was awarded the PRV on November 20, 2020 upon approval by the FDA of the NDA for Zokinvy in Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies (the PRV) to AbbVie. The AbbVie Agreement contains customary representations, warranties, covenants, and indemnification provisions subject to certain limitations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the PRV, AbbVie agreed to pay the Company $<ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="eigr:PaymentForAssetPurchaseAgreement" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAbbvieAssetPurchaseAgreementMember_20201119_20201120" decimals="-5" scale="6">95.0</ix:nonFraction> million. The transaction closed in January 2021. Such consideration was shared equally with The Progeria Research Foundation (&#8220;PRF&#8221;) in accordance with the terms of the PRF Collaboration Agreement, pursuant to which the Company and PRF will equally share any proceeds from the sale of a priority review voucher that the Company may receive as the sponsor of a rare pediatric disease product application. The Company retained approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAbbvieAssetPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20201119_20201120" decimals="-5" scale="6">47.4</ix:nonFraction> million of the proceeds from the sale of the PRV.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000293" name="us-gaap:DebtDisclosureTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000293_dcnt_f5a310a1-63a3-4054-bab8-188099d1dee9">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Debt</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into an aggregate $<ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20161231" decimals="-5" scale="6">25.0</ix:nonFraction> million loan with Oxford Finance LLC (the Oxford Loan). The Company borrowed $<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20161231" decimals="-5" scale="6">15.0</ix:nonFraction> million in December 2016 (Tranche A). In May 2018, the Company entered into an amendment to the Oxford Loan<span style="color:#000000;"> and borrowed </span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanAmendmentMember_20180531" decimals="-5" scale="6">5.0</ix:nonFraction> million (Tranche B). <span style="Background-color:#FFFFFF;">On August 3, 2018, the Company </span>borrowed the remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheCMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanAmendmentMember_20180803" decimals="-5" scale="6">5.0</ix:nonFraction> million (Tranche C) under the Oxford Loan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Oxford Loan bears interest at a <ix:nonNumeric id="F_000523" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20200101_20201231">floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus <ix:nonFraction unitRef="U_xbrlipure" id="F_000524" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20200101_20201231" decimals="INF" scale="-2">6.41</ix:nonFraction>% or <ix:nonFraction unitRef="U_xbrlipure" id="F_000525" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="4" scale="-2">6.95</ix:nonFraction>%.</ix:nonNumeric> The interest only period for borrowed funds is until February 1, 2019, followed by 30 equal monthly payments of principal plus accrued interest.&#160;At the time of final payment, the Company is required to pay an exit fee of <ix:nonFraction unitRef="U_xbrlipure" id="F_000527" name="eigr:DebtInstrumentExitFeePayablePercentage" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="3" scale="-2">7.5</ix:nonFraction>% of the original principal balance of borrowed funds, or $<ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="eigr:DebtInstrumentUnamortizedExitFees" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="-5" scale="6">1.9</ix:nonFraction> million. In addition,&#160;at the time of final payment of Tranche B, the Company is required to pay an additional exit fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="eigr:DebtInstrumentUnamortizedExitFees" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million.&#160;The Company recorded as a liability and debt discount the exit fee at the origination of the </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000293_dcnt_f5a310a1-63a3-4054-bab8-188099d1dee9" continuedAt="F_000293_dcnt_105594ed-ec4c-4fb5-a4de-d1b2a2eabd10">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term loan. In addition, the Company incurred loan origination fees and debt issuance costs of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:DeferredFinanceCostsGross" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20161231" decimals="-5" scale="6">0.4</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million which were recorded as a&#160;direct deduction from the carrying amount of the related debt liability as a debt discount. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 5, 2019, the Company entered into the third amendment to the Oxford Loan (the Amended Oxford Loan) to refinance the Oxford Loan. The Amended Oxford Loan increased the aggregate amount available to be borrowed to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305" decimals="-5" scale="6">35.0</ix:nonFraction> million and extended the maturity date to <ix:nonNumeric id="F_000532" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231" format="ixt:datemonthdayyearen">March 1, 2024</ix:nonNumeric>. On March 5, 2019, prior to entering into the Amended Oxford Loan, the outstanding balance of the Oxford Loan was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:LineOfCredit" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305" decimals="-5" scale="6">23.3</ix:nonFraction> million. At the time of entering into the Amended Oxford Loan, the Company borrowed an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305_20190305" decimals="-5" scale="6">6.7</ix:nonFraction> million in principal under the Amended Oxford Loan, which increased the total amount borrowed to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305" decimals="-5" scale="6">30.0</ix:nonFraction> million (Amended Tranche A). The remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheBMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305" decimals="-5" scale="6">5.0</ix:nonFraction> million (Amended Tranche B) is available to the Company provided that certain milestones are achieved by February 2021. The Company does not currently expect to draw down Amended Tranche B.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Amended Oxford Loan bears interest at a <ix:nonNumeric id="F_000537" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231">floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus <ix:nonFraction unitRef="U_xbrlipure" id="F_000538" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20200101_20201231" decimals="4" scale="-2">6.64</ix:nonFraction>% or <ix:nonFraction unitRef="U_xbrlipure" id="F_000539" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231" decimals="INF" scale="-2">9.15</ix:nonFraction>%.</ix:nonNumeric> The Amended Oxford Loan has an interest only period until April 1, 2021, followed by 36 equal monthly payments of principal and interest. Upon the receipt of Amended Tranche B, the interest only period for borrowed funds will be extended by <ix:nonNumeric id="F_000542" name="eigr:DebtInstrumentExtendedInterestOnlyPaymentPeriod" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheBMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231" format="ixt-sec:durwordsen">one year</ix:nonNumeric><span style="color:#000000;"> until April 1, 2022, followed by 24 equal monthly payments of principal plus accrued interest.</span> At the time of final payment, the Company is required to pay an exit fee of <ix:nonFraction unitRef="U_xbrlipure" id="F_000543" name="eigr:DebtInstrumentExitFeePayablePercentage" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231" decimals="3" scale="-2">7.5</ix:nonFraction>% of the original principal balance of borrowed funds, or $<ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="eigr:DebtInstrumentUnamortizedExitFees" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231" decimals="-5" scale="6">2.3</ix:nonFraction> million. In addition, <span style="color:#000000;">the Company is required to pay an additional exit fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="eigr:DebtInstrumentUnamortizedAdditionalExitFees" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231" decimals="-5" scale="6">1.0</ix:nonFraction> million</span>. The Company recorded as a liability and debt discount the exit fee for the Amended Oxford Loan. At the date of the Amended Oxford Loan, the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="eigr:RepaymentsOfLoanAgreementExitFee" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20190101_20191231" decimals="-5" scale="6">0.9</ix:nonFraction> million for the accrued portion of the Oxford Loan exit fee and the Tranche B additional exit fee. The loan discount balance at the time of the Amended Oxford Loan was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:DeferredFinanceCostsGross" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million, which is being amortized over the remaining term of the Amended Oxford Loan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also required to pay a <ix:nonFraction unitRef="U_xbrlipure" id="F_000548" name="eigr:DebtInstrumentSuccessFeesPayablePercentage" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapRegulatoryAgencyAxis_eigrFoodAndDrugAdministrationMember_20200101_20201231" decimals="3" scale="-2">5.0</ix:nonFraction>% success fee <span style="color:#000000;">of the total amount drawn under the Amended Oxford Loan </span>within <ix:nonNumeric id="F_000549" name="eigr:DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapRegulatoryAgencyAxis_eigrFoodAndDrugAdministrationMember_20200101_20201231" format="ixt-sec:durday">30</ix:nonNumeric> days following the FDA&#8217;s approval of the Company&#8217;s first product, excluding lonafarnib in Progeria and Progeroid Laminopathies. This fee is enforceable within <ix:nonNumeric id="F_000550" name="eigr:DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapRegulatoryAgencyAxis_eigrFoodAndDrugAdministrationMember_20200101_20201231" format="ixt-sec:duryear">10</ix:nonNumeric> years from the funding of Amended Tranche A. The Company determined that the success fee met the scope exemption from derivative accounting and should be accounted for under the guidance for contingencies. Accordingly, the Company will record a liability for the success fee upon receipt of approval from the FDA. <span style="color:#000000;">The Amended Oxford Loan includes contingent interest features and mandatory prepayment features upon an event of default that meet the definition of a derivative but were not bifurcated from the debt instrument as their fair value was deemed to be insignificant</span><span style="color:#548235;">. </span>In connection with the execution of the Oxford Loan, the Company agreed to certain customary representations and warranties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The refinancing of the term loan did not have a material impact on terms, conditions, representations, warranties, covenants or agreements set forth in the Oxford Loan. <span style="color:#000000;">The loan is secured by the perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company&#8217;s intellectual property. <ix:nonNumeric id="F_000552" name="us-gaap:DebtInstrumentCovenantDescription" contextRef="C_0001305253_20200101_20201231">The loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency.</ix:nonNumeric></span> If the Company is unable to comply with these covenants or if the Company defaults on any portion of the outstanding borrowings, the lenders can also impose a <ix:nonFraction unitRef="U_xbrlipure" id="F_000551" name="eigr:DebtInstrumentCovenantNoncompliancePenalty" contextRef="C_0001305253_20200101_20201231" decimals="3" scale="-2">5.0</ix:nonFraction>% penalty, restrict access to additional borrowings under the loan and security agreement, <ix:nonNumeric id="F_000553" name="us-gaap:DebtInstrumentCovenantCompliance" contextRef="C_0001305253_20200101_20201231">and accelerate the maturity of the debt.</ix:nonNumeric> <span style="color:#000000;">As of December 31, 2020, the Company was in compliance with all covenants.&#160;&#160;  </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is permitted to make voluntary prepayments of the Amended Oxford Loan with a prepayment fee, <ix:nonNumeric id="F_000556" name="eigr:PrepaymentOfLoanFeeDescription" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231">calculated as of the loan origination date, equal to (i) <ix:nonFraction unitRef="U_xbrlipure" id="F_000554" name="eigr:DebtInstrumentPrepaymentFeePercentage" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapDebtInstrumentRedemptionPeriodAxis_eigrLoanPrepaidDuringFirstTwelveMonthsMember_20200101_20201231" decimals="3" scale="-2">2.0</ix:nonFraction>% of the loan prepaid during the first 12 months and (ii) <ix:nonFraction unitRef="U_xbrlipure" id="F_000555" name="eigr:DebtInstrumentPrepaymentFeePercentage" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapDebtInstrumentRedemptionPeriodAxis_eigrLoanPrepaidDuringThirteenToTwentyFourMonthsMember_20200101_20201231" decimals="3" scale="-2">1.0</ix:nonFraction>% of the loan prepaid in months 13-24.</ix:nonNumeric> The Company is required to make mandatory prepayments of the outstanding loan upon the acceleration by lender following the occurrence of an event of default, along with a payment of the final payment, the prepayment fee and any other obligations that are due and payable at the time of prepayment.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000293_dcnt_105594ed-ec4c-4fb5-a4de-d1b2a2eabd10">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for the&#160;amortization of the&#160;debt discount utilizing the effective interest method. <ix:nonNumeric id="F_000325" name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000325_cnt_1">Long-term debt and unamortized discount balances are as follows (in thousands):</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000325_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Face value of long term debt</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exit fee</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="eigr:DebtInstrumentUnamortizedExitFees" contextRef="C_0001305253_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="eigr:DebtInstrumentUnamortizedExitFees" contextRef="C_0001305253_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount associated with exit fee, debt issuance costs and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; loan origination fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long term debt, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:LongTermDebt" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:LongTermDebt" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000326" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, future minimum payments of principal, exit fee and interest expense under the Oxford Loan were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,662</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,734</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: unamortized interest</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="eigr:DebtInstrumentUnamortizedInterest" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: exit fee</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="eigr:DebtInstrumentUnamortizedExitFees" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Face value of term loan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 23, 2021, the Company entered into the fifth amendment to the Oxford Loan (Note 14). As the Company refinanced the short-term portion of the Oxford Loan on a long-term basis prior to the issuance of the financial statements, the current portion of long-term debt as of December 31, 2020 was reclassified as long-term at the balance sheet date.&#160;&#160; </p></ix:continuation><ix:nonNumeric id="F_000294" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000294_dcnt_4aee6b52-66b6-4ab6-9c34-313ef4b86dcb">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Company&#8217;s common stock have one vote for each share of common stock. Common stockholders are entitled to dividends when, as, and if declared by the Board of Directors, subject to the prior rights of the convertible preferred stockholders. As of December&#160;31, 2020, <ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="eigr:DividendsDeclared" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> dividends had been declared by the Board of Directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 17, 2019, the Company completed an underwritten public offering of <ix:nonFraction unitRef="U_xbrlishares" id="F_000574" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417_20190417" decimals="INF" format="ixt:numdotdecimal">5,175,000</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="U_xbrlishares" id="F_000575" name="eigr:NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417_20190417" decimals="INF" format="ixt:numdotdecimal">675,000</ix:nonFraction> shares sold upon full exercise of the underwriters&#8217; option to purchase additional shares of common stock, at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000576" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417" decimals="2">11.00</ix:nonFraction> per share. The offering was made under the Company&#8217;s effective shelf registration statement and resulted in net proceeds to the Company of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417_20190417" decimals="-5" scale="6">53.2</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company filed a shelf registration statement on Form S-3 (File No. 333-235655) with the Securities and Exchange Commission, which permits the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" contextRef="C_0001305253_20191201_20191231" decimals="-5" scale="6">150.0</ix:nonFraction> million of the company&#8217;s common stock, preferred stock, debt securities and warrants. Up to a maximum of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="eigr:MaximumEquityDebtWarrantsIssuedDuringThePeriod" contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20191201_20191231" decimals="-5" scale="6">50.0</ix:nonFraction> million of the maximum aggregate offering price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20191201_20191231" decimals="-5" scale="6">150.0</ix:nonFraction> million may be issued and sold pursuant to an at-the-market (ATM) financing facility (2019 ATM Facility) under a sales agreement with Jefferies LLC (Jefferies). In August 2020, the Company entered into a new sales agreement with Jefferies for up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="eigr:AmountOfCommonStockAvailableForSale" contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20200830_20200831" decimals="-5" scale="6">50.0</ix:nonFraction> million of the remaining amount on the shelf registration statement which may be sold pursuant to an ATM financing facility (2020 ATM Facility). </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000294_dcnt_4aee6b52-66b6-4ab6-9c34-313ef4b86dcb">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2020</span><span style="Background-color:#FFFFFF;">, </span><span style="Background-color:#FFFFFF;">the Company</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">has </span><span style="Background-color:#FFFFFF;">completed</span><span style="Background-color:#FFFFFF;"> both</span><span style="Background-color:#FFFFFF;"> the 2019 ATM Facility and the</span><span style="Background-color:#FFFFFF;"> 2020 ATM Facility</span><span style="Background-color:#FFFFFF;"> for a total of </span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000584" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">9,267,760</ix:nonFraction></span><span style="Background-color:#FFFFFF;"> shares resulting in $</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20200101_20201231" decimals="-5" scale="6">97.3</ix:nonFraction><span style="Background-color:#FFFFFF;"> million in net proceeds, after deducting commissions</span><span style="Background-color:#FFFFFF;">.</span><span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2020, the Company filed a new shelf registration statement on Form S-3 (File No. 333-251497) with the Securities and Exchange Commission, which permits the offering, issuance and sale by the Company up to a maximum aggregate offering price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" contextRef="C_0001305253_20201201_20201231" decimals="-5" scale="6">200.0</ix:nonFraction> million </span><span style="color:#000000;">of our common stock, preferred stock, debt securities and warrants. Up to a maximum of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="eigr:MaximumEquityDebtWarrantsIssuedDuringThePeriod" contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20201201_20201231" decimals="-5" scale="6">50.0</ix:nonFraction> million of the maximum aggregate offering price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20201201_20201231" decimals="-5" scale="6">200.0</ix:nonFraction> million may be issued and sold pursuant to a new ATM financing facility under a sales agreement with Jefferies.</span></p><ix:nonNumeric id="F_000327" name="eigr:CommonStockReservedForFutureIssuancesTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved shares of common stock for issuance as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000587" name="eigr:OptionsIssuedAndOutstanding" contextRef="C_0001305253_20201231" decimals="INF" format="ixt:numdotdecimal">3,697,075</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000588" name="eigr:OptionsIssuedAndOutstanding" contextRef="C_0001305253_20191231" decimals="INF" format="ixt:numdotdecimal">2,767,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options available for future grants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000589" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001305253_20201231" decimals="INF" format="ixt:numdotdecimal">1,021,109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000590" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001305253_20191231" decimals="INF" format="ixt:numdotdecimal">823,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000591" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001305253_20201231" decimals="INF" format="ixt:numdotdecimal">4,718,184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000592" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001305253_20191231" decimals="INF" format="ixt:numdotdecimal">3,591,215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000295" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000295_dcnt_19aae538-2ce7-4e17-a9bc-936327d6b3a4">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Equity Incentive Plans</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restated 2013 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Company&#8217;s Board of Directors adopted and in August 2016 the Company&#8217;s stockholders approved the Amended and Restated 2013 Equity Incentive Plan (the Restated 2013&#160;Plan). Under the terms of the Restated 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. <span style="Background-color:#FFFFFF;color:#000000;">Under the terms of the </span>Restated 2013&#160;<span style="Background-color:#FFFFFF;color:#000000;">Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000593" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231" decimals="INF" scale="-2">10</ix:nonFraction>% of the voting rights of all classes of stock, the exercise prices for incentive and non-statutory stock options may not be less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000594" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_eigrHoldersOfTenPercentOrMoreOfVotingPowerMember_20200101_20201231" decimals="INF" scale="-2">110</ix:nonFraction>% of fair market value, as determined by the Board of Directors. The terms of options granted under the Rested 2013 Plan may not exceed <ix:nonNumeric id="F_000595" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. The vesting schedule of newly issued option grants is generally <ix:nonNumeric id="F_000596" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">four years</ix:nonNumeric>.</span> As of December 31, 2020, the Company is authorized to issue up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000597" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">4,705,442</ix:nonFraction> shares under the Restated 2013&#160;Plan.</p><ix:nonNumeric id="F_000328" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000328_cnt_1">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under both the Company&#8217;s stock-based compensation plans during the year ended December 31, 2020 (in thousands, except share and per share data):</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:continuation id="F_000328_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Grant</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per<span style="font-family:Calibri;">&#160;</span>Option</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000598" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001305253_20191231" decimals="INF" format="ixt:numdotdecimal">823,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000604" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001305253_20191231" decimals="INF" format="ixt:numdotdecimal">2,767,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000610" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001305253_20191231" decimals="2">12.14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000616">7.94</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,218</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional options authorized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000599" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,226,169</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000600" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,149,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000605" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,149,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000611" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001305253_20200101_20201231" decimals="2">7.43</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000601" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">37,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000606" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">61,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000612" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001305253_20200101_20201231" decimals="2">8.41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or cancelled</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000602" name="eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">158,592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000607" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">158,592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000613" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001305253_20200101_20201231" decimals="2">10.27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000603" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001305253_20201231" decimals="INF" format="ixt:numdotdecimal">1,021,109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000608" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001305253_20201231" decimals="INF" format="ixt:numdotdecimal">3,697,075</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000614" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001305253_20201231" decimals="2">10.81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000617">7.55</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,048</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable as of December</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000609" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001305253_20201231" decimals="INF" format="ixt:numdotdecimal">2,041,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000615" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001305253_20201231" decimals="2">11.57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000618">6.71</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000621" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,125</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000622" name="eigr:ClosingPriceOfCommonStock" contextRef="C_0001305253_20201231" decimals="2">12.29</ix:nonFraction> as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options exercised in 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001305253_20200101_20201231" decimals="-5" scale="6">0.3</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001305253_20190101_20191231" decimals="-5" scale="6">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001305253_20180101_20181231" decimals="-5" scale="6">0.2</ix:nonFraction> million, respectively.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000295_dcnt_19aae538-2ce7-4e17-a9bc-936327d6b3a4" continuedAt="F_000295_dcnt_239abf25-7633-4655-95fa-076237ff1723">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020, 2019 and 2018, the<span style="Background-color:#FFFFFF;color:#000000;"> weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000626" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2">4.78</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000627" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2">8.98</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000628" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="2">7.50</ix:nonFraction> per share, respectively. </span>The total grant date fair value of options that vested during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_xbrlishares" id="F_000629" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="-5" scale="6">5.6</ix:nonFraction> million, $<ix:nonFraction unitRef="U_xbrlishares" id="F_000630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-5" scale="6">5.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_xbrlishares" id="F_000631" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="-5" scale="6">4.7</ix:nonFraction> million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records stock-based compensation on stock options by estimating the fair value of stock-based awards using the Black-Scholes option pricing model and amortizing the fair value of the stock-based awards granted over the applicable vesting period of the awards on a straight-line basis. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000329" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231" escape="true" continuedAt="F_000329_cnt_1">The fair value of stock options was estimated using the following weighted-average assumptions:</ix:nonNumeric>&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000329_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000632">5.00 - 6.08</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000633">5.27 - 6.08</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000634">5.27 - 6.08</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.00</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.00</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000638">9.67 - 9.84</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000642">73.00%&#160;&#160;- 77.00%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000643">73.14%&#160;&#160;- 83.19%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">84.00%&#160;&#160;- 95.00%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000648">0.39% - 1.37%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000649">1.42% - 2.57%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000650">1.67% - 2.68%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term<span style="font-style:normal;">: The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term for employee options). The Company uses the contractual term to determine the non-employee award fair value at the grant date. </span><span style="color:#000000;font-style:normal;">The contractual term of options granted under the Restated 2013 Plan is ten years.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility<span style="font-style:normal;">: Since the Company does not have a long trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, or stage in the life cycle. Beginning in the third quarter of 2019, as the Company had been publicly traded for four and a half years, the Company began to layer in its historical volatility in the calculation of expected volatility.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate<span style="font-style:normal;">: The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend<span style="font-style:normal;">: The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of <ix:nonFraction unitRef="U_xbrlipure" id="F_000654" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001305253_20200101_20201231" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction>.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2013 Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2013, the Company&#8217;s board of directors adopted and in 2016, upon the merger with Celladon, the Company amended and approved the 2013 Employee Stock Purchase Plan (2013 ESPP). The 2013 ESPP is intended to qualify as an employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code and is administered by the Company&#8217;s board of directors.</p><ix:nonNumeric id="F_000664" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231" continuedAt="F_000664_dcnt_f5965e5e-d570-4293-98df-563c7642608c"><p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock initially reserved for issuance under the 2013 ESPP was <ix:nonFraction unitRef="U_xbrlishares" id="F_000655" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20131231" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction> shares with an automatic annual increase to the shares issuable under the 2013 ESPP to the lower of (i) <ix:nonFraction unitRef="U_xbrlipure" id="F_000656" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" scale="-2">1</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, and (ii) <ix:nonFraction unitRef="U_xbrlishares" id="F_000657" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">165,000</ix:nonFraction> shares of common stock, unless a lower number determined by the board of directors. As of December 31, 2020, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000658" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">618,831</ix:nonFraction> shares are reserved for issuance and <ix:nonFraction unitRef="U_xbrlishares" id="F_000659" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">543,791</ix:nonFraction> shares available for future issuance under the 2013 ESPP. During the years ended December 31, 2020 and December 31, 2019, employees purchased <ix:nonFraction unitRef="U_xbrlishares" id="F_000660" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">25,645</ix:nonFraction> shares for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million and <ix:nonFraction unitRef="U_xbrlishares" id="F_000661" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">15,701</ix:nonFraction> shares for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million, respectively, under the 2013 ESPP.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000295_dcnt_239abf25-7633-4655-95fa-076237ff1723"><ix:continuation id="F_000664_dcnt_f5965e5e-d570-4293-98df-563c7642608c">
</ix:continuation>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2020,&#160;the Company revised its non-employee director compensation policy to approve the granting of restricted stock units (RSUs) in accordance with the Restated 2013 Equity Incentive Plan (the Restated 2013 Plan). Each eligible director who has served for less than six months during the prior calendar year and continues to serve as a non-employee member of the board is granted RSUs, which are pro-rated for the period served during the prior calendar year.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RSUs granted to non-employee directors will vest on the one-year anniversary of the grant date, subject to the eligible director&#8217;s continuous services through the vesting date, and will vest in full upon a change in control, as defined under the Restated 2013 Plan. RSUs granted to employees during the year ended December 31, 2020, commence vesting on the one-year anniversary through the two-year anniversary of the grant date. The fair value of all RSUs is measured at the grant date based on the closing market price of the Company&#8217;s common stock and is recognized as stock-based compensation expense on a straight-line basis over the vesting period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company granted <ix:nonFraction unitRef="U_xbrlishares" id="F_000665" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">37,500</ix:nonFraction> RSUs with a weighted-average grant date fair value of&#160;$<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000666" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="2">6.95</ix:nonFraction> per share. The Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million in stock-based compensation expense for the year ended December 31, 2020, which is included in general and administrative expenses. As of December 31, 2020, the total unrecognized compensation expense related to unvested RSUs was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million, which the Company expects to recognize over an estimated weighted-average period of <ix:nonNumeric id="F_000668" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231" format="ixt-sec:duryear">0.4</ix:nonNumeric> years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p><ix:nonNumeric id="F_000330" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,494</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,550</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,479</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the total unrecognized compensation expense related to unvested options was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001305253_20201231" decimals="-5" scale="6">10.2</ix:nonFraction>  million, which the Company expects to recognize over an estimated weighted average period of <ix:nonNumeric id="F_000680" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001305253_20200101_20201231" format="ixt-sec:duryear">2.5</ix:nonNumeric> years.</p></ix:continuation><ix:nonNumeric id="F_000296" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000296_dcnt_2ea7d0c1-d7db-41e2-ab91-9061a68b267e">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001305253_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001305253_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001305253_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for income taxes was recorded for the years ended December&#160;31, 2020, 2019 and 2018. The Company has incurred net operating losses (NOL) for all the periods presented. The Company has not reflected any benefit of such NOL carryforwards in the accompanying consolidated financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</p><ix:nonNumeric id="F_000331" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000684" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001305253_20200101_20201231" decimals="INF" scale="-2">21.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000685" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001305253_20190101_20191231" decimals="INF" scale="-2">21.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000686" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001305253_20180101_20181231" decimals="INF" scale="-2">21.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000687" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001305253_20200101_20201231" decimals="4" sign="-" scale="-2">26.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000688" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001305253_20190101_20191231" decimals="4" sign="-" scale="-2">27.42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000689" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001305253_20180101_20181231" decimals="4" sign="-" scale="-2">26.02</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000690" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001305253_20200101_20201231" decimals="4" scale="-2">6.43</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000691" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001305253_20190101_20191231" decimals="4" scale="-2">7.27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000692" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001305253_20180101_20181231" decimals="4" scale="-2">5.52</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000693" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001305253_20200101_20201231" decimals="4" scale="-2">0.33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000694" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001305253_20190101_20191231" decimals="4" scale="-2">0.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000695" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001305253_20180101_20181231" decimals="4" scale="-2">0.27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000696" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001305253_20200101_20201231" decimals="4" sign="-" scale="-2">1.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000697" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001305253_20190101_20191231" decimals="4" sign="-" scale="-2">0.89</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000698" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001305253_20180101_20181231" decimals="4" sign="-" scale="-2">0.77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000699" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001305253_20200101_20201231" decimals="4" sign="-" scale="-2">0.01</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000700" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001305253_20190101_20191231" decimals="4" sign="-" scale="-2">0.21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision (benefit) for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000701" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001305253_20200101_20201231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000702" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001305253_20190101_20191231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000703" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001305253_20180101_20181231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000296_dcnt_2ea7d0c1-d7db-41e2-ab91-9061a68b267e" continuedAt="F_000296_dcnt_8e55441f-cbce-4d15-ab56-581f149b815b">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000332" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the deferred tax assets and liabilities are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,523</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,068</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,157</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="eigr:DeferredTaxAssetDepreciationAndAmortization" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,067</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="eigr:DeferredTaxAssetDepreciationAndAmortization" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,452</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,912</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001305253_20201231" decimals="-3" scale="3">606</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001305253_20191231" decimals="-3" scale="3">319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="eigr:DeferredTaxAssetsLeaseLiabilities" contextRef="C_0001305253_20201231" decimals="-3" scale="3">278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="eigr:DeferredTaxAssetsLeaseLiabilities" contextRef="C_0001305253_20191231" decimals="-3" scale="3">389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000717" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000718" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,747</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000720" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001305253_20201231" decimals="-3" scale="3">247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000721" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001305253_20191231" decimals="-3" scale="3">347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000722" name="eigr:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="C_0001305253_20201231" decimals="-3" scale="3">247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="eigr:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="C_0001305253_20191231" decimals="-3" scale="3">347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000724" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001305253_20201231" decimals="-3" scale="3">247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001305253_20191231" decimals="-3" scale="3">347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000726" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the Company&#8217;s lack of earnings history, the deferred tax assets have been fully offset by a valuation allowance as of December 31, 2020 and 2019. The net change in the valuation allowance for the years ended December&#160;31, 2020 and 2019 increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="eigr:IncreaseInDeferredTaxAssetsValuationAllowance" contextRef="C_0001305253_20200101_20201231" decimals="-5" scale="6">7.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000729" name="eigr:IncreaseInDeferredTaxAssetsValuationAllowance" contextRef="C_0001305253_20190101_20191231" decimals="-5" scale="6">7.6</ix:nonFraction> million, respectively.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000730" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">251.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000731" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">25.2</ix:nonFraction> million, respectively, of federal and state NOL carryforwards available to reduce future taxable income that will begin to expire in <ix:nonNumeric id="F_000732" name="eigr:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2030</ix:nonNumeric> and <ix:nonNumeric id="F_000733" name="eigr:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2028</ix:nonNumeric>, respectively, for federal and state tax purposes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company also had research and development tax credit carryforwards of&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000734" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">1.8</ix:nonFraction> million for state purposes, available to offset future taxable income tax. If not utilized, the state credits can be carried forward indefinitely. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if the Company has experienced an ownership change under Section 382 of the Internal Revenue Code (the Code) of 1986, as amended. <span style="letter-spacing:-0.1pt;">The Company&#8217;s merger with Celladon resulted in such an ownership change and, accordingly, Celladon&#8217;s NOL carryforwards and certain other tax attributes will be subject to further limitations on their use. The Company assessed whether it had an ownership change, as defined by Section&#160;382 of the Code from its formation through December 31, 2020. Based upon this assessment, the Company experienced ownership changes on April 20, 2016, October 18, 2018 and December 31, 2020. Due to these ownership changes, reductions were made to the Company&#8217;s NOL and tax credit carryforwards under these rules</span>. <span style="letter-spacing:-0.1pt;">Additional ownership changes in the future could result in additional limitations on the Company&#8217;s NOL and tax credit carryforwards.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000296_dcnt_8e55441f-cbce-4d15-ab56-581f149b815b">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Uncertain Tax Positions</span></p><ix:nonNumeric id="F_000333" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s unrecognized tax benefits for the years ended December&#160;31, 2020, 2019 and 2018 is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000735" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000736" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001305253_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000737" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001305253_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,218</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to prior</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000738" name="eigr:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" contextRef="C_0001305253_20180101_20181231" decimals="-3" sign="-" scale="3">61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; current year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001305253_20200101_20201231" decimals="-3" scale="3">81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,443</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000741" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001305253_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,477</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions based on tax positions related to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; prior year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000742" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001305253_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,907</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000743" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001305253_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions based on tax positions related to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; current year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001305253_20201231" decimals="-3" scale="3">451</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001305253_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001305253_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="C_0001305253_20201231" decimals="-5" scale="6">0.5</ix:nonFraction> million of unrecognized tax benefits is recognized, there would not be an effect on the effective tax rate. The Company does not expect the unrecognized tax benefits to change significantly over the next 12 months. As of December 31, 2020, the unrecognized tax benefits for uncertain tax positions were offset against deferred tax assets and would not affect the income tax rate if recognized due to the Company being in a full valuation allowance position.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to account for interest and penalties in tax expense on the consolidated statements of operations. The Company files income tax returns in the U.S. federal and state jurisdictions. All periods since inception are subject to examination by U.S. federal and state jurisdictions. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001305253_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001305253_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001305253_20181231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> such interest or penalties during the years ended December 31, 2020, 2019 and 2018.</p></ix:continuation><ix:nonNumeric id="F_000297" name="us-gaap:LegalMattersAndContingenciesTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Legal Matters</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time in the ordinary course of business the Company becomes involved in various lawsuits, claims and proceedings, including those pertaining to the defense and enforcement of the Company&#8217;s patent or other intellectual property rights and contractual rights. These proceedings are costly and time consuming. Additionally, successful challenges to the Company&#8217;s patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and may allow third parties to use the Company&#8217;s proprietary technologies without a license from the Company or its collaborators. The outcome of such matters, which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred.</p></ix:nonNumeric><ix:nonNumeric id="F_000298" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000298_dcnt_7ac8efc9-4743-418a-b031-b3f0428375d6">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, the Company entered into a non-cancelable operating facility lease agreement for <ix:nonFraction unitRef="U_utrsqft" id="F_000751" name="us-gaap:LandSubjectToGroundLeases" contextRef="C_0001305253_srtStatementGeographicalAxis_stprCA_20171031" decimals="0" format="ixt:numdotdecimal">8,029</ix:nonFraction> square feet of office space located at 2155 Park Blvd. in Palo Alto, California 94306. The lease commenced on <ix:nonNumeric id="F_000752" name="eigr:LeaseCommencedDate" contextRef="C_0001305253_srtStatementGeographicalAxis_stprCA_20171001_20171031" format="ixt:datemonthdayyearen">March 1, 2018</ix:nonNumeric> and expires in <ix:nonNumeric id="F_000753" name="eigr:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" contextRef="C_0001305253_srtStatementGeographicalAxis_stprCA_20171001_20171031" format="ixt:datemonthyearen">February 2023</ix:nonNumeric>. The lease has a <span style="-sec-ix-hidden:F_000754">three-year</span> renewal option prior to expiration&#59; however, the Company is not reasonably assured to exercise this option. The lease includes rent escalation clauses throughout the lease term. In October 2017, the Company provided a security deposit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" contextRef="C_0001305253_srtStatementGeographicalAxis_stprCA_20171031" decimals="-5" scale="6">0.3</ix:nonFraction> million.&#160;The Company also has additional operating leases that are included in its lease accounting but are not considered significant for disclosure.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000298_dcnt_7ac8efc9-4743-418a-b031-b3f0428375d6">
<ix:nonNumeric id="F_000334" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Undiscounted lease payments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001305253_20201231" decimals="-3" scale="3">673</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001305253_20201231" decimals="-3" scale="3">662</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001305253_20201231" decimals="-3" scale="3">113</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001305253_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,449</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001305253_20201231" decimals="-3" scale="3">129</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001305253_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,320</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion of operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000763" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001305253_20201231" decimals="-3" scale="3">582</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000764" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001305253_20201231" decimals="-3" scale="3">738</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense recognized for the Company&#8217;s operating leases was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000765" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001305253_20200101_20201231" decimals="-5" scale="6">0.6</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001305253_20190101_20191231" decimals="-5" scale="6">0.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000767" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001305253_20180101_20181231" decimals="-5" scale="6">0.8</ix:nonFraction> million for the years ended December 31, 2020, 2019, and 2018, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for the operating leases were <span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000768" name="us-gaap:VariableLeaseCost" contextRef="C_0001305253_20200101_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000769" name="us-gaap:VariableLeaseCost" contextRef="C_0001305253_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction></span> million for each of the years ended December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The operating cash outflows for the operating lease liabilities were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000770" name="us-gaap:OperatingLeasePayments" contextRef="C_0001305253_20200101_20201231" decimals="-5" scale="6">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000771" name="us-gaap:OperatingLeasePayments" contextRef="C_0001305253_20190101_20191231" decimals="-5" scale="6">0.6</ix:nonFraction> million for the year ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the weighted-average remaining lease term and weighted-average discount rate were <ix:nonNumeric id="F_000772" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001305253_20201231" format="ixt-sec:duryear">2.1</ix:nonNumeric> years and <ix:nonFraction unitRef="U_xbrlipure" id="F_000773" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001305253_20201231" decimals="4" scale="-2">9.15</ix:nonFraction>%, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is obligated to make future payments to third parties under asset purchase and license agreements, including royalties and payments that become due and payable on the achievement of certain development and commercialization milestones. However, the amount and timing of these payments are not known. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing Service Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2020, the Company entered into a Master Manufacturing Services Agreement (MMSA) and Product Agreement with Patheon, Inc. (Patheon) for the manufacturing of lonafarnib capsules and packaging of bottles for commercial sale. Under the terms of the agreements, the Company is required to provide Patheon with annual volume forecasts of capsules and Patheon will manufacture <ix:nonFraction unitRef="U_xbrlipure" id="F_000774" name="eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" contextRef="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20200331" decimals="2" scale="-2">80</ix:nonFraction>% of such annual forecasts. If the Company order less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000775" name="eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20200331" decimals="2" scale="-2">80</ix:nonFraction>% of such annual forecasts, it is required to pay <ix:nonFraction unitRef="U_xbrlipure" id="F_000776" name="eigr:PercentageOfPurchasePrice" contextRef="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20200331" decimals="2" scale="-2">70</ix:nonFraction>% of purchase price for the shortfall. The initial terms of the MMSA and Product Agreement end on <ix:nonNumeric id="F_000777" name="eigr:ProductAgreementDateOfExpiration" contextRef="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20201231" format="ixt:datemonthdayyearen">December 31, 2025</ix:nonNumeric> with automatic renewal for successive <span style="-sec-ix-hidden:F_000778">two-year</span> terms, unless earlier terminated pursuant to the terms of each agreement, or upon either party&#8217;s notice of termination to the other.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000299" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Related Party Transactions</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As disclosed in Note 6, the Company entered into license agreements with EGI, which is owned by the founder of the Company.</p></ix:nonNumeric><ix:nonNumeric id="F_000300" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001305253_20200101_20201231" escape="true" continuedAt="F_000300_dcnt_2f53cb94-4593-4b73-95d4-10f86880f2a9">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Subsequent Events</p></td></tr></table></div></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000300_dcnt_2f53cb94-4593-4b73-95d4-10f86880f2a9">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021, the Company entered into the fifth amendment to the Oxford Loan. The amendment extended the interest only period by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000780" name="eigr:DebtInstrumentInterestPaymentPeriod" contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223" format="ixt-sec:durmonth">17</ix:nonNumeric> months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> until September 1, 2022, follow</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19 equal monthly</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payments of principal and interest. Upon the receipt of Amended Tranche B, the interest only period for borrowed funds will be extended by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000782" name="eigr:DebtInstrumentInterestPaymentPeriod" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223" format="ixt-sec:durwordsen">six months</ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> until March 1, 2023, follow</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13 equal monthly</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payments of principal plus accrued interest. In addition, the Company paid the amendment fees of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000783" name="eigr:AmendmendFeesPayment" contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223" decimals="-5" scale="6">0.2</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million to the lenders on the effective date of the fifth amendment.</span></p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">ITEM&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">ITEM&#160;9A. Controls and Procedures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(a) Evaluation of Disclosure Controls and Procedures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are responsible for maintaining disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on our management&#8217;s evaluation (with the participation of our principal executive officer and our principal financial officer) of our disclosure controls and procedures as required by Rule 13a-15 under the Exchange Act, our principal executive officer and our principal financial officer have concluded that our disclosure controls and procedures were effective to achieve their stated purpose as of December 31, 2020, the end of the period covered by this report.<span style="color:#000000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(b) Management&#8217;s Report on Internal Control over Financial Reporting.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance, not absolute assurance, regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are inherent limitations to the effectiveness of any system of internal control over financial reporting. These limitations include the possibility of human error, the circumvention or overriding of the system and reasonable resource constraints. Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework <span style="font-style:italic;">Internal Control - Integrated Framework (2013)</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of December&#160;31, 2020, our internal control over financial reporting was effective based on those criteria.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(c) </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise described above under Management&#8217;s Report on Internal Control over Financial Reporting, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended December 31, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">ITEM&#160;9B. Other Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART III</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">ITEM&#160;10. Directors, Executive Officers and Corporate Governance</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.81%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as set forth below, the information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. A current copy of the code is posted on the Investors Corporate Governance section of our website, which is located at <span style="text-decoration:underline;">www.eigerbio.com</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Code of Business Conduct and Ethics by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of The Nasdaq Global Market, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">ITEM&#160;11. Executive Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">ITEM&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_PA">ITEM&#160;13. Certain Relationships and Related Party Transactions, and Director Independence</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">ITEM&#160;14. Principal Accountant Fees and Services</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">ITEM&#160;15. Exhibits and Financial Statement Schedules</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements and Financial Statement Schedules</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">See Index to Financial Statements at Item&#160;8 herein.</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statement Schedules</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other schedules are omitted because they are not applicable, or the required information is shown in the financial statements or notes thereto.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits<span style="Background-color:#FFFFFF;color:#000000;"> </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:99.7%;">
<tr>
<td valign="bottom" style="width:10.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />Number</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:88.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Document</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;2.1</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312515381300/d19344dex21.htm"><span style="text-decoration:underline;">Agreement and Plan of Merger and Reorganization, dated as of November 18, 2015, by and among Celladon Corporation, Celladon Merger Sub, Inc., and Eiger BioPharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC on November 19, 2015).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312514043152/d674123dex31.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K of Celladon Corporation, filed with the SEC on February 10, 2014).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.2</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312514043152/d674123dex32.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of Celladon Corporation (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on February 10, 2014).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.3</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312516514051/d156666dex31.htm"><span style="text-decoration:underline;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on March 23, 2016).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.4</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312516514051/d156666dex32.htm"><span style="text-decoration:underline;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on March 23, 2016).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.1</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312513414057/d578642dex41.htm"><span style="text-decoration:underline;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1, as amended (File No. 333-191688), originally filed with the SEC on October&#160;29, 2013</span><span style="text-decoration:underline;">).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.2</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312513414057/d578642dex43.htm"><span style="text-decoration:underline;">Form of Warrant to Purchase Common Stock issued to participants in Celladon Corporation&#8217;s Convertible Debt and Warrant financing, dated October 15, 2013 (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1, as amended (File No. 333-191688), originally filed with the SEC on October 11, 2013).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.3</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459020010645/eigr-ex43_1012.htm"><span style="text-decoration:underline;">Description of Registrant&#8217;s Securities (incorporated by reference to Exhibit 4.3 to the Annual Report on Form 10-K (File No. 001-36183), filed with the SEC on March 13, 2020).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312513396992/d578642dex101.htm"><span style="text-decoration:underline;">Form of Indemnity Agreement by and between Celladon Corporation and its directors and officers (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1, as amended (File No. 333-191688), originally filed with the SEC on October 11, 2013).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.2+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312513396992/d578642dex102.htm"><span style="text-decoration:underline;">Celladon Corporation 2001 Stock Option Plan and Form of Notice of Grant of Stock Option, Stock Option Agreement and Stock Option Exercise Notice thereunder (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1, as amended (File No. 333-191688), originally filed with the SEC on October 11, 2013).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.3+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312513396992/d578642dex103.htm"><span style="text-decoration:underline;">Celladon Corporation 2012 Equity Incentive Plan and Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1, as amended (File No. 333-191688), originally filed with the SEC on October 11, 2013).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:99.7%;">
<tr>
<td valign="bottom" style="width:10.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />Number</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:88.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Document</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.4+</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459017010695/eigr-ex101_419.htm"><span style="text-decoration:underline;">Celladon Corporation Non-Employee Director Compensation Policy, amended on April 12, 2017 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-36183), filed with the SEC on May 12, 2017).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.5</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312515401947/d72850dex1044.htm"><span style="text-decoration:underline;">Eiger BioPharmaceuticals, Inc. 2009 Equity Incentive Plan and Form of Notice of Grant of Stock Option, Stock Option Agreement and Stock Option Exercise Notice thereunder (incorporated by reference to Exhibit 10.44 to the Registration Statement on Form S-4, as amended (File No. 333-208521), originally filed with the SEC on December 14, 2015).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.6+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459016028120/eigr-ex102_216.htm"><span style="text-decoration:underline;">Eiger BioPharmaceuticals, Inc. 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form 10-Q (File No. 001-36183), filed with the SEC on November&#160;8, 2016).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.7+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459016028120/eigr-ex101_217.htm"><span style="text-decoration:underline;">Eiger BioPharmaceuticals, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form 10-Q (File No. 001-36183), filed with the SEC on November 8, 2016).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.8</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312515401947/d72850dex1038.htm"><span style="text-decoration:underline;">Lease, dated as of March 19, 2015 by and between JTC, a California general partnership and Eiger BioPharmaceuticals, Inc. (incorporated by reference to Exhibit 10.38 to the Registration Statement on Form S-4, as amended (File No. 333-208521), originally filed with the SEC on December 14, 2015).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.9* <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex109_1145.htm"><span style="text-decoration:underline;">Asset Purchase Agreement, dated September 25, 2015, by and between Eiger BioPharmaceuticals, Inc. and Tracey McLaughlin and Colleen Craig.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.10* <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex1010_1144.htm"><span style="text-decoration:underline;">License Agreement, dated September 3, 2010, by and between Eiger BioPharmaceuticals, Inc. and Merck Corporation.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.11</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312516434995/d72850dex1053.htm"><span style="text-decoration:underline;">Sublease Agreement, dated as of January 8, 2016, by and between Baker Hughes Oilfield Operations, Inc. and Eiger BioPharmaceuticals, Inc. (incorporated by reference to Exhibit 10.53 to the Registration Statement on Form S-4, as amended (File No. 333-208521), originally filed with the SEC on December 14, 2015).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.12* <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex1012_1143.htm"><span style="text-decoration:underline;">License Agreement, dated as of April 20, 2016, by and between Eiger BioPharmaceuticals, Inc. and Bristol-Myers Squibb Company.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.13</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000119312516625162/d207633dex102.htm"><span style="text-decoration:underline;">Common Stock Purchase Agreement, dated as of April 20, 2016, by and between Eiger BioPharmaceuticals, Inc. and Bristol-Myers Squibb Company (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-3, as amended (File No. 333-212114) filed with the SEC on June 17, 2016).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.14</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459017005079/eigr-ex1026_1978.htm"><span style="text-decoration:underline;">Loan and Security Agreement, dated December 30, 2016, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (incorporate by reference to Exhibit 10.26 to the Annual report on Form 10-K (File No. 001-36183) filed with the SEC on March 23, 2017).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.15</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459018005123/eigr-ex1027_830.htm"><span style="text-decoration:underline;">Standard Multi-Tenant Office Lease &#8211; Net, dated October 11, 2017, by and between Eiger BioPharmaceuticals, Inc. and the McDonald Family Co. LLC, and addendum thereto. (incorporated by reference to Exhibit 10.27 to the Annual report on Form 10-K (File No. 001-36183) filed with the SEC on March 9, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.16</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459018013225/eigr-ex102_344.htm"><span style="text-decoration:underline;">First Amendment to Lease, dated April 26, 2018, by and between Eiger BioPharmaceuticals, Inc. and the McDonald Family Co. LLC (incorporated by reference to Exhibit 10.2 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on May 11, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.17* <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex1017_1142.htm"><span style="text-decoration:underline;">Amendment No. 6 to License Agreement, dated September 3, 2010, by and between Eiger BioPharmaceuticals, Inc. and Merck Sharp &#38; Dohme Corp.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.18* <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex1018_1141.htm"><span style="text-decoration:underline;">Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger BioPharmaceuticals, Inc. and The Progeria Research Foundation.</span></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:99.7%;">
<tr>
<td valign="bottom" style="width:10.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />Number</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:88.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Document</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.19</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459018021197/eigr-ex104_259.htm"><span style="text-decoration:underline;">Second Amendment to Loan and Security Agreement, dated May 11, 2018, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (incorporated by reference to Exhibit 10.4 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on August 10, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.20</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459018028934/eigr-ex102_530.htm"><span style="text-decoration:underline;">Common Stock Purchase Agreement, dated September 19, 2018, by and between Eiger BioPharmaceuticals, Inc. and RRD International, LLC (incorporated by reference to Exhibit 10.2 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 9, 2018).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.21</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019007830/eigr-ex1038_1121.htm"><span style="text-decoration:underline;">First Amendment to Loan and Security Agreement, dated August 24, 2017, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (incorporated by reference to Exhibit 10.38 to the Annual report on Form 10-K (File No. 001-36183) with the SEC on March 14, 2019).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.22+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/eigr-ex101_231.htm"><span style="text-decoration:underline;">Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger BioPharmaceuticals, Inc. and David A. Cory (incorporated by reference to Exhibit 10.1 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 7, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.23+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/eigr-ex102_230.htm"><span style="text-decoration:underline;">Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger BioPharmaceuticals, Inc. and Sriram Ryali (incorporated by reference to Exhibit 10.2 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 7, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.24+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/eigr-ex103_229.htm"><span style="text-decoration:underline;">Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger BioPharmaceuticals, Inc. and Stephana E. Patton (incorporated by reference to Exhibit 10.3 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 7, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.25+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/eigr-ex104_227.htm"><span style="text-decoration:underline;">Amended and Restated Offer Letter Agreement, dated as of November 1, 2019, by and between Eiger BioPharmaceuticals, Inc. and James Shaffer (incorporated by reference to Exhibit 10.4 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 7, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.26*</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019041773/eigr-ex105_228.htm"><span style="text-decoration:underline;">License Agreement, dated as of May 10, 2019, by and among the Trustees of the University of Pennsylvania and The Children&#8217;s Hospital of Philadelphia and Eiger BioPharmaceuticals, Inc (incorporated by reference to Exhibit 10.5 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on November 7, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.27*</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459019018009/eigr-ex103_436.htm"><span style="text-decoration:underline;">Third Amendment to Loan and Security Agreement, dated March 5, 2019, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC (incorporated by reference to Exhibit 10.3 to the Quarterly report on Form 10-Q (File No. 001-36183) filed with the SEC on May 9, 2019).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.28+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459020022884/eigr-ex101_191.htm"><span style="text-decoration:underline;">Offer Letter Agreement, by and between Eiger BioPharmaceuticals, Inc. and Eldon Mayer, dated as of December 3, 2019 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-36183) filed with the SEC on May 7, 2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.29+</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459020022884/eigr-ex102_190.htm"><span style="text-decoration:underline;">Eiger BioPharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended. (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q (File No. 001-36183) filed with the SEC on May 7, 2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.30*</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1305253/000156459020037833/eigr-ex101_303.htm"><span style="text-decoration:underline;">Amendment No. 1, dated June 15, 2020, to the Collaboration and Supply Agreement, dated May 15, 2018, by and between Eiger BioPharmaceuticals, Inc. and the Progeria Research Foundation. (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (File No. 001-36183) filed with the SEC on August 6, 2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.31 **</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex1031_1140.htm"><span style="text-decoration:underline;">Asset Purchase Agreement, by and between Eiger BioPharmaceuticals, Inc. and AbbVie Inc., dated as of November 20, 2020.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.32 **</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex1032_1138.htm"><span style="text-decoration:underline;">Amendment No. 7 to License Agreement, dated November 3, 2020, by and between Eiger BioPharmaceuticals, Inc. and Merck Sharp &#38; Dohme Corp. </span></a><span style="text-decoration:underline;"> </span></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:99.7%;">
<tr>
<td valign="bottom" style="width:10.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />Number</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:88.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Document</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:88.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.33 **</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex1033_1139.htm"><span style="text-decoration:underline;">Amendment No. 5 to Loan and Security Agreement, dated February 23, 2021, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;21.1 <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex211_583.htm"><span style="text-decoration:underline;">List of subsidiaries.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;23.1 <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex231_912.htm"><span style="text-decoration:underline;">Consent of independent Registered Public Accounting Firm.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;24.1 <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><span style="text-decoration:underline;">Power of Attorney. Reference is made to the signature page hereto.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.1 <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex311_581.htm"><span style="text-decoration:underline;">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.2 <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex312_580.htm"><span style="text-decoration:underline;">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.1 <span style="color:#000000;">**</span></p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="eigr-ex321_579.htm"><span style="text-decoration:underline;">Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS**</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH**</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="middle" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL**</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="middle" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF**</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="middle" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB**</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE**</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:88.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, has been formatted in Inline XBRL.</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:84.62%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">** </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_Form_10K_Summary">ITEM&#160;16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p></td>
</tr>
<tr>
<td valign="middle" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:47%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 9, 2021</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David A. Cory</p></td>
</tr>
<tr>
<td valign="bottom" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David A. Cory</p></td>
</tr>
<tr>
<td valign="bottom" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director, President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="middle" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p></td>
</tr>
<tr>
<td valign="middle" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:47%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 9, 2021</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sriram Ryali</p></td>
</tr>
<tr>
<td valign="bottom" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:50%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sriram Ryali</p></td>
</tr>
<tr>
<td valign="bottom" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_ATTORNEY"><span style="Background-color:#FFFFFF;">POWER OF ATTORNEY</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David A. Cory and Sriram Ryali, and each of them, as his or her attorneys-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to this report, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, and each of them, or his or her substitute or substitutes may do or cause to be done by virtue hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom" style="width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:41.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:20.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="middle" style="width:34.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:43.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David A. Cory</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David A. Cory</p></td>
<td valign="bottom" style="width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:41.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="bottom" style="width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:43.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sriram Ryali</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sriram Ryali</p></td>
<td valign="bottom" style="width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:41.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
<td valign="bottom" style="width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021<span style="color:#000000;"> </span></p></td>
</tr>
<tr>
<td valign="middle" style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:43.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Thomas J. Dietz</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas J. Dietz</p></td>
<td valign="bottom" style="width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:41.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="bottom" style="width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:43.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Apelian</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Apelian</p></td>
<td valign="bottom" style="width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:41.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member of the Board of Directors</p></td>
<td valign="bottom" style="width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:43.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Evan Loh</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Evan Loh</p></td>
<td valign="bottom" style="width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:41.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member of the Board of Directors</p></td>
<td valign="bottom" style="width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr>
<td valign="middle" style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:43.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeffrey Glenn</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey Glenn</p></td>
<td valign="bottom" style="width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:41.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member of the Board of Directors</p></td>
<td valign="bottom" style="width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:20.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Christine Murray</p></td>
<td valign="top" style="width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:41.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member of the Board of Directors</p></td>
<td valign="top" style="width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:20.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christine Murray</p></td>
<td colspan="2" valign="middle" style="width:43.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:43.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Amit K. Sachdev</p></td>
<td colspan="2" valign="top" style="width:43.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Member of the Board of Directors</p></td>
<td colspan="2" valign="top" style="width:22.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:34.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amit K. Sachdev</p></td>
<td colspan="2" valign="middle" style="width:43.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:43.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:22.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>2
<FILENAME>eigr-ex109_1145.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex109_1145.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.9</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASSET PURCHASE AGREEMENT</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">among:</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EIGER BIOPHARMACEUTICALS, INC.,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TRACEY MCLAUGHLIN AND COLLEEN CRAIG</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:2pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated as of September 25, 2015</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:2pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASSET PURCHASE AGREEMENT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS ASSET PURCHASE AGREEMENT is entered into, effective as of September 25, 2015 (the &#8220;<font style="font-weight:bold;font-style:italic;">Effective Date</font>&#8221;), by and between EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (&#8220;<font style="font-weight:bold;font-style:italic;">Purchaser</font>&#8221;) and TRACEY MCLAUGHLIN AND COLLEEN CRAIG (each individually, &#8220;<font style="font-weight:bold;font-style:italic;">Seller</font>&#8221;, collectively, &#8220;<font style="font-weight:bold;font-style:italic;">Sellers</font>&#8221;). Purchaser and Sellers are referred to herein collectively as the &#8220;<font style="font-weight:bold;font-style:italic;">Parties</font>&#8221; and individually as a &#8220;<font style="font-weight:bold;font-style:italic;">Party.</font>&#8221; Certain other capitalized terms used in this Agreement are defined in <font style="text-decoration:underline;">Exhibit A</font>.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A. Purchaser and Sellers wish to provide for the sale by Sellers to Purchaser of the Designated Assets (as defined in <font style="text-decoration:underline;">Section 1.1</font>) by Purchaser on the terms and subject to the conditions set forth in this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B. In connection with the sale of the Designated Assets, Purchaser is entering into a Consulting Agreement with each Seller in substantially the form attached hereto as <font style="text-decoration:underline;">Exhibit B</font> (the &#8220;<font style="font-weight:bold;font-style:italic;">Consulting Agreement</font>&#8221;).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. This Agreement has received the requisite approvals by Purchaser and Sellers.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AGREEMENT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties, intending to be legally bound, agree as follows:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 1. SALE OF DESIGNATED ASSETS; RELATED TRANSACTIONS.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.1 Sale of Designated Assets<font style="font-weight:normal;">. Each Seller hereby sells, assigns, transfers, conveys and delivers to Purchaser the entirety of their right, title and interest (if any) in and to the Designated Assets on the terms and subject to the conditions set forth in this Agreement. The &#8220;</font><font style="font-style:italic;">Designated Assets</font><font style="font-weight:normal;">&#8221; shall mean the following assets (to the extent not previously or otherwise required to be assigned by Sellers to the Leland Stanford Junior University (&#8220;</font><font style="font-style:italic;">Stanford</font><font style="font-weight:normal;">&#8221;) under their existing employment agreements):</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:normal;">All rights and interests in and to Patents, copyrights, trademarks, trade secrets, know-how, and documentation and related applications related to extending, including provisional patent application Docket No.: [ * ] filed by Sellers [ * ] (the &#8220;</font><font style="font-style:italic;">HH Patents</font><font style="font-weight:normal;">&#8221;), if and to the extent any of the foregoing is the intellectual property of Sellers and not subject to a contractual obligation on the part of Sellers to assign the same to Stanford or not otherwise assigned and subject to the License Agreement (as defined below);</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:normal;">All techniques, technology, trade secrets, inventions (whether patentable or not), methods, know-how, data and results (including pharmacological, toxicological and clinical data and results), analytical and quality control data and results, regulatory documents including investigational new drug applications (INDs) (other than the current IND designated as [ * ] involving [ * ]), and correspondence, as well as other information related to exendin and its </font><font style="font-weight:normal;color:#000000;">uses in the possession of Sellers, if and to the extent any of the foregoing is the intellectual property of Sellers and not subject to a contractual obligation on the part of Sellers to assign the same to Stanford; and</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:normal;">The License Agreement between Stanford and Sellers dated May</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">4, 2015 (the &#8220;</font><font style="font-style:italic;">License Agreement</font><font style="font-weight:normal;">&#8221;), pursuant to which Stanford granted to Sellers an exclusive, worldwide license to use, make, have made, market and sell products in all fields of use based upon, used or made in accordance with that certain invention described in Stanford Docket &#167;12- 372, including as further described in the HH Patents, involving the use of exendin (the &#8220;</font><font style="font-style:italic;">Invention</font><font style="font-weight:normal;">&#8221;). The License Agreement provides for making a product based on the Invention and any modifications, improvements or variations thereof (the &#8220;</font><font style="font-style:italic;">Product</font><font style="font-weight:normal;">&#8221;) &#8220;</font><font style="font-style:italic;">available for public use and benefit</font><font style="font-weight:normal;">&#8221; and Purchaser acknowledges those obligations thereunder.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.2 Purchase Price<font style="font-weight:normal;">. The purchase price for the Designated Assets shall be (the &#8220;</font><font style="font-style:italic;">Purchase Price</font><font style="font-weight:normal;">&#8221;):</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:normal;">Within [ * ] of the Effective Date, the Purchaser shall issue to each of the Sellers: (i) shares of Common Stock of the Company pursuant to a customary Company common stock purchase agreement representing [ * ] of the total number of the Company&#8217;s issued and outstanding shares of capital stock (excluding all shares reserved but unissued under the Plan and any issuances to the Sellers pursuant to this </font><font style="text-decoration:underline;font-weight:normal;">Section 1.2</font><font style="font-weight:normal;">) as of immediately prior to the date of issuance of the shares of Common Stock, which shall not be subject to any vesting; (ii) non-qualified options to purchase Common Stock of the Company to each Seller under Purchaser&#8217;s 2009 Equity Incentive Plan (the &#8220;</font><font style="font-style:italic;">Plan</font><font style="font-weight:normal;">&#8221;) equal to [ * ] of the total number of the Company&#8217;s issued and outstanding shares of capital stock (excluding all shares reserved but unissued under the Plan and any issuances to the Sellers pursuant to this </font><font style="text-decoration:underline;font-weight:normal;">Section 1.2</font><font style="font-weight:normal;">) as of immediately prior to the date of issuance of such options, which options shall have an exercise price equal to the fair market value on the date of grant, as reasonably determined by the Purchaser&#8217;s Board of Directors and shall vest in increments of [ * ] per month from the date of grant for each month after the Effective Date, provided that such Seller is providing Continuous Service (as defined under the Plan) to the Company, it being understood that being on unpaid retainer shall satisfy such definition (collectively, the issuances under subclauses l.2(a)(i) and (ii), the &#8220;</font><font style="font-style:italic;">Initial Time-Based Equity</font><font style="font-weight:normal;">&#8221;) ; and (iii) non-qualified options to each Seller to purchase Common Stock of the Company to each Seller under the Plan to purchase [ * ] of the total number of the Company&#8217;s issued and outstanding shares of capital stock (excluding all shares reserved but unissued under the Plan and any issuances to the Sellers pursuant to this </font><font style="text-decoration:underline;font-weight:normal;">Section 1.2</font><font style="font-weight:normal;">) (the &#8220;</font><font style="font-style:italic;">Milestone Options</font><font style="font-weight:normal;">&#8221;), which Milestone Options shall have a term of [ * ] and shall vest upon the earlier of: (A) [ * ] and (B) [ * ] (each, a &#8220;</font><font style="font-style:italic;">Milestone Vesting Trigger</font><font style="font-weight:normal;">&#8221;), provided that for clarity, with respect to the option grants pursuant to this subclause (iii), vesting shall occur on the achievement of the Milestone Vesting Trigger by the Company regardless of whether Sellers are providing Continuous Service (as defined under the Plan) at the applicable time of achievement during the term of such Milestone Options. The occurrence of a Milestone Vesting Trigger shall be determined by Purchaser&#8217;s Board of Directors in its reasonable discretion, which decision shall be binding upon the Parties and final;</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:normal;">At the closing of the first round of financing after the date of this Agreement pursuant to which Purchaser sells shares of its equity resulting in gross proceeds to the Company of at least [ * ], including a reverse merger whose primary purpose is financing (the &#8220;</font><font style="font-style:italic;">Financing</font><font style="font-weight:normal;">&#8221;), Purchaser will issue to each Seller additional non-qualified options to purchase Common Stock of the Company (the &#8220;</font><font style="font-style:italic;">Total Options</font><font style="font-weight:normal;">&#8221;) to each Seller under the Plan (the &#8220;</font><font style="font-style:italic;">Top-Up Options</font><font style="font-weight:normal;">&#8221;) under the Plan pursuant to this </font><font style="text-decoration:underline;font-weight:normal;">Section l.2(b)</font><font style="font-weight:normal;"> in an amount sufficient to ensure that the sum of the Initial Time-Based Equity </font><font style="text-decoration:underline;font-weight:normal;">plus</font><font style="font-weight:normal;"> the Milestone Options </font><font style="text-decoration:underline;font-weight:normal;">plus</font><font style="font-weight:normal;"> the Top-Up Options held by each Seller represents [ * ] of the total number of the Company&#8217;s issued and outstanding shares of capital stock (excluding all shares reserved but unissued under the Plan and any issuances to the Sellers pursuant to this </font><font style="text-decoration:underline;font-weight:normal;">Section 1.2</font><font style="font-weight:normal;">) as of immediately following the initial closing of the Financing. The Top-Up Options shall have an exercise price equal to the fair market value on the date of grant, as reasonably determined by the Purchaser&#8217;s Board of Directors (or if the Company is publicly traded, pursuant to the terms of the Plan), and shall vest as follows: (i) [ * ] of the shares under the Top-Up Options (i.e., [ * ] of the of the total number of the Company&#8217;s issued and outstanding shares of capital stock (excluding all shares reserved but unissued under the Plan and any issuances to the Sellers pursuant to this </font><font style="text-decoration:underline;font-weight:normal;">Section 1.2</font><font style="font-weight:normal;">) as of immediately prior to the date of issuance of options) shall be vested on issuance and the remainder as of immediately prior to the date of issuance of options) shall vest in increments of [ * ] per month from the Effective Date, provided that such Seller is providing Continuous Service (as defined under the Plan) to the Company, it being understood that being on unpaid retainer shall satisfy such definition; and (ii) the other [ * ] of the Top-Up Options (i.e., [ * ] of the of the total number of the Company&#8217;s issued and outstanding shares of capital stock (excluding all shares reserved but unissued under the Plan and any issuances to the Sellers pursuant to this </font><font style="text-decoration:underline;font-weight:normal;">Section 1.2</font><font style="font-weight:normal;">), shall vest upon the occurrence of a Milestone Vesting Trigger, provided that for clarity, with respect to the Top-Up Option grants pursuant to this subclause (ii), vesting shall occur on the achievement of the Milestone Vesting Trigger by the Company regardless of whether Sellers are providing Continuous Service (as defined under the Plan) at the applicable time of achievement during the term of such Top-Up Options. The occurrence of a Milestone Vesting Trigger shall be determined by Purchaser&#8217;s Board of Directors in its reasonable discretion, which decision shall be binding upon the Parties and final;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="font-weight:normal;">[ * ] shall be payable to each Seller, within [ * ] following [ * ], as reasonably determined by Purchaser&#8217;s Board of Directors;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(d) <font style="font-weight:normal;">[ * ] shall be payable to each Seller, within [ * ] following [ * ], as reasonably determined by Purchaser&#8217;s Board of Directors;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(e) <font style="font-weight:normal;">[ * ] payable to each Seller, within [ * ] following [ * ], as reasonably determined by Purchaser&#8217;s Board of Directors; and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(f) <font style="font-weight:normal;">The Royalty Payments, payable if and to the extent provided in </font><font style="text-decoration:underline;font-weight:normal;">Section 1.4</font><font style="font-weight:normal;"> below.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clarity, the Parties contemplate that the Sellers shall each hold Initial Options and Top-Up Options totaling [ * ] of the outstanding shares of equity of the Company following the Financing. For further clarity, the payments in <font style="text-decoration:underline;">Sections l.2(c)</font>, <font style="text-decoration:underline;">(d)</font> and <font style="text-decoration:underline;">(e)</font> of the Purchaser Price <font style="color:#000000;">shall be payable only once to each Seller upon the first successful achievement by the Purchaser of such payment event with respect to the Product, as determined by Purchaser&#8217;s Board of Directors, as aforesaid.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.3 Assumed Liabilities<font style="font-weight:normal;">. Purchaser shall not assume any Liabilities of Sellers (whether or not related to the Designated Assets), except for the continuing obligations under the terms of the License Agreement arising following the Closing Date, but solely to the extent not related to or arising from any fact, circumstance, act, breach or violation occurring prior to the Closing Date.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 4</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.4 Contingent Consideration</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:normal;">Commencing with the date the Product is first commercially sold and until the last to expire of any Valid Claim of any of the Patents licensed under the License Agreement, as applicable (the &#8220;</font><font style="font-style:italic;">Royalty Period</font><font style="font-weight:normal;">&#8221;), each Seller shall be entitled to receive within [ * ] after the end of each calendar year during the Royalty Period a payment equal to [ * ] of the Annual Net Sales of such Product made during such calendar year (such payments collectively, the &#8220;</font><font style="font-style:italic;">Royalty Payments</font><font style="font-weight:normal;">&#8221;). The determination as to the calculation of the Royalty Payments shall be reasonably made by Purchaser&#8217;s Board of Directors, in its reasonable discretion.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:normal;">Concurrently with each Royalty Payment made hereunder, Purchaser shall submit to Sellers a written statement of account, which statement shall show (i) the Annual Net Sales in a manner consistent with the definition thereof, and (ii) the manner in which the Royalty Payment was calculated (the &#8220;</font><font style="font-style:italic;">Royalty Statement</font><font style="font-weight:normal;">&#8221;).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="font-weight:normal;">For [ * ] following the submission of a Royalty Statement, Sellers and their agents and representatives shall have the right upon written request to conduct reasonable inspection and audit of Purchaser&#8217;s relevant books and records for the sole purpose of verifying the accuracy of the Royalty Statements, provided that: (i) such written request must be reasonable; (ii) Purchaser shall receive reasonable advance notice of such request; (iii) such inspection or audit shall take place during Purchaser&#8217;s regular business hours and at the place where such books and records are maintained; (iv) Purchaser may demand that the Sellers, their agents and representative will execute a nondisclosure agreement in a form reasonably satisfactory to Purchaser prior to such inspection or audit; and (v) in no event shall Purchaser be required to provide access to information that is subject to attorney-client privilege. Any such inspection or audit by Sellers shall be at their sole expense.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.5 Transfer Taxes<font style="font-weight:normal;">. Sellers shall be liable for any sales Taxes, use Taxes, transfer Taxes or similar Taxes, charges or fees that may become payable in connection with the sale of the Designated Assets to Purchaser. Purchaser and Sellers shall cooperate to reduce the amount of such Taxes to the extent permitted by applicable law.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.6 Allocation<font style="font-weight:normal;">. The consideration referred to in </font><font style="text-decoration:underline;font-weight:normal;">Section 1.2</font><font style="font-weight:normal;"> shall be allocated among the Designated Assets pursuant to a purchase price allocation prepared by Purchaser, which shall be delivered to Sellers within [ * ] of the Effective Date, and no Party shall file any tax return or </font><font style="font-weight:normal;color:#000000;">other document with, or make any statement or declaration to, any governmental body that is inconsistent with such allocation, except as required by applicable law.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.7 Closing<font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:normal;">The closing of the sale of the Designated Asset to Purchaser pursuant to this Agreement (the &#8220;</font><font style="font-style:italic;">Closing</font><font style="font-weight:normal;">&#8221;) shall take place concurrently with the execution and delivery of this Agreement (the &#8220;</font><font style="font-style:italic;">Closing Date</font><font style="font-weight:normal;">&#8221;).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="font-weight:normal;"> At the Closing:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i) <font style="font-weight:normal;">Purchaser and each Seller shall execute and deliver to each other a Consulting Agreement; and</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 5</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:normal;">Purchaser and each Seller shall execute and deliver to the other Party that certain instrument, titled &#8220;</font><font style="font-style:italic;">Amendment No.</font><font style="font-style:italic;"> </font><font style="font-style:italic;">1 To License Agreement</font><font style="font-weight:normal;">&#8221; in the form attached hereto as</font><font style="font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">Exhibit C</font><font style="font-weight:normal;">, thereby effectuating the assignment of the License Agreement to Purchaser. (With reference to said Amendment No.</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">1 to License Agreement, in the interest of clarity, the Parties agree that obligations set forth in</font><font style="font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">Section</font><font style="text-decoration:underline;font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">13.3</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">of the amended License Agreement do not and shall not apply to Sellers hereunder.)</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 2. REPRESENTATIONS AND WARRANTIES OF SELLER<font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sellers, severally and not jointly, each represent and warrant to Purchaser that, except as set forth in the Disclosure Schedule (it is hereby agreed that any information disclosed in any section or subsection of the Disclosure Schedule shall be deemed to relate to and qualify the corresponding numbered or lettered section or subsection of this Agreement and any other representation or warranty of Sellers where such disclosure would reasonably be deemed to apply) as of the Effective Date (for the avoidance of doubt and sake of clarity, in this <font style="text-decoration:underline;">Section 2</font>, each Seller shall only make each representation with respect to itself, notwithstanding the fact that &#8220;<font style="font-weight:bold;font-style:italic;">Sellers</font>&#8221; or &#8220;<font style="font-weight:bold;font-style:italic;">each Seller</font>&#8221; may be referenced):</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.1 License Agreement<font style="font-weight:normal;">. Sellers have delivered to Purchaser accurate and complete copies of the License Agreement. The License Agreement is valid and in full force and effect. Neither Seller nor any of the other parties to the License Agreement has violated or breached, or declared or committed any default under the License Agreement. No event has occurred, and no circumstance or condition exists, that might (with or without notice or lapse of time) result in a violation, breach or default by any Seller or any of the other parties to the License Agreement. Neither Seller has waiver any rights under the License Agreement. There are no material disputes regarding the License Agreement and, to the knowledge of Sellers, the relationship between Sellers and Stanford is good.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.2 Authority; Binding Nature of Agreements<font style="font-weight:normal;">. Each Seller has full power and authority to enter into, perform and comply with its obligations under this Agreement, and any other Transaction Agreement which such Seller is required to enter into hereunder and this Agreement constitutes and any such other Transaction Agreement when executed will constitute </font><font style="font-weight:normal;color:#000000;">valid, legally binding and enforceable obligations on such Seller in accordance with its or their respective terms, subject to: (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors; and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.3 Non-Contravention<font style="font-weight:normal;">. The execution and delivery by Sellers of the Transactional Agreements, and the consummation of the transactions contemplated by the Transaction Agreements, including the sale of the Designated Assets by Sellers to Purchaser will not result in the imposition or creation of any lien or Encumbrance upon or with respect to any of the Designated Assets. Sellers are not required to obtain any additional consent from any Person in connection with the execution and delivery of the Transactional Agreements or the consummation of the transactions contemplated thereby, including the sale of the Designated Assets to Purchaser.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.4 Compliance with Law; Permits<font style="font-weight:normal;">. As it relates to the Designated Assets: (a) each Seller has at all times been and is now in compliance with each Legal Requirement that is applicable to the ownership or use of the Designated Assets; (b) no event has occurred, and no condition or circumstance exists, that might (with or without notice or lapse of time) constitute or result in a violation by any Seller of, or a failure on the part of any Seller to comply with, any Legal Requirement; and (c) no Seller has received, at any time, any notice or other communication (in writing or otherwise) from any governmental body or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 6</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">any other Person regarding any actual or alleged violation of, or failure to comply with, any Legal Requirement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.5 Title to Transferred Assets<font style="font-weight:normal;">. Sellers own, and have good and valid title to, all of the Designated Assets, free and clear of any Encumbrances, subject to the qualifications pertaining thereto with respect to Stanford as set forth in Section 1.1, subparts (b) and (c).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.6 Tax Matters<font style="font-weight:normal;">. Each Tax with respect to the Designated Assets required to have been paid, or claimed by any governmental body to be payable, by Sellers has been duly paid in full on a timely basis. With respect to the Designated Assets, no claim or other Proceeding is pending or, to the knowledge of Sellers, has been threatened in respect of any Tax.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.7 Restriction on Business Activities<font style="font-weight:normal;">. There is no order to which Sellers are a party to or otherwise binding upon Sellers or any of their properties or assets (including the Designated Assets) which has or may reasonably be expected to have the effect of prohibiting or impairing the use of the Designated Assets or limiting the freedom of Purchaser to engage in any line of business or to compete with any Person. Sellers have not entered into any contract under which they are, or Purchaser will be after the Closing, restricted from using the Designated Assets to create products or services and sales, licensing, marketing, manufacturing or otherwise distributing or using any such products, services or any of the Designated Assets or from providing services to customers or potential customers or any class of customers, m any geographic area, during any period of time, or in any segment of the market.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.8 No Liability<font style="font-weight:normal;">. The Sellers have no Liability with respect to the Designated Assets.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.9 Intellectual Property<font style="font-weight:normal;">. The Sellers exclusively own or otherwise a valid right to use and practice (through the License Agreement) the Invention, under the HH Patent and the other intellectual property included in the Designated Assets (the &#8220;</font><font style="font-style:italic;">Designated IP</font><font style="font-weight:normal;">&#8221;), free of any Encumbrances, including obligations to pay royalties or indemnification obligations (except as otherwise provided in the License Agreement). The Designated IP is valid, subsisting and enforceable. There are no outstanding options, licenses, or agreements of any kind relating to the Designated IP. To Sellers&#8217; knowledge, the Designated IP does not violate or infringe any intellectual property right of any other Person. Neither Seller has received any communication alleging that any Seller or that the Designated IP has violated or would violate any of the patents, trademarks, service marks, tradenames, copyrights, trade secrets or other proprietary rights or processes of any other Person. Neither the execution or delivery of this Agreement and the other Transaction Agreements, nor the use of the Designated Assets as currently proposed to be conducted will conflict with or result in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract, covenant or instrument under which any Seller is obligated.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.10 Proceedings<font style="font-weight:normal;">. There is no pending or threatened Proceeding: (a) that involves or otherwise can affect any Seller or any of the Designated Assets; or (b) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the transactions contemplated by this Agreement or the other Transaction Agreements. No event has occurred, and no claim, dispute or other condition or circumstance exists, that will or could be expected to, give rise to or serve as a basis for the commencement of any such Proceeding. There is no order, writ, injunction, judgment or decree to which any Seller, or any Designated Asset, is subject.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.11 No Brokers<font style="font-weight:normal;">. Sellers are not obligated to pay any brokerage, commission, finder&#8217;s fee or similar fee in connection with the transactions contemplated hereby.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.12 Full Disclosure<font style="font-weight:normal;">. Sellers have disclosed to Purchaser all facts known to them that are material to the Designated Assets, or may have material effect on Purchaser&#8217;s consideration of the execution of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 7</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">this Agreement or any other Transaction Agreement, or consummation of the transactions contemplated hereby or thereby. No representation or warranty by Sellers in this Agreement or any Schedule hereto contains any untrue statement of a material fact or omits to state any material fact necessary, in each case with respect to the Designated Assets, in order to make the statement made herein or therein, in light of the circumstances under which they were made, not misleading.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 3. REPRESENTATIONS AND WARRANTIES OF PURCHASER<font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchaser represents and warrants to Sellers that:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.1 Due Organization<font style="font-weight:normal;">. Purchaser is a limited liability company duly organized, validly existing and in good standing under the laws of Delaware.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.2 Authority; Binding Nature of Agreements<font style="font-weight:normal;">. Purchaser has the requisite corporate power and authority to enter into and to deliver each of the Transactional Agreements </font><font style="font-weight:normal;color:#000000;">to which it is a party and to perform its obligations under each such Transactional Agreement, and the execution, delivery and performance by Purchaser of each of the Transactional Agreements to which it is a party have been duly authorized by all necessary corporate action on the part of Purchaser. Each of the Transactional Agreements constitutes a legal, valid and binding obligation of Purchaser, enforceable against it or them in accordance with its terms, except to the extent that enforcement thereof may be limited by: (a) bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws now or hereafter in effect relating to creditors&#8217; rights generally; and (b) general principles of equity (regardless of whether enforceability is considered in a Proceeding at law or in equity).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.3 Non-Contravention<font style="font-weight:normal;">. The execution and delivery by Purchaser of the Transactional Agreements, and the purchase of the Designated Assets by Purchaser from Sellers will not result in a violation of the charter documents of Purchaser.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.4 Capitalization Table<font style="font-weight:normal;">. </font><font style="text-decoration:underline;font-weight:normal;">Exhibit D</font><font style="font-weight:normal;"> sets forth the true and correct capitalization of the Company as of the Effective Date.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 4. SURVIVAL AND INDEMNIFICATION<font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">4.1 Survival of Representations<font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:normal;">The representations and warranties of Sellers shall survive the Closing and the sale of the Designated Assets to Purchaser and shall expire on the date that is [ * ] following the Closing Date (the &#8220;</font><font style="font-style:italic;">Representation Termination Date</font><font style="font-weight:normal;">&#8221;); </font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that if Purchaser provides Seller a written notice relating to any representation or warranty prior to the applicable Representation Termination Date, then the claim(s) asserted in such Claim Notice shall survive the Representation Termination Date until such time as such claim is (or claims are) fully and finally resolved. The limitations set forth in this </font><font style="text-decoration:underline;font-weight:normal;">Section 4.l(a)</font><font style="font-weight:normal;"> shall not apply in the case of intentional misrepresentation, willful misconduct or fraud (&#8220;</font><font style="font-style:italic;">Fraud</font><font style="font-weight:normal;">&#8221;). The covenants and obligations of each Party shall survive the Closing and the sale of the Designated Assets to Purchaser and shall expire upon the applicable statute of limitations, which statute shall start to run on the Closing Date, except in the case of Fraud.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:normal;">For purposes of this Agreement, a &#8220;</font><font style="font-style:italic;">Claim Notice</font><font style="font-weight:normal;">&#8221; relating to a particular representation or warranty shall be deemed to have been given if Purchaser delivers to Sellers a written notice stating that Purchaser believes that there is or has been a breach of a representation or warranty, asserting a claim for </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 8</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">recovery under</font><font style="font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">Section</font><font style="text-decoration:underline;font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">4.2</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">based on such alleged breach and setting forth in reasonable detail: (i)</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">the basis for, and a brief description of the circumstances supporting, Purchaser&#8217;s belief that there is or has been such a breach; and (ii)</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">to the extent practicable, a non-binding, preliminary estimate of the aggregate dollar amount of the actual and potential Damages that have arisen and may arise as a result of such breach.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">4.2 Indemnification<font style="font-weight:normal;">. From and after the Closing Date (but subject to the limitations set forth in this </font><font style="text-decoration:underline;font-weight:normal;">Section 4</font><font style="font-weight:normal;">), each of the Sellers shall individually, and not jointly, hold harmless, reimburse and indemnify Purchaser and its agents and representatives from and against, any </font><font style="font-weight:normal;color:#000000;">Damages that are suffered or incurred by Purchaser and that arise from or as a result of or relating to:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:normal;">Any inaccuracy in or breach of any of the representations or warranties made by the applicable Seller in this Agreement or in any other Transaction Agreement;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:normal;">Any breach of any covenant or obligation of the applicable Seller contained in this Agreement or any other Transaction Agreement; and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="font-weight:normal;">Any Liability of such Seller, except for the Assumed Liabilities.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">4.3 Cap<font style="font-weight:normal;">. Notwithstanding anything to the contrary, each Seller&#8217;s liability to Purchaser hereunder shall be capped at the value of such Seller&#8217;s vested shares comprising the Purchase Price (with the value of such shares or options, to the extent necessary in determining the cap, as reasonably determined by Purchaser&#8217;s Board of Directors based upon the available information pertaining thereto) for each of the Sellers pursuant to this Agreement; provided that, to the extent that the liability to Purchaser exceeds the value of the vested shares comprising the Purchase Price with respect to any claim of Purchaser, the liability shall be satisfied in part by any vested shares or options and shall remain in effect until there are no longer shares or options subject to vesting. It is further agreed that each Seller shall have the right to satisfy any liability to Purchaser hereunder by returning to Purchaser that portion of its vested shares or options whose value equals the amount of said liability, not to exceed the return of all of its shares or options comprising the Purchase Price (with the value of such shares or options, to the extent necessary in determining the cap, as reasonably determined by Purchaser&#8217;s Board of Directors based upon the available information pertaining thereto). The limitation set forth in this </font><font style="text-decoration:underline;font-weight:normal;">Section 4.3</font><font style="font-weight:normal;"> shall not apply in the case of Fraud and shall survive the termination or expiration of this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">4.4 Defense of Third-Party Claims<font style="font-weight:normal;">. In the event of the assertion or commencement by any Person of any claim or Proceeding (whether against Purchaser or against any other Person) with respect to which Purchaser may be entitled to indemnification, compensation or reimbursement pursuant to this </font><font style="text-decoration:underline;font-weight:normal;">Section 4.4</font><font style="font-weight:normal;">, Purchaser shall have the right, at its election, to proceed with the defense of such claim or Proceeding on its own with counsel reasonably satisfactory to Sellers (which consent may not be unreasonably withheld, delayed or conditioned). Purchaser shall have the right to settle, adjust or compromise such claim or Proceeding; </font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that if Purchaser settles, adjusts or compromises any such claim or Proceeding without the consent of Sellers (such consent not to be unreasonably withheld or delayed), such settlement, adjustment or compromise shall not be conclusive evidence of the amount of Damages incurred by Purchaser in connection with such claim or Proceeding. Purchaser shall give Sellers prompt notice after it becomes aware of the commencement of any such claim or Proceeding against Purchaser; </font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that any failure on the part of Purchaser to so notify Sellers shall not limit any of the obligations of Sellers, or any of the rights of Purchaser, under this </font><font style="text-decoration:underline;font-weight:normal;">Section 4.4</font><font style="font-weight:normal;"> (except to the extent such failure materially prejudices the defense of such Proceeding). If Purchaser does not elect to proceed with </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 9</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">the defense of any such Proceeding, Sellers may proceed with the defense of such Proceeding with counsel reasonably</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;color:#000000;">satisfactory to Purchaser;</font><font style="font-weight:normal;color:#000000;"> </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided, however</font><font style="font-weight:normal;color:#000000;">, that Sellers may not settle or compromise any such Proceeding without the prior written consent of Purchaser.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 5. CERTAIN POST-CLOSING COVENANTS<font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.1 Further Assurances<font style="font-weight:normal;">. From and after the Closing, each of Purchaser and Sellers will, to the extent reasonably requested by the other Party and at such other Party&#8217;s sole expense, execute and deliver such documents and instruments and take such other actions as such other Party may reasonably request in order to consummate and make effective the transactions contemplated by this Agreement. On and after the Closing Date, each Seller shall execute such documents, further instruments of sale, transfer, conveyance, assignment and confirmation and other papers and take such further actions as may be reasonably required to transfer, convey and assign to Purchaser, and to confirm Purchaser&#8217;s title to, all of the Designated Assets.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.2 Publicity<font style="font-weight:normal;">. Sellers agree that, on and at all times after the date of this Agreement: (a) no press release or other publicity concerning any of the transactions contemplated hereby shall be issued or otherwise disseminated by it or on its behalf without Purchaser&#8217;s prior written consent; and (b) Sellers shall continue to keep the terms of this Agreement strictly confidential.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.3 Tax Cooperation<font style="font-weight:normal;">. Purchaser and Sellers agree to furnish or cause to be furnished to each other, upon request, as promptly as practicable, such information and assistance relating to the Designated Asset (including access to books and records) as is reasonably necessary for the filing of all tax returns, and making of any election related to taxes, the preparation for any audit by any taxing authority and the prosecution or defense of any claim, suit or Proceeding relating to any tax return.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.4 Non-Competition<font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a) Non-Competition<font style="font-weight:normal;">. Each Seller hereby covenants, acknowledges and agrees that it will not, at any time during [ * ] from the Closing Date, either directly or indirectly, as principal, agent, owner, partner, employee, consultant, shareholder, director or officer, as the case may be, in any manner whatsoever, own, be engaged in, be concerned with, be interested in, operate, have any financial interest in or advance, lend money to, guarantee the debts or obligations of, permit its name or any part thereof to be used or applied by any Person, firm or corporation engaged in or concerned with or interested in, directly or indirectly, in any Competitive Activity in any territory in which the Products are currently planned to be commercialized, except as a passive shareholder holding less than [ * ] percent of the outstanding shares of a corporation offering its shares to the public and whose shares are listed and posted for trading on a recognized stock exchange. Notwithstanding the foregoing covenant, Purchaser agrees that said covenant shall not be construed to preclude Sellers from continuing, during said [ * ] period following the Closing Date, their research and mechanistic studies relating to hyperinsulinemic hypoglycemia in connection with their employment at Stanford.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 10</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b) Relief</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i) Injunctive Relief<font style="font-weight:normal;">. Sellers acknowledges that breach of Seller&#8217;s covenants contained in this </font><font style="text-decoration:underline;font-weight:normal;">Section 5.4</font><font style="font-weight:normal;"> may cause irreparable harm to the Business, which may not be compensable through monetary damages. Sellers therefore hereby acknowledges that in the event of a breach or a threatened breach by the them or their respective affiliates of such covenants, Purchaser will be entitled, in addition to any other rights, remedies or damages which may be available to Purchaser, at law or in equity, to obtain an interim and permanent injunction in order to prevent or restrain any breach or threatened breach of this Agreement by Sellers or their affiliates, partners, employers, employees, servants, agents, representatives, and other Persons directly or indirectly acting for, or on behalf of, or with, Sellers. Sellers further agree that Purchaser shall be entitled to injunctive relief without having to prove damages and shall be entitled to all of its costs and expenses incurred in order to obtain relief from any such breach under this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ii) Restrictions Reasonable<font style="font-weight:normal;">. Purchaser and Sellers acknowledge and confirm that:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:22.23%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(1) <font style="font-weight:normal;">they have been independently advised by their respective counsel with respect to the provisions of this </font><font style="text-decoration:underline;font-weight:normal;">Section 5.4</font><font style="font-weight:normal;">;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:22.23%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(2) <font style="font-weight:normal;">they have negotiated the provisions of </font><font style="text-decoration:underline;font-weight:normal;">Section 5.4</font><font style="font-weight:normal;"> on an equal footing based on equal bargaining power at the Closing Date;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:22.23%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(3) <font style="font-weight:normal;">neither Purchaser or Sellers were required or induced by force, threats, or other means of intimidation or in any other manner to enter into this Agreement or the Transaction Documents;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:22.23%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(4) <font style="font-weight:normal;">the provisions of this </font><font style="text-decoration:underline;font-weight:normal;">Section 5</font><font style="font-weight:normal;"> and the Transaction Documents are reasonable and do not go beyond what is necessary to protect the interests of Purchaser; and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:22.23%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(5) <font style="font-weight:normal;">the Transaction Documents are supported by adequate consideration.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.5 Commercially Reasonable Efforts<font style="font-weight:normal;">. Purchaser hereby agrees to use Commercially Reasonable Efforts to pursue and complete [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 6. MISCELLANEOUS PROVISIONS<font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.1 Notices<font style="font-weight:normal;">. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given or made as follows:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:normal;">if sent by registered or certified mail in the United States return receipt requested, upon receipt; (b) if sent designated for overnight delivery by nationally recognized overnight air courier (such as Federal Express), upon receipt; (c) if sent by facsimile transmission before 5:00 p.m. in California, when transmitted and receipt is confirmed; (d) if sent by facsimile transmission after 5:00 p.m. in California and receipt is confirmed, on the </font><font style="font-weight:normal;color:#000000;">following business day; and (e) if otherwise actually personally delivered, when delivered, provided that such notices, requests, demands and other communications are delivered to the address set forth below, or to such other address as either Party shall provide by like notice to the other Party:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 11</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:11.4%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Sellers:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tracey McLaughlin, MD</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 Pasteur Drive, Room S025</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stanford, CA 94305-5103</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: <font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colleen Craig, MD</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 Pasteur Drive, Room S025</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stanford, CA 94305-5103</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: <font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:11.4%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With copies (which shall not constitute notice) to:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blakely, Sokoloff, Taylor &amp; Zafman LLP</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12400 Wilshire Boulevard</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 700</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Los Angeles, California 90025</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Norman Zafman</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: (310) 820-5988</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:11.4%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Purchaser:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350 Cambridge Avenue, Suite 350</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palo Alto, CA 94306</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: David Cory</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: (415) 203-0934</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:11.4%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With copies (which shall not constitute notice) to:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3175 Hanover St.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palo Alto, CA 94304</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Glen Sato</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: (650) 849-7400</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.2 Headings<font style="font-weight:normal;">. The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.3 Counterparts and Exchanges by Electronic Transmission or Facsimile<font style="font-weight:normal;">. This Agreement may be executed in counterparts, each of which shall constitute an original and both of which, when taken together, shall constitute one agreement. The exchange of a fully executed Agreement (in counterparts or otherwise) by electronic transmission or facsimile shall be sufficient to bind the Parties to the terms and conditions of this Agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 12</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.4 Governing Law; Venue</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:normal;">This Agreement shall be construed in accordance with, and governed in all respects by, the internal laws of the State of California (without giving effect to principles of conflicts of laws).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:normal;">Any Proceeding relating to this Agreement or the enforcement of any provision of this Agreement shall be brought or otherwise commenced in any state or federal court located in the State of California. Each Party:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i) <font style="font-weight:normal;">expressly and irrevocably consents and submits to the jurisdiction of each state and federal court located in the State of California (and each appellate court located in the State of California) in connection with any such proceeding;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ii) <font style="font-weight:normal;">agrees that each state and federal court located in the State of California shall be deemed to be a convenient forum; and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(iii) <font style="font-weight:normal;">agrees not to assert (by way of motion, as a defense or otherwise), in any such Proceeding commenced in any state or federal court located in the State of California, any claim that such Party is not subject personally to the jurisdiction of such court, that such Proceeding has been brought in an inconvenient forum, that the venue of such Proceeding is improper or that this Agreement or the subject matter of this Agreement may not be enforced in or by such court.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.5 WAIVER OF TRIAL BY JURY<font style="font-weight:normal;">. EACH PARTY WAIVES THE RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY LAWSUIT, ACTION OR PROCEEDING SEEKING ENFORCEMENT OF SUCH PARTY&#8217;S RIGHTS UNDER THIS AGREEMENT.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.6 Successors and Assigns; Parties in Interest<font style="font-weight:normal;">. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon the parties hereto and their respective successors, assigns, heirs, executors and administrators. Sellers may not assign any of their rights or delegate any of their obligations under this Agreement to any other Person without the prior written consent of Purchaser. Purchaser may freely assign any or all of its rights hereunder, in whole or in part, to any other Person without obtaining the consent or approval of any other Person.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.7 Waiver<font style="font-weight:normal;">. No failure on the part of either Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of either Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.8 Specific Performance<font style="font-weight:normal;">. Each Party agrees that: (a) in the event of any breach or threatened breach by the other Party of any covenant, obligation or other provision set forth in this Agreement, such Party shall be entitled (in addition to any other remedy that may be available to it) to: (i) a decree or order of specific performance or mandamus to enforce the observance and performance of such covenant, obligation or other provision; and (ii) an injunction restraining such breach or threatened breach; and (b) neither Party shall be required to provide any bond or other security in connection with any such decree, order or injunction or in connection with any related legal proceeding.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.9 Amendments<font style="font-weight:normal;">. This Agreement may not be amended, modified, altered or supplemented other than by means of a written instrument duly executed and delivered on behalf of Sellers and Purchaser.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 13</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.10 Severability</font><font style="font-weight:normal;">. In the event that any prov1s10n of this Agreement, or the application of any such provision to either Party or set of circumstances, shall be determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to a Party or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, shall not be impaired or otherwise affected and shall continue to be valid and enforceable to the fullest extent permitted by law.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.11 Expenses<font style="font-weight:normal;">. Each Party shall bear and pay all fees, costs and expenses that have been incurred or that are in the future incurred by, on behalf of or for the benefit of, such Party in connection with the negotiation, preparation and review of this Agreement and the other Transactional Agreements and the consummation and performance of the transactions contemplated herein; </font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that Purchaser shall reimburse the reasonable fees and expenses of Blakely, Sokoloff, Taylor &amp; Zafinan LLP, as counsel to Sellers, not to exceed [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.12 Entire Agreement<font style="font-weight:normal;">. The Transactional Agreements set forth the entire understanding of the Parties relating to the subject matter thereof and supersede all prior agreements and understandings between the Parties relating to the subject matter thereof.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.13 Construction<font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="font-weight:normal;">For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-weight:normal;">The Parties agree that any rule of contractual construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="font-weight:normal;">As used in this Agreement and </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;">, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation</font><font style="font-style:italic;">.</font><font style="font-weight:normal;">&#8221;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(d) <font style="font-weight:normal;">Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; &#8220;Exhibits&#8221; and &#8220;Schedules&#8221; are intended to refer to Sections of this Agreement and Exhibits and Schedules to this Agreement.</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Remainder of page intentionally left blank</font>]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 14</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties have caused this Agreement to be executed and delivered as of the date above mentioned.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">PURCHASER:</p></td>
</tr>
<tr style="height:12pt;">
<td colspan="3" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">EIGER BIOPHARMACEUTICALS, INC.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Cory</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Cory</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and CEO</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="width:77%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SELLERS:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td colspan="3" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Tracey McLaughlin</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tracey McLaughlin</p></td>
</tr>
<tr style="height:12pt;">
<td colspan="3" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Colleen Craig</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colleen Craig</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 15</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">LIST OF EXHIBITS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A - Certain Definitions</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B - Form of Consulting Agreement</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C - Amendment No. 1 To License Agreement Exhibit D - Capitalization Table of the Company</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">LIST OF SCHEDULES</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disclosure Schedule</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 16</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">E<font style="font-size:7.5pt;">XHIBIT</font> A</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">C<font style="font-size:7.5pt;">ERTAIN</font> D<font style="font-size:7.5pt;">EFINITIONS</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the Agreement (including this Exhibit A):</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Affiliate<font style="font-weight:normal;">. &#8220;Affiliate&#8221; shall mean, with respect to a Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with such first Person. For the purpose of this definition, &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; and &#8220;under the common control&#8221;) meaning direct or indirect ownership of fifty percent (50%) or more, including ownership by trusts with substantially the same beneficial interests, of the voting and equity rights of such Person, or the power to direct the management of such Person.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Agreement<font style="font-weight:normal;">. &#8220;Agreement&#8221; shall mean the Asset Purchase Agreement (including the Disclosure Schedule), to which this </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;"> is attached as it may be amended from time to time.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Annual Net Sales<font style="font-weight:normal;">. &#8220;Annual Net Sales&#8221; shall mean the gross amount invoiced by Purchaser, its Affiliate and its sublicensees, for sales of the Product to a third party within a single calendar year, less the following deductions, to the extent accrued and directly allocable to the Product:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) cash discounts;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) returns (including recalls); price protection and shelf stock adjustments; reprocurement charges by customers and other similar charges; chargebacks, allowances, discounts, and rebates;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) other payments required by applicable Legal Requirements or agreed to be made under Medicaid, Medicare or other government special medical assistance programs (including, but not limited to, payments made under the new &#8220;Medicare Part D Coverage Gap Discount Program&#8221; and the &#8220;Annual Fee on Branded Prescription Pharmaceutical Manufacturers&#8221;);</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) relevant managed markets rebates; and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) sales, excise or other similar taxes (excluding income taxes).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For clarity, any subsequent adjustment to an accrual shall be reflected in the Annual Net Sales in the period in which such adjustment is made. Sales between Purchaser and its Affiliates shall be disregarded for purposes of calculating Annual Net Sales except if such Affiliates are end users. Annual Net Sales shall be accounted for in accordance with GAAP, consistent with Purchaser&#8217;s books and records, and in any event consistent with all of its other branded pharmaceutical products.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Business<font style="font-weight:normal;">. &#8220;Business&#8221; shall all activity related to Sellers&#8217; development, ownership and use of the Designated Assets.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 17</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Commercially Reasonable Efforts<font style="font-weight:normal;">. &#8220;Commercially Reasonable Efforts shall mean that level of efforts and resources, with respect to a particular Party, at the relevant point in time, that is consistent with the usual practice followed by a similarly situated company, in the exercise of its reasonable scientific and business judgment relating to other prescription pharmaceutical products owned or licensed by it or to which it has exclusive rights, which have market potential and are at a stage of development or product life similar to the applicable Product, taking into account measures of patent coverage, length of any statutory period of exclusivity, relative safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the compound or product, the regulatory structure involved, the relative profitability of the products (including, without limitation, pricing and reimbursement status) and other relevant factors, including without limitation comparative technical, legal, scientific, and/or medical factors.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Competitive Activity<font style="font-weight:normal;">. &#8220;Competitive Activity&#8221; shall mean the research or development of, sale, testing, marketing, commercialization or offer of the Product or any product or service that competes with the Product or that could be developed and commercialized for the same indications as the Product.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Damages<font style="font-weight:normal;">. &#8220;Damages&#8221; shall mean any loss, damage, injury, decline in value, Liability, lost opportunity, claim, settlement, judgment, fine, penalty, tax, fee (including any reasonable legal fee), charge or expense of any nature.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Disclosure Schedule<font style="font-weight:normal;">. &#8220;Disclosure Schedule&#8221; shall mean the disclosure schedule delivered by Sellers to Purchaser contemporaneously with the execution and delivery of the Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Documents<font style="font-weight:normal;">. &#8220;Equity Documents&#8221; shall mean the documents to be executed by the other purchasers in the Financing.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Encumbrance<font style="font-weight:normal;">. &#8220;Encumbrance&#8221; shall mean any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, equity, trust, equitable interest, claim, preference, right of possession, lease, tenancy, license, encroachment, covenant, infringement, interference, Order, proxy, option, right of first refusal, preemptive right, community property interest, legend, defect, impediment, exception, reservation, limitation, impairment, imperfection of title, condition or restriction of any nature (including any restriction on the transfer of any asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">GAAP<font style="font-weight:normal;">. &#8220;GAAP&#8221; shall mean United States generally accepted accounting principles and practices in effect from time to time, consistently applied.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Knowledge<font style="font-weight:normal;">. Information shall be deemed to be known to or to the &#8220;knowledge&#8221; of the Sellers if that information is actually known, reasonably should be known or reasonably could be expected to be discovered in the course of conducting a reasonable investigation concerning the existence of such fact or other matter by any Seller.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Legal Requirement<font style="font-weight:normal;">. &#8220;Legal Requirement&#8221; shall mean any federal, state, local, municipal, foreign or other law, statute, legislation, constitution, principle of common law, resolution, ordinance, code, edict, decree, proclamation, treaty, convention, rule, regulation, ruling, directive, pronouncement, requirement, specification, determination, decision, opinion or interpretation issued, enacted, adopted, passed, approved, promulgated, made, implemented or otherwise put into effect by or under the authority of any Governmental Body.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 18</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Liability</font><font style="font-weight:normal;">. &#8220;Liability&#8221; shall mean any debt, obligation, duty or liability of any nature (including any unknown, undisclosed, unmatured, unaccrued, unasserted, contingent, indirect, conditional, implied, vicarious, derivative, joint, several or secondary liability), regardless of whether such debt, obligation, duty or liability would be required to be disclosed on a balance sheet prepared in accordance with generally accepted accounting principles and regardless of whether such debt, obligation, duty or liability is immediately due and payable.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Patents<font style="font-weight:normal;">. &#8220;Patents&#8221; shall mean all patents and patent applications (including inventor&#8217;s certificates and utility models) in any country or jurisdiction, including all provisionals, substitutions, counterparts, continuations, continuations-in-part, divisionals, supplementary protection certificates, renewals, all letters patent granted thereon, and all reissues, reexaminations, extensions, confirmations, revalidations, registrations, patents of addition thereof, PCTs, pediatric exclusivity periods, and foreign equivalents to any of the foregoing.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Person<font style="font-weight:normal;">. &#8220;Person&#8221; shall mean any individual, corporation, partnership, limited liability company, or other legal entity or governmental body other than Purchaser and Sellers.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 Clinical Trial<font style="font-weight:normal;">. &#8220;Phase 2 Clinical Trial&#8221; shall mean any controlled human clinical trial designed to: (a) evaluate the effectiveness of the intended use of the therapeutic agent for a particular indication or indications; (b) identify short-term side effects and risks that are associated with the therapeutic agent in the dosage range to be prescribed; and (c) satisfy the requirements of 21 CFR &#167; 312.21(b).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Phase 3 Clinical Trial<font style="font-weight:normal;">. &#8220;Phase 3 Clinical Trial&#8221; shall mean any human clinical trial designed to: (a) establish that the therapeutic agent is safe and efficacious for its intended use; (b) define warnings, precautions and adverse reactions that are associated with the therapeutic agent in the dosage range to be prescribed; and (c) support regulatory approval of the therapeutic agent, that would satisfy the requirements of 21 CFR &#167; 312.21(c).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Proceeding<font style="font-weight:normal;">. &#8220;Proceeding&#8221; shall mean any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding and any informal proceeding), prosecution, contest, hearing, inquiry, inquest, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any governmental body or any arbitrator or arbitration panel.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Act<font style="font-weight:normal;">. &#8220;Securities Act&#8221; means the Securities Act of 1933, as amended.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Tax<font style="font-weight:normal;">. &#8220;Tax&#8221; shall mean any tax (including any income tax, franchise tax, capital gains tax, estimated tax, gross receipts tax, value-added tax, surtax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax, business tax, occupation tax, inventory tax, occupancy tax, withholding tax or payroll tax), levy, assessment, tariff, impost, imposition, toll, duty (including any customs duty), deficiency or fee, and any related charge or amount (including any fine, penalty or interest), that is, has been or may in the future be (a) imposed, assessed or collected by or under the authority of any governmental body, or (b) payable pursuant to any tax-sharing agreement or similar contract.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Transactional Agreements<font style="font-weight:normal;">. &#8220;Transactional Agreements&#8221; shall mean the Agreement and the Consulting Agreements, the Amendment No. 1 to License Agreement and any other documents delivered by Sellers to Purchaser to complete the transactions contemplated hereby.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 19</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Valid Claim</font><font style="font-weight:normal;">. &#8220;Valid Claim&#8221; shall mean a claim of any issued and unexpired Patent within the (a)</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">HH Patents or (b)</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">Patents licensed under the License Agreement, as applicable, that has not been held invalid or unenforceable by a final decision of a court or governmental agency of competent jurisdiction, which decision can no longer be appealed or was not appealed within the time allowed;</font><font style="font-weight:normal;"> </font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that if a claim of a pending patent application within the Patents licensed under the License Agreement, as applicable, shall not have issued within [ * ] after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 20</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBITS</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">FORM OF CONSULTING AGREEMENT</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CONSULTING AGREEMENT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Consulting Agreement (&#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) is made and entered into as of September , 2015, (&#8220;<font style="font-weight:bold;font-style:italic;">Effective Date</font>&#8221;) by and between Eiger BioPharmaceuticals, Inc., a Delaware corporation with an address of 350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306 (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;), and Colleen Craig, MD (&#8220;<font style="font-weight:bold;font-style:italic;">Consultant</font>&#8221;), with an address of 300 Pasteur Drive, Room S025, Stanford, CA 94305. Both Company and Consultant are referred to herein, individually, as a &#8220;<font style="font-weight:bold;font-style:italic;">Party</font>&#8221; and, collectively, as the &#8220;<font style="font-weight:bold;font-style:italic;">Parties</font>&#8221;.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Company desires to retain Consultant to render consulting services to Company and Consultant desires to be so retained by Company and to perform such services further specified herein, all in accordance with the terms and conditions of this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the premises, conditions and representations set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Company and Consultant, Company and Consultant agree as follows.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROFESSIONAL SERVICES</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Services<font style="font-weight:normal;">. Company hereby retains Consultant to provide professional consulting services as set forth on </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;"> (the &#8220;</font><font style="font-style:italic;">Services</font><font style="font-weight:normal;">&#8221;) to Company, which is attached hereto and incorporated herein by reference, and Consultant hereby accepts such engagement. Consultant agrees to perform for Company the professional Services and deliver to Company the work product agreed upon by the Parties, including the time commitments, deliverables and any relevant timetables and specifications set forth on </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;"> hereto.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Best Efforts<font style="font-weight:normal;">. Consultant will use best efforts to perform the Services hereunder for Company in a diligent, timely, and professional manner, in accordance with specifications reasonably requested by Company.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Location and Access<font style="font-weight:normal;">. The consulting Services shall be performed at Consultant&#8217;s premises or such other premises that Company and Consultant may mutually agree upon.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Payroll Taxes<font style="font-weight:normal;">. Consultant will be solely responsible for paying all applicable payroll taxes of any nature, including social security and other social welfare taxes or contributions, that may be due on amounts paid to Consultant pursuant to this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PAYMENT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company agrees to compensate Consultant for the Services performed by Consultant pursuant to this Agreement in accordance with the payment terms set forth in <font style="text-decoration:underline;">Exhibit A</font>. Payment will be made only for work that has been performed to the reasonable satisfaction of Company.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 21</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONFIDENTIAL INFORMATION</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Definition<font style="font-weight:normal;">. As used in this Agreement, the term &#8220;</font><font style="font-style:italic;">Confidential Information </font><font style="font-weight:normal;">&#8220; means (i) any technical or business information furnished by Company, or on behalf of Company by its affiliates, subsidiaries, contractors, advisors, partners, or agents, to Consultant in connection with the Services to be performed hereunder, (ii) any work product produced by Consultant as a result of work hereunder, as well as all work papers related thereto, regardless of whether such information is specifically designated as confidential and regardless of whether such information is in written, oral, electronic or other form, and (iii) Data and Inventions (as defined in </font><font style="text-decoration:underline;font-weight:normal;">Section 4.1</font><font style="font-weight:normal;"> hereof).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Use and Non-disclosure<font style="font-weight:normal;">. Consultant acknowledges that, in the course of performing or preparing to perform Services for Company under this Agreement, Consultant will become acquainted with certain of Company&#8217;s Confidential Information, the protection of which is necessary to the successful conduct of Company&#8217;s business and the preservation of the integrity of Company&#8217;s relationships with its customers. Company will make a reasonable effort to mark media containing Confidential Information with notice of the same and, otherwise, to inform Consultant when the latter is provided, or given access to, Confidential Information. Consultant agrees to (i) maintain all Confidential Information in strict confidence; (ii) use all Confidential Information solely for the purposes of performing Consultant&#8217;s obligations under this Agreement; and (iii) reproduce the Confidential Information only to the extent necessary to perform Consultant&#8217;s obligations under this Agreement, with all such reproductions being considered Confidential Information. Consultant shall not disclose Confidential Information to any third party without Company&#8217;s express written authorization.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exceptions<font style="font-weight:normal;">. The foregoing obligations of Consultant shall not apply to any Confidential Information that Consultant can demonstrate: (i) was already in the public domain prior to the time of its disclosure under this Agreement; (ii) entered the public domain through means other than an unauthorized disclosure resulting from an act or omission by Consultant; (iii) was independently developed or discovered by Consultant prior to the time of its disclosure under this Agreement, as evidenced by Consultant&#8217;s written records; (iv) is or was disclosed to Consultant at any time, whether prior to or after the time of its disclosure under this Agreement, by a third party having no fiduciary relationship with Company and having no obligation of confidentiality with respect to such Confidential Information; or (v) is required to be disclosed to comply with applicable laws or regulations, or with a court or administrative order, provided that Company receives prior written notice of such disclosure and that Consultant takes all reasonable and lawful actions to obtain or to permit Company to obtain confidential treatment for such disclosure and, if possible, to minimize the extent of such disclosure.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">No License<font style="font-weight:normal;">. Consultant acknowledges that, as between Consultant and Company, Company is the sole owner of the Confidential Information disclosed by Company and all patent, copyright, trademark, trade secret, and other intellectual property rights in, or arising from, such Confidential Information or developed hereunder. No option, license, or conveyance of such rights to Consultant is granted or implied under this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 22</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OWNERSHIP OF WORK PRODUCT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Invention Disclosure<font style="font-weight:normal;">. Consultant agrees to disclose promptly and in writing to Company any and all data, ideas, concepts, discoveries, inventions (whether patentable or not), developments, original works of authorship, trade secrets, and know-how that are developed, conceived, devised, invented, developed or reduced to practice or tangible medium by Consultant, under her direction or jointly with others, which arise from or in connection with this Agreement (&#8220;</font><font style="font-style:italic;">Data and Inventions </font><font style="font-weight:normal;">&#8220;). All work products hereunder shall be &#8220;work for hire&#8221;, and Consultant shall have no interest in the Data and Inventions.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Assignment<font style="font-weight:normal;">. Consultant hereby assigns to Company all of Consultant&#8217;s right, title, and interest to the Data and Inventions and any and all related patent rights, copyrights, and applications and registrations therefor. During the Term (as defined in Section 8.1) and thereafter, Consultant shall cooperate with Company, at Company&#8217;s expense, in obtaining proprietary protection for the Data and Inventions, and shall execute all documents which Company shall reasonably request to perfect Company&#8217;s rights in the Data and Inventions. Consultant acknowledges and agrees that without Company&#8217;s substantial investment of time and money, the Data and Inventions could not be developed. In the event that any Data or Invention cannot be assigned to Company as sole owner, and Consultant retains some right to use Data or Inventions, then Consultant agrees only to use the same only for internal, noncommercial research.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONSULTANT REPRESENTATION, WARRANTIES, AND CERTAIN COVENANTS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant represents, warrants, and covenants to Company throughout the Term as follows.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The execution and performance of this Agreement does not, and will not, constitute a breach or default under any contract to which Consultant is a party, or by which Consultant is bound, and Consultant is not, and shall not be, under any contractual or other obligation to any third party which conflicts with any obligations hereunder or prevents or limits the performance of Services under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant is free to disclose to Company, without breach of any obligation to a third party, any and all information, ideas, suggestions, developments, or know-how that Consultant may develop, generate or otherwise create in performing the Services under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant has complied and will comply with all applicable laws, rules, regulations, and guidelines in her conduct of the Services under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant warrants and represents that Consultant is not now, nor has Consultant ever been debarred or disqualified as a clinical investigator or participant in clinical services by the United States Food and Drug Administration or by any other regulatory or governmental authority.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant further warrants and represents that Consultant has no knowledge of any circumstances which may affect the accuracy of the foregoing. Consultant agrees to notify Company immediately if such party becomes aware of any change in circumstances that would render any of the foregoing untrue or misleading in any respect during the Term.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 23</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOLICITATION OF COMPANY EMPLOYEES</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant agrees that during the Term and for a period of [ * ] thereafter, Consultant shall not, without Company&#8217;s prior written consent, recruit, solicit, or hire any employee of Company, or induce or attempt to induce any employee of Company to discontinue his or her employment relationship with Company.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INDEMNIFICATION</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Indemnification of Consultant<font style="font-weight:normal;">. Company shall indemnify and hold harmless each of Consultant and its affiliates, and the successors and assigns of any of the foregoing (the &#8220;</font><font style="font-style:italic;">Consultant Indemnitees</font><font style="font-weight:normal;"> &#8220;), from and against any and all losses, liabilities, damages, penalties, fines, costs and expenses (including reasonable attorneys&#8217; fees and other expenses of litigation) (&#8220;</font><font style="font-style:italic;">Losses</font><font style="font-weight:normal;">&#8221;) from any claims, actions, suits or proceedings brought by a third party (a &#8220;</font><font style="font-style:italic;">Third Party Claim</font><font style="font-weight:normal;">&#8221;) incurred by any Consultant Indemnitee, arising from, or occurring as a result of (a) gross negligence or willful misconduct of Company and its Affiliates and (b) the research, development and regulatory activities relating to the exendin product conducted by or on behalf of Company in connection with the performance of the Services in accordance with this Agreement; except to the extent such Third Party Claims fall within the scope of the indemnification obligations of Consultant set forth in Section 7.2.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Indemnification of Company<font style="font-weight:normal;">. Consultant shall indemnify and hold harmless each of Company and its Affiliates and the directors, officers, shareholders, employees and agents of such entities and the successors and assigns of any of the foregoing (the &#8220;</font><font style="font-style:italic;">Company Indemnitees</font><font style="font-weight:normal;"> &#8220;), from and against any and all Losses from any Third Party Claims incurred by any Company Indemnitee, arising from, or occurring as a result of (a) gross negligence or willful misconduct of Consultant or its Affiliates; and (b) any material breach of any representations, warranties or covenants by Consultant under this Agreement, except to the extent such Third Party Claims fall within the scope of the indemnification obligations of Company set forth in Section 7.1(a) or (b).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Procedure<font style="font-weight:normal;">. A Party that intends to claim indemnification (the &#8220;</font><font style="font-style:italic;">Indemnified Party</font><font style="font-weight:normal;">&#8221;) under this Section 7 shall promptly notify the indemnifying Party in writing of any Third Party Claim, in respect of which the Consultant Indemnitee or Company Indemnitee, as the case may be, intends to claim such indemnification. The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the indemnifying Party&#8217;s expense, in connection with the defense of the Third Party Claim for which indemnity is being sought. The indemnitee may participate in and monitor such defense with counsel of its own choosing at its sole expense; </font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, the indemnitor shall have the right to assume and conduct the defense of the Third Party Claim with counsel of its choice. The indemnitor shall not settle any Third Party Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. So long as the indemnitor is actively defending the Third Party Claim in good faith, the indemnitee shall not settle any such Third Party Claim without the prior written consent of the Indemnifying Party. If the Indemnitor does not assume and conduct the defense of the Third Party Claim as provided above, (a) the indemnitee may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim in any manner the indemnitee may deem reasonably appropriate, and (b) the indemnitor will remain responsible to indemnify the Indemnitee as provided in this Section 7. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the indemnitor of its indemnification obligations under this 7. if and to the extent the indemnitor is actually prejudiced thereby.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 24</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TERM AND TERMINATION</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Term<font style="font-weight:normal;">. This Agreement shall be effective for the period set forth in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;"> hereof (the &#8220;</font><font style="font-style:italic;">Term</font><font style="font-weight:normal;">&#8221;).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Termination<font style="font-weight:normal;">. This Agreement may be terminated (i) by either Party at any time in the exercise of its sole discretion upon [ * ] written notice to the other Party, (ii) by a Party upon the material breach of this Agreement by the other Party, which material breach continues unremedied for [ * ] after delivery to the breaching Party by the nonbreaching Party of notice of material breach, (iii) by a Party immediately in the event of bankruptcy (voluntary or otherwise), insolvency, or other similar financial distress of the other Party.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Return of Company Materials<font style="font-weight:normal;">. Upon expiration or termination of this Agreement for any reason or at any time upon request by Company, Consultant will immediately return to Company all property belonging to Company, including without limitation all Confidential Information and Data and Inventions in Consultant&#8217;s possession or control.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Survival<font style="font-weight:normal;">. Termination or expiration of this Agreement shall not cancel or terminate any rights and/or obligations which arose prior to the effective date of termination or expiration and which must continue in order to give effect to their meaning at the time such right and/or obligation arose, including without limitation Sections 3 4, 7, 8.3, 8.4, 10 and 12.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOTICES</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any notice or approval required or permitted under this Agreement will be delivered in writing and will be sent by (i) facsimile (followed by a copy sent by overnight courier or, if the delivery is international, by two-day courier) or (ii) by overnight courier or, if the delivery is international, by two-day courier to the address specified below or to any other address that may be designated by prior notice. Any notice or approval delivered by facsimile will be deemed to have been delivered the day it is sent, unless it arrives after 5:00 p.m. at the recipient address or on a day other than a business day at the recipient address, in which case it shall be deemed delivered on the next business day. Any notice or approval sent by courier will be deemed delivered on the next business day after its date of posting if domestic or two business days after the day of posting if international.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 25</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Company:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Consultant:</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350 Cambridge Avenue, Suite 350</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palo Alto, CA 94306</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Matthew Bys</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone: 415-203-0934</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: mbvs@eigerbio.com</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colleen Craig, MD</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300 Pasteur Drive, Room S025</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stanford, CA 94305</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Colleen Craig, MD</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone: 650-350-2153</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: cmcraig@stanford.edu</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NON-COMPETITION</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant hereby covenants, acknowledges and agrees that it will not, at any time during [ * ] from the Effective Date, either directly or indirectly, as principal, agent, owner, partner, employee, consultant, shareholder, director or officer, as the case may be, in any manner whatsoever, own, be engaged in, be concerned with, be interested in, operate, have any financial interest in or advance, lend money to, guarantee the debts or obligations of, permit its name or any part thereof to be used or applied by any person, firm or corporation engaged in or concerned with or interested in, directly or indirectly, in any competitive activity in any territory in which the exendin products are currently planned to be commercialized, except as a passive shareholder holding less than [ * ] percent of the outstanding shares of a corporation offering its shares to the public and whose shares are listed and posted for trading on a recognized stock exchange. Notwithstanding the foregoing covenant, Company agrees that said covenant shall not be construed to preclude Consultant from continuing, during said [ * ] period following the Effective Date, their research and mechanistic studies relating to hyperinsulinemic hypoglycemia in connection with their employment at Stanford (as defined below).</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONSULTANT&#8217;S OBLIGATIONS SUBJECT TO THE EMPLOYMENT TERMS AND POLICIES OF STANFORD</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company acknowledges that it is aware that Consultant is a full time employee of the Leland Stanford Junior University (&#8220;<font style="font-weight:bold;font-style:italic;">Stanford</font>&#8221;), and that under Stanford&#8217;s employment terms and policies, it is permissible for Consultant to provide the Services desired by Company under this Agreement; <font style="font-style:italic;">provided, however</font>, in the event of a conflict between Stanford&#8217;s employment terms and policies and Consultant&#8217;s obligations hereunder, Stanford&#8217;s employment terms and policies shall govern, it being agreed that the parties shall in good faith attempt to amend this Agreement to reflect the intent of the parties with respect to the conflicting provision. In this connection, for example, Company acknowledges that it is aware that Stanford currently limits outside consulting services by its employees to a maximum of eight (8) hours per week.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GENERAL</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement<font style="font-weight:normal;">. This Agreement embodies the entire agreement and understanding between the Parties with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 26</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Modifications and Amendments<font style="font-weight:normal;">. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the Parties hereto.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Waivers and Consents<font style="font-weight:normal;">. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the Party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or prov1s1ons of this Agreement, whether or not similar.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Assignment<font style="font-weight:normal;">. Company may assign its rights and obligations hereunder to any person who or entity which succeeds to all or substantially all of Company&#8217;s business or that aspect of Company&#8217;s business in which Consultant is principally involved. Consultant&#8217;s rights and obligations under this Agreement may not be assigned without the prior written consent of Company.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Benefit<font style="font-weight:normal;">. All statements, representations, warranties, covenants, and agreements in this Agreement shall be binding on the Parties hereto and shall inure to the benefit of their respective successors and permitted assigns. Nothing in this Agreement shall be construed to create any rights or obligations except among the Parties hereto, and no person or entity shall be regarded as a third party beneficiary of this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Headings and Captions<font style="font-weight:normal;">. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and shall in no way modify, or affect the meaning or construction of, any of the terms or provisions hereof.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">No Waiver of Rights, Powers, and Remedies<font style="font-weight:normal;">. No failure or delay by a Party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing between the Parties hereto, shall operate as a waiver of any such right, power or remedy of the Party. No single or partial exercise of any right, power or remedy under this Agreement by a Party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such Party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a Party hereto shall not constitute a waiver of the right of such Party to pursue other available remedies. No notice to or demand on a Party not expressly required under this Agreement shall entitle the Party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the Party giving such notice or demand to any other or further action in any circumstances without such notice or demand.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Independent Contractor<font style="font-weight:normal;">. Company and Consultant agree that the relationship of Consultant to Company is at all times that of an independent contractor and not that of an employee, partner or joint-venturer of or with Company.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Counterparts<font style="font-weight:normal;">. This Agreement may be executed in one or more counterparts that together shall constitute one and the same legal instrument.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Governing Law<font style="font-weight:normal;">. This Agreement and the rights and obligations of the Parties hereunder shall be construed in accordance with and governed by the laws of the State of California, without giving effect to the conflict of law principles thereof.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 27</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction and Service of Process</font><font style="font-weight:normal;">. Any legal action or proceeding with respect to this Agreement shall be brought in the state and Federal courts in the City of San Francisco, California. By execution and delivery of this Agreement, each of the Parties hereto accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid courts. Each of the Parties hereto irrevocably consents to the service of process of any of the aforementioned courts in any such action or proceeding by the mailing of copies thereof by certified mail, postage prepaid, to the party at its address set forth in Section</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">9 hereof.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Severability<font style="font-weight:normal;">. The Parties intend this Agreement to be enforced as written. However, (i) if any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a duly authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law; and (ii) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby, the Parties agree that the court making such determination shall have the power to reduce the duration and/or geographic area of such provision, and/or to delete specific words and phrases, and in its reduced form such provision shall then be enforceable and shall be enforced.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Subcontracting<font style="font-weight:normal;">. All services or materials for which Consultant contracts, subcontracts, or purchases for purposes of this Agreement shall be subject to prior written approval by Company. Consultant agrees to provide to Company a copy of any such contract for services or materials prior to execution for comment, in particular regarding costs, source, payment schedule, early termination penalties, confidentiality, and patent rights. Consultant hereby unconditionally guarantees the timely performance of Services and delivery of deliverables in accordance with this Agreement by any affiliate or permitted subcontractor hereunder.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Injunctive Relief<font style="font-weight:normal;">. Consultant acknowledges that breach of Consultant&#8217;s covenants contained in Section 3 or Section 10 may cause irreparable harm to the Company, which may not be compensable through monetary damages. Consultant therefore hereby acknowledges that in the event of a breach or a threatened breach by the them or their respective affiliates of such covenants, the Company will be entitled, in addition to any other rights, remedies or damages which may be available to Company, at law or in equity, to obtain an interim and permanent injunction in order to prevent or restrain any breach or threatened breach of this Agreement by Consultant or their affiliates, partners, employers, employees, servants, agents, representatives, and other persons directly or indirectly acting for, or on behalf of, or with, Consultant. Consultant further agree that the Company shall be entitled to injunctive relief without having to prove damages and shall be entitled to all of its costs and expenses incurred in order to obtain relief from any such breach under this Agreement</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 28</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties the parties hereto have executed this Consulting Agreement on the Effective Date written above.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:13%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David A. Cory</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman, President and CEO, Eiger BioPharmaceuticals</p></td>
</tr>
<tr style="height:12pt;">
<td colspan="3" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CONSULTANT:</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colleen Craig, MD</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;"><br /></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 29</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Services and Documentation</font>.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONSULTANT&#8217;S SERVICES MAY INCLUDE: (I) PROVIDING CONSULTATIVE SERVICES SURROUNDING THE EXENDIN DEVELOPMENT AND CLINICAL PROGRAM; (II) SPEAKING WITH INVESTORS, BANKS AND OTHER OUTSIDE PARTIES REGARDING THE EXENDIN DEVELOPMENT AND CLINICAL PROGRAM; AND (III) OTHER SERVICES AS MUTUALLY AGREED. CONSULTANT SHALL BE AVAILABLE, SUBJECT TO RECEIVING REASONABLE NOTICE FROM COMPANY, FOR MEETINGS TO PARTICIPATE AND FACILITATE COMMUNICATION AND WORK FLOW.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Term</font>.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement shall be effective for the period beginning on the Effective Date and shall continue in full force for one (1) year thereafter, unless earlier terminated as permitted herein. This Agreement shall automatically renew for an annual period thereafter unless either Party provides written notice not less than [ * ] days prior to the then applicable annual expiration date.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Fees</font>.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant shall be paid [ * ] the first month for the value of her Services associated with the transfer of information, documents, and know-how related to the Exendin development and clinical program into the Company, and then the Consultant shall be paid at the rate of [ * ] per month for the remaining eleven (11) months of the first year of the Term, for time spent by Consultant on providing consulting Services requested by Company. In the interest of clarity, it is understood and agreed that Consultant will be paid said monthly amount for being available to provide Services reasonably requested by Company, regardless of whether, or the extent to which, Company requests Services. After the first anniversary, the fees shall paid on a per hour basis on actual consulting services time provided to the Company at the rate of [ * ] per hour.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is further understood and agreed that if this Agreement is terminated during the initial year of the Term for any reason, the monthly amount due and payable to Consultant for the month in which such termination occurs will be appropriately pro-rated.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Payment Terms</font>.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company shall pay consultant on a monthly basis at the end of each month. Company will reimburse Consultant for any reasonable, authorized travel, lodging and other out-of-pocket expenses incurred by personnel in the course of performing hereunder, provided that Consultant furnishes Company with specific documentation therefore and Company approves all such expenses in advance.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All invoices for the above-described out-of-pocket expenses shall be submitted by Consultant directly to Company. Payment of all undisputed amounts shall be made within [ * ] days after receipt of invoice by Company. If Company has a dispute with any charges set forth in an invoice, Company shall notify Consultant of the dispute and provide Consultant details of the dispute. The Parties shall negotiate in good faith to promptly resolve disputes related to any invoiced amounts. Consultant shall maintain records of all time and expenses under this Agreement and shall provide Company reasonable access to the same upon request.</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 30</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT C</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMENDMENT NO. 1 TO LICENSE AGREEMENT</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMENDMENT NO. 1 TO LICENSE AGREEMENT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amendment No. 1 to License Agreement (the &#8220;<font style="font-weight:bold;font-style:italic;">Amendment</font>&#8221;) is effective as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of September 2015 (the &#8220;<font style="font-weight:bold;font-style:italic;">Amendment Effective Date</font>&#8221;), and amends that certain License Agreement effective May 4, 2015 (the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) among The Board of Trustees of the</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leland Stanford Junior University (&#8220;<font style="font-weight:bold;font-style:italic;">Stanford</font>&#8221;), an institution of higher education having powers under the laws of the State of California, and Tracey McLaughlin and Colleen Craig (the &#8220;<font style="font-weight:bold;font-style:italic;">Original Licensees</font>&#8221;), individuals having a principal place of business at Stanford University School of Medicine, and Eiger BioPharmaceuticals, Inc. (&#8220;<font style="font-weight:bold;font-style:italic;">Eiger</font>&#8221;), as assignee of the Original Licensees pursuant to this Amendment. Collectively, Stanford, Original Licensees and Eiger are referred to as the &#8220;<font style="font-weight:bold;font-style:italic;">Parties</font>&#8221;.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Original Licensees are assigning to Eiger all but certain specified rights and interests in technology with respect to Exendin for any and all uses, including the technology described within Stanford Docket S12-372 under the License Agreement;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger desires to become assignee of the Original Licensees as set forth in this Amendment in order to further develop Exendin; and</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stanford desires to accept Eiger as an assignee of the Original Licensees and to amend Sections 1 and 13 of the Agreement as set forth in this Amendment.</p></td>
</tr>
</table></div>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AGREEMENT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Now, therefore, for good and valuable consideration, the receipt of which the parties acknowledge, the parties hereby agree as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the Amendment Effective Date, the Agreement shall be amended as follows:</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger shall replace and be deemed the sole Licensee and assume all of the rights and obligations under the Agreement, and the Original Licensees shall have no rights or obligations under the Agreement.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within [ * ] days after the Amendment Effective Date, Eiger shall pay to Stanford [ * ] to an account designated by Stanford.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 1 of the Agreement is amended to add the following clause to the end of the first sentence:</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 31</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.4%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;, including one or more provisional applications to be filed by Licensee at Licensee&#8217;s discretion between the Amendment Effective Date and the date a PCT patent application claiming priority to Serial No. [ * ] is filed, the PCT application, and any US or foreign patents that issue on or claim priority to any of the foregoing.&#8221;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 13 of the Agreement is hereby amended and restated to read in its entirety as follows:</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:11.4%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;13. Assignment.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1 <font style="text-decoration:underline;">Permitted Assignment by Licensee</font>. Subject to Section 13.3, Licensee may assign this Agreement: (a) as part of a sale or change of control, regardless of whether such a sale or change of control occurs through an asset sale, stock sale, merger or other combination, or any other transfer of Licensee&#8217;s entire business or that part of Licensee&#8217;s business that exercises all rights granted under this Agreement;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:18.53%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) to an Affiliate provided that Licensee remains liable to Stanford for the performance by its Affiliate.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2 Any Other Assignment by Licensee. Except pursuant to Section 13.1, any attempt to assign this Agreement by Licensee without Stanford&#8217;s prior written consent is null and void.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3 Conditions of Assignment. Prior to any assignment, the following conditions must be met:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Licensee must make best efforts to give Stanford [ * ] prior written notice of the assignment, including the new assignee&#8217;s contact information; and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) the new assignee must agree in writing to Stanford to be bound by this Agreement; and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Stanford must have received a [ * ] assignment fee.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:18.53%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4 After the Assignment. Upon a permitted assignment of this Agreement pursuant to this Section 13, Licensee will be released of liability under this Agreement and the term &#8220;<font style="font-weight:bold;font-style:italic;">Eiger</font>&#8221; in this Amendment and &#8220;<font style="font-weight:bold;font-style:italic;">Licensee</font>&#8221; in the Agreement will mean the assignee.<font style="font-weight:bold;font-style:italic;">&#8221;</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stanford and the Original Licensees each represent and warrant to Eiger the following:</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as of the Amendment Effective Date, the Agreement remains in full force and effect;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no notice of any termination, noncompliance or breach has been delivered or received by either of Stanford or Original Licensees; and</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">none of Stanford or the Original Licensees is aware of noncompliance or claim that would result in a breach or termination of the Agreement.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as expressly set forth herein, the Agreement remains in full force and effect and shall not otherwise be amended except in writing entered into by Eiger (as Licensee) and Stanford.</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 32</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In witness whereof, the Parties hereto have executed and delivered this Amendment in their personal capacity or through their duly authorized officers or representatives, as the case may apply.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:41.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stanford:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:50.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:50.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Trustees of the Leland Stanford Junior University</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:50.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:41.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:41.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:41.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:50.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Original Licensees (with respect to the Amendment and as assignors):</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:50.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tracey McLaughlin</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:41.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colleen Craig, M.D.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:41.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:50.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:50.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:50.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:41.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:41.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:49.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:41.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 33</a> of 28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT D</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAPITALIZATION TABLE</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;white-space:nowrap;">
<p style="border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Security Type</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[*]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 34</a> of 28</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>3
<FILENAME>eigr-ex1010_1144.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex1010_1144.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = <font style="font-variant: small-caps;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p>
<p style="text-align:right;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.10</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LICENSE AGREEMENT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS LICENSE AGREEMENT (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;), dated as of September 3, 2010, is by and between SCHERING CORPORATION, a New Jersey corporation having its principal place of business at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (hereinafter referred to as &#8220;<font style="text-decoration:underline;">Schering</font>&#8221;) and Eiger Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware and having its principal place of business at 3350 W Bayshore Road, Suite 120, Palo Alto, CA 94303 (hereinafter referred to as &#8220;<font style="text-decoration:underline;">Licensee</font>&#8221;). Schering and Licensee are sometimes referred to herein individually as a &#8220;Party&#8221; and collectively as the &#8220;Parties&#8221;.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Schering has developed the compound known as Sarasar/Lonafarnib (SCH 66336) and Schering is seeking to out-license rights to develop and commercialize Sarasar/Lonafarnib (SCH 66336);</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Licensee desires to develop and commercialize Sarasar/Lonafarnib (SCH 66336); and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Licensee and Schering desire to enter into a license arrangement whereby Licensee will develop and commercialize Sarasar/Lonafarnib (SCH 66336).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, Licensee and Schering hereby agree as follows:</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE I - DEFINITIONS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in this Agreement, the following capitalized terms, whether used in the singular or plural, shall have the respective meanings set forth below:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 &#8220;<font style="text-decoration:underline;">Additional Indication</font>&#8221; means an indication in the Field for the treatment of a virus that is different from the virus or disease condition caused by the virus that is the subject of the First Indication and any indication previously granted Regulatory Approval in the Field.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2 &#8220;<font style="text-decoration:underline;">Affiliate</font>&#8221; means any individual or entity directly or indirectly controlling, controlled by or under common control with a Party to this Agreement. For purposes of this Agreement, the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of an entity, or the right to receive fifty percent (50%) or more of the profits or earnings of an entity shall be deemed to constitute control. Such other relationship as in fact results in actual control over the management, business and affairs of an entity shall also be deemed to constitute control.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 1</a> of 42</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3 &#8220;<font style="text-decoration:underline;">Business Day</font>&#8221; means a day on which banking institutions in New York, New York, United States are open for business.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4 &#8220;<font style="text-decoration:underline;">Bulk Licensed Product</font>&#8221; means finished capsules of the Licensed Product to be used in clinical trials packaged in bulk.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 &#8220;<font style="text-decoration:underline;">Calendar Quarter</font>&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31, for so long as this Agreement is in effect.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6 &#8220;<font style="text-decoration:underline;">Calendar Year</font>&#8221; means each successive period of twelve (12) months commencing on January 1 and ending on December 31, for so long as this Agreement is in effect.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7 &#8220;<font style="text-decoration:underline;">Combination Product</font>&#8221; means a Licensed Product which comprises two (2) or more active ingredients, at least one (1) of which is a Licensed Compound.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8 &#8220;<font style="text-decoration:underline;">Commercialization</font>&#8221; means, with respect to Licensed Product, any and all activities directed to the marketing, promotion, distribution, offering for sale and selling such product, importing and exporting such product for sale, and interacting with Regulatory Authorities regarding the foregoing. Commercialization shall also include Commercialization Studies. &#8220;Commercialize&#8221; has a correlative meaning.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.9 &#8220;<font style="text-decoration:underline;">Commercialization Studies</font>&#8221; means a study or data collection effort for a Licensed Product that is initiated in the Territory after receipt of Regulatory Approval for such Licensed Product and is principally intended to support the Commercialization of such Licensed Product in the Territory; provided, that such study or data collection effort is not principally to support or maintain a Regulatory Approval or obtain a label change or maintain a label.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10 &#8220;<font style="text-decoration:underline;">Commercially Reasonable Efforts</font>&#8221; means the performance of obligations or tasks in a continuous, sustained manner consistent with the resources and efforts typically used in the pharmaceutical and biotechnology industries for an ethical drug of similar commercial potential as the Licensed Product, at a similar stage in its lifecycle, taking into consideration its safety and efficacy, the cost to Develop and Commercialize the product, the risks inherent in the Development and Commercialization of the product, its competitiveness compared to alternative products, the proprietary position of the product, the scope, timing and likelihood of Regulatory Approvals.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.11 &#8220;<font style="text-decoration:underline;">Compound Patent Rights</font>&#8221; means all patents and patent applications which, as of the Effective Date, are Controlled by Schering (and/or any of its Affiliates), other than the Program Patents, that are reasonably necessary for Licensee to make, have made, use, sell, offer for sale or import Licensed Product in the Territory and in the Field and that are listed on <font style="font-weight:bold;text-decoration:underline;">Schedule 1.11</font>, and all (a) substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, certificates of invention, confirmations, re-examinations, extensions, supplementary protection certificates or the like, or the provisional applications of any such patents and patent applications of any of the foregoing; or (b) foreign equivalents of any of the foregoing.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12 &#8220;<font style="text-decoration:underline;">Controlled</font>&#8221; means, with respect to a Person, that such Person (or any of its Affiliates) has the legal authority to grant a license or sublicense of intellectual property rights to another Person or to otherwise disclose proprietary information to another Person without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.13 &#8220;<font style="text-decoration:underline;">Cross-Field Net Sales</font>&#8221; means the total Net Sales of Licensed Product that are attributable to Cross-Field Sales in any given calendar year.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 2</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.14 &#8220;</font><font style="text-decoration:underline;">Cross-Field Cost of Goods</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means the fully burdened cost to manufacture all Licensed Product sold by a Party in the relevant calendar year (including both bulk and secondary packaging) divided by the total number of units of Licensed Product sold by such Party in the relevant calendar year multiplied by the number of units of Licensed Product sold by such Party that constitute Cross-Field Sales.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.15 &#8220;<font style="text-decoration:underline;">Cross-Field Sales</font>&#8221; means sales of Licensed Products Commercialized by (a) Schering or its collaborators for indications in the Field after the launch of Licensed Product in the Field, or (b) Licensee or its collaborators for indications outside the Field after launch of Licensed Product by Schering outside the Field, in each case as may be applicable following the Commercialization by both Parties of Licensed Product.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.16 &#8220;<font style="text-decoration:underline;">Development</font>&#8221; or &#8220;<font style="text-decoration:underline;">Develop</font>&#8221; means all preclinical research and development activities and all clinical drug development activities, including, among other things: drug discovery, toxicology, formulation, statistical analysis and report writing, conducting clinical trials for the purpose of obtaining and maintaining Regulatory Approval (including without limitation, post-marketing studies), and regulatory affairs related to all of the foregoing. Development shall include all clinical studies (including Phase III-B) that are primarily intended to support or maintain a Regulatory Approval, maintain a label or obtain any label change, but shall exclude Commercialization Studies.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.17 &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221; shall have the meaning set forth in <font style="text-decoration:underline;">Section 12.1</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18 &#8220;<font style="text-decoration:underline;">Field</font>&#8221; means the use of the Licensed Compound or Licensed Product for all human antiviral applications, except for the treatment of Hepatitis C virus, Hepatitis B virus, or HIV infections; provided, however, that the Field specifically includes, without limitation, the treatment of Hepatitis D virus infections, including the treatment of patients co-infected with Hepatitis D virus and either or both of (i) Hepatitis C virus and (ii) Hepatitis B virus.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.19 &#8220;<font style="text-decoration:underline;">First Commercial Sale</font>&#8221; means, with respect to a country in the Territory, the date that commercial quantities of a Licensed Product are first sold in such country to a Third Party on arm&#8217;s length terms by Licensee, its Affiliate or sublicensee for use in the Field after the receipt of Regulatory Approval in such country. Sales for test marketing, sampling and promotional uses, clinical trial purposes or compassionate or similar use shall not be considered to constitute a First Commercial Sale.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20 &#8220;<font style="text-decoration:underline;">First Indication</font>&#8221; means treatment of the Hepatitis D virus infections in humans.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.21 &#8220;<font style="text-decoration:underline;">FTE</font>&#8221; means a full time equivalent person year of professional, scientific and/or technical work. An FTE shall consist of a total of [ * ] hours per year, with any portion of an FTE calculated based upon hours worked divided by such annual total.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.22 &#8220;<font style="text-decoration:underline;">FTE Rate</font>&#8221; means [ * ].</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23 &#8220;<font style="text-decoration:underline;">FTE Cost</font>&#8221; means, for any period of time, the product of (i) the actual total FTEs during such period and (ii) the FTE Rate.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.24 &#8220;<font style="text-decoration:underline;">Good Clinical Practices</font>&#8221; means the then current Good Clinical Practices as such term is defined from time to time by the United States Food and Drug Administration (&#8220;FDA&#8221;) or other relevant Governmental Authority having jurisdiction over the Development, manufacture or sale of Licensed Product in the Territory pursuant to its regulations, guidelines or otherwise.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.25 &#8220;<font style="text-decoration:underline;">Good Laboratory Practices</font>&#8221; means the current good laboratory practice regulations of the FDA as described in the United States Code of Federal Regulations (&#8220;CFR&#8221;) or any comparable corresponding foreign regulations or their respective successor regulations.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.26 &#8220;<font style="text-decoration:underline;">Good Manufacturing Practices</font>&#8221; means the then current Good Manufacturing Practices as such term is defined from time to time by the FDA or other relevant governmental authority having jurisdiction over the Development, manufacture or sale of Licensed Product in the Territory pursuant to its regulations, guidelines or otherwise.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 3</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.27 &#8220;</font><font style="text-decoration:underline;">Governmental Authority</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or any supranational organization of which any such country is a member.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.28 &#8220;<font style="text-decoration:underline;">IND</font>&#8221; means an investigational new drug application with respect to Licensed Product filed with the FDA for beginning clinical trials in humans, or any comparable application filed with the regulatory authorities of a country other than the United States prior to beginning clinical trials in humans in that country, as well as all supplements or amendments filed with respect to such filings.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29 &#8220;<font style="text-decoration:underline;">Know-How</font>&#8221; means any and all proprietary data, information and materials (whether patentable or not) necessary or useful to the Licensed Compound, formulations, the Licensed Product, any Licensed Product Improvements, or the Development, Commercialization, Manufacture or use of any of the foregoing, which are not in the public domain, including, without limitation, (a) ideas, discoveries, inventions, improvements, technology or trade secrets, (b) pharmaceutical, chemical and biological materials, products, components or compositions, (c) methods, procedures, formulas, processes, tests, assays, techniques, regulatory requirements and strategies, (d) biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, Manufacturing and quality control data and information related thereto, (e) technical and non-technical data and other information related to the foregoing, (f) drawings, plans, designs, diagrams, sketches, specifications or other documents containing or relating to such information or materials and (g) all applications, registrations, licenses, authorizations, approvals and correspondence submitted to Regulatory Authorities.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.30 &#8220;<font style="text-decoration:underline;">Licensed Compound</font>&#8221; means that certain Schering compound currently known as Sarasar/Lonafarnib (SCH 66336) with the chemical structure described in <font style="font-weight:bold;text-decoration:underline;">Schedule 1.29</font>, including any prodrug, metabolite, salt, ester, solvate, hydrate and crystalline form thereof.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.31 &#8220;<font style="text-decoration:underline;">Licensed Product</font>&#8221; means any pharmaceutical product or product candidate that contains the Licensed Compound, either alone or in combination with one or more other active pharmaceutical ingredients, including without limitation, all formulations, line extensions and modes of administration thereof.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.32 &#8220;<font style="text-decoration:underline;">Licensed Product Improvement</font>&#8221; means any enhancement to Licensed Compound or any Licensed Product, including without limitation, formulations thereof; the inclusion of any inactive ingredient; and any alternative preparation, presentation, means of delivery, dosage, packaging or manufacture.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.33 &#8220;<font style="text-decoration:underline;">Major European Country</font>&#8221; means any of France, Germany, Italy, Spain or the United Kingdom.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.34 &#8220;<font style="text-decoration:underline;">Manufacture</font>&#8221; means all activities related to the manufacturing of a pharmaceutical product, or any ingredient thereof, including but not limited to test method development and stability testing, formulation, process development, manufacturing scale-up, manufacturing Licensed Compound or Licensed Product quality assurance/quality control development, quality control testing (including in-process release and stability testing), packaging, shipment and release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of product or any component or ingredient thereof, and regulatory activities related to all of the foregoing.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35 &#8220;<font style="text-decoration:underline;">NDA</font>&#8221; means a New Drug Application or its equivalent filed with the FDA seeking approval to market and sell a Licensed Product in the United States or any comparable application filed with a Governmental Authority of a country other than the United States.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.36 &#8220;<font style="text-decoration:underline;">Net Sales</font>&#8221; means, with respect to each country in the Territory, the aggregate gross amount invoiced by Licensee, its Affiliates or sublicensees (other than Schering and its Affiliates) on all sales of Licensed Product to an unaffiliated Third Party (including distributors) in an arm&#8217;s length transaction, and exclusive of intercompany transfers or sales in the Territory, less the reasonable and customary deductions from such gross amounts, including: (i) normal and customary trade, cash and quantity discounts, allowances and credits; (ii) credits or allowances actually granted for damaged goods, returns or rejections of Licensed Product and retroactive price reductions; (iii) </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 4</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sales, use, tariff or similar taxes (including duties or other governmental charges levied on, absorbed or otherwise imposed on the sale of Licensed Product including, without limitation, value added taxes or other governmental charges); (iv)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transportation, freight, postage, shipping, customs duties and insurance charges; (v)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">charge back payments and rebates granted to managed health care organizations or their agencies, and purchasers and reimbursers or to trade customers, including but not limited to, wholesalers and chain and pharmacy buying groups; (vi)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commissions paid to Third Parties other than sales personnel and sale representatives or sales agents; (vii)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bad debt [ * ]; and (viii)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rebates (or equivalents thereof) granted to or charged by national, state or local Governmental Authorities in a country in the Territory. Each of the deductions set forth above shall be reasonable and customary, and shall be determined on an accrual basis in accordance with United States Generally Accepted Accounting Principles (GAAP). Sales made in connection with test marketing, sampling and promotional uses, clinical trial purposes or charitable or compassionate use shall not be included in Net Sales.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that Licensed Product is sold in the form of a Combination Product, Net Sales for such Combination Product will be calculated by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B) where: A is the invoice price of the Licensed Product if sold separately by Licensee, or its Affiliate or sublicensee; and B is the invoice price of any other pharmaceutical product containing an active component or components (not including the Licensed Compound) in the Combination Product if sold separately by Licensee, or its Affiliate or sublicensee.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that the Licensed Product is sold in the form of a Combination Product containing one or more active ingredients other than Licensed Compound and one or more such active ingredients of the Combination Product are not sold separately, then the above formula shall be modified such that A shall be the reasonable fully allocated manufacturing cost to Licensee, and/or its Affiliates or sublicenses of the Licensed Compound and B shall be the reasonable fully allocated manufacturing cost to Licensee, and/or its Affiliates or sublicenses of any other active component or components in the combination that is not the Licensed Compound.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that any discounts or other similar deductions that are based on sales to the customer of Combination Products are excluded from Net Sales of Licensed Products, such discounts or deductions shall be allocated to Licensed Products and the other relevant products on a pro rata basis based on the invoiced prices for such multiple products, which allocation in any event shall not disproportionately be applied to the Licensed Product.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37 &#8220;<font style="text-decoration:underline;">Person</font>&#8221; means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38 &#8220;<font style="text-decoration:underline;">Phase II Study</font>&#8221; means a controlled dose ranging clinical study in humans of a Licensed Product that would fall within the description set forth in 21 C.F.R. Part 312.21(b) (as amended from time to time) or other comparable regulation imposed by an applicable regulatory authority in any country other than the United States, to evaluate the efficacy and safety in the targeted patient population and to attempt to define an appropriate dosing regimen. For clarity, Phase II Study may include a Proof-of-Concept Trial.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.39 &#8220;<font style="text-decoration:underline;">Phase III Study</font>&#8221; means a large scale, pivotal clinical study of a Licensed Product that would fall within the description set forth in 21 C.F.R. Part 312.21(c) (as amended from time to time) or other comparable regulation imposed by an applicable regulatory authority in any country other than the United States performed after evidence suggesting effectiveness and safety of such Licensed Product and establishing a dose has been obtained in Phase II Study(ies) and adequacy of Phase II Study data has been confirmed by the applicable Regulatory Authority in a successful end of Phase II meeting. Phase III Studies are intended to evaluate the therapeutic efficacy and safety of a Licensed Product for the particular indication in question for purposes of submission to a Governmental Authority to obtain Regulatory Approval of the Licensed Product. Phase III Studies have a sufficient number of patients needed to evaluate the overall benefit-risk relationship of the Licensed Product, to provide an adequate basis for extrapolating the results to the general population, and to transmit that information in physician labeling.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 5</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.40 &#8220;</font><font style="text-decoration:underline;">Price Approvals</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means, with respect to a Licensed Product, pricing or pricing reimbursement approval granted in each country in the Territory by the applicable Regulatory Authorities necessary for the commercial sale of such Licensed Product in such regulatory jurisdiction.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.41 &#8220;<font style="text-decoration:underline;">Program IP</font>&#8221; means the Program Know-How and Program Patents, collectively.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.42 &#8220;<font style="text-decoration:underline;">Program Know-How</font>&#8221; means any Know-How that is generated by or on behalf of one or more of the Parties and/or their respective Affiliates as a result of the Development of the Licensed Compound and/or the Licensed Product during the Term. For clarity, Program Know-How shall not include Schering Know-How.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.43 &#8220;<font style="text-decoration:underline;">Program Patents</font>&#8221; means (a) all patents and patent applications (other than the Compound Patent Rights) that claim discoveries, inventions, developments and/or innovations related to the Licensed Compound, including without limitation, Licensed Product Improvements, made by or on behalf of one or more of the Parties and/or their respective Affiliates during the term of this Agreement; (b) all substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, certificates of invention, confirmations, re-examinations, extensions, supplementary protection certificates or the like, or the provisional applications of any such patents and patent applications; or (c) are foreign equivalents of any of the above.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.44 &#8220;<font style="text-decoration:underline;">Proof of Concept Trial</font>&#8221; shall have the meaning set forth in Section 3.2(a).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.45 &#8220;<font style="text-decoration:underline;">Proprietary Information</font>&#8221; means, with respect to each of the Parties, any and all proprietary data, information or materials disclosed or otherwise made available by a Party or its Affiliates to the other Party or any of its Affiliates, including, without limitation, any such data, information or materials related to substances, formulations, devices (and/or any components thereof), techniques, technology, regulatory requirements and strategies, equipment, study results, reports, know-how, sources for manufacture and supply, patent position and business plans.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.46 &#8220;<font style="text-decoration:underline;">Regulatory Application</font>&#8221; means (a) the single application or set of applications for approval and/or pre-market approval to Manufacture and sell commercially a pharmaceutical therapeutic product submitted to the FDA including, without limitation, any related registrations with or notifications to the FDA, and (b) any foreign equivalents to such applications filed with any other national or supranational Regulatory Authority in the Territory, and (c) all supplements and amendments that may be filed with respect to any of the foregoing.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.47 &#8220;<font style="text-decoration:underline;">Regulatory Approval</font>&#8221; means any and all approvals (including Price Approvals), licenses, registrations, or authorizations of any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity necessary for the Manufacture, use, storage, import, export, transport, promotion, marketing or sale of a Licensed Product in the applicable country in the Territory.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.48 &#8220;<font style="text-decoration:underline;">Regulatory Authority</font>&#8221; means any United States federal, state, or local government, or any foreign government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body with responsibility for granting licenses or approvals, including Regulatory Approvals, necessary for the marketing and sale of the Licensed Product in the applicable country in the Territory.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.49 &#8220;<font style="text-decoration:underline;">Schering Know-How</font>&#8221; means any and all Know-How owned or controlled by Schering and/or any of its Affiliates as of the Effective Date.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.50 &#8220;[ * ]&#8221; means the earlier of [ * ] or [ * ].</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.51 &#8220;[ * ]&#8221; means the earlier of [ * ] or the date [ * ].</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52 &#8220;<font style="text-decoration:underline;">Territory</font>&#8221; means the entire world.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 6</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.53 &#8220;</font><font style="text-decoration:underline;">Third Party</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means any Person other than a Party or its Affiliates.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.54 &#8220;<font style="text-decoration:underline;">Valid Claim</font>&#8221; means a claim of an issued and unexpired patent included within the Compound Patent Rights, which has not been (a) revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, (b) finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (c) disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, or (d) lost through an interference proceeding.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.55 <font style="text-decoration:underline;">Additional Definitions</font>. Each of the following definitions is set forth in the Section of this Agreement indicated below.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definition</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AAA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2(a)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AEs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3(a)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1(b)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Commercialization Report</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFR</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.21</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change of Control</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1(c)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data Services</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7(c)(ii)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2(a)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development Report</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.8</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GAAP</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.36</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LIBOR</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5(e)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensee Field Product</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7(c)(i)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensee Indemnified Party</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non- Licensee Field Product</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7(c)(i)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Technology</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5(d)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase II Completion Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5(d)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reacquisition License</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5(b)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROFN Notice</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5(b)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROFN Period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5(b)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales Tracking Methodology</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7(c)(ii)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schering Indemnified Party</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schering Prosecution Patents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublicense Agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5(e)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Patent License</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3(d)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Party Sublicense Agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5(b)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:14pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE II - LICENSE</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 7</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1 <font style="text-decoration:underline;">License Grant</font>. Subject to the terms and conditions of this Agreement, Schering hereby grants to Licensee an exclusive (even as to Schering), sublicensable (subject to the obligations and restrictions in Section 2.5), royalty bearing license, under the Compound Patent Rights, the Schering Know-How and Schering&#8217;s interest in any solely or jointly owned Program IP to Develop, make, have made, use, import, export, Commercialize, sell, offer for sale, and market the Licensed Product in the Field in the Territory.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2 <font style="text-decoration:underline;">No Non-Permitted Use</font>. Licensee hereby covenants that it shall not, nor shall it cause any Affiliate or sublicensee to knowingly use or practice, directly or indirectly, any Schering Know-How or Compound Patent Rights in conflict with the license granted under Section 2.1 above.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3 <font style="text-decoration:underline;">Retained Rights; Covenants</font>. Schering retains any and all other rights under the Compound Patent Rights and Schering Know-How that are outside the scope of the license granted under Section 2.1. Licensee shall not grant any Third Party any license or right under any Compound Patent Rights and/or Schering Know-How, other than as expressly permitted in this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4 <font style="text-decoration:underline;">No Other Licenses</font>. Neither Party grants to the other Party any rights or licenses in or to any intellectual property, whether by implication, estoppel, or otherwise, other than the license rights that are expressly granted under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5 <font style="text-decoration:underline;">Sublicense Agreements; Right of First Negotiation</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Except as provided in Section 2.5(b) and (c) and subject to the obligations and restrictions set forth in this Section 2.5, Licensee may grant sublicenses of the rights granted to it under Section 2.1 without Schering&#8217;s consent.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) In the event Licensee intends to solicit bids from or determine the interest of a Third Party in connection with a sublicense to such Third Party of all rights to the Licensed Product granted by Schering to Licensee in Section 2.1 in the US, the Major European Countries, five or more countries in Asia Pacific (except Japan) and/or Japan in the Field, Licensee shall notify Schering of such intent in writing (&#8220;<font style="text-decoration:underline;">ROFN Notice</font>&#8221;). In such an event, Licensee shall grant to Schering an exclusive right to enter into good faith negotiations with Licensee for an exclusive license to Schering for the rights to the Licensed Product that Licensee intends to sublicense to a Third Party (&#8220;<font style="text-decoration:underline;">Reacquisition License</font>&#8221;) for a period commencing on the date Schering receives the ROFN Notice and expiring [ * ] days thereafter (the &#8220;<font style="text-decoration:underline;">ROFN Period</font>&#8221;). In the event that the Parties are in active negotiations, they will discuss in good faith an extension to such ROFN Period. During the ROFN Period, the Parties will negotiate in good faith the Reacquisition License on commercially reasonable terms and on financial terms that reasonably reflect Licensee&#8217;s actual reasonably documented expenditures and investment Developing and Commercializing the Licensed Product. During the ROFN Period, if [ * ] that [ * ], Schering shall promptly notify Licensee [ * ] and the obligations of Licensee pursuant to this Section 2.5(b) and Section 2.5(c) shall terminate and Schering&#8217;s right of first negotiation shall be deemed terminated, whether or not notification from Schering is provided hereunder.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) In the event that (i) Schering waives its exclusive right to enter into good faith negotiations with Licensee, (ii) Schering fails to notify Licensee that Schering elects to exercise its exclusive right to enter into good faith negotiations with Licensee within [ * ] of receipt of the ROFN Notice or (iii) the Parties are unable to agree upon terms of an agreement for the Reacquisition License within the ROFN Period, then Licensee shall be free to enter into a sublicense agreement with a Third Party for the rights that were the subject of the ROFN Notice (&#8220;<font style="text-decoration:underline;">Third Party Sublicense Agreement</font>&#8221;); provided, however, that [ * ]. If [ * ], Licensee [ * ].</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) In the event that Licensee receives Consideration (as defined herein) from its sublicensees in connection with any sublicense of the rights granted to Licensee in Section 2.1, Licensee shall pay to Schering, within [ * ] of the date Licensee receives such Consideration, a portion of such Consideration equal to the following: (i) [ * ] of the Consideration if the agreement for such sublicense is executed prior to [ * ]; (ii) [ * ] of the Consideration if the agreement for such sublicense is executed after [ * ] and prior to the date that [ * ]; and (iii) [ * ] if the agreement for such sublicense is executed after the date that [ * ]. For purposes of this section, &#8220;<font style="text-decoration:underline;">Consideration</font>&#8221; means any and all amounts received by Licensee from its sublicensee in consideration for granting such sublicensee a sublicense of any of the rights granted by Schering to Licensee in Section 2.1, including any and all payments, including without </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 8</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limitation, up-front payments and milestone payments; provided, however, that the following payments shall be specifically excluded from the calculation of Consideration: (1)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all past and future research and development funding, (2)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any loan amounts, (3)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fair market value of all equity issued by Licensee to a sublicensee (calculated according to the good faith determination of the board of directors of Licensee), (3)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">royalty payments, and (4)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development milestone payments for the corresponding milestones set forth in Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2 up to the amounts that are payable as Development milestone payments due under Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2 of this Agreement. In the event that Licensee grants a sublicense to sublicensee under the rights granted to Licensee in Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1 above in conjunction with a license to other technology or products independently developed by Licensee that is not comprised of Compound Patent Rights or Schering Know-How (&#8220;</font><font style="text-decoration:underline;">Other Technology</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;), the amounts that are allocable to the inclusion of such Other Technology, as reasonably established by Licensee and sublicensee and set out in the applicable Sublicense Agreement (as defined below), or if no such allocation is made in the Sublicense Agreement, then the prorated portion of any fees or payments (not otherwise excluded or deducted pursuant to this Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5(d)) made to Licensee under the applicable Sublicense Agreement in consideration for such Other Technology shall be excluded from the definition of Consideration. In the event that Licensee receives non-cash consideration as part of any Consideration paid under an applicable Sublicense Agreement, the fair market value of such non-cash consideration on the date of the transfer will be the cash amount used to calculate Schering&#8217;s percentage share of such Consideration under this Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5(d).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) Licensee shall, in each agreement under which it grants a sublicense under the license set forth in Section 2.1 (each, a &#8220;<font style="text-decoration:underline;">Sublicense Agreement</font>&#8221;), require the sublicensee to transfer to Schering, if this Agreement terminates for breach by sublicensee, and to Licensee, if only such sublicense terminates, (i) all regulatory filings and Regulatory Approvals held, possessed or Controlled by such sublicensee and (ii) all patent rights and Know-How Controlled by such sublicensee relating to a Licensed Product or its use, Manufacture, sale, or importation (which patent rights and Know-How shall be transferred either by assignment or by a freely sublicensable exclusive license). In the event that this Agreement terminates other than for breach by a sublicensee, Schering shall enter in an agreement with each sublicensee on the same terms as the existing Sublicense Agreement. All Sublicense Agreements shall be consistent with the terms and conditions of this Agreement. Licensee shall use reasonable efforts to (I) procure the performance by any sublicensee of the terms of each applicable Sublicense Agreement, and (II) ensure that any sublicensee will comply with the applicable terms and conditions of this Agreement. Licensee hereby guarantees the performance of its sublicensees that are party to a Sublicense Agreement as permitted herein, and the grant of any such sublicense will not relieve Licensee of its obligations under this Agreement, except to the extent they are satisfactorily performed by such sublicensee.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6 <font style="text-decoration:underline;">Third Party Agreements</font>. Schering shall remain responsible for the payment of royalty, milestone and other payment obligations under all agreements entered into by Schering prior to the Effective Date. In the event that Licensee reasonably determines that rights to intellectual property owned or Controlled by a Third Party are required in order to lawfully perform any activities under this Agreement, Licensee shall have the right to negotiate and acquire such rights through a license or otherwise and to deduct from the payments due to Schering under this Agreement [ * ] of the royalties paid by Licensee to such Third Party; <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that such reduction shall not reduce the royalty rates otherwise applicable to the Net Sales of such Licensed Product by more than [ * ]. Licensee shall ensure that each Third Party clinical trial, contract Manufacturing, or service agreement entered into by Licensee or its Affiliates with respect to the Development of Licensed Product contains provisions obligating such Third Party contractor to assign and/or convey the appropriate intellectual property rights relating to Licensed Product to Licensee so that Licensee can assign and/or convey such rights to Schering as necessary under the terms and conditions of this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7 <font style="text-decoration:underline;">Schering Assistance</font>. Subject to all applicable provisions of this Agreement, Schering shall, promptly following the Effective Date, provide copies to Licensee of all information, including without limitation, Schering Know-How, except to the extent that such Schering Know-How has been previously disclosed to Licensee, that are in Schering&#8217;s actual possession as of the Effective Date and are reasonably necessary for Licensee to use, make, have made, sell, offer to sale or import Licensed Product in the Field. Each Party shall bear its own costs in performing any activities pursuant to this Section 2.7.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 9</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">Section</font><font style="text-decoration:underline;"> </font><font style="text-decoration:underline;">365(n) of the Bankruptcy Code</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. All rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365(n) of the U.S. Bankruptcy Code, licenses of rights to &#8220;intellectual property&#8221; as defined under Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101(35A) of the Bankruptcy Code. Each Party shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code or equivalent legislation in any other jurisdiction. Upon the bankruptcy of either Party, the other Party shall further be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property, and such, if not already in its possession, shall be promptly delivered to such other Party, unless</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Party in bankruptcy elects to continue, and continues, to perform all of its obligations under this Agreement.</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE III &#8211; DEVELOPMENT AND COMMERCIALIZATION</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1 <font style="text-decoration:underline;">Overview</font>. As of the Effective Date, Licensee shall be solely responsible for the Development and Commercialization of the Licensed Product in the Field in the Territory. Licensee shall perform all of its Development activities in accordance with each IND for each applicable Licensed Product and with all applicable laws, rules and regulations.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2 <font style="text-decoration:underline;">Development and Commercialization Plans</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Proof of Concept</font>. Not later than the Effective Date, the Parties shall have agreed on the initial proposed protocol for a proof of concept trial for the Licensed Product in the Field, which shall be incorporated as part of this Agreement as <font style="font-weight:bold;text-decoration:underline;">Schedule 3.2(a)</font> (the <font style="font-weight:bold;">&#8220;Proof of Concept Trial&#8221;</font>). The Parties acknowledge that the Proof of Concept Trial protocol may change in light of regulatory and clinical developments affecting the Licensed Product.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Initial Development Plan</font>. Not later than the Effective Date, the Parties shall have agreed on the initial Development plan and related timelines for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as <font style="font-weight:bold;text-decoration:underline;">Schedule 3.2(b)</font> (as may be amended and updated annually in accordance with this Agreement, the &#8220;<font style="text-decoration:underline;">Development Plan</font>&#8221;). Schering shall have the right to review and comment on the clinical protocols for studies conducted in accordance with the Development Plan, including review of the design and endpoints of such studies so that such studies will lead to an outcome that is credible and reproducible, which comments Licensee shall consider and incorporate as Licensee deems appropriate in good faith. At Schering&#8217;s written request, the President of Schering&#8217;s research division, or his designee, and the President of Licensee&#8217;s research division or equivalent position, or his designee, shall meet to discuss such comments. Any revision of the clinical protocols shall be submitted to Schering promptly after their completion.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="text-decoration:underline;">Annual Development Plan</font>. Not later than thirty (30) days after December 31 of each Calendar Year, Licensee shall submit to Schering an updated Development Plan for the pending Calendar Year. Such update shall take into account completion, commencement, changes in or cessation of Development activities not contemplated by the then-current Development Plan in sufficient detail to reflect the continued diligence of Licensee and shall reflect effort and resources consistent with other priority projects of Licensee. Schering shall have the right to comment on such annual plan. In the event Schering reasonably disagrees with the plan, Licensee shall consider Schering&#8217;s comments for revising the plan. At Schering&#8217;s written request, the President of Schering&#8217;s research division, or his designee, and the President of Licensee&#8217;s research division or equivalent position, or his designee, shall meet to discuss such comments. Any revision of the annual plan shall be submitted to Schering promptly after its completion.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) <font style="text-decoration:underline;">Commercial Launch</font>. Licensee shall give Schering prior written notice of at least sixty (60) days of its intent to file an NDA for the Licensed Product and at that time shall further provide Schering with the anticipated date of First Commercial Sale for the Licensed Product in the country of filing. Licensee shall promptly provide Schering with notice of any Regulatory Approval of Licensed Product.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 10</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">Performance</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Licensee shall perform, and shall ensure that its Affiliates, sublicensees, and Third Party contractors perform, the activities described in the Development Plan in a professional manner and in compliance with, to the extent applicable, Good Laboratory Practices, Good Clinical Practices and/or Good Manufacturing Practices and in compliance with all other applicable laws, rules, and regulations.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) <font style="text-decoration:underline;">Program Know-How</font>. Each Party shall share Program Know-How owned or Controlled by it with the other Party in a reasonably detailed annual report (&#8220;<font style="text-decoration:underline;">Know-How Report</font>&#8221;). Such Know-How Reports will be exchanged by the Parties prior to January 31<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup></font> of each Calendar Year of the Term.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3 <font style="text-decoration:underline;">Development Reports</font>. Licensee shall provide Schering with reasonably detailed reports describing its progress with respect to its Development efforts under this Agreement (hereinafter &#8220;<font style="text-decoration:underline;">Development Reports</font>&#8221;). Such Development Reports shall be furnished annually until the First Commercial Sale. Each Development Report shall include the following information for the Licensed Product: a description of the Development work to be conducted during the year in reasonable detail, including, to the extent applicable, clinical studies, formulation work, Manufacturing work, other testing work and regulatory activity; timelines for such work; and key decision gates and milestones for such work.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4 <font style="text-decoration:underline;">Commercialization Reports</font>. Commencing with the First Commercial Sale and thereafter on an annual basis, Licensee shall provide Schering with a written non-binding estimate of annual Net Sales for the Licensed Product in the Territory (&#8220;<font style="text-decoration:underline;">Annual Commercialization Report</font>&#8221;). The Annual Commercialization Report shall also list all ongoing Commercialization Studies and the status of such studies in the United States, the Major European Countries and Japan.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5 <font style="text-decoration:underline;">Contract Sales Force</font>. Notwithstanding anything to the contrary in this Agreement, Licensee shall not use the services of sales representatives employed by a Third Party as a contract sales force for Licensed Product without the prior written consent of Schering, such consent not to be unreasonably withheld.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6 <font style="text-decoration:underline;">Development and Commercialization Costs</font>. Licensee shall be solely responsible for all costs related to the Development and/or Commercialization of the Licensed Product in the Field in the Territory following the Effective Date.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7 <font style="text-decoration:underline;">Commercialization of Licensed Product in the Field</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Sales in the Field</font>. Licensee hereby covenants that it shall not, nor shall it authorize any Affiliate, permitted sublicensee or Third Party contractor to Commercialize Licensed Product in the Territory for any use outside the Field. Schering hereby covenants that it shall not, nor shall it authorize any Affiliate, permitted sublicensee or Third Party contractor to Commercialize Licensed Product in the Territory for any use in the Field. Each Party acknowledges and understands that the other Party cannot control the ultimate use of the Licensed Products it sells and that the purpose of the foregoing covenant is to prevent such Party and its Affiliates and sublicensees from facilitating or encouraging uses in the other Party&#8217;s Field. To the extent either Party can prove the other Party materially breached this Section 3.7(a), such material breach shall permit such non-breaching Party to terminate this Agreement for cause under Section 12.4.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Licensed Product Packaging</font>. Each Party shall use reasonable efforts to ensure that Licensed Product it is Commercializing (in the Field with respect to Licensee and outside the Field with respect to Schering) is packaged and identified in a manner such that it is distinguishable from Licensed Product that the other Party is Commercializing in its respective Field, including not using trademarks, trade dress, product appearance, product packaging, and other such distinguishing characteristics that the other Party is using or is planning to use. The Parties shall cooperate in good faith to share information about each Party&#8217;s respective Licensed Product (which information shall constitute the Proprietary Information of the disclosing Party) in order to allow each Party to comply with its obligations under this Section 3.7(b).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 11</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">Lost Sales</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Parties recognize that Schering has the right to Commercialize Licensed Products for indications outside the Field. As a result, the Parties acknowledge and desire to address the potential for Cross-Field Sales such that the Parties agree as follows:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) If at any time during the Term of this Agreement, Schering, its Affiliate, or licensees (other than Licensee) is Commercializing a product containing a Licensed Compound approved by the relevant Regulatory Authority for an indication outside the Field (a &#8220;<font style="text-decoration:underline;">Non-Licensee Field Product</font>&#8221;) and Licensee is at the same time Commercializing a Licensed Product approved by the relevant Regulatory Authority for an indication in the Field (a &#8220;<font style="text-decoration:underline;">Licensee Field Product</font>&#8221;), and a Party reasonably believes that (1) sales of a Non-Licensee Field Product are occurring or will occur for use in the approved indication in the Field; or (2) sales of the Licensee Field Product are occurring or will occur for use in the approved indication outside the Field, then such Party may provide notice to the other Party of its desire to track sales of Licensed Product for the relevant indications either in the Field or outside the Field, as applicable.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) Upon receipt of notice under Section 3.7(c)(i), Schering and Licensee shall meet and agree upon a method of tracking sales of each possible Cross-Field Sale (a &#8220;<font style="text-decoration:underline;">Sales Tracking Methodology</font>&#8221;) including (1) the acquisition of one or more prescription data products or services (including, by way of example, IMS Xponent, NDC, or DDD data, data from the UNOS database or other data from organizations tracking transplant surgeries or patients) or other relevant pharmaceutical sales tracking research services (including, for example, use of random sampling, use of data regarding distribution channels as a proxy for indication-specific sales or development of mathematical models for approximating indication-specific sales) generally recognized in the pharmaceutical industry as having a reasonably high degree of accuracy and reliability in the tracking of sales of pharmaceutical products that have a similar nature as and are prescribed by similar physicians as the applicable License Product (collectively, the &#8220;<font style="text-decoration:underline;">Data Services</font>&#8221;), and (ii) the methodology for applying any such resulting data and information provided by such Data Services to determine the extent of Cross-Field Sales.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii) In the event that Schering and Licensee are unable to agree on a Sales Tracking Methodology pursuant to Section 3.7(c)(ii), then the following default methodologies shall apply:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) With respect to each of the U.S., the Major EU Countries and Japan (collectively, the &#8220;<font style="text-decoration:underline;">Major Regulatory Jurisdictions</font>&#8221;), in which a Licensee Field Product and a Non-Licensee Field Product have received Regulatory Approval and in which Data Services are available at a reasonable cost (evaluated in light of the anticipated accuracy of such data and anticipated magnitude of Cross-Field Sales in such country), sales in the approved indications in the Field in such country and sales in the approved indications outside the Field in such country shall be calculated for each Licensee Field Product and each Non-Licensee Field Product based on the sales levels reported by the Data Services for such country.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) For all countries other than Major Regulatory Jurisdictions, the percentage of sales of each Licensee Field Product attributable to use in the approved indications outside the Field and the percentage of sales of each Non-Licensee Field Product attributable to use in the approved indications in the Field shall be calculated from total sales of such products based on the assumption that the ratio of Cross-Field Sales to total sales in such country is equal to the ratio of Cross-Field Sales to total sales calculated across all Major Regulatory Jurisdictions in which Cross-Field Sales are evaluated pursuant to Section 3.7(c)(iii)(1). In the event that there are no Major Regulatory Jurisdictions in which Cross-Field Sales are evaluated pursuant to Section 3.7(c)(iii)(1), then no Sales Tracking Methodology shall apply unless and until the Parties agree on a Sales Tracking Methodology pursuant to Section 3.7(c)(ii).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) All costs associated with the acquisition and application of such Data Services and Sales Tracking Methodology shall be shared equally by the Parties. In addition, the Parties shall also meet and confer with respect to: (A) how to account for prescriptions to patients with multiple afflictions that are both within and outside the Field (i.e., approved indications in the Field and approved indications outside of the Field); (B) the right for each Party to audit, on a periodic basis, the application of the Data Services and Sales Tracking Methodology; and (C) a mechanism for addressing prescriptions that are tracked back to sole source purchasing agreements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 12</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv) If in the course of applying the foregoing Data Services and methodologies to track sales of the Licensee Field Product and Non- Licensee Field Product pursuant to this Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7, or in the course of performing an audit of such application by the other Party, a</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Party determines that Cross-Field Sales by the other Party are occurring at more than the greater of (A)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] or (B)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] of such Party&#8217;s total Net Sales of the Licensed Product, then the Parties shall compensate each other as follows:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) In the event that there are Cross-Field Sales by Licensee, Licensee shall make a payment to Schering equal to the amount of Licensee&#8217;s Cross-Field Net Sales less Licensee&#8217;s Cross-Field Sales Cost of Goods; and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) In the event that there are Cross-Field Sales of Schering, Schering shall make a payment to License equal to the amount of Schering&#8217;s Cross-Field Net Sales less Schering&#8217;s Cross-Field Cost of Goods.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v) Both Parties acknowledge that in order to respect confidentiality, it may not be possible to share non-publicly available data with each other. Therefore, any discussion or dispute in relation to the compensation for Cross-Field Sales under Section 3.7(iv) will be submitted to an independent auditor acceptable to both Parties and that is subject to appropriate confidentiality obligations.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IV - REGULATORY</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1 <font style="text-decoration:underline;">Regulatory Filings Transfer</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Schering covenants that, as of the Effective Date, it does not have any INDs or other Regulatory Applications covering the Licensed Product in the Field in the Territory. After the Effective Date, Licensee or its Affiliates or sublicensee, as applicable, shall hold all INDs and other Regulatory Applications and Regulatory Approvals for Licensed Product in the Field throughout the Territory. Schering shall be the exclusive owner of all INDs and other Regulatory Applications related to the Licensed Compounds and/or Licensed Product outside the Field in the Territory.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) As soon as practicable after the Effective Date (or such other date as mutually agreed by the Parties), Schering shall provide to Licensee one (1) electronic copy in Microsoft Word or Adobe Acrobat (whichever format the document is currently available) of (i) all material documents and records that have been generated by or on behalf of Schering with respect to any existing INDs and other Regulatory Applications covering the Licensed Product in the Territory sufficient for Eiger to file an IND in its own name; and (ii) any documents and records (not provided pursuant to (b)(i)) between Schering and Regulatory Authorities related to Licensed Product in the Field, if any.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Licensee shall oversee, monitor and coordinate all regulatory actions, communications and filings with, and submissions to, the FDA and other Regulatory Authorities in the Territory with respect to Licensed Product in the Field.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Licensee shall be solely responsible for interfacing, corresponding and meeting with the FDA and other Regulatory Authorities throughout the Territory with respect to Licensed Product in the Field. Each Party shall provide the other Party with copies of any material correspondence with FDA or other Regulatory Authorities in the United States, the Major European Countries and Japan relating to Regulatory Approval of Licensed Product, and respond to all reasonable inquiries by the other Party with respect thereto. Each Party shall also provide the other Party in a timely manner with meeting minutes from any material meetings with Regulatory Authorities in the United States, the Major European Countries and Japan concerning the Regulatory Approval of Licensed Product in the Field.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) Each Party shall provide to the other Party a table report on an annual basis that contains the status of Regulatory Approvals for the Licensed Product in the Territory.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 13</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) In the event that any Regulatory Authority (a)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">threatens or initiates any action to remove a Licensed Product from the market in any country in the Territory or (b)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requires a Party, its Affiliates, or its sublicensees to distribute a &#8220;Dear Doctor&#8221; letter or its equivalent regarding use of Licensed Product in the Territory, such Party shall notify the other Party of such event within one (1)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Business Day after such Party becomes aware of the action, threat, or requirement (as applicable). The Parties shall consult prior to initiating a recall or withdrawal of Licensed Product in the U.S., Japan, or a Major European Country; provided, however, that the final decision as to whether to recall or withdraw a Licensed Product in the Territory shall be made by (i)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensee in the Field in its sole discretion, or (ii)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schering outside the Field in its sole discretion. A Party initiating a recall shall be responsible, at its sole expense, for conducting such recalls or taking such other necessary remedial action.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g) Schering&#8217;s obligations to provide assistance and support under this Section 4.1 shall not extend beyond Licensee&#8217;s initial IND filing date with respect to the Licensed Product in the Field.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h) Schering shall also provide copies of all safety reports with respect to Licensed Product outside of the Field in the Territory.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2 <font style="text-decoration:underline;">Right of Reference</font>. Schering grants to Licensee, the right to reference its Regulatory Application(s) or Regulatory Approval(s) covering the Licensed Product outside the Field in the Territory only to the extent required for Licensee to Develop, Manufacture and obtain and maintain Regulatory Approvals for the Licensed Product in the Field in the Territory; provided, however, that (a) such right of reference shall be used solely for purposes of this Agreement and (b) all information which is subject to the right of reference shall be treated by Licensee as Proprietary Information of Schering in accordance with Article 9. Except with the prior written consent of Licensee, which shall not be unreasonably withheld, conditioned or delayed, Schering shall not withdraw any Regulatory Application or Regulatory Approval that is subject to reference by Licensee hereunder.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3 <font style="text-decoration:underline;">Pharmacovigilance.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) After the Effective Date, Licensee shall be solely responsible for the collection, review, assessment, tracking and regulatory submission of safety-related information with respect to adverse events (&#8220;<font style="text-decoration:underline;">AEs</font>&#8221;) associated with Licensed Product developed and commercialized by the Licensee in the Field, in accordance with 21 CFR 312.32, 314.80 and comparable applicable law governing AEs outside of the United States.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Within a reasonable period of time following the Effective Date, Schering will provide Licensee with all AEs for Licensed Product to the extent not previously provided to Licensee. In addition to the foregoing, Schering shall transfer to Licensee in an agreed upon format, all relevant information (sufficient for Licensee to comply with its obligations to regulatory authorities and Investigators) regarding AEs that have been observed during any clinical trials conducted with the Licensed Product prior to the Effective Date.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Within a reasonable period of time following receipt of all such information described in this Section 4.3, Licensee shall assume responsibility for maintaining a safety database for the Licensed Product developed and commercialized by the Licensee consistent with industry practices.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) During the Term of this Agreement, Schering shall notify Licensee of all information coming into its possession concerning AEs associated with commercial or clinical uses, studies, investigations or tests with Licensed Products in the Territory, involving the Licensed Product. In addition, Licensee shall forward to Schering, completed AE case reports associated with commercial or clinical uses, studies, investigations or tests with Licensed Products in the Field, within 5 business days for any death/fatal-life threatening assessed AEs or, within 10 business days for all other serious AEs, to assure Schering remains in compliance with Investigator notifications outside the Field. Such AE information should be faxed to Schering at (US) 973-921-7422. If deemed necessary by both Parties, within a reasonable period of time following the Effective Date, the Parties can begin to negotiate a pharmacovigilance agreement between the Parties to revise this mutual exchange of AE reports and safety information associated with the Licensed Product. Such pharmacovigilance agreement shall be implemented at a time sufficient to permit compliance, and shall supersede this Section 4.3(d).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 14</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE V - DILIGENCE</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1 <font style="text-decoration:underline;">Generally</font>. Licensee shall use Commercially Reasonable Efforts to Develop the Licensed Product in the Field in accordance with the Development Plan and to Commercialize the Licensed Product in the Field in the Territory. The activities of any Affiliate or sublicensee of Licensee will be treated as activities of Licensee in any determination whether Licensee has satisfied its obligation with respect to this Article V.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2 <font style="text-decoration:underline;">Failure</font>. Any failure by Licensee to comply with the obligations set forth in this Article V shall be deemed to be a material breach for which Schering may exercise its termination rights under Section 12.4(b).</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VI &#8211; MANUFACTURING</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1 <font style="text-decoration:underline;">Manufacturing Responsibility</font>. With the exception of the supplies of Bulk Licensed Product to be supplied by Schering to Licensee pursuant to Section 6.2, Licensee will be responsible for the Manufacture of Licensed Product for Development and Commercialization of Licensed Product by Licensee, its Affiliates, and its sublicensees in the Field in the Territory. Schering shall, if requested by Licensee, reasonably cooperate in the transfer of any Manufacturing Know-How related to the Manufacture of the License Product in the Field and existing Third Party manufacturing agreements to Licensee for use pursuant to the license granted in Section 2.1.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2 <font style="text-decoration:underline;">Transfer of Bulk License Product</font>. Promptly following the Effective Date of this Agreement, Schering shall transfer to Licensee free of charge (except reasonable costs of transfer as set forth below), in a mutually agreed manner, quantities of Bulk Licensed Product and related documentation (eg, batch records, process and release testing results, protocols, stability data and location of stability specimens) that are reasonably sufficient for Licensee to complete the Proof of Concept Trial and as are further described in <font style="font-weight:bold;">Schedule 6.2</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3 <font style="text-decoration:underline;">Quality</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Licensee shall be solely responsible for the release of Bulk Licensed Product transferred by Schering to Licensee pursuant to Section 6.2 to any clinical trial sites.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Licensee will, within three (3) Business Days of receipt, notify Schering in writing of any complaints related to the manufacture of the Bulk Licensed Product transferred by Schering to Licensee pursuant to section 6.2.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Licensee will, within one (1) Business Day, notify Schering of any recalls or stock recovery of an Bulk Licensed Product due to the quality of the Bulk Licensed Product.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4 <font style="text-decoration:underline;">Transfer of Manufacturing Technology</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Upon request by Licensee, Schering shall transfer or cause to be transferred to Licensee, or a Third Party manufacturer designated by Licensee reasonably acceptable to Schering, all Schering Know-How that is reasonably necessary to enable Licensee or such Third Party manufacturer (as appropriate) to replicate the process employed by or on behalf of Schering to Manufacture Licensed Compound and, if applicable, the Licensed Product, in the Field to the extent not previously transferred.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Licensee and/or its Third Party manufacturer shall use any information transferred pursuant to Section 6.3(a) in accordance with the license granted in Section 2.1 and solely for the purpose of Manufacturing the Licensed Compound and Licensed Product under this Agreement and for no other purpose.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) At the request of Licensee, during the six (6) month period following Licensee&#8217;s request under Section 6.3(a), Schering will make employees and consultants of it and its Affiliates available to Licensee or Licensee&#8217;s Third Party manufacturer for consultation, for a reasonable duration of time and at mutually agreed locations, as reasonably required by the Licensee or its Third Party manufacturer to ensure an orderly transition of Schering&#8217;s manufacturing technology and operations. The scope of Schering&#8217;s efforts for such consultation shall be defined in a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 15</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">written manufacturing transition plan to be agreed upon by the Parties promptly after Licensee&#8217;s request under Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3(a). Licensee shall reimburse Schering for any FTE Costs and for all related reasonable out-of-pocket expenses, including reasonable travel expenses. Schering shall invoice Licensee monthly for such support.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Schering&#8217;s obligations to provide assistance and support under this Section 6.2 shall not extend beyond six (6) months after Licensee&#8217;s request under Section 6.3(a).</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VII - PAYMENTS; ROYALTIES AND REPORTS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1 <font style="text-decoration:underline;">Equity</font>. Licensee shall contemporaneously issue equity in Licensee to Schering in the amount of Five Hundred Thousand Dollars ($500,000) pursuant to Share Purchase Agreement and related agreements dated as of even date herewith.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2 <font style="text-decoration:underline;">Development Milestones</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">First Indication</font>. Licensee shall make each of the following one-time, non-refundable, non-creditable milestone payments to Schering upon first occurrence of the corresponding milestone event with respect to the Development of Licensed Product for the First Indication in the Field.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Event</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payment</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Additional Indications</font>. Licensee shall make each of the following one-time, non-refundable, non-creditable milestone payments to Schering upon first occurrence of the corresponding milestone events with respect to the Development of a Licensed Product for up to [ * ] Additional Indications.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Event</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payment</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 16</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="text-decoration:underline;">Payment of Milestones</font>. Licensee shall notify Schering in writing within [ * ] after the achievement of each such milestone event giving rise to a payment obligation under this Section and Licensee shall pay Schering the indicated amount no later than [ * ] after notification to Schering of achievement of the specified milestone. For clarity, each of the milestones under this Section shall be payable to Schering regardless of whether Licensee, its Affiliates, or sublicensees achieves them. Under no circumstances will Licensee owe more than an aggregate total of Twenty-Seven Million Dollars ($27,000,000) pursuant to this Section 7.2.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3 <font style="text-decoration:underline;">Royalties</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Royalty Rates</font>. Subject to the terms and conditions of this Agreement, Licensee shall pay to Schering during the Royalty Term royalties on worldwide annual Net Sales of Licensed Product (for all indications and without regard to formulation) on a country-by-country basis in an amount equal to the following:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Calendar Year Net Sales</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Royalty Rate</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First [ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portion above [ * ] and up to and including [ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portion above [ * ] and up to and including [ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portion above [ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Term of Royalty Obligation</font>. Royalties on the Licensed Product shall commence upon the First Commercial Sale of a Licensed Product in a particular country in the Territory and will continue on a product-by-product, country-by-country basis until the later of (i) the expiration of the last to expire Valid Claim covering a Licensed Product in such country or (ii) the [ * ] anniversary of the date of the First Commercial Sale of the Licensed Product in such country (&#8220;<font style="text-decoration:underline;">Royalty Term</font>&#8221;). For clarity, during the Royal Term, the royalty payments pursuant to this Section 7.3 shall be payable regardless of whether Licensee, its Affiliate, or its sublicensee is selling the Licensed Product.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4 <font style="text-decoration:underline;">Reports; Payment of Royalty; Payment Exchange Rate and Currency Conversions</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Royalties Paid Quarterly</font>. Within [ * ] following the end of each Calendar Quarter, following the First Commercial Sale of a Licensed Product, Licensee shall furnish to Schering a written report for the Calendar Quarter showing the Net Sales of Licensed Product sold by Licensee, its Affiliates and its sublicensees in the Territory during such Calendar Quarter and the royalties payable under this Agreement for such Calendar Quarter. Such written report shall include the gross sales of Licensed Product on a country-by-country basis, an itemized calculation of any deductions taken from such gross sales to arrive at Net Sales for the applicable Calendar Quarter and the calculation of the amount of royalty payment due on such Net Sales. Simultaneously with the submission of the written report, Licensee shall pay to Schering, for the account of Licensee or the applicable Affiliate or sublicensee, as the case may be, a sum equal to the aggregate royalty due for such Calendar Quarter calculated in accordance with this Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 17</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">Method of Payment</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. All payments to be made by Licensee to Schering under this Agreement shall be paid by bank wire transfer in immediately available funds to such bank account as is designated in writing by Schering from time to time. Royalty payments shall be made in United States dollars to the extent that free conversion to United States dollars is permitted. The rate of exchange to be used in any such conversion from the currency in the country where such Net Sales are made shall be the rate of exchange used by Licensee for reporting such sales for United States financial statement purposes. If, due to restrictions or prohibitions imposed by national or international authority, payments cannot be made as aforesaid, the Parties shall consult with a view to finding a prompt and acceptable solution, and Licensee will make such payments in any manner as Schering may lawfully direct; provided that Licensee shall not be obligated to incur any additional out-of-pocket expenses in connection with such payments. Notwithstanding the foregoing, if royalties in any country cannot be remitted to Schering for any reason within [ * ] after the end of the Calendar Quarter during which they are earned, then Licensee shall be obligated to deposit the royalties in a bank account in such country in the name of Schering.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5 <font style="text-decoration:underline;">Maintenance of Records; Audits</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Record Keeping by Licensee</font>. Licensee and its Affiliates shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined. Upon [ * ] prior written notice from Schering, Licensee shall permit an independent certified public accounting firm of nationally recognized standing selected by Schering and reasonably acceptable to Licensee, at Schering&#8217;s expense, to have access during normal business hours to examine the pertinent books and records of Licensee as may be reasonably necessary to verify the accuracy of the royalty reports hereunder. The examination shall be limited to the pertinent books and records for any year ending not more than [ * ] prior to the date of such request. An examination under this Section 7.5(a) shall not occur more than [ * ] in any Calendar Year. Licensee may designate competitively sensitive information which such auditor may not disclose to Schering, <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that such designation shall not encompass the auditor&#8217;s conclusions. The accounting firm shall disclose to Schering only whether the royalty reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Schering. All such accounting firms shall sign a confidentiality agreement (in form and substance reasonably acceptable to Licensee) as to any of Licensee&#8217;s or its Affiliate&#8217;s or sublicensee&#8217;s confidential information which such accounting firms are provided, or to which they have access, while conducting any audit pursuant to this Section 7.5(a).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Underpayments/Overpayments</font>. If such accounting firm correctly concludes that additional royalties were owed during such period, Licensee shall pay such additional royalties within [ * ] of the date Schering delivers to Licensee such accounting firm&#8217;s written report so correctly concluding. If such underpayment exceeds [ * ] of the sums correctly due Schering then the fees charged by such accounting firm for the work associated with the underpayment audit shall be paid by Licensee. Any overpayments by Licensee will be credited against future royalty obligations or refunded to Licensee within [ * ] following request by Licensee for the same, at Licensee&#8217;s option.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="text-decoration:underline;">Record Keeping by Sublicensees</font>. Licensee shall include in each Sublicense Agreement entered into pursuant to this Agreement a provision requiring the sublicensee to make reports to Licensee and to keep and maintain records of sales made pursuant to such sublicense and provide copies of such records to Licensee upon reasonable request in order for Schering&#8217;s independent accountant to review such records to the same extent required of Licensee under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) <font style="text-decoration:underline;">Confidentiality</font>. Schering shall treat all financial information subject to review under this Section 7.5, or under any Sublicense Agreement, in accordance with the confidentiality provisions of Article IX of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with Licensee obligating it to retain all such financial information in confidence pursuant to such confidentiality agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) <font style="text-decoration:underline;">Late Payments</font>. Any amount owed by Licensee to Schering under this Agreement that is not paid within the applicable time period set forth herein shall accrue interest at the lower of the rate of the one (1) month London Inter-Bank Offering Rate (&#8220;<font style="text-decoration:underline;">LIBOR</font>&#8221;) plus [ * ] as set by the British Bankers Association as of the due date, or the maximum extent allowable by applicable law.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 18</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VIII &#8211; INTELLECTUAL PROPERTY</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1 <font style="text-decoration:underline;">Ownership of Intellectual Property</font>. The Parties acknowledge and agree that Schering is and shall remain the owner of Compound Patent Rights and Schering Know-How.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2 <font style="text-decoration:underline;">Ownership of Program IP</font>. All rights title and interest in or to any and all Program IP shall be determined in accordance with the following terms and conditions:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Schering shall own all Program IP that is conceived solely by one or more employees, agents or consultants of Schering, its Affiliates, or Schering&#8217;s subcontractors.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Licensee shall own all Program IP that is conceived solely by one or more employees, agents or consultants of Licensee, its Affiliates, its subcontractors or its sublicensees.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Licensee and Schering shall jointly own all Program IP that is conceived by one or more employees, agents or consultants of Schering or its Affiliates, together with one or more employees, agents or consultants of Licensee, its Affiliates, its subcontractors or its sublicensees.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Licensee hereby grants to Schering an exclusive, sublicensable, royalty free license, under all Program IP to which Schering does not have an interest (either solely or jointly) solely to the extent necessary to Develop, make, have made, use, import, export, Commercialize, sell, offer for sale, and market the Licensed Product outside the Field in the Territory.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) Schering hereby grants to Licensee a non-exclusive, sublicensable (subject to the obligations and restrictions in Section 2.5), royalty free license, under all Program IP to which Licensee does not have an interest (either solely or jointly) solely to the extent necessary to Develop, make, have made, use, import, export, Commercialize, sell, offer for sale, and market the Licensed Product in the Field in the Territory.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) In the event of a dispute regarding inventorship, the Parties shall establish a procedure to resolve such dispute, which may include engaging independent Third Party patent attorneys jointly selected by the Parties to resolve such dispute. The Parties acknowledge that the ownership rights set out in this Section 8.2 are subject to the terms and conditions of this Agreement (including the licenses granted by Schering to Licensee), and subject thereto, each Party shall be free to use and exploit (which shall include the right to grant licenses under) any jointly owned Program IP, without any duty of accounting to the other Party.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3 <font style="text-decoration:underline;">Prosecution and Maintenance of Patents</font>. Schering shall be solely responsible for the prosecution and maintenance in the Territory, on its own or through outside counsel, of the Compound Patent Rights and Program Patents solely owned or Controlled by Schering (&#8220;<font style="text-decoration:underline;">Schering Prosecution Patents</font>&#8221;). Licensee shall be solely responsible for the prosecution and maintenance in the Territory, on its own or through outside counsel, of the Program Patent Rights solely owned or Controlled by Licensee or jointly owned by Schering and Licensee (&#8220;<font style="text-decoration:underline;">Licensee Prosecution Patents</font>&#8221;). In connection with the Schering Prosecution Patents and the Licensee Prosecution Patents, each Party shall keep the other Party reasonably advised of the prosecuting Party&#8217;s patent prosecution and maintenance and upon the written reasonable request of the other Party, will provide advance copies of any substantive papers related to the prosecution and maintenance of such patent filings.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4 <font style="text-decoration:underline;">Option of Licensee to Prosecute and Maintain Patents</font>. Schering shall give notice to Licensee of any desire to cease prosecution and/or maintenance of the Schering Prosecution Patents and, in such case, shall permit Licensee, at Licensee&#8217;s sole discretion, to continue the prosecution or maintenance at its own expense. If Licensee elects to continue the prosecution or maintenance, Schering shall execute such documents and perform such acts, at Licensee&#8217;s expense, as may be reasonably necessary to effect an assignment of such Schering Prosecution Patents to Licensee. Any such assignment shall be completed in a timely manner to allow Licensee to continue such prosecution or maintenance. Any patents or patent applications so assigned shall no longer be considered Compound Patent Rights or Program Patents, as applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 19</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">Enforcement</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In the event that either Licensee or Schering becomes aware of any alleged or threatened infringement in a country in the Field in the Territory of any issued patent within the Schering Prosecution Patents, it will notify the other Party in writing to that effect. [ * ] shall have three (3)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months from the date of said notice to obtain a discontinuance of such infringement or bring suit against the Third Party infringer if such infringement relates to the use of the Licensed Product in the Field. If [ * ] fails to proceed within the specified 3-month period of time, then [ * ] shall have the right to obtain a discontinuance of such infringement or bring suit against the Third Party infringer only in the event that: (i)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] a discontinuance of such infringement or [ * ] suit against the Third Party infringer [ * ] or (ii)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] a discontinuance of such infringement or [ * ] suit against the Third Party infringer [ * ] and, in such discontinuance or suit, if [ * ], [ * ] discontinuance or suit. In the event that [ * ] is able to exercise its &#8220;step-in&#8221; rights to enforce Schering Prosecution Patents under this Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5, [ * ] shall reimburse [ * ] costs and expenses for cooperation following the exercise of [ * ] step-in rights and all costs of enforcement going forward (provided, however, that if [ * ] later joins the enforcement action, then [ * ] shall be obligated for [ * ] costs and expenses after joining). The Party not initiating an action hereunder shall be notified prior to commencement of the trial, suit or action brought by the other Party and may join any such suit or action. In the event a Party joins an action hereunder, it shall pay one-half of the costs of such suit or action. In the event that a Party has joined in the action and shared in the costs thereof as set forth above, no settlement, consent judgment or other voluntary final disposition of the suit may be entered into without the consent of joining Party, which consent shall not be unreasonably withheld. In the event that a Party has not joined the suit or action, such Party will in any event reasonably cooperate with the acting Party in any such suit or action and shall have the right to consult with such acting Party and be represented by its own counsel at its own expense. Any recovery or damages derived from a suit which a Party has joined and shared costs shall be used first to reimburse each of the Parties for its documented out-of-pocket legal expenses relating to the suit, with any remaining amounts to be shared [ * ], and [ * ]. Any recovery or damages derived from a suit which a Party has not joined shall be [ * ]. Schering shall incur no liability to Licensee as a consequence of litigation or any unfavorable decision resulting therefrom, including any decision holding any of the Schering Prosecution Patents invalid or unenforceable. Licensee shall incur no liability to Schering as a consequence of litigation or any unfavorable decision resulting therefrom brought pursuant to this Section</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6 <font style="text-decoration:underline;">Infringement and Third Party Licenses</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Course of Action</font>. In the event that Licensee&#8217;s, its Affiliates&#8217; or its sublicensees&#8217; making, having made, importing, exporting, using, manufacturing, having manufactured Licensed Compound or Licensed Product or distributing, marketing, promoting, offering for sale or selling Licensed Product infringes, will infringe or is alleged by a Third Party to infringe, a claim of a patent that specifically covers the Licensed Compound, Licensed Product or its Manufacture, the Party becoming aware of same shall promptly notify the other. The Parties shall thereafter attempt to agree upon a course of action which may include: (i) modification of the Licensed Product or Licensed Compound or its use and Manufacture so as to be non-infringing; or (ii) obtaining a license or assignment from said Third Party.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Licensee Right to Negotiate</font>. In the event the Parties cannot agree on modifying the Licensed Product or Licensed Compound pursuant to Section 8.6(a), Licensee shall have the first right, but not the obligation, to negotiate with said Third Party for a suitable license or assignment. In the event that such negotiation results in a definitive agreement and the claimed infringement is for the making, using or selling of the Licensed Compound, then any lump sum or royalty payment made thereunder shall be paid by Licensee and Licensee shall have the right to offset such amount in accordance with Section 2.6. If Licensee fails to enter into a license or assignment pursuant to this Section 8.6(b), then following written notice from Licensee of such failure, Schering shall have the right to negotiate with said Third Party for a suitable license or assignment.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7 <font style="text-decoration:underline;">Third Party Infringement Suit</font>. In the event that a Third Party sues Licensee alleging that Licensee&#8217;s, its Affiliates&#8217; or its sublicensees&#8217; making, having made, importing, exporting, using, manufacturing, having manufactured Licensed Compound or Licensed Product or distributing, marketing, promoting, offering for sale or selling Licensed Product infringes or will infringe a claim of a patent that specifically covers the Licensed Compound, Licensed Product or its manufacture, then Licensee may elect to defend such suit and, during the period in which such suit is pending, notwithstanding Licensee&#8217;s obligation to indemnify Schering under Section 11.1 herein, Licensee shall have the right to apply up to [ * ] of the royalties due Schering on sales of the allegedly infringing Licensed Product against its reasonable out-of-pocket litigation expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 20</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.8</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">Abandonment</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Schering shall promptly give notice to Licensee of the grant lapse, revocation, surrender, invalidation or abandonment of any Schering Prosecution Patents licensed to Licensee.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.9 <font style="text-decoration:underline;">Patent Term Extension</font>. The Party obtaining first Regulatory Approval for the Licensed Product in the United States shall be entitled to seek patent term extension in connection with the Compound Patent Rights. In the event that Licensee obtains such first Regulatory Approval, Schering agrees to cooperate with Licensee in the event that Licensee seeks patent term extension for the Compound Patent Rights; provided that Licensee reimburses all Schering&#8217;s costs and expenses in connection therewith, including Schering&#8217;s internal costs.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IX - CONFIDENTIALITY AND PUBLICATION</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1 <font style="text-decoration:underline;">Confidentiality</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Nondisclosure Obligation</font>. Each of Schering and Licensee shall use any Proprietary Information received by it from the other Party only in accordance with this Agreement and shall not disclose, except as expressly provided herein, to any Third Party any such Proprietary Information without the prior written consent of the other Party. The foregoing obligations shall survive the expiration or termination of this Agreement for a period of [ * ]. These obligations shall not apply to Proprietary Information that:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party&#8217;s competent written records;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) is at the time of disclosure, or thereafter becomes, published or otherwise part of the public domain without breach of this Agreement by the receiving Party;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii) is subsequently lawfully disclosed to the receiving Party by a Third Party who has the right to make such disclosure, as documented by the receiving Party&#8217;s competent written records;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv) is independently developed by the receiving Party or its Affiliates and without the aid, use or application of any of the disclosing Party&#8217;s Proprietary Information, and such independent development can be documented by the receiving Party&#8217;s competent written records;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v) is disclosed to any institutional review board of any entity conducting clinical trials with Licensed Product or to any governmental or other regulatory agencies in order to obtain patents or to gain approval to conduct clinical trials or to market Licensed Product, provided that such disclosure may be made only to the extent reasonably necessary to obtain such patents or authorizations.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Permitted Disclosures</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) Notwithstanding anything to the contrary herein, the receiving Party may disclose the Proprietary Information of the disclosing Party solely to the extent such disclosure is required by applicable law, regulation, rule, act or order of any Governmental Authority or agency to be disclosed, provided that notice is promptly delivered to the disclosing Party in order to provide an opportunity to seek a protective order or other similar order with respect to such Proprietary Information and thereafter the receiving Party discloses to the requesting entity only the minimum information required to be disclosed in order to comply with the request, whether or not a protective order or other similar order is obtained by the disclosing Party.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) Each of the Parties agrees not to disclose the terms and conditions of this Agreement to any Third Party and shall not make any public announcement or issue any press release in relation thereto, or otherwise publicize the existence or contents of this Agreement without the prior written approval by the other Party of the form, content and timing of such announcement, press release or other public disclosure. The foregoing provisions of this Section 9.1(b)(ii) notwithstanding, each Party shall have the right to disclose information related to the existence and/or terms and conditions of this Agreement as follows: (i) to the extent necessary (as reasonably </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 21</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determined by its legal counsel) to be disclosed in order to comply with the rules and regulations of the United States Securities and Exchange Commission (or another similar</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">securities exchange authority in Territory); (ii)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to existing or potential acquirers or merger candidates, potential sublicensees or collaborators (to the extent contemplated hereunder), or to Affiliates, each of whom prior to disclosure must be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 9; (iii)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to investment bankers, existing or potential investors, venture capital firms or other financial institutions or investors for purposes of obtaining financing, if such recipients are bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 9; or (iv)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in response to a valid order of a court or other governmental body. In each such event, the Party so required to disclose shall notify the other Party in advance of any such disclosure, shall provide the other Party with a reasonable opportunity to review and comment on the form and content of any such disclosure, shall disclose only the minimum information required in order to comply with such disclosure requirements, and shall use commercially reasonable efforts to obtain confidential treatment (to the fullest extent available).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2 <font style="text-decoration:underline;">Return of Confidential Information</font>. The receiving Party will return all documents, and copies thereof, including those in the possession of the receiving Party&#8217;s Agents pursuant to Section 9.1(b), containing the disclosing Party&#8217;s Proprietary Information at any time upon the written request of the disclosing Party. However, the receiving Party may retain one (1) copy of such documents in a secure location solely for the purposes of (a) determining its obligations hereunder, (b) complying with any applicable regulatory requirements, or (c) defending against any product liability claim.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3 <font style="text-decoration:underline;">Breach of Confidentiality</font>. The Parties agree that the disclosure of the disclosing Party&#8217;s Proprietary Information in violation of this Agreement may cause the disclosing Party irreparable harm and that any breach or threatened breach of this Agreement by the receiving Party entitles disclosing Party to seek injunctive relief, in addition to any other legal or equitable remedies available to it, in any court of competent jurisdiction.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4 <font style="text-decoration:underline;">No Publicity</font>. A Party may not use the name of the other Party in any publicity or advertising and may not issue a press release or otherwise publicize or disclose any information related to the existence of this Agreement or the terms or conditions herein, except (a) on the advice of its counsel as required by law (e.g., any Securities and Exchange Commission filings and disclosures) and provided the Party who will be disclosing such information has consulted with the other Party to the extent feasible prior to such disclosure with respect to the substance of the disclosure; or (b) as consented to in advance by the other Party in writing. The Parties shall agree on a form of initial press release that may be used by either Party on an ongoing basis to describe this Agreement. Each Party shall use good faith efforts to provide the other Party with reasonable advance written notice of any press release or other public disclosure of the results of any of its work on Licensed Products during the Term, provided that a Party&#8217;s failure to do so shall not constitute a material breach of this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5 <font style="text-decoration:underline;">Publication</font>. To the extent that any proposed publication or public presentation (including without limitation any abstracts or manuscripts for publication, slides and texts of oral or other public presentations, and texts of any transmission through any electronic media (e.g., any computer access system such as the Internet, World Wide Web etc.) collectively or individually a &#8220;<font style="text-decoration:underline;">Public Presentation</font>&#8221;) to be made by a Party or its Affiliates may contain Proprietary Information of the other Party, the Party intending to make such publication or presentation shall provide to such other Party an advance copy of any such proposed publication or presentation prior to its submission or dissemination to any Third Party. The Party receiving such proposed publication or presentation shall have a period of at least [ * ] to review and recommend any changes it reasonably believes are necessary to protect its Proprietary Information. The Party intending to make such publication or presentation shall remove any Proprietary Information of the other Party therefrom; other changes recommended by such other Party shall not be unreasonably refused. In addition, if such publication could in the reviewing Party&#8217;s reasonable judgment be expected to have a material adverse effect on the commercial value of the reviewing Party&#8217;s Proprietary Information (or in the case of a proposed publication by Schering, on the Licensed Product in the Field), then the reviewing Party shall have the right to delay or prevent such publication as proposed by providing written notice to that effect during such [ * ] period. In the case where such publication may disclose any Program IP, any such delay shall be sufficiently long to permit the timely preparation and filing of a patent application(s) (or application(s) for other appropriate forms of protection) on the Proprietary Information involved.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 22</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE X - REPRESENTATIONS AND WARRANTIES</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1 <font style="text-decoration:underline;">Representations and Warranties of Each Party</font>. Each of Schering and Licensee hereby represents, warrants and covenants to the other Party hereto as follows:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) it is a corporation duly organized and validly existing under the laws of the state or other jurisdiction of its incorporation;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite corporate action;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions herein does not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) a loan agreement, guaranty, financing agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property; (ii) the provisions of its corporate charter or other operative documents or bylaws; or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) except for the governmental and Regulatory Approvals required to market the Licensed Product in the Territory, the execution, delivery and performance of this Agreement by such Party does not require the consent, approval or authorization of, or notice, declaration, filing or registration with, any governmental or Regulatory Authority and the execution, delivery or performance of this Agreement will not violate any law, rule or regulation applicable to such Party;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) this Agreement has been duly authorized, executed and delivered and constitutes such Party&#8217;s legal, valid and binding obligation enforceable against it in accordance with its terms subject, as to enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors&#8217; rights and to the availability of particular remedies under general equity principles; and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g) it shall comply with all applicable material laws and regulations relating to its activities under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2 <font style="text-decoration:underline;">Schering&#8217;s Representations</font>. Schering hereby represents, warrants and covenants to Licensee as follows:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) to the best of Schering&#8217;s knowledge, as of the Effective Date the Compound Patent Rights and Schering Know-How in the Field are subsisting and are not invalid or unenforceable, in whole or in part;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) as of the Effective Date, it has the full right, power and authority to grant all of the right, title and interest in the license granted under Article II herein;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) as of the Effective Date, it has not assigned, transferred, conveyed or otherwise encumbered, and during the Term of this Agreement will not assign, transfer, convey or otherwise encumber, its right, title and interest in the Compound Patent Rights or Schering Know-How in the Field except in accordance with this Agreement;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) to the best of Schering&#8217;s knowledge, as of the Effective Date, it is the sole and exclusive owner of the Compound Patent Rights and Schering Know-How in the Field, all of which is free and clear of any liens, charges and encumbrances, and no other person, corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim of ownership with respect to the Compound Patent Rights and Schering Know-How in the Field, whatsoever;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 23</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) to the best of Schering&#8217;s knowledge, as of the Effective Date, the Manufacture, use or Commercialization of Licensed Compound and Licensed Product in the Field do not infringe any valid and enforceable patent rights owned or possessed by any Third Party;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) as of the Effective Date there are no claims, judgments or settlements against or owed by Schering or pending or threatened claims or litigation against Schering relating to Compound Patent Rights and Schering Know-How in the Field;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g) to the best of Schering&#8217;s knowledge as of the Effective Date, there are no commitments under or activities ongoing under any agreements with any third parties for the Manufacture of Licensed Product for Development and Commercialization of Licensed Product; and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h) as of the Effective Date, it is in compliance in all material respects with any agreements with Third Parties concerning the Compound Patent Rights and Schering Know-How in the Field and during the Term of this Agreement (i) it will use Commercially Reasonable Efforts not to diminish the rights under the Compound Patent Rights, Schering Know-How and Program Know-How owned or Controlled by Schering in the Field granted to Licensee hereunder, including without limitation, by not committing or permitting any actions or omissions which would cause the breach of any such agreements between itself and Third Parties which provide for intellectual property rights applicable to the Manufacture or use of Licensed Compound or the Development, distribution, marketing, promotion or sale of Licensed Product in the Field, and (ii) it will provide Licensee promptly with notice of any such alleged breach.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3 <font style="text-decoration:underline;">Licensee&#8217;s Representations</font>. Licensee hereby represents, warrants and covenants to Schering as follows:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) during the Term of this Agreement it will not use in any capacity, in connection with performing its obligations under this Agreement, any individual who has been debarred pursuant to the United States Food, Drug and Cosmetic Act;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) it has or will have the capacity and resources to Develop and Commercialize Licensed Product and to Manufacture Licensed Compound as such obligations come due under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4 <font style="text-decoration:underline;">No Inconsistent Agreements</font>. Neither Party has in effect, and after the Effective Date neither Party shall enter into, any oral or written agreement or arrangement that would be inconsistent with its obligations under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5 <font style="text-decoration:underline;">Representation by Legal Counsel</font>. Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting of this Agreement. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption shall exist or be implied against the Party which drafted such terms and provisions.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6 <font style="text-decoration:underline;">Disclaimer</font>. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 10, THE LICENSED COMPOUND, LICENSED PRODUCT, COMPOUND PATENT RIGHTS AND SCHERING KNOW-HOW ARE PROVIDED &#8220;AS IS&#8221; AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7 <font style="text-decoration:underline;">No Warranty</font>. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY HERETO MAKES ANY REPRESENTATION AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED. IN PARTICULAR, BUT WITHOUT LIMITATION, SCHERING MAKES NO REPRESENTATION AND EXTENDS NO WARRANTY CONCERNING WHETHER THE DESIGNATED COMPOUND OR A DESIGNATED PRODUCT IS FIT FOR ANY PARTICULAR PURPOSE OR SAFE FOR HUMAN CONSUMPTION.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 24</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE XI - INDEMNIFICATION AND LIMITATION ON LIABILITY</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1 <font style="text-decoration:underline;">Indemnification by Licensee</font>. Licensee shall indemnify, defend and hold harmless Schering and its Affiliates, and each of its and their respective employees, officers, directors and agents (each, a &#8220;<font style="text-decoration:underline;">Schering Indemnified Party</font>&#8221;) from and against any and all Third Party liability, loss, damage, cost, and expense (including reasonable attorneys&#8217; fees), subject to the limitations in Section 11.5 (collectively, a &#8220;<font style="text-decoration:underline;">Liability</font>&#8221;) which a Schering Indemnified Party may incur, suffer or be required to pay resulting from or arising out of (a) the Development, Manufacture, promotion, distribution, use, marketing, sale or other disposition of the Licensed Product in the Field by Licensee, its Affiliates or sublicensees, and (b) any material breach by Licensee of any of its representations, warranties and covenants contained in herein. Notwithstanding the foregoing, Licensee shall have no obligation under this Agreement to indemnify, defend or hold harmless any Schering Indemnified Party with respect to claims, demands, costs or judgments which result from the negligence or willful misconduct of Schering, its Affiliates, or any of their respective employees, officers, directors or agents, or Schering&#8217;s breach of its obligations under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2 <font style="text-decoration:underline;">Indemnification by Schering</font>. Schering shall indemnify, defend and hold harmless Licensee and its Affiliates, and each of its and their respective employees, officers, directors and agents (each, a &#8220;<font style="text-decoration:underline;">Licensee Indemnified Party</font>&#8221;) from and against any Third Party Liability which a Licensee Indemnified Party may incur, suffer or be required to pay resulting from or arising out of (i) the Development, Manufacture, promotion, distribution, use, marketing, sale or other disposition of the Licensed Product outside the Field by Schering, it Affiliates or sublicensees, and (ii) any material breach by Schering of any of its representations, warranties and covenants contained herein. Notwithstanding the foregoing, Schering shall have no obligation under this Agreement to indemnify, defend or hold harmless any Licensee Indemnified Party with respect to claims, demands, costs or judgments which result from the negligence or willful misconduct of Licensee, its Affiliates, or any of their respective employees, officers, directors or agents, or Licensee&#8217;s breach of its obligations under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3 <font style="text-decoration:underline;">Conditions to Indemnification</font>. The obligations of the indemnifying Party under Sections 11.1 and 11.2 are conditioned upon the delivery of written notice to the indemnifying Party of any potential Liability promptly after the indemnified Party becomes aware of such potential Liability. The indemnifying Party shall have the right to assume the defense of any suit or claim related to the Liability if it has assumed responsibility for the suit or claim in writing; however, if in the reasonable judgment of the indemnified Party, such suit or claim involves an issue or matter which could have a materially adverse effect on the business operations or assets of the indemnified Party, the indemnified Party may retain control of the defense or settlement thereof by providing written notice of such effect to the indemnifying Party, but in no event shall such action or notice be construed as a waiver of any indemnification rights that the indemnified Party may have at law or in equity. If the indemnifying Party defends the suit or claim, the indemnified Party may participate in (but not control) the defense thereof at its sole cost and expense. The foregoing notwithstanding, the Parties acknowledge and agree that failure of the indemnified Party to promptly notify the indemnifying Party of a potential Liability shall not constitute a waiver of, or result in the loss of, such Party&#8217;s right to indemnification under Section 11.1 or 11.2, as appropriate, except to the extent that the indemnifying Party&#8217;s rights, and/or its ability to defend against such Liability, are materially prejudiced by such failure to notify.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4 <font style="text-decoration:underline;">Settlements</font>. Neither Party may settle a claim or action related to a Liability without the consent of the other Party, which consent shall not be unreasonably withheld, if such settlement would impose any monetary obligation on the other Party or require the other Party to submit to an injunction or otherwise limit the other Party&#8217;s rights under this Agreement. Any payment made by a Party to settle any such claim or action shall be at its own cost and expense.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5 <font style="text-decoration:underline;">Limitation of Liability</font>. With respect to any claim by one Party against the other arising out of the performance or failure of performance of the other Party under this Agreement, the Parties expressly agree that the liability of such Party to the other Party for such breach shall be limited under this Agreement or otherwise at law or equity to direct damages only and in no event shall a Party be liable for punitive, exemplary or consequential damages, except to the extent the liability of such Party relates to its indemnification obligations of the other Party pursuant to this Article XI or a breach of the obligations of confidentiality and non-use set forth in Article IX.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 25</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.6</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">Insurance</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Each Party acknowledges and agrees that during the Term of this Agreement it shall maintain adequate insurance and/or a self-insurance program for liability insurance, including products liability and contractual liability insurance, to cover such Party&#8217;s obligations under this Agreement. In the case of Licensee, it will maintain a minimum of [ * ] of coverage for such insurance. Each Party shall provide the other Party with evidence of such insurance and/or self-insurance program, upon request.</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE XII - TERM AND TERMINATION</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1 <font style="font-weight:bold;">HSR Act.</font> To the extent required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (&#8220;<font style="text-decoration:underline;">HSR Act</font>&#8221;), each Party will (i) file or cause to be filed, as promptly as practicable after the date hereof, with the United States Federal Trade Commission (&#8220;<font style="text-decoration:underline;">FTC</font>&#8221;) and the United States Department of Justice (&#8220;<font style="text-decoration:underline;">DOJ</font>&#8221;), all reports and other documents required to be filed by such Party under the HSR Act concerning the transactions contemplated hereby and (ii) promptly comply with or cause to be complied with any requests by the FTC or DOJ for additional information concerning such transactions, in each case so that the waiting period applicable to this Agreement and the transactions contemplated hereby under the HSR Act will expire as soon as practicable after the date hereof. Each Party agrees to request, and to cooperate with the other Party in requesting, early termination of any applicable waiting period under the HSR Act. Each Party shall be responsible for its own costs, expenses, and filing fees in connection with the filings. This Agreement is effective on the earlier of: (i) the date after which the waiting period pursuant to the HSR Act has expired, (ii) the date on which the transaction contemplated in this Agreement has been approved by the FTC and DOJ, and (iii) if the Parties agree that no filing is required under the HSR Act, the date first written above (&#8220;Effective Date&#8221;).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2 <font style="text-decoration:underline;">Term and Expiration</font>. This Agreement shall be effective as of the Effective Date and unless terminated earlier by mutual written agreement of the Parties or pursuant to Sections 12.3 or 12.4 below, the Term of this Agreement shall continue in effect on a country-by-country and product-by-product basis until the expiration of Licensee&#8217;s obligation to pay royalties under Article VII herein (the &#8220;<font style="text-decoration:underline;">Term</font>&#8221;). Upon expiration of this Agreement in its entirety, Licensee&#8217;s license pursuant to Section 2.1 shall become a fully paid-up, non-exclusive, perpetual license.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3 <font style="text-decoration:underline;">Termination by Licensee</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Licensee&#8217;s Right to Terminate</font>. Notwithstanding anything contained herein to the contrary, Licensee shall have the unilateral right to terminate this Agreement in its entirety with or without cause, at any time by giving [ * ] advance written notice to Schering. In the event of such termination, the rights and obligations hereunder shall terminate; provided, however, that any payment obligations due and owing as of the termination date shall continue. For clarity, milestones achieved prior to the date of notice shall continue to be payable, but no additional milestone payments shall apply for activities conducted during the [ * ] notice period.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Effect of Termination</font>. Notwithstanding anything contained herein to the contrary, following any termination of this Agreement in its entirety under Section 12.3(a), all rights and licenses granted to Licensee hereunder shall revert back to Schering pursuant to Section 12.6.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.4 <font style="text-decoration:underline;">Termination for Cause</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Termination for Cause</font>. This Agreement may be terminated, in its entirety by written notice by either Party at any time during the Term of this Agreement:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) if the other Party is in breach of its material obligations hereunder (except with respect to a breach by Licensee of its obligations under Section 5.2, for which termination pursuant to Section 12.4(b) shall be Schering&#8217;s sole and exclusive remedy) and has not cured such breach within [ * ] after receipt of written notice requesting cure of the breach, or in the event that the breach cannot be reasonably cured within such [ * ] period, has not initiated actions reasonably expected to cure such breach within [ * ] after receipt of such notice; or</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 26</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings by or against the other Party, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party, or in the event a receiver or custodian is appointed for such Party&#8217;s business, or if a substantial portion of such Party&#8217;s</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business is subject to attachment or similar process; provided, however, that in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the proceeding is not dismissed within [ * ] after the filing thereof.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Termination for Breach of Section 5.2</font>. Subject to the terms and conditions of this Section 12.4(b), Schering shall have the right, and such right shall be its sole and exclusive remedy and Licensee&#8217;s sole and exclusive liability, to terminate this Agreement in the event Licensee and its Affiliates and sublicensees have ceased employing Commercially Reasonable Efforts to Develop and Commercialize Licensed Products in the Field for a period of [ * ] or more. In order to exercise such termination right, Schering shall first provide written notice to Licensee stating Schering&#8217;s reasons for concluding that Licensee and its Affiliates and sublicensees have ceased employing Commercially Reasonable Efforts to Develop and Commercialize Licensed Product in the Field for the aforementioned period. If Licensee disagrees with the conclusion that Licensee and its Affiliates and sublicensees have ceased employing Commercially Reasonable Efforts to Develop and Commercialize Licensed Product in the Field for the aforementioned period, Licensee shall have a period of [ * ] after such written notice to provide Schering with evidence that Licensee or any of its Affiliates or sublicensees has not ceased employing Commercially Reasonable Efforts to Develop and Commercialize Licensed Product in the Field for the aforementioned period. If Licensee has not provided Schering with such evidence within such [ * ] period, this Agreement shall terminate at the end of such [ * ] period upon written notice from Schering. Notwithstanding the foregoing, if Schering gives Licensee a notice pursuant to the second sentence of this Section 12.4(b), and Licensee provides notice during the [ * ] period set forth above that Licensee disputes the conclusion that Licensee and its Affiliates and sublicensees have ceased employing Commercially Reasonable Efforts to Develop and Commercialize Licensed Product in the Field for the aforementioned period, then this Agreement shall not terminate unless and until an arbitrator issues a final award pursuant to Article 13 upholding the basis for termination under this Section 12.4(b).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="text-decoration:underline;">Effect of Termination for Cause on License</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) <font style="text-decoration:underline;">Termination by Licensee for Cause</font>. In the event this Agreement is properly terminated by Licensee under Section 12.4(a), Licensee&#8217;s license pursuant to Section 2.1 shall become a fully paid-up, perpetual license and the payments to be made to Schering by Licensee hereunder shall be reduced by [ * ]. Notwithstanding the preceding sentence, Licensee shall be responsible for the full amount of all payments due and owed to Schering prior to any written notice of termination.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) <font style="text-decoration:underline;">Termination by Schering for Cause</font>. In the event this Agreement is terminated by Schering under Section 12.4(a), the rights and license granted to Licensee under Section 2.1 of this Agreement shall terminate and all rights to the Licensed Compound and Licensed Product shall revert to Schering pursuant to Section 12.6.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5 <font style="text-decoration:underline;">Effect of Termination Generally</font>. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination, and the provisions of Sections 10.6, 10.7, 12.3(b), 12.4(c), 12.5 and 12.6 and Articles IX, XIII<font style="font-size:8pt;"> </font>and XIV shall survive the expiration or termination of this Agreement. Any expiration or early termination of this Agreement shall be without prejudice to the rights of either Party against the other that has accrued and is owed under this Agreement prior to termination, including the obligation to pay royalties for Licensed Product sold prior to such termination.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.6 <font style="text-decoration:underline;">Licensed Product Reversion</font>. Upon termination of this Agreement in its entirety by Schering for any reason or by Licensee pursuant to Section 12.3, the following provisions shall apply:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Effective upon such termination, without further action by either Party, [ * ] license from Licensee under any Program IP that is owned or Controlled by Licensee that is necessary or useful for the use, Development, Manufacture, or Commercialization of the Licensed Product in the Field.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 27</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Licensee shall reasonably cooperate with Schering in order to enable Schering to assume responsibility for the Development, Manufacture and/or Commercialization of all Licensed Products then being Developed, Manufactured or Commercialized by Licensee. Such cooperation and assistance shall be provided in a timely manner and shall include without limitation:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) Licensee shall transfer to Schering (or its nominee) all INDs, Regulatory Approvals, drug approval applications for Regulatory Approvals, and all supporting documentation for such filings and applications (to the extent assignable and not cancelled), made or obtained by Licensee or its Affiliates or any of its sublicensees to the extent relating to Licensed Product then being Commercialized or in Development.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) Licensee shall assign to Schering all of its rights in any trademarks and shall transfer to Schering all of its rights in any domain names containing trademarks, in each case to the extent owned or Controlled by Licensee and to the extent that such trademarks have actually been or are planned to be utilized by Licensee in connection with the Commercialization of Licensed Product in the Field. Any assignment or transfer to Schering pursuant to this Section 12.6(b)(ii) shall be at no cost to Schering.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii) Licensee shall transfer to Schering (or its nominee), to the extent not previously provided, a copy of all Know-How owned or Controlled by Licensee relating to any Licensed Product then being Commercialized in the Field or in clinical Development by Licensee in the Field and reasonably necessary or useful for its continued Development, Manufacture and/or Commercialization in the Field, including without limitation all information contained in Licensee&#8217;s regulatory and/or safety databases, all in the format then currently maintained by Licensee.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv) Upon the request of Schering, Licensee shall use reasonable and Commercially Reasonable Efforts to assign to Schering any Sublicense Agreements previously granted by Licensee related to the Development of Licensed Product in the Field.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v) Upon the request of Schering, Licensee, its Affiliates and its sublicensees shall complete any clinical studies related to Licensed Product in the Field that (x) are being conducted under Licensee&#8217;s IND for Licensed Product and are ongoing as of the date this Agreement is terminated, and (y) for which it is not practicable to transfer responsibility for conducting such studies to Schering; provided, however, that Schering agrees to reimburse Licensee for all Development costs incurred by Licensee after termination in completing such studies.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi) Upon the request of Schering, Licensee shall transfer to Schering, at a price to be agreed in good faith, which shall not be more than [ * ] of Licensee&#8217;s fully allocated manufacturing cost for the Licensed Product, all quantities of Licensed Product in the possession of Licensee or its Affiliates (including, without limitation, clinical trial supplies and Licensed Product intended for commercial sale).</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii) At Schering&#8217;s request, Licensee shall promptly provide to Schering copies of all clinical trial, contract manufacturing, or service agreements entered into by Licensee or its Affiliates with respect to the Development or Manufacture of Licensed Product in the Field. At Schering&#8217;s request, Licensee shall promptly assign (or cause to be assigned), such agreements to Schering, to the extent such assignment is permitted under such agreement or, in the case that such agreements involve products other than the Licensed Product, to the extent that the portion of the agreement involving solely the Development or Manufacture of Licensed Product in the Field can be assigned. In the event that such an assignment is not permitted under a particular clinical trial, contract manufacturing, or service agreement, then Licensee shall reasonably cooperate (at Schering&#8217;s request) to assist Schering in obtaining the benefits of such agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties shall use commercially reasonable efforts to complete the transition of the Development, Manufacture and Commercialization of the Licensed Product from Licensee to Schering pursuant to this Section 12.6 as soon as is reasonably possible.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 28</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE XIII &#8211; DISPUTE RESOLUTION</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1 <font style="text-decoration:underline;">Informal Discussions</font>. Except as otherwise provided herein, in the event of any controversy or claim arising out of or relating to this Agreement, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to the Licensed Compound or Licensed Product, the Parties shall first try to settle their differences amicably between themselves. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and within [ * ] after such notice appropriate representatives of the Parties shall meet for attempted resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within the said [ * ], either Party may refer the matter by written notice to the other to the Chief Executive Officer of Schering, or his designee, and the Chief Executive Officer of Licensee, or his designee, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within [ * ] of such written notice, either Party may initiate arbitration proceedings in accordance with the provisions of this Article XIII.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2 <font style="text-decoration:underline;">Arbitration</font>. All disputes arising out of or relating to this Agreement, or the rights or obligations of the Parties hereunder, or relating in any way to the relationship between the Parties with respect to the Licensed Compound or Licensed Product, other than disputes relating to patent rights which shall be submitted to a court of competent jurisdiction (unless mutually agreed by the Parties), shall be finally and exclusively settled by arbitration by a panel of three (3) arbitrators.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The arbitration proceeding shall be conducted under the Commercial Arbitration Rules of the American Arbitration Association (&#8220;<font style="text-decoration:underline;">AAA</font>&#8221;) with such proceedings to be held in Newark, New Jersey, United States should a dispute be brought to arbitration by Licensee or in San Francisco, California should a dispute be brought to arbitration by Schering. In all cases, the arbitration proceedings shall be conducted in the English language, and all documents that are submitted in the proceeding shall be in the English language. Judgment upon the award rendered by arbitration may be issued and enforced by any court having competent jurisdiction.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) If a Party intends to begin an arbitration to resolve a dispute, such Party shall provide written notice to the other Party, informing the other Party of such intention and any statement of claim required under the applicable arbitration rules (as determined in accordance with Section 13.2(a)). Within [ * ] after its receipt of such notice, the other Party shall, by written notice to the Party initiating arbitration, add any additional issues to be resolved which would be considered mandatory counterclaims under New York law. For clarity, the resolution of any disputes regarding such counterclaims shall be conducted in the same proceedings as the initial claims.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Within [ * ] following the receipt of the notice of arbitration, the Party referring the matter to arbitration shall appoint an arbitrator and promptly notify the other Party of such appointment. The other Party shall, upon receiving such notice, appoint a second arbitrator within [ * ], and the two (2) arbitrators shall, within [ * ] of the appointment of the second arbitrator, agree on the appointment of a third arbitrator who will act with them and be the chairperson of the arbitration panel. In the event that either Party shall fail to appoint an arbitrator within [ * ] after the commencement of the arbitration proceeding, the arbitrator shall be appointed by the AAA. In the event of the failure of the two (2) arbitrators to agree within [ * ] after the commencement of the arbitration proceeding to appoint the chairperson, the chairperson shall also be appointed by the AAA.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) All of the arbitrators shall have significant legal or business experience in pharmaceutical licensing matters. The arbitrators shall not be employees, directors or shareholders of either Party or any of their Affiliates.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) Each Party shall have the right to be represented by counsel throughout the arbitration proceedings.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii) To the extent possible, the arbitration hearings and award will be maintained in confidence.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv) In any arbitration pursuant to this Agreement, the award or decision shall be rendered by a majority of the members of the panel provided for herein, with each member having one (1) vote. The arbitrators shall render a written decision with their resolution of the dispute, which decision shall set forth in reasonable detail the facts of the dispute, and the reasons for their decision. The decision of the arbitrators shall be final and non-appealable and binding on the Parties.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 29</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.3</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">Injunctive Relief</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. By agreeing to arbitration, the Parties do not intend to deprive any competent court of such court&#8217;s jurisdiction to issue a pre-arbitral injunction, pre-arbitral attachment or other order in aid of the arbitration proceedings and the enforcement of any award or judgment. Without prejudice to such provisional remedies in aid of arbitration as may be available under the jurisdiction of a national court, the court of arbitration shall have full authority to grant provisional remedies and to award damages for failure of any Party to respect the court of arbitration&#8217;s order to that effect.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4 <font style="text-decoration:underline;">Expenses of Arbitration and Expert Determination</font>. Each Party shall bear its own attorneys&#8217; fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrators; <font style="font-style:italic;">provided, however</font>, that the arbitrators shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing Party reimbursement for its reasonable attorneys&#8217; fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges and travel expenses). Absent the filing of an application to correct or vacate the arbitration award as permitted by applicable law, each Party shall fully perform and satisfy the arbitration award within [ * ] of the service of the award.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE XIV - MISCELLANEOUS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1 <font style="text-decoration:underline;">Assignment/Change of Control</font>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Assignment</font>. Neither this Agreement nor any or all of the rights and obligations of a Party hereunder may be assigned, delegated, sold, transferred, sublicensed (except as otherwise provided herein) or otherwise disposed of, by operation of law or otherwise, to any Third Party without the prior written consent of the other Party, and any attempted assignment, delegation, sale, transfer, prohibited sublicense or other disposition, by operation of law or otherwise, of this Agreement or of any rights or obligations hereunder contrary to this Section 14.1 shall be a material breach of this Agreement by the attempting Party, and shall be void and without force or effect; <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that either Party may, without such consent of such Party, assign the Agreement and its rights and obligations hereunder to an Affiliate or in connection with the transfer or sale of all or substantially all of its assets related to the division or the subject business, or in the event of its merger or consolidation or change in control or similar transaction. This Agreement shall be binding upon, and inure to the benefit of, each Party, its Affiliates, and its permitted successors and assigns. Each Party shall be responsible for the compliance by its Affiliates with the terms and conditions of this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Change of Control of Licensee</font>. In the event that any Change of Control (as defined below) causes Licensee&#8217;s rights and obligations hereunder to pass to any Third Party, such Third Party shall, within [ * ] after the effective date of such Change of Control, notify Schering of its intentions with regard to the Development and Commercialization of the Licensed Product under this Agreement. If the Third Party succeeding to Licensee&#8217;s rights and obligations under this Agreement decides it will not continue the Development and/or Commercialization of the Licensed Product, then Schering shall have the right to terminate this Agreement upon [ * ] written notice to Licensee without any opportunity to cure and the effects of such termination shall be as set forth in Section 12.6. If the Third Party succeeding to Licensee&#8217;s rights and obligations under this Agreement decides to continue the Development and Commercialization of the Licensed Product, then all of the rights and obligations of Licensee under this Agreement shall inure to such Third Party; <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">that</font> for the immediate [ * ] period following such Change of Control, such Third Party shall follow the same Development Plan and budget as was in effect prior to such Change of Control; and <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">further</font> that within such [ * ] period the Third Party successor shall submit to Schering a new Development Plan for the next succeeding [ * ] period, which shall not, without the prior written approval of Schering, which approval shall not be unreasonably withheld, materially differ from the Development Plan in effect prior to such Change of Control.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="text-decoration:underline;">Definition of Change of Control</font>. As used in this Section 14.1 the term &#8220;Change of Control&#8221; means (i) any merger, reorganization, consolidation or combination in which Licensee is not the surviving corporation, or (ii) any &#8220;person&#8221; (within the meaning of Sections 13(d) and 14 (d)(2) of the Securities Exchange Act of 1934), excluding Licensee and its Affiliates, is or becomes the beneficial owner, directly or indirectly, of securities of Licensee representing 50% or more of either (A) the then-outstanding shares of common stock of Licensee or its parent </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 30</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">corporation, or (B)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the combined voting power of Licensee&#8217;s then-outstanding voting securities; or (C)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if individuals who as of the Effective Date constitute the Board of Directors of Licensee or its parent corporation (the &#8220;</font><font style="text-decoration:underline;">Incumbent Board</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) cease for any reason to constitute at least a majority of such Board of Directors; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by Licensee&#8217;s stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Incumbent Board; or (D)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval by the stockholders of Licensee of a complete liquidation or the complete dissolution of Licensee.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2 <font style="text-decoration:underline;">Governing Law</font>. This Agreement shall be governed, interpreted and construed in accordance with the laws of the State of New York, without giving effect to its conflict of law principles. Subject to the terms of this Agreement, all disputes under this Agreement shall be governed by binding arbitration pursuant to the mechanism set forth in Article XIII herein.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.3 <font style="text-decoration:underline;">Waiver</font>. Any delay or failure in enforcing a Party&#8217;s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party&#8217;s rights to the future enforcement of its rights under this Agreement, nor operate to bar the exercise or enforcement thereof at any time or times thereafter, excepting only as to an express written and signed waiver as to a particular matter for a particular period of time.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.4 <font style="text-decoration:underline;">Independent Relationship</font>. Nothing herein contained shall be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party shall have any power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.5 <font style="text-decoration:underline;">Export Control</font>. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States of America which may be imposed upon or related to Schering or Licensee from time to time by the government of the United States of America. Furthermore, Licensee agrees that it will not export, directly or indirectly, any technical information acquired from Schering under this Agreement or any products using such technical information to any country for which the United States government or any agency thereof at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the Department of Commerce or other agency of the United States government when required by an applicable statute or regulation.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.6 <font style="text-decoration:underline;">Entire Agreement; Amendment</font>. This Agreement, including the Exhibits and Schedules hereto and thereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and understandings between the Parties with regard to the subject matter of this Agreement in the Territory. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment, change, waiver or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. As of the Effective Date, this Agreement supersedes and terminates that certain Secrecy Agreement between the Parties effective as of November 20, 2008.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 31</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.7</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">Notices</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Any notice required or permitted to be given or sent under this Agreement shall be hand delivered or sent by express delivery service or certified or registered mail, postage prepaid, or by facsimile transmission (with written confirmation copy by registered first-class mail) to the Parties at the addresses and facsimile numbers indicated below.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Schering, to:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schering Corporation</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o Merck &amp; Co., Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One Merck Drive</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Chief Licensing Officer</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P.O. Box 100, WS2A-30</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whitehouse Station, NJ 08889-0100</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: (908)735-1214</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy to:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schering Corporation</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o Merck &amp; Co., inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One Merck Drive</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P.O. Box 100</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whitehouse Station, NJ 08889-0100</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Vice President and Associate General Counsel,</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Business Development &amp; Licensing</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax No.: 908-735-1345</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Licensee, to:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3350 W Bayshore Road, Suite 120</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palo Alto, CA 94303</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Chief Executive Officer</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax No.: 650-320-9901</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy to:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley, LLP</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3000 El Camino Real</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Five Palo Alto Square</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palo Alto, CA 94306</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Glen Y. Sato, Esq.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax No.: 650-849-7400</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any such notice shall be deemed to have been received on the earlier of the date actually received or the date five (5) days after the same was posted or sent. Either Party may change its address or its facsimile number by giving the other Party written notice, delivered in accordance with this Section 14.7.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.8 <font style="text-decoration:underline;">Force Majeure</font>. Failure of any Party to perform its obligations under this Agreement (except the obligation to make payments when properly due) shall not subject such Party to any liability or place them in breach of any term or condition of this Agreement to the other Party if such failure is due to any cause beyond the reasonable control of such non-performing Party (&#8220;<font style="text-decoration:underline;">Force Majeure</font>&#8221;), unless conclusive evidence to the contrary is provided. Causes of non-performance constituting Force Majeure shall include, without limitation, acts of God, fire, explosion, flood, drought, earthquake, war, riot, sabotage, embargo, strikes or other labor trouble, failure in whole or in part of suppliers to deliver on schedule materials, equipment or machinery, interruption of or delay in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 32</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transportation, a national health emergency or compliance with any order or regulation of any government entity acting with color of right. The Party affected shall promptly notify the other Party of the condition constituting Force Majeure as defined herein and shall exert reasonable efforts to eliminate, cure and overcome any such causes and to resume performance of its obligations with all possible speed; provided that nothing herein shall obligate a Party to settle on terms unsatisfactory to such Party any strike, lockout or other labor difficulty, any investigation or other proceeding by any public authority or any litigation by any Third Party. If a condition constituting Force Majeure as defined herein exists for more than ninety (90)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consecutive days, the Parties shall meet to negotiate a mutually satisfactory resolution to the problem, if practicable. If the Parties cannot in good faith reach a satisfactory resolution to the problem within sixty (60)</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">days of meeting, the matter shall be handled pursuant to the dispute resolution provisions of Article XIII herein.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.9 <font style="text-decoration:underline;">Severability</font>. If any provision of this Agreement is declared illegal, invalid or unenforceable by a court having competent jurisdiction, it is mutually agreed that this Agreement shall continue in accordance with its terms except for the part declared invalid or unenforceable by order of such court, provided, however, that in the event that the terms and conditions of this Agreement are materially altered, the Parties will, in good faith, renegotiate the terms and conditions of this Agreement to reasonably substitute such invalid or unenforceable provisions in light of the intent of this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.10 <font style="text-decoration:underline;">Counterpart</font>. This Agreement shall become binding when any one or more counterparts of it, individually or taken together, shall bear the signatures of each of the Parties hereto. This Agreement may be executed in any number of counterparts, each of which shall be an original as against either Party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.11 <font style="text-decoration:underline;">Captions</font>. The captions of this Agreement are solely for the convenience of reference and shall not affect its interpretation.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.12 <font style="text-decoration:underline;">Further Actions</font>. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, this Agreement has been executed by the duly authorized representatives of the Parties.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SCHERING CORPORATION</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EIGER BIOPHARMACEUTICALS, INC.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Nicholson</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Cory</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: SVP Licensing &amp; Knowledge Management</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: CEO</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 33</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 1.11</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPOUND PATENT RIGHTS</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 34</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:20.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Case Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Status</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Appln No.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Appln Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exp Date</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:20.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 35</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 1.29</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LICENSED COMPOUND</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcntzzpazujl000001.jpg" title="" alt="" style="width:208px;height:142px;"></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sarasar/Lonafarnib (SCH 66366)</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4(2[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]-cyclohepta</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[1,2b]pyridin-11yl)-piperidino]-2-oxoethyl]-1-piperidinecarboxamide).</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 36</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 3.2(a)</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PROOF OF CONCEPT PROTOCOL</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients will undergo pre-study screening, which may include the following assessments:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ].</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 37</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 3.2(b)</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INITIAL DEVELOPMENT PLAN</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial plan for development of the Licensed Compound in the Field includes the following studies.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:21%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goal:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dosages assessed:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary outcome:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary endpoint:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secondary outcomes:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Projected number of patients:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study location:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of sites:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Projected study initiation:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Projected study termination:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] Study</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goal:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dosages assessed:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 38</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:21%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary outcome:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary endpoint:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secondary outcomes:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Projected number of patients:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study location:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of sites:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Projected study initiation:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Projected study termination:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 39</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] Study</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:21%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goal:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ].</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dosage assessed:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary outcome:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary endpoint:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secondary outcomes:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Projected number of patients:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Study location:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of sites:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Projected study initiation:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Projected study termination:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 40</a> of 41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 6.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BULK LICENSE PRODUCT TO BE TRANSFERRED</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Bulk Licensed Product to be transferred from Schering to Licensee is [ * ] of Licensed Product in the form of [ * ].</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 41</a> of 41</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>4
<FILENAME>eigr-ex1012_1143.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex1012_1143.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65349949"></a>[*]&#160;=&#160;CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.12</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION VERSION</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Confidential</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:2pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">LICENSE AGREEMENT</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">EIGER BIOPHARMACEUTICALS, INC.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">BRISTOL-MYERS SQUIBB COMPANY</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:2pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"><a name="_Hlk65349950"></a>&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTION VERSION</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Confidential Information</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">LICENSE AGREEMENT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS LICENSE AGREEMENT (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is made and entered into as of the date last signed by a party below (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;), by and between&#160;<font style="font-weight:bold;">Bristol-Myers Squibb Company</font>, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (&#8220;<font style="text-decoration:underline;">BMS</font>&#8221;), and&#160;<font style="font-weight:bold;">Eiger BioPharmaceuticals, Inc.,&#160;</font>a Delaware corporation, with offices at 350 Cambridge Ave, Suite 350, Palo Alto, CA 94306 (&#8220;<font style="text-decoration:underline;">Eiger</font>&#8221;). BMS and Eiger are sometimes referred to herein individually as a &#8220;<font style="text-decoration:underline;">Party</font>&#8221; and collectively as the &#8220;<font style="text-decoration:underline;">Parties</font>.&#8221;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, BMS and its Affiliates Control (as defined below) certain patent rights and know-how rights with respect to the Licensed Compounds (as defined below); and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Eiger desires to obtain from BMS the licenses set forth herein, and BMS desires to grant such licenses to Eiger, all on the terms and conditions set forth in this Agreement;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE in consideration of the foregoing and the mutual agreements set forth below, the Parties agree as follows:</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">DEFINITIONS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms in this Agreement with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set forth below or, if not listed below, the meaning designated in places throughout this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.1&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Act</font><font style="font-weight:normal;">&#8221; means the United States Food, Drug and Cosmetic Act, as amended.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.2&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Affiliate</font><font style="font-weight:normal;">&#8221; of a Person means any other Person which (directly or indirectly) is controlled by, controls or is under common control with such Person. For the purposes of this definition, the term &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) as used with respect to a Person, shall mean the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise, and &#8220;control&#8221; shall be presumed to exist if either of the following conditions is met: (i)&#160;in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least fifty percent (50%)&#160;of the votes in the election of directors or (ii)&#160;in the case of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%)&#160;of the equity interests with the power to direct the management and policies of such entity.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.3&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Approval</font><font style="font-weight:normal;">&#8221; means, with respect to any Licensed Product in any regulatory jurisdiction, approval from the applicable Regulatory Authority sufficient for the manufacture, distribution, use, marketing, and sale of the Licensed Product in such jurisdiction in accordance with applicable Laws; provided, however </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">that for purposes of the U.S., Approval means BLA Approval and for purposes of the EU, Approval means MAA Approval.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.4&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">BLA</font><font style="font-weight:normal;">&#8221; means a biologics license application for a new biologics drug filed with the FDA required for marketing approval for the applicable Licensed Product in the U.S.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.5&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">BLA Approval</font><font style="font-weight:normal;">&#8221; means the final approval of a BLA for a given indication by the FDA for the applicable Licensed Product in the U.S.; provided, that, for milestone payment purposes, BLA Approval shall in any event be deemed achieved upon First Commercial Sale in the U.S. for such indication.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.6&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">BLA Filing</font><font style="font-weight:normal;">&#8221; means the acceptance by the FDA of the filing of a BLA for the applicable Licensed Product.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.7&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">BMS Know-How</font><font style="font-weight:normal;">&#8221; means Know-How that, as of the Effective Date, is Controlled by BMS and directly relates to and is reasonably necessary for, Eiger&#8217;s Development and Commercialization of the Licensed Compounds and/or Licensed Products in the Field or is used by BMS to manufacture the Licensed Compounds as manufactured by BMS as of the Effective Date.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.8&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">BMS Patent Rights</font><font style="font-weight:normal;">&#8221; means (a)&#160;the patents and patent applications listed in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 1</font><font style="font-weight:normal;">, (b)&#160;all divisionals, continuations, continuations-in-part thereof (excluding claims in continuations-in-part that necessarily rely on new matter invented by BMS after the Effective Date) or any other patent application claiming priority directly or indirectly to (i)&#160;any of the patents or patent applications in subsection (a), or (ii)&#160;any patent or patent application from which the patents or patent applications in (a)&#160;claim direct or indirect priority, (c)&#160;all patents issuing on any of the foregoing in (a)&#160;and (b), (d)&#160;all foreign counterparts of any of the foregoing in (a)&#160;through(c), including any patent applications filed under the Patent Cooperation Treaty (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">PCT Applications</font><font style="font-weight:normal;">&#8221;), and (e)&#160;all registrations, reissues, re-examinations, supplemental protection certificates, or extensions of any of the foregoing in (a)&#160;through (d). BMS Patent Rights in clause (a)&#160;above shall also include any claims in any patents or patent applications existing as of the Effective Date that are Controlled by BMS and cover the composition of matter of any intermediate or starting material reasonably necessary in or reasonably useful for the manufacture of any Licensed Compound as manufactured by BMS as of the Effective Date. BMS Patent Rights do not include any claims covering the composition of matter, manufacture or method of use of only a compound other than (i)&#160;a Licensed Compound or (ii)&#160;an intermediate or starting material reasonably necessary in or reasonably useful for the manufacture of any Licensed Compound as manufactured by BMS as of the Effective Date.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.9&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Business Day</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">business day</font><font style="font-weight:normal;">&#8221; means a day other than Saturday, Sunday or any day on which commercial banks located in New York, New York are authorized or obligated by Law to close.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.10&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Calendar Quarter</font><font style="font-weight:normal;">&#8221; means the respective periods of three consecutive calendar months ending on March&#160;31,&#160;June&#160;30,&#160;September&#160;30 and December&#160;31.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.11&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Calendar Year</font><font style="font-weight:normal;">&#8221; means each one-year period commencing on January&#160;1 and ending on December&#160;31.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.12&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Clinical Trial</font><font style="font-weight:normal;">&#8221; means any human clinical study of a pharmaceutical product.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.13&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Combination Product</font><font style="font-weight:normal;">&#8221; means a Licensed Product that includes at least one additional active ingredient other than the Licensed Compound. Drug delivery vehicles, adjuvants, and excipients shall not </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 2</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">be deemed to be &#8220;active ingredients&#8221;, except in the case where such delivery vehicle, adjuvant, or excipient is recognized by the FDA as an active ingredient in accordance with 21 CFR 210.3(b)(7).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.14&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Commercialization</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Commercialize</font><font style="font-weight:normal;">&#8221; means activities directed to commercially manufacturing, obtaining pricing and reimbursement approvals including regulatory activities relating to same, marketing, promoting, distributing, importing or selling a Licensed Product.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.15&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Commercially Reasonable Efforts</font><font style="font-weight:normal;">&#8221; means,</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;<font style="font-weight:normal;">with respect to the efforts to be expended by Eiger with respect to any objective, activity or decision to be undertaken under this Agreement, those efforts that a company within the bio-pharmaceutical industry of comparable size and resources [ * ] would reasonably use to accomplish such objective, activity or decision, and specifically means the carrying out of Development and Commercialization activities using efforts that a company within the bio-pharmaceutical industry of comparable size and resources [ * ] would reasonably devote to a product at a similar stage in its development or product life and of similar market potential, profit potential, based on conditions then prevailing and taking into account efficacy, safety, intellectual property protection, approved labeling, the competitiveness of alternative products sold by Third Parties in the marketplace, the patent and other proprietary position of the product, and the likelihood of regulatory approval given the regulatory structure involved. Commercially Reasonable Efforts shall be determined on a Major Markets Countries-by-Major Markets Countries basis for the Licensed Product, and it is anticipated that the level of effort will change over time, reflecting changes in the status of the Licensed Product and the Major Market(s) Country(ies) involved. Without limiting the foregoing, Commercially Reasonable Efforts require that Eiger: (i)&#160;promptly assign responsibility for such Development and Commercialization activities to specific individuals who are held accountable for progress and monitor such progress on an on-going basis, (ii)&#160;set and consistently seek to achieve specific and meaningful objectives and timelines for carrying out such Development and Commercialization activities, and (iii)&#160;consistently make and implement decisions and allocate resources designed to advance progress with respect to such objectives and timelines.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<font style="font-weight:normal;">with respect to the efforts to be expended by BMS with respect to any objective, activity or decision to be undertaken under this Agreement, those efforts consistent with the commercially reasonable practices normally devoted by BMS.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.16&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Competitive Compound</font><font style="font-weight:normal;">&#8221; means [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.17&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Confidential Information</font><font style="font-weight:normal;">&#8221; means all trade secrets, processes, formulae, data, Know-How, improvements, inventions, chemical or biological materials, techniques, marketing plans, strategies, customer lists, or other information (including all information and materials of a Party&#8217;s customers and any other Third Party and their consultants) that has been disclosed by a Party to the other Party under this Agreement or that certain Confidential Disclose Agreement between the Parties, dated May&#160;13, 2015 (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">CDA</font><font style="font-weight:normal;">&#8221;), regardless of whether any of the foregoing are marked &#8220;confidential&#8221; or &#8220;proprietary&#8221; or communicated to the other by the disclosing Party in oral, written, graphic, or electronic form. &#8220;Confidential Information&#8221; of BMS shall include the BMS Know-How.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.18&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Controlled</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Controls</font><font style="font-weight:normal;">&#8221;, when used in reference to intellectual property right or other intangible rights, shall mean the legal authority or right of a Party (or any of its Affiliates) to grant a license or sublicense of intellectual property rights to the other Party or any Third Party, or to otherwise </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 3</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">disclose confidential, proprietary or trade secret information to such other Party or to any Third Party, without breaching the terms of any agreement with any Third Party.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.19&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Development</font><font style="font-weight:normal;">&#8221; means non-clinical and clinical drug development activities reasonably related to the development and submission of information to a Regulatory Authority, including toxicology, pharmacology and other discovery and pre-clinical efforts, test method development and stability testing, process development, formulation development, development manufacturing, delivery system development, quality assurance and quality control development, statistical analysis, clinical studies (including pre- and&#160;post-Approval&#160;studies but specifically excluding regulatory activities directed to obtaining pricing and reimbursement approvals), and post-marketing commitments/requirements. When used as a verb, &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Develop</font><font style="font-weight:normal;">&#8221; means to engage in Development.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.20&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Development Plan</font><font style="font-weight:normal;">&#8221; means, with respect to a Licensed Product, a plan and related timing estimates prepared by Eiger for the then current calendar year and the two (2)&#160;following years (or through first BLA or MAA filing if later) setting forth a summary of the Development activities to be conducted for such Licensed Product in all Major Market Countries, including the indications expected to be targeted, a good faith estimate of reasonable timelines for completing key Development activities and filing of key regulatory submissions (including estimated timelines for commencement of each stage of clinical Development), and including, where known, the primary endpoints and any comparator or agents to be used in combination with a Licensed Compound/Licensed Product for any such studies and any go/no-go decision criteria for any such studies. The initial Development Plan as of the Effective Date is attached hereto as&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix&#160;2</font><font style="font-weight:normal;">. A copy of the study protocol for a given study will be provided to BMS if available and if requested by BMS.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.21&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Distributor</font><font style="font-weight:normal;">&#8221; means, with respect to a country, any Third Party that is used by pharmaceutical manufacturers generally in such country on a non-exclusive basis (and without any grant or license by Eiger of any intellectual property rights) to sell and distribute finished, packaged pharmaceutical products to pharmacies, managed care organizations, governmental agencies (</font><font style="font-style:italic;font-weight:normal;">e.g</font><font style="font-weight:normal;">., federal, state and local), and other group purchasing organizations (</font><font style="font-style:italic;font-weight:normal;">e.g.</font><font style="font-weight:normal;">, pharmaceutical benefits managers) and the like in such country; provided, that Eiger shall be permitted to grant or license such intellectual property rights to the Third Party solely to the extent reasonably necessary to comply with applicable law or to enable such distributor to sell and distribute (but not to market or promote) a Licensed Product. For clarity, a Distributor of a Licensed Product in a country shall not include any person or entity that has been granted a right, whether by license or otherwise and whether express or implied (including by subcontract or agency), by a Party or its Affiliates to research, Develop or manufacture (but a Distributor may have the right to repackage or relabel finished product specifically for sale or distribution in such country) any such Licensed Product or that otherwise assumes any regulatory or other responsibilities with respect to obtaining or maintaining regulatory approvals for such Licensed Product in such country.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.22&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Dollar</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">$</font><font style="font-weight:normal;">&#8221; means the lawful currency of the United States.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.23&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">EMA</font><font style="font-weight:normal;">&#8221; means the European Medicines Agency, or any successor agency thereto.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.24&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">EU</font><font style="font-weight:normal;">&#8221; means the European Union, as its membership may be altered from time to time, and any successor thereto.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.25&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">FDA</font><font style="font-weight:normal;">&#8221; means the U.S. Food and Drug Administration, or any successor agency thereto.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 4</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.26&#160;</font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Field</font><font style="font-weight:normal;">&#8221; means all therapeutic and diagnostic uses in humans and animals, including the prevention, treatment or control of any disease, disorder or condition.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.27&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">First Commercial Sale</font><font style="font-weight:normal;">&#8221; means, with respect to any Licensed Product in a country in the Territory, the first sale for use or consumption by the general public of such Licensed Product in such country after Approval of such Licensed Product has been granted, or such marketing and sale is otherwise permitted, by the Regulatory Authority of such country.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.28&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">GAAP</font><font style="font-weight:normal;">&#8221; means United States generally accepted accounting principles, consistently applied.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.29&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Governmental Authority</font><font style="font-weight:normal;">&#8221; means any multi-national, national, federal, state, local, municipal, provincial, county, or other political subdivision, agency or other body, domestic or foreign or other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court, tribunal or other entity).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.30&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">IND</font><font style="font-weight:normal;">&#8221; means an Investigational New Drug Application, as defined in the Act, filed with the FDA or its foreign counterparts, including as applicable clinical trial applications (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">CTAs</font><font style="font-weight:normal;">&#8221;), clinical trial exemptions (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">CTXs</font><font style="font-weight:normal;">&#8221;) and investigational medicinal product dossiers.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.31&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Initiation</font><font style="font-weight:normal;">&#8221; means, when used with respect to a Clinical Trial, the dosing of the first patient with the first dose in such Clinical Trial.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.32&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Know-How</font><font style="font-weight:normal;">&#8221; means tangible and intangible information, techniques, technology, practices, inventions (whether patentable or not), methods, knowledge, trade secrets, data and results (including all biological, chemical, pharmacological, toxicological, clinical, analytical and quality control data and methods (including any applicable reference standards), manufacturing assay and related data, manufacturing and formulation processes, data and results relating to drug substance, drug product, starting materials, and radiolabeled compounds, know-how and trade secrets).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.33&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Knowledge</font><font style="font-weight:normal;">&#8221; means, with respect to BMS, the actual knowledge of the individuals listed on Appendix 9 hereto, based on such individuals&#8217; good faith understanding of the facts and information in their possession or control without any duty to conduct any additional investigation within such individual&#8217;s scope of responsibility with respect to such facts and information.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.34&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Laws</font><font style="font-weight:normal;">&#8221; means all applicable laws, statutes, rules, regulations and other pronouncements having the effect of law of any Governmental Authority that may be in effect from time to time, including for clarity any applicable rules, regulations and other requirements of any Regulatory Authority that may be in effect from time to time.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.35&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Licensed Compound</font><font style="font-weight:normal;">&#8221; means (i)&#160;the proprietary BMS molecule known as PEG-interferon Lambda-1a having chemical structure set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 3</font><font style="font-weight:normal;">, [ * ], as well as (ii)&#160;[ * ], (iii)&#160;[ * ], and (iv)&#160;[ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.36&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Licensed Product</font><font style="font-weight:normal;">&#8221; means any pharmaceutical product containing a Licensed Compound (alone or with other active ingredients Controlled by Eiger), in all forms, presentations, formulations and dosage forms. For clarity, &#8220;other active ingredients&#8221; does not include any other active ingredients or molecules that are proprietary to, or Controlled by, BMS and its Affiliates and would require a license from BMS with respect to the composition, method of use or manufacture of such other molecule, unless </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 5</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">separately licensed from BMS or its Affiliates (with BMS and its Affiliates having no obligation, express or implied, to do so).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.37&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">MAA</font><font style="font-weight:normal;">&#8221; means a marketing authorization application filed for Approval in the EU of the applicable Licensed Product.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.38&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">MAA Approval</font><font style="font-weight:normal;">&#8221; means Approval by the EMA of a MAA filed with the EMA for the applicable Licensed Product under the centralized European procedure. If the centralized EMA filing procedure is not used, MAA Approval shall be achieved upon the first Approval for the applicable Licensed Product in three of the following countries: France, Germany, Italy, Spain and the United Kingdom. For clarity, MAA Approval shall include any pricing and reimbursement approvals required prior to sale of such Licensed Product in the European Union, or in connection with Approvals achieved in three of the foregoing five European Union member states; provided, that MAA Approval shall in any event be deemed achieved upon First Commercial Sale in any country in the European Union.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.39&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">MAA Filing</font><font style="font-weight:normal;">&#8221; means the validation by the EMA of a centralized filing of an MAA for the applicable Licensed Product.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.40&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Major Market Countries</font><font style="font-weight:normal;">&#8221; means the following countries: [ * ]. &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Major Market Country</font><font style="font-weight:normal;">&#8221; means any one of these countries.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.41&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Net Sales</font><font style="font-weight:normal;">&#8221; means, with respect to any Licensed Product, the gross amount invoiced in arm&#8217;s-length transactions by a Party, an Affiliate of such Party, or any permitted Sublicensee (or such Sublicensee&#8217;s Affiliates) (all of the foregoing persons and entities, for purposes of this definition and Sections 8.4, 8.6, and 8.7), shall be considered a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Related Party</font><font style="font-weight:normal;">&#8221;) for sales of such Licensed Product to a Third Party, less the sum of the following (to the extent not reimbursed by any Third Party):</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;<font style="font-weight:normal;">discounts (including cash discounts and quantity discounts), cash and&#160;non-cash&#160;coupons, retroactive price reductions,&#160;charge-back&#160;payments and rebates granted to managed care organizations or to federal, state and local governments, their agencies, and purchasers and reimbursers or to customers;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<font style="font-weight:normal;">credits or allowances actually granted upon claims, damaged goods, rejections or returns (including inventory management fees) of such Licensed Product, including Licensed Product returned in connection with recalls or withdrawals;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;<font style="font-weight:normal;">amounts written off by reason of uncollectible debts;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;<font style="font-weight:normal;">freight, postage, shipping, transportation and insurance charges for the delivery of the Licensed Product; and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;<font style="font-weight:normal;">taxes or duties levied on, absorbed or otherwise imposed on sale of the Licensed Product, including&#160;value-added&#160;taxes, healthcare taxes or other governmental charges otherwise imposed upon the billed amount (to the extent not paid by the Third Party), as adjusted for rebates and refunds, in each case as accounted for by the party recording such Net Sales.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No deduction shall be made for any item of cost incurred by any Related Party in Developing or Commercializing Licensed Products except as permitted pursuant to clauses (a)&#160;to (d)&#160;of the foregoing sentence; provided that, Licensed Products transferred to Third Parties in connection with clinical and non-clinical research and trials, Licensed Product samples, compassionate sales or use, or an indigent </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 6</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">program or for similar bona fide business purposes in accordance with applicable local laws and regulations in which a Related Party agrees to forego a normal profit margin for good faith business shall give rise to Net Sales only to the extent that any Related Party invoices or receives amounts therefor exceeding the cost of goods.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such amounts shall be determined consistent with a Related Party&#8217;s customary practices and in accordance with GAAP.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is understood that any accruals for individual items reflected in Net Sales are periodically [ * ] trued up and adjusted by each Related Party consistent with its customary practices and in accordance with GAAP.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sale or transfer of Licensed Products between any of the Related Parties shall not result in any Net Sales, with Net Sales to be based only on any subsequent sales or dispositions to a non-Related Party. To the extent that any Related Party receives consideration other than or in addition to cash upon the sale or disposition of a Licensed Product to a non-Related Party, Net Sales shall be calculated based on the average price charged for such Licensed Product, as</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable, during the preceding royalty period, or in the absence of such sales, based on the fair market value of the Licensed Products, as determined by the Parties in good faith. For clarity, (i)&#160;Net Sales shall not include amounts [ * ] in consideration of [ * ], provided that such consideration [ * ], (ii)&#160;sales to [ * ], or [ * ] shall be considered sales to [ * ], (iii)&#160;Net Sales by a Related Party to a non-Related Party consignee are not recognized as Net Sales by such Related Party until the non-Related Party consignee sells the Licensed Product and (iv)&#160;[ * ].</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the case of any Combination Product sold in the Territory, Net Sales for such Combination Product shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B) where A is the invoice price of the Licensed Product that contains only Licensed Compound as its active ingredient if sold separately, and B is the total invoice price of the other active ingredient or ingredients in the Combination Product, if sold separately. If, on a country-by-country basis, the other active ingredient or ingredients in the Combination Product are not sold separately in said country, Net Sales for the purpose of determining royalties of the Combination Product shall be calculated by multiplying actual Net Sales of the Combination Product by the fraction C/D, where C is the invoice price of the Licensed Product that contains only Licensed Compound as its active ingredient if sold separately, and D is the invoice price of the Combination Product. If neither the Licensed Product that contains only Licensed Compound as its active ingredient nor the other active ingredient(s) are sold separately in a given country, the Parties shall determine Net Sales in accordance with the formulas provided above in this paragraph based on [ * ], or, if neither the Licensed Product that contains only Licensed Compound as its active ingredient nor the other active ingredient(s) are sold in any other countries, the Parties shall negotiate in good faith a reasonable adjustment to Net Sales in such country [ * ]. Notwithstanding the foregoing, for purposes of determining royalties and milestones on Net Sales under this Agreement, the portion of Net Sales of the Combination Product allocated to the Licensed Product shall [ * ].</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should Eiger, its Affiliates or Sublicensees enter into a Third Party agreement for the purchase of a Licensed Product that provides discounts or rebates on such Licensed Product that are conditioned on pricing terms or conditions for purchase of another product or products owned or Controlled by Eiger, its Affiliates or Sublicensees, as the case may be, then the discount or rebate on such Licensed Product under such agreement shall be determined, for purposes of determining Net Sales under this Agreement for a given accounting period, based on [ * ].</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 7</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.42&#160;</font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Patent Rights</font><font style="font-weight:normal;">&#8221; means (a)&#160;patents and patent applications, (b)&#160;all divisionals, continuations, continuations-in-part thereof or any other patent application claiming priority directly or indirectly to (i)&#160;any of the patents or patent applications in subsection (a), or (ii)&#160;any patent or patent application from which the patents or patent applications in (a)&#160;claim direct or indirect priority, (c)&#160;all patents issuing on any of the foregoing in (a)-(b), (d)&#160;all foreign counterparts of any of the foregoing in (a)-(c), including PCT Applications, and (e)&#160;all registrations, reissues, re-examinations, supplemental protection certificates, or extensions of any of the foregoing in (a)-(d).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.43&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Person</font><font style="font-weight:normal;">&#8221; means any individual, firm, corporation, partnership, limited liability Eiger, trust, business trust, joint venture, governmental authority, association or other entity.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.44&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Phase II Clinical Trial</font><font style="font-weight:normal;">&#8221; means a Clinical Trial of a Licensed Product on a sufficient number of subjects that is designed to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, as described in 21 C.F.R. 312.21(b), or a similar clinical study prescribed by a Regulatory Authority outside the U.S.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.45&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Phase IIa Clinical Trial</font><font style="font-weight:normal;">&#8221; means a Phase II clinical trial of a compound or product, the principal purpose of which is a preliminary determination of safety and pharmacodynamic effect or efficacy in the target population over a range of doses.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.46&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Phase IIb Clinical Trial</font><font style="font-weight:normal;">&#8221; means a Phase II clinical trial of a compound or product, the principal purpose of which is a further determination of efficacy and safety, in the target population, at the intended clinical dose or doses or range of doses, on a sufficient number of subjects and for a sufficient period of time to confirm the optimal manner of use of such compound or product (dose and dose regimen) prior to initiation of the Phase III Clinical Trials.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.47&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Phase III Clinical Trial</font><font style="font-weight:normal;">&#8221; means a Clinical Trial of a Licensed Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range and dose duration to be prescribed, which trial is intended to support Approval of a Licensed Product, as described in 21 C.F.R. 312.21(c), or a similar clinical study prescribed by a Regulatory Authority outside the U.S.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.48&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">PMDA</font><font style="font-weight:normal;">&#8221; means the Japanese Pharmaceutical and Medical Device Agency or its successor, or Ministry of Health, Labour and Welfare.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.49&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">PMDA Filing</font><font style="font-weight:normal;">&#8221; means the acceptance by the PMDA of the filing of an MAA for the applicable Licensed Product in Japan.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.50&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Regulatory Authority</font><font style="font-weight:normal;">&#8221; means any national or supranational governmental authority, including the FDA, PMDA or EMA, that has responsibility in countries in the Territory over the Development and/or Commercialization of the Licensed Compounds and/or Licensed Products.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.51&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sublicense Revenues</font><font style="font-weight:normal;">&#8221; means all consideration Eiger receives from a Sublicensee pursuant to any Sublicense or from a Third Party assignee pursuant to an assignment of this Agreement that is not a permitted assignment pursuant to Section&#160;15.4.2, including any upfront payment, milestone payments and royalty payments (excluding that portion of any milestone or royalty payment amounts received from a Sublicensee or assignee that are paid by Eiger as milestone and royalty payments to BMS under Article 8 hereof); collaboration fee; and premiums on equity investments in Eiger in connection with the grant of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 8</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">the Sublicense (with the premium to be reasonably allocated to the value of this Agreement as compared to Eiger&#8217;s other assets) [ * ]; and in any event excluding, for clarity, any amounts received by Eiger: (a)&#160;as bona</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 9</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fide, fair market value, actual reimbursement for research, Development or Commercialization activities performed or paid for by Eiger after the grant of a Sublicense, and only to the extent they are documented and are reasonably detailed [ * ]; (b)&#160;for reimbursement of Eiger&#8217;s fully-burdened cost to manufacture and supply Licensed Products or Licensed Compounds; or (c)&#160;in the form of bona fide loans made by Sublicensee or assignee to Eiger. For clarity, Sublicense Revenues from milestones and royalties include the amounts received by Eiger in excess of the amounts paid to BMS under Article 8 for substantially the same milestone or royalties. By way of illustration, and not limitation, if Eiger receives a [ * ] milestone payment from a Sublicensee in the amount of [ * ], then (assuming Eiger pays the [ * ] milestone due to BMS [ * ]) the Sublicense Revenue amount shall be [ * ] with respect to such payment. For further clarity, a Change of Control of Eiger shall not be deemed a Sublicense. &#8220;Change of Control&#8221; shall mean any transaction of series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%)&#160;of the outstanding stock of Eiger in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.52&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sublicense</font><font style="font-weight:normal;">&#8221; means a grant of rights by Eiger to a Sublicensee under any of the rights licensed to Eiger by BMS under Section&#160;2.1 with respect to the Development, manufacture, or Commercialization of any Licensed Product or Licensed Compound, and includes any reverse co-promotion agreements.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.53&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sublicense Agreement</font><font style="font-weight:normal;">&#8221; means a written, definitive agreement for a Sublicense.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.54&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sublicensee</font><font style="font-weight:normal;">&#8221; means any Third Party to whom rights are granted under any of the rights licensed to Eiger by BMS under Section&#160;2.1 with respect to any Licensed Product or Licensed Compound, including through any license, sublicense, co-development,&#160;co-discovery,&#160;co-promotion, distribution, joint venture, Development and Commercialization collaboration or similar transaction between Eiger (or an Affiliate of Eiger) and a Third Party. For clarity, a Distributor or an Eiger contractor permitted pursuant to Section&#160;3.7 is not considered a Sublicensee.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.55&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Territory</font><font style="font-weight:normal;">&#8221; means worldwide.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.56&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Third Party</font><font style="font-weight:normal;">&#8221; means any Person other than Eiger and BMS, and any Affiliates of Eiger and BMS.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.57&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">United States</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">U.S.</font><font style="font-weight:normal;">&#8221; means the United States of America including Puerto Rico and any U.S. territories and possessions.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.58&#160;<font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Valid Claim</font><font style="font-weight:normal;">&#8221; means a claim of (i)&#160;an issued and unexpired patent, which claim has not been held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid or unenforceable through&#160;re-examination&#160;or disclaimer, opposition procedure, nullity suit or otherwise, or (ii)&#160;a pending patent application that has not been finally abandoned, finally rejected or expired;&#160;</font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that if a claim of a pending patent application shall not</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 10</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have issued within [ * ] after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and until a patent issues with such claim.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Additional Definitions</font><font style="font-weight:normal;">. In addition to those terms defined above, definitions for each of the following terms are found in the body of this Agreement as indicated below:</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;white-space:nowrap;">
<p style="border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Defined Term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">BMS</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">BMS Reversion Products</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4.1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Business Combination</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2.4</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">CDA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.17</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">CTA</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.30</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">CTX</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.30</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Eiger</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Effective Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Force Majeure</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Indemnification Claim</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Indemnitee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Indemnitor</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Indication</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2.1(v)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Inventory Disposal Period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4.5</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Joint Invention</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Joint Patent Rights</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Know-How Transfer Period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Liability Cap</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Losses and Claims</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">&#8220;Party&#8221; or &#8220;Parties&#8221;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preamble</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">PCT Application</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Pharmacovigilance Agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Related Party</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.41</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Royalty Term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4.2</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Skipped Milestone</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2.1(iii)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2.1(i)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Surviving Sublicensee</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.1(g)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">TA Period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Third Party Compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4.4</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Title 11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.10</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Transferred Materials</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:11pt;text-transform:none;font-variant: normal;">Triggering Event</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6.2</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 11</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">LICENSE GRANT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.1&#160;<font style="text-decoration:underline;font-weight:normal;">BMS Patent Rights and BMS Know-How</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.1.1&#160;<font style="font-weight:normal;">Subject to all the terms and conditions set forth in this Agreement, BMS hereby grants to Eiger a&#160;non-transferable&#160;(except in accordance with Section&#160;15.4), exclusive license, with the right to sublicense in accordance with Section&#160;2.2, under the BMS Patent Rights and BMS&#160;Know-How&#160;solely to the extent necessary to research, discover, Develop, make, have made, use, sell, offer to sell, export and import Licensed Compounds and/or Licensed Products in the Field in the Territory. For clarification, nothing in this Section&#160;2.1 or this Agreement shall be interpreted as a grant of rights to make, have made, sell, use, co-formulate or use in combination a Licensed Compound with any molecule that is not a Licensed Compound and is proprietary to BMS or its Affiliate or would require a license from BMS with respect to the composition, method of use or manufacture of such other molecule (unless separately licensed from BMS or its Affiliates with BMS and its Affiliates being under no obligation, express or implied, to do so).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.1.2&#160;<font style="font-weight:normal;">Subject to all the terms and conditions set forth in this Agreement, BMS hereby grants to Eiger a&#160;non-transferable&#160;(except in accordance with Section&#160;15.4), non-exclusive license, without the right to sublicense except to Eiger Affiliates and non-profit institutions solely for the purpose identified in Section&#160;5.7), under patent rights and know-how Controlled by BMS or its Affiliates covering the manufacture, composition of matter or method of use of the reagents and research tools set forth on Appendix 10 hereto, solely to the extent necessary to research, discover, Develop, make, have made, use, sell, offer to sell, export and import Licensed Compounds and/or Licensed Products in the Field in the Territory.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.2&#160;<font style="text-decoration:underline;font-weight:normal;">Sublicenses</font><font style="font-weight:normal;">. Eiger shall have the right to grant Sublicenses with respect to the rights licensed to Eiger under Section&#160;2.1: [ * ],&#160;</font><font style="font-style:italic;font-weight:normal;">provided</font><font style="font-weight:normal;">&#160;that, in each case (x)&#160;and (y), such Sublicenses are granted solely in accordance with this Section&#160;2.2:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.2.1&#160;<font style="font-weight:normal;">Eiger shall have the right to enter into a Sublicense Agreement [ * ], provided that:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;<font style="font-weight:normal;">such Sublicense Agreement shall refer to this Agreement and shall be subordinate to and consistent with the terms and conditions of this Agreement, and, shall not limit Eiger&#8217;s ability to fully perform all of its obligations under this Agreement (except to the extent assumed by Sublicensee but as to which Eiger remains responsible to BMS for the performance thereof by the Sublicensee) or BMS&#8217; rights under this Agreement;</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 12</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<font style="font-weight:normal;">in such Sublicense Agreement, the Sublicensee shall agree in writing to fully perform the terms and conditions of this Agreement applicable to the Sublicensee;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;<font style="font-weight:normal;">promptly after the execution of such Sublicense Agreement, Eiger shall provide a copy of such Sublicense Agreement to BMS, which copy may be redacted to remove confidential terms that are not necessary for BMS to confirm the Sublicense Agreement&#8217;s compliance with, or calculations of Sublicense Revenues under, the terms and conditions of this Agreement;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;<font style="font-weight:normal;">Eiger shall remain primarily responsible and liable for performance of all of its obligations under this Agreement (even where sublicensed or assumed by a Sublicensee) and for compliance by its Sublicensees with applicable terms of this Agreement, including all payments due (including, without limitation, its payment obligations under Sections 11.1 and Articles 8 and 10 hereof) and the making of reports under this Agreement on account of its Sublicensees&#8217; activities under the Sublicense Agreement, and shall use Commercially Reasonable Efforts to monitor such Sublicensee&#8217;s compliance with and to enforce the terms of such Sublicense Agreement;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;<font style="font-weight:normal;">the Sublicensee shall assume and agree in writing to be bound by and comply with the applicable terms and conditions of this Agreement in the same manner as Eiger, including, without limiting the generality of the foregoing, the Sublicensee shall [ * ];</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(f)&#160;<font style="font-weight:normal;">such Sublicensees shall [ * ], except with prior written consent of Eiger and BMS in each of their sole discretion and in any event in accordance with and subject to all of the terms and conditions of this Section&#160;2.2 and all of the other terms and conditions of this Agreement;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(g)&#160;<font style="font-weight:normal;">any Sublicense rights granted by Eiger in a Sublicense Agreement (to the extent such Sublicense rights are granted to Eiger in this Agreement) shall terminate effective upon the termination under Article 13 of the license from BMS to Eiger with respect to such sublicensed rights, provided that such Sublicense rights shall not terminate if, as of the effective date of such termination under Article 13, the Sublicensee is not in material breach of its obligations to Eiger under its Sublicense Agreement, the Sublicensee was previously granted an exclusive Sublicense to Develop and Commercialize the Licensed Products or Licensed Compounds, and, within sixty (60)&#160;days of such termination, the Sublicensee agrees in writing to be bound directly to BMS under a license agreement substantially similar to this Agreement with respect to the rights and obligations Sublicensed by Eiger to the Sublicensee under the Sublicense Agreement, substituting such Sublicensee (a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Surviving Sublicensee</font><font style="font-weight:normal;">&#8221;) for Eiger, and provided further that (A)&#160;such license agreement shall [ * ]; (B)&#160;the scope of the rights granted to and obligations assumed by the Surviving Sublicensee under such license agreement (with respect to licensed activities, Licensed Products and territory) shall [ * ]; (C)&#160;Eiger shall no longer be obligated under this Agreement to pay amounts set forth in this Agreement, to the</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extent such amounts are payable based on the activities of such Surviving Sublicensee, its Affiliates and its sublicensees from and after the effective date of such termination; (D)&#160;such license agreement shall obligate the Surviving Sublicensee to [ * ] from and after the effective date of such termination, [ * ]; (E)&#160;the Sublicensee [ * ] as of the effective date of termination; and (F)&#160;except as expressly set forth in the license agreement or agreed by Eiger, such license agreement shall not [ * ];</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(h)&#160;<font style="font-weight:normal;">the provisions of this Section&#160;2.2 shall also apply in the event of any subsequent amendment or modification of any such Sublicense Agreement; and</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 13</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i)&#160;</font><font style="font-weight:normal;">BMS shall be made an express third party beneficiary of the Sublicensee&#8217;s obligations under such Sublicense that relate to compliance with the applicable terms and conditions of this Agreement with the express right to enforce same directly against the Sublicensee or against Eiger as BMS may elect .</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.2.2&#160;<font style="font-weight:normal;">For clarity, where provisions of this Agreement provide that Eiger shall be &#8220;solely&#8221; responsible or the like with respect to a matter (for example, Sections 5.4, 5.5, or 7.1), it is understood that such responsibilities may be carried out or borne on Eiger&#8217;s behalf by an Affiliate of Eiger or by a permitted Sublicensee or contractor of Eiger.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.2.3&#160;<font style="font-weight:normal;">It shall be a material breach of this Agreement for Eiger to enter into any Sublicense hereunder not in compliance with this Section&#160;2.2 without the prior written consent of BMS.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.3&#160;<font style="text-decoration:underline;font-weight:normal;">No Trademark License</font><font style="font-weight:normal;">. No right or license, express or implied, is granted to Eiger to use any trademark, trade name, trade dress, domain name, logos, slogans, or service mark owned or Controlled by BMS or any of its Affiliates. Eiger, at its sole cost and expense, shall be responsible for the selection, registration and maintenance of all trademarks which it employs in connection with Licensed Products and its activities conducted pursuant to this Agreement, if any, and shall own and Control such trademarks.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.4&#160;<font style="text-decoration:underline;font-weight:normal;">No Implied Licenses</font><font style="font-weight:normal;">. No license or other right is or shall be created or granted hereunder by implication, estoppel or otherwise. All such licenses and rights are or shall be granted only as expressly provided in this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.5&#160;<font style="text-decoration:underline;font-weight:normal;">Retained Rights</font><font style="font-weight:normal;">. All rights not expressly granted by a Party hereunder are reserved by such Party and may be used by such Party for any purpose. Without limiting the foregoing, [ * ]. Nothing in this Agreement shall prevent (i)&#160;Eiger and its Affiliates from using for any purpose any BMS Know-How that is in the public domain as of the Effective Date (or enters the public domain thereafter) and is not covered by a Valid Claim of a BMS patent right or (ii)&#160;BMS and its Affiliates from using for any purpose any BMS Know-How that is in the public domain as of the Effective Date (or enters the public domain thereafter) and, subject to terms of this Agreement, is not covered by a Valid Claim of a BMS Patent Right.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 14</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 3</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSFER OF KNOW-HOW, IND AND PGX DATABASE; TECHNICAL ASSISTANCE</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.1&#160;<font style="text-decoration:underline;font-weight:normal;">Documentation</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.1.1&#160;<font style="font-weight:normal;">BMS shall provide Eiger with electronic (or tangible embodiments, if electronic is not available) of the Know-How listed on&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 6</font><font style="font-weight:normal;">&#160;within the period of time following the Effective Date and in the format set forth on&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 6</font><font style="font-weight:normal;">, including copies of originals of laboratory notebooks or pages thereof and, where required by Eiger to fulfill its duties under applicable Law, copies of manufacturing run and batch records required to be maintained by BMS under applicable Law;&#160;</font><font style="font-style:italic;font-weight:normal;">provided&#160;</font><font style="font-weight:normal;">that, with respect to BMS Know-How contained in laboratory notebooks, BMS shall only be required to provide Eiger with copies of those laboratory notebook pages (electronic copies, if they exist) [ * ] that contain BMS Know-How relating to Licensed Compounds. Such documentation is Confidential Information of BMS licensed in accordance with this Agreement and shall not be used by Eiger for any purpose other than for the discovery, research, manufacture, Development or Commercialization (including any import, manufacture, use, offer for sale, or sale) of Licensed Compounds and/or Licensed Products in accordance with this Agreement. BMS shall be responsible for providing one (1)&#160;set of copies (electronic, where they exist) only and Eiger shall [ * ]. BMS shall have no obligation to reformat or otherwise alter or modify any materials, or to create materials in electronic form, in order to provide them to Eiger. Any and all materials and other BMS Know-How delivered to Eiger pursuant to this Section&#160;3.1 are and shall remain the sole property of BMS.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Without limiting the foregoing, if, within [ * ] after the Effective Date, if Eiger reasonably determines that there is additional, specific BMS Know-How Controlled by BMS and its Affiliates that existed as of the Effective Date that is reasonably necessary for the continued Development or manufacture (but only those manufacturing and formulation processes, techniques and trade secrets used by BMS for making such Licensed Compounds as of the Effective Date) of any Licensed Compound or Licensed Product that has not been provided during the Know-How Transfer Period, then Eiger may request within such [ * ] that BMS transfer to Eiger such additional BMS Know-How and BMS will endeavor to locate and provide same, provided that BMS shall not be required to conduct an unreasonable search for any such additional BMS Know-How. BMS shall have no obligation to reformat or otherwise alter or modify any materials, or to create materials in electronic form, in order to provide them to Eiger.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.1.2&#160;<font style="font-weight:normal;">Notwithstanding Sections 3.1.1 or 3.2, nothing herein shall require BMS to transfer, disclose or provide to Eiger (i)&#160;any reagents, assays or other tangible biological or chemical materials that are not listed on&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 4</font><font style="font-weight:normal;">&#160;and, (ii)&#160;any general information or know-how that should reasonably be known to a pharmaceutical company engaged in the research, development, manufacture or commercialization of interferon therapeutic agents to treat Hepatitis B or Hepatitis C.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.1.3&#160;<font style="font-weight:normal;">Any data or information included in the INDs to be transferred under Section&#160;3.3 does not need to be separately transferred pursuant to Section&#160;3.1.1 or Section&#160;3.2.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 15</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.2&#160;</font><font style="text-decoration:underline;font-weight:normal;">Technical Assistance</font><font style="font-weight:normal;">. During the [ * ] period following the Effective Date (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">TA Period</font><font style="font-weight:normal;">&#8221;), BMS shall reasonably cooperate with Eiger to provide transition and technical assistance to Eiger in order to understand and use the BMS&#160;Know-How&#160;provided to Eiger under Section&#160;3.1 (for clarity, this support does not include integration of the data/information into Eiger systems/repositories). Such cooperation shall include providing Eiger with reasonable access by teleconference or&#160;in-person&#160;at BMS&#8217; facilities (subject to BMS&#8217; customary rules and restrictions with respect to site visits by non-BMS personnel) to BMS personnel who are appropriately qualified and experienced for such purpose, directly involved in the research and Development or manufacture of Licensed Compounds and Licensed Products. In no event shall BMS be obligated to provide Eiger with more than [ * ] FTE hours of technical assistance and consultation in connection with the BMS Know-How transferred under Section&#160;3.1 to the extent the Know-How does not relate to manufacturing Know-How, and (y)&#160;[ * ] FTE hours technical assistance and consultation in connection with the BMS Know-How transferred under Section&#160;3.1 to the extent it relates to manufacturing (including CMC) Know-How. [ * ]. If Eiger believes it needs additional assistance, it will discuss same with BMS, and, at BMS&#8217; sole discretion, BMS may provide additional assistance requested by Eiger, and [ * ]. Further: (i)&#160;such access shall be requested and coordinated through a single contact person to be designated by BMS, (ii)&#160;BMS makes no warranty, express or implied, that Eiger shall be able to successfully implement and use the BMS Know-How, and (iii)&#160;BMS shall not be in default hereunder for any inadvertent failure to disclose all pertinent information related to the BMS Know-How, provided that such information shall be supplied to Eiger promptly upon discovery of such failure to disclose or upon request of Eiger identifying with reasonable specificity the nature of the information to be disclosed. Eiger shall be responsible for ensuring that its personnel who receive such assistance are appropriately qualified and experienced for such purpose.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.3&#160;<font style="text-decoration:underline;font-weight:normal;">IND</font><font style="font-weight:normal;">. BMS will assign and transfer within [ * ] after the Effective Date all of its rights, title and interests in and to the active IND [ * ] (but, for clarity, not any CTAs, CTXs or investigational medicinal product dossiers nor any inactive IND) for the Licensed Compounds. Eiger will cooperate in connection therewith and shall perform all duties under such IND from and after such assignment. Subject to the foregoing, the Parties will reasonably cooperate to ensure an orderly transition of duties under such IND and to fulfill applicable filing obligations with regulatory authorities. BMS will continue to conduct and close out any existing CTAs and CTXs in the ordinary course following the Effective Date.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.4&#160;<font style="text-decoration:underline;font-weight:normal;">Safety Database</font><font style="font-weight:normal;">. BMS shall transfer to Eiger the safety database for the Licensed Compounds, in the form in which it is held by BMS, as soon as practicable and in any event within [ * ] after the Effective Date, and Eiger shall perform all responsibilities thereafter with respect to reporting of adverse events relating to the Licensed Compounds.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.5&#160;<font style="text-decoration:underline;font-weight:normal;">[ * ]</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.6&#160;<font style="text-decoration:underline;font-weight:normal;">Third Party Agreements</font><font style="font-weight:normal;">. BMS shall use Commercially Reasonable Efforts to promptly assign to Eiger any unexpired Third Party agreements solely and exclusively related to the research and non-clinical Development of the Licensed Compound (and not related as well to any other proprietary molecules of BMS that are not interferons) set forth on&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 11</font><font style="font-weight:normal;">&#160;and is assignable to Eiger without consent of such Third Party, provided, however, that if such Third Party agreement is not assignable to Eiger without the written consent of such Third Party, BMS shall use Commercially Reasonable Efforts to obtain a consent to such assignment (but which shall not, for clarity, require BMS to pay any termination fee or additional consideration to the other party to such agreement).</font></p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 16</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.7&#160;</font><font style="text-decoration:underline;font-weight:normal;">Eiger Contractors</font><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-weight:normal;">&#160;For clarity, references to Eiger in Article 3 (except&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section&#160;3.8</font><font style="font-weight:normal;">) and Article 4 shall include Third Party contractors engaged by Eiger to perform services for the benefit of Eiger (i.e., Third Parties who receive limited rights to perform services similar to other parties on a basis and on terms customarily understood for a vendor, such as a contract manufacturing organization) who have entered into appropriate agreements protecting the confidentiality and proprietary nature of the BMS Know-How, Licensed Compounds, technical data and information and other Transferred Materials (as defined below) in accordance with this Agreement, provided, that Eiger shall remain responsible and liable for the compliance by such individuals with the terms of this Agreement and shall use Commercially Reasonable Efforts to require such Third Parties to assign to Eiger any inventions and know-how relating to the License Compounds and Licensed Products that may be made or generated by them in the course of their services for Eiger.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.8&#160;<font style="text-decoration:underline;font-weight:normal;">USAN</font><font style="font-weight:normal;">. Within [ * ] after the Effective Date, BMS and Eiger shall take all reasonably necessary actions (including the filing of any necessary forms) for the United States Adopted Names Council to remove BMS and include Eiger as the manufacturer of the Licensed Compounds and Licensed Products. Eiger shall be solely responsible for the payment all related fees.</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 4</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSFER OF MATERIALS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">4.1&#160;<font style="text-decoration:underline;font-weight:normal;">Materials</font><font style="font-weight:normal;">. BMS shall initiate the transfer to Eiger (i)&#160;within the time period after the Effective Date specified in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 4</font><font style="font-weight:normal;">, those Licensed Compounds identified in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 4</font><font style="font-weight:normal;">, ex-works (EXW) BMS designated site in the United States and/or Belgium, in the quantities set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 4,</font><font style="font-weight:normal;">&#160;and (ii)&#160;within [ * ] after the Effective Date, those reagents and research tools set forth on&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 10</font><font style="font-weight:normal;">&#160;(any such materials that are actually transferred, the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Transferred Materials</font><font style="font-weight:normal;">&#8221;). The Transferred Materials shall be transferred to Eiger at the location(s) designated by Eiger within [ * ] after the Effective Date. Title and risk of loss shall be transferred to and borne by Eiger upon delivery of the Transferred Materials by BMS to a common carrier for shipment to Eiger, and Eiger shall be responsible for any indirect taxes levied upon the transfer, including customs duties and import VAT if applicable. [ * ]. Other than the Transferred Materials, unless included within the scope of BMS Know-How and identified on&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 4</font><font style="font-weight:normal;">&#160;or&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 10</font><font style="font-weight:normal;">&#160;and subject to Section&#160;3.2, BMS shall have no obligation to provide Eiger with any compounds or other materials, such as assays or biomaterials, under this Agreement. To the</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 17</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extent set forth in&#160;<font style="text-decoration:underline;">Appendix 4</font>, BMS represents and warrants that the Transferred Materials are manufactured in accordance with cGMP and any manufacturing specifications included within the IND relating to such Transferred Materials. Except as expressly set forth above, the Transferred Materials are provided&#160;<font style="font-weight:bold;">&#8220;AS IS&#8221; and BMS makes no representations or warranties, express or implied, as to the Transferred Materials, including any warranty as to merchantability or fitness for a particular use or purpose.</font>&#160;If requalification of any Licensed Compound included within the Transferred Material is required, it will be the responsibility of Eiger to perform such requalification at its expense and BMS will not be responsible for such requalification. Eiger agrees that: (a)&#160;Eiger shall be fully responsible for its and its Affiliates&#8217;, Sublicensees&#8217; and contractors&#8217; use, storage, handling and disposition of the Transferred Materials, (b)&#160;under no circumstances shall BMS be liable or responsible for Eiger&#8217;s or its Affiliates&#8217;, Sublicensees&#8217; and contractors&#8217; use, storage, handling or disposition of the Transferred Materials (except for BMS&#8217; breach of the warranty set forth above), and (c)&#160;Eiger assumes sole responsibility for any claims, liabilities, damages and losses that might arise as a result of Eiger&#8217;s and its Affiliates&#8217;, Sublicensees&#8217; and contractors&#8217; use, storage, handling or disposition of any Transferred Material (except to the extent resulting from BMS&#8217; breach of the warranty set forth above). Eiger shall indemnify, defend and hold harmless BMS and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives, from and against any and all third party damages, liabilities, losses, costs and expenses (including reasonable legal expenses, costs of litigation and reasonable attorney&#8217;s fees) arising in connection with any claims, suits, proceedings, whether for money damages or equitable relief, of any kind, arising out of or relating to Eiger&#8217;s, or any of its Affiliates&#8217;, Sublicensees&#8217; or contractors&#8217; use, storage, handling or disposition of any Transferred Material (except for BMS&#8217; breach of the warranty set forth above). Transferred Materials may only be provided by Eiger to Affiliates of Eiger, Sublicensees and contractors of Eiger.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 5</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">DEVELOPMENT</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.1&#160;<font style="text-decoration:underline;font-weight:normal;">Development</font><font style="font-weight:normal;">. Eiger shall itself or through its Affiliates or Sublicensees use Commercially Reasonable Efforts to Develop Licensed Products for Approval in the Major Market Countries, including by (i)&#160;setting forth in the Development Plan a program of Development activities and reasonable estimated timelines therefor for each phase of pre-clinical and clinical Development for Licensed Compounds and Licensed Products (it being understood that such Development Plan may be revised as a result of input from Regulatory Authorities and data generated by Eiger as it Develops Licensed Products), and (ii)&#160;assigning appropriately qualified and experienced personnel to perform and monitor the progress of, or overseeing Third Parties who perform, such Development activities on an on-going basis. The initial Development Plan as of the Effective Date is attached hereto as&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 2</font><font style="font-weight:normal;">. During the Term, Eiger shall promptly provide BMS no later than January&#160;31 of each Calendar Year with a copy of the revised Development Plan (such annual updates to the Development Plan may be provided as part of the Development Report outlined in Section&#160;5.2). Eiger shall notify BMS of any material change (including any material delay in Development or Commercialization of Licensed Product) to the Development Plan last provided to BMS within thirty (30)&#160;days after becoming aware of such material change and the reasons therefor.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 18</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.2&#160;<font style="text-decoration:underline;font-weight:normal;">Development Reports</font><font style="font-weight:normal;">. Eiger shall provide BMS with written Development reports on or before January&#160;31 of each Calendar Year during the term of Development activities summarizing (but without disclosing specific data or results) such activities in sufficient detail to enable BMS to determine Eiger&#8217;s compliance with its diligence obligations in Section&#160;5.1. Such reports shall include without limitation (a)&#160;the research and other Development activities accomplished by Eiger under the existing Development Plan through the end of the immediately preceding Calendar Year with respect to Licensed Compounds and Licensed Products, and (b)&#160;updates on Eiger&#8217;s progress against the existing Development Plan; provided, however, that the first such report shall be due on or before January&#160;31, 2017. If any such Development obligations have been sublicensed to a Sublicensee, Eiger shall require the Sublicensee to provide to BMS the same information as required of Eiger hereunder with respect to the progress of the Development of Licensed Compounds and Licensed Products by such Sublicensee. If requested by BMS, Eiger (and, if applicable, Sublicensee) personnel who prepared the report will meet with BMS (which may be by teleconference) to discuss and answer any reasonable questions or comments that BMS might have on the report and Eiger&#8217;s (and, if applicable, each of its Sublicensee&#8217;s) Development activities.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.3&#160;<font style="text-decoration:underline;font-weight:normal;">Records</font><font style="font-weight:normal;">. Eiger shall maintain complete and accurate records of all work conducted in furtherance of the research, Development and Commercialization of the Licensed Compounds and/or Licensed Products and all results, data and developments made in furtherance thereof to the extent required under applicable Laws. Such records shall properly reflect all work done and results achieved in sufficient detail and in good scientific manner to the extent required under applicable Laws.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.4&#160;<font style="text-decoration:underline;font-weight:normal;">Development Responsibilities and Costs</font><font style="font-weight:normal;">. As between the Parties, Eiger shall have sole responsibility for, and shall bear the cost of conducting, research and Development with respect to the Licensed Compounds and/or Licensed Products. Eiger shall research and Develop the Licensed Compounds and/or Licensed Products in compliance with all applicable Laws, including all legal and regulatory requirements pertaining to the design and conduct of clinical studies.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.5&#160;<font style="text-decoration:underline;font-weight:normal;">Regulatory Responsibilities and Costs</font><font style="font-weight:normal;">. As between the Parties, Eiger shall have sole responsibility for, and shall bear the cost of preparing, all regulatory filings and related submissions with respect to the Licensed Compounds and/or Licensed Products. Except as set forth in Article 13, Eiger shall own all INDs, Approvals and submissions in connection therewith and all Approvals shall be obtained by and in the name of Eiger.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.6&#160;<font style="text-decoration:underline;font-weight:normal;">Competitive Compound</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.6.1&#160;<font style="font-weight:normal;">For [ * ] after the Effective Date, neither Eiger nor its Affiliates (nor any Sublicensee of Eiger or any Affiliate of such Sublicensee) shall itself or through any Third Party, or in collaboration with any Third Party, engage, directly or indirectly in the clinical Development or Commercialization of a Competitive Compound.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 19</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.6.2&#160;<font style="font-weight:normal;">Notwithstanding Section&#160;5.6.1, if Eiger or any of its Affiliates, either through its own development efforts or by acquisition, or obtains ownership of or a license to, or is acquired by or otherwise merges with an entity (or an Affiliate of such entity) that owns or has a license to, a Competitive Compound, in all such cases that would result in a violation of Section&#160;5.6.1 (any such event, a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Triggering Event</font><font style="font-weight:normal;">&#8221;), then Eiger shall promptly notify BMS in writing and elect (as applicable) one of the following actions within [ * ] after such Triggering Event:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;<font style="font-weight:normal;">divest itself of such Competitive Compound and notify BMS in writing of such divestiture, which divestiture may occur by an outright sale to a Third Party of all of Eiger&#8217;s and its Affiliate&#8217;s rights to such Competitive Compound or by an outlicense arrangement under which Eiger has no continuing active involvement in the development or commercialization of such Competitive Compound (for clarity, efforts in connection with (i)&#160;the receipt and audit of payments in respect of the Competitive Compound, (ii)&#160;the maintenance, defense and enforcement of any applicable licensed patents, and (iii)&#160;the receipt of information to ensure compliance with the applicable agreement (including efforts to enforce or terminate same, or seek damages, for breach) shall not constitute continuing active involvement). Eiger shall use Commercially Reasonable Efforts to complete such divestiture within [ * ] after the applicable Triggering Event. If Eiger is unable to complete the divesture within such [ * ] period, Eiger may continue to divest such Competitive Compound thereafter,&#160;</font><font style="font-style:italic;font-weight:normal;">provided,</font><font style="font-weight:normal;">&#160;that Eiger or its Affiliate shall cease the Development and Commercialization of the Competitive Compound prior to the end of such [ * ] period and shall not restart the Development and Commercialization of the Competitive Compound thereafter (and if such Development or Commercialization is restarted, then BMS may immediately terminate this Agreement upon written notice to Eiger). For clarity, Eiger&#8217;s (or its Affiliates&#8217;) Development and Commercialization of the Competitive Compound in the ordinary course during such [ * ] period shall not be deemed a breach of Eiger&#8217;s exclusivity obligations set forth herein; or</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<font style="font-weight:normal;">Eiger shall notify BMS in writing whether Eiger desires to negotiate terms under which the Competitive Compound would be included as a Product within this Agreement. If the Parties can agree and execute a binding agreement, within [ * ] after notice from Eiger electing this option, on the terms (including compensation to BMS) for including the Competitive Compound as a Product within this Agreement and Eiger&#8217;s Commercially Reasonable Efforts obligations under Sections 5.1 and 6.1, then Eiger shall not be deemed in breach of Section&#160;5.6.1; provided, that BMS shall not be under any obligation, express or implied to negotiate or enter into any such agreement. If the Parties are unable to reach written agreement during the applicable time period, then, Eiger may elect to either divest such Competitive Compound under clause (a)&#160;or terminate this Agreement pursuant to Section&#160;13.3.2 hereof.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.7&#160;<font style="text-decoration:underline;font-weight:normal;">Institution Requests</font><font style="font-weight:normal;">. Eiger shall be responsible for receiving, evaluating, responding and, as applicable, fulfilling (at Eiger&#8217;s discretion) requests from scientists at non-profit institutes for [ * ] and related reagents, including [ * ], for non-commercial research purposes.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 20</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 6</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">COMMERCIALIZATION</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.1&#160;<font style="text-decoration:underline;font-weight:normal;">Eiger Obligations</font><font style="font-weight:normal;">. Eiger shall use Commercially Reasonable Efforts to (i)&#160;obtain Approvals in each Major Market Country for at least one Licensed Product, (ii)&#160;effect the First Commercial Sale of each Licensed Product for which such Approvals are obtained into each Major Market Country as soon as reasonably practicable after receipt of such Approvals and (iii)&#160;Commercialize each such Licensed Product in each such Major Market Country following such First Commercial Sale therein with the goal of maximizing the Net Sales of such Licensed Product in such Major Market Country.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.2&#160;<font style="text-decoration:underline;font-weight:normal;">Reports</font><font style="font-weight:normal;">. Following the First Commercial Sale of a Licensed Product in a country in the Territory, Eiger shall provide BMS with a written report within thirty (30)&#160;days of the filing of the Eiger Annual Report with the U.S. Securities and Exchange Commission (or if no such report is filed, then within 30 days after the end of a calendar year), summarizing significant Commercialization activities with respect to Licensed Products during the just ended Calendar Year in countries in which there has been a First Commercial Sale of a Licensed Product, [ * ]. If requested by BMS, Eiger personnel who prepared the report will meet with BMS, which may be by teleconference, to discuss and answer any questions or comments that BMS might have on the report and Eiger&#8217;s Commercialization activities.</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 7</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">MANUFACTURE AND SUPPLY</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">7.1&#160;<font style="text-decoration:underline;font-weight:normal;">Manufacture and Supply</font><font style="font-weight:normal;">. As between the Parties, Eiger shall be solely responsible at its expense for making or having made all of its requirements of the Licensed Compounds and/or Licensed Products needed for Development and Commercialization of same in the Territory, except for Transferred Materials.</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 8</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">FINANCIAL TERMS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In partial consideration of the rights granted by BMS to Eiger pursuant to this Agreement, Eiger shall make the payments provided for in this Article 8.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.1&#160;<font style="text-decoration:underline;font-weight:normal;">Initial Payment</font><font style="font-weight:normal;">. Eiger shall (x)&#160;pay to BMS a nonrefundable, noncreditable payment of Two Million Dollars ($2,000,000) in cash by wire transfer into an account designated in writing by BMS within [ * ] after the Effective Date and (y)&#160;enter into a Stock Purchase Agreement with BMS, issuing common stock to BMS valued at Three Million Dollars ($3,000,000) on the Effective Date, in the form attached as&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 7</font><font style="font-weight:normal;">&#160;concurrently with the execution of this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 21</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.2&#160;<font style="text-decoration:underline;font-weight:normal;">Milestone Payments</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.2.1&#160;<font style="text-decoration:underline;font-weight:normal;">Development Milestones</font><font style="font-weight:normal;">. Eiger shall pay to BMS the following milestone payments set forth in the table below within [ * ] after the first achievement of the specified milestone event by Eiger, its Affiliates, and Sublicensees for the first Licensed Product to achieve such milestone event in any Indication. Eiger shall provide written notice to BMS within [ * ] after the first achievement of the specified milestone event by Eiger, Affiliates, and Sublicensees. Each milestone payment shall not be refundable or returnable in any event.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td rowspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Milestone</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount&#160;of&#160;Milestone</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payment (Dollars)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;* ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;* ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;* ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;* ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;* ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;* ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;* ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Total Development Milestones for First Indication</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;* ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">61&#160;million</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this Section:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:22.23%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i)&#160;<font style="font-weight:normal;">A [ * ] means that [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:22.23%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ii)&#160;<font style="font-weight:normal;">The set of milestone payments in the table above shall be payable by Eiger to BMS once per Indication upon the first achievement of each such milestone event for the first such Licensed Compound (whether the first such Licensed Compound is the lead Licensed Compound or any back-up Licensed Compound) to achieve the milestone event. Milestones payments for additional Indications that achieve the above milestones events for such additional Indication will be at [ * ] of the above milestone payment amounts for the first Indication.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:22.23%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(iii)&#160;<font style="font-weight:normal;">If a particular milestone event is not achieved with respect to an Indication (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Skipped Milestone</font><font style="font-weight:normal;">&#8221;), such Skipped Milestone will be deemed to have been achieved upon the occurrence of the next most successive milestone with respect to such Indication, and payment for such Skipped Milestone then shall be due.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:22.23%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(iv)&#160;<font style="font-weight:normal;">For purposes of this Section&#160;8.2.1, &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indication</font><font style="font-weight:normal;">&#8221; shall mean any separately defined, well-categorized class of human disease, syndrome or medical condition for which a separate marketing authorization application may be filed with a Regulatory Authority.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.2.2&#160;<font style="text-decoration:underline;font-weight:normal;">Sales-Based Milestones</font><font style="font-weight:normal;">. Each of the following milestone payments shall be paid by Eiger to BMS for total annual sales of Licensed Product within [ * ] after the Net Sales of all Licensed Products in a given Calendar Year first reach the threshold amounts set forth in the table below:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 22</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Milestone &#8211;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td rowspan="4" colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount&#160;of&#160;Milestone</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payment (Dollars)</p></td>
<td rowspan="4" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">First Achievement of annual Net Sales</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of all Licensed Products</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in any Calendar Year of:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Total Sales-Based Milestones</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128.0&#160;million</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each milestone payment shall not be refundable or returnable in any event, nor shall it be creditable against royalties or other payments.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.3<font style="font-weight:normal;">&#160;</font><font style="text-decoration:underline;font-weight:normal;">Sublicense Revenue Sharing</font><font style="font-weight:normal;">. In addition to the milestones and royalty payments set forth in Sections 8.2 and 8.4, Eiger shall pay to BMS the following percentage of all Sublicense Revenues Eiger receives in connection with any Sublicense or any assignment of rights to the BMS Patents, the Licensed Compounds and/or Licensed Products, depending on the stage of Development of the most advanced Licensed Compound or Licensed Product that is subject to the applicable Sublicense or such assignment. Eiger shall pay to BMS its share of Sublicense Revenues within [ * ] after receipt of payment by Eiger from the Sublicensee.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">DEVELOPMENT STAGE OF LICENSED</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">COMPOUND&#160;OR&#160;LICENSED&#160;PRODUCT&#160;AS&#160;OF&#160;THE</p>
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">DATE OF THE SUBLICENSE</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 23</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:92%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="font-weight:normal;"><br /></font>PRIOR&#160;TO&#160;[&#160;*&#160;]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="font-weight:normal;"><br /></font>IF&#160;AFTER&#160;(A)&#160;AND<br />PRIOR TO [ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(C)<font style="font-weight:normal;"><br /></font>IF&#160;AFTER&#160;(B)<br />AND&#160;PRIOR&#160;TO&#160;[&#160;*&#160;]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(D)<font style="font-weight:normal;"><br /></font>[&#160;*&#160;]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">PERCENT OF SUBLICENSE REVENUES PAYABLE TO BMS</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[&#160;*&#160;]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[&#160;*&#160;]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[&#160;*&#160;]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[&#160;*&#160;]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.4<font style="font-weight:normal;">&#160;</font><font style="text-decoration:underline;font-weight:normal;">Royalty Payments</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.4.1&#160;<font style="font-weight:normal;">Subject to the terms of this Agreement Eiger shall pay to BMS tiered royalties based on the total annual worldwide Net Sales in the Territory of each Licensed Products (including all indications and formulations for such Licensed Product) by Eiger, its Affiliates and Sublicensees during the applicable Royalty Term for such Licensed Product. The royalty payable with respect to each particular Licensed Product shall be calculated by multiplying the applicable royalty rate below by the portion of total annual worldwide Net Sales in the applicable tier in a Calendar Year of the applicable Licensed Product by Eiger, its Affiliates and Sublicensees, as follows.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Portion of total annual worldwide Net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td rowspan="4" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Royalty&#160;Rate</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales in a Calendar Year for such</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licensed Product that falls within the</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">following tiers</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;*&#160;]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;*&#160;]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;*&#160;]</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&#160;*&#160;]</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.69%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By way of example, in a given Calendar Year, if the total annual worldwide Net Sales for a Licensed Product is [ * ], the following royalty payment would be payable under this Section&#160;8.4 (subject to the reductions set forth below): [ * ]. For clarity, all dosages, dosage forms, SKUs, methods of delivery and presentations of a Licensed Product containing the same Licensed Compound shall be considered as one Licensed Product for purposes of this Section&#160;8.4.1.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 24</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.4.2&#160;<font style="text-decoration:underline;font-weight:normal;">Royalty Term</font><font style="font-weight:normal;">. Royalties shall be payable on a product-by-product and country-by-country basis on Net Sales of Licensed Products from the First Commercial Sale of a particular Licensed Product in a country until the later of (i)&#160;[ * ] after the First Commercial Sale of such Licensed Product in such country, (ii)&#160;the expiration of the last to expire Valid Claim in BMS Patent Right that would be infringed by the manufacture, use, sale, importation or offer for sale in such country of a given Licensed Product (including by reasons of extensions thereof under applicable Laws, including patent term extensions, or supplemental protection certificates or their equivalents in any country), or (iii)&#160;the expiration of any regulatory or marketing exclusivity for such Licensed Product in such country, including but not limited to any pediatric exclusivity and data exclusivity (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Royalty Term</font><font style="font-weight:normal;">&#8221;);&#160;</font><font style="font-style:italic;font-weight:normal;">provided</font><font style="font-weight:normal;">&#160;that, if (ii)&#160;no longer applies, the royalty payable by Eiger to BMS with respect to such Licensed Product shall be determined by a royalty rate equal to [ * ] of the royalty rate set forth in Section&#160;8.4.1.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.4.3&#160;<font style="text-decoration:underline;font-weight:normal;">Royalty Conditions</font><font style="font-weight:normal;">. The royalties under Section&#160;8.4.1 shall be subject to the following conditions:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;<font style="font-weight:normal;">only one royalty shall be due with respect to the same unit of Licensed Product;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<font style="font-weight:normal;">no royalties shall be due upon the sale or other transfer among any Related Party, but in such cases the royalty shall be due and calculated upon the Related Party&#8217;s Net Sales of Licensed Product to the first non-Related Party; and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;<font style="font-weight:normal;">no royalties shall accrue on the disposition of Licensed Product in reasonable quantities by any Related Party as part of an expanded access program or as&#160;</font><font style="font-style:italic;font-weight:normal;">bona fide</font><font style="font-weight:normal;">&#160;samples or as donations to&#160;non-profit&#160;institutions or government agencies for&#160;non-commercial&#160;purposes or for the performance of clinical trials,&#160;</font><font style="font-style:italic;font-weight:normal;">provided</font><font style="font-weight:normal;">, in each case, that such Related Party does not receive any payment for such Licensed Product exceeding the cost of goods.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.4.4&#160;<font style="text-decoration:underline;font-weight:normal;">Royalty Reduction</font><font style="font-weight:normal;">. If (i)&#160;Eiger, in its reasonable judgment, determines that it is required to obtain a license from any Third Party in order to avoid infringement of such Third Party&#8217;s Patent Rights as a result of the Development or Commercialization (but excluding manufacturing) of any Licensed Product, (ii)&#160;such Patent Rights cover or claim the composition or method of use of a Licensed Product, and (iii)&#160;Eiger is required to pay to such Third Party a royalty, milestone payments or other monetary compensation in consideration for the grant or maintenance of such license (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Third Party Compensation</font><font style="font-weight:normal;">&#8221;), then for the period during which Eiger owes royalties to BMS hereunder, the amounts that would otherwise have been payable as royalties to BMS under this Agreement shall be reduced by [ * ] of all Third Party Compensation payable by or on behalf of Eiger to such Third Party. Notwithstanding the foregoing, (x)&#160;in no event shall the royalty reductions described in this Section&#160;8.4.4 act to reduce the royalties payable by Eiger to less than [ * ] of the amounts payable by Eiger for a given Calendar Quarter pursuant to Section&#160;8.4.1, and (y)&#160;if [ * ], then the royalty reduction set forth in this</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 25</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;8.4.4 [ * ]. For further clarity, Eiger may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter, to any subsequent Calendar Quarter(s) in which royalties are due, subject to the same limitations set forth above and provided that if carryover cannot be so applied to future royalties, such carryover amounts shall lapse and shall not be subject any refund or other repayment from BMS.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.4.5&#160;<font style="text-decoration:underline;font-weight:normal;">Forecast.</font><font style="font-weight:normal;">&#160;Eiger shall provide on or before September&#160;30 of each Calendar Year a non-binding good faith forecast of sales, royalties and milestones for the entire current and next Calendar Year.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.4.6&#160;<font style="text-decoration:underline;font-weight:normal;">Effect of Patent Challenge</font><font style="font-weight:normal;">. In the event Eiger (or any of its Affiliates or Sublicensees) challenges or knowingly assists (other than in response to a subpoena or court order), including without limitation by providing information, documents, advice, and/or funding, a challenge to the validity, scope, patentability or enforceability of any of the BMS Patent Rights, and such challenge is unsuccessful either because (i)&#160;Eiger files a suit or initiates another legal proceeding to challenging the validity or enforceability of any such BMS Patent Right and then withdraws or terminates the suit or proceeding, (ii)&#160;any challenged claim that would be infringed but for the license has been upheld, even in amended form, as determined by a court of competent jurisdiction or other legal tribunal, or (iii)&#160;Eiger, in connection with such challenge, fails to produce reasonably credible evidence demonstrating the invalidity or unenforceability of all applicable patent claims in the BMS Patent Rights in such country; then the royalty rates set forth in Section&#160;8.4.1 above shall be increased by [ * ] of the percentages set forth above [ * ], [ * ]; provided however that if such challenge is by a Sublicensee, the foregoing shall not apply if Eiger promptly terminates such Sublicensee&#8217;s Sublicense after become aware of such challenge (which in any event must be prior to any decision rendered with respect to such challenge).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.5&#160;<font style="text-decoration:underline;font-weight:normal;">Manner of Payment</font><font style="font-weight:normal;">. All payments to be made by Eiger under this Agreement shall be made in U.S. Dollars by wire transfer of immediately available funds to such bank account as shall be designated by BMS. Late payments shall bear interest at the rate provided in Section&#160;8.10.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.6&#160;<font style="text-decoration:underline;font-weight:normal;">Sales Reports and Royalty Payments</font><font style="font-weight:normal;">. After the First Commercial Sale of a Licensed Product and during the term of this Agreement, Eiger shall furnish to BMS a written report, within [ * ] after the end of each Calendar Quarter (or portion thereof, if this Agreement terminates during a Calendar Quarter), showing the amount of royalty due for such Calendar Quarter (or portion thereof). Royalty payments for each Calendar Quarter shall be due at the same time as such written report for the Calendar Quarter. With each quarterly payment, Eiger shall deliver to BMS a full and accurate accounting to include at least the following information:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.6.1&#160;<font style="font-weight:normal;">the total gross sales for each Licensed Product (by country) by Eiger and its applicable Related Parties, if any, and the calculation of Net Sales from such gross sales;</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 26</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.6.2&#160;<font style="font-weight:normal;">the deductions by category of permitted deductions set forth in the Net Sales definition;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.6.3&#160;<font style="font-weight:normal;">the total Net Sales for each Licensed Product (by country) by Eiger and its applicable Related Parties, if any, and the calculation of Net Sales from such gross sales;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.6.4&#160;<font style="font-weight:normal;">the calculation of royalties payable in Dollars which shall have accrued hereunder in respect of such Net Sales;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.6.5&#160;<font style="font-weight:normal;">withholding taxes, if any, required by applicable Law to be deducted in respect of such royalties; and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.6.6&#160;<font style="font-weight:normal;">the exchange rates used in determining the amount of Dollars payable hereunder.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If no royalty or payment is due for any royalty period hereunder, Eiger shall so report.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.7&#160;<font style="text-decoration:underline;font-weight:normal;">Sales Record Audit</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.7.1&#160;<font style="font-weight:normal;">Eiger shall keep, and shall cause each of its applicable Related Parties, if any, to keep, complete, true and accurate books of accounts and records in accordance with GAAP, including gross sales in accordance with GAAP and any deductions thereto in accordance with this Agreement&#8217;s Net Sales definition in connection with the calculation of Net Sales, sufficient to determine and establish the amounts payable incurred under this Agreement, and compliance with the other terms and conditions of this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.7.2&#160;<font style="font-weight:normal;">Such books of accounting of Eiger and its Affiliates shall be kept at their principal place of business and, with all necessary supporting data and records, shall during all reasonable times for the [ * ] next following the end of the Calendar Year to which each shall pertain, be open for inspection not more than once per Calendar Year at reasonable times by an independent certified public accountant selected by BMS and as to which Eiger has no reasonable objection, at BMS&#8217; expense, for the purpose of verifying royalty statements and payments for compliance with this Agreement for any period within the preceding [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.7.3&#160;<font style="font-weight:normal;">Eiger shall include in its Sublicense Agreements with any Sublicensees, a right for Eiger to inspect or have such an accountant inspect, not more than once during any Calendar Year, the books of accounting and such supporting data and records of such Sublicensees for the purpose of verifying royalty statements and payments for compliance with this Agreement for any period within the preceding [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.7.4&#160;<font style="font-weight:normal;">Results of any inspection under Section&#160;8.7.2 or 8.7.3 shall be made available to both Eiger and BMS, and shall be deemed Eiger&#8217;s Confidential Information under this Agreement; provided that the independent, certified public accountant shall disclose to BMS only the amounts that the independent auditor believes to be due and</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 27</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payable hereunder to BMS, details concerning any discrepancy from the amount paid (including the reasons therefor) and the amount due, and shall disclose no other information revealed in such audit.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.7.5&#160;<font style="font-weight:normal;">Such accountant must have agreed in writing to maintain all information learned in confidence, except as necessary to disclose to BMS such compliance or noncompliance by Eiger, its Affiliates or Sublicensees (who must agree in the Sublicense Agreement that such audit report may be disclosed to BMS). The results of each inspection, if any, shall be binding on both Parties. BMS shall pay for such inspections, except that in the event there is any upward adjustment in aggregate royalties payable for any Calendar Year shown by such inspection of more than [ * ] of the amount paid, Eiger shall pay for such inspection. Any underpayments shall be paid by Eiger within [ * ] after notification of the results of such inspection. Any overpayments shall be fully creditable against amounts payable in subsequent payment periods.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.8&#160;<font style="text-decoration:underline;font-weight:normal;">Currency Exchange</font><font style="font-weight:normal;">. Eiger&#8217;s then current standard exchange rate methodology will be employed for the translation of foreign currency sales into Dollars, provided such methodology is used by Eiger in the translation of its foreign currency operating results, is consistent with GAAP, and is audited by Eiger&#8217;s independent certified public accountants in connection with the audit of the consolidated financial statements of Eiger, and is used for Eiger&#8217;s external reporting of foreign currency operating results.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.9&#160;<font style="text-decoration:underline;font-weight:normal;">Taxes</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.9.1&#160;<font style="font-weight:normal;">Each Party will pay any and all taxes levied on account of all payments it receives under this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.9.2&#160;<font style="font-weight:normal;">If laws or regulations require that taxes be withheld with respect to any royalty payments by Eiger to BMS under this Agreement, Eiger will: (a)&#160;deduct those taxes from the remittable payment, (b)&#160;pay the taxes to the proper taxing authority, and (c)&#160;send evidence of the obligation together with proof of tax payment to BMS on a reasonable and timely basis following that tax payment. Each Party agrees to cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant agreement or treaty which is in effect. The Parties shall discuss applicable mechanisms for minimizing such taxes to the extent possible in compliance with applicable Laws. BMS will pay any and all taxes levied on account of all payments it receives under this Agreement; provided, that notwithstanding the foregoing, in the event that [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.9.3&#160;<font style="font-weight:normal;">The Parties shall cooperate in accordance with applicable Laws to minimize indirect taxes (such as value added tax, sales tax, consumption tax and other similar taxes) in connection with this Agreement</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">8.10&#160;<font style="text-decoration:underline;font-weight:normal;">Interest Due</font><font style="font-weight:normal;">. Without limiting any other rights or remedies available to BMS, Eiger shall pay BMS interest on any payments that are not paid on or before the date such payments are due under this Agreement at a rate of [ * ] or the maximum applicable legal rate, if less, calculated on the total number of days payment is delinquent.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 28</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 9</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">REPRESENTATIONS AND WARRANTIES; DISCLAIMER;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">LIMITATION OF LIABILITY</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.1&#160;<font style="text-decoration:underline;font-weight:normal;">Mutual Representations and Warranties</font><font style="font-weight:normal;">. Each Party represents and warrants to the other Party that, as of the Effective Date: (i)&#160;it is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to enter into this Agreement and to perform its obligations under this Agreement, (ii)&#160;execution of this Agreement and the performance by such Party of its obligations hereunder have been duly authorized, (iii)&#160;this Agreement has been duly executed and delivered on behalf of such Party, and is legally binding and enforceable on each Party in accordance with its terms, (iv)&#160;the performance of this Agreement by it does not create a breach or default under any other agreement to which it is a Party, (v)&#160;the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Law or regulation of any court, governmental body or administrative or other agency having jurisdiction over such Party, (vi)&#160;no government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Laws currently in effect, is or will be necessary for, or in connection with, the transaction contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such other agreements, and (vii)&#160;neither such Party, nor any of its employees, officers, subcontractors, or consultants who have rendered services relating to the Licensed Compounds: (a)&#160;has ever been debarred or is subject to debarment or convicted of a crime for which an entity or person could be debarred by the FDA under 21 U.S.C. Section&#160;335a or (b)&#160;has ever been under indictment for a crime for which a person or entity could be so debarred.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.2&#160;<font style="text-decoration:underline;font-weight:normal;">Representations, Warranties, and Covenants of BMS</font><font style="font-weight:normal;">. Except as set forth on&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 8</font><font style="font-weight:normal;">:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.2.1&#160;<font style="font-weight:normal;">BMS represents and warrants to Eiger that, as of the Effective Date:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;<font style="font-weight:normal;">there is no pending litigation, or litigation that has been threatened in writing, which alleges, or any written communication alleging, that BMS&#8217; activities with respect to the research, Development or manufacture of the Licensed Compounds prior to the Effective Date have infringed or misappropriated, or would infringe or misappropriate, any of the intellectual property rights of any Third Party, and to BMS&#8217; Knowledge, the research, Development or manufacture of the Licensed Compounds prior to the Effective Date did not infringe or misappropriate any Third Party rights.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<font style="font-weight:normal;">no Third Party has challenged in writing the ownership, scope, duration, validity, enforceability, priority or right to use any BMS Patent Rights (including, by way of example, through the institution of or written threat of institution of interference,&#160;</font><font style="font-style:italic;font-weight:normal;">inter partes</font><font style="font-weight:normal;">&#160;review, reexamination, protest, opposition, nullity or similar invalidity proceeding before the United States Patent and Trademark Office or any foreign patent authority or court) or BMS Know-How,</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 29</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;<font style="font-weight:normal;">there is no actual, pending, or, to BMS&#8217;s Knowledge, alleged or threatened in writing, adverse interferences or governmental investigations or suits involving the Licensed Compounds;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;<font style="font-weight:normal;">no BMS Patents or BMS Know-How has been licensed to BMS from any Third Party that BMS does not Control and which is material to the Development of the Licensed Compound as contemplated by the Development Plan;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;<font style="font-weight:normal;">to BMS&#8217; Knowledge, it has complied with all applicable Laws in the Development of the Licensed Compounds prior to the Effective Date;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(f)&#160;<font style="font-weight:normal;">except for the patent and patent applications that have been abandoned prior to the Effective Date, all fees required to be paid by BMS in any jurisdiction in order to maintain the Patent Rights licensed to Eiger hereunder have, to BMS&#8217; Knowledge, been timely paid as of the Effective Date and, to BMS&#8217; Knowledge, the claims included in any issued patents included in such Patent Rights are in full force and effect as of the Effective Date;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(g)&#160;<font style="font-weight:normal;">BMS has full unencumbered title to the Transferred Material and sufficient right under the BMS Patent Rights and BMS Know-How to grant the licenses to Eiger as purported to be granted hereunder, and has not previously assigned, transferred, conveyed, or granted any license or other rights to its right, title and interest in the BMS Patent Rights or the BMS Know-How, in any way that would materially conflict with or materially limit the scope of any of the rights or licenses granted to Eiger hereunder;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(h)&#160;<font style="font-weight:normal;">BMS solely owns all the rights, title and interest in the BMS Patent Rights and the BMS Patent Rights are free of any lien or security interest;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i)&#160;<font style="font-weight:normal;">except as set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 1</font><font style="font-weight:normal;">, BMS and its Affiliates do not own or control any other Patent Rights that are necessary or, to BMS&#8217;s Knowledge and reasonable belief as of the Effective Date, reasonably useful to carry out the Development (including manufacture) of Licensed Compounds and/or Licensed Products as contemplated by the Development Plan attached as&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 2</font><font style="font-weight:normal;">&#160;hereto; and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(j)&#160;<font style="font-weight:normal;">subject to Section&#160;3.1.2, to BMS&#8217; Knowledge, the documents, data and information that are included in the BMS Know-How transferred to Eiger pursuant to Section&#160;3.1 comprise all of the Know-How Controlled by BMS that is reasonably necessary for the manufacture of BMS molecule known as PEG-interferon Lambda-1a as the same is manufactured as of the Effective Date, and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.2.2&#160;<font style="font-weight:normal;">BMS covenants that it shall not license, sell, assign or otherwise transfer to any person (including any Affiliate of BMS) any BMS Patent Rights or any BMS Know-How, or assign or otherwise transfer any of its rights or obligations thereunder to any person (including any Affiliate of BMS) (or offer or agree to do any of the foregoing) in any manner that would have a material adverse impact on the rights granted to Eiger under this Agreement, except to the extent permitted by, and in compliance with, Section&#160;15.4. In addition, BMS hereby covenants and agrees that after the Effective Date BMS shall use commercially reasonable efforts to not incur or permit to exist (and to cause each of its Affiliates not to incur or permit to exist), with respect to any BMS Patent Rights or any BMS Know-How, any lien, encumbrance, or security interest (including in connection with any indebtedness) in any manner that would have a material adverse impact on the rights granted to Eiger under this Agreement, except to the extent permitted by, and in compliance with, Section&#160;15.4.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.3&#160;<font style="text-decoration:underline;font-weight:normal;">Representations and Warranties of Eiger</font><font style="font-weight:normal;">. Eiger represents, warrants and covenants that:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 30</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.3.1&#160;</font><font style="font-weight:normal;">it shall not engage in any activities that use the BMS Patent Rights and/or BMS Know-How in a manner that is outside the scope of the license rights granted to it hereunder,</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.3.2&#160;<font style="font-weight:normal;">all of its activities related to its use of the BMS Patent Rights and BMS Know-How, and the research, Development and Commercialization of the Licensed Compounds and/or Licensed Products, pursuant to this Agreement shall comply with all applicable Law,</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.3.3&#160;<font style="font-weight:normal;">prior to filing the first drug application (i.e., a BLA or its foreign equivalent) for a Licensed Product, Eiger shall have all licenses that are necessary in order for the manufacture, use or sale of such Licensed Product not to infringe the intellectual property of any Third Party known to Eiger as of such date, but excluding licenses applicable to any Third Party issued patents for which Eiger shall have obtained a well-reasoned, written opinion of an outside patent attorney that Eiger&#8217;s activities under the scope of this Agreement are not reasonably likely to infringe any Valid Claim of such Third Party issued patent, and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.3.4&#160;<font style="font-weight:normal;">it will make available funds necessary to consummate the transaction contemplated by this Agreement and to Develop and Commercialize the Licensed Compounds and Licensed Products in accordance with the terms of this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.4&#160;<font style="text-decoration:underline;font-weight:normal;">DISCLAIMER</font><font style="font-weight:normal;">. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY LICENSED COMPOUNDS, LICENSED PRODUCTS, TRANSFERRED MATERIALS, THE BMS PATENT RIGHTS OR BMS KNOW-HOW OR ANY RIGHT OR LICENSE GRANTED BY BMS HEREUNDER, AND NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY BY BMS THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE BMS PATENT RIGHTS ARE VALID OR ENFORCEABLE OR THAT USE OF THE BMS PATENT RIGHTS, BMS KNOW-HOW AND TRANSFERRED MATERIALS CONTEMPLATED HEREUNDER DOES NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.5&#160;<font style="text-decoration:underline;font-weight:normal;">Limitation of Liability</font><font style="font-weight:normal;">. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY INCIDENTAL, INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, LOSS OF USE, DAMAGE TO GOODWILL, OR LOSS OF BUSINESS), AND IN ANY CASE, BMS SHALL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND (INCLUDING DIRECT DAMAGES) IN AN AMOUNT GREATER THAN THE AMOUNTS PAID BY EIGER TO BMS UNDER SECTIONS 8.1 AND 8.2 OF THIS AGREEMENT;&#160;</font><font style="font-style:italic;font-weight:normal;">PROVIDED, HOWEVER</font><font style="font-weight:normal;">, THAT THE FOREGOING SHALL NOT APPLY TO ANY BREACH BY A PARTY OF ARTICLE 11 HEREOF, TO A BREACH BY EIGER OF SECTION 5.6, WILLFUL MISCONDUCT BY A PARTY, OR FOR AMOUNTS SOUGHT BY THIRD PARTIES IN CLAIMS THAT ARE SUBJECT TO THE PARTIES&#8217; RESPECTIVE INDEMNITY OBLIGATIONS UNDER ARTICLE 12. FOR THE AVOIDANCE OF DOUBT, ANY DAMAGES IN THE NATURE OF LOST ROYALTIES TO BMS SHALL BE CONSIDERED DIRECT DAMAGES.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 31</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 10</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">PATENT MAINTENANCE; INFRINGEMENT; PATENT EXTENSIONS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.1&#160;<font style="text-decoration:underline;font-weight:normal;">Inventions</font><font style="font-weight:normal;">. Inventorship of inventions conceived or reduced to practice in the course of Development activities under this Agreement shall be determined by application of United States patent Laws pertaining to inventorship. If such inventions are jointly invented in the course of Development activities by one or more employees or consultants or contractors of both Parties, such inventions shall be jointly owned (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Joint Invention</font><font style="font-weight:normal;">&#8221;), and if one or more claims included in an issued patent or pending patent application which is filed in a patent office in the Territory claim such Joint Invention, such patent or patent application shall be jointly owned (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Joint Patent Rights</font><font style="font-weight:normal;">&#8221;). If such an invention is solely invented by an employee or consultant of a Party, such invention shall be solely owned by such Party, and any patent filed claiming such solely owned invention shall also be solely owned by such Party. This Agreement shall be understood to be a joint research agreement in accordance with 35&#160;U.S.C. &#167;&#160;102(c) to develop the Licensed Compounds and/or Licensed Products. Each Party shall enter into binding agreements obligating all employees and consultants performing activities under or contemplated by this Agreement, including activities related to the BMS Patent Rights, Licensed Compounds or Licensed Products, to assign his/her interest in any invention conceived or reduced to practice in the course of such activities to the Party for which such employee or consultant is providing its services. With respect to contractors, Eiger shall use good faith and reasonable efforts to secure an agreement from such contractor to assign or license (with the right to sublicense) to Eiger inventions (and patent rights covering such inventions) made by such contractor in performing such services for Eiger.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.2&#160;<font style="text-decoration:underline;font-weight:normal;">Filing, Prosecution and Maintenance of BMS Patent Rights</font><font style="font-weight:normal;">. Eiger will have lead responsibility, using its in-house patent counsel or outside patent counsel selected by Eiger (such determination and outside patent counsel selection to be subject to BMS&#8217; approval, such approval not to be unreasonably withheld), for the preparation, prosecution (including any interferences, reissue proceedings and reexaminations) and maintenance of the BMS Patent Rights. Eiger shall be responsible for the costs incurred with respect to the filing, prosecution and maintenance of the BMS Patent Rights. Eiger shall provide BMS with [ * ] updates of the filing, prosecution and maintenance status for each of the BMS Patent Rights, and shall promptly provide copies of any material official correspondence to or from patent offices. The Parties shall reasonably consult with each other and cooperate with respect to the preparation, prosecution and maintenance of the BMS Patent Rights, including by providing assistance as described in Section&#160;3.2, and will confer regarding where to prosecute the BMS Patent Rights. Eiger shall not take any action during prosecution and maintenance of the BMS Patent Rights that would materially adversely affect them (including reduction in claims scope), without BMS&#8217; prior express written consent (which consent shall not be unreasonably withheld, delayed or conditioned and shall be considered to be given if Eiger notifies BMS of proposed claim amendments or cancellations and BMS fails to object within [ * ] of such notification). Eiger may file a notice with governmental patent offices of the exclusive license to the BMS Patent Rights granted to Eiger hereunder. Post-grant proceedings involving the BMS Patent Rights, including oppositions, cancellations</font><font style="font-style:italic;font-weight:normal;">, inter partes</font><font style="font-weight:normal;">&#160;review, and the like, shall be conducted by Eiger at the expense of Eiger, and Eiger shall promptly notify BMS of the initiation of such proceeding (or vice versa) and Eiger shall give BMS the opportunity to participate, at the sole expense of BMS, and BMS shall also participate and appear as necessary under the applicable rules governing the proceeding. Any settlement or compromise of such post-grant proceeding shall be subject to the approval of BMS, which approval shall not be unreasonably withheld, delayed or conditioned.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 32</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.3&#160;</font><font style="text-decoration:underline;font-weight:normal;">Patent Abandonment</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.3.1&#160;<font style="font-weight:normal;">The Parties will confer and must mutually agree before any of the BMS Patent Rights may be abandoned in any Major Market Country; provided that BMS shall not unreasonably withhold, delay or condition its consent to a request by Eiger to abandon a BMS Patent Right if such abandonment will not adversely affect the amount or duration of any royalty payable to BMS hereunder. Eiger shall provide BMS with notice of the allowance and expected issuance date of any patent within the BMS Patent Rights, or any of the deadline for filing a new patent application, and BMS shall provide Eiger with prompt notice as to whether BMS desires Eiger to file such new patent application.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.3.2&#160;<font style="font-weight:normal;">Subject to Section&#160;10.3.1, in the event that Eiger decides either (a)&#160;not to continue the prosecution or maintenance of a patent application or patent within the BMS Patent Rights in any country, or (b)&#160;not to file any new patent application requested to be filed by BMS, Eiger shall provide BMS with express written notice of this decision at least [ * ] prior to any pending lapse or abandonment thereof, or if a decision not to continue prosecution or maintenance is responsive to an official communication from governmental agency that is received by Eiger less than [ * ] prior to a deadline for taking action in response thereto, then the deadline for giving such notice to BMS shall be [ * ] of the time remaining for response after such communication is received by Eiger. In such event, provided that the Parties have not expressly agreed to abandon a patent or not file a patent application under Section&#160;10.3.1, then Eiger shall provide BMS with an opportunity</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to assume responsibility for all external costs reasonably associated with the filing and/or further prosecution and maintenance of such patent application and any patent issuing thereon (such filing to occur prior to the issuance of the patent to which the application claims priority or expiration of the applicable filing deadline, as set forth above). In the event that BMS assumes such responsibility for such filing, prosecution and maintenance costs, Eiger shall transfer the responsibility for such filing, prosecution and maintenance of such patent applications and patents to BMS and Eiger shall no longer have any right or license in and to such patent application and patents issuing therefrom under this Agreement.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.4&#160;<font style="text-decoration:underline;font-weight:normal;">Enforcement of BMS Patent Rights against Infringers</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.4.1&#160;<font style="text-decoration:underline;font-weight:normal;">Enforcement by Eiger</font><font style="font-weight:normal;">. In the event that BMS or Eiger becomes aware of a suspected infringement of any BMS Patent Right in the Field, including actual or alleged infringement under 35 USC &#167;271(e)(2) that is or would be infringing activity involving the using, making, importing, offering for sale or selling of articles that the Party reasonably believes infringes any of the Patent Rights conferred under this Agreement, such Party shall notify the other Party promptly, including all information available to such Party with respect to such alleged infringement, and following such notification, the Parties shall confer. Eiger shall have the first right, but shall not be obligated, to bring an infringement action for suspected infringement in the Field at its own expense, in its own name and entirely under its own direction and control, subject to the following: (a)&#160;BMS shall reasonably assist Eiger (at Eiger&#8217;s expense) in any action or proceeding being prosecuted for suspected infringement in the Field if so requested, including by being named or joined as a plaintiff to such actions or proceedings if requested by Eiger or required by Law, (b)&#160;BMS shall have the right to participate and be represented in any such suit by its own counsel at its own expense, (c)&#160;no settlement of any such action or proceeding which restricts the scope, or adversely affects the enforceability, of a BMS Patent Right in the Field may be entered into by Eiger without the prior written consent of BMS, which consent shall not be unreasonably withheld, delayed or conditioned, and further, no settlement of any such action or proceeding which pertains to the infringement of the BMS Patent Rights by virtue of the Development or Commercialization of a Licensed Compound in the Field by a Third Party that is not a Sublicensee may </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 33</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">be entered into by Eiger without the prior written consent of BMS, which consent shall not be unreasonably withheld, delayed or conditioned.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.4.2&#160;<font style="text-decoration:underline;font-weight:normal;">Timing; Enforcement by BMS</font><font style="font-weight:normal;">. Eiger will have a period of [ * ] after its receipt or delivery of notice and evidence pursuant to Section&#160;10.4.1 or receipt of written notice from a Third Party that reasonably evidences such infringement of the BMS Patent Rights, to elect to so enforce such BMS Patent Rights in the applicable jurisdiction (or to settle or otherwise secure the abatement of such infringement in accordance with Section&#160;10.4.1), provided however, that such period will be (i)&#160;more than [ * ] to the extent applicable Law prevents earlier enforcement of such BMS Patent Right (such as the enforcement process set forth in or under the Hatch-Waxman Act), and provided further that if such period is extended because applicable Law prevents earlier enforcement, Eiger shall have until the date that is [ * ] following the date upon which applicable Law first permits such proceeding, and (ii)&#160;less than [ * ] to the extent that a delay in bringing such proceeding against such alleged Third Party infringer would materially limit or compromise the remedies (including monetary relief, and stay of regulatory approval) available against such alleged Third Party infringer. In the event Eiger does not so elect (or settle or otherwise secure the abatement of such infringement) before the first to occur of (A)&#160;the expiration of the applicable period of time set forth in the preceding subsections (i)&#160;and (ii), or (B)&#160;[ * ] before the expiration of any time period under applicable Law, that would, if a proceeding was not filed within such time period, limit or compromise the remedies available from such proceeding, it will so notify BMS in writing and in the case where BMS then desires to commence a suit or take action to enforce the applicable BMS Patent Right in the applicable jurisdiction, BMS will thereafter have the right to commence such a suit or take such action to enforce the applicable BMS Patent Right, as applicable, at BMS&#8217; expense, provided that BMS shall first consult with Eiger concerning the reasons Eiger elected not to bring such action and shall consider those reasons in good faith in deciding whether to bring such action. Eiger shall reasonably assist BMS (at BMS&#8217; expense) in any action or proceeding being prosecuted if so requested, including by being named or joined as a plaintiff to such actions or proceedings if requested by BMS or required by Law. Eiger shall have the right to participate and be represented in any such suit by its own counsel at its own expense. No settlement of any such action or proceeding which restricts the scope, or adversely affects the enforceability, of a BMS Patent Right may be entered into by BMS without the prior written consent of Eiger, which consent shall not be unreasonably withheld, delayed or conditioned.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.4.3&#160;<font style="text-decoration:underline;font-weight:normal;">Withdrawal</font><font style="font-weight:normal;">. If either Party brings an action or proceeding under this Section&#160;10.4 and subsequently ceases to pursue or withdraws from such action or proceeding, it shall promptly notify the other Party and the other Party may substitute itself for the withdrawing Party under the terms of this Section&#160;10.4.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.4.4&#160;<font style="text-decoration:underline;font-weight:normal;">Damages</font><font style="font-weight:normal;">. In the event that either Party exercises the rights conferred in this Section&#160;10.4 and recovers any damages or other sums in such action, suit or proceeding or in settlement thereof, such damages or other sums recovered shall first be applied to all reasonable out-of-pocket costs and expenses incurred by the Parties in connection therewith, including attorneys&#8217; fees. If such recovery is insufficient to cover all such costs and expenses of both Parties, it shall be [ * ]. If after such reimbursement any funds shall remain from such damages or other sums recovered, such funds shall be [ * ];&#160;</font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that if [ * ], such remaining amount [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.5&#160;<font style="text-decoration:underline;font-weight:normal;">Infringement of Third Party Rights</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.5.1&#160;<font style="font-weight:normal;">The Parties will promptly notify each other of any allegation that any activity under this Agreement infringes or may infringe the intellectual property rights of any Third Party.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 34</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.5.2&#160;</font><font style="font-weight:normal;">In any legal allegation related to the infringement of a Third Party intellectual property right, Eiger will have the first right to control, at its expense, the defense of such allegation. BMS will have the right, at its own expense and with its own choice of counsel, to be represented in the defense of the allegation.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.5.3&#160;<font style="font-weight:normal;">The Parties will reasonably cooperate with each other in all respects with all matters related to the defense of any legal allegation under this section.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.6&#160;<font style="text-decoration:underline;font-weight:normal;">Patent Term Extensions</font><font style="font-weight:normal;">. BMS and Eiger shall each reasonably cooperate with one another and shall use Commercially Reasonable Efforts in obtaining patent term extension (including any pediatric exclusivity extensions as may be available) or supplemental protection certificates or their equivalents in any country with respect to Patent Rights covering the Licensed Products. If elections with respect to obtaining such patent term extensions are to be made, Eiger shall have the right, at its discretion, to make the election to seek patent term extension or supplemental protection with respect to the Patent Right for which such extension or supplemental protection should be sought,&#160;</font><font style="font-style:italic;font-weight:normal;">provided</font><font style="font-weight:normal;">&#160;that Eiger shall use Commercially Reasonable Efforts to make such election so as to maximize the period of marketing exclusivity for the Licensed Product. For such purpose, for all Approvals Eiger shall provide BMS with written notice within [ * ] following receipt of each Approval. Notification of the receipt of an Approval shall be in accordance with Section&#160;15.2 except that the notification shall be sent to:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol-Myers Squibb Company</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P.O. Box 4000</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Route 206&#160;&amp; Province Line Road</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Princeton, New Jersey 08543-4000</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Vice President and Chief Patent Counsel</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone: 609-252-4825</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: 609-252-7884</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.7&#160;<font style="text-decoration:underline;font-weight:normal;">Data Exclusivity and Orange Book Listings</font><font style="font-weight:normal;">. With respect to data exclusivity periods (including any available pediatric extensions) or periods under national implementations of Article 10.1 of Directive 2001/EC/83 (and all international equivalents), Eiger shall use Commercially Reasonable Efforts consistent with its obligations under applicable Law to seek, maintain and enforce all such data exclusivity periods available for the Licensed Products. With respect to patent listing filings in the FDA Orange Book (and foreign equivalents thereof) for issued patents for a Licensed Product, Eiger shall, consistent with its obligations under applicable Law, have the right to list in a timely manner and maintain all applicable BMS Patent Rights. At least [ * ] prior to an anticipated deadline for the filing of patent listing information for BMS Patent Rights, Eiger shall consult with BMS regarding the content of such filing, and shall consider BMS&#8217;s comments in good faith, provided that Eiger shall have the final decision right with respect to such filing, including the Patent Rights to be listed in any FDA Orange Book or any equivalent. BMS shall provide, consistent with its obligations under applicable Law, reasonable cooperation to Eiger in filing and maintaining such Orange Book (and foreign equivalent) listings.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.8&#160;<font style="text-decoration:underline;font-weight:normal;">Notification of Patent Certification</font><font style="font-weight:normal;">. Eiger shall notify and provide BMS with copies of any allegations of alleged patent invalidity, unenforceability or non-infringement of a BMS Patent Right by a Third Party filing a bioequivalent or biosimilar application or other similar patent certification or filing, and any foreign equivalent thereof. Such notification and copies shall be provided to BMS within [ * ] after Eiger receives such certification, and shall be sent to the address set forth in Section&#160;10.6. In addition, upon request by BMS, Eiger shall provide reasonable assistance and cooperation (including </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 35</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">making available to BMS documents possessed by Eiger that are reasonably required by BMS and making available personnel for interviews and testimony), at BMS&#8217; cost, in any actions reasonably undertaken by BMS to contest any such patent allegation or certification.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.9&#160;<font style="text-decoration:underline;font-weight:normal;">No Conflict Actions</font><font style="font-weight:normal;">. BMS shall not be required to take any action pursuant to Sections 10.4, 10.7 or 10.8 that BMS reasonably determines in its sole judgment and discretion conflicts with or violates any court or government order or decree that BMS is then subject to or otherwise may create legal liability on the part of BMS.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.10&#160;<font style="text-decoration:underline;font-weight:normal;">Assignment of BMS Patent Rights to a BMS Affiliate</font><font style="font-weight:normal;">. Notwithstanding any provision in this Agreement to the contrary, BMS shall have the right to transfer or assign ownership of any BMS Patent Rights to a BMS Affiliate as long as any such transfer or assignment is made expressly subject to and assumption in writing of the rights, obligations and licenses granted to Eiger under this Agreement. BMS shall remain responsible for the compliance by such Affiliate with the terms of this Agreement.</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 11</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">NONDISCLOSURE OF CONFIDENTIAL INFORMATION</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.1&#160;<font style="text-decoration:underline;font-weight:normal;">Nondisclosure</font><font style="font-weight:normal;">. Each Party agrees that, for so long as this Agreement is in effect and for a period of [ * ] thereafter, a Party receiving Confidential Information of the other Party (or that has received any such Confidential Information from the other Party prior to the Effective Date under the CDA) shall (i)&#160;maintain in confidence such Confidential Information using not less than the efforts such Party uses to maintain in confidence its own proprietary industrial information of similar kind and value, (ii)&#160;not disclose such Confidential Information to any Third Party without the prior written consent of the other Party, except for disclosures expressly permitted below, and (iii)&#160;not use such Confidential Information for any purpose except those permitted by this Agreement (which includes the performance of its obligations and the exercise of its rights under this Agreement, but it being understood that this clause (iii)&#160;shall not create or imply any rights or licenses not expressly granted under Article 2).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.2&#160;<font style="text-decoration:underline;font-weight:normal;">Exceptions</font><font style="font-weight:normal;">. The obligations in Section&#160;11.1 shall not apply with respect to any portion of the Confidential Information that the receiving Party can show by competent proof:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.2.1&#160;<font style="font-weight:normal;">is publicly disclosed by the disclosing Party, either before or after it is disclosed to the receiving Party hereunder; or</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.2.2&#160;<font style="font-weight:normal;">was known to the receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the disclosing Party; or</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.2.3&#160;<font style="font-weight:normal;">is subsequently disclosed to the receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and is disclosed without any obligation to keep it confidential or any restriction on its use; or</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.2.4&#160;<font style="font-weight:normal;">is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is disclosed to the receiving Party, other than through the receiving Party&#8217;s breach of its confidentiality obligations set forth herein; or</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 36</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.2.5&#160;</font><font style="font-weight:normal;">has been independently developed by employees or contractors of the receiving Party or any of its Affiliates without the aid, application or use of Confidential Information of the disclosing Party.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.3&#160;<font style="text-decoration:underline;font-weight:normal;">Authorized Disclosure</font><font style="font-weight:normal;">. The receiving Party may disclose Confidential Information belonging to the other Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.3.1&#160;<font style="font-weight:normal;">filing or prosecuting patents as set forth in this Agreement;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.3.2&#160;<font style="font-weight:normal;">Eiger&#8217;s research, Development or Commercialization (including any import, manufacture, use, offer for sale, or sale) activities, including Eiger&#8217;s regulatory filings, with respect to Licensed Compounds and/or Licensed Product, including any Approvals or applications therefor;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.3.3&#160;<font style="font-weight:normal;">prosecuting or defending litigation in relation to the BMS Patent Rights, BMS Know How or this Agreement, including responding to a subpoena in a Third Party litigation;, provided it has used good faith and reasonable efforts to obtain a protective order for such Confidential Information;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.3.4&#160;<font style="font-weight:normal;">subject to Section&#160;11.4, complying with applicable Laws (including the rules and regulations of the Securities and Exchange Commission or any national securities exchange) and with judicial process, if in the reasonable opinion of the receiving Party&#8217;s counsel, such disclosure is necessary for such compliance;&#160;</font><font style="font-style:italic;font-weight:normal;">provided, however,&#160;</font><font style="font-weight:normal;">that except where impracticable, the receiving Party shall give the disclosing Party reasonable advance notice of such disclosure requirement (which shall include a copy of any applicable subpoena or order) and shall afford the disclosing Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required disclosure, and in the event of any such required disclosure, the receiving Party shall disclose only that portion of the Confidential Information of the disclosing Party that the receiving Party is legally required to disclose;</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.3.5&#160;<font style="font-weight:normal;">disclosure, in connection with the performance of this Agreement and solely on a &#8220;need to know basis&#8221;, to Affiliates, existing or potential collaborators (including existing or potential co-marketing and co-promotion contractors), research collaborators, employees, consultants, or agents, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use no less restrictive than the obligations set forth in this Article 11;&#160;</font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that the receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Article 11 to treat such Confidential Information as required under this Article 11; and</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.3.6&#160;<font style="font-weight:normal;">made by such Party to existing or potential acquirers or merger candidates; investment bankers; public and private sources of funding; existing or potential investors, venture capital firms or other financial institutions or investors for purposes of evaluating or carrying out an acquisition, merger, or financing transaction,&#160;</font><font style="font-style:italic;font-weight:normal;">provided</font><font style="font-weight:normal;">&#160;that such Party has used good faith and reasonable efforts to secure an agreement from any such Third Party to be bound by obligations of confidentiality and restrictions on use of Confidential Information that are no less restrictive than the obligations in this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If and whenever any Confidential Information is disclosed in accordance with this Section&#160;11.3, such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (otherwise than by breach of this Agreement). Where reasonably possible and subject to Section&#160;11.4, the receiving Party shall notify the disclosing Party of the receiving Party&#8217;s intent to make such disclosure pursuant to this Section&#160;11.3 sufficiently prior to making such disclosure so as to allow the disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 37</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.4&#160;</font><font style="text-decoration:underline;font-weight:normal;">Terms of this Agreement</font><font style="font-weight:normal;">. The Parties acknowledge that the terms of this Agreement shall be treated as Confidential Information of both Parties. For the avoidance of doubt, this Section&#160;11.4 shall in no way prevent a Party from disclosing the existence of this Agreement or any terms of this Agreement in order to seek legal advice whenever deemed appropriate by such Party or to enforce such Party&#8217;s rights under this Agreement, whether through arbitral proceedings, court proceedings or otherwise, or to defend itself against allegations or claims relating to this Agreement, or to comply with Applicable Law (except as provided in Section&#160;11.5 below) when advised in a written opinion of outside counsel that terms of the Agreement are required to be disclosed to comply with Applicable Law.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.5&#160;<font style="text-decoration:underline;font-weight:normal;">Securities Filings</font><font style="font-weight:normal;">. Notwithstanding anything to the contrary in this Agreement, in the event either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document which describes or refers to this Agreement under the Securities Act of 1933, as amended, the Securities Exchange Act, of 1934, as amended, any other applicable securities Law or the rules of any national securities exchange, the Party shall notify the other Party of such intention and shall use reasonable efforts to provide such other Party with a copy of relevant portions of the proposed filing not less than [ * ] prior to (but in no event later than [ * ] prior to) such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto relating to this Agreement, and shall use reasonable efforts to obtain confidential treatment of any information concerning this Agreement that such other Party requests be kept confidential, and shall only disclose Confidential Information which it is advised by counsel is legally required to be disclosed. No such notice shall be required under this Section&#160;11.5 if the substance of the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by the either Party hereunder or otherwise approved by the other Party.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.6&#160;<font style="text-decoration:underline;font-weight:normal;">Publication by Eiger</font><font style="font-weight:normal;">. Eiger may publish or present data and/or results relating to a Licensed Compound or Licensed Product developed in the Field in scientific journals and/or at scientific conferences, provided that Eiger shall notify BMS at least [ * ] in advance of the intended submission for publication or presentation of any proposed abstract, manuscript or presentation which discloses Confidential Information of BMS or discloses a patentable invention by delivering a copy thereof to BMS. BMS shall have [ * ] from its receipt of any such abstract, manuscript or presentation in which to notify Eiger in writing of any specific, reasonable objections to the disclosure, based on concern regarding the specific disclosure of Confidential Information of BMS, and Eiger will delete any BMS Confidential Information, and consider any other such objections in good faith, including whether it is necessary or advisable to delete any other information from such proposed publication. Once any such abstract or manuscript is accepted for publication, Eiger shall provide BMS with a copy of the final version of the manuscript or abstract.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 38</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 12</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">INDEMNITY</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">12.1&#160;<font style="text-decoration:underline;font-weight:normal;">Eiger Indemnity</font><font style="font-weight:normal;">. Eiger shall indemnify, defend and hold harmless BMS and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives, from and against any and all damages, liabilities, losses, costs and expenses (including reasonable legal expenses, costs of litigation and reasonable attorney&#8217;s fees) arising in connection with any claims, suits, proceedings, whether for money damages or equitable relief, of any kind brought by any Third Party (collectively &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Losses and Claims</font><font style="font-weight:normal;">&#8221;) and arising out of or relating to (a)&#160;a breach of this Agreement by Eiger or any of its Affiliates, Sublicensees, agents and contractors, (b)&#160;the research, Development, Commercialization (including promotion, advertising, offering for sale, sale or other disposition), transfer, importation or exportation, manufacture, labeling, handling or storage, or use of, or exposure to, any Licensed Compound or any Licensed Product by or for, or failure to comply with applicable Law by, Eiger or any of its Affiliates, Distributors, Sublicensees, agents and contractors, including claims and threatened claims based on product liability, bodily injury, risk of bodily injury, death or property damage, infringement or misappropriation of Third Party patents, copyrights, trademarks or other intellectual property rights, or the failure to comply with applicable Law related to the matters referred to in this subsection (a)&#160;with respect to any Licensed Compound or any Licensed Product, (c)&#160;the prosecution, maintenance, enforcement and defense of the BMS Patents by Eiger, its Affiliates, Sublicensees, representatives and agents; and/or (d)&#160;the gross negligence, recklessness or willful misconduct of Eiger or its Affiliates or its or their respective directors, officers, employees and agents, in connection with Eiger&#8217;s performance of its obligations or exercise of its rights under this Agreement;&#160;</font><font style="font-style:italic;font-weight:normal;">except</font><font style="font-weight:normal;">&#160;in any such case for Losses and Claims to the extent reasonably attributable to any breach of this Agreement by BMS (including its representations and warranties set forth in Section&#160;4.1 and Article 9), or BMS having committed an act or acts of gross negligence, recklessness or willful misconduct, or to the extent BMS has an indemnification obligation to Eiger pursuant to Section&#160;12.2.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">12.2&#160;<font style="text-decoration:underline;font-weight:normal;">BMS Indemnity</font><font style="font-weight:normal;">. BMS shall indemnify, defend and hold harmless Eiger and its Affiliates, and their respective officers, directors, employees, agents, licensors, and their respective successors, heirs and assigns and representatives, from and against any and all Losses payable to a Third Party based on Claims brought by a Third Party arising out of or relating to (a)&#160;a breach of this Agreement by BMS, including the representations, warranties and covenants of BMS set forth in Section&#160;4.1 and/or Article 9, (b)&#160;the gross negligence, recklessness or willful misconduct of BMS or its Affiliates or its or their respective directors, officers, employees and agents, in connection with BMS&#8217;s performance of its obligations or exercise of its rights under this Agreement, (c)&#160;personal injury arising out of the conduct by BMS of clinical studies for the Licensed Compounds prior to the Effective Date, (d)&#160;payments for services rendered to BMS prior to the Effective Date related to the Licensed Compounds, (e)&#160;the conduct and close of any existing CTAs and CTXs for the Licensed Compound not assigned to Eiger under Section&#160;3.3 after the Effective Date; and/or (f)&#160;any Development, use, manufacture, or Commercialization of BMS Reversion Products by BMS following the reversion thereof to BMS pursuant to Section&#160;13.4 in the Territory, including any product liability claims and intellectual property infringement claims in the Territory or any personal injury, property damage or other damage in the Territory arising therefrom;&#160;</font><font style="font-style:italic;font-weight:normal;">except</font><font style="font-weight:normal;">&#160;in any such case for Losses and Claims to the extent reasonably attributable to any breach of this Agreement by Eiger, its Affiliates or Sublicensees, failure of Eiger, its Affiliates or Sublicensees to comply with Applicable Law with respect to its Development or Commercialization of the Licensed Compounds or Licensed Products, or Eiger, its Affiliates or Sublicensees having committed an act or acts of gross negligence, recklessness or willful misconduct, or to the extent Eiger has an indemnification obligation to BMS pursuant to Section&#160;12.1.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 39</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">12.3&#160;</font><font style="text-decoration:underline;font-weight:normal;">Indemnification Procedure</font><font style="font-weight:normal;">. A claim to which indemnification applies under Section&#160;12.1 shall be referred to herein as an &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indemnification Claim</font><font style="font-weight:normal;">&#8221;. If any Person or Persons (collectively, the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indemnitee</font><font style="font-weight:normal;">&#8221;) intends to claim indemnification under this Article 12, the Indemnitee shall notify the Party subject to the indemnification obligation (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indemnitor</font><font style="font-weight:normal;">&#8221;) in writing promptly upon becoming aware of any claim that may be an Indemnification Claim (it being understood and agreed, however, that the failure by an Indemnitee to give such notice shall not relieve Indemnitor of its indemnification obligation under this Agreement except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice). The Indemnitor shall have the right to assume and control the defense of the Indemnification Claim at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee,&#160;</font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitee, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnitee and any other party represented by such counsel in such proceedings. If the Indemnitor does not assume the defense of the Indemnification Claim as aforesaid, the Indemnitee may defend the Indemnification Claim but shall have no obligation to do so. The Indemnitee shall not settle or compromise the Indemnification Claim without the prior written consent of the Indemnitor, and the Indemnitor shall not settle or compromise the Indemnification Claim in any manner which would have an</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">adverse effect on the Indemnitee&#8217;s interests (including any rights under this Agreement or the scope or enforceability of the BMS Patents Rights or BMS Know-How), without the prior written consent of the Indemnitee, which consent, in each case, shall not be unreasonably withheld, delayed or conditioned if the settlement or compromise would impose no financial or other obligations or burdens on the Indemnitee. The Indemnitee shall reasonably cooperate with the Indemnitor at the Indemnitor&#8217;s expense and shall make available to the Indemnitor all pertinent information under the control of the Indemnitee, which information shall be subject to Article 11.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">12.4&#160;<font style="text-decoration:underline;font-weight:normal;">Insurance</font><font style="font-weight:normal;">. Eiger shall, beginning with the initiation of the first clinical trial for a Licensed Product, maintain at all times thereafter during the term of this Agreement, and until the later of (i)&#160;[ * ] after termination or expiration of this Agreement or (ii)&#160;the date that all statutes of limitation covering claims or suits that may be brought for personal injury based on the sale or use of a Licensed Product have expired in all states in the U.S., insurance relating to the Licensed Product from a recognized, creditworthy insurance company, on a claims-made basis, with endorsements for contractual liability and for clinical trial and product liability, that is comparable in type and amount to the insurance customarily maintained by Eiger with respect to similar prescription pharmaceutical products that are marketed, distributed and sold in the Territory. Within ten (10)&#160;days following the Effective Date, and within thirty (30)&#160;days following any material change or cancellation in coverage, Eiger shall furnish to BMS a certificate of insurance evidencing such coverage as of such date, and in the case of cancellation, provide a certificate evidencing that Eiger&#8217;s replacement coverage meets the requirements in the first sentence of this Section&#160;12.4. The foregoing insurance requirement shall not be construed to create a limit on Eiger&#8217;s liability hereunder.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 40</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 13</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">TERM AND TERMINATION</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.1&#160;<font style="text-decoration:underline;font-weight:normal;">Term</font><font style="font-weight:normal;">. This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof or by mutual written consent, shall expire on a country-by-country basis and Licensed Product-by-Licensed Product basis, upon the expiration of the Royalty Term with respect to a given Licensed Product in the applicable country.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.2&#160;<font style="text-decoration:underline;font-weight:normal;">Termination by BMS</font><font style="font-weight:normal;">. BMS shall have the right to terminate this Agreement, at BMS&#8217; sole discretion, as follows:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.2.1&#160;<font style="text-decoration:underline;font-weight:normal;">Insolvency</font><font style="font-weight:normal;">. To the extent permitted under applicable Laws, BMS shall have the right to terminate this Agreement in its entirety, at BMS&#8217; sole discretion, upon delivery of written notice to Eiger upon the filing by Eiger in any court or agency pursuant to any statute or regulation of the United States or any other jurisdiction a petition in bankruptcy or insolvency or for reorganization or similar arrangement for the benefit of creditors or for the appointment of a receiver or trustee of Eiger or its assets, upon the proposal by Eiger of a written agreement of composition or extension of its debts, or if Eiger is served by a Third Party (and not by BMS) with an involuntary petition against it inany insolvency proceeding, upon the [ * ] after such service if such involuntary petition has not previously been stayed or dismissed, or upon the making by Eiger of an assignment for the benefit of its creditors.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.2.2&#160;<font style="text-decoration:underline;font-weight:normal;">Breach</font><font style="font-weight:normal;">. BMS shall have the right to terminate this Agreement in its entirety, at BMS&#8217; sole discretion, (x)&#160;as provided in Section&#160;5.6 or (y)&#160;upon delivery of written notice to Eiger in the event of any material breach by Eiger of this Agreement (except that this Section&#160;13.2.2 shall not apply to any breach of Sections 5.1 or 6.1, which are covered under Section&#160;13.2.3), provided that such breach has not been cured within [ * ] after written notice is given by BMS to Eiger; provided, however, that if such breach relates to the failure to make a payment when due, such breach must be cured within [ * ] after written notice thereof is given by BMS. Notwithstanding the foregoing, in the case of a bona fide dispute over whether or to what extent Eiger has breached this Agreement, this Section&#160;13.2.2 shall not be triggered until such dispute is resolved in BMS&#8217; favor and Eiger fails to cure such breach within the applicable cure period (which shall be tolled until the resolution of the dispute); provided, that Eiger shall have timely paid any amounts that are not in dispute. Any such termination of this Agreement shall become effective at the end of the applicable cure period, unless Eiger has cured any such breach or default prior to the expiration of such cure period.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.2.3&#160;<font style="text-decoration:underline;font-weight:normal;">Termination for Failure to Develop or Commercialize</font><font style="font-weight:normal;">. BMS shall have the right to terminate this Agreement in its entirety in the event that Eiger fails to fulfill its obligations to Develop Licensed Compounds and/or Licensed Products in accordance with Section&#160;5.1, or to Commercialize Licensed Products in accordance with Section&#160;6.1,&#160;</font><font style="font-style:italic;font-weight:normal;">provided</font><font style="font-weight:normal;">&#160;that Eiger has not cured such breach within [ * ] following written notice by BMS which notice shall be labeled as a &#8220;notice of material breach for failure to use Commercially Reasonable Efforts,&#8221; and identifies the Major Market Country(ies) in which such breach has occurred. If Eiger disputes the material breach of its obligations under Sections 5.1 and 6.1, this Section&#160;13.2.3 shall not be triggered until such dispute is resolved in BMS&#8217; favor and Eiger fails to cure such breach within any portion of the applicable cure period then remaining (which shall be tolled until the resolution of the dispute. For clarity, if arbitration is triggered under Section&#160;14.2 [ * ] after receipt of the notice from BMS, it shall have [ * ] after an arbitrator&#8217;s decision in favor of BMS to cure the breach). Any such termination of this Agreement shall become effective at the end of the applicable remaining cure period, unless Eiger has cured any such breach or default prior to the expiration of such </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 41</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">remaining cure period. If there is a dispute as to whether Eiger has cured within the remaining cure period following the arbitrator&#8217;s decision, such dispute [ * ], provided, that [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.2.4&#160;<font style="text-decoration:underline;font-weight:normal;">Termination for Patent Challenge</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;<font style="font-weight:normal;">BMS shall have the right to terminate this Agreement in its entirety in the event Eiger (or any of its Affiliates) challenges or knowingly supports (other than as may be necessary or reasonably required to assert a cross-claim or a counter-claim, or in response to a subpoena or court or administrative law request or order), including by providing information, documents, and/or funding, a challenge to the validity, scope, enforceability or patentability of any of the BMS Patent Rights. BMS&#8217;s right to terminate this Agreement under this Section&#160;13.2.4 may be exercised at any time after Eiger (or any of its Affiliates) may have challenged or knowingly supports (other than in response to a subpoena or court order) a challenge to the validity, scope, enforceability or patentability of any of the BMS Patent Rights. For the avoidance of doubt, an action by Eiger or any Affiliate in accordance with Article 10 to amend claims within a pending patent application within the BMS Patent Rights during the course of Eiger&#8217;s prosecution and maintenance of such pending patent application or in defense of a Third Party proceeding, or to make a negative determination of patentability of claims of a patent application of BMS or to abandon a patent application of BMS during the course of Eiger&#8217;s Prosecution and Maintenance of such pending patent application, shall not, where undertaken in accordance with Article 9 hereof, constitute a challenge under this Section&#160;13.2.4.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:17%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<font style="font-weight:normal;">If a Sublicensee of Eiger challenges the validity, scope or enforceability of or otherwise opposes any of the BMS Patent Rights under which such Sublicensee is sublicensed, then Eiger shall, at BMS&#8217; election and upon written notice from BMS, promptly terminate such Sublicense. Eiger shall include within each License Agreement with each Sublicensee a right on the part of Eiger to terminate such License Agreement in the event such Sublicensee challenges or knowingly supports a Third Party in challenging (other than in response to a subpoena or court order), in a judicial or administrative proceeding, including without limitation by providing information, documents, or funding, the validity, scope or enforceability of any of the BMS Patent Rights after grant of the patent and (ii)&#160;Eiger shall exercise such right to terminate the License Agreement with a Sublicensee should such Sublicensee challenge or knowingly support a Third Party in challenging (other than in response to a subpoena or court order) in a judicial or administrative proceeding the validity or enforceability of any of the BMS Patent Rights after grant of the patent. If Eiger fails to exercise such termination right against such Sublicensee or is unable to do so because it did not include such a provision in its Sublicense, BMS may terminate this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.3&#160;<font style="text-decoration:underline;font-weight:normal;">Termination by Eiger</font><font style="font-weight:normal;">. Eiger shall have the right to terminate this Agreement, at Eiger&#8217;s sole discretion, as follows.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.3.1&#160;<font style="font-weight:normal;">Following completion by Eiger of the [ * ] of the Licensed Product, upon [ * ] prior written notice in the case where [ * ], or upon [ * ] prior written notice in the case where [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.3.2&#160;<font style="font-weight:normal;">Eiger may terminate this Agreement in the event of a material breach by BMS, provided that such breach has not been cured within [ * ] following written notice by Eiger. Any such termination of this Agreement shall become effective at the end of the applicable cure period, unless BMS has cured any such breach or default prior to the expiration of such cure period.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4&#160;<font style="text-decoration:underline;font-weight:normal;">Effect of Termination</font><font style="font-weight:normal;">. Upon termination of this Agreement in its entirety by BMS under Section&#160;13.2 or by Eiger under Section&#160;13.3.1:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 42</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.1&#160;</font><font style="font-weight:normal;">All rights and licenses granted to Eiger in Article 2 shall terminate, all rights of Eiger under the BMS Patent Rights and BMS Know-How shall revert to BMS, and Eiger and its Affiliates shall cease all use of the BMS Patent Rights, the BMS Know-How and the Transferred Materials, and shall return to BMS all unused portions of the Transferred Materials, subject, in the case of [ * ], to [ * ]. Following the effective date of such termination, all Licensed Compounds and/or Licensed Products shall thereafter be deemed &#8220;</font><font style="text-decoration:underline;font-weight:normal;">BMS Reversion Products</font><font style="font-weight:normal;">&#8221;.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.2&#160;<font style="font-weight:normal;">With respect to all regulatory filings (including all INDs, MAAs, MAs, CTAs, CTXs and BLAs) and Approvals and all other regulatory filings and documents necessary to further Develop and Commercialize the BMS Reversion Products, as they exist as of the date of such termination (and all of Eiger&#8217;s right, title and interest therein and thereto), BMS shall determine in its sole discretion which of these shall be (i)&#160;assigned to BMS, and Eiger shall provide to BMS one (1)&#160;copy of the applicable documents and filings, all documents and filings contained in or referenced in any such filings, together with the raw and summarized data for any preclinical and clinical studies of the BMS Reversion Products as well as any final documentation to inactivate any open INDs as BMS may elect to inactivate, subject, in the case of [ * ], to [ * ], and [ * ], or (ii)&#160;withdrawn, closed out, or inactivated [ * ]. For clarity, BMS shall have the right to use the foregoing material information, materials and data developed by Eiger solely in connection with BMS&#8217; development, manufacture and commercialization of BMS Reversion Products. BMS shall have the right to obtain specific performance of Eiger&#8217;s obligations referenced in this Section&#160;13.4.2 and/or in the event of failure to obtain assignment, Eiger hereby consents and grants to BMS the right to access and reference (without any further action required on the part of Eiger, whose authorization to file this consent with any Regulatory Authority is hereby granted) any and all such regulatory filings for any regulatory or other use or purpose in the Territory. Without limiting the foregoing in this paragraph, to the extent applicable, Eiger&#8217;s obligations under Article 10 shall continue with respect to all countries in the Territory for which there is a failure to obtain assignment of all regulatory filings and Approvals.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.3&#160;<font style="font-weight:normal;">All amounts due or payable to BMS that were accrued prior to the effective date of termination shall remain due and payable; but (except as otherwise expressly provided herein) no additional amounts shall be payable based on events occurring after the effective date of termination; provided, that the foregoing shall not be deemed to limit either Party&#8217;s indemnification obligations under this Agreement for acts or omissions incurring prior to the termination date that are the subject of such indemnification even if the indemnification amount cannot be accrued or determined as of the termination date.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.4&#160;<font style="font-weight:normal;">Should Eiger have any inventory of any Licensed Compound included in the BMS Reversion Products suitable for use in clinical trials, Eiger shall [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.5&#160;<font style="font-weight:normal;">Should Eiger have any inventory of any Licensed Product included in the BMS Reversion Products approved and allocated prior to termination, Eiger shall have [ * ] thereafter in which to dispose of such inventory (subject to the payment to BMS of any royalties due hereunder thereon) (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Inventory Disposal Period</font><font style="font-weight:normal;">&#8221;), provided however, that (i)&#160;such right shall terminate at such time that BMS purchases all remaining stocks of inventory of such BMS Reversion Product as described in this Section&#160;13.4.6, below, and (ii)&#160;such Licensed Product shall [ * ] provided to such purchaser for the Licensed Product in the applicable country during the [ * ] period preceding such termination and, in addition, such sales shall [ * ] for the [ * ] period preceding such termination. Notwithstanding the foregoing, if BMS takes over responsibility for sale of the BMS Reversion Products in any country in the Territory prior to the end of the Inventory Disposal Period, BMS shall be required to purchase all </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 43</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">remaining stocks of saleable inventory that meets BMS specifications and return policies of such BMS Reversion Product at [ * ] for such BMS Reversion Product, [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.6&#160;<font style="font-weight:normal;">Eiger shall provide to BMS the tangible embodiments of all Know-How owned or Controlled by Eiger and its Affiliates to the extent necessary for the Development and Commercialization of the BMS Reversion Products in existence as of the date of such termination, subject, in the case of [ * ], to [ * ], and [ * ], including Eiger&#8217;s manufacturing processes, techniques and trade secrets for making such BMS Reversion Products and all Know-How specifically relating to any composition, formulation, method of use or manufacture of such BMS Reversion Products, and BMS shall [ * ]. Eiger shall reasonably cooperate with BMS to assist BMS with understanding and using the&#160;Know-How&#160;provided to BMS under this Section&#160;13.4.7. Such cooperation shall include providing BMS with reasonable access by teleconference or&#160;in-person&#160;at Eiger&#8217;s facilities (subject to Eiger&#8217;s customary rules and restrictions with respect to site visits by non-Eiger personnel and subject, in the case of [ * ], to [ * ]).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.7&#160;<font style="font-weight:normal;">To the extent that Eiger owns any trademark(s), USAN names, and/or domain names that are used in connection with a BMS Reversion Product that BMS believes would be necessary for the Commercialization of a BMS Reversion Product (as then currently marketed, but not including any marks that include, in whole or part, any corporate name or logo of Eiger), Eiger shall assign (or, if applicable, cause its Affiliate to assign) to BMS all of Eiger&#8217;s (and such Affiliate&#8217;s) right, title and interest in and to any such trademark, USAN name or internet domain name in each terminated country.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.8&#160;<font style="font-weight:normal;">Eiger shall grant and hereby grants to BMS an exclusive, royalty-bearing [ * ], non-transferable (except as provided in Section&#160;15.4) license, with the right to grant sublicenses, under (a)(i) any Patent Rights owned or Controlled by Eiger or its Affiliates as at the effective date of termination (other than Patent Rights Controlled by BMS and its Affiliates that were licensed to Eiger under this Agreement) and (ii)&#160;all Patent Rights owned or Controlled by Eiger or its Affiliates after the date of such termination claiming any invention conceived or reduced to practice by or on behalf of Eiger during the term of this Agreement and (b)&#160;any Trademarks and USAN names owned by Eiger that are used in connection with the Licensed Product, in each case (a)(i) and (ii)&#160;that are not Patent Rights licensed from BMS and only to the extent such Patent Rights cover the composition of matter, use, or manufacture of BMS Reversion Products (solely to the extent actually practiced in connection with the BMS Reversion Products as of such termination effective date) and that, in each case of (a)&#160;and (b), are necessary to develop, manufacture or commercialize BMS Reversion Products.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.9&#160;<font style="font-weight:normal;">Eiger shall provide to BMS all data generated during the term of this Agreement necessary for the development and/or commercialization of the relevant BMS Reversion Products and [ * ], subject to [ * ], and [ * ].</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.10&#160;<font style="font-weight:normal;">Neither Party shall be relieved of any obligation that accrued prior to the effective date of such termination.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.11&#160;<font style="font-weight:normal;">BMS shall not owe any other compensation to Eiger for the research, Development and Commercialization of any BMS Reversion Product in the event of any such termination of the Agreement by BMS, except as expressly set forth in Section&#160;13.4.8.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.12&#160;<font style="font-weight:normal;">Any costs and expenses incurred by Eiger in connection with the assignments and transfers made by Eiger under this Section&#160;13.4 shall be [ * ] unless [ * ], in which case any such costs and expenses reasonably incurred by Eiger shall be [ * ].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 44</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.13&#160;</font><font style="font-weight:normal;">It is understood and agreed that BMS shall be entitled to specific performance as a remedy to enforce the provisions of this Section&#160;13.4, in addition to any other remedy to which it may be entitled by applicable Law.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.14&#160;<font style="font-weight:normal;">If Eiger is using Third Parties to manufacture and supply Licensed Compound and Licensed Product to it at the time of termination, Eiger will, at BMS&#8217; request, reasonably cooperate with BMS to assign such Third Party agreements to BMS as BMS may request. If Eiger is manufacturing any portion of the Licensed Compound and/or Licensed Product for itself, and has the capability in place as of the date of such termination to commercially manufacture and supply to BMS all or part of BMS&#8217; requirements of the applicable BMS Reversion Products for use and sale in the Territory, if BMS so elects in its sole discretion, Eiger shall supply to BMS for a period not to exceed [ * ] (with the period of time being within the sole discretion of BMS) as much of BMS&#8217; requirements of such BMS Reversion Products as reasonably possible for use and sale in the Territory, [ * ] for such BMS Reversion Products. In the event that Eiger has, prior to the date of such termination, engaged a Third Party to manufacture and supply any BMS Reversion Products, Eiger shall use reasonable efforts, at BMS&#8217; sole cost and expense, to assist in the transfer of such supply arrangements to BMS, or if not assigned or assignable, then Eiger shall supply such BMS Reversion Products [ * ] associated with providing such BMS Reversion Products to BMS.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.4.15&#160;<font style="font-weight:normal;">Nothing in this Section&#160;13.4 shall be deemed to limit any remedy to which either Party may be entitled by applicable Law.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.5&#160;<font style="text-decoration:underline;font-weight:normal;">Effect of Termination by Eiger for Breach by BMS</font><font style="font-weight:normal;">. Upon termination of this Agreement by Eiger pursuant to Section&#160;13.3.2:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.5.1&#160;<font style="font-weight:normal;">All rights and licenses granted to Eiger in Article 2 shall terminate, all rights of Eiger under the BMS Patent Rights and BMS Know-How shall revert to BMS, and Eiger and its Affiliates shall cease all use of the BMS Patent Rights, the BMS Know-How and the Transferred Materials, and shall return to BMS all unused portions of the Transferred Materials.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.5.2&#160;<font style="font-weight:normal;">All amounts due or payable to BMS that were accrued, or that arise out of acts or events occurring, prior to the effective date of termination or expiration shall remain due and payable; but (except as otherwise expressly provided herein) no additional amounts shall be payable based on events occurring after the effective date of termination or expiration.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.5.3&#160;<font style="font-weight:normal;">Should Eiger have any inventory of any Licensed Product approved and allocated prior to termination for sale in a terminated country, Eiger shall have [ * ] thereafter in which to dispose of such inventory (subject to the payment to BMS of any royalties due hereunder thereon).</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.5.4&#160;<font style="font-weight:normal;">Neither Party shall be relieved of any obligation that accrued prior to the effective date of such termination or expiration.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.5.5&#160;<font style="font-weight:normal;">Nothing in this Section&#160;13.5 shall be deemed to limit any remedy to which Eiger may be entitled by applicable Law.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.6&#160;<font style="text-decoration:underline;font-weight:normal;">Effect of Expiration of this Agreement</font><font style="font-weight:normal;">. Upon expiration of this Agreement:</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.6.1&#160;<font style="font-weight:normal;">All amounts due or payable to BMS that were accrued, or that arise out of acts or events occurring, prior to the effective date of expiration shall remain due and payable; but (except as otherwise </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 45</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">expressly provided herein) no additional amounts shall be payable based on events occurring after the effective date of expiration.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.6.2&#160;<font style="font-weight:normal;">BMS shall have the right to retain all amounts previously paid to BMS by Eiger.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.6.3&#160;<font style="font-weight:normal;">Neither Party shall be relieved of any obligation that accrued prior to the effective date of expiration.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.6.4&#160;<font style="font-weight:normal;">The license with respect to BMS Patent Rights and BMS Know-How granted under Section&#160;2.1 shall remain in effect and shall be fully paid-up.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.7&#160;<font style="text-decoration:underline;font-weight:normal;">Scope of Termination</font><font style="font-weight:normal;">. Termination of this Agreement shall be as to all countries in the Territory and all Licensed Compounds and all Licensed Products.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.8&#160;<font style="text-decoration:underline;font-weight:normal;">Survival</font><font style="font-weight:normal;">. The following provisions shall survive termination or expiration of this Agreement, as well as any other provisions which by their nature are intended to survive termination: Article 1 (as applicable), Sections 8.7 (for three (3)&#160;years after the end of the Calendar Year in which this Agreement was terminated), Section&#160;9.4, Section&#160;9.5, Section&#160;10.1, Section&#160;10.4 (with respect to an action, suit or proceeding commenced prior to termination), Section&#160;10.8, Article 11, Article 12, Section&#160;13.4 (if terminated by BMS under Section&#160;13.2 or by Eiger under Section&#160;13.3.1, Section&#160;13.5 (if terminated by Eiger pursuant to Section&#160;13.3.2), Section&#160;13.6, Section&#160;13.7, this Section&#160;13.8, Section&#160;13.10, Article 14 and Article 15.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.9&#160;<font style="text-decoration:underline;font-weight:normal;">Bankruptcy</font><font style="font-weight:normal;">. The Parties agree that in the event a Party becomes a debtor under Title 11 of the U.S. Code (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Title 11</font><font style="font-weight:normal;">&#8221;), this Agreement shall be deemed to be, for purposes of Section&#160;365(n) of Title 11, a license to rights to &#8220;intellectual property&#8221; as defined therein. Each Party as a licensee hereunder shall have the rights and elections as specified in Title 11. Any agreements supplemental hereto shall be deemed to be &#8220;agreements supplementary to&#8221; this Agreement for purposes of Section&#160;365(n) of Title 11.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.10&#160;<font style="text-decoration:underline;font-weight:normal;">No Limitation of Remedies</font><font style="font-weight:normal;">. Except as herein expressly provided, notwithstanding anything to the contrary in this Agreement, except as otherwise set forth in this Agreement, termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor prejudice either Party&#8217;s right to obtain performance of any obligation. Each Party shall be free, pursuant to Article 14, to seek (without restriction as to the number of times it may seek) damages, costs and remedies that may be available under applicable Law or in equity and shall be entitled to offset the amount of any damages and costs obtained in a final determination under Article 14 of monetary damages or costs (as permitted by this Agreement) against the other Party against any amounts otherwise due to such other Party under this Agreement.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU22"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 46</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 14</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">DISPUTE RESOLUTION</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">14.1&#160;<font style="text-decoration:underline;font-weight:normal;">Resolution by Senior Executives</font><font style="font-weight:normal;">. Except as provided in Sections 8.7 and 14.3, in the event of any dispute between the Parties in connection with this Agreement, the construction hereof, or the rights, duties or liabilities of either Party hereunder, including any disagreement as to whether there has been a material breach of this Agreement pursuant to Sections 13.2.2, 13.2.3, or 13.3.2, the Parties shall first attempt in good faith to resolve such dispute by negotiation and consultation between themselves. In the event that such dispute is not resolved on an informal basis within [ * ], either Party may, by written notice to the other Party, refer the dispute to (i)&#160;[ * ] and (ii)&#160;[ * ] or, [ * ] for attempted resolution by good faith negotiation within [ * ] after such notice is received; provided, however, such executive officers of Eiger and BMS may each designate a senior manager to whom such dispute is delegated instead for such attempted resolution.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">14.2&#160;<font style="text-decoration:underline;font-weight:normal;">Arbitration</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">14.2.1&#160;<font style="font-weight:normal;">Except as provided in Sections 8.7 and 14.3, if any dispute between the Parties relating to or arising out this Agreement cannot be resolved in accordance with Section&#160;14.1, such dispute shall be resolved by binding arbitration administered by JAMS pursuant to JAMS&#8217; Comprehensive Arbitration Rules and Procedures then in effect (the&#160;</font>&#8220;JAMS Rules&#8221;<font style="font-weight:normal;">), and judgment on the arbitration award may be entered in any court having jurisdiction thereof.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">14.2.2&#160;<font style="font-weight:normal;">The arbitration shall be conducted by a panel of three (3)&#160;persons experienced in the pharmaceutical business: within [ * ] after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within [ * ] of their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by JAMS. The place of arbitration shall be in [ * ], and all proceedings and communications shall be in English.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">14.2.3&#160;<font style="font-weight:normal;">The arbitrators shall apply the terms and conditions of this Agreement and shall not award damages in contradiction to Section&#160;9.5. Each Party shall bear its own costs and expenses and attorneys&#8217; fees and an equal share of the arbitrators&#8217; fees and any administrative fees of arbitration regardless of the outcome of such arbitration.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">14.2.4&#160;<font style="font-weight:normal;">Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an arbitrator may disclose the existence, content or results of an arbitration without the prior written consent of both Parties The arbitrators shall have no authority to award any relief on the basis of any dispute, controversy or claim that is barred by the applicable Delaware statute of limitations.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">14.3&#160;<font style="text-decoration:underline;font-weight:normal;">Injunctive Relief</font><font style="font-weight:normal;">. Notwithstanding anything in this Article 14, each Party shall have the right to seek injunctive or other equitable relief from the arbitrator or a court of competent jurisdiction pursuant to Section&#160;15.8 that may be necessary to avoid irreparable harm, maintain the status quo or preserve the subject matter of the dispute, including any breach or threatened breach of Article 11.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 47</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 15</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">MISCELLANEOUS</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.1&#160;<font style="text-decoration:underline;font-weight:normal;">Severability</font><font style="font-weight:normal;">. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement with respect to such provision may be realized.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.2&#160;<font style="text-decoration:underline;font-weight:normal;">Notices</font><font style="font-weight:normal;">. Any notice required or permitted to be given by this Agreement shall be in writing and shall be delivered by hand or overnight courier with tracking capabilities or mailed postage prepaid by first class, registered or certified mail, return receipt requested and addressed as set forth below unless changed by notice so given:</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Eiger:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350 Cambridge Ave, Suite 350</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palo Alto, CA 94306</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Chief Executive Officer</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3175 Hanover St.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palo Alto, CA 94304</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Glen Sato</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gsato @cooley.com</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to BMS:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol-Myers Squibb Company</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P.O. Box 4000</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Route 206&#160;&amp; Province Line Road</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Princeton, New Jersey 08543-4000</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Vice President, Business Development</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol-Myers Squibb Company</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P.O. Box 4000</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Route 206&#160;&amp; Province Line Road</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Princeton, New Jersey 08543-4000</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Vice President&#160;&amp; Assistant General Counsel, Business Development and Licensing</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any such notice shall be deemed delivered on the date received. A Party may add, delete, or change the person or address to whom notices should be sent at any time upon written notice delivered to the Party&#8217;s notices in accordance with this Section&#160;15.2.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.3&#160;<font style="text-decoration:underline;font-weight:normal;">Force Majeure</font><font style="font-weight:normal;">. Neither Party shall be liable for delay or failure in the performance of any of its obligations hereunder if such delay or failure is due to causes beyond its reasonable control, including </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 48</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">acts of God, fires, earthquakes, strikes and labor disputes, acts of war, terrorism, civil unrest or intervention of any governmental authority (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Force Majeure&#8221;</font><font style="font-weight:normal;">);&#160;</font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that the affected Party promptly notifies the other Party and further provided that the affected Party shall use Commercially Reasonable Efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and shall continue performance with the utmost dispatch whenever such causes are removed. When such circumstances arise, the Parties shall negotiate in good faith any modifications of the terms of this Agreement that may be necessary or appropriate in order to arrive at an equitable solution.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.4&#160;<font style="text-decoration:underline;font-weight:normal;">Assignment</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.4.1&#160;<font style="font-weight:normal;">BMS may, without Eiger&#8217;s consent, (x)&#160;assign, delegate or transfer some or all of its rights and obligations hereunder to any Affiliate of BMS, and (y)&#160;assign or transfer, in connection with any transfer or assignment of all of the BMS Patent Rights and BMS Know-How, to any Third Party (including a successor in interest by reason of merger, consolidation or sale of substantially all of the assets of BMS to which this Agreement relates).</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.4.2&#160;<font style="font-weight:normal;">Eiger may assign or transfer all of its rights and obligations hereunder without BMS&#8217;s consent to a successor in interest by reason of merger, consolidation or sale of substantially all of the assets of Eiger (and so long as such assignment or transfer includes, without limitation, all Approvals, all manufacturing assets relating to this Agreement, and all rights and obligations under this Agreement);&#160;</font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that such successor in interest shall have agreed no later than the closing of such assignment or transfer transaction to be bound by the terms of this Agreement in a writing provided to BMS.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.4.3&#160;<font style="font-weight:normal;">Subject to the foregoing, this Agreement shall inure to the benefit of, and be binding on, the Parties&#8217; permitted successors and assigns. Any assignment or transfer in violation of the foregoing shall be null and void and wholly invalid, the assignee or transferee in any such assignment or transfer shall acquire no rights whatsoever, and the non-assigning non-transferring Party shall not recognize, nor shall it be required to recognize, such assignment or transfer.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.4.4&#160;<font style="font-weight:normal;">In the event that BMS assigns, delegates or otherwise transfers this Agreement in whole or in part, to an Affiliate of BMS, BMS hereby agrees to be jointly and severally liable with any such Affiliates for the actions of such Affiliates and for any and all amounts that become due and payable hereunder to Eiger. In the event that Eiger assigns or otherwise transfers or assigns this Agreement to an Affiliate of Eiger, Eiger hereby agrees to be jointly and severally liable with any such Affiliates for the actions of such Affiliates and for any and all amounts that become due and payable hereunder to BMS.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.4.5&#160;<font style="font-weight:normal;">Notwithstanding anything to the contrary in this Agreement, in the event of any such transfer or assignment to a Third Party (including a successor in interest by reason of merger, consolidation or sale of assets permitted), the intellectual property rights of the acquiring party (if other than one of the Parties) or the acquired party (if acquired by a Party or its Affiliates) shall not be included in the technology licensed to the other Party hereunder to the extent (x)&#160;held by such Third Party that is acquired or is acquiring such Party prior to such transaction, or (y)&#160;such technology is developed thereafter outside the scope of activities conducted with respect to the Licensed Compounds or Licensed Products.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.5&#160;<font style="text-decoration:underline;font-weight:normal;">Further Assurances</font><font style="font-weight:normal;">. Each Party agrees to do and perform all such further acts and things and shall execute and deliver such other agreements, certificates, instruments and documents necessary or that </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 49</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">the other Party may deem advisable in order to carry out the intent and accomplish the purposes of this Agreement and to evidence, perfect or otherwise confirm its rights hereunder.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.6&#160;<font style="text-decoration:underline;font-weight:normal;">Waivers and Modifications</font><font style="font-weight:normal;">. The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation. Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach of such provision or any other provision on such occasion or any succeeding occasion. No waiver, modification, release or amendment of any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by each of the Parties.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.7&#160;<font style="text-decoration:underline;font-weight:normal;">Choice of Law</font><font style="font-weight:normal;">. This Agreement shall be governed by, enforced, and shall be construed in accordance with the laws of the [ * ] without regard to its conflicts of law provisions.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.8&#160;<font style="text-decoration:underline;font-weight:normal;">Jurisdiction</font><font style="font-weight:normal;">. Subject to Article 14, each Party irrevocably submits to the exclusive jurisdiction and venue of the state and federal courts for the [ * ] for the purposes of any suit, action, dispute, or other proceeding arising out of this Agreement or out of any transaction contemplated hereby. Each Party irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated hereby in the state and federal courts for the [ * ], and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.9&#160;<font style="text-decoration:underline;font-weight:normal;">Publicity</font><font style="font-weight:normal;">. Upon execution of this Agreement, Eiger may issue the press release announcing the existence of this Agreement in the form and substance as set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Appendix 5</font><font style="font-weight:normal;">. Each Party agrees not to issue any other press release or other public statement disclosing other information relating to this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, such consent not to be unreasonably withheld, delayed or conditioned,&#160;</font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that such consent shall not be required for any disclosure which is required by Law or the rules of a securities exchange, as reasonably advised by the disclosing Party&#8217;s outside counsel, and&#160;</font><font style="font-style:italic;font-weight:normal;">provided, further</font><font style="font-weight:normal;">, that Eiger may from time to time issue public statements relating to the ongoing Development and/or Commercialization of Licensed Compounds and/or Licensed Products (excluding disclosure of the financial terms of this Agreement) pursuant to this Agreement without the prior written consent of BMS. The Parties agree that any such required disclosure shall not contain confidential business or technical information and, if disclosure of confidential business or technical information is required by Law, the Parties shall use appropriate diligent efforts to minimize such disclosure and obtain confidential treatment for any such information which is disclosed to a governmental agency. Each Party agrees to provide to the other Party a copy of any public announcement regarding this Agreement or the subject matter thereof as soon as reasonably practicable under the circumstances prior to its scheduled release. Except under extraordinary circumstances, each Party shall provide the other with an advance copy of any such announcement at least [ * ] prior to its scheduled release. Each Party shall have the right to expeditiously review and recommend changes to any such announcement and, except as otherwise required by Law, the Party whose announcement has been reviewed shall remove any information the reviewing Party reasonably deems to be inappropriate for disclosure. The contents of any announcement or similar publicity which has been reviewed and approved by the reviewing Party can be re-released by either Party without a requirement for re-approval.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.10&#160;<font style="text-decoration:underline;font-weight:normal;">Relationship of the Parties</font><font style="font-weight:normal;">. Each Party is an independent contractor under this Agreement. Nothing contained herein is intended or is to be construed so as to constitute BMS and Eiger as partners, agents or joint venturers. Neither Party shall have any express or implied right or authority to assume or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 50</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any Third Party.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.11&#160;<font style="text-decoration:underline;font-weight:normal;">Headings</font><font style="font-weight:normal;">. Headings and captions are for convenience only and are not be used in the interpretation of this Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.12&#160;<font style="text-decoration:underline;font-weight:normal;">Entire Agreement</font><font style="font-weight:normal;">. This Agreement constitutes the entire agreement between the Parties as to the subject matter of this Agreement, and supersedes and merges all prior negotiations, representations, agreements and understandings regarding the same.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.13&#160;<font style="text-decoration:underline;font-weight:normal;">Counterparts; Electronic Delivery</font><font style="font-weight:normal;">. This Agreement may be executed in counter-parts with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. Signatures to this Agreement transmitted by email in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;), or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement shall have the same effect as physical delivery of the paper document bearing original signature.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.14&#160;<font style="text-decoration:underline;font-weight:normal;">Performance by Affiliates</font><font style="font-weight:normal;">. Each Party recognizes that the other Party may perform some or all of its obligations under this Agreement through Affiliates to the extent permitted under this Agreement;&#160;</font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that such other Party shall remain responsible for the performance by its Affiliates as if such obligations were performed by such other Party.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.15&#160;<font style="text-decoration:underline;font-weight:normal;">Exports</font><font style="font-weight:normal;">. Eiger agrees not to export or re-export, directly or indirectly, any information, technical data, the direct product of such data, samples or equipment received or generated under this Agreement in violation of any applicable export control Laws.</font></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.16&#160;<font style="text-decoration:underline;font-weight:normal;">Interpretation</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.16.1&#160;<font style="font-weight:normal;">Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.16.2&#160;<font style="font-weight:normal;">The definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;. The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;. The word &#8220;any&#8221; shall mean &#8220;any and all&#8221; unless otherwise clearly indicated by context.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.16.3&#160;<font style="font-weight:normal;">Unless the context requires otherwise, (a)&#160;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (b)&#160;any reference to any Laws herein shall be construed as referring to such Laws as from time to time </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 51</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">enacted, repealed or amended, (c)&#160;any reference herein to any Person shall be construed to include the Person&#8217;s successors and assigns, (d)&#160;the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (e)&#160;all references herein to Articles, Sections or Appendices, unless otherwise specifically provided, shall be construed to refer to Articles, Sections and Appendices of this Agreement; and (f)&#160;the term &#8220;and/or&#8221; in a sentence shall be construed such that the phrase &#8220;X and/or Y&#8221; means &#8220;X or Y, or both X and Y&#8221;.</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:10.46%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.16.4&#160;<font style="font-weight:normal;">This Agreement should be interpreted in its entirety and the fact that certain provisions of this Agreement may be cross-referenced in a Section shall not be deemed or construed to limit the application of other provisions of this Agreement to such Section and vice versa.</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">* * *</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[S<font style="font-size:7.5pt;">IGNATURE</font>&#160;<font style="font-size:7.5pt;">PAGE</font>&#160;<font style="font-size:7.5pt;">FOLLOWS</font>&#160;]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 52</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties have caused this License Agreement to be executed by their respective duly authorized officers.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="middle"  style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">EIGER BIOPHARMACEUTICALS, INC.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Cory</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Cory</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and CEO</p></td>
</tr>
<tr style="height:12pt;">
<td colspan="3" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 19, 2016</p></td>
</tr>
<tr style="height:12pt;">
<td colspan="3" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">BRISTOL-MYERS SQUIBB COMPANY</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Graham R. Brazier</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Graham R. Brazier</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Business Development</p></td>
</tr>
<tr style="height:12pt;">
<td colspan="3" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: April 20, 2016</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 53</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 1</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">BMS Patent Rights</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SEE ATTACHED</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 2</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Initial Development Plan</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 3</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Licensed Compound</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 4</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Transferred Materials to be provided by BMS</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 5</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Press Release</font></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals Announces License of Worldwide Rights to Pegylated Interferon Lambda-1a from Bristol-Myers Squibb</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Including Rights for All Indications and Associated Patents</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PALO ALTO, CALIF,&#160;April 19, 2016&#160;/<font style="text-decoration:underline;">PRNewswire</font>/ &#8212;&#160;Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) announced today that it has licensed Pegylated Interferon Lambda-1a (&#8220;Lambda&#8221;), a novel, well-characterized, first in class Type III interferon to be studied as an investigational therapy for hepatitis delta virus (HDV) infection, from Bristol-Myers Squibb. Lambda has been administered in clinical trials involving over 3,000 subjects. It has not been approved for any indication. Eiger plans to evaluate Lambda as a potential monotherapy and combination treatment for chronic HDV infection, the most aggressive and deadly form of human viral hepatitis.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are very excited to execute this license with Bristol-Myers Squibb.&#160;The addition of Lambda to our pipeline is a significant step toward building a leading HDV franchise,&#8221; said David Cory, President and CEO of Eiger. &#8220;There is no approved therapy for HDV. Along with Lonafarnib, our Phase 2 candidate for the treatment of HDV, Eiger has established a strategic position with the addition of Lambda. Eiger will leverage existing relationships with clinical investigators and clinical sites for efficient exploration of Lambda alone or in combination with other agents toward an approved therapy for HDV.&#8221;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Most cells in the body express the receptor for interferon alpha, a Type I interferon. However, receptors for Lambda, a Type III interferon, are expressed on liver cells, a desirable location for treating viral hepatitis, but less so on some blood cells and non-liver cells. Lambda represents a promising and potentially better tolerated interferon therapy for HDV,&#8221; said Eduardo Martins, MD, DPhil, Senior Vice President of Liver and Infectious Diseases at Eiger.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exclusive worldwide license from Bristol-Myers Squibb involved an upfront payment and the issuance of Eiger Common Stock and includes development and regulatory milestones through first commercial sale in the US, EU, and Japan and milestone payments based on commercial sales achievement as well as tiered annual net sales royalties.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Sarasar&#8482;&#160;(lonafarnib)</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lonafarnib is a well-characterized, late-stage, orally active inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation. HDV uses this host cell process inside liver cells to complete a key step in its life cycle. Lonafarnib inhibits the prenylation step of HDV replication inside liver cells and blocks the virus life cycle at the stage of assembly.&#160;Since prenylation is carried out by a host enzyme, this compound may present a higher barrier to development of viral resistance mutations to therapy.&#160;Lonafarnib has been dosed in over 100 HDV-infected patients across international academic centers and is in Phase 2 development for HDV.&#160;Lonafarnib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and Fast Track Designation by U.S. FDA.&#160;Lonafarnib is not approved for any indication, and is licensed from Merck Sharp&#160;&amp; Dohme Corp. (known as MSD outside of the United States and Canada).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Hepatitis Delta Virus (HDV)</font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hepatitis Delta (or Hepatitis D) is caused by infection with HDV and is considered to be one of the most severe forms of viral hepatitis in humans.&#160;Hepatitis D occurs only as a co-infection in individuals harboring Hepatitis B Virus (HBV).&#160;Hepatitis D leads to more severe liver disease than HBV alone and is associated with accelerated liver fibrosis, liver cancer, and liver failure. Hepatitis D is a disease with a significant impact on global health, which may affect up to approximately 15-20&#160;million people worldwide.&#160;The prevalence of HDV varies among different parts of the world.&#160;Globally, HDV infection is reported to be present in approximately 4.3% to 5.7% of chronic Hepatitis B carriers.&#160;The prevalence of HDV in patients infected with chronic HBV is even higher in certain regions, including certain parts of Mongolia, China, Russia, Central Asia, Pakistan, Turkey, Africa, and South America, with an HDV prevalence as high as 60% being reported in HBV-infected patients in Mongolia and Pakistan.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Eiger</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases.&#160;The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Note Regarding Forward-Looking Statements</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives, intentions, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. Examples of such statements include, but are not limited to, whether or not pegylated interferon lambda-1a or lonafarnib may be further developed and approved, statements relating to the availability of cash for Eiger&#8217;s future operations, Eiger&#8217;s ability to develop its drug candidates for potential commercialization, the timing of the commencement and completion of Phase 2 trials and whether the Lamda product can be successfully developed or commercialized. Eiger may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and one should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including the risks that Eiger&#8217;s planned clinical trials may be prolonged or delayed requiring Eiger to incur additional costs; that Eiger&#8217;s planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities; that Eiger&#8217;s product candidates may have undesirable side effects which may delay or prevent marketing approval; that, even if approved by the FDA or non-U.S. regulatory authorities, Eiger&#8217;s product candidates may not achieve broad market acceptance; and the risks described in the &#8220;Risk Factors&#8221; sections the Registration Statement on Form S-4 (file no. 333-208521) and of Eiger&#8217;s periodic reports filed with the SEC. Eiger does not assume any obligation to update any forward-looking statements, except as required by law.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 2</a> -</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gr4bxuv5eowy000001.jpg" title="" alt="" style="width:199px;height:63px;"></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SOURCE Eiger Bio, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors: Jim Shaffer, Eiger Bio, Inc., 919-345-4256, jshaffer@eigerbio.com</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 3</a> -</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 6</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Documentation to be provided</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1 -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 7</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Form of Stock Purchase Agreement</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 8</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exceptions to Section 9.2</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 9</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">List of &#8216;Knowledge&#8221; Individuals of BMS</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 10</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Reagents and Research Tools</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appendix 11</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Third Party Agreements</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- 1</a> -</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>5
<FILENAME>eigr-ex1017_1142.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex1017_1142.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65347363"></a>[*] =<font style="font-weight:normal;">&#160;</font><font style="font-family:Times New Roman Bold;font-weight:normal;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AMENDMENT #6 TO LICENSE AGREEMENT</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amendment #6 to License Agreement (&#8220;Amendment #6&#8221;) is entered into as of the date of last signature below (&#8220;Amendment #6 Effective Date&#8221;) by and between Merck Sharp &amp; Dohme Corp. (formerly known as Schering Corporation), a New Jersey corporation having a place of business at 2000 Galloping Hill Road, Kenilworth, NJ 07033 (&#8220;Merck&#8221;) and Eiger BioPharmaceuticals, Inc., a Delaware corporation having a place of business at 350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306 (&#8220;Licensee&#8221;) (each of Merck and Licensee, a &#8220;Party&#8221;, and together, the &#8220;Parties&#8221;) to amend that certain License Agreement between the Parties dated September 3, 2010, as amended on January 18, 2011 and subsequently first amended June 11, 2013, as second amended November 20, 2014, as third amended March 6, 2015, as fourth amended June 9, 2015, and as fifth amended December 15, 2015 (collectively, the &#8220;Agreement&#8221;).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN CONSIDERATION OF the mutual promises and covenants contained herein, the parties agree as follows:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>1.<font style="margin-left:26pt;"></font>Definitions.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:10.96%;text-indent:-5.03%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The following definition is hereby added to Article I of the Agreement:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Progeria</font>&#8221; shall mean Hutchinson-Gilford Progeria Syndrome.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>(b)<font style="margin-left:26pt;"></font>Section 1.18 of the Agreement is hereby deleted and replaced with the following:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1"></a>&#8220;<font style="text-decoration:underline;">Field</font>&#8221; means (i) the use of the Licensed Compound or Licensed Product for all human antiviral applications, except for the treatment of Hepatitis C virus, Hepatitis B virus, or HIV infections, provided, however, that the Field specifically includes, without limitation, the treatment of Hepatitis D virus infections, including the treatment of patients co-infected with Hepatitis D virus and either or both of Hepatitis C virus and Hepatitis B virus; and (ii) the Progeria Field.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_5"></a><a name="_cp_blt_1_6"></a><a name="_cp_blt_2_2"></a>&#160;<font style="margin-left:26pt;"></font>(c)<font style="margin-left:26pt;"><a name="_cp_blt_2_5"></a><a name="_cp_blt_1_6"></a><a name="_cp_blt_2_2"></a></font>The definition of the term &#8220;Progeria Field&#8221;, as set forth in Amendment #5 to the Agreement, is hereby deleted and replaced with the following:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Progeria Field</font>&#8221; shall mean the use of any Licensed Product (including the Licensed Progeria Product) for purposes related to the treatment of Progeria in humans.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_7"></a><a name="_cp_blt_1_8"></a>&#160;<font style="margin-left:26pt;"></font>(d)<font style="margin-left:26pt;"><a name="_cp_blt_2_7"></a><a name="_cp_blt_1_8"></a></font>The definition of the term &#8220;Licensed Progeria Product&#8221; as set forth in Amendment #5 to the Agreement, is hereby deleted and replaced with the following:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_9"></a>&#8220;<font style="text-decoration:underline;">Licensed Progeria Product</font>&#8221; shall mean a Licensed Product in finished capsule form containing the Licensed Compound as the sole active pharmaceutical ingredient for use in the Progeria Field&#8221;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-top:12pt;margin-bottom:0pt;line-height:10pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><a name="_cp_text_2_11"></a><a name="_cp_blt_2_10"></a>&#160;<font style="margin-left:26pt;"></font>(e)<font style="margin-left:26pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><a name="_cp_text_2_11"></a><a name="_cp_blt_2_10"></a></font>The definition of the term &#8220;First Indication&#8221;, as set forth in Section 1.20 of the Agreement, is hereby deleted and replaced&#160;throughout the Agreement&#160;with the following:<font style="margin-left:26pt;"></font>&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_12"></a>&#8220;<font style="text-decoration:underline;">First Antiviral Indication</font>&#8221; means treatment of the Hepatitis D virus infections in humans.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>2.<font style="margin-left:26pt;"></font>Section 2.1 of the Agreement is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;<font style="text-decoration:underline;">License Grant</font>. Subject to the terms and conditions of this Agreement, including Merck&#8217;s retained rights under Section 2.3, Merck hereby grants to Licensee&#160;&#160;an exclusive (even as to Merck), sub-licensable (subject to the obligations and restrictions in&#160;<font style="text-decoration:underline;">Section 2.5</font>), royalty-bearing license under the Merck Know-How, Compound Patent Rights, and Merck&#8217;s interest in any solely or jointly owned Program IP to Develop, make, have made, use, import, export, Commercialize, sell, offer for sale, and market the Licensed Compound and Licensed Product in the Field in the Territory.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<font style="text-decoration:underline;">License Expansion</font>. In the event Licensee would like to expand the license granted in this Section 2.1 beyond the Field, it shall provide Merck with a reasonably detailed development plan including evidence of existing resources and capabilities, and proposed terms relating thereto. Merck will consider any such proposed requests from Licensee&#160;in good faith.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>3.<font style="margin-left:26pt;"></font>Section 2.3 of the Agreement is hereby deleted in its entirety and replaced with the following:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Retained Rights; Covenants</font>. Merck retains any and all other rights under the Compound Patent Rights and Merck Know-How that are outside the scope of the license granted under Section 2.1, including, for the avoidance of doubt, the right to Develop the Licensed Compound and Licensed Product outside the Field. Notwithstanding the foregoing, Merck shall not Commercialize the Licensed Compound or Licensed Product or grant any Third Party any license or right under any Compound Patent Rights and/or Merck Know-How rights to Commercialize the Licensed Compound or the Licensed Product for any use whether in or outside of the Field. Licensee shall not grant any Third Party any license or right under any Compound Patent Rights and/or Merck Know-How, other than as expressly permitted by this Agreement.&#160;&#160;Any breach of this Section 2.3 shall be deemed a material breach of the Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;"><br /></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">[ * ] = <font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:normal;font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>&#160;<font style="margin-left:26pt;"></font>4.<font style="margin-left:26pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a></font>Section 2.5(e) of the Agreement (as subsequently amended) is hereby deleted in its entirety and replaced with the following:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)Licensee shall, in each agreement under which it grants a sublicense under the license set forth in Section 2.1 (each, a &#8220;Sublicense Agreement&#8221;), require the sublicensee to transfer to Merck, if Merck terminates this Agreement under Section 12.4, and to Licensee, if only such Sublicense Agreement terminates, (i) all regulatory filings and Regulatory Approvals held, possessed or Controlled by such sublicensee&#160;with respect to a Licensed Product and (ii) all patent rights and Know-How Controlled by such sublicensee with respect to a Licensed Product or its use, Manufacture, sale, or importation (which patent rights and Know-How shall be transferred either by assignment or by a freely sublicensable exclusive license).&#160;&#160;In the event that this Agreement terminates other than for breach by a sublicensee, Merck may, in its sole discretion, elect to enter in an agreement with each sublicensee on the same terms as the existing Sublicense Agreement.&#160;&#160;All Sublicense Agreements shall be consistent with the terms and conditions of this Agreement.&#160;&#160;Licensee shall (I) use reasonable efforts to procure the performance by any sublicensee of the terms of each applicable Sublicense Agreement and (II) be responsible to Merck for any material breach by a sublicensee of any terms and conditions of this Agreement or obligations of Licensee hereunder<font style="color:#0000FF;">.</font>&#160;Licensee hereby guarantees the performance of its sublicensees that are party to a Sublicense Agreement as permitted herein, and the grant of any such sublicense will not relieve Licensee of its obligations under this Agreement, except to the extent they are satisfactorily performed by such sublicensee.&#160;&#160;[ * ].</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>5.<font style="margin-left:26pt;"></font>Section 3.2(b) is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Development Plan</font>. Licensee shall provide Merck with a reasonably detailed report updating its Development activities and timelines with respect to the following Calendar Year in accordance with Section 3.2(c) (the &#8220;Development Plan&#8221;).&#160;&#160;[ * ]. At Merck's written request, the President of Merck's research division, or his designee, and the President of Licensee's research division or equivalent position, or his designee, shall meet to discuss such comments. Any revision of the clinical protocols shall be submitted to Merck promptly after their completion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">[ * ] = <font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:normal;font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>&#160;<font style="margin-left:26pt;"></font>6.<font style="margin-left:26pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a></font>Section 3.7 is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Commercialization of Licensed Product in the Field</font>. Licensee hereby covenants that it shall not, nor shall it authorize any Affiliate, permitted sublicensee or Third Party contractor to Commercialize Licensed Product in the Territory for any use outside the Field.&#160;&#160;Merck hereby covenants that neither it nor its Affiliates shall Commercialize the Licensed Compound or Licensed Product or grant any Third Party any license or right under any Compound Patent Rights and/or Merck Know-How rights to Commercialize the Licensed Compound or the Licensed Product for any use whether in or outside of the Field.&#160;&#160;[ * ]. To the extent either Party can prove the other Party materially breached this Section 3.7(a), such material breach shall permit such non-breaching Party to terminate this Agreement for cause under Section 12.4.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>7.<font style="margin-left:26pt;"></font>Sections 4.1(d) and 4.1(e) are each hereby deleted in their entirety and replaced with the following:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)Licensee shall be solely responsible for (i) interfacing, corresponding and meeting with the FDA and other Regulatory Authorities throughout the Territory with respect to Licensed Product in the Field, including the Progeria Field and (ii) obtaining and maintaining Regulatory Approvals in the Territory with respect to Licensed Products in the Field, including the Progeria Field.&#160;&#160;Merck shall be under no obligation to provide Licensee with Regulatory assistance in fulfilling the necessary regulatory activities to achieve Regulatory Approval in the Field, including the Progeria Field, in the Territory other than providing copies of any available data in Merck&#8217;s possession during the Term required to be submitted for obtaining and maintaining Regulatory Approvals in the Territory with respect to the Licensed Products in the Field, including the Progeria Field. Assistance shall include copies of material correspondence with FDA or other Regulatory Authorities in the United States, the Major European Countries and Japan relating to Regulatory Approval of Licensed Product, and responding to all reasonable inquiries by the other Party with respect thereto.&#160;&#160;Each Party shall also provide the other Party in a timely manner with meeting minutes from any material meetings with Regulatory Authorities in the United States, the Major European Countries and Japan concerning the Regulatory Approval of Licensed Product in the Field, including the Progeria Field.&#160;&#160;For mutual convenience, Licensee shall direct any such material correspondence with Regulatory Authorities, or any requests for data from Merck, via the following e-mail address&#160;[ * ].</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:32.88%;text-indent:-10.05%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:51pt;"></font>(e)<font style="margin-left:51pt;"></font>Licensee shall provide Merck with a table report on an annual basis that contains the status of Regulatory Approvals for the Licensed Product in the Field in the Territory.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">[ * ] = <font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:normal;font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>&#160;<font style="margin-left:26pt;"></font>8.<font style="margin-left:26pt;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a></font>The following is added as Section 4.4 to the Agreement:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Regulatory Approvals; Progeria Field</font>. Licensee agrees to use Commercially Reasonable Efforts to achieve Regulatory Approval for a Licensed Product in the Progeria Field in the Territory.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>9.<font style="margin-left:26pt;"></font>Section 6.1 of the Agreement is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Manufacturing Responsibility</font>. Licensee will be solely responsible for the Manufacture of Licensed Compound and Licensed Product for Development and Commercialization of Licensed Product by Licensee, its Affiliates and its sublicensees in the Field in the Territory.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>10.<font style="margin-left:26pt;"></font>The following sentence is added to the end of Section 6.2 of the Agreement:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, as of the Amendment #6 Effective Date,&#160;&#160;&#160;&#160;&#160;&#160; [ *].</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>11.<font style="margin-left:26pt;"></font>Section 6.3 of the Agreement is hereby deleted in its entirety.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>12.<font style="margin-left:26pt;"></font>Section 6.5 is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5 Licensee acknowledges receipt of Licensed Product, Licensed Compound, and Starting Material, as described in Amendment #5 from Merck.&#160;&#160;Licensee shall have sole responsibility for its supply of Licensed Compound and Licensed Product for purposes of the Agreement.&#160;&#160;In the event that Licensee requests any additional Starting Material, and to the extent such Starting Material is available, Merck shall employ good faith efforts to transfer such available Starting Material to Licensee's designated CMO as soon as practicable at a cost of [ * ] plus a reasonable cost of shipping.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>13.<font style="margin-left:26pt;"></font>Section 6.6 is hereby deleted in its entirety and replaced with the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>6.6(a)&#160;<font style="text-decoration:underline;">Manufacture and Transfer</font>.&#160;&#160;During the Term and subject to all applicable provisions of the Agreement, Licensee will be responsible for the Manufacture and supply of PRF&#8217;s requirements for Licensed Progeria Product in [ * ], and/or [ * ] capsules as may be separately agreed with PRF under the supply agreement referenced in Section 6.6(b) as reasonably requested with respect to delivery dates and quantities for use by PRF in the Progeria Field in the Territory, at no cost to PRF or Merck.&#160;&#160;Licensee will be responsible for the Manufacture and supply of Licensed Compound and/or Licensed Product for Merck&#8217;s use pursuant to&#160;<font style="text-decoration:underline;">Section 2.3</font>&#160;as reasonably requested by Merck from time to time during the Term of the Agreement<font style="color:#0000FF;">&#160;</font>solely for Merck to exercise its right to Develop the Licensed Compound and Licensed Product outside the Field pursuant to</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">[ * ] = <font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:normal;font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 2.3; provided that Merck shall pay actual labelling and shipping and handling costs for delivery of Licensed Product to Merck for quantities delivered for such uses. For any requests exceeding&#160;[&#160;*&#160;]&#160;of Licensed Compound, Merck will compensate Eiger for the cost of such drug plus&#160;[&#160;*&#160;]. Licensee shall transfer to Merck such amounts of Licensed Compound and/or Licensed Product on such schedule as is&#160;mutually agreed based on&#160;reasonable&#160;requests&#160;by Merck for Merck&#8217;s use pursuant to&#160;<font style="text-decoration:underline;">Section 2.3</font>.&#160;&#160;Notwithstanding the foregoing, Licensee shall&#160;[&#160;*&#160;].</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6(b)&#160;<font style="text-decoration:underline;">PRF Supply Agreement</font>. Within ten (10) days of the Amendment #6 Effective Date, Licensee shall execute an agreement with PRF for the supply of Licensed Progeria Product needed by PRF, at no cost to PRF, to be used by PRF for (i) Development purposes in the Progeria Field and (ii) expanded access beyond clinical trials.&#160;&#160;[ * ].</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6(c)&#160;&#160;<font style="text-decoration:underline;">Continuity of Supply to PRF</font>.&#160;&#160;(A) Upon expiration or termination of this Agreement; and/or (B) [ * ]; or (C) at any time in the event that Licensee terminates (i) this Agreement pursuant to Article XII, (ii) Licensee&#8217;s Development, Manufacture or Commercialization of Licensed Product under this Agreement, (iii) Licensee&#8217;s supply agreement contemplated in&#160;<font style="text-decoration:underline;">Section 6.6(b)</font>; or (iv) Licensee&#8217;s Sublicense Agreement(s) with its CMO(s) for the Manufacture of Licensed Product, Licensee hereby grants to Merck [ *&#160;<font style="text-decoration:underline;">]</font>. In the event that Merck does not [ * ], then Licensee shall use commercially reasonable efforts to [ * ].&#160;&#160;Merck shall have the right, but not the obligation, at its sole discretion, to purchase any raw materials, in process materials and/or finished goods originally manufactured for Licensee in the amounts deemed desirable by Merck and at Licensee&#8217;s cost of goods.&#160;&#160;Merck shall have no obligation to purchase remaining materials in inventory.&#160;&#160;[ * ].</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>14.<font style="margin-left:26pt;"></font>The following shall be added as Section 7.2(d) to the Agreement:</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">No Progeria Milestone Payments</font>. Licensee shall have no obligation to make any milestone payments to Merck in relation to any Licensed Product (including the Licensed Progeria Product) for use in the Progeria Field.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>15.<font style="margin-left:26pt;"></font>Section 7.3(b) to the Agreement<font style="font-family:Calibri;">&#160;</font>is hereby deleted in its entirety and replaced with the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_14"></a><a name="_cp_text_1_13"></a><a name="_cp_text_2_15"></a><font style="text-decoration:underline;">Term of Royalty Obligation.</font>&#160;&#160;Royalties on the Licensed Product shall commence upon the First Commercial Sale of a Licensed Product&#160;in a particular country in the Territory and will continue, on a product-by-product and country-by-country basis, until the [ * ]&#160;of the date of First Commercial Sale of the Licensed Product for the First Antiviral Indication in such country (&#8220;Royalty Term&#8221;).&#160;&#160;For clarity, during the Royalty Term, the royalty payments pursuant to this Section 7.3 shall be payable regardless of whether it is Licensee, its Affiliate, or its sublicensee that is selling the Licensed Product.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">[ * ] = <font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:normal;font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>16.<font style="margin-left:26pt;"></font>The following shall be added as Section 7.3(c) to the Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_16"></a><a name="_cp_text_1_18"></a><a name="_cp_text_1_20"></a><a name="_cp_text_1_22"></a><a name="_cp_text_2_23"></a><a name="_cp_text_1_24"></a><a name="_cp_text_1_25"></a><a name="_cp_text_1_27"></a><a name="_cp_text_1_28"></a><a name="_cp_text_1_26"></a><font style="text-decoration:underline;">Licensed Progeria Product Royalty Exemption</font>. It is understood and agreed by the Parties that it is Merck&#8217;s intent that it shall receive no royalties for sales of Licensed Progeria Product. Subject to Regulatory Approval for Licensed Progeria Product, Merck shall receive no royalties on the sale of any Licensed Progeria Product for the [ * ]&#160;sold per Calendar Year (the approximate quantity needed to treat the currently estimated worldwide prevalence of patients with Progeria per year).&#160;&#160;The Parties shall amend the Agreement to adjust&#160;this amount in the future if there is a change in prevalence&#160;rates of Progeria or&#160;changes in the approved dosing regimen for Licensed Progeria Product in the Progeria Field. In order for the Parties to effectuate the intent of this Section 7.3(c), Licensee&#8217;s Net Sales reports for Licensed Product (including the Licensed Progeria Product) as required by Section 7.4(a) shall include [&#160;* ]&#160;in such Calendar Quarter.&#160;&#160;For clarity, Additional Indication shall not include the treatment or amelioration of Progeria.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>17.<font style="margin-left:26pt;"></font>Section 13.3 is hereby deleted in its entirety and replaced with the following:</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:21.91%;margin-right:10.9%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Equitable Relief</font>.&#160;&#160;By agreeing to arbitration, the Parties do not intend to deprive any competent court of such court's jurisdiction to issue a pre-arbitral injunction, pre-arbitral attachment or other order in aid of the arbitration proceedings and the enforcement of any award or judgment. Without prejudice to such provisional remedies in aid of arbitration as may be available under the jurisdiction of a national court, the court of arbitration shall have full authority to grant provisional remedies and to award damages for failure of any Party to respect the court of arbitration's order to that effect. With respect to any pre-arbitral preliminary injunction sought under this Section 13.3, both Parties agree to waive any requirement that the other (i)&#160;post a bond or other security as a condition for obtaining any such relief or (b)&#160;show irreparable harm, balancing of harms, consideration of the public interest, or inadequacy of monetary damages as a remedy.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>18.<font style="margin-left:26pt;"></font>Except as set forth herein, all capitalized terms not defined in this Amendment #6 shall have the meanings given to them in the Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>19.<font style="margin-left:26pt;"></font>In the event of any inconsistency between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall govern.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="margin-left:26pt;"></font>20.<font style="margin-left:26pt;"></font>Except as expressly amended hereby, all of the terms and conditions of the Agreement remain in full force and effect.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><a name="_Hlk65347364"></a>&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">[ * ] = <font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:normal;font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties have executed this Amendment #6 by their duly authorized representatives as of the Amendment #6 Effective Date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="bottom"  style="width:48.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p></td>
<td valign="top"  style="width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:48.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Merck Sharp &amp; Dohme Corp.</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:48.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="width:48.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Cory</p></td>
<td valign="top"  style="width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.38%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Bryan Rafalko</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:0.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, CEO</p></td>
<td valign="top"  style="width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:0.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, Director of Business Development and Licensing</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:7.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:0.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/15/18</p></td>
<td valign="top"  style="width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:0.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/15/18</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">[ * ] = <font style="font-family:Times New Roman Bold;font-size:10pt;font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>6
<FILENAME>eigr-ex1018_1141.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex1018_1141.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;"><a name="_Hlk65350926"></a>[&#160;&#160;*&#160;&#160;] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;text-transform:uppercase;font-family:Times New Roman;font-size:11pt;font-style:normal;font-variant: normal;"><a name="_cp_text_1_56"></a>COLLABORATION AND SUPPLY AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:10.05%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This&#160;<font style="font-weight:bold;font-variant: small-caps;">Collaboration and Supply Agreement</font>&#160;(&#8220;<font style="font-weight:bold;">Agreement</font>&#8221;) is made and entered into as of May 15, 2018 (the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;) by and between Eiger BioPharmaceuticals, Inc., a Delaware corporation having a place of business at 350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306 (&#8220;<font style="font-weight:bold;">Eiger</font>&#8221;), and The Progeria Research Foundation, Inc., a 501(c)(3) not-for-profit organization currently located at 200 Lake St., Peabody MA 01960 (&#8220;<font style="font-weight:bold;">PRF</font>&#8221;).&#160;&#160;Eiger and PRF are individually referred to as a &#8220;<font style="font-weight:bold;">Party</font>&#8221; and collectively referred to as the &#8220;<font style="font-weight:bold;">Parties.</font>&#8221;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:10.05%;font-weight:bold;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, PRF is engaged in research, development, investigation and testing activities for the treatment of Progeria (as defined below) and diseases related to Progeria;</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:10.05%;font-weight:bold;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Eiger</font>&#160;<font style="font-weight:normal;font-variant: normal;">is engaged in the business of the research, development and commercialization of pharmaceutical products;</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:10.05%;font-weight:bold;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Eiger and Merck Sharp &amp; Dohme Corp. (successor-in-interest of Schering Corporation), a New Jersey corporation having a place of business at 2000 Galloping Hill Road, Kenilworth, NJ 07033 (&#8220;</font><font style="font-variant: normal;">Merck</font><font style="font-weight:normal;font-variant: normal;">&#8221;) are parties to that certain License Agreement, dated September 3, 2010, as amended (the &#8220;</font><font style="font-variant: normal;">Merck License Agreement</font><font style="font-weight:normal;font-variant: normal;">&#8221;), under which Eiger obtained a license from Merck to develop, make, use and commercialize lonafarnib for certain uses;</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:10.05%;font-weight:bold;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, Eiger and Merck have agreed that Eiger will license and supply lonafarnib to PRF and that Eiger and Merck will execute an amendment to the Merck License Agreement (&#8220;</font><font style="font-variant: normal;">Merck Amendment</font><font style="font-weight:normal;font-variant: normal;">&#8221;) expanding the license from Merck to Eiger for exclusive (even as to Merck) license rights to lonafarnib in certain specified indications, including Progeria, and, as between Merck and Eiger during the term of the Merck License Agreement and Merck Amendment, making Eiger solely responsible for granting a sublicense to PRF with respect to lonafarnib in the Field (as defined below) and supplying lonafarnib to PRF, in each case, on terms and conditions agreed upon by PRF and Eiger; and</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:10.05%;font-weight:bold;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, the Parties desire to collaborate to explore the use and commercialization of lonafarnib in the treatment of Progeria;</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:10.05%;font-weight:bold;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">Now therefore<font style="font-weight:normal;font-variant: normal;">, in consideration of the mutual promises and agreement set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="text-decoration:underline;">Definitions</font><font style="font-weight:normal;">.&#160;&#160;The following terms shall have the following respective meanings when used in this Agreement:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="font-weight:normal;">&#8220;</font>Additional Site<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(e)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(b)</font><font style="font-weight:normal;">&#8220;</font>Affiliate<font style="font-weight:normal;">&#8221; of a Party means any person or entity that at any time is controlling, controlled by, or under common control with such Party, where &#8220;control&#8221; (or any of its correlates) means beneficial ownership, directly or indirectly, of more than fifty percent (50%) of the equity or other interests entitled to vote for the election of directors or equivalent governing body of a person or entity.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-top:12pt;margin-bottom:0pt;line-height:10pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="text-decoration:underline;">(c)</font><font style="font-weight:normal;">&#8220;</font><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CoA</font><font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(c)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(d)</font><font style="font-weight:normal;">&#8220;</font>Combination Drug<font style="font-weight:normal;">&#8221; means a co-formulated pharmaceutical product or product candidate containing the Licensed Compound and one or more active pharmaceutical ingredient(s) in a single vehicle.&#160;&#160;For the avoidance of doubt, a Combination Drug does not cover the simultaneous administration of the Licensed Compound and one or more active pharmaceutical ingredients using more than one (1) vehicle.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(e)</font><font style="font-weight:normal;">&#8220;</font>Commercialize<font style="font-weight:normal;">&#8221; or &#8220;</font>Commercialization<font style="font-weight:normal;">&#8221; means all activities comprising or relating to the manufacture, promotion, marketing, advertising, sale, distribution, disposal and other exploitation of any Licensed Products, including any Research Activities and any activities necessary to maintain any regulatory approvals.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(f)</font><font style="font-weight:normal;">&#8220;</font>Controlled<font style="font-weight:normal;">&#8221; means, with respect to any Intellectual Property, know-how or Data, a Party has the legal authority or right (whether by ownership, license or otherwise) to grant a license, sublicense, right of access or right to use (as applicable) with respect to such Intellectual Property, know-how or Data to the other Party on the terms and conditions set forth in this Agreement at the time of such grant, in each case without breaching the terms of any applicable agreement with a third party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(g)</font><font style="font-weight:normal;">&#8220;</font>Data<font style="font-weight:normal;">&#8221; means, in any form or format, all clinical and non-clinical data, natural history data, correspondence with all regulatory authorities, regulatory documents , orphan drug designation of lonafarnib for Progeria (pursuant to 21 CFR &#167;&#160;316.27) or other regulatory exclusivities owned or Controlled by a Party, including any data relating to any Licensed Product collected, compiled, reviewed or analyzed by Accenture PLC and any summaries, memoranda or analyses prepared by Accenture PLC with respect to any such data.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(h)</font><font style="font-weight:normal;">&#8220;</font>Default<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(h)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(i)</font><font style="font-weight:normal;">&#8220;</font>Defense<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20(d)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(j)</font><font style="font-weight:normal;">&#8220;</font>Eiger Indemnified Parties<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20(c)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(k)</font><font style="font-weight:normal;">&#8220;</font>FDA<font style="font-weight:normal;">&#8221; means the U.S. Food and Drug Administration, an agency of the U.S. Department of Health and Human Services.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(l)</font><font style="font-weight:normal;">&#8220;</font>Federal Arbitration Act<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 27(b)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(m)</font><font style="font-weight:normal;">&#8220;</font>Field<font style="font-weight:normal;">&#8221; means the treatment of Progeria.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(n)</font><font style="font-weight:normal;">&#8220;</font>IND<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 5(c)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(o)</font><font style="font-weight:normal;">&#8220;</font>Indemnified Party<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20(d)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(p)</font><font style="font-weight:normal;">&#8220;</font>Indemnifying Party<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20(d)</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;"><br /></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="text-decoration:underline;">(q)</font><font style="font-weight:normal;">&#8220;</font>Initial Term<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 21</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(r)</font><font style="font-weight:normal;">&#8220;</font>Intellectual Property<font style="font-weight:normal;">&#8221; means all patents, copyrights, trademarks, trade secrets and all other intellectual property and industrial property under the laws of any jurisdiction and all rights in, to and under each of the foregoing, together with all applications for registration or issuances with respect to any of the foregoing and all registrations and issuances with respect to any of the foregoing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(s)</font><font style="font-weight:normal;">&#8220;</font>JSC<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 4</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(t)</font><font style="font-weight:normal;">&#8220;</font>Licensed API<font style="font-weight:normal;">&#8221; means (i) prior to the filing of the Progeria NDA, the active pharmaceutical ingredient of the Licensed Compound in the form as previously supplied to PRF by Eiger prior to the Effective Date or (ii) following the filing of the Progeria NDA, the form of the active pharmaceutical ingredient of the Licensed Compound used for the Licensed Progeria Product under the Progeria NDA.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(u)</font><font style="font-weight:normal;">&#8220;</font>Licensed Compound<font style="font-weight:normal;">&#8221; means that certain compound known as of the Effective Date as lonafarnib with the chemical structure described in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Exhibit A</font><font style="font-weight:normal;">, including any prodrug, metabolite, salt, ester, solvate, hydrate or crystalline form thereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(v)</font><font style="font-weight:normal;">&#8220;</font>Licensed Product<font style="font-weight:normal;">&#8221; means any (i) pharmaceutical product or product candidate that contains the Licensed Compound, either alone or in combination with one or more other active pharmaceutical ingredients (including all formulations, line extensions and modes of administration thereof) and (ii) Licensed API.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(w)</font><font style="font-weight:normal;">&#8220;</font>Licensed Progeria Product<font style="font-weight:normal;">&#8221; means any Licensed Product in finished capsule form containing lonafarnib as the sole active pharmaceutical ingredient (i) as manufactured and supplied by or on behalf of Eiger to Boston Children&#8217;s Hospital&#160;&#160;pursuant to the Boston Children&#8217;s Hospital Investigator Sponsored Clinical Trial Research Agreement, dated October 4, 2016, as amended on October 28, 2016, by and between Eiger and Boston Children&#8217;s Hospital or (ii) following the filing of the Progeria NDA, as submitted to the FDA under the Progeria NDA.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(x)</font><font style="font-weight:normal;">&#8220;</font>Losses<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20(b)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(y)</font><font style="font-weight:normal;">&#8220;</font>Merck License Agreement Termination Notice<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 22(b)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(z)</font><font style="font-weight:normal;">&#8220;</font>NDA<font style="font-weight:normal;">&#8221; means any new drug application (as defined in Title 21 of the United States Code of Federal Regulations, as amended from time to time) filed with the FDA seeking regulatory approval to market and sell any Licensed Product in the United States for a particular indication.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(aa)</font><font style="font-weight:normal;">&#8220;</font>Non-Conforming Product<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 12(a)</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(bb)<font style="font-weight:normal;">&#8220;</font>Pre-existing Eiger IP<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 15</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(cc)<font style="font-weight:normal;">&#8220;</font>Pre-existing PRF IP<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 15</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(dd)<font style="font-weight:normal;">&#8220;</font>PRF IND<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 5(c)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ee)<font style="font-weight:normal;">&#8220;</font>PRF Indemnified Parties<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20(b)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ff)<font style="font-weight:normal;">&#8220;</font>PRF Second Source<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(g)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(gg)<font style="font-weight:normal;">&#8220;</font>Progeria<font style="font-weight:normal;">&#8221; means Hutchinson-Gilford Progeria Syndrome and progeroid laminopathies.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(hh)<font style="font-weight:normal;">&#8220;</font>Progeria NDA<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 5(a)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="font-weight:normal;">&#8220;</font>Progeria PRV<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 6(a)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(jj)<font style="font-weight:normal;">&#8220;</font>PRV Sale<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 6(a)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(kk)<font style="font-weight:normal;">&#8220;</font>Publishing Party<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 17(a)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ll)<font style="font-weight:normal;">&#8220;</font>Renewal Term<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 21</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(mm)<font style="font-weight:normal;">&#8220;</font>Research Activities<font style="font-weight:normal;">&#8221; means any research, development, investigation or testing activities (including any activities in connection with any pre-clinical research or clinical trials and any activities conducted under any PRF IND (as defined below)) using any Licensed Product conducted by, on behalf of, under the direction or supervision of, as instructed by, with funding from or in collaboration with PRF.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(nn)<font style="font-weight:normal;">&#8220;</font>Right of Reference<font style="font-weight:normal;">&#8221; means any written and signed statement by a Party to the applicable regulatory authority that authorizes such regulatory authority to reference data and information submitted previously by such Party to such regulatory authority, as described in 21 CFR &#167;&#160;312.23(b), or the equivalent authorization in a jurisdiction other than the United States.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(oo)<font style="font-weight:normal;">&#8220;</font>Term<font style="font-weight:normal;">&#8221; shall have the meaning set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 21</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="text-decoration:underline;">License Grants; Certain Covenants</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="font-weight:normal;">Subject to the terms and conditions of this Agreement, Eiger hereby grants to PRF a non-exclusive, world-wide, royalty-free, fully paid-up sub-licensable (i) license under and to all Intellectual Property, know-how and Data Controlled by Eiger or any of its Affiliates and (ii) sublicense under and to all Intellectual Property, know-how and Data licensed by Merck or any of its Affiliates to Eiger or any of its Affiliates, in each case (i) and (ii) solely to (A) conduct or perform, or have conducted or performed, any Research Activities using any Licensed Product in the Field and (B) prepare, file, own and maintain any Progeria IND.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="font-weight:normal;">Subject to the terms and conditions of this Agreement, PRF hereby grants to Eiger a non-exclusive, world-wide, fully paid-up, sub-licensable license under and to all Intellectual Property, know-how and Data Controlled by PRF solely to prepare and file any NDA for the Licensed Product, including the Progeria NDA.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="font-weight:normal;">Eiger shall not amend the Merck License Agreement to narrow or limit the scope of the Licensed Progeria Product or Eiger&#8217;s rights with respect to the Licensed Progeria Product or any Intellectual Property, know-how or Data related thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_4"></a>(d)<font style="font-weight:normal;">After the Effective Date, Eiger shall not, without PRF&#8217;s prior written consent, enter into any agreement or amend any agreement that would limit Eiger&#8217;s ability to fulfill its obligations pursuant to this Agreement, provided that this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 2(d)</font><font style="font-weight:normal;">&#160;shall not be deemed to limit or restrict Eiger&#8217;s ability, or require PRF&#8217;s consent, to amend or terminate an existing manufacturing agreement, or enter into a new manufacturing agreement, for Licensed Progeria Product so long as (i) Eiger replaces any existing manufacturer with at least a comparable manufacturer and (ii) Eiger continues to fulfill its obligations pursuant to this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="font-weight:normal;">PRF shall not conduct or have conducted any clinical trial involving use in humans of the Licensed Progeria Product in the Field at any Additional Site if such Additional Site does not agree in a written agreement (to which Eiger is an express third party beneficiary) to indemnify the Eiger Indemnified Parties for any Losses resulting from any suit, action, claim, demand or proceeding of any kind or nature arising from any death of, or bodily injury to, any person enrolled in such clinical trial that is caused by the ingestion or use of the Licensed Progeria Product by such person in the conduct of such clinical trial (except to the extent arising from (i) Eiger&#8217;s breach of any of its representations, warranties, covenants or agreements set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 18</font><font style="font-weight:normal;">, (ii) any of Eiger&#8217;s actions or failure to take action with respect to any Licensed Progeria Product in accordance with this Agreement or (iii) Eiger&#8217;s negligence or willful misconduct).&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="text-decoration:underline;">No Implied License</font><font style="font-weight:normal;">.&#160;&#160;Nothing herein shall be deemed to grant either Party or any third party acting on behalf of either Party any implied license or right under any Intellectual Property rights Controlled by the other Party except as expressly set forth in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="text-decoration:underline;">Management of Collaboration</font><font style="font-weight:normal;">.&#160;&#160;Within [ * ] after the execution of this Agreement, the Parties shall establish a Joint Steering Committee (&#8220;</font>JSC<font style="font-weight:normal;">&#8221;) to oversee the preparation and filing of regulatory filings and collaboration activities of the Parties (including as further described in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 4(c)</font><font style="font-weight:normal;">) and to conduct or perform any other activities as the Parties may agree upon in writing.&#160;&#160;</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;"><br /></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><a name="_cp_text_1_12"></a>(a)<font style="font-weight:normal;">The JSC will be comprised of&#160;[&#160;*&#160;]&#160;appointed by Eiger and&#160;[&#160;*&#160;]&#160;appointed by PRF.&#160;&#160;All JSC decisions will be made by unanimous vote, with the JSC representatives of Eiger collectively having one vote and the JSC representatives of PRF collectively having one vote.&#160;&#160;If the JSC is unable to decide or resolve unanimously: (i) when to file the Progeria NDA with the FDA;&#160;or&#160;(ii) any other matter subsequent to a change of control of Eiger, then in each case (i)&#160;and&#160;(ii), the Parties agree to resolve such dispute in accordance with the dispute resolution procedures set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 27</font><font style="font-weight:normal;">.&#160;&#160;For all other matters that are within the scope of the JSC&#8217;s responsibility as agreed upon by the Parties in writing, that are properly presented to the JSC for action and that the JSC is unable to decide or resolve unanimously, Eiger shall have final decision making authority with respect to such matter.&#160;&#160;For purposes of this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 4(a)</font><font style="font-weight:normal;">, &#8220;change of control&#8221; means any transaction or series of transactions as a result of which all or a majority of Eiger&#8217;s outstanding voting stock or all or a majority of the business or assets of Eiger are sold or otherwise transferred or disposed of and are no longer directly or indirectly owned by the persons owning a majority of the voting stock of Eiger prior to the first such transaction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="font-weight:normal;">The JSC shall meet in accordance with a schedule established by mutual written agreement of the Parties, but no less frequently than [ * ] per calendar year, unless the Parties mutually agree in writing to a different frequency, with the location for such meetings to be determined by the JSC.&#160;&#160;The JSC shall remain in effect as long as necessary to support regulatory preparation and filing for approval of the Licensed Progeria Product in all territories.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_16"></a><a name="_cp_text_1_18"></a><a name="_cp_text_1_20"></a><a name="_cp_text_4_21"></a>(c)<font style="font-weight:normal;">The responsibilities of the JSC shall include (i) reviewing and providing input on current and proposed future Research Activities; however, the Parties acknowledge and agree that the JSC does not have any right to approve or veto any such Research Activities, (ii) discussing overall regulatory requirements for obtaining regulatory approval of any Licensed Progeria Product in the Field, (iii) determining when to submit applications for regulatory approval of any Licensed Progeria Product in the Field, (iv) discussing whether to make the Licensed Progeria Product available in the Field as an investigational drug for treatment use pursuant to&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 8(b)</font><font style="font-weight:normal;">&#160;in a particular jurisdiction outside the United States if Eiger believes in good faith that doing so will subject Eiger to an unreasonable risk of liability, (v) discussing whether to make the Licensed Progeria Product available in the Field as an investigational drug for treatment use pursuant to&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 8(b)</font><font style="font-weight:normal;">, (vi) reviewing and commenting on correspondence and submissions to regulatory authorities, (vii) coordinating safety monitoring activities between the Parties with respect to the Licensed Progeria Product and any Licensed API supplied by or for Eiger under this Agreement, (viii) facilitating the flow of information between the Parties,&#160;(ix) discussing whether to seek regulatory approval of the Licensed Progeria Product in the Field in any country outside of the United States and (ix) performing such other functions as may be appropriate to further the purposes of this Agreement and that are agreed upon by the Parties in writing.&#160;&#160;</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="text-decoration:underline;">Regulatory</font><font style="font-weight:normal;">.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="font-weight:normal;">Promptly after the Effective Date and delivery to Eiger of Data and know-how Controlled by PRF in the Field, Eiger shall undertake a review of the regulatory and clinical Data and information provided by PRF and provide the JSC with its reasonable determination of the estimated time for filing of a NDA for a Licensed Progeria Product in [ * ] and [ * ] capsule formulations in the Field (&#8220;</font>Progeria NDA<font style="font-weight:normal;">&#8221;) by Eiger.&#160;&#160;In the event that the JSC determines that such PRF Data and know-how and any other information Controlled or possessed by Eiger or any of its Affiliates supports the filing of the Progeria NDA by the first anniversary of the Effective Date, Eiger agrees to use commercially reasonable efforts to prepare and file the Progeria NDA [ * ].&#160;&#160;Eiger agrees that if the JSC determines that filing the Progeria NDA [ * ] is impracticable, then Eiger will use commercially reasonable efforts to file the Progeria NDA as soon as practicable thereafter, as determined by the JSC.&#160;&#160;In any event, Eiger agrees to use commercially reasonable efforts to file the Progeria NDA [ * ] for the Licensed Product.&#160;&#160;The Parties agree that Eiger will submit a request to the FDA for a rare pediatric disease designation for the Licensed Progeria Product for the treatment of Progeria prior to submission of the Progeria NDA, and will use commercially reasonable efforts to submit such request (i) [ * ] it submits any request for expedited approval of the Progeria NDA under 21 USC &#167; 356 or (ii) by the [ * ], whichever is earlier, unless the parties mutually agree upon an alternate submission date in writing after conferring with each other in good faith.&#160;&#160;Following the approval of the Progeria NDA, Eiger agrees to use commercially reasonable efforts to develop and register a [ * ] of the Licensed Progeria Product for use in the Field.&#160;&#160;The Parties further agree to use commercially reasonable efforts to prepare and file NDA equivalents outside of the United States for the Licensed Progeria Product for the treatment of Progeria as determined by the JSC.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="font-weight:normal;">Eiger shall be the sole sponsor of the Progeria NDA or similar submission during the Term.&#160;&#160;During the Term, PRF shall, at Eiger&#8217;s sole cost and expense, provide reasonable cooperation and assistance reasonably requested by Eiger with respect to obtaining and maintaining regulatory approvals for an NDA for any Licensed Progeria Product in the Field.&#160;&#160;Upon the reasonable written request of PRF, Eiger shall make available to PRF records of the Licensed Product reasonably necessary for PRF to fulfill its regulatory requirements with respect to its use of the Licensed Progeria Product in the Field.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="font-weight:normal;">PRF shall have the right, but not the obligation, at its sole cost and expense, to own and maintain an Investigational New Drug (&#8220;</font>IND<font style="font-weight:normal;">&#8221;) application under which Research Activities of PRF are conducted with respect to Licensed Product (&#8220;</font>PRF IND<font style="font-weight:normal;">&#8221;); provided that if PRF elects to exercise such right, then (i) Eiger shall be the exclusive (subject to&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(h)</font><font style="font-weight:normal;">) provider of the Licensed Progeria Product under the PRF IND and shall supply the Licensed Progeria Product to PRF as set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9</font><font style="font-weight:normal;">; (ii) PRF shall grant Eiger a Right of Reference to Data included in or as part of the PRF IND; (iii) in connection with the PRF IND, Eiger shall grant PRF a Right of Reference to Data included in or as part of any IND or NDA submitted, sponsored or obtained by Eiger for any Licensed Product; and (iv) any material regulatory correspondence or material submission under a PRF IND shall be reviewed and discussed by the JSC prior to submission by PRF to the FDA.&#160;&#160;If PRF desires to pursue a study of a Combination Drug in the Field under the PRF IND, Eiger shall consider in good faith entering into a third party collaboration with another drug supplier to enable PRF to pursue such study with Licensed Product.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>(d)<font style="font-weight:normal;">Eiger shall be solely responsible for any additional clinical or non-clinical studies necessary for obtaining and maintaining approval of the Progeria NDA.&#160;&#160;Eiger shall be solely responsible for the costs of such additional studies up to a cumulative total of&#160;[&#160;*&#160;].&#160;&#160;The Parties will negotiate in good faith regarding the allocation of any costs in excess of this amount.&#160;&#160;Eiger agrees to maintain complete and accurate books and records relating to such additional studies.&#160;&#160;Eiger shall promptly notify PRF in writing when the costs of such additional studies total each of&#160;[&#160;*&#160;].&#160;&#160;If the costs of such additional studies exceeds&#160;[&#160;*&#160;]&#160;and the Parties agree that PRF shall share the costs of any such additional studies in excess of such amount, PRF shall have the right to inspect such books and records (upon reasonable prior written notice to Eiger and during Eiger&#8217;s normal business hours and no more than once per year), using an independent certified public accountant retained by PRF and reasonably acceptable to Eiger, for the sole purpose of verifying the costs of such additional studies.&#160;&#160;PRF shall bear the expense of any such inspection, except that if any such inspection reveals that the actual costs of such additional studies are less than&#160;[&#160;*&#160;]&#160;by&#160;[&#160;*&#160;]&#160;or more, then Eiger shall bear the expense of such investigation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="font-weight:normal;">The Parties shall reasonably cooperate in good faith with respect to the conduct of any inspections by any regulatory authority of a Party's site or facility (or, in the case of PRF, any clinical site conducting Research Activities with PRF as permitted under this Agreement) related to any Licensed Product.&#160;&#160;To the extent permitted by applicable law, Eiger shall be allowed to attend any such inspection relating to any Research Activities (other than any Research Activities using Licensed API and no other Licensed Product).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="text-decoration:underline;">Priority Review Voucher</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(a)</font><font style="font-weight:normal;">The Parties acknowledge that a Priority Review Voucher may be available and awarded to Eiger as the sponsor of the Progeria NDA (&#8220;</font>Progeria PRV<font style="font-weight:normal;">&#8221;).&#160;&#160;The Parties agree that, if awarded, Eiger will use commercially reasonable efforts to sell the Progeria PRV to a third party (&#8220;</font>PRV Sale<font style="font-weight:normal;">&#8221;) on commercially reasonable terms within twelve (12) months of the issuance of such Progeria PRV.&#160;&#160;Eiger agrees not to retain the Progeria PRV for itself or any of its Affiliates.&#160;&#160;[ * ].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(b)</font><font style="font-weight:normal;">PRF and Eiger shall share the proceeds of any PRV Sale [ * ].&#160;&#160; For clarity, as used in this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 6(b)</font><font style="font-weight:normal;">, &#8220;proceeds&#8221; means the gross amounts received by Eiger with respect to any PRV Sale, less applicable taxes on such amounts.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="text-decoration:underline;">Commercialization Diligence; Patient Support Programs</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(a)</font><font style="font-weight:normal;">Eiger shall use commercially reasonable efforts to Commercialize the Licensed Progeria Product in the Field in the United States within [ * ] of the Progeria NDA approval in the United States.&#160;&#160;In addition, Eiger shall use commercially reasonable efforts to obtain regulatory approval of and Commercialize the Licensed Progeria Product in the Field outside the United States.&#160;&#160;</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_37"></a><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="text-decoration:underline;"><br /></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(b)</font><font style="font-weight:normal;">Eiger shall&#160;(i) establish a patient support program prior to the first commercial sale of the Licensed Progeria Product in the United States and (ii)&#160;use commercially reasonable efforts to&#160;[&#160;*&#160;]&#160;in which Eiger seeks regulatory approval of the Licensed Progeria Product to treat Progeria, in each case (i) and (ii),&#160;to&#160;[&#160;*&#160;]&#160;after the Licensed Progeria Product is approved by the applicable regulatory authority to treat Progeria in each applicable country.&#160;&#160;For the avoidance of doubt, Eiger&#8217;s obligations under this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 7</font><font style="font-weight:normal;">&#160;to provide the Licensed Progeria Product&#160;[&#160;*&#160;]&#160;means that Eiger will&#160;[&#160;*&#160;].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(c)</font><font style="font-weight:normal;">Prior to seeking regulatory approval in any particular country outside the United States, if Eiger in good faith believes that (i) it will not be commercially reasonable to establish any such program described in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 7(b)(ii)</font><font style="font-weight:normal;">&#160;in such country and (ii) following regulatory approval of the Licensed Progeria Product in such country, [ * ], then the JSC shall discuss whether to seek regulatory approval of the Licensed Progeria Product for the Field in such country as set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 4(c)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_39"></a><a name="_cp_text_1_40"></a><a name="_cp_text_1_41"></a><a name="_cp_text_1_44"></a><a name="_cp_text_1_46"></a><a name="_cp_text_4_47"></a><a name="_cp_text_4_48"></a><a name="_cp_text_1_52"></a>8.<font style="text-decoration:underline;">Expanded Access</font><font style="font-weight:normal;">.</font>&#160;&#160;<font style="font-weight:normal;">Eiger shall use commercially reasonable efforts to make the Licensed Progeria Product available in the Field as an investigational drug for treatment use (a) in the United States in a manner consistent with all applicable laws, rules and regulations, as each such law, rule or regulation is then in effect and (b) outside the United States, in accordance with &#8220;named patient&#8221; programs in countries where they are available and delivery by or for Eiger is permitted under applicable law without unreasonable cost, expense or risk of liability, in each case (a) and (b), [ * ]; provided that, with respect to (a) and (b), the aggregate net cost to Eiger for making the Licensed Progeria Product available as an investigational drug for treatment use under this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 8</font><font style="font-weight:normal;">&#160;shall not in the aggregate exceed [ * ].&#160;&#160;For the avoidance of doubt, such [ * ]&#160;excludes the costs of manufacturing the Licensed Progeria Product.&#160;&#160;Eiger shall notify PRF promptly in writing if the aggregate costs of making the Licensed Progeria Product available in the Field as an investigational drug for treatment use pursuant to the foregoing clauses (a) and (b) will exceed such [ * ].&#160;&#160;If Eiger in good faith believes that (i) it is not commercially reasonable to make the Licensed Progeria Product available in the Field as an investigational drug for treatment use pursuant to the foregoing clauses (a) or (b) or (ii) making the Licensed Progeria Product available in the Field as an investigational drug for treatment use pursuant to the foregoing clause (b) will subject Eiger to an unreasonable cost, expense or risk of liability, then&#160;the Parties shall discuss in good faith potential alternatives.&#160;&#160;For purposes of this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 8</font><font style="font-weight:normal;">, &#8220;commercially reasonable efforts&#8221; shall be deemed met if Eiger spends, excluding the costs of manufacturing the Licensed Progeria Product, [&#160;* ]&#160;to make the Licensed Progeria Product available as an investigational drug for treatment use&#160;in accordance with the foregoing clauses (a) and (b).</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="text-decoration:underline;">Supply of Licensed Progeria Product; Second Source</font><font style="font-weight:normal;">.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="font-weight:normal;">Eiger shall supply and deliver to PRF the Licensed Progeria Product&#160;&#160;requested by PRF for any Research Activities, by delivery dates reasonably agreed upon by the Parties, in the quantities and to the delivery locations as reasonably agreed upon by the Parties, at no cost or expense to PRF, provided that:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="font-weight:normal;">each month, PRF shall provide Eiger in writing with a rolling non-binding estimate of its monthly requirement for the Licensed Progeria Product for Research Activities in each of the following [ * ], which PRF shall, if applicable, update such estimate before the beginning of each month;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="font-weight:normal;">the quantities set forth in the non-binding estimate are reasonably consistent with the quantities ordered and within a reasonable variance from the applicable forecast, provided that Eiger may request that the Parties mutually agree to specific minimum or maximum order variance limits to the extent quantities actually ordered deviate substantially from forecasted orders; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="font-weight:normal;">PRF shall specify, on a best estimates basis, each estimated order and the related factors or contingencies for the delivery of the Licensed Progeria Product [ * ] before PRF&#8217;s requested delivery date, unless otherwise mutually agreed upon by the Parties in writing, and the Parties shall regularly update and discuss the status and timing of delivery over the course of such period, provided that in any event any quantities originally estimated shall be within any maximum order variance set forth under&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(a)(ii)</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(b)</font><font style="font-weight:normal;">Eiger will package the Licensed Progeria Product in accordance with Eiger's IND application number [ * ] approved by the U.S. Food and Drug Administration on March 7, 2011 or Eiger&#8217;s then-approved NDA for a Licensed Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_55"></a><font style="text-decoration:underline;">(c)</font><font style="font-weight:normal;">Eiger shall (i) retain a sample of each batch of the Licensed Progeria Product supplied under or pursuant to this Agreement and (ii) maintain and provide to PRF access to records of the Licensed Progeria Product in each shipment, including certificates of analysis that include the dates of manufacture (such certificates, &#8220;</font>CoAs<font style="font-weight:normal;">&#8221;).&#160;&#160;As reasonably requested by PRF, Eiger shall promptly provide PRF (A) a copy of such CoAs and (B) access to a copy of any such other records described in subclause (ii) of the foregoing sentence and any records of testing performed on such Licensed Progeria Product (as such testing records are required to be maintained by Eiger pursuant to any applicable law, statute, rule or regulation).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(d)</font><font style="font-weight:normal;">PRF shall use the Licensed Progeria Product in the formulation supplied by Eiger and shall in no way modify, reverse-engineer, create derivatives of, reformulate or otherwise use a different form of such Licensed Progeria Product.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="text-decoration:underline;"><br /></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(e)</font><font style="font-weight:normal;">If PRF wishes to conduct (or have conducted) any Research Activities or clinical trials at a site other than Boston Children&#8217;s Hospital (&#8220;</font>Additional Site<font style="font-weight:normal;">&#8221;) for any Licensed Progeria Product in the Field, PRF shall notify Eiger and Eiger shall promptly and as soon as practicable enter into a material transfer agreement directly with such Additional Site to provide the Licensed Progeria Product for use in the Field.&#160;&#160;The JSC shall discuss in good faith plans and supply needs for the Licensed Progeria Product for any Additional Sites.&#160;&#160;Eiger acknowledges and agrees that PRF has the right to conduct, direct or sponsor any clinical trials at any Additional Sites using the Licensed Progeria Product, alone or in combination with other therapeutic or pharmaceutical agents, solely in the Field.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(f)</font><font style="font-weight:normal;">Eiger shall (i) continue to supply the Licensed Progeria Product at no charge to Boston Children&#8217;s Hospital pursuant to the Boston Children&#8217;s Hospital Investigator Sponsored Clinical Trial Research Agreement, dated October 4, 2016, as amended on October 28, 2016, by and between Eiger and Boston Children&#8217;s Hospital and (ii) supply any Additional Sites, in each case (i) and (ii), until [ * ] (or such longer period of time that PRF and Eiger may agree upon in writing) after regulatory approval of the Licensed Progeria Product in the Field in the territory in which Boston Children&#8217;s Hospital or such Additional Site, as applicable, is located.&#160;&#160;If, however, any patient is enrolled in any PRF conducted, directed or sponsored clinical trial and receiving the Licensed Progeria Product from Eiger at the end of such [ * ], Eiger will continue to supply the Licensed Progeria Product at no charge to each such patient for the duration of the clinical trial.&#160;&#160;In the event that any Additional Site is located in a territory where a Licensed Progeria Product does not receive regulatory approval during the Term for commercial sale, Eiger will provide the Licensed Progeria Product [ * ] to such Additional Site for the Term.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_59"></a><font style="text-decoration:underline;">(g)</font><font style="font-weight:normal;">From time to time during the Term, PRF may identify a second source of supply for the Licensed Progeria Product or Licensed API reasonably acceptable to Eiger (&#8220;</font>PRF Second Source<font style="font-weight:normal;">&#8221;).&#160;&#160;Upon written request from PRF, Eiger agrees to: (i) work with such PRF Second Source in good faith; (ii) use commercially reasonable efforts to qualify such PRF Second Source for the manufacture of the Licensed Progeria Product and Licensed API; (iii) provide such PRF Second Source with all information and support necessary, and reasonable assistance, to enable such PRF Second Source to manufacture the Licensed Progeria Product and Licensed API for supply in accordance with this Agreement; and (iv) grant to such PRF Second Source a non-exclusive, world-wide, royalty-free, fully paid-up, non-sublicensable license under and to all Intellectual Property Controlled by Eiger necessary to manufacture the Licensed Progeria Product and Licensed API for supply in accordance with this Agreement.&#160;&#160;All costs and expenses with respect to the engagement, assessment, review and commitment of such PRF Second Source shall be the responsibility of PRF, provided that Eiger [ * ] from Eiger to such PRF Second Source.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><a name="_cp_text_1_62"></a><a name="_cp_text_1_64"></a><a name="_cp_text_1_66"></a><font style="text-decoration:underline;"><br /></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(h)</font><font style="font-weight:normal;">Eiger agrees that, if, for any reason, Eiger Defaults (as defined below) on any of its obligations to supply any Licensed Progeria Product to PRF in accordance with this Agreement, and fails to cure such Default within&#160;[&#160;*&#160;]&#160;after its receipt from PRF of a written notice describing such Default, PRF has the right to obtain such Licensed Progeria Product or Licensed API from such PRF Second Source.&#160;&#160;Commencing on the&#160;[&#160;*&#160;]&#160;anniversary of the Effective Date, Eiger shall, at all times during the remainder of the Term,&#160;maintain an existing inventory of Licensed Progeria Product in an amount equal to the total amount of Licensed Progeria Product set forth in PRF&#8217;s then-current monthly orders for the subsequent&#160;[&#160;*&#160;].&#160;&#160;If, at any time during the Term, Eiger engages a second source to supply the Licensed Progeria Product or Licensed API, then Eiger shall identify to PRF in writing such alternative manufacturer and, at PRF&#8217;s request, Eiger shall use commercially reasonable efforts to facilitate the manufacture of the Licensed Progeria Product or Licensed API for PRF by such alternative manufacturer&#160;[&#160;*&#160;]&#160;as the terms and conditions pursuant to which such alternative manufacturer agrees to manufacture the Licensed Progeria Product or Licensed API for Eiger.&#160;&#160;For purposes of this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(h)</font><font style="font-weight:normal;">, &#8220;</font>Default<font style="font-weight:normal;">&#8221; means&#160;that&#160;Eiger fails to deliver&#160;to PRF&#160;at least&#160;[&#160;*&#160;]&#160;of&#160;the&#160;quantities of Licensed Progeria Product ordered&#160;under&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(a)</font><font style="font-weight:normal;">&#160;(excluding all Non-Conforming Product for purposes of determining such failure level)&#160;in any&#160;[&#160;*&#160;]&#160;orders.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><a name="_cp_text_1_69"></a><a name="_cp_text_1_70"></a><a name="_cp_text_29_73"></a><a name="_cp_text_1_75"></a><a name="_cp_text_1_77"></a><a name="_cp_text_1_79"></a><a name="_cp_text_1_81"></a>(i)<font style="font-weight:normal;">In the event of (i) expiration or any termination of this Agreement (other than Eiger&#8217;s termination of this Agreement in accordance with&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 22(b)(i)</font><font style="font-weight:normal;">&#160;for an uncured, material breach of this Agreement by PRF), (ii) expiration or any termination of the Merck License Agreement, or (iii) the termination of development (including efforts to seek regulatory approval) or commercialization of Licensed Product by Eiger for any reason, Eiger shall: (A) upon PRF&#8217;s written request, to the extent practicable,&#160;assign to PRF all manufacturing agreements and supply agreements that Eiger has not assigned to Merck pursuant to the Merck License Agreement relating to the manufacture or supply of Licensed Product then Controlled by Eiger and, to the extent Eiger has such rights, provide the necessary regulatory licenses and any other rights to PRF to enable continuity of supply of the Licensed Product (which manufacturing agreements and supply agreements assigned to PRF (</font>&#8220;Assigned Manufacturing Agreements<font style="font-weight:normal;">&#8221;)&#160;may require payment by PRF for supply of the Licensed Product, it being understood that, with respect to any Assigned Manufacturing Agreement: (1) after the assignment of such Assigned Manufacturing Agreement by Eiger to PRF becomes effective (&#8220;</font>Assignment Effective Time<font style="font-weight:normal;">&#8221;), PRF shall be responsible for all ongoing obligations of Eiger under such Assigned Manufacturing Agreement, but only to the extent that such obligations: (w) arise after the Assignment Effective Time; (x) do not arise from or relate to any breach by Eiger of any provision of such Assigned Manufacturing Agreement; (y) are not the result of any event, circumstance or condition occurring or existing on or prior to the Assignment Effective Time; and (z) are ascertainable solely by reference to the express terms of such Assigned Manufacturing Agreement; provided, however, that (I) PRF shall not be obligated to assume, discharge or perform any obligation or liability under such Assigned Manufacturing Agreement if there shall not have been obtained prior to the assignment of such Assigned Manufacturing Agreement by Eiger to PRF any consent required to be obtained from any third party with respect to the assignment or delegation to PRF of any rights or obligations under such Assigned Manufacturing Agreement and (II) in no event shall PRF assume or be deemed to assume, pursuant to this Agreement or otherwise, any obligation or liability arising under such Assigned</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing Agreement that accrued or arose prior to the&#160;Assignment Effective Time,&#160;unless expressly agreed&#160;upon by PRF and Eiger&#160;in the&#160;written&#160;assignment&#160;agreement&#160;effectuating&#160;such assignment; and&#160;(2)&#160;such Assigned Manufacturing Agreement&#160;shall, if agreed upon by the third party counter-party to such Assigned Manufacturing Agreement,&#160;be novated and assigned&#160;to PRF in its&#160;entirety&#160;(as may be modified by PRF and such counter-party));&#160;(B) fulfill any&#160;outstanding&#160;orders for Licensed Progeria Product submitted by PRF pursuant to&#160;<font style="text-decoration:underline;">Section 22(c)</font>; and (C) except to the extent Eiger is obligated under the Merck License Agreement to deliver Eiger&#8217;s remaining inventory of Licensed Progeria Product to Merck, deliver to PRF all of&#160;the safety stock maintained by Eiger pursuant to&#160;<font style="text-decoration:underline;">Section 9(h)</font>.&#160;With respect to any other&#160;remaining inventory&#160;of Licensed Progeria Product of Eiger, the Parties shall discuss in good faith Eiger (as&#160;may be permitted by Merck if Merck&#160;does not exercise its rights&#160;under the Merck License Agreement&#160;to the Licensed Progeria Product possessed by Eiger) making available any&#160;such&#160;remaining&#160;inventory&#160;of Licensed Progeria Product&#160;to PRF.&#160;For the avoidance of doubt, any&#160;such remaining&#160;inventory&#160;of Licensed Progeria Product&#160;assigned to PRF other than the safety stock maintained by Eiger pursuant to&#160;<font style="text-decoration:underline;">Section 9(h)</font>&#160;shall be delivered on an &#8220;as is&#8221; basis without warranty of any kind, and PRF shall be responsible for requalification or other requirements for research use or use in humans under any applicable laws, rules and regulations with respect to such&#160;remaining&#160;inventory.&#160;&#160;In the event Eiger provides to PRF any&#160;such remaining&#160;inventory of Licensed Progeria Product other than such safety stock, Eiger shall provide to PRF&#160;[&#160;*&#160;].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="text-decoration:underline;">Delivery</font><font style="font-weight:normal;">.&#160;&#160;Eiger shall deliver the Licensed Progeria Product [ * ] to PRF or its designee (provided that all products in a single order will be delivered to a single place of destination in the U.S.) by PRF&#8217;s requested delivery date, provided that with respect to Licensed Progeria Product, PRF supply orders are made in accordance with&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(a)</font><font style="font-weight:normal;">. Delivery of the Licensed Progeria Product intended to be used for Research Activities outside of the U.S. shall be [ * ] for PRF to undertake export, shipment and delivery outside of the U.S.&#160;&#160;For clarity, this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 10</font><font style="font-weight:normal;">&#160;does not apply to, and Eiger remains solely responsible for, the delivery of all Licensed Progeria Product under the global patient support program described in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 7</font><font style="font-weight:normal;">&#160;and the expanded access or other &#8220;named patient&#8221; programs described in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 8</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="text-decoration:underline;">Supply of Licensed API</font><font style="font-weight:normal;">.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="font-weight:normal;">Eiger shall supply and deliver to PRF an average quantity of [ * ] of Licensed API (or such higher quantity as reasonably agreed upon by the Parties) per calendar year (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Applicable Calendar Year</font><font style="font-weight:normal;">&#8221;), at no cost or expense to PRF, for inclusion in and distribution by PRF&#8217;s Cell and Tissue Bank (information about which is located, as of the Effective Date, at&#160;https://www.progeriaresearch.org/cell-and-tissue-bank/).&#160;&#160;Eiger may supply and deliver such average quantity of Licensed API during such Applicable Calendar Year or the immediately subsequent calendar year (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Subsequent Calendar Year</font><font style="font-weight:normal;">&#8221;), but the supply and delivery of such average quantity of Licensed API for the Applicable Calendar Year during the Subsequent Calendar Year shall not decrease Eiger&#8217;s obligation to supply and deliver such average quantity of Licensed API for the Subsequent Calendar Year.&#160;&#160;Eiger shall deliver such Licensed API to [ * ], unless the Parties otherwise agree in writing to an alternative delivery location, [ * ], by delivery dates reasonably agreed upon by the Parties in writing.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><a name="_cp_text_1_82"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="font-weight:normal;">Eiger shall (i) retain a sample of each batch of the Licensed API supplied under or pursuant to this Agreement and (ii) maintain and provide to PRF&#160;reasonable&#160;access to records of the Licensed API in each shipment, including CoAs.&#160;&#160;As reasonably requested by PRF, Eiger shall promptly provide PRF (A) a copy of such CoAs and (B) access to a copy of any such other records described in subclause (ii) of the foregoing sentence and any records of testing performed on such Licensed API (as such testing records are required to be maintained by Eiger pursuant to any applicable law, statute, rule or regulation).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="text-decoration:underline;">Rejection</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="font-weight:normal;">For each shipment of the Licensed Progeria Product, Eiger shall provide PRF with a CoA no less than [ * ] days before shipping.&#160;&#160;PRF shall reasonably promptly review the CoA and notify Eiger in writing within [ * ] days after PRF&#8217;s receipt of such CoA of any non-conformance PRF identifies in the CoA.&#160;&#160;If no notification is provided from PRF, then Eiger shall ship the Licensed Progeria Product as scheduled, and PRF (or its designee) shall inspect the Licensed Progeria Product upon its receipt thereof.&#160;&#160;Within ten [ * ] days after delivery of any Licensed Progeria Product, PRF may reject all or any portion of any shipment of the Licensed Progeria Product&#160;&#160;that (i) has been damaged or tampered with (or the container or packaging of which has been damaged or tampered with) prior to receipt of such Licensed Progeria Product&#160;&#160;by or on behalf of PRF or its designee, (ii) is not in conformance with the approved Eiger IND or NDA for such Licensed Progeria Product&#160;&#160;or (iii) is adulterated or misbranded within the meaning of such terms under the Federal Food, Drug and Cosmetic Act (each of such Licensed Progeria Product, a &#8220;</font>Non-Conforming Product<font style="font-weight:normal;">&#8221;).&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="font-weight:normal;">In order to reject a shipment of the Licensed Progeria Product, PRF must provide Eiger with a written notice of rejection and the basis therefor within [ * ] days after PRF&#8217;s receipt of such shipment, except that in the case of any Licensed Progeria Product&#160;&#160;having any latent defect which, upon reasonable examination by PRF or its designee, could not have been discovered within such [ * ] day period after receipt thereof, PRF must provide Eiger with a notice of rejection and the basis therefor within [ * ] days after PRF becomes aware of such defect.&#160;&#160;Any notice of rejection from PRF must contain reasonable documentation to allow Eiger to reasonably determine whether such rejected Licensed Progeria Product is a Non-Conforming Product.&#160;&#160;If no such notice of rejection is received by Eiger within the applicable [ * ] day period set forth above, PRF shall be deemed to have accepted such delivery of such Licensed Progeria Product, as the case may be.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="font-weight:normal;">If in good faith Eiger does not accept PRF&#8217;s basis for rejection of any Licensed Progeria Product, the Parties shall engage a mutually acceptable independent third party laboratory to test the putative Non-Conforming Product in question to determine if such Licensed Progeria Product&#160;&#160;is a Non-Conforming Product.&#160;&#160;The determination of such laboratory shall be binding upon the Parties, and the costs of such testing shall be shared equally by the Parties.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="font-weight:normal;">If Eiger accepts PRF&#8217;s basis for rejection of any Licensed Progeria Product or if any such independent third party laboratory determines that the Licensed Progeria Product in question is a Non-Conforming Product, promptly upon receipt of such notice of rejection or such determination, Eiger shall, at PRF&#8217;s request, use commercially reasonable efforts to promptly provide PRF with replacement Licensed Progeria Product in the same quantity as the Non-Conforming Product.&#160;&#160;Unless Eiger requests the return of a rejected batch of the Licensed Progeria Product within&#160;[&#160;*&#160;]&#160;after the later of the receipt of PRF&#8217;s notice of rejection or, if applicable, the independent third party laboratory&#8217;s determination that such Licensed Progeria Product is a Non-Conforming Product, PRF shall destroy such rejected batch of the Licensed Progeria Product and provide Eiger with written certification of such destruction.&#160;&#160;Within&#160;[&#160;*&#160;]&#160;after PRF&#8217;s receipt of a written request from Eiger for the return of a rejected batch of the Licensed Progeria Product, PRF shall return such rejected batch to Eiger, at Eiger&#8217;s cost and expense.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="text-decoration:underline;">Recalls; Safety Reporting</font><font style="font-weight:normal;">.&#160;&#160;Eiger shall have sole decision-making authority with respect to, and shall bear all costs and expenses relating to, issuing any recall, market withdrawal or correction of any Licensed Progeria Product provided by Eiger or with respect to issuing any advisory letter or other safety related communication with respect to any Licensed Progeria Product provided by Eiger.&#160;&#160;Eiger shall notify PRF in writing promptly (and in any event within (a) [ * ] after Eiger&#8217;s receipt of any written notice or other communication from a regulatory agency that could reasonably be expected to result in any recall, market withdrawal, correction or suspension of distribution of any Licensed Progeria Product or (b) [ * ] after Eiger&#8217;s receipt of any written notice or other communication from a regulatory agency that could reasonably be expected to result in any clinical hold of any Licensed Progeria Product) if any Licensed Progeria Product, or any Licensed API contained therein, is alleged or proven to be the subject of any recall, market withdrawal, correction, clinical hold or suspension of distribution.&#160;&#160;PRF will make available to Eiger, upon Eiger&#8217;s written request, all of PRF's pertinent records in its Control relating to such Licensed Progeria Product that Eiger may reasonably request to assist in effecting any such recall, market withdrawal or correction.&#160;&#160;If either Party becomes aware of any information that reasonably suggests that a death or serious adverse reaction or injury will impact the Commercialization or development of the Licensed Progeria Product, such Party will (i) furnish such information to the other Party within [ * ] after such Party becomes aware of such information and (ii) make, maintain and retain records of such information.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="text-decoration:underline;">Inventory Records</font><font style="font-weight:normal;">.&#160;&#160;PRF shall keep Eiger reasonably informed of its use of all Licensed Progeria Product and shall keep full and accurate records of its receipt, use and inventory of any Licensed Progeria Product.&#160;&#160;Within [ * ] after the end of each [ * ], PRF shall provide Eiger with a written inventory report for the Licensed Progeria Product, documenting amounts of the Licensed Progeria Product being allocated to Research Activities and amounts otherwise being held in the possession of PRF, if any.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="text-decoration:underline;">Intellectual Property</font><font style="font-weight:normal;">.</font>&#160;&#160;<font style="font-weight:normal;">Except as specifically set forth in this Agreement, Eiger retains all right, title, and interest in and to all Intellectual Property, information, know-how, Data and inventions that Eiger Controls as of the Effective Date (&#8220;</font>Pre-existing Eiger IP<font style="font-weight:normal;">&#8221;) and all enhancements, modifications, extensions, improvements and derivatives of any Pre-existing Eiger IP developed independently by or for Eiger (either solely or jointly with any third party) and without use of the Confidential Information of PRF.&#160;&#160;Except as specifically set forth in this Agreement, PRF retains all right, title and interest in and to all Intellectual Property, information, know-how, Data and inventions that PRF Controls as of the Effective Date (&#8220;</font>Pre-existing PRF IP<font style="font-weight:normal;">&#8221;) and all enhancements, modifications, extensions, improvements and derivatives of any Pre-existing PRF IP developed independently by or for PRF (either solely or jointly with any third party) and without use of the Confidential Information of Eiger (other than use of any Licensed Product in the Field).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">16.<font style="text-decoration:underline;">Confidential Information</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="text-decoration:underline;font-weight:normal;">Obligations</font><font style="font-weight:normal;">.&#160;&#160;Each Party (the &#8220;</font>Receiving Party<font style="font-weight:normal;">&#8221;) will maintain in strict trust and confidence, and will not (i) use for any purpose other than the performance of its obligations and exercise of its rights under this Agreement, any Confidential Information (as defined below) received from the other Party in connection with this Agreement (the &#8220;</font>Disclosing Party<font style="font-weight:normal;">&#8221;) or (ii) disclose any Confidential Information of the Disclosing Party to any persons or entities (other than the Receiving Party&#8217;s employees, clinical site staff, contractors, consultants, agents or, in the case PRF is the Receiving Party, any person or entity to whom it provides any Licensed Progeria Product or Licensed API for any Research Activities, in each case who require such access for the purpose of this Agreement (including for the Receiving Party to perform its obligations or exercise its rights under this Agreement) and are obligated to keep the Disclosing Party&#8217;s Confidential Information in confidence).&#160;&#160;&#8220;</font>Confidential Information<font style="font-weight:normal;">&#8221; of the Disclosing Party means (i) any information disclosed, directly or indirectly, by the Disclosing Party to the Receiving Party pursuant to this Agreement that (A) is in written, graphic, electronic or other tangible form (including documents, samples, know-how, data, product plans, research and development) and is marked &#8220;Confidential&#8221; or in a similar manner to indicate its confidential nature, (B) is disclosed orally, provided that such information is designated as confidential at the time of initial disclosure, or (C) otherwise should reasonably be considered confidential by the Receiving Party based on the circumstances of disclosure or the nature of the information itself or (ii) any Data owned or Controlled by the Disclosing Party.&#160;&#160;Confidential Information may include information of a third party disclosed by the Disclosing Party to the Receiving Party under this Agreement.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>(b)<font style="text-decoration:underline;font-weight:normal;">Exceptions to Confidential Information</font><font style="font-weight:normal;">.&#160;&#160;Obligations of non-disclosure and non-use will not apply to any information which: (i) is in the public domain or comes into the public domain through no breach of the confidentiality obligations set forth herein; (ii) is disclosed to the Receiving Party without restriction on disclosure and use by an independent third party having a legal right to make such disclosure without making such disclosure subject to confidentiality obligations; (iii) is already rightfully known by the Receiving Party without any confidentiality obligations at the time of receiving such information from the Disclosing</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Party, as evidenced by the Receiving Party&#8217;s prior written records and other competent evidence; or (iv) is independently developed by the Receiving Party without any use of or reference to the Disclosing Party&#8217;s Confidential Information, as evidenced by written records and other competent evidence.&#160;&#160;If the Receiving Party becomes legally compelled to disclose any Confidential Information, the Receiving Party shall provide the Disclosing Party prompt written notice, if legally permissible, and shall reasonably assist the Disclosing Party in seeking a protective order, confidential treatment or other appropriate restriction on disclosure or remedy.&#160;&#160;In any event, the Receiving Party shall disclose only that portion of such Confidential Information that the Receiving Party is legally required to disclose and shall maintain the confidentiality of such disclosed Confidential Information for all other purposes in accordance with this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(c)</font><font style="text-decoration:underline;font-weight:normal;">Maintenance of Confidentiality</font><font style="font-weight:normal;">.&#160;&#160;The Receiving Party shall protect the Disclosing Party&#8217;s Confidential Information against unauthorized use and disclosure using at least the same degree of care and taking at least the same measures the Receiving Party uses and takes to protect its own confidential information of a similar nature, but in no event will the Receiving Party use or take less than reasonable care or reasonable measures.&#160;&#160;The Receiving Party shall promptly notify the Disclosing Party of any actual or suspected unauthorized use or disclosure of any of the Disclosing Party&#8217;s Confidential Information, of which the Receiving Party becomes aware.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">17.<font style="text-decoration:underline;">Publicity</font><font style="font-weight:normal;">.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(a)</font><font style="text-decoration:underline;font-weight:normal;">Publications</font><font style="font-weight:normal;">.&#160;&#160;If either Party desires to publish findings related to any Research Activities conducted after the Effective Date (such Party, the &#8220;</font>Publishing Party<font style="font-weight:normal;">&#8221;): (i) the Publishing Party shall provide a copy of the proposed publication to the other Party for review at least [ * ] prior to publication if reasonably possible and, if not, as soon as reasonably possible prior to submission for publication but in no event less than [ * ] prior to publication; (ii) such other Party shall provide the Publishing Party with any comments to such proposed publication at least [ * ] prior to the proposed publishing date; and (iii) the Publishing Party shall consider such comments in good faith.&#160;&#160;Upon such other Party&#8217;s reasonable written request, the Publishing Party shall remove any Confidential Information of such other Party contained in such publication.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(b)</font><font style="text-decoration:underline;font-weight:normal;">Public Announcement</font><font style="font-weight:normal;">.&#160;&#160;Other than as required by law or regulation, neither Party shall issue any press release or public announcement relating to this Agreement, or otherwise publicize the collaboration between the Parties under this Agreement, without the prior written approval of the other Party, which approval shall not be unreasonably withheld, conditioned or delayed, except that, once a press release or public announcement has been approved in writing by both Parties, a Party may make subsequent public disclosure of the information contained in such statement without any further approval of the other Party.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">18.<font style="text-decoration:underline;">Representations and Warranties</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:1.37%;text-indent:18.86%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="font-weight:normal;">Eiger hereby represents, warrants, covenants and agrees that:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="font-weight:normal;">as of the Effective Date, Eiger has all rights, approvals and authorities necessary to enter into, and perform all of its obligations under, this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="font-weight:normal;">Eiger shall manufacture, package, handle, supply and ship the Licensed Progeria Product and Licensed API in compliance with (A) the approved Eiger IND, (B) all applicable laws, statutes, rules and regulations, and (C) all standards consistent with and necessary for products intended for use in humans;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="font-weight:normal;">Eiger shall manufacture the Licensed Progeria Product and Licensed API in compliance with the good manufacturing practices promulgated by the FDA and the quality assurance and quality control practices that are standard in the pharmaceutical industry;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="font-weight:normal;">neither the Licensed Progeria Product nor Licensed API will be adulterated or misbranded within the meaning of such terms under the Federal Food, Drug and Cosmetic Act;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="font-weight:normal;">accompanying each shipment of the Licensed Progeria Product for use in humans, Eiger shall supply the CoA confirming that the Licensed Progeria Product meets all requirements and specifications set forth in the Eiger IND or NDA (including specifications of purity, stability, and composition), as applicable;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="font-weight:normal;">&#160;as of the Effective Date, Eiger has all rights necessary to grant to PRF all licenses, sublicenses, rights of access and rights of use (as applicable) to all Intellectual Property, know-how and Data pursuant to and accordance with the terms and conditions of this Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="font-weight:normal;">Eiger has provided to PRF a true and complete copy of the Merck License Agreement in effect as of the Effective Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="font-weight:normal;">PRF hereby represents, warrants, covenants and agrees that:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="font-weight:normal;">as of the Effective Date, PRF has all rights, approvals and authorities necessary to enter into, and fulfill all of its obligations under, this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="font-weight:normal;">PRF shall handle, store, and use the Licensed Progeria Product and Licensed API in accordance with all applicable laws and regulations and any written instructions provided by Eiger with respect to the proper handling, storage, and use of the Licensed Progeria Product and Licensed API;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="font-weight:normal;">PRF shall not take any action to adulterate or misbrand (within the meaning of such terms under the Federal Food, Drug and Cosmetic Act) the Licensed Progeria Product or Licensed API;</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="font-weight:normal;">the provisions of this Agreement cover, in addition to other matters, all covenants and obligations of Merck to PRF as of the Effective Date with respect to the supply of Licensed Progeria Product and Licensed API to PRF and the use of the Licensed Progeria Product and Licensed API in the Field;</font><font style="font-style:italic;">&#160;</font><font style="font-weight:normal;">and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">19.<font style="text-decoration:underline;">Warranty Disclaimer</font><font style="font-weight:normal;">.&#160;&#160;EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES PROVIDED BY THE PARTIES IN&#160;</font><font style="text-decoration:underline;font-weight:normal;">SECTION 18</font><font style="font-weight:normal;">, (a) THE LICENSED PROGERIA PRODUCT AND LICENSED API ARE SUPPLIED BY EIGER TO PRF WITH NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AND (b) BOTH PARTIES HEREBY DISCLAIM ALL WARRANTIES, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">20.<font style="text-decoration:underline;">Insurance; Indemnification</font><font style="font-weight:normal;">.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(a)</font><font style="font-weight:normal;">Each Party shall obtain and maintain insurance, including product liability insurance, in commercially reasonable and appropriate amounts at all times during the Term.&#160;&#160;Within [ * ] after a Party&#8217;s written request, the other Party shall provide to the requesting Party copies of certificates of such insurance of such other Party.&#160;&#160;Each such insurance policy shall entitle the other Party to receive at least [ * ] prior written notice of any cancellation (including for nonrenewal) or change of any such insurance policy.&#160;&#160;All such insurance policies of Eiger will include PRF as an additional insured with respect to the Licensed Product.&#160;&#160;[ * ].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(b)</font><font style="font-weight:normal;">Eiger shall indemnify, defend and hold harmless PRF and each of its officers, directors, employees and agents (collectively, &#8220;</font>PRF Indemnified Parties<font style="font-weight:normal;">&#8221;) from and against any and all third party claims, losses, liabilities, damages, settlements, costs and expenses of any kind, as incurred, including reasonable attorneys&#8217; fees (collectively, &#8220;</font>Losses<font style="font-weight:normal;">&#8221;) resulting from any suit, action, claim, demand or proceeding of any kind or nature arising from (i) Eiger&#8217;s breach of any of its representations, warranties, covenants or agreements set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 18</font><font style="font-weight:normal;">, (ii) any of Eiger&#8217;s actions or failure to take action with respect to any Licensed Product in accordance with this Agreement or (iii) Eiger&#8217;s gross negligence or willful misconduct, except in each case (i), (ii) and (iii) to the extent resulting from PRF&#8217;s gross negligence or willful misconduct or to the extent such Losses would otherwise be subject to indemnification by PRF pursuant to&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20(c)</font><font style="font-weight:normal;">&#160;if such Losses were incurred or suffered by Eiger.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(c)</font><font style="font-weight:normal;">PRF shall indemnify, defend and hold harmless Eiger and each of its officers, directors, employees and agents (collectively, &#8220;</font>Eiger Indemnified Parties<font style="font-weight:normal;">&#8221;) from and against any and all third party Losses resulting from any suit, action, claim, demand or proceeding of any kind or nature arising from (i) PRF&#8217;s use, handling, transfer or storage of the Licensed Progeria Product and Licensed API, in each case other than Losses in connection with any clinical trial agreement between PRF and an Additional Site that conducts, on behalf of, under the direction or supervision of, as instructed by or in collaboration with PRF, any clinical trial involving use in humans of the Licensed Progeria Product in the Field, (ii) PRF&#8217;s breach of any of its representations and warranties set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 18</font><font style="font-weight:normal;">&#160;or (iii) PRF&#8217;s gross negligence or willful misconduct, except in each case (i), (ii) and (iii) to the extent resulting from Eiger&#8217;s gross negligence or willful misconduct or to the extent such Losses would otherwise be subject to indemnification by Eiger pursuant to&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20(b)</font><font style="font-weight:normal;">&#160;if such Losses were incurred or suffered by PRF.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="text-decoration:underline;"><br /></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(d)</font><font style="font-weight:normal;">With respect to the indemnification obligations of each Party (&#8220;</font>Indemnifying Party<font style="font-weight:normal;">&#8221;) set forth above in this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20</font><font style="font-weight:normal;">: (a) the indemnified Party (&#8220;</font>Indemnified Party<font style="font-weight:normal;">&#8221;) shall reasonably promptly notify the Indemnifying Party in writing of any claim for which the Indemnified Party seeks indemnification under this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20</font><font style="font-weight:normal;">, provided, however, that the failure to reasonably promptly provide such notice will not relieve the Indemnifying Party from its liability or obligations under this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 20</font><font style="font-weight:normal;">, except to the extent the Indemnifying Party&#8217;s defense of such claim is materially prejudiced by such failure; (b) the Indemnifying Party shall have sole control of the defense, settlement and negotiations for settlement (collectively, &#8220;</font>Defense<font style="font-weight:normal;">&#8221;) of such claim at the Indemnifying Party&#8217;s expense, provided, however, that the Indemnifying Party shall not, without the Indemnified Party&#8217;s prior written consent, settle any such claim if such settlement (i) requires that any of the PRF Indemnified Parties (in the case PRF is the Indemnified Party) or any of the Eiger Indemnified Parties (in the case Eiger is the Indemnified Party) makes any payment or bears any other obligations (beyond those required under this Agreement), (ii) includes any admission of wrongdoing, fault or liability on the part of any of the PRF Indemnified Parties (in the case PRF is the Indemnified Party) or any of the Eiger Indemnified Parties (in the case Eiger is the Indemnified Party), (iii) does not include a full release of all PRF Indemnified Parties (in the case PRF is the Indemnified Party) or all Eiger Indemnified Parties (in the case Eiger is the Indemnified Party) or (iv) includes any injunctive or other equitable relief; and (c) the Indemnified Party shall, as reasonably requested by the Indemnifying Party, reasonably cooperate and provide reasonable assistance in connection with the Defense of such claim.&#160;&#160;The Indemnified Party shall have the right to participate in (but not control) such Defense through its own counsel and at its own cost and expense to monitor such Defense.&#160;&#160;The Indemnifying Party shall in good faith consult with such counsel for the Indemnified Party and keep such counsel reasonably advised of the status of such Defense.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">21.<font style="text-decoration:underline;">Term</font><font style="font-weight:normal;">.&#160;&#160;Unless earlier terminated in accordance with&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 22</font><font style="font-weight:normal;">, this Agreement shall commence as of the Effective Date and continue in effect for an initial term of [ * ] (&#8220;</font>Initial Term<font style="font-weight:normal;">&#8221;), and shall thereafter automatically renew for subsequent renewal terms of two (2) years each (each a &#8220;</font>Renewal Term<font style="font-weight:normal;">&#8221;), unless either Party notifies the other Party in writing no later than [ * ] prior to the end of the then existing Initial Term or Renewal Term (as the case may be) that it does not intend to renew this Agreement for a subsequent Renewal Term.&#160;&#160;The Initial Term together with all Renewal Terms are referred to in this Agreement as the &#8220;</font>Term<font style="font-weight:normal;">.&#8221;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">22.<font style="text-decoration:underline;">Termination</font><font style="font-weight:normal;">.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="text-decoration:underline;font-weight:normal;">PRF Termination</font><font style="font-weight:normal;">.&#160;&#160;PRF may terminate this Agreement: (i) for any reason upon [ * ] prior written notice to Eiger; or (ii) [ * ].&#160;&#160;The Parties agree that any termination pursuant to the foregoing clause (ii) in this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 22(a)</font><font style="font-weight:normal;">&#160;shall be deemed a termination for convenience by Eiger.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="text-decoration:underline;font-weight:normal;">Eiger Termination</font><font style="font-weight:normal;">.&#160;&#160;Eiger may terminate this Agreement: (i) immediately upon PRF&#8217;s material breach of this Agreement if PRF fails to cure such breach within [ * ] after its receipt from Eiger of a written notice reasonably describing such breach; or (ii) immediately upon written notice to PRF of the rightful termination or expiration of the Merck License Agreement pursuant to the terms and conditions thereof, provided that Eiger has notified PRF in writing immediately upon Eiger&#8217;s receipt from Merck, or Eiger&#8217;s sending to Merck, any notice of termination of the Merck License Agreement (&#8220;</font>Merck License Agreement Termination Notice<font style="font-weight:normal;">&#8221;).</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><a name="_cp_text_1_84"></a><font style="text-decoration:underline;"><br /></font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(c)</font><font style="text-decoration:underline;font-weight:normal;">Orders Prior to Termination</font><font style="font-weight:normal;">.&#160;&#160;In the event PRF terminates this Agreement for any reason or Eiger terminates this Agreement pursuant to&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 22(b)(ii)</font><font style="font-weight:normal;">, Eiger agrees that, subject to Eiger&#8217;s obligation to continue to supply the Licensed Progeria Product as set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(f)</font><font style="font-weight:normal;">, PRF has the right (but not the obligation) to submit to Eiger prior to the effective date of termination, and Eiger will fulfill, any final orders in accordance with&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(a)</font><font style="font-weight:normal;">&#160;for any Licensed Progeria Product in quantities specified by PRF (such quantities to be reasonable&#160;based on the then-current estimates pursuant to&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 9(a)(iii)</font><font style="font-weight:normal;">&#160;as finally agreed&#160;upon&#160;by the Parties after conferring with each other in good faith), notwithstanding any prior forecasts by PRF for such Licensed Progeria Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_86"></a><font style="text-decoration:underline;">(d)</font><font style="text-decoration:underline;font-weight:normal;">Effects of Termination</font><font style="font-weight:normal;">.&#160;&#160;In the event of expiration or termination of this Agreement for any reason (other than (1) Eiger&#8217;s termination of this Agreement in accordance with&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 22(b)(i)</font><font style="font-weight:normal;">&#160;for PRF&#8217;s uncured material breach or (2) PRF&#8217;s termination of this Agreement in accordance with&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 22(a)(i)</font><font style="font-weight:normal;">&#160;for convenience and not due to any breach of this Agreement by Eiger), Eiger shall, to the extent Eiger has rights or is permitted under the Merck License Agreement or Merck (or any successor of Merck or of Merck&#8217;s rights in the Licensed Compound) otherwise agrees or permits in writing:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="font-weight:normal;">[ * ] (A) [ * ] (B) * ];</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_87"></a>(ii)<font style="font-weight:normal;">[&#160;* ] (A) [ * ] and (B) [ * ];</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_89"></a><a name="_cp_text_1_90"></a>(iii)<font style="font-weight:normal;">provide PRF with complete and unredacted copies of all Data and all draft regulatory filings (it being understood that &#8220;draft&#8221; means documents reasonably available and in the possession or control of Eiger (or any of its Affiliates) as of the date of such expiration or termination), in each case&#160;to the extent&#160;Controlled by Eiger that may be necessary to (A) Commercialize the Licensed Product in the Field and (B) prepare, file or maintain any Progeria NDA, it being understood that with respect to access to Data and information regarding chemistry, manufacturing and controls such information may be provided solely by Right of Reference granted by Eiger to PRF (or its designee);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="font-weight:normal;">(A) [ * ] (B) [ * ];</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="font-weight:normal;">[ * ] (A) [ * ]; (B) [ * ; and (C) [ * ]; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="font-weight:normal;">[ * ] (A) [ * ] or (B) [ * ].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="text-decoration:underline;font-weight:normal;">Return or Destruction of Confidential Information</font><font style="font-weight:normal;">.&#160;&#160;Upon the expiration or termination of all licenses granted by a Party (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Granting Party</font><font style="font-weight:normal;">&#8221;) to the other Party under or pursuant to this Agreement (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Former Licensee</font><font style="font-weight:normal;">&#8221;), such Former Licensee shall (a) reasonably promptly return to such Granting Party or destroy all of such Granting Party&#8217;s Confidential Information, and all copies, notes or extracts thereof, in the possession or control of such Former Licensee and (b) in the case of destruction, provide such Granting Party with written certification of such destruction signed by an officer of such Former Licensee.</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="text-decoration:underline;font-weight:normal;">Survival</font><font style="font-weight:normal;">.&#160;&#160;Upon&#160;the expiration or&#160;any termination of this Agreement, the following provisions shall survive:&#160;</font><font style="text-decoration:underline;font-weight:normal;">Sections 1</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">3</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">6</font><font style="font-weight:normal;">,&#160;the last sentence of&#160;</font><font style="text-decoration:underline;font-weight:normal;">9(c)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">9(f)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">9(i)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">10</font><font style="font-weight:normal;">,&#160;the last sentence of&#160;</font><font style="text-decoration:underline;font-weight:normal;">11(b)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">13</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">15</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">16</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">17(a)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">18</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">19</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">20(b)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">20(c)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">20(d)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">22(c)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">22(d)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">22(e)</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">22(f)</font><font style="font-weight:normal;">,&#160;and&#160;</font><font style="text-decoration:underline;font-weight:normal;">23</font><font style="font-weight:normal;">&#160;through and including&#160;</font><font style="text-decoration:underline;font-weight:normal;">31</font><font style="font-weight:normal;">.&#160;In addition,&#160;upon the&#160;expiration or&#160;termination of this Agreement for any reason (other than for Eiger&#8217;s termination of this Agreement in accordance with&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 22(b)</font><font style="font-weight:normal;">&#160;or PRF&#8217;s termination of this Agreement in accordance with&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 22(a)(i)</font><font style="font-weight:normal;">&#160;for convenience and not due to any breach of this Agreement by Eiger),&#160;</font><font style="text-decoration:underline;font-weight:normal;">Sections 2(c)</font><font style="font-weight:normal;">&#160;and&#160;</font><font style="text-decoration:underline;font-weight:normal;">2(d)</font><font style="font-weight:normal;">&#160;shall survive&#160;so long as the Merck License Agreement is in effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">23.<font style="text-decoration:underline;">Assignment</font><font style="font-weight:normal;">.&#160;&#160;Neither Party may assign this Agreement, including by operation of law, without the prior written consent of the other Party, which consent will not be unreasonably withheld or delayed, except that either Party may assign this Agreement (i) to an Affiliate of such Party or (ii) as part of a merger, consolidation, corporate reorganization or sale of all or substantially all of such Party&#8217;s assets, in each case (i) and (ii), without the prior written consent of the other Party provided that (A) the permitted assignee assumes in writing the performance of all of the assigning Party&#8217;s obligations under this Agreement and (B) in the case Eiger is the assigning Party, Eiger simultaneously assigns the Merck License Agreement to the permitted assignee.&#160;&#160;Any attempted assignment in violation of the foregoing restriction will be void.&#160;&#160;Subject to the foregoing restriction, this Agreement will be binding upon, enforceable by, and inure to the benefit of the Parties and their respective successors and permitted assigns.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">24.<font style="text-decoration:underline;">Entire Agreement</font><font style="font-weight:normal;">.&#160;&#160;This Agreement sets forth the complete and final agreement of the Parties with respect to the subject matter hereof and supersedes and terminates all prior agreements and understandings, written or oral, between the Parties with respect to such subject matter, including the Non-Binding Term Sheet, dated July 14, 2017, by and between the Parties.&#160;&#160;This Agreement may be amended, and the observance of any provision of this Agreement may be waived, only by a writing signed by both Parties.&#160;&#160;The failure by either Party to enforce any provision of this Agreement will not constitute a waiver of future enforcement of that or any other provision.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">25.<font style="text-decoration:underline;">Relationship of the Parties</font><font style="font-weight:normal;">.&#160;&#160;PRF and Eiger are independent contractors, and nothing in this Agreement will be construed as making them partners or as creating the relationships of employer and employee, master and servant, or principal and agent between them, for any purpose whatsoever.&#160;&#160;Neither Party will make any contracts, warranties or representations or assume or create any other obligations, express or implied, in the other Party&#8217;s name or on its behalf.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">26.<font style="text-decoration:underline;">Governing Law</font><font style="font-weight:normal;">.&#160;&#160;The validity, performance, construction, and effect of this Agreement shall be governed by and construed under the substantive laws of the State of New York, without regard to conflicts of law rules that would cause the application of the laws of another jurisdiction.&#160;&#160;</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">27.<font style="text-decoration:underline;">Dispute Resolution</font><font style="font-weight:normal;">.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="text-decoration:underline;font-weight:normal;">Resolution by Executives</font><font style="font-weight:normal;">.&#160;&#160;If any unresolved dispute as to matters arising under or relating to this Agreement or either Party's rights or obligations hereunder arises, either Party may refer such dispute to the Executive Director (if referring the dispute to PRF) or the Chief Executive Officer (if referring the dispute to Eiger), who shall meet in person or by telephone within [ * ] after such referral to attempt in good faith to resolve such dispute.&#160;&#160;If such matter cannot be resolved by discussion of such officers within such [ * ] period (as may be extended by mutual written agreement of the Parties), such dispute shall be resolved in accordance with&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 27(b)</font><font style="font-weight:normal;">.&#160;&#160;The Parties acknowledge that discussions between the Parties in an attempt to resolve any disputes are settlement discussions under applicable rules of evidence and without prejudice to either Party's legal position.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:20.12%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="text-decoration:underline;font-weight:normal;">Arbitration</font><font style="font-weight:normal;">. Any dispute that is not resolved pursuant to&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 27(a)</font><font style="font-weight:normal;">, except for any dispute, claim or controversy subject to&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 27(b)(vi)</font><font style="font-weight:normal;">, shall be settled by binding arbitration administered by federal arbitration before a single arbitrator having substantial experience with commercial transactions in the pharmaceutical industry.&#160;&#160;Such arbitration shall be governed by the U.S. Federal Arbitration Act, 9 U.S.C. &#167;&#167; 1-16 (the &#8220;</font>Federal Arbitration Act<font style="font-weight:normal;">&#8221;), to the exclusion of any inconsistent state laws and conducted in accordance with the Arbitration Rules and Procedures of the Judicial Arbitration and Mediation Service, Inc. (&#8220;</font>JAMS<font style="font-weight:normal;">&#8221;) then in effect.&#160;&#160;The arbitration will be conducted promptly in Boston, Massachusetts, and the Parties consent to the personal jurisdiction of the Federal District Court in the District of Massachusetts for any case arising out of or otherwise related to the arbitration, its conduct or its enforcement.&#160;&#160;Each Party shall have [ * ] to present its case, and the Parties shall jointly request that the arbitrator render a final decision within [ * ] following completion of each Party&#8217;s presentation or as soon thereafter as is practicable.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="font-weight:normal;">Any award shall be promptly paid free of any tax, deduction or offset, and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the Party resisting enforcement.&#160;&#160;The prevailing Party in the arbitration shall be entitled to receive reimbursement of its reasonable expenses (including reasonable attorneys&#8217; fees, expert witness fees and all other expenses) incurred in connection with such arbitration.&#160;&#160;Each Party agrees (A) to abide by the award rendered in any arbitration conducted pursuant to this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 27(b)</font><font style="font-weight:normal;">&#160;and (B) that, subject to the Federal Arbitration Act, judgment may be entered upon the final award in the Federal District Court in the District of Massachusetts and that other courts may award full faith and credit to such judgment in order to enforce such award.&#160;&#160;The award shall include interest from the date of any damages incurred for breach of this Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="font-weight:normal;">Except as set forth in&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 27(b)(i)</font><font style="font-weight:normal;">, each Party shall bear its own legal fees.&#160;&#160;The arbitrators shall have the authority to grant specific performance or to allocate between the Parties the costs of arbitration (including service fees, arbitrator fees and all other fees related to the arbitration) in such equitable manner as the arbitrator may determine.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>(iii)<font style="font-weight:normal;">Provided a Party has made a sufficient showing under the rules and standards set forth in the U.S. Federal Rules of Civil Procedure and applicable case law, the arbitrator shall have the freedom to invoke, and the Parties agree to abide by, injunctive</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">measures after either Party submits in writing for arbitration claims requiring immediate relief.&#160;&#160; Additionally, nothing in this&#160;<font style="text-decoration:underline;">Section 27</font>&#160;will preclude either Party from seeking any injunctive relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction, permanent injunction or other equitable relief, concerning a dispute either prior to, during or after any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="font-weight:normal;">The arbitration proceeding will be confidential and the arbitrator shall issue appropriate protective orders to safeguard each Party's Confidential Information.&#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="font-weight:normal;">Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after expiration or termination of this Agreement for any reason.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:27.66%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="font-weight:normal;">Any dispute, controversy or claim relating to the scope, validity, enforceability, infringement, violation, ownership, license or other rights of or with respect to any patents, trademarks or other intellectual property shall be submitted to a court of competent jurisdiction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">28.<font style="text-decoration:underline;">Notices</font><font style="font-weight:normal;">.&#160;&#160;All notices required or permitted to be given under this Agreement will be in writing and will be sent by an overnight courier service with package tracking capabilities and costs prepaid, by registered or certified airmail, return receipt requested and postage prepaid, to the other Party at the addresses set forth in the preamble of this Agreement and to the attention of President and Executive Director (in the case of PRF) or the President and CEO (in the case of Eiger).&#160;&#160;Such notices will be deemed to have been given when received by the addressee.&#160;&#160;Any Party may give written notice of a change of address in accordance with this&#160;</font><font style="text-decoration:underline;font-weight:normal;">Section 28</font><font style="font-weight:normal;">, whereupon any notice or request will thereafter be given to such Party as above provided at such changed address.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">29.<font style="text-decoration:underline;">Severability</font><font style="font-weight:normal;">.&#160;&#160;If any provision of this Agreement is held to be illegal or unenforceable, such provision will be limited or eliminated to the minimum extent necessary so that the remainder of this Agreement will continue in full force and effect and be enforceable, and the validity, legality and enforceability of the remaining provisions will not in any way be affected or impaired thereby.&#160;&#160;The Parties agree to negotiate in good faith an enforceable substitute provision for any invalid or unenforceable provision that most nearly achieves the Parties&#8217; intent of such provision.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">30.<font style="text-decoration:underline;">Construction; Headings</font><font style="font-weight:normal;">.&#160;&#160;No rule of construction that disfavors the drafting party will apply to this Agreement.&#160;&#160;As used in this Agreement, &#8220;including&#8221; and words of similar import mean &#8220;including but not limited to.&#8221;&#160;&#160;The use of &#8220;or&#8221; will not be deemed to be exclusive.&#160;&#160;Headings and titles used in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">31.<font style="text-decoration:underline;">Counterparts</font><font style="font-weight:normal;">.&#160;&#160;This Agreement may be executed in counterparts (including by facsimile or electronic transmission), each of which shall be deemed to be an original copy of this Agreement and all of which taken together shall be regarded as one and the same instrument.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">SIGNATURE PAGE FOLLOWS.</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"><a name="_Hlk65350927"></a>&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-right:2.56%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:10.05%;font-weight:bold;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>In Witness Whereof<font style="font-weight:normal;font-variant: normal;">, the Parties have executed this Agreement in duplicate originals by their respective authorized officers as of the Effective Date.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:44.42%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">Eiger BioPharmaceuticals, Inc.</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;">The Progeria Research Foundation, Inc.</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:6.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Cory</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Meryl Fink</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:6.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Cory</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Meryl Fink</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:6.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:0.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, CEO</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:7.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:0.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:41.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Director, President</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:12pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">[Signature Page to Collaboration and Supply Agreement]</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-variant: small-caps;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">EXECUTION VERSION</font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-right:2.56%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>Exhibit&#160;A</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-weight:bold;">&#160;</font>* ]</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman Bold;font-variant: small-caps;letter-spacing:-0.1pt;font-size:11pt;font-style:normal;text-transform:none;">[&#160;&#160;*&#160;&#160;] = <font style="font-variant: normal;">Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;">
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:7pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>7
<FILENAME>eigr-ex1031_1140.htm
<DESCRIPTION>EX-10.31
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex1031_1140.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.31</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Execution Version</p>
<p style="text-align:center;margin-bottom:36pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_mps499070520000000000000003929000000000"></a>ASSET PURCHASE AGREEMENT</p>
<p style="text-align:center;margin-bottom:36pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">BY AND BETWEEN</p>
<p style="text-align:center;margin-bottom:36pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ABBVIE INC.</p>
<p style="text-align:center;margin-bottom:36pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">AND</p>
<p style="text-align:center;margin-bottom:36pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">EIGER BIOPHARMACEUTICALS, INC.</p>
<p style="margin-bottom:84pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">NOVEMBER 20, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk62732000"></a>&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="zzmpTOCHeader_Primary"></a>Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_mps377646540000000000000004054000000000"></a>Table</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:13%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="mpTableOfContents"></a>ARTICLE 1</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEFINITIONS</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain Definitions</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 2</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PURCHASE AND SALE; CLOSING</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase and Sale of Purchased Assets.</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase Price</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Closing</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title Passage; Delivery of Purchased Assets.</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Closing Deliveries by Seller</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Closing Deliveries by Buyer</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Withholding</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer Taxes</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Broker Fees</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 3</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REPRESENTATIONS AND WARRANTIES OF SELLER</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Organization, Standing and Power</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due Authority</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Contravention</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Consents</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title to Purchased Assets</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contracts</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with Legal Requirements</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Compliance</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal Proceedings</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.10</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Governmental Authorizations</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.11</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revocation; Use of Purchased Assets</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.12</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketed Product</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.13</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brokers</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.14</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Solvency</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.15</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Other Representations</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 4</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REPRESENTATIONS AND WARRANTIES OF BUYER</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Organization, Standing and Power</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:44.58%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"><a name="zzmpTOCFooter"></a>&nbsp;</p></td>
<td valign="top"  style="width:10.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-i-</p></td>
<td valign="top"  style="width:44.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(continued)</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</font></p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authority</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Contravention</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Consents</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brokers</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Reliance</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 5</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVENANTS</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Solicitation.</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Antitrust Notification.</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further Assurances</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public Announcements</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Use of Name</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with Legal Requirements</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketing</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.10</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Covenants</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 6</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONDITIONS PRECEDENT TO CLOSING</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conditions Precedent to Seller&#8217;s Obligation</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conditions Precedent to Buyer&#8217;s Obligation</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 7</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TERMINATION</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.1</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Termination</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of Termination</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 8</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INDEMNIFICATION</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indemnification.</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notice of Loss; Third Party Claims.</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Survival</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Indemnification Matters</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limits on Indemnification</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exclusivity</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:44.58%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-ii-</p></td>
<td valign="top"  style="width:44.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table of Contents</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(continued)</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:13%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE 9</font></p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GENERAL PROVISIONS</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notice Requirements</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">References</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entire Agreement; Amendments</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assignment</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Severability</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Governing Law</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Submission to Jurisdiction.</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.9</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WAIVER OF JURY TRIAL</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.10</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waiver and Non-Exclusion of Remedies.</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.11</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Benefit to Third Parties</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:13%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;margin-right:3.21%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.12</p></td>
<td valign="top"  style="width:82%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Counterparts; Facsimile Execution</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:15.38%;margin-right:7.69%;text-indent:-15.38%;font-family:Times New Roman;font-size:10pt;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:44.58%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-iii</a>-</p></td>
<td valign="top"  style="width:44.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;"><a name="_mps905587920000000000000004054000000000"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">List of Exhibits </font></p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval Letter </p></td>
</tr>
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lender Consent </p></td>
</tr>
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRF Consent </p></td>
</tr>
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.4(b) </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Seller Cover Letter </p></td>
</tr>
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.5(a) </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Bill of Sale </p></td>
</tr>
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.5(b) </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Seller PRV Transfer Letter </p></td>
</tr>
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.5(c) </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Seller Closing Certificate </p></td>
</tr>
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.5(d) </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Seller Secretary&#8217;s Certificate </p></td>
</tr>
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.6(c) </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Buyer PRV Transfer Letter </p></td>
</tr>
<tr>
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.6(d) </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Buyer Closing Certificate </p></td>
</tr>
<tr style="height:4.3pt;">
<td valign="top"  style="width:18.24%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 5.6 </p></td>
<td valign="top"  style="width:81.76%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Public Announcement </p></td>
</tr>
</table></div>
<p style="margin-bottom:36pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk62732001"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;"><a name="_mps905587920000000000000004054000000000"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:24pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ASSET PURCHASE AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This ASSET PURCHASE AGREEMENT (this &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) is made and entered into as of November 20, 2020 (the &#8220;<font style="font-weight:bold;font-style:italic;">Effective Date</font>&#8221;), by and between <font style="font-weight:bold;">ABBVIE INC</font>., a corporation organized under the laws of Delaware (&#8220;<font style="font-weight:bold;font-style:italic;">Buyer</font>&#8221;), and <font style="font-weight:bold;">EIGER BIOPHARMACEUTICALS, INC.</font>, a corporation organized under the laws of Delaware (&#8220;<font style="font-weight:bold;font-style:italic;">Seller</font>&#8221;). Buyer and Seller may hereinafter be referred to individually as a &#8220;<font style="font-weight:bold;font-style:italic;">Party</font>&#8221; and collectively as the &#8220;<font style="font-weight:bold;font-style:italic;">Parties.</font>&#8221;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">RECITALS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Seller and Buyer each (a) desire that Buyer purchase from Seller, and Seller sell, transfer and assign to Buyer, the Purchased Assets (as defined below), all on the terms set forth herein (such transaction, the &#8220;</font><font style="font-style:italic;">Asset Purchase</font><font style="font-weight:normal;">&#8221;) and (b) in furtherance thereof, have adopted and approved this Agreement and, upon the terms and subject to the conditions set forth in this Agreement, have adopted and approved the Asset Purchase as contemplated by this Agreement in accordance with all applicable Legal Requirements (as defined below).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Seller and Buyer desire to make certain representations, warranties, covenants and other agreements as set forth herein in connection with the Asset Purchase contemplated by this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE<font style="font-weight:normal;">, in consideration of the foregoing and their mutual undertakings hereinafter set forth, and intending to be legally bound, the Parties agree as follows:</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc62733556"></a>Article 1<br />DEFINITIONS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733557"></a>1.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Certain Definitions</font>. As used in this Agreement, the following capitalized terms shall have the meanings indicated below:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Action</font>&#8221; means any claim, audit, examination, action, cause of action or suit (whether in contract or tort or otherwise), litigation (whether at law or in equity, whether civil or criminal), assessment, arbitration, mediation, investigation, hearing, charge, complaint, demand, notice or proceeding.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Adverse Claim</font>&#8221; means (a) a claim asserted by any Third Party that Seller does not have the right to sell and transfer the Priority Review Voucher to Buyer, (b) a Judgment of a Governmental Entity that prohibits Buyer from using the Priority Review Voucher, or (c) a Judgment involving a Third Party that would prevent Buyer from using the Priority Review Voucher.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Affiliate</font>&#8221; means any Person which, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, a Party to this Agreement, for so long as such control exists, whether such Person is or becomes an Affiliate on or after the Effective Date. A Person shall be deemed to &#8220;<font style="font-weight:bold;font-style:italic;">control</font>&#8221; another Person if it: (i) owns, directly or indirectly, beneficially or legally, at least fifty percent (50%) of the outstanding capital stock, voting securities or other ownership interest (or such lesser percentage which is the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">maximum allowed to be owned by such Person in a particular jurisdiction) of such other Person (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity); or (ii) has the power, whether pursuant to Contract, ownership of securities or otherwise, to direct the management and policies of such other Person.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Alternative Transaction</font>&#8221; means, other than the transactions contemplated by this Agreement, any proposal or offer from any Person or group of Persons (other than Buyer or its Affiliates or their respective Representatives) for any acquisition by, or transfer, license or other grant of rights to, such Person or group of Persons of any right, title or interest in or to the Purchased Assets; provided, that &#8220;<font style="font-weight:bold;font-style:italic;">Alternative Transaction</font>&#8221; shall not include any acquisition of substantially all of Seller&#8217;s assets (whether through a stock purchase, merger, sale of all or substantially all assets or otherwise) so long as such acquisition provides that this Agreement continues to be binding, enforceable and in full force and effect on the same terms in effect as of the Effective Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Approval Letter</font>&#8221; means the letter, dated November 20, 2020, from the FDA to Seller, issuing the FDA Approval and granting the Priority Review Voucher, attached hereto as Exhibit A.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Asset Purchase</font>&#8221; has the meaning set forth in the Recitals.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Business Day</font>&#8221; means a day (i) other than Saturday or Sunday and (ii) on which commercial banks are open for business in New York, New York, United States.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Consent</font>&#8221; means any and all filings, authorizations, consents, approvals, notices, permits, orders, registrations or declarations.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Contract</font>&#8221; means any written or oral legally binding contract, agreement, instrument, commitment or undertaking (including leases, licenses, mortgages, notes, guarantees, sublicenses, subcontracts and purchase orders).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">DOJ</font>&#8221; means the United States Department of Justice.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Encumbrance</font>&#8221; means any lien, pledge, charge, mortgage, owner&#8217;s mortgage, easement, encroachment, imperfection of title, title exception, title defect, right of possession, right of negotiation or refusal, leasehold interest, security interest, encumbrance, adverse claim, interference, or other restriction on transfer, ownership or use.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">FDA</font>&#8221; means the U.S. Food and Drug Administration.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">FDA Approval</font>&#8221; means commercial marketing authorization issued by FDA to the Seller relating to NDA 213969 for lonafarnib in accordance with Section 505(b)(1) of the FFDCA on November 20, 2020.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">FFDCA</font>&#8221; means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167; 301 et seq., as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">FTC</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> means the United States Federal Trade Commission.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(p)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Fundamental Representations</font>&#8221; means the representations and warranties contained in Section 3.1 (Organization; Standing and Power), Section 3.2 (Due Authority), Section</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3(b)(i) (No Contravention), Section 3.5 (Title to Purchased Assets), Section 3.8 (Regulatory Compliance), Section 3.11 (Revocation; Use of Purchased Assets), Section 3.12 (Marketed Product), Section 3.13 (Brokers) and Section 3.14 (Solvency).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(q)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Governmental Entity</font>&#8221; means any supranational, national, state, municipal, local or foreign government, any court, tribunal, arbitrator, administrative agency, commission or other governmental official, authority or instrumentality, in each case whether domestic or foreign, any stock exchange or similar self-regulatory organization or any quasi-governmental, private body or arbitral body exercising any executive, legislative, judicial, quasi-judicial, regulatory, taxing, importing, administrative or other governmental or quasi-governmental authority.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(r)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">HSR Act</font>&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended from time to time.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(s)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Indemnified Party</font>&#8221; means any of the Buyer Indemnified Parties or Seller Indemnified Parties, as applicable.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(t)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Indemnifying Party</font>&#8221; means any Person against whom a claim for indemnification is being asserted under any provision of Article 8.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(u)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Judgment</font>&#8221; means any orders, writs, injunctions, awards, judgments, settlements, stipulations, determinations and decrees entered by or with any Governmental Entity.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Knowledge</font>&#8221; means, with respect to Seller, the actual knowledge of the facts and information of any director or officer of Seller, after performing a reasonable inquiry with respect to such facts and information.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(w)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Law</font>&#8221; means any federal, state, foreign, local, municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Entity.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(x)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Legal Requirement</font>&#8221; means any Law, or any Judgment, or any license, franchise, authorization of any Governmental Entity or similar right granted under any of the forgoing, or any similar provision having the force or effect of Law applicable to a Party or to any of its assets, properties or businesses. Legal Requirements shall include, with respect to Seller or its Affiliates, any requirements, conditions or obligations relating to the Priority Review Voucher set forth in the FFDCA or the Approval Letter or in any other correspondence received by Seller or its Affiliates from the FDA regarding the Priority Review Voucher.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(y)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Lender Consent</font>&#8221; means that certain Consent Agreement between Seller and Oxford Finance, LLC, attached hereto as Exhibit B.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(z)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Liabilities</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> means all debts, liabilities and obligations, whether presently in existence or arising hereafter, accrued or fixed, absolute or contingent, matured or unmatured, determined or determinable, asserted or unasserted, known or unknown, including those arising under any Law, action or governmental order and those arising under any Contract.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(aa)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Losses</font>&#8221; means all losses, Liabilities, damages, claims, causes of action, judgments, awards, suits, Taxes, fines, penalties, costs or expenses (including reasonable attorneys&#8217; and experts&#8217; fees and expenses).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(bb)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Market</font>&#8221; or &#8220;<font style="font-weight:bold;font-style:italic;">Marketing</font>&#8221; means to market a drug within the meaning of Section 529(e)(1) of the FFDCA.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(cc)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Mutual Confidential Disclosure Agreement</font>&#8221; means that certain bilateral confidential disclosure agreement by and between the Parties, dated August 21, 2020.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(dd)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Person</font>&#8221; means any natural person, company, corporation, limited liability company, general partnership, limited partnership, trust, proprietorship, joint venture, business organization or Governmental Entity.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ee)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">PRF Agreement</font>&#8221; means that certain Collaboration and Supply Agreement, by and between Seller and The Progeria Research Foundation, Inc. dated May 15, 2018, as amended from time to time.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ff)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">PRF Consent</font>&#8221; means that certain Consent Agreement between Seller and The Progeria Research Foundation, Inc., attached hereto as Exhibit C.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(gg)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Priority Review</font>&#8221; means a priority review of and action upon a human drug application, which is submitted under Section 505(b)(1) or 505(b)(2) of the FFDCA or under Section 351 of the Public Health Service Act, by the FDA not later than six (6) months after the filing of such application by the FDA, as defined in the FFDCA.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(hh)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Priority Review Voucher</font>&#8221; means the priority review voucher issued by the Secretary of the Department of Health and Human Services pursuant to section 529(b)(1) of the FFDCA to Seller as evidenced by the Approval Letter, and assigned tracking number PRV NDA 213969.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Proceeding</font>&#8221; means any action, arbitration, audit, hearing, investigation, litigation or suit (whether civil, criminal, administrative, judicial or investigative, whether formal or informal, whether public or private) commenced, brought, conducted or heard by or before, or otherwise involving, any Governmental Entity or arbitrator.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(jj)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Purchased Assets</font>&#8221; means (i) the Priority Review Voucher and (ii) any and all rights, benefits and entitlements with respect thereto afforded to the holder of the Priority Review Voucher.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(kk)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Rare Pediatric Disease</font>&#8221; means rare pediatric disease as defined in Section 529(a)(3) of the FFDCA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ll)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Regulatory Change</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> means any (i) changed or additional Legal Requirement, amendment, supplement or interpretation to any then-existing Legal Requirement, or (ii) additional, amended or supplemented term or condition that is not set forth in the Approval Letter imposed on the Priority Review Voucher or a party seeking to use or transfer the Priority Review Voucher, that in either case of (i) or (ii) has been enacted, adopted, approved, or imposed by a Governmental Entity with appropriate jurisdiction over the matter between the Effective Date and the Closing Date and materially adversely impacts or limits the manner in which Buyer may use, receive, hold, transfer or otherwise exploit the Priority Review Voucher.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(mm)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Representative</font>&#8221; means, with respect to a particular Person, any director, officer, manager, employee, agent, consultant, advisor, accountant, financial advisor, legal counsel or other representative of that Person.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(nn)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Tax</font>&#8221; or &#8220;<font style="font-weight:bold;font-style:italic;">Taxes</font>&#8221; means any net income, alternative or add-on minimum tax, gross income, gross receipts, sales, use, value added tax, ad valorem, transfer, franchise, profits, license, withholding, payroll, employment, excise, severance, stamp, occupation, municipal tax, municipal surcharge premium, property, environmental or windfall profit tax, social security contribution or other tax of any kind whatsoever, together with any interest or any penalty, addition to tax or additional amount in the nature of a tax imposed by any Governmental Entity responsible for the imposition of any such tax (domestic or foreign), whether disputed or not and including (i) the tax liability of any other Person imposed pursuant to Treasury Regulations Section 1.1502-6 or any similar provision of other tax Law, and (ii) the obligation to indemnify or assume or otherwise succeed to the tax liability of any other Person, by contract or pursuant to any Law.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(oo)<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;font-style:italic;">Third Party</font>&#8221; means any Person other than a Party and such Party&#8217;s Affiliates.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(pp)<font style="margin-left:36pt;"></font>Other capitalized terms defined elsewhere in this Agreement and not defined in this Section 1.1 shall have the meanings assigned to such terms in this Agreement.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc62733558"></a>Article 2<font style="text-transform:none;"><br />PURCHASE AND SALE; CLOSING</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733559"></a>2.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Purchase and Sale of Purchased Assets</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Upon the terms and subject to the conditions of this Agreement, at and as of the Closing (as defined in <font style="text-decoration:underline;">Section 2.3</font>), Buyer shall purchase from Seller and Seller shall sell, transfer, convey, assign and deliver to Buyer all of Seller&#8217;s right, title and interest in and to the Purchased Assets free and clear of all Encumbrances. Seller shall perform all actions necessary to facilitate the transfer of the Purchased Assets to Buyer.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Buyer shall not assume, nor shall it be liable for, or otherwise be obligated to pay, perform or discharge, any Liabilities of Seller or its Affiliates, including any Liabilities arising from or related to Seller&#8217;s ownership prior to the Closing of any rights with respect to the Purchased Assets (such Liabilities, the &#8220;<font style="font-weight:bold;font-style:italic;">Excluded Liabilities</font>&#8221;). Seller shall be solely responsible for all such Excluded Liabilities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733560"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Purchase Price</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The total consideration to be paid by Buyer for all of the Purchased Assets shall be NINETY FIVE MILLION U.S. DOLLARS (U.S. $95,000,000) (the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Purchase Price</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). Buyer shall pay the Purchase Price to Seller on the Closing Date in United States dollars by wire transfer of immediately available funds to a bank account of Seller in accordance with the wire instructions provided by the Seller to the Buyer at least fourteen (14) Business Days prior to the Closing Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733561"></a>2.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Closing</font>. The closing of the transactions contemplated hereby (the &#8220;<font style="font-weight:bold;font-style:italic;">Closing</font>&#8221;) shall take place remotely via the exchange of documents and signatures, at 10:00 a.m. Eastern time on the third (3rd) Business Day following the date on which all of the conditions precedent set forth in Article 6 have been satisfied or waived (other than conditions to be satisfied only by the delivery of certificates or other documents at the Closing, but subject to the satisfaction or waiver of such conditions at the Closing), or at such other time and place as the Parties may mutually agree in writing. The date on which the Closing actually takes place is referred to in this Agreement as the &#8220;<font style="font-weight:bold;font-style:italic;">Closing Date.</font>&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733562"></a>2.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Title Passage; Delivery of Purchased Assets</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Title Passage</font>. Upon the Closing, all of the right, title and interest in and to the Purchased Assets shall pass to Buyer free and clear of all Encumbrances.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Method of Delivery of Assets</font>. On a date mutually agreed upon by the Parties, but in no event later than five (5) Business Days following the Closing Date, Seller will submit to FDA the separate notifications referred to in <font style="text-decoration:underline;">Section 2.5(b)</font> and <font style="text-decoration:underline;">Section 2.6(c)</font>, respectively, as a submission to NDA 213969 through FDA&#8217;s Electronic Submissions Gateway under the cover letter substantially in the form attached as <font style="text-decoration:underline;">Exhibit 2.4(b)</font>, and Buyer will submit to FDA a paper copy of such separate notifications and cover letter. Seller shall provide to Buyer confirmation from FDA of successful electronic submission and a complete copy of such submission. Notwithstanding anything to the contrary set forth herein, the Parties acknowledge and agree that Seller is not making any representation or warranty regarding, and shall not be liable to Buyer or any other Buyer Indemnified Party hereunder with respect to, the adequacy of the requirements set forth in this <font style="text-decoration:underline;">Section 2.4(b)</font> to comply with Legal Requirements applicable to the transfer of the Priority Review Voucher as contemplated by this Agreement; provided, however, that the foregoing shall not limit the obligations of the Seller pursuant to <font style="text-decoration:underline;">Section 5.5</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Filings; Notifications</font>. Buyer and Seller agree to cooperate and assist each other with respect to all filings or notifications to FDA related to the transfer and assignment of the Purchased Assets.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733563"></a>2.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Closing Deliveries by Seller</font>. At the Closing, Seller shall deliver to Buyer the following:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>an executed Bill of Sale substantially in the form attached hereto as Exhibit 2.5(a);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>a copy of the notification of the purchase and sale of the Priority Review Voucher pursuant to this Agreement to be submitted to the FDA pursuant to Section 2.4(b), which </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">notification shall be substantially in the form of Exhibit 2.5(b) or such other form as the FDA may require as of the Closing Date;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>a certificate of Seller dated as of the Closing Date, in the form set forth in Exhibit 2.5(c), duly executed by Seller, certifying as to the satisfaction of the conditions set forth in Sections 6.2(a) and 6.2(b);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>a certificate of Seller dated as of the Closing Date, in the form set forth in Exhibit 2.5(d), duly executed by Seller, certifying as to the resolutions of the Board of Directors of Seller authorizing the execution, delivery and performance of this Agreement, the transactions contemplated hereunder and authorizing the person or persons executing this Agreement on behalf of Seller or any instrument delivered, or to be delivered, hereunder to so execute and deliver such instrument; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>such other documents and instruments as may be required to be delivered by Seller by any other provision of this Agreement or as may be reasonably required to consummate the transactions contemplated by this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733564"></a>2.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Closing Deliveries by Buyer</font>. At the Closing, Buyer shall deliver to Seller the following:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>payment of the Purchase Price in accordance with Section 2.2;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>an executed Bill of Sale substantially in the form attached hereto as Exhibit 2.5(a);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>a copy of the notification of the purchase and sale of the Priority Review Voucher pursuant to this Agreement to be submitted to the FDA pursuant to Section 2.4(b), which notification shall be substantially in the form of Exhibit 2.6(c) or such other form as the FDA may require as of the Closing Date;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>a certificate of Buyer dated as of the Closing Date, in the form set forth in Exhibit 2.6(d), duly executed by Buyer, certifying as to the satisfaction of the conditions set forth in Sections 6.1(a) and 6.1(b); and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>such other documents and instruments as may be required to be delivered by Buyer by any other provision of this Agreement or as may be reasonably required to consummate the transactions contemplated by this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733565"></a>2.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Withholding</font>. Any payments by Buyer to Seller shall be made without any deduction or withholding for or on account of any Taxes, levies, duties, deductions, withholdings, assessments, fees or other charges imposed by any Governmental Entity (collectively, &#8220;<font style="font-weight:bold;font-style:italic;">Withholding Taxes</font>&#8221;), other than as required for taxes imposed on Seller&#8217;s net income; provided, however, that if Buyer assigns its rights under this Agreement to any Person pursuant to <font style="text-decoration:underline;">Section&#160;9.5</font> on or prior to the Closing Date, any such payment to Seller shall be increased such that the amount received by Seller after any deduction or withholding (including such deductions and withholdings applicable to additional sums payable under this <font style="text-decoration:underline;">Section 2.7</font>) is equal to the amount Seller would have received in the absence of such assignment. Where any sum due to be paid to </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">either Party hereunder is subject to any Withholding Taxes, the Parties shall use their commercially reasonable efforts to do all such acts and things and to sign all such documents as will enable them to take advantage of any applicable double taxation agreement or treaty. If a Governmental Entity retroactively determines that a payment made by Buyer to Seller should have been subject to Withholding Taxes (or to additional Withholding Taxes) (including any penalties, interest and additions thereto), Seller shall cooperate as reasonably requested by Buyer, at Buyer</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s sole cost and expense, in preparing and filing any tax returns or other filings required in respect of any Withholding Taxes. At Buyer</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s reasonable request, Seller shall use commercially reasonable efforts to assist Buyer in mitigating, reducing or eliminating any such Withholding Taxes, at Buyer</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s sole cost and expense. For clarity, nothing in this provision or elsewhere in this Agreement shall make Buyer liable for any taxes imposed on Seller</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s net income.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733566"></a>2.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Transfer Taxes</font>. Notwithstanding any other provision in this Agreement to the contrary, Buyer shall bear and pay any and all sales Taxes, value added Taxes, use Taxes, transfer Taxes, documentary charges, recording fees or similar Taxes, charges or fees (including any penalties, interest and additions thereto) that may become payable by either Party or its Affiliates in connection with the sale of the Purchased Assets to Buyer (collectively, &#8220;<font style="font-weight:bold;font-style:italic;">Transfer Taxes</font>&#8221;). Seller shall cooperate as reasonably requested by Buyer, at Buyer&#8217;s sole cost and expense, in timely paying any Transfer Taxes to the applicable Governmental Entity and preparing and timely filing any tax returns required to be filed in respect of any Transfer Taxes. At Buyer&#8217;s reasonable request, Seller shall use commercially reasonable efforts to assist Buyer in mitigating, reducing or eliminating any such Transfer Taxes, at Buyer&#8217;s sole cost and expense. For clarity, nothing in this provision or elsewhere in this Agreement shall make Buyer liable for any taxes imposed on Seller&#8217;s net income.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733567"></a>2.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Broker Fees</font>. Notwithstanding any other provision in this Agreement to the contrary, Seller shall bear and pay any and all fees and expenses that may become payable by either Party or its Affiliates in connection with any arrangement made by Seller or its Affiliates with any broker, finder or investment banker in connection with the purchase and sale of the Purchased Assets hereunder or any of the other transactions contemplated by this Agreement.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc62733568"></a>Article 3<font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">R</font>EPRESENTATIONS AND WARRANTIES OF SELLER</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seller hereby represents and warrants to Buyer, as of the Effective Date and the Closing Date (or in the case of representations and warranties that are made as of a specified date, as of such specified date) as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733569"></a>3.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Organization, Standing and Power</font>. Seller is a corporation duly organized, validly existing and in good standing under the laws of Delaware. Seller has the requisite corporate power and authority to own, operate and lease its properties and to carry on its business as presently conducted and is duly qualified or licensed to do business and is in good standing in each jurisdiction where the character of its properties owned or leased or the nature of its activities make such qualification or licensing necessary, except where the failure to be so qualified or licensed would not, individually or in the aggregate, reasonably be expected to materially adversely affect any of the Purchased Assets, Seller&#8217;s ability to consummate the transactions contemplated by this </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement, or Buyer</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s ownership and rights with respect to any of the Purchased Assets after the Closing. Seller is not in violation of its organizational documents, as amended to date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733570"></a>3.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Due Authority</font>. Seller has all requisite corporate power and authority to execute and deliver, perform its obligations under, and consummate the transactions contemplated by, this Agreement. The execution, delivery and performance of this Agreement, and the consummation of the Asset Purchase, have been duly and validly authorized by all necessary corporate action on the part of Seller. This Agreement has been duly executed and delivered by Seller. This Agreement, upon due execution and delivery by the Parties, will constitute a valid and binding obligation of Seller enforceable against Seller in accordance with its terms, subject only to the effect, if any, of (a) applicable bankruptcy and other similar Laws affecting the rights of creditors generally and (b) rules of Law governing specific performance, injunctive relief and other equitable remedies (whether considered in an action at Law or in equity).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733571"></a>3.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Contravention</font>. The execution and delivery by Seller of this Agreement does not, and the consummation of the transactions contemplated hereby, including the transfer of title to, ownership in, and possession of the Purchased Assets, will not, (a) result in the creation of any Encumbrance on the Purchased Assets or (b) conflict with, or result in any violation of or default under (with or without notice or lapse of time, or both), or give rise to a right of termination, revocation, suspension, cancellation or acceleration of any obligation or loss of any benefit under, or require any consent (other than the Lender Consent and the PRF Consent), approval or waiver from any Person pursuant to, (i) any provision of the organizational or governing documents of Seller, in each case as amended to date, (ii) the Priority Review Voucher, the Approval Letter or any Contract to which Seller or any Affiliate of Seller is a party or bound which involves or affects in any way any of the Purchased Assets or (iii) except as may be required to comply with the HSR Act, any Legal Requirements applicable to Seller or any Affiliate of Seller or any of the Purchased Assets, except, in the case of clause (b)(ii) with respect to the Contracts referenced therein but expressly excluding the Priority Review Voucher, or in the case of clause (b)(iii), for any such conflicts, violations or other occurrences that would not, individually or in the aggregate, reasonably be expected to (A) have a material adverse effect on the ability of Seller to consummate the sale of the Purchased Assets at Closing or (B) delay, restrict, limit, preclude or otherwise negatively impact, in a material manner, the transfer to Buyer of, or ownership or use by Buyer of, the Purchased Assets.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733572"></a>3.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Consents</font>. Except for (a) any Antitrust Approvals (as defined in Section 5.3(b)) required by the HSR Act, (b) the Lender Consent, (c) the PRF Consent and (d) the letters referenced in <font style="text-decoration:underline;">Section 2.4(b)</font>, no Consent of a Governmental Entity or any other Person, is necessary or required in connection with the execution, delivery and performance by Seller of this Agreement, and the consummation by Seller or its Affiliates of the transactions contemplated hereby. Each of the Lender Consent and the PRF Consent has been duly executed and delivered by Seller to Buyer on the Effective Date and has been duly and validly approved and authorized by Seller and, to Seller&#8217;s Knowledge, the other parties thereto, and necessary corporation action by Seller and, to Seller&#8217;s Knowledge, the other parties thereto, and constitutes a valid and binding obligation of Seller, and to Seller&#8217;s Knowledge, the other parties thereto, enforceable against Seller and, to Seller&#8217;s Knowledge, the other parties thereto, in accordance with their respective terms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733573"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Title to Purchased Assets</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Seller is the sole and exclusive owner of all right, title and interest in and to the Purchased Assets (subject, prior to the Closing, to the Encumbrances in favor of PRF pursuant to the PRF Agreement and Oxford Finance, LLC pursuant to the credit documents described in the Lender Consent, which Encumbrances will be released at or prior to Closing), owns good title to the Purchased Assets and at the Closing will transfer to Buyer good and transferable title to the Purchased Assets free and clear of any Encumbrances. Seller has performed all actions necessary to perfect its ownership of, and its ability to transfer, the Purchased Assets. Seller has the full right to sell, transfer, convey, assign and deliver the Purchased Assets to Buyer at the Closing free and clear of all Encumbrances. The right, title and interest in and to the Purchased Assets that are to be sold, transferred, conveyed, assigned and delivered by Seller to Buyer at the Closing in accordance with this Agreement collectively constitutes the entire right, title and interest in and to the Purchased Assets and immediately following the Closing, Buyer shall have all right, title and interest in and to the Purchased Assets free and clear of all Encumbrances. In addition to the foregoing, there are no Adverse Claims with respect to any of the Purchased Assets.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733574"></a>3.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Contracts</font>. Except for this Agreement, the PRF Agreement, the Loan Agreement (as defined in the Lender Consent), there is no Contract to which Seller or any of its Affiliates is a party to or bound by that involves or affects (or may involve or affect) the issuance of, ownership of, transfer or licensing of, title to, or use of any of the Purchased Assets, or that otherwise assigned, transferred, licensed, conveyed or encumbered, or granted or allowed to exist any Encumbrance with respect to, any of Seller&#8217;s right, title or interest in, to or under the Purchased Assets.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733575"></a>3.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Compliance with Legal Requirements</font>. Seller and its Affiliates are, and at all times have been, in compliance with all Legal Requirements that are or were applicable to the Purchased Assets. None of Seller or any of its Affiliates has received any written notice or other written communication from any Person regarding any actual or alleged violation of, or failure to comply with, any such Legal Requirement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733576"></a>3.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Regulatory Compliance</font>. Since the three (3) year period prior to the Effective Date and as it relates to the FDA Approval, the Approval Letter, the Priority Review Voucher or the activities giving rise to such FDA Approval, the Approval Letter or the Priority Review Voucher, neither Seller, any Affiliate of Seller, nor to the Knowledge of Seller, any Representative of Seller or any Affiliate of Seller, has made an untrue statement of material fact or a fraudulent statement to the FDA or any other Governmental Entity, failed to disclose a material fact or a fraudulent statement to the FDA or any other Governmental Entity or committed an act, made a statement or failed to make a statement that, at the time such disclosure was made, would reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;<font style="font-weight:bold;font-style:italic;">Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,</font>&#8221; set forth in 56 Fed. Reg. 46191 (September 10, 1991) or for any other Governmental Entity to invoke any similar policy, or for the FDA to withdraw, suspend or revoke the FDA Approval or Priority Review Voucher.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733577"></a>3.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Legal Proceedings</font>. There is no pending, or to Seller&#8217;s Knowledge, threatened, Action involving Seller or any of its Affiliates, nor has there been an Action involving Seller or any of its Affiliates, and neither Seller nor any of its Affiliates are a party or subject to the provisions of any Judgment, (a) that involves or affects the issuance of, continued validity of, </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ownership of, transfer or license of, title to, or use of any of the Purchased Assets, including, but not limited to, any such Action or Judgment that seeks to prohibit or limit in any respect, or place any conditions on, the ownership or use by Buyer or its Affiliates of any of the Purchased Assets, in each case as a result of the transactions contemplated by this Agreement (b) that otherwise challenges or seeks to restrain, prohibit, prevent, enjoin, alter or delay the consummation the transactions contemplated by this Agreement, or (c) that seeks to obtain from Buyer or any of its Affiliates in connection with the transactions contemplated by this Agreement any damages or which would result in the transactions contemplated hereby being rescinded following consummation. To the Knowledge of Seller, there is no fact or circumstance that would reasonably be expected to serve as a basis for any of the foregoing Actions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733578"></a>3.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Governmental Authorizations</font>. Neither Seller nor any of its Affiliates is required to hold any license, registration, or permit issued by any Governmental Entity to own, use or transfer the Purchased Assets, other than such licenses, registrations or permits that have already been obtained.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733579"></a>3.11<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Revocation; Use of Purchased Assets</font>. The Priority Review Voucher was awarded to Seller by the FDA in respect of Seller&#8217;s sponsorship of a Rare Pediatric Disease product application pursuant to Section 529(b)(1) of the FFDCA. The Priority Review Voucher has been duly granted and issued and has not been terminated, redeemed, transferred, suspended, cancelled or revoked and to Seller&#8217;s Knowledge there are no facts or circumstances that could reasonably be expected to (with or without notice or lapse of time, or both) result in the termination, suspension, cancellation or revocation of the Priority Review Voucher by a Governmental Entity, give rise to a right of FDA to revoke the Priority Review Voucher, result in the redemption or transfer of the Priority Review Voucher (other than pursuant to the transactions contemplated by this Agreement), or that could reasonably be expected to preclude or interfere with the sale and transfer of the Purchased Assets to Buyer or Buyer&#8217;s use of the Purchased Assets following the Closing to obtain Priority Review or any other benefits associated with the Purchased Assets. There is no term or condition imposed by the FDA on the Priority Review Voucher as of the date hereof that is not set forth in the Approval Letter. Seller has provided to Buyer true and complete copies of the Approval Letter and all other correspondence submitted or received by Seller or any of its respective Affiliates regarding the Priority Review Voucher. Neither Seller nor any of its Affiliates has notified FDA of intent to use the Priority Review Voucher.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733580"></a>3.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Marketed Product</font>. Seller has initiated or will initiate, and subsequently continue, Marketing in the United States of the Rare Pediatric Disease product for which the Priority Review Voucher was awarded within the three hundred and sixty five (365) day period beginning on the date of the FDA approval of such Rare Pediatric Disease product.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733581"></a>3.13<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Brokers</font>. No broker, finder or investment banker is entitled to any brokerage or finder&#8217;s fee in connection with the purchase and sale of the Purchased Assets hereunder or any of the other transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller or its Affiliates.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733582"></a>3.14<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Solvency</font>. Seller is not entering into this Agreement with the actual intent to hinder, delay, or defraud any creditor of Seller or any Affiliate of Seller. The remaining assets of Seller after the Closing will not be unreasonably small in relation to the business in which Seller will </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">engage after the Closing. After the Closing, Seller will not be insolvent and will have the ability to pay its debts as they become due.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733583"></a>3.15<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Other Representations</font>. Neither Seller nor any of its Affiliates or their respective Representatives is making any representation or warranty of any kind or nature whatsoever, oral or written, express or implied, except as otherwise expressly set forth in this <font style="text-decoration:underline;">ARTICLE 3</font>.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc62733584"></a>Article 4<font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">R</font>EPRESENTATIONS AND WARRANTIES OF BUYER</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buyer hereby represents and warrants to Seller as of the Effective Date and as of the Closing Date as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733585"></a>4.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Organization, Standing and Power</font>. Buyer is a company duly organized, validly existing and in good standing under the laws of Delaware.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733586"></a>4.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Authority</font>. Buyer has all requisite corporate power and authority to execute and deliver, perform its obligations under, and consummate the transactions contemplated by, this Agreement. The execution, delivery and performance of, and the consummation of the transactions contemplated by, this Agreement have been duly and validly approved and authorized by all necessary corporation action. This Agreement has been duly executed and delivered by Buyer.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement, upon due execution and delivery by the Parties, will constitute a valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, subject only to the effect, if any, of (a) applicable bankruptcy and other similar Laws affecting the rights of creditors generally and (b) rules of Law governing specific performance, injunctive relief and other equitable remedies (whether considered in an action at Law or in equity).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733587"></a>4.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Contravention</font>. The execution and delivery by Buyer of this Agreement does not, and the consummation of the transactions contemplated hereby will not, conflict with, or result in any violation of or default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or loss of any benefit under, or require any consent, approval or waiver from any Person pursuant to, (a) any provision of the organizational or governing documents of Buyer, in each case as amended to date, (b) any Contract to which Buyer or any Affiliate of Buyer is a party or bound by or by which it or its assets or properties are bound or under which Buyer or any Affiliate of Buyer has material rights or benefits, or (c) except as may be required to comply with the HSR Act, any Legal Requirements applicable to Buyer.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733588"></a>4.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Consents</font>. Except for (a) any Antitrust Approvals (as defined in <font style="text-decoration:underline;">Section 5.3(b)</font>) required by the HSR Act and (b) the letters referenced in <font style="text-decoration:underline;">Section 2.5(b)</font>, no Consent of any Governmental Entity or any other Person is necessary or required in connection with the execution, delivery and performance by Buyer of this Agreement or the consummation by Buyer of the transactions contemplated hereby.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733589"></a>4.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Brokers</font>. No broker, finder or investment banker is entitled to any brokerage or finder&#8217;s fee in connection with the purchase and sale of the Purchased Assets hereunder or any of </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the other transactions contemplated by this Agreement based upon arrangements made by or on behalf of Buyer or its Affiliates.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733590"></a>4.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Non-Reliance</font>. Except for the representations and warranties expressly set forth in <font style="text-decoration:underline;">ARTICLE 3</font> or in any other certificate or document delivered by or on behalf of the Seller or any of its Affiliates pursuant to this Agreement, neither Seller nor any of its Affiliates or their respective Representatives makes, or has made any representation or warranty, oral or written, express or implied, relating to Seller, the Purchased Assets or otherwise in connection with the Asset Purchase, and Seller and its Affiliates and their respective Representatives expressly disclaim any liability with respect thereto. Except for the representations and warranties expressly set forth in <font style="text-decoration:underline;">ARTICLE 3</font> or in any other certificate or document delivered by or on behalf of the Seller or any of its Affiliates pursuant to this Agreement, Buyer has not relied, and is not relying, on any representation or warranty of the Seller or any of its Affiliates relating to Seller, the Purchased Assets or otherwise in connection with the Asset Purchase.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc62733591"></a>Article 5<font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">C</font>OVENANTS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733592"></a>5.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Efforts</font>. During the period from the Effective Date and continuing until the earlier of the termination of this Agreement or the Closing Date (the &#8220;<font style="font-weight:bold;font-style:italic;">Pre-Closing Period</font>&#8221;), except as otherwise expressly contemplated by this Agreement or with such other Party&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed, each Party shall not, and shall cause its Affiliates not to, knowingly take or permit any action that, or omit to take any action the absence of which, could reasonably be expected to prevent the satisfaction of the conditions set forth in Article 6.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733593"></a>5.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Solicitation</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>During the Pre-Closing Period, Seller shall not, nor shall it authorize, instruct or permit any of its Affiliates or its or their Representatives to (i) solicit, initiate, facilitate or encourage any inquiries, proposals or offers with respect to, or the submission of, any Alternative Transaction by any Person (other than Buyer or its Affiliates or their respective Representatives) or any inquiry, proposal or offer that is reasonably likely to lead to an Alternative Transaction, (ii) engage, continue or participate in any discussions or negotiations regarding, or take any other action intended or reasonably expected to facilitate the making of any inquiry, proposal or offer to Seller that constitutes, or may reasonably be expected to lead to, any Alternative Transaction by any Person (other than Buyer or its Affiliates or their respective Representatives) other than to state that they are not permitted to have discussions, (iii) accept any inquiry, proposal or offer from any Person (other than Buyer) in respect of an Alternative Transaction, or (iv) resolve to propose or agree to do any of the foregoing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Upon execution of this Agreement, Seller and its Affiliates shall immediately cease and cause to be terminated any existing discussions with any Person (other than Buyer) that are in respect of an Alternative Transaction.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Without limiting Section 5.2(a), it is understood that any violation of the restrictions set forth in Section 5.2(a) by any Person covered by Section 5.2(a), whether or not </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such Person is purporting to act on behalf of Seller, shall be deemed to be a breach of Section 5.2(a) by Seller.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733594"></a>5.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Antitrust Notification</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Unless this Agreement shall have been validly terminated in accordance with Section 7.1, Buyer and Seller shall, within fifteen (15) Business Days after the Effective Date. file with the FTC and the DOJ the premerger notification and report form required as a result of the contemplated purchase and sale of the Purchased Assets and the other transactions contemplated hereby, and shall include any supplemental information requested in connection therewith, pursuant to the HSR Act. Any such filing, notification and report form and supplemental information shall be in substantial compliance with the requirements of the HSR Act. The Parties shall work together and shall furnish to one another such necessary information and reasonable assistance as the other may request in connection with its preparation of any filing or submission which is necessary under the HSR Act. The Parties shall (i) cooperate with one another and promptly inform the other Party of any communications with, and any inquiries or requests for additional information from, the FTC, the DOJ or any other applicable Governmental Entity, (ii) comply promptly with any such reasonable inquiry or request, (iii) not participate, or permit its Affiliates to participate, in any substantive meeting or discussion with any Governmental Entity in respect of any filings, investigation or inquiry concerning this Agreement unless it consults with the other Party in advance and, to the extent permitted by such Governmental Entity, gives the other Party the opportunity to attend and participate thereat, and (iv) with the exception of business documents deemed highly confidential by the possessing Party (including documents submitted as attachments to the Party&#8217;s notification and report form under the HSR Act), furnish the other Party or the other Party&#8217;s outside counsel with copies of all correspondence, filings, and communications (and memoranda setting forth the substance thereof) between a Party or its Affiliates, on the one hand, and any Governmental Entity, on the other hand, with respect to the transactions contemplated hereunder or any investigation with respect to the transactions contemplated hereunder. Buyer shall pay all filing fees for the filing under the HSR Act.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>From and after the date on which the filings are made pursuant to Section 5.3(a), Buyer and Seller shall use reasonable best efforts to obtain any clearance required under the HSR Act (the &#8220;<font style="font-weight:bold;font-style:italic;">Antitrust Approval</font>&#8221;), including replying at the earliest practicable date to any requests for information received from the FTC or DOJ pursuant to the HSR Act and requesting early expiration or termination of the applicable waiting periods under the HSR Act as soon as possible. Notwithstanding the foregoing, in connection with and as a result of any Antitrust Approval granted during the Pre-Closing Period, nothing in this Agreement shall require, or be construed to require, Buyer or any of its respective Affiliates to offer or agree to (i)(A) sell, hold, separate, divest, license, discontinue, or limit any assets, businesses, equity, holdings, intellectual property, or other interests or (B) any conditions relating to, or changes or restrictions in, the operation or use of any such assets, businesses, equity holdings, intellectual property or interests (including but not limited to any requirements to enter into new contracts or modify or terminate existing contracts), including with respect to the Purchased Assets and use of the Priority Review Voucher to obtain Priority Review of a product candidate of Buyer or its Affiliates or any other benefit associated with the Purchased Assets or (ii) any modification or waiver of the terms and conditions of this Agreement (any item set forth in clauses (i) or (ii), a &#8220;<font style="font-weight:bold;font-style:italic;">Burdensome Condition</font>&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733595"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Expenses</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Whether or not the purchase and sale of the Purchased Assets and the other transactions contemplated by this Agreement are consummated, and except as otherwise set forth in this Agreement, each of the Parties shall bear its own fees and expenses incurred or owed in connection with the purchase and sale of the Purchased Assets, this Agreement and the transactions contemplated hereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733596"></a>5.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Further Assurances</font>. During the Pre-Closing Period, and from and after the Closing, the Parties shall cooperate reasonably with each other in connection with any steps required to be taken as part of their respective obligations under this Agreement, including without limitation any notifications or filings required to be made to the FDA in connection with the transfer of the Purchased Assets, and shall, at no expense to the other Party, (a) furnish upon request to each other such further information, (b) execute and deliver to each other such other documents, and (c) do such other acts and things, all as the other Party may reasonably request for the purpose of carrying out the intent of this Agreement and the transactions contemplated by this Agreement, including the use of the Purchased Assets to obtain Priority Review. The Parties agree that the user fees to be paid in connection with the use of the Priority Review Voucher by Buyer or any transferee of the Priority Review Voucher, and all other user fees under the FFDCA applicable to the human drug application for which the Priority Review Voucher is redeemed, shall be borne exclusively by the Buyer or any transferee of the Priority Review Voucher. In any such event, Seller shall have no liability or obligation for any such fees.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733597"></a>5.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Public Announcements</font>. Forthwith upon execution of this Agreement, Seller will issue the public announcement set forth in Exhibit 5.6. Except as may be required by applicable Law or as may be required to comply with the requirements of any applicable stock exchange or any Governmental Entity, including the U.S. Securities and Exchange Commission, neither Party shall (i) other than the public announcement contemplated by the first sentence of this Section 5.6, disclose the existence or terms of this Agreement (other than disclosures to Representatives on a need-to-know basis and who are bound by confidentiality terms substantially no less stringent than the terms of the Mutual Confidential Disclosure Agreement) or (ii) issue any press release, publication, or other public announcement relating to this Agreement, the performance of this Agreement, or that otherwise identifies the other Party as a party to this Agreement. To the extent practicable, the disclosing Party shall give at least three (3) Business Days&#8217; advance notice of any legally required disclosure to the non-disclosing Party, and the non-disclosing Party may provide any comments on the proposed legally required disclosure during the foregoing time period; provided, that such disclosing Party shall be under no obligation to accept any such comments provided by the non-disclosing Party.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733598"></a>5.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Use of Name</font>. Except as expressly provided herein, neither Party shall mention or otherwise use the name, logo, or trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material, or other form of publicity without the prior written approval of such other Party in each instance. The restrictions imposed by this <font style="text-decoration:underline;">Section 5.7</font> shall not prohibit either Party from making any disclosure identifying the other Party that, in the opinion of the disclosing Party&#8217;s counsel, is required by applicable Law or the rules of a stock exchange on which the securities of the&nbsp;&nbsp;disclosing Party are listed; <font style="font-style:italic;">provided</font>, that such disclosing Party shall submit the proposed disclosure identifying the other Party in writing to the other Party as far in advance as reasonably </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">practicable (and in no event less than two (2) Business Days prior to the anticipated date of disclosure) so as to provide a reasonable opportunity to comment thereon.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733599"></a>5.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Compliance with Legal Requirements</font>. Seller shall, and shall cause its Affiliates and each of their respective successors in interest and assigns to the Rare Pediatric Disease product for which the Priority Review Voucher was awarded, to materially comply with all Legal Requirements applicable to such Persons (as the sponsor of such Rare Pediatric Disease product and, through the Closing, as the owner of the Priority Review Voucher), in any case relating to the Priority Review Voucher, including, but not limited to, any Legal Requirements applicable to such Persons that would impact the validity, maintenance, use or transfer of the Priority Review Voucher. Seller shall promptly forward to Buyer any written communications or notices it or its Affiliates receive from any Governmental Entity to the extent relating to or otherwise materially impacting the Priority Review Voucher; provided that Seller may redact any portion of such written communications or other notices that is not relevant to the Priority Review Voucher. Without limiting the generality of the foregoing, to the extent required, now or in the future, under applicable Legal Requirements or otherwise by the FDA for the use or transfer of the Priority Review Voucher, or to avoid revocation of the Priority Review Voucher, Seller shall, and shall cause its Affiliates and each of their respective successors in interest and assigns to the Rare Pediatric Disease product for which the Priority Review Voucher was awarded, to submit a post-approval production report to the FDA not later than five (5) years after the approval of such Rare Pediatric Disease product in accordance with section 529(e)(2) of the FFDCA.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733600"></a>5.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Marketing</font>. Seller shall, and shall cause its Affiliates and each of their respective successors in interest and assigns (if any) to, within the 365-day period beginning on the date of FDA approval of the Rare Pediatric Disease product for which the Priority Review Voucher was awarded, Market in the United States such Rare Pediatric Disease product to the extent and in a manner required under applicable Legal Requirements or otherwise by FDA to preclude FDA from exercising its authority to revoke the Priority Review Voucher pursuant to Section 529(e)(1) of the FFDCA.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733601"></a>5.10<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Other Covenants</font>. During the Pre-Closing Period, (i) Seller shall, and shall cause each of its Affiliates to, provide Buyer with prompt written notice of the occurrence of any Regulatory Change and maintain the Priority Review Voucher in full force and effect, (ii) Seller shall not, and shall cause each of its Affiliates not to, (A) enter into any Contract with respect to the Purchased Assets or (B) take or permit, or omit to take any action that would reasonably be expected to (x) prevent the satisfaction of the conditions set forth in Article 6 or (y) adversely affect any of the Purchased Assets, Seller&#8217;s or any of its Affiliates&#8217; ability to consummate the transactions contemplated by this Agreement or Buyer&#8217;s ownership and rights with respect to any of the Purchased Assets after the Closing and (iii) Seller shall, and shall cause each of its Affiliates to, provide Buyer with prompt written notice of the occurrence or non-occurrence of any event the occurrence or non-occurrence of which has caused or would reasonably be expected to cause any condition to the obligations of Seller to effect the Closing or the failure of Seller to comply with or satisfy in any material respect any covenant to be complied with or satisfied by Seller following the Closing pursuant to this Agreement; provided the failure by Seller to give notice of any such occurrence as required pursuant to this Section 5.10 with respect to a breach of or inaccuracy in a&nbsp;&nbsp;representation or warranty contained herein shall not, in and of itself, render such breach or inaccuracy to become a failure to comply with a covenant. Such notices provided pursuant to this </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 5.10 shall not be deemed to amend, modify or supplement any representation or warranty provided by Seller in this Agreement or any certificate or document delivered hereunder and shall not operate as a waiver or otherwise affect or impair any of Buyer</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s rights under this Agreement (including with respect to </font><font style="text-decoration:underline;">Article 7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="text-decoration:underline;">Article 8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc62733602"></a>Article 6<font style="font-weight:normal;text-transform:none;"><br />C</font>ONDITIONS PRECEDENT TO CLOSING</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733603"></a>6.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Conditions Precedent to Seller&#8217;s Obligation</font>. The obligation of Seller to consummate the transactions contemplated by this Agreement is subject to the satisfaction or waiver on or prior to the Closing Date of the following conditions:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Representations and Warranties of Buyer</font>. Each of the representations and warranties of Buyer made in Article 4 shall be true and correct (without giving effect to any limitation or qualification as to &#8220;<font style="font-weight:bold;font-style:italic;">materiality</font>&#8221; (including the word &#8220;<font style="font-weight:bold;font-style:italic;">material</font>&#8221;) or &#8220;<font style="font-weight:bold;font-style:italic;">material adverse effect</font>&#8221; set forth therein) in all material respects as of the Effective Date and as of the Closing Date (or in the case of representations and warranties that are made as of a specified date, such representations and warranties shall be true and correct as of such specified date).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Compliance with Agreements and Covenants</font>. Buyer and its Affiliates shall have performed in all material respects all obligations and agreements and complied in all material respects with all covenants and conditions required by this Agreement to be performed or complied with by Buyer or any such Affiliate on or before the Closing Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Antitrust</font>. Any waiting period (or extension thereof) applicable to the transactions contemplated by this Agreement under the HSR Act shall have been terminated or shall have expired, in each case, without the imposition of a Burdensome Condition.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Injunction or Legal Restraint</font>. No Governmental Entity shall have enacted, issued, promulgated, enforced or entered any Law nor shall any temporary restraining order, preliminary or permanent injunction or other order or decree have been issued or be pending by any court of competent jurisdiction that is in effect and which has the effect of, or that if in effect would have the effect of, making the transactions contemplated by this Agreement illegal or otherwise preventing, prohibiting or restraining the consummation of the transactions contemplated by this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Closing Deliveries</font>. Buyer shall have made the deliveries contemplated under Section 2.6.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733604"></a>6.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Conditions Precedent to Buyer&#8217;s Obligation</font>. The obligation of Buyer to consummate the transactions contemplated by this Agreement is subject to the satisfaction or waiver on or prior to the Closing Date of the following conditions:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Representations and Warranties of Seller</font>. Each of the representations and warranties of Seller made in Article 3, other than the Fundamental Representations, shall be true and correct (without giving effect to any limitation or qualification as to &#8220;<font style="font-weight:bold;font-style:italic;">materiality</font>&#8221; (including   the word &#8220;<font style="font-weight:bold;font-style:italic;">material</font>&#8221;) or &#8220;<font style="font-weight:bold;font-style:italic;">material adverse effect</font>&#8221; set forth therein) in all material respects as of the Effective Date and as of the Closing Date (or in the case of representations and warranties that are made as of a specified date, such representations and warranties shall be true and correct as of such specified date); <font style="font-style:italic;">provided</font>, that any such failure of such representations and warranties to be true and correct shall be disregarded if it would not, individually or in the aggregate, reasonably be expected to delay, restrict, limit, preclude or otherwise negatively impact in a material manner the transfer to Buyer of, or ownership or use by Buyer of, the Purchased Assets. The Fundamental Representations shall be true and correct in all respects as of the Effective Date and as of the Closing Date (or in the case of representations and warranties that </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are made as of a specified date, such representations and warranties shall be true and correct as of such specified date).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Compliance with Agreements and Covenants</font>. Seller and its Affiliates shall have performed in all material respects all obligations and agreements and complied in all material respects with all covenants and conditions required by this Agreement to be performed or complied with by Seller or any such Affiliate on or before the Closing Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Antitrust</font>. Any waiting period (or extension thereof) applicable to the transactions contemplated by this Agreement under the HSR Act shall have been terminated or shall have expired, in each case, without the imposition of a Burdensome Condition.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Injunction or Legal Restraint</font>. No Governmental Entity shall have enacted, issued, promulgated, enforced or entered any Law nor shall any temporary restraining order, preliminary or permanent injunction or other order or decree have been issued or be pending by any court of competent jurisdiction that is in effect and which has the effect of, or that if in effect would have the effect of, making the transactions contemplated by this Agreement illegal or otherwise preventing, prohibiting or restraining the consummation of the transactions contemplated by this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Consents</font>. Each of the Lender Consent and the PRF Consent has been executed and has not been terminated or rescinded at or before the Closing and otherwise remains in effect on and after the Closing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Closing Deliveries</font>. Seller shall have made the deliveries contemplated under Section 2.5.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Regulatory Change</font>. There shall not have occurred and remain in effect any Regulatory Change.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc62733605"></a>Article 7<font style="font-weight:normal;text-transform:none;"><br />T</font>ERMINATION</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733606"></a>7.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination</font>. This Agreement may be terminated, and the transactions contemplated hereby may be abandoned, at any time prior to Closing:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>by mutual written consent of Buyer and Seller;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>by Buyer or Seller, if the Closing has not occurred by 11:59 p.m. Eastern time on the date that is ninety (90) days following the Effective Date (the &#8220;<font style="font-weight:bold;font-style:italic;">Outside Date</font>&#8221;); provided, that neither Party may terminate this Agreement pursuant to this clause (b) if such Party is in breach of this Agreement;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by Buyer or Seller, if (i) any Law having the effect referred to in </font><font style="text-decoration:underline;">Section</font><font style="text-decoration:underline;">&#160;</font><font style="text-decoration:underline;">6.2(d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </font><font style="text-decoration:underline;">Section 6.1(d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as applicable, has been enacted, issued, promulgated, enforced or entered, or (ii) any order, injunction or decree having the effect referred to in </font><font style="text-decoration:underline;">Section 6.2(d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </font><font style="text-decoration:underline;">Section 6.1(d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as applicable, is in effect and has become final and non-appealable; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>by Buyer, if Buyer is not in material breach of its obligations under this Agreement and there has been a violation or breach by Seller of any of its representations, warranties, covenants or other agreements contained in this Agreement, which has prevented or would prevent the satisfaction of any condition to the obligations of Buyer at the Closing set forth in <font style="text-decoration:underline;">Section 6.2</font>, and (i) such violation or breach has not been waived by Buyer, (ii) Buyer has provided written notice to Seller of such violation or breach setting forth the allegations of violation or breach in reasonable detail, and (iii) such violation or breach cannot be or has not been cured by Seller within twenty (20) Business Days after receiving written notice thereof from Buyer (provided that in no event shall such twenty (20) Business Day extend beyond the Outside Date); or</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>by Seller, if Seller is not in material breach of its obligations under this Agreement and there has been a violation or breach by Buyer of any of its representations, warranties, covenants or other agreements contained in this Agreement, which has prevented or would prevent the satisfaction of any condition to the obligations of Seller at the Closing set forth in <font style="text-decoration:underline;">Section 6.1</font> and (i) such violation or breach has not been waived by Seller, (ii) Seller has provided written notice to Buyer of such violation or breach setting forth the allegations of violation or breach in reasonable detail, and (iii) such violation or breach cannot be or has not been cured by Buyer within twenty (20) Business Days after receiving written notice thereof from Seller (provided that in no event shall such twenty (20) Business Day extend beyond the Outside Date).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733607"></a>7.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Effect of Termination</font>. If this Agreement is terminated and the transactions contemplated hereby are abandoned as described in this Article 7, this Agreement shall become void and of no further force or effect and there shall be no liability on the part of Buyer or Seller, except for Losses resulting from any willful and intentional breach prior to termination of this Agreement by Buyer or Seller, as applicable, except that (i) the provisions of this Section 7.2, <font style="text-decoration:underline;">Sections 5</font>.<font style="text-decoration:underline;">4</font>, <font style="text-decoration:underline;">5.6</font>, <font style="text-decoration:underline;">5.7</font>, and <font style="text-decoration:underline;">Article 1</font> and <font style="text-decoration:underline;">Article 9</font> shall survive the termination of this Agreement and shall remain in full force and effect and (ii) the Mutual Confidential Disclosure Agreement shall survive termination in accordance with its terms.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc62733608"></a>Article 8<font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">I</font>NDEMNIFICATION</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733609"></a>8.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnification</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Indemnification by Seller. From and after the Closing, Seller shall indemnify, defend and hold Buyer and its Affiliates and its and their respective directors, officers, employees, shareholders, partners, members, agents, Representatives, successors and assigns (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Buyer Indemnified Party</font>&#8221;) harmless for, from and against any and all Losses, whether&nbsp;&nbsp;or not arising from, relating to or otherwise in connection with a claim of a Third Party (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Third Party Claim</font>&#8221;), which any Buyer Indemnified Party may suffer, incur, sustain or become subject to, to the extent arising from, relating to or otherwise in connection with (i) any breach of </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or inaccuracy in any representations and warranties of Seller made under this Agreement or any certificate or document delivered hereunder; (ii) any breach of or failure to perform any covenants or obligations of Seller made under this Agreement or any certificate or document delivered hereunder; and (iii) all Excluded Liabilities.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnification by Buyer</font>. From and after the Closing, Buyer shall indemnify, defend and hold harmless Seller and its Affiliates, and its and their respective directors, officers, employees, agents, Representatives, successors and assigns (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Seller Indemnified Party</font>&#8221;) from and against any and all Losses, whether or not arising from, relating to or otherwise in connection with a Third Party Claim, which any Seller Indemnified Party may suffer, incur, sustain or become subject to, to the extent arising from, relating to or otherwise in connection with (i) any breach of or inaccuracy in any representations and warranties of Buyer made under this Agreement or any certificate or document delivered hereunder; and (ii) any breach of or failure to perform any covenants or obligations of Buyer made under this Agreement or any certificate or document delivered hereunder.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733610"></a>8.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Notice of Loss; Third Party Claims</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>(a) A claim for indemnification for any matter not involving a Third Party Claim may be asserted by written notice to the Party from whom indemnification is sought. Such notice shall be made, or caused to be made, promptly by the Indemnified Party and shall include the facts constituting the basis for such claim for indemnification, the Sections of this Agreement upon which such claim for indemnification is then based and an estimate, if possible, of the amount of Losses suffered or reasonably expected to be suffered by the Indemnified Party; <font style="font-style:italic;">provided</font>, that the failure to give such notification or any deficiency in such notification will not relieve such Indemnifying Party from any obligation under this <font style="text-decoration:underline;">Article 8</font>, except (i) to the extent such failure to give such notification or any deficiency in such notification actually and materially prejudices such Indemnifying Party or (ii) as provided in <font style="text-decoration:underline;">Section 8.3</font>. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>In the event of any instituted or asserted Third Party Claim against an Indemnified Party, the Indemnified Party shall promptly cause written notice of the assertion of any Third Party Claim of which it has knowledge which is covered by the provisions of <font style="text-decoration:underline;">Section 8.1(a)</font> or <font style="text-decoration:underline;">Section 8.1(b)</font>, as applicable, to be forwarded to the Indemnifying Party. The failure to give such notification or any deficiency in such notification will not relieve such Indemnifying Party from any obligation under this <font style="text-decoration:underline;">Article 8</font>, except (i) to the extent such failure to give such notification or any deficiency in such notification actually and materially prejudices such Indemnifying Party or (ii) as provided in Section 8.3. The Indemnifying Party shall have the right, at its sole option and expense, to be represented by counsel reasonably acceptable to the Indemnified Party and to defend against, negotiate, settle or otherwise deal with any Third Party Claim which relates to any Losses indemnified by it hereunder, subject to the provisions below; <font style="font-style:italic;">provided, however</font>, that the Indemnifying Party may not assume control of defense to a Third Party Claim (i) unless it provides written notice within twenty (20) Business Days after the Indemnified Party has given notice of the Third Party Claim to the Indemnifying Party that the Indemnifying Party elects to assume the defense and that the Indemnifying Party will be liable to indemnify the Indemnified Party with respect to all Losses relating to such Third Party Claim, (ii) in which equitable relief other than monetary damages is sought, (iii) if such Third Party Claim is brought by a Governmental Entity or is otherwise related to or arises in connection with any FDA, tax or </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">criminal or regulatory enforcement matter, (iv) if the Indemnified Party has been advised in writing by outside counsel that a legal conflict exists between the Indemnified Party and the Indemnifying Party in connection with conducting the defense of the Third Party Claim, or (v) the Indemnifying Party fails to diligently and in good faith conduct the defense of the Third Party Claim.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>If the Indemnifying Party elects to defend against, negotiate, settle or otherwise deal with any Third Party Claim which relates to any Losses indemnified by it hereunder, it shall within thirty (30) days (or sooner, if the nature of the Third Party Claim so requires) notify the Indemnified Party of its intent to do so. If the Indemnifying Party elects not to defend against, negotiate, settle or otherwise deal with any Third Party Claim which relates to any Losses indemnified against hereunder, or is not permitted to assume the defense of a Third Party Claim pursuant to the proviso to the third sentence of <font style="text-decoration:underline;">Section 8.2(b)</font>, the Indemnified Party may defend against, negotiate, settle or otherwise deal with such Third Party Claim, subject to the provisions below. If the Indemnifying Party shall assume the defense of any Third Party Claim pursuant to the terms of this Agreement, the Indemnified Party may participate, at its own expense, in the defense of such Third Party Claim. The Parties agree to reasonably cooperate with each other in connection with the defense, negotiation or settlement of any such Third Party Claim. Notwithstanding anything in this <font style="text-decoration:underline;">Section 8.2</font> to the contrary, the Indemnifying Party shall not, without the prior written consent of the Indemnified Party, settle or compromise any Third Party Claim or permit a default or consent to entry of any judgment unless (1) the claimant provides to the Indemnified Party a full and unqualified release of the Indemnified Parties and their respective Affiliates and Representatives from all liability in respect of such Third Party Claim, (2) such settlement does not involve any injunctive relief binding upon the Indemnified Party or any of its Affiliates or Representatives, (3) such settlement does not create an Encumbrance upon any of the assets of any Indemnified Party or impose any restriction or condition that would apply to or materially affect any Indemnified Party or the conduct of any Indemnified Party&#8217;s business, and (4) such settlement does not involve any admission of liability or wrongdoing by any Indemnified Party or any of its Affiliates or Representatives.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>In the event that the Indemnified Party conducts the defense of the Third Party Claim pursuant to this <font style="text-decoration:underline;">Section 8.2</font>, the Indemnifying Party will (i) advance the Indemnified Party promptly and periodically for the reasonable costs of defending against the Third Party Claim (including reasonable attorneys&#8217; and experts&#8217; fees and expenses) and (ii) remain responsible for any and all other Losses that the Indemnified Party may incur or suffer resulting from, arising out of, relating to, in the nature of or caused by the Third Party Claim to the fullest extent provided in this <font style="text-decoration:underline;">Article 8</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733611"></a>8.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Survival</font>. The representations and warranties of Seller and Buyer under this Agreement, and liability for the breach thereof, shall survive the Closing Date and shall remain in full force and effect for a period of eighteen (18) months following the Closing Date; provided, however, that all covenants, and the Fundamental Representations shall survive the Closing Date and shall remain in full force and effect for a period of six (6) years following the Closing Date. No claim for breach of any representation, warranty, covenant or agreement may be brought after expiration of the survival periods set forth in this <font style="text-decoration:underline;">Section 8.3</font>. Notwithstanding the foregoing, if written notice of a claim has been given in the manner required by <font style="text-decoration:underline;">Section 8.2</font> prior to the expiration of the applicable survival period by the Party seeking indemnification for such claim, </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">then the relevant covenants, representations and warranties of the other Party shall survive as to such claim until such claim has been finally resolved pursuant to this </font><font style="text-decoration:underline;">Article 8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733612"></a>8.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Additional Indemnification Matters</font>. The right of indemnification provided under this <font style="text-decoration:underline;">Article 8</font> shall not be affected by any knowledge acquired (or capable of being acquired) at any time, whether before or after the Effective Date, with respect to the accuracy or inaccuracy of, or compliance or noncompliance with, any representation, warranty, covenant or agreement contained herein. If, following the Closing, the Priority Review Voucher is terminated, revoked or cancelled by FDA as a result of the failure by Seller and its Affiliates to comply with the requirements set forth in <font style="text-decoration:underline;">Section 5.9</font>, Seller shall indemnify Buyer for Losses in an amount equal to the Purchase Price paid by Buyer. Amounts paid pursuant to this <font style="text-decoration:underline;">Section 8.4</font> shall be deemed indemnifiable Losses for purposes of <font style="text-decoration:underline;">Section 8.6</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733613"></a>8.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Adjustments</font>. Any amount paid under this <font style="text-decoration:underline;">Article 8</font> shall be treated as an adjustment to the Purchase Price for all Tax purposes unless otherwise required by applicable Law.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733614"></a>8.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Limits on Indemnification</font>. Notwithstanding anything to the contrary contained in this Agreement, the maximum aggregate amount of indemnifiable Losses that may be recovered from (a) Seller by Buyer Indemnified Parties pursuant to <font style="text-decoration:underline;">Section 8.1(a)</font> shall equal the Purchase Price and (b) Buyer by Seller Indemnified Parties pursuant to <font style="text-decoration:underline;">Section 8.1(b)</font> shall equal the Purchase Price. Notwithstanding anything to the contrary set forth herein, except to the extent actually awarded against an Indemnified Party pursuant to a Judgment with respect to (i) a Third Party Claim, or (ii) a claim for fraud, no Party hereto shall have any liability under any provision of this Agreement (including this <font style="text-decoration:underline;">Article VIII</font>) for any punitive, incidental, special or indirect damages or damages for or otherwise based on business interruption, diminution of value, loss of future revenue, profits or income, or loss of business reputation or opportunity relating to the breach or alleged breach of this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733615"></a>8.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exclusivity</font>. From and after the Closing, this <font style="text-decoration:underline;">ARTICLE 8</font> will provide the exclusive remedy against either Party for any breach of any representation, warranty, covenant or other claim arising out of or relating to this Agreement and/or the transactions contemplated hereby, except nothing in this Agreement will prevent or otherwise limit either Party from seeking or obtaining injunctive or other equitable relief for any breach of any covenant or agreement set forth herein or making any claim in the event of fraud. The Parties hereto agree that the provisions in this Agreement relating to indemnification, and the limits imposed on Buyer&#8217;s remedies with respect to this Agreement and the transactions contemplated hereby, were specifically bargained for between sophisticated parties and were specifically taken into account in the determination of the amounts to be paid to Seller hereunder.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc62733616"></a>Article 9<font style="font-weight:normal;text-transform:none;"><br />G</font>ENERAL PROVISIONS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733617"></a>9.1<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Notice Requirements</font>. Any notice, request, demand, waiver, consent, approval, or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if (a) delivered by hand, or (b) sent by internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in this <font style="text-decoration:underline;">Section 9.1</font> or to such other </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Section 9.1. Such notice shall be deemed to have been given as of the date delivered by hand or on the second Business Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter.</font></p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:78%;">
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Buyer, to:</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 North Waukegan Road North </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chicago, IL 60064 </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Vice Chairman, External Affairs, Chief Legal Officer and Corporate Secretary</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: 1-847- 935-3294 </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy (which shall not constitute notice) to:</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ropes &amp; Gray LLP</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prudential Tower </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800 Boylston Street </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, MA 02199 </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Patrick O&#8217;Brien </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: 617-235-0392 </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Seller, to:</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2155 Park Blvd </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Palo Alto, CA 94306 </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: General Counsel </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: <font style="text-decoration:underline;">legal@eigerbio.com</font> </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy (which shall not constitute notice) to:</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Covington &amp; Burling LLP</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The New York Times Building </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620 Eighth Avenue </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10018 </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Stephen A. Infante </p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: 646-441-9039</p></td>
</tr>
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733618"></a>9.2<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Construction</font>. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word &#8220;or&#8221; is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extend, or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">include,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">includes</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as used herein shall mean </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including, but not limited to,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and shall not limit the generality of any description preceding such term. The words </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> have the same meaning. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733619"></a>9.3<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">References</font>. Unless otherwise specified, (a) references in this Agreement to any <font style="text-decoration:underline;">Article</font>, <font style="text-decoration:underline;">Section</font>, <font style="text-decoration:underline;">Schedule</font> or <font style="text-decoration:underline;">Exhibit</font> shall mean references to such <font style="text-decoration:underline;">Article</font>, <font style="text-decoration:underline;">Section</font>, <font style="text-decoration:underline;">Schedule</font> or <font style="text-decoration:underline;">Exhibit</font> of this Agreement, (b) references in any <font style="text-decoration:underline;">Section</font> to any clause are references to such clause of such <font style="text-decoration:underline;">Section</font>, and (c) references to any agreement, instrument, or other document in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so amended, replaced, or supplemented and in effect at the relevant time of reference thereto.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733620"></a>9.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Entire Agreement; Amendments</font>. This Agreement, the documents, Exhibits and Schedules referred to herein, and the Mutual Confidential Disclosure Agreement sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises, and representations, whether written or oral, with respect thereto are superseded hereby. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement. No amendment, modification, release, or discharge shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733621"></a>9.5<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Assignment</font>. Without the prior written consent of the other Party neither Party shall sell, transfer, assign, delegate, pledge, or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided, that (a) either Party may make such an assignment without the other Party&#8217;s consent to any of its Affiliates, and (b) Buyer may make such an assignment, in whole or in part, without Seller&#8217;s consent, to any Affiliate, purchaser, transferee, or assignee of the Purchased Assets. With respect to any permitted assignment, the assigning Party shall remain responsible for the performance by such permitted assignee of the assigning Party&#8217;s duties and obligations hereunder. Any attempted assignment or delegation in violation of this Section 9.5 shall be void and of no effect. All validly assigned and delegated rights and obligations of the Parties hereunder shall be binding upon and inure to the benefit of and be enforceable by and against the successors and permitted assigns of Buyer or Seller, as the case may be. For the avoidance of doubt, no assignment made pursuant to this <font style="text-decoration:underline;">Section 9.5</font> shall relieve the assigning Party of any of its obligations under this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733622"></a>9.6<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Severability</font>. If any provision of this Agreement is held to be illegal, invalid, or unenforceable under any present or future law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable; (b) this Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a part hereof; (c) the remaining provisions of this </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid, or&nbsp;&nbsp;unenforceable provision or by its severance herefrom; and (d) in lieu of such illegal, invalid, or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid, and enforceable provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by applicable Law, each Party hereby waives any provision of Law that would render any provision hereof illegal, invalid, or unenforceable in any respect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733623"></a>9.7<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Governing Law</font>. This Agreement or the performance, enforcement, breach or termination hereof shall be interpreted, governed by and construed in accordance with the laws of the State of New York, United States (&#8220;<font style="font-weight:bold;font-style:italic;">New York</font>&#8221;), excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733624"></a>9.8<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Submission to Jurisdiction</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Party irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement brought by such Party or its successors or assigns shall be brought and determined in any New York state or federal court, and each Party hereby irrevocably (a) submits to the exclusive jurisdiction of the aforesaid courts with regard to any such action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby and (b) agrees that service of any court paper may be made in the manner provided for in <font style="text-decoration:underline;">Section 9.1</font> or such other as may be provided under applicable Laws or court rules governing service of process</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Each Party agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in New York, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in New York as described herein. Each Party hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, (a) any claim that it is not personally subject to the jurisdiction of the courts in New York as described herein for any reason, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733625"></a>9.9<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">WAIVER OF JURY TRIAL</font>. EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES. THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733626"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.10</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Waiver and Non-Exclusion of Remedies</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise, and nothing in this Agreement shall be deemed a waiver by any Party of any right to specific performance or injunctive relief. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by applicable Law or otherwise available except as expressly set forth herein.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>The Parties agree that irreparable harm would occur in the event that the Closing is not consummated in accordance with the terms of this Agreement, and that money damages or other legal remedies would not be an adequate remedy for any such harm. Accordingly, the Parties acknowledge and hereby covenant and agree that in the event of any breach or threatened breach of the covenants, agreements or obligations set forth in this Agreement, then in addition to any other remedy available at law or in equity, the non-breaching Party will be entitled to seek an injunction or injunctions to prevent or restrain any breaches or threatened breaches of this Agreement, and to specifically enforce the terms and provisions of this Agreement to enforce compliance with the covenants, agreements and obligations under this Agreement. Each Party hereby covenants and agrees not to raise, and irrevocably waives, any objections to the availability of such relief that a remedy at law would be adequate and that a bond or other security will be required.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733627"></a>9.11<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">No Benefit to Third Parties</font>. Except as provided in <font style="text-decoration:underline;">Article 8,</font> the covenants and agreements set forth in this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other Persons.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc62733628"></a>9.12<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Counterparts; Facsimile Execution</font>. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. This Agreement may be executed by facsimile or electronically transmitted signatures and such signatures shall be deemed to bind each Party hereto as if they were original signatures.</p>
<p style="text-align:center;margin-bottom:36pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[SIGNATURE PAGE FOLLOWS]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;"><a name="_mps905587920000000000000004054000000000"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF<font style="font-weight:normal;">, each of Buyer and Seller has caused this Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ABBVIE, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:12pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Henry Gosebrud</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:12pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Henry Gosebrud</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EVP, Chief Strategy Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:60pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page to Asset Purchase Agreement]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;"><a name="_mps905587920000000000000004054000000000"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF<font style="font-weight:normal;">, each of Buyer and Seller has caused this Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EIGER BIOPHARMACEUTICALS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42%;">
<p style="margin-top:12pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sriram Ryali</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:42%;">
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sriram Ryali</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page to Asset Purchase Agreement]</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Omitted Attachments</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibits to Asset Purchase Agreement</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.9%;">
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval Letter </p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lender Consent </p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRF Consent </p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.4(b) </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Seller Cover Letter </p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.5(a) </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Bill of Sale </p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.5(b) </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Seller PRV Transfer Letter </p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.5(c) </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Seller Closing Certificate </p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.5(d) </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Seller Secretary&#8217;s Certificate </p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.6(c) </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Buyer PRV Transfer Letter </p></td>
</tr>
<tr>
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2.6(d) </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Buyer Closing Certificate </p></td>
</tr>
<tr style="height:4.3pt;">
<td valign="top"  style="width:18%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 5.6 </p></td>
<td valign="top"  style="width:82%;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form of Public Announcement </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Pursuant to Item 601(a)(5) of Regulation S-K, the registrant hereby undertakes to furnish supplementally a copy of any of the above-listed attachments to the Commission upon request.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>8
<FILENAME>eigr-ex1032_1138.htm
<DESCRIPTION>EX-10.32
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex1032_1138.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_mps024319320000000000000004054000000000"></a>Exhibit 10.32</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:center;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-style:normal;font-variant: normal;"><a name="_mps663614560000000000000004054000000000"></a>AMENDMENT #7 TO LICENSE AGREEMENT</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amendment #7 to License Agreement (&#8220;Amendment #7&#8221;) is entered into as of the date of last signature below (&#8220;Amendment #7 Effective Date&#8221;) by and between Merck Sharp &amp; Dohme Corp. (formerly known as Schering Corporation), a New Jersey corporation having a place of business at 2000 Galloping Hill Road, Kenilworth, NJ 07033 (&#8220;Merck&#8221;) and Eiger BioPharmaceuticals, Inc., a Delaware corporation having a place of business at 2155 Park Boulevard, CA 94306 (&#8220;Licensee&#8221;) (each of Merck and Licensee, a &#8220;Party&#8221;, and together, the &#8220;Parties&#8221;) to amend that certain License Agreement between the Parties dated September 3, 2010, as amended on January 18, 2011 and subsequently first amended June 11, 2013, as second amended November 20, 2014, as third amended March 6, 2015, as fourth amended June 9, 2015, as fifth amended December 15, 2015, as sixth amended on May 15, 2018 (collectively, the &#8220;Agreement&#8221;).</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN CONSIDERATION OF the mutual promises and covenants contained herein, the parties agree as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Definitions</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The following definition in Article I is hereby deleted and replaced with the following:</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Progeria</font>&#8221; shall mean Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Except as set forth herein, all capitalized terms not defined in this Amendment #7 shall have the meaning given to them in the Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In the event of any inconsistency between the terms of this Amendment #7 and the terms of the Agreement, the terms of this Amendment #7 shall govern.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Except as expressly amended hereby, all of the terms and conditions of the Agreement remain in full force and effect.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties have executed this Amendment #7 by their duly authorized representatives as of the Amendment #7 Effective Date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65924556"></a>Eiger BioPharmaceuticals, Inc.</p></td>
<td valign="top"  style="width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:48.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Merck Sharp &amp; Dohme Corp.</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Sriram Ryali</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">/s/ Benjamin Thorner</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sriram Ryali</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benjamin Thorner</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP &amp; Head of BD&amp;L, MRL</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 3, 2020</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 3, 2020</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>9
<FILENAME>eigr-ex1033_1139.htm
<DESCRIPTION>EX-10.33
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex1033_1139.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.33</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-variant: normal;font-weight:bold;font-family:Times New Roman Bold;font-size:10pt;font-style:normal;">FIFTH AMENDMENT TO<br />LOAN AND SECURITY AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS <font style="font-weight:bold;">FIFTH AMENDMENT </font>to Loan and Security Agreement (this &#8220;<font style="font-weight:bold;">Amendment</font>&#8221;) is entered into as of February [__], 2021, by and between <font style="font-weight:bold;">OXFORD FINANCE LLC</font>, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (&#8220;<font style="font-weight:bold;">Oxford</font>&#8221;), as collateral agent (in such capacity, &#8220;<font style="font-weight:bold;">Collateral Agent</font>&#8221;), the Lenders listed on <font style="text-decoration:underline;">Schedule 1.1</font> of the Loan Agreement (as defined below) or otherwise party thereto from time to time including Oxford in its capacity as a Lender (each a &#8220;<font style="font-weight:bold;">Lender</font>&#8221; and collectively, the &#8220;<font style="font-weight:bold;">Lenders</font>&#8221;), and EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (&#8220;<font style="font-weight:bold;">Parent</font>&#8221;), EB Pharma, LLC, a Delaware limited liability company (&#8220;<font style="font-weight:bold;">EB Pharma</font>&#8221;) and EBPI Merger, Inc., a Delaware corporation (&#8220;<font style="font-weight:bold;">EBPI</font>&#8221;), each with offices located at 2155 Park Blvd., Palo Alto, CA&nbsp;&nbsp;94306 (Parent, EB Pharma and EBPI, individually and collectively, jointly and severally, &#8220;<font style="font-weight:bold;">Borrower</font>&#8221;).</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:10pt;font-style:normal;text-transform:none;">Recitals</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">A.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Collateral Agent, Lenders and Borrower have entered into that certain Loan and Security Agreement dated as of December 30, 2016 (as amended from time to time, including by that certain First Amendment to Loan and Security Agreement dated as of April 24, 2017, that certain Second Amendment to Loan and Security Agreement dated as of May 11, 2018, that certain Second Amendment to Loan and Security Agreement dated as of May 11, 2018, that certain Third Amendment to Loan and Security Agreement dated as of March 5, 2019 and that certain Default Waiver and Fourth Amendment to Loan and Security Agreement dated as of March 10, 2020, the &#8220;</font><font style="color:#000000;">Loan Agreement</font><font style="font-weight:normal;color:#000000;">&#8221;). Lenders have extended credit to Borrower for the purposes permitted in the Loan Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">B.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Borrower has requested that Collateral Agent and Lenders (i) modify the repayment schedule and (ii) make certain other revisions to the Loan Agreement as more fully set forth herein. Collateral Agent and the Lenders have agreed to so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:10pt;font-style:normal;text-transform:none;">Agreement</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:10pt;font-style:normal;text-transform:none;">Now, Therefore<font style="font-family:Times New Roman;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-weight:normal;font-variant: normal;"> in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">Definitions.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">Amendments to Loan Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Section 2.2(b) (Term Loans)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Section 2.2(b) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Repayment</font>.&nbsp;&nbsp;Borrower shall make monthly payments of interest only commencing on the first (1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup>) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date.&nbsp;&nbsp;Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof.&nbsp;&nbsp;Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender&#8217;s Term&#160;Loan then outstanding, (2) the effective rate of interest, as determined in Section&#160;2.3(a), and (3) a repayment schedule equal to (i) if the Amortization Date is September 1, 2022, nineteen (19) months and (ii) if the Amortization Date is March 1, 2023, thirteen (13) months.&nbsp;&nbsp;All unpaid principal </p>
<p style="text-align:center;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.33</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date.&nbsp;&nbsp;Each Term&#160;Loan may only be prepaid in accordance with Sections 2.2(c)&#160;and 2.2(d).&#8221;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Section 2.5 (Fees)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;New Section 2.5(f) of the Loan Agreement hereby is added to the Loan Agreement to read as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;(f)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Fifth Amendment Fee</font>.&nbsp;&nbsp;A fully-earned, non-refundable final payment, due in connection with the Term Loans, in the aggregate amount of One Hundred Seventy-Five Thousand Dollars ($175,000.00) (the &#8220;Fifth Amendment Fee&#8221;), payable to the Lenders in accordance with their respective Pro Rata Shares and due on the Fifth Amendment Effective Date; and&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Section 10 (Notices).</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;The notice information for Collateral Agent in Section 10 of the Loan Agreement hereby is amended and restated as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:16.54%;width:67.95%;">
<tr>
<td style="width:23.08%;"></td>
<td style="width:44.87%;"></td>
</tr>
<tr style="height:57.5pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;If to Collateral Agent:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OXFORD FINANCE LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115 South Union Street, Suite 300</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alexandria, Virginia 22314</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Legal Department</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax: (703) 519&#8209;5225</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: <font style="text-decoration:underline;">LegalDepartment@oxfordfinance.com</font>&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Section 13 (Definitions).</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;The following terms and their respective definitions hereby are added, in appropriate alphabetical order, or amended and restated in their entirety, as applicable, to Section 13.1 of the Loan Agreement as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Amortization Date</font>&#8221; is September 1, 2022; provided that, if Borrower achieves the Second Draw Period Milestone, the Amortization Date shall automatically be extended to March 1, 2023.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Fifth Amendment Effective Date</font>&#8221; is February [__], 2021.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Second Draw Period</font>&#8221; is the period commencing on the on the latest of (a) the date of the occurrence of the Second Draw Milestone, and (b) January 1, 2021, and ending on the earliest of (x) thirty (30) days from the occurrence of the Second Draw Period Milestone, (y) August 31, 2022, and (z) the occurrence of any Event of Default; provided, however, that the Second Draw Period shall not commence if on the date of the occurrence of the Second Draw Period Milestone an Event of Default has occurred and is continuing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">Limitation of Amendment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The amendments set forth in </font><font style="color:#000000;">Section 2 </font><font style="font-weight:normal;color:#000000;">are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Collateral Agent or any Lender may now have or may have in the future under or in connection with any Loan Document.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.</font></p>
<p style="text-align:center;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.33</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">4.</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">Representations and Warranties.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;To induce </font><font style="font-weight:normal;text-transform:none;color:#000000;">Collateral Agent and </font><font style="font-weight:normal;text-transform:none;color:#000000;">Lender</font><font style="font-weight:normal;text-transform:none;color:#000000;">s</font><font style="font-weight:normal;text-transform:none;color:#000000;"> to enter into this Amendment, </font><font style="font-weight:normal;text-transform:none;color:#000000;">Borrower</font><font style="font-weight:normal;text-transform:none;color:#000000;"> hereby represents and warrants to </font><font style="font-weight:normal;text-transform:none;color:#000000;">Collateral Agent and </font><font style="font-weight:normal;text-transform:none;color:#000000;">Lender</font><font style="font-weight:normal;text-transform:none;color:#000000;">s</font><font style="font-weight:normal;text-transform:none;color:#000000;"> as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The organizational documents of Borrower delivered to Collateral Agent and Lenders on the Effective Date, or subsequent thereto, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&#8217; rights.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">Prior Agreement</font><font style="font-weight:normal;text-transform:none;color:#000000;">.&nbsp;&nbsp;The Loan Documents are hereby ratified and reaffirmed and shall remain in full force and effect. This Amendment is not a novation and the terms and conditions of this Amendment shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents.&nbsp;&nbsp;In the event of any conflict or inconsistency between this Amendment and the terms of such documents, the terms of this Amendment shall be controlling, but such document shall not otherwise be affected or the rights therein impaired.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">Miscellaneous</font><font style="font-weight:normal;text-transform:none;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">This Amendment shall constitute a Loan Document under the Loan Agreement; the failure to comply with the covenants contained herein shall constitute an Event of Default under the Loan Agreement; and all obligations included in this Amendment (including, without limitation, all obligations for the payment of principal, interest, fees, and other amounts and expenses) shall constitute obligations under the Loan Agreement and secured by the Collateral.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">Counterparts.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.</font></p>
<p style="text-align:center;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.33</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">8.</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">Effectiveness.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;This Amendment </font><font style="font-weight:normal;text-transform:none;color:#000000;">shall be deemed effective upon</font><font style="font-weight:normal;text-transform:none;color:#000000;"> </font><font style="font-weight:normal;text-transform:none;color:#000000;">(a) </font><font style="font-weight:normal;text-transform:none;color:#000000;">the due execution and delivery to </font><font style="font-weight:normal;text-transform:none;color:#000000;">Collateral Agent and </font><font style="font-weight:normal;text-transform:none;color:#000000;">Lender</font><font style="font-weight:normal;text-transform:none;color:#000000;">s</font><font style="font-weight:normal;text-transform:none;color:#000000;"> of </font><font style="font-weight:normal;text-transform:none;color:#000000;">(i) </font><font style="font-weight:normal;text-transform:none;color:#000000;">this</font><font style="font-weight:normal;text-transform:none;color:#000000;"> Amendment by each party hereto</font><font style="font-weight:normal;text-transform:none;color:#000000;">, </font><font style="font-weight:normal;text-transform:none;color:#000000;">and </font><font style="font-weight:normal;text-transform:none;color:#000000;">(ii) </font><font style="font-weight:normal;text-transform:none;color:#000000;">the Corporate Borrowing Certificate for each Borrower, the form of which is attached hereto</font><font style="font-weight:normal;text-transform:none;color:#000000;">, </font><font style="font-weight:normal;text-transform:none;color:#000000;">and </font><font style="font-weight:normal;text-transform:none;color:#000000;">(</font><font style="font-weight:normal;text-transform:none;color:#000000;">b</font><font style="font-weight:normal;text-transform:none;color:#000000;">)</font><font style="font-weight:normal;text-transform:none;color:#000000;"> </font><font style="font-weight:normal;text-transform:none;color:#000000;">Borrower&#8217;s pay</font><font style="font-weight:normal;text-transform:none;color:#000000;">ment of </font><font style="font-weight:normal;text-transform:none;color:#000000;">(i) the Fifth Amendment Fee due as specified in Section 2.5(f) of the Loan Agreement, and (ii) </font><font style="font-weight:normal;text-transform:none;color:#000000;">all Lenders&#8217; </font><font style="font-weight:normal;text-transform:none;color:#000000;">Expenses incurred through the date of this Amendment</font><font style="font-weight:normal;text-transform:none;color:#000000;">.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-weight:bold;font-style:italic;">Balance of Page Intentionally Left Blank</font>]</p>
<p style="text-align:center;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:10pt;font-style:normal;text-transform:none;">In Witness Whereof,<font style="font-family:Times New Roman;font-weight:normal;font-variant: normal;"> the parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:216pt;"></td>
<td style="width:36pt;"></td>
<td style="width:216pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BORROWER:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EIGER BIOPHARMACEUTICALS, INC.</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EB PHARMA, LLC</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EBPI MERGER, INC.</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COLLATERAL AGENT AND LENDER:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OXFORD FINANCE LLC</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;text-indent:0%;font-size:16pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">[Signature Page to Fifth Amendment to Loan and Security Agreement]</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">CORPORATE BORROWING CERTIFICATE<br /></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:13.95%;"></td>
<td style="width:43.81%;"></td>
<td style="width:13.09%;"></td>
<td style="width:29.15%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Borrower<font style="font-variant: normal;">:</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EIGER BIOPHARMACEUTICALS, INC.</p></td>
<td colspan="2" valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Date<font style="font-weight:normal;font-variant: normal;">: February [__], 2021</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Lender:</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OXFORD FINANCE LLC, as Collateral Agent and Lender</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I hereby certify as follows, as of the date set forth above:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;">I am the Secretary, Assistant Secretary or other officer of Borrower.&nbsp;&nbsp;My title is as set forth below.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;">Borrower&#8217;s exact legal name is set forth above.&nbsp;&nbsp;Borrower is a corporation existing under the laws of </font><font style="color:#000000;">the State</font> of Delaware<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;">Attached hereto as </font><font style="text-decoration:underline;">Exhibit&#160;A</font> and <font style="text-decoration:underline;">Exhibit&#160;B</font>, respectively, are true, correct and complete copies of (i)&#160;Borrower&#8217;s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii)&#160;Borrower&#8217;s Bylaws.&nbsp;&nbsp;Neither such Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;">The following resolutions were duly and validly adopted by Borrower&#8217;s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action).&nbsp;&nbsp;Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and the Lenders may rely on them until each Lender receives written notice of revocation from Borrower.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Balance of Page Intentionally Left Blank</font>]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved<font style="font-weight:normal;font-variant: normal;">, that </font><font style="font-variant: normal;">any one </font><font style="font-weight:normal;font-variant: normal;">of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-7.82%;width:117.95%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:17.95%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name</font></p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title</font></p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Signature</font></p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized to Add or Remove<font style="text-decoration:underline;"> Signatories</font></p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved Further, <font style="font-weight:normal;font-variant: normal;">that </font><font style="font-variant: normal;">any one</font><font style="font-weight:normal;font-variant: normal;"> of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved Further<font style="font-variant: normal;">, </font><font style="font-weight:normal;font-variant: normal;">that such individuals may, on behalf of Borrower:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Borrow Money<font style="font-weight:normal;">.&nbsp;&nbsp;Borrow money from the Lenders.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Execute Loan Documents<font style="font-weight:normal;">.&nbsp;&nbsp;Execute any loan documents any Lender requires. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Security<font style="font-weight:normal;">.&nbsp;&nbsp;Grant Collateral Agent a security interest in any of Borrower&#8217;s assets.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Negotiate Items<font style="font-weight:normal;">.&nbsp;&nbsp;Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Further Acts<font style="font-weight:normal;">.&nbsp;&nbsp;Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower&#8217;s right to a jury trial) they believe to be necessary to effectuate such resolutions.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved Further<font style="font-variant: normal;">,</font><font style="font-weight:normal;font-variant: normal;"> that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Balance of Page Intentionally Left Blank</font>]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;">T</font>he persons listed above are Borrower&#8217;s officers or employees with their titles and signatures shown next to their names.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:216pt;"></td>
<td style="width:36pt;"></td>
<td style="width:216pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, the __________________________ of <font style="color:#000000;">B</font>orrower, hereby certify as to paragraphs 1 through 5 above, as </p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[print title]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the date set forth above.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:216pt;"></td>
<td style="width:36pt;"></td>
<td style="width:216pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Signature Page to Corporate Borrowing Certificate<br /></font>EIGER BIOPHARMACEUTICALS, INC.]</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A<br /><br /><font style="text-decoration:underline;">Certificate of Incorporation (including amendments)</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[see attached]</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B<br /><br /><font style="text-decoration:underline;">Bylaws</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[see attached]</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Cambria;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;font-weight:bold;font-size:16pt;font-family:Cambria;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;">CORPORATE BORROWING CERTIFICATE</font><font style="font-size:11pt;font-family:Times New Roman;"><br /></font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:13.96%;"></td>
<td style="width:43.45%;"></td>
<td style="width:13.19%;"></td>
<td style="width:29.39%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Borrower<font style="font-variant: normal;">:</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EB PHARMA, LLC</p></td>
<td colspan="2" valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Date<font style="font-weight:normal;font-variant: normal;">: February [__], 2021</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Lender:</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OXFORD FINANCE LLC, as Collateral Agent and Lender</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I hereby certify as follows, as of the date set forth above:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;">I am the Secretary, Assistant Secretary or other officer of Borrower.&nbsp;&nbsp;My title is as set forth below.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;">Borrower&#8217;s exact legal name is set forth above.&nbsp;&nbsp;Borrower is a </font>limited liability company existing under the laws of <font style="color:#000000;">the State</font> of Delaware<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;">Attached hereto as </font><font style="text-decoration:underline;">Exhibit&#160;A</font> and <font style="text-decoration:underline;">Exhibit&#160;B</font>, respectively, are true, correct and complete copies of (i)&#160;Borrower&#8217;s Certificate of Formation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii)&#160;Borrower&#8217;s operating agreement.&nbsp;&nbsp;Neither such Certificate of Formation nor such operating agreement have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Formation and such operating agreement remain in full force and effect as of the date hereof.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;">The following resolutions were duly and validly adopted by Borrower&#8217;s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action).&nbsp;&nbsp;Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and the Lenders may rely on them until each Lender receives written notice of revocation from Borrower.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Balance of Page Intentionally Left Blank</font>]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved<font style="font-weight:normal;font-variant: normal;">, that </font><font style="font-variant: normal;">any one </font><font style="font-weight:normal;font-variant: normal;">of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-7.82%;width:117.95%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:17.95%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name</font></p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title</font></p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Signature</font></p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized to Add or Remove<font style="text-decoration:underline;"> Signatories</font></p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved Further, <font style="font-weight:normal;font-variant: normal;">that </font><font style="font-variant: normal;">any one</font><font style="font-weight:normal;font-variant: normal;"> of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved Further<font style="font-variant: normal;">, </font><font style="font-weight:normal;font-variant: normal;">that such individuals may, on behalf of Borrower:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Borrow Money<font style="font-weight:normal;">.&nbsp;&nbsp;Borrow money from the Lenders.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Execute Loan Documents<font style="font-weight:normal;">.&nbsp;&nbsp;Execute any loan documents any Lender requires. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Security<font style="font-weight:normal;">.&nbsp;&nbsp;Grant Collateral Agent a security interest in any of Borrower&#8217;s assets.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Negotiate Items<font style="font-weight:normal;">.&nbsp;&nbsp;Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Further Acts<font style="font-weight:normal;">.&nbsp;&nbsp;Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower&#8217;s right to a jury trial) they believe to be necessary to effectuate such resolutions.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved Further<font style="font-variant: normal;">,</font><font style="font-weight:normal;font-variant: normal;"> that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Balance of Page Intentionally Left Blank</font>]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;">T</font>he persons listed above are Borrower&#8217;s officers or employees with their titles and signatures shown next to their names.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:216pt;"></td>
<td style="width:36pt;"></td>
<td style="width:216pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, the __________________________ of <font style="color:#000000;">B</font>orrower, hereby certify as to paragraphs 1 through 5 above, as </p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[print title]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the date set forth above.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:216pt;"></td>
<td style="width:36pt;"></td>
<td style="width:216pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Signature Page to Corporate Borrowing Certificate</font></p>
<p style="text-align:center;line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EB PHARMA, LLC]</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A<br /><br /><font style="text-decoration:underline;">Certificate of Formation (including amendments)</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[see attached]</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B<br /><br /><font style="text-decoration:underline;">Operating Agreement</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[see attached]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Cambria;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;font-weight:bold;font-size:16pt;font-family:Cambria;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;">CORPORATE BORROWING CERTIFICATE</font><font style="font-size:11pt;font-family:Times New Roman;"><br /></font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:13.96%;"></td>
<td style="width:43.45%;"></td>
<td style="width:13.19%;"></td>
<td style="width:29.39%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Borrower<font style="font-variant: normal;">:</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EBPI MERGER, INC. </p></td>
<td colspan="2" valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Date<font style="font-weight:normal;font-variant: normal;">: February [__], 2021</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Lender:</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OXFORD FINANCE LLC, as Collateral Agent and Lender</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I hereby certify as follows, as of the date set forth above:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;">I am the Secretary, Assistant Secretary or other officer of Borrower.&nbsp;&nbsp;My title is as set forth below.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;">Borrower&#8217;s exact legal name is set forth above.&nbsp;&nbsp;Borrower is a corporation existing under the laws of </font><font style="color:#000000;">the State</font> of Delaware<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;">Attached hereto as </font><font style="text-decoration:underline;">Exhibit&#160;A</font> and <font style="text-decoration:underline;">Exhibit&#160;B</font>, respectively, are true, correct and complete copies of (i)&#160;Borrower&#8217;s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii)&#160;Borrower&#8217;s Bylaws.&nbsp;&nbsp;Neither such Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;">The following resolutions were duly and validly adopted by Borrower&#8217;s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action).&nbsp;&nbsp;Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and the Lenders may rely on them until each Lender receives written notice of revocation from Borrower.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Balance of Page Intentionally Left Blank</font>]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved<font style="font-weight:normal;font-variant: normal;">, that </font><font style="font-variant: normal;">any one </font><font style="font-weight:normal;font-variant: normal;">of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-7.82%;width:117.95%;">
<tr>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:33.33%;"></td>
<td style="width:17.95%;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name</font></p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title</font></p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Signature</font></p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized to Add or Remove<font style="text-decoration:underline;"> Signatories</font></p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" >
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9633;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved Further, <font style="font-weight:normal;font-variant: normal;">that </font><font style="font-variant: normal;">any one</font><font style="font-weight:normal;font-variant: normal;"> of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved Further<font style="font-variant: normal;">, </font><font style="font-weight:normal;font-variant: normal;">that such individuals may, on behalf of Borrower:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Borrow Money<font style="font-weight:normal;">.&nbsp;&nbsp;Borrow money from the Lenders.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Execute Loan Documents<font style="font-weight:normal;">.&nbsp;&nbsp;Execute any loan documents any Lender requires. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Security<font style="font-weight:normal;">.&nbsp;&nbsp;Grant Collateral Agent a security interest in any of Borrower&#8217;s assets.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Negotiate Items<font style="font-weight:normal;">.&nbsp;&nbsp;Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Further Acts<font style="font-weight:normal;">.&nbsp;&nbsp;Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower&#8217;s right to a jury trial) they believe to be necessary to effectuate such resolutions.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;">Resolved Further<font style="font-variant: normal;">,</font><font style="font-weight:normal;font-variant: normal;"> that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Balance of Page Intentionally Left Blank</font>]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;">T</font>he persons listed above are Borrower&#8217;s officers or employees with their titles and signatures shown next to their names.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:216pt;"></td>
<td style="width:36pt;"></td>
<td style="width:216pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, the __________________________ of <font style="color:#000000;">B</font>orrower, hereby certify as to paragraphs 1 through 5 above, as </p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[print title]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the date set forth above.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:468pt;;">
<tr>
<td style="width:216pt;"></td>
<td style="width:36pt;"></td>
<td style="width:216pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Signature Page to Corporate Borrowing Certificate<br /></font>EBPI MERGER, INC.]</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A<br /><br /><font style="text-decoration:underline;">Certificate of Incorporation (including amendments)</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[see attached]</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B<br /><br /><font style="text-decoration:underline;">Bylaws</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[see attached]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:3pt;margin-top:12pt;text-indent:0%;font-size:16pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WEST\292803821.3</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>10
<FILENAME>eigr-ex211_583.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex211_583.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiaries of Registrant </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:70%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Subsidiary</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:29%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Incorporation</p></td>
</tr>
<tr>
<td valign="top"  style="width:70%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:29%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EBPI Merger, Inc.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:29%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:29%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EB Pharma LLC</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:29%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:29%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals Europe Limited </p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:29%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">England and Wales</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:29%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:70%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EigerBio Europe Limited</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:29%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ireland</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>eigr-ex231_912.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex231_912.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Consent of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc.:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the registration statements (Nos. 333-251497, 333-235655, 333-221972, 333-212114, and 333-203153) on Form S-3 and the registration statements (Nos. 333-237156, 333-230287, 333-224872, 333-219936, 333-211009, 333-203154, and 333-193662) on Form S-8 of Eiger BioPharmaceuticals, Inc. of our report dated March&#160;9, 2021, with respect to the consolidated balance sheets of Eiger BioPharmaceuticals, Inc. as of December&#160;31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December&#160;31, 2020, and the related notes, which report appears in the December 31, 2020 annual report on Form 10-K of Eiger BioPharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30.77%;text-indent:7.69%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:30.77%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30.77%;text-indent:7.69%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">&nbsp;&nbsp; </font>&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>12
<FILENAME>eigr-ex311_581.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex311_581.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certification of the Chief Executive Officer </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act Rules 13A-14(A) and 15D-14(A)</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, David A. Cory, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>I have reviewed this Annual Report on Form 10-K of Eiger BioPharmaceuticals, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Disclosed in this report any change in the registrant<font style="color:#000000;">&#8217;</font>s internal control over financial reporting that occurred during the registrant<font style="color:#000000;">&#8217;</font>s most recent fiscal quarter (the registrant<font style="color:#000000;">&#8217;</font>s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant<font style="color:#000000;">&#8217;</font>s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 9, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David A. Cory</p></td>
</tr>
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David A. Cory</p></td>
</tr>
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>13
<FILENAME>eigr-ex312_580.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex312_580.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certification of Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act Rules 13A-14(A) and 15D-14(A)</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Sriram Ryali, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>I have reviewed this Annual Report on Form 10-K of Eiger BioPharmaceuticals, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Disclosed in this report any change in the registrant<font style="color:#000000;">&#8217;</font>s internal control over financial reporting that occurred during the registrant<font style="color:#000000;">&#8217;</font>s most recent fiscal quarter (the registrant<font style="color:#000000;">&#8217;</font>s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant<font style="color:#000000;">&#8217;</font>s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;"></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 9, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <font style="color:#000000;">Sriram Ryali</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sriram Ryali</p></td>
</tr>
<tr style="height:26.1pt;">
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>14
<FILENAME>eigr-ex321_579.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
eigr-ex321_579.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certification Pursuant to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. Section 1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Adopted Pursuant to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 906 of the Sarbanes-Oxley Act of 2002</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),<font style="font-weight:bold;"> </font>David A. Cory, Chief Executive Officer of Eiger BioPharmaceuticals, Inc. (the &#8220;Company&#8221;), and Sriram Ryali, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="color:#000000;">&#160;</font>The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">In Witness Whereof<font style="font-weight:normal;font-variant: normal;">, the undersigned have set their hands hereto as of the 9th day of March, 2021.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:58.25%;"></td>
<td style="width:41.75%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 9, 2021</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David A. Cory</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David A. Cory</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer (Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sriram Ryali</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sriram Ryali</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Eiger BioPharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0.74%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gzbwht3f4aft000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" + !<H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(JX0<Y<L3.I4C3CS2V/2:*Y3X=:AJ>K^#X-2U6_^V3W,LC*?)6/RU5MFWY0
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M3S@=,U/7.=845\Z>-?&VH^,-7>RL9)3I9D\JVMH-W^D_,-K,N 68D*0I'R\
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M!2%;![ARF,<@X/;-;TJ2G"4F]CFK5W"I&"6Y]&T445@=(4444 %%?,7CZ_\
M[0\=ZU<&+RMMR82-V<^6!'GH.NS..V<<U:\3_#O7/"UBE[>""XM6;:\EJS,(
MCVWY48!Z ],\'!(SV+"JRO*S9P/&RO+EA=+S_P" ?2=%>/?!GQ%?W%]>:'=3
MS7%NEN)H/,DW>2$*IL7(SM(9>,X&W@<FO8:YZM-TY<K.JC556"F@HHHK,U"B
MBB@ HHHH 9--%;PR332)'%&I=W=@%51R22>@ JA:^(=$OKE+:TUC3[B=\[(H
MKI'9L#)P <G@$_A6!\4-5_LOP'?!)_*FNRMK%\F[?N/SKT(&8P_)_#G%>=?!
M;3VG\57=\UNDD-K:E1*V"8Y'8!<9Y!*B09';([\[PHITG4?0YJE=QK1I);GN
MU%>2?$3XE:MHVO7.B:/Y4'DQQ^9</$&<.</\F25V[2HY7.=WL:]"\)37MUX2
MTNZU"\^UW5S;K.\WE+'G?\P&%XX!"Y[XSWJ)4I1BI/J:0K1G-P70V:***S-0
MHHKFO&_BV'PEH+W0,+W\OR6EO(Q_>-D9.!SM4')Z=AD%A3C%R=D3*2BN9['2
MT5X3\/O#-WXT\0R^(];=+NSBF/G>?\QN)=HPNT8 505.#Q@!0",X]VK2K35-
M\M[F=&JZL>:UET"BBBLC8**** "BBO(?BKX[OK+4/^$?TBX>V,:H]U<1,RR;
MC\P0'C QM)(/.<<8(.E.FZDN5&5:K&E#FD>O45\X2?#G4X_ 2^)F="&59A:(
MA=OL[8Q)D9'?<1V7DD$$5W7PB\8:AJLUWHFIW$UT\4?VB">4[F"[@'5F)R>6
M4C@_Q<X"BM9T$HN497L8T\2W-0G&U]CU6BOG/Q-#_P (3\3Y)[&WFC@M[F.Z
MAC4^4'1@&9$(& F2Z< C (.<&OHRLZE+D2=[W-*-;VCE%JS3"BBBLC<****
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M/T5S;O#-=:H;B3?D%R5E56P>@**F,<$<]\U+_>4H*75E+]U6FX;)&4+SQ/\
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MG/&:]5\DJG+;5'BQ]I"ESW]V3U/1/"N@W'PU\.:KXIUJTWWPC$45K'("R*7
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M36-2>W3:QCMX9S@MD9:11W YC)['CKCC@/'U_P#VAXZUJY,7E;+AH2N[.?*
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M55S5O&_CZTUF^MK/POYUK#<21PR_V?.V] Q"MD-@Y&#D53_X3[XC_P#0I?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% #9)$AB>65U2-%+,[' 4#J2>PJI!J^F74RPV^HVDLK?=2.=68\9X
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M4SV\C%I4RH4)NR W48/3/3C-/VD/:.:DK..GEMH+V-7V*IN#YE--NSUWUO\
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M8U>?>);?7!'!=>(;@_:2QCMX"%.4'+O\GRKR5'J?HHKT#P*P;P;8$'/,@_\
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M(\#3%F8C!#*#DD<D,<\93CDUBZK#=MH^D7\L#FU2R\C[2$ 1 DSJJ$CA<!D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSJZM9NRW_#TN=B?B:(KB^M+C1I8;RUA68Q--C@R1H0V5!4XF1AP<C/3C-O\
MX3__ (I'4->_LS_CTO(K7R//^_O:(;MVWC'F],?P^_'"1:QK%[H.L6<K7=W;
MF**ZE,N^5H&$\(^]D[5V[R1T_=DC&&):M];?\(#K&CO(8[J>^M[F(L/E=0\.
MX ]B!$3SCJ,$\X'A8[*.JE9VOM85/'RO%RGHXO=):I_UZG2:OXO_ .$F\+:[
M;_8?LWV3[&^[SM^_?/C'W1C'E_K5;0)K6#X=:Y+>VAN[==3CW0B9HMQQ;X^9
M>>#@^^,=ZP=,_P"0%XL_ZYZ;_P"E$E:NG_\ )+=?_P"PG#_[;U?)%14%M[3]
M#*%6<Y*I+5^S?YFII7B72]#T2?4].\/K UQJ(LY5^U%F;$/F!MS*3@<@+T!)
M/4G-A/B;<F.2>30-EN)?*CE%V2&;;NP?W> <<XR3CFN0_P"9''_8P?\ MI4^
MC11R?#7Q)))&CO#KD;1LR@E"4MU)'H=K,,CL2.]+V5*ZYHWO)K=]QPQ%=KEA
M*R4.;9;GJ?AOQ#;^)-+-W"C121OY5Q$V3Y<@4,0#@;AA@01V/.#D"UK%]/IN
MERW=M927LR% ((\[FRP!Z ] 2>G:O/O!ND7>K^&;J*SU2;3GCU<RO)"#F1?L
MZ+M.&'&6!_X"*Z73_"VJV>K6=Y-XGO+F&!V9[=PVV4%&4 Y<C@L&Z'E1]:XI
M4Z<).[V>VNNO<]*E7K5*<&H_$EKIH_0\]\,:O?:=K<NIQ6EQK-XUDZNB,S22
M\Q_.3AB?N*/Q%=WXB^(-IH>HS6,=I)<2V^TW#N_E1H"I;AB#N(&PGC&&^]D$
M5P?@K5;?P[K<=UJBS01+9R6\I,9S"V48[U^]QY97 !.2.,9(JZM:S:+XRN4N
M%)>#5UU+;&"#)"UQYXV[L DC*YZ;E89X)KOK4HSQ$KQV5UY_UY'EX?$5*6%T
MGJY6?]V[>O\ PYW+?$Z&SNY(]5TBXM(H@/.97WO$3M.60J#C:2QQDX PIS7?
M5XSXNNE\3>+&;2(Y;KS+6.UBCV[?-<&1B1GH/GP2V,;2>G-=E'X+UI%0'QC?
ML5BB0DA^2D2(S?ZSJS*7/NQZ]3RUJ--.-_=NMM7_ ,$[L-B:LN=+]YRM6:LK
M_IH'Q#\0W.DVMGI]D\D-Q?>86F4<I$@4,%;.58ETP<'C=C!P:YGP=H.B2627
M^M7MG';3B2*RLS-Y7$;;'8\@G## "\ ')R6 6[XE\%ZC!I*7CZE>ZO=07+%4
M*NS+%*(D*JOS$X:-6Z@ ,Y-9?AN[\-RV-M8^(;<O]D:X>SN$WA%25D=E;:V2
MQ;)!VXPHY!Z[4TU17LK[N]M_(YZ\D\3>NDO=]U2VOUOTN;UYH'AJS@UW4](U
M!9+DZ/=0BVCN4D18RJEB!RW5%Y)/WC[8QO!NK_V%9^(=1\CS_*2S'E[]N=TD
MB]<'INST[5E>&?,^S:UYW^M_L"ZW_7"9IVFJ[>&/%.R-W(6P8A5)PHG<L>.P
M ))[ $UK*DE>$G?WHF$*SG*G."2LIVML=W_PG_\ Q2.H:]_9G_'I>16OD>?]
M_>T0W;MO&/-Z8_A]^$T[XBVUU:ZO=7>GR00Z=% Y$3^:TIE9U50,#!RH&2<?
M-R0 37!K?6W_  @.L:.\ACNI[ZWN8BP^5U#P[@#V($1/..HP3SC.@L);NSU:
MY0 I8265S+P20FVZC)& >GF DG "ACGBLGA8*_,K>];Y&\,PJ2Y.5\SY6VO-
M'HJ?$>:<73VV@RS1VX+NRSD[$R=K/A#MR%)ZXX/)QFFS_%*TBLK25-.=II+:
M&YN0\NR.$21>9M#D9<@%,G:!ANN05K*\!^(K#P]INK0ZA)+ODNOM405-V\&)
M%V#T.8SUP/F'/7'(O-Y>N)?^7(%DU"+64C"X=X))A<*!G )VDH>=NY6&>,TO
M80=1IPM9.RUUM_707URHJ"FJB;;5]%[M_P"NIZ(WQ.AL[N2/5=(N+2*(#SF5
M][Q$[3ED*@XVDL<9. ,*<U8U+XD6=KJ+V5G92W3QW#6K,S^6&E#!=J#!+'=E
M>@R1QD$&N/\ %UTOB;Q8S:1'+=>9:QVL4>W;YK@R,2,]!\^"6QC:3TYJE-9:
M59PW$=GJ%\=3TZ0B5[U<B\N$?$DD;AF9&+H[_/\ Q.H!4 XJ.&I<ZO%ZK;71
M^?44L974)*,T[->]HKJUW;I='<VOQ/T]X[X7EA=0SVD\4!BBQ(69]XQD[=I7
MRI-P;&-H ))VU4C^*BMY?F:2HW/M<)=[B,;2X7Y!DJ'4XX^\N<9S7"W<VKZB
MD%W=22W.GZ<SP">7>[K).0V"YR"H\I1R<@RH.C*!MZ.- E\."#6-0U"*:WFE
MD2T@_P!4Q)8JT8P0&(;!)(^8MV.2XX6FE>4;ZM:7=OZ\R9X^M)I1E;2]W97_
M *\CN_$.I6^L?"W6=1M2?*GTBX<*2"R'RFRK8)&Y3D$9.""*\UT&'3KC5KB+
M5YF@L1IT[^:IPR2AH]I7@[G +D+@YQT.*[RYMK*U^#&I#3C<&TFT>ZN8OM&/
M, EC>3#;>,_/V_6N#\/:4VN:S<:<C 2'39YH-S;5$RO$$W'!^7YB#P>">^*S
MPLHJC-MM*ZU1MCU*=:BN5-^]H]MD7/A['J3^*].GB@^Y"ZZ@Z %4C9"<9/K*
ML> .3M/8-756WQ)?4+-[_3M NI[!5#><SXV#8&._:K!2 ?4\8/>N.\-^*KOP
MS%J*0P2.MU'(T5LUJSR+?!0B!E&'PQ41LO)!"_=^8U NMW=S;:DNHZOJ,L4M
MI(8E$FZ.65VQA\L (\,25"XVY *X56VE1]I6E*<;[=_OT.:EB/8X>$*<[-MW
MVT:Z:_TST;3?'1U31KZYMM*FDU&S>,264;%]R.^U75PO(P&)&,@J>V&/!>&-
M7OM.UN74XK2XUF\:R=71&9I)>8_G)PQ/W%'XBNC^%O\ Q_ZW_P!<K;^<U<WX
M*U6W\.ZW'=:HLT$2V<EO*3&<PME&.]?O<>65P 3DCC&2(C",(5H*-[6_KY%S
MK5*OU>K*?+>_:U_^"=#87.@W?CR.S/AX?:1J-P1<R7;R 2IYC;]AXZKD#^$D
M$?=%:NI?$>WM=5>QL].FNC%.UL[N_E[I0P4*@P2WS%EYQR!C<"#7+Z)_R56/
M_L)WO_H,]8?AQ#X9\3:3'?DAM'N#!="-3_SR>+< <$K\ZN#C)7D Y )*C!SD
M[7LEI=_\.5'$U(T]&HWFTW9:?I\V>B:?\2+:XU6.QOM.FM3+.MLCH_F!92Q7
M:XP"OS;5X!Y/.T FNWKQ+4[>X\6>,M0&CRW$37MPABG48>W5$CC,PP1@ KO'
M(/*CACBO;:Y,53C3DN72Z3MV/0P-:=6,N9WL[)]PHHHKF.X**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "LGQ397&I>$-:L;2/S+FYL)X8DW
M;G:-@!D\#DCK6M10G8#SGP1X7UG2/$PO+ZS\J#[#+%O\U&^<O$0, D]%;\JE
M\=>#]1UC6$U*P43B2V6UDB#!&0*9&#9) (.\C'4$#KDX]!HKH^LS]JZO5_=M
M8XE@::P_U>[M^.]SQG4?"/BW4ED6721F&SCM("KV\:E$0@!50@ 9)/0<L< *
M !O:WHOBW4KC4;>[M+?4+9Y'^QS$QHULA<LOEL"K XV!@V0=F.03N](HJOK<
MKI\JTV_JY/\ 9\+27/+WM]5_D<!X7\':A!HFN1W[+9S:I;_95CP)&B"B10Y*
MM@Y\S(4'H!DY)"T_#NA>*_#VL[X;.)K>>2.&YS(A5HP_,@Y#9"ER/][E2<8]
M+HJ?K,VI)V?,5]1IKDY6UR;?\$\X\!>%]9T774N=0L_)A%@\);S4;YRT9 X)
M[*?RK)\+>"O$.F^)O#MY=Z?Y<%FSF=_.C.S-O(@X#9/S,!QZUZ[13GBISY[I
M>]:_R"& IP4$F_=;:^?R/,(/!6HW/C":74-/W:5<75YYQ\Y1NBE251T;<,AQ
MTY&>U5;?PEXLT+59;G38P\T<4ENEU&T0$J. <A7)VG<%.#T9,99<[O6:\_LO
MAG+ING/IUGXAN([)@5,7E'YUQM&_# ,=H )P,XZ <5M3Q/.WSM).W1O8YZV"
M4$G23;NWHTFK[[]#C_!TRR>.-!;SS-YD\Q65F8F7_1Y3N)<!B3U^89YYYKUC
MQ+H*^(M)^QF802)*LL<I4L$(.#\H(SE2PY/&<]JK>'_!^G^'Y1=1M+-?&(Q-
M.[$#:=I8! < 90'G)'3-=#6->OS5O:0-L'A73P[IU>M[_,\UT;1O&/AB>>*P
MM+::WD8O(F]#')(50;\DJ^0%"\X'7@\&H-!\$:S8:?JOFVZHSZ7/90Q-*I>1
MF5-IR/E X(Y(Y'3'->HT4WBY--))7M?SL$<OIQ:?,WR[)O;\#SSPQX2U6&P\
M165]']C&HV:6\4NY9,'$H)PK=MZGJ,^M8T?AGQ9IUAJUM#I*W$5_;/:3Q+/%
MB5>5#*2P(X9L9QPW(S@#URBCZU.\KI:ZA_9]-1@DVN79WUU/)M(\ :I/J%S'
MJ=H+:VFTZ6))3(KB.;S87C.U6!.#'G' .W!ZU;T70/%OAG4;F:RL;:9IXDCE
M/FJ8WV\J1DJWREG';.3P>"/3J*'BYMR<DG?H)9=3C&*C)IQO9WUU^1Y+J?@#
MQ#J-K]ONQ;W=[>QG[?!O"N6+;4(/"<0[%8#:!Y1(WELU:U#P]XN\0WVG+JD"
M(L*>3]H+180'EY&"G)9MJC XR!@*,FO4**(XN<4M%=;/JASR^E-MMNSM=7T=
MNYPFI:%KNFM8:?H=O;7>A06ZJ]G/'"1)*&8L\F0,DDH^5(^923C//.67PSU'
M4KEHM2A%C:P!I(6>3SOWA#"/;A]Q"$JQW'G 'S98CUZBICB9QAR121<\%3G4
M523;MLNG]?,\QT70/%OAG4;F:RL;:9IXDCE/FJ8WV\J1DJWREG';.3P>".T\
M,_VZUE<RZ_L6XDN7:&)=O[J+  7Y>.H8CDG!&3G(&U14U:SJ[I)^16'PD:'P
MR=NS>B"BBBL3J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[FY>! 'D+J(C'EMH+#AMR@ GC'8 ^B;Z]M]-T^YO[N3R[:VB::9]I.U%!+'
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M7IB@#WFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKEKX6U+2].M;(X:ZL?)GG9(F904+9D=G'E@KG"[,CCD Z/X#^*K^XTWQ9?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0I8_O>3M4 9Z<XQDYU+'X(7/A_6+;5/"WBZ?2+I+1()S]C$RROM =MK/C:Q
M;8=V&Y!X&/7Z* ,#P?X>O/#.A_8;_7;[6KII6E>ZO&)/. %4$DJH '&3R2>^
M!XCXOT+5_!/Q \6:A::5?7^C:YI5WYUS#;O*+?SE8G<P 5=LJ@G.<1GN:^C:
M* /EWX;_  TO_'W@2Z4>)Y+#3EU++61M/.4RI&,2 [QM)60@@=<#.<#'HB?
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MI\4Z_P"-==M9-.GOGEB%E+;O$Q9W65G ?D(#@#KGGD8Y],_X223_ * FJ?\
M?@T?\)))_P! 35/^_!H WJ*P?^$DD_Z FJ?]^#1_PDDG_0$U3_OP: -ZBL'_
M (223_H":I_WX-'_  DDG_0$U3_OP: -ZBL'_A))/^@)JG_?@TA\2R $G1-4
MX_Z8&@#?HK-T/6K;7].^VVJR+'YCQE9%VL&4X(Q]:TJ "BBB@ HHHH ****
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M_P"^&_PH ZBBN7_X6'X8_P"@D/\ OAO\*/\ A8?AC_H)#_OAO\* .HHKE_\
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M $+\'_@2O^- '445R_\ :GBS_H7X/_ E?\:/[4\6?]"_!_X$K_C0!U%%<O\
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MUU%=(9"0R*6"Y'M@4 =__:WBO_H6(O\ P/2C^UO%?_0L1?\ @>E=-10!S/\
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ME?\ "C^P])_Z!MI_WY7_  H C_X2'2/^?^'\Z/\ A(=(_P"?^'\ZD_L/2?\
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MBGY5+10 BJJ+M4  =A2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNOHH Y#^W?&?_0IVG_@Q/_QNC^W?&?\ T*=I_P"#$_\ QNNOHH Y#^W?&?\
MT*=I_P"#$_\ QNL6[L=8OM674[CP)827:X^<ZDW)'0D>7SBO2:* /.#::R=8
M&K'P)I_VT'/F?VBW7UQY>,TMK;:U9:J^IV_@33X[QR29!J+=^N!Y?&:]&HH
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M;RWNHU.TM#(' /ID4 9W_"*:)_SXI^9JU8Z'INFSM-:6D<4K+M+@<X]*T**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKB?B)XPO/#-K8VNEPQ2ZE
MJ$ZP0B7.U<G&?Z53\(>+M;E\67?ACQ)# M['#Y\4L (##(&/U_2@#T*BL_6M
M8M-!TJ;4;TL((AD[1DGZ5P7@/Q_J7BOQAJ5I/ L%E$@>&,J0X!Z$_4<_C0!Z
M;17"_$OQW_PA^DJEGL?4I_\ 5(PR%7NQ%;O@W5;G6_"6FZE=[?/N(0[[1@9-
M &[7C_QS_P!?X5_Z^I/YQU[!7C_QS_U_A7_KZD_G'0![!1110 4444 %%%%
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M %XS_P#H!IOA?_D5M,_Z]U_E3O$__(IZQ_UXS_\ H!IOA?\ Y%;3/^O=?Y4
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MCE3L)QGCKBO2HO@_:?\ "1+8WG]H7EDL)D-Y)*/O9'R@ Y_2@#TZ7Q5H,/\
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MG]*T** .9U3P3X>FTVZ6#0=/$YA<1[+= =V#CMZU\[?\*K\;?] "?_OY'_\
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M]G74+8S$[=@D&<^F*OUR,.D::/B!.XTZT#"U5P1"N0V3STZ^] '7445S&O\
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M_P!<C_,U>CDNXUU:Q.EQVFG6\)^RR1D 2 J2?E'3!JC\,O\ DGFD?]<C_,T
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MVL[6WO)Y8A;R%U,9ZDC%<?;_  )T6"YBF^W7+>6X;:2,'!SZ5ZQ10!YE\4/
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M9W0LR@E#D Y!..@Z=*MT 13W$-K"TUQ-'%$O5Y&"@?B:CL]0L]0C,EE=0W"
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M>*UMY+B9@D4:EG8]@*\*^*_BK1?$ESX<72;Z.Y:"Y8R!/X<E,?R- 'O-%%%
M!117,>-_%UOX3T1K@X>\E^2VASR[?X"@#!^)'B^YM/)\-Z$&FUB^^7]WUB4]
MSZ&MWP-X/M_"&B+;@B2\E^>YF[LYZ_A6#\-_"%U:F;Q-KQ\W6+\[P&'^I0]
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M$KHQ=!CA2><@5LT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/489FN-/%EJ=L%MYD8?.4 ^4_0\_E744 %%%% !1110 4444 %%%% !1110
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M " =8_Z^D_\ 0: /8:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8"]SG!J'PWJE]K&F+>7EE':B0!HU2829'OP,4 ;-%%% !1110 4444 %%%%
M!0>1BBB@#S[Q&&\'^*[?Q5""-/N=MKJJJ. I.$E_X">#[<=Z] 5E=0RD%2,@
M@\$54U/3X-4TZ>SN8Q)#,A1U/<$5RO@/4)[%[OPCJ4A:\TO!MI&ZSVI^XW_
M?NG\*OXH^:,_AEY/\Q-<\)7FGZC)X@\)%(;YCNNK!CB&\'_LK^__ -?.IX8\
M6V?B&!U4/;WL!V7-I,-LD+>A']:Z.N6\3^#EU>X35M+N/[/UV ?NKI!Q(/[D
M@_B7^7Z4)J6D@<7'6/W'4T5Q_AOQ>]U>/HNMV_\ 9^MPCYX&/RRC^_&?XE/Z
M5UX((R*EIIV9<9*2NA:***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .,^+$&I77PQUJWTF*ZFO)4C18[16:1U,J!P O)
M!7<"/3.>*^1;I;:^U&&WT:RN/WL5O$L&"SO/Y:+)@9).Z3<0!ZC@=!]A?$K4
M]7T7X>:OJ6ANZ:A;(CQND0D*KYB[SM((P$W$DC@9/:OF6_\ B;XXU&[CUB+7
M=5BBM/)C)1PL7F8+89458SN*N0K*3M&"6VYH ^LO#D-];^%])@U,N=0CLH4N
MC))O8RA 'RV3N.<\Y.:TZS/#FHS:QX7TG4[A46:\LH;B18P0H9T#$#))QD^M
M:= !37=8T9W.%49)/84ZJ&N!CX?U()G>;67;CUV&@#SV;XPJD\UQ%HES+I$-
MQ]G>\!& WYUZ9;W$=U;17$+!HI4#HP[@C(KPG3W@_P"&?=05ROFBY8,,\[^.
MM>L^#[F.'PCHD%Q/&D[VD>U&<!F&.,"@#(\<?$S3?!^R! MY>EL- C?<'OZ5
MVEM-]HM8IL8\Q0V/3->2_&/P[I=AX7N]3@M@+VYN5:28\DY(X^E>JZ9_R"[7
M_KDO\J ++':I;T&:^8?B'\0;GQ/J=M!)816XTNZDV,KD[^0.?3[OZU]+WQG%
MA.;90\_EGRU;H6QQ7R)XAT'6M-U1VU2Q:WENIG**2/F)/./;F@#V#X46Y\7Z
MQJ7C#5F\Z\CG\J%#R(AM!&/H#C\*]CKRSX1V%YX2\&ZK/KEM)9H+@S?,,DH$
M7D8^E=X-2O+NZTV;3H(Y],NDWR7!8J5&,K@8[\4 7-3U.TT?3I;^^E\JVB +
MO@G&2!T'/4U5-YJ,VJV@M;5'TJ:$N]R7PRGC: O7D$TZQT6&S-[OEDN4NY?,
M99R&"^P]JT@ J@ 8 & !0!F:9HD.GVMQ;O-+=)-,TQ$[;MI/89[5J444 %%%
M% &1=61L[ZYUE7N9V%OL%HK?*<$G@>IS7F?@6YDT;XJ:KI\MO+:PZK&+J**3
M VDC)X]<DC\*]CKR?XKQMHGB+P_XMA1V:VD$4H4]5!R!^))H ]8KBO$?_)2O
M"/UN/_13UO>']7N=5T:WO-0L?[.GF)Q;O*&.,\'/?(Y_&N?\2LJ?$?PD[L%5
M3<$DG  \IZ .BUW48;&VBBN+6YN([R3[,1!&6V[@>3CH/>K&E:7::+IL.GV,
M9CMX@0BDYQDY_K5>Q%[-J5Q=F]@GTV11]G1%Y4\Y.<\UJT %%%<K\1=?O?#/
M@N[U33_+^TQ/&J^8N1\S@'CZ&@!-$_Y'[Q'_ -<[?^35U=?+5M\6?$UKJEWJ
M$;6GGW0029B./ESC'/O7T[83/<:=:SR8WR0H[8]2 : .;\? ?V;I?'_,3@_K
M765RGC[_ )!NE_\ 84@_K75T 9NKZ3_::0O'</;75N^^&=!DJ<8/'<$$C'O5
M.WT*[FU*"]U:_%V;8[K>)8PJHV""WN<$C\:WJ* "BBB@ HHKF_&]WJVF^';C
M4=)N887M5,CB6(N' '0<C% '245E^'QJ7]D0OJEU%<W$@#[XHM@"D @8R:U*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:EI9["E%WYH[EQ'#C(-.KSF.^U3X>7*6FKRRWWAYV"V^HD9>WST27';T;_\
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M[&O_ !C#:Z]--% ZQR?8[?9E=CJ5(?N<@D'&.M8OPQ_XD/B[Q'X5D&(XYC-
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M!MX]< \?C0!TM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3?\ "2Z#_P!!K3O_  *3_&C_ (270?\ H-:=_P"!2?XU#_PA_AC_ *%S2/\
MP!B_^)H_X0_PQ_T+FD?^ ,7_ ,31[@>_Y$W_  DN@_\ 0:T[_P "D_QH_P"$
MET'_ *#6G?\ @4G^-0_\(?X8_P"A<TC_ , 8O_B:/^$/\,?]"YI'_@#%_P#$
MT>X'O^1-_P )+H/_ $&M._\  I/\:/\ A)=!_P"@UIW_ (%)_C4/_"'^&/\
MH7-(_P# &+_XFC_A#_#'_0N:1_X Q?\ Q-'N![_D3?\ "2Z$3@:UIW_@4G^-
M:F0:\V^)OAS0M.\!WUU9:+IUM<))#MEAM41AF50<$#/2NQT2^>\BW-1)*R:"
M,G=IFQ1114%A1110!Y)XD^(FO&^U+1IOA/J6KZ?'</$'='>*X5'^5]I@((.
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MXL\,VGBO0IM.NEPQ&Z*0=4<="*XOX<>*+JQOIO!FODIJ%F<6\C_\M4[#_/\
M2@#=\,:[XEU/7KZRU*UL8K>Q?RI6A<EBQ0,,>WS"NSKDO"O_ "-'BO\ Z_8_
M_1,==;0!R'C;_D)^%?\ L*_^T9*Z^N0\;?\ (3\*_P#85_\ :,E/\:>.K#PE
M9[2?M&HRC$%JG+,?4^@H \@^/?\ R.]E_P!@]/\ T8]8_P 'I%B^(UB7<("C
MJ"3C)(Z5Z#H_PUN_&DLFO^-IYA-< >1;0OM,:=0"<<=>E:-Y\#O#ZVSMI=U>
MVMX!F*5I=P4_3 H&>HUS%O\ \E(N_P#L'K_Z$*XG2?'>M>"KY=%\;PNT &(=
M10;@P[9_SGVJU#\2?"B^-[B_.J*+9[,1J^QN6W XZ4"/4Z*AM;J&]M8KFW??
M#*H9&]14U !114%Y;B[LYK<R/&)4*[XSAESW'O0!/17"> =-EAO]6N)=3O;G
M[/<O:HDTFY=HVG/UKNZ ..\2?\CWX6_WIOY"NQKCO$G_ "/?A;_>F_D*ZRYN
MH+.!I[F9(8E&6=VP!0!Q?CKQYX>T>SU30[V\>/4);)U2,0NP)="%Y Q1X"\<
M:!K5G9Z-8WC27T-L&>,Q.H & >2,=Q7AWQ5UJPU[QS<7FG3>=;B)(PX& 2HY
MQ5?X=:MJFB^)S>:3IIU&X$#!H VWY<KDY_*@#ZRKF-,_Y'[7/^N,/_H(KA-5
M^--Q!HTP70[RQU(#"&:+=$#WR3BN M_B[XGAU>XU!39>=<A5DS#Q@<#'- 'U
M#7!_$S1=-O=.L[JYLX99Q>P1"1T!.QI%!'T(KJ-+URPU"Q@E6^M7D= 6595X
M/TS7F7Q ^)^A.[:,L5Z;BSOHGD<1KL(1PQP=WH/2@#URUMH+*VCMK:)8H8QM
M1%& HJ6N7\'^/-*\;?;/[,BNH_LNSS/M"*N=V<8P3_=-=10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 5[V^L]-LY+N_NH+6UCQOFGD"(N3@98\#D@?C7EGC7^S?%&L
M0WNE_&*TT*".W$36UKJ"[78,QWG;,HR0P'3^$<UWGC>WTZX\$:S_ &K8_;K&
M&T>XEMO-:+S?*'F!=R\KRHY'ZU\^"?P%_P ((_BIOAP@A&I+IR0#7;@L6\LR
M,Q.,  ;0.N<GICD [_X?>#O#.G^-_P"VKCX@6OBC7G0K;8NE,@.PJS$>8[.=
MG [ 9X/!'L=?//POUCP;-\1M/L[7P%/HFIO"\EK<'4IIL9B+<H^!M:,DAN>J
MX'.1]#4 %-DC26-HW4,C## ]Q3J* /')_A;XEM1?Z5I6L1QZ)?2;I$9?F49Z
M=:W=?^&?VGPYI%KI%T(+[22KPRL.&8')S^.37HU% 'GW@WP-J>G>)+KQ'X@O
M4N=1EC\M @P$7O\ TKT&BB@"O??\@^Y_ZY-_(UY-^S]_R =8_P"OI/\ T&O6
M;[_D'W/_ %R;^1KR;]G[_D ZQ_U])_Z#0![#1110 4444 %%4K[5],TMD74-
M1M+0R E!<3K'NQUQD\U4_P"$L\-_]#!I7_@;'_C0!L45!:7EK?VZW%G<PW,#
M$@20R!U..O(XJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .*\,?\E-\<_P#;A_Z):NUKBO#'_)3?'/\ VX?^B6KM:N>_R7Y&=/;YO\PH
MHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .)
M^+7_ "3C4?\ KI!_Z-2M'PM_Q[BL[XM?\DXU'_KI!_Z-2M'PM_Q[BK?P+Y_H
M9KXWZ+]3I:***@T"BBB@#YV^*6FZ!K'Q-E73-?CT#Q-;-"9Y=1D:*WF(B#I)
M',N[RW4!1AMH)QCD'=?N/A1XW\=ZII=]XN\6:=?:4B@K)8.23$WS9C41JF6X
M^?GC!^; %>O:_P"#O#OBF-EUK1[2\8H$$S)ME50VX!9%PZC.> 1U/J:\T?X4
M^+?!<=U/\//%LZQMEAIMZJE6^4;B"04,A*J 2B\'!;CD ]C@@AM;>.WMXDAA
MB0)''&H544#   X  [5)6!X.OO$M_H7F>*])@TW4UE9#'!*KI(G!#C#-MZD8
M+'[N>^!OT (RJZE74,IZ@C(-,6W@2(Q)#&L;#!0* #^%244 5K73K&QW_9+.
MWM]_WO*B5-WUP.:DBMX(2QBACC+=2B@9J6B@"*6VMYR#-!%(1T+H#BI0 !@#
M HHH *\?^.?^O\*_]?4G\XZ]@KQ_XY_Z_P *_P#7U)_..@#V"BBB@ HHHH *
M*** "BBB@ HHHH 9*GF1.F<;@1FO#9/V?KQY&;_A(8!N)/\ Q['_ .*KW6B@
M#E_ /A*3P9X<.ER7:73&=I?,5-O4#C&3Z58UOP3X<\1WJWFKZ8EU<+&(U=I'
M7"@D@<$=R:Z"B@#G-'\!^&= U!;_ $O2H[:Z52HD61SP>O4D5T=%% !1110
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M8C5%B(R(TCX!XY"\MAJ]ZK'L?%GAS4[Q+.P\0:5=W4F=D-O>1R.V!DX4')P
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MK7H **Y#Q?XY_P"$5\0>&=*_L[[5_;EW]F\WS]GD?-&N[&T[O]9TR.GO77T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD#H:^</B3X6\$^&/B3HFCS64^F:%+:^==SVDLDDV69U!_>%AM4HIX7."W4X
M^GJ\9^+FHZMJWC?0/!>BZ9I4M]<1&Y6ZO[:*?8I+A@!(K!5 B+,0"QP .F&
M./\ AM#X=C^/T@\,6T]_HXAE>TG)D'V3,8+,00"5!+1#?_?4Y)QGZ6KPGX8>
M(-6\-_$J\\":[INE1W4P8_:-.LHH2[*GF)N,84&/9O(RNX%P#CD#W:@ HHHH
M **Q/$?BK2_"\$$NHS;3/((XT498D^WI3]:\3Z5X>TI-1U*Y$,,@&S@DMGL
M.: -BBN?\,^,]%\61RMI5SYC1??1E*L/P-=!0!7OO^0?<_\ 7)OY&O)OV?O^
M0#K'_7TG_H->LWW_ "#[G_KDW\C7DW[/W_(!UC_KZ3_T&@#V&BBB@ HHHH *
M*BN;JWL[=I[J>*"%!EI)7"JOU)XJOI^L:9JRLVFZC:7JI]XVTZR ?7:30!=H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BO#'_ "4W
MQS_VX?\ HEJ[6N*\,?\ )3?'/_;A_P"B6KM:N>_R7Y&=/;YO\PHHHJ#0^=_A
M_)J47Q[\9MI=I:7,Q>\#)=730*%^TKR&6-R3G'&.YY]3Q_)J4OQZ\&-JEI:6
MTP>S"I:W33J5^TMR6:-"#G/&.PY].Z\&?#K5_#OQ2\0^)[NYL7LM2^T>3'"[
MF1?,F60;@5 ' .<$\TOC/X=:OXB^*/A[Q/:7-BEEIOV?SHYG<2-Y<S2': I!
MX(QDCF@#F_#?Q:U:S^#VJ>)=:N$U#5$U)K*R62(1JS&-& /EJ!@ NW.,XQD9
M%3^(]0\>Z1\*-.\86GC)Y)VMX;B\AEL+<+MFV[1'B/(*EP#DG=R?EQM-G1?@
MQ<_\*NOO">M7UJEU+J7VZWNK7?*L)VHN2IV9) <8/'S ]16'\38O%^A?!_3]
M%U670X+*'R;.5[66622\V8,:JK1@)@)N8EN2O!&=I (_B3<ZMK$'PENK>ZC7
M6;P))'<2* HN'%N0Y !&-QSC&/;M71S>*O$/@[XK:?H6M^)/[3T>?2I+RYDF
ML8XVAV1R,S+Y0!/,)('/#8P2 U6;GP)J^NV'PONXC!;?V!';RWD-T723@0$J
M%VGYAY;#!QSBM?7/ EYK'Q:T?Q.YL9-)M;"2TN;:8DO)N692-NTJ5/FC.3Z\
M>H!P&G?$K6?$?A_Q/KTOC.QT"6#<=*TH&V=VV+N*LLB;WW?*H8$?-NXP M4]
M4^,_BJ_\/>%M1T98XM0N+ZXM;RTBM0\=RZ&$HJ@EGP5D X())..U>A>#?!_B
M3X?1:GI>DQZ5J>D371N;5[N\DMYTRH!5]L3JWW5 (QT)[X5?$W@GQ'XFU3P/
MJ5U=:4+K1KO[3?B(21HV7B;;$"&)P$(RQ&>#QG  .C\):5XGTVVE/B;Q&FL3
MRK&52.S2%;=@#O 9<%P21R0/N]!FO-?$FG73_M)^'H5UF^22;3Y)(YU2#? N
M+@[$!C*E>"/F#-R>>F/;:X75/!>HWOQCT3Q?%-:C3["R:WEC9V\TL1,,J-N,
M?O%ZD=#0!S?BOQ+<Z+'JT</Q.,VJI%(;*PLM,@G,;0J3(L^U'(8@<L?+53N.
MW:-HS-9^)7C*/X*Z%XBL8$-W=N\=]J21*PMPDA13Y9!&7V\MC:#D  LN+FE_
M"KQ)X5T_Q;I.@SZ5=66N1+!#<7\\B201X<-N1(R&;$A (8#(!QSMKHO#7A[Q
MIX0\&>']%TPZ!</:--_:'VF690ZM*741,J\'#,"64X..#0!S/CR235/A#XBU
M.U\:R:[I<C6A@000*T7SIN21D0<DNC8VHR[5!ZG-/P_J6K>&/V:#KFFZK.ET
MH'V='BB9+?\ TLHVT;,G<&.=Y;VQ6Q;_  9^WR^*+K5)+'2Y-8B6VMK31TS!
M:QJT;JQW*NYBT2Y "@_,>"PVSP_#SQ&WP6N? LS:4ETH46]REU(R2?Z1YK;@
M8@4P.!C=GVH S/&/C'Q?#H_PWCT35H[;4/$$"+<2R01LKRNL&&.4.T;I&/RC
MOTZ5IV^N^*= ^,VC^%-0\0?VQ8:CIYF<S6<4+(X20DJ8P/XHCC.<!\<D;JL:
MM\.=7O\ _A7'E7-B/^$9,/VS<[_O-GDY\OY>?]4W7;U%:>J^"]2OOC%H?B^*
M>U&GV%D]O+&SMYI8B894;<8_>+U(Z&@# \+^*];^)?B3Q*=(\02:/I.FJL-B
M+>TBE,S,7VS.94)Q\F=@"\$#(():Q\(_$GB?6-8\6:9XFU*.^GTBYCMU:.%$
M4,&E5R-JJ2"4'4?E1X=^'WB'P!K.NR^%FT>ZT_4UW117TDT36KJS^6ORA_,1
M0^#DJ6]5QSB?L_M>76H>,]2NI?M7VJ[B)O4C*1SR9E9RN57^^IQ@$!AD#- '
MMM%%% '$_%K_ ))QJ/\ UT@_]&I6CX6_X]Q6=\6O^2<:C_UT@_\ 1J5H^%O^
M/<5;^!?/]#-?&_1?J=+1114&@4444 >2>)+'XL65]J6H0^-O#^FZ*+AV@-X$
M00Q%\(K,T!&<%1R3SW-<W_;/Q#_Z*[X&_P# NW_^,UZQ\0[C0[7P+J4_B2SG
MO-(7R_M$$!(=_P!X@7!#+T;:>HZ?A7S/XMO?A[K&G6MEX'\-:K:ZQ)=(,S,S
M^8A##8J^:^6+%,8';KZ@'UAH;W$GA_37N[N"\N6M8C-<VY!CF?8-SH0 "I.2
M, <&K]9GARVFL_"^DVMQ:I:30V4,<EO&Q98F" % 26) (QG)Z=3UK3H \H^+
M7[WQ+X/MW^:%]0CW(>A^<#^5%G#'9?M 3QVR+$DFGY<*, \C_ 5U'CSP;)XK
MLK5[.Y6VU&RF$UO(^=NX>N*RO#O@36K34=3US6=3@GUNXMFMX'@W;(\C@\C.
M<X[4 'QHE>/P(J*V%EO8HW'JIW9%<]XIMH=.\0_#^2S@2.0")<H,$C ./UK6
ML?A_XGU#0=6TSQ7KRWPN!&UHZR,_DNN[)Y ZY%+H7P\U_P#M[3;[Q+JMM=0:
M4@6TB@W=NA;('- '&:3+K5WXW\8-INFVE[<"6;S&NAG:@8C:N?7I7IWPRU6R
MU;PBDMG816)21EE@B&%#]R/K6/K/P]UV'Q-?:QX6U2UM#J"E;F.<-WZD8!YS
MS74^"O"L?A'0$TY9O.E+&263&-S'K^% &W>7!M;*:X$3RF-"PC0?,V.P]Z\
M^)/BR;Q+=^'TET+4-,\BY8@W:;1)DIT^F/UKZ&KQ[XY@"?PK@?\ +U)_..@#
MV&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  -E_P#BJ+0[_A_P0O/M^/\ P#M<T9KBO^%5>%?^?>\_\#9?_BJ/^%5>%?\
MGWO/_ V7_P"*HM#O^'_!"\^WX_\  .US1FN*_P"%5>%?^?>\_P# V7_XJC_A
M57A7_GWO/_ V7_XJBT._X?\ !"\^WX_\ [7-&:XK_A57A7_GWO/_  -E_P#B
MJ/\ A57A7_GWO/\ P-E_^*HM#O\ A_P0O/M^/_ .US1FN*_X55X5_P"?>\_\
M#9?_ (JC_A57A7_GWO/_  -E_P#BJ+0[_A_P0O/M^/\ P#M<T5Q7_"JO"O\
MS[WG_@;+_P#%5B?#V]73?[8TN,N8H=6N(XP[%B%!  R?84.*M=,%*5TFCU"B
MFQMN0'UIU0:!1110 5Y!\9/#7AJ>_P!,\0ZKXMG\/:E'M@MI4B:;(0L^51,.
M&#,/G!P.!C)%>OUX#\9#;:5\6/#^OZWH<^HZ!!:QQ3C8?+=]\Q"Y/RLPX;83
M\P&#P30!I_"GPUX8NO%5QXDB\;R>*-8B0K&9T>&6,;0C.RR,7<;6503\HR1R
M<;?:Z^;OAH8-;^.L^L^$=-NK'PZJ.UQ'@1K&KQ$;6 8K@RC*H">F0 %X^D:
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M:RADDN(U*K*Q0$N 0I ).<8'7H.E:=1P00VMO';V\20PQ($CCC4*J*!@  <
M =JDH **X7XD>++_ ,/V^G6.D"/^T=1N%@C:09"9.,_GQ5+P=XGU^+QC>>%O
M$KPS7*PB>&:)<9&<8/Y_I0!Z/17-^._$C>%?"MQJ,2JUP6$4*MT+GI_(UQ&C
M^*_%NC>(]$MO$DD$]IK**T?EI@Q,W0?A0!ZW17G_ ,3_ !S)X5TH6VG$-JDX
MRO&?+0=6(KH?!.I7.K^#M,O[Q]]Q/"KNP&,F@#?KQ_XY_P"O\*_]?4G\XZ]@
MKQ_XY_Z_PK_U]2?SCH ]@HHHH **** "O@S5O^0S??\ 7Q)_Z$:^\Z\&N_V;
M/M5[/<?\)9M\V1GV_P!G9QDYQ_K: /.?@E_R5[0O^WC_ -$25]?UX_X)^!G_
M  AWB^QU_P#X2/[9]E\S]Q]A\O=NC9/O>8<8W9Z=J]@H *\J^.-[<7.D:)X2
MLI/+N?$&H)#N=1Y9167ACR1\[Q'@=%/T/JM><WWPXN-=^+3^)=?:QO=$@M!#
M963J'.=N")$9-I7<TK#DG.WL,4 <IX(\3:UX<^&7BK1;&UM;G6/"%PZ_,#Y,
MD1E9G;.Y2Q&V8_P\!."<BMAOBCJFK7'@?3_#@TZ;4-=MS-?^=;R%;<+P[("Z
M9"LD_&XD[!CJ";\'PQ;2_BD=>TB/3;?P]>636NHZ<8U <%2-J1A-H0E8V/.2
M=W8X.?\ #;X2ZCX.\4SZGJVI6M_!;V[VVFJJLS1JSEBWS#$9P6^52?\ 6/S_
M '@#/F^,FHZFFNWVBW7ABQT_35<6L>J7#&XU!E).8T#(R@IC *GYL+DY)66Y
M^-EW8?V3K-UI< \/:OI\\ML"2LT=U%N5HBP+!E+J &V+Q*I/W6%:_AOP;XO\
M"WFN6GAU]#N=#O)GN+&"\FEC>VD8 #)",74 !2"V6V@@J2<U_$WPV\1^/=>M
M9?$VH:5%I=II[QPPV:2,PNI(@'<YP=HD^8?,<B-01\S&@# T;QCXKUCQ_P"&
M;?4]'\+6FHZKI[7=I?\ V!YIH("LI49\T$;@K<!N _/.153X1S:E9?"+Q-?Q
MOILVGV[WDDME=6;2&9EME."_F ;#\H*E#D9YYXW_  K\-O&-AXV\-ZUKU_H\
M]OHMDUBGV9Y/,:()($R"@!(\P#/' '4Y)N>%_A[XC\->"_$'A,-I5S:ZE]J\
MJ^-U(CKYD/EINB\HCJH)PYQDXSCD Q]'^)6KS:!X.T7POHVAPZWK GE>V$3P
MVEM"LL@W!01UV.QPQ/R-\I+"LNTU^Z\)_&CQSK7B!K2:XL]'W'[(CQQS'-N(
ME .XJ6R@/W@"3R0,UN:9\)/$&AIX0U33]1L?[;T3?#<PO(P@G@:65R%?RRRL
M5E922I^]D8*\SGX6:WKWBWQ3JWB672HK?6]/-K''92RR&!PT1B8[E3=M\I2>
M1DCH <  SV^-.IV&GZ9KFH2>')K"\NRDNDV-SYE_;0,"4<G?M+#!W JO\(^4
ML=GMU<!X5TWXAZ%H>DZ-=GPY<0V<L<4ET)YMYM%P-BH(U'F <!BV.!D$Y-=_
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_!=#_P#$UT%% &/8^$_#FF7B7EAX?TJTNH\[)K>SCC=<C!PP&1D$C\:V***
M"BBB@ HHHH **** *]]_R#[G_KDW\C7DW[/W_(!UC_KZ3_T&O6;[_D'W/_7)
MOY&O)OV?O^0#K'_7TG_H- 'L-%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <5X8_P"2F^.?^W#_ -$M7:UQ7AC_
M )*;XY_[</\ T2U=K5SW^2_(SI[?-_F%%%<!\9/$&J>'/AW=7.DK.EQ-*ENU
MS"<&V1LY?.#C.-@/&"X(.0*@T._HKSGP-\._"0\'^&]0_L2#[=Y5KJ7VG<WF
M^?Y:MNW9SMSSLSMSVKE/ADD/Q"\:^,-7\6:5'=75L\4%O::A&)!91EI,Q!&
M (V 9V@YW'JS9 /<:*^//%FI7EG9^(/"$,4[:'I^OEK,EBR6F#.OE@D$_,.0
M"W\#'!)8UZ5XO\)Z1X%\<_#-/#\+VLLE\+>>=9#YDZ^9$"7(X)(D<'CD-M^Z
M   >\T5X=9*GC_X^:SIWB>P>:PT:W<V-C<,WEH5DB DV\!@X.[Y@00P'( K/
M^*=A#H^NZ#X(T;3+JQT'6;T7=Y'8N%%W*\BH8TW_ "*5"J0N0@+H2!@&@#Z!
MHKQE?#7B73OBIINM>%/"L^BZ'+Y4>J6KW,$<4G+*SF**8@[48$8'WAG!).>)
M^'G@O0M5^$?C#7]0M/M-]#'<Q0,['$/EQ+*K)CHQ8C)]!CH6! /??&'C#2_!
M&A?VMJOGM"95A2.!-SNYR<#) Z!CR1T]< ZFE:C#K&CV.IVZNL-Y;QW$:R !
M@KJ& ."1G!]:^;?%'^F?LU>$;RY_?745^\,<TGS.D>9QL#'D+A$&.GRKZ"K/
MC?1A_P (]\)[/0T@TZ]OHT99H1Y7^D.EL!*S*,[LX);D\4 ?2E%>):_HGPV\
M"7^E^'$\.7VK:Q>>5+;VING\N>8$I$TVYQ'\S%Q]T@ M\H!P:_P\L?LWQK\4
MZ//I%OIEG<Z4);G1XI_/MU9Q"2IX"M_K'& -HW,!QU /0_#GQ!L?'-OKL7A=
M)/M6G+MBEOH]D,KL'\MOE);9E,G(!P>F:Z+1/[8_LB#^WOL/]I_-YWV#?Y/W
MCMV[_F^[C.>^:^;/A/86<_@OXBWDUI!)=6NF-]GF>,%XMT,X;:W5<C@XZU/J
MOB#5-)_9U\*Z?8">*WU*6YBNKJ,X 032?NB<<;\D]1D(PY!- 'TY17B/Q@T+
M2_ OAG0];\+6$&DZG8WZ0PW5JFURAC?(<_\ +3.P9WYSSG[QSF:3HECXW_:"
MU"?7M-=%33+;4&T^;HLODVX\N0$ L%+G((&2HR,9! /H&BOF_0?#FM:E8?$[
MPMX5OGLXK74E6&S,AVRQ!IU:(,3\I8*@+?Q; K'!)'9?#6[\-:7KECHU]X;G
M\/\ C./3Q9.'A*I>HFXM(K+\CY,6XN0,] S 4 >O4444 <3\6O\ DG&H_P#7
M2#_T:E:/A;_CW%9WQ:_Y)QJ/_72#_P!&I6CX6_X]Q5OX%\_T,U\;]%^ITM%%
M%0:!1110 4444 %%%% 'E'Q>_P!&UKPIJ,WRVMO?QF20]% 8$Y_ 56T_5+/4
MOC1?ZS93"?3[332TLT?S*,<GI7JNI:78ZO9M::A;1W$#=4D7(JCI_A71=*T^
MYLK"QBMX;E"DOEC!8$$=?QH \T\?>+M)\;^!;LZ')--_9UU!/<;XBFU3N&>?
MI576=5LO$WB3P-;Z1<+<RPI&\HB.?+P.0<=",5Z-X>^'_A_PS%>Q:?;2&.]5
M5G2:0N&"YQU^IJ[I'A#0-"NGN=-TRWMYG&"Z( 0/04 >*^(X/%,1\2:KJF@N
M_P!K1HUN7SB"+_9';BO2_A-=7EQX%LDNK3R(X8U2%O\ GHN/O5V5[8VVHV<E
MI>0K-;RKM>-QD,*+*QMM-LXK2SA6&WB7:D:# 44 +>PR7%E-#%*8I'0JL@ZJ
M3WKY_P#B/X=U;0KO0&U/7)M3$MRP02?P8*9_/(_*OH>O'_CG_K_"O_7U)_..
M@#V"BBB@ HHHH ***Y'6_B1X>T74WTO?=7^HQC,EKIUNT[Q_[VW@'V)S0!UU
M%<[X;\;Z#XJDF@TV[87<'^MM+B-HID]]C8)'N,BNBH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AK.EV^M:/=:==+
MNAN(RC>HSW'N.OX5@^ =5N+C2IM&U%C_ &KH[_9;C/5U'^KD^C+W]C76UPGB
MD?\ ",>*M.\5Q_+9RXL=3QT$;'Y)#_NMU/H0*N.JY3.>CYCNZ*.HR**@T"BH
MYYX;6WDN+B5(88D+R22,%5% R22>  .]1V5_9ZG9QWEA=P7=K)G9-!()$;!(
M.&'!P01^% %BBBB@ HHHH Y#XC>!O^$_\.P:3_:/V#RKI;GS?(\W.%=<8W+_
M '^N>U7SI.MWT<UGK>HZ5>:9<Q/#<V\&G2P/(C*5(#_:&V]?3\NH72O&WAO6
MM#N-:LM7@_LRWE\F:ZG#0(C_ "\$R!?[Z_G6W!/#=6\5Q;RI-!*@>.2-@RNI
M&001P01WH \\MOAQKNG>#;SPEI_BR"/2)O-CB,VEB2XAAD)+1[Q*JMG+?,4S
M\QQCC%CQ!\*=+U;X=V/@^QO)[&WL95FMYV'FG?\ -N+@D9W;W/!7!(QP,5W]
M4]1U;3M'MUN-4U"UL8&<(LEU,L2EB"<98@9P#Q[&@#S76_@C9ZMX+\/^'XM;
MGMY-'\W;<M '$OFG=)E,C'S 8^8X'!W'FM_Q#\-[/5]#T"TLM0GL;_P_Y7]F
MWY02F/9L'SH<*^=BGMR!VR#V]9^MZWIWAW2)]5U6X^SV,&WS9=C/MW,%'"@D
M\D#@4 4[.P\1C5(;C4=>M)+2)'!M;+3O)$K'&"[/)(<+S@+MY/)(&*S/ASX&
M_P"$ \/W&E?VC]O\Z[:Y\WR/*QE47;C<W]S.<]ZZ>QO;?4M/MK^TD\RVN8EF
MA?:1N1@"IP>1D$=:L4 %%%% !1110 4444 %>/>$O^0_KO\ V&+G_P!"KV&O
M'O"7_(?UW_L,7/\ Z%5Q^%F<OC1Z[!_J5^E25'!_J5^E25!H%%%% !1110 4
M444 %%%17,<DMK+'$_ER,A"O_=/K0!3EU_2(;O[++J=FD^<>6TR@Y^F:MW-W
M;6=NUQ<SQPPJ,EY&"C\S7AGB[P)I/A3P;=W.I77VO7I[C-K,K-O.>@QGZ\_2
MI?$?V_4H_ OAF^DDQ<QQ2W"DD%DSC!]\4 >U66HV6I1&6RNH;A <%HG# ?E5
MJO'/#EDGA+XSSZ)IS.FG7%IYGD;LJ#GCK^/YU['0!7OO^0?<_P#7)OY&O)OV
M?O\ D ZQ_P!?2?\ H->C:[XBT?3(I[2]U&VM[AH2PCDD"L00<<&O.?V?O^0#
MK'_7TG_H- 'L-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <5X8_P"2F^.?^W#_ -$M7:UQ7AC_ )*;XY_[</\
MT2U=K5SW^2_(SI[?-_F%4]4TNQUO2[C3=2MH[FSN$V2Q..&'\P0<$$<@@$<B
MKE%0:'(:;X".EVFF64/BOQ&UCITJ20VS3P@,%.1&[+$':/!QM+8Q@=AB1O 5
ME!XDO==TC4]2T:[OT NTL3%Y4[ YWLDD;C?SU&.I[LQ/5T4 >>W7P;\-7?AM
MM&EGU$F6]^W7-^9E:ZN9<. 9'92" ';@ >O4DG?\1^"].\3ZQH6IWL]U'-HM
MQ]HMUA=0K-N1L/E22,QCH1WJYI'BC1M>U'4[#3;SS[K2Y?)O$\IU\I\L,98
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MZWX=RJS-O.& RS*,G.">: .WKQ[PE_R']=_[#%S_ .A5[#7CWA+_ )#^N_\
M88N?_0JN/PLSE\:/78/]2OTJ2HX/]2OTJ2H- HHHH **** "BBB@ J"]NEL;
M&>Z<$K#&SD#J0!FIZ0@$$$ @]0: /G&S\0F_\93:[XFTR^NUC;_1;=%.Q?PQ
M76>.IKB\?PSXVLK&=8;61?.C"Y9(PV2#7K_V>#_GC'_WR*<8T*;"BE/[N.*
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MGP0S)N!VNL:AAD<'!!Z4 >7>/-.A^(WQCTKPA(S_ -GZ5927-]);D)+$T@!
MRX(8?ZCH#]\^G%SX0ZKJD'P\USP[%;P-X@\.RW$$5HW0N=S(';=M.91(O##A
M1TZE_P .OAQ.;GQ#K7CG0=.?4-4O3*EK/!%.L(RS%D;<^ Q<C'7Y!G.:N:9X
M.UCPQ\9I=1T.Q@B\*ZG:!;N.$)%';NJ$+MC##+;D!W;>DK#U- %?1?B]]O\
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M,L-/N/#!LK&VMB]T^XPQ*F[!3&<#FO:Z\?\ CG_K_"O_ %]2?SCH ]@HHHH
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M_P!?4G\XZ /8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"AP;_OF3_XJ@#VZBO$?^%)>(?^AP;_ +YD_P#BJ/\ A27B'_H<&_[YD_\
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M_P#BJ/\ A27B'_H<&_[YD_\ BJ /;J*\1_X4EXA_Z'!O^^9/_BJ/^%)>(?\
MH<&_[YD_^*H ]NHKYLO/ 6MV?CFT\,'Q)*TMQ;^>)P7PHR1C&[VKI?\ A27B
M'_H<&_[YD_\ BJ /;J*\1_X4EXA_Z'!O^^9/_BJ/^%)>(?\ H<&_[YD_^*H
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M[@_*C[)%_<'Y5/10!!]DB_N#\J/LD7]P?E4]% $'V2+^X/RH^R1?W!^53T4
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MK8$*9&B4C)Z='-74\0_&22-9$T.V*L 0?+3D'_@= 'M%%>,_V]\9O^@#;_\
M?M/_ (NC^WOC-_T ;?\ []I_\70![-17C/\ ;WQF_P"@#;_]^T_^+H_M[XS?
M] &W_P"_:?\ Q= 'LU%>,_V]\9O^@#;_ /?M/_BZK:AXM^+FEV$U]>Z/:PVT
M"[I)#$A"CUX>@#V^BO$K+Q7\7M1LHKRTT:VEMYE#1N(D 8?B]3_V]\9O^@#;
M_P#?M/\ XN@#V:BO&?[>^,W_ $ ;?_OVG_Q=']O?&;_H V__ '[3_P"+H ]F
MHKQG^WOC-_T ;?\ []I_\71_;WQF_P"@#;_]^T_^+H ]FHKQAM?^,JJ6.A6P
M &3^[3_XNJ6E>-OBOKEF;O3=+M;B .8RZQ*/F'4<O0![I17C/]O?&;_H V__
M '[3_P"+H_M[XS?] &W_ ._:?_%T >S45XS_ &]\9O\ H V__?M/_BZ/[>^,
MW_0!M_\ OVG_ ,70![-17C/]O?&;_H V_P#W[3_XNC^WOC-_T ;?_OVG_P 7
M0![-17A-CXY^*NIWEU:6>F6DL]HVR=!$HV'TY>M#^WOC-_T ;?\ []I_\70!
M[-17C/\ ;WQF_P"@#;_]^T_^+H_M[XS?] &W_P"_:?\ Q= 'LU%>,_V]\9O^
M@#;_ /?M/_BZ/[>^,W_0!M_^_:?_ != 'LU%>,_V]\9O^@#;_P#?M/\ XNL]
M/'7Q4DUM]&73+0ZA''YK0>4N0O3.=^* /=J*\9_M[XS?] &W_P"_:?\ Q=']
MO?&;_H V_P#W[3_XN@#V:BO&?[>^,W_0!M_^_:?_ !=']O?&;_H V_\ W[3_
M .+H ]FHKQG^WOC-_P! &W_[]I_\71_;WQF_Z -O_P!^T_\ BZ /9J*\,NO&
MOQ7LK^UL;C2K6.YNB1#&8ER^/^!U=_M[XS?] &W_ ._:?_%T >S45XS_ &]\
M9O\ H V__?M/_BZ/[>^,W_0!M_\ OVG_ ,70![-17C/]O?&;_H V_P#W[3_X
MNC^WOC-_T ;?_OVG_P 70![-17C/]O?&;_H V_\ W[3_ .+JM=>.?B;HES8R
M:YIEK;6EQ=)!N,2_,2>@PQP< T >WT4V-_,B1\8W*#BG4 %%%% !1110!QWP
MU_Y%Z^_["EU_Z,-=C7'?#7_D7K[_ +"EU_Z,-=C5U/B9%/X$%%%%06%%%% '
M >*O ^J>)OB1X:UB6\@70]'_ 'WD!L3>>&+9'R$%25B!RW0-C!Y-SXG^"YO'
M7@]M+M)XX;R*X2XMVE<K'N&5(?"DXVLW0=<=LUV=% 'G/CGP!J_C#PEH>W48
M(?%6E>7(MZ&=$:3:OF[2@&W+*&!"Y&T  9.,>7X(V\OPKMO#GVF!-;@E:\%Z
MJDHT[##(<Y81E0BG;C.Q6*Y&T^O44 <Y:2>-9)+".\M/#]LBNIO9X;J:8NH4
M[A'&8TVDMC!+MM&>&KSS5O@_K_B?4-6\0ZQXA\C7_-#:.MK*S0VB*=R*6V*W
M'3*@8.7^8DBO9J* /-=?\$>)O$=[X"U"]N=-%YH5P)M182MB8AXB6CQ&!EA&
M3@A0"<<CFC1_AWJ7AGXK:GXHTV6TN]/U1'$\5S.T4L#22J[E=L;!P-IP"5ZX
M)XR?2J* /,='^&-Y%-\08M4GL7M?$TK/;%%,IARTI5F5@!N4NI&#U7J.#5.+
MP1X]TWX<3^"=.N= ^SEI84U"2659&MG9BRF/RV <[B,AB #@#(W5ZU10!Y+/
M\'YM1^$.F>%[VYM8]:TQI9;>ZB!:/<SNVPDJ&V,&&< <J#@[<'M[23QK))81
MWEIX?MD5U-[/#=33%U"G<(XS&FTEL8)=MHSPU='10 4444 %%%% !7CWA+_D
M/Z[_ -ABY_\ 0J]AKQ[PE_R']=_[#%S_ .A5<?A9G+XT>NP?ZE?I4E1P?ZE?
MI4E0:!1110 4444 %%%% !1110 55U#3;+5K1[2_MH[B!_O(XR#5JB@#.TG0
M=*T*%HM+L8;6-CEA&.M:-%% "$ C!Z&H;:SMK-66VA2)6.2%&,FN4\8>/X/#
M-Y!IUM92:AJ<PW+;1G&%]2:D\/>/[#6]+O[N:":RDT\$W,4HY7 YQZT ==17
MEUC\8X;C48?M6C36VEW$OE07I?(8^XQQU]:]1!R,B@ HHHH *BN+:"[B\JXB
M62/.=K#(J6N'\8?$1/#>IQZ58Z;)J6HNF\PHVW:O7K@T =NJA%"J,*!@ =J6
MN<\'>+[3QAI;75O&T,T3^7/"W5&]/>NCH **** "BBN#\4_$J/0]9&CZ=IDN
MIWZC?+'&VT(OUP>?:@#M396S7BW9@0W"C"R8^8"IZY"Q^(>DWGA*Y\0.LL$-
ML=LL;KA@W8?C6+H'Q935-9MK*_TB73X;W_CTG=\B7\,#% 'I-%%% !117$^.
M/B/8>#Q#"D:WE[*X'D"3;M'J3@T =L>1@U!;65M9AQ;0)$';<VT8R?6L7Q-X
MNL?"VA)J5Z&)E(2*).2[D9Q_.N:T'XIF_P!<MM+U?19M+DN\?9F=]PDST[#&
M: /1J*\[\2_%)=(UN?3--TB74I+1=UTR/M$0!Y['.*Z_PYK]IXFT2WU2SR(I
M0?E;JI!P0: -6BBFNZQHSNP55&22>!0 ZH;FU@O(#!<Q)+$2"4<9!KC-/^)-
MGJWCMO#EA )H5C+-=B3C<",@#'OUS3_%_C\^'-5M])L-+EU/49D\P0HVW"_7
M!YH [555$"J % P .U+7*>'/'5EKN@7>IS1-:-9$BYA<Y*5S-A\9(+G4H!<:
M//;Z7<R^5!>E\ACG'3''YT >HT4BL'4,IR",@TM !17)>-/'5OX2%M EJ][J
M%T2(;9#C=]3VJMX.^(*^)M1N-+O=-DTW4H%W- [;N,^N!S0!USV5J]VMV\"&
MX0;5D(Y ]*L5QOCOQ_:^"H+<>0+J[G;"P>9MPO<DX-3>)_'5KX9T.TO9;=YK
MF\P(+=#RS$=,^E '645Q7@WX@Q^)[^XTR[T^33M2@4,T#MNR/8\5VM !117G
M6O?%1=-U6[LM.T:XU!;)L74JMM6/U/0YH ]%J"VL[:TW_9X4BWG+;1C)KG+C
MQ[I-OX)3Q.69K5U^5!U+9QM_/BL;PU\44U?6X=+U+29=,FNEW6I=]PE'Y#%
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M?]##IW_@0M8'_" 6/_/C;?\ ?E?\*/\ A +'_GQMO^_*_P"%+W/,?[SR-_\
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MB;XLKJ'AYEADN[3]R]TO,:9ZX&><U>E\1:I<>&/%^AZE' VJ60RTT8V^8GF
M$G\ZZ[Q3\.+F;5[36O"EQ;Z;?6R>6(RNV/:"3P /<U)X;^&[V>GZRVMW276H
MZNK+/*@X7//&??F@#B-=1!\!?#; #=YR<]_OM7M^F$G2[4L228ESGZ5Y3;_"
MKQ!*UGI.HZQ!)X?LY?,BB3<'//3I_6O8$540(HPH& * %HHHH *\HTQ5D^/N
MJ>8 V++Y<]N17J]>=^+O FK7GB1/$7AK4(K34#'Y4PESM9?P!H P_@\TH\4>
M+(PN(!=.0?\ :WGC\L5[!7(^ O!I\(Z?<"XN!<7UW*9IY5Z9/85UU !1110
M5X%8+KUS\5/%$&ASP07#,S233#)"C' ^O]*]]KS/Q)\/-9_X2F;Q#X6U&&TN
M;E"DZ2@X.>I& ?:@#A=<\17>L_"S5+:]ABCO+*^2"=X5PLA##FMOXCHD6C>"
MI;;BY1P(@IZ@[,UTNG?"N"+P3?Z+?79EN[]_.FG7.!(#D8]L@5FZ/\-/$$FK
MZ7)XBU6WN;'2B?LT<8))^N0/04 >L4444 %>+_%?P=I6DZ--K,,1:_NKV,O*
MYS@>@]*]HKD_B#X6N_%OA]-/LYH8I%G24M,3C ^@- &AJ=EHUSH<4^MV]O+;
MVJB8-,H(0@=1[UYOIS3_ !(^(-GJ]M;M#H.CD"%W&/,93G@?YXKK_'WA76?$
M_ANWTG3+VWM@'!G,K, Z@'C@'O@_A6#X:\%>.]"FL;<ZWIHTR!P7@B# LN>0
M/EZT 4/ @$GB3QX9U&\M(&!].<UH_ YF_P"$:U5,GRTU%UC'8+M7I[4FO_#G
M71XAU#4O#6J0VT>IJ4NHI<_Q=2, UV?@[PQ#X2\.P:9$_F,N6DDQ]YCUH WZ
MI:OID.LZ3=:=<%A#<1F-RO7!&#5VB@#Q31-#L?#OQQBT[3HO+MX[#(!.23D9
M)]ZL^,CJ%Q\5;=/"A"ZW#;XG>7_5A2O&?PKK#X-OC\4?^$I^T6_V3[-Y/E9.
M_.?IC'XU0\4^!-9F\5_\)-X8U&*TOV0)*LP.UL#;Z'M0!P6GS+'\//&UI<QN
MFM*RF]8]'&>,?3G\ZN>*X;=/@3HS(%#*49,?WB1G^M=GX:^&S66E:PNMW275
M]JPQ.Z [1],_YXKG[;X3>()#9:3J6LP2Z#9S^:D2@[V&<X/']: /5=&9FT2Q
M+_>,"9_*KU-CC6*)(T&%10H'L*=0!SGBF3P]I,*:_K%M T]IS!*R N&[!:X3
MP8;J\UC6/B)JT!MK5H"((^Y4=#^0Q6K\2? FO^-+VT%C?6<%E;KD),SY+D\G
M !&.!4WAWPGXNM[@6_B#5;"[TDQ&-K:%6&1C@8*@8H \=\2:K8>([2\U^\U%
M'U26Z1+>T!.8H0?ICO78>)M3M-9\4>!9;2=+BSP5W+G&]2 >O<&NM\7?"?3=
M5TA8-#M+.RNA*K&1U(&T=1P*D\0?#*.^T#3;?2)8K&^TY_-B<#Y2W?MGD\T
M9<H"?M!VY0 %K)MV.]>L5Y]X-\"ZIIWB*X\1>(K^.\U*5-B>7G:@QCN!7H-
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M7L$:CIW- 'HM%%% !1110 48HHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
M,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#T
MHHH ,#THP/2BB@ P/2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA;XPZ=XCUC5HYH+73M%L7\M-5NK]469BQ\L!'52"RH[8R<;<&NK\<_\ )/\
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M_M]_]*DKWV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT#X%^)G_  EWB'6- OM(_LK4]-SN@^T^?OVL4D^8(%&UMHZG.[CH:[^O O\
MF[K\/_;&O?: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M87Y>!EF.!W)/>B?P;X6NKB6XN/#6CS3S,7DDDL8F9V)R225R23WK;HH Q_\
MA$_#G]G?V=_PC^E?8?-\_P"S?8X_+\S&-^W&-V.,]<4MUX4\.7WD?;- TJX^
MSQ+##YUG&_EQK]U%R.%&> .!6O10!Y[X)^%D/A?Q+J7B+4]236-6O'+I<-:"
M$PLQ8R%0&(RV1R , $#@D5Z%110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gzbwht3f4aft000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,!!YX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2_\ "W[W_H$V_P#W];_"C_A;][_T";?_ +^M_A1]3K=@_M+#]_P9ZU17DO\
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M/_A1_P +%\,?]! _]^G_ ,*\'HH^HT^[#^U:W9?U\SWC_A8OAC_H('_OT_\
MA1_PL7PQ_P!! _\ ?I_\*\'HH^HT^[#^U:W9?U\SWC_A8OAC_H('_OT_^%'_
M  L7PQ_T$#_WZ?\ PKP>BCZC3[L/[5K=E_7S/>/^%B^&/^@@?^_3_P"%'_"Q
M?#'_ $$#_P!^G_PKP>BCZC3[L/[5K=E_7S/>/^%B^&/^@@?^_3_X4?\ "Q?#
M'_00/_?I_P#"O!Z*/J-/NP_M6MV7]?,]X_X6+X8_Z"!_[]/_ (4?\+%\,?\
M00/_ 'Z?_"O!Z*/J-/NP_M6MV7]?,]X_X6+X8_Z"!_[]/_A1_P +%\,?]! _
M]^G_ ,*\'HH^HT^[#^U:W9?U\SWC_A8OAC_H('_OT_\ A1_PL7PQ_P!! _\
M?I_\*\'HH^HT^[#^U:W9?U\SWC_A8OAC_H('_OT_^%'_  L7PQ_T$#_WZ?\
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M^@@?^_3_ .%'_"Q?#'_00/\ WZ?_  KP>BCZC3[L/[5K=E_7S/>/^%B^&/\
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M\5S%Y;_9+R:W\Q9/+<KO7HV.XHC4C)M)[!*E.$5*2T9!1115F04444 %%%%
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M)'TO1117SQ]D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH3B,/&G",E?7N4****Z#C%7[P^M?3EM_QZ0_[B_RKYC7[P^M?3EM_P >D/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>.;7PUI$]E/9S3-)*7#(P &0!W^E</16DZ<9KED8TJLZ4N:&Y->3"YO9YU!
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M% !1110 4444 %8_BK_D4]5_Z]7_ )5L5D>*06\*:H "2;9\ ?2JA\2,ZO\
M#EZ,^=**E^SS_P#/&3_ODT?9Y_\ GC)_WR:]^Z/D+,BI02"""01T(J3[//\
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MS >@D-,DGEE_UDKOC^\Q-+]GG_YXR?\ ?)H^SS_\\9/^^31H'O$5%2_9Y_\
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MBBBN8[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+10 FU?[H_*@*!T 'X4M% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !129&<9&?2EH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"^!_A1]AUG_H-G_O@?X5K44 9/V'6?^@V?^^!_A1]AUG_H-G_O@?X5K44
M9/V'6?\ H-G_ +X'^%'V'6?^@V?^^!_A6M10!D_8=9_Z#9_[X'^%'V'6?^@V
M?^^!_A6M10!D_8=9_P"@V?\ O@?X4?8=9_Z#9_[X'^%:U% &3]AUG_H-G_O@
M?X4?8=9_Z#9_[X'^%:U% &3]AUG_ *#9_P"^!_A1]AUG_H-G_O@?X5K44 9/
MV'6?^@V?^^!_A1]AUG_H-G_O@?X5K44 9/V'6?\ H-G_ +X'^%'V'6?^@V?^
M^!_A6M10!D_8=9_Z#9_[X'^%'V'6?^@V?^^!_A6M10!D_8=9_P"@V?\ O@?X
M4?8=9_Z#9_[X'^%:U% &3]AUG_H-G_O@?X4?8=9_Z#9_[X'^%:U% &3]AUG_
M *#1_P"^!_A1]AUG_H-'_O@?X5K44 9/V'6?^@T?^^!_A1]AUG_H-'_O@?X5
MK44 9/V'6?\ H-G_ +X'^%'V'6?^@T?^^!_A6M10!D_8=9_Z#1_[X'^%'V'6
M?^@T?^^!_A6M10!D_8=9_P"@T?\ O@?X4?8=9_Z#1_[X'^%:U% &3]AUG_H-
M'_O@?X4?8=9_Z#1_[X'^%:U% &3]AUG_ *#1_P"^!_A1]AUG_H-G_O@?X5K4
M4 9/V'6?^@V?^^!_A1]AUG_H-'_O@?X5K44 9/V'6?\ H-'_ +X'^%'V'6?^
M@T?^^!_A6M10!D_8=9_Z#1_[X'^%'V'6?^@T?^^!_A6M10!D?8=9_P"@T?\
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M110 4444 %%%% !1110 45S=WXMM[>]FMDADE:%MCE1T-1?\)C'_ ,^<WY4
M=317*_\ "8Q_\^<WY4?\)C'_ ,^<WY4 =517*_\ "8Q_\^<WY4?\)C'_ ,^<
MWY4 =517*_\ "8Q_\^<WY4?\)C'_ ,^<WY4 =517*_\ "8Q_\^<WY4?\)C'W
MLYA^% '545RW_"8Q_P#/G-^5)_PF,?\ SYS?E0!U5%<K_P )C'_SYS?E2_\
M"8I_SYS?E0!U-%<M_P )BG_/G-^5'_"8I_SYS?E0!U-%<K_PF*?\^<WY4O\
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MKJ***"T%%%% !1110.P4444""BBBBX!1111< HHHHN 44447 **** "BBB@
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M^$NM/[7UBP^S_-IT0D8XZ@BF^ O$Y\1:9,DTB/<6C^7(Z=']Q7(#_D=O&O\
MUYI_(T =(?'UB/#VF:M]E.R^F\I5V]#D#^M=I&L<D2N$7#*#TKPM_P#DFWA3
M_K]'_H2U[K:_\>L/^XO\J .4\9J%O/#6U0/^)Q!V_P!ZNPKD?&O_ !^^&?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_'5[HFJP>=I%P_ENCCC:> P^F?TKV#!5[^9?^6=\"?S:K'Q(^'=GXRT5KJ%
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M8_Z^W_G3-:\$:%X@NQ=:C:F68# (<BI/#W_'_K'_ %^/_.M^@#BO^%5>$O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %/B_UJ_6F4^+_6K]: +E%%% !1110 4444 %%%% !1110
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MGQ#T*ST"UU"XNL"9?D3^(^M;FBZ_I^OZ<+VQG5XOXO\ 9^M &IQ17&7OQ/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH *?%_K5^M,I\7^M7ZT 7****
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MCB$WJ=#10.G&**U.E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%%*SZ %13VT5U&8Y5)4^AJ6C)^E--H+')V_@BWAOI+@$HK9X5L=:BB\#*E
M[/*9W\MX]JC>>M=C]:#[5LJ\DK$.$3 LO"UK!8&.5Y/,'3$AK-'@@!@WF.!N
MSC<>:[$DYZ]>M*3GD]14JM*X<J.:O-&M['2W :59 C$'S#Z5L:,S/HUL7))\
ML<DY)XJ'6EWV$K#G$;<GZ4GA^YBN-(MPC9(0 X]:N2NKCT-,9[T4<GJ,5"+J
M%I)(P_S1_>'I6/+*X[DU%5(]2M)(#,LH*!BI/N#BK:_/&LB\JPR*;BT.X44N
M#Z55>_MH[@0-(!(3@#WJ;/L*Y9HHP0>013)94A7=(=HIV87'T4V*19H/.CY3
MUIY4BBS'<2BBBD 4444 %%%% !3XO]:OUIE/B_UJ_6@"Y1110 4444 %%%%
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M9XYIVD1T0G()J?\ X2?4/^@-<_\ ?L_X4 =717*?\)/J'_0&N?\ OV?\*/\
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M.!<0M&#Z$C -<;!J7B*/PPWAUM!OO[2$?V9+K9FV*]-Q?K]WVZT :GPO+?\
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M%C.#AGV?)]<UW^FZQI^KVZSV-U'/&PR"IH O<T<TM% "<T<TM)F@ YHYI:*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6SHZ*;$WFQAMI7OS3JT-[W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 44M(*6@ HHHH **QO#7B.W\3:8U];PRPH)&CVR8SD'':DO?$EO8^*+#
M0G@E::\B:5)!C:H4@8/?O0!M45Q]_P".9;?Q'<Z)8^'M0U&XMT5Y&@>-0 V<
M?>8>AJ]I7BZWU6QOI%L[B&\L03/928\Q2!G'!QSQWH Z*BLCPUXAMO$^BQZE
M:H\:,S(8Y,;E93@@X]Q45[XGMK3Q-9:"L$LUU<HSDIC$:C'+?G^E &Y1110
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M:RAE/4$9%<OXM\$6?B>WB_>O:W$'^IDB.-I^G2@#J,@CCD'O2XKS_4_$5_X
MT[3[:ZMIM2@ VS7*CYATKJ;7Q+IMQI]M=O.L"7(S&LIP30!L44R.5)4#QN&4
M]"*=0 M%)2T %)2T4 9^HZ+IVJQ-'>VD<RL,'<O->>ZG\+;G3YC>>%-3DLI
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5YE\<?\ D0Y?]\?UKTVO,OCC_P B'+_OC^M %SX7?\B)9_Y]*[*N-^%W_(B6
M?^?2NRH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !P<B
M@';THHI TF5KJPM[QU>9,LO2I&MXG@$++E!VJ6BDE'L0J<.PR*WCBB:-%PI[
M5S,,DFE:N8)(TQ+)N!'I73NK%?D;!KE=5T:^FU*.=7+$="!P*SDK/8PJ14=;
M'69)8CMC-)7+VVKRV6J&WO;A3$HQG'>NFMYXKJ(20N&4]#6BDF72JQDA]%*!
MGI251N%%%%%P6H4444 %%%% !1110 4444 %%%% !1110 HI:04M !1110!Y
M/\-_$AT[P[+ -#UFZQ<R?O+6V#H?F/?<*GN=6.K?%O0'.G7]EY=I*-MY"(RW
MS#D<G(K;^%]I<V7A>2*ZMY8)/M,AVR(5.-Q[&F:[9W4OQ5\/W4=O*UO':2J\
MJH2JDL.">@H QXM7.E?%S7&&FZA>[[:$8LX1(5Y?KR*O^!9!J/B;Q#J-WLM[
MV9PC6#?ZR*/ P7'8GTJFVI?\(]\4=8O;S3]2DMKBWB6.2VLY)02"V>5'N*TO
M#UO=:QXZN_$JV<UGIYMQ;Q"9"CS'.=Q4X(ZXY]* (?!@7P[XOU_PX[_NW?[=
M;CT5OF?'XM4G@^(:WXRUWQ*_S1K)]BMCZ*A.3^.X53^)UCJ=E>Z=X@T6UEGN
MT)M94B0L2C=^/3 KK/!NB_\ "/\ A6QT]O\ 7)&#*?[S]S0!O4444 %-YIU-
MYS0 .HDC*%F (QP:Y75/":33VLMJ\GF)("Q:0],UU5&>*:DT(S(M(2*)$>YN
M0W<+(<4_^R8U;'VFYQ_UT-:/;WI.@SU--SD'*9YTF/;Q<W/_ '\-5K[0_/M@
ML=S.6_VI#6S[GK1P>HQ0IR#E.6'AJX&A30>=+YS!L#S#CK5?PYX6N[*.7[7+
M(N5 &R0UV/)X/049/7;FK]J["Y2A_9"<8NKGCK^\-+;Z4$OHY4GF8(V</(2#
M5XC=CG%/B)\U1C@'K4<[8[%RBBBI&%%%% !1110 4444 %%%% !1110 4C?=
M/TI:1ONGZ4 <KX1_X_=;_P"OG^IKJC7*^$?^/W6_^OG^IKJC0!R^G8M?&5]%
MT69 RCU/%=37*ZL!:^+].GSCS4,9S^)_I74YXH 6BBB@ HHHH **** $HI:*
M $KS3XG?$+4/!%W8_9K42VTG,K$9_"O3*R];T&P\06#V>H6ZRQ,#C(Z4 9/A
M#QWI/B^P6:TF43X^>(GD&NIKYG\5?#C7O &H_P!L>'9)7M5;=B/DJ/<"N^^'
M/Q@M=?\ +TW6&%OJ P SG 8_C0!ZW2&D!! (.0><TOUH CF@BN(3'-&LB'JK
M#(-<[XC\#:3XCM88)U>'R,^48CMVG\*Z>B@#SW5O^$@\%:+8Q:' ^I6\6?/W
MG<V,GOS6[IGB^SN-,L[C4!]BFN>%CD/.:Z0@$8(R*Y_Q3X0T[Q3IWV:Z3:Z\
MQ2+P4/K0!OJP90P((/0BEK@-3?Q)X.T2QM],@.IK%D2LWWMM;6E>+K:;3;.?
M5=NGSW)*K%.=AR/K]* .FHID<J2H'C8,AZ%3D&G4 +12#-+0 4AI:* $Q4<L
M,5PFR:-77NK#(J6B@#F=3\!^&]5C99M+MU9OXTC /YUQMQ\.-=T"5IO"VLS*
M@Y%O,Y9?RKUC%&* /)[;XAZ_X=E%OXMTITCSA;E%P#[UV.D^/O#FM;1::@A<
M\;6.*Z"XM(+J,QSQ)(A&"&&:Y#5OA?X<U,,ZV@@FZK)&<8- ':*ZNN5((]J=
M7DC:3XW\#L9-.NCJFFISY+GY@/I6E9?&'2"JIJ5K=6<P.'$D3  _B* /2:*R
M]/\ $.E:I$DEG?V\N\9"K("?RK3S0 M%)FB@!:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ^>=$_Y.IOO^NLW_ *)KZ&KYYT3_ ).IOO\ KK-_Z)KZ&H *
M*** "BBB@ HHHH *\R^)WAC7]5OK*^\/2O%<(I21D_N\_P"->FT4 ?/VD+XV
M\(>)=+N-:NII;6XG$)5B<<@G^E?0->=?%M+J/2]+OK:%I1:WBR,JKDXVM6'_
M ,+?O?\ H$W/_?EO\* /8:*\>_X6_>_] FY_[\M_A6MX8^)LFM^(K?2Y[*6!
MI@2I>,KG'UH ]+HHHH **** $S[&EHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O,OCC_P B'+_OC^M>FUYE\<?^1#E_WQ_6@"Y\+O\
MD1+/_/I795QOPN_Y$2S_ ,^E=E0 4444 %%%% !1110 4444 %%%% !1110
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M:2@ HHHH **** "BBB@ HHHH *?%_K5^M,I\7^M7ZT 7**** "BBB@ HHHH
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M,\.ZK+Y)NA;S?W)5*UUDUK!<#$T,<G^\N:YG6_AWX>UQ<S6:Q2CI)%\I'Y4
M=1%<0SJ&BE20'NK U+7E$GPW\0:*=_A_Q#-C/$<J\#]:C7Q5XW\+2[=<TL7E
MK_SVA8D_EB@#UNBN!T[XM>';O;'<O-:S'JLJ8 _6NLT_7=+U09L;V&;V5N:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_"NQH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXA:=";N[MY!;Q8:3*CI7MNAZD-7T2TU!5VB>,/CTS0!H4444 %%%% !1110
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MDV=K9Z:5_M+4)1# 6&0O=F_!<G\*?I/A.&PNH;Q]8U6ZNE&9%DO6:)F[_)G
M&>W:N:^)%@][XL\)HUQ)! ]PZ,Z'!^XV1^(X_&F^)-"LO!FJZ'JOA]#9RRW8
MMIX48E9T8$G(/?*B@#TVBD'04M !1110 5YI\<V9?AU)M4G,Z@^PP:]+KSCX
MW_\ ).;C_KJO\C0!8^%X!\!V6WK_ /JKL.E<;\+<_P#""6G^?2NRH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@'J XZ4N>,4E% =+!1].*** 6@C*' # $>A'6H/L%IVMX^N?NBK%%
M*R$XI[D L;3YMT*<C@;:R]4\/6UW;R%%5/E[+TK;/04I".C*1PPP>:EQ1E5I
M1:,3P_:Q+I\+[1YFWEO6MHC QTKFK=39:J(TE98 V I/&*Z175PK*P;Z4HVN
M*DU'07'%%'._D<45IIT-D@HHHH&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4^+_6K]:93XO\ 6K]: +E%%% !1110 444
M4 8?C#5VT+PGJ6HQG$L4#&,^C8./UKE(/ VF7/@1KVXMU;6);?[4;\K^^#XW
MC#=?0?2N@^(6GRZEX$U:WA4M)Y#,%'4X!-16VMV9^&BW_FJ(DL/+)SG#!=F/
MKNXH L^!-5GUGP=I]W=$FX\L)*Q[L!@G\ZYGQ9K%CJ'C%='U6^%IHVGPK<7A
M9]JREB0J-ZC*\COFMGP'Y>C>!M+749HK62=0X69PIRPSMY[^U84>F6<7QNNK
MF_C4^?8H;1I/NLV7W >IQB@#JO"J^$98YKGPM'INW.R5[)%'O@XKHZ\^6&"V
M^,(&E!5\RPS?K'TSNXW#L<;:]!H *I:GJMEI,"RWUPD,;':K,>IQ5VJU[8VU
M]$$N8ED53D CO0!S'@>Z@O9=8N+>021/<95AT/)KL*Y'P7#%;W&LQ0H$C6YX
M4=N3774 ':N9\7P%+2"_3AK=P21UQ735GZS;"[TFXBQG*\4 6;283VD4HZ.H
M-3UA>%+CS]$C!.3&2AK<H 6BBB@ HHHH **** "BBB@ HHHH **** $HI:*
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M444R@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *?%_K5^M,I\7^M7ZT
M7**** "BBB@ HHHH 0@,"" 0>H-<W_P@/AT:@;P6;AR^\QB=_*)_ZYYV_I72
MT4 9FJZ!IFM);I?VPE6WD$L0#%=K#H>*;K/AW3-?MHX-0MRZQG*,CLCK]&4@
MC\ZU:* ,K1?#NF:!'(NGVY0R'+N[L[M]68D_K6K110 4C?=/TI:1ONGZ4 <M
MX1_X_=:_Z^?ZFNJKE/"/_'[K?_7S_4UU= !36 92IZ$8IU)0!RNA/_9FO7>F
M2\"0^9'CI_GBNJ%<QXJ@:U,&K6XQ-"X#'U7/-=%:S"XMHIA@AU!XH FHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "DQ2T4 ,DBCF0I(BNIZAAFO
M/O&7PFT3Q):RO;PK:WF,JZ#&3[UZ)24 ?*T%UX\^&=W) (IIK2-N,\H1_.O0
M?#/QYLKV:.VUFV:WE8@;P.,U[#<V=O>(4N8(Y5/9US7#:W\(/"^L7"SFV,+A
MLGR^ : .\M[B.YMXYXFW(XW*1Z5)FH+*TCL;*&UA_P!7$H49]*SO$?B73?#&
MG?;-2E\N+.![F@#8S17/Z1XUT'6XU:TOXSN&<$@&M]2&4%2"#T(H =12"EH
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MY\+O^1$L_P#/I795QOPN_P"1$L_\^E=E0 4444 %%%% !1110 4444 %%%%
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M%>*>#_&OBH^+K*PUZT>&&ZW*I?'4 G^E>U AAD$$>U "T444 %%%% !1110
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M\/ZQX?\ ^%UQ?\([IMO)IT[;0&B'RG'5/2OIJ@ HHHH **** "BBB@ HHHH
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M*J6,"J/X1S5D CJ<U:B]S2GS6"BBBJ- HHHH **** "GQ?ZU?K3*?%_K5^M
M%RBBB@ HHHH **** "BBB@ HHHH **** "D;[I^E+2-]T_2@#E?"/_'[K?\
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MM/TG[+K5P+B9&(63')6NBH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#YYT3_DZF^_ZZS?^B:^AJ^>=$_Y.IOO^NLW_HFOH:@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;[I^E<7\/F4#6
M\D#_ $^3O_M-7:'D$5Y+<>$O%]GJM^^ER(MO<3-(!N(ZDG^M 'K08'H0?H:6
MO/\ P.=>M=>O;#6G#%8D=,-GKG_"O0* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH YS5]>T"ZNY?#=W?*+J==AA4_-R,UYMXC^%WPV\*60
MN]8N[F"-C\HW!F;Z #)KG%OK32OVAY[C6'$2!@4>3H..#^54/$$\GQ<^+D>F
M6D['3(3M5EZ! ?F8?48H ])^&&E?#EKN2\\+R&XNXQ]Z<%74>P(%>JU\S:=H
MR> ?CG9Z?I<[O QP5)[%<8/\Z^F: "BBH[AS';2NOWE0D?E0!S%YXRF.JW-A
MHNC2ZLUH/])DCG6-8SC.,M]X_2M3PWXAM?$NE+?6RO&0Q26&08:-QU4UROPC
M'F>&[^Y?F6?4KDN3WQ*]2^"P8?&OBRW0XA^TB0*!P&);/\A0!WE<G:^/=/O/
M'L_A2WB:2>"'S7G5P5'3Y?KS^E6/&/B%M%TY(+1?-U*];R;6(=2QZM] ,G\*
MX7P]H*>'OBO8VI;?</ILLMQ)W>1G0MSZ9)Q0!Z]1110 4444 %>3?'>TFE\+
M+<K<LD4?#1#HY/>O6:\R^./_ "(<O^^/ZT 7OA=QX$L\XR!D#\J[ G)S7&_"
M[GP)9Y^G\J[*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "C%%** #%&*6B@!,48I:* $Q1BEHH 3%
M&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $
MQ1BEHH :161KJN4BVH6'/05L&FL-PQC.*EHF2D]C(_MB"VTY""=Z*!M*FIH-
M:MYD+.VP^@4U9GL8+A"IC SUXHALX8E*^6ISZBI2=S*TTQG]JVBC_6,?^ FH
M[G6+6&W9U8D@9^Z:N?9XL?ZM/RJ*>RADA=2JX(]*;;')SL4=-UZ"_P Y8"3L
M *U0Q*AE&<USVC64-KJCH%#?("..G6NC/RG^E";'1<KA12GK259L]PI\7^M7
MZTRGQ?ZU?K0(N4444 %%%% !1110!6U"^ATS3KB^N&VPV\;2.?8#)KAO^$B\
M8S:+)XCM[?3QI@_>)9M&WGM&#@G=NQG&3TK3^)YD'P\U;R\Y\DYQZ8.:T;5(
MU\!Q*,;/[-&?^_?- &AH^J0:WI%KJ5MGR;F-9%!ZC(SBIKZ]@TZQGO+EPD,*
M%W8]@!DURWPO&WP'8CG;EMN?[O:LSQ%JD'BCQ.OAB.[CAT^T*S:A*9 H<@\1
M<_3GV- %GX<>-[WQH=8>ZMD@CM;GRX %(8I@$$Y]<UW=>9_#.6UC\1>*X(98
MMOVQ!&JN.0(U'%>F4 %-;[M.K)U^POM0LTCL;H6\BMEF/<8Z4 9?A'B^UK_K
MY_J:ZJN+\ P3VW]K0W,OFS)<?,_KR:[2@ HHHH **** $]ZY#6P-'\1VNIJ"
M5G(CD'U__7785EZ]8?VAI4T2J#(!N0^A% &BK!E5AT89%/K"\+WYN]*6.5\S
MP'8X[C%;F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**6B@"-H8G^]
M&A^JUD:KX4T364*WMA#)D8SMQ6W10!Y'J?P%\/W;,UH[6S$\;:[;P1X0@\&Z
M(-.AF:7YBQ9JZ:DQ0!'/O\B3RO\ 6%3M^N.*^<-:UGXFZ5K-TRBY>/S#MVH2
M,9KZ3Q37BC?[R*WU% 'S-'\4O'^FD-=VERR#D[HC6]:_M$,-BW>F[<<.0#7N
M<VF65PA66UB=3U!05SMY\./#%[&Z/IL*[^I50#0!D>'_ (Q>&=< 0W'V>0G&
M)/E'ZUW]O<0W,*S02))&W1E.0:\:U[X Z=<%I=)N6@D[!B:]%\$>'9O#'AN#
M3;BY:XD3JQ.: .D^M%5[V62"QGFA7?(D9*KZD"OGJ7XT^+--OITN],;8KD!=
MG3F@#Z-I:X+X;>/Y/&UG,TUF\$D)P21@&N]H **** "BBB@ HHHH **** .<
M\6^)FT"&TM[6'S]1OY?)M8CT+8)R?8 &LM/$'B#0M?L+#Q']AGM]0?RH;BSC
M9 C]@P8GKG]*J^*P6^*7A(-_JUWLN?[V&_I5CXG!3IVB[?\ 7?VM;[,=>] '
M<UQWQ%\:GP9H/GV\0FOYF"01E2PSGDL!VQFNFNKV#3=+DO+N01PPQ;W8]@!F
MO)=4FBU_PYKOBB_N8E>6'RK"U,BYCC#K\V,]3C/XT >J:#?RZIH%A?3*JRW$
M"R,%' )&>*T:P?!<L<O@W2?+D1]MK&#M8'!Q6]0 4444 ?/.B?\ )U-]_P!=
M9O\ T37T-7SSHG_)U-]_UUF_]$U]#4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >1_$Z;Q9I7B&"^\,PR2>?%LEV
MJ3C'3^=<)<^-/BA8P_:+N&6*!"-[M&< 9Q7TL0#U K'\4:(-?\.W>F;MGGJ!
MN Z8(/\ 2@"30M1%YH-C<SRJ998$=SGN0":T/M,/_/1?SKP_5OAOXOT^RA32
M]:N)=N%V9Z"L;_A"?B1_T$+C_OJ@#Z)^TP_\]%_.GI(DGW&!QZ&OG/\ X0GX
MD?\ 00N/^^J]0^%VD:_I&FWL>OSO+*\BF,N<X'.: .^HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#SGX@_"/3O'5ZE^+MK*] "M*J;@X'3(R*N?#_X8Z;X
M#BE>&8W5[*,-<,N./8=J[JB@#S33?A.UO\0&\6ZCK1O9R[.(O(V 9&!SD]*]
M+HHH *1E#*5/0C!I:* /.M%_M#P)=:CIK:1J-]97$[W-K-9PF4*78L5;TY;]
M*NZ)9:KH.AZQKTVGM<ZO>N]S]BC//JJ#CKU[5W%% '&R>$[;Q6]CK^H_VIIF
MIK#M$<%TT9BY/'3WKG/^$$N8OBE:W"W>N26*6;9NWNF8[\KA-WH>>/:O5:*
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M7?E9!]MIJ:W\8W5CJ$5CXFTO^S9+B01V\L4GFPN2,X+X&#[5G^'O^2L^)/\
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M)(]NI+'U)KH:* . \%?#ZW\.Z_K&H2Z;8QB6X#631*"T:;0"!Q\O.:[^BB@
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MMYX?O+?2_#VEQ7SH!"_DJN#D=\<<9KN:* ,/PEX?M_#GAVSL8K2"WE6)?/\
M)  9\<GWK<HHH **** /G/0'D/[4-XS#YS+-G_OU7T97SSHG_)U-]_UUF_\
M1-?0U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M87"(,LT3 #U)%3T4 <E\.-+O='\()::A;M!<"YG<HV,X:1B#QZ@U%=:3?O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\\Z)_R=3??]=9O_1-?0U?/.B?\G4WW_76;_P!$
MU]#4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7F7QQ_P"1#E_WQ_6O3:\R
M^./_ "(<O^^/ZT 7/A=_R(EG_GTKLJXWX7?\B)9_Y]*[*@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "C-%% "YHS244 +FC-)10 N:,TE% "YHS244 +FC-)10 N:,TE% "YHS244
M +FC-)10 N:,TE% "YHS244 +FC-)10 N:,TE% !1110 4444 %%%% !1110
M 4444 %/B_UJ_6F4^+_6K]: +E%%% !1110 4444 %%%% !1110 4444 %(W
MW3]*6D;[I^E '*^$?^/W6_\ KY_J:ZNN4\(_\?NM_P#7S_4UU= !1110 444
M4 %%%% !2<TM% &%XDTP7-K]KB^2ZM_G1QU..U6- U3^U-,29AB1?E<>XK38
M @ANA&#7(23'POK8 !-A=-\P_N-0!V-%,1E= R$%3T(I] !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?/.B?\ )U-]_P!=9O\ T37T
M-7SSHG_)U-]_UUF_]$U]#4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F7
MQQ_Y$.7_ 'Q_6O3:\U^.11?AY*6QN,RJ#^!H L_"[_D1+/\ SZ5V5<=\+A_Q
M0EGC_/2NQ/6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "GQ?ZU?K3*?%_K5^M %RBBB@ HHHH **** "BBB@ HHHH **** "D;[I^
ME+2-]T_2@#E?"/\ Q^ZW_P!?/]375URGA'_C]UO_ *^?ZFNKH **** "BBB@
M HHHH **** $QFL[6=*BU73Y('X;'RMZ&M*@]* .<\-7TB(VE7IVWEOQ@_Q+
MV(KHJY;Q79SPM!J]FI\ZV/S8[KW_ )5KZ-JT.K62S1GYL89?0T :6>:6D%+0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/.B?\G4WW_76;
M_P!$U]#5\\Z)_P G4WW_ %UF_P#1-?0U !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G
MQ?ZU?K3*?%_K5^M %RBBB@ HHHH **** #IUKGY/''AJ+4#8OJT(N VPKM;
M/IG&/UJ/Q[J<ND>"=5NX6*RK P1AU4D'!JA:>';+_A5W]G20J8Y;+SG'JY&_
M/UW<T =D"& (((/0BLO5_$FD:#Y?]IWT=N9/N @L3^ !-97PYO)[WP-ISW#%
MI8T\HL3G.WC-;@TBQ&LMJWV=/MS1"$S8YVC.!^IH -*UG3M;M/M6FW:7$.<;
MES_(\U>KSKP4\%Q\0_$]QIBC^S@51V3[C387/XXS7HM !2-]T_2EK,UO5AI%
MJDQMII][;=L2[B.* ,CPC_Q^ZU_U\_U-=57&> [L7QU:Y$;Q![C[CC!')KLZ
M "BBB@ HHHH **** "BBB@ HHHH :RJRE6 (/!!Z5Q_V;_A&/$'GC(T^Z.#Z
M(W^<5V55[RTAOK62WG4-&XP0: )8Y4E0,C!@>A%.KBC#JWA9F=-UW8Y^YU*B
MNDTO6+;5;5989 '/#)GE30!I44#I10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%Y>VVGVKW-
MW,L,*#+.QX%9ND^+-"UR=H--U&.>51DIM93^H%<MXZ_XF7C/POH<N39RSF>>
M//#A5; /XX/X5+\0X5L;[P_KL*@7,&H1P%AP2CGE?I\HH [WH,FN>N?'7AFS
MO6M+C5X4F5@K#:Q )]P,?K6Z5$]L4?[LB8./<5SGB&ST/0_ ^H6TEM!#IYB;
M,6T ,Q.?S+'- '3*RNH96#*1D$'(-+7*_#>&[@^'^CQWH<3"W7Y7Z@8&!754
M %%%% 'SSHG_ "=3??\ 76;_ -$U]#5\\Z)_R=3??]=9O_1-?0U !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXN%@SE87.TX'H#DF@#T&BD9E12S$!0,DGM7/-X\\)HQ5O$6FAE."#<+P?SH
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M ./&[DM_IS0!U.]?[P_.E^E<A_PB6H)\R:O(6'3*G_&D^Q>+$.Q+J,J.A+4
M=A17'?9O%R_,;B,@=MW6G#7/$47R-I8<C^+=U_2@#L**Y >(=>3F32?E]C_]
M:GCQI&O$EC<AN^(S0!UE%<H/&]JI_>6MPB]V,9P*Z.TO(;VV6>!PR,,@YH L
M44FX>HHW#U% "T4FX>HHW#U% "T4FX>HHW#U% "T4FX>HHW#U% "T4FX>HHW
M#U% "T4FX>HHW#U% "T4FX>HHW#U% "T4FX>HHW#U% "T4FX>HHW#U% "T4F
MX>HHW#U% "T4@.:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/GG1/^3J;[_KK-_Z)KZ&KYYT3_DZF^_ZZS?^B:^AJ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KS+XX_\ (AR_[X_K7IM>3?'>_@A\*+9-(!-,=RICJ!U_
MG0!L?"S_ )$.T_SZ5V5<;\+2/^$$M.V.OZ5V76@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "G4VG4 %%%% !1110!Y59:/=ZK\4/$@M=;
MOM,V*A)M0GS].NY37>>'_#=GX?BF\IY)[JX;?/=3',DI]^WY5/::%86.KWFJ
M01,MW=@"9BY(./;M6E0 UR0C$+N./N^M<:^H:B)& ^'KN,GYO.M^??K7:44
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M?X4?\(A??]!>?\Q_A78T4 <=_P (A??]!>?\Q_A1_P (A??]!>?\Q_A78T4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-']HV'_/_:?]_P!?\: +-%5O[2L/^?\ M/\ O^O^-)_:6G_]!"T_[_K_ (T
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MOVZT_P"?J#_OX* +%%5_MUI_S]0?]_!1]NM/^?J#_OX* +%%5_MUI_S]0?\
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MN_\ "IOB-_SV'_?YO\*4?"/XBL,_:5'UG;_"OJ&B@#Y?_P"%0_$7_GZ3_O\
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M?^NK?X5]&44 ?.@^ 'B3/.NIC_KJW^%._P"&?M?_ .@ZO_?QJ^B:* /G27X
MZY%!)(^NCY%)P':N<\(_"W5?%?VWRM7,7V68Q'<YYP3_ (5]6LJNI5@"I&"#
MWJCIVBZ9I'F_V=8PVWFMOD\I<;CZF@#PD?L]:OCG7N?]XTH_9YU0_>U\_@37
MT)10!\^_\,\:C_T'V_6E'[.UYCGQ ^?I7T#10!\_C]G:Z)Y\0/CZ4[_AG2;_
M *&"7_OFO?J* / A^SFY'S>()<^R4O\ PSD?^AAF_P"^!7OE% '@O_#.$?\
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M<_:C_P!M6_QI1^S_ .#L\K<G_MJW^->K44 >5_\ "@/!G_/.Y_[_ #?XTX?
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M9:"LQMC-+/.VZ:XN'WRRGI\S=^,#\*UJ "LS6]%AUNU2":1T5&W H>>E:=%
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M]C_%L?\ ,&O/^_2?XTG]E?%H==%O/^_2?XU]4T4 ?*W]F_%@==%N_P#OVO\
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M/RHVCT'Y4 ?)L>K^-(V<MHMR^XY )/%2?V]XP'709_S-?5VT>@_*C:OH/RH
M^4/^$A\6CKH$_P#WT:/^$D\5CKH$W_?35]7[5_NC\J-J_P!T?E0!\H?\)/XI
M'70)O^^FJ&#Q)XIA#;]%N),MD;F;BOK7:O\ ='Y4;5_NC\J /D__ (2SQ(.O
MA^;_ +[:C_A+_$0Z^'Y?^^WKZPVK_='Y4;%_NC\J /D[_A,M?'7P]+_W\?\
MPH_X3770<GP])_W\?_"OK'8O]T?E1L7^Z/RH ^9-!^+7BG0()84\/M,CMN D
M9OE]NE:__"^_%(Z^%8_^^F_PKZ#V+_='Y4;%_NC\J /GS_A?WB8=?"D?_?;_
M .%;?A+XSZ[X@\26NF7/AQ+>*9L-*';Y?S%>T;$_NK^5+M4=%'Y4 +1110 4
M444 %%%% 'GOBL!/BCX2DD(",71<_P![#'^56?B9B2QT2V49FDU:#:/SS6YX
MH\-1>([.%1,UO>6T@EM;A>L;],^XP2/QK/T_PMJ<VLP:GXDU2#4);7_CUCM[
M<PHA/5B"QR>!@_6@#7\0HS>$-5C7[YL)E'U\LUC_  _=/^%=Z>000D+!B/49
MS6C:Z-J,7B2_OKG5Y+C3KB,)'8LORQ'G)Z]ZP5\%:WIPNK'1=?BM='N)"YMY
M;<R/'N.7"/N&,DGMWH =\+ESHNIS 8CEU2X9/<;J[FJ.D:3::'I<&G6*%8(5
M"KDY)]R>YJ]0 4444 ?'_BKQ9>Z+\8-7U_1I!%<+.PC:1 V 4"G@\>M7/^%\
M>//^@A;?^ L?^%?1US\._!]Y<R7%QX<T^6:0[G=H02QJ+_A67@C_ *%C3?\
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M:_X4O_#0?BS_ )YVO_? _P *]Z_X5EX(_P"A8TW_ +\BC_A67@C_ *%C3?\
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MB[FN?*65W;^Z%;C'OFL_POKFJCQ#J?AO7)4NKJT"RQ7<:!!)&V2,J. 1QTH
M[&BBB@ HHHH **** "BBB@ HHHH **1F"J68X4#)/I7F>B^/M2UOXMR:-" N
MAK;RE"4&9'0@$ANN.?UH ]-HHHH **** "BBB@ HHHH **** "BF32I!"\LA
MPB*68^PKB=*OO$7C&.74].U9-)TLN5M=MLDS3)_?.[IGCI0!W-%16Z2QVZ)-
M-YTBC#2;0NX^N!TJ6@ HHHH **** "BBB@ HHHH **YWQKXBD\-: UW!$)+F
M1Q%"K=-Q]:P+O5/$OA.\T>75]4BU.UO9EMYU%ND1B9B "I7[PY/7TH ]!HI
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MC^18;6U2\806B$_QMP#]!Q6-\(KN]O/!2R7]Q+/<"9PS2.6.<^IH [VBBB@
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M "BBB@ HHHH **** "BBB@ HHHH **9)-%$ 9)$3/3<P%.5U=0R,&4]"#D4
M+1110 4444 %%%% !1110 4444 %%8-]XU\-Z;>FSO-7MXK@$ H<G!_ 5MQ2
MQSQ++$X>-P&5@>"* 'T444 %%%% !1110 4444 %%%% !12,RHC.Q 51DD]A
M5+3-8T[6H9)M-NX[F.-S&S1G@,#@C]* +U%%% !1110 4444 %%%% !1110
M44C,J*68@*.236#!XV\-W.IKIL&K027C2>4(E#9+>G3% &_1110 4444 %%%
M% !1110 4444 %%4-5UO3=#MUGU.\CMHF. S]S^%)I.MZ9KMJ;G3+R.YA#%2
MR=C^- &A1110 4444 %%%% !1110 4444 %%56U&S6_6Q:YC%TZ[UBS\Q'K2
M:CJ=EI-F]W?W"6\"?>=SP* +=%96D>)=&U[>-+U"*Y,?W@F01^=:M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
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M3J "BBB@ HHHH **** "BBB@#@?BR /"]K@?\OT?\FI?BLK-X'AQPHO;8O\
M[NX9K:\9^')_$^D0V<$\<+1W"REI 2"!GCCZUI:SHUMKNB7&EW>?*GC*%EZJ
M<8R/<4 9?B9HQ\/KPMC9]BX_[YXJ;P1&T?@C15<8/V*(_P#C@K#_ .$5\37V
MG6^BZKJEB^E1, [PHXGE13E0V?E[ ' KN(88[>%(8D"1QJ%51T '04 /HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSZ<6N+BX?<78,HX]!6[KK?VO\6-%TF?)M;2"2[*=F<;2I(]N:+K_ )+9:?\
M8-;_ -#6E\18T/XF:/KMP ME/"]K+*1Q&QV[<GL.O/M0 >+8ETCQWX9U:U0+
M)<2/:S <!DVG&?H3FO0*X#6YHO$_C?0;33I4G@L&>YN)HSN094A1D<9R.E=_
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!@:WX/TG7KJ.ZN1<PW"# FM+AH7(]"RD$BM'2=(LM$LEM+&+9&#DDG+,?4G
MJ3[FKU% !1110 4444 %%%% !1110 4A 92K $'J#2T4 8S>$O#;,6;0-,))
MR2;1.?TK0LM.LM-A\FQM(+6(G.R&,(,_059HH **** "BBB@ HHHH **** "
MBBB@ ZU!;6=K9JZVMO%"KL781H%W,>I..]3T4 %%%% !1110 4444 %%%% !
M1110 CHLB,CJ&5AAE(R"*H66A:1ILQFL-+LK64C:7@@5#CTR!6A10 4444 %
M%%% !1110 4444 %%%% %6^TRPU2)8M0LK>[C5MRK/$' /J :+'3;'3(C%86
M=O:QDY*P1A 3]!5JB@ HHHH **** "BBB@ HHHH **** (#9VQNQ=FWB-P%V
MB78-X'IGKBENK2VO;=H+N"*>%OO1RH&4_@:FHH J6.EZ?I<;1V%E;VJ,<LL$
M00$_@*MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2+>.V#9.#C' /UYKIOA)XQNT\977AQ=5?4]+96-O/)G(P>.H!Z4 ?0%%?/\
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M0Z@@DD'H< 9I_AWQCH/BL3?V+J"77D@&0!67;GIU H W:*** "BBB@ HHHH
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M5>$-+\8Z>EGJ@F\N-MRF)]K _7!KG-%^#/A'1+]+V."YNIHSE/M<H<*?;@4
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MC(P.15W1]6CUFS:YCMKFWVR&-HKF/8ZL.N1DT :%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6+K^G7.H2Z>UNH(AGWOEL8%;5%
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M"B[:PVR-$ET4P6CSL#>V><5XQIWPI\?Z)J=]>Z3XITV"2[E9W=HB[')]60T
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MP_U%/!LVBR:A#+<2:@EWYS X(5E)!XZ_+6[XA\-W&LC0_*GBC_L^Y$TF_/S
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M4[ZR$D5JT AMPVU"3D$9&?SIEUX8\0ZW<6":S+I/DV=PDXN;8/\ :&*]LD8
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MT^6R,-S%'#<QS[MP5<\KCC/)ZU/X9\.3:++K;7,L4JZC>&X4)GY5**N#GO\
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M4N-TD/\ K67G*QC^\>W!KC?"?B*:?Q+J6D+>ZK=67V(31MJD+)*&.[/4#*X
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gzbwht3f4aft000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *7!?$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA3C*G-M;(WQ=:<*U*,7HWJ:&J^/KC3M<GLA91O##)L+;CN(KK+S4EAT.74H
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MC..C%034E&(Q/ME'2U@P6"^K.7O7O^%CS?QS_P CEIG_ %RC_P#1C5W&N_\
M( O_ /K@_P#*KKPQ2,&>-&8="5!(IQ 8$$ @]0:F=?F4%;X2Z>%<)5)7^/\
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M4ZLJU5U9N;-L+06'I*FN@4445D= 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -\Q/[PH\Q/[PJI1
M0!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH
M\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10
M!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\
MQ/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!
M;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q
M/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;
M\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/
M[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\
MQ/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[
MPJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q
M/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[P
MJI10!;\Q/[PH\Q/[PJI10!;\Q/[PH\Q/[PJI10!;\Q/[PI0P;H<U3JQ!]T_6
M@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M P_$'B:WT+R8O*>XNYO]7 G4UE3>,M1TUHGUC09;6VD./-64/CZ_X50OC_Q=
MBU$^-H0>7_WR<?K6WX\,0\(7GF8W$ILS_>W#^F:9)T,$T=S!'/$P:.10RL.X
M-25Y=JTUW:^"/#I2:2*4N<$'!QV_3%6]3L[GPWK6B7%OJ5U,]W*$F\U\AN5S
MQZ?-18+GHU9ESKMG::U;:3)YGVFX7<F%^7'/4_@:IWWBRVL+Z2T>PU&1D."\
M4&Y3]#FN3U[2+>?XA6$!EN EZOF.=^&4G=POH.*$AMGI=%><>)K>ZB\3:/I5
MC>S0AH!"KER3CD9/J<4OB,WWA[3]-T.UN[F?[3*S/(IQ(XR,*#^-%@N>C45Y
MOHT&MV7B&S:UL=4ALG8+<+=/O!!ZGH,4FNSZ1-JU\&O]8N;@$X6U&4B/I]!1
M8+GH%_?0Z;837EQN\J%=S;1DXHT^^AU*PAO+?=Y4R[EW#!Q7G%N9=8^'5Y+>
M7$[O92$QG?UX'#>HYK1TO3(['X?7.HPSW'G3V39!D^5>OW1VHL*YW]%>4KI]
MS-X#_MU]4N_M$7$2"3"JH?;CZ]\T_5+>]A\*67B)M5NWOI77^/"@'. !^%%@
MN>IT5YYXJUG4)VT6Q@,^+NW6:5+<[7D)'0'\#3O#<.LVGB2%8[/4H-,D4B5;
MMM^#@D'.!WQ18=ST&H;NZCLK2:YESY<2%VP,G KSG0M/GU_6-8MI]1NHK>*4
MMLC?&6)('/H/2DTOSM4\':Q:WES,XL7+1,'YX!X/J*+!<] TK4[?6-/2]M=_
ME.2!O&#P<5=KBOA[I,,>D0ZF)9S-(&0H7^0#/8>M=K0P6P4444AA1110 444
M4 %%%% !1110 4444 %%%% !1110 R5_+A>3&=JDX^E<1;^.=5NK.:]@T#S+
M6$XD=9^5_#&:[6Z_X])O^N;?RKRSPS?ZG'H%_8Z?I4MRT[E?.!^5,C'--"9Z
M/HFLV^NZ:E[;@J"=K(W52.U:->9WT6H>$?"5I81S>5=7TY\UT/W!@< _ES4O
MB'2I_"=O::E8:G=M,) L@E?(?\/3VHL*YZ/5#5]7M=$L3>7>_P H,%^1<G)K
MB_%37SZM;75ZMZ=&:!219M@JQ'.?Q_2J7B&WL+CP3;WMG?W5RL,NQ3*W(R>C
M#U%%@;/3()DN+>.>/.R1 ZY]",U#J-_#IFGS7MQN\J(9;:,GKBN?T[[)X4T"
M"Z"7]T+E8V94_>%3M[#C JEXDO+;Q%X1O;I(;ZW^R$$+,OE[B<=1SD<T6'<Z
M[3[^'4["&]M]WE2KN7<,&K->?Z3ID=E\/[C489[CSI[1L@R?*N"?NCM4/AFQ
MO/[(7Q%-J4TGV:*0I;DG:0H/!_&BP7/1J*\?MCJVKV<E]]GU:YNG8^7/!+B-
M3Z;<5U%]=$>$-._X2"]O+.Y+$/'"/WDN"0 ?PP:+!<[BLRWUVSN=:N-*C\S[
M3 -SY7Y?P/XUP.B7WV;QG9P:?+J*VDXP\=[U/!I=,\/6LWCJ_P!/:XNQ% NY
M7$N'/3J<<T6%<]0HKSR^AN-2^)5UIOVVX@MY(E+B)\$@(IP/3FJNCZ9<WGB/
M4M"?5;Q;&V);"O\ ,W.!S^-%AW/3:*\Y\-ZQ>V&C>(T:9YO[/(\DR')!)8?T
M!K&MX]8O[ 7L-OK$UZYW+<I+^[//IC^M%A7/7Z*\X\3W>J?9/#AFEEMKV0XD
MQP0V0,D4^[M9_#/BW24MK^YF6Z($PF?(;G!HL.YV+:[9KKPT<^9]J*;Q\ORX
MQGK6G7F5WH5O/\2&L6GN1'*AE++)A@2,X!]*]*BC$4*1J20BA02<GBA@A]%%
M%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?\_\/YU8M-3LKYV2UN4E91DA3T% 7+=%%8VH^&[;5KMIKNYNF3: D22E53W
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MATC_ )_X?SH"YIT5F?\ "0Z1_P _\/YT?\)#I'_/_#^= 7-.BLS_ (2'2/\
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MI4WAW;X1T2&+4_-4[C<L/D[_ 'VQ7>>"/#%MX4\,6UA!:I;S,JR701RP:7:
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M+&7_ ,(YH_\ SX1_F?\ &C_A'-'_ .?"/\S_ (UJ44!8R_\ A'-'_P"?"/\
M,_XT?\(YH_\ SX1_F?\ &M2B@+&7_P (YH__ #X1_F?\:/\ A'-'_P"?"/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %6(/NGZU7JQ!]T_6@"6BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HK"U#QGX=TJ^DLK[588+F+&^-@V1D CH/0BJO_"Q/"7_0
M;M_^^6_PJU3F^C,W5IIV<E]YT]%<Q_PL3PE_T&[?_OEO\*/^%B>$O^@W;_\
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M^@W;_P#?+?X4?\+$\)?]!NW_ .^6_P */93[,/;4_P"9?>=/17,?\+$\)?\
M0;M_^^6_PH_X6)X2_P"@W;_]\M_A1[*?9A[:G_,OO.GHKF/^%B>$O^@W;_\
M?+?X4?\ "Q/"7_0;M_\ OEO\*/93[,/;4_YE]YT]%<Q_PL3PE_T&[?\ [Y;_
M  H_X6)X2_Z#=O\ ]\M_A1[*?9A[:G_,OO.GHKF/^%B>$O\ H-V__?+?X4?\
M+$\)?]!NW_[Y;_"CV4^S#VU/^9?>=/17,?\ "Q/"7_0;M_\ OEO\*/\ A8GA
M+_H-V_\ WRW^%'LI]F'MJ?\ ,OO.GHKF/^%B>$O^@W;_ /?+?X4?\+$\)?\
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M+!<U:*RO^$DT?_G^C_(_X4?\))H__/\ 1_D?\*+!<U:*RO\ A)-'_P"?Z/\
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M* "BBB@ HH)P,F@$$9'- !1110 4444 %%%% !1110 4444 %%%)D9QD9]*
M%HHHH **** "BBD+*#@L ?3- "T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !5B#[I^M5ZL0?=/UH EHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \(\81QR?$K7=Z*V!!C<,_P#+):S?LUO_ ,\(O^^!6IXM_P"2E:]](/\
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M^S[+_GSM_P#OTO\ A5FB@"M_9]E_SYV__?I?\*/[/LO^?.W_ ._2_P"%6:*
M.=UJV@@U/1C#!'&3=#)1 ,]/2NBK"U__ )"6B_\ 7U_A6[3$%%%%(84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% %*BBB@ K(U_Q3HGA>".;6M1B
MLTE.$WY)8^P )/Y5KUYA\6/AG?\ CJ6PN],O((KBV1HVCN"0C*3G((!P?PH
M]&T_4;/5;&*]L+F.XM91N26,Y#"K-<O\/O";^#/"5OI$MR+B97:21USMW-V7
MVKJ* "@YQQUHHH \ZO\ PSX\OH+G4)/&'V&Z7<\%G:0#R0!T#$\GCO5OX?\
MBG5_%?P_DOG2 ZO"9( S#$<DBCY20.@/&<4>//$]PN/"OAY?M'B"_39M7I;1
MGK(Y[<=*WO"'ANW\)^&;32+=M_E+F60]9)#RS?G0!POB/1_'>A^'KKQ'_P )
MH\UY9QF>6T%NJP%1R0/PKO?">LOXA\*:9JTL8CDNH%D=5Z ]\>U<9XVU*X\:
M:@? WA]MT;,O]KWB_<MX\YV9[L<=/_KUZ%INGV^DZ9;:?:)LM[:-8XQ[ 8H
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MD%_-?&WD,2X,D9 R#CJ.?UJ"STNRU+]H35S>VZ3_ &;38YH@XR%?*C./7!-
M';6?CSPM?Z;<:A;ZW:FVMN)F<E"F>F58 \]N.:L:%XMT'Q-YHT?4HKIH?]8@
M!5E]RK ''OBN G\.Z3/^T %DLHFC_LM;LQX^0RABH8KT)P*OSVT-E\?-.:UB
M6'[3I,GG!!@/@\9'Y4 =7=^-O#=@]\EWJT$+6,@BG5PP*N1D*!CYCC^[FK.A
M>)M%\2P23:/J$5VD9VR!<AD/NI (_$5YYX0TFPO_ (R^-[J[MHYYK22'R/,&
M0FY3N('3/RCFK ABTO\ :"BBTY%CCOM*,EW'&, L&."1Z\#\Z )_A42=7\:9
M)/\ Q-F_D:Z*^^(OA'3=0:QN]=MDN$;:X 9@A]&8 A?Q-<#X:N[BPT/XG7=J
M2+B&ZF>,CJ&"-BH_!/\ ;\?@2RM[7X?VVH6EU#ODN9+Z$&XW9)9@3G\^E '=
M>/?&=KX<\'3:A:W\2W5Q$38.$,BR-P<C (Q@]^*=X'\;Z;XJTNUB2^$^J);+
M)=((70!N_) '7T-<:-#U;0_@+K-AKEL(;B%)3#&9%D\N,L"HR"1700S2:9\$
M3?62+'=1Z*71U49!\OK^'6@#8O?B+X0T[4&L;K7;9+A&VN &94/HS %1^)KH
MA=VQLQ>"XB-L4\P3;QLVXSG/3&.]>-^#1KZ> K&TM?A_;7UG<V^Y[A[Z$-<;
MN2QR<@G/?I5/7;'7O#7P&_LO55:TF:^$+*LJOY<#/D#()&* .P\6>/O"VL^#
M/$-AI^M6\UT=/G"H-R[SL/W20 WX$UO?#@D_#CP^2<_Z%'_*LWQ[X:T1/AAJ
MENFGVZQV5B[VQ"@%&5<J0?P_&M+X;_\ )-_#W_7E'_*@";Q-8>(]3DM;71=4
MBTRV.XW5SY>^7M@(#QZ\UQEEJ/B7P?\ $G2O#NIZT^M:=JT;&.2>,+)&R@^G
MT_6O2=4U2RT739M0U"X2"UA7<[MV_P 3[5P/A'3+[Q9XN?QWJ]N]O;I'Y.D6
MK_>6/G]XWN<\?6@#K/%_B./PQX?FO=OFW3D16D ZRRMPJC\?T%<?\,]0\1/X
MG\1Z5XAU*2\FLU@;:V-L;.NY@OL,X_"L_6/$UJ_Q2DN-<LM2-AHHV6,4-F\B
MR3'[TI(&..@JOX*\8:=-\5O$TBP7X74Y+=(,VK@J0@'SC'R_C0![!=W4-C9S
M7=P^R"%#)(V"=J@9)P.>E5K/6M.U#15UBUNDDT]HS*)P"!M'4\\]C5V2-)8G
MCD4,CJ593T(/6O"[349]#^&_BCP<'8WMMJ']FVRD\M'.V%_3?0![-I&MZ;KN
ME1ZIIETMQ92;MLH! X)!X(!&"#4-GXGT6_T:35X-0B_LZ-F5[B3,: KP>6 K
MR73;]_ 'A3QOX:,A,NGE6L^<EA.%5<?B1^M-\8:9<Z%X1\ ^&H;/[7'+<!KF
MV,@07$H ;:S'C!9VZ^E 'IVE>/\ PKK5^MCI^M02W+?<C(9"_P#N[@-WX9K5
MU?6],T&R-YJM[#:0 XWRMC)] .I/L*\K\5Z7XR\2:;;6UOX$M]/N;6=);>ZB
MOX-T.T]L&E\97&J7'QETBUAT=-7^R:7]HBLY)EC3S"S!GRW!(P./:@#T;0_&
M'A_Q+))%I&J0W,L8RT6&1P/7:P!Q[XKD?#Y/_"]O% R<?V?#_-:HMI7BW5?'
MGA_66\)0Z.MG*5NIX[R)S)$PP00IR>_YUR_C*\UJQ^(?B^;1@P L8!=R1_ZR
M.#*[V3WH ]IL?%&B:E-?Q6>H12G3SBZ< A(OJY&WL>AJEIOC_P *ZQJ:Z=8:
MU;S73DA$ 8!R/[I(PWX$UEVOAK1=7^%4VC^&)EBLK^U(CGZEF/=^Y)(P?QK$
MT76Y/#EWHWA_Q?X:@M90ZPV.I6RJ\+N. ?52?ZT >IU@:WXV\-^';A;;5=6A
M@N",^4 SN!ZE5!('UK?KR[X16MOJ=IKNN7T,<^I7.I2I+)(H9E5>BC/0#/2@
M#NK3Q1HE]HD^L6FI0SV$"L\LL66V #)R!SG';&:\>\.:AX2\7>/]:N]=O9KB
M[?41'I Q,H$8/R[<#Y>@ZXKJ-$M8-*^.>M:?IZ+'976G)<3P(/D$F>N.@R.?
MQJ;X9P1?\)+XZ/E)E-:?;\H^7KTH [K6;"XU+2IK2TU&;3YG VW,(!=.>V:\
MHUO2?%.E>-?#F@IX[U:2/5O/WRE%!C\M=PP.^:]GKSCQC_R6#P!_V^?^BQ0!
M)K.GZWX0\ ^(;QO%%_J-TMOO@EG55,)']W%8L6E^+(OA_;>*K3QKJ#W9T]+Y
MK>Z1&B.4#E>GY5V/Q._Y)IK_ /UZ-7E^IZ3XMM_A5I&H3:_+?: +.W>YTV&%
M(76 HORB0+DX&!SUH ],T;Q]ITO@O1M=UN9;'^T-L>=C%/,SCJ =H)'?\ZWM
M6U_2]#2V?4;M81<RB&$;68R.>@ 4$UB7NF>&]9^&1M5$<.A-8AXG_P">*A<J
MWU'7ZUYK\+KN;Q-XNLSXBN6DFTBQ!TJ*1"OFH21YW/4XP/\ ]5 'N]%%% !1
M110 4444 %%%% !1110 58@^Z?K5>K$'W3]: ):*** "BBB@ HHHH **** "
MBBB@ HHHH **** /"O%O_)2M>^D'_HI:H5?\6_\ )2M>^D'_ **6J%?387^#
M'T/A\P_WJ?J%%%%;G&22031(CR1.BR#*%E(##U'K4==1XG_Y /AW_KT_PK'T
MRTL+KS3?:C]C" ;<1%R_Y5E"K>'._P"M3>I0Y:OLXOMY=+F?16UJNAQ6>G0:
MA97HN[25RF_R]A5AV(S6C+X3L;2:WCO-;2%KA5,:B'<W/J,\#/>DZ]-*]_P?
M0:PE5MJVUNJZ[:W.4J>UL[B^E,5M$TKJI<JOH.IKH_\ A$;:"_%A>ZS#%=R-
MB*-(RV?3)SQFG^$;*2T\57=E,562.WE1CGCMS]*F6(CR.4>BN:0P<_:1C45D
MW;H<E172+X9M+JWN!I^KQW5W;H7>$1%0P'7:V>?RJOI^@0S:5_:6HWXLK9G\
MN,^679S[#(XJ_;PM?]&9_5:M[6_%6^_8RFL[A+..[:)A;R,523L2.HJ"NPUV
MTCL_!>F0Q74=Q$;IV65.A!![=C[53M= T>\GCMH-?#7,G"*;8A2WIG/]*B.(
MBX\S\^CZ%SPDE-0CO9=5U[=SFZ?'%)-(L<2,[MP%49)_"G7,#VMS+;R##Q.4
M;Z@UT7@_5I;75;2RAAA7SIL22[<NR_W<]A6E2;C!RBKF-&FIU%";L<RZ-&Y1
MU*LIP588(-3K87CP^<EI.T6,[Q&2OYU=UAD3Q/=M(NY!<DLOJ,UW3#59]:@U
M2RO\:'M#X4\(@'*[?7@UE4KN"3MNOZ1TT,(JDI*[T=M/S]$>8JC.X1%+,3@
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M.><XZ8KIZ* .$T[X>76C0ZQ9:3X@N;'3;UQ-;0PIAK.3()VMGE3C!7'2FP^
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MX/-<Q13IX=0=[]_Q%5Q;J)JW;KV.LUJ6-OB#!(LBE!/"2P/'5>]7;": >/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH PM?_ .0EHO\ U]?X5NUA:_\ \A+1?^OK_"MVF(****0P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *5%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<PM HRT@<%0/K2O>6T=I]K>XB6WP#YI8;<'H<T 3T5#+=VT$ GFGCCA.,.S
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MT]JJ_"KPWI&L?#]=1U2QMK^\U2662ZFGC#LQWD8R>0!C\ZR?A[_Q3NB_$/[
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M>N!T%4M8TB?1KM89F2174/'*A^5U/<4*K!RY4]0E0J1ASM:&?1116AD%%%%
M!116SI.A)J5A=7LU]':06S*K,Z%OO=.E3.:@KR+ITY5)<L=S&HK9U/P^;+3X
M]0MKR&\LV?RS)&"-K>A!JO>:2]GING7IE5EO0Y50.5VD#G\Z2JP=K/<J5"I&
M]UMK\C.HKI[GPG:V4ZV]UKUM#.RAMCQL.O3FLC5M'NM'N5BN I5QNCD0Y5QZ
M@TH5H3=DRJF&JTU>2V]'^1GT445H8!4^B?\ (\^'O^OD_P J@J?1/^1Y\/?]
M?)_E6.(_A2]#JP/^\0]3WVL*R_Y''4_^N,?\A6[6%9?\CCJ?_7&/^0KYD^Y9
MNT444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!A:__ ,A+1?\ KZ_PK=K"U_\ Y"6B
M_P#7U_A6[3$%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M*BBB@ HHHH **** "FNI:-E#%200&'44ZB@#@I=!^(D:/:VWBS3Y+=LA9Y[/
M]^H_#@GWK4\,>#$\)^&KK3K"]=[ZZWR2WLJ\M,P^_CT![5U-% '*V6A>)HO!
M:Z=<^(]VM*VX:@(MP^]D J<9&.*Q-0\'^-/$=J=,U[Q-9II<F!.MA:E))E]"
M3P,^U>BT4 5M/L;?3-.M["T3R[>WC6*-?10,"N=\0>$Y]8\:^&]=CN8XXM):
M8R1L#N?> !C\JZNB@#B=?\$W\OB<>)O#6J)IVJM$(;A)H]\,ZCIN'4$?T%)H
M_@K4I/$\/B/Q1JL>H7]LA2UAMXO+A@SU(!Y)KMZ* /#M 2/5/%/BJX3Q?)X9
M8ZD^;".50SD'!D82>OMQ75?#WQ!JE[XGUO1Y=737=,LD1H=26,+ESU3*\'O^
M5==J7A+P]K,_GZEHMC=3=WEA5B?QK0L=/LM,MA;V-K#;0CD)$@4?I0!F>,-#
ME\2>$M2T>"9(9;J+8LC@D*<@\X^E13>'9I/ '_"."=/._L\6GFD';D)MSZXK
MH:* .>L/#LUIX C\.M.C3+8&T,H!V[BA7/KCFLF+X>Q7/PTM/">I7.9+=%V7
M, ^Y(IR&7-=O10!P,6A?$9(5LV\5Z:(%&T7(LB9B/<$[<U<\6>#K_5]3TG6]
M(U1+36--5D1YH]\<JMU# =/P]:[*B@#SJW\">(;GQIHWB;6]>M[N>Q,@:"*$
MI&JLA ">^3DDUMV7A2>U^)&I^)VN8V@O+6.!80#N4J!DGMCBNJHH Y>Z\+SS
M_$:Q\3"XC$%M9/;-"0=Q+'KZ8KIV4.C*PRK#!'K2T4 >;V'@+Q-X>^U:;X=\
M206NAW$K2+'-;[YK?=U"'I^=:G@SP&/"T6NVT]U]LMM2GWCS"2Y4K@[SW)R:
M[2B@#SK3_!GB_P ,1-I_AOQ%9?V3O9H8;^V+O "<X!'7KWK?N/"T^M>#+C0O
M$>HF^FN0?,N8XA'M.<J5 _N\5TU% 'GUCX5\=06]OIDWBVV&FP%5$L5K_I#H
MO122<#TS6K%X3N(_B;-XJ-U&;=]/%H(<'?N# YSTQQ7644 <EX;\(W&B>(O%
M.IRW44B:S+&\:*#F,*&'/_?7Z5+X!\+3^#_#7]EW%Q'<2?:))=\8(&&.0.:Z
MBB@#D/#O@LZ7#XCM]0EBN;?6+R6<H@(VH_8Y[\UDZ?X0\;>'+4:9H?B6Q?2X
MR1 +ZU+2PKZ C@X]Z]%HH HZ1;7UGI<,&HWWVZ[4'S)_+"!CGLHZ5A^,?"D_
MB:ZT*:&YCA&FWHN7#@G>H[#'>NJHH Y34_"<]]\1='\2K<QK!8VTD+PD'<Q;
M.".W>I/$WA>?7=>\.:A%<1Q)I5V9Y%<'+@C&!73T4 %<IH/A.XTCQOXDUZ2Y
MBDBU8Q>7$H.Y-BX.:ZNB@#E/&?A.X\3W7A^6"YBA&F:C'>.'!.]5/08[U3\<
M^$-7\0:OH>J:+?VMI=:6[NIN$+ EL=A]*[>B@#S>Z\"^*_$RK:^*_%$3Z;N#
M26FGV_E^;CLS'G'YUZ%:6D%A9PVEK&L5O @CC11PJ@8 J:B@#S;2?A<^F_$.
M37C?1OI:SRW5O9@'*32  MZ=J])HHH Y3QYX4N/%VG:9;6]S% UIJ45XQD!(
M94# @8[_ #59\;>%T\7>%;K2#(L4KX>&5AD(X.0:Z*B@#B]9\(:GK>G>&([F
M^@-UI5U%<7$F#B79UQ[G'>MKQ7X<MO%?AR[TBZ.U9ERD@',;CE6'T-;5% 'F
M>F_#C6-,^%]_X6AU6V^V7DK,USM;:$8C(]<X'ZUWVCZ9!HNC6>F6P_<VL*Q+
M[X'7\>M7J* .1M/"%QI_Q*O/$UI=1+97]L([FV(.XR#&&';M^IKKJ** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML]0FD-K&I>TF>-&XZ #@UE44H^YYO[K>IT490FO:7ULKOSN_)]/(YCQ8UO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#^O1_P@GC3_GQL?^__ /\ 7KVVBC^T*P?V1A>QXE_P@GC3_GQL?^__ /\
M7H_X03QI_P ^-C_W_P#_ *]>VT4?VA6#^R,+V/$O^$$\:?\ /C8_]_\ _P"O
M1_P@GC3_ )\;'_O_ /\ UZ]MHH_M"L']D87L>)?\()XT_P"?&Q_[_P#_ ->C
M_A!/&G_/C8_]_P#_ .O7MM%']H5@_LC"]CQ+_A!/&G_/C8_]_P#_ .O1_P (
M)XT_Y\;'_O\ _P#UZ]MHH_M"L']D87L>)?\ "">-/^?&Q_[_ /\ ]>C_ (03
MQI_SXV/_ '__ /KU[;11_:%8/[(PO8\2_P"$$\:?\^-C_P!__P#Z]'_"">-/
M^?&Q_P"__P#]>O;:*/[0K!_9&%['B7_"">-/^?&Q_P"__P#]>C_A!/&G_/C8
M_P#?_P#^O7MM%']H5@_LC"]CQ+_A!/&G_/C8_P#?_P#^O1_P@GC3_GQL?^__
M /\ 7KVVBC^T*P?V1A>QXE_P@GC3_GQL?^__ /\ 7H_X03QI_P ^-C_W_P#_
M *]>VT4?VA6#^R,+V/$O^$$\:?\ /C8_]_\ _P"O5W0O OBB#Q1I5_?6UJEO
M:S;W,<P)Q]*]@IDLB0Q/+(P2-%+,Q/  ZFIECJTEROJ7#*\/3DIQ6J*=QK-C
M:ZQ::7+,%N[M6>)/4+U_S[&LVXM=7M]>NKVQ@@D29%7]X^.@%>#^(?%MUJ?C
M1M<MW*&"4&V_V54\?GW^M?1&A:O!KNB6NI6Y&R= Q /W6[C\#6=6@Z<4^YO0
MQ*K2E'L4_M'B;_GQL?\ OX?\:/M'B;_GQL?^_A_QK=HK Z;&%]H\3?\ /C8_
M]_#_ (T?:/$W_/C8_P#?P_XUNT4!8POM'B;_ )\;'_OX?\:/M'B;_GQL?^_A
M_P :W:* L87VCQ-_SXV/_?P_XT?:/$W_ #XV/_?P_P"-;M% 6,+[1XF_Y\;'
M_OX?\:/M'B;_ )\;'_OX?\:W:* L87VCQ-_SXV/_ '\/^-'VCQ-_SXV/_?P_
MXUNT4!8POM'B;_GQL?\ OX?\:/M'B;_GQL?^_A_QK=HH"QA?:/$W_/C8_P#?
MP_XT?:/$W_/C8_\ ?P_XUNT4!8POM'B;_GQL?^_A_P :/M'B;_GQL?\ OX?\
M:W:* L87VCQ-_P ^-C_W\/\ C1]H\3?\^-C_ -_#_C6[10%C"^T>)O\ GQL?
M^_A_QH^T>)O^?&Q_[^'_ !K=HH"QA?:/$W_/C8_]_#_C1]H\3?\ /C8_]_#_
M (UNT4!8POM'B;_GQL?^_A_QH^T>)O\ GQL?^_A_QK=HH"QA?:/$W_/C8_\
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M'A:/Y]/TK_3]0 Z,W&Q3_G^*@!TFJ>)H=)\&Z#<:D\&JZR6-U?>6I>-50N0
M1C=C Z5I^&M?O-.U?Q/H^N:B;N#1?+E6^E0*QC>,/AL #(S70^(O#%CXDAMQ
M<R7-O/:R>;;W-K)LEB;IE201^8->:W^DZ?)J>I:/:S7=UI5B?MOB"_FDWRW4
MBC*0;@ .PR ..E '8>"WU/7;Z[\57TUQ#9W:^7IUBSD(D /$C+TW-USV%4+V
M9O#?QDL65B+/Q%:M$ZYX$\7(/X@@?G4&G^-/$5M;^'M2U+3],CT3698X(([;
M>)K<."8RQ)VL"!V I/BB2GB3P&\?^L_MN)<CKM)7=^E 'I=<_J_CCPQH5T;7
M4M:M8+A?O1;BS+]0N<?C705YM<^)+&3Q'JMIX:\%G6KR*7;?W2B.-/,Z%2[]
M3QT]J .^T[4['5[)+S3KN&ZMG^[)$P8?_KK'O?'OA33M1-A=Z[9Q7(.UD+YV
MGT)' _$UYMX$O[S3O#7Q&EBM?L$UK/-+':A@PMWV,<#''&!TXXKK/AIX<T>3
MX:Z=YME;W)OH3+<O+&&,C,3G)/- %+QW>1K\0_ LZW*BW,\CF0/A"N!SGIC%
M=?I?C3PWK6HMI^G:S:W%TN?W2-R<=<9^]^&:X+XA:'I\_C+P'HSVX_L_S6B\
MD'C8 ,+].*M?$[3++2[OP;J%A:PVUQ%K4%LK0H%_=L#E>.WRB@#J-1(_X6'I
M0_X25[8FU?&CB/(N,$_/NSQCZ=JT]:\3:+X=C1]7U*WM _W!(WS-] .37%:_
M_P EY\,_]@Z7^;5SMK?:K<_%7Q3>Q^%CKTUI*MM#NGC06\8Z8#GOUR* /5[/
MQ-HFH:3-JEGJ5O/90J6EEC;.P#DY'4?E5W3]0M-5T^&_L9TGM9EW1RIT85YM
MX4T/6W^(6IZC>>&/[&T>_P!/,-Q;^?&Z22[A@X0\$KN[>M9?AGQ _@GP?XPT
M2Y?_ $C097%H&ZNDF?+/Y_SH ]3LO$.D:C:W=U:W\,EO9RM%<2YVK&Z@%@2>
M.,BJ&G>._"VK:@+"QURTFNB<+&&QN/L3P?PKRCQ'I=WX<^%_A/1!;R3OJ5^D
ME]"'VF9F^;86/ R<#GTK2\5:=XEU[P\NGV/PY_L^Y@='M;F.[MP82I!XPWID
M4 >M:IJVGZ+9->:G>0VMNIP9)6P,^GN?:O+OB!XGTG7Y?!\VBZG%<HNO0+)Y
M3D%>>XZC\:L^(H3K'Q9\(Z/JZ![:&Q>Z:%^5>8 YSV/W:@^*NB:9:^(?!NI6
MUG%#=OK$,+O&H7<NX'D#KR* /7*Q[KQ5H5E/?0W6J6\$EB$-R)&V^7O&5Z]2
M<=!6Q7DNF:/I^K?'OQ(]_;I<?9;6"6)).5#[5&['0D G'IF@#T31/$VB^(XY
M'T?4H+L1'#B,\KZ9!Y%5[SQKX:T\79N]8MH?LDP@F#$Y5\9VXQDG'IFN+U.U
M@T;XZZ"^FQI"=0LI5NXX@%# 9PQ ^GZ54\%:%IVI_%7QM>7UJEQ);786)90&
M5=V<G!XSP.: .NO+N"\\9>'[BW\5&"&X@>2+35CRMZN"=V[/&![=JU[SQ7H.
MGSWD-YJEO!)9*C7"R-C8&SM^I.#P*XCQ)%'!\:_!,42+'&EK.JHHP%&UN *J
MZ=I%AJGQ\UY[ZV2?[+9Q2Q+(,J'X&<=R 3^= '>6GC3PW?:7/J5OK5H]G <2
MRF3;L],@\C/;UJ?1/$VB^(XY'T?4H+L1G#B,\K]0>:\Y7PQI$OQ[N(Y+*,P"
MP2[\C&(S+G&XKT/^-:"VD&G?'^(6<20)=:,SS)& JNP? ) [\"@#JM5\=^%]
M$NVM-1UNUAN%.&CW%F4^X4''XUK6NJZ??:;_ &C:WD,]GM+^=&VY<#KR/2N
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MQ+IYCMK5)5#+$F.H![GKGWH [W1?$FC>(HGETC48+M4^^(VY7Z@\BLK1"/\
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MBBB@ HHHH **** "BBB@#Q#QG_R6S3?^OBS_ /0EKV^O$/&?_);--_Z^+/\
M]"6O;ZZ<1\$/0X\-\=3U"BBBN8[ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *5%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %6(/NGZU7JQ!]T_6@"6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#Q#QG_ ,ELTW_KXL__ $):]OKQ#QG_ ,ELTW_KXL__ $):]OKIQ'P0]#CP
MWQU/4****YCL"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH I4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 58@^Z?K5>K$'W3]: ):*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /$/&?_);--_Z^
M+/\ ]"6O;Z\0\9_\ELTW_KXL_P#T):]OKIQ'P0]#CPWQU/4****YCL"BBB@
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MU!Y'GW2VT9:XRO&01@8Z<5I^)UUB3X\6,6B2017<FD;#-.NY8DWMN;'<CL*
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M6O;Z\0\9_P#);--_Z^+/_P!"6O;ZZ<1\$/0X\-\=3U"BBBN8[ HHHH ****
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MY27*LJ&?/)C#=NM=MXZL'U3P)K=G&"7DM'V@=20,X_2NAHZC!H X[P+JZO\
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M3\QH2<["RYQGOC->G44 %%%% !1110 58@^Z?K5>K$'W3]: ):*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /$/&?_ "6S3?\ KXL__0EKV^O$/&?_ "6S3?\ KXL__0EKV^NG$?!#T./#
M?'4]0HHHKF.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEJ+?2AJ )**:#2YH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH I4444 %%%% !1110 4444 >;?!J1$\/:W"[!9(M8N"ZDX*@[<9_(U4^&
M\\5UX@^(4\$BR1/J+E74Y##YN170ZA\,/#NH:O<:D?MML]V<W4-K<M''.?\
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MPG_";0?\^TWYBE_X3:#_ )]IOS%'U.O_ "A_:>$_G_,[P3BI5F%< /'%N/\
MEUF_,5*OCVU7K:3_ )BCZG7_ )0_M/"?S_F>@*^:E!K+L;H7-K#.H($B!P#V
MR,UH(V17*U9V.U--71-2TT4Z@84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (5Q)_T%%_[\?_95UU,51IRY9.S/.HX#$5H<].-UZHX:BNY_X5Q)_P!!1?\
MOQ_]E1_PKB3_ *"B_P#?C_[*L_KV'_F_,U_LK&?R?BO\SAJ*[G_A7$G_ $%%
M_P"_'_V5'_"N)/\ H*+_ -^/_LJ/KV'_ )OS#^RL9_)^*_S.&HKN?^%<2?\
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M#^RL9_)^*_S.&HKN?^%<2?\ 047_ +\?_94?\*XD_P"@HO\ WX_^RH^O8?\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4J***
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M&M \+0ZE+8?,S->+$2ORY/S8'5AWKM?#&H:[J.G22^(-%32;I92J0I<+,&3
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M<GCBJ$/Q9TZ*YN;#5M)U'3M5C"F*P>/?)<;N $V\$T >A5$MS \\D"31M-&
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M?E QSZT >8>#=)\8:AX)TQ],\7:='8M;*JP_V:&*#&"I.[DCO53QAX:;PE\
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M?[0NX[F*\*!&FMKAHF91T!P>:T=&\-:3H&E-IFG6:16KDF13R9">"6)Y)(H
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M45";RU%J+HW,(MR,B7>-F/7/2EM[F"[B$MM/'-&>CQN&'YB@"6BBB@ HHHH
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MNLKCM&.K:5&P_P"$?GEN)FW3W#W";G/^'M78#) )&#Z4V".=\/\ _(P>(?\
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M#[I^M $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ JQ!]T_6J]6(/NGZT 2T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 1/TJI/T-6WZ54GZ&@#F/$G_ "![O_KF:\RKTWQ)_P @>[_ZYFO,J]O+/X<O
M4^7SW^-'T_4[/X=?\A*\_P"N(_G7HE>=_#K_ )"5Y_UQ'\Z]$KAS#^._D>ID
M_P#ND?G^84445Q'J!7-^- YTRR6.0QLU[&H=>JY!YKI*S]6TM=6AMXVE,?DS
MI,"!G.W/'ZTT)G/ZW9IX;T-UTXS"2[E2.23?ECUR1GH35<Z?<6\]K+I6C7UK
M<)(OF2/*I61>^[YCFNMU/3H-5L7M+@-L;D%3@J1T(K.@T2_CDC\W7;J2&-@=
MFQ06QV)[T7"Q0N;9-<\7W-E>.YM+2!66$,0&9N<GZ4W1K%-.\;7MO')(\8LU
M*>8V2HW#C/H*U=1T'[7J*ZA:WLMG=A-C.BA@R^A!INF>'ETW5)K_ .US3RS1
M;',O4G.<Y_#I1<+%7PB2=&N\G/\ I,O\ZP[:[G@\"1K#*T;3WIA,@/*@L<X_
M*M__ (1<QS7 MM4N;>UN'+R0(!U/7![5+!X8M8_#[Z1)(\D1<N'QAE.<C'TI
MW0K,6U\+V%E-'+;M,C!2L@\PD2@C!W?SK$\.:)I[:YJI,'-I<KY/S'Y>I_I6
MY9:'<6]S#+<ZM<W2P_ZN,@*/3G'6@:"\.LRW]K?RP).ZO-"%!#D>_:E<=C,M
M+J2TNO%ERG+0D.H/J%8TRS\-VE[H"7]S--)?30^<;CS#E21GCV%;MKHT5O<Z
ME*[F5;]@70K@ 8(Q[]:SE\*S10-9PZS=1V)R/("@D*>H#47%8Q;V^N;[P7I<
MTDK"?[6B>:.IP2 WUJ]J&E0:%J>CW-B\RR37:0S%I"WF*QYS6S>^'[>ZTRTL
M(G,$-M(KK@9SM[?C4^IZ6NI263M*8_LMPLX 7.[!Z47"QH$@ DG '4UY]?0Z
M7<6EY=:?IM_*4W$7@DP P[C)R1]*] 90RE2,@C!KG!X4=+26QBU:X2QD+'R0
MBY&>V[KCVH0V8NNPQZAX7T>_N%WW#&*-G)Z@GFNTL-.M=,MS!:1^7&6+8R3S
M_D50F\/0S^'X=*>=P(0NR51R".AQ5[3[6>TMC'<WCW<A;/F.H7CTP* 2,#7H
M;B?Q;I$=K<_9IC%+B79OQP>V:T)K34;?1-16XU#[7(T#[#Y(3;\I]"<T[5=$
MDU"_MKV"^>UFMU9598PW7KUJ;3["]M9':[U-[Q&7 1H@N#Z\4 5_"31-X7L?
M*Q@)@X]<\U2E_>?$:#RCGR[,^;CL"3@'\Q4O_"+/;2R'2]4N+&*1MS0J R@^
MV>E7])T2#2O-D$DD]S,<RSRG+-_]:@"A?_\ (]:3_P!>\O\ (UT59\^EK/K=
MKJ1E(:WC9 F.&S[UH4AA1110 4444 >-^(O^1CU#_KNW\ZS*T_$7_(QZA_UW
M;^=9E?54OX<?1'P%?^++U?YGJFB_\@ZU_P"N2?R%=##TKGM%_P"0=:_]<D_D
M*Z&'I7R\_B9]W2_AQ]"VM25&M25)H%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %*BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=%
M %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_
M=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=%
M%2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=
M%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %
M2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%
M'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2
MBK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'
MEI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2B
MK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'E
MI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK
M?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI_=% %2BK?EI_=%'EI
M_=% %2K$'W3]:?Y:?W12A0O08H 6BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@")^E5)^AJXU5)NAH Y?Q)_R!
M[O\ ZYFO,J]/\2#_ (DUY_US->85[>6?PY>I\OGO\:/I^IV?PZ_Y"5Y_UQ'\
MZ]$KR?PMKMOH5W/+<12R+)&% C XYSW-=3_PL/3?^?2[_)?\:Y\;AZLZSE&-
MT=>68VA2PRA.5GJ=?17(?\+#TW_GTN_R7_&C_A8>F_\ /I=_DO\ C7+]3K_R
MG?\ VEA?YT=?17(?\+#TW_GTN_R7_&C_ (6'IO\ SZ7?Y+_C1]3K_P H?VEA
M?YT=?17(?\+#TW_GTN_R7_&C_A8>F_\ /I=_DO\ C1]3K_RA_:6%_G1U]%<A
M_P +#TW_ )]+O\E_QH_X6'IO_/I=_DO^-'U.O_*']I87^='7T5R'_"P]-_Y]
M+O\ )?\ &C_A8>F_\^EW^2_XT?4Z_P#*']I87^='7T5R'_"P]-_Y]+O\E_QH
M_P"%AZ;_ ,^EW^2_XT?4Z_\ *']I87^='7T5R'_"P]-_Y]+O\E_QH_X6'IO_
M #Z7?Y+_ (T?4Z_\H?VEA?YT=?17(?\ "P]-_P"?2[_)?\:/^%AZ;_SZ7?Y+
M_C1]3K_RA_:6%_G1U]%<A_PL/3?^?2[_ "7_ !H_X6'IO_/I=_DO^-'U.O\
MRA_:6%_G1U]%<A_PL/3?^?2[_)?\:/\ A8>F_P#/I=_DO^-'U.O_ "A_:6%_
MG1U]%<A_PL/3?^?2[_)?\:/^%AZ;_P ^EW^2_P"-'U.O_*']I87^='7T5R'_
M  L/3?\ GTN_R7_&C_A8>F_\^EW^2_XT?4Z_\H?VEA?YT=?17(?\+#TW_GTN
M_P E_P :/^%AZ;_SZ7?Y+_C1]3K_ ,H?VEA?YT=?17(?\+#TW_GTN_R7_&C_
M (6'IO\ SZ7?Y+_C1]3K_P H?VEA?YT=?17(?\+#TW_GTN_R7_&C_A8>F_\
M/I=_DO\ C1]3K_RA_:6%_G1Q7B+_ )&/4/\ KNW\ZS*MZI=I?:K=74:LJ32%
MU#=0":J5]#334$GV/C:S4JDFN[/5=%_Y!UK_ -<D_D*Z"'I6!HH_XEMI_P!<
M4_D*Z"$<5\O/XF?>4OX<?0M+4E,6GU)H%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6_\ WT?\*/\ A$-2_O6__?1_PH^MT/YD']GXK^1F!16__P (AJ7]ZW_[Z/\
MA1_PB&I?WK?_ +Z/^%'UNA_,@_L_%?R,P**W_P#A$-2_O6__ 'T?\*/^$/U+
M^];_ /?9_P */K=#^9!_9^*_D9@45T(\&ZF?X[?_ +[/^%/7P1JK='MO^^S_
M (4?6Z'\R#^S\5_(SM]%7_B5VA_Z8I_Z"*W8AQ6?IMJ]O8V\+XW1QJK8Z9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** $Q1BBB@ Q2;:** #;1MHHH -M&VBB@ VT;:
M** #;1MHHH -M&VBB@ VT;:** #;1MHHH -M&VBB@ VT;:** #;1MHHH -M&
MVBB@ VT;:** #;1MHHH -M&VBB@ VT;:** %Q1BBB@ Q2T44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gzbwht3f4aft000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *\!48# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?PSUC5Q_:+^,-3&HHNZ..,JD*GTP!DCZUQ7QW_Y*/X3_ -U/_1U?02_<!]J
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M%D##IU ]?2L?POX0\>:3I4.AW6N6,>EPKY:-;IF4)Z9*C!]\UZ?10!Y+X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPE]?<K:<OZGG^E7^HZ=XCU:;3K-;E\OO5CT7?UK4\*QOKOB.76+N9%GB/^H
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M?2H=2,Z$I-^]:WXFJH5*>*A%+W;M^EUJOO.VHHHKS3VPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **3-)F@!U%,W"C=0 ^BF;J-PH ?13-PHW"@!]%,W"C<
M* 'T4S<*-PH ?13-PHW"@!]%,W"C<* 'T4S<*-PH ?13-PHW"@!]%,W"C<*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[\FC_A.[/_GWO/\ OR:/8S[![>GW.\^T>]'VCWK@_P#A.[/_ )][S_OR:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME<*N^ (Q(E4$YZ_2N4\/_P#(X_%3_KC_ $>LO2]-N=.\!:)XSTR-C=Z9.?M
M0<R0%OF'TP6H ]-L/'.MZQ)XBMM,TJVEO-,G6*!&D($H.W)/IP3^58%E\2?'
M5_XEO= @\,:<;ZRC$DJ^>V #C'\Q3O@[?1ZEK_BB]B(,<\ZN,>Z)4GA/_DX'
MQ=_UXQ?^TZ /4-/DNIM/@DO84AN60&2-#D*V.0*LT44 %%%% !1110 4444
M%<;X[_UVB?\ 7\E=E7&^._\ 7:)_U_)5T_B,ZWP&E:=JUHNE9-IVK6BZ5!H6
M!THH'2B@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !3)AF"0>JG^5/KEOB!X@G\-^%I+RV4&9Y!"A/120>?TJH1<I)(F<E&+D^A
MYAX?B_XEGB:V/6*>-P/IOKV'PL<^%]//_3$5\WZ5J]\FHR 7+@7;8G&?O_6O
MH7P1<>?X7MQG/EDQ_E_^NO2Q<&J-_/\ 0\; SB\5;^[^IT5%%%>6>V%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% "&HGJ4U$] &=<]#7"3?\ )6] _P"N
M$G\FKN[GH:X2;_DK>@?]<)/Y-6M'=^C_ ",*_P *]5^9ZE11161N%%%% !11
M10 4444 %<1J_P *?#6M:W-J]R+U+R;AVAN2@/X"NWHH Y*3X=:#-X6'AV;[
M7+8"X%Q\\Y+[Q_M>GM6GXB\*Z5XHT7^R=4A:2U!!&UL,,=,&MJB@#DKSX<>'
MK[PI:^&YH9_[.M3F)5E(8<YZU3T_X2>$["[AN?LUQ=/"08Q=3&4*1TP#7<T4
M <]XB\%Z-XHFL9=2BE9K&020^7)M (Z9]:Z&BB@#C]=^&7AGQ!J1U&ZMI8KM
MOO2VTGELWU(ZUH>&_!6A^%!(=+M=DDOWYG.YV^K5T%% '-6O@31+/4-:O88Y
MO.UE=MWF4D$<]!VZFK>E>%M*T?P^VAVT+&P=65DD;=D-U!-;5% '.>%? ^B>
M#%N5T>&6-;E][AY-W/MZ"K%EX4TO3_%%]XB@20:A>Q"*9B^5*C&,#MT%;=%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:B>I343T 9U
MST-<)-_R5O0/^N$G\FKN[GH:X2;_ )*WH'_7"3^35K1W?H_R,*_PKU7YGJ5%
M%%9&Y@^*-'N]7M84LTL7DCD#8O/,V?DA&?QINAVOB.UG$>I'1ELPIPEC%(C
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M;"6WAN+O3FL[8C9)%; 3N!T#$C'Y8I%\(:KINKWTNAZI%:V.HS":XC=,O&V
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M>&;K0XKV(6YOOM%MD$^5'QA/Y_G7=T4 <5XW\"'Q58V0MKI;6]M2!YQ7(9.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AJ)ZE-1/0!G7
M/0UPDW_)6] _ZX2?R:N[N>AKA)O^2MZ!_P!<)/Y-6M'=^C_(PK_"O5?F>I44
M45D;A1110 5QVK>.M.L_$NCV4>H1"WF>9;O*GY=L>5[>OI78US.I^$+*]\0Z
M1?I96@BM7F:=3&,R;DVCMSSS0!T%I=P7ULES;2"2%^5<=#7EWBG4;V[U^^UF
MPOY8X= ,:"%)2%F+%=Y*YPV%9NOI7IY@^S6#PV,<<3*C")0,*&[?AFN&TOX7
MV']ES#5GF>_NGD>=X9VVDL2>/IF@"SXSU0S:?X:O+"YD6&ZU"(AHV*[T:-C@
M^W2H/B7X>MI/#^J:ZMWJ4-[#;@IY%]+&@P0/N*P'Z55N/!WB-/"6EZ; ]G<7
M6F:AYL'FRLJM H94!(4X.TBMK4K#Q+XB\(:OINI6>G6EU<1A(/(N6D4\\[B5
M&.GO0!<\+>&K+1;=;BVGOY9)XUW_ &F\DF'X!B<5Q7CF?68O'ZW&E74^ZPLU
MN3;+(=DJ@L67;T)(&*]2M(F@LX8GQN1 #BL%M!NF\??VV3%]D^R"#;GYMV6[
M8Z<T 8EMKPU7QQH=S;W+_9)[%Y&C#G;D!LY'J"*<_CW4I+:;5;/09)=%A=E:
M<L-[*IPS*,XP"#U]*KZ3\/[[2O'LNH1SQ'1&CD$<)8[XRX(( QTYSU[TV'P]
MXQT[0Y_#=E'I;Z;(9$6[DG82K'(Q+?)MQGYCWH T]2\<RQZKI]AI6G->R:A8
M_:X#G 'S#AO08_6FWWC/58-8_L>UT0W%\+99V ?"IP,@GZG%6=/\)S:;XDTJ
M[A=#9V6E_8CD_,7W YQZ<5;CT.Z3QO=:P6C^S2VHA49^;=QV].* .<3XDW\N
MDR:G'X>G%K9N8[YG8 JP.&V<\X/K6_K?B+4;,0G3=.CG1TWF6>4(GT'.<UGC
MPGJ'_"#ZWHV^#[3>W,\L1W': [[ADX]*I:SX2UJXUF"[CM=/U*UCM1$+6]F9
M41Q_$!M(.?Z4 1Z[X@B\2^!]-U&*,Q$ZI;I)&3G:P<9'ZUKV5\__  E>LP6D
M4DEU%9QNJR3L8V.3@!>B_4"LK3_ ^J6W@N#27-HEPFII=D1L0@0$$@<=>*US
MH.L6VM:WJ5E);B6ZLEAMB['Y9!G!;CIR* *^A^,-7U'5]2L+K28@UC%N=K>0
ML-_79DXYP0?QI+3QQ??VU;:;J&F1PR7NY;4Q3!_G"EMK\\< ]*HZ+X<\56WA
MN^TF>WTZSEGC9C>V]T[R2RG/+948],Y.!572_!&M1>(?#][/I>CVD>G.6GFM
MYB\LQ,;+DDH,\G/6@"[X4\2^)]7O]6AU*TM_LMO*R%T;#1C!X&!S]:72?%D.
MF>$8IX+:YN+BXOY+6W@:8R.[Y/=CG'!J]I.AZ[I.O:LL<=G+I=_(9?-:4B5"
M0>-NW!&3ZUE+X$U6VT*P-NULVJZ?J3WD(:0B-@2?E)QQU]* -O2_%UX^LMH^
MLZ;]BOFA::$JVY)%7K@]<C(_.L:V^)5]+H]IK4NA21:7(X2:8L,C)QN49Y7Z
MUH66@Z_J?B:/6]?CLK9K6W>&WAM9FD!WXR22H_NBH;GP;J4WPJM_#2O;_;HX
M@A8N=F<GOCW]* .ZC<2Q)(OW74,/QIU16L;0VD,38W)&JG'J!4M !1110 5Q
MOCO_ %VB?]?R5V5<;X[_ -=HG_7\E73^(SK? :5IVK6BZ5DVG:M:+I4&A8'2
MB@=** '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% "&HGJ4U$] &=<]#7"3?\
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MG6^ TK3M6M%TK)M.U:T72H-"P.E% Z44 .HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *M]IUIJ,:I=Q>8JYP"2.OTJ.+1["%(D2W4+$V],DG::O
M44 46T;3WNOM#6J&7.<GIGZ=*O=*** "BBB@ HHHH *QO%>EIK'AF^M' YB+
M+GU'(_E6S7-^/9;N#P9J#V6[SM@'R]=N1G],U<+\RL14MR.YR7PQ\76,&D_V
M)J-W'#<V\C+'O. PR2>>G6KWB?XEPVDYTW08C?W[?+N0$JI_K7@A))R<Y-?0
M'PN\/6MCX9M[^6S5;Z<EC(PR<9XQGIQ7=7I4Z;]H]?(\W#5ZM5>RCI;J<Q+X
M1U]M*EUG6RDTSOO># R%]3CBO3/#%]9WVBPO9Q1PJHVM$@QM-:[HLB,C@%6&
M"#7GKB3P5XEWJ&.F7)Y'9?\ ]50IO$PY'\2V_P @E36"J^U7PRT?D^_^9Z)1
M3(I$FB62-@R,,@CO3ZX3U=PHHHH XCQ;\/+36R;[3V^Q:DG*O'P&/O6!H?CS
M4O#5XNB^+H77!PEUC/'OCK^%>K5E:[X>T[Q#9-;7\"N"/E?'S+]#6\*J:Y:F
MJ.>=%I\]/1_@S0M[B&ZA6:WE26-NC(<@U+7CDEOXD^&-V9+8OJ&BL>5/.T?T
M_"O2/#OBG3/$MFL]E,-_\<+'#*:F=)Q7-'5#IUE)\LM)=C;HHHK(W"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y_QEXD
M3POH$E[A6F)V0HW1F_\ U9KQ^S^+GB.._22YEBEM]WS1>6HX^H&:WIX>=1<R
M.>KBJ=*7+(^@**I:7J=OJNGV]Y ZE9HPX7<"1D=#5VL6K:,W335T%%%%(844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/FCN?6.D:K:ZUID-_9R!X95R/4>H-7J\%^%7BQM*U?\ LJYD/V2Z/R9/"/\
M_7Z5[U7C5Z3ISL?08>LJT.;J%%%%8FX4444 %%%% !1110 5QOCO_7:)_P!?
MR5V5<;X[_P!=HG_7\E73^(SK? :5IVK6BZ5DVG:M:+I4&A8'2B@=** '4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4V2-)8VCD4,C##*1D$4ZB@#D/^%9>%C>_:OL#>9NW;?,.W/TZ8KK8XTBC6.-
M0B*,*JC  IU%5*<I;LB,(Q^%6"L_6M)AUG39+2;C<,JV.5/K6A12C)Q=T.<(
MSBXRV9P_@_5IK&[D\/ZA\LD1Q$Q/7VKN*Y+QGH;W$*ZK9 K>6_)*]2!_A6CX
M;UZ+6-,5W<+<1_+*I..:ZJ\54C[:'S]3@PLW1F\-4>WPONO^ ;E%%%<AZ(44
M44 ,EBCGB:*5%>-AAE89!%>9^(_AY=:;>'6O"4K07*_,ULIP&^G^'2O3Z*N%
M24'H9U*4:BLS@/"?Q'AOY!IFN)]BU)3M^<85_P#Z]=\"",@@@]"*Y;Q9X%TW
MQ/$9&407RCY)T'/X^M<9IOBC7O E\FE^)8WGL"<1W Y('8Y/45JX1J:T]^W^
M1BJDZ3M5U7?_ #/7:*J:?J5IJMFEU93I-"XR&4U;KG:MN=*::N@HHHH&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !116=J^NZ;H5J;C4+I(D'0$\GZ"
MFDV[(3:2NS1KF_$?C?1_#<1^T3B6X(^6"+EC7$7OC7Q'XPNFL?"UH\%OG#7+
M<''KGM6YX<^%]AI\@O=7?[??,=S>9RH/]?K6ZI1AK4?R.9UI5-*2^?0Y2^A\
M6?%#&+6*RTV)M\7F\ GIUQG-8EG\*/$<^I&VG@6&%6YG)^4CVKZ$1%1 B*%4
M#  [4M4L5**M%61#P4).\VVSRJ?X5ZOID:G0?$4ZL#G9(QC7_P =S3?[2^)/
MA^<+<6::E;(.2BC!_'K7J]%1]8D_B29I]5BO@;1YA8_%^*,,NM:1<VT@./W2
M[A^.<5UFG>.O#FIA!!J<0D?_ )9OD$?TK8O=+L=1C*7EI#.I[2(#7*ZE\+/#
M5_EDMFMG[&(X _"B]&6Z:#EKQV:?X'8QSQ3#,<J/_NL#4E>5R?#+7-(;?X>\
M02K_ +#L4'Z$YJ,:Q\2-!#"[T];^"/JZ#/'^]UH]BG\$D_P#ZQ*/QQ:_$]8H
MKS.Q^+]H,+J^FW%H^<'8-P_7%=9IWC?P[JCK';:G"96&1&QPU3*C4CNBX5Z<
M]F=!13$ECE&8W5A['-$LT4*[I9%0>K'%9&P^BF1RQS+NC=7'JIS3Z "BBB@
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M(M T"VL4 W*N9& ^\QZFMBO+K3YYMH]G#TW3IJ+"BBBLC8*YSQ[_ ,B)K/\
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MO+4%@ .77N*^?R"K%2,$'!%>SAZOM(>9\_BJ+I5&NC$HHHK<Y@HHHH ****
M"BBB@":SMI+V\AMH@2\KA ![G%?5&@Z:FD:'9V*#'E1@$?[7?]:\G^$GA)KB
MZ.O7<?[J/*P*P^\?7Z?X5[37F8RKS2Y%T/9P%%QCSOJ%%%%<1Z 4444 %%%%
M !1110 5QOCO_7:)_P!?R5V5<;X[_P!=HG_7\E73^(SK? :5IVK6BZ5DVG:M
M:+I4&A8'2B@=** '4444 9\FK11ZW#I9C<RRQF0/Q@ 5;FN8+< S31QYZ;V
MS^=<QJ4\5IX\L9YVV1"V8;B#C.#4,\UA/XEN)=5*O:-;#[-O4LAY.2!CKUH
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M%% !1110 4444 %%%% !1110 4444 8>K_\ (=T?_KJ?_06K<K#U?_D.Z/\
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MJFGW$>W9 Y9\GG&"./SK3K*FFI2;[_HC>M).$$NB_5A1116I@%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.\FQ!2T@I:9(4444 %%%% !1110 4444 %%%% !1WHHH 3;S2T44 %%%% "
M8%%+10 F*3;3J*  <#%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M AJ)ZE-1/0!G7/0UPDW_ "5O0/\ KA)_)J[NYZ&N$F_Y*WH'_7"3^35K1W?H
M_P C"O\ "O5?F>I4445D;A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<;X[_UVB?\ 7\E=E7&^._\
M7:)_U_)5T_B,ZWP&E:=JUHNE9-IVK6BZ5!H6!THH'2B@!U%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>M2QE"KI&6O;9FE11UHK$Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "&HGJ4U$] &=<]#7"3?\E;T#_KA)_)J[NYZ&N$F
M_P"2MZ!_UPD_DU:T=WZ/\C"O\*]5^9ZE11161N%%%% !1110 4444 %%%% !
M1110 4452O=6L-.4FZN8XR/X2PS^5-1<G9$RE&*O)V+M%<A=?$32H6Q#'+-C
MN!M_G5/_ (6;:Y_Y!TW_ '\'^%="P==_9..6982+LYH[NBN+A^)&G.P$MM+$
M/7.[^E;]AXDTK4L"WNTW'HKG:?R-1/#U8:RB:4\;AZKM":-6BBBL3J"BBB@
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MI5RL/5_^0[H__74_^@M6Y6<)-RDGT?Z&U6"C"#75?JPHHHK0Q"BBB@ HHHH
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M5^LI1<79G1&<9KFB[H****104444 %%%% !1110 4444 %%%% "&HGJ4U$]
M&=<]#7"3?\E;T#_KA)_)J[NYZ&N$F_Y*WH'_ %PD_DU:T=WZ/\C"O\*]5^9Z
ME11161N%'?%%<W<ZO]A\8I:R-B&XB4<GHW.*N$'.Z1E5JQII.75V.DHHHJ#4
M**** "BBFNVR-F/89H X/XA:X8T72H&P6&Z4@]NP_G7G-7=7OFU'5;BZ;_EH
MY('H*I5]-AJ2I4U$^%QN(>(K.?3IZ!1116YRA1110 4444 %%%% '3^"M;.E
MZL()&_T>X.UO8]C_ "KUW.1D5\^*Q1@RG!!R#7M_AR^.HZ#:W!^\4VG\./Z5
MX^944FJBZGTF1XER3HOIJC4HHHKRCZ **** "BBB@ HHHH *XWQW_KM$_P"O
MY*[*N-\=_P"NT3_K^2KI_$9UO@-*T[5K1=*R;3M6M%TJ#0L#I10.E% #J***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K>Z;9:DBI>VL5PJG*B10P
M!IQL;0K"IMXRL!S$-OW/IZ58HH I-I.G/??;6LH#=?\ /8H-WYU=HHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y3QAX:BU#3I+
MBTMD%XAWDHOS/[5YE;Z7>W-T+:.WD,N<8QTKWBDVJ#G _*NZACITH<MKGE8O
M*:>(J>T3MW. M]+\9Z2BK;W$<T:J J,Y8 >F*D'B;Q/8,?M^D&11W VUWE&
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M>75Z9\,Q_P 2J]]YA_*N+,/X#/3R=OZVO1G<4445\^?8!1110 4444 %%%%
M!7&^._\ 7:)_U_)795QOCO\ UVB?]?R5=/XC.M\!I6G:M:+I63:=JUHNE0:%
M@=**!THH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML]>$%"*C'9!1112*"J6KVGV[2+JUSCS(R,U=I",C!Z&G%M.Z)E%2BXOJ?/K
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M:?\ /8?D: +5%5?[1M/^>P_(T?VC:?\ /8?D: +5%5?[1M/^>P_(T?VC:?\
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M*FJI3E+=W(A3A#X58****DL**** "BBB@ HHHH **** "BBB@ HHHH ****
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M.M\!I6G:M:+I63:=JUHNE0:%@=**!THH =1110 4444 %%%% !1110 4444
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M@_YXQ_\ ?(H^SP?\\8_^^14M% $7V>#_ )XQ_P#?(H^SP?\ /&/_ +Y%2T4
M1?9X/^>,?_?(H^SP?\\8_P#OD5+10!%]G@_YXQ_]\BC[/!_SQC_[Y%2T4 4K
MRP2>%4CCC4AU;.WL#5@6T( 'DQ_]\BI:3(SC- $?V>#_ )XQ_P#?(H^SP?\
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M]/O+N2ZFFW21O*67R^^1],U?TS1=3L];N-0N-0MY5G4!T2 J>,XP=Q]:BL=
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M<T^>WAO(O+F3<F<XS5*U+%1NJ^G2@#$L-%MO[1OC);$(L@\HDG&-HZ?C70
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH R/$MA+J.A7$-LFZZ4;X.<8<=*Y^XT35QX=MKB&$?VN)O-D3<.
MK8W<].PKMZ* .,O_  U)"^FR1VLMY';Q&-X8YO+89[@Y'<TV\\.,^GV<EMI<
MB>3.TDEI]H.]]P ^]NZ_C7:T4 <5<Z ]UX<OK6UTJ6TDN)XF9))][, RY.=Q
M[#]*V?#MG>:7%+I\\8,$9S#,"/F!YP1ZC/Z5N44 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 -89JO)$,$U:I"N1B@#%>RWG)'6F'3$/\(_*MGRA2^6*
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MG\FKO;D<&N$N!CXM^'_^N$G\FK6CN_1_D85_A7JOS/4****R-PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N-\=_Z_1/\ K^2NRKC?'7^OT/\ Z_DJZ?Q&=;X#3M.U:L72LRU'2M2+
MI4&A..E% Z44 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gzbwht3f4aft000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )N!,D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ZK:VR"[LG#$HO+*3@Y^G)KI_A9KMOK_ (#T^XB6))HT\J9(\?*5X&?<@ T
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M&\2Z1KZL=.O8Y77[T1.'7ZJ>10!K45S>I>/?#.DW)MKO5K<3!]C1JX9@W3!
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M]Z]A\1:C9:?HEXUY=10!H'"^8X&3M/2@#R']G($6OB(,<D7*9/KP:]4\;_\
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M7=?;(#;I!$C2AP5#;FXS0!TOQI\.:/;_  WN+F#3X(I[>2/RY$3##+ 'GO\
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M>>B:S.)+?3?)9([F5"%DR&&1WZ\<UTWQQU;3W^'<D27<1DG93&@;YF&0<XH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B:R==BN8Y]*
M$4T87#0/QD^N:VZ*J$N5WM<BI#GC:[7H<98:!JNI:ZFJZWLC\K[D*G./RIEQ
MH>L:-KL]_HL4<T=QG?&S 8SR>OO7;45O]:G?96M:W0Y/J%/EM=WO>_6YR_AG
MP_<V%U<ZGJ!4WD^?E4_=!Y(HBTR\U;Q"U]J4?EVML<6\).=Q_O?I7445+Q$G
M)RZO\/0TC@Z:C&"V3OZOS.'U#0]8BO\ 5EL[:.>#4NKLP!CZ^_O75:/8G3=(
MMK-FW-$FTGUJ]12J5Y3BHL='"PI3<X]?\[_F<?K?AN_36AK.C.HN#]]"?O'\
M?:JUYIGB7Q'LM]0CBLK92"P1L[OU-=S15QQ4TEHKK9]3*6 IR;U:3W5]&<AX
MJ\/7-UH=A8Z;"'\B0$C('&TC/-=-I\3P:=:PR##QQ*K#W %6:*SE5E*"@^AO
M##PA4=2.[27W$%[$T]E-$GWF0@5S_@K2+S2-.FBO8O+=GR!N!X_"NGHI*HU!
MPZ,<J$958U7NK_B<A8:)?P>.[K4Y(<6KAMK[ASGVZUG6NF>)-'UJ^NK+3HIE
MG. 7D X_.O0**U6*EU2>B7W'.\!3TM)JS;^;^1QNG^&M1O\ 64U7774M'_JX
M5/W?3I6AXPT6;6-,3[*NZYA<.@R!FNBHJ7B)\ZGV+6"I*E*G_-N^IRO@S0KO
M2H;B;4$"W,S>H) ^HKHVLK1G+-:PEB<DF,9J>BHJ593FYOJ:T:$*5-4ULCD-
M0T.^F\<V>I10@VD>W<VX#&/:I8=&O4\>/J1B_P!%,1 ?<.OTZUU5%:?6)VMY
M6,OJ5/FYM?BYOF<'XP\)WM_??:]-C#^: )4# 9([\U/X@\/:A>:=I,5O$'>W
M(\P;@,5VM%4L742BOY3.6749.;U][?\ ,C@4I;QHW54 /Y5P.GZ7XDT36;Z[
MM--BG6=VQOD X+9]:]"HK.G6=.ZM>YM7PL:KB[M..UCGOL>H>(-&N;76;2.U
MD8_N_+;=^/4UCV%KXMT6 V-O!#<PCA)&<#;].:[FBJ6(:35E;L1+!QDU+F?,
MM+]7ZF;I\&H+I1CU"59;ELY(& /:LKP;I%[I-K<I>1>6SR$J-P.1^%=/14>U
M?+*/<U^KQYHSN[Q_4XG4M+UNV\7?VOIUG'<+L( =P!R,>M:UC<:_>I<PZEIT
M%LC1,$9'SDD?4UT%%5*NY12:6G4SAA%"3E&3LW>VEOR//-'T_P 4Z$EU%:Z=
M$ZS/NWM(,CZ<UKZ#X9NH=4?5]6E$MVWW%'\/^>E=9153Q4Y7T2ON12R^G#EN
MVU'9/9%>^B:>QFB099D(%8/@W1KC2]+>*^MU24N2,X;BNFHK)5&H."V9T2H1
ME555[K]3DO$6BWVM>(+%'@#:9#AG;<!G/WAZ]A3]3\$:2^G3+962I<[28SO/
M7\37545:Q-1)*+M8R>!HR<G-7<N_Z'$C1]8F\"2:7-; 7*,!&N\?,H(.<Y^M
M;OARPN-/\-V]G<)MF16#+G.,DULT43KRG%Q:ZW'2PD*<U--W2Y?D<AX;T._L
M)-7-S#L%P7\OY@<YZ5EZ%8^*/#RW$=OI4,RS.&)>4=OH:]#HJ_K4G>Z3O;\#
M+^SX)1Y9-<M[;=?D<AKECK.N^&8XYK-([T3AC$CC&T9YR35[5M"?4O#*6> M
MS$@*'/1A[UT-%1[>2M;2SN:_5(/F<FW=69Q_@C0]0TAKM[^,(9<!?F!SCZ5-
MJ.CWUQXSL]0CBS;1QX9]PX.3VKJJ*;Q,W-SZO0F."IQI1I)NR=_U,;7!K2M#
M-I)1@OWX6Q\WXUS_ /8&LZ]K5O?:Q'%;1P=(T.<]_P"==S12A7E!6BE?OU'5
MPD:LKS;MVOH5M0\_^SYQ;)OF*$(N<9-<IH'@JV_L\OK5F'NV<DY<\#\#7:45
M,*TX1<8Z7+J8:G5FIS5[=.AQ*^&;G2_&%O=:5;!+# 63#]!WZG-6M#T6]M/%
M&I7EQ"%MYC\C;@=W7M7645<L3.2L^UC*.!I0DI1Z.]NG8X_2-"U#2/%MQ+#$
M/[.G!);<./3CZUEZ7IGB70]3O;BUTR*83L?OR#IG/K7HE%5];EK=)W27W$O+
MZ>G+)JS;6W7Y&=I$^IW%LS:I:1VTH;"JC9!'YFL_Q3X<.N0Q20R".Z@.48]#
M[5T-%8QJN,^>.ATSH1G2]E/5''0/XR:)+1X((\<&Z+ G'TS_ $HO-"U*7QI8
MZCL$D$03S)-P'(Z\5V-%:?66G=)+_@F#P46DI2;LT]7V.5AT:^3QX^I&+_1&
MB(W[AU^G6H;_ $*_M_&$&JZ="&B<CS\,!WY//M7844+$SO?RL-X*FXVN]^;Y
MG(:;H=_;^-KK4980+63.U]PY^7'2D70K_3O&?V^RBW64W^M"L!CCW]^:["BC
MZS._RL"P--))-Z/F^?\ D<CX<T._T_Q-J5Y<1!8)@VQMP.<L#1XCT._U#Q%I
M]U;Q!H8OOMN Q7744?69\_/UM8/J5/V7LKNU[_C<Y+Q#X:O+C5H]8TN55NHP
M,H>^.F*IWECXI\01K9WL4-G;_P ;*P.[]:[FBG'%3BDK)VV%/ TY2;NTI;I/
M1E"UTU+#1UL8.0D>T'U-9?@[2[O2M.N8KR+RW>X9U&X'(('I71T5E[67*XOJ
M;^PASQFOLJR.2.B7W_"?)JGE#[( <ON']W'3K4.K>&]1M=:.KZ(Z^8WWXB<9
MKLZ*T6)FFGY6^1B\#2<6M=7S>:?D<WIS>)KK4(I;](;2W3[\2$-O_G5CQ7:W
MU]HCVMA'ODE8*WS ?+WZ_A6Y14>U]]326AI]77LW3<F[]>IS%AX(T>/3X4N[
M-9+@(/,?>W)_.JWAC0[_ $/7;V/R?^)?)]R0L.W3C\:["BJ>)J-24G>Y"P-&
M,HR@K./;]3DO!VBWVE7-\]Y%L65LI\P.>?:NMHHJ*M1U)<S-:%&-"FJ<=D>>
M:?I7B31-8OKJST^*9;AF +R <%LYZUH6'AO4K_68]4UR1=T?*0K@X_\ K5V=
M%;2Q<Y:V2?<YH9=3C9-MI.]NESD+S1-0D\>1:I'#FU15^?<.H'IUJ'3_  HV
MH:Q?WVN6F5D?,2&3/!SZ&NUHI?6II66FEBOJ%)RYI:ZMVZ79PVN^#VMIK2Z\
M/6@2:)]S#?\ 3'4U:U;PQ>/J$>L:9*(;T+^\0_Q&NOHH6*J:>7]:B>7T6Y65
MKVVTLUU1Y_JFE^)_$2V]O>VD,$<39\P.#G]:T->T"_N]2T>2WC#QVRHLC;@,
M8-=A13^M335DE:_XB_L^FT^9MMVU]-CE_%^@7.IQPW>G@?;(<@<XW*>H_6H]
M-\-2R>"QI-\OE3%F8<@[23D5UE%0L1-04.SN:/!4G5E5?56?8X:RM_%NC6IL
M+>WAN8APDI<#:/;FK^@>&;FQDN=0NYP^HS@X?LN>M=513EB9--))7W\R88&$
M6FVW;:[V.*NX_%]Q:RZ>]O!)')E3<;@#@^V?Z47/A2YMO!,FF6H$UU)*LC $
M 9R,XS["NUHI_6I*W*DK.XOJ$'?F;=U;7HF<P;37;+1+!-/V>="N)86(^;D]
MZSO["UK7M8M[S6(X[:. @A$(.<<^_>NXHI+$RC=I*_<J6"A*RDW96TOIH%%%
M%<YV!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6EO+: HLUQ%$TGW [A2WTSUK-\0^)K#PS:Q7%^S!)&VKM&?\]:\R^*?]J_\
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M 77\7D,2OZ@5<HHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)F@!:*;FDW4
M/HJ/?2&2@"6BH/,H\WWH GHJ#S?>CS: )Z*A\RE\R@"6BH]]+NH ?129HS0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6TCT,2@]Z>)*P+75;>Y&8+B*4#J8W#?RJ\ET#WK$WO<U U.!JBDX/>IUE!H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)VD)/"YX'T%4:*]2E0A36FYXM;$SJO78****V.<**** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?]]5Y]_PA>M_W8O^_M'_  A>M_W8O^_M'UO$?\^@_L_!_P#/]?@>@_VE9?\
M/U%_WU1_:5E_S]1?]]5Y]_PA>M_W8O\ O[5:_P##.JZ=9O=7 01)C)63)Y.*
M3QE=*[IE1RW"2:C&LKOT/3X;F"XSY,JOCKM-2UP_@ DM=Y)/ _I7<5VX>JZM
M-3:/,QF'6'K.FG>P4445L<H4444 %%%% !1110 4444 %%%% !1110 4444
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MRBWE63RG,;X[,.HH L4444 %%%5K:^MKN6>."0.\#;9 /X30!9HHHH ****
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M5NUA>,/^19NOJO\ Z$*QQ'\&7HSIP?\ O%/U7YF)\/\ [UW]!_2NXKA_A_\
M>N_H/Z5W%8X#^!$Z<V_WN7R_(****[#S0HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** $-02-@5*QJG.^ : *5W,$5B3@ 9)K
MP+QOKQUK7'",?L\!*(/7U/YUZ;\0-=_LK0Y%C;$UQ^[3^OZ9KPSJ<FO0P5+[
M;/+S"MM37S"BBBO0/*"BBB@ HHHH **** "BBB@ J6VN);.ZBN86VRQ.'0^A
M!R*BHH M:CJ%SJM_+>WC[[B4Y=L8SQC^E2Z5K.H:+<^?I]R\+G@[3P?J.]4*
M*5E:P^9WOU-C6?%&L:\%74+QY47HF<+^5=3K7CR:&QT!=#O9(Y+6R\FX7^'=
MA>W?H:\^HJ'2B[:;&BK35]=R]=ZSJ%]J7]H7%U*UT#D2;CE?IZ5L-X_\2M+#
M(=2DS%]T=C]1WKF:*IPB]T2JDULS7B\3:K#:W=LER1%=DF9<?>SUJ>Q\9Z]I
MVG_8;;4)$@Q@#.2OT/:L&BAPB^@*I-;,UKSQ+JU_J%O?3W;FYMU"QR X( JU
M<>-=>NK^VO9;UFFMB3$<<#@CI^-<_11R1[![2?<U(O$.J0:L^IQ7<D=TYRSJ
M<;OJ*FU?Q9K>N1K'?7TCQC^ '"GZCO6+11R1O>P<\K6N:=UX@U*]TJWTR>?=
M:VX C3'3%)J.O:CJEE:VEW/YD-J"(EQ]W/\ ^JLVBCE787/)]0HI*3-4*P[-
M)FFYI-U*X[#\T9IFZC=1<+#\TM,S2YHN*PZBDS2TP"O4OACX@W1/I,[G<GS1
M9/;N*\MJYI5_)IFIV]Y$<-$X-95J?M(.)MAZKI5%(^G[>3(%7T.:YW2-0BO[
M*&ZA),<JAUSUP:W86R*\1JQ]$G=719%+313J "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *1E5QA@"/0TM% %"XTNWF4D#8?45Q^NZ+.B,
M8B''IWKOCTK%U1<HU 'AFKQ212L'0J0>];OAR8"P STJYXGM_,MIACD#(KGM
M"N=MLRYZ&O*S"-VF=^&=Z;1U,UTH[U1ENE(/-9\UUG/(K*EO&\WR\\GH*X(T
M[G1L7[NYW*<&N3U.0LK5OG<4(/4=:P+Y<AZZ:228KE/0<G64Q_<;^55X+B2R
MUBX4@A9"3S6UX/M5;6UEG81QE& +>XI^NV-O-?.MN1\AX<=ZZ5&4JKC;H2ZD
M(PU?4S1=!L\U$KM(Y5>34D6ER@\L,5K66FA/NKR>IK:%!MZF4Z\8K34JP6AX
MW#)J_#9,W:MJSTHMCY:W;71P ,K79"E&.R..524MV<W;:4S$?+6Y9Z2!C*UN
MPZ<J#I5Q(%4=*UY3*Y0M[%4'2K@C"CBIL8%,-,14OB18S $C(&?SJUX1U<::
MDZ.FY'8$D=1Q534/^/*7Z#^=4]+_ -7)]17FU?\ ?H>G^9[-'_D5U/\ $OT/
M4K74+:\7,,H)].XJU7F2R/$X>-BK#H0:VK'Q3<0$)<CS4]>XKN<3R+G9T50M
M-8LKU<PS#=W4\$4Z:\5!UJ1EPL!3#,H[UASZLJY^:LZ77 #]ZAM(:3>QU9N$
M]:3[2GK7&/KP'\51-XA\OJ&_ 4N9=RO9S['="=3WIX=3WKBK?Q#'(2!(,CJ/
M2M"/6D(^]3)::T9TV12YK!35T/\ %4PU1?[PH$;&:,UD?VFG]X4?VHG]X4 :
M]%92ZDI_B%3)?H>] %^BH%N5;O4H<'H: '5A>,/^19NOJO\ Z$*W:PO&'_(L
MW7U7_P!"%8XC^#+T9TX/_>*?JOS,3X?_ 'KOZ#^E=Q7#_#_[UW]!_2NXK' ?
MP(G3FW^]R^7Y!11178>:%%%% !17.^,]:NM"T:.ZM"@D:YAB)<9&UG53^AK0
MU'4EMM$N;J*:+SH[=I%^8'D+F@#2HKAI?&-]_86AQVT4<VL:JB[ ?E5?ER6/
MMQ5B[_X3+28X[L7,&JH&'FVJ6XC;'?:1G- '8T5R.L>(M1G\10>'M$C1+HQ>
M=<3S#(A3MQW)Y].E.CD\5:5JUI'=O'JEC.VR22*$1M#[D#.1^- '64444 %%
M%% !1110 4444 %%%% !1110 4AI::QH BD; K-N9, U>F; -<OXFU-=,T>Z
MNF;:40[3_M'I^M-)MV0I-)79X_\ $#6?[4\0O$C PVPV*0>">I_7BN3I\LC3
M3/*YRSL6/U-,KW(14(J*/FJDW.;D^H44459 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%)0 9I":0FF%J3920XM3"U7].T:[U
M-LQKMC[R,.*ZZP\,V-HH:1/.D[ENGX5Y>+S6AAO=;N^R/;R_(L5C%S)<L>[_
M $.)M[*[N_\ 46\DF.NT5HQ>%]4E7=L1/9FP:[U45!A5 'L*=7AU<_KM^Y%+
M\3ZBAPGAHK][-M^6G^9PG_"):G_TQ_[[IC^%=412=L38[!^:[ZBLEGN*\ON-
MWPM@//[_ /@'F,^G7UHNZ>VD1?4CBJP:O5B >H!^M9=]X?L+T$F+RY#_ !)Q
M7=0X@3=JT;>:/+Q7"4DKX>=_)_YG !J<#6AJ?A^[T[+@>;"/XE'3ZUEAJ^@H
M8BG6CS4W='R6)PE7#3]G5C9DN:6F TZN@Y6CUGX6ZR)+&739'&^%MR GD@]?
MRXKU6WDR!7S?X0U/^RO$EK,6VQL=DA_V37T-:294&O)Q=/EJ7[GN8&ISTK/H
M;"'(J2J\39%3BN4[!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)$PQW R*IM3$4]0_X\I?H/YU3TO_ %4OU%7-0_X\I?H/YU2TPXBE^HKS:O\
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MD6;9 K5CZ5XI]"3T4@Z4M !1110 4444 %%%% !1110 4444 %%%% !1110
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M'J=H.*\R5K>Y\,VFGS>(+MV"QH;"+3U#JPQP#M'0CKFMFYU>X@\07=I+?+I
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M;@[RN=@[\_2J,-G-K&L[_F>VMUPN5./<?GDUJDK:F-VWH=+HES?ZGOGO)1'
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M\8_^^14M%%D',^Y%]G@_YXQ_]\BC[/!_SQC_ .^14M%%D',^Y%]G@_YXQ_\
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M>3\M48]#^?[M=T]NK=J8+10>E &)8Z4$QE:W(;=4 XJ58@O05)0 @4"EHHH
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MZ=="^MY%>988D/"@8)J*PT6>?63J<3)+&H_U>>OI4)OK2+4); Q@1L,^8W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7Y'C-%%%>P> %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT_2[:U7I$@6N/&SM!1[G?ET+S<NQNVZ\"KJCBJ\*\"K0KS#V!:*** "BBB@
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M(7VLQ;.-W 'O7+:PIWJ-G7E3ZBNT/AB\W(J3(R @LQ7!/K5RQ\&QPS+)</\
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MCBLZYCX-&P-7/E_4+1[#4)[612K1N5P1V[56KO\ XGZ,+74HM2C7"W'RN?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5_AK>\I?2E"@4 4H;%4'2K20JO:I:* $ Q2T44 %%%% !1110 4444 %%%%
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M"BBBK,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLCR/^P-3_P"?5Z/[ U/_ )]7KURBC^S*/F']N8GLCR/^P-3_ .?5Z/[ U/\
MY]7KURBC^S*/F']N8GLCR/\ L#4_^?5Z/[ U/_GU>O7**/[,H^8?VYB>R/(_
M[ U/_GU>C^P-3_Y]7KURBC^S*/F']N8GLCR/^P-3_P"?5Z/[ U/_ )]7KURB
MC^S*/F']N8GLCR/^P-3_ .?5Z/[ U/\ Y]7KURBC^S*/F']N8GLCR/\ L#4_
M^?5Z/[ U/_GU>O7**/[,H^8?VYB>R/(_[ U/_GU>C^P-3_Y]7KURBC^S*/F'
M]N8GLCR/^P-3_P"?5Z/[ U/_ )]7KURBC^S*/F']N8GLCR/^P-3_ .?5Z/[
MU/\ Y]7KURBC^S*/F']N8GLCR/\ L#4_^?5Z/[ U/_GU>O7**/[,H^8?VYB>
MR/(_[ U/_GU>C^P-3_Y]7KURBC^S*/F']N8GLCR/^P-3_P"?5Z/[ U/_ )]7
MKURBC^S*/F']N8GLCR/^P-3_ .?5Z/[ U/\ Y]7KURBC^S*/F']N8GLCR/\
ML#4_^?5Z/[ U/_GU>O7**/[,H^8?VYB>R/(_[ U/_GU>C^P-3_Y]7KURBC^S
M*/F']N8GLC#\*QO%HZQNI#*V"#6Y5#3/N3_]=3_*K]>A%65D>1.3E)R?4***
M*9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% #&7-5I8@:N5&RYH P-0T^&Z@>&>-9(W&&5AP17B/C'P
M;-H,[7-LK/8,>#W3V-?0LL6165>V$=Q"\4L8>-AAE(X-;4:TJ3NMC#$8>-:-
MGN?,-%=[XO\  ,VGL][IJ-);]6B R4^GM7!$$'!ZBO7IU(U%>)X-6E*E+ED%
M%%%69A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%36MK/>7"P6\;22L<!5&30-*^B(E5G8*H)8G  KU3P/X$\@QZCJ<>9
M?O1Q$?=]S[U<\'> 8]-V7E^HDN^H7LG_ ->O1H+?&.*\W$8J_NP/6PF#Y??J
M;]A+>W  XK1CC '2DCCQ4X%<)Z0 4ZBB@ HHHH **** "BBB@ HHHH ****
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MOKFVL?%VGZZ\@_LZ:V,0E'*J>V3V'-6=$D&J^+;[5;<$V@@6%),<.023C\Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=2/%.1 !4@%<QU@!BG444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO^^5_P * -&BL[[!>?\ 03F_[Y7_  H^P7G_ $$YO^^5_P * +%__P >,O\
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ML-Y_T$I?^^5_PH N>1#O+^5'O/!;:,FE\J/R_+\M=G]W;Q^54OL-Y_T$I?\
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MI;*I'5B,L?QK>BML=JLI"/2IU3%<;;;NSO45%61$D0':IU6G 4N*0P I:**
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M*4MV;1A&/PJQ02U'I4ZVX]*MB,4\+4E$"P@=JE" 4\"EQ0 @6EQ2T4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!1O
M?^/NS_W_ /"KU9VHRQPW%H\C!5#\D_A4O]J6/_/U'^= &=XOT:?7_#D^GVS(
MLLC(07.!PP-0ZUH%SJ/@LZ-$\8G,:+N8_+E2"?Y5K_VI8_\ /U'^=']J6/\
MS]1_G0!R.N>$=6NI]%NM.GMTN-/MQ$?,Z9 Z]*N:/X7U ZX-;UV[CFO$7:B0
MKA1[UT7]J6/_ #]1_G1_:EC_ ,_4?YT <=KG@.?5/%*WL4J)8R,K3Q[B"2.^
M*[P#  ':JG]J6/\ S]1_G1_:EC_S]1_G0!<HJG_:EC_S]1_G1_:EC_S]1_G0
M ^__ ./&7_=J2W_X]HO]P?RJC>ZE9/9RJMS&25X&:D@U.Q%O&#<Q@A #S[4
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M% #=M+BEHH 3%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.U+_7VO\ O_X5)4>I?Z^U
M_P!__"I* ,/Q;_R+TW^\G_H0K*U+36B\,&X^V7#C8I\MB-O4>U==+#'/&8Y4
M#H>H-(\$4D/DNBF/IM(XKEJX;VDI2?56._#XUT81BEM*[_#_ ".1OW5-3T)G
M8*H@&23@#BK.KW$>J:M96MH1*4?<[IR%_&NAELK:8*)(4;8,+D=!3H;6"W_U
M,*)GN!4_5I:J^C:_ T^NP]V5GS137EK?_,Y?6ICHNO"^5,I/$5('KQ6MX:MC
M;Z-$S<O+^\)(YY[5IS6T-P )HE?'3(J15"J%4  = *N%!QJN=].GSW,JN+4Z
M"IVUTN^]MA:***Z3A(+W_CSE_P!VGP?\>\?^X/Y4R]_X\Y?]VGP?\>\?^X/Y
M4 8WBB],%@MK&?WMPP08Z@>M5-:TXVGA>""-?]2ZL^/H<FNCDMX99%DDC5F3
M[I(Z5(RJZE64,IZ@BN:=#G<FWNK+R.VEBU2C!16SN_/^D<G>W,.HW^CI;,)&
M!W,%YVCCK4FH:7;+?I;V2D74AW$Y^6(=V^O^%=%#9VT#;HH$1CW HCM((KB2
M=(P)9/O-G.:CZLY7YK7?]:&OUY1LH722?S;=]3EK#5+BUFA@C\H1>?Y1B(^?
MM\Q_.M[7K3[9H\\8^\HW@_3FK?V.V$WG>2GF?WL<U,0""",@\$5<*#4'"3NF
M95<5%U8U(1LT>?-=3:AY=_@HE@B*??D?XU>@+7NEZOJ;@@R_*A_V01_A76K9
M6R1O&L*!'.67'!IRVT"P&!8E$1_AQQ6,<').\I7_ ,]OR.J>90:M&-K-?==-
MK[SBKN&'^SM)FD0;3@.Q]*T=8AMI=6T2%%5K=B0 IX(XKHVM+=X1"T2&,=%(
MX%'V6#,9\I<Q?<X^[]*KZH[-::V_ AY@KIV>G-^-_P CE[>)+76-4@A&R+R\
M[0>.]9TB[]"L%.<&Y(_E7=?9H?,:3RUW.,,<=:;]BMMBIY*;5.0,=#2E@VU:
M_?\ %W*AF,4U)KM^"L<]';16?BZSCMTV*]N68 ]3@UM:K%:3V1BO'V1,1\V<
M=ZM&"(S+,47S%& V.0*66*.9-DJ*ZGL16\:/+&4>YR5,3SSA-WO%?/<Y*W"V
M?B.W@TVZ>:%E/F#=N4<<<_E706[ZI]H/VI+=8!GE<Y_G5J&TM[<DPPHA/<"I
MB 00>AI4J#@M^O38K$8I5&K1Z6N]_4Y66ZMCXRCE$\7E^5C<'&.W>E\U+/QF
M\L[JD<D1*N3@?G6[_9=C_P ^L?Y5-+:6\X EA1\=,BL_J\][J][FOUREHDG;
MEY?^"8?AW,^HZE?(#Y$SC8?7%/\ %T"2:.9CQ)$P*D>YK<CB2% D:!5'0 42
MQ1SQF.5 RGJ#6GL/W+IOJ9?6_P#:562T5ON6GY''ZO;_ &70-,CB)5&D!D8]
M.?6I]/M$M;QYTO+>51$2T4&?F&/K74/!$\7E/&K(/X2.*9#96T!)B@1<C!P*
MR^J^_P WI^!M_:%Z3@_/YW9P-S<)/%#-%!;P S# 1CYG7OS6S)90ZAXP:*X!
M9!;ABN>O3K71?V=9Y)^S1Y)S]VIA!$)O.$:B0C&['.*F&#:^)WU7X&E3,HOX
M$UHUOWM_D<AJUM!8WCSHT$T<:A#;R-RH]N:ZNQE$UC#(J% R@A3VHDL;663S
M)((V?U(J<  8 P!V%;TJ+IS;Z,Y,1B55IQB]UU%HHHKH.,**** "BBB@ HHH
MH CTC_4S?]=#6C6=I'^IF_ZZ&M&@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *5_;37!A:!HPT;9^?.#^50^1J7K:_FU:=% &9Y&I>MK^;4>1J
M7K:_FU:=% &9Y&I>MK^;4>1J7K:_FU:=% &9Y&I>MK^;4>1J7K:_FU:=% &9
MY&I>MK^;4>1J7K:_FU:=% &3-9ZC+$T9:U&X8SEO\*<EMJ*1JN;7Y0!U:M2B
M@#,\C4O6U_-J/(U+UM?S:M.B@#,\C4O6U_-J/(U+UM?S:M.B@#,\C4O6U_-J
M/(U+UM?S:M.B@#,\C4O6U_-J/(U+UM?S:M.B@#,\C4O6U_-J/(U+UM?S:M.B
M@#,\C4O6U_-J/(U+UM?S:M.B@#,\C4O6U_-J/(U+UM?S:M.B@#,\C4O6U_-J
M/(U+UM?S:M.B@#,\C4O6U_-J/(U+UM?S:M.B@#,\C4O6U_-J/(U+UM?S:M.B
M@#,\C4O6U_-J/(U+UM?S:M.B@#,\C4O6U_-J/(U+UM?S:M.B@#,\C4O6U_-J
M/(U+UM?S:M.B@#,\C4O6U_-J/(U+UM?S:M.B@#,\C4O6U_-J/(U+UM?S:M.B
M@#,\C4O6U_-J/(U+UM?S:M.B@#,\C4O6U_-J/(U+UM?S:M.B@"GI]M+:PNLS
M(69MWR9Q5RBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gzbwht3f4aft000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,[!UX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDKSJBCZ_6#^R<-Y_>>B_\)QIW_/.2C_A.-._YYR5YU11]?K!_9.&\_O/1?\
MA.-._P"><E'_  G&G?\ /.2O.J*/K]8/[)PWG]YZ+_PG&G?\\Y*/^$XT[_GG
M)7G5%'U^L']DX;S^\]%_X3C3O^><E'_"<:=_SSDKSJBCZ_6#^R<-Y_>>B_\
M"<:=_P \Y*/^$XT[_GG)7G5%'U^L']DX;S^\]%_X3C3O^><E'_"<:=_SSDKS
MJBCZ_6#^R<-Y_>>B_P#"<:=_SSDH_P"$XT[_ )YR5YU11]?K!_9.&\_O/5]*
M\06FK,XBRI7^\>M:U>0:1(Z:I;A6(!?G!ZUZ\/NCZ5Z&$KNM%\VZ/'S#"1P\
MTH[,6BBBNL\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI=Y,\&G'[<HW?[(KSFYYN'(! +<9%37I*G*R9.$Q,JZ=U:Q%1116)V!1110
M4444 %%%% !1110!<TK_ )"EM_OU[ OW1]*\?TK_ )"EM_OU[ OW1]*];+OA
MD?/9U\<?06BBBO2/%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MY3QU_P @R+_>KSVO0O'7_(,B_P!ZO/:\/'?QF?4Y5_NR]6%%%%<9Z04444 %
M%%% !1110  $G K;TJ#58]LD$;M'Z \5B D'(K1M]<U"UB\N*<JH[5M1G&+N
MV_D85XSE&T4OF=I>,CZ/)]KB6.3;QD<U5\- >3*%Y&P_RKDKG5[V\7$\Q84V
MVU.[M%*PRE01BNE8N/M'*VZL<*P$_9.%]6SL](M56\-T_ 5CS^-3*FG?VB7%
M_P#.6SLKB5UB]6,QB8[2<D54$T@F\T-\^<YI1Q<8\J2V!X"<I-RE:YV'B2S
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG[:"C&+>C-%AIS:TU2.E^R^5HR1/_?INL>9'IXCA.-R<U6U+Q#93Z<JQRCS
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MN'5KL/HJ,3PL<"6,_1A2^;'G&]<GMFD ^BD+*HR2!]30K*PRK CV- "T444
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M,5I0ESTYS>[M?U(K1Y)P@MM6OF=S1114%A1110 4444 %%%% !1110 4444
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M!11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG54@Z-13GJO78\\D;?(S8QD]*;5B]18[R5$^Z&XJO7F'M1=TF%%%% PHHHH
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M_P"@!+_G\:3_ (61J?\ T )?\_C1[.0_:1/0A:VX)(MX@3U.P<TC6-HQRUK
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M\_C2?\+-U7_H79?\_C1R,/:1/2([:"+_ %<,:?[J 4OD0AMPB3=Z[1FO-O\
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MVB'_ )Z"@"6BHOM$/_/04?:(?^>@H EHJ+[1#_ST%'VB'_GH* ):*B^T0_\
M/04?:(?^>@H EHJ+[1#_ ,]!1]HA_P">@H EHJ+[1#_ST%'VB'_GH* ):*B^
MT0_\]!1]HA_YZ"@"6BHOM$/_ #T%'VB'_GH* ):*B^T0_P#/04?:(?\ GH*
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MHOM$/_/04?:(?^>@H EHJ+[1#_ST%'VB'_GH* ):*B^T0_\ /04?:(?^>@H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *M+_JOPJK5I?]5^% %7O11WHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* )(?OTZ?J*;#]^G3]10!#1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]XV_P"0
M3#_O5-X&_P"00_\ O_XU#XV_Y!,/^]4W@;_D$/\ [_\ C7!_S&?(]9_\B[YG
M44445WGDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!Y9)_R-G_;:O4E^Z/I7ELG_ "-G
M_;:O4E^Z/I7!@=Y^IZV:;4_06BBBN\\D**** ///BG_QXVWUKQX]:]A^*?\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH Y[QM_R"8?]ZIO W_((?\ W_\
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MUZ&'^ \[$?&)2&EI#6Y@(>E-IQZ4V@8AI*4TE(!#24II*!C310:*0#*2EI*
M$H/2B@]*!C:;3J;2 0TAI32&@8E-/6G4T]:0!3:=3: "FTZFT@$I*6DH&-I*
M6DI (>M)2GK24 -I#2TAH&--%!HI#$I#2TAH ;2&EI#2&)2&EI#2 2FTZFT
M)3:=3:!B'I6_X7_Y&'3_ /KJ*P#TK?\ "_\ R,.G_P#745,MAK<^N8O]2G^Z
M*?3(O]2G^Z*?7&=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)
M8EF0HXR",&N'\0^%M.@C>6&%MYYXKNZ:\:.,.H;ZBE;5,=]&CFM \-:?;VD-
MPL1$I&3FNG' Q2*H484  =A2U<I79$8V04445)04444 %%%% !1110 4444
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M110 4444 %%%% !1110!)#]^G3]138?OTZ?J* (:*** "BBB@ HHHH ****
M"BBB@ HHHH *9-_J7^AI]-D!,3 =2*3V&MSS6]L1?Z\L6,DYHDOC'%-:2'B,
M;5K=M]*NU\1QW#1'RAG)JKXF\.SS3)+:(6).6Q36D8KHQ/6<G]Q-IU\MGX8B
M8G[QVU>T&V%I:37#C&YMPKG;>&:2"/39 1(C!BM=;J$%PNC&&VCW/L%7/:4E
MU(@M8P?34YAXDU/4+PRNNU!E<FM+PI>>7_H98$Y[&JUGX,:XC\Z>>6*1Q\R@
MFG6/AZYTG6E>'?)$!]XFG"R?+_5PG>5Y';44U,[%W=<<TZLRT%%%% !1110
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M3C/(K6IM-;B33V"BBBD,**** "BBB@ HHHH **** "HI_N5+44_W* *]%%%
M!1110 4444 %%%% !1110 4444 %%%% !5>ZM(KN$QRJ&!]:L44; U<\^OO#
M$J7ZI']USU Z5UFCZ/%IT"_*#)CEJU, ]0*6M9UIS5F84\/3IR<HH****R-P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *M+_JOPJK5I?]5^% %7O11W
MHH **** "BBB@ HHHH **** "BBB@ HHHH 9+$DT91QE3U%<3K?AIEN/,@'R
MNV, =*[FD(!Z@&M*=65-WB95:,:JM(P="T&.QB#R -)U!K?Z445,I.3NRX0C
M!<L0HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH DA^_3I^HIL/WZ
M=/U% $-%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6%A;"Y-QY0\
MT]6JSTHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#GO&W_()
MA_WJF\#?\@A_]_\ QJ'QM_R"8?\ >J;P-_R"'_W_ /&N#_F,^1ZS_P"1=\SJ
M*JW\WD6KN/0U:JK?V_VBU9!Z&NR=^5V/+A;F5SA-$L#KU]-+=MYB1R$;36]-
MH":<9+BU(B51G KG]-OF\,WLJ70(1W)X':M.XUZ768Y8K#)7'<5K)Z)TS/[3
MYS/6?5M;N\6EVT*#BF0ZS?V"W$%Q.TCCA6J+2-5_X1^8P7@(R2>!4!BGU5[F
MZ13Y:G(X[4;64=K!)ZN^]]"2WNM9U%W$5XZ;5W4VRO\ 6+X/"MVX8-MW5J>&
M4($V5/\ JCV]C47AI"+F;*G_ %I[>]&UUY7!N]Y>=B+3];OXA>033,[Q+PU0
MZ?)K>IVYDCOF7DU#M(U#4SM/3THT+7X=.LS$^<Y(X%&Z;ZV!KE=EM<D&KW$V
MF7EO=.7=/ER:F367L?#]JD3[&8[<^E4([.>:SO;DJ=K'<.*2?2GET2UD*G;G
M+?2F]M>^OW!IT^1;_M*_TZ5;B74Q.F,[ :B\1+=7?V&;S_\ 6\K[=:2WA\,,
M LAG+]ZU/$=O&EMI\ML"88QGIVYI2LN5ON$+MZ=BG<'5=*TN&3[:2"X&!^%:
M%_KER((K:*4B:1 0PK-U74HK[1($C#%O,';Z4E];3V\EM>A3LC09XIO5^]M<
M4=$K;V+$PUO3HX;F:^9T<\K4=]K]]/,/L\S(,8P*=J&O)JUK;VUN&,@.&R*J
M?8I;2^5)%.2,]*(J[M+:^@7LKK>SN3M=ZOIEY:/<7C21R\[:]"M;C[18><.X
M-</XH4[]-PI^[Z?6NOT?/]B+G^Z?Y4KWI-OHPM:<?-'(WNKWT>MK$L[!#GBJ
M45WK.H7%T(;QD$7-&H*W_"0(=I[]JO>'%/F:EE3T]/I2@O<O_=_4JJ[3LNY<
M\*ZM=27?V2ZE,C@=378S0QW$9210RGJ#7G_AU6'B9N"!M]*[+6-0_L^PDE&=
MP&13J-<L9/JA03YY17<Y?Q/IFFVRQFVB03;NW6LZ]FNXM#:)G923QFH;;6]/
MNKXSZAYG7(P.]:>N2QZMI37%BIV+QR*5N6*OW5RKIRTZ)A)H5K'H(O/+7SO+
MW;O>IO#"6^IZ2D5Z@D &<FJ#>(X9=)&G8;SMFS&.]5(KV71-(C0 B3.&X[4[
MVYK[/8A*ZCWZEN\LX(?$ENNG(%7OM]:Z#6M+O+O3 5N-NQ<L/6L/0]9T:"0.
M_F&8G/(KH=7\1V4&FDMNQ*N%P*51<L$MQQ?--LP?!L7E7H7TKT"O,O#>MVUO
MJ +AP"?2O2HI%EB61>C#(JYW<8OR%&W-)+N/HHHK,L\LD_Y&S_MM7J2_='TK
MRV3_ )&S_MM7J2_='TK@P.\_4];--J?H+1117>>2%%%% 'GGQ3_X\;;ZUX\>
MM>P_%/\ X\;;ZUX\>M>AA_@/.Q'QB4AI:0UN8"'I2 %B !R:M65C+?W*P1 E
MF]J]:\,?#VUBMUFU")9&897VK.I44-S6G2<]CRJ'0M2N5W0VKL#Z4^3PWJT2
M[GLY !WKZ(M=(L[)0L$6T"IIK*"="DB94US?67V.CZJNY\O2Q/"Q612I':HZ
M^@M4\":3>1.8[91*1PQ]:\;\3>'9=!OV@D=6/4!:VIUHST,:E%PU.?-%7[?2
M;RY7<D$F/78:671+Z(9^SRGZ(:TYD9\K,RDJV=.O1_RZS?\ ?!J)[.Y3[T$B
M_531= TR"@]*4@J<$$4AZ4P&TVG4VD AI#5FSM6O+N.W0@-(V 370:UX'O=%
MT];N:5&1CC J924;7ZE1BY.R.5IIZUU>C^"+W6-/DO(945(S@@UA7.E74%W)
M;B)Y&0X)52:')*7+U'ROEYNA1IM69+*ZC&7MY5^J$4"PO& (M9B#T^0T7%8K
M4VK$EG<Q#]Y;RKG^\A%*-/O&&5M9B/9#1<+%6DK8TSPY?ZG<K D,B$G&60UI
MZEX2N?#MZ%O8FGC!&=BYI-I-)O<:3:?*KV.2I*[75/['O8HH-/TF>"8K@LR'
MD_E45U\/]2LM-AU!_GC?G8HY%1SI*\M$5R-M*.K../6DKMH)M#BT5XI]'N&N
M@?\ 6;#C^5<K+8W,LSM!:3;"> $/%/F]YH7+[JE^!1I#4LL$L+8EC=#Z,,5$
M:H0TT4&BD,2D-+2&@!M(:6D-(8E(:6D-(!*;3J;0 E-IU-H&(>E;_A?_ )&'
M3_\ KJ*P#TK?\+_\C#I__745,MAK<^N8O]2G^Z*?3(O]2G^Z*?7&=P4444 %
M%%% !1110 4444 %%%% "'I7F?B&YFMO%$CP1>8V.E>FGI7,77ARXGUUKX.O
MED8Q2BOWB8V_<:.9L'?5-8MY;I?(=#@+ZU)=(!KLR'D;JZ2]\.227D%Q;,J&
M,<U67PO>&_-Q)*IR<FKBU>/2QG).TNMT82VUO_PEL2&)2A3.,?2@K%<ZY'%(
M J*^ O8UM:KX6OI]16[LI5C95QDU#>>$;^0PRP3(LZ<LWJ:4'91;Z%35W*W4
MH>+(+>RD!M0J/O (7ZU2M(%N]>M%E&05Y!_"MRW\):C/<F34YTF']:N0>%YX
M=8AN@Z^7&,8IPM%I/S)J7DG9=CF;]4T[6%\L!5W\XJ]J.NH\YAM]+CG.W[V*
MTM4\)W-]>^<LBA=V<&JDWA#58[KS+*X2-<8Q4K6*3\RGI)M>1A:,KW<=VA38
M6;[H[5>75#8I_9Y;D?+BMS0_"UWI\K27,BN6.3BH;_P9-=:P;M70)N!Q5NS:
MCT:)C?5]F85]9?9=+DR.6.ZG:N@DBTA#T/'\ZZS6?#TU_;"*%E7"@<_2JEWX
M6NIQ8;9%'V?[WOUI)W=WW?Y#2M;T-S1K""UM%*1J&_O 5IU#;1&& (>HJ:B;
MO(4%:*04445)84444 %%%% !1110 4444 %13_<J6HI_N4 5Z*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ JTO\ JOPJK5I?]5^% %7O11WHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** )(?OTZ?J*;#]^G3]10!#1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M <]XV_Y!,/\ O5-X&_Y!#_[_ /C4/C;_ )!,/^]4W@;_ )!#_P"__C7!_P Q
MGR/6?_(N^9U%%%%=YY)6EL+2<YEMT<^XI8K&U@_U4")GT%6** *LFFV4S;I+
M:-CZD4]+*VC0JD**IZ@"IZ* (8[6"+.R)5R,<"A+2WB)*0JI)SP*FHH R-6T
M^-K*<PP+YC*>0.36)X6T0);?Z9:+NS_$*[*BG%\M_,)>\DB 6=LL900H%/48
MH^R6_EB/R4V#MBIZ*0%+^R=/!S]DBS]*G>TMY$"/$I4= 14U% %0:99!0HMH
M\#MBI6M+=TV-"I7T(J:B@"HFEV,;;DM8P?4"I&L[=VW-"I;U(J>B@""2TMY=
MOF0JVWID=*E5%1-JJ OH*=10!7-E;,^\P(6]<4Y+2WCW;(E7=UP.M344 0)9
MV\<GF)"BMZ@4^6"*9=LB!E/8U)10!2_LC3_^?.+_ +YJ9;*V2/RUA0(?X0*G
MHH I_P!E6 ;<+6+=ZXI[Z?9R##V\;#W%6:* *8TFP4Y%I$#]*?)I]I*H62W1
ME'0$59HH IKI5@ARMK$#]*MJH50%& .@I:* "BBB@#RR3_D;/^VU>I+]T?2O
M+9/^1L_[;5ZDOW1]*X,#O/U/6S3:GZ"T445WGDA1110!YY\4_P#CQMOK7CQZ
MU[#\4_\ CQMOK7CQZUZ&'^ \[$?&)28)Z4M:NA:>=0NGC S@9K:3LKF,5=V.
M\^&.A0SP?VE(,R(^ "./\\5ZF  , 8%<OX%L#I^CO$1C+Y_G74UYM67-)L].
ME'EBD%%%%9FA7OI_LUE--W1":\<@M'\;>*Q+<9$ RI*^QKOO'FI-8:6%4X\T
M%:I_#:Q2/13.Z#S"Y.>];0]V+D8S]Z2B=78Z5:V5K' D,9"#&2@JQ]EMCUMX
MO^^!4U%97-;%<V-JPQ]FA_[X%9M]X8T^_7:\:K_NJ*VJH:KJ<&F64DTKJI"Y
M4'O0F^@-+J>+^//#NE:-(XMY6,X_A-<$>E;_ (LUUM<UB2Y *J>-M8!Z5Z--
M-1U/.J-.6@VFTZFU1!I:#_R'+3_KI7M_B&WT:?08UU>=HHMW!7UX]Z\.T21(
MM9M7=@JA\DFO2O'6JV-UX<BC@NHW</T!^E8XG507F;X;^(_0Z;0+71X]!N$T
M>=I8R>2W_P"NI+30GM%DNK6V26:09PZYYKEO VKV-GX>N4FN8T<MPI-;5OXH
MM-3CELQ?):E5P),]:RK1DJDN74UI2BZ<>;34MW.C3:GI!;4[2*&;=T11T_(4
MNK75MH6GP[;>$LJ<;D'-<K<:9+"?,'BT3_-_J\__ %J["_L;2[TFW6[ND3]W
M]]N]1-62:>ERXN[LUT,?5((=>\,VU\((UE+;@$0#GBJ.AW'BMSL31[1K=3C<
M4&?_ $&K.I^(M,T/2;6RMYHKD(X!*GMQ6G'JVFW]JK0ZK%9Y RH/>JCHVXKW
M;DRU45)^]9FI(38-:,UM"DTI^<!!Q^E<OXV\1SV^IBR$$+)N'+*,]?I6AK'B
M'38'T]%OXIRK?,P/UK(\40Z3JLRWR:K"K%A\F?\ ZU1!>_%O:^II>T6ENUH6
M=?G2SBLKJ.WAW^4&QL%7=7\27%KX4M;E8(F:48(*C _2N>\7ZOI_V"W6&ZCE
M*1 8!JW#<Z5K?A&VMY=0A@DC7.":.5NFW_>_ F,DJL+_ ,OXDVD30ZEX0FN+
MB")6\SJ$'O6K;X73'.BVL-Q,%^8.@Z_D:P].GTNQ\*S67]I0ER^1S]:KZ-I5
MO97JW@\4QB,MN:+/7VZ5<XJ4Y):(F+:A%O5W9Y]XREU634)#J=I%;R9Y6,8_
MH*Y0UZ1\3-6L;ZZDCMBDA#9\Q>]>;FJP[O#:Q&(5I;WT&FB@T5L8B4AI:0T
M-I#2TAI#$I#2TAI )3:=3: $IM.IM Q#TK?\+_\ (PZ?_P!=16 >E;_A?_D8
M=/\ ^NHJ9;#6Y]<Q?ZE/]T4^F1?ZE/\ =%/KC.X**** "BBB@ HHHH ****
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M1?W6_*K7E)_<'Y4>4G]P?E0!5_M*+^ZWY4?VE%_=;\JM>4G]P?E1Y2?W!^5
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M '11L7^Z* (/MB>AH^V)Z&I]B_W11L7^Z* (/MB>AH^V)Z&I]B_W11L7^Z*
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M]39(2QCQD;CDU*J3YUS;/8OV<'%\NK6_D<=2&EI#72<PVD-+2&D,2D-+2&D
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M_P#R,.G_ /745,MAK<^N8O\ 4I_NBGTR+_4I_NBGUQG<%%%% !1110 4444
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M44 20_?IT_44V'[].GZB@"&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y[QM_R"
M8?\ >J;P-_R"'_W_ /&H?&W_ ""8?]ZIO W_ ""'_P!__&N#_F,^1ZS_ .1=
M\SJ****[SR0HHHH **C>>*/[\B+]6Q31=6['"SQD^S"@":BL6X\1VUO?FT9&
M+@XR*V4;>BL.XS1TN'6PM%%% !1110 4444 %%1-<P(<--&I]"PIR31R?<D5
MOH<T /HI&94&68 >YJ'[9;?\_$7_ 'V* )Z*S[_5H+% [?.",_*:GL+Q+^T6
MXC!"MT!H6JN#T=BS1110 4444 %%%% !11378(C,>@&: '45C6?B.WO+O[.B
M,&SC)K9IVTN'6P4444@"BBB@#RR3_D;/^VU>I+]T?2O+9/\ D;/^VU>I+]T?
M2N# [S]3ULTVI^@M%%%=YY(4444 >>?%/_CQMOK7CQZU[#\4_P#CQMOK7CQZ
MUZ&'^ \[$?&)2&EI#6Y@(>E-IQZ4V@8AI*4TE(!#24II*!C310:*0#*2EI*
M$H/2B@]*!C:;3J;2 0TAI32&@8E-/6G4T]:0!3:=3: "FTZFT@$I*6DH&-I*
M6DI (>M)2GK24 -I#2TAH&--%!HI#$I#2TAH ;2&EI#2&)2&EI#2 2FTZFT
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M*BEB3SBO0]#T*/3X0[@-(>0?2NRM&G2I\G4X,/*K6J\^R-RBBBO//4"BBB@
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M '_\:A\;?\@F'_>J;P-_R"'_ -__ !K@_P"8SY'K/_D7?,ZBBBBN\\D****
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M:/\ \@]*OU$E:314'>*84445)04444 %%%% !1110 4444 %13_<J6HI_N4
M5Z*** "BBB@ HHHH **** "BBB@ HHHH **** *>H:?%?P,DB@G'RD]J\XU?
M2)=.N&4@E?4#BO4ZIZAI\-_;F*4?I6]"NZ3\CFQ&'C6CYGE\6H7$,#0I(0C=
M14=O;2W<P1%))/85JWOAVZAO1$J<.?EKK]"T*/3XA(Z_OB/FS7=4Q,(1O#=G
MG4L)4G+EGL@T+0H]/A5Y &EZAO2MRBBO,E)R=V>Q&*BK(****DH**** "BBB
M@ HHHH **** "BBB@ HHHH *M+_JOPJK5I?]5^% %7O11WHH **** "BBB@
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M#,H+#H:?110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5I?\
M5?A56K2_ZK\* *O>BCO10 4444 %%%% !1110 4444 %%%% !1110 4UXTDQ
MO4''3-.HH  ,# HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"2'[].GZBFP_?IT_44 0T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/>-O^03#
M_O5-X&_Y!#_[_P#C4/C;_D$P_P"]4W@;_D$/_O\ ^-<'_,9\CUG_ ,B[YG44
M445WGDA1110 4444 13R-'$S(NY@#@5Q>H:]JTXDA.C,RYP#7<T4K7W'>VQY
MYINA73P7<SQM&TB\)1H:ZG;0M8M:.J<G?7H=%4W>_F3;[SRDV>H0-<QMIC3>
M8W#D=*LZ9I5\L;[K5DRIP*]-HHOHUW"WO)G->$K.>VTZ1)XRC%R0#^-8#VFH
M:=KKS0VKRI))DGTKT2BFY/VG.)12@X=RI%))<6+,\91RI^7\*XB#3+Q;R5C
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M6Y@(>E-IQZ4V@8AI*4TE(!#24II*!C310:*0#*2EI* $H/2B@]*!C:;3J;2
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M\^+T<R[CY7V.=I#70_\ "%:__P ^+T'P3K__ #XO2YD'*^QSM(:Z+_A"=?\
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M;!_ST%'VV#_GH*[SR2Q15?[;!_ST%'VV#_GH* +%%5_ML'_/04?;8/\ GH*
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M@_YYBC[%!_SS%6** *_V*#_GF*/L4'_/,58HH K_ &*#_GF*/L4'_/,58HH
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MT7]VI:* (OLT7]VC[-%_=J6B@"+[-%_=H^S1?W:EHH B^S1?W:/LT7]VI:*
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M_P!R@"O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %6E_P!5^%5:M+_JOPH J]Z*
M.]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!)#]^G3]138?OTZ?J* (:*** "BBB@
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M** )(?OTZ?J*;#]^G3]10!#1110 4444 %%%% !1110 4444 %%%% !1110
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M]:ODO?L\P(YD!_6M(8:7,E+8SGBH\C<=SOHI%E0.O0C-9]]K=KI\L<<V=SG
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M.UV.S3A)?GQ]?_UUUU<?;-]K\2VLZ<JB!2?RKL*SD:1"BBBI*"BBB@ HHHH
M**** "BBB@ HHHH *BG^Y4M13_<H KT444 %%%% !1110 4444 %%%% !111
M0 5%) DARPS4M% 'GGB/0YK:=KA1N5SG '2L>POYK"<.C$8KU>>!+B)HW (8
M8Z5Y_P"(/#[V,C30J?)]:]##UU)>SJ'EXG#2@_:TSJ++Q!!-8-,Q 9!R">M<
M?K>MR7\S*K$1YX%8XD= 5#$ ]>:O:5I<VHW 5%R!R:UCAX4FYR,98JI62IQ6
MH:9I4VI3JB@@'^(CBO1],TR'3K=510'(^8CO2Z;IL.GVX2,>YR*O5Q5Z[J/R
M/0PV&5&/F%%%%<YU!1110 4444 %%%% !1110 4444 %%%% !5I?]5^%5:M+
M_JOPH J]Z*.]% !1110 4444 %%%% !1110 4444 (1D8/>N-\3Z%(SM=Q#(
M_N@5V=(RAU*L 0?6KIU'"7,C.K3C4CRL\@AFELYPRDJRFN]T3Q#'<VVR9L.B
MY))ZUF>(O#FS=<6RY7JU<B&>)B 2#]:])QAB8W6YY*E4PD[/5'2>(/$#7+M#
M"Q"5A6=G+?7"JJD[CR<465E-?W CC!+&O1M%T:+3H =O[QA\V:4YPP\>6.XZ
M=.>*GSSV$T718].A4E09>[5L445YDI.3NSUXQ459!1112*"BBB@ HHHH ***
M* "BBB@ HHHH **** )(?OTZ?J*;#]^G3]10!#1110!7O_\ CQF_W:\ZLK6Z
MNM7=+:;RV(ZUZ5+&)8FC;HPP:S;30;6SNC<1[MYKHH5534K]3FQ-*55)+N95
MKX=:SB>:X822=0:YH07,NK7(MI-A'6O3)(Q)&4/0UF0:!:07+SKG<_6KIXBS
M;D9U<*G!1AW.4T3Y-85;OF3'WC2>(HO[/OH;B,<$YXKK)?#]I+=BY)8.!CBG
MWVB6NH1(DV<(,"J^L1YU+[R5AI*,H=]CDM"!U767GD!*D9&:[BXAC>U\N3 7
M&.:JZ;HMMIG^HSTQS5VX@6YA:)R0#Z5E7J1G)<NR-<+1E3BW/=G#7UM)I5R9
MK2[0!CRJFJ5_=7%Y"LL@8KN'45U9\(V+2^87D)SGDU>?1+5[3[.1\OTK98B"
ML]V8O#3E)]$SG-2N;9]'2-<-)LP #7.O$Z6=L6!'S"NW3PC8)*) TA(/0FK4
M_AZSN%0-D!#D8IPKTX;=R9X:I-:]$<6^8]:@>4?*$')_"I-:FAEN;/RL<'G'
MXUU]YX=L[T 2;A@8XJLOA"P5U;<Y*],FB.(IZ-] >%J)22ZFAIG_ "#!]#7)
M-G_A(XL?WC7;PVZ00^4OW:H_V%:_;5NN=ZG(K"%2*G)OK<Z)T9.C&"W5CCYR
MT>NLTP(7?P34WB&2*YN0L(#-M'*\UU5_H5KJ&/-R,=Q5>U\+V5I+YBEV/^US
M6L:\-&]T8SP]3WE':1R.G1?\3*V#CD-7I( 5<#@5E+X?M%N5G&=RG(K5(R,>
MM95ZJJ6L;8>@Z;E?J9&JV.GWF?.:,28X)-<A-YME>+#!,&C9L$+Z5T6N^'#>
M*TL#/YV.!FDTOPM#!$K3[O,(YR:THSA"%V_D9XB$YSY5'YF5-I$J3&XM[V.)
MB.A/-9^E6LTNK*TS;U5N6[5UMQX5L[B7S&DD!] :MVVB6MK"T:9P>YZU2Q,5
M'N1+"2E+MKW*&H:=HWE2.1$9<'O7,:295N"B9$.3]*ZJ7PG932F1I)<GMN-7
M;;1+6UA\I <>IJ(UHQ@U>]S25"<JB=DDF<%:V:W,M\2,LIX_2JZ/<2!+#)PA
MSBO0;;P_:6SRNF[,AR<TU/#EE'>-<C.\UJL5"^NQ@\'4L[;W_ Y&2U%MK5HH
M'5<FO0+;_CW3Z51FT*UGNX[AL[T&!6DB!$"CH*YZM53BEU1U4:#IU)/HQU%%
M%<YU'/>-O^03#_O5-X&_Y!#_ .__ (U#XV_Y!,/^]4W@;_D$/_O_ .-<'_,9
M\CUG_P B[YG4445',Y2)F'4 FNYNRN>2245YZ/$GB"[O)(K-(R%8J,UHG5-?
ML[=Y;U(QA<C%-Z1YF'VN4[&BN#\.>,;K4=1%O<[1D]JZ;6M6&G6+2*1O*Y6G
M-<B38H/F=D:U%<-X8\5WVK:DT%P%VA<\5>\3>(YM+81V^#(5R :)+ELGU"+Y
MFTNAU=%8^@ZJVI6BM)CS,98"K]],T%LSIU I3]S<(/GV+-%>>P>(?$E_/.+2
M.-DC;'-:6E^)[D79MM3PL@XP/6J46W83DD=A16-?>)M.TY@L\A!(SQ4EAXAL
M-11V@DR$ZYJ5JKHIZ;FK4;S11L%>15)[$UB7/C#2K2<PRRG>/053N=4T;4+F
M.9II P' %"UV!V6C.J!!&0<BD>1(UW.P4>IK&F\0:;IMK&TDAV'I52YU_2-4
MLB&E<1D]1Q0_(%TOU.D21)!E&##V-.K$T^^T^WM'DAD8QJ.2:KGQMHXDV>:V
M2<=*;6MD)/2[.CHK)E\16$,'G/)\F,U27QKH[R*@E.6.!Q2MK8+JUSHZ*B@N
M$N8A)&<J:R=9DUE"/[.C5ACG-#T=F-:ZHVZ*X2U\3:M!=O!J*HI' QZU9M_$
MUY+X@CLVV^4PS5*-VDNHG*R;?0[*BL#7M8FT^.,PE26'-5EU#6KS1X[BS1&E
M8\YJ5JF^P^J7<ZBBN%@\1:S:ZI%:ZDB*']*V]8\0)868D0_,PXH>B3[B3N[&
M_17)>&O$-YJDP6<+@^E=;52BUN"DG<****D9Y9)_R-G_ &VKU)?NCZ5Y;)_R
M-G_;:O4E^Z/I7!@=Y^IZV:;4_06BBBN\\D**** ///BG_P >-M]:\>/6O8?B
MG_QXVWUKQX]:]##_  'G8CXQ*0TM(:W,!#TIM./2FT#$-/@AEGE6.!2TAZ 4
MB(9)%11DD@5Z]X)\&VUC"MYJ/E^<?F1B0,"LJE101I3IN;)?!5E/I%D9]3N6
M6-TXCDZ"NBM=6T6Y8Q6LT*RG.-O6JWB6P.K6RP6]Y;JHZ@R#_&N4L/ TFGW8
MN(;VU5P>OF+_ (UQZ2U9VZQT1S7C31=3BO7G=I9H2Q()Z**XROI22TL[_3!:
M74\,C%-IPXYKQ;QEX6;1+QY8@!;$X4"MZ-6_NLYZU*WO(Y&DI325T'.)0>E%
M!Z4#&TVG4VD AI#5BTM7O+J.W0@-(<#-;^M>";_1=/6\GDC9"<8'_P"NIE)1
MM?J5&+D[(Y>FGK4R6\TG^KB=_P#=4FE:SNEY:VF ]T-,""K.GWK6%['<J,E#
MG%1K:W#KE8)6'J$)H-E=#_EVF_[]FA.PK7/1$^*D)MTCN=(29E.0S>OYUSOB
M;QK-X@&P1&&/;C8#Q7/):3JZM);3;,\_(>E=///X<.AND>EW O.,2;3@?I6,
MJ<%[UKFT*D[\M['&TE66M+ACE+:;:>GR&HY+:XC&9()$'JR$5I<SL04E3K:W
M$G*02L/]E":1[6X3[]O*N?5"* (#UI*G^Q71Z6TQ^D9IKVMPGWX)5SZH10!!
M2&K LKIAE;:8CU$9J]I/AV_U>_CM(X9(W?H70@4)7 QS176W7@F]T?4[:*\3
MS(WD"G:M=-XO\'Z=8>'_ +18V;^=QRHS_(5G*I%14M[NQI&G)RY?*YY72&K]
MI!Y%Y&;VUE\K/S*4(S70ZY-X=DTJ)=/TRXAN,_,[*<']*J3LD]Q1CS2ML<;2
M&K(LKI^4M9B/:,U&;:<':8),^FPT"(:0U8:RNU&6M9@/4QFJ[ @X-(!*;3J;
M0 E-IU-H&(>E;_A?_D8=/_ZZBL ]*W_"_P#R,.G_ /745,MAK<^N8O\ 4I_N
MBGTR+_4I_NBGUQG<%%%% !1110 5@Z]I)O9;>2([2CY..];U96K:[;Z2BF16
M<MV3DTXWOH*5K:DL.GQ-,L[H-X&.:KW7A^">7?'B/U '6J5KXRM;F81_9YTS
MW92!_*K>I>)+735C+(\GF#(V<U5I)V%>+5R[:Z9;VT158UW$8+8ZU)9V<=E&
MR1@ ,<G%<\GCFR:14:WF3<< LI']*T-0\26NGE1(C,64, M)QD"E$OPV$,4D
MK!1^\^][U0N?#T,LV^,B,>@%4$\;VC2JAM;@;CC)4X_E6A>>)+2TLQ<%692<
M87DT<LD'-%EB'1[6"1)$C4,O<"IXK**.XDF"C<_6LBR\5VUY,L0@E4MT+ _X
M5IVNJ0W5W);("&3K0TUN":>Q!?:)!=-O7$;>H%0VVBV/G*Z['DC/7'-6IM5A
M34!88/F$9![5B:)J @GU*29LK&V0._:A7L#M<Z%+")+][L ;V&":=)91R7:7
M! WKT-<__P )O:%P/LL^"<9VG_"M"?Q):06AG(+ #.T=:'&2!2BS0NK..Z*%
MP#M.1FHDTR%+O[0%&[&*RK7Q?:W,JH()EW' )4_X5LWU_'8VWGR E?:AIK0$
MT]2A-X>MI&9D549CDD"A-&AM;9P$#R,I&['-5;3Q?:7EVMND$P).,E3C^52Z
MCXIM=/F:)HI'9>H09IVE>PKQW'>'M+-C!)YOS.7)!/:MRLO2=<M]6CW1HR'.
M-K\&M)Y$C^^ZK]3BIE>^I4;6T'45#]KM\X\Z/_OH4J7$+G"R(3Z!A2&2T5$]
MQ"APTB ^A84Y9HG.%D1CZ!A0 ^BN<UW7'T_4+6)"2KGY@O-1W'C2TM'V2V\V
M?7:?\*I0;V)<DCIZ*YC_ (3:QV;O)E^F#_A6GI.N0ZN7\J*1-O\ >!%#BT',
MF:E%->1(QEW51[G%1BZ@/_+:/_OH5)1-142W,+G"RH3[,*'N(4.&E0'T+"@"
M6HI_N4Y)HI/N2(WT8&FS_<H KT444 %%%% !1110 4444 %%%% !1110 444
M4 %1SP1W$9210P/K4E% '$7OA0_;U\MB4<Y..U=3INFQ:?;JBJ"PZMZU>HK2
M56<E9LRA1A!N44%%%%9FH4444 %%%% !1110 4444 %%%% !1110 4444 %6
ME_U7X55JTO\ JOPH J]Z*.]% !1110 4444 %%%% !1110 4444 %%%% #71
M9%*N 5/4&N1UKPP))Q+!T=N5 Z5V%%7"I*#O$SJ4XU%:1D:-HL6G0C(#/UW>
ME:]%%3*3D[LJ,5%604444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M444 %%%% !1110 4444 %%%% !1110 4444 <]XV_P"03#_O5-X&_P"00_\
MO_XU#XV_Y!,/^]4W@;_D$/\ [_\ C7!_S&?(]9_\B[YG44445WGDA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!Y9)_R-G_;:O4E^Z/I7ELG_ "-G_;:O4E^Z/I7!@=Y^
MIZV:;4_06BBBN\\D**** ///BG_QXVWUKQX]:]A^*?\ QXVWUKQX]:]##_ >
M=B/C$I#2TAK<P$/2FTX]*;0,0TE*:2D AI*4TE QIHH-%(!E)2TE "4'I10>
ME QM-IU-I '2E,DF/OM^=--(:!B^8_\ ?;\Z0R2?WV_.DIIZTAB[VQC<?SI-
M[#HQ_.BFT +O8=&(_&DWOC&YOSHIM( +L1]X_G2;VQC<<?6BDH -[CHS#\:G
ML[GR;V&61F*HX)YJM24)V=P/1_$WC33M3\/&SMF<2X _2O."['JQ/XTAZTE9
MQ@HMM=2W-M)/H+YCCH[#\::9'/5V_.DI#5DBF1_[[?G32[$<L3^-(:*0Q=[X
MQN;\Z:78\%C^=%(: %\QQT=A^-(99/\ GHWYTVD-(8ID<]78_C3#2TAI )3:
M=3: $IM.IM Q#TK?\+_\C#I__745@'I6_P"%_P#D8=/_ .NHJ9;#6Y]<Q?ZE
M/]T4^F1?ZE/]T4^N,[@HHHH **** "BBB@ HHHH *@:TB>Y6<CYU'!J>B@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ()[6*XQO7I4D<21+M4#
M'TI]% !1110 4444 %%%% !4$]I%<??6IZ* &1Q)$H5!@"FS_<J6HI_N4 5Z
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JTO^J_"JM6E_U7X4 5>]%'>B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH DA^_3I^HIL/WZ=/U% $-%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+EEW#FAV.N_X0$_]!.V_[Z%-_P"$!/\ T%+;_OH5R/VB?_GM)_WT:0W$^?\
M72?]]&CEEW'S1['7_P#" '_H*6W_ 'T*3_A #_T%+;_OH5R'VB?_ )[2?]]&
MF_:)_P#GM)_WT:7++N'-'L=C_P *_/\ T%+;_OH4W_A7Y_Z"EM_WT*Y#[1/_
M ,]I/^^C3?M$_P#SVD_[Z-'++N'-'L=C_P *^/\ T%+;_OH4G_"OC_T%+;_O
MH5QWVB?_ )[2?]]&D^T3_P#/:3_OHT6EW#FCV.Q_X5Z?^@K;?]]BD_X5Z?\
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MH8C4>4W  Z4[^T?^F3?E5J)5\E.!]T=J?M7^Z/RKE.PI?VC_ -,F_*C^T?\
MIDWY5=VK_='Y4;5_NC\J *7]H_\ 3)ORH_M'_IDWY5=VK_='Y4;5_NC\J *7
M]H_],F_*C^T?^F3?E5W:O]T?E1M7^Z/RH I?VC_TR;\J/[1_Z9-^57=J_P!T
M?E1M7^Z/RH I?VC_ -,F_*C^T?\ IDWY5=VK_='Y4;5_NC\J *7]H_\ 3)OR
MH_M'_IDWY5=VK_='Y4;5_NC\J *7]H_],F_*C^T?^F3?E5W:O]T?E1M7^Z/R
MH I?VC_TR;\J/[1_Z9-^57=J_P!T?E1M7^Z/RH I?VC_ -,F_*C^T?\ IDWY
M5=VK_='Y4;5_NC\J *7]H_\ 3)ORH_M'_IDWY5=VK_='Y4;5_NC\J *7]H_]
M,F_*C^T?^F3?E5W:O]T?E1M7^Z/RH I?VC_TR;\J/[1_Z9-^57=J_P!T?E1M
M7^Z/RH I?VC_ -,F_*C^T?\ IDWY5=VK_='Y4;5_NC\J *7]H_\ 3)ORH_M'
M_IDWY5=VK_='Y4;5_NC\J *7]H_],F_*C^T?^F3?E5W:O]T?E1M7^Z/RH I?
MVC_TR;\J/[1_Z9-^57=J_P!T?E1M7^Z/RH I?VC_ -,F_*C^T?\ IDWY5=VK
M_='Y4;5_NC\J *7]H_\ 3)ORH_M'_IDWY5=VK_='Y4;5_NC\J *7]H_],F_*
MF27^Y<>4P_"M#:O]T?E44RC9T'Y4 9WVO_IFWY4?:_\ IFWY59P/048'H* *
MWVO_ *9M^5'VO_IFWY59P/048'H* *WVO_IFWY4?:_\ IFWY59P/048'H* *
MWVO_ *9M^5'VO_IFWY59P/048'H* *WVO_IFWY4?:_\ IFWY59P/048'H* *
MWVO_ *9M^5'VO_IFWY59P/048'H* *WVO_IFWY4?:_\ IFWY59P/048'H* *
MWVO_ *9M^5'VO_IFWY59P/048'H* *WVO_IFWY4?:_\ IFWY59P/048'H* *
MWVO_ *9M^5'VO_IFWY59P/048'H* *WVO_IFWY4?:_\ IFWY59P/048'H* *
MWVO_ *9M^5'VO_IFWY59P/048'H* *WVO_IFWY4?:_\ IFWY59P/048'H* *
MWVO_ *9M^5'VO_IFWY59P/048'H* *WVO_IFWY4?:_\ IFWY59P/048'H* *
MWVO_ *9M^5'VO_IFWY59P/048'H* *WVO_IFWY4?:_\ IFWY59P/048'H* *
MWVO_ *9M^53C4/DQY3?E3L#T%6E5?*Z#IZ4 9OVS_IFWY4GVO_IFWY5:P/04
MF!Z"@"M]K_Z9M^5'VO\ Z9M^56<#T%&!Z"@"M]K_ .F;?E1]K_Z9M^56<#T%
M&!Z"@"M]K_Z9M^5'VO\ Z9M^56<#T%&!Z"@"M]K_ .F;?E1]K_Z9M^56<#T%
M&!Z"@"M]K_Z9M^5'VO\ Z9M^56<#T%&!Z"@"M]K_ .F;?E1]K_Z9M^56<#T%
M&!Z"@"M]K_Z9M^5'VO\ Z9M^56<#T%&!Z"@"M]K_ .F;?E1]K_Z9M^56<#T%
M&!Z"@"M]K_Z9M^5'VO\ Z9M^56<#T%&!Z"@"M]K_ .F;?E1]K_Z9M^56<#T%
M&!Z"@"M]K_Z9M^5'VO\ Z9M^56<#T%&!Z"@"M]K_ .F;?E1]K_Z9M^56<#T%
M&!Z"@"M]K_Z9M^5'VO\ Z9M^56<#T%&!Z"@"M]K_ .F;?E1]K_Z9M^56<#T%
M&!Z"@"M]K_Z9M^5'VO\ Z9M^56<#T%&!Z"@"M]K_ .F;?E1]K_Z9M^56<#T%
M&!Z"@"&.]VMGRV_*EEOMQ'[MA^%685&_H/RITZC(X'Y4 4/M?_3-ORH^U_\
M3-ORJS@>@HP/04 5OM?_ $S;\J/M?_3-ORJS@>@HP/04 5OM?_3-ORH^U_\
M3-ORJS@>@HP/04 5OM?_ $S;\J/M?_3-ORJS@>@HP/04 5OM?_3-ORH^U_\
M3-ORJS@>@HP/04 5OM?_ $S;\J/M?_3-ORJS@>@HP/04 5OM?_3-ORH^U_\
M3-ORJS@>@HP/04 5OM?_ $S;\J/M?_3-ORJS@>@HP/04 5OM?_3-ORH^U_\
M3-ORJS@>@HP/04 5OM?_ $S;\J/M?_3-ORJS@>@HP/04 5OM?_3-ORH^U_\
M3-ORJS@>@HP/04 5OM?_ $S;\J/M?_3-ORJS@>@HP/04 5OM?_3-ORH^U_\
M3-ORJS@>@HP/04 5OM?_ $S;\J/M?_3-ORJS@>@HP/04 5OM?_3-ORH^U_\
M3-ORJS@>@HP/04 5OM?_ $S;\J/M?_3-ORJS@>@HP/04 5OM?_3-ORH^U_\
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M:/\ TR;\JN[5_NC\J-J_W1^5 %+^T?\ IDWY4?VC_P!,F_*KNU?[H_*C:O\
M='Y4 4O[1_Z9-^5']H_],F_*KNU?[H_*C:O]T?E0!2_M'_IDWY4?VC_TR;\J
MN[5_NC\J-J_W1^5 %+^T?^F3?E1_:/\ TR;\JN[5_NC\J-J_W1^5 %+^T?\
MIDWY4?VC_P!,F_*KNU?[H_*C:O\ ='Y4 4O[1_Z9-^5']H_],F_*KNU?[H_*
MC:O]T?E0!2_M'_IDWY4?VC_TR;\JN[5_NC\J-J_W1^5 %+^T?^F3?E1_:/\
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M0 4444 %%%% !5I?]5^%5:M+_JOPH J]Z*.]% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!)#]^G3]138?OTZ?J* (:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@"2'[].GZBFP_?IT_44 0T444 %%%% !1110
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M#%<O)X4\(VLJVD\;_:"=O7O3O#?C\ZKJL4<RK N<;13M8\/WM[X@2]A#F'S
MVX=,5@H.$U%Z)FW-&<)/=Q,Z7X<6_P#;RQHH%H5SR:?JFA>#-&"I<P3>81U4
M<5K^)=0NTNU@TU3-.%'RCK5RU$^J:'/_ &QIJ6[1K@.PYH4I<JE?1?>-QCSV
MMJU]Q8L%T'_A$XS'&?LNT[<CGI7B?B.*Q?4F.E0R^5D[LKWKV:UMXY?#JVUF
M1(44G ^E<#_PELGAR22UN]$@9RY(+J,XS2C_ !9/^F$_X2CYLW?A1$WEWGR
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M110 445!<W<-I$9)W"*.I- $]%0V]U#=('A<,IZ$5-0 4444 %%%% !1110
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M%% !1110 4444 %13_<J6HI_N4 5Z*** "BBB@ HHHH **** "BBB@ HHHH
M*0LHZD"EJ":W$S9)(^E &-J?B2&RF5 ,\X.#6GIVI0ZA )$(!/;/-<%X@TNX
MM;II6!V,>.:JZ3JTNG7"LIX]S7=]54J?-!ZGG?7)0JN-161ZI4<TR0QEW8
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M/XXC@DVM83X]=IK2M?$EM<V,ER%P$Z@FN.O=;U.^C/V:WA,..NT9_E619RW
MTN]SQD_-BA+W7\ART>AU6H^-89X)(4M)2"I&[!Q69X6UV*PB;?&Q!<G/XU?T
MZ.U;PRK.!OV'M6)868GT.8H/F\PX_6JC:$I+TN2VYP7KH>BW.LPV]HEP1D.N
M0*L:=?+J-HMPJ%0W8UYV=2:]N+*S4Y\L[6%>C6-N+6U6(# %'+:+;Z[>@<UV
ME]Y9HHHJ"PHHHH **** /+)/^1L_[;5ZDOW1]*\MD_Y&S_MM7J2_='TK@P.\
M_4];--J?H+1117>>2%%%% 'GGQ3_ ./&V^M>/'K7L/Q3_P"/&V^M>/'K7H8?
MX#SL1\8E(:6E52[JHZDXK<P$CBDF<)&I9CT KOO#WPWEU&-9YY6B&,X(ZU'X
M-\-R#7[9YTS&1D\?2O5]3U2UT*RW2<*J\#-<E6L[VB==*BK<TCE)/AE;/%L$
MR@^N*R)OA$-Q*W_Z?_6K5M?BAITMT$*R8)QS_P#JKN[:YCNH$EC8%6&>#FLG
M.I#<V4*<]CR^W^$8$JLU]P#G!'7]*[_1?#]KH\"I'&A<?Q 5KT5G*I*6YI&G
M&.P4445!85YE\3O$"P6T=O;RY9OE<*>E=3XG\46VBV4A$@,@&1M-> ZSJ<FJ
M7\L[-D,V16]&FV[LYZ]1)61G$Y)/K2'I10>E=QQ#:;3J;2 LV%K]MOH;?=M\
MQL9]*ZKQ%X$&B:6EX+KS-S8VUSV@_P#(<M/^NE>W^(9]&@T&-M7@:6+=P%]>
M/:LJ\G%1:ZLUH14IM/L>8^'_  '_ &YI<MV+K84.-OK7/ZKX<O\ 3;AU:WD,
M8/#D<&O;O#]WH[Z%</HT#11@\AO7\J9.B>(;5K8X9HQ652K)5'9:+H:PI1=-
M7>[W/#;?0M4NXO,M[*61/4"I/^$7UO/_ "#IORKV_3A_PCVA^1G:^_M3?$?B
M&XTZ6P$+,/-7)P*J5;WK1VO84*-X^]H[7/"+K2+^R(%S:R1Y.!N%2P^&]8N$
MWQ6$SKZ@5[CJVEQ:[I5I<3+F0R DGZBJ/B?7+CPJL<%B2B>6"0![4E5>D7NW
M8%14ES1VM<\6GT;4;9U2:TD1F. ".M3KX6UMUW+ITQ'KBO=TM+76[+3KRZC+
M2D;LGUJ\3?V6IN_VR%+ )Q&6 .?SI.LUI+<<:*DKQ>AY7X&\.21WZ)J=@1EN
MD@K,\:^'KD:Y=?8K!A"IS\@X KT:TUUM4\11J'W!'*]:L6^HBY\0:G92'C85
M J93G)QG;6VWS+IPC!3CYG@EOI-_=OMM[5Y&Z8%6(_#>L2LRII\S%>H Z5[E
MHFAKH0:Z8!?F)S]:M:]>G1=*FO+([99$W;AZTYXA15Q1P[;:\SY^GT#5;8XF
ML94R<<BI?^$6UO9O_LV;;ZXKT3P7JVI>+]7:/4YA+&J[U'H:]">WU2/4H4:_
MMTL0,-&S@$_K5SE*%HO<SC&,FW'9'S;%H^H3S-#%:R-(GWE Z5;'A372,C39
M\?05[A8V-G:ZW=SVY0L[?,58&BW\279\:'3!(?L^S.VI55RLH[VO]Q<J2BY7
M>BM^)X8OA?6VSMTZ8XZ\5O>');C2I)H9O#QNY A!##E??K7J=UXAFMO$EM90
ML5CF?#CUK4AM8HM:OY$7#-&<G\Z7M7R7MHT'L8\UKZH\#U#2]2U>\,MII,D8
MR?D4?_7JC<>&=:MHR\VGS(H&22*]62#Q3+JC#1KM((]Q^^.^?K77_8M4?P[>
MC6KF.X<1<;#T_4U/M.2DI(IPYJSB^Y\R$%3@C!IIK0UB)(=0D1!A16>:VC+F
M29E4CR2<>PE-IU-ID"4VG4V@8AZ5O^%_^1AT_P#ZZBL ]*W_  O_ ,C#I_\
MUU%3+8:W/KF+_4I_NBGTR+_4I_NBGUQG<%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %13_<J6HI_N4 5Z*** "BBB@ HHHH **** "BBB@ HHHH ****
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M25@.6(ZU%_PC44>I"[@81 #[JUO447=[A96L-1=J!<YQ3J**0PHHHH ****
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M* "BBB@ HHHH **** "K2_ZK\*JU:7_5?A0!5[T4=Z* "BBB@ HHHH ****
M"BBB@ HHHH **** "D95;[R@_44M% !THHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"2'[].GZBFP_?IT_44 0T444 %%%% !1110 4444
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MZ*.]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!)#]^G3]138?OTZ?J* (:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1NNO[HH MT54W77]T4;KK^Z* +=%5-UU_=%&ZZ_NB@"W153==?W11NNO[HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#GO&W_ ""8?]ZIO W_ ""'_P!__&H?&W_(
M)A_WJF\#?\@A_P#?_P :X/\ F,^1ZS_Y%WS.HHHHKO/)"BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $D/WZ=/U%-A^_3I^HH AHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.>\;?\@F'_>J;P-_R"'_ -__ !J'QM_R"8?]ZIO W_((?_?_ ,:X/^8SY'K/
M_D7?,ZBBBBN\\D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /+)/^1L_[;5ZDOW1]*\MD
M_P"1L_[;5ZDOW1]*X,#O/U/6S3:GZ"T445WGDF9""(QFI*;&1LQGFG4 <%\2
M\&RM_K7DYZUZE\1F)@B'H:\M/6O0P_P'G8CXQ*0TM(:W,!#TJYI2E-2MY61O
M+1\L<5)HVF-JVHQVBYR_I7N-CX2LDT5;9H4$C)M+XY%8U:JAH;TJ3GJ7='U*
MTDTA9XG C ]?:H-.\4VFI7;00EB5;:>*P5^'TL?[N/4YECST!XKI=%\/V^D1
M$+AW/.XCFN)J*.U.3'^(O^01<?\ 7,U@?#+_ )%V3_KL?YFM_P 1?\@BX_ZY
MFL#X9?\ (NR?]=C_ #-"^!@_XB-K6O$5OHUQ!'/N_>=,"K8U*VN]-DF21=I1
MNI]J35M(@U6W:.11NQA6QR*Y'_A7TZ?(FJSA/0'BDE%K4;<D]#RGQ'MN-1ED
MA4E Q!./>L$U]%6W@FRATN2T<+(SG/F$<UXMXLT&71M1DRA$;-\I]:ZZ51/W
M3CJTFO>.<H[445L8B4VG4V@!54NP4=372:9X%U;5H%E@50IZ;N*S_#UNMSK5
MJC]#)@UZKXWNVT'0$CM!Y9#8RO'I6=:?LTN[-*,/:2?9'FFK^#=3T9"UR%(
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M4AC/&Y:A2VTW7]&>1+&&)E0ME5IRK6NTKV$J#LN9VN>76L7AAM&;SDF-[GC
MXJ!O ^IRVDM]!'_HRC<,CG%>D:'IUE;>%9YGM(I'64@$CZUT<>LQ1>'[B46<
M>V*/.W'!J:U3E<G'=?<53I-J,9>?J?-S02AMOEOG_=--,,@ZQN![J:]-T_Q+
M/?:F\UIX<AF##[H6NS6P76?#UP][HT5E+G PO-:.;@N9HE4U*?*F<7:^"-*E
M\+"_=&\[RBWXUY?* LC*.@)%?05S;K:^&)H5Z+"0*^?IO]<_^\:SA-RJS[:#
ME!1I1[Z_F1TAI:0UN8C:0TM(:0Q*0TM(:0"4VG4V@!*;3J;0,0]*W_"__(PZ
M?_UU%8!Z5O\ A?\ Y&'3_P#KJ*F6PUN?7,7^I3_=%/ID7^I3_=%/KC.X****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *BG^Y4M13_<H KT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4455O;V*R@9Y& .,@'O0E<&["W
ME[#91>9*<"FV.HP7Z%H6X!Q7G>LZU+?SM@D)Z U=\+K=F\1EW>5GYO2NMX5Q
MI\[.*.,4JO)%:'H5%%%<AVA1110 4444 %%%% !1110 4444 %6E_P!5^%5:
MM+_JOPH J]Z*.]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!)#]^G3]138?OTZ?J*
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M@ HHHH **** "K2_ZK\*JU:7_5?A0!5[T4=Z* "BBB@ HHHH **** "BBB@
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M_P"__C4/C;_D$P_[U3>!O^00_P#O_P"-<'_,9\CUG_R+OF=11117>>2%%%%
M!1110 4444 %%%% "%@HRQ 'J:A-[:@X-Q$#_O"JNN,5TF<@X.VO.=,TI-3F
MG>:XF!1"PPQI)W;\@>B3[GHFIZW;:=9M<DB15_NG-3Z??IJ%NLR*0&&>:\FG
MO9DTR:UW%DW$9)R:UM.US6[*S0Q0H8%7DGT_*K25FR9-W2/3Z*YJUUF^U'1D
MN+-%><GD5D7&O^)+!]UY;QI$.I_R*5K2Y6-.\>9'>45QE]XMFCL+>2WVM++Q
M@U+8ZOKH'G7\")!CJ/\ ]5%M&^P7V\SKJ*X-_$VN3/,]I#&T,1^8G_\ 570:
M!K9U.%5E($V,L!346U<3DDS9>1(QEW51ZDU&MY;,<+<1D^@85!J6F1:E T4C
MNH;NIK@M7TB/0[^U-K/*Q=^0S&IB[RL^I;3M='I><]**J:<[R6:M)]ZK=-JS
ML3%W5PHHHI#"BBB@ HHHH **** "BBB@#RR3_D;/^VU>I+]T?2O+9/\ D;/^
MVU>I+]T?2N# [S]3ULTVI^@M%%%=YY)3&!:J35>?_4G%/F.+)/K2A/,4+ZB@
M#AOB3_R"+/->2'K7KWQ/79IMJOH:\A/6O0P_P'G8CXQ*EMD$EW"AZ,X%15+:
MN([R%ST5P?UK=[&*W/H7PUI<6GZ2D2J,. Q_*K4VAZ;.Q9[2,L>Y%5_#>I1:
MEI:21GA0%/Y5/?ZW:V$D<<AW,YP IKRG?F/45N4MVMI%9Q"*% JCL*J:[J!T
MO2)KL)N\L9Q5VWG6XA$B@@'UKG_&MU$OANZCWJ6*\#/-$5>0V[1(9-4&J^%7
MN=NTO$21Z5D>!;T6'A&:=AP)3_,T_2863P5O/0PFL[PU;O<^!+B-.OG'^M:V
M5FC*[NGY'8^'=<?6&N-T101G /K6W-"DZ;'4$>AKB_ E["S7<!8*\9P03C/2
MNV9@J,W4 9K*2LS6#NC-C\/:8C%OL<18G.<5/>V$,^G2VP0!63 ]JJVWB&TN
M;GR!E&SCYCBKU]=);6,LY885<]:-;ZAI8^<?%FE#1];DM@<XYK!-=!XOU1=7
MUV2Y4D@\5SYZ5Z,;\JN>=.W,[#:2EIIID@:0U?TB".ZU2WAE&4=\$5Z!XM\'
MZ;I^AQW%E:MYI;!P,^E14DH6OU+IP<Y61Y?33UKU+PCX,T[4]%GFN[9O.4X4
ML,5@^(/ -[IKFXC*?9V/R@=14SJ1C/D94:<I1YD<73:[#2?AYJNL67VJ!XU3
M./FJ\?A/K0(!F@&>F2/\:ISC%V;)C"4E=' TVNGUGP3J6BE?/*MN;:"HS6A9
M?#'5[Z 2K+"@/9R ?YTE.+7-?0;A).S6IP]*D3RMMC4LQ["NJD\ :K'=BW)0
ML6P#VK5'PTUW3'687$"MGC)'^-"G#1MZ,'3GJDM3B;G2;^T0//:R1J1D$BJ%
M>E^(M+\5/#%!?W,3H4PN/3\ZSK?X6ZQ<VR3B:%5?IN(_QJ(SO=LN4+62['"'
MK25V6H_#?5]/;$C(_NO-6O\ A5>L+9BY>XMT4KN 9@#_ #JO:1M>XO9RO:VI
MP1I#79VOPXU6[W^5+$0BEB<^GXU4TOP-J6K3O% R!E8J<^HHYX]_,7+*U_D8
M<&CZC=1EX+221 ,D@4XZ'J8@\[[%+Y?]['%>W^&M*N-'TB^MI2IECB(R/6N5
MDM_%5QHCM#<QBR+D;3U_G6<ZEFU'I;\36E2<HIR/*F4JQ5A@CJ*0 LP4#))X
M%=['\+];O<S&6$;N22?_ *]5]3^'&LZ+'%<O)$X+?*4Y_K5<\5\3(4)2^%'+
MOHFI1VQN'LY1".KD<5GL".#7I\UEXNN/"TN^YC-D,!DQSW]ZSH?A5K5W;+=&
M>!%<;OG(']:3E9N^R'&-X)K=GG](:["W^'FIW6KOIL4T+2H,D@@C^=:8^#^N
M.#B>WR.V1G^=-R2U%R2;M8\[IM>ACX1:XVX>= "HR02/\:X_6M#NM"O#;7.-
MX]*7/&]KC]G*U[&73:=3:HD0]*W_  O_ ,C#I_\ UU%8!Z5O^%_^1AT__KJ*
MF6PUN?7,7^I3_=%/ID7^I3_=%/KC.X**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *BG^Y4M13_ '* *]%%% !1110 4444 %%%% !1110 4444 %1O$KG+
M &I** ."\1Z!)%*UQ%EPQR0.U<]:7<ME.&1B"/2O6Y8EFC9'&01@UPGB'P\;
M9FG@7]WZ"O0P^(4E[.9Y>*PSB_:TS=L/$D,FGM)(55T'0GK7(ZSK,M_.P#$)
MG@5D_,F5Y%:>D:1-J-P !\HY.16T:%.BW-F$L35KI4XH-(T>74;A1@JAZM7H
MUA816,"HB@,!@D=Z-/L(;"W$<2X]:N5P5Z[JOR/2PV&C1CYA1116!TA1110
M4444 %%%% !1110 4444 %%%% !5I?\ 5?A56K2_ZK\* *O>BCO10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 20_?IT_44V'[].GZB@"&BBB@ HHHH **** "BBB@
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MK<^N8O\ 4I_NBGTR+_4I_NBGUQG<%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %13_ '*EJ*?[E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDD
M22H5=00?44^B@#C[[PHKWZM'G8QRWM726%A%8VZQH!D=\<U<HK2564E9LRA1
MA!MQ04445F:A1110 4444 %%%% !1110 4444 %%%% !1110 5:7_5?A56K2
M_P"J_"@"KWHH[T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% $D/WZ=/U%-A^_3I^HH
MAHHHH **** "BBB@ HHHH **** "BBB@ HHHH :Z*Z[64$>AKD=4\*B2\5X0
M2KMEL=J["BKA4E!WB14IQJ*TD9^EZ7%IUNL:@$CN1S6A114MMN[*225D%%%%
M(84444 %%%% !1110 4444 %%%% !1110 4444 <]XV_Y!,/^]4W@;_D$/\
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MHJ9;#6Y]<Q?ZE/\ =%/ID7^I3_=%/KC.X**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *BG^Y4M13_<H KT444 %%%% !1110 4444 %%%% !1110 4444
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M>BCO10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#O4&A1^WR_\ /NU'V^7_ )]VJ_10!0^WR_\ /NU'V^7_ )]VJ_10!0^WR_\
M/NU'V^7_ )]VJ_10!0^WR_\ /NU'V^7_ )]VJ_10!0^WR_\ /NU'V^7_ )]V
MJ_10!0^WR_\ /NU'V^7_ )]VJ_10!0^WR_\ /NU'V^7_ )]VJ_10!0^WR_\
M/NU'V^7_ )]VJ_10!0^WR_\ /NU'V^7_ )]VJ_10!0^WR_\ /NU'V^7_ )]V
MJ_10!0^WR_\ /NU'V^7_ )]VJ_10!0^WR_\ /NU'V^7_ )]VJ_10!0^WR_\
M/NU'V^7_ )]VJ_10!0^WR_\ /NU'V^7_ )]VJ_10!0^WR_\ /NU'V^7_ )]V
MJ_10!0^WR_\ /NU'V^7_ )]VJ_10!0^WR_\ /NU'V^7_ )]VJ_10!0^WR_\
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M?^>+4>?+_P \6K6HH R?/E_YXM1Y\O\ SQ:M:B@#)\^7_GBU'GR_\\6K6HH
MR?/E_P">+4>?+_SQ:M:B@#)\^7_GBU'GR_\ /%JUJ* ,GSY?^>+5*+V4)M^S
MM6C10!D^?+_SP:CSY?\ GBU:U% &3Y\O_/%J//E_YXM6M10!D^?+_P \6H\^
M7_GBU:U% &3Y\O\ SQ:CSY?^>+5K44 9/GR_\\6H\^7_ )XM6M10!D^?+_SQ
M:CSY?^>+5K44 9/GR_\ /%J//E_YXM6M10!D^?+_ ,\6H\^7_GBU:U% &3Y\
MO_/%J//E_P">+5K44 9/GR_\\6H\^7_GBU:U% &3Y\O_ #Q:CSY?^>+5K44
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M\6H\^7_GBU:U% &3Y\O_ #Q:CSY?^>+5K44 <3XPG>338E:(KANIK+T+Q/\
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MA:M;%]!2"--P.T9H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gzbwht3f4aft000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +N!L4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1QGBKVE^);&^TS[2US'NCC#S8!PM<GXP47N@6^HW-H(+IW 8<\#-:IT^SM/
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M=M1&S;)%.4?TK9HIW"QP</@75$D7S=<=X5.=@W?XUH:_X-.K26\]O=>1/"N
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M45P/E^*_[UW^='E^*_[UW^=%@N=]17 ^7XK_ +UW^='E^*_[UW^=%@N=]17
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MP!P<413Q3;O+<-M.#CL: )**B2YADE>))%9XSAE':H&U6Q6;R6NHQ)G&W/-
M%RBDR,9SQ51-4L9)O)2ZC,G]T'F@"Y165JUQ+#?Z6D<C*LLY5P/XAM-7Y+J"
M&1(Y)55W^Z#WH FHJK/J-G:R".>X1'/8FK".LB!T(*GH10 ZBBN:\1+K+74?
M]FF81[?F\OIF@#I:*X'R_%?]Z[_.CR_%?]Z[_.G85SOJ*X'R_%?]Z[_.CR_%
M?]Z[_.BP7-OQ%>ZGI\L<]M@VX'S#&>:='K4&J:/-A@LH3YE-<Y<IXD%N_P!H
M:Y\K'S;CQ6+ +@NWD[MW.[%.PKG9^!S_ *#./^FG]*ZNN2\#G_19Q_M5UM)[
MC6P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444E "TF:,TF: %S1FFYHW4 .HIFZC=0 ^BF;J-U #Z*9NHW4 /HIFZC=0
M ^BF;J-U #Z*9NHW4 /HIFZC=0 ^BF;J-U #Z*9NHW4 /HIFZC=0 ^BF;J-U
M #Z*9NHW4 /HIFZC=0 ^BF;J-U #Z*9NHW4 /HIFZC=0 ^BF;J-U #Z*9NHW
M4 /HIFZC=0 ^BF;J-U #Z*9NHW4 /HIFZC=0 ^BF;J-U #Z*9NHW4 /HIFZC
M=0 ^BF;J-U #Z*9NHW4 /HIFZC=0 ^BF;J-U #\T9INZC- #LTM-S2T +124
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5R_C7_D')_O#^==17.^+K::XTY1%&7(8=/K36XGL:&@?\@6V
M_P!P5I5G:'&\6D6Z2*58*,@UHTAA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 1SS);P/-(<(@R37(*Z7UG>ZG<O&)&!2-=P
MX R ?Q%=C)&DT;1R*&1AAE(X(K-U#2+:33Y8H+6,.5PH"TT)E'P_+;?\(A;^
M<Z^6L(W\]!6-;IJ\>GSC3LFQ9B07X8+WP*VK'0V_X1/^SI$6&>2'8YQT-)#=
MZM:VWV1M->1E&U94P%Q],T 6_#LEH^EJ+4GY3A]PP=W?-0>*H)&L8KB+.Z"5
M7./[H.34V@Z5)IL,SS,#+.YD8#MGM6C>0_:+.:'^^A7\Z.H=#B_$UQ<:D]HM
MNS?N56=L>AJ_?3OJ[:1#&3AB)FQZ XJ?0=)NHOM3WJ89D\E ?[HZ4SP[I-Y9
MW\C72D1PJ8X3ZJ>?YT"*MW?V\7B:9+U+F6."-?+2*(N.1SG%.M+Z.7Q+$]A;
MW4<,@Q+YD+*.OO6G=6EY8ZI)J%G&9EE4+)$.O'I5NRNK^ZG)FM&MH0.CX)/Y
M4#.:LM6LQ?W5Q>PW<LA8J D#.H XJ]H%PDFJWJVL-Q':&+>/.C*_-GG&:LK#
M?:-=2FWMWNK:0Y")@%3^-:-C->W"R-<P>2I'RH>M '&V=S+-<?V6)/)BF8L\
MA[X/3\<UO:YIKPZ3!'9H6CA;+H#RPXJ.'P^\^FSQ3IY<P??$_<'G%6H)]7M]
M.C$EJ99D8JP&,LHZ&@0[1K[3KR7=!&\-PJ[61U*G\CUK;KGK.SN;S6EU&:V-
MJJ(5"-C<?RKH:3&@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !4%Y_QYR_[M3U%<J6MI% R2M ')>"S_I%T/]NNRKDO"5I<
M6]U<F6)E4L<$UUM-[B6P4444AA1110 4444 %(2 ,DX I:PO$9U)H4AL('D1
M_P#6%#@@>U $(F;5_$4;0\V]GG+_ -XGBG:Y<B[O8=*61%1_FF);'R],4:;<
MW%E#';QZ%=(N?F8LO7N36P^GV<DQE>VC:0]6*\TQ'-6;6\/C)D22,((L###'
MW:ZWJ/K7.QZ(%\3M=?9D^S[>#CC.*Z,# P*&".2LYY-*U+5H')VD&6+/H%YJ
MCX:FGL=4NA<,2MU'YL>3W.36OXBTR[N;VVGLTS\IBD_W2>:C\0:/=2V=B;!/
MWT!P2.I&,4"*ENDUOH.IZGN(:Z)D0CD@8Q_2F1ZCI']CB#[)?-(R;BWV=OO8
M]?K71_V7OT$:?G:?+VY]#5.&[U:TB%JVGO*4&U95P%P.G>@9D2W]R/"-LDZS
M(9"(V.T[\8].N:+G4-*DTM8(K._\U!E&^SL#N^OUKHKZQGU'2XU9A'=+\RMC
M@-5:._U946 Z;)O'!FR-I]\9H S[^ZF2PT&YDC9I@^YE(YSM-6=!@&I2G5+F
M7?*20D>?]6/3'X5>U"TN+FXTM]N[R9MTI'0#:151]-NM-UA;JP4M!,?WL8['
MUH SWD72M9N6U."26*;[DBJ6P,_I7569@-I']F(,./EYS63>7.I/YML=->57
MX608V@>]7=%L&TW3(K=VRRCG'2@$:%%%%(84444 %%%% '.^(=/U+498XK9@
M+<CYOFQS4D.BP:7I,P50TI0[F/TK>JO>J7LIE49)4X%.XK',>"#^ZG'O77UR
MG@^UN+<3>=$R GC-=70]P6P4444AA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1124 %)F@FF$T *332U,9JA:2@"<O2;ZJF6F&:@"WOH
MWU3\[WI/.]Z +N^C?5+SO>CSO>@"[OHWU2\[WH\[WH N[Z-]4O.]Z/.]Z +N
M^C?5+SO>CSO>@"[OHWU2\[WH\[WH N[Z-]4O.]Z/.]Z +N^C?5+SO>CSO>@"
M[OHWU2\[WH\[WH N[Z-]4O.]Z/.]Z +N^C?5+SO>CSO>@"[OHWU2\[WH\[WH
M N[Z-]4O.]Z/.]Z +N^C?5+SO>CSO>@"[OHWU2\[WH\[WH N[Z-]4O.]Z/.]
MZ +N^C?5+SO>CSO>@"[OHWU2\[WH\[WH N[Z-]4O.]Z/.]Z +N^C?5+SO>CS
MO>@"[OHWU2\[WH\[WH N[Z-]4O.]Z/.]Z +N^C?5+SO>CSO>@"[OHWU2\[WH
M\[WH N[Z-]4O.]Z/.]Z +N^C?5+SO>CSO>@"[OHWU2\[WH\[WH N[Z-]4O.]
MZ/.]Z +N^EWU1\ZE\[WH O;Z4-5(2U(LM %P-3@:JJ]2AJ )A2TP&GT +111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<_\ /%_RH\NY_P">+_E72T4 <UY=S_SQ?\J/+N?^>+_E72T4 <UY=S_SQ?\
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MP[A_:-3LCZ<_X3SPU_T%K;_ONC_A//#7_06MO^^Z^8Z*/J,.X?VC4[(^G/\
MA//#7_06MO\ ONC_ (3SPU_T%K;_ +[KYCHH^HP[A_:-3LCZ<_X3SPU_T%K;
M_ONC_A//#7_06MO^^Z^8Z*/J,.X?VC4[(^G/^$\\-?\ 06MO^^Z/^$\\-?\
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MR>M'G)ZT 245'YR>M'G)ZT 244@.1D4M %74#BS;ZBLZ%JT-2_X\7^HK+A-
M&C&:LK52*K24 2BEI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %9?B/\ Y%V__P"N#_\ H)K4K+\1_P#(NW__
M %P?_P!!-5'XD3/X6?*E%%%>\?,!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !72_#[_D?='_Z[_T-<U72_#[_ )'W1_\ KO\ T-14^!^AI1_B1]4?
M0>E?\A35O^NJ?^@UKUD:5_R%-6_ZZI_Z#6O7A,^E04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!DZ/_P ?>J?]?1_D*UJR='_X^]4_Z^C_ "%:U D%%%% PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!#333C330!!)5.:KDE4YJ *2_P#'
MU'_O5T2_='TKG%_X^H_]ZNC7[H^E "U!/U6IZ@GZK0!#1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 6X_N"G4V/[@IU %/4_^/!_J*RH*U=4_P"/!_J*R;?M
M0!HQ5:6JL56EH E%.IHIU !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !67XC_ .1=O_\ K@__ *":U*R_$?\ R+M_
M_P!<'_\ 0351^)$S^%GRI1117O'S 4444 %%%% !14IMYA )S$PB/ ?'%14
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M7/&_B:\:(87>>]8E/FE>>9Y9&+.Y))-,KIBK*QR2=Y-A1113)"BBB@ HHHH
M**** "BBB@ HHHH *Z7X??\ (^Z/_P!=_P"AKFJZ7X??\C[H_P#UW_H:BI\#
M]#2C_$CZH^@]*_Y"FK?]=4_]!K7K(TK_ )"FK?\ 75/_ $&M>O"9]*@HHHH
M**** "BBB@ HJ*XG6W@>9\[4&3BN?B\8QW$8DATN^DC/1E08/ZT!<Z6BH+.Y
M^UVRS>5)%G^"08(J>@ HK$U[76T>2T41A_/D"<]LD#^M+?:XUIKMKIPC!$W\
M7IUHL%S:HHHH **** "BBHKF=;:WDF<$JBECCVH EHJGIFHQ:K9+=0JRHW0-
MUJ+^V8/[;72MK^<R%]W; _\ UT :-%%% !1110 4444 %%%% !1110!DZ/\
M\?>J?]?1_D*UJR='_P"/O5/^OH_R%:U D%%%% PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!#333C330!!)5.:KDE4YJ **_\?4?^]71K
M]T?2N<7_ (^H_P#>KHU^Z/I0 M03]5J>H)^JT 0T444 %%%% !1110 4444
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MLKE3CGTKU[PYX)T+PMN.EVGELW!9CN/YFM73=(T_1X#!IUG%:Q$Y*1+@5=H
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M/^/!_J*RK?M0!HQ5:6JL56EH E%.IHIU !1110 4444 %%%% !1110 4444
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M-3:.:*_7:%V].3_C4/A#X=ZSX/\ %\UQ972G2I7PT1&?E_/K0!ZG=2F"TFF
MSY<;-CZ#-?-6D^.=(M?B+J&N>(_M,KQN1;(B!MG/^%?3) 92& ((P0:SF\/:
M*[%FTFQ9CU)MTR?TH ^7KWQGIEQ\4CXC19OL7F*V"OS8&.WX5Z)\5/B*+C2K
M/3=,0J-016,CC!56QBK]W\)IIOB*=91+9=/+AO($0VX&.W2N@^('PTM?%UK
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MU=;_ ,+*/_/DG_?1H_X64?\ GR3_ +Z-')C.WY![?+N_YG)?\*1U7_H+6?\
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M.WY![?+N_P"9R7_"D=5_Z"UG_P!\-1_PI'5?^@M9_P#?#5UO_"RC_P ^2?\
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M )\D_P"^C1R8SM^0>WR[O^9R7_"D=5_Z"UG_ -\-1_PI'5?^@M9_]\-76_\
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MM\N[_F<E_P *1U7_ *"UG_WPU:WAKX3ZCH?B.QU.74K62.WDWLB*V3P16O\
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MF^(?^?2U_P"_W_UJ (OM'B'_ )XP_P#?)H^T>(?^>,/_ 'R:E\WQ#_SZ6O\
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M],YZXJOK&GZEHEM'?KJ4LA5AO0L<')JWK7_(^Z5_NC^9J[XV_P"1?;_?7^=
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M4X3KC)KHQ6BCZHY,#JYZ?9>Q)?17-CX':"^)EF=SM;=OV].]4=/_ .1'O/\
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MT]F;TJ=/FITG&_,M7UU*FDZ'!+:37VHRM#;1G;\HR2:LS:'IM]I,]YI4\K-
M,LCH!Q5O5_E\&@)]TW#9_P"^J@\#G)U-6_U9MQG/3K4N<W%U;[/8J-*FJD:#
MCNM^MSDCP<582PNW"%+:5@_W<*>?I44W^NDQTW&NXU#49-,\(Z:\"J))&(#$
M<K@#I735J2CRJ*W.*A1C-2<W911QCV%W',L+V\JR-T4J<FDN+.YM"!<021$]
M-ZXS7<WNK2+X0M-1,<;7APGF%<GG-4;R=]5\$"\N0&GCD(#X]\5E'$3=FUI>
MQO/!TU=1EK;F^1RMO8W=V";>WEE Z[%)IT^G7MK'YEQ:RQ)ZNA KLEAU!/#>
MG'2-BLR R\A23]:J^,[^5[6RM9)P\@7,P4\9XQ1'$2E-125O\@G@X0I.<F[I
M+T=SE+* 7-Y%"QP';!-=3<:5X>M=2_L^:>X$V0"1&,9/XUS>D_\ (5MO]^NQ
MU:;0(?$C/>13&=2I9A)\O0=L45Y2YTE?;H&%A!TG)VW6YS.L:0NF:RMF'+(X
M5@Q]#5S4]"@L]<L[)'8I-C)(Z5;\46LIU:TU#>'MY]JQ$#' [5:U[_D;=,^H
M_G4*K)J.O1FDL/!.:M]I6]&5M0TSP[IE[]DN)[@2!025C!'/XUGZSH$=I;)?
M6,WGVC_Q'J#]*=XU_P"1CD_ZYI_*M#3<GP%?^:. QV?E1%RC"$[WO;\0E&G.
MI4I<J5KV:\CCJ***[CRPHHHH **** "BBB@ HHHH **** "BBB@ K:\)?\C5
MIW_77^AK%K:\)?\ (U:=_P!=?Z&LZW\.7HS;#?QX>J_,]3TK_D*:M_UU3_T&
MM>LC2O\ D*:M_P!=4_\ 0:UZ^69]\@HHHH **** "BBB@"KJ,KP:?-+&<,JD
M@US&CVVMZKID-X=<GC\P9VB-3CFNDU?_ )!5Q_N&N3\.+X@.AV_V2:W6#!VA
MHLG&3[TT)[G5I*-,L U]=[]O65\#-5X/$FEW$RQ)<KN8X&2.:PM>$]WJ6EZ?
M>N-CDF3 P&P :L^*](L(= FGA@2&6!2T;( IS18+D7C2XEAFTSRI"H:= <'J
M-PIVL3RIXSTV)7(1B,CUX-9.OS23V&AR2?>,J9_[Z%:.N?\ ([Z9^'\C3$=+
M?:K9Z:J_:IE0MT!/)IEEK=AJ#,EO.K,HR5SS7,Z?#'JOC"\^V@2B#B-'Y &/
M2GZW9PZ7XBTRYLT6-YG*.B# ( ]*5AW.IM=1MKR66*&3<\1VN/0TD.I6MQ=R
M6T4H:6/[P!KE?,7P_P"++F60XANHS+CWX%9^C;K#5H]2F?"7;RYSV R118+G
M>)?6\EZ]HK@S(,LOI2:E*\&G7$L9VNL;$'T.*Y[PJOVO4M2U)AS)*54^W%;V
MK_\ ()NO^N3?R- %/PQ>SW^BQ3W,A>0]6-5!J5W_ ,)Q'8>:?LQ@=BF.XQBG
M^"R#X>AP>G6J*D'XDICG%O)G]* -ZXUS3[6=X9KA4= "03ZT6.MZ?J$ICMYU
M9Q_#GFN5^Q6][\0)EN$#JL2D*>AZU)K-M#IWB[3&LT6(R<.J#&1FBP7.WHH'
M2BD,**** "BBB@ HHHH R='_ ./O5/\ KZ/\A6M63H__ !]ZI_U]'^0K6H$@
MHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:::<::
M: ()*IS5<DJG-0!17_CZC_WJZ-?NCZ5SB_\ 'U'_ +U=&OW1]* %J"?JM3U!
M/U6@"&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JO>BX-JXM=OG8^7<<"K%% 'FWB9/$"VL']H^3L\SY-CYY
MQ]*Z+3(_$PEA-SY'V? SB3)Q^5:.O:,=9@AC$HC\M]V2.M:D:[(U3^Z *=Q6
MU'4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!;C^X*=38_N"G4 4M4_X\'^HK*M^U:NJ?\>#_45E6_:@
M#1BJTM58JM+0!**=313J "BBB@ HHHH **** "BBB@ HHHH **** .3U-3_P
MG.GG'&!_6LWQEI\FGSMJ%LI,4ZE)5'J>!7=F*-G#F-2XZ,1R*5XTE7;(BNOH
MPR*=Q6*FC\:-9_\ 7%?Y5'J.G7-[*C0:G<6@48*Q 8;WYK0 "J H  Z 4M(9
MD6>D7EM<K++K-W<*.L;A<'\A6O110!P'B[7+*Z>UCB?+0W"%_;##-=-+XBM/
M['FU"$F1(QV]:T38VC')M8"3U)C%/%M;B,QB"((>JA!@_A3$<#H^L6$EZVIZ
MI/NN#Q&F>$%==>ZY:V4,$TL;F*495P.!5W[!9_\ /I!_W['^%2-!$Z!'B1D'
M12H(% )'%WUS'X@UJQ.G0L5A<,\N. ,UVZC"@>@ID<$,/^JBC3_=4"I*0!5'
M6/\ D$77_7)OY&KU4=8_Y!%U_P!<F_D:J'Q(BK_#?H>$T445]6?GXJJ78*HR
M2<"NFM_#%M%$K:I?I;2.,JF1G\<U0T"WVZM:RW,3" M]XKQTI?$ZW"ZY<>?N
MP6^3/3'M7/.4I3Y(NQUTH1A2=6<;ZVL=#$;S1+?R[IA>:2_ =3D+4=R^H:=;
M_;](O7FT\#+(<?)]:H>$[^5[IM.F_>6\R-E6YQQ63>2S6%S=V,4Q,.XJ0#P1
M6*I-S<7O^#7^9U2Q"5)3C>VV^J?KU1)K.O7&M>4;A%#1C ([UE445V1BHJT=
MCS*E2527-)W844451(4444 %%%% !5G3Y5@U&WE?[J2!C^=5J*&KJPXNSN;O
MB#5([GQ +VU8[55<'Z5<U;5;*_O-/U!#MF7'G+[YKEJ*Q]A'3R.AXJ;<K_:=
M_F=)K.L03>)XK^ [HU2,'\!S4VOW6E7=RVIVUQ*;ACN$9 P#7*T4*A%6L]M!
MO%SES)KXG?YG8WEUHFO+#<74\L$R*%95 P<?6L_7=8MKB.UL;(-]FMR"&;J3
M7/44HX>,6M=M@GBY335DF]WW.@\5ZE;ZE=V[V[95(]I_2K&KZS;3V>EK"=S6
MX&\'Z"N7HIJA%**["EBIMRE_-^AV]W>Z%J5W%J$UW/&PY,0 QFLSQ/JMO>ZM
M!/:,2D:H ?H*YNBIAAXQ:=]BJF,G4BXV2OJSM=8\36UQH86W ^USKLG/M6;X
M>U2WL=-U&*=L/,N%_(USE%-8:"@X()8VI*HJCW2L='9:I;0^$;NQ=OWTC$J/
MRKG***TA!1;:ZF%2JYJ*?16+^E6]E/.PO9VA0 $%<<UU.J7&B7VE6]J+R0?9
MTPIXYYKAZ*B='GDI7V-:6)]G!PY4[G2:)JEG':7.F7Q;[-(?E8=1S5J.]TC0
MK*X.GS2374R% S ?+^5<C12E0BW>^XXXN<8I65UL^J.GTK5K*YTF72]39DC9
MMZ.O4'K4DFH:7H^DW%KITDDTUP-K.P' Z]JY2BAX>+=[Z;V!8R:C:RNE:_6P
MI.3GUKH=8U.WN_#FG6D39EA=BX_ 5SM%:2@I--]#&%5PC**ZG1W>J6TOA"VL
M5;]\C@D?G1!J4 \(-I^?](:7('XUSE*"58$=0<U'L(VMYW-?K4[W\K?([R^N
M;"VTK3X]2219A",>4,\5D:YI-FNDPZI922&.0X*R#GKBFP>*LVL<%Y:)<>6,
M*V #BJ.KZ[-JBI#L6*WC^[&HQBL*=*I&2Z:ZG77KT9P?73336_J4K"98+^&5
M_NJV374:DF@:GJ+WLM]*I?&5 '85QU%=$Z7-+F3LSBI5^2+@TFM]3I==UV"\
MDLK2V!^R6I!5CU)Z&I-6U>UN?$-C=1L3'$1N/XURU%)8>*M;I?\ $N6+J2;;
MZV_#8[?4_P#A'-5O_MLU],K%0"B@8XK+UK6[4V*:9IB%;9?O,>"QKG**F&'4
M;7;=AU,9*=[))O=A11170<@4444 %%%% !1110 4444 %%%% !1110 5M>$O
M^1JT[_KK_0UBUM>$O^1JT[_KK_0UG6_AR]&;8;^/#U7YGJ>E?\A35O\ KJG_
M *#6O61I7_(4U;_KJG_H-:]?+,^^04444 %%%% !1110!7OH&N;*6%2 SK@9
MJIH&GRZ9HUO:3%3)&N"5Z=:TZ* ,;Q!HG]KPQM%)Y=Q"=T;5E/H6MZIL@U6Y
MC^S*?F$;9+?6NNHIW%8YO7_#TVHC3UM2BI;.I(8XX!!_I4NHZ)<7?B.SU!&0
M10XW GGO6_11<+',ZCX?NTU0ZEI,RQSL,.K'"M2V&@WLNJ)J.K3J\T?W$0Y4
M5TM%%PL<SXL\.W&MI"UHZ)*G!+''%)K'AN:\T*WL[5D2>(#YB>,\9KIZ*+A8
MSM#TW^RM*AMFP9%7YR.YJ]+&LT+Q.,JZE3^-/HI#.07P_K.E2NNCW2?9G.=D
MK8V_3%:&B>'WL;J2_O9C->R?>;L/85OT4[BL>>W=M=W'CJX^Q3>5.D2E>>#U
MZUMV&@7TNJKJ&KS*\D8Q&B'(%;":/9QZF^HJC?:'4*3NXP/:K]%PL%%%%(84
M444 %%%% !1110!DZ/\ \?>J?]?1_D*UJR='_P"/O5/^OH_R%:U D%%%% PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#333C330!!)5.
M:KDE4YJ **_\?4?^]71K]T?2N<7_ (^H_P#>KHU^Z/I0 M03]5J>H)^JT 0T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %N/[@IU-C^X*=0!2U3_ (\'^HK*
MM^U:NJ?\>#_45E6_:@#1BJTM58JM+0!**=313J "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.L?\@BZ_P"N3?R-
M7JHZQ_R"+K_KDW\C50^)&=7^&_0\)K5\/6*:AJR12 &-5+L#W K*J_H^H'3-
M2CN1]T'#?3O7U%12<'R[GP=%Q52+GM<OZUKL\\S6D($5M"V$1?:KUMK5CK%L
MMMK$3&1!A9UZ@>]+JOA]-2)U#2)%E63YGBS\RGZ4W3]+;1+*ZO=0VJ[1E(HS
MR23WQ7(W2<%;?\;GHI8A56Y:Q?W6'_:]$T..1].=[BY=2JNQ!VYKDW=I'+L<
MDG)I';<[-ZG-)753IJ&N[."M6=2RM9+H@HHHK0Q"BBB@ HHHH **** "BBB@
M HHHH **** -*W\/ZM=0K-!8321MT8#@U5N["ZL9/+NH'B<]F%=7K!OAHND_
M8EF/RMN\L'U]J=K>?^$5LC?C%WO^3(YQCO7)&O*ZO:S=O,]&>$IJ,K7NDGY'
M.P^'=7N(5EAT^9XVY# <&J][IE[IQ47=L\);IN'6NPUFUU.?3M*-@'VB%MVT
MGKFN?CL+VXUFWL[\ON8Y^8]J=.NY+F;5M?4BMA8P?+%.^FO37Y%"STF_OP3:
M6LDH'7:*2\TN^T\C[7;20YZ;A72>(=7N+:].DZ:GEQQ?)B,<L:S9M0UC^S9+
M>[MI6B/1I(R-OXXJHU*DK2LK/[Q5*-&%XW;:Z]+F%5A[&ZCM5NGA<0/PKD<&
MJ]=9J'_(BV?^^?YUI4FXN*75F%&DJBDWT5S'@\.:Q<PK-#I\SQN,JP'!%5[K
M2;^RGCAN;62*27[BL.6KK=::]7PUI'V,2G]V,^6">WM7-VS7C:U9?;!+N$JX
M\P'U]ZRIU9R3D[6U.BMAZ=-J"O?37IK\BI>:=>:>5%W;O"6Z;AUIL5C=3VTE
MQ%"[0QG#N.@KT?Q#%#K,4]B /M5N@D3WS_\ JKGM$4IX1U=6&"),$'_=J(8I
MRI\S6NGXFE3 QA6Y$_=L_P #D:**UM*M=,DADEU"Y>/;T54R375*2BKGGP@Y
MRLC)JZ=,G&F"_P"/)+E/QK6U+1K :(=2T^=WC5@K!UQU-64V_P#"#Q[_ +OV
MAL_E6+KW2<>]CICA6I-3[71EV'AN^U"T^TH D79F[UE31-#,\3?>1B#7H&IG
M3(O"MF//F2/;E"JGDY[USEM::&+=9+R\E\UV^ZL>:BG7<KRDOP-:^$C'EA%J
M]KMW.?HK=\0:+#IJ6]Q;2F2"=-RDC!ZXK"KIA-3CS(XJM*5*7++<O6FC:C?I
MOM;225?514%U97-E+Y5S"T3_ -UA5E-:OX[>.WCF*I&,*%&*Z3Q8Y?0]/:XQ
M]I9>3CG'%8NI.,TG:S.B-&E.E*46[Q^XXNBNAM[30$MH3=7DWG. 658\A:K^
M(-&329XC#(9(9EW(2,<5:K1<N4SEAYQASZ->IC4445J8!1110 4444 %%%%
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M>3-NJ@A<?6FZKKE[/JW]EZ0!YR_ZQS_#18+G545Q=[>>(]$5+FZE2XM\@.,
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MFJ1UM_)/+X'N7FM8K?,R86-=O>J'_,AI_P!?#?R%8ESK.H7<4D4]PSI(067
MP2.E0_;[G[$+/S3Y ;<$]ZB-"25O.YK4Q<)2NK_#;\3I=;_Y$_3?I_6K3VL.
MEZ%9S6EC'=33_>9U# <"N1FU&ZGM8[628M#']Q?2I[77=2LH/)M[EDC_ +N
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MHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:::<:::
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M2/\ D7;?_KE5G4M-AU2U\B;.W.>*E@M4M[1;9/N*N!0'4YKP5]V^_P"NS?\
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M_A!='_YY?I1_P@NC_P#/+]*/[2H^8?V)B.Z/(J*]=_X071_^>7Z4?\(+H_\
MSR_2C^TJ/F']B8CNCR*BO7?^$%T?_GE^E'_""Z/_ ,\OTH_M*CYA_8F([H\B
MHKUW_A!='_YY?I1_P@NC_P#/+]*/[2H^8?V)B.Z/(J*]=_X071_^>7Z4?\(+
MH_\ SR_2C^TJ/F']B8CNCR*BO7?^$%T?_GE^E'_""Z/_ ,\OTH_M*CYA_8F(
M[H\BHKUW_A!='_YY?I1_P@NC_P#/+]*/[2H^8?V)B.Z/(JVO"7_(U:=_UU_H
M:]#_ .$%T?\ YY?I5BR\(:987D5U#'B2,Y4XJ*F84I0<5?5&E')\1"I&3MHT
M6-*_Y"FK?]=4_P#0:UZR9=%=KN:>#4+BW,I!98\8.*3^Q[K_ *#-Y_X[_A7C
M'TYKT5D?V/=?]!F\_P#'?\*/['NO^@S>?^._X4AFO161_8]U_P!!F\_\=_PH
M_L>Z_P"@S>?^._X4 :]%9']CW7_09O/_ !W_  H_L>Z_Z#-Y_P"._P"% &O1
M61_8]U_T&;S_ ,=_PH_L>Z_Z#-Y_X[_A0!KT5D?V/=?]!F\_\=_PH_L>Z_Z#
M-Y_X[_A0!KT5D?V/=?\ 09O/_'?\*/['NO\ H,WG_CO^% &O161_8]U_T&;S
M_P =_P */['NO^@S>?\ CO\ A0!KT5D?V/=?]!F\_P#'?\*/['NO^@S>?^._
MX4 :]%9']CW7_09O/_'?\*/['NO^@S>?^._X4 :]%9']CW7_ $&;S_QW_"C^
MQ[K_ *#-Y_X[_A0!KT5D?V/=?]!F\_\ '?\ "C^Q[K_H,WG_ ([_ (4 :]%9
M']CW7_09O/\ QW_"C^Q[K_H,WG_CO^% &O161_8]U_T&;S_QW_"C^Q[K_H,W
MG_CO^% &O161_8]U_P!!F\_\=_PH_L>Z_P"@S>?^._X4 :]%9']CW7_09O/_
M !W_  H_L>Z_Z#-Y_P"._P"% "Z/_P ?>J?]?1_D*UJI:=IXL$E'G/,TK[V=
M^I-7: 04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M(:::<::: ()*IS5<DJG-0!17_CZC_P!ZNC7[H^E<XO\ Q]1_[U=&OW1]* %J
M"?JM3U!/U6@"&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQFI_^$;D_P"?^7\S_C4^C?\ (0U/_KHG_H-;-?57/@&M3G_^$;D_Y_Y?S/\
MC1_PC<G_ #_R_F?\:Z"BG<5CG_\ A&Y/^?\ E_,_XT?\(W)_S_R_F?\ &N@H
MHN%CG_\ A&Y/^?\ E_,_XT?\(W)_S_R_F?\ &N@HHN%CG_\ A&Y/^?\ E_,_
MXT?\(W)_S_R_F?\ &N@HHN%CG_\ A&Y/^?\ E_,_XT?\(W)_S_R_F?\ &N@H
MHN%CG_\ A&Y/^?\ E_,_XT?\(W)_S_R_F?\ &N@HHN%CG_\ A&Y/^?\ E_,_
MXT?\(W)_S_R_F?\ &N@HHN%CG_\ A&Y/^?\ E_,_XT?\(W)_S_R_F?\ &N@H
MHN%CG_\ A&Y/^?\ E_,_XT?\(W)_S_R_F?\ &N@HHN%CG_\ A&Y/^?\ E_,_
MXT?\(W)_S_R_F?\ &N@HHN%CG_\ A&Y/^?\ E_,_XT?\(W)_S_R_F?\ &N@H
MHN%CG_\ A&Y/^?\ E_,_XT?\(W)_S_R_F?\ &N@HHN%CG_\ A&Y/^?\ E_,_
MXT?\(W)_S_R_F?\ &N@HHN%CG_\ A&Y/^?\ E_,_XT?\(W)_S_R_F?\ &N@H
MHN%CG_\ A&Y/^?\ E_,_XT?\(W)_S_R_F?\ &N@HHN%C&T 21B]@>0R>3.4!
M/IBMFLG1_P#C[U3_ *^C_(5K4@04444#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** $---.--- $$E4YJN253FH HK_P ?4?\ O5T:_='T
MKG%_X^H_]ZNC7[H^E "U#."2,"IJ* *>T^A_*C:?0_E5RB@"GM/H?RHVGT/Y
M5<HH I[3Z'\J-I]#^57** *>T^A_*C:?0_E5RB@"GM/H?RHVGT/Y5<HH I[3
MZ'\J-I]#^57** *>T^A_*C:?0_E5RB@"GM/H?RHVGT/Y5<HH I[3Z'\J-I]#
M^57** *>T^A_*C:?0_E5RB@"GM/H?RHVGT/Y5<HH I[3Z'\J-I]#^57** *>
MT^A_*C:?0_E5RB@"GM/H?RHVGT/Y5<HH I[3Z'\J-I]#^57** *>T^A_*C:?
M0_E5RB@"GM/H?RHVGT/Y5<HH I[3Z'\J-I]#^57** *>T^A_*C:?0_E5RB@"
MGM/H?RHVGT/Y5<HH I[3Z'\J-I]#^57** *>T^A_*C:?0_E5RB@"GM/H?RHV
MGT/Y5<HH I[3Z'\J-I]#^57** *>T^A_*C:?0_E5RB@"GM/H?RHVGT/Y5<HH
M I[3Z'\J-I]#^57** *>T^A_*C:?0_E5RB@"GM/H?RHVGT/Y5<HH :GW!3J*
M* *6J?\ '@_U%95OVK5U3_CP?ZBLJW[4 :,56EJK%5I: )13J:*=0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S
MOC;_ )%N3_KHG\ZZ*N=\;?\ (MR?]=$_G6&*_@R]#KP/^\T_5'F5%%%?+GW8
M4444 %%%% !115B.QN94WI"[+ZXII-["<E'=E>BG,C(VUE(([&FTAA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %7-+_P"0G;_[]4ZN:7_R$[?_ 'ZJG\:(J_PY>C/2M&_Y"&I_
M]=$_]!K9K&T;_D(:G_UT3_T&MFOK3\\"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,G1_^/O5/
M^OH_R%:U9.C_ /'WJG_7T?Y"M:@2"HI[B*VB,DSA%'<FI:YQ8O[:UZ8R/FTM
M#L\OLY/(- S177;(L 3(@8X#.F ?QK2ZC(JO+96TT0CDA0HO0$=*S&U"\O+Z
M6UT[RT6 [7DD7<,^E &W16+8ZC=)JLFGWS1O(%#*T:X!JG'J^IWNMWEC:^6L
M<+$!V3(IV%<Z:F+-$TAC612XY*@\BLO3KR]EFO;6Y>)IH ,.BX7D<<5B:##J
ML^J7UT+BWXD,;$QGG![46"YV50W5PMI;M,ZNRKV1<G\JP+O6=1/B%=-M!&1L
M)9BN<'BIK[4;_3A902R0O<7$I7*I@8 STHL%S2N=4M[46_F[P9V"( O.3ZU=
MKD_$-U*==TZV@C\R0KO '\)!ZFKAU+4;'5;6VOFBDCN<[3&F-N!WHL%SH**R
MX]2DE\0/9*!Y*1;F..=V:9<:G./$-O80[?+9&:3(YX'%(9IM-$DBQO(BNYPJ
MD\FH[R\2RC5W21@S!<1H6/-<U=6FI7GBL*MQ;@VR"5,H3C)Q6G=W][;75G9A
MHWGE^9R%XV@\XIV%<V5;<H89Y&>:6L:YU&ZN-1:RT\(&C4,\CC*C-);WU[;Z
MNEC?R1/YL9=&C7 X.,4AFU17-3ZQJ,GB.73;18]BHK;V7.,CO5S3[V]_M62Q
MO6BD8)O5HUP,9QBG85S8---.---(9!)5.:KDE4YJ **_\?4?^]71K]T?2N<7
M_CZC_P!ZNC7[H^E "TUG"=>].J"?JM #_.3WH\Y/>JU% %GSD]Z/.3WJM10!
M9\Y/>CSD]ZK44 6?.3WH\Y/>JU% %GSD]Z/.3WJM10!9\Y/>CSD]ZK44 6?.
M3WH\Y/>JU% %GSD]Z/.3WJM10!9\Y/>CSD]ZK44 6?.3WH\Y/>JU% %GSD]Z
M/.3WJM10!9\Y/>CSD]ZK44 6?.3WH\Y/>JU% %GSD]Z/.3WJM10!9\Y/>CSD
M]ZK44 6?.3WH\Y/>JU% %GSD]Z/.3WJM10!9\Y/>CSD]ZK44 6?.3WH\Y/>J
MU% %GSD]Z/.3WJM10!9\Y/>CSD]ZK44 6?.3WH\Y/>JU% %GSD]Z/.3WJM10
M!9\Y/>CSD]ZK44 6?.3WH\Y/>JU% %GSD]Z/.3WJM10!9\Y/>CSD]ZK44 6?
M.3WH\Y/>JU% %GSD]Z/.3WJM10!<!R,BEIL?W!3J *6J?\>#_45E6_:M75/^
M/!_J*RK?M0!HQ5:6JL56EH E%.IHIU !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7.^-O^1;D_ZZ)_.NBKG?&W_(
MMR?]=$_G6&*_@R]#KP/^\T_5'F5%%%?+GW84444 %%%*H!8 G ]: +^BV:WV
MI)"_W0"Y'J!S6E>>)+NVNV@M"(H(CM5 .HI\-A)I4T&HV;B>'&'P.0#UI=3T
M5=0)OM-=9!(<O'G!6NV,*D*=H;_H>9.I1J54ZFL;:7Z/S'L]MXCLI&*+'?QJ
M6^7^(#K7+D%6*D8(ZBNETFPDT=)M0NR(R$*(A/+$USDTAEF>0C!8DUG7NXQE
M+XC;"V4I1@[Q6W^0RBBBN8[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<';GBIX)5U/Q)]J5,V]M&8]YZ$YSD5LR6-M)(7:)=QZG'6I(X(HH]D<:JI[
M47"Q@>&2+A[V^;EGE9,^RDTFA.;K7M4N.HCE,:GVX-;\-O% A2)%1222 /6B
M*WB@+F)%7>=S8'4T7"Q(:::<:::0R"2J<U7)*IS4 45_X^H_]ZNC7[H^E<XO
M_'U'_O5T:_='TH 6H)^JU/4$_5: (:*** "BBB@ HHHH **** "BBB@ HJL^
MH643[)+RW1O[K2@'^=3I(DB[HW5U/=3D4 .HHHH **** "BBB@ HHHH ****
M "BJ.IZQ8Z/")KZ=84)P"U6;>XBNK=)X7#QN-RL.XH EHHHH **** "BBB@
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M^E<XO_'U'_O5T:_='TH 6H)^JU/4$_5: (:*** "BBB@ HHHH **** "N/\
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M%% !1110 5<TO_D)V_\ OU3JYI?_ "$[?_?JJ?QHBK_#EZ,]*T;_ )"&I_\
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M'>/_ /A)-(M'N[=W+L$'3.<Y_.F^)]9\5_$A+?1[;0Y[:V+@R.X'!]>#TKZ
M9%<890P]",TBPQ(<I&B_10* /-/%'AB32?@[+H]I&995"$JHZMD9JQ\&+&ZL
M/!8BNH6B<N#M;Z5Z*RJXPR@CT(I%14&$4*/0#% 'SW\,M$U*T^+MQ<W%G+'
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MNB?^@ULUC:-_R$-3_P"NB?\ H-;-?6GYX%%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBB@"W']P4ZFQ_<%.H I:I_QX/\ 45E6_:M75/\
MCP?ZBLJW[4 :,56EJK%5I: )13J:*=0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5SOC;_D6Y/\ KHG\ZZ*N=\;?
M\BW)_P!=$_G6&*_@R]#KP/\ O-/U1YE1117RY]V%%%% !1110 4444 %%%%
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M_E1T?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\
MGTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@
M^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG
M_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/
M_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_
M /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA
M_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM
M1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\
MGTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@
M^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG
M_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/
M_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_
M /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA
M_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM
M1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\
MGTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@
M^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG
M_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/
M_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_
M /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA
M_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM
M1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\
MGTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@
M^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG
M_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/
M_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_
M /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA
M_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM
M1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\
MGTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@
M^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG
M_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/
M_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_
M /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM1_E0?7L5_.SG_P"P?#G_ #WA
M_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\ GTA_[X%']EV/_/I#_P!\"CZM
M1_E0?7L5_.SG_P"P?#G_ #WA_P"^_P#Z]']@^'/^>\/_ 'W_ /7KH/[+L?\
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MP*/[+L/^?2'_ +X%%PL9GV/P[_?@_P"_O_UZ/L?AW^_!_P!_?_KUI_V78?\
M/I#_ -\"C^R[#_GTA_[X%%PL9GV/P[_?@_[^_P#UZ/L?AW^_!_W]_P#KUI_V
M78?\^D/_ 'P*/[+L/^?2'_O@47"QF?8_#O\ ?@_[^_\ UZ/L?AW^_!_W]_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M#Q+UT_\ Z['^5;]8'B7KI_\ UV/\J:W%+8FT;_D(ZG_UT3_T&MFL;1O^0CJ?
M_71/_0:V:3!!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0GTJ2D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHH) &3T% !15%M9TU6*M?6X(Z@R#BIUNX'MVGCD62-5+$H<]* )Z*
MI:;J=OJML9[8ML#;3N&.:NT %%%% !1110 450L-7M=1GN(8"^^W(#[ACK5^
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"M:LG1_^/O5/^OH_R%:U D%%%% PHHHH **** "BBB@ HHHH **** "BBB@
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MG4]1NM;72M,D,+*,NXJZ\^MZ9IT*^4+VX+X<\G S3L%SH**YOQ5J-Y8Z$EQ
MYAF)YV]JVM.E>?3X9'.69 2?PI#N6J*** "BBB@ HHHH **CN'>.WD>-=SA2
M57U-4M&N[V\M&DOK46\H8@*,]/6@#1HHHH **** "BBB@ HHHH MQ_<%.IL?
MW!3J *6J?\>#_45E6_:M75/^/!_J*RK?M0!HQ5:6JL56EH E%.IHIU !1110
M 4444 %%%% !1110 4444 %%%% !1110!A:1I,]EJ]]<R8V3_=_,FLS6/"3W
M&OV^H6?RKO#RKGJ?6NPHIW%8:@PBJ>PQ4365JS%FMH23U)C%3T4AD<=O!"<Q
M0QIGKM4"JVJ1WLEJ?L,JQS#D9&<U=HH Y&XTG7=8$=OJ$L:6RN&8*!EL?2KV
MKZ#)*MK/I[B.YM>$)Y!&,5T%%.XK'*Q:-JFHZC!<:M(@2 Y5% Y/X5U0X&**
M*0PK&\3_ /()7_KO'_Z%6S6-XG_Y!*_]=X__ $*FMQ/8U8/]0GTJ2HX/]0GT
MJ2D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ I& 92IZ$8-+10!4L=.MM.61;9"HD;>V3GFK+HLD;(PRK @_2G44 4K?2K
M.VLWM(XOW+G+*3G-4D\*Z2F[$#'<,$,V16U10!7:QMWLQ:/&&A"[0IYXJG9>
M'].L)O-AA.[MO.['TS6I10!0U#1K+4]OVF+)'1E.#^=&GZ19Z9G[,A!/!+')
MJ_10!DR^&],F\PM"<R'+$-@_G5JPTRTTV,QVT>T'J3R3^-7** ,N^\/Z=J$O
MFSPD/ZH=N?RJU9:?;:?%Y=M&%'KW/XU:HH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P/$O73_^NQ_E6_6!XEZZ
M?_UV/\J:W%+8FT;_ )".I_\ 71/_ $&MFL;1O^0CJ?\ UT3_ -!K9I,$%%%%
M PHHHH **** &2Q)-$T;C*L,$5'9V<-C;);P*5C08 )S4]% $%U:07L!AGC#
MH>QK/M/#6F6<XEBA8L.1O;<!^=:]% %*^TNTU Q&X0MY3!DP<8(YI9]+M;B^
MBO)$)FB^Z<]*N44 4-0T>RU,#[3%DCHRG!_.BPT:RTW)MHL,>K,<G\ZOT4 4
M=1TFSU6-4NX]ZJ<C!Q2W>E6E]9K:3Q[H5   ..E7:* (K:WCM+>."%=L:#"C
MVJ6BB@#)O/#>F7TWFS0D/W*';G\JNV6GVVGQ>7;1*B_3DU9HH XAM-6]\;W2
MW$#-"T2_-CCJ>]=/I^BV.F,S6T6&/5F.3^=:%%.XK!1112&%%%% !1110 44
M44 9.C_\?>J?]?1_D*UJR='_ ./O5/\ KZ/\A6M0)!1110,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH 0TTTXTTT 0253FJY)5.:@"BO_
M !]1_P"]71K]T?2N<7_CZC_WJZ-?NCZ4 +4$_5:GJ"?JM $-%%% !1110 44
M44 <=XV_X^M-_P"NH_\ 0A6GXFO[C3M&\ZV8!QZBLSQM_P ?6F_]=1_Z$*M>
M,_\ D7_QID]RBDOB6[T\WRS)$H7<$V@YJ/3-7UW7(S#!LB:/[\A .?PKI[3_
M ) 2_P#7+^E8W@O_ %=Y_P!=F_G0 W2-6U*#77TO4660D95P,4NOZS?V6NP6
MUKAE=<;2.^*BN?\ D>X?]P_S%5_$L\=MXKLY96"H,9)^E,.A)?OXDTRS-])<
M1NJ#<Z!!P*V#J[W/A@ZA </M/..XJ+Q)J]E_PCUR$F5S+&50 ]:HV4$EMX!,
M<BD-ACCZYI 5M+N_$>LVT<\4B1QKP25'S&KNK:W?_P!HPZ38;?M)7+N1TJ_X
M1_Y%^#Z5A33)IWQ#:XN2$BD0A6/3M3#H3WK>(])@^V27$<T2<NH0# JWJ>M7
M$_AJ+4K [6X9@1G JSXCU:S319E$R.\@PJYZU%X>TYG\*+;SJ1YJ$8/:D!I6
M>II/HBWI8'$>2?<"L;1=;NI["^U6[8?9D)*+CM7-1:C)9:;=Z+R)#+B,>Q:N
MGO-(>V\$R6B#]XD/('<T[!<K6-SK.M1-=QWT-M$2=BE02<5>\/:O=W%]<Z?>
ME7EA&0Z]",XK \/:987NG*9-2N(9E)#1A@,5T.AZ5IMCJ$TEK>O/.R8<,<X&
M:&",V\U?5Y/$MQIMD5XY4D#Y1CFJ]]JNO:%>PI<2).LIP % YJU8?\E$N_\
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MQ5"UOM5UN\N?)O8K6.)]JHR@DU%X8(N-9U&^"XMSG#=C@FIKS3-*OI'OM/U
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MH R='_X^]4_Z^C_(5K5DZ/\ \?>J?]?1_D*UJ!(****!A1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%+@^AHP?0T )12X/H:,'T- "44N#Z&C!]#0 E%+@^AHP?0T )12X/H:,'T-
M"44N#Z&C!]#0 E%+@^AHP?0T 6H_N"G4V/[@IU %/5/^/!_J*R;>M;4_^/%_
MJ*RH!0!H15:6JL56EH E%.IHIU !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6-XGXT@'L)HR?IFMFFLBNNUU#+Z$
M9H$]C*A\0:8L* W4>0/6G_\ "0Z9_P _4?YU>^R6W_/O#_WP*/LEM_S[P_\
M? IZ!J4?^$ATS_GZC_.C_A(=,_Y^H_SJ]]DMO^?>'_O@4?9+;_GWA_[X%&@:
ME'_A(=,_Y^H_SH_X2'3/^?J/\ZO?9+;_ )]X?^^!1]DMO^?>'_O@4:!J4?\
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M[X%'V2V_Y]X?^^!1H&I1_P"$ATS_ )^H_P Z/^$ATS_GZC_.KWV2V_Y]X?\
MO@4?9+;_ )]X?^^!1H&I1_X2'3/^?J/\Z/\ A(=,_P"?J/\ .KWV2V_Y]X?^
M^!1]DMO^?>'_ +X%&@:E'_A(=,_Y^H_SH_X2'3/^?J/\ZO?9+;_GWA_[X%'V
M2V_Y]X?^^!1H&I1_X2'3/^?J/\Z/^$ATS_GZC_.KWV2V_P"?>'_O@4?9+;_G
MWA_[X%&@:E'_ (2'3/\ GZC_ #H_X2'3/^?J/\ZO?9+;_GWA_P"^!1]DMO\
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M]\"@-2A_PD6E_P#/W'^='_"1:7_S]Q_G5_[';?\ /M#_ -\"C[';?\^T/_?
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJ7-D_U%9<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7?%#0ZWH=KI]U&8[N9EE P=RA<C%<;&Q_LWQ$Q!$+:A!YW_7/:=V?;%7-?\
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MK7FFIV^GM<^$X].5!<20_P#+,=04&<_A5#49[B#6+GP5$F$O[LX'98",?SH
M]B5E= RD%2,@CO2UFVE_807$.CK<I]KCB \KG. *TJ "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JN+
M*W6[-T(AYY&-_?%6*R=3UZ+3[Z&PCB:XO9D,D<"'!*CJ<GTS0!=GT^UN9HYI
MH5:2/.UCU&1BHSI%B88(C;KL@8-&/[IINEZK#J=JTRJ8BKF-T?J&'45>W*#@
ML,^F: ,KQ'H_]N:++8!]F\J<X]#4>C^&['2K> +"&FB4#>?Z#M6L9X1UECY.
M/O"G.Z1C+NJCU)Q0!0ET+39KAIY+96=OO9Z'\*?<:18W4$,,L"E(?]6!QM^E
M6_-CV;]Z[?7/%5+W4'M_*^SVQNM[[6V2 ;/<YH DBTVTAF>9(5$CC#$\YJ"+
M0].@N//CMP'SGKQGZ=*O--&B@R.J9'1F I=Z;0=RX/0YH @BL+:">:>.)5DF
M.Z1A_$:C;2+%[-K1K=# S%RF.Y.<U%>:I+;W5O%;V;74<K!7E250(_<YZTMK
MKNF7E_<6,%W&]Q;@&5,_=STH 230=.EA2)X,J@P/F/2KT,,=O$L42!$7H *=
MO0)O+KM_O9XI<C&<\>M %8:=:"\:[$*^>R[2_?%,@TFQMHIXHK=%2?\ U@ ^
M]5I9HF;:LJ%O0,,TX.I!(88'4YH JIIEG&L 2!0("3'_ +.1BGV]E;VLDTD,
M01IFW2$?Q&I3+&J[C(@4]RW%+O0J&#+M/0YX- %*[T:POI3+<6ZO(0!NZ'\Z
MDBTRSALS:I;IY)&"I&<_6K*R(^=CJV.N#FN>NO%@@N[N"#3YK@6I(E9' QB@
M#5L](LK&0R6\(5CW)SCZ>E3W-G;W?E^?&'\L[ESV-<_=>-K""RM+F&-KC[4V
MR-5.#NS@CGWK5M-3GE65[RPDLHXUW;I'!!_*@"U]BM_MB7?E#ST4HK]P#VJ)
MM*L6BEC-NA24Y<8ZFLA?%RSQRW-GI\]Q919W7"L ,#J<'FMNVO8KJP6\CSY;
M)O&1CC&: *L&@:9;S>=';*)-NS<3DX]*F.DV12-#;KMC8LH]":QCXUL/[)EU
M!$9DCD\O:#R3BK<6OS&SDN[G3)K>W2/S-[.#D8SVH TS96[7HO#$IN FP/WQ
MZ5 FBZ>C2E;=1YH(<=CGVK/\.^+M.\3:.^I63?NDX8$\BM+2M3AU>Q%W!GRR
MS+S['% $-OX?TRUDCDBM5#1G*$G.*F&DV(A,0MUV%P^/]H=#5IY8X\;W5<]-
MQQ6;K&N1:.ML7B:43S+$-K 8W'&: +LEE;RSPS/$#)"<HWIVJM)H>GRW)N'M
MQYA.3@D GW%9P\5Q2>)9M%M[5II(8U=Y%D4 9SV_"M\31E]GF)O[KN&: *EY
MI%C?&,W$"L8ON$<8J2STZTT\.+6!8@[;FVC&35EF"J6/0#)KF[SQE;Z?/']J
MM98[223RUN2?E^N.M &Q>Z39:@ZO<P!G3@,."/QIPTRS%F;00+Y)ZKCK4WVB
M'8CF5 KC*DG&14@(89!!![B@"%[2"1XW:,%HQA3Z4MS:PWD#07$:R1MU5AP:
M>TT2'#2(/JPIQ=57<6 7U)XH HVNC6%G.9H+=5D(QGK@>E0-X;TEY"[6:9+;
MB.V>N<5H27=O% \[3)Y:#+,#D"H-,U>QUBV^T6%PDT08KE?4<&@!MWH]C>E3
M/ "RC (.#C\*>FEV4<R2K;H'12JG'0'K5II$3[SJO?DXI&FB0 M(B@],L.:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YCQ%X<N;W4[?6M-N
M#%J%K"\<:G[K@D'!/IQ73UEZCH%IJ<ZS3RW2LJE0(IV0<^PH X;_ (2B]U?0
M@;F!+6\M[IHIA$3M."!G)K;U6YD3QQI\*R$*VG.Q7/4[NM:G_"'Z1_9$FF^7
M+Y$C;V;S#O)SG[W7M3(O"&FVM_\ VA%]I>Z2(Q(99BP"GG'- 'GOAO2AJWA'
M5-1O+Z5[B*]G,+D_ZO;(< ?7%7/[9GUBXT.'4H[RZ@>Q6ZEA@3=O;<1\WM6C
MX4^'JQ:3=1:RMS'++>2R[([DA2I<E>!Q767?A?3;PVY998FMQM0P2&,X]#CM
M[4 >;:_/JEOX.OHE2YL[87UNML9%VN S\UOZG9KI&B:*UNS":63]])GF0[>I
MKJ+OPGIE_I?]G7/VB2W\U)?FF).Y3D<_6K5YH=E?6]M#.KE+8[H\-C!QB@#B
M=(C_ .$N\2:[!JKEH;!DB@BSP-R9S^=8LU[J5SX:6S74)5:'49;=)EQD(I "
M_E7HEUX0TJZO)+HB>*61=KF&8INXQSCJ:=_PB>D_88;01.(H9#(N'Y+'J2>_
M2@#D?$=I'HVK^';:RS&DUQ'YN#]_GO4'AW0+%_'?B8);*LBP(8VR?E9@V37>
MZCX?L-4NK.YND<R6CAXBKD8(Z9]:C3PSIT>O2ZR@F6[E55?;*0I Z?+TH \^
MAU:YFT^'PG<2/]I6\^Q.P^\4QG=^==OXHN[C2?"W^C$^9\D&[NH/RD_A5"S\
M+L?']UKL]OY<80I'\V0QSG=CL:ZJ[M(;ZUDMIUW1R @B@#S[4["/0=-T74K%
MV-X7_?/GFY^7O_/BH$O[[3H-=TNXE8-.ZI9L>OS+SC\3786W@[2K62U=?M,G
MV8YC66=G4<8Z&IM2\+Z9JNI6M_<I)YUL<Q['*KUSR.] 'G4M_-'XEMO#>H6U
MW=6MK913.L*[B[L"#G\JEN&UJ+P[>P>9=6EO]L5;%I%PZ1[?3ZYKT/4?#FGZ
MG=)=3+(DZ# DA<H2/0D=13'\,Z?)9_99#<21^8)/GF).1[F@"30-*M]-TZ'R
MES+)&K2R$\NV.2?QKBHG\0CQ9KB:+;6,H:5MQN9&4@\>E>D1HL4:QK]U0%'T
M%4K32+2ROKF\A5A-<-ND);()H \Q\1:)+H=MH%@LNZ;[09&;T9G!(^F374^.
M4U*+P%J7[PO)LY*]<;A6YKGAG3O$)@-\LI,!W(8Y"A!SGM4MKH-G:+*H,\JR
MKM99I2XQ]#0!@WU[-IO@G^T=-,9C@M3(4SPQ S6KH>I2:OX0M[^5%1Y[;>57
MH,KFJS^!M'>&2$M>>3)]Z/[0VWZ8]*W+6PM[/3TLH%VP(FQ5ST&,4 >-J9!X
M#O#$%,GVU=H8\9P:[4S:_)X/N1JMK8Q0BS_=M!(S$_)WS6PO@S1UTY[$1R^0
M\@E(\PYW?6M:?3X+C3C82!C 8_+(!YVXQUH \6\)H_ACPMH6KB0KI]_9K%.O
M97))WG\!7;^$-;6P\*6Q6RN[E9)92&MX]PQN-;X\(:0/"R>'#"YTY(O*52^6
M"_[WK5_2-)M-#TV.PLE9;>/.T,V3^= '':]J>EZA?,EQ;W]U*+<.MHD>?(/]
MXX.0>U<_IFH7.J>#-$ENY'D?[>BY?KC><"O0KWPCI=_J,E_()TN)$\MFBF*9
M7\*CM/!>CV6FV]A#'-Y%O*)8PTI)W YY/?DT <AHVF:;#\2-?N'B6,Q6J2+)
MD_(26R:S[W5K2/\ LN]TQ;^6XEO$63473"W"Y.>1Q[<#M7I,?AO3H]1O+Y8W
M\^\C$4N7R"HSV_&LM/AYH4<5O$HNQ%;R"2-/M#;01[4 :%MXA\ZY2V.G7P)'
M,IB^3\ZY_P 62_\ "1WT/ARP"MB3_2Y!_P LUZ'\:[CRU\GRN0NW;UYQ7.VW
M@71[6YN+B%KQ9;A]\C?:6R30!CZ_)I2W#6-S:WFH3V]OM184W"#Y>#P?QK6\
M"W4MUX=7S3(?+8HOF## #UJU=^$M,O+MKJ0W*RNFQC',5W#&.<5>TG2+71;/
M[+9A_+SGYW+'/U- '"C2SJFK^+)[JYE=;9@((^T9V9R/<&JMQJM[>S>%]%EG
M9;6ZD:.=L\RA4R,_C7H46B64+Z@Z*^Z_(,^6ZX&./3BJEQX2TFYM+>W>.0+;
ML6B=7(=2??K0!R%_81Z7XDN=&MV+Z==V,D[VY/"L" ,=^E7_ (5Z99VOAEYX
M8%25KF568$\@,<5T=AX8TW3IYIXEEDEE&&::0N0/09Z"ET+PSI_AR.:/3_/"
M2R-(RR2EP&8Y.,].M '/:O8/JWQ'@M);F1;-++S)(%^[+\V,&LB^N([OQ;J5
MC<VE[<VUE&JV\,";E0LO4]^M>A_V5:_VS_:NUOM7D^3G=QMSGI5.\\+Z=>Z@
M;YS<1SL,,89B@;ZXZT >>7.J:R(=!T>]$UO!>Z@UNP<89H@A(S^(JU-;OI/C
MEK.UNY#;'3IF2#/$9 '3^==S=^&--OK.&VN%E=86WQN9#O4XQD-UKG[?P?)9
M>.X+^!)'L?LLD<CRR[SDXP.: ,G4+^=?A;/.)V$HG W9Y^\M7I;N?_A)(4\U
MMITJ1L>^X<UK3?#S0I[:2W?[9Y,DIE9!<MC=G/2M5O#FG->+=%)/-6 VX.\X
MV$Y- 'GWA(M;>!K[79=]S?+<SQI(>JC<0,?2FZ/)<7-MH=Y866HI?LRM=W+Q
MX6<<YR?\*]$TOP]IVD:3)IEK&WV61W=E=MQRQR>:ALO"NGZ>83;R78$7W%,[
M%?RH Y!-/3Q&=>N=1E=I((CY2'_EB0IY'Y=ZVOAJI3PE"K.9"#RQZGBK]WX,
MTF\N;B=S=(]P )!%.R \8Z"I(/"6FVMG:6L#7,<5K)YD86=ADXQ\WJ/8T ;M
M%(!@ >E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gzbwht3f4aft000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +B!ED# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[CRPRV""3@8QTP=)85\KE%IV,8XV/,HRBU<]RHHHKE.T**** "BBB@ HHHH
M*H7NN:3ILPAO]4LK65EWA)[A$8KR,X)Z<'\JOU\T?$34_P"U?'FJRJTQCAE^
MS(LI^YY8V,%&3A2P9A_O9ZDUO0I>UE8Y\37]C#F1](VMW;7ULES:7$5Q ^=L
ML+AU;!P<$<'D$5-7-?#ZQ_L[P#HT/F^;OMQ/NV[<>83)CJ>F_&>^,\5Y)?\
MQ:\6ZI=1IIHBLRSD106T E>3<1M4[PVYAT^4+DD\=,*-%SDU'H$\1&G%.>[/
MH"BBBL3H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP,@+@%ASG->>^.OA_JVBZK?7]I9>=I$DC3(]K& L"G<Q5D'*A0"-V-N,<@G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"J&MZ/::_H]SI=\'-O<* VQMK @@@@^H(!YXXY!'%7Z*:;3NA-)JS/ESQ+X1
MU?PK<"+4[<&)MH2YBRT+D@G:&('/#<'!XSC&#3U\<^*$TZ6R&O7WDRMO9FF)
MD!XZ2'YU' X! Z^IKZ@HKL^N77OQN<'U"SO3FT>(>&!J.D^"/%7BS51=FZN[
M:.WM+M]WVGYAM#AVP=F7B.X$_P"K_P!D5R/@*Q_M'QYHMOYOE;;D3[MN[/E@
MR8ZCKLQGMG//2OIVBH6)LI:;EO!W<?>^'\3SGXS:@UMX/@M([A$:[NE5XCC=
M)&H+' /. PCR1[#OSROP1LI9/$6I7ZLGDP6@A=23N+.X*D<8QB-L\^GX>X45
M$:UJ3II;FDL/S5E5;VZ'@?Q@TN]M_%[:A(;F6SN(8_+D:-O+A."/*#=,_(SX
M&/OGCN;WPFU[7;O6;+08KR)=*LHY[B:(HNYT; "@X)XD<-U'5LDC KVZBJ>(
MO3]FT2L+:M[52^1\H:WIFI:5JMQ:ZNLOVP.Q>64-^_\ F(,@+ %E8@D-WKU'
M1)?$GQ$\ >(Q>7L4V[R8;2)(U4^;$%D<'[H_>?)R6P"3P  *]>HISQ//%*VJ
M%3P?))OFT?0^5-/O-3\*^((+Q8'MM0M&W>5<Q$$;EY#*<$ JQ]#@\8X-+XCU
M/5]8UEM0UE)EGN(UEB$D91/).=GE@_P=<$=>3DDDU]545?UQ7YN74R^H/E<>
M?0\M^"%C%'H6J:@&?S9[I8&4D;0L:A@1QG/[QL\]A^/J5%%<M2?/)R.VE3]G
M!0['G_Q:M]3N]!TV/2K&^N+B._6<26B%C$51L'Y?F!RW! P,<D'&?-+#XK>*
M[.QDMOMT5T&B$<4L\09XL C<",;FZ'+[LD#WS]%T5K3K1C'EE&YC5P\I3YHS
M:/ERPT[7?'&O2&(2WMY/(#<7+@[(\YP78#"+A3@>BX4=!7=?$[PFVB>#/#J6
MF)+33/,AG<!LEY=I,F.=JEU;J>"Z@5[3152Q4G)-+1="(X**A)-W;ZGR_P"&
M_%6L^'8[NUT0(+G4&B0,(O,DW*3M" Y!)W$8(/7C!KTKXWZ;<3:9I6IQKFWM
M))(IL DKYFW:3Q@+E,9)'+*.]>K44I8B]132M8<,):DZ;E=/\#Y<\.>)M;\/
M27$.B3;)K_RXL+"LC%@WR[00<MRRXP<[CQG!&;J<%Q;:I=07DOFW:2L+ABQ8
M^;GYP2>K!L@GD$@D$C!/UK16JQB4N91,G@&X\KGM_7<\^A\,-?\ P2M]'T]W
M,T]E'<QA\$M(6$^SJ  6RH)Z C.<<^*Z?>:GX5\007BP/;:A:-N\JYB((W+R
M&4X(!5CZ'!XQP:^JZ*RIXEPNFKIFU7"*?*T[-'RKXCU/5]8UEM0UE)EGN(UE
MB$D91/).=GE@_P '7!'7DY))->L?!"QBCT+5-0#/YL]TL#*2-H6-0P(XSG]X
MV>>P_'U*N=\8^*T\(:;:W\MHUS%+=I!($?:R*59BPX^8C;TXSGJ*J5=U(>SC
M$B&&5&;JRE<YOXS:>USX0@O([=':TNE9Y3C='&P*G!/."QCR!['MQXOH.CS:
M_KUGI5N=LEU(%+X!V*!EFP2,X4$XSSC%='X\^(,_C Q6L5L+73;>0R(C$,\C
M<@.QQ\ORG[HZ9/+<8]%^%?@J70;&35]2@>'4KI2B1LYS%"=IPR]F)&3G) "C
M@[A6\9.A1][?H<\HQQ.(]W9;G>:=IUGI.GPV%A;I;VL*[8XT' [GZDG))/))
M)-6J**\T];8\J^.%]LTC2=.\K/G7#S^9N^[Y:[<8QSGS>N>-OOQE? ^RBDU;
M6+XL_G001PJH(VE9&))/?.8ACGN:]JHK=5[4O9I',\/>M[5OY'AGQJTS[-XD
ML=21(42\M]C;!AVDC/+-QS\K( <D_+CL*Z3X*:G]H\/ZAIK-,SVEP)%WG**D
M@X5>>/F1R1@#YL]S7I]%-U[TE3:%'#<M9U4]^A\P^+O"%_X4U2>":WE.GF3%
MM=$;DD0YV@L !OP#E<#H2!C!.R/BKXQN;:WL(+F(W1E 6:*V5IIB2<)MP5[@
M#"@\#WS]"T5?UI-)3C>QG]3<9-TYM)GET+>(=+^"E[>O=:N-8<M)(;LNTT">
M:$;;N&Y5\M2V>V2P(XQPMA\5O%=E926YO8KH-$(XY;B(,\6 1N!&-S=#E]V2
M![Y^BZ*B%:*OS1O<TGAYNW+-JRL?.GP\\):KJWB'3-2CM98]-MKA)FNF4;#L
M)("Y(W99-IVYVYYK=^-NFW$>NZ?JI7-K+;"V# 'Y75F;!.,#(?CG)VMZ5[=1
M5/%2=13ML2L'%4G3OOU/F3PWXA\36ULWAWP_,ZM?S[E2%%\PL4*MM8_=& "6
MR-NP$%><\[($C=E25)44D+(@(5QV(W '!]P#[5]>T5:QB3;4=S)X!RBDY['G
MWQ$\/7W_  KBTTO1?M,Z6+P(\2[FDGB52@&%'S'<48\ ?*3V%>*:%XBU#PS>
MR7VF3K%,\+PLS(&&UN_/<$!A[J,Y&0?JRBLZ6(Y(N+5[FU;"^TFIQE9H\?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QM
M=\*Z+XE:W.KV7VDVV[ROWKIMW8W?=(S]T=?2MFBFFT[H32DK,YK3?A_X6TF]
M6\L]'B$Z8V-*[R["""& <D!@0,$<CUKI:**')R=VQ1C&*M%6"BBBD4%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445!?7:6&GW-Y(CNEO$TK*@
M!8A020,XYXH2N)M)79YGXW\3W/\ ;LD&GZC/#;VB>7)Y,FU3(,ECE3DXX4@]
M"IXZYM_#_7;F;6KBSOKR:<W$(:(SW);#(3\JJ>I(8DX[)W[8'A2SGUGQ;:-,
M[R.LIO+B5"JG*G=NQC&"^T$ ?Q<8ZB+]YX4\6?\ +4"QN?\ 8>1XOY9:,^WW
MNQZ>Y*E!TWATO>2N?+1Q%55EC&_=<K?+_AOR/;**X#XA-JUA=6M_::A<PVDB
M>0T<4I0+("6!X/)8$]N-G7D5I>$=:SX*FO+I[JX>Q,QF>1M[R8S)\I)Y^5@!
MG'3'2O+>'?LE53O?0]Z.,B\1*A)6:5[G6T5Y)X/N=7U+Q#96LFJ:A+#%^]FS
M=$_*GKN/S MM!'7#?C2ZMXJUGQ!JYMM)FG6 R;;:*U)1I ,X9FX/(.2#A0,9
MZ$UL\#)3Y+K17?D<RS6FZ7M.5ZNR75GK5%>2:E=>*?"FI1";4Y99'C#J7=Y8
M7&[E?G &?E&<8(#=1FNF\6_;[S0;77])O+RVC$*R2P([JS(V"#A3@%<G/MDY
M^45#PMI1]Y6ELS2.8*49^X^:.ZZG:T5Y?I'CZ;3_  _<V]S_ *1?QD?9&F=V
M,NYB6WG!^[UZC(PHQC-2>!EUC5]3^T3ZI>M8V9&]9)Y")6(.%SG!QPQR3V!&
M&IRP<X*4INR7XBAF5.I*$::NY?AZD_A?POKVG>*DO+Q-L2^9YLWGAO.R"/7+
M9;#?,!TR><"NF\4>)T\-V\)^RO<S3Y\M-X1?E*YRW)'#<8!Z=NM</X.U?4[K
MQ790W&HW<T3;]R23LRGY&/()J/QOI^IV>HB:^O//@N)I6MD\UF\M<@XP1@<%
M>GI77.A[3$J-5K;I\SSJ>+5'!2GAT]^NMMCTK0M4.M:-;Z@8?),V[]WOW8PQ
M7K@>GI7%_P#"+Z]_PG?]H[/]'^V^=]H\\?ZO.<==WW?DQC';[O-/\#Z5K/\
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MQ_K&CF,<2D!>.H0-@@X')SG'4UH6MCXNM=<TO[>VK&%[E"VRY>1-H9<[]C$
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M6;#!<A3Z%22!D@US2P4DG[RNM;'=#-(2:?*U%NR?2YZC6=KW_(NZG_UZ2_\
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MA6&DZ7M%WL>I+&PCB'0:V5[G=45XQ%JWBC7]3VV][>2W3*2(K:0Q1JH)/0$
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MY!R#QTSR7_-1?^XM_P"U:[W2O ^FZ1J<%_;W%XTL.["R.A4Y4KSA0>_K2_\
M"$:;_;7]J^?=^?\ :/M.W>NW=NW8^[G&?>B.(HPJ3E%OWE^(IX/$U*-.$DKQ
M?X*WXG!>.5=?&%\6C90PC*EEP&'EJ,CU&01]0?2NFO\ QMHTGA26SLU5+I[0
M1"S2-U2+< I4-L"D*">F,[<<5T>M^%]+U\K)=Q,EPJ[%N(FVN%SG'<$=>H.,
MG&,UEV_P[T6"1W9[J;=&R!964A21C<,+]X=LY ZXR!A+$4)TX*I>\2G@\52J
MU'1M:??I_5SF?AK_ ,C%<?\ 7HW_ *&E<A&A,T<4Q-MF14E,D9S$,X;*]<@9
MXZY&*]CT/PC8:!>O=6LUR\CQF,B5E(P2#V4<\4:UX/TK7)_M$Z2PW!QNE@8
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MBE]%Y4C.REE&&&5^7&?F/7-8O$4W2G#O*_RNCJC@JRKTJFGNQL_6S_S.#O=
MT.>"XO\ 3/$=FD))>&UN59'50?F!S\YZ''R9/ YSFG?#[4;BS\01Z?$ZBUO"
MQDC(XW!"0P]&^4 GN/H,=0/AIHX&/M=^?<NG_P 16UH?AG3= 5C:([S.NUYY
M6R[#.<<8 'T S@9SBKJ8NFZ3@VY7VNMC*EE]98B-114$M[-Z_(\5C0F:.*8F
MVS(J2F2,YB&<-E>N0,\=<C%=#-X=T6"UBN'\76Q27&T)9,[C(S\RJY9?Q QT
M/->A:UX/TK7)_M$Z2PW!QNE@8 N " """#UZXSP!G Q6:OPVT99$8W%\RJP)
M0R+AAZ'"YP?8@UH\=":3YG%^21BLIJ4Y.*C&2Z-MK\CE?'5F]A?Z9;-N=8=/
MCA$VPJKE2P./?H<9.,BM_1O&VC:;X7@M]JQ7L,#8M4C?:[C/5PFT%SR3V+'K
M74ZSH&G:] D=]#N:/=Y4J':\9(P2#^1P<@D#(.!6+;?#O1;>ZBG:2ZG6-MQB
MF92C_P"\ HR.^,\]\CBN?ZQ1J45"K>Z[=3K^IXFCB)5*%K2[]#B? _\ R.-A
M_P!M/_1;5['7-:5X(TW1]2AO[>>[:6+.T2.I7D$<X4>M=+6>-K0K5%*'8WRO
M#5,-1<*F][_@CCOB5_R+MO\ ]?:_^@/5+P#I&F7^A3RWNG6ES(+EE#S0*Y V
MKQDCIR?SKJ]<T.VU^R2UNGF2-)!(#$0#D CN#ZT:'H=MH%D]K:O,\;R&0F4@
MG) '8#TH5>*PWLUO<3PDWC?;->[:QS_C9?[#\-1)H^W3EDO%\P6BB+=\K'JN
M".57IU QTR*XS1M)T-]%NK[5=3,7EMMBM+0@2\>S#G)(QC@8R3U"^L:MI-IK
M>GO9WB;D;E6'WHV[,I[$9_F#D$BL"V^'>BV]U%,SW5PL9R8IF4H_^\ HR/;O
MWR.*TH8F$*3BVT[].IEB\%5J5U.*3C:UGLO.QQ/@?_D<;#_MI_Z+:MS7-)\-
MZSKEP]OKEOIL\3E;N.:(JKR9/*EBHSD'.,YX/!.3T6E>"--T?4H;^WGNVEBS
MM$CJ5Y!'.%'K5>Z^'NE7=[<7<MU?;YY6E8!T !8YP/DZ<UI4Q5.5;GC)K0PH
MX"M3PWLI04M;ZOR6S/-K:[G\/:R;JSN8'G@RC2Q9:.0?Q+D@%ER/T!'8UVGQ
M0/.E#_KM_P"R5NZ5X&T?2KP72B>XE1@T9N&!$9&>0  #U[YQ@$8K0UWP]8^(
M;5(;Q75XVS'-$0'3ID D$8..01CH>H!"GC*;K0FEMN^Y5/+:ZPM2E)_%:RZ*
MSO\ B<]X$\1:<VFVFB%Y$OE,@5&B;:XR7R& QT/<@Y!XZ9Y+_FHO_<6_]JUW
MNE>!]-TC4X+^WN+QI8=V%D="IRI7G"@]_6E_X0C3?[:_M7S[OS_M'VG;O7;N
MW;L?=SC/O1'$485)RBW[R_$)X/$U*-.$DKQ?X*WXG(_$K_D8K?\ Z]%_]#>N
MR_YIU_W"?_:5.USPC8:_>I=74URDB1B,")E P"3W4\\UI_V;#_8O]E;I/(^S
M_9MV1NV[=N>F,X]JRG7@Z5.*W1T4L)4C7JU'M):'G'PU_P"1BN/^O1O_ $-*
MY_0KJ+3-?L[B^M@8X9AYL<RD&,]-Q&"=RGYL8SE>U>J:'X1L- O7NK6:Y>1X
MS&1*RD8)![*.>*YK7+3P?+XEN+6]:[TZ[\Q3))$/W4SR '/1@N.I)"C+$G/)
M'4L5"=6=DVFOZ_,X)8&K2H4VVE*,G:[TUU_0K>-O%6FZUIUK::;(9E$IDD=H
MWC*$# &&49SN//;;[UN?#7_D7;C_ *^V_P#0$KA-9.A0PQ6^AO+<J[&26YN8
MRKK@85%R%P/O$_+SE>>,#OOAU;7-OX<D:X@:)9K@R0EOXT*( V/0D'KUQGH0
M:FO&,,)RJ^_7<O"3G5S!SE9V738ZZO%?%^DW&G^(+U;E6:&ZE>:*0KA75CD@
M<G[I;:>_ . "*]JJM?:?9ZG;&WO;>.>(\@.,[3@C(/4'!/(YYKBPN(]A/FW1
MZF/P:Q5/EO9K5''VGC;0=8T]8O$%K&LD>&99;?SHF;D908)''J.-V,GDUPNN
MW%C=:U=2Z9 L%F6 B18P@P  2%'0$@GUYY /%>A-\-M&:5W%Q?*K,2$$BX4>
M@RN<#W)-/@^'&AQRLTS7EPC*5\N2;:![@H%;/X]Z[*6(PU&3G"_H>9B,)CL3
M%4ZG+IUZ_P!?(YKXE?\ (Q6__7HO_H;UH>+& ^'>A GJ8 /^_+5TFN>$;#7[
MU+JZFN4D2,1@1,H& 2>ZGGFM"31K*?18])N$>6T2-(\%RI8)C&2N.ZBLOK4%
M"FE]G<W> JRJ5F]%-:' >"/%6G:-8W-GJ+F!6E$D4@1Y-Y(P1A5.,;1R3SN]
MJP-.NS?^,;2\:,1M<:@DI0-NV[I <9P,XSUQ7=K\-=&#(6N;]PK LID0;QZ'
M"@X/M@^A%6HO >DP:HE_"]S&T<XF2)"@C4ALA0-O"]L>E;+$X>,I25[R.9X'
M&2A3A*UHLX?QW%)%XONV=-HE2.1.0=R[0N?;E6'/I77Z3X\T%-*LXKF46DZQ
M*CP16LGEH0,87:" O' STQGFM[6=!T_7K=8KZ(LR;O*E0[7C)&,@_D<'() R
M#BN?/PTT?;C[7J /KO3_ .(K'V]"K2C"K=./8Z?JN*P]>=2A9J7<S/B'(;[2
M]$U&*-EMY58@N0""ZJRJ1GKA6Z9'%)X,\5Z3HVB/:ZC+';R_:&*^3;2,9%(7
MYG*@Y.<C/HJCM7<?V1:/H<>D7"&XM5A6$^;]Y@H !)&,-P#D8P>1BN=;X;:,
M9'87%\JLQ(02+A1Z#*YP/<DTH5Z,J7L:ETD]"JF%Q,,1]8HV;:LT_E_D>?ZS
M>2ZYXCN9H@DCW%QY5N$^0.,[(_O'@D;<YQR>U=KXKT_P_J^MF!M6ATW4X0&N
M'EB.R1,# ))5=W*X.<XR,''&YHO@W2=#N?M4*RSW(SLEG8$H" "   !T/.,\
MD9P<5!JG@;3=7U2?4+BYO%DFVY1&0*,*%XRN>WK6DL53E.*BVE%:/[C*& K1
MIR<DI2F[M=.NS[W9YC<Q'1-:5[*_@GEMWW17-L<@9Z<D8R5/(&1R1D\UK^-;
MF6]N])O98\&XTR*3>JD(6)8L%)],CC)QD>M=G9_#W1+2Z$[_ &BY"](IW!3.
M0<X &>G0Y!R<BN@U'3++5K3[-?0+-#N# $D$$=P1R/P[$CO52QU-5(R2O;=F
M=/*JSHSA)VOLMTCR+1M!L-5M#)/XCM;&X4G?!- ?E&XA<,SJ&R "<=,\UV_@
M#3K2UM+RZLM3^WPS.J$_96@*%03C#')^^*:/AIHX7'VO4#[[T_\ B*Z+1-%M
M=!T_[':-*RER[/*P+,3ZX '0 <#MZUGB<3&<&HR;OTLC; X&=*HI3@E;JF[_
M .1HUYC\2;NZ_MB&S^TR?9#:JYMPV$9M[<D?Q?=7&<XQQC)SZ=6)KOA;3O$#
M1270DBFBX$T) 9EY^4Y!R,G/MVZG/-A:D*=52FM#NQ]&I6H.%-V9YK?Z7HEA
MX>M9EU1KO59U!\NV(,2]SN!&X8!QS@D\X'('1_"__F*_]L?_ &>M6+X=Z+'%
M.A>ZD:554.[*6BP<G;\N 3C!)SQP,9.=30?#5GX>^T?9)9W\_;N\U@<;<XQ@
M#U-==;%4Y4903;;[_(\[#X"K#%0JN*22Z>C/-? __(XV'_;3_P!%M70_%#_F
M%?\ ;;_V2MW2O!&FZ/J4-_;SW;2Q9VB1U*\@CG"CUJYKWAJS\0_9_M<LZ>1N
MV^4P&=V,YR#Z"B>*IO$QJK9+_,*67UHX&=!_$W?\O\CAM15V^%>DE8V95NV+
M$+D*,RC)]!D@?4BG>"/$FDZ':7D>H8@DDD5EF6)G:08/RG:I("]1D_QG\>\@
M\/Z?%H']B21M<66""LQY.6+9R,8()R",$8!ZUA2?#;1G9RMS?1AF)"K(F$![
M#*G@>^:2Q-&<94YWLVV-X+$TZE.K2LVHI-/TL<!XBU)-6\07E[$N(W?"<GYE
M4!0W(&,@ X[9Q7N%<G<_#S1+B<R(US N% CA=0HP .ZDY.,DD\DDUUE98NO3
MJ1A&'3_@'1E^%K4:E256WO/I\_\ ,KW]U]ATZZN]F_R(7EV9QNV@G&>W2N23
MQMX9U>RC&L6PC='#>1<6QG4/M^\I"D8Y(!(!Z\#-=C<01W5M+;S+NBE0HZY(
MRI&",BN03X9Z0J@&\U!SZL\>?T2LZ'L+?O+I^1OBOK7,O8I-=4SSK4X[*75;
MB+28YY+1WVP(P+.V>, =3D],\XQGFNV^*'_,*_[;?^R5MZ7X"T;3+U;O_2+J
M6-@\7VAP5C89Y 4 $\@_-G! (P:O:]X:L_$/V?[7+.GD;MOE,!G=C.<@^@KK
M>,INM!ZVC?UV/-CEM98:K'3FG;1;*SN<-J*NWPKTDK&S*MVQ8A<A1F49/H,D
M#ZD4[P1XDTG0[2\CU#$$DDBLLRQ,[2#!^4[5) 7J,G^,_CVLND:;IOA*?3[B
M*2ZT^"%W='(+L 2_!&,$'H1C! Y[UP8L_ EQ T_]J:G:EF&83&2T18$A1^[;
M(&""06 XR>1EQJPJPG"2=F[W0JE"KAZM.I&4>912:;[*QC>(M135O$%Y>Q+B
M-WPG)^95 4-R!C( ..V<5UWQ0_YA7_;;_P!DKB;A6U35'CTJQQYK;+:VC7!V
M@87.2><#+,3C.237K^O>&K/Q#]G^URSIY&[;Y3 9W8SG(/H*VK5(49TF]DG^
M5CGPU&IB:6(4=7)K7H];LK^!_P#D3K#_ +:?^C&KSWP/_P CC8?]M/\ T6U>
MKZ5IL.CZ;#86[2-%%G:9""W))YP!ZUC:5X(TW1]2AO[>>[:6+.T2.I7D$<X4
M>M<D,1!>UO\ :V_$]"K@JLOJ]OL6O^'^1P/CC_D<;_\ [9_^BUKT+QQ_R)U_
M_P!L_P#T8M1ZKX(TW6-2FO[B>[667&X1NH7@ <94^E;.JZ;#K&FS6%PTBQ2X
MW&,@-P0>,@^E$\1!^RM]G?\  *6"JQ^L7^W>WX_YG$_"_P#YBO\ VQ_]GKGO
M''_(XW__ &S_ /1:UZ5H/AJS\/?:/LDL[^?MW>:P.-N<8P!ZFJ>J^"--UC4I
MK^XGNUEEQN$;J%X '&5/I5PQ5-8F55[-?Y&57+ZTL#"@OB3O^?\ F<I\2XI%
MUVTF9,1R6VQ&R/F*L2PQUXW+^=:?ACQKHMAX?MK.^<6D\)9-D5LY5AG(;Y0>
M3GDG&6W'&,5V.I:79:O:?9;^W6:+<' )((([@CD'J..Q(Z&N8'PTT<+@W>H$
M^I=/_B*B->C4HJG5NK=C6>%Q-'$RKT+/FZ,C\8:[)<>$;6_TJ[GMXY[O9O0[
M&=5W]^H!* ]CC@]2*Y#1M)T-]%NK[5=3,7EMMBM+0@2\>S#G)(QC@8R3U"^E
M#PIIQ\-IH<QEFMXRS1RR%?,1B2=P(  (W$=.G!SDYSK;X=Z+;W44S/=7"QG)
MBF92C_[P"C(]N_?(XITL12A3<4VM?FT3B,'B*M6-224M+6=[)]6<3X'_ .1Q
ML/\ MI_Z+:CQQ_R.-_\ ]L__ $6M=]I7@C3='U*&_MY[MI8L[1(ZE>01SA1Z
MT:KX(TW6-2FO[B>[667&X1NH7@ <94^E;?7:7UCVG2UOQ.;^S,1]3]CI?FOO
MTM8D\<?\B=?_ /;/_P!&+7/?"_\ YBO_ &Q_]GKMM5TV'6--FL+AI%BEQN,9
M ;@@\9!]*I:#X:L_#WVC[)+._G[=WFL#C;G&, >IKDA6@L-*D]V_\CT:N&J2
MQT*Z^%*WY_YGFOC@_P#%8W_MY?\ Z+6NMUWQ%IWB#P3J3V+R%HA"98Y(F0QE
MG7 .1@]#T)''6M76O!FE:Y?"\F,T$^W$C0,J^;TP6R#R ,9X..#G Q%;>!]-
MM=.OK%+B\,-[Y?F;G7*[#D8^7WYSFMGB*,H4[WO&WZ?Y',L%B85*RC9QG?\
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MW#"_>';.0.N,@8S6(H3IP52]XFSP>*I5:CHVM/OT_JYS/PU_Y&*X_P"O1O\
MT-*Q-0O#9>,+R]CC$S6^H22"/=MW%9"<9YQTQG%>GZ'X1L- O7NK6:Y>1XS&
M1*RD8)![*.>*CU?P5I6LWS7LQN8IWYD:*3[_   ,A@0,!>V.^<U?URE[>4GL
MU8R_LVO]5C!6YHNYRGC;Q5IVM6%M9Z=(9E$IDD=D>/80, 891G.X\@\;?>FZ
M5%)-\+=96--Q6X\P\@85?+9CSZ $_A71+\.M%6U>$O=,[2!_.9EWJ "-@.W
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MPHTR1$RD5R7D.0-H+R*#[\LHX]:Z(_#K1?LL4(>Z#(S,TP9=\F<8#';C Q@
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M>,LQ&_#YSSC&?F/:LO;P]A"GU3O^9T+"5/K=2KTE&R^Y?Y'G_P -?^1BN/\
MKT;_ -#2L'3T;7M<@_M?5@@<YEN;AN=HRQ5?X5R2<#A1G@'A3ZEH?A&PT"]>
MZM9KEY'C,9$K*1@D'LHYXJA<_#K19[F69'NK=9#D0PL@1/\ =!4X'MT'; XK
MH^MTG5E+NM'V.-9=B%0A#1V;;5]&>=:W!IEKJ;P:3<3W%O&-K2RE3N;OM( R
MO3G'/.,C!KV+0?\ D7=,_P"O2+_T 5AR_#O194A57NHO*C"$HRYD.22S97EC
MGZ<   "NGM+9+*R@M8RQC@C6-2W4@# S[\5ABL1"K3C&+=UW.K+\%5H5ISFD
MD^Q-1117 >N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<QJG@;3M7U6?4+BZO1)-MRB,
M@5<*%X^7/;N:Z>BKA4E3=X.QE5HTZT>6HKHY2S^'NB6MT)W^TW(7I%.X*9R#
MG"@9Z=#D')R*ZNBBB=2=1WF[A2H4Z*M3C8****@U"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQI<:+XS:#5(8956X\J-%=4(R'B9 H.0RMAQV ^0YK4^+/QFU/2=;31?"L\<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\ Y&2!6UCXD_$KX;>+([#Q/=6.K1-$DOEK&BI)&6Y9&1596^5E^8$=3M/!H
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M9Y]JJ.""&UMX[>WB2&&) D<<:A510,  #@ #M4E !1110 445!=R7,=K(]I
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M>=DT%E'&ZY!!PP&1D$C\: /D[XL:=#H_Q$O-,MV=H+.WM+>-I""Q5+:)03@
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MAKC2]$TVQF9-C26MJD3%<@X)4 XR!Q[4 ?)_Q+\/W'A;_A%]'NVS<P:*C3#
M^1WGG=EX)!VEBN0><9[U)XC\+WTOPN\)>)X(Y);..WFM+G:G$!%U*R,QSG#%
MR.F 5'.6 KZLU+PWH6LW"W&J:+IU],J;%DNK5)6"Y)P"P)QDGCW-7+*QL]-L
MX[2PM8+6VCSLA@C"(N3DX4<#DD_C0!\F:!I_PGNO#:W6N:MX@LM6C0B6SBVN
M)6 ZQMY1 #=@S#!X)P-QZ+QAINA6/[/^F7'AQM1.GW^N?:%&HE/-#".6,@[!
MC'[OCKUKWG_A!/"'_0J:'_X+HO\ XFM34M)TW6+=;?5-/M;Z!7#K%=0K*H8
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MK5)6"Y)P"P)QDGCW-$?AO0H=+FTN+1--33YGWRVBVJ")VXY9,8)^5>2.P]*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^PPQRJ$MXE/S;R/E "QQX(<\9W<UF?"B*X\2?$CQ?XY^T^=82RO86C^6%\U
MRE3C@KMC2(<KSNZY!H ]EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N-^+&I3:5\+?$%S
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M"^C>&?M@T:S^QQW<OG2Q)*YCW^JH253T^4#@ =AC7HH **** "BBB@ HHHH
MIZKIEIK6EW&FWR2/:7*;)425XRR]QN0@X/0C/(R#P:-*TJQT32[?3=-MDMK.
MW39%$@X4?S))R23R223R:N44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9^N:M#H6A
M7NJW"LT-I"TSJO4@"H_#FMP>)/#UEK%LC)#=Q[U5NHY(_I0!J4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1I_A?1M*UR_U
MFPL_L]]J&/M31RN$E/\ >,>=F[K\V,\MS\QSKT44 %%%% !1110!D?\ "+Z,
M?%'_  DCV?F:N(O)2XDE=_+3IA%)*IW^Z!]YO[QSKT44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M<)XY^((\/:??II,(O-1M8]T@_P"6<(/=C_2@#NZ*S/#M_-JGAS3K^X"B:XMT
MD<(.,D9.*X?XE?$U_"ES:Z9I,<<^H22+YQ=<I$A/?W- 'I=%<AXS\73^'=#L
M7M($FU+4'6&V1CA=Y .3[5B:GXC\8^#187WB!M/OM/N)EAF%K$8V@+=\D\B@
M#TJBFHRR(KHP96&01WIU "-]QOI7CWP<_P"1N\:?]?G]:]A;[C?2O'O@Y_R-
MWC3_ *_/ZT >Q4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!S'Q&_Y)OXA_Z\9?Y54^%'_)+?#_ /U[?^S&K?Q&_P"2;^(?
M^O&7^55/A1_R2WP__P!>W_LQH [*BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***:)$8X#J3Z T .HHIK2(IPSJ#[F@!U%&
M>,YIHD1CA74GT!H =12,RH,LP4>YH#!AE2"/4&@!:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC/K0 45E7GB;0]/D
M\N[U6TA?.-KR@&K5GJEAJ*;K.\@G7_IFX- %NN#^*5I;VWPXUV2"%(WF3=(R
MK@N<]SWKO*Q/%OA\>*/#5YHYN#;_ &E=OFA=VW\* .:D\2GPK\(],U"."2>X
M-G%'"D:%OF*\$@=A7EGB34M!@\"1H-1DO=<N[Z*YO)GMG4^Z@D=!TQ7T)HNF
MC2-$LM.\SS?LL*Q;R,;L#&<5D>-_"(\8Z-%I_P!K-KY=PDV\(&SM[4 <%XQU
M&UU34_ >H6LC267VH)O9"HW8]#6]\;/^2<3*I =KF$+]=U=%XH\(6WB?08=/
MFG>":W*O!<1_>C<=#6&_P_U75[BP'B;Q%_:5E9.)$@CMA%O8="Q!YH ['1E=
M=$L5D^^($!^N!6/>:IXGCNY$MM&@DA!^1S(02*Z4 *  , =!2T <FNK>+"P#
MZ';A2<,?,/ KB?@Y_P C=XS_ .OO^M>PM]QOI7CWP<_Y&[QI_P!?G]: /8J*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BD)X) KD;OQ9J]JTS-X=G\F(
MG,A;C []*UIT95':)A7Q%.@KS_)O\CKZ*XNV\9ZM>0K-;^'9I8FZ.CY!_2NQ
MB=GA1W0HS $J>U%6C.E\7YBH8JG7_A_DU^8^BBBLCH"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HKQ/4_BEXRU3Q%J-GX1\.F]M+"4PO(!DEAP<UT/@7Q'X_P!4
M\0FW\2^'FL+#R6;SBN/G&,#^= 'I=%%(P+*0"02,9]* ,+5/&GAO1;W['J.K
MVUO<8R8V))'Y"M-M4L4TPZDUU$+)4\PS[OE"^N:Y[1_!&D:!8ZBUV?M[W3O-
M/<7:AFP<\9/0"O*;>_GMO@KXC1/,:PN=0>WL002?++]O;B@#UF'XC^#[B9(H
M=>M7=R%4#=R?RKJ 0P!'(/(KS?1/$>C:9%IMA?\ AFXTV$K'##>75L@1WP,<
M^]>D#&..G:@#$U7QEX=T.[%IJ6K6]M<$9\MB<X_"M*+4K*>P^WQ7,3VFW=YP
M;Y<>N:\X^&=C9Z[/XEUF_MHKB>YOWAS*H;:B\8&>E<5/?OIG@/Q5X=M9'6"/
M6A:1_-RL<C9Q].* /9K'QQX9U.^%E9:S:S7+' C4G)/MD5=UCQ#I'A^))=6O
MX;1)#A#(>I^@K@?B5H6FZ1\.8+JQM(H)M,DADA>-=K<'D$CDYJ/2?(\4?%V6
M6\C6:'3])A:*.0;EW/U.#WYH ]&TG6],UVT^U:7>Q74(.TM&>AJ_7F.EB#0O
MC=?:?:H(K;4+ 3&)>%#@]0.@KTZ@#F/B-_R3CQ#_ ->,O\JJ?"C_ ));X?\
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M']G8CL']M8/^;\&>C45YS_PLN;_GP3_OHT?\++F_Y\$_[Z-']G8CL']M8/\
MF_!GHU%><_\ "RYO^?!/^^C1_P ++F_Y\$_[Z-']G8CL']M8/^;\&>C45YS_
M ,++F_Y\$_[Z-'_"RYO^?!/^^C1_9V([!_;6#_F_!GHU%>?VGQ%FN;R& V2
M2.%SD\9KOZYZV'J46E-;G9AL91Q*;I.]A:***Q.D**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&W+MYK1ID<,4(Q%&B ]0J@4^N6;BY>[L=]-344IN["BBBI+"BBB@ K-\0?\
M(O7_ /UP;^5:59OB#_D7K_\ ZX-_*KI?&O4RK_PI>C,_P/\ \BC9?0_S-=%7
M.^!_^11LOH?YFNBJ\3_&EZLSP7^[4_1?D%%%%8G2%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV6BO)-=T_6? %CI>NQ>(;^^7[3%%?Q7<FY&5^I4=L&O6(I%EB21?NNH8?C0
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MN,\)?\C!K'/_ "TKLJWQG\7Y+\CERW^!\W^;%HHHKE.\**** "F2Q1S1F.5
MZ'JI'!I]% -7W.$\=V%I;6VFF"WCCW70!VKC(KL(=-LH762*UB1P.&"\BN8^
M(7_'KI?_ %]K78K]T?2NRK*7L(:]SSJ%.'UJKHOL_D+1117&>B%%%% !2'@$
M^E+10!R5UXSN;6:5#H%ZR1D_O.Q'KTJ"'QY/<1>9!H%Y*AZ,AR/Y5T^L?\@>
M[_ZY-_*L;P'_ ,BM#_OM7=%T?9.?)L[;L\J2Q*Q"I*KHTWLCHH)#-;QRE"A=
M0Q1NJY[5)117"SU%L%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG?)LNBIDD3^Z6.<5U]%% !1110 5%]E@^U?:O)3S]NSS,?-CTS4M% !1110
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MUM-""-P?!'ZUJZ7XVU?3L*TWVB+^[+R<>QKQJN6\WO497/I\/GBA:GB(6?\
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M**1CM1F]!F@!:*XI_'$R2.OV0?*Q'WJ;_P )S-_SYC_OJJY&9>V@=O17$?\
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MY)SI?T;_ -"-=G7&?"G_ ))SI?T;_P!"-=G7R5?^++U9^EQV04445D,****
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M[LKK1;R"PL+R*[DB*PN5/RMV->P_V'I/_0,M/^_*_P"%']A:3_T#+3_ORO\
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M3112;;W+C%1V"BBBD4%%%% !1110 4444 >1?&=7>]T58SASNP:\^_L_5?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9+L,+B
M3[FT[OIWI]<%XZ^(,WA.^BLUT*ZU".:/):%20.V.* .8NM(^#AO)C<-9B8N3
M("Y'S9YK*\ ?\(QI_P 9;BW\+1_:;.6T/[T GR3QD ^AKGYM8\)7$SS2_#.^
M:21BS$AN37>?"S7-(FUN73=+\'3:.&A,C3R(><=LF@#UVBBB@ HHHH ****
M"BBB@!&^XWTKQ[X.?\C=XT_Z_/ZU["WW&^E>/?!S_D;O&G_7Y_6@#V*BBB@
MHHHH **** .$\3>'98)9+^V!>-CF1>Z__6KEJ]C(# @C(/4&N>?PC9/J@N@2
M(<Y,/;-:1GW.:I1N[Q.0M/#^I7UMY\%N"AZ;CC--ET/4[?[UI(,?W.:]2551
M J *H& !VI:/:,?U>-MSR3;>VYSMN(R/7(J>+7M3A.$O9!CJ":]1:*-_OHK?
M49JM+I5C,/GM8OP4"CG75"]@ULSAHO%^J1]6CD_WA5Z'QS./]=:JW^X:W)?"
MFD2DG[.5)[AC5&7P/9O_ *NXEC_ &B\6')56S"+QQ9O_ *RWEC_$&J&O^*H[
MRU^RV0.U_ON1^E-NO!-Q'&S6]PLA SM88)KF'1XI&CD4JZG!4]15)1W1$YU$
MK2.H\,^(UM52PNSB/I&_I[&NX!# $'(/0UX[C/&,UHV>OZE8 )%<':/X7&:4
MH7V'3K<JM(]2HKB[7QPPP+NUX_O(>:W+3Q-I=W@"X$;GHK\&H<6CH52+ZFQ1
M3$E2091U8'T.:?4EA2'H:6D/0T <UX4_U^H_]=C735S/A3_7ZC_UV-=-52W,
MZ7PA1114F@4444 %%%% ',>,_P#CVL/^OE:Z8?='TKC/&6I02&"UA??-#()&
MQT'M6QHOB.VU&VQ*ZQ3H/F5CU]Q5M/E1C&2YVC<HK/EUW3(?]9>Q#\:I2^+=
M*C^[*TG^Z*FS-'.*ZF[17*2>.;0#]U;RD_[0Q5.3QS.3B*SC'N6-/D9#K074
M[>BO.I?&.J/]QHX_^ YJE+X@U2X!5[MN?[O%/V;)>(B=9XC\2)9H]I:D/.PP
MQ[+7/>'M?;2IC%-EK9SEO53ZUAMN+$OG<>23U-)6BBK6,'5DY<Q[!#-'<1++
M$X=&&014E>46FK7^G#;;W#(O]T\BM2'QEJ<>/,\N7ZC%9NFS=8B/4]#HKC8?
M'7_/>SQ_N'-:$/C+39<;Q)'Z[A2Y66JL'U.BJ.6&*="DT:NI&"&&:HPZ_I<_
MW+R//H35Y9X9!E)4;Z,*6J*O&2/,O'NCV.ES6\EG$(C*3N4=*XW->]7-C:7H
M7[3!'+M^[N&<5QVNP:2-=TZWMX8!ME_?!0,8]Z]?#YDH04))MH^<QN2.I5=2
M$DD^AC_#A-VN3.&QMB/'K7J-5K;3[.T<O;6\4;,.2BXS5JN#%5U7J<Z5CV,O
MPKPM!4F[A1117,=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'BOBWXMZTFM7=OX=L0=.T^=8;J\<9&XL 178>&_'[ZGXQO
M/#.H63VUS%$)K>0])D[FO)/%UMK_ (.7Q#H/]D27>GZM>B]ANHU)P=VXK79>
M H]=\7>/D\6:EI;:=8V=G]E@C?JY]: /8Z*** "BO.OB'\0)]%T^^M]"3S;Z
MU*?:)F7*0!B/S;VK8\3>(;G1_AM<:S'(HO5M5:-B.#(<8X_&@#K:*X'1M$\;
MW-I97MYXPP9$622 628YYVYKO5!"@$Y..30 M%>96NI^*_&>NZP=&U>+2]-T
MZ7[/'^X$AF<=<YZ"FVWQ&OH/AWJNHW\,?]LZ=<-9M&OW6DW84_CUH ]/HKRK
M4M1\;>$=,L-?U35X;^VDEC6[M! J")7[AAR<5J:[KVMZQXRMO#/AZ\2QVVHN
M[F[,8D*J>B@&@#T&BN$\):[K,7BK4?"NOSQW5S;Q"X@NU4)YL9./NCTKNZ .
M8^(W_)-_$/\ UXR_RJI\*/\ DEOA_P#Z]O\ V8U;^(W_ "3?Q#_UXR_RJI\*
M/^26^'_^O;_V8T =E1110 4444 %%%% !1110 4444 %%%% !1110!Y1JO\
MR'+S_KX/\Z]2M?\ CUB_W!_*O+=5_P"0Y>?]?!_G7J5K_P >L/\ N#^5:3V1
MS4/B9+11169TA1110 4444 %%%% !1110 4444 %%%% 'DOQA_Y">A_5JY:N
MJ^,/_(3T/ZM7*U]+EW\!'Q_$'\>/H%%%%=QX(4444 %%%% !1110 4444 %%
M%% !1110 4444 %177_'G/\ ]<S_ "J6HKK_ (\Y_P#KF?Y4BZ?QKU/5?A3_
M ,DYTOZ-_P"A&NSKC/A3_P DYTOZ/_Z$:[.ODJ_\67JS]*CL@HHHK(84444
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M\%QR,C6$65.#^Y%)_;'@K_GPB_[\BNCZY5_Y]LY/[.R[_G[^)Y)_;]AZR?\
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M HHHH *I:KI%AK>GR6.HVT=Q;R#!1QG\JNU'<3+;VTL[<K&A<X] ,T >9M\
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MK^&[L\=_X0K6_P#GV_6D_P"$*UO_ )]J]CHH_M6MV0?ZOX;NSQS_ (0K6_\
MGV%'_"%:W_S["O8Z*/[5K=D'^K^&[L\<_P"$*UO_ )]A1_PA6M_\^PKV.BC^
MU:W9!_J_AN[/);#P=K,.H6\KV^%20$G\:]:HI*Y<1BIXAIRZ'H8+ T\(FJ;>
MHM%%%<QVA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.PYQR2,UVO@.^\80?$6;2?%>LQRE+4R0PJH ESCYA@#I0!Z_1110 C,$4LQ
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M_P"26^'_ /KV_P#9C5OXC?\ )./$/_7C+_*JGPH_Y);X?_Z]O_9C0!V5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7,>)O''ASPW,+'6KSR6GC)"E<Y4\5T]><_$_6/!NB+;
M3^(='34[V3Y8(0N7(_I0!YZTOP\31=;TF'Q1*+.^E6>U0K_QZR YR*T_A19Z
M7=>-9+^X\3OK&JQVY2%2/NQCO5WP9?\ PX\7:FVEOX1BTW4 -R07*<N/45Z;
MI7A#P]H=X;O2])MK6X*[#)&N#CTH VZ*** "JM]IMEJ< AO[6*YB5@P25 P!
M'0U:HH AGM+>ZM6M9X(Y8&7:8W7*D>F*S=/\*>'])NA<Z?H]G;3@8$D40!%;
M%% !28'H*6B@!K ;3P.E>/\ P<_Y&[QI_P!?G]:]A;[C?2O'O@Y_R-WC3_K\
M_K0![%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Y[\6O"E]XBT&UN])&=2TN<7,*]WQVKT*B@#Q
M&V^/WV:Q6WU+PWJ']IQKM?8HVEQ^O6M#X::7K?B'QA?>/=>MS:M-%Y%I"PP0
MGK7JKZ?9R2B5[2%I!T8H,U8  &   .PH 6BBB@#S7XL:38V/@+6[VW@5;F[E
MB::3NV& %5/B03_PA'A9,_*U_:AAZC%=+\3])O\ 6_ EY8:;;FXNG9"L8.,X
M8$U#XM\,7FN_#Z'3[<*FHVRQ30ANTB=J *'QG++\-9&C&76X@*_7=7=Z<2=+
MM"WWC"F?^^17F6JKXJ\=6VE:)?>'9M+MH[B.6_N)7!5PG9,>IKN;OQ NE^(]
M)T%K&9EOD817((V*4&2".O2@#E/@YEM(UMVY=M4FW$]3\QKSG5WD_L[Q=$<B
M$^)(1CL<GFN^L8/$G@37=:AL?#\NK:;?S&YMWMW"F-SU#9[5##\/=3N_AQK$
M%Z%77-2N3?;0>$DW95: -?XNC_BUUZ>X$9'MR*RO [R3?%75GG'[Q=(M@,]N
ME1ZP/%WC72+#PY=^'IM.0RQF^O)'!1E7KM YYK2UK2=9\.^.;;Q)HNF/J5M)
M9K:75M$P#_+]UAF@"&1Y$_: C$8^5]+(D^F:U/'R>-VN;+_A$GB6+8WG^9ZY
M&/ZU#X1TC5K_ ,9:EXMUJQ:P>6$6UM:.061 <Y)'<UW] '@'BF/XK#PIJIU6
M2V-A]F?[0%Z[,<XKTWX4?\DM\/\ _7M_[,:M_$;_ ))QXA_Z\9?Y54^%'_)+
M?#__ %[?^S&@#LJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O"OBIJ%AI7Q<\.7VJ#-C#$6D
M!&1UXKW6LW4?#VD:O*LFHZ=;W3J,*TJ D"@#P#Q#X^\+W7Q4T;7K%R+6!-MQ
M(D>"?2O8O#7Q*\.>+-4;3M*N7DN!&9""F.!6A_PA'A?_ * 5C_WZ%6M.\-:)
MI-R;G3]+M;:8KM+Q1@''I0!JT444 %%%% !1110 4444 (WW&^E>/?!S_D;O
M&G_7Y_6O86^XWTKQ[X.?\C=XT_Z_/ZT >Q4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 9NOV^J76B7,&CW,5M?2)MBFE!(0
M^O%<%JGPZT[2O"%Q?W6H7AUBWA,SZB+AP3(.<[<XQGMBO1-2U*STC3YKZ_G2
M"VA7<[N< 5YJ;VY^*TB+&[6'A.-\R,[A9+TCMCLM &+=>+=:UKX?^%K*6YEA
MO=9N/(FG3AGC!^\/0FM'QIX<@^'^D67B#P_<W5O+;7$:7.^=G$Z,<'(8D5/\
M3+6VTFX\(ZC;A$TW3[P1N$'RQJ1P>*L_&*_M+_P5;Z;;3)/<:A=1+ D3;BPR
M"3QVH ](M;A;NTAN$&%E0.!]14U5-,MS::5:6[##11*A'T%3-<0*<--&".Q8
M4 2-]QOI7CWP<_Y&[QI_U^?UKUQKF J0)XLD?WQ7D?P<_P"1N\:?]?G]: /8
MJ*** "BBB@ HHHH **** "BBB@ KF?$^B76JS0-;[<(#G-=-133L[DRBI*S/
M._\ A#M3_P"F?YT?\(=J?_3/\Z]$HJN=F?L('G?_  AVI_\ 3/\ .C_A#M3]
M(_SKT2BCG8>P@>175I/97#07$920=CWI+6UGO;A8+>,O(W85Z7K&C6^KV^R0
M;91]R0#D4:/HMOI%OM3YI6^_(1R:KVFAG[!\WD<=_P (=J?I'^='_"':G_TS
M_.O1**GG9I["!YW_ ,(=J?\ TS_.C_A#M3](_P Z]$HHYV'L(',>&-#N]*N)
MWN-N'  Q73T45+=W<TC%15D>8:7<+X$\?ZQIUPPCTO48C?6Q/17'WE'ZUSTE
MSJ%K\/?%/CJ,LFH:HQ6!L<QP9P,?K7HOCCP1;>-;*U@ENGM9+>82++&N6([K
M]#6T^B6$NA'1I(%:Q,7DF/\ V<4BCR71[(R> X=._P"%>7ER;BWW->--%O=V
M&=^XG</6LKQ-;:L?@OI5CKHVSKJD<0*RB0^7DX^8=\5WX^'FL6^FOHUEXNN8
M-&;Y1;F!6D5/[HDSD"K>L?#>PU#PGI_AZRN'LK:SN$G#!=Y<KUSGUH YKXGZ
M%I>E_#6VFL;**WFMGA:*6-0'!R/XNIJ.^D9OC!X4N6^>7^RG<G').RN[\6^$
MT\5>&?[&:[>V7*'S50,?EQV_"JK>!T;Q?H^O_;WW:;:FW$.P8DXQDGM0!QGP
MGTRR\1#Q#JVL01WMY/=O$_VA0^Q/[HST_"J7CS0+'PU\,[C3].U-[VW&I(P1
MY _D9;[@QT'L:[*3X>7.GZK>WOAC79-(6^):YA\@2J6/\2Y/RFJ\_P )=./@
MU]!MKZ6&2:Y6ZN+LJ&>5P<Y(- ')^([J[O\ XIZ7I\VDW&KV=E8)-'81.JAF
M('SG=P<5=OH-<?QIHNK:/X4ET-ED\J[,D\2I-&>VU3R17:Z_X$AU>YL-1M+Z
M:PU>Q01Q7<0SE1V9>XJ.Q\#SR:]#K/B+6'U>ZMABV7R1%'%GJ=H."?>@#LJ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG?&.I>&['1_L_B
M>6%+*[)C"S#(8XS715A^)?">D>+;:"WU>W\Z.!RZ#.,'&* /"Y_"'PCEN3)%
MXJFBB)R8@^<?2O9? -AX7T_0%A\+20RVW5Y%;+,?5JRO^%,^"_\ H&_^/5R7
MAC1H/!'QUET/2I)/[.N['S6@+9VM_G^= 'MM%%% !1110 4444 %%%% !111
M0 4444 <Q\1O^2;^(?\ KQE_E53X4?\ )+?#_P#U[?\ LQJW\1O^2;^(?^O&
M7^55/A1_R2WP_P#]>W_LQH [*BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M444 %%%% !1110 4444 %%%,ED$43R-G:H).* ;L.HKDV^(6D*S*5FR#C[M
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M_)+?#_\ U[?^S&@#LJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $;[C?2O'O@Y_R-WC3_ *_/ZU["WW&^E>/?!S_D;O&G_7Y_6@#V
M*BBB@ HHHH **** "BBB@ HHHH *X'X@:G?6%U:+:7<T 93N$;8S7?5#-:6]
MR09H4D(Z;ESBML/5C2J*<E='+C*$J]%TX2Y6^IXK_P )%K7_ $%+K_OLT?\
M"1:U_P!!2Z_[[->R_P!EV'_/I#_WP*/[,L/^?2'_ +X%>E_:-'_GW^1XO]BX
MG_G]^?\ F>-?\)%K7_04NO\ OLTC>(-8=2K:E=%2,$%SS7LW]F6'_/I#_P!\
M"H[C2;.2WDC2UA#,I .P<4+,:-_X?Y">2XFW\;\_\SPLG))/4T X.1U%=H_P
MYU-I&(N(,$DCK2+\.-3#J3<P8!SWKT?KN'_F/&_LO&7^!G/+X@UA$")J5T%
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M,]!6]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJW_Y[Q_]]B@"6BHOM5O_ ,]X_P#OL4?:K?\ Y[Q_]]B@"6BHOM5O_P ]X_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!X- 'DNH>-?$-UXU\,I%&^G:3?N^(''[R4#NWH/05O\ Q&\2:EI#Z/INFO\
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M8:?"G1Q%%:R:CJ\VGQ/O2QDNLPCVVXZ5W=% #(HHX(4BB0)&@VJJC@"GT44
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M\ZYVOHL+A:,Z,92CJ?)9EF>*HXF5.G*R1O\ _">>*O\ GO:?]^Z/^$\\5?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %17/_ !ZS?[A_E4M!&1@T >$VNHV,2RI)=Q(XE;*L>1S4_P#:
MNG?\_P!#^=>PMHVF,Q9K"V+'DDQCFD_L32_^@?;?]^A72ZL&[V9S/#^9X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gzbwht3f4aft000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,7!E<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /-?'DWBM-8C&BK*;?9SM8#G/UJY\/9?$
MDDES_;JR  C9O8'M]:Y_XF:=K5UKT;Z>)/+$>#M)ZYK0^%=CJMI+>?VB) "1
MMW$^E=K2]AT_4\^+?UBVOZ'IU%%%<1Z 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?5+5)A'DQ,>J$CJ* +_]J:?_ ,_]K_W^7_&IH;JWN<^1/%+CKL<-C\J^0_\
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MNN=LDN3R">2*^M_#OAK2_#-@;;2[5($D(>3;_$V.IH V**** "BBB@ HHHH
M**** "BBB@ HJ"^E:#3[F5/O)$S#Z@$UXS\)/B-K?BSQ==Z?J,@:&.!G49[@
M@4 >LZ]K!T336NQ:R7.TCY$/-<!I/QLL=6\6V?A]-)GCFN)O*+M(/D.#U&/:
MO4B >HS7S,T,</[2=GL4#=J!8X]<&@#Z:HH[44 %%%% !1110 4444 %%%%
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M_/5/^^A7F?\ 8_B/_GC<?G1_8_B/_GC<?G7)]>J?\^V>C_9=+_G\CTSSHO\
MGJG_ 'T*?U&17F*Z1XCW#,-QU]:](M%=;.%9,[P@#9]<5T8>O*JWS1L<>+PD
M*"3C-2OV)JI3Z39W%V+F6+=(/7I^57:*Z'%2W..,Y0=XNQA>*E5/#TZJH4!>
M@&*X/PU_R'(/K7>^+/\ D 7'^[7!>&O^0Y!]:\?&?[S#Y'T>6?[C4^?Y'K-%
M%%>R?-",<*3C.!FO![OXK>*(/B@^CI;%M/6Y,0A\KEAZYQ7O-9YT+2VU(:B;
M& W@.1-M^8?C0!=B<R0HY&"R@D>E/HHH RO$O_(M:C_UP;^5>"? ?_D==6^O
M]37O?B7_ )%K4?\ K@W\J^:?A5HEUK?BO4XK75+K3V5B2]N^TGDT ?0'Q!\0
M66A^#]1EGFC\PPD)&6&6/IBO&?@'H5W<^+;GQ 8F2VC#J"1C.\'IZUZ*WP=L
MM0N5GUO5]0U$H<A9I P_E7?Z7I5EHUBEG86Z00(.$08% 'CG[2/_ " M$_Z^
MV_\ 0*L>$M:\5W_@G3[+PO8HHAC(>YF( SD\ -UJO^TA_P @+1/^OMO_ $&O
M0OAB OP\TD 8'E'^9H \QM_BAXQ\+>,(M(\7)%(DC  QH ,'IR*]Z#J8P^?E
M(S7@OQ^C0:SH,@4!VN "W<CBO<-. ;2K<-R#&,T >7#XF:AXK\9OX=\-2);"
M/<&N9$#9*]?E/TJIXM\6>-_AY+:76J7D&I6$TFPE(5C.<9QQ5B&U\$> _%LU
MY832WNLS,Q^RHP+ MUQQ[USWQGU76]5\+VLMWI;V%IYQ*I.!YF<>QQ0![=X?
MUJ#Q!HEMJ=MGRIUR,COWKA=7\=:IJOC$^&/#1CCEB ,URX#!>O&#[BM;X1?\
MDTTG_=;_ -"->5^,O#GB;P)XYF\3:#!)<6TS>9(0,KDY)!]N: .S\4W?Q%\*
MZ)<7ZZC;Z@J(2Q$"IY?OCO7>^%M5EU7PQ::A=$>8\0:0XP,X&37DNE?'73M5
MA;3/$NGM$LZ^7*^ $ /7->AZM>V6F?#FZN-(<26IA(C*>C"@##O/'NJ^(O%$
MV@>$D3_1C_I%X^"J]N >#57Q)JOCWP78KJMU?PZI9HP$L:0*A&?I7GGP>N?%
M,%A>3Z#9V\^Z3$DDJ$GMQUKT'66^(VM:5<:?<:99^7,A4D1G(R,>M '=^#_%
M-IXO\/PZI:9 ;Y70_P +=Q6_7F?P?\*:UX2TNYL=4&(V8N@QW)KTR@#COB1X
MS'@OPV]XB[[F3Y85/<UQGA#PQ/X^T*+7-9UNZDDN1O,=O(T0C)[?*:]#\7>#
MM,\9Z:MEJ0<*IRKI]Y?I5GP[X?T_PKHT6G6(VPQ#&YCRWN: /$_&\.O?"B_L
M[_2M5FN+*5OGCG8OM&1QEB>M>S>#O$D/BKPW:ZG%PTBCS%_NMW%>.?&?61XM
MU.Q\.Z$OVR9&_>^7S@Y%>K_#SPT?"WA"TL'7;.5#S#T;'- '54A^Z?I2TA^Z
M?I0!\M3?\G(/_P!A-?Y"OJ:OEF;_ ).0?_L)K_(5]34 %<?\0?'=KX'T?[3(
MGFW$G$4?K[UUY( R3@>]<7\1?#GAK7-)2;Q'<_9H(""LP.".^/QH Q[1_'^M
M:'%K-GK-M LT0ECMOLZMP1G&ZH?AQ\2-0UW7KKP[KD"IJ-N"Q<< @8[?C5O1
M_%RR:5'IWA+2+F[M8$\I+L8,?'&3T->=>"/MA^/FI&_\L76UO,\L87.%Z4 >
MR^-;CQ'::8;GP^(BT2L\H?'0#/>O)_ GQA\1ZWJES;7,(O)6CQ;0)'M!?/&6
M X'N:]SUC_D"7_\ U[2?^@FOG;]G0#_A+=0./^74_P#H0H Z;Q9XD^*?AJV_
MM>=+9=/##?$BJ[+D]..:W- ^*5YXJT")=&T\S:NQV.C':B<?>SC%=OXRACG\
M(:HLBAE%M(0#ZA37F?[.T48\,7<P0>89F4MW(XH S_$_C+XF>"IHK_5_LSZ>
M[ %$1?RR*]>\)^(K?Q3X>MM4M_NR###T8=17"_M!?\DT/_7Y%_6K'P&_Y)C!
M_P!?4O\ ,4 <-^T8<:KI9_Z8_P#LQKMX+GQ[JN@6;Z*D%A$EO&J&3:Y?"CL>
ME<1^T7_R%M*_ZY?^S&O=]#_Y &F_]>L7_H(H \?T[XKZ]X:\3+HOC6!?G.//
MC4  >N!UKVC[7 ++[69 (-GF;\\8QFO$OVCK*!-(TJ_6-1<M<&,R8YVA2<4E
M_P")+^T_9RM;[S6DGG86[LQY*L6'\J -@_$?6_%OB6?1?"$*)';G][>/@CJ1
MP#]*?XNC\>Z1X6OY;F_@U.W,+"95A6,HN.3[U%^SWI=M#X)DU-4'VF:=XG;U
M5<$#]:]$\8C/@[5@?^?9_P"5 'C?[.#%[K7W(QNV''XFO4OB#XWM_ VA"^EB
M,LLC;(HQ_$V,]>U>7_LZ?\?WB+ZI_,UZ7\1M!\.ZYHD8\27IM+6!_,$@;'./
MI0!S^EW/CWQ)H*:SI^LVT"R@M';_ &=&SCMNJ+X>?$Z\U?Q!=>&_$$:1ZC Q
M0.I&'8'D8%7-!\40Q:5%I7@[1;BZLXLJETN/*'UZ&O'O!QG;X_QFZ"B<W\GF
M!>F<'- 'U91110!PWQ;_ .2=:I_UQ;^5>2_&306L(/#WB6SB(<V\)FD[!E5=
MM>M?%O\ Y)UJG_7%OY4OBKP]'XF^%BV,A(VV<<RXZDHF0* -'P!KZ^(_!UA>
M^:))O+"SD#^/'-8'BIW\2>/](\.12?Z);@WESA<XDC8%03VR":X#X!^)S8)J
MFAWK)#'"AG3?P2Y(&*]*^'%L]ZFI>)KA5\[5)]ZC'*!<KC\<4 >,:R /CO$
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M;?7?$5W]FN(B-F&QYFWH#Q4TOB_5==TIQH.C3);LGR7=P 8R/7@YH D^&'Q
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MTR6WTF;4KQ6^W7\ADE9NI )V_IB@#K85=8465][@89L8R:S_ !#ISZMX>O\
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MQ\#7.TX;[0^#[\5R/QGM/%D&DQOK>I0W%H91Y:)"JD<G'(KK_P!GC_D2I_\
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M_GWMJT<W>2!@C'\<4RQ^&/AVQM);;R[B=9$*;KB3>RCV..* /+/V>;^T@O\
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MS=3&0KQC ]!0!X#;:>WPS^-2WNI>:;&=W*S;>,R=OPS7T;_:5E]E^T_:X?(
MSYF\;<?6JVM>'],\06OV?4K5)E[$@97Z&N7'PHT,+L^VZMY/3R?M9V8],8H
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MRH;HJGY8K>T#PCHWAL$Z?:A96ZRO@N?J: )8[ Z;X1^P [C!9&+/KA,5\Y_
MV^M=*^(-\;^>.V#6[(#*P7G<..:^HB RE2,@C!%<!J_P;\):SJKZC-#<Q3NV
MXB"78N?IB@#MK34K&_+BTNX9]GWO+<-CZXKYOGGB_P"&D+-]Z[5OR&.>G!KW
M*U\!:18:/-IMF]W;I,07EBEVR''3YL5SA^!OA1KXWIGU4W1;?YWVOYL^N<4
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MU?0M>:V7P0\+:=<>?9W.K02GJ\=V0?Y5W^FV":9I\-G'--,L0P'G?>Y^I[T
M?.7C^[6?XUP0ZZS+8H(\)D[?8U[KJ>OZ+I^B2>5<P,"F(XH"&9_95'4U#XI^
M'WA_Q>ZR:I;MYR_\M8FVO[<XJ/0OASH'A^5);=)YWC.4-S)YFP^HXXH \L^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR,6VW=A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^(M22&Y94BD.!Z"NZ\'ZLVJ:*C32;[A#A_Z4ZN$E3IJI>Y.'S"%:LZ-K-7_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/Y:X8*.GO6ZJ156,&]E8Y)4IRP]2JEHY7^1W-O\ \>T7^X/Y5YGIG_)1YO\
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MDMB.6"&;'FQ1R8Z;U!J,6-F#D6L _P"V8JQ11=B<8O="*JH,*H4>@%#*&&&
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MU%--K8&D]R.."&+_ %<2)_NJ!3GC25=LB*ZGLPR*=11=A96L(B+&@1%"J.@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!RWB.>YO-7L=&@F:%)]QD=3@X SP>U4T@
MG\-^)K*WAN9YK2[81E9Y"Y!^IJ;Q%+_9GB73M4F4_95#+(XZ+D8&:AGOH?$/
MBG3CISB>WM'$KRIROIB@#M:.@S12,-R,/48H X7Q#X[>RO'M;% 60X+L,@U9
M\,^-#JMR+2[0+,WW6' -<'XBT^?3]7G296P6RK'^*HM*6]@G6]M8'<0G)('
MKW?JE%T=-^Y\I_:.)CB?>>E]O(]SHKS:Z^(UP;=5AME67'S$YP/I5[PYXY>^
MO%M;Y$0M]UP>]>;+!5HQYFCVH9IAI34$]SNZ***Y#T0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 9)%',NV6-'7T9<BFQ6T$'^I@CCSUV(!_*I:* "BB
MB@"O<V5M=C$\*/[E1FB.RMH8C''!&JD8P%%6**?,[6)Y(WO8\:\6:3/8:W<.
M8B(9&+(5'&*B\,Z;<:AK$(A4[48,S=ACFO7-5LHK[3YHI8U?*\9'2N/^'DBQ
MW.H6W0A\#\,UZ\,8Y8>6FJ/G*N71AC(IO23;_P" =]1117CGTH4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 !&1@UYOX:0V/CF>V)
MP'WM_6O2*\VU8MI_Q!25>%?:H/UQ79A/>4X=T>9F/NNG4[2_,])HHHKC/3"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSSQZGD:
MQIUP!C+@D_0BO0ZXSXB6X;2H[C',3 #\375@W:LO,X,SCS8:5NFOW'66DWVF
MTBF'\:@U/63X:G$_A^S8')$8!^M:U<\URR:.NE+GIJ7=!1114F@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%(2%4D]!0 M%<B-:UG59[J32X8Q;6[%-S-@LPZ]:UO#NM'
M6;%GDC\N>)MDJ>AH V**YWQ+JU[87%C;607?<,PR3TQ5W2TU99F_M!D,>/EV
MD=: -6BBB@ HHHH *P/&-K]K\.3H.H(;\JWZJZE%YVF7*>L38_(U=*7+-2,J
M\.>E*/='/?#^;S?#^"<[9"*ZNN ^',KHUW:-_ -Q'OFN_K;&1Y:TCFRV?-A8
M!1117,=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \Z\>1&WURSO1QT6O0;=MUM$P[H/
MY5QOQ'@+:=:S*/N2Y/TQ70>&[H7>AVTFX%MN#7;5][#PEVNCR\/:&,JP[V9K
M4445Q'J!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!YM\0]6E-VFGKQ&%W'WKE=*U:ZTV\BEBE?:IY3/!'TKT/QAX4DU=UN[4CSE&
M"I_B'M7 3:1<Z1>V_P#:4#QQ,P)SW&>:]["3I2HJ"W['R684\1#$NH[VZ,]H
MLYS<V4,Y&/,0-CZU/573I(9-/@:W.8M@V_3%6J\*6C9]7!WBF%%%%(H****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ^AIXBC[.6FSV%@\3[:%I:26C0ZBBBN<[ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9!KZ3"XA5X7Z]3XK'X*6%J6Z/8=11172<(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%5I+^TAN4MY+B-)G^ZA;D_A0!9HJM%J
M%I/<-!%<Q/*GWD5LD59H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ IKHLB%' *D8(-.HH \TUO3;GPKK"ZE8[OLS-E@.W
MM7=Z/JL&KV"7,+ Y'S#T-6+VSBOK62WF4,KC'/:O.(WN_!6O['R;.4_@17>K
M8F%G\:_$\B2>!J\R_ARW\F>GT5#;7,5W;I/"P9'&014U<#5M&>LFFKH****!
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*&'0C(I:9$ L* 9P% &:?0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9FN:/#K-@\$BC?CY&]#6G151DXOF1$X1G%QELSS?PYJ
M]QX=U1M)U#(B+84MV_\ K5Z.K!U#*<@C(-<WXL\.IK%F9HEQ=1#Y2.I]JR_!
MWB-]W]DW[$31DA&;KQVKLJQ5>'M8;K=?J>9AYRPE3ZO4?NOX7^AW-%%%<)ZP
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !6?K.H#3=,EGR X7Y/<UH5PGCK4-TL=DC94?,WUKGQ57V5
M)R.S 8?V]>,.G4XZ:5IIGD8Y+$DTRBBOF&[GW25E9!1110 4444 %%%% &OX
M;6U;681=8V9XSTKI_&=W"EC$MM/MD!&!&W&/PK@:U-(MM.N6;^T+EH@#Q@CF
MNNC6:INBEOU//Q.&BZRQ$F[1Z6N=OX.N9KO1\3DOAB,MSFN7\96T%MK \@ ;
MUW,!V.:[&S5$TCR]#>%P,\D]Z\\UJ&^BU!S?[O-8YR>]=>+;CAXP>OF>=ER4
M\9.HG9:Z=?N/2M M$LM'A11C(W$_6N7NKS1!K4PN8GDD+D%]W _"NIT2Z2\T
M>)T(/R[?RKS/5T9-;N5(P?-/\ZTQ=3V=*#BKHQR^DZN(JJ;:?_!.VU+PG8W=
MD9;12DH7*\\&N-TK49=#U,N5SM.UU]:]-TP^5I,+2'&U,G->5:I(LNJ7+I]T
MR''YUEC8QI\E6&C.C*ZDZWM*%5\T4=-=W^C7^J6VHM=>48^6C*DY/UK1ENH]
M9*W$JE-/@^Z#_P M#VKD=#TAM3N<O\MO'S(YZ 5LR:G#?:M;:?" MG$P&/[Q
M%*G6DX\TTE=_>_\ (JMAX1DH4VVXK[E_F-U6ROM6(N9=MO:CB)3Z?2L74=$O
M--4/*F8VZ..E=9X\)6RM57A?,Z#Z5H"-+GP>?/ .(B1GU XJJF&C.I./5*]R
M*..G2HTYI+E;M8\QHHHKR3Z **** "BBB@ HHHH ['P/J9CN'L9&^5^5SZ^E
M=]7C%C=-97L5PO6-LU[#:3K<VL<JG.Y0:]W+:W-3Y'T/E,[PW)555;2_,FHH
MHKTCQ HHHH **** "BBB@"-((8V9HXHU+?>*J!GZTD=O!%N\J&--W7:H&::]
MY;QW*V[S*)G^ZAZFIZ (XX(8MWEPQINZ[5 S49L+-FW&T@+>IC&:L44 126U
MO,H66")U'0,@.*2.TMHFW1V\2-C&50"IJAN+J"T0//*L:DX!:@!4MX(E98X8
MT5OO!5 !^M.BABA7;%&D:YSA% %->XBCA\YY L>,[CTJ-[^U2W%PTZ"$]'/2
M@"26VM[@CSH(I,=-Z X_.FQV=K"VZ*VA0^JH!4,.KZ?<.$BNXW8]@:FEO;:"
M18Y9E1W^Z">M $DD,4R[98TD7T9013(K2V@;=#;Q1GU1 *?+*D,322L%11DL
M>U)#/%<1"6%PZ'HPH 8]E:2/O>UA9O[S1@FG&V@+JY@C++]UM@R/I5>;5]/M
MY#'-=QHXZ@FIX;J"XB\V*573U!H 5;>!79UAC#-]XA1D_6A+:".-HT@C5&ZJ
MJ  _A4=O?VMT[)!.DC+]X ]*>+N!K@VXE4R@9*=Z '+;PI'Y:PQJG]T* /RJ
M-;&S1MR6D"MZB, TMS>VUFH:XF6,'H6J6.1)8UDC8,C#(([T .HHHH ****
M"BBB@ HI"P'4@?4TM !12%E7J0/J: ZMT8'Z&@!:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "N'\8^'6W?VM8 K,F"X7OBNXI&4.I5AD$8(K6C5E2ES(
MPQ.'C7IN$CF_"?B-=7LQ#,P%U&,,/[WO72UYOXBTBX\.:HNKZ:,1%LLHZ#_Z
MU=IH6LP:SIZ3QL-X&'7N#6V(I1M[6G\+_ Y<'B)7="M\2_%=S4HHHKD/1"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ***P.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$90RE6 (/4&N'\2>$&$AU#2<I,IW%%.,_2NYHK6E6E2E>)SXC#4Z\>69Q7AK
MQAYKBPU/]W.ORAB,9KM 0PR""#W%<OXE\(PZJK7-L!'= 9R/XC[USFG^+K_0
M%>PU*)W>/A"W7V_"NJ5&-=<]'?JCAAB9X1^SQ.JZ2_S/3**X+3_B*LMT$NX%
MCC8X#+V^M=W&ZR1JZG*L,BN6K0G2=IH[L/BJ6(3=-WL.HHHK(Z HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2TA 92#T(P:$)ZHX#PEJ-E8W]^+JYCAW.<;VQGFF:[K,D_B 0VUW';0A21<
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MGRV99HZW[NE\/YA1117I'B!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<YXH\,1:U;F2,!;I1\K>OM71T5=.I*
MG+FB95J,*T'":NF>?^&O$LVG77]DZL2I4[4=_P!*[\$, 0<@US?B?PQ%J\!F
MA 2Z095AWK%\,>)9;&Y_LC5LHRG:CM_G]:ZZE.->/M*>_5'GT:L\)-4*SO%[
M/]&=_12 A@"#D'H:6N$]4**** "BBB@ HHHH **YW7_%UIHDGDX\V?&=HZ?G
M4&A>-;75[A;>1/)F;A1U!_&MEAZKASVT.5XV@JGLG+4ZFBBBL3J"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/%WB%M#LE\@ S
M2' ![>];MS=0VD+2SR*B*,DDXKRSQ1JO_"2:@J6%O)(L? 8*>?PKKP='VE2\
MEHCSLRQ/L:+4'[SV(+;QMJ\-UYKSM(A/*,>*]5TR^74=/AN5Q\Z@D#L:\3@T
MB_N+@0I:R[B<<H0!736TWB3PLHC:$R09SM7YA^==^+PU.:2IV3/(R_&UJ3;J
MIN/Y'J-%<?IOCZRN6$=XC6\O3&"174V]Y;W2AH)HY ?[K UY52C4IOWD?0T<
M32K*].5R>BBBLC<**** "BBB@ HHHH **** "BBB@ HJCJ>K6FD6QGNGVKV
MY)K&L/'.E7UT( SHS'"EEP*TC1J2CS16AA/$T82Y)229T]%("",@Y!I:S-PH
MHHH **** "BD) !). .I-8MSXLTBTN/(DN"7SCY1D?G51A*?PJYG4JPIJ\W8
MVZ*K0W]K/ )DGC,9[[A5.\\1Z78@F6Z1L?W"&IJ$F[)!*K3BN9M6-6BN)N_B
M):@D6-N\Y[;@168WB/Q-JC;;2V>%3ZIQ^>*Z(X*J]9:>IQ3S/#IVC[S\CT9Y
M$B4L[!5'4FLB\\5:/9@AKR-G'\(/-<E'X2\0:BX>_NC&#_=?^E:UI\/K"(@W
M4KW![YXJO8X>'QSOZ$_6<75_AT[>I6N_B+ "5L[9V;L6Z&N%UFYN;W49+JZC
M,;S'<!VKV.TT+3;$ 06J#'J,U'J?A_3]60+<0+E>A7C%:T<50I2]V/S.?$Y?
MBL1#]Y--]NAX]H\<TNK6JPJ682*3CTR,U[JN=HSUK'TKPSIND2&2WA_>'^(G
M-;-8XS$QKR7+LCHRS!2PL&IO5A14=P)#;R"$XD*G:3ZUY\([VT\>6T-S=/*S
M+N;G Y'3%8TJ/M$];6.K$8CV+C[M[NQZ+1D5QGC>:YCDM$,CQ63']ZZ=169H
M<Q@\1,+"YEGM$A+/O)Z[<UI'"N5/GN85,>H5O9<O5+?OY'HV117GME8W'BF>
M^O)+N2)%8K&J'I6OX'U&:[LKFWG8L;:38&/?K2J8;DBW?5;E4<;[2:BXV4KV
M?>QU=%<[KWB<Z+>PP?9O-$G<'G\JS%\=3I=&VN--*2G_ %:@D[C^53'#591Y
MDBYXZA"3A)ZH[6BN:T;Q4;^]EM+RU^S3(NX+DG(ZU5D\97$MS,NGZ<;B&(X+
MY-'U:I>U@^O4.52OO_6QU]%<OJ/BN2VN8[6TLC/<E-[QDD;:E\.^([G6KB:.
M6R6 1<$[B3GZ4GAZBCSM:#6,HNI[-/7T.CI,CUKFO&&K7%C:1VUJ<3SD*#[5
MFMX0F_LS[2-0G^TA/,/S''3..M5"@G%2G*UR:F*DIN%./-;?6QW%%>;&_O-:
M\&3,\C"6S;)93@D 5:UC6S/X)M_*9EFE95!!YX.#6GU.5TK];&/]I0Y7*VEK
MKS\COZ*X/0]4FB\%WQE<^?!D#)Y["MSP=$Z:#'+(6+RDL=Q)[FLZF'<$VWL[
M&U'&*K**2W5_0Z"BBBN<[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** $(# @C(/45RVM^#X+O=-9@12]=N.#7545E5HPJQY9HWH8BI0ES4W8\:O
M=/N;"4QW$3(>V1UJK7LUW86U]$8[B)74^W-<AJG@8Y:2P?\ X W&*\>OETX:
MT]4?2X7.J53W:ONO\#B**MW6FWEDY6:!QCN <?G52O.<7%V9[$91DKQ=PHHH
MI%!1110 4444 %%%% !113XXI)6VQHS'T49H!NPRE +$ #)/:N@TWPC?WQ#2
M+Y49[GK^5=GI?ABQTW#;/,E'\3?X5V4<#5J:O1'FXG-:%#1.[\CD=&\(W5\5
MEN088>N#U-=]8:;;:; (K>,*.YQR:M  # &!2U[5#"TZ*TW[GS&+Q];$OWG9
M=@HHHKI.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH/ S6);^)(KB\^S#3M0
M0YQO> A?SH K7_BF>RDE(T6ZF@C.&F5U"BMG3=0AU2PBO(#F.49%9'BC54M;
M0V-N@EO;CY4C'OW-7O#VFG2=#MK-L;T7YCZG.: (=>\0?V*]M&ME+=RW!(5(
MV /'UJ32M5O;^9DN=&N;%57(>5U(/MQ57Q'HMUJD]G-:2B.2W+')/K5.QUK4
M[/Q"FDZHB-YR[HY$;)Z]Z .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N0\;Z
M';3Z9+J*X2>!=V1_%77U0UJP_M/2+FT!VF1, UK0J.%12N<^*I*K1E%J^GXG
MD,?B75HE15O),)P/F-=EHWC^#["%U$?OU[C@$5Q%SH.I6URT)M)6(. 0IP:[
M7PMX*@-J9]5MP[O]V-OX:]C%+#<EY?@?-X!XWVO+!_?L6Y/B)8+]RUFD_P!U
MA523XCJW^JTZ8?7!KIX_#.CQ?<L8Q^=6H]+LHON6R#\*\[VF&6T&_F>S[''2
MWJ)>B.&/CW4Y?]19'\4IO_"3>*KCB.S3!]$_^O7H8@B P(D'_ 13@B#HJ_E1
M]8I+:F@^I8A_%6?R/.//\:7/2V=0>XX_K0-)\7W'W[B:+/\ M?\ UZ])Z44?
M7&MHI?(/[,3^*I)_,\,UNRO;+4&BOF9YL EF[U6LIIK:[CN(02\9W# KVS4M
M$L-64"[@5R.A[BH=.\.:9I@/D6Z[B,%B.M=D<RA[.TEJ>=+)*GM;QEI^)EZ-
MXVL+U4BN2;>8 #YSU-=0DB2*&1@P/<&N;U;P3IVH[I(0;>8\[D'4US)MO$GA
M:3,1:>V!Z*<C'O7+[*C6UI.S[,[_ *QB<-I7CS+NOU1Z917):1X[LKPB*\'V
M>;O_ '?S-=5%-%/&)(G5T/0J<BN6I2G3=I([Z.(I5E>F[CZ***S-@HHHH **
M** "BBB@ HHHH **** "BBB@ HHH)P,F@ K+UG7K/1;<R3N"^/EC!Y-8_B+Q
MC!IP:VLB)KH\<=!6+H_A:]URY&H:T[[&.X(>I^HKKIX=*/M*NB_%GG5\;)R]
MCAU>7X(K8UCQM>=X;,'GCC%=WH^A6>C6X2",%\?,YZFK]M;0VD*Q0($11@ "
MI:FMB'-<L=(]B\-@HTG[2;YIOK_D,6*-6+*@#'J0*<RJZE6 *GJ#2T5S7.VR
M,'4O".E:B"3 (G/>/BN7N/!^L:0QETJ[9D'(C0D&O1J*Z:>*J0TO=>9QULOH
M57S6L^ZT/.K7QKJFF2B'5K1F"_W1@_G75:;XJTO4@ DZI(?X&/-:=S8VMY&8
M[B%'4]017*ZEX LYBTEE*UN_95Z?G6G/AZOQ+E?EL8>SQE#X'SKL]SL0RL,J
M0?H:6O,Q%XI\-MA2T\ _A7D8_*M?3OB#;R,(M1@,$G0[1D?K4RP<[7@^9>1=
M/,J=^6JG!^?^9VM%<G>>/]+MIA&F^3N2%XK2M/%6DW=I]H^U)&/[KD UD\/5
MBKN)T1QE"4N535S:HKF+OQWI%MD!WD;MM7(K&F^(-U.2MAIXDSW.<U<<)6ET
M,ZF8X:&CE?TU/0*C>>*-2SR*H'7)KSDWOB_5#B-9;=3V(P/Y5)'X*UJ]8-?W
MF,_W7S6GU6,?XDTC'^T)S_A4F_70ZVZ\4Z/:9$EXFX=AFL2Z^(EFF5M[664]
MF4C%/M?A[I\6#//).>X85N6OAO2;/'DV: CO1_LL.\@MCZG:/XGEOB/6[O6Y
MDFEC>.)1A5(XK$3=O79G=GC'K7N.I:)8ZI:?9YX5VC[I ^Z:Q[#P)IEE=+.Q
M:;:<A6' -=E+'THPM:UNAYE?*,1.KS<U[]3FK6X\8BUC\JWD:/:-I/<?G4WV
MSQH/^71OR_\ KUZ.  ,   48'I7&\8F_@1Z2RV27\61YQ_:/C(?\NA_+_P"O
M1_:WC$?\NG_CO_UZ]'P/04;1Z#\J7UN/\B'_ &?/_G[(\Y_MOQ@/^7,?]\__
M %Z/[?\ %P_Y<T_[X_\ KUZ-M7^Z/RHVK_='Y4?6H?\ /M!]0J?\_I'F5YXB
M\4M:2I-;*D94AF"<@?G7%,Q9BS')/)->_36\4\+Q2(I1Q@C':N*N_AQ;RW1>
M&Y=(V.2N!Q77AL;2C=-<IY^.RS$3LXR<_4Y;P[I.I:V'@M[MH8%^]DG%=?9_
M#NR0AKN9Y6[[3@5T6BZ+;:):>1;C.>68CEC6E7-7QLY2?LW9';A<KI0@O;*\
MC*M?#NEV8 CM(R1_$R@FM-$6-=J*% ["G45QRG*6[/3A3A!6BK!1114EA111
M0 4444 1SRK! \K?=1<FO-+[6X)?&<6I+')Y**%/'M7IY (P1FF>3%_SR3_O
MD5O0JQIWNKW.3%8>=>RC*UG?8X/Q1>27LFFW7E2MIK@-(H[\FJ6GQ_:O$)_L
M>&2&W>(J^?N]*]*,:%=I1<#H,4+&B?=11]!6L<4HPY5$PGE[G4YY2[/;\GV/
M/-,U1_"\U]97%M(^6)C*C[U;7@?3IK2RN;B92IN9-ZJ>H'-=08HV.612?4BG
M  # &*FIB>>+25F]RZ."=.:;E=1O9>IQ'BN-G\26!"$C<.WM3=3B8^.;!MA(
MP.<>]=R45CDJ"1W(HV*6W%1D=\41Q-DE;9-!/ \TI/FW:?W'#W4+R?$.8*AP
MUM@''&2AJEX>U;_A&1=65Y:RF7S"1CO7HNU=V[:-WKCFFF*-CDQJ3ZD4_K*<
M>64=++\"?J,E/VD)6=V]NYYCKU[(OBEKBWD-L[1_>()X('I72^"Y+/R)DCN1
M-=,Q>4\YYIVJ>%[F?6'U&RO#%(XP1@8';O5KP_X;_LB>:ZEG:6XFX8D#US6U
M6K3E1Y4];(YJ&'KPQ3DUI=_TM=_D5/&VG7-Q:PWEJI:2!@=H].N:I2>-D_L@
MPBTF-QY>P@_3&:[<@$8(S3#!"P(,28(P?E%<\*\>51G&]CMJ86;G*=*=N;?2
MYQ?@VPAN/#EU;F96>Y^\O=>*PM&MY+W6;72Y8F$5L[MDC@\YKT&RT&RT^^>Z
MMD\MG&"HZ5I"-%;<$4'U K5XM*4FM;_@<\<O;A!2TY?Q5[GE.KP7EOK]W8PH
MWEW3_= XQG/]*]1LH1;V<,2C 51Q4IC0MN**3ZXIU8UL1[6*5K6.C"X-4)RE
M>]_P"BBBN<[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+/48HIHUP[/'N#<>F:@TSP[/#J9U+4[M;JZV[5*+M5?PKH:* "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4$ C!&1110!QWCG189M):[A@421?,Q48R
M*\LKZ!DC2:-HY%#(PP0>]<\_@C2'N?.\MASG8.E>GA,;&E#EF>'F&5RKU/:4
MK>9P^A#Q'!8>=IO$!8\'U^E:G_"4^);0XN+5Y,?W8_\ ZU>AVUM#:0+# @2-
M>@ J0@$8(XK.>,C*3<H)FU/+:E."4:K7Y' Q?$*YCXN-,<>I.1_2KT'Q#TQO
M]<KQ_12:Z>73;*;_ %MM&^?450G\+:/-_P N42^ZK4^TPTMX->C+]CCH?#43
M]410>,=&N,;+@C/]Y<5I1:K8S#*7</XN*P)_ &D3=#*A_P!DBLZ7X<1@YMKL
MJ>Q8TN3"RVDT'M<?#XH)^C.X6>)_NRHWT8&J6HZW8:5C[5.%)_A')_*N,;P=
MK]IS;ZIG'0)FN)U"6ZEO9/MDKR3(=A9SSQ6U'!4ZDM)W1SXG-*U&/O4[-]]C
MTK5_'=G!;!=/W33N/E^7I61I/AJ_\077]H:L["(G(0GK^':N8\,HLGB.Q1T#
M*TH!!%>V@   # ' JL1;">Y3W?4C!\V8-U*[T73H0VMI!90+#;QJB*,  5/1
M17F-MN[/=225D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1117,=P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2-]QOI2TC?<;Z4 CF_"?\ KM4_Z[C^5=+7->$_
M]=JG_7<?RKI:Y\+_  E\_P SLQ_^\2^7Y(****Z#C"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N3U[P1;:M<FYBE,,A^\ .#7645I3JS
MIOF@[&-:A3KQY:BNCF?#W@ZVT27SVD,TW8L/NUTU%%*I4E4ES2>HZ-&G1CR4
MU9!1114&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4456^VQ_;A:*"SD$DCM0!9H
MHHH **** "D;[C?2EI&^XWTH!'-^$_\ 7:I_UW'\JZ6N:\)_Z[5/^NX_E72U
MSX7^$OG^9V8__>)?+\D%%%%=!QA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%5[N]M[*/?<2!%[9/6H[+5+/4-PMIE
M<KU7N/PH N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!!>726=J\S]%&<>M4](MG2-[J;_
M %TQR?IVJ"XSJ>JK .8+<[G]SZ5L@   =!0("P523T R:IV%\U\9F" 1*V$;
M^\*KZQ<,1'90G][,<$C^$5?M;=+6V2%!@**!DU%%% !2-]QOI2TA&01ZT <W
MX3_UVJ?]=Q_*NEK/TS2TTU[ED;=Y[AC[5H5C0@X4U%G1BZD:E9RCMI^04445
ML<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%5[F^M;0@7$Z1EN1N/6K%5+S3+6_93<1[BHP.<4 4]5?2YK);NYMTNXXS\AQ
MG'TKE_#DMG=^,[FXLD%J@BV-%T+'/6NEU"2XTJ&*.RT])[?)WAFY7\.]8EEI
M]]JGBJ'5'M5L[>!<84\N<]Q0!VM%%% #)'$43.1D*,UG?VW#_P \GK4ZC!IO
MEQ_W%_*@#-_MN'_GD]']MP_\\GK2\N/^XOY4>7'_ '%_*@6IF_VW#_SR>C^V
MX?\ GD]:7EQ_W%_*CRX_[B_E0&IF_P!MP_\ /)Z/[;A_YY/6EY<?]Q?RH\N/
M^XOY4!J9O]MP_P#/)Z/[;A_YY/6EY<?]Q?RH\N/^XOY4!J9O]MP_\\GH_MN'
M_GD]:7EQ_P!Q?RH\N/\ N+^5 :F;_;</_/)Z/[;A_P">3UI>7'_<7\J/+C_N
M+^5 :F;_ &W#_P \GH_MN'_GD]:7EQ_W%_*CRX_[B_E0&IF_VW#_ ,\GH_MN
M'_GD]:7EQ_W%_*CRX_[B_E0&IF_VW#_SR>C^VX?^>3UI>7'_ '%_*CRX_P"X
MOY4!J9O]MP_\\GH_MN'_ )Y/6EY<?]Q?RH\N/^XOY4!J9O\ ;</_ #R>C^VX
M?^>3UI>7'_<7\J/+C_N+^5 :F;_;</\ SR>C^VX?^>3UI>7'_<7\J/+C_N+^
M5 :F;_;</_/)Z/[;A_YY/6EY<?\ <7\J/+C_ +B_E0&IF_VW#_SR>C^VX?\
MGD]:7EQ_W%_*CRX_[B_E0&IF_P!MP_\ /)Z/[;A_YY/6EY<?]Q?RH\N/^XOY
M4!J9O]MP_P#/)Z/[;A_YY/6EY<?]Q?RH\N/^XOY4!J9O]MP_\\GH_MN'_GD]
M:7EQ_P!Q?RH\N/\ N+^5 :F;_;</_/)Z/[;A_P">3UI>7'_<7\J/+C_N+^5
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M;A_YY/6EY<?]Q?RH\N/^XOY4!J9O]MP_\\GH_MN'_GD]:7EQ_P!Q?RH\N/\
MN+^5 :F;_;</_/)Z/[;A_P">3UI>7'_<7\J/+C_N+^5 :F;_ &W#_P \GH_M
MN'_GD]:7EQ_W%_*CRX_[B_E0&IF_VW#_ ,\GH_MN'_GD]:7EQ_W%_*CRX_[B
M_E0&IF_VW#_SR>C^VX?^>3UI>7'_ '%_*CRX_P"XOY4!J9O]MP_\\GJ"[U^,
M1;(XW\U_E7/O6P4C R44#Z5C6R+J6J-<[!Y$/RQ\=3T-,-2_I=F;2T ?F5_F
MD/J:LS2K!"\KG"J,FI*QM2=KZ]CT^(G:#NE([8[?C2&4;#44-W->SQNSO\J>
MR]JT_P"VX?\ GD]:"01(@58UP!@<4[RX_P"XOY4Q&;_;</\ SR>C^VX?^>3U
MI>7'_<7\J/+C_N+^5(-3-_MN'_GD]']MP_\ /)ZTO+C_ +B_E1Y<?]Q?RH#4
MS?[;A_YY/1_;</\ SR>M+RX_[B_E1Y<?]Q?RH#4S?[;A_P">3T?VW#_SR>M+
MRX_[B_E1Y<?]Q?RH#4S?[;A_YY/1_;</_/)ZTO+C_N+^5'EQ_P!Q?RH#4S?[
M;A_YY/1_;</_ #R>M+RX_P"XOY4>7'_<7\J U(K6Y6ZB\Q00,XP:GI  HP !
M]*6@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%1RW$, S+(J#_ &CBG)(DJ!D8,I[B@!U%%% !1110 4444 %%%1F>(2B(
MR*)#T7/- $E%%% !1110 4444 %%%0RW4$#!99D0GH&- $U%(K!E#*<@]"*6
M@ HHHH **** "BBF"6,R&,.I<=5SS0 ^BHY9XH%W2R*@]6.*6.5)4WQN&4]P
M: 'T444 %%%% !113))8XEW2.%7U)H ?10#D9'>H'O+:.3RWF17_ +I/- $]
M%%% !1110 444UW6-2SL%4=S0 ZBHHKB&?/E2J^.NTYHEN(8!F614!_O'% $
MM%-21)$#(P93T(IU !1110 4444 %%0->6R2>6TZ!_[I/-3T %%1FXA$WDF1
M?,/\.>:DH **** "BBB@ HIDLL<*;Y75%]2:(IHYTWQ.KKZJ: 'T5#+=6\+!
M99D1CT!-2@AAD'(- "T444 %%%% !114"WEN\OE+,A?^Z#S0!/13))4B3?(X
M51W)I(IXIUW12*X]5.: )**** "BBB@ HHJ*:XAMP#-*J9_O'% $M%-CD25
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M9!\BW.3[MZ5L@8&!VH$%%%% PHHHH **:\B1(6=@JCJ35?\ M*Q_Y^HO^^J
M+5%1O/%''YCR*J'^(GBEBFCG7=$ZNOJIH ?1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=!11VH XJVM
M3XD\3ZDUU))]FLG$2(CE1R >:E\-%M.\2ZEI'FNT*(LD8=BQ!8G-013W'AKQ
M+J+S6\KV=X_F*Z#@$ #%7/#4$]WKE_K,]N\23HL<:N.?E)Y_6@#JZ*** "BB
MB@ HHHH JZC>QZ?927$AP%''N>PK@+);MO%.G7]R\BO>2!Q&6.%4YXQ76^)-
M%GUJWBBBG\L(P8CL2#D5S%_I6M#Q-IQ:X+[6&'!X7K0!Z'12("$4,<D#DTM
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MQN 6?)Y;BH=!T/4;OPG<6<\YC$K?(#_"00: *EXUUJ.I:?K4C.D4E\D=LH.
M8SZCZUZ./NCZ5Y_K.BZS!%I<*W.^-+I0@4_<Z\UWL"NL"+(=SA1D^IH DHHH
MH **** *&L:C'I>G27#GYONH/5CP/UKD/#]M=V_B]9;R1_M%U:^=*A;A6+=
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MT4 %%%% !1110 4UD1QAU5AZ$9IU% $8@A4Y$,8/J%%.:-'^^BM]1FG44 (
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MFU=V[ W>N*6B@!K1H_WT5OJ,TJJJC"@ >@%+10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %(JJHPJ@?04M% #'BCD^_&K8
M_O#-"PQ(<K$BGU"@4^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0D*,D@ =S0 M%-6
M1'7<CJP]0<TB2QR9V2*V.NTYQ0 ^BF++&SE%=2PZ@'D4^@ HHJ.>>.V@>>5M
ML:#<Q]!0!)1533M3M-6M!=64HEA+%=P&.1UJW0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %5M0A$^GW$9&<QM@?A5FCJ,4 >7>%-2GTWPAKD<DA%U:
MDE%)Y&!57X>:G-I^MWMK> [KB,SG)Z  M5+Q1I>IV_BZ\@MHI##J#GE5.W!X
MYK5\8VEQH]UIU]96SO,]J89-B$_P!>U $^@:A'97/B#Q.[E[=G947/7D'BI8
MOB-?J\,UW80)9R.%W*3N&3WI%\+2M\-%AA#?:'3SC&>"6/:N>T^STB6.&VN=
M&U%KG< P,KA<^O3% ':Z]XZ-A>066G6Z3W$J"3]X2%VD<=*IP>,6US2]6T^Z
MMUANXH&)$>2N,>]8?BK13;>(;2]EL;B33A D>V)SN& >,CFK.DV>GM#J<NG:
M3=PLUJZ^;-(Q+>V"* #PSXG.C>$;6ULX1<W\US($B/0#=U.*],LGN)+.)[I$
M2X*YD5#P#[5X[8Z->Z?X?L]>M89!<P7#B6-E))7=C@?2O7M,O/[0TVWO/+:/
MSD#;&'*T 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gzbwht3f4aft000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" **!= # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW+W)-Q7^8_5M7\8:+#'+>26ZI(VU=H4\UK:9-XLWK<7QMVM=NX[2N:A^(_\
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M[F<L7*GBYQ:;5EHM36\.:]?:CK.I6UPZM' ?D 4#')IVB:]>WOB;4;*=U,$
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MH*4@$8(K;Z[437+HET.;^RZ+C+GUD[ZG#V'VRY^']U;2PN)8T\M$/4@8JUX
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MT%*0",$4JF(YG&RLHCI8/DC-.5W+<Y+X?VT]KHLR3QM&QF) /IBNMI H48
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M*Q/DUK$@ DG '6OG;PS8:3J'Q-LCX)$T%C N^X+N?F'!QS^-?0EW_P >4_\
MUS;^5 &%<>/?"EI<26]QK]C'-&VUT:7E3Z5IZ3KNEZ[ \VE7T%Y'&VUVB;(!
M]*^8]-G\&1>,-</C"*XDC,A\GR0Q.[/.<>U>P:7J?ASPC\.[S7?"=E(UHX\[
MRYF(+$#'?..E 'IE%>+#XSZ[<:4VJ6OA8R6:?>EWMC\.*ZM_BAIZ_#]?%"Q$
M[CL\D_WQC('MDT =1XC\0VGAC1IM3O5D:&$981C)-2:!K5MXBT.UU:S#BWN5
MW('&#C..?RKPOQG\0M;\0>")5O?#YM;2[CS%.K,P_'CBO4_A/_R3#0_^N)_]
M"- '9T5PGCOXB+X4N+:PLK/[=J-P<+""1@<=<?6L"#XN:G8:W:67B+0#807+
M!5F5F;D]!T% ':^+?'&D>#;9)M2=RSGY8X\%C^%7_#GB"T\3Z-#JED'$$HRH
M<8->&_$C5=4E^*VGJ^E)*MM)MMHF;(N!SR>.*]Q\,2SS^'[66YL(["9E^:WC
MZ)S]!0 S4_%WA[1;LVNI:O:6LX )CE?!P:?I7BG0M=F>'2]5MKN1!EEB?) K
MPSX@1:/<?'.2+7LG3_LT>\!L<[.*[_P>GP^T,ZA?^'F\MHH0T[-*3\N>.I]:
M /2ZS];UBWT'29]1N@QAA7<P0<FO+8_B]KVI)=76C^%S=6,+$"3>P+#Z8JQJ
M7C:#QK\*]5N5A\BY@!2>'^X<'_"@#II?B9HL7A&/Q(T=Q]C>3RPH4;LYQTS[
MUU&E:E#J^E6NHVX80W,8D0,.<&OGF]_Y(#:?]?3?^A"O0#X[MO!/POT"9HOM
M%U-;(D,.<;CCOZ4 >I45X[-\7];TE[2?7/#)M;"9@&F5V8J/ICK[5O:A\3/[
M.\8:?I<EFOV&_13#<!^26Q@8_&@#T2BO-/$'Q8BT'Q]#X>DM%>W<)NG#<AF[
M8^M:6K>/9+#XBZ9X6@LUF6[QYDV[_5]>WX4 =S6;'K^DRZN=)CU"!M0"[C;A
MOGQUSBM*O#]&_P"3D9O^O5__ $"@#V'5-:TW184EU.]AM8W.U6E; )JU;7,-
MW;QW%O(LL,@W(ZG((KR/]H G^P=(Y_Y>6_D*LR>/_P#A"?!'AEGM//CN(E5S
MN.5'/0=Z /6*HZAJUEIB$W,RJYC>1(\_,X49.*\JN?C'K.G/;7.H^&6M]-G<
M#SRS9 /?&.OM6Q\1](NO%>D6,^G6?FAH&F%P)RC1J5!P .N1VH ZS0?&&E:_
M;0RP2&&28D)#-PY[]*WZ\-^%GA/4K#4[34GLFGMF)!GGF*/%QVC[U[E0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4J_>'UI*5?O#ZT
M7**** "BBB@ HHHH **** "BBB@ HHK,UFYU&VAC;3K83N6PP(Z"@#3HKE/[
M4\4?] M?R_\ KT?VIXH_Z!:_E_\ 7IV%<ZNBN4_M3Q1_T"U_+_Z]']J>*/\
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MT9D#2I%@''WCC-7ZXG4M4>_\&07D^,K>1@D#@A7'/XUHZ=>WFM7LE[#*T=G
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M##!*X:O;KSP;X<U"]^VW>C6DUSG/FNF3FM*?3K.YL6L9[>.2U9=IB8?*1Z4
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** *1ZFB@]310 4444 %%%%
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M ;]%8_AG7D\1Z-'J,<31J[,NUNO!(_I5+Q1XRL_#1AA,,MW>SG$5M#C>WYT
M=+17GTWQ&U#356?5_"VI6=F2 T[A=J?7FNODUW3HM".M-=)]@$?FF;/&WUH
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MM=EB<I(MJ2K X(.17%V7A74]:\&0ZU=ZW<B_BA\RW5 -L>.@]\\=:['XF_\
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M&I:#I5AXL37+F74'FA$BLH"LCD97\!Q75^*?LFHZ+8W&HZ^=)MI%W.@V@2Y
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MWX!#'CM6IX1\.:I;W&M:UJD"6]UJ3EE@1PP4$#N/I0!:^%?_ "(]O_UTD_\
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MG\)'BXW^.PHHHKI.0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 4444 %5[JQM;Y%2ZMXYE5@P#KG!'0U8HH **** "BBB@ HHHH ****
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M+<),\-PH ,J=3^%2:=H5O8&60LTTTHVO(_4CTK5HH YW_A$;82D)<2K;,<F
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MQE[>2WE+AN<8.0,<UVDW^HD_W37F^AZ#X)/B*UGL;S4;R^B^:)I;IYE7GW)
MKTB;_42?[IH \J\$^.-!T"PU.QU&\6*X&IW#[21T+<54/B#3O$7QHTJYTV<3
M1);!&(]=QKH/ASH^F7NC:E-=Z=:3R_VK<C?+"K'&X=R*R]2L;6Q^-^D1V=K#
M;QFU4E8HPH)W'TH -/MX;GXZZBD\22J+=N'4$=%]:L_$W1H-%M;;Q-I@^RW<
M%S$C^7P'0L 01TZ5F?VQ8Z)\;M0N-0F$,30, S=SA:L^,_$$7CE+3PYH,4UP
M);B.6>8H5151@3\W3IF@!=8N/[,\<>'_ !7YA6VU.-8)E X "D@_F:V/B=-)
M?VFG>'K>0B35)Q%)CJ$(//Z5<\;>'!<^ FL[9-TUFBM"?3:0?Y"N6\!:F_CS
MQ/#KMQ R)I]MY&">/-#9S^1H ]5LK=;2Q@MU  CC5>/85Y)J=WI=G\?+B359
M;:.#[%'S<$;?N'UKV.O))[&VOOV@+B.[MHIX_L4?RRH&'W#ZT &E*FJ?%S^T
M?#P_XE,<"I<21C$;L"<@8X/:N9\1Z1>7OQ&U[4-,+C4-.)N(0O)8@#C'XUV%
ME&G@CXH&Q@C,>F:P/W:@_*LO).!T' I_AL9^,7B#(R"I_DM $?B?7X/$?PVT
MZ^A+;OM]NDBL,$.&P<CZ@UUGB'5UT7P/)=,,DP")0.NYAM'ZFO)_&NGS^$-:
M72K:.0Z3J=]%<)DEO+93R,]LDFNG\=?:/$%]H'A:PN?)F<":5BNX*% 9<CZB
M@#$T+3I_!&K^&-4E#1?VK&MO?;ST?!8DY^@KW$$,H8=",BO*/''A#Q;?^'))
M;S7K:[%G^^CABLA&Q/L0>.*[OP;K/]O>$]/U J$>2/#)G.T@D?TH W:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I5^\/K24J_>'UH N444
M4 8-EXIM;S6GTSRGCD7.&8C#8JY+K$<6LQ::8F+R#(?/ KA8-.>[O-8N8!_I
M-K*LB-[ DD?CBM*TU)-4\3V%RK#<8L.!_"V#D55B;G=5!=W*VELTS*6VC[HZ
MFN8O-2N$NY576;6,!N$9^1^E;.AW#W-M(9;N*Z((^:,Y I6'<I0^*T^VQ6]Y
M836@E_U;R,"&_*M'5-7ATM(PR&6:0XCB4\L:P-2V>(O$%O:VOS0V;;I95Z ]
MA^8IFIB\D\=JMH(6=+=6 E)P.3TQ0%SH-,U2XOI&2;39K3 R#(P.?RK3K!L-
M3OUUHZ;J,<"LT?F1M&3R,X[UO4AH*BN?^/6;_</\JEJ*Y_X]9O\ </\ *A S
M"\"_\B7IO^XW_H9KHJYWP+_R)>F_[C?^AFNBJZGQLSI?PX^@55U&]73M/FNW
M0NL2Y*@\FK59'B?_ )%J^_ZY_P!14&AJ1OYD2N!@, <4^H('$=C&YZ",$_E7
M-Z?'J>N0SWHU2>V4NR1QQ8Q\I(YR* .KHKDO[6O?^$9O"9B+NVE\KS!U."!F
MH;Z74]/TN#53J4TC$[G@.-F/3IF@#LZ:[B.-G;HH)-8&KW"YM2=5GM99$R(8
M<9?/?FJ-C->7<>JV4E]<_NH@ZR.!OY!XH U=,UJ;4[AC%:/]F#E1+D8XK:KB
MO#=NT7A^>XDU2>"+)&1C"=.>E"7US%?:>\&IWEQ#+.$;S NUA^% ':T5S.I2
MW]SXA@T^WO9+>-XV=BF,\8IFJ_VC#?:=86^HS R%M\AQDX'TH ZGM67-JSQ6
M%]<O:R1BU&0&(^?CJ*S+>6\T[Q*MC-?3744L8(\W'RG/M4=U=33Z9XE260LL
M1VH#_"-HH Z#3KP7]C'<A2N\9P:MUQ-C9:DGAM;V'5)HS&I<0C&S _#-=9IL
M[7.FVT[_ 'I(U8_4B@#.O=?DMK]K2'39[EE7)*,!_.KD&I[K"2[NK=[54&66
M0@G'X5GWNF:E_:4EY931KN7&&/7FL;5M6NKWPU?13QB.>"01R!>AR": -8>*
MU 662PGCM68*)RPVG)X]ZZ!'61%=#E6&0?6L#5XXW\'H) -HA0CZXK1T/_D!
M6/\ UQ7^5 &A17)0?VEJ>N:G"-3G@@@E(01XR.!QR.E5].&KW^GW,DFK3QM;
M[@I3'S]>O% ':T5R+ZS=GP>+MIS',)Q$THZ@;L$U72>YEUNSMK'7KBZA<YE(
MVG:,?2@#M6.U2?2N<7Q6[1-.-)N/LZL09=ZXX/)KH9.(F^E</:KK$GAJ9(%M
M_LI:3."=^,G/M0!U5UJ\-OI:7X4R1N5 "G^\0/ZU%J^MC2Y;>);62XEG;:BH
M0.<9[UBW$\$_@J$P*55)8T(/7(89JWKG_(R:)_UW/_H)H LP>)%-TEO>V<MF
MTAPAD((8_A6X#D9%<]XR6'^PG:0X=6S&?]KM6U9$FPMR>OE+G\A0!/1110!S
M'C3_ %.C_P#83A_K73US'C3_ %.C_P#83A_K73U<OA1G'XY?(\4^-'_(2M/]
MW^E>5UZI\:/^0E:?[O\ 2O*Z]3"?PD>+C?X["BBBNDY HHHH **** "BBB@
MK9T#PW=^(7N!:LJBW4,Y;I@G%8U=U\/K=+K3?$4,ES';*UO'F60X"_,:BI)Q
MC=&M&*E-)F#K?ABYT.WCFFGBD#MM 0UAUU@\*V\^J6-E;ZY:7K7,WEE8)"Q7
M@G/2MB-O"HU1/#_]EJQ9A$;TC]X&/?KBH]I9=RW1N^QRFA>'IM=%T8IDC^SQ
MF0[@3G )_I4$NCR1>';;6#*ICGG> 1XY!4 Y_6N[\,Z4VBZKKUDQ)"6SE2>Z
ME6Q^E<_-'YOPYT>/IOU.5?S5:7M&Y:;:#=)*&N^OYHY*BO0;H^&/"]U_95UI
M@OYEXGFD'*G_ &<&I(O"VG6OB>XTZ2$2075HTEH\G4-@8 _$T_;+L3]7=[7/
M.J*]#T+P=9S^&[U[D*;Z1Y%M]W5?*)W8K)OM+M]+\!V<]Q9QF^NYV*RG.X1[
M<BFJL6[(3H22N^US!TC2KC6M1CLK;'FR' S5?[+)]N^R?\M/,\O\<XKIOAM_
MR.EC_OC^=9 _Y&P_]?I_]#I\SYFA<BY$^[(M:T>YT.^%I=8\PQK)QZ'I6=7J
MNM6-IJ/Q2M;>^B$MN=/4LI]D)JCIT/A;6;R30(-.\N0@K%>8_>$CN><=JA5O
M=3:-98?WFD^MCSBBI+B+R+F2+.=C%:CK<Y0HHHH **** "BBB@ HHHH =%_K
M4_WA7U/X8_Y%JP_ZY?UKY8B_UJ?[PKZG\,?\BU8?]<OZUY^.^R>IEOVC6HHH
MKSSU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *1ZFB@]310 44
M44 %%%% !1110!F-X>T=]1_M!M.MS>?\]B@W?G4T6D:=!:26L5G"EO*S.\87
MAB>I/UJ[10!!#96T%DMG% B6R+L6)1\H7TQ26UA:6=FMI;V\<5NHP(U&% ^E
M6** ,JW\-:):"<6^EVT0GSYNV,#?GKFKZVENEHMHL*"W5=@C X ]*FHH Q[/
MPKH.GW7VJTTFTAGSGS$C -7=0TNQU6V^SW]K%<PYSLD7(JW10!673[-++[&M
MM&+;&WR@ORX^E4K#PQH>EW!GL=+M;>4]7CC -:U% %/4=)T_5X/(U"SAN8@<
M[)5R*?9:?::=;BWL[>."$=$C7 JS10!FVN@:197LEY;:?;Q7,F=\J)AFSZFF
M#PSH@O)+P:7:BYD^_+Y8W-^-:M% %'^QM-^PQV/V*'[+%]R+;\J_05"OAS1E
MU 7ZZ;;"[ P)@@W ?6M2B@"K=Z=97YC-W;1S&([DWKG:?44Z\L;74+=K>\@C
MGA;JCC(-6** ,W3?#^D:.S-IVG6]J6ZF) ,UI$ C!Z&BB@"O:6-K81O':01P
MH[F1E08!8]3]33)-,L9=02_DM8FNT7:LQ7Y@/3-6Z* ,?4/"F@:M<?:-0TBT
MN9C_ !RQ@FKEAI5AI<7E6%I%;Q_W8UP*N44 (RJZ,C %6&"#W%4]-TC3M'B>
M+3K.&UCD;>ZQ+@$^M7:* "JG]EV/]I'4?LL7VPKM,^WYL>F:MT4 5;K3;*]F
M@FNK6*62!MT3.N2AQC(I(M,L8+V2]BM8DN9?ORA?F;ZFK=% %2]TRQU)46]M
M8IQ&P=1(N<$=#2+I.GKJ'V];.$7>T)YVWYMHZ#-7** $90RE6&01@BJ]EI]I
MIL'D65O'!$#G9&N!5FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "E7[P^M)2K]X?6@"Y1110!AZ+HLFFWVH3R,&6Y8$#\ZIVWA9K3Q*;
M^*0?9R2^ST)SFNHHIW%8H2:-82R,[VZEF.2:@O\ 2W_LJ6UTTB!Y."1Z5K44
MAG(:7HNNZ9&D,,L2Q[LOR"3SSS6AJNASW%_#J5E-Y=X@VG/1AZ5OT4[BL8FE
MZ1<Q7[ZA?S^;<,NP# PH]*VZ**0PJ*Y_X]9O]P_RJ6HKG_CUF_W#_*A S"\"
M_P#(EZ;_ +C?^AFNBKG? O\ R)>F_P"XW_H9KHJNI\;,Z7\./H%4=8LWU#2+
MFTC(#RI@$_6KU%0:'/V5KKL4L2SSQM N PXY%1)HVJV#2Q6%V/L\C%L, "I)
MR:Z6B@#";0&709K%9=\LK^8[D8R<@G^5.U31I+W0DL$<!E&,FMNB@#!O=&N6
MO;6\MG7S(8O+*N!@].?TI;#1[J"XU":XG$K7484' &.#Q^M;M% &!;^'W3P]
M-ILDN&D;.X<XZ?X5#_8VI3RV1GEC$=M(&VJ!\V.]=+10!EG3'/B"'4-PV)$R
M8^N*+W37N=7L[M6 6#=D?45J44 9%QI4DVOPZ@&&R-0"/SJ%]%E:UUB(,,WK
M97VXQ6[10!R@\/ZHEFNGK??Z*0-QP,CU%=+:VZVMI%;J<K&@4'Z5-10!BWEK
MK1N9#;7BF%S\H8 ;/\:;;^'(DTJYM)92\ESS)(1SGUK<HH Y=M!U2[ACLKR]
MS9QD= ,L!T%=+#$D$*11C"(,*/04^B@#*T[2WM-2U"Y9@5N9-ZCTX%-T[29+
M2SNH68$S$D5KT4 </K5BVF>&X[-V^=KG>'_A7+ \TY+ZZTV^M1'=V]]YS[2L
M:J"!CVKLI8(KA-DT:2+Z,,BHX["SBD#QVL*N.C*@!% $Q!>/'0D5S$&D:U!:
M/91SHD+,WS @D FNIHH PI- V:"NG0ODB59"Q[D$$TNNZ5=WMS:7-G(JRV[[
MAGZ$5N44 <V-#U"_EC.JWF^*-PXB51@GZUT:J$4*HP ,"EHH **** .8\:?Z
MG1_^PG#_ %KIZYCQI_J='_["</\ 6NGJY?"C./QR^1XI\:/^0E:?[O\ 2O*Z
M]4^-'_(2M/\ =_I7E=>IA/X2/%QO\=A11172<@4444 %%%% !1110 5T/A[6
M+33-*UJWN"_F7<*)%M7(R&R<^E<]12E%25F5&3B[HO:/J3Z1K%MJ$:AF@?<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\KKU,)_"1XN-_CL****Z3D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP+_R)>F_[C?^AFNBJZGQLSI?PX^@4U_]6WT-.HJ#0X_PYI)FTC4+>Z@*&5R
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M(O\ 6I_O"OJ?PQ_R+5A_UR_K7GX[[)ZF6_:-:BBBO//5"BBB@ HHHH ****
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M\7W^H:-KD%VL::EID#L7C;<K?*Q5O3MFLKP1KGC'Q;:6.I&6*&RC^6;(&9F
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M\KS\[B-AYR>M:7PHU:WM--D\/SI<1WXO;E]K0L%*[R<[L8Z4 >@ZI_R";O\
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MF_[C?^AFNBKSSPOXJ&F>'+2SDT?4Y&B# O'#E3\QZ'-;'_"<)_T ]7_\!_\
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MPG"?] /5_P#P'_\ KT?\)PG_ $ ]7_\  ?\ ^O1[*?8/;0[G5T5RG_"<)_T
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M<XYH  Z"EHH :44G) -+@8QCBEHH ,#&.U)@8QCBEHH 0* , <4!0O08I:*
M"D*@G)'-+10 FT<\=>M   P!2T4 (  , 4;5ST'-+10   # INQ0<X&:=10
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *5?O#ZTE*OWA]: +E%%% !1110 4444 %%%
M% !1110 5B>+O^14U'_KE_45MUB>+O\ D5-1_P"N7]150^)$5/@9Q7P4_P"0
M-JW_ %]#_P!!KU"O+_@I_P @;5O^OH?^@UZA6N)_BLQPG\&(4445@=(4444
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M:7XGEET.\U/5K"6PCM>6612"5QUYH Z2BN.L?'0GO[:&[L)[6&[SY$CH1GG
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M,!,X[UK?&$R#PG"81F47D&P>IWC%4-<N_%'B7P^N@'0)K>2<A)[DR*4P"#D
M<]J -[6&3Q#X;LKN?6ETRSF0-(-P1GZ\!LC%<CX?U"'2?&UMH>F:W)J&FWT$
MC2*\A=HV& ,,23W-7O%OA._BO_#\L%BVIZ581A)K'(PQR3NYX]JIZ=H5[/\
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MN&O/_"'AK1;G0(+N]M(II),DF0=.:] ^)7_(E7W^X:\W\/:CY?ANUA)7*@X
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MTHHHH **** ,;Q)X<MO$MC':7,LD:1S),#'C.58$?RK750JA1VIU% !1110
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MT6-S%<0DXWQ-N&: +-%%,FFCMX7FF=4C0;F9C@ >M #Z*KPWUK<VGVJ">.2
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M!X:^+&H3:H_DPZC'O@E*G')'&?PKJ-9UNP\0^$M>ATN;[0\=JZ-M4]2IQ]:
M.4^$=SK0\&QF:"-]-42'<6!)P.F*N0>-)[?P9?ZS8:;;PQVEVT<J1JJC;P,\
M#KS4/PLU6S3P NEM,!>@39A(.1@5)\/=.AU3P5KEC<Q!XY;R4%&'7@8_6@#J
M/$7BVWTCP7)KD++(6AW0 ?QMZ5EW/B)D\0^';6ZT^"2:_MGF\QD4M'C;P#CW
MKS_0IKO6K[1_!%S NW1[@27*LOWD!/'_ (\*[/Q7&$^)WA5$7"K;3  =AE:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 4CU-%!ZFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC,-K#$3DHBJ2/85+7(]SM6P4444AA1110 4444 %%%% !1110 4444 %%%%
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M^5:59OB#3CJ_A^^T\'!N(BF?K0!Y#X0\1Z19:,][+HLVHW;R.US<O$20"3@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+9FW-;Q$GN4%2@!0 H  Z 4M% #719%*NH93U!&13$M;>-MR01*P[A *EHH
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M;%VV-=[#M4_ET]ZZC5_$FFZ+HXU.ZF_T=ON%1G<3V&*Y36[>(?!62)4 062
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M!E&?PP.:P_B;#%'X>T@(@41ZA:JN.PWCBLWQ/Y'_  N#P[]HV^7@YW=/N'%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 0U#)TJ8U!+TH SKD\5X7\3?^1J_[8+_6O<KGH:\-^)G_ "-7_;!?ZUUX
M/^*<68?P?F=5X5^'6E:OX<L[Z=W$DT>YL"MC_A4^B?WY/RK8^'__ ").F?\
M7$?S-=-45*U13:3*I8>DX)N/0X'_ (5/HG]^3\J/^%3Z)_?D_*N^HJ?;U.YI
M]6H_RG _\*GT3^_)^5'_  J?1/[\GY5WU%'MZG</JU'^4X'_ (5/HG]^3\J/
M^%3Z)_?D_*N^HH]O4[A]6H_RG _\*GT3^_)^5'_"I]$_OR?E7?44>WJ=P^K4
M?Y3@?^%3Z)_?D_*C_A4^B?WY/RKOJ*/;U.X?5J/\IP/_  J?1/[\GY4?\*GT
M3^_)^5=]11[>IW#ZM1_E.!_X5/HG]^3\J/\ A4^B?WY/RKOJ*/;U.X?5J/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "E7[P^M)2K]X?6@"Y1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY/R$55U?P7H.NWR7FH60DN$&%D#E3^AK?HH CAA2W@CAB&(XU"J,] *DHHH
M**** "O-?C+_ ,@'3_\ KY/_ *":]*KS7XR_\@'3_P#KY/\ Z":WPW\5'/B_
MX,B;P-_R*UC_ +I_F:[.#H*XSP-_R*UC_NG^9KLX.@J*OQOU-*/\./HBZE25
M&E25F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !2K]X?6DI5^\/K0!<HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4J_>'UI*5?O#ZT 7**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 0U!+TJ<U!+TH S+GH:\-^)G_ "-7_;!?ZU[E<]#7
MAOQ,_P"1J_[8+_6NO!_Q3BS#^#\SUKX?_P#(DZ9_UQ'\S735S/P__P"1)TS_
M *XC^9KIJYZOQLZ:/\./H%4=5TU=4LS;/(8P2#D#-7J*@T*MY9K>:=+9ERJR
M)L+ =*I3:#'-IMO9&=@L,BN&V]<'-:]% &/?:+-=3F2+4)(%9 C($!! ^M$W
MAVVDTB/3U=D$8^20#D'UK8HH"QC2Z#]HL4@N+MY)48,DVT J13(/#Q^U1SWM
M[)=^5]Q64 #\JW**+BL9W]DQG6)M0,A)EB$13'  S_C6=_PB[1>9';:E-!;N
M<F$*"![9KH&D1656=0S= 3UIV1G&:+A8Y7Q!816>DVEI#&PA292SJ,E>N35=
M'EM;^V33+QKD.1YBB,!0/<CO78.J.-CA6![&F1V]O;Y,<4<>>I50*=PL9\&A
M0Q7EY<-(7%T,,A' YJK!X::#;&NH2_95/$.T 8],]:WZ:SHJEF90HZDG@4KA
M81HPT)CS@%=M9"^'HUT:73?M#%9)3(7V\C)SBMD,&&5((/<4M S)N="CN='B
MTXS,JQ@ .!R<5->Z6EZ]HS2LOV:0.,#[V*T** L<=<V$EYXRD$<[P,(^)%&<
M<5M6.A1V:W#/.TT\ZE7E88./I^-:GEQAS)L4/W;'-+O3^\OYT[BL9^CZ0FCZ
M>+1)6D7^\1BJ!\+M&9$M=1FM[>0Y,2J"/SKH<XZT@8'H0?H:5QV*=MIEO:Z<
MUE$,1LI#'N<]3531O#\&C-*R2M*T@QEAT'85KE@.I ^IH#*>A!^AH Q)?#[B
M[EGL[^2U\UMSJJ @G\:EN]#^VZ4MC-=.Q#!C)M&3CVK7SD9%&1ZT"L96H:(F
MH6MK TS(+=E((&<[<?X5-=Z6MWJ%I=F0JULQ8*!][(Q5^B@9C7>@>;>M=VEV
M]K,_WRJAMWYU/'I3C3[BUFNWF,ZE3(5 (X]*TJ*+A8S+W1DO=%336F954(-X
M'/RU'=Z&MS9VD"7+Q/:G,<@4$YQCI6O10%B&UB>"VCBDE,KJ,%R,%JFHHH *
M\U^,O_(!T_\ Z^3_ .@FO2J\U^,O_(!T_P#Z^3_Z":WPW\5'/B_X,B;P-_R*
MUC_NG^9KLX.@KC/ W_(K6/\ NG^9KLX.@J*OQOU-*/\ #CZ(NI4E1I4E9F@4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2C_#CZ(NI3Z8E/K,U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAV1QO_"$Z/\ \^@_.C_A"='_ .?0?G79>0/2E^S^U'M)]P]E#LCCQX(T;/\
MQYC\ZF3P1HG>S'YUU8A]J>(L4>TGW#V4.R*>GV$-A:QVUNFR)!A5]*T47%(J
M8J4"HW-$K"BEI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** $Q28IU% #-M&VG&B@!NVC;3J*
M &[:-M.HH ;MHVTZB@!NVC;3J* &[:-M.HH ;MHVTZB@!NVC;3J* &[:-M.H
MH ;MHVTZB@!NVC;3J* &[:-M.HH ;MHVTZB@!NVC;3J* &[:-M.HH ;MHVTZ
MB@!NVDV4^B@!NVC;3J* &[:-M.I: $Q12T4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gzbwht3f4aft000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .N!WT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRQ6OH2:EX3TS5;DSW46YS[5Y%\3])T[1YH(+*,*V[YN.V*]Y)P":^=OB=?\
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MJ3[E^@->[Z=K2W7@=+\MDM 2?K@T\9[]*-5$X*].M*BSP_QM=G4/&%P<Y4N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[_D#/_OUTJC%T'5ZW.&>*E'%QH):-7.OHHHKF.X**** "BBB@ HHHH ****
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MI9K(EI&LOWP.:VG248*=]SFIUY2K2IN+277N3T445B=(4444 %%%% !1110
M4444 9MUKVFV5RMO<7*I*QP%-:((8 CH:\J\4?\ (V1?]=!_,5ZE!_J$^E=-
M:C&%.$UU.'#XJ52O4IM:1),XZTWS$_OK^=9'BB1XM!N&1BK =17G>@Z)J&OM
M*8]1:+9S\S,>].CAU4@YRE9(,5C)4:D:<8\SEYGK@93T(/T-+7E7GZIX3U:.
M":X,L9())SR/QKT^TG%S:13#C>H-36P_LTI)W3'AL9[:4J<H\LET)J***YSM
M"BBB@ HHHH **** "BBB@ HHHH *S;C7]-M;H6TURJS$X"UI5Y1X@_Y'$?\
M77^HKIPM%5I\LCBQ^)EAZ//%:GJP((R.AI:9%_JE^E/KF9V)W5PHHHH&%%%%
M !1110 A91U('U-)YB?WU_.O.?B#<SQWL:1RN@S_  L1VJ.U\&:K<V2W4>JG
ME=P3+9KLCA8NFJDY6OY'F5<?-5W1IT^9KS/2P0>AS02!U.*\UTOQ!J6BZFMA
MJ))C)VC(Y^M=1XIBO;_10=-W.S$$!.I%1/#.$DF]'U-:.-C5A)I/FCNNIT0(
M/0@TM<YX/M;^TTPI?JZOQ@/U%='656"A-Q3N=%"JZM-3:M?H%%%%9FP4444
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M[%<$MT_"L+PC>Q:9X@N$NB$WG:"W&.32A&'/4G!:I:(*DZOL:5.I+1MIM/\
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M]E^'\Z] T[_D'P_[M8XI\]&%1K5G5@8NEB:E%/W45/$4KPZ).\;%6 X(KE_
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M\DKUYKM-(OGO+8;[66W*@#$@ZUHT5P3K*5-0ML>O3PSA6=7FW\ALCK'&78X
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M-CD5?HI2K3DTV]45##TH)QC'1[G%#X;V EW_ &N8C.=NT8KIM,TFUTJ#R[=
M/4XZU?HJIXBK45I,BE@Z%*7-"-F%<Y?>#[._U(WLLKY.<I@8-='140J2@[Q=
MC6K2A5CRS5T<=+\.].DN/-%Q(@SG8%&*Z:PT^WTVV6"W0*H]!UJW153KU)KE
MD[HSIX6C2DYPC9G%_$);?^SHB^/,W';^56/ FG_9M(\UA\[L>?:K.O>%1KLZ
MR27;QJO1 H(K;L;-+&TCMX^BC&?6MW6BL,J:>MSE^K2EC?;26B6A8IDL23Q-
M'(H96&"#3Z*XSTCD+SX?:==3&1)I(0?X448K0T?PE8:0ZR)F61>CN.16_16[
MQ-5QY7+0Y5@<.I\Z@KF!KOA2VUV17EGDB*_W0*QU^&M@&!^VSG';:*[>BB&)
MJPCRQEH*K@</5ESSC=F3I?AVPTH9AB!?^^1S4NLZ1%K5D;:9V120<J.:T:*S
M=2;ESMZFT:-.,.1+0RM)T*#2;%K5)&E1A@[A6+=_#[3[JX:43R19.=JJ,5U]
M%7'$58R<D]69RPE"4%3<=$<H/ =@DT4L<TB&,YX4<UIZSX>@UFSBMY9701]&
M4<]*V**'7J-IM[#CA*$4U&.CW*.E:9'I5F+:-V=1W859NMAM9=_W=AS^52U7
MOK8W=J\ D,>\8W"LW)RE>1K&$81Y8K1'EFD:?%>^,'CB&858D?A7K2C:H'H*
MYW0?"<.B3M,)VFD/0L,8KHZZ<76C4DE%W21PY=AI45*4U9R=PHHHKD/1"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MJIJEK/?:9<6MM=R6<TB;4N(Q\T9]10!-#<07*LT$T<H4[6*,#@^E2U\D66M>
M)M$NM1L]/\17D$:7<F[9CYVSRQ]S5W_A,?&O_0V7_P"G^%;QPU22ND<T\72A
M)Q;U/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_  JOJE7L3]>H=SZJ
MHKY5_P"$Q\:_]#9?_I_A1_PF/C7_ *&R_P#T_P */JE7L'UZAW/JJBOE7_A,
M?&O_ $-E_P#I_A1_PF/C7_H;+_\ 3_"CZI5[!]>H=SZJHKY5_P"$Q\:_]#9?
M_I_A1_PF/C7_ *&R_P#T_P */JE7L'UZAW/JJBOE7_A,?&O_ $-E_P#I_A1_
MPF/C7_H;+_\ 3_"CZI5[!]>H=SZJHKY5_P"$Q\:_]#9?_I_A1_PF/C7_ *&R
M_P#T_P */JE7L'UZAW/JJBOE7_A,?&O_ $-E_P#I_A1_PF/C7_H;+_\ 3_"C
MZI5[!]>H=SZJHKY5_P"$Q\:_]#9?_I_A1_PF/C7_ *&R_P#T_P */JE7L'UZ
MAW/JJBOE7_A,?&O_ $-E_P#I_A1_PF/C7_H;+_\ 3_"CZI5[!]>H=SZJHKY5
M_P"$Q\:_]#9?_I_A1_PF/C7_ *&R_P#T_P */JE7L'UZAW/JJBOE7_A,?&O_
M $-E_P#I_A1_PF/C7_H;+_\ 3_"CZI5[!]>H=SZJHKY5_P"$Q\:_]#9?_I_A
M1_PF/C7_ *&R_P#T_P */JE7L'UZAW/JJBOE7_A,?&O_ $-E_P#I_A1_PF/C
M7_H;+_\ 3_"CZI5[!]>H=SZJHKY5_P"$Q\:_]#9?_I_A1_PF/C7_ *&R_P#T
M_P */JE7L'UZAW/JJBOE7_A,?&O_ $-E_P#I_A1_PF/C7_H;+_\ 3_"CZI5[
M!]>H=SZJHKY5_P"$Q\:_]#9?_I_A1_PF/C7_ *&R_P#T_P */JE7L'UZAW/J
MJBOE7_A,?&O_ $-E_P#I_A1_PF/C7_H;+_\ 3_"CZI5[!]>H=SZJHKY5_P"$
MQ\:_]#9?_I_A1_PF/C7_ *&R_P#T_P */JE7L'UZAW/JJBOE7_A,?&O_ $-E
M_P#I_A1_PF/C7_H;+_\ 3_"CZI5[!]>H=SZJHKY5_P"$Q\:_]#9?_I_A1_PF
M/C7_ *&R_P#T_P */JE7L'UZAW/JJBOE7_A,?&O_ $-E_P#I_A1_PF/C7_H;
M+_\ 3_"CZI5[!]>H=SZJHKY5_P"$Q\:_]#9?_I_A1_PF/C7_ *&R_P#T_P *
M/JE7L'UZAW/JJBOE7_A,?&O_ $-E_P#I_A1_PF/C7_H;+_\ 3_"CZI5[!]>H
M=SZJHKY5_P"$Q\:_]#9?_I_A1_PF/C7_ *&R_P#T_P */JE7L'UZAW/JJBOE
M7_A,?&O_ $-E_P#I_A1_PF/C7_H;+_\ 3_"CZI5[!]>H=SZJHKY5_P"$Q\:_
M]#9?_I_A1_PF/C7_ *&R_P#T_P */JE7L'UZAW/JJBOE7_A,?&O_ $-E_P#I
M_A1_PF/C7_H;+_\ 3_"CZI5[!]>H=SZJHKY5_P"$Q\:_]#9?_I_A1_PF/C7_
M *&R_P#T_P */JE7L'UZAW/JJBOE7_A,?&O_ $-E_P#I_A1_PF/C7_H;+_\
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M5_X3'QK_ -#9?_I_A1_PF/C7_H;+_P#3_"G]4J]A?7J'<^JJ*^5?^$Q\:_\
M0V7_ .G^%'_"8^-?^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T-E_^G^%'
M_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_ .G^%'_"8^-?
M^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_
M  H^J5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_ .G^%'_"8^-?^ALO_P!/\*/JE7L'
MUZAW/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ
M*^5?^$Q\:_\ 0V7_ .G^%'_"8^-?^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'
MQK_T-E_^G^%'_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_
M .G^%'_"8^-?^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T-E_^G^%'_"8^
M-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_ .G^%'_"8^-?^ALO
M_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_  H^
MJ5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_ .G^%'_"8^-?^ALO_P!/\*/JE7L'UZAW
M/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?
M^$Q\:_\ 0V7_ .G^%'_"8^-?^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T
M-E_^G^%'_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_ .G^
M%'_"8^-?^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\
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M (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?^$Q\:_\
M0V7_ .G^%'_"8^-?^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T-E_^G^%'
M_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_ .G^%'_"8^-?
M^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_
M  H^J5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_ .G^%'_"8^-?^ALO_P!/\*/JE7L'
MUZAW/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ
M*^5?^$Q\:_\ 0V7_ .G^%'_"8^-?^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'
MQK_T-E_^G^%'_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_
M .G^%'_"8^-?^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T-E_^G^%'_"8^
M-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_ .G^%'_"8^-?^ALO
M_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_  H^
MJ5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_ .G^%'_"8^-?^ALO_P!/\*/JE7L'UZAW
M/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?
M^$Q\:_\ 0V7_ .G^%'_"8^-?^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T
M-E_^G^%'_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?^$Q\:_\ 0V7_ .G^
M%'_"8^-?^ALO_P!/\*/JE7L'UZAW/JJBOE7_ (3'QK_T-E_^G^%'_"8^-?\
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M (3'QK_T-E_^G^%'_"8^-?\ H;+_ /3_  H^J5>P?7J'<^JJ*^5?^$Q\:_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %6]*_Y#%E_U\1_^A"JE6]*_Y#%E_P!?$?\ Z$*3
MV''=&W\0?^1YU3_KK_2N9KIOB#_R/.J?]=?Z5S-33^!>A=;^)+U"BBBK,PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHP3T%&".HH **,$]!10 4444 %%%% !1110 45;T[
M3+S5;I;:Q@::9NBKUJ34]%U#1I1%J%L\#GLU)R2=F4HMJZ6A0HHHIDA1110
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M#_\ UZC^9KYHNO\ CUE_W#7TO\,/^29^'_\ KU'\S7G8[>)ZV6_#(ZVBBBN
M],**** "BBB@ HHHH **** "BBB@#Y!N/^0WJW_7[+_Z$:2EN/\ D-ZM_P!?
MLO\ Z$:2O:H?PHGSN*_C2]0HHHK8P"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/M/#VKW]M]IM=/FEA_OJ.*]/^,G_ ![V'^Z:U/AQ_P B,WT;^="Q,O8.K;5
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M."#)(Y)J/K7[KFMK>WS-/J5ZJ@GHU>_D<W\+-*OM*U:ZCOK62!R!@.,5QGQ
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M%)4BO':C!?PWZLK,/XJ]$%%%%=9PA1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*MZ5_P ABR_Z^(__ $(54JWI7_(8LO\ KXC_ /0A2>PX[HV_B#_R/.J?]=?Z
M5S-=-\0?^1YU3_KK_2N9J:?P+T+K?Q)>H44459F%%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_PHOQ1_T,&G?]^&H_X47XH_Z&#3O^_#5[]11[>I_,P^KTOY4> _\*+\4?\
M0P:=_P!^&H_X47XH_P"A@T[_ +\-7OU%'MZG\S#ZO2_E1X#_ ,*+\4?]#!IW
M_?AJ/^%%^*/^A@T[_OPU>_44>WJ?S,/J]+^5'@/_  HOQ1_T,&G?]^&H_P"%
M%^*/^A@T[_OPU>_44>WJ?S,/J]+^5'@/_"B_%'_0P:=_WX:C_A1?BC_H8-._
M[\-7OU%'MZG\S#ZO2_E1X#_PHOQ1_P!#!IW_ 'X:C_A1?BC_ *&#3O\ OPU>
M_44>WJ?S,/J]+^5'@/\ PHOQ1_T,&G?]^&H_X47XH_Z&#3O^_#5[]11[>I_,
MP^KTOY4> _\ "B_%'_0P:=_WX:C_ (47XH_Z&#3O^_#5[]11[>I_,P^KTOY4
M> _\*+\4?]#!IW_?AJ/^%%^*/^A@T[_OPU>_44>WJ?S,/J]+^5'@/_"B_%'_
M $,&G?\ ?AJ/^%%^*/\ H8-._P"_#5[]11[>I_,P^KTOY4> _P#"B_%'_0P:
M=_WX:C_A1?BC_H8-._[\-7OU%'MZG\S#ZO2_E1X#_P *+\4?]#!IW_?AJ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M -A3.<'-;U&I5H5?/7R,Z2Y*<J?D<K\9XICX+TV49,2A-P _VJZ[X=Z[I?\
MPK2W4W$2F*W(=2P!SS75ZMX6M-:\-C1[T"1 N WN.AKR^P_9_2UU'S9M9:2T
M_P">"@BH5_WD.DG>X67+3EUBK6,/X87,5W\3+Z:#_5L_%8/Q6M]4M/BB)[1R
MD[!/)<\ '!KV+PM\*XO"WB:75+:\!A;&(=O(_&M?QG\/],\80J;@;+A.5E'8
MTI:*FX_95BXN\JG-]IGA]]I/Q3US3!;7FH136KK]QKE.E>P_";1]0T3PL;74
M45)!)QM?<,5P\?[/EXMR';Q*YB#9V8;IZ5['H.CKH>E1622%P@ W$]:UBTHR
M\S*2;E'R-.BBBLRPHHHH **** "BBB@ HHHH **** "O//AU_P C7XZ_["B_
M^@"O0Z\\^'7_ "-?CK_L*+_Z * /0Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** /*_CCKW]F^$VLD?#W89,?K7F'A?PQ\5+#2E;0F:&UF^< 2 9SS7KGC
MSX8S>-M3M[A]3$,$+9$13/;%=[IMDFG:=!:)R(D5,^N!BIIQ2A)O=O\  JI*
M[C%;+\SY7T(Z[X,^(]N=<!2ZN7'F'=G()KUWXQ:&NL^%H]5MAF:%E=6']T<U
M>\>?"[_A,-7M]1AOUM)H0,$IGI761Z 6\++HUU,)F$!B,F.IQC-$FY4$OM1>
M@1M&MS;IK4^:M6\2S^*=)\.:+&2[*BB4#N=]>L^/]!DL?A(UE:@@11C*@5#X
M2^"4?AKQ(NJRZBMQ&@(6+9C&:]5O+*"^LWM9T#1.,$5=5*5*T=V[OU)I^[53
M>T59'RAX+?X@?V>T7AR_6"W4G*F55[^]=5X,\(>,(O'EKJVL>3*2Z^9(LZL<
M#/85TNM? 2*\NVETK5FL$9B2@R:W?!/PJD\)327$FK-=3L,!CGCGT-5"?O<[
MW2(J0O%P6S9SOQRUJRGM;?18X5GOG<%1GD9KA/A:\?A+QG#'KEJ(Y)T(C=O?
M@5ZM:_")W\8-KNJ:HMYA]R1["-O/%7_'7POA\6SV]U:W2V5S!C;)MSP#FHH_
MNK2W;W\C2JE4O#HEIZE'XYLK_#^1E((,J8(^IJ/X-_\ )//^V1_D:V-<^']Y
MKO@>'P_<ZJIE3;F<IUP3VK3\$>$#X1T%=,>Y%QA=I8+C-$(J,:L>^PIMR5/R
MW/&?AU<PVWQ3NQ/(L>9.-YQW->M?$R>*?X?:L8I$<>0>58$=JY7Q7\#H]=UE
M]0L-3^PLYRP"FN@LOALUIX#N?#AU$R/.K SL"<9(_P *B2<\.HO=67XEIJ.(
M<ULW<X3X+*[^#]36/.\A\8^M8OPNO[;3/B?J"7SB-F+@,_'->N?#WX?MX(LI
M;=[U;K>Q.0N.M<_XP^"=MXAU5K^POA8R.<N0"<FMI3M64UJFK&2CS4Y0>FMT
M<Y\<]5L;B_TRVAE227>IRISCYQ4WQ)M+B;X56$L62B1C<!]:TY?@/:/I<$*Z
M@?MD;JS7#9.<')XKT=?#-K+X9CT6] GB5-I.,9K)PM1E!/7F3-%/][&36EFC
MYN\*-\29-%2+0]26*R (5#,JX_.NQ^%OA'Q-I?C"6^U58F\S:7=)@QZY[5=U
M+]G\S73/IVN-9PDY$8W<5VGP_P#AU_PA0E>2_:\FE&"Y)Z9SWK:$ES.?4RG%
M\O(CNZ***S+"BBB@ HHHH **** "BBB@ HHHH **** ,KQ-_R*VJ_P#7K)_Z
M":Q_AA_R3/P__P!>H_F:V/$W_(K:K_UZR?\ H)K'^&'_ "3/P_\ ]>H_F: .
MMHHHH **** "BBB@ HHHH **** "BBB@#Y!N/^0WJW_7[+_Z$:2EN/\ D-ZM
M_P!?LO\ Z$:2O:H?PHGSN*_C2]0HHHK8P"BBB@ HHHH **** "BBB@ HHHH
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MX/Z-_P (,^IJ\YU%8!()&E)'0=JPOCI'*?$FGI C.X;Y5'4XJSJGQ@,7A!M
MFTRYAU)X0@+@8Z#'\JY8_P"[-1^*[M]YT2_CQ;VLK_@6_A3XGNK'PIK%O*[/
M]B5W4DYZ'%8/@7PQ!\2?$U]<ZU+++;!F(02$8KJ_A3X.NIO"FI2WD;1/?*Z
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M(-Q_R&]6_P"OV7_T(TE+<?\ (;U;_K]E_P#0C25[5#^%$^=Q7\:7J%%%%;&
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M[F)9(V@4$,,]A7SOX+D?0OBY=VMJ2L+2LFT= ,U[AJ'C/1M$\,QW$E_;R,L
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M6EC**L4@8Y(]C58IITE;:R"BFJTK[W_ \H^!=\]EXLO-*!/E,6;'T%+\6_\
MDHVF_P#73^HJS\!M(EN=7O-;DC95W%5)&,Y%5?BZRI\1--9F"J'.23CN*T=U
M6H*6_7\2=XUVMO\ ACWEK*WO]$6&YB61#",AAGM7SKX,9] ^,7V"U)$,TP#*
M.F,DU[EJ'C+1=&\/K/+?V[D1#Y8Y%8]/0&O%OAG977B;XDRZXL1%O#)OW$8!
M&344?]Y;6UG?] G_ +K9]6K'TF#D TM':BD4%%%% !1110 4444 %%%% !11
M10 4444 97B;_D5M5_Z]9/\ T$UC_##_ ))GX?\ ^O4?S-;'B;_D5M5_Z]9/
M_036/\,/^29^'_\ KU'\S0!UM%%% !1110 4444 %%%% !1110 4444 ?(-Q
M_P AO5O^OV7_ -"-)2W'_(;U;_K]E_\ 0C25[5#^%$^=Q7\:7J%%%%;& 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5'/_P >\G^X?Y5)4<__ ![R?[A_E2>PX[H^
MC_A-_P DPT/_ *X?U-=I7%_";_DF&A_]</ZFNTKP#Z@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *9-_J)/\ =/\ *GTR;_42?[I_
ME0!P?P?_ .1+F_["-S_Z'7?UP'P?_P"1+F_["-S_ .AUW] !1110 4444 %%
M%% !1110 4444 %<CXX\!6?C:R6"YF:%D.5=5R0<5UU%)Q4MQJ36QX=;_LXV
M$4Z/+KD\J*<E&C&#7K'A_P ,:9X;TW[%86Z1QD?/@?>-;-%5S.W*397N>6^+
M?@EI'B747O8;EK&60Y<QH#N-;/@GX8Z5X,'F1-]HN?\ GLRX-=S12A[BM$<_
M?^(*X+Q[\,X/',T$DNH26WE-G"(#GC%=[12MJGV&FTFNYB-X=1O"IT/SVV&#
MR?,QSTQFL/P)\.X?!'G^5?27/FL6^90,5V]%4FU)RZLFRY5#HCSSQ)\++?Q#
MXHMM;?4I(6@.1&$!!Y!_I7)_%O7XI[^U\,20KY4GRM*QQC%>WUPWCKX::?XS
M"R,_D72_=EQTK-JRC&UXIWL:)IMRZM6N>67/P1T.VTQKYO%9&$W[!L/X=:U_
M@5J.HOJ6I:?)=23V,"_NBW3[V,T6_P"SS)'<*T_B*26('F/!Y%>J>%/!^F^$
MK#[/8Q@,?O/ZUO!\O,V]UL8S5TEU[G0]J\A\2_ JU\1ZS-J+ZS/"TC$[%C!Q
MFO7J*Q<4W<T4FE8\5TW]G?3+.\2:YU::ZC7K&\8P:]5MM L[+0O[)M$$, C*
M#:.E:M%7)\T>5[$I6ES=3@O!'PR@\&:A=W<6H27)N&R59 ,51\=?"*W\;:J+
MZ75);9@ -JH#T%>ET4I>\TWT*3:;:Z[GBFG_ +.^F6MR)+G5IKJ,?\LWC&*]
M6T'P[IOARQ%KIULD*=]HZGUK5HJN9VL3RJ]PHHHJ1A1110 4444 %%%% !11
M10 4444 %>>?#K_D:_'7_847_P! %>AUYY\.O^1K\=?]A1?_ $ 4 >AT444
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M\+@\3_WK7_OR*/8XC^;\0^L83^7\#TK_ (51X4_Y]9O^_IH_X51X4_Y]9O\
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M]CB/YOQ#ZQA/Y?P/2O\ A5'A3_GUF_[^FC_A5'A3_GUF_P"_IKS7_A<'B?\
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M_$/K&$_E_ ]*_P"%4>%/^?6;_OZ:/^%4>%/^?6;_ +^FO-?^%P>)_P"]:_\
M?D4?\+@\3_WK7_OR*/8XC^;\0^L83^7\#TK_ (51X4_Y]9O^_IH_X51X4_Y]
M9O\ OZ:\U_X7!XG_ +UK_P!^11_PN#Q/_>M?^_(H]CB/YOQ#ZQA/Y?P/2O\
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M .^C_A1_PM;P-_T,EG_WT?\ "N@_X1[1?^@38_\ @.O^%'_"/:+_ - FQ_\
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M  KH/^$>T7_H$V/_ (#K_A1_PCVB_P#0)L?_  '7_"@#G_\ A:W@;_H9+/\
M[Z/^%'_"UO W_0R6?_?1_P *Z#_A'M%_Z!-C_P" Z_X4?\(]HO\ T";'_P !
MU_PH Y__ (6MX&_Z&2S_ .^C_A1_PM;P-_T,EG_WT?\ "N@_X1[1?^@38_\
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MX'B.S)*D#YC_ (5T?_"/:+_T";'_ ,!U_P *9-X?T802?\2FR^Z?^6"^GTH
M\P^&/Q!\*:/X5EM=0UNVMYC?3R!')SM9L@_C79?\+6\#?]#)9_\ ?1_PK%^$
MNC:9<^#II)]/M97&H7"[GA4G ?@<BNZ_X1[1?^@38_\ @.O^% '/_P#"UO W
M_0R6?_?1_P */^%K>!O^ADL_^^C_ (5T'_"/:+_T";'_ ,!U_P */^$>T7_H
M$V/_ (#K_A0!S_\ PM;P-_T,EG_WT?\ "C_A:W@;_H9+/_OH_P"%=!_PCVB_
M] FQ_P# =?\ "C_A'M%_Z!-C_P" Z_X4 <__ ,+6\#?]#)9_]]'_  H_X6MX
M&_Z&2S_[Z/\ A70?\(]HO_0)L?\ P'7_  H_X1[1?^@38_\ @.O^% '/_P#"
MUO W_0R6?_?1_P */^%K>!O^ADL_^^C_ (5T'_"/:+_T";'_ ,!U_P */^$>
MT7_H$V/_ (#K_A0!S_\ PM;P-_T,EG_WT?\ "C_A:W@;_H9+/_OH_P"%=!_P
MCVB_] FQ_P# =?\ "C_A'M%_Z!-C_P" Z_X4 <__ ,+6\#?]#)9_]]'_  H_
MX6MX&_Z&2S_[Z/\ A70?\(]HO_0)L?\ P'7_  H_X1[1?^@38_\ @.O^% '/
M_P#"UO W_0R6?_?1_P */^%K>!O^ADL_^^C_ (5T'_"/:+_T";'_ ,!U_P *
M/^$>T7_H$V/_ (#K_A0!S_\ PM;P-_T,EG_WT?\ "C_A:W@;_H9+/_OH_P"%
M=!_PCVB_] FQ_P# =?\ "C_A'M%_Z!-C_P" Z_X4 <__ ,+6\#?]#)9_]]'_
M  H_X6MX&_Z&2S_[Z/\ A70?\(]HO_0)L?\ P'7_  H_X1[1?^@38_\ @.O^
M% '/_P#"UO W_0R6?_?1_P */^%K>!O^ADL_^^C_ (5T'_"/:+_T";'_ ,!U
M_P */^$>T7_H$V/_ (#K_A0!S_\ PM;P-_T,EG_WT?\ "C_A:W@;_H9+/_OH
M_P"%=!_PCVB_] FQ_P# =?\ "C_A'M%_Z!-C_P" Z_X4 <__ ,+6\#?]#)9_
M]]'_  H_X6MX&_Z&2S_[Z/\ A70?\(]HO_0)L?\ P'7_  H_X1[1?^@38_\
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M'_"/:+_T";'_ ,!U_P */^$>T7_H$V/_ (#K_A0!S_\ PM;P-_T,EG_WT?\
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M^C_A1_PM;P-_T,EG_P!]'_"N@_X1[1?^@38_^ Z_X4?\(]HO_0)L?_ =?\*
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M_P!Q"?Y4"(**FGM+FV.)X)8B?[Z$?SJ&B]QM-;A1110(**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH RO$W_(K:K_UZR?\ H)K'^&'_ "3/
MP_\ ]>H_F:V/$W_(K:K_ ->LG_H)K'^&'_),_#__ %ZC^9H ZVBBB@ HHHH
M**** "BBB@ HHHH **** /D&X_Y#>K?]?LO_ *$:NZ/#'/J]I%*H:-Y5#*>X
MS5*X_P"0WJW_ %^R_P#H1K0T'_D.V7_79?YU[F&_AQ/G<5_&EZGM6K:9X T
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MWM<YOP]/K\7@B[CM=-@ELV#;I6EPPX]*X?3-#O\ 6[HPV40>3/0G%>L^$_\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.?_ (]Y/]P_RJ2HY_\
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MSSSP+X4U*SU:\US5SMNKK!\LK@KBO0Z**;=TEV$EJV]V%%%%(84444 %%%%
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M&K(8KJZ0)Y+#E #D?SKT&BFI-/F>KVN*235EHMPHHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,KQ-_P BMJO_ %ZR?^@FL?X8?\DS
M\/\ _7J/YFMCQ-_R*VJ_]>LG_H)K'^&'_),_#_\ UZC^9H ZVBBB@ HHHH *
M*** "BBB@ HHHH **** /D&X_P"0WJW_ %^R_P#H1I*6X_Y#>K?]?LO_ *$:
M2O:H?PHGSN*_C2]0HHHK8P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY_\ CWD_
MW#_*I*CG_P"/>3_</\J3V''='T?\)O\ DF&A_P#7#^IKM*XOX3?\DPT/_KA_
M4UVE> ?4!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!3)O]1)_NG^5/IDW^HD_W3_*@#@_@_\ \B7-_P!A&Y_]#KOZX#X/_P#(ES?]
MA&Y_]#KOZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KSSX=?\ (U^.O^PHO_H KT.O//AU_P C7XZ_["B_^@"@#T.BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,KQ-_R*VJ_]>LG_H)K'^&'_),_#_\ UZC^9K8\3?\ (K:K_P!>LG_H)K'^
M&'_),_#_ /UZC^9H ZVBBB@ HHHH **** "BBB@ HHHH **** /F+3?$.G:7
M?:O!=>'K*_D^WRGS9F8'&X\<5H_\)EHO_0F:9_WT_P#C7&W'_(;U;_K]E_\
M0C25Z]&G%TTSPL15DJLDOR1V?_"9:+_T)FF?]]/_ (T?\)EHO_0F:9_WT_\
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M:U_WPG^%>B44 >=_\*\\1?\ 11-:_P"^$_PH_P"%>>(O^BB:U_WPG^%>B44
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M_A7>PWD$]JMRK@1,,@MQ6);^-]!N];.D07F^\&,H%R.?>BVO+U%?3FZ'._\
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M*)K7_?"?X5Z)10!YW_PKSQ%_T436O^^$_P */^%>>(O^BB:U_P!\)_A7HE%
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MJ3M)A1116AD%%%% !1110 45I:'H\NNZI'80NJ._1F&0*[U_@KJB1%QJ=LQ
MSM"-DUG.K"G\3L:TZ,ZGP*YYA16S-X>N[/7DTNYC82LV,8QFNF\>>%=(\/:;
M9-9I*MQ( 9-SY'(S0ZL5R_WMAQH3?,MN7<X"BBBM#$**** "BBK%C;&[OH;<
M DR-C H6H,KT5Z#XV\*:3X?T2SEMHY5NI I?<^1R/2O/JSIU%45T:U:4J32E
MUU"BBBM#(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.?_ (]Y/]P_RJ2HY_\
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M1C:3?6WY]":SO"W2_P"74]EHHHJ1A1110 4444 %%%% !1110 4444 %%%%
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M&SC)Z5VGPMNFN? .FECEA%S^=7"W)*,=DU^3)FY.49RZW_0[.BBBH*"BBB@
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M*** "F3?ZB3_ '3_ "I],F_U$G^Z?Y4 <'\'_P#D2YO^PC<_^AUW]<!\'_\
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M?FR:BBBH- HHHH **** "BBB@ HHHH **** "BBB@ KSSX=?\C7XZ_["B_\
MH KT.O//AU_R-?CK_L*+_P"@"@#T.BBB@ HHHH **** "BBB@ HHHH ****
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MHKL_^$-T7_H<],_[Y?\ PH_X0W1?^ASTS_OE_P#"CVL?Z3#V$_Z:.,HKL_\
MA#=%_P"ASTS_ +Y?_"C_ (0W1?\ H<],_P"^7_PH]K'^DP]A/^FCC**[/_A#
M=%_Z'/3/^^7_ ,*/^$-T7_H<],_[Y?\ PH]K'^DP]A/^FCC**[/_ (0W1?\
MH<],_P"^7_PH_P"$-T7_ *'/3/\ OE_\*/:Q_I,/83_IHXRBNS_X0W1?^AST
MS_OE_P#"C_A#=%_Z'/3/^^7_ ,*/:Q_I,/83_IHXRBNS_P"$-T7_ *'/3/\
MOE_\*/\ A#=%_P"ASTS_ +Y?_"CVL?Z3#V$_Z:.,HKL_^$-T7_H<],_[Y?\
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MHKL_^$-T7_H<],_[Y?\ PH_X0W1?^ASTS_OE_P#"CVL?Z3#V$_Z:.,HKL_\
MA#=%_P"ASTS_ +Y?_"C_ (0W1?\ H<],_P"^7_PH]K'^DP]A/^FCC**[/_A#
M=%_Z'/3/^^7_ ,*/^$-T7_H<],_[Y?\ PH]K'^DP]A/^FCC**[/_ (0W1?\
MH<],_P"^7_PH_P"$-T7_ *'/3/\ OE_\*/:Q_I,/83_IHXRBNS_X0W1?^AST
MS_OE_P#"C_A#=%_Z'/3/^^7_ ,*/:Q_I,/83_IHXRBNS_P"$-T7_ *'/3/\
MOE_\*/\ A#=%_P"ASTS_ +Y?_"CVL?Z3#V$_Z:.,HKL_^$-T7_H<],_[Y?\
MPH_X0W1?^ASTS_OE_P#"CVL?Z3#V$_Z:.,HKL_\ A#=%_P"ASTS_ +Y?_"C_
M (0W1?\ H<],_P"^7_PH]K'^DP]A/^FCC**[/_A#=%_Z'/3/^^7_ ,*/^$-T
M7_H<],_[Y?\ PH]K'^DP]A/^FCC**[/_ (0W1?\ H<],_P"^7_PH_P"$-T7_
M *'/3/\ OE_\*/:Q_I,/83_IHXRBNS_X0W1?^ASTS_OE_P#"C_A#=%_Z'/3/
M^^7_ ,*/:Q_I,/83_IHXRBNS_P"$-T7_ *'/3/\ OE_\*/\ A#=%_P"ASTS_
M +Y?_"CVL?Z3#V$_Z:.,HKL_^$-T7_H<],_[Y?\ PH_X0W1?^ASTS_OE_P#"
MCVL?Z3#V$_Z:.,HKL_\ A#=%_P"ASTS_ +Y?_"C_ (0W1?\ H<],_P"^7_PH
M]K'^DP]A/^FCC**[/_A#=%_Z'/3/^^7_ ,*/^$-T7_H<],_[Y?\ PH]K'^DP
M]A/^FCC**[/_ (0W1?\ H<],_P"^7_PH_P"$-T7_ *'/3/\ OE_\*/:Q_I,/
M83_IHXRBNS_X0W1?^ASTS_OE_P#"C_A#=%_Z'/3/^^7_ ,*/:Q_I,/83_IHX
MRBNS_P"$-T7_ *'/3/\ OE_\*/\ A#=%_P"ASTS_ +Y?_"CVL?Z3#V$_Z:.,
MHKL_^$-T7_H<],_[Y?\ PH_X0W1?^ASTS_OE_P#"CVL?Z3#V$_Z:.,HKL_\
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M-'_"P_$7_1.]:_[[3_&@#T2BO._^%A^(O^B=ZU_WVG^-'_"P_$7_ $3O6O\
MOM/\: /1**\[_P"%A^(O^B=ZU_WVG^-'_"P_$7_1.]:_[[3_ !H ]$HKSO\
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M $3O6O\ OM/\: /1**\[_P"%A^(O^B=ZU_WVG^-'_"P_$7_1.]:_[[3_ !H
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M5K'9ZSHECKUD;/4(S)">JAL5RT?PA\'Q8\NRF7'/$["JO_"P_$7_ $3O6O\
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M=U:1G3" @\GFNF^&'_),_#__ %ZC^9H ZVBBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'3Y:4ZO+*,5U'3H<T)R?V?\ ,\<HKK?&'@S_ (1F6'R9WN(I0"KE<<FKUYX
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MT?1_PF_Y)AH?_7#^IKM*XOX3?\DPT/\ ZX?U-=I7@'U 4444 %%%% !1110
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M<!\'_P#D2YO^PC<_^AUW] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% #9)$B0O(ZHHZEC@"FPW$-PNZ":.5?5&##]*X#XA:;XBU:.6"TG
M:UTY(]SR(PRWJ,4?"*+[/X>NH=Q;9-C)[\40]Y2\@G[KCYGH=%%9FO:Q!HFE
M37D[ !1@#U/:E*2BKL:3;LBXUY:K.(&N81,>D9D&X_A2W%Y;6BAKFYAA4]#(
MX4'\Z^?-..J7_P 3='UG4&95NIB$C)Z "NQ^+*6U[J'ARPN]IMY;HK(&.!C;
M5<KM#O)V]-PTYY+HE<]*76M*=@J:G9LQX $ZDG]:N@AAD$$'N*X;3/A_X#B:
MWFM].L#<( P99,G/YUW$:)%&J( %48 %#21*=QU%%%(84444 %%%% !1110
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M HHHH **** "BBB@ KSSX=?\C7XZ_P"PHO\ Z *]#KSSX=?\C7XZ_P"PHO\
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MZY5WN;-%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]</ZFNTKP#Z@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *9-_J)/]T_RI],F_U$G^Z?Y4 <'\'_\ D2YO^PC<_P#H==_7 ?!__D2Y
MO^PC<_\ H==_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMX3?2ML0\9W&KG_"P/%?_0;N?S%>O1<_9JUCPL0J?M97;,?^Q]3_ .@?=?\
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MPL#Q7_T&[G\Q1>IV06I=W]W_  3'_L?4_P#H'W7_ 'Y;_"C^Q]3_ .@?=?\
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MPL#Q7_T&[G\Q1>IV06I=W]W_  3'_L?4_P#H'W7_ 'Y;_"C^Q]3_ .@?=?\
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MB_\ 06L?_ A?\:Y__A5/@;_H6[/_ +Y/^-'_  JGP-_T+=G_ -\G_&@#H/\
MA(=%_P"@M8_^!"_XT?\ "0Z+_P!!:Q_\"%_QKG_^%4^!O^A;L_\ OD_XT?\
M"J? W_0MV?\ WR?\: .@_P"$AT7_ *"UC_X$+_C1_P )#HO_ $%K'_P(7_&N
M?_X53X&_Z%NS_P"^3_C1_P *I\#?]"W9_P#?)_QH Z#_ (2'1?\ H+6/_@0O
M^-'_  D.B_\ 06L?_ A?\:Y__A5/@;_H6[/_ +Y/^-'_  JGP-_T+=G_ -\G
M_&@#H/\ A(=%_P"@M8_^!"_XT?\ "0Z+_P!!:Q_\"%_QKG_^%4^!O^A;L_\
MOD_XT?\ "J? W_0MV?\ WR?\: .@_P"$AT7_ *"UC_X$+_C1_P )#HO_ $%K
M'_P(7_&N?_X53X&_Z%NS_P"^3_C1_P *I\#?]"W9_P#?)_QH Z#_ (2'1?\
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MPD.B_P#06L?_  (7_&N?_P"%4^!O^A;L_P#OD_XT?\*I\#?]"W9_]\G_ !H
MZ#_A(=%_Z"UC_P"!"_XT?\)#HO\ T%K'_P "%_QKG_\ A5/@;_H6[/\ [Y/^
M-'_"J? W_0MV?_?)_P : .@_X2'1?^@M8_\ @0O^-'_"0Z+_ -!:Q_\  A?\
M:Y__ (53X&_Z%NS_ .^3_C1_PJGP-_T+=G_WR?\ &@#H/^$AT7_H+6/_ ($+
M_C1_PD.B_P#06L?_  (7_&N?_P"%4^!O^A;L_P#OD_XT?\*I\#?]"W9_]\G_
M !H Z#_A(=%_Z"UC_P"!"_XT?\)#HO\ T%K'_P "%_QKG_\ A5/@;_H6[/\
M[Y/^-'_"J? W_0MV?_?)_P : .@_X2'1?^@M8_\ @0O^-'_"0Z+_ -!:Q_\
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M+_Z$:2EN/^0WJW_7[+_Z$:2O:H?PHGSN*_C2]0HHHK8P"BBB@ HHHH ****
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M49;M7%4]U2:^R[>I[-1114@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5YY\.O^1K\=?\ 847_ - %>AUYY\.O^1K\=?\ 847_ - % 'H=%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,RJ,L0!ZDT
MM9FN:6VKZ>]J)C$&!!(S2DVEH-6OJ4AXVT$ZR-)6]5KP_P  &:Z"O#?!'AVR
MA^)UU]E#O'#%\S.Q;YP>>M>Y55ER1EW1+?ORCV*>HZG::5:M<WDOEQ+U.*YR
MR^)OA:_O$M(+\F5S@!HR ?Q-:7BC^Q(M.^TZ[,(K6-A\Q8@9[5YGXEO-)\:/
M;:;X3CCN&C8;IX !LP<\]ZF&LK;Z_P!,II<M]CUK5-9L='TU]0O9A';(NYGZ
M\5RZ?%GP@[!5OY"2>/W+5S?Q1U"'3/#VG:3>S;$G&R1SVP!73^%==\':I:V]
MEID]C<31QJ&41C.<8]*J"YKO=)V)D[*-]&U<Z^VN([NWCGA.8Y%#*<=C4M(J
MA5 4  = !2TF"OU"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &5XF_Y%;5?^O63_T$UC_##_DF?A__ *]1_,UL>)O^16U7_KUD_P#036/\
M,/\ DF?A_P#Z]1_,T =;1110 4444 %%%% !1110 4444 %%%% 'R#<?\AO5
MO^OV7_T(TE+<?\AO5O\ K]E_]"-)7M4/X43YW%?QI>H4445L8!1110 4444
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<__ ![R?[A_E4E1S_\
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MT^U2WMHECC48 48I4[0NUZ#G[^A8HHHI#"BBB@ HHHH **** "BBB@ HHHH
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M,_#_ /UZC^9K8\3?\BMJO_7K)_Z":Q_AA_R3/P__ ->H_F: .MHHHH ****
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MPOK%RT9&-I(QC\JIVFOZK8>9]EOI8O-^_M/WJ5.C4C%QNMK!4Q%*<E*SWO\
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M_/9Q2740(CE(Y7/6KBU&<7'9?Y"DG.,N;=_TB\.0#2T=!BBI&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4R;_ %$G^Z?Y4^F3?ZB3_=/\J .#
M^#__ ")<W_81N?\ T.N_K@/@_P#\B7-_V$;G_P!#KOZ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"&ZN8K.W>>9PL:#))-4=%UVUUVW,]JDHC'=UQGZ
M5R'Q'OY;FZL?#UNQ62Z(D)'HK<BD\1>+3X"33-*L+%+CSE("\Y!_"E%W5WU=
MD.2::2[7?H>B45YQ9?$#7(]=L[#6M'MK2*\;;"\<I8GC//I3M0\7>,X+QX[3
M2="DA!^5I=1"L1[BF^GF(]%KD=>^(FC:!=?9Y4N;B0?>%M'YFWZXZ5EVOB[Q
M(]A?S:O8:5;Q0P%U:TO/-;/TJGX%TF&71=4UJY0/+=[G#-V4CI2:>KZ)7_X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,11(@_V5 J2C2R2Z?J*[;;?]6.$U'X<Z)I^A:@NBV AN98&0$,3FN0TSQ?\
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MM1_PA6E_]#AI?_?+5QM%')+^;\@YX?R_BSLO^$*TO_H<-+_[Y:C_ (0K2_\
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M_0X:7_WRU'_"%:7_ -#AI?\ WRU<;11R2_F_(.>'\OXL[+_A"M+_ .APTO\
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MF_(.>'\OXL[+_A"M+_Z'#2_^^6J"\\':9'8W#KXMTQRL3$*%;+<=*Y2HY_\
MCWD_W#_*DX2M\7Y%*<+_  _BSUKX?>-]5TSP+I=G!X,U:^BBBVK<0LNR3GJ,
MUT__  L;6_\ HGVM_P#?25>^$W_),-#_ .N']37:5XA]$>>_\+&UO_HGVM_]
M])1_PL;6_P#HGVM_]])7H5% 'GO_  L;6_\ HGVM_P#?24?\+&UO_HGVM_\
M?25Z%10!Y[_PL;6_^B?:W_WTE'_"QM;_ .B?:W_WTE>A44 >>_\ "QM;_P"B
M?:W_ -])1_PL;6_^B?:W_P!])7H5% 'GO_"QM;_Z)]K?_?24?\+&UO\ Z)]K
M?_?25Z%10!Y[_P +&UO_ *)]K?\ WTE'_"QM;_Z)]K?_ 'TE>A44 >>_\+&U
MO_HGVM_]])1_PL;6_P#HGVM_]])7H5% 'GO_  L;6_\ HGVM_P#?24?\+&UO
M_HGVM_\ ?25Z%10!Y[_PL;6_^B?:W_WTE'_"QM;_ .B?:W_WTE>A44 >>_\
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M 'TE>A44 >>_\+&UO_HGVM_]])1_PL;6_P#HGVM_]])7H5% 'GO_  L;6_\
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M_P!$^UO_ +Z2O0J* //?^%C:W_T3[6_^^DH_X6-K?_1/M;_[Z2O0J* //?\
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M*=T39C****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM%8=FF4'^=68Y8YD#Q2*ZGH5.10 ^BBB@ HHHH **** "BBB@ HHHH ****
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M[YE+JA6]UQ[[@!@8':BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M2UF$CKY(^<#MP*["W@CMHECBC1% Z(H J6BDG:/*-ZN["BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O//AU_R-?CK_L*+_P"@"O0Z\\^'
M7_(U^.O^PHO_ * * /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "N3U3PC/J'BZTUI;J-(X&4F,J<G KK**%I)2ZH'JFNYB^*-&
MN-=T2:QMKK[-+(I DYX_*L&U\ ,W@]=$U.\^TR+@K,">& X//-=Q12LK-=_T
M'=W3['F*>"/',-D--B\36 TY1M"&W8OM]-U=%I7@M-%\/26%A/LN9!\TS$G)
M_G7644V[IKN)*S7D>;MX7^(IA:W'BK3! >WV5MV/K6]X/\%6WA9))?,,UY-_
MK9<D@\Y[^]=5133M>W435PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,KQ-_R*VJ_P#7K)_Z":Q_AA_R3/P__P!>H_F:V/$W_(K:
MK_UZR?\ H)K'^&'_ "3/P_\ ]>H_F: .MHHHH **** "BBB@ HHHH **** "
MBBB@#Y!N/^0WJW_7[+_Z$:2K#6-W<:QJSP6L\J_;91N2,L/O'TI_]E:C_P ^
M%U_WY;_"O:H->SB?/8E/VTO4J45;_LK4?^?"Z_[\M_A1_96H_P#/A=?]^6_P
MK6Z,.5]BI15O^RM1_P"?"Z_[\M_A1_96H_\ /A=?]^6_PHN@Y7V*E%6_[*U'
M_GPNO^_+?X4?V5J/_/A=?]^6_P *+H.5]BI15O\ LK4?^?"Z_P"_+?X4?V5J
M/_/A=?\ ?EO\*+H.5]BI15O^RM1_Y\+K_ORW^%']E:C_ ,^%U_WY;_"BZ#E?
M8J45;_LK4?\ GPNO^_+?X4?V5J/_ #X77_?EO\*+H.5]BI15O^RM1_Y\+K_O
MRW^%']E:C_SX77_?EO\ "BZ#E?8J45;_ +*U'_GPNO\ ORW^%']E:C_SX77_
M 'Y;_"BZ#E?8J45;_LK4?^?"Z_[\M_A1_96H_P#/A=?]^6_PHN@Y7V*E%6_[
M*U'_ )\+K_ORW^%']E:C_P ^%U_WY;_"BZ#E?8J45;_LK4?^?"Z_[\M_A1_9
M6H_\^%U_WY;_  HN@Y7V*E%6_P"RM1_Y\+K_ +\M_A1_96H_\^%U_P!^6_PH
MN@Y7V*E%6_[*U'_GPNO^_+?X4?V5J/\ SX77_?EO\*+H.5]BI15O^RM1_P"?
M"Z_[\M_A1_96H_\ /A=?]^6_PHN@Y7V*E%6_[*U'_GPNO^_+?X4?V5J/_/A=
M?]^6_P *+H.5]BI15O\ LK4?^?"Z_P"_+?X4?V5J/_/A=?\ ?EO\*+H.5]BI
M15O^RM1_Y\+K_ORW^%']E:C_ ,^%U_WY;_"BZ#E?8J45;_LK4?\ GPNO^_+?
MX4?V5J/_ #X77_?EO\*+H.5]BI15O^RM1_Y\+K_ORW^%']E:C_SX77_?EO\
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M]^6_PHN@Y7V*E%6_[*U'_GPNO^_+?X4?V5J/_/A=?]^6_P *+H.5]BI15O\
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M0G^-']N:1_T%+'_P(3_&@"_15#^W-(_Z"EC_ .!"?XT?VYI'_04L?_ A/\:
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M_H,3_I1_PL'Q3_T&)_TKF:*/9P[![:I_,SIO^%@^*?\ H,3_ *4?\+!\4_\
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M:*/9P[![:I_,SIO^%@^*?^@Q/^E'_"P?%/\ T&)_TKF:*/9P[![:I_,SIO\
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M]M>&WL;29]JSM+GCUQ0M79 ]%=FM_P *H\$?]"_;?K_C1_PJCP1_T+]M^O\
MC776UPEU;1SQG*2*&!]C4M#T!.YQG_"J/!'_ $+]M^O^-'_"J/!'_0OVWZ_X
MUV=% '&?\*H\$?\ 0OVWZ_XT?\*H\$?]"_;?K_C79T4 <9_PJCP1_P!"_;?K
M_C1_PJCP1_T+]M^O^-=G10!QG_"J/!'_ $+]M^O^-'_"J/!'_0OVWZ_XUV=%
M '&?\*H\$?\ 0OVWZ_XT?\*H\$?]"_;?K_C79T4 <9_PJCP1_P!"_;?K_C1_
MPJCP1_T+]M^O^-=G10!QG_"J/!'_ $+]M^O^-'_"J/!'_0OVWZ_XUV=% '&?
M\*H\$?\ 0OVWZ_XT?\*H\$?]"_;?K_C79T4 <9_PJCP1_P!"_;?K_C1_PJCP
M1_T+]M^O^-=G10!YWK_PO\&6OA[4)X="MTECMW9&&>" <=ZU_AA_R3/P_P#]
M>H_F:V/$W_(K:K_UZR?^@FL?X8?\DS\/_P#7J/YF@#K:*** "BBB@ HHHH *
M*** "BBB@ HHHH ^0;C_ )#>K?\ 7[+_ .A&DI;C_D-ZM_U^R_\ H1I*]JA_
M"B?.XK^-+U"BBBMC **** "BBB@ HHHH ***WO"_A>[\3:@((/E08WN1P!0W
M978TFW9&#17LP\ ^![(+!J6I%;KN/.(KF7\,:;!XTM+3391/;[E<Y;=QFL88
MB$Y<J.B>%J0CS.QY_17JWQ)T*YNK^WATG2RZQQ_.88P.<UY=<6T]I.T%Q$T<
MJG!5AR*=&LJD;DUZ$J4K,BHK4MO#>LWEN)[?3IY(CSO5>*CGT/5+6V^TSV,T
M</\ ?9>*OFC>US)0DU=(SZ*TET#5FBCE6PF,<APC;>&--O="U338A)>6,T"'
MHSKC-'-':X<DFKV,^BK=CI=]J3[+*UDG;T09K1;P=XB52S:/=  9)V4W)+=@
MH2>R,.BK46FWL]R;>*VD>8'!0#FK=UX9UJRA,USIMQ%&!DLR\4G**W8*$GLC
M*HHZ'%>C?#3PE_:5\;V]@8P1C*@C@FB4E&+D^@0@YR45NSSFBO6OB!=QW:?V
M/8^'WAN X*N(U&X>V*\Z7PUK3M(JZ;.6B^^-OW:SI5E./,]#:MAW3ERIW^1E
M45H6FAZG?NR6EE-,R]0@Z4V_T?4=,(%]:2P$]-XQ6O,KVN8\DK7L4:*NVVD:
MA>6[W%O:2RPH,LZC@58?PUK4=L;E]-G6$#)<KQ0Y);L%"3V1E45IQ^'=8EM3
M<QZ?.T &2X7BLT@J2",$4)INPG%I7:$HK>\(:-#KOB"&RN WE."3M.#7J4OP
MV\&"X^Q+=2+>D<1F8YS]*SJUHTVDS:CAY54W'H>'T5V&H>#Y-*\8P:7D,DC@
M*WUKH_BC!;6=A86D%O$DBJNXH@!/RU+KQ]WEUYBEAI7FI:<JN>645K)X8UN2
MW$Z:9<&(C(<+QBJ]WH^HV$*S75G+#&_*LPX-:\T=KF')*U[%&BM"QT/5-34M
M964TX'4H,U'?:5?Z;(([VUD@8] XQ3YE>P<LFKVT*=%:UOX7UR[B$MOIEQ)&
M>C*O%-L-*N#KMO8W$+1R.X4JXH33=KB<9)7L9=%>Q>/=!EDT:RLM,TT23(JE
MS%&,]*\DNK.XLIC#<PM%(.JL.:RI5E41M6H.E;KH045I6.@:KJ4>^RL)IU'=
M%S5>]TV\TV7R[RVD@?\ NN,5KS*]C+EE:]M"K1113)"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ J.?_ (]Y/]P_RJ2HY_\ CWD_W#_*D]AQW1]'_";_ ))AH?\ UP_J
M:[2N+^$W_),-#_ZX?U-=I7@'U 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 45S7CKQ!-X:\+7>HVQ03QKE-PR*ROAGXUG\7:,SWY07J,2
MRJN/ESQQ1#WKVZ!+W4F^IW5%<'>^+]0'Q"CT*U\O[.(U>3*Y//7FNA\4:]'X
M?T:6[8CS,$1J>[=A2NN13Z,?*^?DZFW17+>%]8U2Z\,G5=9\M"\?FHJIMVC!
MX-<7X7^*.HZ]\09-*/E#3F+>2=@W$ >M6HMU/9];7)NN3GZ'KM%%%2,****
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M;I[9AA&TG'!J(1<G%6]Z]V5*2C%M/W.6R]3SFBBBO5/$"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ J.?_CWD_W#_*I*CG_X]Y/]P_RI/8<=T?1_PF_Y)AH?_7#^IKM*
MXOX3?\DPT/\ ZX?U-=I7@'U 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!YA\6YOM*:?I R3=N5(%9.F6X\#^/[<?<L]0ABA4=@P&36KKU
MG<ZO\4-,4PR_9[23<6*';R/6K7Q9T"XO_#L=]8(6NK#,J!1R3C'%1&3ITU/N
MW?T>GZ)E2BJDW3[)??O_ , S/!136?B%J>K-RB(8@>WRM3M7ED\;^-XM,A)^
MP69WR'L74]*Q?"']I:!\.KF<VMP=0NI751Y9R"><UW/@_2#X<\,3:C-$SWDZ
MF>0;<MG'2M6E!Z[07XD<SE=K>;_ POBGXFATFQM=!M9XX7G903G 5-V#^AKD
MH(](TCQOX=BTR\@FV1.LC1,#DD]ZZ/PIX77QAXAO]=\0V/F0B0K!!<(<;2/0
M^]-\=^#[#2-2TV\T/2$A*L YMXS_ 'J5*\)P<MV]?GHE^(ZEI1E&.R37]?D>
MOH<QJ?4"G5%:DFUB)!!V#.?I4M#W$M@HHHI#"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ IDW^HD_P!T_P J?3)O]1)_NG^5 '!_!_\ Y$N;_L(W/_H=
M=_7 ?!__ )$N;_L(W/\ Z'7?T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !145S<Q6EN\\SA8T&22:HZ-KMIKL!FM%E\L=W3&?I0M0>AIT444 %%%<E
MKWQ$T7P_<_9[@7,\@^\+:(R;?KCI2NKV'9G1W&G65W,DUQ;12R)]UF7)%3R1
M1S1F.1 R$8*D<5GZ'KUEXAT]+VQ<F-AG####ZCM5C4=2M=*M'N;N0)&HYR:<
MERJTA1?-JAUGI]G81F.TMHX$/547 JG/X9T2ZN//GTNUDE/\;1@FL#2_B?H.
MK:FEA$EY%)(VU&GA**WT)KHM6URQT6T^T7<H52/E ZM]!WH>B4F"U?*B]##%
M;QB.&-40=%48 J2N4T+Q_IGB"_:TM;348V7^.:V9%/T)JUK_ (UT7PX%^VW&
MYV8*$BPS9^E#TM?J"UT70Z&BJUA>Q:C80WD&[RIEW+N&#BLKQ)XOTGPM"DFH
MRD;R JH,L<G'2AZ.S"/O:HWJ*P)?%^F0RV*2><OVW_5$IQ^/I6\I#*&'0C(I
MV8KH6BBBD,**** "BBB@ HHHH **** "BBB@ HHHH *\\^'7_(U^.O\ L*+_
M .@"O0Z\\^'7_(U^.O\ L*+_ .@"@#T.BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***QKKQ-I]KJT>FDR27$@R!&NX#Z^E'6P=+FS1110 5F7G
MA[1]0D\R\TVVG?\ O21@FM.L_5]9L]$LFNKR3:BC.!U/T'>DVEJQJ[T0^QT?
M3M,!%E90VX/7RT I4TJPCO#=I:0K<'K(%^8_C7-Z)\2=#UW4?L,"W<,V,C[1
M"8PWTSUKL"0!DGBJ=]V2K;$<]O#<Q&*>-9(SU5AD&FVUK;V<"P6\*11+P$08
M KEM<^)&AZ#>_9)UNIY!][[-"9 OUQTK:TWQ#I^JZ2NI6\P%NR[LN<$?6DOA
M<EL-Z-)BW?AO1;^7S;O3+69S_$\8)JQ8Z58::FVRM(;=3VC7%<DWQ6\/+J0L
MBMX"6V^=Y!\O_OKI773:E9V]D+N:>-(2NX,S <4;1OT!ZRY7N6Z*YS0/&ND^
M);R>VT]I6:'.YF3"G![&F^(O&VF^&G5+N&\F8]K>$R']*'I:_4%K>W0Z6BN<
MT3QMI.O6%Q=VGG*+<$R1R)M<8&?N]:T=$URSU^P6\LBWEL.CC!'U%.S%=6N:
M5%%%(84444 %%%% !1110 4444 %%%% !1110 4444 97B;_ )%;5?\ KUD_
M]!-8_P ,/^29^'_^O4?S-;'B;_D5M5_Z]9/_ $$UC_##_DF?A_\ Z]1_,T =
M;1110 4444 %%%% !1110 4444 %%%% 'R#<?\AO5O\ K]E_]"-)2W'_ "&]
M6_Z_9?\ T(TE>U0_A1/G<5_&EZA1116Q@%%%% !1110 4444 %%%% !1110
M4444 %%%% !6IX?U--)UB"[DC#JC G/:LNB@#T[7-4\)^([^&_NM8NH9$&3$
ML&1USUK+\8>-(=3TV'2=/R;2(8WD8+8/I7"T5@L/%671'3+%3=WU>EPHHHK<
MYCLO FH>&M/NI9=?A#D+^Z.PM@YJW\0/&=KX@$5IIX_T6+&TX(_2N"HK*5*,
MIJ;Z&T*\H4W"/7[PHHHK4Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]NDC1&SE2N.?2K?PQD;[5K,('[E)5"?3%4O"KW?ASP-J%SJ.8EN.+>,GIE2
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M\5?]!S3O^_+4?\*.\5?]!S3O^_+4?7*?F']GUO(\_HKT#_A1WBK_ *#FG?\
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M1WBK_H.:=_WY:C_A1WBK_H.:=_WY:CZY3\P_L^MY'G]%>@?\*.\5?]!S3O\
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M^-']F_%/_H8-$_\  ,_XT >A45Y[_9OQ3_Z&#1/_  #/^-']F_%/_H8-$_\
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M^-']F_%/_H8-$_\  ,_XT >A45Y[_9OQ3_Z&#1/_  #/^-']F_%/_H8-$_\
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M-$_\ S_C0!WSP12$%XD8CH64'%$L$,Z[98HY!Z.H-<#_ &;\4_\ H8-$_P#
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M_P :+DI65CT*HI;>"<8FACDQTWJ#_.N"_LWXI_\ 0P:)_P" 9_QH_LWXI_\
M0P:)_P" 9_QH&=\D$,:%$BC5#U4* *5(8HU*I&BJ>H50!7 ?V;\4_P#H8-$_
M\ S_ (T?V;\4_P#H8-$_\ S_ (T =V+*T63S!:PA_P"\(QG\ZE>-)%VR(K+Z
M,,BO/_[-^*?_ $,&B?\ @&?\:/[-^*?_ $,&B?\ @&?\: .\BM;> YAMXHR?
M[B 5(\:2*5D174]0PR*\_P#[-^*?_0P:)_X!G_&C^S?BG_T,&B?^ 9_QH ]
M"($V!5"^@'%0'3[(MN-G;[O7RES_ "KAO[-^*?\ T,&B?^ 9_P :/[-^*?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^K'FUOX9U#Q'=7^HZE UL;B((D;=1@U%'=>(=,TJXT4:--,S9"2@@#':O3P
M!@#%)M4G)49]<4VE;E6PKN]WN<MX$L;RQT>1+Z%HI6DW;3754=.E%5*7,[BB
MK*P4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:RIO&FE0;0\F&89"YYK@AJDNO6FFZ$I/F1%&E_X">:THM(M)?B'Y$L2O'&'
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M:GX5U2Q9;\W*3R[&1G+'&,U2OK!M;\?LHNI;8LB'=&<'D5)XA\/OX<>UU/\
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M[O=7N9YHCD;P.*[9$"1+'UVJ!3Z*=]+=!6UN<3>^![A;Z2XTK5;BS$OWTB
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MM# MZ9H8'&Z3X&DL];BU:ZU.XN;A5((D [UV,D?F1-'G&X8I]%#U5GL%M;G
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MES^==+K]K!#X#LV2% P13D*,]*J;M>3Z-(F*N^5=;FGJ5Y9R^([!Q<8+PED
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M)AT]O -RVR,_*VYBH)SWYJ[\.]HT.4)]WS3BM%'E<X]K$-W47YLV]:UZST.
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MM%3[G6Z7XML-3AE9'"R1#+H>HK);XCZ<58Q)YFQB'P>F*Y_5=B>-Y5L\!?\
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MW2_\!_4]&HIB2QN<*P-/I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KFM<\&6.LS?:-\L$_P#?A?;GZXKI:*328T['
M(Z3X#LK"Z6YGGGN9%.5\Z0N!^=:;^&;-]7DU$[Q*Z*A /&!6W13>HEH<TG@O
M3TT][,&3RVE:4_-SDU?O=!MK[2(].D+>4@ &#S6M10]=P6CN<\GA"Q2>RE!?
M-I%Y2?-VS535_ UGJ%XUU%//;R.<OY4A4'\JZRBAZ@M#EAX$TO\ LIK)A(Q8
M<R%OG_.J/_"M[&:!HKJ[NY5(PH,Q(%=O11UN!SR^$;%;FVGS)NMP OS>@HBT
MRR\-K=7R+(_F,789SUKH:9)$DR%)%#*>H-#OT!)'G?A331J?BJZULV[1198*
M&'7/>O1ZCA@BMTV0QJB^BBI*;:LDMD+6[D^IA'PO9G4KJ])?S+C[WS<4^S\-
MVEGHLFF1E_)D))RW/)S6U12MI;H5?6YBV?AJTLM$FTN,OY,I8MEN>:XOQ=X<
MC@BTZP@$AB:X7<0>1^->G5');PS%3)&K%3D9'2C>7,Q+16.2TSP%96UREQ-<
M7$^SE%DE+ ?@:NZYX.LM8F6X#RP3J,!H7VY_*NDHH>HHZ'-Z/X/LM*\R3?+-
M-(,%Y7W'\,U?T;0;;187BMRV'))W'/6M6BG<+')OX"TUM2DNQ).!+]]!(=I_
M"JJ_#FS#LGVN[$#'/EB8X_*NVHI)6T*;OJ<K%X$TV'3_ +$K2^5YPE&7YR*U
M-3T"VU324TZ8MY2,K#!P>*UJ*'KN):.Z.=U+P?8:EIT%I(TJB 81E;!_.M;3
M;!=-L$M4=W5!C+MDU<HIW>OF*VWD9%GX?M;/6;C4XR_G3H$;)XP*KR:#9V6K
M3:Y^\,OEX(W<8%;](RJZE6 *GJ#2U5K=![WOU/-(K1/$_C=+U+9XX(%Y9AU8
M&K7Q!TXZA>V,.U]A(!*\8^:N]AM8+?/DQ*F>NT4LEO#,P:2-6(Z$CI196BNB
M!MMR?=6.5TSP'96=VMQ-<7%P4^XLLA8#\#5G6O!MGJTXN%DE@G'\43[<_E72
MT4/4%H<UI?A2UT.&::+S+BY9?O2MO/ZUP-U!ILTER]Q#?V\^YAY4<FU6Y]*]
MCJK)IME+)YDEM&S_ -XKS2:N[L:=D<%X/\)K/H4T5VDL:23%T!.#BM#Q5<V^
MGZ-%HD=M)*S*%0CG':NV5510J@ #H!4,MG;S2+))"CNO0D<BG/W].@H>Z[]3
M#\':(-)\-06TJ8D9,2#'>L^]^'UG<7;30W-S KG+)'*5'Y"NSHIR?-+F%%<L
M>4YV7P;I<NDKI^QE5<X<'# GWK/L?A_:6]XD\]U<SB(Y19)2P'X&NRHH3:=P
MMI8QH/#EI;ZT=33<)3'Y>,\8^E);^&[2VUQ]50OYS @Y;CFMJBEL-ZW\S$3P
MU9IJ5S>@OYEP&W?-QR,53;P/IK:2; ^9L/1MW(_&NGHI6TL.[O<XC_A6]C-"
MT=U=W<H[!IB0*Z^QM$L;2.WC)*H,#)JQ157=K$V1B'PQ9-JTU^P8R31^6P)X
MQ6'+\.;-KAC'=W:0NV6C68@?E7;T4DK%-W*FFZ;;Z591VMLN(T&!GJ:S=>\+
MVFNA6E:2.9/NO&VT_G6[10]7=B6FQQ^G?#^QLM1@OWN+B6>(Y!DE+"I-6\#6
M=_=FZAGGMY6&&\J0J#^5=910]; M#G=.\'V&G6$]LID=IU*N[MECGWHC\(6,
M>E-IX,GE,^\_-SFNBHH>H+0P/^$4LOM5E/E]UI'Y:?-VSFI=5\-VFK7]M=SE
M]\ (7!P*VJ*=]F%O\CE=7\$6>HW/VF*:>WF/4Q2%<_E5K1O"-AI$4@&^9Y1A
MVE;<3^==!126BL#U=V<3<?#FQEFDV75TD#DEHUF('/7BNCT/1+?0;+[+;%BF
M<_,<FM.BFG96!J[NS!\0>%[37PC2M)'*GW7C;:162/AU8.5DN+FZEE5@07E)
MQ7:44E[NP/7<Y+5/ MG?7/VF&>>"4_>,<A7/Y5I:!X9M-!1C"9))7^\\C;B?
MQK;HH6BL@:ON4-7TJ'6-/DLY]WEN,':<5#-H5M-H@TMBWDA-G7G%:M%*VEAW
M=T^QS<W@S3I](BT]O,"Q !'#888]ZIZ=X!L[6\6XN+FYN&3[@EE+ ?G78452
M;3N396L<KK?@BSU:[%TLT\$W<Q2%<_E2Z9X&T_3)I)4DG>2089G<DFNIHI)6
M5AO74RM&T*VT6R>U@W-&[LYW'/).:PKWX?V=Q=O-!<W,"R'+I'*5!_ 5V5%#
MU=V"T5CE+_1K;0_#KP6MLTZG[^1N8^]>=WFGZ=<V*):IJ+7#LN(6ERJ\^E>W
M,H92K#(/45533+*.3S$M8E?^\%YHW;;'>RLCF]+\)0?V;ICW6\36B$  XK$\
M7%/$>J6FE0VLFZ-L-(1P*]*[5 MG;I,95A02'JP'--N\[O:]_F3%<L;+>UBJ
M=(MI]&73YD!B,85A^%<W%\.K-+I6:[NGA5MPB:8E?RKM:*77F']GE.9U;P5I
M^I"-HVDMY(UVJT3;>/PIFG>$+/1X;BX#RSW#1L-\K[CT[9KJ:0@$8/0T=&D&
M]KGE/A_P>-5GO9I)[FW;>.(Y"H/Y5WEEX7T^RTQK%4+QN,,SG)/XUKQ010Y\
MJ-4SUP.M24?9Y0ZW.(/PXLS-M^V7?V<G)C\XX_*MFX\*6$[61PRBT<.@!QR!
MCFMZBFFT!C:SX=M=9-N;@O\ N7#KM..13;?PQ96^HO>#<7=64@GC!K;HI+0'
MJ<7=?#RSENVDANKJ&-SEHTE(7\JZC3-,M]*LTMK9<(H[]35RBA.RL#U=V8&O
M^%K37=DDCR13(<J\;;3^=4]*\'6>BS-?22SW$RC@RN6QCTS75TA 88(R#0KQ
M^$'KN>9WL*^*?&<,D5JZ1VQ!9V'!P:[;5_#UIJ\<"3;@(75UVG'(.:T8;2W@
M8M%"B$]2HZU-36D4ET_,'=R;^7R,76/#=IK+0-.7_<D%=K8Z'-+JOA^UU1X)
M)B^8!\N#BMFBE_PX?\,>56_A?^U_%^I!Y)X-B)L>-RN:[;1O"ECI$$B(9)7E
M&'>1MQ/XUM);PQR-(D:J[=6 Y-2T+2*CY6!ZR<CE;/P)IUG/<NLDS)< [D9\
MKSZ"J8^'-G]H_P"/N[^S[L^7YQQ^5=M11Y@8-UX4L+E;5=K*ML $"G'0YJ35
M?#=IJU[:W,Q??;CY<-BMJBB^M_F%O\C'O_#UKJ%]9W4I??;'*X-96J^!;2^O
M#=PSW%O*P ;RI"H('TKK:*5AW,70?#=IH,3" N\C<L\C;B?QJ[JFEVVK6C6U
MRN5/<=15VBG+WMQ+38XNT^'EE!=*\MU=31(<I')*6'Y&K>L>";'4IQ<122VT
MW<POLS^5=310]0.<TKP?8Z9!*H:26248:21MQ_.KNE:#;:5IKV,);RV9F.3D
M\G-:U%#UNGU!:'+IX(TY-,GL09/+F=G;YN<FK-QX3LKBVLH&+[;0J4PWI6_1
M3NP,>U\/6MIK#:DA?SF!!R>.:5/#]JFN'507\XY[\<UKT4NWD%C%B\-VD6NR
MZLI?SY#D_-Q0GAFR75KF_(9GG4*P)R,#VK:HHZ6 XF?X=6;W#&*[NXX7.6C6
M8@<^U;3>%=-.D?V=L/EC^+/S9]<UN44=+!UN<,OPUL6=#-=W<BQL&16F) Q7
M:6\"VUND*9VH,#-2T4[NUA65[G+:UX(LM8OS>O+/'/V:.0K4FB^$K31)6NC)
M+//_ 'I7W8_.NEH(R,&DO=5HC>NYYEJB)XK\6VBPVKJEM*#([#@CD5Z5%&(H
M4C7HHP*CBM+>!V>*%$9NI ZU/36D5% ]9<QF:SH=GK=KY-TI]0R\$?C7+Q?#
M6U$P\V^O7A!R$,Y(KNZ*2T=T#=U8YO5O!NG:IIT-DV^..(878V*R5^&=CD"2
M^OF0?PF<XKNJ*.MPZ6*%IH]G9:=]ABB7R<8((ZUR][\.;.6=I+6[NH-QR528
MJ/R%=O10]7<%HK(YO1/!FGZ-)YRF6:8CEY6W']:L6?ABSL]4NK]"YDN2=X+<
M<C%;E%.^MQ6.?TSPEI^EWUU=0!M\YR<GIQCBK>DZ#;:1-/) 6S-][<<UJT4E
MI^0WK^91U72K;6+)[6Z7*,,9'4?2N:L_A]9V]VDLMU<S)&V4CDE+ ?@:[.BA
M:.Z!ZJS.5U?P/8ZC.L\,DUM*!C,+[./PJQI7A"QTRVF0-))),I5Y)&W-R,'F
MNBHH6BL#U,G2] MM*TQK&$MY;+M.3DU2M?!NFV^G366':.7KDY(KHZ*'KN&Q
MQ=M\/+.*[626ZNI8D.5C>4E?RJ[K'@JQU*19HWEMYE4*&A?;P.G2NGHH>H=;
MG-Z+X/LM(+R;Y9IG&"\C[CC\:NZ5H%KI)NS 6_TER[Y.>:UZ*=Q6.>MO"-A;
MR7[C>?MC;GRW?&*SH?AYIT-I);>=<-$[!@K2$XQZ5V5%):;?U89DZGH%IJFE
M?8)PWEA=H(/(_&N>_P"%<64L+17-W=R)C"J9B0*[>BCK<.ECF+_P1I]_I\%J
M[S*(,;&5\$8]ZEL?"%E9WT=WOEDD2(Q?.^<@UT5%.XK:6.-OOA_9W%X\\%S<
MP"0Y=(Y2H/X"M$>#].713IBA_+8@LV?F./>NAHI=+#OK<R;K0;:ZT-M*<MY+
M#!P>:S+SP-IUUI\-LK2QM"=R2(^&S]:ZFBAZZ@M%9'+:-X)M-,N_M<DT]Q,.
M 99"V/SKJ:**;;8K!5:>PMKB"2)X4VR?>P.M6:*EJX[G$'X<67G8%W=BW)SY
M8F./RK;OO"VG7NE+8,A1$'RLG# ^N:W**>ZL'6YQVG^ +.UO$GGN;F?RSE%D
ME+ ?@:[ *%0*!@ 8 I:*;=U85M;F/8^'K6PO[J[C+[[EBS9/J*;IOAJTTV^O
M+J(OONFW/EO;%;5%+_AAO4Y'4M#@TBPO[FW@>X>?!=#\V?I7GVH:?I]SITL=
MJFHM=29"0F7*@_2O;B PP1D&JJ:99))YB6L0?.=P7FDEKK_5AW.:\,>$X[#R
M;R;=YOEK\I/3BM+7O"UGKA621I(IEZ/&VT_G6]152?,]28KE1Q^G_#^QLKY;
MQI[B6<*5S)*6J&[^&]A<:A/>+<W43S-N;RY2O-=M12&<WH7A&'1+DS)=W4I/
M:64L*Z2BBFVV))(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gzbwht3f4aft000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +D!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBLS7[N6RT>:>$X<#@XJ92Y8ML<5=V-.BO/-,3Q+J5H+J"Y7:>F<5K:#X@O
MGU1M,U11YP&0W3I41JIM)JURY4VDVG>QUM%,,L8)!=01U&:$FBD.$D1B.RL#
M6IF/HICS11G#RHI_VF IRNKC*,&'J#F@!:**Q=?M=5N5C_LZ8)C[P(ZU,G97
MM<<5=V-JBO-]5?Q%I(A,]R/WK;1C'6M.VTWQ-YL4CW2^7D$].E91K7=K,T=*
MRO<[6BH4FC6(;YD) P6W#K4BNCC*.K#U!S6YD.HJ(W$ ;:9HP?0L*E!R,B@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(QVJ6/0#-
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M9<N"?NFM5'21=R,K+ZJ<BLI1<79D#J*9YL?F;/,3?_=W#-/J0"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K&\5?\B_<?A6S6-XJ_P"1?N/PK.M_#9=/XT8GAC7M
M-T_052XNXUD'\!/-5M,8Z_XO;4(HV%L@P6]\<5-X6\/:;?:1'/<0EI#WW5V-
MO:PVD8C@C5%'H*B,)R:<NA<I15TNIYWJIO[OQ;):6L[(9&V9ST%;L>E)X6MY
M=0:YED.TC:3P6(_QK-C_ .2@_P#;2NB\70O/X>F2,$D$'CT%8QC:G*?74TD_
M>4>FAS.GV#^($>]U'4&3<?D0-TJ32K^?1->73Y+DSVS\+ST/:F>'=!T[4M-6
M1[EED!PR^81^F:V[3PKI-O>I*)P\JG(!DR?YU4(2NFOS%*4=4SH7NX(VVO*J
MGT)I\<T<P)C<,!UQ6%>>$[2\NGG>64,YR0'-7M(T:'2$D6)W;>03N8FNB+G?
M5&+4;:,P?'?W-._Z[_TKI9R5TIR#@B'@_A7->._N:=_UW_I727/_ "")/^N/
M]*RAO,N7PQ/.]$L+[7;R>W:ZD2V1BS8/7)K;U.1_"VEBRMIY'FG8;68_='2F
M^ _^/B^^O]:;X^@+36<K ^2O#$=N:RY>6DI+=FK=ZO*]B%/#J36(N9=4;[8P
MW<MP*T?!^L3W#S6%S(9)(S\K$]J9:^%M+N+6.47;890?]:>/UK1TS1M.T837
M5JXED53G#YK2$7&5]D1*2E&V[*DOA6[O[R674-0D:(L3&J'H*R[;[1X>\30V
M<5RTMM.>%8].U1644_B?4[I[F_:!(SA5#8XS5=K"#3_%=C%#=&X^8;B6S@YK
M*^L7%6NR[;ILL^+=$CMKNVE%Q,QN)2"&/W?I74:3X=ATF4SQW,\A*XPY&*R_
M&Y"R::3P!+_A75)+&\8"2*QV] <UI"$4Y&<Y2<8GG&E66H:QJ=[ ET\=NLK;
M\'KR:?JEO?>&=2C@L+J1EG'R@FM;P5_R$=5_ZZ'_ -"-,\8?\AW3OJ/YU"@O
M9QEU-')\[70BNO#%TFF-?O>RM>@;^#QZUL>'-;>X\.M=71+- ,.QZFMBY_Y!
M,G_7$_RKC_#4;3>#M0C099L@#\*M^Y-J/8S3YXWEW*]J)?$]Y-->7K0VR$A$
M!IHFE\,ZQ"D5X9K21N5SVJ'PSHUCJ*3)<3M',C$%=^WO6^OA'2%G0O<;F!X5
MI>3^M3",FE)?F:2E%-IE7QQ<3>7I[6[LK.<C'KQBFKX3O;RQ:ZN[R7[:R[E&
M>GUJ3QHH2?2E7HL@ _,5V(_U7X52IJ3FW_6AFYN,8I'(>'WFUS2;G3[R>0-"
MX'F*?FK(TCP[#>:]?VC7,ZK#G#*1D\]ZU_!/_'SJ?_77_&CP_*B>+=6#N%R3
MC)QWJ5%2<'+JBFW'F2.HT^R73[-+9)'D5?XGZU#KG_($N_\ KG5]65QE6!'J
M#5#7/^0)=_\ 7.NBI\#]#&'QHX?PYXGATFQDA>VFD8MP5QBETO41K7C"*ZN7
M6$QXV(W5NO%:W@K[+_9DGG>3NW?QXSW]:H>,!9C4;1K(K]IW#/E>GX5SR4DH
MR;OL;KE<I12[FAXNFD35]*5'(4N,@=_F%6O%FLS6%K#;VK8GG.W<.HK.\59_
MM+1<]<KG\Q4?C2-HM0L;IL^7N _2G*32EZDQ2;CZ,GB\&2SVOG7%]*;MAG(/
M%+X7U6ZAU.;2+V0R,AQ&Q-=5!>6SVJ2":/;M'.X5Q>E W_C>:YB ,<1Y(Z=Z
MIQ4)QY>HE)RB^8@U+^T;GQC<6ME,R,W!(/0<9JQJOAJ?2+'^T+6]E,\?S29/
M7Z4"\AL_B#.\[[58%0?<XKH?$MW N@7!\U#N7@!AS6:C%TW+KJ6Y24U'IH9<
MOB"XE\'B[B.+C&UR.QYJAI/AV/5M/%V-1D:[)R2&X%:/A2UAB\.'[85$5P>-
MYQ5#6-!BTJ"34--OO+"<B,/D']:J:?QR5U;[A1:^&.FH_P 117NE#3;QIF<P
M +(V?O'.:Z>ZU)(M"-Z3P8P<CU(K'0R>(?!Y:X7,P3(..IKE/[4EGT>'1AN,
MGG%7^F:)2<&TNNPE'G2OTW.I\$Q3R6T][.[DROE<]"*ZRJNFVBV&G06R](UQ
MFK5=,8\L4C&4N9MA1115$A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'D8-
M%% '.>*K:&V\+7JPQJ@*DD*/8U2^&O\ R*,?_75OZ5?\8SP_\(U>+YJ;MIXW
M#/0UF_#::)?"<:F1 WFMP6&>U=$;^QEZHT?P+U#XA:(FH:4MZLZPSVQRK-TQ
MU_.N)_X65J']CK8>6@DQY?G=L=,UN_$.X>;Q#I>GS2&.SE/S\X!^:NKDT/07
MT,VA2W\@)PP(ST]:UA*,*4>=7N5=*URIX!TB+3=&:9+A+A[IA([H>,^U=97E
MOPWGG@\07VGPR-)8J203R 0.*]2K'$)JIJ]S.2:D[GC^M#6+[XAW5EIMQ)&7
M)5BI^ZO&:D\1^'KWPA;0:G8ZA.TV?WI)[UJ:=_R5R^_W&_I6I\3/^1:/^\/Y
MBNCVCBX16SL:IWJ<O0Q;#PGJ/BG31JFI:C()9DW0(IX7ZU>^'^K7F=1TZ^F,
MOV+.UB><9/\ A73^$_\ D5-._P"N/]37%^#%+>(/$:CJ00/S:I<G)3B]EM]Y
MFW>#;\B S:CX[\27%M#=20:; Q'RGJ/\:-=\,7WA"$:II.HS>5&1YBLW)I_P
MZNX['6-1T^Z*Q3;RWSG'IZUT/Q!U*UC\,SP><C2R$!54@D\U4I2A4C".VGS+
MUY^7H.OM6;5?AO<:@"%DDM2QV]C7(^%O#&I>)=,2>_U"9;,$B-%/>MNUM'M/
MA),),[GM"V".E:WPZ_Y$ZV_WV_G4W]G&?)W(3:AIW.<\.75[X=\9OH4\\LUK
M(=L0<].>M9WCCPS#9:S8%;NX?[7+\VXCY>1T_.M+4?\ DJ]C_O#^=6OB.P35
M=#9C@"7D_P# A5QD_:0DNJU+VD[=OT.@T/PG!H$LTT5Y<S%TVE92"!7F_AC0
M]1UW4=1@ANW@LQ,?-VG&[DXKV7SXI481RHYQG"L#7!?#+_7:S_UW_J:QI5)6
MG)[V7YDJ3Y6S)O(+OP)XDLOL]W/)8RL ZL>OM6Q\0M8NH(M.MX;@V\-WCS9
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M%?>#$M]0T^_G9R<2$GJ36C:>#]0\2Z9_:FH:C(+B9-\*@\+]:T_BA_R 8_\
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MA_Z",G_?L4UOAQ O749/^_8HY:7<=ZG8]D_X6)X1_P"@]:?F?\*/^%B>$?\
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M#UI^9_PKQ[_A6D/_ $$9/^_8I?\ A6D'_01D_P"_8HM2[CO4['L'_"Q/"/\
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M*.6EW"]3L>P?\+$\(_\ 0>M/S/\ A1_PL3PC_P!!ZT_,_P"%>/\ _"M(<?\
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M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M  KYU_X135/.,7EQ[A_MTL?A/59)&18DRO7+XH]E3[C_ 'O\I]$_\+$\(_\
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MQ[X&VN8\KE!W-:43MY(8C/TK,U1))6)8X5.:DMKAWCBP_"C#+5O6*-6O=1H
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M/08ON"GTR+[@I]<IT!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML&S&<K5=T2([B<J>@J2=QHA#2LTA!&<C%3;=ZY[#I52V4FY=LD#T-.DN/LV
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MYWKZ(\)_\>MO_P!<U_E48G9$4>IZ#%]P4^F1?<%/KE.@**** "BBB@ HHHH
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M87FG9WL2T;"NK9P>E/Q5"RO+6YRT,BEC]X \BKX- @Q24II*H0F>:6DI:5@
M4444 )2%CNQBEHP*  ].:0<BG44 QH7!SFEQ2T4 -SSB@CBEI*+ "@@<TM)W
MI#2&'-(.M+13$(<XXHZXR*-PSBEI#$YSFH[K_CTF_P!P_P JDJ.Z_P"/2;_<
M/\JI;B/#;_\ X_Y_]\T[3/\ D*VO_75?YTV__P"/^?\ WS3M,_Y"MK_UU7^=
M>E]DX>I](>'.BUV"_=KC_#G1:[!?NUYIVBT444 %%%% !1110 4444 %%%%
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M4D1%W8M%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAS0'WZ5I-O:MG.4!_J:W:I-*"@B&FY\["BBBI*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OG[XV?\C?;_\ 7L/YFOH&OG[XV?\ (WV_
M_7L/YFMJ'QF=7X3SNQ4MJ5N%Z[Q_.O7."$W<8'->2Z>2NI0$8W!QC/UKU^W$
M=W$!(-KCK1B?C1M0=J:(E>"Z1ACCIFHMDB!XXAP%X-2RP?8^%'R$]:?"Y,C
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M;@#O6/97;'4W.TE&.%--7:87;N;SO&K88 MVJM)-&CJ[\<U'>2;)B>>@JM%
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MW@C9PK=#@$UQOPO^(E]X[CNFO+*"V\D<>42<\X[T1]YM+H$O=2;ZZ'HM%%%
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M?XMM,5S=PPQ0(B^23NV]#6UI=S*;>:TL8$:1N6;' I-O<=K&!/\ :5*0R B
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M@:?Q%-I,B^)+?RKJ.3:IQC>OK749 [BJDK.Q*=Q:*0$'H:6D,**3</4?G2T
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MV<LI&X"K=W&\:;]N_%1,/,A#<@TKW5R+W5T*"84W,W2H)+IF7E,*3UJO*99
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M*44HGD]%>A_\*AUK_GX@_P"^31_PJ'6O^?B#_ODUV>VI]SB]C4['GE%>A_\
M"H=:_P"?B#_ODT?\*AUK_GX@_P"^31[:GW#V-3L>>45Z'_PJ'6O^?B#_ +Y-
M'_"H=:_Y^(/^^31[:GW#V-3L>>45Z'_PJ'6O^?B#_ODT?\*AUK_GX@_[Y-'M
MJ?</8U.QYY17H?\ PJ'6O^?B#_ODT?\ "H=:_P"?B#_ODT>VI]P]C4['GE%>
MA_\ "H=:_P"?B#_ODT?\*AUK_GX@_P"^31[:GW#V-3L>>45Z'_PJ'6O^?B#_
M +Y-'_"H=:_Y^(/^^31[:GW#V-3L>>45Z'_PJ'6O^?B#_ODT?\*AUK_GX@_[
MY-'MJ?</8U.QYY17H?\ PJ'6O^?B#_ODT?\ "H=:_P"?B#_ODT>VI]P]C4['
MGE%>A_\ "H=:_P"?B#_ODT?\*AUK_GX@_P"^31[:GW#V-3L>>45Z'_PJ'6O^
M?B#_ +Y-'_"H=:_Y^(/^^31[:GW#V-3L>>45Z'_PJ'6O^?B#_ODT?\*AUK_G
MX@_[Y-'MJ?</8U.QYY17H?\ PJ'6O^?B#_ODT?\ "H=:_P"?B#_ODT>VI]P]
MC4['GE%>A_\ "H=:_P"?B#_ODT?\*AUK_GX@_P"^31[:GW#V-3L>>45Z'_PJ
M'6O^?B#_ +Y-'_"H=:_Y^(/^^31[:GW#V-3L>>45Z'_PJ'6O^?B#_ODT?\*A
MUK_GX@_[Y-'MJ?</8U.QYY17H?\ PJ'6O^?B#_ODT?\ "H=:_P"?B#_ODT>V
MI]P]C4['GE%>A_\ "H=:_P"?B#_ODT?\*AUK_GX@_P"^31[:GW#V-3L>>45Z
M'_PJ'6O^?B#_ +Y-'_"H=:_Y^(/^^31[:GW#V-3L>>45Z'_PJ'6O^?B#_ODT
M?\*AUK_GX@_[Y-'MJ?</8U.QYY17H?\ PJ'6O^?B#_ODT?\ "H=:_P"?B#_O
MDT>VI]P]C4['GE%>A_\ "H=:_P"?B#_ODT?\*AUK_GX@_P"^31[:GW#V-3L>
M>45HZYH\^A:F]C<,K2* 25Z<TS2=*NM9OX[.TC+R.>PZ#UK3F5KD<KO8-*TJ
MZUB_CM+2,N['DXX%?0/A#P?:^&;%0%#W3#]Y(?6CPAX/M/#-BN%#W3C+R$<_
M2NGKSZ]?GT6QZ%"@H:O<****YCI"BBB@ HHHH *^?OC9_P C?;_]>P_F:^@:
M^?OC9_R-]O\ ]>P_F:VH?&9U?A/.K.5H;V%E."&!KU..07MG&P8!PN17D,KF
M-T<=J] \*SFZLP1+\Z_+@GM1B8^\I'3AU>BC:@&R4ACES5TDNN .15)%6&7E
MLR9[]ZL"X&7)&"HZ5DS7<@\_>AW*?W; &GW++.(T#$=QBG6S*8Y'9>&/0TZ5
M$7RW7@GBCJ'PLCRRS*2P&1@@FK@&Q"1SQVJG# 'RTA#9/'M5I=\,BX&8^]#!
M@JC'RKWS4P \MWJ",M]J8LXV$\"IQA=R]C28F-+J4^E-; 'F%>HZ&J-U-)#<
MA40;&.2:OROF-">,#)IV&D-M,R$N4V[3567,;2F-F8MZ]J)[B=U'V4%@.N*A
M6X$T1BDE6-^>.]4D]RK-.Y4247.^WG0!4/!)ZTEO 'GV*^V->O:KT<=L8EWC
M<P.=QI\:0^>WR@9'3UIM]BF^PV$+:/M520_0]:M17#?:_+. HP<GBJTE[%:V
M[1JI+@X /:JT)EOXF9P5D3E:+=6"C=7.K$D;Q[2RY(Z9K-N21&Z1_>%95G<.
M'5IF!*]ZORWBJ&?;CC\ZGE<78S4'&1#&\D+JKC*2'GV-7I5 B(3&>U8\3M>2
MYBD8*3DAC6DUP@C**X:11R*<EJ5):E.XLC=6+L^=Z<A5/>JR&:.S7S,C'08S
M5J.YECE\R/#1$99:F%S#<)M( SV-.[7H&NS(8KH"!3\Q;I@BIF*E5#KRW)JF
MLA2[,0&X(,@^E.NY)&F7'"]S2MJ4HW);B2..0 *& Y^E%S<'$;QKD$@&HD#7
M<<D:H!(!PQJ.&&Z$1B=<G-"2ZBMH)-;D*S(?F)R/:M(7BK#$@Y<CK5>3?;A5
M=-P(JI$SJ9-ZY4]/5::5UJ"5]6;1A613N(.1S4%K;[%VCA0:2PG1U"J2PZ$U
M=A3#=<@U#NM"&W'0IW3M'^\5B=O!3%)#%%'%YH;"L<GFG/ ?M#EF;![9I@L@
M(3$')4G/S4[Z6N"9:+-Y++"XY&0:H6RLUUF9OG3CKUJS$1$OED?='45%;RPW
M#,1M+#OZ4*Z3#7H6UB)D+J<47)$5N[EN!R<5&4<-@2Y3'(J">Y1H'B5,[1\V
M>])+4%=L=9L&!8G(;ID8JW?3BWMUXZU2CN46%9&B*J!U-$DK7D:[<%6.1]*=
MO>N]AM>]=C7V&+[5L.1TP*K6MX/."R*VZ0YZ=*WH426$1\!E'(ISZ;$Z] 'Q
M]X=J:E'9@JD?M%2X<0VQ<*3]!FJD,P>V8@88C('2MT0[4"=0!BLN\M?);S%&
M!U)I1:M8F,D]#+6.$PMY[G<3DC-3;'EMO]$&3G!8FB&PCDC9Y6R2<A_Z5*KE
MK*6.V'DLAQN;O5MZFET,^R_*C[B0 =P/%.BVSJT:NJ[AA3GFJ]S/+E8GRG3+
M=C5F+3U^T13QX,8&3]:-EJ#VU+<D.+<HZ@G&"U5;:SA:#:"5).*<TDEVX428
M7GD5!(98)  3(JKSBI5[6N)7M:Y:FM8HHS*<<#FL+[06G,A.84.5-7+F[78L
M4THVN#P>M.@MH);;[-&,KU)JEHKLI)VU)+J9)+>/R_F;&>M4X6^PAI&^;SN,
M+SBKD$"J\L6P$@845:M;.)%^>,%\=#VI725@YDE8Q[:U>89C#/"QR=XQ2WEH
MEK& 8^6/X"NC!1(R%7\JRWN5GN#;O$2,]^E'/*3N)2E+Y$5E'ON(9)$X P"#
MTIVL6Z%6N%'[T<* >M9UQ-<6,S8W^6S KZ 5(C231EII<9Y7'>CE:?-<.5O4
MBLI3\\>P"0G/S&KHMBY$LF-X[@\4BV 6 RQ@F5A_'S5FR23R6CGVEB.,=*)-
M;HMR5M#/MI#]H9G3]X3U'>KEP%AFCGP,MU_"JLEO+:EYW=0N<+GTIVV2>WP'
MR1\P8]Z;M>Z%))ZFM'?QO;(=Z@GWJ&5(FE$SG#GT-9<JQ&!'V@*IR=M:D*P3
M6ZX&6 []JBRCJB+)*Z'75L/DF@ W*?F..HJS'M:+((R1SS45FS6>Y9WW1N?E
MSVJP;#YM\+#:><=J3[7(;MHSF?%G.DMSC'ZUYQ7J'BZU$6AR,Y!;M7E]=F'^
M$X,2[S"OHCPG_P >MO\ ]<U_E7SO7T1X3_X];?\ ZYK_ "J,3LB:/4]!B^X*
M?3(ON"GURG0%(RAE*L,@C!%+10!XYXW^##ZCJSZUX=N/LUZ6WF/(4%O7/:L^
M#0/C4(UM'U"T6V^Z2)4) _*O<Z*45RKEZ#D[N_4\[L?AQ-+X,OM'U;4)+BXO
M"6:5N=I..E<#IGPW^)?A2YGM?#U[;)82MAG:5<D?0U]!44_M.7<72Q\[3_!?
MQ:/%-IJAN(;SYQ)/))*%(/? KTCQQX3\1:I'87>@7_V>\M(MNPL K'CKGZ5Z
M#10_A4>VH+XG+NK'@5]\/?B?XM:*T\3WUM]B1LYCD4D?@*]6T_P3IUEX._X1
MT+N@,94DCN>_ZUT]%#LXN/1AKS*78\$'PL\=>$;^23P;J$1AD/(E=5P/H:V-
M,\%_$76+^WF\4ZRL<<$JN$@93NP<\XQ7L=%.+:L][ U?;0:B[(U7.<#&:P/&
M6@7'B/07LK2[>UF#AUD3U':NAHJ9+FW'%\NQX:/#OQGL5-I8ZE:O:CA6>5,D
M?E6CX.^#]S;:V->\377VB_W;]@((#>N17L-%5%V?-U):NK=#FO&_A6/Q;X9G
MTO=Y;,/D;'0UY5X2\ _$SPM>K:6EU;1:2TH:3$JDE?I7O5%*'NR<EU'+WH\K
MZ' ?$;X>?\)KHD,:R!;^W&4?L3@5PFB_#CXC/IZZ%J>I16VC@;<12*[8_G7O
M5%))*_9C;;2\CPSP3\)-=\+^/X]1986TZ/.)/-!8\'M79_$SX<Q>-[!&A817
MT/W']1Z5Z!13E[T5%]!1]V3DNIX+I7P]^)C60T/4-3B@T?./W<JLV/YU-X2^
M$.N>&?B$-040OI<<F4D,HWD?[M>Z452DU+FZB<4X\O0RO$FG0ZIX?O;6?&QH
MF.3V.#7R1X2\*MJ?Q"ATE,2PQ3@2,#QM]:^MO$FGWVJ:'<6>G7$=O<2KM$D@
M) !Z]*X3X:_"B;P3J,]_?WT%W<2#:K1@C'YU-'W:SF^B^]CJZTN5;MGIEM"M
MM:Q0*,+&@4?@,5+110W<25E8\]\>V?Q#N;R'_A$;BWCM]I$HE=1G\Z\B'P@^
M)0UW^V0ME]N\SS?,^TK][UQ7T_12BN5W6Y4G=6.'^']KXYM4N%\83P2=!#Y3
M*<#'M7<4454G<E*P4444AA45S_QZ3?[A_E4M17/_ !Z3?[A_E0!\?7?_ !^S
M_P#71OYU?\.9_MZUQZG^54+O_C]G_P"NC?SJQHX8ZK $D$;%OO'M7HS5X-''
M'XD;EXT4VMR27+GR\%MBC.<5NS6EMJMK;LI:)4Y4;<$\57U;2K?3K87D:R22
ML1GGK6;97MV]PDTA8PH3A >3[5YKU2<>AW%BXT.:RNX;N*X#-(X4[L# -5+V
MXNO[8 ,WF21XV@#K72:?J%OJ=LTDUJ0J,/OXXKG8HO,\3-<VI#6^</G^'%5%
MMWYMT@-DZS 7C;5(C!+&05VDD5237S<7TTUQ"TEKP$^3.*DU[1WO[U&\S$!&
M7)[&KAMHK"S\U4+JJJ-G8^]0G%)>8$&J3SZ@L$;Q^592D9;/)JE'<OIENUOI
M\B@AN_IFIM1FN]56*WL8&:V!RSKV-8%SIFI?:_+ABD*C[Q4\FFEI9_<!T=_K
M]NEHR%#<2;,/@97=]:Y,HMP'NKBW*@\($&:U]-M4M@\<L,HPV[RV(^:NC@ET
M^>-C##&L<2Y88HTCL@.2M=#F;19;V%RI3D(5Y(K"N'\[4[<HA4*0&*K^=>D6
MU_8ZAI\B6S&-0,, >5K!\*+;W6H3J\"LL;$9(ZTXNS<FMAFZ=8M;&."%HY&4
M("&"DC\Z5KLL#/+Y5M%C[VX$D?0UA:R&L=;$3RN;>3E4SPI]*)8,-&;Q'FLI
M" &'8]JE16ENH$6I7-O(\4MDS.Z/DR., ^U;+Z_"+,6TT>ZXV\KT4CZT]["P
M@$-NJ K(?D4CBLBY6.74A)*JHJR*HCQUYJM):=A%^RTU+VQ8LOD(_P!T YQ2
MWMC:Q6\,-_<'>G,9"UJVR327,R21!+51^[91C-5)U.LQ-$+<1LC8#2C)QWQ4
MZMWZ 95M93VL-Q<K*D:2\*X(SC/I706\L3^6/M2$@<G<,_E5*#181,86DF*H
MH.';*G\*TDTFWW>9#;1[N_RU4FGN!-<R0+&!+<(/[I)'%9MS/IM_/'9S,9M_
M(=!D#'N*L7EK!,KI/;IY:+RV.17 KJOV2Z:*Q>..%"5WL,U,%?;= =1KEU:>
M'TC:S4O*3M0!B>:K2VNLZO9K->3^7&XR$Z5C6?VRXN?M4L#7$49+;QT/YU?N
M-0U/5[4"-_(2/@MVJM=%U[E6MJ0_V8D-RL38:0#.6/ JG?W@AFV69WR@<_+D
M#\:V;+PS?7+>?<7>Y0H((SS[5$+$"]E_T? 4X^7 %2U&^KN-,RM L7U:^:"Y
M+1JQRS!>#6SJZ1:6LEMIL4HE)VLYC.#]#5@:FEC$UM!"GV@C.X#[H]ZS#K&I
M7UJ\$TD:XY4XYI7>]M!IMO46"2&UTQI+V5W<9VC)ZFLJ+6;]89H4G81CE1WJ
MOYBJC"[=Y "< &EE\B6*W>%@CN,.?2A7;U+T0^^L9+5(Y[ARYF&>O%:%IJ$<
M-HMMMWNS<DCCZ9K:@T0+!;OJ5U$;3@HK \DUKSV.F"5+9K= N-R[!C)JN96U
MU,6SD+Z_>-RSVD3LPVKL?.W\!4=C9W!@#RA=B/N/S<5)J%E:.)+BPN#"0Q5U
M<YZ'':K%GX:OKG3!+#>&=7X*QD_K3LDM[#N8MS<&YNDC\I\DX"C)_&M;_A%=
M;*B0R(!M^4LXSBNFT_1;;2M/^UZAM$\8.-WZ5RVI^)-0E1I/-Q&_"!?2G%N3
MM#H*YU$'AZRFMOW[*4A3.[.><<UREWJT$,YMK%'E*_(' /\ *KEK)JUW;2?9
M;>7R73&T]SCFJ>G6<NBWL8GM7,NWS,&A1>M]?($R"TN[Z%\?9CY;'YR4_K6^
MUGIEK9/?Q78:=OF*C!/TQ6RD!U33Q')&;?=R0O%<)?):Z9K$RQ2JX7H#TS6=
MU*_1_F5N6;J4K$TZRAI&_AK*4J!M<[2YSD<U)$YG>24QC_@/2MK2-*CO\75T
MB+##R0HQFHY;ZE7L9-HFHW7F+:IYB(<G-=3IWAO[79+/<W,D4I.2N,8K3TR_
MTXVLSZ?"$\O[^!SQ20W\%[*MS+,4&=HCSR:TU6B5K$-W,NZ\/QPV[QP3'S3T
M)&/UK 32]6G<VT,9(7J2YP:Z[6I+JX,<-K;-&S<!FQTJ.?\ M#3Y[." %I%^
M9Q_?R.E5!M+6P7)['2UL="2>YA7S47<V>Y%065YIVNV$OVF-(&#$#:V#BKMU
MJ,ERB075L]O&Q!8N1@^W%.L(M)N7=+:UB.P_,=M1I9M[^705SE4O8K.\>RNX
MWELBVU793Q^-:=]X9LIM/\_39@VW)*JU6+R^LY[Z;2AIQE=!\A&,50GL=9TV
M#SK:'8O.]4&.*N5W9K1_F5&33,2'RY;0VWG.KH<LC<#\ZWK"W6PTT1K=AH9C
MR./E/UJII*Z3J2&VOLP7#G"-G!:L[6=/;2KP6PFE6!NS-UI6N^78;U9J3:(8
M96NIKN)452<JX):J\3WH<R66Q0_R^9NR33F-GJNGP642O',5PKL>M9%QIVIZ
M5(L,CR1J3^[(/RYII.2UW$:ME#?QWK-/,8<=)2N=U4;C5+R[O2DWS*"5&!C-
M:VCSC42^F:I(RL3E&SC\*GB\-36\<SD^9L)*2#TI72;YMQ6U,(Z;/Y$LS1LD
M*G&,=:VM&DO4M@@\M8E!/S$541[B\M2KWGRH,>6A(Y]*G@T?S+8NFI<I]Z/)
MXHE:UI 1"4'S[VZE)7S.(\=:I2.;U3<0EE1#R,XJ*[BV(RO<;U7[JKU/O5_2
MC VEM;&"24R,,M&0-ISWI)=1O0D@B-W8M*$ V+SGC)JSHEAIXCGGU#)9>0II
M+BWDL--^QA)99&DRC(>^*SK-;F;45M9-S2'^$_P_6I:T?*.+ON6KJ[C\[S;5
M J@\#/;Z557;',6@!EE8$LI&,5=O[!K'4?LRJ#(R94@<9IMNJVMI-+D23 @;
ME[5&RN6]2KI\EQ#J"SCY&SP,Y_.O4!-OTMC(PW&,YY]J\WA#,JS_ "MO;&Q>
MM:<>J3)&5<L<J?ESTK3FNT1*)Q=__P ?\_\ OFGZ9_R%;7_KJO\ .HKMMUW*
MWJQJ73/^0K:_]=5_G7J_9/,ZGTAX<Z+78+]VN/\ #G1:[!?NUYIVBT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '@WC?2KK6/B%):6D9=V1,G' Z]:]2\(>#[3PS8J H>Z89DD([
MULP:39P:A+?)$/M$@ 9R.<"KU;3K.45%;&,**C)R>X4445B;!1110 4444 %
M%%% !7S]\;/^1OM_^O8?S-?0-?/WQL_Y&^W_ .O8?S-;4/C,ZOPGFS0B2SE?
M'*D8K3\':DMI-)%(#D_=Q46GVK7<%PB9R%)Q^%9.FB:TU%7)XW<@UK57-='7
MA4W2T/68Y8[Y?E!##G.*G"O(1N4 #@D=ZIVXE15:+: 5'&*LC4883Y<Q"L1U
M]:Y4]-#1HN&.,QJF<"DNE'DHJ]NE,BN(9PH1U/M4MRJNNPMM&.M(774JP,P4
MD_*>X'.:MNS&V&W@UGF[MK3;&TFXGH:MV\B77"2#%4UU!V1 T!\DEI"'ZBIU
ME*VQE(8A1@\5I)!  -RJS#UITJ+Y)"H"/2ES(GGZ&#&S79\T':!QAN*9?3RQ
MP?.> < CO5YX ^5'RGT%$MJ9;/RV X[U::N:IJX^V$/EH2P4]CGK4ZZ=9SR^
M9@%O8U1DC'V7:B9*],5)IJRVZ[I#U/2IV5[D2B[73+SZ3"/F08.*SY+=8"[R
M(?EZ$5MQW,;G;D;O2G20I*I# <U*D^IG&;CHSE(9!>JYP 0WISBKMD@A+Y(V
MD<5.^B^7)))$V-W:JUQIES, JN4 ';O6KY9:)Z&_-&6B>@QH8YG\Q7!;&"H[
MTKVP$P<H< <U-9:/+;LC,0=HQ@=ZV4A!'S"E)V>@G44=M3G5@*,?(SR=P&,4
M\6YC_>E?F/!S70BUC&"%'%5+R!G(4 ;>]+FN3[7F=C$D2,9"?>;@J#587,;X
M0$( >M:LVFMC=$?F'0UC.B^;()HU7'0 8)JEJC6-O4EP6N&2,C>5^5L]:F$8
MD$2%CD?>%44@,<L;!W!(RO-:%I#*M[)))PA7@GZ4]D-I(L*8X9ODX8\&A;E7
MF,6P\@D,.QIT,<,]P"K@LO44&ZA2%Q;@%R>!46(E9[$-R#-:,XYE3Y>*BL$"
ML69B7 Y!%.%R]O!*!%EV7<32I=PO'YGED2=.*K6UBM=D(MVR998MI#= .M65
MOI(T+D9'I5663RX/-(/#9XIBQLTDD\DI\O< N#Q2:3)T9-;ZK-,9OW1&WH2,
M4^VU1'C'G@K(><*,U5F>Y@;<$WP$\E>WUJ*S5YM8W87RP,# I\J:;L'*M3;B
MF$C;@N5/<T\01H6$:XW\U0DDALF\OS"2S$]>E6X;I'.,_/Z5%FM2&GNB2W@Q
M$Y93NJI+#MD#+)]1BM"WNA,63:5QUJI(@5U/7GFEU!7N[D03[1&R!\J.HQ0T
M+V=H)4R^!M"XZ5)9IL:5N,$]*MHX,+Y' IWLP;,W3WF^TFX?*J0 0:Z$7$13
M<'7 'K66J;EP1\IJ@]FT4FZ&5MI;YE8\8H:4GV%)*3-.]U'[.-P<!#TJLUZ9
MK52Q#<\YXJ%;)R8Q.!(H.1CM4\L495@D:L <':.E/W59#M&-B&%+:YB4*'^1
MLX.1WJ80 7+,9 %/:L^ZF,.VWA.V1N<U75Y7E6-G)QU;-59O6YHH-ZW-6XA4
MMD@%0,YS5!6N/..QSY>,GV%686D"8_U@&<BGQ>6'X.UGX9#VI+1"V1!;!8
MP)=SV[5:$"0AW$G!Z@U74EF) X4\D5.C>>SQ[!MQG-*3#J8PC,OG&?YE#C::
MV;*VC@MFE1B6(Q]*R+B*YCF\MODC9N#ZUIVY>.U>-FRQZ5<]5HRYKW=&6K5@
M8S*0-Q/-#AG9GB/)&#56SE-RDD2J5VGDU?M8MBE2<FLY:,R:Y=1%F54PQ%59
M)?)8%8=V[OCI4\=M^\)9>M2GA6SVI:7$G9F+=-]O6-$4@8.X8JK+83Q0C8Q\
ML'D$5OVZ1JAD4#FFW$J)'\W1NM5S-.T4:*>MHG.V=YY$K#<S(PX)'2K<&I$2
MM&03CD$BJTL\=L[*T.8R>#CO5K[%+- 9$"C(RIQ5R2ZEM+=C6NTOV,,JE0O3
M/0TEIF..0DXYPO/6JPA> HUQ*&8L#@= *GU,-$T7D+N!P0!^M)K7E0FEL6!:
MK)$%V$;TR6["K46$B2,.H;ID&L];J5DD*DX5?N>M65CAFM_-CD59  2OI2Z:
MDI=R_+$DNT2@_+Z5-:73"9H-ORJ,J3WJI:7\5TFTL#*H^859+'<I  Q4-/X6
M1).UF<]XRO6ETYXB""IYXKS>O2O%X232W<##8YKS6NRA\!YV)^(*^B/"?_'K
M;_\ 7-?Y5\[U]$>$_P#CUM_^N:_RJ,3LB:/4]!B^X*?3(ON"GURG0%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5%<_\>DW^X?Y5+45S_QZ3?[A_E0!\?7?_'[/
M_P!=&_G5O0WCCUBW:569 W(49-5+O_C]G_ZZ-_.KF@S16^M6\LS!8U;DGMQ7
MHS^!G''XD>B2WB7%M&T<1,9ZAUP:S;[3[*RN[.\W;<N21VZ5)J&L6>EVAE=S
M([#*H#UKEFO=5\07,;I"$M8N<$5YD4]UHCN.RAEAE9V!3RR?X3P:SYH;6TB>
M*56$$S%F*CISFLFW6;4HFLH$DB"\[D.-N/6M&XBO+>VBM[R:&2W88)"G</QI
MQBT[7 MM/!>Q(UHV^-1TSR:IK?I<&2WN7=&) 0%<=#4D>D3&QC>U<6S)R6(Z
MC\*'FMYI8U@1;D+]^0#H1UHLEL!HPFXM5;S-HC09)Z5AIJD6GZC))8P&6)_]
M8^2<5KV=VFJQRQJ"RYVL&[U FFR)=S0V:Q11!02&7.XT1LK\PV375M;ZQ;++
MNVL1\KCM6'<O=VLR6TT:RH.C X)_*MG1K*6,3_:&'#_*J\+CZ5#XDU&VLXHU
M6$/*>A7&10GRRY5J(H:A:'3]/\^&0))*.8P:Y[2WEM=17R+D1I(WS-D<&DNF
MO1)'--*Q4C=\YR!5^\TW3O\ 1S;%Y#-@LR'@&A.V^MRCIKOPO!=.+N;4B93R
M&(&*AEBO=(6.&Y*7-L[#!) (K%O=#UL6[/#=.;<'Y5).0/>GW$\ET5A,LLJ*
MH7>&X!HBG97::_(1T>IRSVYM&L8%DWMCKTI\UCIMW(3(5:YP&9=W(Q7.:A'>
M:/:6\ME=R32D<H[9 -9L.L:O'<K.8+?S&X9RG_UZ$M+I@>A0R6T3)!&X+D9V
MYJ!+J/5#/;C=%L^4G;BN6@U]SJ*I)]G651@2*E6+ _VE>SC[1(F.?E;&34V6
M[ Z46;V]GY N%0A<*[$9KG;S7;_3IEABE6YD0'=@\?I5^UAM(I,WEW*W/W)'
MS5R6;0]/B$ODQEG/IR:I.*>NHCE7UC4]89HY4*1==B]6]JKV]O%9Q[9;)6+2
M Y<D&NBGUFW#>9:621$]691S7-WMU>:A,),!55NI'!IWZ)60R;7[F:39#%.%
MBVCY% &*O:+)<VNG"+9 0W0E^:DL=*B>)KB\VJH'0CDUF&ZL+8A%@N9"IW J
MXP,5%DU9%7TL:.K:K=VEDH-T ['"JF#^=8J1ZA?LRO<+CJWS 8JL[27.I#Y&
M4,=P#].:VH?#TL]JHAOHE+,-P(-%DNMAII"BW;3[(P(1---CY@<E15@:=I$&
MR-W,MRP^9\X J[I_ANYL$DE:X6X8@@!.#^M<Y9:+J$>HE[IO)C23Y5EYWU22
M:=I?\$EMW%&DQ7VJ-"DA\GGDC'2KEOI$%VNR5P(+3Y<CJXZY'K47]OM:WDL3
MV\)5,@,BXQGUJ))-2G>-EM'\L' \L8!'I32?H#;:U-K5;)UM8(S<XA;!4$CH
M.:S?[4@N-0$!N)&1.6)7!K&U"^O&)M[E9?,1LH"> #6YX5TB6\N#/)$AB!PQ
M9>32M:-Y,0T6%@\+SW4TB02MA$5<DX-1R:W_ &7:R"SN'AC1\1H%SN'K3]4U
MFQLKZXMHX-X48CW<J#WK$:Z#I%OMT:4]3MXQ3;=M1I(CO]8O=4V-<SLPS]T\
M5TF@:=%J@"7<3JD2[DRO'YUSUL(I-0BFN(B8T/S!>]=ZVN0K/!':1H;-EPQ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?/WQL_Y&^W_ .O8?S-?0-?/WQL_Y&^W_P"O8?S-
M;4/C,ZOPG,>$O+^TRB3H1C]*Q-<C^QZY(@X0G*UM>$X#/=R!3@@5F>-H)XM2
M1F7G'4"M)?Q6O(ZL)*T-#KK4I/;0R)(?.9>0#Q4K6$\KJTN N>QS6'X7G;[)
M"I&<L.?3FN[=,. !QBN9-Q=C92Y69UOIJ(RLF=RGCFKE]%(P52-P[\U9B(QQ
MC-1;YPTC2KE1]T>M%VW<F^MR..UME49C!(JQ+*D$&Z) <=<"J<=Q(Q(,+!3_
M !&D2\A0["268T6=]0Y2X\[>0'!QD4ZTF9SDL2#ZU6BF:YWQ^7M Z$TZ.-XA
MMZD]"*+:6$[)6'&.1;MG#$J>U3QSA@Z'J*2)FP^[[PZ5!%$Q=V;C/84;[CO=
M#\X1V5EXYY-%E,EW&V&&X'! -/6*-EV%, TEO;1V\I,*@9ZXHTLQ7T*ES;3)
M-YT;'<O2KUGJS%O+G7# #)J261<  9)ZU4N?+CVDX&>,T[W5F/22LT;:SQLN
M0X_.GC:>:YT1E7"K)F/.#ZBDN[NYM9H_+D^3T/>DHW=DR%3N[(W)KD0]1Q5<
MZH@4'U/0UFRW$\H7+!<MT/I55519W20GU!-4HKJ7&DNIO/J<:!,G[_2J4^I,
MTOEHN<]*I7$BJ8D(!S]TXI($D17\LC/8GM3Y4E<I4XI7-2TU",J4DXD7J*YN
MX@.J:A,P?8$/;I4=_)<1'S&=<C^(#K4VE%3O96R9!R/2FER)R1:AR+F0_P"S
M;BJ(Q)3HU:%N[;"-N2HZ>M%JBAVC(QZ&K,5B;>0N)&.X]SQ4MKJ*<TU9D,#;
M6,D<&V0CYO2H;:R*N9V'S$]/2M9\*.%J'>J@C..:7,R%)]"L+<I*9H^I^\IZ
M4PYD0^7LW9Y!XP*NQRH0QZ^M9]_8D@S02>6P'3L::=WJ">I!)YLKS01D'*#:
M>U%O;E,Q/(2H89R,<TZQ/FQ?-P\9R2O -6HXQ<R>9N'RC)7UIWMH.]F0R(%N
M7'F8&T?)1;QLX9F95XXVTRXG5;O<R@@C:1CD5%<3%E,=J>4&6']*=F6KDI%M
M<1R>8/G7@-ZTV.UAAV,Q.\<@@\4EK;&2+<2-I&2I[&J]U>36T)1HMX#A1]*:
MNW9 XZV1KQW6UU"+EGZ4P?/.VXX=3R,]*IP2EVMYURN&(P:T9@/M(98C\QY8
M=ZEI(AI)A J1^9EP6;L35F#C*L."*@:"%I-Y!W'&<&E:2478 3]V!UJ-R7[P
MXS<;6&,'BJ\S@!BS +CM5:^O20X@P6'KVJ",W!AB^02.1\WH*M1TN7&.A.+O
M>A^9^.,XI%E,0D0?-YG(.>352;4D\U;94"MW"]Z6/SDA>5H6R/NU7*:<JMJ*
MB,\[QE2[@94FF6]E</,SL?+*\8'-/LYWWB1C@G(Q4\,TB33LQZ<@&AMJX:JZ
M0ZS1H]Q#YV]0:G2))T<EBK?WJS+60R7C1A\<Y/O5^=F%R8E5@A')[4FG<F2:
M8A"6T1@5BTAY!/>ELEGA5Y'95#=B>E.2S$LT;[CA0>]2:A MU UN'\MSTI73
MT[DWOH4M1+R,&9OE[8J2RNHI(VC/WE'&>]5V@DBA,/FAV Z'O4-O 1)%O4HP
M;G/>G9<MBK+E-^R\H$A,9/44@5TN&E#Y'3%-M;-(I'F!.2.E,W@(X)[\UGZ&
M>[T+*32,68JN,\8.::Q(5SU([57BF3:!'T)P:D@VQ2LC/R3W-%A.-A4VP6JG
M!&3WIJ21W+;>H!YJ>3$B[>N#5%IH;2Z$07#M36OJ.*NO,MW]E#+;[%C'/>L>
M&>\M6^R2A?+_ (&SVK96X25S&) 2HY%-FABE*@CGL:(NVD@BVM&4?[+6X5C(
M3@]/:IK:U0;[<L&"K\I[U>FC'V;"M@X[56M;=85=@2TA[YH<FUJP<N97;.9E
M\VRNI(G0D*^,^HJ8^7M/V<D#J5K0N_*N5>2;*2)P1ZBJ,"P+* -V&'#9ZUHY
M7U-(ROKU-+3)(7C81##*<$D8)J[</(D8>->AYS69&IMY054J67D&M&/<+!RS
M[VZBHDM;DSWN8OB619]#EDQ@YQ7FU=[KMQOT:08P2.1[UP5==%65CS<4K3L%
M?1'A/_CUM_\ KFO\J^=Z^B/"?_'K;_\ 7-?Y5GB=D11ZGH,7W!3Z9%]P4^N4
MZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "HKG_CTF_P!P_P JEJ*Y_P"/2;_<
M/\J /CZ[_P"/V?\ ZZ-_.BV3S+A%YY/847?_ !^S_P#71OYTZQC,MY&@8J2>
MJ]:]&7PLXX_$CH8K":[)CDF=857"[EI&E?2[0I#<));Y]1NW=^*2 74*Y+2>
M2O\ K%<Y(J*"WM+D^88995WG8$;&#[UYUNYW%^VOS97T=W)@^:A^5>3^(JW)
M/_:#^=/8[%BY1F) -95^\&G'S/*=[I#L4$\$&H3/?7SF7S_+7: 8#T^OI22T
MN@-"[UR]V2!G1(<[5,;;B1]*@L)=+LK63-RWVE\M\XP/6H(/#[6ZF>]NU4E<
MK$:ATW2]-NI)9;V<87(VGK[4KQ2:3^XJQ,GB^ZB5HT0$ 9+H,YJYINL27-HT
MD$P%TQ(9'. :Q$BMUOW^R02M!C:0#UI8;$FY'E0RJJMD+N^8'ZU?*NPC?-AX
MCE@>-8H(8I.I,O/\J8_AJ]:W4AH0R]_-S]:HW,VH&\D2YU+]S$>BY^;VJ+S;
MR:U<^5=HH(Q('^7'TH7-;H(L+X>D\S(FCGE R4+TFD^'-8G>2=&6.-2=N6JU
M;^([:SMOW%D99U&QI.,FJ4E]K,MNR/?16T;G< H((_*B[5[_ (CL7]5-S;Z6
MMK-<A)'.T@-P3[GM7/SF\CA-@)%,?!)B.[GMS6EI,NE1JYU::69T;AF;*M5\
MZ[I-MO&G::99'P,G&*E)[6N5>Q@6$%ZX>%8!-)G[Q<U.OA2_D'F7-Q%;AC]U
MI,?SIFIZS?13K&BPP9&<1)AA[9%0R7+W)\TW3"0+]V?+9^E#;W_X(DV:"^'4
MT^2.XM[Z"5T.2C2#FGW4EW;(IAAAW9P1')DG/K7+?Z0\ID##=W '2M'<T,J_
M:$G12,[@_>EKUU*9LAUC*2>2//5LND;%L_6L^^U&:Z<K)B!!RF.>E4/.*WN;
M5YMS=?FZU?FTS43&COI\I0]R13LV)66XS[=?PM!Y[1S+G*?-_A3F349KADM=
MEN'(/EAL_P Z62-S)#;S0BWQ_&PZ"FK/"MY&)I75 "#*AQ2CH]@?D:T5GK1M
M]BWRR,O^M0$' J)-.O-4N(X[5W"[3N++@#VK0N=2@TBWC.F.DQF&&8C)K$77
M=7TWS+>'86E/4+TIIMJZ2$2:M#KEHGV>:'<L0!5T&?Z5G6^IWE[/Y94NZJ<+
MG%:<'BR]L<QWT9F<C@=JH2WT=X3-:VK0W1<?=P,T)6Z?,:?0D_M761?+&)6A
M<@*%K3FN-30$:M=LMNO!"*"2:?;:-J^J2PW$Z);^6/O.O)I]WH#WBRO!?M<S
M1_?CR>3^-%UUL#L]C&EMK!CYUA-)-@[FC=<9KH;'7+]H(UECMEA=>!O^8?45
MR8L+JR82J2C;B&3TK6TP9*_;X2F!PQHE'FWU!DFD:#=7^I/>&95MPYR<Y/7T
MKH]0U7^S;.:W@(5MNV,)U^IJ&XN8])M8;>T S.26)YP.M85X;7SF(F=I^JY;
M.?:DWSN[V$8D;K)(REBLSL<\9SFKQT6\,( /RJN!BIM0T1M.^S7*9W3<E6YK
M?@TJ_N+9'CN-BLN"ASGZBDW>SN.Z*-CHLUO)%& I4KN8N<>YK4M+FS5Y'CA7
MRXQSZ'Z5#_PC^HPWT+"_WQ $,&R>O6M*YTNP6+R&D,08XX;%-\JZW]"6[DQB
M6XODO!>[8=G$1 QTJKJ<VF7.G22R3"4QG("MW_"N;EG;S#;(SJL>1SDDCZU:
MTBPMDN8?,AD6WG./G/!-5RM:M[ 4[2W%Y,EX/,\E3M)([&NITXV<GFVNGS$K
M&<NAJ>VD^>6W6R"6H!V' P:CLXX+(R3"-$8C+$#&:)S37Y!8G6(F[\MUC"*.
M#NYS65/:ZA?ZE&JK&LMM*7#;NJ]!3+*6;4)I]2R52$\1YZ_YQ4D5S.NNP7J9
M2*= 'B;^'OFB,6F_01<2ZMK/4E\]62XFX]B>E5I6N9]?\IG2.,?P9^\*OS1M
M/<(UP(6ECR4.WMUK \07;*4E8".0MA''7/I2C9O3L,Z\CY=C ;".H-8L&FJ?
M-GA11<QN=F3C(J'0[B;=Y0,DL3(268_=/I4LU_\ V?,IE1B';;QVJ;-72 S+
MS5+G4+;[#+'%%/NY97J[Y5U=V2V2^4-BC=(K]:H75M:375S\K^8.<J^!TK1T
MJ[LHK%K>4,JE?F.>?SJG:VB KOX7:Y:WDN9E6.(?=0Y#<U?LYI+EGMA9*D41
MPC9/-26VHV9MEAB20J.%RV2:S-8UFXMY1:6D;*",E@.:+2D^4"U?V]W);3QW
MEQM#-^ZQCCCI5!IK.?2FTVY20%!E7*G!/U_"JUFE]JD!N[QI B#(.?E7W(JU
M9?O+:66[GB>W!P&"'/6AIVL^G8$<8SQG<RY''ZU+ IN+M<R;,J 2>*O:[IRV
M-U'+!@V\PW#BHK*%+@3J%+.%!0#]:RE_,C=-6%N+2QCG6-RV,??3DYHFL+>.
M1)+)I'*X)&WO[U#^Z>7<2R87@$\DU=TUKJQNTEECVQMU9N015P<N^I+5BVNL
M0WEM)::BOD-&,!T&[/M4<@T>%%\F:26X?"@E<8_(UO:GH]G=Z+)/\@EQN5D&
M*Y"WTV:X?; FY8N7D':B+BU=:"TL2Q+;P7LEK=$LOF;20>U3I]G6Y1%5"BY'
M+8//M39H)K>QD;,-T[#(95P5/J<U']GM$BMYW#^8,[AGJ:IO3<@GF3R;F++,
M_.U"PQ^-9X:26\5=Q;#;F]\5+--+>3&4*_EQ#KN^[511/,TAC!48)RO'2L^8
MT2TN;$LTIBDN%MRF]B%D'/'I5K1;.>29_LY2('EY%.2/PK/M]1N'TJ&$,OEJ
MV2,<BNFTV6PL+5#!N8NPW-[U234=$0]RW?7_ -@@6-H9)9 N$.WJ:Y_[-/=(
M[-'Y<I!8*>X[UTEY'/+*C+(I3KT[54:_:*^83Q*JF-@FX<]/6A6MHB3SZ8$3
MN#U!J?3/^0K:_P#75?YU'>'=>3$=V-2:9_R%;7_KJO\ .O5^R>?U/I#PYT6N
MP7[M<?X<Z+78+]VO-.T6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KY^^-G_ "-]O_U[#^9KZ!KY^^-G_(WV_P#U[#^9K:A\9G5^$YCP@)/M
MKM&V" 3CUXI?$2O?,TL@VE6(_"I/!6/M[[CCBMWQ1;I_9DD@51MR20*=5KVA
MU8-I)7.>\/950$ (0\5W$-SDJ&/:N \(SH-28NX$9!XKM517N<C[O8UE)6DT
M;5$N;0L7%Q';,K'/S?I3EE:==P;">IIK6:72D$D[?>I3;8MUC'0>E+0EV([J
M"5K<+"^ .IK.@A6.Y3S&W,3^5:4X;[+@-MST-00QA2S8#-L&#33T&G9#X994
MN608*GI4-Y'<-,LGF$!?X13X2/M*-@[B.:N2$$MD< 4]F'6Y';S,;0E4^?/(
M-3)=*B 2<,>N*K03"64B(<8YJPZQDDLF6 J>HG;9DJ]2H[4 -L?:><=:;&ZL
M&('.>E+$Z&8@,2<<@4B;F7%<R0@^9EG'>KD<HN]I;;@>II9+7<SH>YXHBM%B
M@8 C/8XJVUN:-IJZ#R5S)O(56. 0:RM157C17))1NWI5V7(A\ILLPY&.YJ"]
MPP5HT(( !JHNSN7%>]<NP!9=.R&&Y1\N:STDD:[16"E&X!4YZ5%:0W"7PB+?
MN7&3GT]JFT]HUGDB?Y2A.P_6BUKBMN6C(AN'C9%81=\\T^PECN':93@=-M9@
M\]=3FCCVDRG&XCM6A91DO\H 7.#@8YIM6B-VL0ZU9&6']U@]\>]9UJ@BMG)3
M]X." >E=#>0.8OD;FLJ.R:20R12;AG$BU,975F2I^[8OZ3F8*V/E7H:T;EBL
M7&.2.]5X52*+RU.T ]J8Z*\*J920ISG-1N[D/65R7[45?8R\=JD,8<945$52
M1 PZBK$'$; M\V*-$)Z:HS[J8!?) ()/4"K8C2>T*DY&*HK(/MK(P);'7M6D
MD82U=4ZXIRV2*EHC#@D-HT@<?*IR,=ZM6SR>>RE<(>A%0SP;XI6R0S#!!I(D
MNH8?-B!=NX-6TGJ4UI<@GB>\O#Y<Q&TX*D8J269K19!Y3,Y_B J419S.?DD8
M<^U-NF80;&F4-CGCK3NGH4F6-/8M;%R@R1US5*.S%PTHEX;.1[T^T:;&%($:
MC(]S5'^T;E+Q)&4-&3C@8P*%%W=AJ+N[&K-#&D$;9(\KD #K4PO5^PQ.Q )7
M(K.EDEF9C'RC=?:I[:W5D^=@R)Q@]JEQ5M27!6U8RVU,J#YHSEC@UK%S-:L%
M[C&:KR6<1MMT<2G!]*=;._ELC#!ZXI2L]43.SU1273E6W= 23G.:K(9HITM0
MQ!V\UNPC"2,>_2L?4DF1TGB WAL'Z4XR<G9E*6MBO/I #K*K$<\GO6NLBV]L
M"W,>,<^M1R2AK; ^:3 .T50)NS9R!X6^9N_:B[DM1N\E9D]LT;W31QX^89S1
M-:2NK1&0!F.>M5(4GM$,RA1QP2*;;SO>.WVIC&V<+MX-4UK=%6MJA=,M7BNW
MRY9TSQC@_C5YKF:67H,?=8"H;>Z*N5BB(3."[<YJ\\*_*Y&T@YRO&:4GK=DR
M=WJ6[91&JKU^M-F6-IP<C(J!;L1288?*1]ZHHVA\]W#EB3TK.W4R6A,+>.64
MN>HJ.^LQ/"H#88'@BJZZE$DI1FQZG%:$96>$&-@W.:>L7<MMH;IQ98S$TC.1
MQDBGFW!<_-^%$B.F/+*AL\TVYG6V&]@<D<TM6]"%J_=(C+%9R+&1C)IC6I^V
M&X>;*=5'I4D@BN;3S]N3C@TR.W6:T5-S!CUYIWL5?7\R65G%L[0 -)VS5:4*
MT,<ER,2G@@<FKR0^3&H7Z<U0FRMQ&\QZ,>/:A,2>I/:P)'F95.7]:E$X\S&#
MQZU+YT3@;>,4Y(HW.0.M3S=6)ROJR"6[#7"VX/S%<_2G0+M+<_C53["4UEK@
ML<-P!5Z1@K[=M5*RLD&BT15U.U\RS:1.&'ZU@Q$)%&P!9XV)/'K75O\ O8@J
MXQWKEYHI;2YEAQG=RM.#NK#@[Z,VH'-T"9@JL?N8/:F>=%$SQ%B .YK*0SM&
MIC?YAPP]*?;127M\SM]P ##<T^7[BW$SO$3E]/D\M04'5JX:O2O$\$<6@R!<
M9[XKS6NF@[QT/-Q;3GH%?1'A/_CUM_\ KFO\J^=Z^B/"?_'K;_\ 7-?Y5&)V
M1G1ZGH,7W!3Z9%]P4^N4Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKG_CTF
M_P!P_P JEJ*Y_P"/2;_</\J /CZ[_P"/V?\ ZZ-_.K&D78L=4AN2NX(2<?A5
M>[_X_9_^NC?SI]AY7VV/SL^7GG%>C/6#../Q(ZB#4I+Y9'NC)%',IVA4R#5?
M2<KJ!6TC)09#^9Q^-6)M=@MX8[6V@#," -XJ::VN$M?-\O#2?>9. /PKSNFU
MKG<4M0LX+R M=7301HW& ,M50PZ:L/[J_*<<J,<XZ5I7R:;9:9&+UC/.#P@;
MI6/:06EQ/(4B6)3@[7&3^%"E=>0RG(WFS17,\LKQE@#D<GZ"MRYTZ"ULC/!"
MI$@!^8X8?A1J_P!CMK>*&%-RB/<&]#60;HS &03NB@8PU+5I-#YF]"^/$,]F
MRQ1VL9.WYES4$6ML6DDDG>!&_P"62*#]:B6QGD/VI09%Q@[1C!IXTNXU5(V@
MM\,K$.<<4E%(>A>@N[!;B&46W+-]_G)^M;-QXH,CI;6D$8SP?-^6J4/A6?;_
M ,?<:,I[@FK-YH5O8::)-KW$X.<AL9_.FE!M7=R#FM6"Q7LCY!D8;BL?*Y^M
M9UK:7VHW@$<4CL1Z' KL+Y;&ZTR,16Q6]$>2B\8^M6M)U*WL-'92\2W.#\P7
MO0]%L4I:%*+P_=1Z2]M=*J9YS'\QI\OAN*';#/J;JLP! *J.E,.O:H+"/,.9
M)SM63;WJQ=6TZFTEU#]\ #N*#&W-.TD[-DF;-H]G8WL;6DL$K;L'S'Q5;5[=
MHH"7>'+,,J&Y%=%:Z3IVJ733&-A'&?D ."?>I[S2M,>-[DK\P8*26R/2I;5U
M?<=SF/#.FV\[3/+M:1&_=ASA6/UJS?V%Q'<R*"IDD( CC.[:*NV\5@]ZMHNX
M@/QY9Q^-;EQ_HS-*D*LRCE@.2/K1>TM0NSD_[*_L\PSF1WE5\E"H_P XKJA>
MZE+,L<5G#Y>W[S,013[40:E/'<E-H &5;KGWJW_9_P!FDEDAD=O,Y +9%$K=
M5J*YQGBV*Z1[=DA19)&V[U.>:K7'A[4YDMA<897&,CJ!6_JHWZQ9/<G]U%AF
M Z9Q5^?4YI;)[BUMF:1"%6,^E-72C9#N<\GA46[*OVQB>P !(J2'0/M!?RYI
MBQ^4^8@%7&#-MOB'BE88:,MG\JMV>M6HE$3AH\CEW;-$N9(+G,P>%[JYU:6R
MEQMC4$2=^::VC76@7<<CJ9564,2!GBMJ W%SXB>\AN,Q( "%/!'-;%\Y>S,C
M ,0P;%-RLT@N,35(M4MF^QL%GQ@1O\N:L16\EG;K)(BI(1F3:<\U@6=G<W5R
M]RX2W&/W3*,<_A4\&J36%P]MJ,ZRH6X8#[M3RI*T1$>K:/'/NO+<[0V/,7OQ
M3-)>QU"_*I&2T"[F+#&2*GUZ>Q-B+B.Z8<8548C)KGM >^BNPMN@(/\ K'*\
MD52O*#8R*_O5:6X=E)D5]JJ_ QFM'1-)\QVO6$9F49CC9N":=XA6,6$<,<2O
M.[DLP7G&:72=.D\Z)VE?9)'O4@XV\T/6-UH DL%]KUZ7E<0_9\86,Y KHX90
ML,8>;<RCGU-5]'TY-*CN-\QD:5LY)[9JVP@5LPH"PZDC-1)IOE6R!%73TN]D
MLSW/FQ[CM!QQ27%I#J40FFXB0Y.#S3H$8SOY2L(;A6'LI _QJ+P]!<QM<VER
MK; <!F[U3NKR$7=(>R:U*Q(NX$YW#G%&KV7]I6"Q02>45.59!7):G/=:=? V
MJDPY(+?6M7P_!=W+_:Y[T%$/^K&0 />AQY7SW'8L74=WI\'R7BE<#AV ^M07
M<D-WI:RM<X51AQGO6EJ.F0ZG"TC[LQJ2@4UQF1:V$WF#S2[$&(=5I+WE?J!U
M'AQ"-)E20 +NX(YS5V74K80R6HBD$J("&V<8SZUD^&;BYDM\>4?+'7/>KMSJ
M3N9(EL\8^\Y /%.UYNX%F2V6_GMY5<QF,?-ZU@W^FHVK1$Q*T#S'YRQ^4UM1
M620E[E9I#Y@Y4OG'%0ZC;$6R2J6$9 P3V/K1!V>C$:;D18MX5 4#MU%8T-S>
M7<D]E&SM(C$DR+C [8IVGSQI?K/<3GS9!MV$\>F:OWQD@N\QE$28;?, Y7ZU
M,4E[HS#C\,3'(FE.X\LQ.,UKV%O9VD/V9%,C-E<L*E3_ $6.&.^NM[/PK*#S
MDTZ2&6RO=SE!9%<EB.0?K3;<M&P*VF6UGI)D9YA'D\+_ 'OI5V=HW4RPA#+(
M,;CUQ5#3])AN+IKJ4NT"_P"K\QLYI;T&SEENQ&[1*!M13UHEK+?4$%_<FTTM
M@T2ON&PJ#P<U@:9>W-B[+):_Z+(>$;.%-;ICFU'2S/%MB).5609Q4EKIT5H#
MN9II'4;P[97\ :6D8M,9SGB+4%OX_(6-0T0P0AR!5+0M2%G#*^Q7DP5.?2K_
M (@\B"61+:W99&&XOGBL*!&BM<IM,DA._([=JEQ3C;H4GH2;3>ML50".5QU^
ME-CN&17A<EE[;NQ%6=/>.)2V=LD;<9[TR8/=7H8QJ@!R1CM2ZEIZ69,;N_N;
M1E67="B_ZL'M4"7%\O[B*,Q)*.1]*T+W^RK$PFTDE=G/[Q QJ*W0G5(_M!=(
M9.!SFJ6JV%<9!:?VBWDP#;+$O[W!Z^],EW1VY7S!*O(PW!7'I6KKVG/H%RMQ
M8LRPR+AF)SBJ4 A-_! [K)$1DNHQR:K>-^A.SN8ZC8,*6^<<YJ_!8S#0GOPP
M^]M4?C@U#=6H&M7%HK$1H2J9/6M/3;K<\>GE0;96^^.A-3&%G?Y_(N4M-#0T
M7P^OV6.\/RO+&!L'(^M2WEP+34M@?="PQY0'!-:6M7D^F:;$+-5 5MN"N>*N
M6EK;3>3+/$A(&0V.]4G]M[,QN9MOJ:QGR+E4B;^$9X^E1WUO)<0EY -B].>M
M7M<LX+EU9(1E>0_& ?>L^;42]JD&W#%3SCCBA*]G$.AP=R,7,@_VC4VF?\A6
MU_ZZK_.H;G/VF3/7=4VF?\A6U_ZZK_.O4^R>?U/I#PYT6NP7[M<?X<Z+78+]
MVO-.T6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY^^-G_(W
MV_\ U[#^9KZ!KY^^-G_(WV__ %[#^9K:A\9G5^$Y7PJ!]M8M]T#)KJ]99;C1
MYMOW0M<MX4*"XEWGMT_"NR6&&>V,>,(PY&:,1\5SHPUO9H\OT8.FI8 ;&3BO
M5-/3S+8#.,+]X^M</(EM8:X$C)*Y.?:NXM[A9;)?)&5/I4U7=IF\[[$]K;R6
MP8,VY2<BIV ,F5./:DCSY0P<_6HBY))W 8/I6;U=R-6R.^)2TVXR<<54@9A;
M!B3G&#5B_CEG5?+8#CFJUO&8X'!;))JEL6DK&E;(GDE@O(J 12RSD[R%/6G6
M4ZA&0G/:IRI$3>7]ZELQ)M.Q#Y+P6X6WP7W<D]ZD>,S6[;CAL<XJ/S9!P!\Q
MJVN1;DL/FH=P=T5[5$CCD!/S&F6P:+<6.<G@U,D:;]W/3'6E,81<#GO1<$]R
M0MNVEO7I5+4998D38, MTJR">O\ =I3-$^ Z@_6A.S$M'<CV,T09E )Z8J**
MW5%<-W[U=E=?+7C&*II,97=0OR^M--V'%MF7?QSP2QLLGR 8#>M1&]:VDC)4
M.7XSVJ^\99)H9/N#E">U4;6,7%N]JPS(K94UHK-:FMVE<LBSD>83P[?-'/)Q
MBKL[R*@W.J,HRP!JK#:N2AW,).C#-3ZG;!X\QR#S!@$5-]5<ERN]2#^T9)XE
M0ISV:M:QCCAM^2-S=:YQIGMD\L8+ \#%;5G"_EJY8X(Y!J9)= G%6&3P2&0^
M4V,TD%H\<3;Y-Q?C'I4DNXW:[6PB]34L?^MYZ8-%W8F[M8KVEM) =K.<5<50
M)B^><=*%[YS3EB\Q7;G..U)O6XI/J1R#"[@HY/:I%F6,+N(YJK;B5"^\Y7/>
MH[Z*4RPF,9C[FFE=V8TM;,GNH<QL4.,\U-IL+-'AVR!4<N3:E8^6 R15. 7D
M,9\J3YCSS0M58-91L:E_ 5B(CC!4]:Y_4EFF"^6C#(P..E='!<F6TS/PX&&K
M.E\O)+.V&/ !JH2LPI2:T*<EN8-.660GS$'5:K[UN8%"(A;TSTJW,VVTE@7)
M)Y&3DU3TVSB$1>7>F#UW52>C;-HZ)MB012PW>Y6'SC&":U+%P@DB=?WA.36>
ML,23^<+CY5)(#5-82SRZFPE"E2IVL!BB6J%4U1KP2;T8*.E4E^T>6[+&JONZ
MYZU94BV+*3UY%2$Y3)Z5GL8K34JW*7#60:-MI!RV#69-<RS*R[#@+CZUT0@6
M6U8$G!'K6/:I''(Z,V?FQS3C)6]"H2W*VF6<F_S]YP>Q[5MG!@(JD&6*9T4_
M*>P[4\3E&:-\;2,BE)MNXVW+4@ENH%B=7;&#4-G9B5OM1[\A:@%DEW>@[OW>
M<GFMF")81)\WRFFVHJR!V6PUHMMLRQ* :A4S&WV, 2.,YJ>1]D!*G-16<BDO
M'*",\AJ70F[*-K'(DIWL2-U6S*D5Z(BN0_7':E0)'/\ *P;GE:BN(,WV]6PV
M.13=F]2F[O48ZK'/Y*INR>XJ]#&;:?:"-I'3TJ":VF>$O'CS .*BTV>=Y2MR
MN'48SCK2M>-T3+5:%FY7?<(YD*[>P[U#>78Z%#*IX*XZ5?FC0Q;B.<\&J$RR
M%"(U <]Z(M:!%ZHO6T0DM% !1>N,5#:L@NFC+8*GI2)<-;VXW9SW%-EV,Z>4
MN'89S2[BL[LDO;M8IU4_Q4DB^>F%'..*BVM+,XEBY7A2:M!UA09[4[6L/9%9
MK:0A<XW8P>:LQ!H0(PU3>8C8P1D=:@E8JP('>EJR=RI]HEAG=[K 4-\IS3KM
M)I7$D!R& [U-=0I(P$JY4\XH24,0L0^[VIWZHM/:2)K?>D(1NU9?B#A(2"=Q
M.!Q6AYP!R3BJ&K[9C!@Y"G)Q3A\:9*3<A8K<Q6"9.YF'4\8K+A-Y#>?NPI13
MPN:MZI=SQ^0(U 4#)!'2K>F6K'=/)RSCCTJE>,;OJ:IVC=F?XD<MX=9G4ASU
MKS:O2?%<C#1W0#(/Z5YM71A_A/*Q/QA7T1X3_P"/6W_ZYK_*OG>OHCPG_P >
MMO\ ]<U_E48G9$T>IZ#%]P4^F1?<%/KE.@**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ J*Y_P"/2;_</\JEJ*Y_X])O]P_RH ^/KO\ X_9_^NC?SHM7,=RC@ X.
M>:+O_C]G_P"NC?SJ., N Q('M7HS^!G'#XT;NHR27TL-PL,9^8#@\UM_:V>?
MREP\GDJJQ=LUAZ6+F:?S!"7C7E0#CFIXXKSSFEB(CN-Q(!&:\M;6/1<695WI
M=V+H2RX9Y#DQJ<D&MV**RCMEF>!7N  I1N/:J9L;MKIIKF< *<DJ<&K^G0Z9
M+>21,92V Q=I.]/FOJ^G8&K"/ISQ:C;-JB!X77]W&O(7FMXV]C#;D6UJGF#E
M0?6HY+J>69E81R1 XB.WD?C39()XPLBMD@\TF[V(($N[F]C2W\OR[B*0$[1\
MI]LU45+R"Z$45W"-I9F <<Y[4_4YI+2-I;=MC2\,".A]:R8;BVCN%G:*1F .
M?GZDBMH4I27-%:&<JT(.TF:L=TL=I*L4@^U?>^<X'X5*MW=:Q9-!+#&/+P=R
ML3FN=$[_ &HR_*4#952.U;:>((8U4):E2.N"!FJ>'JK9$_6*7<?_ &A8[5MU
MCD$A/ER,5^:I[W3].L[+RT<AG8%5 ]ZR+W48;BZ%Q# 8Y#]_)X/_ ->JS79E
MD#3;F Z8/--8>IIH'UBEW-F]>>UGLEEE5(RPV '[OO6QO33XDEN+D.C=7?'>
MN5FOH)(U_=.TJ]&=L@5->:G:7MFL$MO+D8/W^.*3PTVE=!]9I=RS(\]MK+W&
MGL95D&XJ.F*GB@>2QG5("$9PTADR/RK-TO54L+QYI(F="FQ5!Q@4\ZQ&4,>R
M;R^2!O[TW0J]@^LTNY+*+F22.338'B6,8)5>M6HKRZ"1_:;IT\Q@!O !J%?$
MIBMXXXH=K*,,>QJ-]>BFVB:U#[3GG%)4*G6(?6:7<Z0Q)=P-;1ET./\ 6 51
M743 K:9:O)--&#ND8?=K(N?$,I9&M%,14Y.XY!J+3=7CLY+F:6%I)ISDL&P!
MQ0L/5Y7=!]8I=QMVUQ'+YC32'G@L.]=/;-J,2.69)-ZYC7/M7-76LBZEMF>$
M;(6W%<#GBKC^)P]RK^0PC4850<4I4*K2]T/K%+N7TLY;Z)WD)BGR00O./I7-
MSZ(]C<1VMQ*S>>WWAU%;!\3Q*CB*V=6;N6%9FIZO)?S6TR+LDA[GD'FJC1K7
MVT#ZQ2[FJ=-FT&U:XLG\Q0 &$AQ6E-+<7>C*T:1F9Q\RD\5S5_KU[=P- I1(
MV4!OEYSZU+I^MK9V:0R1O(ZC!;=UJ'AZS2;6H?6*7<W+%(;.)$NY%7'S!2>A
MK-U&XB$<]VFG*_RD>9S@^]5+S6(+K$GV=A,!@$MQ^516VK>1<9=&>WV[?*SQ
M5+#U-V@^LTNY)X3T^"[G>:ZR&3YEB/O74Z6VFBYNH5*1OYF"I^E<E>:L9+B.
M>SC$$B<>Q%1Z;J/V;47N[Q/.+=D^6F\/4E=M!]8I=S:O=-EMKZ8QW#[7(PS
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M[C4KRRCF=2<DCD@&O)Z]C^'UI]N\"7%OY@CWEAN;H.35XAM4W8C#).HKF?\
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M*?NA5[[2'TT0,O*9*D51I0"L<DH/W<#'KFN/,/X2]3LR[^*_0WK>-)_#$P6
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M4^D/#G1:[!?NUQ_ASHM=@OW:\T[1:*** "BBB@ HHHH **** "BBB@ HHHH
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M/ O]JZ1=W-XD\<BIF(;>M<?>:9>6/-S;21*3@%UQFO8/!/BG4=2T"\EG\C=
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MSHM=@OW:\T[1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?9'E(_-;?*^\G-;5E!';W2_.22.YJ9VW)GU,WQ>!%H;1)P!7F%>D>,VE^PN
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MET+12;E_O#\Z-R_WA^=;F M%)N7^\/SHW+_>'YT +12;E_O#\Z-R_P!X?G0
MM%)N7^\/SHW+_>'YT +12;E_O#\Z-R_WA^= "T4FY?[P_.C<O]X?G0 M%)N7
M^\/SHW+_ 'A^= "T4FY?[P_.C<O]X?G0 M%)N7^\/SHW+_>'YT +12;E_O#\
MZ-R_WA^= #D8HZNIPRG(-:&JZY?ZR83>SM*8EVKN/:LW<O\ >'YT;E_O#\Z5
MDQIM;"T4FY?[P_.C<O\ >'YTQ"T4FY?[P_.C<O\ >'YT +12;E_O#\Z-R_WA
M^= "T4FY?[P_.C<O]X?G0 M%)N7^\/SHW+_>'YT +12;E_O#\Z-R_P!X?G0
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M<K16HNC/Y;LQ<;3CA":E707='99#A "=RXZT_:P[A[*?8QJ*Z:#PGY\2R"Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\_?&S_D;[?\ Z]A_,U] U\_?&S_D;[?_
M *]A_,UM0^,SJ_">:445WFF^&M,N--MYI(6+N@+'<>M=4ZB@KLYXQ<MC@Z*]
M&_X132?^>#?]]FC_ (132?\ G@W_ 'V:CZQ$OV,CSFBO1_\ A%-)_P">#?\
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MI!JO,</M28HXJZ)"T05CSCJ.])W(?,A(-R+G<.>U2/=%!@KS5=H&)!#&AHF
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M=2($KR.[_P"/R?\ ZZ-_.O7*\CN_^/R?_KHW\ZZL-NSGK]"&OHCPG_QZV_\
MUS7^5?.]?1'A/_CUM_\ KFO\JK$[(FCU/08ON"GTR+[@I]<IT!1110 4444
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M2&1 R@9!^M1WD2[]C,61AQ[41GRT\N1 1CY235:)S(?*SDJ,\]JR6YJ]!]M
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M7DEW_P ?D_\ UT;^==6&W9SU^A#7T1X3_P"/6W_ZYK_*OG>OHCPG_P >MO\
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M7^55B=D31ZGH,7W!3Z9%]P4^N4Z HHHH **** "BBB@ HHHH **** "BBB@
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M ,>DW^X?Y5+45S_QZ3?[A_E0!\?7?_'[/_UT;^=>H>%_^0+#7E]W_P ?L_\
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M+L ^YTKK%$I5B.'7CFJ"Z[=I#]F*AIL[0V.@'K6E%J$C&%3<#@_/O.#6?<M
M=;&T@QL.6'0'ZTUKI) 1M;7EY S&[_>;M^1G%21V]Y#82,D*S2=<N,U!+/=V
M]W(((0R(O!]:GBO[F&P:X* ,<@H:4KVL",G[1+&'EEGB7S$VJ@3&TU1LY8'M
M&CD,BMN):0-QUXJVLEK>N7G&U5&6V\Y-)L%S:[+94C"Y^3/4]J4K(M;$(MXX
M;B-OWCJZ\?-U-22V6RQ%WLDW,V#\W3FBW5S:-)<S R0\;"?TIJZ@]Q#)&R@1
M=D]*3?4$B_;7%JT ABMF>3&YV+#/YU%$\VGV]Q%(24D1MHSTXJGIUM+>.\$
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MHPIA[Y%2J\!YW#WYH\R,J=A##V-22,<(Q98B&(ZBJ[;C%L973WW5.L95&=5
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MTI_G[D?=D9.0A_B^GI3A;QQ*O[[RG/4+T-27$T,QAQ$=\(P<#Y6'UI*T@U1
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M4,0R.3TQVJG%IB75F9+)&"R)G!':E;34I-6%3RH;^)[I"L,PX(YQ3Y9+>TU
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MI-2.?$SE"*<3JO\ A<6H?\^J_D*/^%Q:A_SZK^0KS*BNSV%/L<7UBIW/3?\
MA<6H?\^J_D*/^%Q:A_SZK^0KS*BCV%/L'UBIW/3?^%Q:A_SZK^0H_P"%Q:A_
MSZK^0KS*BCV%/L'UBIW/3?\ A<6H?\^J_D*/^%Q:A_SZK^0KS*BCV%/L'UBI
MW/3?^%Q:A_SZK^0H_P"%Q:A_SZK^0KS*BCV%/L'UBIW/3?\ A<6H?\^J_D*/
M^%Q:A_SZK^0KS*BCV%/L'UBIW/3?^%Q:A_SZK^0H_P"%Q:A_SZK^0KS*BCV%
M/L'UBIW/3?\ A<6H?\^J_D*/^%Q:A_SZK^0KS*BCV%/L'UBIW/3?^%Q:A_SZ
MK^0H_P"%Q:A_SZK^0KS*BCV%/L'UBIW/3?\ A<6H?\^J_D*/^%Q:A_SZK^0K
MS*BCV%/L'UBIW/3?^%Q:A_SZK^0H_P"%Q:A_SZK^0KS*BCV%/L'UBIW/3?\
MA<6H?\^J_D*/^%Q:A_SZK^0KS*BCV%/L'UBIW/3?^%Q:A_SZK^0H_P"%Q:A_
MSZK^0KS*BCV%/L'UBIW/3?\ A<6H?\^J_D*/^%Q:A_SZK^0KS*BCV%/L'UBI
MW/3?^%Q:A_SZK^0H_P"%Q:A_SZK^0KS*BCV%/L'UBIW/3?\ A<6H?\^J_D*/
M^%Q:A_SZK^0KS*BCV%/L'UBIW/3?^%Q:A_SZK^0H_P"%Q:A_SZK^0KS*BCV%
M/L'UBIW/3?\ A<6H?\^J_D*/^%Q:A_SZK^0KS*BCV%/L'UBIW/3?^%Q:A_SZ
MK^0H_P"%Q:A_SZK^0KS*BCV%/L'UBIW/3?\ A<6H?\^J_D*/^%Q:A_SZK^0K
MS*BCV%/L'UBIW/3?^%Q:A_SZK^0H_P"%Q:A_SZK^0KS*BCV%/L'UBIW/3?\
MA<6H?\^J_D*/^%Q:A_SZK^0KS*BCV%/L'UBIW-3Q!K4FOZL]_*@5F4# ]JAT
MK5;K1[Z.[M)"CH<XSP?K5&BM>56L9\SO<^C_  AXPM?$UBI#!+I!AXR?UKIZ
M^5])U6ZT>_CN[21DD0]CUKZ!\(>,+7Q-8KAE2[4?O(\_J/:O/KT.35;'H4*_
M.K/<Z>BBBN8Z0HHHH **** "OG[XV?\ (WV__7L/YFOH&OG[XV?\C?;_ /7L
M/YFMJ'QF=7X3S2NWLO.:PM0@XV#-<17?:8SC2[<DX78*VQ&R'A':3+6WY<8P
M<4Q(Y ,<$9IV"^&W#;3N",$8Q7)<[+B;,#YFI@6&-CLSSUR:?M3J3^50FWC\
MWS=YX[4(:MU$$X>9HSD+V-656,>IJLEU$^55>AH%ZA+*JA2*;3&T^B)+DS%,
M0D4L*D1#SCEO:HTGBEE,0SQWJ<$*F"*'M8EZ*PPI!'+YF">W6B2X=AMB SVX
MIC/$XVD=^34J.L+9"_*1U%(&01L=^V=P'] *LEU^Z?P(%4I(8_MAG)8DGI5E
MKI ,;!Q3?D4UV'B7Y<')%-\S@E(\CWIBW <=!FI5#&(HN#GDFD2U8:)6VY)
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M_P!>W^->-_M"1,FLZ7<G_5EA@_0"O4?#^OZ=:_"^TOY;A%@2VY)/?GBLXO\
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MUD&9"Y]/2MM]5\E?)BB+L5RNRJ=D?M+F&[$:[_XEZCV-.#:38RVMKY[03V9
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MSEQ:;BK'%45K_P#"+:[_ - NY_[XH_X1;7?^@7<_]\5W<T>YP<LNQD45K_\
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M[XH_X1;7?^@7<_\ ?%'-'N'++L9%%:__  BVN_\ 0+N?^^*/^$6UW_H%W/\
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MOYC[_6FI>7T,TI4FXCS\N.:3U^$"S%I44%QN\YE7&,%^M5]6O;.2(6C[FWL
M?D)'YTV2ZDN%CFG@QY+;F4CG%2W%Q:7%@/+0  \$]%HL[IL M])2RLV6TCP3
MTRV:CE>W>R:*4J)E'\0QS4UK>/:V*[SYS;N-OI4\NG07P+W,$9S]TD<BD][R
M PHI0L23;U,B-CKC-:T5Q 9Q,9(BNTG: ,YK!,-I%JDFF3*'<C=&3VS4.F:0
M1+<-)(T:12!EJW%;M@=9</'>VH12Z,YXX-9K7=E8(MFS%Y@.A& :>VN);QH
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MXOY4>5'_ '%_*GT4 ,\J/^XOY4>5'_<7\J?10 SRH_[B_E1Y4?\ <7\J?10
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M2<%@8A[<U9EN01P=V*I"Y=G(V<#O0MM@BG8A-B9Y_-:7+#^$<5#=6UW&[-$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/HH H#<IY&&%6XI?,'N.M,GCXW#\:A1RAR* +M%(K!E##O2T %%%% !1110
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M\TZG<Q^X>QICF816ZRX6-VZ_CQ^=37,+22R"RA69D.&W#.#[4TDR+L?/&EC
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MNJ6%SI^6R<?P]\TN5K1; 5S#)?7<L\/,; +\_&,=>*J2N+743;V<Q0!?F(Y
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MSZ0\.=%KL%^[7'^'.BUV"_=KS#M%HHHH **** "BBB@ HHHH **** "BBB@
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MWI%C6-C@$L>QI0H9_F*@BGDHHR9.>U 7 6TCY:0J@'2H9/)7*Y8GUQ2R3ON
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MU]Z@L582R2#IVJ:ZN'7:$.&/<T-6=D&ST#SMHVK$?;BHY3<2$1[3@^U/#2L
M?,0GOMJ1781[F=FV_P!TTD%[="*2RD\Q2&VY'(I]O:1P9=WRW7%.M;I+EG&2
M2#QNJ1X\/DX--M[,F[(3%;33?/#\W7-(UG:*[.J88#K4TD@0#@<\9/:HG94B
M+%PP]J+L:WT*XE>4$1?.JG!)&"*%N)1)MSL'J1UJ1&/"Q1_>&<^]1Q6UQ/,1
M-&2GO3T+Y59E[>" N<@^]&$B7=Z5$(H[(#S9/E[9/2EDEAGCQ$P('>I(]!][
M(/L(8*6R> !0J%HE^8+P.,U&I$JA1*/E_A%/DVOCY<$=Z.EA)-:%>>W$?S*<
MGTHM)EN7(,>TKWQ4H21#P Z^_6FF1EN%58MB$<D=Z?0J]T6R(RK$G<PKS6X_
MX^9?]\_SKT#E)3M[UY_<?\?,O^^?YUT8=:LX\4K)$5?1'A/_ (];?_KFO\J^
M=Z^B/"?_ !ZV_P#US7^5&)V1C1ZGH,7W!3Z9%]P4^N4Z"DQ58@3U)P*;4A3?
M#G^Z<U'0 5=C7:@ JBP)4@9S[5?7[H^E "T444 %%%% $4R%D)4?,.E5/T(K
M0JM/&0VX=#UH EADWIUY'6I*HJY0[@,U=5@ZA@<@T +1110 4A( R:CDF6/(
M'S,.PJNSLYRQX]!0!+)/QA/SJ#G)).2>M%% $T$H!V'OTJS6>1GN1]*NQ2"1
M<CJ.M #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "HKG_CTF_P!P_P J
MEJ*Y_P"/2;_</\J /CZ[_P"/V?\ ZZ-_.NN\/PM?6<<(F)$;9_W:Y&[_ ./V
M?_KHW\ZLZ#>S6]TT:2-&2>N>*Z\2FX71ST?B.[U:R:&V\V.:3S.Y ZU/!++-
MID1VDYX<G@_E4:ZPDEHD9(DE(PV.U3PW"BU$C.I,;'A:X+OE5SJ*:!K(,[H!
M"HP45LGZT^WO96C?RX%2$<A@<DU9GO+-8#-,%"R#:6QUS5"PCNX9YE5#):N
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MU4Y 'UHLKFRCGDVLZ[SR&'%5YII++SF$( Z D?K3Q8PW"1,S%QURAQ19)>3
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MJQWX;'TK/:V\Z3RTD4Q@_*#C -&IK)]H9A\S  ;DZ?C5>VNWCCDBN8E54_>
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MSZ0\.=%KL%^[7'^'.BUV"_=KS#M%HHHH **** "BBB@ HHHH **** "BBB@
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MX"X/L*?$H5R[INR.E%]-2FW;4: NY650 3@X[U8G(B Y_"H047<6'S=E':H
MP9]SDLW8>E(BS;T)2GVB-@R':#T]:J,82C(L;+M]<U<#R+(KE]B=,&HS;EI&
MD+A@>PIIV*6FA44715)8I2V!@J1BK4%U,S8(Y'6I(,,&PI0KT]Z'GA7&[Y7/
M<=Z&[O8&];-$=S$MS(ID).WM49A54*1@@&IH9I K&6(')^4 <FGRSLCJHA^]
M[=*>NP1>I6M;1T<G.![U9E$G\)&*00.LWF.[<]%S44YE5PI*C<> 12W8W*[N
M31LP3#MDTY8S&5<D[?2H_.B$BQ8._P!>U/;>\3H6Y7D4$R&B:2>=HU4C!P3B
MO/[CBZE'^V?YUZ!;7+&,!QMD(Y]Z\_N?^/J;_?/\ZZ,/HVCEQ>R(J^B/"?\
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M!%<&VS^\ZF2K/9VEC_IL#*JMM( )YJLNLZ7%N\F>="?^F=.\03)+H@P#N60
MYZUR-=U"A&I'F9PU\1.G/E1TG]N6HD#EG=EZ,5Q1<^(DE*LH.5Z+C@US=%;_
M %2F8_6ZAMR:VEXZM<1"/R^5V<Y-:*ZWI9F65FE#!0#A*Y.BD\'3Z!];J'5W
MFM:7<J-K2JZG(8)5.YU:RFA*^67? PS#I6!10L)37</K=0ZBPUVR2SCCNBXD
MCZ,J9S4[>);,,,;F'<E*Y"BCZG3O</K=0Z.?6K5KYGA>189(]K?+T.>M-O\
M4[">QV1/)YXZ'9C-<]13^JPNF'UNH;.CZE#ITK.99/WBX88S@^M7+C6;.ZC0
M32RL4;(&W&>:YJBAX6%[A];J'4)JNC2NSW*R<\!0IQ3UU?1K=R]NL@/NIKE*
M*7U2'=A];J';Q^*=/Q^]:1@1@CRZJ2^(;.*Y$MJ\FP_>C*8%<G10L'30?6ZA
MU,'B:$3RM(A5,?*!SGZU+/XCL%V/;HV[/S*5P/K7(T4?5*8?6ZALWNH6NH72
M[VDAA!R2@Y-3W>JVD5NB64DC[6!V.F!QWS7/T57U:&GD'URH=9!X@LD*RM+*
M)&7#@)D42:_8O)$XEE&SJ-G6N3HJ?JE.]P^MU#MSXIT_R"H>4/Z^75%->LG6
M4R-)'(WW75,D5RU%"P=-!];J'76'B2U@#BXEED_NDQUFG4+*YU9[BZ>3R.JH
M%K#HIK"TTVUU#ZW4.TB\3Z;&P4(RH..$JMJ/B2UN)H(X%;R%;+DKS7*45*P=
M-.X?6ZAV/_"4V<**L2O)C^\,8I\?BZT')A*L?05Q=%'U.D'UNH=9<^([&] ,
MR,&5@5POO6?X@O-,U1-\#2+,#N!V8R:PZ*:PE---#6,J+8UH]22?2_LUTS(Z
M_=*#-0_;(EA51N+ 8W=#6?14/ TGW*6/JKL;<FI6?]FBV0,7)!+$53$EGM8%
MG+.,$XZ50HH6!I+N'UZKY&G9:@EO=1W1!\P<,N."*V]0\5PR>2+9"1G]X&7'
M&*Y&BK>#I-W9/URIY&O:7-@+EY+J25LMN4A?N^U%UJ5M)>^=$A&.CXY/X5D4
M4G@Z;=V-8ZJNQH17-O'(SG+$C'(]:>EQ9A74LXR/E(7H:S**7U&DG?4;Q]5]
MC4N;V#8%AD=P2"RLN,8JR=7MKR)8[H-$J#"^6,YK"HI_4J?F+Z[5\B_)=1/(
MH#-MZ$XY^M/N9[20I(DD@=!@#;UK-HH^IT_,/KM7R-RQU:VBMIQ.G[YQA6 S
M5&">",32.[F1^B[>!5&BA8*DKV!XVJS?T_5-/C(>[B+.!@8&:9>:T'O5ELW:
M%%]!UK#HIK!TT[B^N5#IF\6RC:BPJ0."Y/-/M?$5M#&Z$.NXDE@,\URU%+ZG
M2M8/KE0W(-=\F>67&XLV0"*RKB^NGO!<PRE"&SL'2H**I86FG</KE3R.A7Q;
M.RL&LXD8C&\-DBH+?5HQ:R1S%O,W95A[GFL6BDL)36P?7*AO_;M/^RR0O<3R
M!VSRG2M"V\1:=:6FR)7+J/E!7BN0HH>$IO=L/KE0U[KQ!>W(8B<QAC_JP!C'
MUJUHL$E[-#Y<2A4.7DW<USU;UAJ36FG)'" ';.2!S7-BJ,:4+P.G"UYU9N+.
MBU#7&BD-M!&KD#!8G@5RLL%Y=K<EF_=JI8DCVJ5"[RN96V@\EC3I&E>TG0,W
MEJAY7C/%>?&_-9'>TE$XRK>F?\A6U_ZZK_.JE6],_P"0K:_]=5_G7N/8\I;G
MTAX<Z+78+]VN/\.=%KL%^[7F':+1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5\_?&S_D;[?_ *]A_,U] U\_?&S_ )&^W_Z]A_,UM0^,SJ_"
M>:5Z#I?S:7;@GCRQ7GU>@Z:/^)5;9R/W8K7$;(6&^)DIM_FSOP*%15;J32L&
MV$ @>F:CC\SHY!/; KE.[6P7:R !DP<]J>CLL:YCYILJ$O\ +)RHY%-!FFB_
M=JP(XYIVT"ZLD2,[R'@;:0@(-S-TI466./$@YIC;2"&%(!B2F9SL^Z*IZA)+
M8^7(AY8XJ13OD_=95 .<=ZI:L93''OSLR=M:THIS29GB9N-)RCH2-XAE:+9Y
M"9]<U VK%\>9 K8]ZS:*[E0IKH>.L566TC777710%@08]ZC?67D/,*_G6911
M["GV'];K?S&BNK.OW8E'.>M6#XAE,6PP+]<UC44>PI]A/%5G]HTUUEUZ0K^=
M2+KLBC!A4_C6111["GV#ZW6_F-8ZXV<_9U_[Z-*->D QY"_G6111["GV'];K
M?S&Y'XDDC!'V5#]6JI%JODLY6W7#')&XUG44_84^POK5;^8U6UMVCV>0H'UJ
M2/Q!*A!:!6QTR:QJ*7L*?8/K5;N;4GB*61]Q@7_OJHFUIW.6A4_C6511]7I]
M@6*K+[1J+K<R-E4 'IFIHO$4L1/[A#GWK%HH^KT^P/%5GNS?/BB0C!M8_P#O
MJJ;:S*9-XC ]LUF44+#TUL@6)JK9E^7599,'8 :<FKRKC,8./>LZBG["GV']
M;K?S&F^L,5PD*H?4&ECUN9!\T:L?4FLNBE["GV%]:K?S&J=;D.?W*\^],35F
M1B1 O/O6;11["GV']<K?S&J=:<C'D*/QIJ:U+&<J@'/(SUK,HI^PI]A?6JW<
MVF\12M'L,"8^M0IK)3!%LF[UW&LNBE["GV#ZU6[FJ=9#<M:J3_O&GKKQ7I:I
M_P!]&L>BCV%/L'UFKW+TVIRRME5V#/0&I?[8?R3&85.>ISUK,HI^QI]A_6ZW
M\QHVVJM;,2L*G/\ M4Z767D??Y*ANWS5F44>QA>]@>+K-W<C1M]5> DF(.Q[
MDU))K<DI4O"I"G.,UE44>QIWO87UJM_,:XUP@8%L@_X$::=:9CEH%)^M95%+
MV%/L/ZW6_F-8:[+D'REX]Z!KC+(9!;IN/7YC6311["GV%]:K=S6_MQRV3 N?
MK2-K<C$?N5'_  *LJBCZO3[!]:K?S&NFNLBD?9T.?5C3AX@9?NVJ _[QK&HH
M^KT^P?6JW\QK'793)N,2D>F:!KC \6Z_]]&LFBCV%/L'UJM_,:[:_*RE?)49
M]ZU[9_\ 1O/"!F(& :Y&NKT\,L*NQVC:, US8FG""5D=F#K3FWSNY8BDDE3+
MQ!3[4/*P'SD "A9)9.@P/:F-:M(?F; ]ZY-#T%:XN5E_>(VYE'%4YFEFE1U'
MW3TJU(L=I:.(N6 X%1V=R!; RJ V>XJEHKH%Y$H+R$?)@]SBBY&V+.<GT%++
M)(R97@>U%N68?,N:2[CMI<KM-"5PB'@9R:X2?_7R?[Q_G7H%PB,<+@<<\5Y_
M/_Q\2?[Q_G73A^IQXK9$=?1'A/\ X];?_KFO\J^=Z^B/"?\ QZV__7-?Y48G
M9&-'J>@Q?<%/ID7W!3ZY3H(H/N56)!8D>M68/N57==CD4 %OG[4?3;5VJ]MM
M.YAU!P:L4 %%%% !1110 4444 %5)FS(1CI5NJ<K;G- #**** "BBB@ J:UR
M=^1T/!J'KQ5R%2D2JW4#F@!Q&1@U2=2CE3^%7J@N(]PW@X(_E0! "5.1UJZK
M!E!'>J-202;7VD\'^= %NBBB@ HHHH **** "BBB@ HHI"0HR3B@!:K23D\)
M^=-DF+G"GY?YU'0 5%<_\>LO^X?Y5+45S_QZR_[A_E0!\FW?_'Y/_P!=&_G7
M2P/:W.BPQR2*DB$X#\9KFKO_ (_)_P#KHW\Z[?1-/L[[2(I)H1N4D D5TXJW
M*FS"A\1AP1107<UFK(T,J%T*G.TBK>C:Q);VLEBS!F1B00<GK47B'2DM)HS;
MDIO/53C K+NX/[*\JZ25=Q(XQRU<.C^9U&]JNJ2WMIY1BVHK#GU/O6)6SJ,H
M;3H_*3,<A#LWH?2L:O4P;3I:'EXO^(%%%>A?#KP]IFJ07ESJ*,ZQ+D '&,5T
MRDHQ<F<\(N3LCSVBO5S=_#L$C:W'^U_]:O.]>?3Y-6E;2U9;7C:&.:F%3F=K
M%SI\JO<S**[WX>^#X=;E>]U '[)'P!TR:S?B#I-IH_B5[>R4K%L4@$^HH]HN
M?DZ@J4G#G.4HHHK0R"BE568X4$GT IPBD;.V-SCKA: &44NUMVW:=WICFG-%
M(@RR,H]QB@8RBBI/(FQGRGQZ[30(CHH[XI_E29 \MLGIQUH :JL[!5!)/0"E
M='C8JZE6'4$5N^#X,^+M.CFBRIDY5UZ\&KGQ$BCA\7W21(J+QPHP.@J'.TE'
MN:1IW@Y=CE**<4=0"RL >A(I5BD?[B,WT&:LS&44K*RG#*0?0B@*6.%!)] *
M !5+'"@DGL*&1D8JZE6'4&NA\&VV[Q78I/"2A8Y#KP>*T?B7;PVWB=EAB2-2
M#D*,5FYVFH]S14[P<NQQE/:*1%5G1E##()'6G6X!NH01D%Q_.O4?B)8V\/A/
M36@MD5R5&47GO1.?*TNX0AS)OL>4T4]HI$&6C91[C%-568X523Z 5H0)13Q%
M(PR(W('HIKJ_#;>'U\/:@-45C>'/E8],?2IE+E5RHQYG8Y&BG/M\QM@.W)V_
M2G>3*!DQN!ZE35+4D1XWC +HRYZ9'6F5Z-\2+6"#2M$:*%(V:'YBJXSP*\[6
M-W^XC-]!FHA/F5RZD.1V&T5)Y$P_Y9/_ -\FNH\%MH*2W7]M*WW/D[\Y^E.3
MLKDQC=V.3HJ:=5>[E$"DIO.T =LTP12MG;&YQUPIIW$U9C**4@@X((/H:549
MSA%+'V&:8AM%2>1-_P \G_[Y-,((.",&@8E3QV=S+&9(X)'0=6"Y J?1[07N
MK6L#*Q2255; [$UZKXD\16OA*>/2;72$>,1 N^P'=D5G4FXM)*[9I3IJ2;;L
MD>.4\0R-&9 C%!U;' KMK^Z\-7/A'S%B*:D[9*J,8//M6AH5M _PHU"5H4,@
M=L.5YZBDZMHMM%1H\TE%/<\VHJ0PRXSY3X]=IJ.M3$**?Y,N<>6^?3:::RLI
MPRD'T(H 2BGB&4C(B<CU"FFD$'!&#[T )13EC=_N(S?09I=A1P)%8#/((Q0(
M9177:ZWA\^%; :>K"^&/-S]/I7)JCN<*K-]!FIC*Y4HV&T4YHW3[Z,OU&*;5
M$A73:# &@5C%OSZ]JYFO1/"T*MH<+8Y)/\ZXL>KTUZG9@G:H_0BFT.UG1FD+
M*6Y( JQ-9Q6^B3K&N (FZCV-;!0 8Q5341_Q++K_ *XM_*O-CT1Z;;:/%:MZ
M9_R%;7_KJO\ .JE6],_Y"MK_ -=5_G7L/8\Y;GTAX<Z+78+]VN/\.=%KL%^[
M7F':+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\_?&S_D;[
M?_KV'\S7T#7S]\;/^1OM_P#KV'\S6U#XS.K\)YI7>Z:KG3+;'38*X*N\TW<=
M+@"G'[L5MB-D+"_$RZHP3NYQ2(0X; *]@<4V(-CYB,U(1GA:Y#M8GF!?ER"Q
MZFG,YSM#X(YJNMKB3?N/7N:L>3N;C\Z'8'9$(F+L5,I9AZBGEP1C&:LK9Q*=
MV/F/4TTVT0DW;^?K1="YHE8;8^ O7L*Q]9C9(HR3\I<D5O++"MQY88$]\BLO
MQ*RF* */XC_*MJ'\1'/BF_9,YVBBBO3/%"BO5]!T/PU:^"[75M6C;,H&YMW?
MGVJ"ZN_A^;601*QDVG;AN_Y5BZVK26QNJ.B;=KGE]%=!X;\+W'B6]=(76*!.
M6D?H*[;7_".@Z=X(N+FQ8S31D*9=V?FS@U4ZL8NS)A1E/8\IHHHK0R"BBE",
MP)52<=<"@!**>(I"NX1N5]=II%1W.%5F/H!0,;12LC(<,I4^A&*[+16\-#PM
M<"^5C?D':??G':IE+E5RHQYG8X](I) Q1&8*,D@=*97JGPTLK:X\/:BTT$<C
M<C++GTKS&Z %Y, , 2, /QJ8SO-Q[#<+04NY#3S%(J!V1@IZ$CBE6&4X/E/M
MSUVFO2_$UG;Q_#&SF2"-9=ZC<%YZTYSY;>;%"'-<\PHHIP1BNX*<>N*L@;13
M_)EV[O+?'KM-,H **<L;O]Q&;Z#-#1NGWT9?J,4#&T4JJS?=4GZ"G"*0KN$;
ME?7;0 RBNI\/>#I=<TR[N_.$7DKE0RGFN9DB>,D,C#G'(Q4J2;L-Q:5QE%/$
M,K#*QN1ZA332"IPP(/H:H0[RI/*\S8VS^]CBF5Z-';P?\*<:;RD\WSC\^.?O
M5YS4J5VUV=BI1Y4GW"IWL[E(A*\$BQGHQ7BNH^'FC1ZIXBC-P@>",$E2O!XK
MH/$_BZU2?4-%ETE1;*3$KJ@&/<&IE-J2BD5"FG'F;L>84]HI$179&"MT)'!K
MJO&#:"T%A_8X(?9^]XQS@>U;/BNUB7X<Z!)'"HD<+EE7D\&CGT3MN[![/5J^
MRN><T4]HI$&6C91ZD8IJJS'"@D^@%:&8E%/$,IZ1N<>BFFX.<8.?2@!**D,$
MH&3$X'KM-1T %%/6&5AE8W(]0IJ2U$2W<8N5;RPWS@<'% $%%=3XT;0VFL_[
M&! \H^;QCGCVKF5BD<96-F'L,U,975QRCRNPRBE*E3A@0?0BDJB0KK()&%I'
MYI &T8 -<G73QVQ>&(EOX!7)B]D>CEUN:1:%Q&V !2O= ML7&[T)J.2 11 H
MIW$]34,DD<3*[QGSJX4CT_=99;:!LE^^1P!5-V"G!E8<]"M*GFRR><QRWH.U
M2W%LS%905([C%-;AHA(YSN*!@RCCGBIVN3&,LF !VYJ&.U@<Y+$>U2D;,*C
MCT;FDTK@RM%?F:1D2+;ZDUPT_P#Q\R_[Y_G7H3.%5F$0#CVKSV<YN)#_ +9_
MG73A]W8Y,5LF1U]$>$_^/6W_ .N:_P J^=Z^B/"?_'K;_P#7-?Y48G9&-'J>
M@Q?<%/ID7W!3ZY3H(H/N5!-GSVSTP,5/!]RH[K QC[Q'% #K5"B,3_$<U/4=
MN6-NA;[V.:DH **** "BBB@ HHHH 0]*I-]XXJQ=$BV<CKBJPZ"@ HHHH **
M** '1@&10>]7:JVZ@OD]15J@ HHHH IRIL?V/2F5;F3?&0.O8U4H M0R;UP>
MHJ6J<;^6V<9JV"",CH: %HHHH **** "BBHY)1&#QD^E #G=4'-5)6,DF3T'
M04W+,=S')HH **** "HKG_CUE_W#_*I:BN?^/67_ '#_ "H ^3;O_C\G_P"N
MC?SKM=-FG.D0"V#!XSN.1PU<5=_\?D__ %T;^==MHMQ=+IT6%5$'3<N=U=>(
M7NHYZ/Q#GMSJZ3),[*P."N.AKB=16ZMI6MKA_,C1N,<E1VKMGO+RTOVE^S9B
M<Y<@54UBR@$G]J1Q&0.,.N<@?A^-<5N5Z['68J71-HD+%?G^9<'L*91YEJ^$
MV%+B+Y0/;K17I8-?N_F>7C/X@5ZM\+8FGTG48DQN="!G\:\IKU/X8LR:+J;*
M2&$9((_&M:_\-F=#^(C#;X7>(2Y.+;D_\]/_ *U8-GX<O+CQ FD[5,P?#X/
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M7IFK:WI?AK09M*T*UF9I@1)(RDX'OQ[UY4<YYK6C%<SDMC.M)\JB]SJ_ WB
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MJO\ .O8>QP+<^D/#G1:[!?NUQ_ASHM=@OW:\P[1:*** "BBB@ HHHH ****
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MW_ZYK_*GB=D94>IZ#%]P4^F1?<%/KE.@B@^Y45R"9XO3FI8/N4YT#X/<4 .
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP]DC3\V/^^/SH\V/^^/SK,HHYP]DC3\V/^^/SH\V/^^/SK,HHYP]DC3\V/\
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MM%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^?OC9_R-]O\
M]>P_F:^@:^?OC9_R-]O_ ->P_F:VH?&9U?A/-*T8]:NHX4B5L*HP*SJ*['%/
M<YHR<=C5&OW8Z']:/[?O#U;]:RJ*7LX]BO:3[FF-<NP<[OUJ3_A(K[&-_P"M
M9%%'LX]@]K/N:IU^\;J0:3^W+D'(P*RZ*/9Q[![6?<U'UVZ=-I( ^M1QWS3+
MME(&.02:SZ*<8QB[I"E.4H\K9I^;'_?'YT>;'_?'YUF45ISG/[)&GYL?]\?G
M1YL?]\?G6911SA[)&GYL?]\?G1YL?]\?G6911SA[)&GYL?\ ?'YT>;'_ 'Q^
M=9E%'.'LD:?FQ_WQ^='FQ_WQ^=9E%'.'LD:?FQ_WQ^='FQ_WQ^=9E%'.'LD:
M?FQ_WQ^='FQ_WQ^=9E%'.'LD:?FQ_P!\?G1YL?\ ?'YUF44<X>R1I^;'_?'Y
MT>;'_?'YUF44<X>R1I^;'_?'YT>;'_?'YUF44<X>R1I^;'_?'YT>;'_?'YUF
M44<X>R1I^;'_ 'Q^='FQ_P!\?G6911SA[)&GYL?]\?G1YL?]\?G6911SA[)&
MGYL?]\?G1YL?]\?G6911SA[)&GYL?]\?G1YL?]\?G6911SA[)&GYL?\ ?'YT
M>;'_ 'Q^=9E%'.'LD:?FQ_WQ^='FQ_WQ^=9E%'.'LD:?FQ_WQ^='FQ_WQ^=9
ME%'.'LD:?FQ_WQ^='FQ_WQ^=9E%'.'LD:?FQ_P!\?G1YL?\ ?'YUF44<X>R1
MI^;'_?'YT>;'_?'YUF44<X>R1I^;'_?'YT>;'_?'YUF44<X>R1I^;'_?'YT>
M;'_?'YUF44<X>R1I^;'_ 'Q^='FQ_P!\?G6911SA[)&GYL?]\?G2/K%QPH/"
M\#FLVBIE:6YK3O3=XLT4UFZ3(#<'M4J>(+V,85L#TS6314<D>QHZLWU-?_A(
MKW^]^M(?$-XQ^8@CTS6311[./8/:3[FI_;UYNR&Q[ T/KMW(N&/%9=%')'L'
MM9]S537KI!@8K+=B[LQZL<FDHIJ*6PI2E+=A7T1X3_X];?\ ZYK_ "KYWKZ)
M\)@_9;?_ *YK_*N?$[(TH]3T"+[@I],B^X*?7*= 4444 %%%% !1110 4444
M %%%(_W#]* *3 !VQW.:2CZ\T4 %%%% !5F"0;=A/(]>]5J.1R#@^M %^BH8
M9=ZX;AA^M34 %%%% !1110 5%.A9,C.1SQWJ6B@"A14DL960G^$]*CH ****
M "BBB@ HHHH *;_R\0_[U.IO_+Q#_O4 22$&9@.W6F, RE2,@C!%*X(N)#ZF
ME'6@#F+KX?>&Y4+KHMLKMR2 >OYUD/\ #G1MW&F0C\#7I>!BD\M?2JYY=Q<J
M['F7_"N-(_Z!L/Y&C_A7&D?] V'\C7IGEKZ4>6OI1SR[ARKL>9_\*XTC_H&P
M_D:/^%<:1_T#8?R->F>6OI1Y:^E'/+N'*NQYG_PKC2/^@;#^1J.7X<Z4%RNF
MQ<=>#7J'EKZ4>6OH*.>7<.5=CRG_ (5]I7;3H?RJPGP\T9ES_9L/'7BO0YH
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M% [4M2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gcntzzpazujl000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcntzzpazujl000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &\ HH# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%-!]:7J* %HI..E% "T4G6CVH 6BBB@ HHHH ****
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M)<V,QQU8BJY'BC2!^[@1E'][G^E-3Q)',/+UE$C]=JB@#JM/\96=ZV'Q$?\
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MW^'T1C\VZNBU9/-TJY3'5,5Q/@V8VVH?8?3G% 'H=)UI:3O0 M%%% !1110
M4444 %%%% !1110 G6D)QQ3JH:O="RT^2<_PT >?VT9U3Q9<H>1#)D5H^.[@
MR6?V%3\Q XJ'P5$SZYJ%VWW7Y%1ZT?MWC1(!RI7I0!V?A^ 6^C6HQR4YK4J&
MTC$=I$G]U<5,* %HHHH **** "BBB@ HHHH *0]:6D- '+>-[@0Z7&,XW/M_
ME1X*L19Z?(?[[;JRO'\GG0P0*>1,O\Q77Z/!Y&GPCU0?RH OCI2T44 %%%%
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M6\=7HA\.7"@_-_\ 6K0U3Q'9:=%N$J2-_=!YKS'Q-XAO-:D+1V,HMP,$8X-
M'=^%K;RM %PH^9X\UE:587,_BM;R1/D'&?QK7\)ZQ9SZ5#:[T615PR9Y%=(E
MO#&<QH ?44 2C[N!VI03WHQ1GGI0 M%%% !1110 4444 )FC-)CYLYH!R3Q0
M N<#FD_K0?SJ*XE$-NTAZ** /.]9_P!.\4R6I.0C!OUKT6V7;;1+Z*!7G>BH
M;_Q[=RGE"N1^M>D ;0!Z"@!U%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:*
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MA^Y#&/HHH \UM? VM:@P?5;B.53U'^374:?X#T6R"M]E'F#J0174X&..*.E
M$$%G#;)MA7:!5CM110 F*/K2T4 )@T4M% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 E(?6G4F,4 -'/-.[T 4=Z %HHHH
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MZ;.&"<5S_@" O91WC#YG&,U8\<7>V$6H/,JXQ6AX.M_LOAVWC(PP_P#K4 =
M*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5\_67BS7O"GB!;+5IY)8QU(!Q7NFF7JZAI\%RO1UW4 70>U HXSFB@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!DO^J;Z5Y_;*A\>MN56&WN,UZ!-_JF^E<!:
M?\CZW^[0!Z H4*  !]!2^U(OW12]* %HHHH **** "BBB@ HHHH **** $K"
M\7JI\/7&0#]16]6%XN_Y%ZXH H^#A_HW']VNJZCFN4\'_P#'N/\ =KJSP.E
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M>BGI7GNJ*J>,V91@XH []&W(".XI0><4RV_X]H_]VI: "BBB@ HHHH ****
M"BBB@ HHHH *PO%W_(O7%;M87B[_ )%ZXH H^#O^/;_@-=2,]ZY;P=_Q[?\
M :ZN@!*.U+10 T>U+2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%(: &L-PQ@$>]59M.M;@@M#&2/]D57\07+V>D2RH3N'I6;X8U
M*6]$ADR=H[T =##;Q0C"1HOT4"I<8Z5R\FNO_P ),+':0,9S73(<J#0 [MS1
M2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Y]JW_(XM]*]!KS[5O^1Q;Z4
M=Y;?\>T?^[4M16W_ ![1_P"[4M !1110 4444 %%%% !1110 4444 %87B[_
M )%ZXK=K"\7?\B]<4 4?!W_'M_P&NKKE/!W_ ![?\!KJZ "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3Q2/^)%-6
M/X,.1,/:M?Q0,:%-S61X,'^N^E &?.,>/U'^S7H$0_=K]*X"X/\ Q7R_[M=_
M%_JE^E #^]%)WI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\^U0C_A,V!]*
M]!KS?Q!=)9>*VFN"$BZ;J /0;5@;9,=A4U4]-NH+NSC:%PPVU<[4 +1110 E
M+110 4444 %%%% !2&EI#0 =JP_%W'AVX)_SUK< YSFN9\:ZA;VVA3QR. Q'
M2@"/P:<VW_ :ZNN3\%-YEFKC[I7@UUE !1110 4444 %%%% !1110 F<T9I#
MTXH_G0 O>CWHS5&^U6TTX9N)0@]Z +V<BEK*L]=T[4#_ *-<!S[5J9!&1TH
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MML(@.%51]!0!QNE^!HH766^*SMUYKJ[;3;6T'[B)4'M5DXZ4HXH ,48H- %
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M+C/6@# XH 3-+G-!% &!B@! .:=28Q2T %%%% !1110 4444 %%%% !1110
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MGR;%REFQP5=377^'?!-GI0$TD0^T'[S#UKH[33K:TB"0Q(N!U JUMQWH  ,
M =!2T'IQ1VH 1AD?6N;UKPAIVJQLTD.9_P"$UTM)T- 'DS6VO^$I]RR?Z&.
MJ@DUUN@^-K34@(Y-RR#@E^.:ZB>WBN(RLL:N#ZBN.UWP-%<(\UK*T4@Z*G%
M'9)(D@W1L#GT-.7.<-UKRVTUC6?#++#/;L\(XWN:[;2?%&GZC&,3KO/4"@#>
M'M5>XO(K5"TKJ,>IK!UGQA8:>A2*96F/ 7WKCIHM8\6SYD62WA;^)#0!JZSX
MX-Q,;+3!()B=N[!(S5/2O!5WJMT+O7-LI/7%=5H'A2UTB++ 3.PY9QDBNB "
M\*,>U %:QTZWTV 16Z;5 Q5OH*,GTH!/<4  YI.<TZDH .]9VHZ+::E'MGCW
M UH]*3K0!YUJ7@FYL)#-HFV)ATS4%CXOO]'E^SZQYDG. 54XKTP@$8(JA>Z1
M:7L3(\$>6'WMO(H ATS7K/4XP\3A0>S&M8%6Y!!^AKSC4O!5Q8R&XL;B5B.B
M G%1V7BK5M*S#>VNU1QN:@#TIG5?O$#ZFL#6?%ECI (D)=L=$.:Y.\\3:MK1
M-M9VI,9_C6IM(\!--,+N^N)6<'.QR2* *DNOZUXBE:/3':.(]G4]*TM(^']O
MYJW.JQ"2XZ[A7:6FG6UG$JQPHI'<"K0]Q0!#:VL5I$L<0PBC %6*;CGK3A0
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M50O-&LKX?Z3$'K0HH H6.DV6G@"VAV5>QS2T4 (>:#TI:* $ Q2T44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@
M]*6B@!O(I>U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gzbwht3f4aft000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .B!QD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML4L'EAR%_=]J]+^'/BNY\1Z?*;UD,Z-@;1CBM)86<8<[,HXRG*?(MSN**0G
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MPEMJ:;)&.!(,!:]/CD2:-9(V#(PR".]8U*,Z?Q'12KPJKW6/HHHK(V"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \[^+>H?9_#GV<'YI&4_K7F?P[T:/5_$
MD:3H'A&=P(KI/C)J'F:E:VJG@(<_G6?\,];TW0Y+B>^<JV1MP/:O1PB<</*2
MZW_R/*QK4L1&':QTGQ"\#Z;9Z))?VJ>6\0S@< UP/P_NY;7QA8JC$"24*P]>
MM='X^^(<&MVQL-/#>2>&+#%9_P ,-"FO_$45X4(BMV#[B.#VK3"J<:<G4\_R
M,\8Z<JL52W_X)[3XHO!:>&KR4G!\HXKYML(O[2\00J1D2S#/XFO;_BI?_8_#
M0B!_UI*?I7BOAK4+72]9BN[L,8XR#\HS66 C\4S7,I.T('MNH?#[1Y=";,.R
M2.(MN48Y KP;8;/551&Y208(^M>H>(/BW#=6$EOIT39<;274C@UP7AK0[S7]
M:B5(V*[@S.1QQ[UIA8U(R<IZ(RQ<J4H1C3U9]%^'9WN-"MI9,[BO.:\3^*U_
M]I\3- #E8P#^E>ZP0K8:6(AP(T_I7S-XHNS?^(KF;.<MM_(USX=*>(;6QU8E
MNGA%%[Z(]9^#UAY6AO=E<,[,OY&K?Q8U#[+X>6('YG?%;O@:P_L_PQ;Q8QN^
M?\P*\Y^,=_OOH;,'@*&I5?WF*MY_D.A^ZPG-Y?F>9+:.UDUR =BMM)KV?X,R
M;M(O%STD7C\*X*#363X>SW)7&;A<?3%=C\%I +:^3UD!_2NVM+FIU%V//H1Y
M:E.?<])U_5(](TB>ZD;&U>*^:;Z2XUN_NKUR2%.6/H*]%^+/B(RSII-N_0XD
M ]:YNZTT:)X*2208GO000?:N7"QY(>T>[T1VXR?/-45LM69G@>R-YXNL4QE5
ME&?UKZ9C4)&J#H!BO#/@_8?:-<N)V'$2*P/XU[G)(L4;2.<*HR33Q\O>4>R)
MRV'NREW9RGC[Q"FB:%( P\V4;0._->)^&-$E\0ZA<229*K$[LQ]0,UH?$/7W
MUWQ T$3$QQG8 .YS7I'@7PXNE>#YII$_>W$)?D<CY2*5->PP[J/=CKOV^(5)
M;+<\C\+R?9/%D!R!AL5]-1',2'U45\NJ?LOB@=1B8#]17T]9OOLX6]4'\JK&
M:TX2%@O=K5(_UU.6^)%\+/PE=+G#2H0*\0\(:<-5\2VT4B[D,@+CVKTCXRZA
MLL[6U4_>8Y_*O/\ P/KUCX?U9[N]5RNT;=JYYIX%6IREW_X8G,97J1AV_K\C
MU'Q=X"TE=#FN(8_+DB0L-O'2O&-$FDM=<M6C8@^:HX^HKO/%OQ1&KV+6=@A6
M-^&9@0<5A> O#-UK.MPRF-A#&=Y8CCCFM,(IP3E4V,L9*E-QC2U9]"#-SIQ#
M#EXR/TKYH\461TOQ1<0XP$D!%?4"J%4*.@KPKXNZ9]FUI+M5P)LDFN/"SY:_
MJ=V+IN6&L]U8[W3?%,-EX!CU&5QN5" /7%>*2M>>*_$7&7DF?:/8<XJJ^L7D
M^F1:=O/DH3A0>N:]?^%_@X6-M_:EVG[Z3[@(Z>AKMY(T92K2^1P>TE7C"A'I
MN=AX3\/PZ!H\4"*!(1ES[UOT45Y<YN<G)GL4X*G%1B%<_P",-<CT/0IIV8!R
M,*/K6^S!5+'H!DUX+\4?$9U36/L$#YCA)4XZ&G2INI-0%5JJE!S9S^@Z;-XG
M\0G?EE8DLWI5>R7^S_%<(! \J;'Y9KUCX7^&Q8Z))?S)^\G7C(Z5Y/K@^S>)
MYC@C$A/ZFO6IU$\1[-;)'BU*3^K.K+=L^G+)M]A;MZQJ?TK&\9WHLO#5TQ.-
MR%1^5:.B2>;HMFW_ $Q7^0KA_BYJ'V?04@4\LXS7DRC>IR^9[4)I4^?R/%;.
MQGU2XD$0RP4N?H*Z7X:ZJ=-\41*S;8W!!!]:U?A5I8O;B[D9<CRGC_-:Y35+
M9]"\621#*^3, #[9%>QSIU'2?8\+DE[+VZW3/IZ1P+=G_P!G/Z5\R>*+EM4\
M53N.2S;1^%>\/K22^"?[05N#'UKPCP[ =3\8P1D;O,F.?UKCP4.6M)OH=^.J
M\V'CR_:_K]3Z(\-V@LM!M8@,?NU;\P*\A^+^H";6H[93PJ U[?"!#:1KT"(!
M^E?-/CB]-_XFN&SG8Q0?@:RPZ=3$7-<1^ZPO*O)'9_"WPQ9ZI93W%Y"K@/M&
M1[5L>-/AOIYTR2\L%*31C.T=,=ZW_AM8?8O"\1Q@R@/^E=#KA T:Z+=/+;^1
MHQ5:2JMQ>P8*A&5%*2W/F;P_J,VD:W!-&Q!#[3^=?45E,+BSBE'\2@_I7RDO
MS:HN/^>H_G7U)H@*Z1;@_P!P?RKIQJ3IQD<N O&K**V-"J>J3-;Z7<2K]Y$)
M%7*BN81<6TD+='&#7EO8]A;GROJ<KWVO3M*QR\IY)Z<U[KX3\%Z/'H%M));Q
MS/*@9F8 UX_XS\/W6B:Y,6C;RW<LK <5T?@CXDR:4(K#4,M;\*K=2*]>2=2@
MO9GB1:I8ENJCTI_A]HC7R7:P['0Y"J !73OB*W;' 5:CL[R"_MDN+=P\;C((
M-4_$-W]BT2YGSC:M>74E.W*^A[%.$+\T>I\Y^,+W[?XFN9<YYV_E7KW@WP9I
MLGAV&2[MD:5OFR5'0UX5=3&2^EE/.7)_6NVM/BOJ]G:QV\=M!MC4*.3VKU9T
MY>Q4('BPK0^L2J3VU/7QX*T0'_CSC_[Y%:5S);Z+I#LH5(X4.T?05Y[X'\?:
MMXDU@VL\$2QJNXE2:T_BMJ36?ALQHQ#.X''I7GU:=2,E"3W/4HU:4DYQ6QX]
MXEURY\2:Y)(6)1GQ&OIFO2?!/PSMQ:1WVJ*6D89"=OQ%<!X TM=5\4P12+E%
M!;\N:^E$4(BJ!@ 8KLQ$_8P5.!P86'UBI*K4,&;P9HDT7EFRB7C&0@S4'A_P
M3IWAV_FNK4,3(,?-VYS73U4U2Y^QZ9<7'_/-,UYWM9I.S/4]C"36AX]\4_%D
MD]Y_9=M)B)>6(/4^E8_@+P.WB*?[3=!EMD/YFN6U&634M=F).6DE('YU]'^#
M]-33?#EK&B@%D#-]:]'_ '>@K;L\O_>L2T]D1KX)T1;3R!9QD8QN*C->'>/?
M#:>'=:,<)/DR$E,]J^DZ\-^,;JVL6R@\A6S^=<N&J3]LM=SLQ5*'L):;'0?!
M[5)+BQN+21B5B VYKL?&UZ+'PK?29PWEG%>??!:-O,OGQQA:V_B[?_9]!CMP
M?]<2I_*KQD4\0HKK8SP$VL.Y/I<\5M[*;4I;F2(9V R-^==-\.-4.E^)T1FP
M)/DP?<UI_"K2EU"ZOQ(N4>';^M<OJ<+Z'XL<X*^7/N7Z9KOYE[1T7V/-Y'[+
MVR[GTY-($MY),\*I-?,_BBY.I>,[ELY#S@#\<5[K_;"R^!OMN[E[<Y^I!KP7
MP] VK>*801N+/O/X$5Q8*G:M*_0]#'5;X>-OM'T3X8LQ8>'K6 #&U:\C^+]_
MYVL1VH/^J.?S%>WJ!#: #@*G]*^:O'-Z;_Q5<R9R,@"LZ'[S$<S\V:8C]UA>
M7T1V7PL\,6FIVDUU>0K(I!"Y&>0:V/&GPXT_^RY;VQ4I)$I8J.F*W_AI8?8?
M"4((PS.S?GBM_P 0$#0;TGIY1IXJM)5GRO86#H1=!<RW/FGP_?S:5KUO(C%2
M) K?3-?4%E<"[LHIQTD7-?+ ^;7%V]YAC\Z^G="_=^'[3=QMBYK?&V=.,F<^
M O&M*"V_X)1\8:Y'H>AS3LP#D84?6O!-!TV;Q/XB._+*S$L?2N@^*/B,ZIK'
MV"!\QPDJ<=#78?"_PV+'17OYD_>3KQD<BLZ,?94)57N]C3%2=:M&A'9;GDUD
MO]G^*X0"!Y4V/YU].V+;["W;UC4_I7S'KH^S>)YC@C$A/ZFOI31)/-T6S;_I
MBO\ (56*]ZC"0L*N3$U(&=XSO19>&[IR<;D*C\J^=-$M#J>N6\1&[?("WTR*
M]E^+FH?9] 2!3RSC->2>$=5M-&UQ+R]#&-5/W1GFG@%:,IBS.5W&![-KWP^T
M>31Y62(1R(A(*C'2O![=GM-40QL0R28!'UKTSQ-\6([^PDM=.C8;Q@LRD&N,
M\)>'KK7];B C;RMV6?'%:815(-RJ;&6,E2FHQI:L^C-*D,^DV[..3&,Y^E?.
M_C[33IOBB= ,!@'_ #R:^D;:$6]M'$/X% _2O'_C)IFV>"_5?OD(3]!7'0GR
MUTUU.ZO3;PSB]U9G2^#_ !'%!X%-W,X'D J,GK@5X_K.H77BGQ"S+N;S'P@]
M 35%-8NTTK^SD<B$ON(!ZUZ=\+?!W_,6O(_]Q2/UKN]G&E.5:7R/.56=6G'#
MQ^9VW@;PQ'X>T:,,H^T2 &0^]=5117EU)N<G)GL4J<:<%&(5X!\6;_[3XE,"
MGY8U4_I7ODK!(G8]A7R]XLO3?^(KJ8G/S%?R)K;"1YJU^QCCI<M!^9Z)\,/"
MUEJ6CO=7D"OERHW#-=]_PA.B?\^<?_?(KQ30_B-J6@Z>+.VMX2@.<DFNET+X
MH:UJFKV]J;:':[@,03TKJKT:LZC<=CBP]>A"FE/<];L=.M=*MVCM8EC3J0!B
MOG[XB7AO_&%S&IR$DVK^-?0E]-Y.F7$C<%8F/Z&OF9W;5?%?F=3),#^HK#!1
M<ZUWT.G'24,/9=64KBTGTF^19,AE(.:^D_"&I#5/#MM< Y.-I_"O+?BEH0M8
M;.[C7&Y?G(^E;/P=U<2VDVGLW^J&X#ZFMZDO;8=R['+2C]7Q"3V:&?&74"MM
M;6BG^/)_$5%\&[#Y9KTKZIFN;^*U_P#:O%#1 Y5$7\Z],^&-A]B\+J2N#(V[
M\ZSI^YA&^_ZFM7]YC5'M^A=\?WXL/"\[YQO^3\Z\#\*Z<-5\006S#<"<D?2O
M5/C%?F/2X[0'EF#?K7)_"33_ +1XD^TD?+&K#]*K!>[3E4_K068OGJ0I_P!:
MGI]Y\/=$O+0Q^0$8KU4 5X5XHT-_#VMRVF3M4Y4U]1]J\ ^++*?$S =1C/Y5
MCA:L_:I7T9OC*,/8MVU1Z#\*]8DU'P\(9F+21$\GT[5M>.;T67A>Z.<%T*BN
M.^#2D65PV."#_.K7Q?U#R-&AMU/+/S^5&*@GB.5=;!@IM8;F?2YY'X>LO[4U
M^WB8;@T@+#VS7L_B7X?:2^B2O%&(Y(U+ KQT&:\J\ WUEIVOBYOF(C53C'K7
M=>,OBA9SZ?)9Z9O9WX+,,<5T8M5&XQIG)@G32E.J>5Z5/)9:S \;899 ,CZU
M]+WNK)IOAXWTQQMC!_2OGCPEH\^M:]!&B$J&W,V.!CFO4/BM?&Q\/V]BAQYB
M[3^%&-7-R0ZL> ?*YSZ)'E&M:G=^(]:>1BSL[8117KG@[X:V5K91W6H)YDS@
M':>0!7GWPTTH:EXHAD<96!@Q!KZ*50JA1T P*6*G[**IPT#"4_;SE5J:G#^*
MO >E7>D3/! L,D:E@4&.E>$VK2Z9K4>UBKQ2@$@^]?4>JD+I5T3T$9KY=OOW
MFOR[><S<5&!G)S<6]#3,:<534DM3Z>T2[-]HUK<GK(F:\F^,>H>9>6UJI^YG
M->G>%5,/A2Q#<%8>:\*^(U]]M\6W*@Y56P*SIP3Q5ET;-JE1K!\SW:1UOP9L
M,SW=TPXVC:?QKN?B%?"R\*70S@R(5%9WPKL?LWA:.8KAI"<_G63\8]0\K3+:
MU4\LYS^5/%?O,0H^:7W"P?[O#.;\W_D>/6EA/J'GR1C/EJ7;Z5V/PKU8V'B+
MR';$<BD8/K6A\,='%_8Z@S+D21-&*XYE?0_%FWE1#.!^ -=_,I5)4GV/,4&J
M:KKN?3EW)Y5G-)_=1C^E?,>JS-JGBR20<F28?SKWK6-90^"&OU;B6/@_4&O#
MO!5H=1\76Z,,Y8DUQX&'+4DWT._'U.:C%1^UK_7WGT+INGQIH4-HPPA09'X5
MCW/@70DCDF> <<DX%=5&NV-5] !6-XMN_L7AF^FSAEB)%<4IRNVGJSOA3CRJ
M+6B/FO5DC_MBXB@7""0JH'UKV_PUX#TF;0K6:X@S(\88\5XMI,7V_P 2P(1G
MS9^?QKZ@T^$6^GP0@8V(!7I8J3A2BEN>5A(JI7E)K0R(]"L?#^FW<ME%M;RV
M.0/8U\X7\[ZAK3R3,2TL@R37U5<PB>UEA/\ &A7\Q7S7XQ\/7.A:Y,#&PA+Y
M1P.*Y\'/]Z^;=G3CJ?[GW%I<]C\+>"M'AT2!GMXYG=<EF -6S\/]%_M&&\2+
M8\3;@JC ->;>"/B3)I8CL=1RUN. _4BO;;.\AOK9)X'#QL,@@T8A5:<W*^C#
M"RHU*:A;4F50B*HZ*,"EHHKC.\*\^^*'B0:7H_V.%\3S<\'MT-=U=W*6EK)/
M(0%12QS7S;XJU:7Q+XG<H2T9DVQCV.*VP]+VM1+HC#$UO8TG+KT#0/#[ZG87
ME\X^6'U[YJ[\.)O(\:6R9P#)BO3]/\.IH_@!X"G[UH\N0.M>0^$)?(\:6K>D
MQKTJ=3VE2<5LE_F>15I>SI4YO=N_Y'TT.F:\3^*?BR2>\_LNVD(B498@]?45
MZ_?W7V71I;G^Y'NKY@OW?4M=FR26DE('YUPX2DIU=>AZ6-K.G1TW9T_@3P,_
MB.?[1<Y6U0\]B37LMOX*T2W@$0LXF &,LH)J3PCIL>F^';6-% +1AF^M;M/$
MUY2FTMD+"8:,8*4EJSC9OAOHSZC'>1H49#G:.!71:K.EAH\TG143%:%<A\1K
M[['X3NL'#,O%<TI2FE!O^F=<80@W-+^D?/\ *'U#6G4<M)*0/S-?3^AVPM=&
MM8@,8B7/Y"OEFSO7L[]+M%#,C;@#T-=TGQ>UJ.-4%M!A1@<FO5Q%*4X*,>AX
MN&KPA5E.?4]-^(U_]B\,2\X,F4KQ'P39&_\ $UNF,[6#_D:L>(_'FI>)+1;:
MYCC1%;/R$UT'P@L#-KS71'RHC+4X>G*A"4I;EXJM'$3A&![?<,(;25N@5"?T
MKY@\277]H^)KB7.=\F*^C/%-X+'P_<S$X^4K^8-?-FEP-J&NQ1]2TF?UKGP$
M;U')G3F4N6DH]W^1]$^!['[!X7M8L8.,_G7FWQCO_,U&&S!_U>&_,5['9Q""
MPA0#&V,?RKYS^(5^;_Q7.^<A0%_+-32_>8GF]675_=83E]$=-\+/#=KJJS7%
MY")$Y R,\UZ;_P (3HG_ #YQ_P#?(KP[PYX]U#PU9&UM8(F4L6RQ.:Z/3OBQ
MK5YJ-O;_ &:#$CA3@GN:Z:]*K.I>&QR8:O1IT[3W/7K+1K+2[6:.TA6,.#G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M45U_0]&U33O(^%-N.A?8YK"^&^L1Z/8:C-(X4<XY[[>*]"\7VBP^ E@Q_JU
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M(Z*6*I>S5V>EUY5\8[_R[.WM5/W\Y%>@^']4;6=$M[]DV&5=VW/2O%?BQ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5\1RCQ3\85%AF1"ZC<O(XKT_XQ>'/[0\!V\ZIF2RCWGCGA0*%.4:=*O+=/\
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M4OC@YD\#1N?XD)_05XE8:3::+\2(+*RNFN8(Y,+*P S^5>U_&S_D08?^N?\
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MJ[3X7>)M,D\ 6B/<PQ/;PX=6< ]_6LZ:7)4EU3^Y"G)VI+HU^)XCI-E=:?\
M%N&UO)&DFCDP78\FO7?CA_R(T?\ N'^0KS*34X=5^-JW-N<QM+P:]-^.'_(C
M1_[A_D*BJV\)!OO^J-8)+%22[?YE'X(?\D^N/]^3^=>26%SK"^.M2L]&;;/<
MS/%G=C&37K?P0_Y)]<?[\G\Z\\\#?\E;NO\ KX/_ *%75**EC.5[.)SJ7+AF
MU_,SU'X?_"R^\-ZZNL:A<F:X>,B3+ \FO6J**SE)NR[%*-G?J%%%%24%%%%
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M"/UKGI)NBY+>[U.BJTJB72VQT7P2\875[]MTB^N&F-J"5<G.?FQ7">*=0O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<2(HD/3A2:UDE]8C;:[_ "9C!OV#[V_5%SXD>'K2P\.0W^GP)!-9'>&C4*2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /(->@BN/C)I<<T22(1)E74$?K4OQ:LM*LM'CEM$2WU '
M]T( $)/X=:S/&>CQZW\5M.LI9YX%</\ / ^UA^-=QI7PTTC3K@3R7-Y>L.0+
MJ4R ?G135Z<&]+-O_P F8YRM5EUT7Y _B;4]%\/Z<T?AZ^U222-0WV<@%?E'
M)S5+_A8VM_\ 1/\ 6_\ OI*W_$4/BCRX4\-2V,04X<7*9XQVK \CXI_\_NB?
M]^C1?F;9*CRQ2,CXB:Y=ZAI.EV[6T]@UU<QK)#(?G /4<5NZWX-TY/ [006R
M)+!%O64*-^5!/7K7/?$2SU..TT>^U1HGGBNH_,:(848/)KM==UNUB\$37@E4
MQRP,JG/4D'%14LJ$FM[O_@%QO[6"\OUU,[X4ZI-J/@RU6X??+"@5B>M4?BU>
MS)I4%A%*4^TM@X.#UJ#X4RPZ1X(COM1E2VBF"G=(<"F?%)H;S2K'5K:036\+
M9WH<CK6U=7JQOWC?\"*6D9<O]ZWXV-74O!FFGP$]M#;(LQ@#"4 ;\D#^+K4?
MPLUIKOPE(;N7)MIY(RS'HJG K8U+6[6#P*]^)D,:VXYS["O(=,DUJR^'LRV%
MA<S_ &V\F#^2N6"$Y!%1S-2J+T^_4%%.%/U?W6+7CN:[\;M?3Q.R:78JV"#]
MYU]Q7J/@17;P#IRQ,%<VP"D]CBO,+_Q,MAX%FTQ/"^K0,T9\R:2,8W8Y)-=U
M\+->;4/#-E:'3KJ 0Q!?-E7"OCTJX12A."VT_+5BJ2;E"3\_^ <1X_\ !TNF
ME-6O[QKB[EO(BNUB%4%AD8->VV:+)I\2NH92@R",BN ^,'_(&L_^OJ'_ -#K
MT"P_X\8?]T5,/X-NS?Y(JI_$B^Z_4HZA9:-8V4UU-IUD%1<DF!?\*\]^&FD1
MZGKNH>)FMTB1R88D10H&QCSQQ6A\4]7D>VM] M&/VB_8I\O4=Z[/PWI46C:'
M;6D:XP@9O]X@9I4OM5/DOU_R"ILH=]7^AK4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M']I6/_/[;_\ ?U?\:-DET0/5WZEFBJW]I6/_ #^V_P#W]7_&C^TK'_G]M_\
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M5_QH_M*Q_P"?VW_[^K_C0!9HJM_:5C_S^V__ ']7_&C^TK'_ )_;?_OZO^-
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M #-'_"">&_\ H&Q_F:Z.B@#G/^$$\-_] V/\S1_P@GAO_H&Q_F:Z.B@#G/\
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MO_H&Q_F:Z.B@#G/^$$\-_P#0-C_,T?\ "">&_P#H&Q_F:Z.B@#G/^$$\-_\
M0-C_ #-'_"">&_\ H&Q_F:Z.B@#G/^$$\-_] V/\S1_P@GAO_H&Q_F:Z.B@#
MG/\ A!/#?_0-C_,T?\()X;_Z!L?YFNCHH YS_A!/#?\ T#8_S-'_  @GAO\
MZ!L?YFNCHH YS_A!/#?_ $#8_P S1_P@GAO_ *!L?YFNCHH YS_A!/#?_0-C
M_,T?\()X;_Z!L?YFNCHH YS_ (03PW_T#8_S-'_"">&_^@;'^9KHZ* .<_X0
M3PW_ - V/\S1_P ()X;_ .@;'^9KHZ* .<_X03PW_P! V/\ ,UQ'Q0\"6!\*
M3+I&G*+HXV[2?6O6J1E5AAE!'N* /F[P=\![^[,=UK<IME!SY0P=PKZ"T71[
M70M,CL;1 L2=AZUH 8&!10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 8GB;PQ8>*-.:TOHPPQ\I]*^??&'P+U33#)<:0QNX1R0<# KZ=I"
M1@@$>] '!>%/ FB_\([:"\TU/M C7?DGKBMO_A!/#?\ T#8_S-=$  ,  ?2E
MH YS_A!/#?\ T#8_S-'_  @GAO\ Z!L?YFNCHH YS_A!/#?_ $#8_P S1_P@
MGAO_ *!L?YFNCHH YS_A!/#?_0-C_,T?\()X;_Z!L?YFNCHH YS_ (03PW_T
M#8_S-'_"">&_^@;'^9KHZ* .<_X03PW_ - V/\S1_P ()X;_ .@;'^9KHZ*
M.<_X03PW_P! V/\ ,T?\()X;_P"@;'^9KHZ* .<_X03PW_T#8_S-'_"">&_^
M@;'^9KHZ* .<_P"$$\-_] V/\S1_P@GAO_H&Q_F:Z.B@#G/^$$\-_P#0-C_,
MT?\ "">&_P#H&Q_F:Z.B@#G/^$$\-_\ 0-C_ #-'_"">&_\ H&Q_F:Z.B@#G
M/^$$\-_] V/\S1_P@GAO_H&Q_F:Z.B@#G/\ A!/#?_0-C_,T?\()X;_Z!L?Y
MFNCHH YS_A!/#?\ T#8_S-'_  @GAO\ Z!L?YFNCHH YS_A!/#?_ $#8_P S
M1_P@GAO_ *!L?YFNCHH YS_A!/#?_0-C_,T?\()X;_Z!L?YFNCHH YS_ (03
MPW_T#8_S-'_"">&_^@;'^9KHZ* .<_X03PW_ - V/\S1_P ()X;_ .@;'^9K
MHZ* .<_X03PW_P! V/\ ,T?\()X;_P"@;'^9KHZ* .<_X03PW_T#8_S-'_""
M>&_^@;'^9KHZ* .<_P"$$\-_] V/\S1_P@GAO_H&Q_F:Z.B@#G/^$$\-_P#0
M-C_,T?\ "">&_P#H&Q_F:Z.B@#G/^$$\-_\ 0-C_ #-'_"">&_\ H&Q_F:Z.
MB@#G/^$$\-_] V/\S65XB\"Z$-"N_LVFIYWEMMP3UP:[BD(!&",B@#Y7\*?!
M+6M;E$VH9L[8ME6&"2/I7T-X1\'V/A'3_LUH,L1AW_O5T2JJC"@ >@%+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15
M*35],A<I+J-HCCJK3J"/UJ:"^M+K_CWNH)O^N<@;^5 $]%%% !144]U;VR[K
MB>*)?61PH_6H[?4+*[.+:\MYB.T<JM_(T 6:**CEGB@3?-*D:CJSL /UH DH
MJI#J>GW+[(+ZVE?^ZDRL?T-3RSPVZ;YI8XU]78 ?K0!)15.+5M-G?9#J%K(Y
M_A292?YU:>1(T+R.J*.I8X% #J*I+K&F.^Q-2LV;^Z)U)_G5LR($WEU"_P!X
MGB@!U%4O[9TLOL_M*SW9QM\]<_SJXK*ZAE8,#T(- "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 17,ZVUM+.WW8U+'\*
M^?-9\?>-?%GBBXTWPG*]NL!8 H^-P'.>:^@;V%;BRGA<X5T*D^F17S(VN?\
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MD]:GUE9/&OQ#BT6>4_V;%&[/&.0Q4@C-2?%F=9M6T:R3F7[5&_'IFH_#4?\
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M*UIS7F%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4/PE_P"27Z%_UP_J:[6N*^$O_)+]"_ZX?U-=K0 4444 %%%% !1110 4444
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M#G%:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_T&=2_[_5UM% ')?\(+'_T&=2_[_4?\(+'_ -!G4O\ O]76T4 <E_P@L?\
MT&=2_P"_U'_""Q_]!G4O^_U=;10!R7_""Q_]!G4O^_U'_""Q_P#09U+_ +_5
MUM% ')?\(+'_ -!G4O\ O]1_P@L?_09U+_O]76T4 <E_P@L?_09U+_O]1_P@
ML?\ T&=2_P"_U=;10!R7_""Q_P#09U+_ +_4?\(+'_T&=2_[_5UM% ')?\(+
M'_T&=2_[_4?\(+'_ -!G4O\ O]75NZQH7=@J@9))P!7$7OQ8\-6-Y-:R27#/
M$VTE(\J?H:WH86MB&U2BY6[$3J1A\3L7/^$%C_Z#.I?]_J/^$%C_ .@SJ7_?
MZLS_ (7%X7_O77_?DT?\+B\+_P!ZZ_[\FNG^R<=_SZ?W$?6*7\R-)O L>T_\
M3G4NG_/6OGGQ!\/M:U?QO<6EE#/(G'[^8$CJ>]>Z?\+B\+_WKK_OR:CC^+?A
M*)BT:W*D]2(3S1_9.._Y]/[@^L4OYD4OAW\+[CPMLN;O49S+CF))/D_*O4:\
M_P#^%Q>%_P"]=?\ ?DT?\+B\+_WKK_OR:/[)QW_/I_<'UBE_,CT"BO/_ /A<
M7A?^]=?]^33H_B_X8DD5 UT"Q &8CBC^RL;_ ,^G]P?6*7\R.^HJ*WN(KJ!)
MH)%DC<9#*<BI:X&FG9FP4444@"BBB@ HHHH **** "BBB@ HHHH **** .6U
MGQYI.BWOV67?*X&28^0/:L[_ (6GHO\ SQN/^^:6]^&6G7M[-=/>SJTKEB !
M@9J#_A4^F?\ /]<?]\BO.F\=S/E2L?1THY(H+VDI-]=R;_A:>B_\\;C_ +YH
M_P"%IZ+_ ,\;C_OFH?\ A4^F?\_UQ_WR*/\ A4^F?\_UQ_WR*F^/\C3ER'O+
M\2;_ (6GHO\ SQN/^^:/^%IZ+_SQN/\ OFO-_%&CQ:'KTMA#(TB( 0S=>:[R
MU^%NFSVD,S7MP#)&K$ #N,UC3Q&,J2<8VNCKQ& R>A3A5J<UI[;ES_A:>B_\
M\;C_ +YH_P"%IZ+_ ,\;C_OFH?\ A4^F?\_UQ_WR*/\ A4^F?\_UQ_WR*VOC
M_(Y.7(>\OQ)O^%IZ+_SQN/\ OFNMTK4H=7TV&^@#".494-UKC/\ A4^F?\_U
MQ_WR*[+1],CT?2X;")V=(A@,W4UOA_K/-^^M8X,P66JFOJ;?-?K?8O4445V'
MCA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^@SJ7_?ZNMHH Y+_ (06/_H,ZE_W^H_X06/_ *#.I?\ ?ZNMHH Y+_A!8_\
MH,ZE_P!_J/\ A!8_^@SJ7_?ZNMHH Y+_ (06/_H,ZE_W^H_X06/_ *#.I?\
M?ZNMHH Y+_A!8_\ H,ZE_P!_J/\ A!8_^@SJ7_?ZNMHH Y+_ (06/_H,ZE_W
M^H_X06/_ *#.I?\ ?ZNMHH Y+_A!8_\ H,ZE_P!_J/\ A!8_^@SJ7_?ZNMHH
M Y+_ (06/_H,ZE_W^KQ/XH^"-1F\206NG_;+S<2-\F6Q7TS4?D1>;YOEC?\
MWN] 'B'P]^#FH:5-#?ZA?RP,#N"0/C/UKW&-/+C5,D[0!D]33J* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#T(U[V1YI6QSFJJ6EMCDQ5"-*W+U.IM_A=XHNK:.XBM83'(H9291T-2_\
M"IO%G_/I#_W]%>]:#_R+^G_]>Z?R%:->)4XFQD9M)1T\G_F=2P--J^I\Z?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KXI^)/\ R4?7O^OIOZ5]K5\4_$G_ )*/KW_7TW]* /J'X2_\DOT+
M_KA_4UVM<5\)?^27Z%_UP_J:[6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ;)_JG_W37R1J?\ R%KS_KN__H1KZWD_U3_[IKY(U/\ Y"UY_P!=
MW_\ 0C7U_"GQ5?E^IYV8;1/JC0?^1?T__KW3^0K1K.T'_D7]/_Z]T_D*T:^4
MK?Q)>K.^/PH****S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%% !7Q3\2?\ DH^O?]?3?TK[6KXI^)/_ "4?7O\
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M% !1110 4444 %%%% !1110 4444 >'_ !$_Y'*X_P!U:]GT[_D%VG_7%/\
MT$5XQ\1/^1RN/]U:]GT[_D%VG_7%/_017F8+^/5]3Z?.O]PPOI^B+-%%%>F?
M,!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\@NT_P"N*?\ H(KS,%_'J^I]/G7^X87T_1%FBBBO3/F HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HJ)[JWC.))XE/HS@4]71QE&5AZ@YH =14<D\47^L
ME1/]Y@*6.6.49CD1QZJP- #Z*1F5!EF 'J34:75O(VU)XF/HK@T 2T444 ?$
MGC__ )'[6_\ KZ:OJ[X7_P#),O#_ /UZC^9KY1\?_P#(_:W_ -?35]7?"_\
MY)EX?_Z]1_,T =;1110 4444 %%%% !1110 4444 %%%% !1110 U_N-]*^?
M/#W_ "46V_Z_6_F:^@W^XWTKY\\/?\E%MO\ K];^9KS\=\=/U_R/*S'XZ7K_
M )'T+1117H'JA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!'/*(())6^ZBEC^%?/VKW&M_%#Q==Z197YM-/MG*[Q[<CI7NVM_\@.]_P"N
M#_RKY6\+:)KWB3Q!J&FZ3>BT5Y"SRD'J!Z@YJ(KFJV:O9-EM\M+F3MJD>A^#
MO"_C7P=XL6W7SK_2\_/-G@_F:M?%SQ1J3W]KX=TUFCEG.UR.O(KF?#NK>(/A
MQXU31M5NVN[:5L%FR=WT)-2>+)7G^-5DS?<9E*Y]UK2RJRI1;NG^G0S3Y/:-
M*S2O_P $H:CHGB'X5SZ?K']K/<QW+#>ISQQGO]:^B=#U6/5-&M;OS%S)&K-S
MW(KS'XZ 'P58\#C./^^17B?C+4M0M[VQ2*\N(5^QQ_+'*RCIZ TZ<G.G)/[+
M%.*C*#7VEK\C[*\V/^^OYU\6?$@@_$;7B#D?:F_I6)_;6J_]!.\_[_M_C5.2
M1Y9&DD=G=CDLQR3^-24?9'PE_P"27Z%_UP_J:[6N*^$O_)+]"_ZX?U-=K0 4
M444 %%%% !1110 4444 %%%07ERMG937+*66)"Y [XH;L)NRNR>BO-?^%Q:=
M_P! NY_[[6C_ (7%IW_0+N?^^UKF^N4/YCE^OX?^8]*HKS7_ (7%IW_0+N?^
M^UH_X7%IW_0+N?\ OM:/KE#^8/K^'_F/2J*\U_X7%IW_ $"[G_OM:/\ A<6G
M?] NY_[[6CZY0_F#Z_A_YCTJBO-?^%Q:=_T"[G_OM:/^%Q:=_P! NY_[[6CZ
MY0_F#Z_A_P"8]*HKS=/C!ISR*@TRY&X@??6O18I!+"D@& ZA@/K6E.M"I\#N
M:TL13JWY'>P^BBBM38**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!LG^J?\ W37R1J?_ "%KS_KN_P#Z$:^MY/\ 5/\ [IKY(U/_ )"UY_UW?_T(
MU]?PI\57Y?J>=F&T3ZHT'_D7]/\ ^O=/Y"M&L[0?^1?T_P#Z]T_D*T:^4K?Q
M)>K.^/PH****S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#P_XB?\CE<?[JU[/IW_(+M/\ KBG_ *"*\8^(G_(Y7'^ZM>SZ=_R"
M[3_KBG_H(KS,%_'J^I]/G7^X87T_1%FBBBO3/F HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2OBGXD_\E'U[_KZ;^E24?4/PE_Y)?H7_ %P_J:[6N*^$O_)+]"_ZX?U-=K0
M4444 %%%% !1110 4444 %(RJZ%'4,I&"#WI:* .+O?ACH-[>RW+><C2-N*H
MV%'T%5_^%3>'_P"_<_\ ?==Y16#PU%Z\J.9X.@W=P1P?_"IO#_\ ?N?^^Z/^
M%3>'_P"_<_\ ?==Y11]5H_RH/J>'_D1\VV.EP7'BV/3'+>0UR8C@\XR:]6_X
M5-X?_OW/_?=>;:5_R46'_K^;^9KZ%KAP5&G-2YE?4\[+L/2J1ESQOJ<'_P *
MF\/_ -^Y_P"^Z/\ A4WA_P#OW/\ WW7>45W?5:/\J/1^IX?^1'':9\-M#TR_
MCNXUED9.BR-E?RKL    !@#H*6BM(4X05HJQK3I0IJT%8****LT"BBB@ HHH
MH **** "BBB@ HK,U_7+7P[I4FHW@<PH0#L&3S7'?\+E\-_W+K_OW770P&)Q
M$>>E!M>1G*K"#M)V/1**\[_X7+X;_N77_?NC_A<OAO\ N77_ '[K;^R,=_SZ
M9/UBE_,>B45YW_PN7PW_ '+K_OW1_P +E\-_W+K_ +]T?V1CO^?3#ZQ2_F/1
M**\[_P"%R^&_[EU_W[H_X7+X;_N77_?NC^R,=_SZ8?6*7\QZ%)_JG_W37R1J
M?_(6O/\ KN__ *$:]S?XR>&V1@$NN1C_ %=>$WDJSWUQ,F=LDK,,^A.:^GX;
MP=?#RJ>V@XWMO\SAQM2$TN5W/JO0?^1?T_\ Z]T_D*T:\PTOXN>'K/2K6VD2
MZWQ1*C8CXR!5O_A<OAO^Y=?]^Z^<JY3C7-M4GN=L<12LO>/1**\[_P"%R^&_
M[EU_W[H_X7+X;_N77_?NL_[(QW_/IC^L4OYCT2BO._\ A<OAO^Y=?]^Z/^%R
M^&_[EU_W[H_LC'?\^F'UBE_,>B45YW_PN7PW_<NO^_='_"Y?#?\ <NO^_=']
MD8[_ )],/K%+^8]$HK#\,^*;#Q59RW-@)!'$^QO,7!S6Y7#5I3I3<)JS1K&2
MDKH****@84444 %<G\1;B:V\)R202O&_FH-RG!KK*X_XF?\ (G2?]=D_G6&*
M=J,O0[\K2>-I)_S(\A_MG4_^?^X_[^&C^V=3_P"?^X_[^&J-%?+\\NY^H>QI
M_P J^XO?VSJ?_/\ W'_?PT?VSJ?_ #_W'_?PU1HHYY=P]C3_ )5]Q>_MG4_^
M?^X_[^&C^V=3_P"?^X_[^&J-%'/+N'L:?\J^XO?VSJ?_ #_W'_?PT?VSJ?\
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M27Z%_P!</ZFNUKBOA+_R2_0O^N']37:T %%%% !1110 4444 %%%% !1110
M4444 %%%% 'SUI7_ "46'_K^;^9KZ%KYZTK_ )*+#_U_-_,U]"UY^7_#+U/*
MROX9^H4445Z!ZH4444 %%%% !1110 4444 %%%% !1110!Q/Q7_Y$*Z_ZZ)_
M.OG*OHWXK_\ (A77_71/YU\Y5]]PQ_N;_P 3_)'D8[^)\@HHHKZ0X@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ]T^"7_(NW_P#U\#^5>GUYA\$O^1=O
M_P#KX'\J]/K\QSK_ '^KZ_H>[AOX,0HHHKRS<**** "N/^)G_(G2?]=D_G78
M5Q_Q,_Y$Z3_KLG\ZY\5_ GZ'?E?^^TO\2/$Z***^5/U4**** "BBB@ HHHH
M**** "BBB@ HHHH **** "NX^%O_ ",TG_7$UP]=Q\+?^1FD_P"N)KIP?\>/
MJ>;G'^XU?0]DHHHKZD_+0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHI&&48>HH YKQ+X[T/PM$6O[GY^R1C<?RKSF]^/+;S_9VCRSQ]
MF:)Q74O\*=+U'7YM5U;_ $LN1B-QP*ZJU\*Z+91B."PB10,8 I13M>3U&VKV
M2/+;+X\G<#J6D2P)GDK$YKTCPWXWT7Q1"&L+GY\<H_RG\JA\0:=X7L[,-JUM
M$(7.WD5S^E_#;1[?5X-<T*3R(F .Q!P0:N#3=FM.Y,DTKK<])HHHJ1A1110
M4444 %%%% !1110 4444 ?$GC_\ Y'[6_P#KZ:OJ[X7_ /),O#__ %ZC^9KY
M1\?_ /(_:W_U]-7U=\+_ /DF7A__ *]1_,T =;1110 4444 %%%% !1110 4
M444 %%%% !1110 U_N-]*^?/#W_)1;;_ *_6_F:^@W^XWTKY\\/?\E%MO^OU
MOYFO/QWQT_7_ "/*S'XZ7K_D?0M%%%>@>J%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 (SJBEG8*HZDG %5_[0LO\ G\M_^_H_QJKX
MAM)K[P_?6MNNZ:6(J@SC)KR'_A7_ (E_Y]A_W\KDQ&(J4I)0AS'KY=@,/B8.
M5:LH-/K_ ,.>T?VA9?\ /Y;_ /?T?XT?VA9?\_EO_P!_1_C7B_\ PK_Q+_S[
M#_OY1_PK_P 2_P#/L/\ OY7/]=K_ //I_P!?(]#^Q<#_ -!2_#_,]H_M"R_Y
M_+?_ +^C_&C^T++_ )_+?_OZ/\:\5?P#XD1&=K8;5&3^\K"LK&[U"_2RM@6G
M<[0N[O42S&K%I2I[FM/A[#5$Y0Q":6^BT_$^A_[0LO\ G\M_^_H_QH_M"R_Y
M_+?_ +^C_&O%_P#A7_B7_GV'_?RC_A7_ (E_Y]A_W\J_KM?_ )]/^OD9?V+@
M?^@I?A_F>T?VA9?\_EO_ -_1_C3X[NVF?;%<1.WHK@FO%/\ A7_B7_GV'_?R
MMKPMX+\0V.MQSS2-:(H.9%;=GV_&JAC*TI).FS*ME&#A3<HXE-K^NYZO1117
MHGSH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>2
M?&B_NBEAH\$IB2[/S,/K7K=<+\2_!<OBO25:T?9>0<QGGZUG/=-JZ35S2GN^
MCLSR>#PE#X4^(.@I%.96E?+-D^F:W_%LWV3XO:&]O*VZ22,.H;C&TUY_?:3\
M1X-6MY9-,N))K4_N7\L?3UKOOA[X \07WB2/Q%XG5XYHB&2.0$'C_P#7713U
M<&WI&_X[(PJ>ZI*VK27S[GN41+0H3U*BLOQ)I<VL:1)90RF(R#!8=A6L!@8'
M:EK*24E9EQ;C9GGF@?"'P_I:+)=0_:KK^*1F/-=4OA71E3:+*/ _V16S2'H:
MIR;$E8\[UOP?X)U>^.FR)&E^>%"G!!K8\$^$I/"<$UK]I,T!^YG/'->93R2?
M\- HF]MN_IGCI7O*_='THAI34U]I?J.HOWG(^EG]Z%HHHI %%%% !1110 44
M44 %?%/Q)_Y*/KW_ %]-_2OM:OBGXD_\E'U[_KZ;^E 'U#\)?^27Z%_UP_J:
M[6N*^$O_ "2_0O\ KA_4UVM !1110 4444 %%%% !1110 4444 %%%% !111
M0!\]:5_R46'_ *_F_F:^A:^>M*_Y*+#_ -?S?S-?0M>?E_PR]3RLK^&?J%%%
M%>@>J%%%% !1110 4444 %%%% !1110 4444 <3\5_\ D0KK_KHG\Z^<J^C?
MBO\ \B%=?]=$_G7SE7WW#'^YO_$_R1Y&._B?(****^D.(**** "BBB@ HHHH
M **** "BBB@ HHHH **** /=/@E_R+M__P!? _E7I]>8?!+_ )%V_P#^O@?R
MKT^OS'.O]_J^OZ'NX;^#$****\LW"BBB@ KC_B9_R)TG_79/YUV%<?\ $S_D
M3I/^NR?SKGQ7\"?H=^5_[[2_Q(\3HHHKY4_50HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *[CX6_\C-)_P!<37#UW'PM_P"1FD_ZXFNG!_QX^IYN<?[C
M5]#V2BBBOJ3\M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAK&J0Z-I
M5Q?W!Q'"A8U?KF?'VG2ZGX.U"WA)WM$V .]9U9.,&T732<DF>.ZE\?[YKR1;
M&PD\I6(!!SFJT/QXUN2>-#8RX9@.E=#\*-3\*Z9I4VGZHUI'?1RD%9U#$_I7
MI*ZOX-+#;)IF<\8B7_"MG%0=KW,N9ROI8U/#VH2:IH%G>RJ5>:/<0:TZBMG@
MDMT>V*&$CY-@P,5(X)1@.I%$W[S:003Y4FQ#)&#@NH_&D\V/_GHG_?0KPSQ5
MX#\::AX@N+FQOI$MV^ZHW?XUC?\ "MOB!_T$I?\ Q[_&LXMM)LN2L[':_':4
M?\(K;;)!GS_X6]J[7P"2?!6EDG/[A:\-N_A/XUOU5+N\>5 <X96/]:]^\*Z=
M+I/ANQLI_P#60Q!6X[BM*:4:4E?=DU)<TH+M<V:***D84444 %%%% !1110
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M^$]\*_\ 0<M?^^C_ (5T?4\3_P ^Y?<R/:0[HZ.BN<_X3WPK_P!!RU_[Z/\
MA1_PGOA7_H.6O_?1_P */J>)_P"?<ON8>TAW1T=%<Y_PGOA7_H.6O_?1_P *
M/^$]\*_]!RU_[Z/^%'U/$_\ /N7W,/:0[HZ.BN<_X3WPK_T'+7_OH_X4?\)[
MX5_Z#EK_ -]'_"CZGB?^?<ON8>TAW1T=%8VG^*]!U:[%K8:I!<3L"0B$Y(%;
M-8U*<Z;M--/S*4D]4%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MH7_7#^IKM: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YZTK_DHL/\
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M,QW\:EZ_Y'T^1?[IB?\ #^C/=****],^8"BBB@ HHHH **** "BBB@ HHHH
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MD_\ "S/#/_/W)_W[-9RK4XNSDC&6(I1=I229U]%<A_PLSPS_ ,_<G_?LT?\
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MXK_\B%=?]=$_G7SE7WW#'^YO_$_R1Y&._B?(****^D.(**** "BBB@ HHHH
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M?FF_]<V_G7E]>H?&/_C\TW_KFW\Z\OKY_&?QY'RV8?[S+^N@4445RG&%%%%
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M6_\ (S2?]<373@_X\?4\W./]QJ^A[)1117U)^6A1110 4444 %%%% !1110
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M]/\ P_JSBP/P/U"BBBOFCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"&Z_X\Y_^N;?RKQ'P9_R/5K_UU;^M>W77_'G/_P!<V_E7
MB/@S_D>K7_KJW]:\S'?QJ7K_ )'T^1?[IB?\/Z,]THHHKTSY@**** "BBB@
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M8_\ 6:;]&KU>O*/C'_K--^C5R8W^ SAS'_=I?UU/*Z***\ ^8"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KV#X.?\@G4O\ KNO_ *#7C]>P?!S_ )!.
MI?\ 7=?_ $&NS _QT=^6_P"\KYGI=%%%>\?3!1110 4444 <3\5_^1"NO^NB
M?SKYRKZ-^*__ "(5U_UT3^=?.5??<,?[F_\ $_R1Y&._B?(****^D.(****
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M9AYD9<G<OI7MGA2:UF\,:?):)Y<#0J40G.!5+X60_B1LT444B@HHHH ****
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MJK4:E)['30RS"T(2A3C92WU9Z;_PMH_] P?]]T?\+:/_ $#!_P!]UYE16O\
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M"*P_"FLV>BZDUS=Q-(-N%VCH:BUGQ!=ZGJDD\4TJQEOD7=T%7#V$()R7,W^
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ML$J56G4I\L]=+:OM8@\52+X<\7V][:Q@&3)8 >]7[Z+PUXG"W=Q<-;RXRPP
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MFD_ZXFNG!_QX^IYN<?[C5]#V2BBBOJ3\M"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"&XM8+N(QW$2R(>JL*YF]^''A>]DWMI-LC
M'J53K7644K(=V<I9?#GPO9/O32;9F'0E.E=-;VT%K$(H(EC0=%4<5+1579-D
M%%%%(84444 %%%% !1110 4444 %%%% 'Q)X_P#^1^UO_KZ:OJ[X7_\ ),O#
M_P#UZC^9KY1\?_\ (_:W_P!?35]7?"__ ))EX?\ ^O4?S- '6T444 %%%% !
M1110!Y)\8_\ C\TW_KFW\Z\OKU#XQ_\ 'YIO_7-OYUY?7S^,_CR/ELP_WF7]
M= HHHKE.,**** "BBB@ HHHH **** "BBB@ HHHH **** /I'PC_ ,BEIG_7
M 5M5B^$?^12TS_K@*VJ^GI_ O0^QH_PX^B"BBBK- HHHH *\1^.'_(9TO_KW
M;_T*O;J\1^.'_(9TO_KW;_T*O<X=_P"1A'T?Y'+C/X+/*J***_1CQ0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *^J_"G_(J:9_U[K7RI7U7X4_Y%33/
M^O=:^4XK_@T_5_D>A@/B9L4445\0>H%%%% !1110!Y'\5_\ D-V?_7$_SKS^
MO0/BO_R&[/\ ZXG^=>?U\OC?]XD?I^2?[A2]/U"BBBN4]4**** "BBB@ HHH
MH **** "BBB@ HHHH **** /HW0_^0%8_P#7%?Y5?JAH?_("L?\ KBO\JOU]
MA#X4?D%?^++U844451D%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q3\2?^2CZ]_P!?
M3?TK[6KXI^)/_)1]>_Z^F_I0!]0_"7_DE^A?]</ZFNUKBOA+_P DOT+_ *X?
MU-=K0 4444 %%%% !7E'QC_UFF_1J]7KRCXQ_P"LTWZ-7)C?X#.',?\ =I?U
MU/*Z***\ ^8"BBB@ IR2/&VY&(([BFT4[V ?)(\K;G8L?4TL4\L.?+<KGKBH
MZ*+A=WN*2222<DT E2"#@BDHI 227$LP D<L!TR:CHHH!MO<E-Q*T7EER4';
M-1444]PN%%%%( KV#X.?\@G4O^NZ_P#H->/U[!\'/^03J7_7=?\ T&NS _QT
M=^6_[ROF>ET445[Q],%%%% !1110!Q/Q7_Y$*Z_ZZ)_.OG*OHWXK_P#(A77_
M %T3^=?.5??<,?[F_P#$_P D>1COXGR"BBBOI#B"BBB@!<GU-)110 4444 %
M%%% !1110 4444 %%%% 'NGP2_Y%V_\ ^O@?RKT^O,/@E_R+M_\ ]? _E7I]
M?F.=?[_5]?T/=PW\&(4445Y9N%%%% !7'_$S_D3I/^NR?SKL*X_XF?\ (G2?
M]=D_G7/BOX$_0[\K_P!]I?XD>)T445\J?JH4444 21320N&C<J1Z&II]0NKE
M=LLS,/3-5:*KF=K7(<(MW:U"K4.HW=NFR*9E7TS56BDI-;#E&,E:2N/DE>5M
MSL6)[FECFDASY;E<]<5'11=A96L2QW$L3%D<@GJ0:D_M"Z_Y[-^=5J*?-+N)
MPB]T6'O;AUVM*Q'IFJ]%%)MO<:BEL@HHHI%!7<?"W_D9I/\ KB:X>NX^%O\
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M\=FUS872W*J,E5%<.RE&*L,$'!J:E*=)VFA8;&4<2FZ3O82BBBLSJ/HW0_\
MD!6/_7%?Y5?JAH?_ " K'_KBO\JOU]A#X4?D%?\ BR]6%%%%49!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\4_$G_DH^O?]?3?TK[6KXI^)/\ R4?7O^OIOZ4 ?4/P
ME_Y)?H7_ %P_J:[6N*^$O_)+]"_ZX?U-=K0 4444 %%%% !7E'QC_P!9IOT:
MO5Z\H^,?^LTWZ-7)C?X#.',?]VE_74\KHHHKP#Y@**** "BBB@ HHHH ****
M "BBB@ HHHH **** "O8/@Y_R"=2_P"NZ_\ H->/U[!\'/\ D$ZE_P!=U_\
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M(^30M79 ]%<UZ*** /B3Q_\ \C]K?_7TU?5WPO\ ^29>'_\ KU'\S7RCX_\
M^1^UO_KZ:OJ[X7_\DR\/_P#7J/YF@#K:*** "BBB@ HHHH \D^,?_'YIO_7-
MOYUY?7J'QC_X_--_ZYM_.O+Z^?QG\>1\MF'^\R_KH%/BB>:58T!+,< "F5Z!
M\./#J:A=-?2X98N57W!J<-0=:=NBW.:G3E4FH1W9O>&;2V\)V=M)<J#>73
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M_ O0^QH_PX^B"BBBK- HHHH *\1^.'_(9TO_ *]V_P#0J]NKQ'XX?\AG2_\
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MQ*OA9)RMIOV//DKU+>9ZYXJT/POJ.M,^M:I%'+DA(_,*D5POBWX>_P!EV?\
M:6ERB>R/.5R<?C7(ZVM_!JTT-_*[W$;8)8GK7K/A*667X=7'VUB8@GREZ\1T
MZ^74J=2%7F6BMTU['=SQKUO9RC:_WGBAX.#14D^/M$F.F\_SJ.OIEL><]PKZ
MK\*?\BIIG_7NM?*E?5?A3_D5-,_Z]UKY7BO^#3]7^1WX#XF;%%%%?$'J!111
M0 4444 >1_%?_D-V?_7$_P Z\_KT#XK_ /(;L_\ KB?YUY_7R^-_WB1^GY)_
MN%+T_4*N:7>C3]1ANBF\1G.WUJG3XH9)Y!'$A=ST K"$I1DG'<]*<8RBU+8Z
M/5M8U+Q3>K]CBFPB@"-#T[5V-G'+I'@6XCU9BLD@;8LG6O/]-U2_\-W;E(56
M5E (D7H*]$TK4_\ A--"G@O4 E0$@J,"O2P[4X3L[S:UN?-YG3E2A",8I48M
M:K<QOAK:%[ZXNU7HC**L:GX*UV^O[J\2]>-7;<L>6_QK#TO5M4\.M>6]E;[X
ME8@OMSBLR+Q-JIU);DW4F2X)3<<?E4NK0<(4Y)Z&DL+BYXJ=>C**32M?7_AB
MKJUGJ.G7/D7QFW \%V/-5X[J\D=42YGR3@ 2&O2?&*QZCX0@U.1%$Q4<@>]<
MIX'TP:AKT3.N8XSEJR^K-8GV-SKP^/C/!RKU(I.-T_5'81RGPAX3,TTSO>SJ
M=F]B?0C@UY;<W$EU</-*Q9G))R:ZOX@:H;O6/LJ-^YA VCWQBN/K/%5O:5--
MEHAY3AW&E[>?QSU?Z(L6-PEK?0SR(75&#%1WKH/$_BTZV8$M$EMX8UP5W=3^
M%<O73>&?"<^L2":4>7:KRS-QFE1]K4C[*&QTXN.&IM8FM]G;_ACHOAQ]K:*[
MDE=VMP#G<<]JXG7FA;6;@P8\O=QBNS\1^)+32+#^Q]'Q@#:\@[_C7G;,68L3
MDFM,74B^6G%WY>IQY;2G4K3Q<ERJ6R\N[$HHHKB/:/HW0_\ D!6/_7%?Y5?J
MAH?_ " K'_KBO\JOU]A#X4?D%?\ BR]6%%%%49!1110 4444 %%%% !1110
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M*SJ*SI8*E3Y[?;W"51R@H=CV*;7_  ?XE2.ZU!'2Y  8A!SBL3Q7XXLGTO\
ML?0XC%:]&.W&?6O.**Y:644:<TVVTMDWHC7ZU.WGW.S\$ZIH-AY_]L6HF+*=
MN4SBJ>G^)5T/Q9-J%@FVW9R F.BFN8HKJ>"IRG.4KOF5FNAE[1\G+YW/8[G6
MO!7B!UOKM'CGZN @Y-8?BSQS9RZ7_8^B1F*U P3MQ7G%%<M+**-.2;;:CLF]
M$;/%3^?<"<G)[T445ZIS!7U7X4_Y%33/^O=:^5*^J_"G_(J:9_U[K7RG%?\
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M^1FD_P"N)KAZ[CX6_P#(S2?]<373@_X\?4\W./\ <:OH>R4445]2?EH4444
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MCZ]_U]-_2@#ZA^$O_)+]"_ZX?U-=K7%?"7_DE^A?]</ZFNUH **** "BBB@
MKRCXQ_ZS3?HU>KUY1\8_]9IOT:N3&_P&<.8_[M+^NIY71117@'S 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>P?!S_ )!.I?\ 7=?_ $&O'Z]@^#G_
M ""=2_Z[K_Z#79@?XZ._+?\ >5\STNBBBO>/I@HHHH **** .)^*_P#R(5U_
MUT3^=?.5?1OQ7_Y$*Z_ZZ)_.OG*OON&/]S?^)_DCR,=_$^04445](<04444
M%%%% !1110 4444 %%%% !1110 4444 >Z?!+_D7;_\ Z^!_*O3Z\P^"7_(N
MW_\ U\#^5>GU^8YU_O\ 5]?T/=PW\&(4445Y9N%%%% !7'_$S_D3I/\ KLG\
MZ["N/^)G_(G2?]=D_G7/BOX$_0[\K_WVE_B1XG1117RI^JA1110 4444 %%%
M% !1110 4444 %%%% !1110 5W'PM_Y&:3_KB:X>NX^%O_(S2?\ 7$UTX/\
MCQ]3S<X_W&KZ'LE%%%?4GY:%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M$GC_ /Y'[6_^OIJ^KOA?_P DR\/_ /7J/YFOE'Q__P C]K?_ %]-7U=\+_\
MDF7A_P#Z]1_,T =;1110 4444 %%%% 'DGQC_P"/S3?^N;?SKR^O4/C'_P ?
MFF_]<V_G7E]?/XS^/(^6S#_>9?UT"BBBN4XPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ^D?"/\ R*6F?]<!6U6+X1_Y%+3/^N K:KZ>G\"]#[&C_#CZ
M(****LT"BBB@ KQ'XX?\AG2_^O=O_0J]NKQ'XX?\AG2_^O=O_0J]SAW_ )&$
M?1_D<N,_@L\JHHHK]&/%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ
MK\*?\BIIG_7NM?*E?5?A3_D5-,_Z]UKY3BO^#3]7^1Z& ^)FQ1117Q!Z@444
M4 %%%% 'D?Q7_P"0W9_]<3_.O/Z] ^*__(;L_P#KB?YUY_7R^-_WB1^GY)_N
M%+T_4****Y3U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^C=#_Y 5C_
M -<5_E5^J&A_\@*Q_P"N*_RJ_7V$/A1^05_XLO5A1115&04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?%/Q)_Y*/KW_ %]-_2OM:OBGXD_\E'U[_KZ;^E 'U#\)?^27
MZ%_UP_J:[6N*^$O_ "2_0O\ KA_4UVM !1110 4444 %>4?&/_6:;]&KU>O*
M/C'_ *S3?HU<F-_@,X<Q_P!VE_74\KHHHKP#Y@**** "BBB@ HHHH **** "
MBBB@ HHHH **** "O8/@Y_R"=2_Z[K_Z#7C]>P?!S_D$ZE_UW7_T&NS _P =
M'?EO^\KYGI=%%%>\?3!1110 4444 <3\5_\ D0KK_KHG\Z^<J^C?BO\ \B%=
M?]=$_G7SE7WW#'^YO_$_R1Y&._B?(****^D.(**** "BBB@ HHHH **** "B
MBB@ HHHH **** /=/@E_R+M__P!? _E7I]>8?!+_ )%V_P#^O@?RKT^OS'.O
M]_J^OZ'NX;^#$****\LW"BBB@ KC_B9_R)TG_79/YUV%<?\ $S_D3I/^NR?S
MKGQ7\"?H=^5_[[2_Q(\3HHHKY4_50HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *[CX6_\C-)_P!<37#UW'PM_P"1FD_ZXFNG!_QX^IYN<?[C5]#V2BBB
MOJ3\M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B3Q_\ \C]K?_7TU?5W
MPO\ ^29>'_\ KU'\S7RCX_\ ^1^UO_KZ:OJ[X7_\DR\/_P#7J/YF@#K:***
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M444 %%%% !1110 4444 %%%% !1110 4444 ?1NA_P#("L?^N*_RJ_5#0_\
MD!6/_7%?Y5?K["'PH_(*_P#%EZL****HR"BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%% !1110!\2>/_\ D?M;_P"OIJ^KOA?_ ,DR\/\
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M* "BBB@ HHHH **** "BBB@ HHHH ^C=#_Y 5C_UQ7^57ZH:'_R K'_KBO\
M*K]?80^%'Y!7_BR]6%%%%49!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\4_$G_ )*/
MKW_7TW]*^UJ^*?B3_P E'U[_ *^F_I0!]0_"7_DE^A?]</ZFNUKBOA+_ ,DO
MT+_KA_4UVM !1110 4444 %>4?&/_6:;]&KU>O*/C'_K--^C5R8W^ SAS'_=
MI?UU/*Z***\ ^8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KV#X.?\
M()U+_KNO_H->/U[!\'/^03J7_7=?_0:[,#_'1WY;_O*^9Z71117O'TP4444
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MS^OE\;_O$C]/R3_<*7I^H4445RGJA1110 4444 %%%% !1110 4444 %%%%
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M_P!9IOT:N3&_P&<.8_[M+^NIY71117@'S 4444 %%%% !1110 4444 %%%%
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MI'PC_P BEIG_ %P%;58OA'_D4M,_ZX"MJOIZ?P+T/L:/\./H@HHHJS0****
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M>]_YXS_]\FO+_LE?S?@?5?ZV/_GU^/\ P#U;[1!_SVC_ .^A1]H@_P">T?\
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M!7SG]GO?^>,__?)IRPWRG*QW /LK5I1RU4ZBGS;'-C.)'B:$J/L[<RMO_P
M^ZO[5T[_ )_[7_O\O^-']JZ=_P _]K_W^7_&OA?;J/\ =NOR:C;J/]VZ_)J]
M0^7/NC^U=._Y_P"U_P"_R_XT?VKIW_/_ &O_ '^7_&OA?;J/]VZ_)J-NH_W;
MK\FH ^Z/[5T[_G_M?^_R_P"-']JZ=_S_ -K_ -_E_P :^%]NH_W;K\FHVZC_
M ';K\FH ^Z/[5T[_ )_[7_O\O^-307-O<@F">*4#@F-PV/RKX1VZC_=NOR:O
MH;]G(7 T36O/$H/VE,>9G^[[T >VT444 %%%% !1110 4444 %%%% !1110
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M+S#^RJ'=C?\ A)M,_P">C_\ ?-'_  DVF?\ /1_^^:=_PICQS_T!S_WV*/\
MA3'CG_H#G_OL4?V=2\P_LJAW9[-X>^-'@S3_  _8VEQ>3B:*(*X$)/-:7_"]
M/ W_ #_7'_?@UX/_ ,*8\<_] <_]]BC_ (4QXY_Z Y_[[%=T5961Z48J*270
M]X_X7IX&_P"?ZX_[\&C_ (7IX&_Y_KC_ +\&O!_^%,>.?^@.?^^Q1_PICQS_
M - <_P#?8IC/>/\ A>G@;_G^N/\ OP:/^%Z>!O\ G^N/^_!KP?\ X4QXY_Z
MY_[[%'_"F/'/_0'/_?8H ]X_X7IX&_Y_KC_OP:\Q^*'Q"\/^)M2L9M,N)9$A
MB97+1XP2:Y7_ (4QXY_Z Y_[[%'_  ICQS_T!S_WV*ZL'BYX2LJU/==S.I35
M2/*S,_MNR_OM_P!\T?VW9?WV_P"^:T_^%,>.?^@.?^^Q1_PICQS_ - <_P#?
M8KV?]9\9VC]S_P SF^HT_,S/[;LO[[?]\T?VW9?WV_[YK3_X4QXY_P"@.?\
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M^W_?-']MV7]]O^^:T_\ A3'CG_H#G_OL4?\ "F/'/_0'/_?8H_UGQG:/W/\
MS#ZC3\S,_MNR_OM_WS1_;=E_?;_OFM/_ (4QXY_Z Y_[[%'_  ICQS_T!S_W
MV*/]9\9VC]S_ ,P^HT_,S/[;LO[[?]\U[UH'QI\%V&@6-I/>3B6*$*X$).#7
MC'_"F/'/_0'/_?8H_P"%,>.?^@.?^^Q7!C\VKXZ*C52T[&U'#PI.\3WC_A>G
M@;_G^N/^_!H_X7IX&_Y_KC_OP:\'_P"%,>.?^@.?^^Q1_P *8\<_] <_]]BO
M+-SWC_A>G@;_ )_KC_OP:/\ A>G@;_G^N/\ OP:\'_X4QXY_Z Y_[[%'_"F/
M'/\ T!S_ -]B@#WC_A>G@;_G^N/^_!H_X7IX&_Y_KC_OP:\'_P"%,>.?^@.?
M^^Q1_P *8\<_] <_]]B@#MO'WQ*\-Z]J=M/87,KHD15BT9'.:Y+_ (2W2?\
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M?ZX_[\&C_A>G@;_G^N/^_!KP?_A3'CG_ * Y_P"^Q1_PICQS_P! <_\ ?8H
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M]+_A5JB@"K_9EA_SXVW_ 'Z7_"C^S+#_ )\;;_OTO^%6J* *O]F6'_/C;?\
M?I?\*/[,L/\ GQMO^_2_X5:HH J_V98?\^-M_P!^E_PH_LRP_P"?&V_[]+_A
M5JB@"K_9EA_SXVW_ 'Z7_"C^S+#_ )\;;_OTO^%6J* *O]F6'_/C;?\ ?I?\
M*AN]-L!93D65M_JV_P"62^GTK0J*Z4M:3*HR3&P _"@#X/U( :K> # $[_\
MH1KZ=^ UE:S_  UB>:VAD;[5*-SQ@GK[UX3J'PZ\82:E=.GA^]*M,Y!"=1DU
M]%?!72-0T3X?1V>I6DEK<"YD8QR#!P3P: .Z_LRP_P"?&V_[]+_A1_9EA_SX
MVW_?I?\ "K5% %7^S+#_ )\;;_OTO^%']F6'_/C;?]^E_P *M44 5?[,L/\
MGQMO^_2_X4?V98?\^-M_WZ7_  JU10!5_LRP_P"?&V_[]+_A1_9EA_SXVW_?
MI?\ "K5% %7^S+#_ )\;;_OTO^%']F6'_/C;?]^E_P *M44 5?[,L/\ GQMO
M^_2_X4?V98?\^-M_WZ7_  JU10!5_LRP_P"?&V_[]+_A1_9EA_SXVW_?I?\
M"K5% %7^S+#_ )\;;_OTO^%2PV\%N"((8X@>H10N?RJ6B@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \X^*
M7@&7Q391W5AQ?6_*8')->;1^#_B-XLEM],\00R6^GP-A7:/ QT[&OI"BE!*#
M\KWMYCDW)>>URAH^FQZ3I5O91 8C0 X[G%7Z**IMMW9,4HJR"BBBD,**** "
MBBB@ HHHH **** "BBB@ HHHH **** .)^+G_)+];_ZX_P!:^8?AG_R4G0?^
MOH?R-?6OC70)O$_A'4-'MYDAEN8]JNXR!7D?A/X#ZOX?\5:;JTVK6DL=K,)&
M1$8$CVH ][HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N"^,O\ R2_5O]U?YUWM<YX[\.3^*_"-YH]O,D,LX #N,@4 ?*WP
MG_Y*AH/_ %\#^1K[,KPGP9\"]7\,^+M.UB?5;26*UEWLB(P)KW:@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /._C=_P D
MOU#_ 'T_G7S]\'O^2H:/_P!=#_*OI[X@>&;CQ?X1N='MIXX)9F4AY 2!BO-/
M _P/U;PMXNL=8N-4M)HK=MS(B,": /<J*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBJ=_JEEID)EO+B.)1_?8"DVEN"5RY17/:;XVT+5+G[
M/;WT1D[ N.:Z&JLPN%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***0D*,D@ =S0 V:00P22$9V*6_*N&\._$NSUSQ%=:2\8A>)L(6!!;ZY
MKII_$6D17'V66\C$C<;=PKPOXK:+<>'/$<7B/23M2<G>Z=!GBIYN6:;V>GSZ
M%<O-%I;[GL-]\0_#>GZ@+&>]Q,3CY0"/SS7.?%SQ'-9^"A-IDWRW(93(AZ#
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M  5%I6EP:18I:6[2&-!@&1RQ_.KM&BTCL&KUEN%%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %2_P!3L],@,UY<)"@&<N<5QO\ PMGP
MR][]C%TOS';OWC%>=?&FUU2TU^TGDNYSIDK?.@/R@;JB\9:%X1A\ 0WNG-$M
MV5!CVXW,<U$97ASO:]K%N/O*"W:O<7QA-<^$?'MGXCMKB2;3[AP?O$C@5ZCX
MAT]?&GA:WD@OC! R[I&5RO! XXKBM&\.7/BOX0+!>(3<JK>2SCD5G_#;6[F[
MT75/!]S*4NHPRQ%S@DEL#^57*/+&5'=PU7FO^ 0I7E&MM?1^O<R/$.EZ5J-@
M^D^'K"2::V&Z2["@@D<'FM?X=WT7BGP[>>$=6;-S%D)N[8%8>@?\)=X<O;[1
M+722_P!I=A]H=&QR?6O4/"7PRMM(O8M9FFD6_=/WJK]TD]:J,4T^;6,E^(IM
MIKETE%Z>G_!//K+PAX\\+74^FZ5,&M)&PK,"0HZ5Z=X \'7GA^VGFU2[:XN[
MDAI,L2N?QKN:*%)I>8-)OR(8[6WB;='"BMZA<5-114C"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBL;4_%.CZ3(([N^A1S_  EQFBX6
M-FBJEAJ=GJ< FL[B.9#W1@:@UV^GT[1[B[MHQ))&A8*1UP*4GRJ['%<SLBU=
MWUK8Q&6ZG2&,?Q.<"N"\8_$A;"&*W\.E-0O9@=@B&\#%>>VFJZE\7=82PN;E
M[&.%&$D<3;<MU'!K*TS3Y/AQ\3;>&^9I+3<5C=^:<8.4HQD[7V\P<E%2<5?E
MW.M\(?%/6Y?$?]C>)[9;=ICM3Y-N,^M9?BG0]:^'_B&7Q%H]U;K;W6.),GW_
M *UN_&#PR;S3[?Q'I:_OX!YC,G4\<58N]1;Q)\'YKF]LI#<01,%5T.<C J7+
MW/:+24='YIC2]Y0WC/\ -',:1XCTKPU?/KM_.FH:K<I]RU.0N>>E>I^"/B!8
M^,HY!#&\,T9PR/UKR3P?=^$=)T-YGL'O=28D",Q;B#7=?"[PM<V=[=ZY<P"W
M^TNQCB QA3[5NEJXO9+^D8MNW,MV_O/2+S2[+4&4W=M'-MZ;U!Q5B.-(4"1H
M$4= !@"GT5D:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2
M "3P!UH 6BO//$WQ8TG0=0:QCCFN9T)#B)-P&/I6MX0^(&E>+HB+9S'.O6.0
M8/Y41]Y7B$O=T9U4LT<$32RN$11DL3P*\_\ &'Q,@TJ%8M$7^T+MV*@0_, ?
M>NXU.R74=.FM6) D7&17SIX3B_X1#XIRZ?JB[DG<>47Z#))_E4Q3G4]G>W];
M%-J--SWL2#Q;J?Q"URWT/70UFGF LB?(2.F*3Q9X3?X8^(;/5=*DE^PLZB3<
MV>IK>^+/AQ]*U.S\4Z5'C8R[A&.N.<UW$=I!\1? $*7$9$KQ@Y8=&Q3BWR*I
M!6E%ZKN)VY^6;O&2T\C@O''A[3]5T&+QGI+7*W4I#2?9WP<,>>GL*PM \2W5
MM!L\+Z9=7-^P_>W%ROF<_6O4=/\ !-WX>\ 76EI,UQ,4X5CD# / K@/!^J>(
M=*TTZ/9:"4O/NM/)$P!]\TTDISA#;I\^GH+5PC*6^S_1G7_#3QSK.K:K=:1K
MD2K<18QM7'6O5JX;P+X+ET26;4]2?S-1N<%SG('TKN:N=M.]M?4B.[?2^@44
M45!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M -=UC4L[ *.237(:U\2_#FBS>5+>1R.#@JCCBF?$VRU*Z\*3MIMQ)#+&"QV'
M!( KR;X::7X<UG2-0DUQE:^CR&,^,_=]ZF+<G+^Z5)**3[Z'6^/9[;QUX3_M
M'0[QC+;8)C1_?/(%:7PL\4'Q'X6;3Y9<7D"[6)/-<)\+;<CQQJ=A8[I-)9F4
MGM]WBFW*3_#3XFB505TZZD_"M(1C?DZ5%=>3_P""1)R:;ZP?WHV=6T71/"]U
M-_:7F:IJMRQ$<6[>1SD<&N0\,WU[X"\=K%>QM%:7Q!,;# 56)-;_ ([LM:L_
M&MEXKTVU-] =C(B@M@A?;ZUMZ5X+U#Q]='6/$L?V7Y L21\$8]C4T;Z2^37E
MV'5L[Q[ZKU*'BGX?ZK!K2>(_"L@'G .5&><\]JT_#G@WQ7K6KP:GXBO2D4/(
MBC8KD]1Q7K&FV*:;80VB.SK$H4%NO%6Z<;0?NZVV\A2O->]N]R![.WD;<\,;
M,.Y7FI@ HP!@4M%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4455OM2M--@,UW<1PH.[L!0W8$KEJBL73?%6C:K,8;2^A>0?PAQDUM=
MJ&K!<1F"J68X ZFN?U7QGHNFV\Q^WP//&IQ$K?,3BO-/'OQ$U:UU[_A'1$((
M[@[%F&0>>.M<AXQ^&U[H&CVVOPWLUTQ96FW-GOS^%9W;CS;)Z7+Y;2Y=WV-C
M4/BWXQMKN+4&TWRM)=AM=XOX2?6NC\7:(?B-X<LM>TF=([B%2XW'O^%:7A]=
M/\=?"^.T"(72'E<?=;DBN8^%%WJ.BZO?>&KZWE:$':AVDJ!6TH>]*EUCJF9J
M?NJKT>C1SL6L2^((H1XIU*S%K8,0(8SM=L<5W_A_XPZ3<:I:Z0MG/#$=L43N
M  <<?TK@Y+/PY;?$J]76+<QVT>UHX]G#$DYK=32X?&GBJP?1]*^QZ=92*YE,
M>PMC@_6BD^;E[/5_YA52BY)=-O\ )'N$L,%];;)462)QT89!%-L["TL(A':V
M\<2CLB@5+!$(((X@<A% J2EL] 5VM0HHHI#"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **Y[Q1XOT[PK9^=>N2Q^ZB\D_A7(Z+\9]'U'4X[.XA
MGMFD^XTJ;0?SHC[SL@E[JNST^L#7?%VDZ%;3//=1F:,9\H-\QK<CD2:,.C!E
M8<$&O OC9X>N+'5(=<A+/"[9E7L *B3M)1>B>E^Q<$FF][?B5O$GQC\2"*=!
MI[6]E,"L<CQX/X&I;WX6VFI>"SK]G<S2:CM,Q)<GDC.!^==K>:/IWCSX9+]D
MBC\Y8=L9 Z,  :QO@WK5QY=YX;U"-V\AF +#@C.,?I5\GQTUI);/R,_:>["I
M]E[HS?"'V/QYX5ET+6"_VVR)V;3AOE%<?97%MX?UFZLKZWU*]N;>7;:0LVY,
M#IP?>O8])^&0TKQE/K,%PT<4N244]237%>(5U/P_\29-2;1FO87#",K$7 SC
M'2GS)U$]N9:^O_!'RVA**UMMZ$<?Q%\8Z5J]G+J=@L%C<, L?E;2 3BO>[:8
M3VT<H&-R@UY38>&M<\:ZQ!J>O(MO90G,4"G\>0?>O68T6*-448"C JGI!)[_
M *$?;NMK?CY#J***@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .8\=^&H?$WAJXM'4%PNY3CTR:\!^'/ARSU'Q4VDZ_.^ZV
M?$4#*"IKZD(!!!Z&O/[OX8VLWC5?$,%P8) V615^]12]RK?H_P ^XZCYJ5NJ
MV_R.ZM;2"SM4M[>-4B48"CI7$#X8V2>-_P#A(H;J2$C:?*11AB,_XUWJ#:BK
MG.!BEIIVES]1?9Y>@@&!BEHHI %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !5*_U>PTR(R7=U%$!V9P#5FX,@MY#$,R;3M'O7C,G
M@#6?%>N7=WXIN3#:QG,<18$8J;MNR*TM=GI\/B/3]3L9Y-.N4E=%Z!AFO"?!
MGA^U^('B;6!KEP[S1LP0, =H#D#%6?!EG9^'/B5=6MK>K_9Z!-Y+  ]:AU59
M?AY\1DU:U^;3+ME+NAR#G)/3ZU48P<XR>THZ>3_X),G+DE%;Q=_5?\ ?I%YJ
M/PO\>+I,TKOIMP^$#=!D]:^A%:*^L]PPT4J_F#7A_P 7M2TK6]!T[4;*5'O&
MD4C;UZ5ZMX':9_!VF&?._P A<YJHWG2]_=.WJ3*T:BE#:2O\SQ7Q%9S?#CXH
M1:K;AA9WCDD <#) KT+Q]X/7QYH=K>Z:%^U+@QL3COSS78Z[X9TOQ''''J-L
MDRH05W=L'-:-I9P6-JEM;1A(D&%4=JB*_=J,MXO3T+;_ 'G/'JM3'\.Z-/:^
M&H=.U8BX=5P^XYS6M_9]I]C:T\A/L[#!CQP:LT54GS-M]28KE22Z&!9>"?#>
MG71N;32+:*8G)=5.<UO  # & *6BE?H/K<**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH YOQ=XRT_PG8^=<L6E;A(U&23VX'-9GA/Q3J7BK
M1[Z>ZL!:@JPAP&RPV]>:\Z\?7,0^*-J=4.;2*(.%;ID&K.I_%76;21I=-T;_
M (E4+;0X8C</6I@U*G=_:_ J::GRKI;YF;X"CL?^%EZO8:O CSR2MM,@_P!D
M9J+QOH\OP\\:VVMZ4ICM)GRR+P!53Q"9=6DM?'.@H5ER&N8X^H)/3\A5OQAX
M^M?&7A>#38;:0ZBV 5V'Y3GUJES14.7XHZ-=T+W92G?X9:_,][T;48]4TFWN
MXSD.@)^N*\]^*7@&\\0S6FHZ.%74(W^\6V\ <<UUG@*PN--\(V=M<C$H&2/K
M72U56"53W>CT(HS?L]>J,'2M)DN/#EM9:Y#'-(L85U)W \5K6=C;:?;K!:0K
M%$HP%7I5BBDW=M]QJ-DEV"DP*6BD,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#:PK%&O15Z"IZ*2T5D-ZN["BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD*Q01JB#H%&*FHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gzbwht3f4aft000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )Q!48# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *RM<\2Z/X;AAEU:^2V69BL8*LS-CK
MA5!.!QDXP,CU%:M>'_&Z]ED\1:;8,J>3!:&9& .XL[D,#STQ&N..Y_#6C352
M:BS#$572IN:/6]#\2Z/XDBFDTB^2Y6%@L@"LK+GIE6 .#S@XP<'T-6=4U2RT
M739=0U";R;6'&^3:6QDA1P 3U(KY\^&/B&31?&-HBEWM=09;66-<G)8X1L9
MR&QR<X4O@9-=U\<+[9I.D:=Y6?.N'N/,W?=\M=N,8YSYO7/&WWXUEA[55#HS
M*&*O0=1[H[S0O%6B^)6N!I%[]I-N%,O[ITV[L[?O 9SM/3TK9KSSX10?V;\/
MY;V[FA2WGN9;D.7P(XU 0EB< 8,;'TQBBY^,WAB"Y>**+4;F-<8FB@4*W&>
M[*W'3D#I6<J3<W&"O8UC72IJ51VN>AT5S7A7QSH_BXSI8--%<0\M!<*JN5X^
M< $@KDXZ\'KC(S0U[XH>'-!U!K&1[F[N(V*3+:1AA$PQP2Q )YQP3@@@X-0J
M<W+EMJ6ZU-1YKZ':45Q&A?%3P]KNKQ:;&MW:S3<1/=(BH[=D!#'YCVSUZ=2
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M\2*TC)P#\P0$KD,",XSVIND>.?#>O:@MAIVIK+=,I98VB=-P'7!90"<<X'.
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MNRH))'5F)VC<"5 &0Q88QQC%?0>H>++7PWX>L;SQ*ZVU]- "]K"-[-,$!=4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*2!T QN8G'.*N7N@^(-<N+:QL/!4FFQ1-+Y(6VD0LK'=B6:4X8@# )(ZX Y
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M?<B1P13'(7#$LZCL3\L9/<<>O/$:V7\3_$:ZA:]1A?:E]FBN44,HC+^7&1C
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MXC741O4=;[4OLT5RBAE$9?RXV&,!@%V]^<=><UZ'\;WL4T_2T-JO]H33,RW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 >0^&OA3K-AXKLM5UJ[LKN
M*&8SRE9Y6D>0 E6R5&3OVDY//.<]*]>HHK2I4E4=Y&5*E&DK1"BBBLS4****
M "BBB@ HHHH **** "BBB@ HHHH **** //_ ![XB\6Z7JD-IX=TJYGA:T8R
M7"6K3*'9L#&!@,@7/)(._E>!7'>#_AUJ^N:__;?B2W>WM3,;F2.>-0]U(7)*
MF,CY5)!)R!D' '.1[C16\:SC#EBK>9SRPZG/FD[KMT"BBBL#H"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT-<AX*FL[#Q7;_;(Y$(9H(E"$&.=CM^8#GNRD$'!.3C&1T?BO_DHNA_]L/\
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M_P#T8M<__,7_ -O?J=G_ #+O^W/_ &T\HTV[GT75;'465T5'$R[ K-)%DJ^
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MS81Z.\TT<Y@BVS_ZQ@^W^[D9&<8SS@=\C$^&B)'XAG2,JR+9LJE00"-Z8QD
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MF&TA>64=2,D#)K>T+QI8:O8W$LX%I<6R-+- 6+GRU_C4@ L,8S@9!..X)S/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$U%VN%3#TJC4IQ3:"BBBLS8**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ4<\C:E)$
M6_=@<# ]J +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(I!$OV=9'/*$L?O$ GJ0,@= #VJ^O;?3=/N;^[D\NVMHFFF?:3M102QP.3@
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M6[=LWH&QG SC.,X%7Z "BBB@ HHHH **** "BBB@ HHHH *SH?\ D,2_[O\
MA6C6=#_R&)?]W_"@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC((ZT >4K\"TT?Q':ZSX3\2SZ/-;PA%\ZT6Z._849OF8#Y@>1@X).,# '?\
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MZ\*HX(_4UZ_10 4444 %%%% !1110 4444 %%%% !1110 5G0_\ (8E_W?\
M"M&LZ'_D,2_[O^% &C1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXL%PA#;@21R,9S[510!X3IGPA\<:'XHM?%UIK&AW>NM+/-=QW:2K#OD##*E
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MT;)W(HQA3WKI_BQX*U+QWX5MM+TN>UAGBO4N&:Z=E7:$=<?*K'.6';UKNZ*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6BZ_?.BM?::C)!&F%@"2R1L >I!='?GD;]N3MR?0O&?CKX@^$O$]EX?O]?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **KV]_:7<T\-O<Q2R6[;)E1@2C>
MA]#1>WUIIUJUS>W$5O I ,DK!5!)P.30!8HI%8.H92"I&01WI: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MLZ'_ )#$O^[_ (5HUG0_\AB7_=_PH T:*** "BBB@ HHHH **** "BBB@ HK
MG/\ A+[;_A//^$4^SR?:?LOVGSLC;CTQ71T %%%% !1110 4455U&X>TTZXN
M(P"\:%@#TH M44V-BT:L>I -.H **** "BBB@ HHJI873W4<S.%!25D&/04
M6Z*** "BBB@ HHHH **J7UT]LUJ$"GSIUB;/8$'_  JW0 4444 %%%% !112
M,<*3Z"@!:*JZ?<O=VBRN &)(P*M4 %%%% !1110 4454N;IX;RUA4*5F8AB>
MW&: +=%%% !1110 4444 %%1SN8[>20#)52PS["F64S7%E#,X 9U!('2@">B
MBB@ HHHH **** "BJDERZ:G#; #8Z%B>_%6Z "BBB@ HHHH ***:YVQLP[#-
M #J*K:?</=V$4[@!G&2!TZU9H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *RO$-KJUYI$EOHM['97<C!?/=-VQ?XB!ZXZ5JT4 >7
M?"2P&DW_ (ML3<23_9]1*M/*?F<[>6-8'Q,O+KQ;I5]J%M*Z:!I%Q$D1 P+J
M?S &/NJYQ]:Z;P=IEQ=:CX\MG\^T%U?LJ3;"#@KC<N>M<=XQ^%6I:!X)F^R^
M*]8OK>)XPMB(\H<N.< GIG/X4 >Y6AV:9 Q!^6%3C\*\W;XW:8KLO_"/ZX<$
MCBU-=UX7TV;2/#5C8W%]/?2QQ_-<3_?;///TSC\*UMH]!^5 ''^"_B+IOC>Z
MO+>RM;NWDM #(+A-O7M]:[&O+?AI_P C[XW_ .OM?Y5ZE0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6=#_R&)?\
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MG1YL?_/1?SH ?131(A. ZD^@-.H **** "BBB@ HHHH **** "BBB@ HHHH
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M?\AZV_ZY-6C0 4444 %%%% !3)?]2_\ NFGTR7_4O_NF@"GHW_((M_\ =/\
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MW:7W'+_\43_S\>(_^_'_ ->C_BB?^?CQ'_WX_P#KUU&?\XHS_G%:_7GY_?\
M\ CZM3_E7W'+_P#%$_\ /QXC_P"_'_UZ/^*)_P"?CQ'_ -^/_KUU&?\ .*,_
MYQ1]>?G]_P#P ^K4_P"5?<<O_P 43_S\>(_^_'_UZCF_X0[R7\B?Q"9<?(&@
MXS[UUF?\XHS_ )Q1]>?G]_\ P ^K4_Y5]QRP_P"$*VC-QXCSCG$'_P!>E_XH
MG_GX\1_]^/\ Z]=1G_.*,_YQ1]>?G]__   ^K4_Y5]QR_P#Q1/\ S\>(_P#O
MQ_\ 7H_XHG_GX\1_]^/_ *]=1G_.*,_YQ1]>?G]__ #ZM3_E7W'+_P#%$_\
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M10!Y;\-/^1]\;_\ 7VO\J]2KRWX:?\C[XW_Z^U_E7J5 !1110 4444 %%%%
M!6)XGTZXU/3DAME!</DY-;=% 'G'_"(ZM_SS3_OJLW4--N-,F6*Y #,,C!KU
MFN \;_\ (5B_ZYT[@4;7PUJ-Y;)<0HIC<9&6K3T?PSJ5GK%K<2HHCC?+$-[5
MTOAS_D 6G^Y_6M6BX!1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRI] !1110 4444 %9VC_ .IN?^OE_P"E:-9VC_ZFY_Z^7_I0!HT444 %%%%
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MW_R,&G?]<Y?Y"M.LR[_Y&#3O^N<O\A6G0 4444 %%%% !1110 4444 %%%%
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MH \;^#D^JS^,?%[ZI:);SM*K3(K9"R=Q^5>R5Y;\-/\ D??&_P#U]K_*O4J
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MI?\ W30!3T;_ )!%O_NG^9J_5#1O^01;_P"Z?YFK] !1110!F7?_ ",&G?\
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M??&__7VO\J]2KRWX:?\ (^^-_P#K[7^5>I4 %%%% !1110 4444 %%%% !7
M^-_^0K%_USKOJX'QO_R%8O\ KG0@.I\.?\@"T_W/ZUJUE>'/^0!:?[G]:U:
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MB,<;@<9/J<\_\,_#VF>)_@=HFFZO \]FS2N\2SO&'(GDQNV,"1GG!XR >H%
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M *&BX_*C[5XM_P"AHN/RH]E#^=?C_D',^Q[=17B/VKQ;_P!#1<?E1]J\6_\
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M7_"VFZK+"8I+J!9&3T/>M>@#RWX:?\C[XW_Z^U_E7J5>6_#3_D??''_7VO\
M*O4J "BBB@ HHHH **** "BBB@ K@?&__(5B_P"N==]7 ^-_^0K%_P!<Z$!U
M/AS_ ) %I_N?UK5K*\.?\@"T_P!S^M:M !1110 4444 %%%% !1110 4444
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M]S?^A5WU:XG^-+U%#X49NK??T_\ Z_$_D:TJS=6^_I__ %^)_(UI5@4%%%%
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MJ4DTQ>"&81QP[,X#)WZ5[W7#:O\ "+P?K>LR:K=V$@N)&#2+%,41SZE1Z]Z
M+_P]U2ZUKX?Z7>W"(DSPE047"D*2H8#T( -<LWA_XK;V*^)[$+DX'D]J].M;
M6"RM8K:VB6*")0J(HP% [5+0!XW\'(-4@\8^+TU2Y2>=9565D& S]S^5>R5Y
M;\-/^1]\;_\ 7VO\J]2H **** "BBB@ HHHH **** "N!\;_ /(5B_ZYUWU<
M#XW_ .0K%_USH0'4^'/^0!:?[G]:U:RO#G_( M/]S^M:M !1110 4444 %%%
M% !1110 4444 %%%% !1110!#<6EO=H$N(4E4'(##.#5;^Q=,_Y\8/\ OBK]
M%4IR6B9$J<).[29Y)X]MH;77Q'!$L:>4IVJ,5W/AW2M/F\/V<DEG"SM&"6*\
MFN*^(G_(QC_KBM>@^&?^1<L?^N8KU<5*2PE-W/G\!3@\PK)K3_@EJ'2[""42
MQ6D2.O1E7D5<HHKR7)O<^AC&,5:*L%%%%(H**** "BBB@ HHHH **** "BBB
M@ HHHH *SH?^0Q+_ +O^%:-9T/\ R&)?]W_"@#1HHHH **** "BBB@ HHHH
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M?^^Z/^$3TO\ NR_]]UN44 8?_")Z7_=E_P"^ZOZ=I5KI8D%L&'F8W;FST_\
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M"&+RA"K=5R.01R^?GK[4HH XSX4!E^&.BH=2CU$(DB+<QF3:RB5PH'F*K84
M+@@8V\<8KLZ** "BBB@ HHHH **** ,S4/\ D+Z5_P!=)/\ T UIUF:A_P A
M?2O^NDG_ * :TZ "BBB@ HHHH **** "N8^(=OH=UX%U*#Q)>3V>D-Y?VB>
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M<$YQ0!].T57L;VWU+3[:_M)/,MKF)9H7VD;D8 J<'D9!'6K% !1110 4444
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MC_KBM>@^&?\ D7+'_KF*]7%?[I3/G\O_ .1C7_KJ:U%%%>4?0!1110 4444
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M10!F7?\ R,&G?]<Y?Y"M.LR[_P"1@T[_ *YR_P A6G0 4444 %%%% !1110
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M4445D,**** (;O\ X\Y_^N;?RJ'2O^07;?\ 7,5-=_\ 'G/_ -<V_E4.E?\
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MQB5UYXZ9QU_&@"C\-9[^[^'&DR7KN;AH6"O)]XKN(4G\,5SC>$_BJ6)'CVS
MSP/L0_\ B:]/C1(HUCC4*BC"JHP *=0!XY\'K75+;QEXP34[]+N9)E6614V[
MY.[?E7L=>6_#3_D??&__ %]K_*O4J "BBB@ KSSXN?\ ($T[_K\6O0Z\\^+G
M_($T[_K\6ML/_%1,MCGNP^E%'8?2BLQA1110 4444 %%%% !1110!0UK_D"W
M?_7,UZMX,_Y$[2O^O=:\IUK_ ) MW_US->K>#/\ D3M*_P"O=:U?\'Y_H+[1
MNT445@4%%%% !1110 4444 %%%% !1110!Y1\1/^1C'_ %Q6O0?#/_(N6/\
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M%% !1110 4444 %%%% !1110 4444 %1:/\ \E*T3_<?^52U%H__ "4K1/\
M<?\ E6U#XGZ/\B9;'K$W_(>MO^N35HUG3?\ (>MO^N35HUSEA1110 4444 %
M,E_U+_[II],E_P!2_P#NF@"GHW_((M_]T_S-7ZH:-_R"+?\ W3_,U?H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *YCXAW&AVO@74I_$EG/>:0OE_:((
M"0[_ +Q N"&7HVT]1T_"NGKR3QU=^.;+Q9<+IOQ \,Z+I\J(]M9ZC-$DH7:
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MPDA"D_\ "0ZCP/:O2::_^K;Z&CZS5[_@@Y$>86/PLBN[59FU_4 22,#%6?\
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M:M?'S^)GZ0M@HHHJ1A1110 4444 %%%% !1110 5G0_\AB7_ '?\*T:SH?\
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M -?+_P!* -&BBB@ HHHH **** ,W5OOZ?_U^)_(UI5FZM]_3_P#K\3^1K2H
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MH5AC^\1GD_A5'4-#\57FGS6X\*Z@ID7 . :UO'*W#_&-UMKN6UD.G)^]B.&
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ME34IJ,5).]P3N[$U%%%9%!1110!FZM]_3_\ K\3^1K2K-U;[^G_]?B?R-:5
M!1110 4444 %-?\ U;?0TZFO_JV^AH HZ+_R#4_WF_G6A6?HO_(-3_>;^=:%
M !1110 4444 %9M__P A/3O^NC?^@FM*LV__ .0GIW_71O\ T$T :5%%% !1
M110 4444 0W?_'G/_P!<V_E4.E?\@NV_ZYBIKO\ X\Y_^N;?RJ'2O^07;?\
M7,4 7**** "BBB@ HHHH SIO^0];?]<FK1K.F_Y#UM_UR:M&@ HHHH ****
M"F2_ZE_]TT^F2_ZE_P#=- %/1O\ D$6_^Z?YFK]4-&_Y!%O_ +I_F:OT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,R;B-R,"&&1R,@GI5?1-$T_P[I$&E:5;_9[*WW>5%O9]NYBQY8DGDGJ:T**
M,C2/"^C:#J&IW^FV?D7.J2^=>/YKMYKY8YPQ('+MTQUK7HHH \.\9?\ ):6_
M[!R?S-7:I>,O^2TM_P!@Y/YFKM5T$%%%% !1110 4444 %%%% !1110 4444
M %%%% &/XE_Y!'_;5/YU[K9?\>%O_P!<E_E7A7B7_D$?]M4_G7NME_QX6_\
MUR7^5:S_ (,?5_H)?$3T445@4%%%% &;JWW]/_Z_$_D:TJS=6^_I_P#U^)_(
MUI4 %%%% !1110 4U_\ 5M]#3J:_^K;Z&@"CHO\ R#4_WF_G6A6?HO\ R#4_
MWF_G6A0 4444 %%%% !6;?\ _(3T[_KHW_H)K2K-O_\ D)Z=_P!=&_\ 030!
MI4444 %%%% !1110!#=_\><__7-OY5#I7_(+MO\ KF*FN_\ CSG_ .N;?RJ'
M2O\ D%VW_7,4 7**** "BBB@ HHHH SIO^0];?\ 7)JT:SIO^0];?]<FK1H
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MZQ91RI;H&1IE!!Q6C_PF'AO_ *#EA_W_ %_QKX^?Q,_15L;=%8G_  F'AO\
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MW8ZBBBL"@HHHH S=6^_I_P#U^)_(UI5FZM]_3_\ K\3^1K2H **** "BBB@
MIK_ZMOH:=37_ -6WT- %'1?^0:G^\W\ZT*S]%_Y!J?[S?SK0H **** "BBB@
M K-O_P#D)Z=_UT;_ -!-:59M_P#\A/3O^NC?^@F@#2HHHH **** "BBB@"&[
M_P"/.?\ ZYM_*H=*_P"07;?]<Q4UW_QYS_\ 7-OY5#I?_(+MO^N8H N4444
M%%%% !1110!G3?\ (>MO^N35HUG3?\AZV_ZY-6C0 4444 %%%% !3)?]2_\
MNFGTR7_4O_NF@"GHW_((M_\ =/\ ,U?JAHW_ ""+?_=/\S5^@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0@,"#R#P:\GO/
MA?XI@FU*RT'Q6MCH6H2M)):M$69 Q^8*>U>LT4 9NAZ-;Z%H%II%OEH+:(1
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MXUW-% %'2-'L-!TV+3M-MUM[6+.R-3P,U>HHH **** "BBB@ HHHH *SH?\
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M "2W1_\ <;_T(UWE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFY6\TQK+QPI;L,C]*Z'X*3R0:SXGTBSN9+G0[.Y*V;LVX+SC /TH ]CHHHH
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M  '84^B@ HHHH **** "N2UCX9^$=?U2;4M3TA;B[FQOD,KC.!@< X[5UM%
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M(K[#(D>1Y@53\TB]Z\I\?>5_PT,?[=\C[#Y*?8_[4W_9=WV?]UNQ_P LO/\
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M'>LB^\7Z!IGB2S\/7NHI!JEZ@>WA=& <$L!\^-H)*D $Y)P.XKY?\,:GXO\
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MDY.3G)))SGFN3_X4I\/<8_X1_C.?^/VX_P#CE=_10!@?\(5X>_X2_P#X2O\
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MSRSL-I(#[E^ZB*I)^7<YP>A]>HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gzbwht3f4aft000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !9 9P# 2(  A$! Q$!_\0
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M(_7BO1?#'@_1/!]B;71K-80^#)(3N>0^I8\UNT (B+&BHBA548"@8 %+110
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M-%<ZI8^'8=^ZT_?SGMEA\H'KQFLCX2?$C1? >C:A'?6=Y/<W=RIW0J-H15P
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MTRRU>QDLM0MH[BVDQNCD&0<53\.>&=*\*Z;]@TBU6" NTA[EB23R>IQG ]J
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gzbwht3f4aft000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzbwht3f4aft000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *0!M,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***CG?RX6?T%
M$E%8FE:NU[J,UN4(V#.:VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **9(VR,MZ5BV&L
M-=:A- 4(V'&: -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK-
MUF^;3[)IPI.* -*BJ&EWWVZW#[<<5?H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_GXDH_X0RV_Y^)*Z>BBX61S'_"&6W_/Q)1_PAEM_S\25T]%%PLCF/^$,MO\
MGXDH_P"$,MO^?B2NGHHN%D<Q_P (9;?\_$E'_"&6W_/Q)73T47"R.8_X0RV_
MY^)*/^$,MO\ GXDKIZ*+A9',?\(9;?\ /Q)1_P (9;?\_$E=/11<+(YC_A#+
M;_GXDH_X0RV_Y^)*Z>BBX61S'_"&6W_/Q)1_PAEM_P _$E=/11<+(QM+\/0Z
M7<F9)78D8P:V:**0RIJ-R;2QDF'\(S7F\NJZ?,UX]Q,/,=?E4^M>H21),A21
M0RGJ#63>^&=-NH'1;:-'88W8Z5-G=LKI8X_P]K%C%H_V=W!DVGY3]*J1VEQ-
MI\L\0/E>8>G2NML?!UK:6?DDJ[X(WXK/_P"$%NU#)'JKK$6SL X_E6DFG)M>
M1FDTM>YK>%KJ.>S9% !3@XK#\4@Z9>QW"\!VR375Z1I*:5 8PP8GJ?6H==T-
M=9B5&?9M[TJC]]2B.DO=Y9'GLTKI<'5@3LEX!_S]:COY9KRW_M"/)Q\N0:[?
M_A$4.C16!F!\LYW8ZU8L_#$-MI;6;,'!.<XH=DK+IL)7O=]7J<-#;:U>Z>T<
M.G(0W_+0#G^55;Q=5MIK.&:(EU.%0G@UUY\&Z@CL8=8DC0GA1V_2KUSX6>YM
MHT>Z)FC'$AZYIMZW0):6.5.G:[=7$<G]GK"H8$E.*I>(EN1KJB,'>$&<&NNM
MO"FI02JS:S(Z@_=_R*M2>%1+JOVUY\_)MVD4/=?,%LS*T6RAU'0IH4;,I/)'
M4&JUA+)HFHK;WEI&%=L([#DUJR>#[A68VFH- "<D*/\ ZU1P>"[D7<<]UJ33
M^6<@,/\ ZU-2O/FV3%RVCR[V.MAD26(.GW3TI[+N1E]1BFQ1B*,(O04^I>^A
M2O;4YJ3P?;R2,YN)/F.:;_PAEM_S\25T]%%PLCF/^$,MO^?B2C_A#+;_ )^)
M*Z>BBX61S'_"&6W_ #\24?\ "&6W_/Q)73T47"R.8_X0RV_Y^)*/^$,MO^?B
M2NGHHN%D<Q_PAEM_S\24?\(9;?\ /Q)73T47"R.8_P"$,MO^?B2C_A#+;_GX
MDKIZ*+A9',?\(9;?\_$E'_"&6W_/Q)73T47"R.8_X0RV_P"?B2C_ (0RV_Y^
M)*Z>BBX61S'_  AEM_S\24?\(9;?\_$E=/11<+(YC_A#+;_GXDH_X0RV_P"?
MB2NGHHN%D<Q_PAEM_P _$E'_  AEM_S\25T]%%PLCF/^$,MO^?B2C_A#+;_G
MXDKIZ*+A9',?\(9;?\_$E'_"&6W_ #\25T]%%PLCF/\ A#+;_GXDH_X0RV_Y
M^)*Z>BBX61S'_"&6W_/Q)1_PAEM_S\25T]%%PLCF/^$,MO\ GXDKGH='C?5Y
M;7S&"HV,UZ17$VO_ ",MS_OT)B:+_P#PAEM_S\24?\(9;?\ /Q)73]J*+CLC
MF/\ A#+;_GXDH_X0RV_Y^)*Z>BBX61S'_"&6W_/Q)1_PAEM_S\25T]%%PLCF
M/^$,MO\ GXDH_P"$,MO^?B2NGHHN%D<Q_P (9;?\_$E'_"&6W_/Q)73T47"R
M.8_X0RV_Y^)*U-)T:/21((Y&??US6G12N%@JM>WD5E 9)6VCM5FL77M#DUFW
M\I+DP\YXJ97Z%*W4P1!<>(=56=H\6ZY4L*BU[4X;:ZMK29]L*_*Q]JF@\$ZA
M;#$6LR*OH/\ ]5=''H5FT"+=Q)/(HP78=:MI626R(N[MO=GGMKJ&GQ:V/)E!
MC+C!KTF<1WVGL4.5VG'Y5A_\(7:#43<KM"[LA,=*Z98D2+RT "XQ@42M*FH@
MDU.YY8\[Q6D^EYQ))(6 _$U':W3V=E-8N3OFZ UV<_A%)M86_P#.  &-F*2?
MP?'-J$%UYP CZKCK1%W2OUW'):RY?D<'LO8IH%CA\Q@W"GO6E/I^OO/)<_8!
M "O.SBNPU/PPMZJ>1-Y#K_$!5:T\+:A!(3+J\DJ$8VG_ /50G<F2_$XW3'U2
M:1A#9+<,"1\_-:4&G:I::9=O=PF-6.<9XK>NO!T[S^9::@UL,<A?7\JL6_AJ
M[6QEMKC47FW]V[?I0W>.A37O?,\^T_S1JD7G$K$7]>M=CKFC-/"MS9)YBJV[
M;VXJ]'X0C2!D,P+$85L=*J'P=J/E>6NLR*OI_D4Y.Z27026K;ZEOPWJL5QB!
MX(XIAQA173U@:%X;_L@[GG\Z3/WC6_3FT]A035S,U?1H]6\OS)&39TQ67_PA
MEM_S\25T]%1<JQS'_"&6W_/Q)1_PAEM_S\25T]%.X61S'_"&6W_/Q)1_PAEM
M_P _$E=/11<+(YC_ (0RV_Y^)*/^$,MO^?B2NGHHN%D<Q_PAEM_S\25S^LZ9
M:V#>7%.SOG!!KT>LRXT6&XN?.< \YP:+@T<AH7A^2[D667<L8Y!%=)XDC$7A
MYT!SC K;BACA0)&H51V%9'BK_D!2_6BX6LAOAK_CR_"M:ZD:*VDD4991D"LG
MPU_QY?A6O<NL=O([#*@9(J9[,<=T>%:_\4=5T+Q7,D\""U.%R3[UPWC/6-.\
M0>)8+^"4-&$&X@=#Q79_$3QEI#7,NGIH4,]R>-XZ\_C7C<VDWT5P5EC>!G.Y
M8SZ&LZ$G[LK:QV?<UJJSDD]UJNQZY>?%J2TLK/3=&5)F$85NQ!KV3P;JEUJF
MB02W<820IDBOFSP=K%OX4NE35]"6<RG*2R=A^=?37A?4K;4],CGM8%BC9<A5
MKLY4H-K7S.1OWE':WXF[1116!L%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %,E7?$R^HI]% ',Z?ITMOK4TW1&Z5TPZ4F
M!Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<M!IDRZY-.?NLV1Q74TF!Z"@!:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "LO7[9[O2I(D^\36I1UZT 96A
MVSVUKM?KBM*2-98VC<95A@BG]*@N96B3*T6YM!-\JN<;<?#71IM;EU.6U5B5
MR/7(KQSXCV6H?\)C";.PG:%$"Y5"1VKZ#_M&?U%1M<[SEHHF/J4%:PH3C.$E
MM'H9O$P:E=:LY6'P)I?B/0K-[VS_ 'ZP@?/VKM=$T>WT73XK6W0*J+CBJXOY
ME&!M ]A5^SG>8'=VIRA**=M$R83C*R>K1;HHHK$W"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JK>_ZJK55;W_554/B(G\+,6BBBN\\X*U--Z-676IIO1JRK?";4/C-"
MBBBN,[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH YOQ?J%SI]G$]M(48M@FN._X2?5O^?HUU'CO_ )!\/^]7G]>-
MC:DXU6DSZ7+:-.6'3E%,V/\ A)]6_P"?HT?\)/JW_/T:QZ*Y/;5/YF=_U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/
MJW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_
M "K[C8_X2?5O^?HT?\)/JW_/T:QZ*/;5/YF'U:C_ "K[C8_X2?5O^?HUU'@_
M5;S4)9Q<REPHXS7G]=GX"_UUS]*Z<)4FZR39QX^A3CAY.,4B_=3:G=^()[.U
MN?+5%R,_C4W]F:]_T$!19_\ (YW7^Y_C72U[A\L<U_9FO?\ 00%']F:]_P!!
M 5TM%%PL<U_9FO?]! 4?V9KW_00%=+11<+'-?V9KW_00%']F:]_T$!72T47"
MQS7]F:]_T$!1_9FO?]! 5TM%%PL<U_9FO?\ 00%']F:]_P!! 5TM%%PL<U_9
MFO?]! 4?V9KW_00%=+11<+'-?V9KW_00%']F:]_T$!72T47"QS7]F:]_T$!1
M_9FO?]! 5TM%%PL<U_9FO?\ 00%']F:]_P!! 5TM%%PL<U_9FO?]! 4?V9KW
M_00%=+11<+'-?V9KW_00%']F:]_T$!72T47"QS7]F:]_T$!1_9FO?]! 5TM%
M%PL<U_9FO?\ 00%']F:]_P!! 5TM%%PL<U_9FO?]! 4?V9KW_00%=+11<+'-
M?V9KW_00%']F:]_T$!72T47"QS7]F:]_T$!1_9FO?]! 5TM%%PL<U_9FO?\
M00%']F:]_P!! 5TM%%PL<U_9FO?]! 4?V9KW_00%=+11<+'-?V9KW_00%5=1
MBUO3K1KA[X,JGH*Z^L7Q3_R Y?J*+A8TK&1I;&%W.69<DTV]_P!51IO_ "#;
M?_<%%[_JJ</B)G\)BT445WGG!6IIO1JRZU--Z-65;X3:A\9H4445QG<%%%%
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M 4444 %%%% !1110 4444 %8OBG_ ) <OU%;58OBG_D!R_44 S0TW_D&V_\
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M\\X*U--Z-676IIO1JRK?";4/C-"BBBN,[@HHHH **** "BBB@ HHHH ****
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M2:M96]39OIKH:Y"N2%W< 'BI/$43W!M$.0S-CBJ?_"7(47=9(74<,>M4;_Q
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M;V6Q<\/E6T>5[N1EC#<OGD4MUJVGVME/%:W+R,X_B[5?L;U+C2Y)8+16.?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y+QW_P @^'_>KS^O0/'?
M_(/A_P!ZO/Z\/'?QF?4Y5_NR^84445QGI!1110 4444 %%%% !1110 4444
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M-JP4444""BBB@ HJ"ZN4M8O,DZ9Q3H)TN$W)THN/E=KDM%%% @HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KW=C;WR!+B,.HZ U3
M_P"$=TO_ )]5K4HJ'3BW=HTC5J15HMHR_P#A'=+_ .?5:/\ A'=+_P"?5:U*
M*7LH=D/V]7^9_>9?_".Z7_SZK1_PCNE_\^JUJ44>RAV0>WJ_S/[S+_X1W2_^
M?5:/^$=TO_GU6M2BCV4.R#V]7^9_>9?_  CNE_\ /JM'_".Z7_SZK6I11[*'
M9![>K_,_O,O_ (1W2_\ GU6C_A'=+_Y]5K4HH]E#L@]O5_F?WF7_ ,([I?\
MSZK1_P ([I?_ #ZK6I11[*'9![>K_,_O,O\ X1W2_P#GU6C_ (1W2_\ GU6M
M2BCV4.R#V]7^9_>9?_".Z7_SZK1_PCNE_P#/JM:E%'LH=D'MZO\ ,_O,O_A'
M=+_Y]5H_X1W2_P#GU6M2BCV4.R#V]7^9_>9?_".Z7_SZK1_PCNE_\^JUJ44>
MRAV0>WJ_S/[S+_X1W2_^?5:/^$=TO_GU6M2BCV4.R#V]7^9_>9?_  CNE_\
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MR#V]7^9_>9?_  CNE_\ /JM'_".Z7_SZK6I11[*'9![>K_,_O,O_ (1W2_\
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M9![>K_,_O,O_ (1W2_\ GU6C_A'=+_Y]5K4HH]E#L@]O5_F?WF7_ ,([I?\
MSZK1_P ([I?_ #ZK6I11[*'9![>K_,_O,O\ X1W2_P#GU6C_ (1W2_\ GU6M
M2BCV4.R#V]7^9_>9?_".Z7_SZK1_PCNE_P#/JM:E%'LH=D'MZO\ ,_O,O_A'
M=+_Y]5H_X1W2_P#GU6M2BCV4.R#V]7^9_>9?_".Z7_SZK1_PCNE_\^JUJ44>
MRAV0>WJ_S/[S+_X1W2_^?5:/^$=TO_GU6M2BCV4.R#V]7^9_>9?_  CNE_\
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M\^RUIT4!8S/[ TS_ )]EH_L#3/\ GV6M.B@+&9_8&F?\^RT?V!IG_/LM:=%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ57FO4E7:JG.:TK5?W8H5F[E24XPY66%I:2EJC$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *9(XCC9ST I]5M0_X\)O]V@"M8ZQ#?7<E
MNF-R#)K2KS[P=_R-%]_NUZ#38D%%%%(84444 %%%% !1110 4444 %%%% !1
M110 4444 %5[VZ6RM7G?HM6*R/$PSH-Q]* +6GZE%J"%HR..N*NUQ?@3I=?Y
M]*[-F51EB !U)-#!"T5674+)WV)=P,WH) 35GJ,B@ HHHH *0D 9-!( R:S;
MR\SE$/%5"#D[$3FHJ["\O,_(E9Q.3DT$Y.:*[8Q459'#.;D[LVM/_P"/5:M5
M2L956V )%6//3U'YUQS3YF=M-KE1+147GIZC\Z//3U'YU-F7S(EHJ+ST]1^=
M'GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>>
MGJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(E
MHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z+
M,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]/
M4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1^
M='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>
M>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(
MEHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z
M+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]
M/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1
M^='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1
M>>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS
M(EHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\
MZ+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\
M]/4?G19AS(EHJ+ST]1^='GIZC\Z+,.9$M%1>>GJ/SH\]/4?G19AS(EHJ+ST]
M1^='GIZC\Z+,.9$M4M0<+&!ZU))>1H*R[B<S/[=JUIP;=V8U:B4;(@HHHKK.
M(*U=-Z-656U9)MB!]16-9^Z;T%[Q:HHHKD.T**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $Q01D4M% $'D\YI/(JQ10%B(1 =
MJ&3V%2T4 1;#Z#\J!'ST%2T4 1;/84;/85+10!%L]A1L_P!D5+10!%L/H*7:
M?2I** (\'THVFI** (I(MZ;:JBQ4'.*OT4FBE)K8HFQ4]J3^SQZ5?HHLA^TD
M4/L ]*/L ]*OT4<J'[610^P#TI/L ]*T**.5![610%@H.<5<C38N*?10E8F4
MW+<****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56U
M#_CPF_W:LU6U#_CPF_W: .&\'$#Q1?9/\->A @]#FO)M-BNI=>O!:[MVWG;7
MH?AZ*YATT+=[O,S_ !4V)&M4<TZ6\322'"@9-25G:MI_V^#;YK( .U1)M*Z*
M23>I%9^(K"^N6MX9"9%ZBG:CK]EI?_'RS#Z"N-\/6HM/$MU"&+;>YKN;V&S,
M#/<QHPQU85<TE%21,6W)Q94T[Q)I^IR".W<ECV(K7R ,DUY_IEN+CQ-'<6:X
MMTR#MZ9S76:ZDITB;RF97"\$42LHJ7<(W<W$U-PQG(HW#&<BO.Y=9G@TA(/,
M8S;<$YYI+76YH= C660^<6Y)/-#6CMT!/5>9Z+N7^\/SH#*>C _C7DSZK+)<
MBUN+QX8V&=X/2I;/7_[+N1'%=M<HQY9CTIV%S'JF]1U8?G6?J]Z]E9^;%@FO
M.9-3CO[BXEEU)X"O**#UJ]9:N]UI1MV<N%4G<3R>*B2?(WU149+G2.N\.:M-
MJEDTUQM#!R.*VMRC^(?G7DVC:C/=!M,A8IN<G<IYZUJ:V+N">WADN9(H2OS2
M ]*TFO>TZD0;MJ>BA@>A!^AI:Y[PU9QPPF2.^>Y##^(]*Z&E)6=AQE=7$) Z
MG%9'B5E_L*X^8=/6E\1174VF%;3=YF?X:X+4K'6DL9&F$OECKDTD-LT?#FJ1
M:3IVH74IPL:[OY55A^)>D>(;*\M(K@B41'V[4SPS:0W.F:A%?2;(V7!)].*\
M>\=:5HFB7;3:+K#/<.V'B7C K"33DXSV9K&-X)QW+7A$SQ>/76:[F,0!;F0X
MZ_6O8%^*>D)K%OID<Q;Y<-QW%?+PU"]6Y$@=XV/!<'G%>M?#O0/#=S<Q7<^L
M>9>9SL:NRDG)1B]D<]::YY36\CZ)MITN;=)D.5<9%2$@#)J&S1([2)(SE N
M:IWT[AMHX'K4*/-*R"4^6-V%Y>9RB'BLXG)S03GK179&*BK(XIS<G=A1115$
M"Y([FC<WJ?SI**!B[F]3^=&YO4_G244 +N;U/YT;F]3^=)10 NYO4_G1N;U/
MYTE% "[F]3^=&YO4_G244 5=2NWL[&293RHKQ\?$?QA?ZK=VVFPPND#8Y_\
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M;/4QJERS3/@QEN!3]0M]8?0HM<74+A27"F,-Q5>U23;6SLQ*ES6L]]CZ"\S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "JVH?\>$W^[5FH;M-]K(OJ* .$\'?\C3??[M>@UY]X>C
MEM?%EYA&"D8SBO01TIL2"LO6=1EL8,Q6SS$CHM:E%2U=6*3LSR^PO=0BUR6\
M;3)MLIZ8Z5H^(M4U.=A'#93;,@G KOL#TI<#TJF[I+L2EJWW.(T/6)89$@71
MI(L]7QW_ #KL77[1:X9<;AR#4V!Z443?,K!%<KN>8S:->/XAD'E.8 _!QQ2W
MNA7<FO&)8V^SC!''%>FT41=G'R"2O?S/.M8T/['?Q7/V,W,:H 4 Z]*6W6WO
ML0#06@9N/,(Z5Z)1@>E):*S!K6Z/,%LUTN[E$NCM=*3P0*UD5+K3R(-*:V8@
M\8KN<#THH>L>5@E:7,CR^ST2[M+-[Z.%UF#\*!SUK1OM9GN+189]%EE8+C<1
M_P#7KOZ3 ]*<GS;A%<NJW.0\'VUW'),\J/%&WW4/:NPHHIRES,48V"LCQ-_R
M KCZ5KUD^)%+:'<!02<=!4E,XG2=-EU/1M2MX9-CNF ?RKD+#X0FS^UZAJDZ
MSXC+ ,.XKTKP-&Z?:=Z%?J/I75W-K%>6[P3+F-QM(]JAQ<7*4=V-2YHJ+V/E
M/PW9Z?J7C9[26%#!M*@'IFN^M/A)<Z?XEM[JSNMD##=A1P,XKT2R^&7A?3[_
M .VVUB5GSG=D?X5UR(L:*BCA1@5M&2BHM;HFHN><_P"5D-C UM910LVYD7!/
MK2SVZRJ>.:GHJ>9WN+E5K&!-"T3X(X]:BK=N(%F3D<UCS0M$^"*ZZ=3F1QU*
M;BR*BBBM3$**M0V,DT8=2,&I/[,E_O"H=2*ZFBIS>J11HJ]_9DO]X4?V9+_>
M%'M(=P]E/L4:*O?V9+_>%']F2_WA1[2'</93[%&BKW]F2_WA1_9DO]X4>TAW
M#V4^Q1HJ]_9DO]X4?V9+_>%'M(=P]E/L8&N1O+I4R(I9B. *\;\*^$&N_$]^
M^J:8S1&3Y2XX[5]!?V9+_>6C^RY?5:B+IJK[1N^EC1JI[/V:1RS:!I^FZ9<)
M86BQDQD +]*\Y\#Z3?VWC!YIK62./!^8CBO</[,E_O"D_LN7U6G&48U/:7Z6
M)<)NFX6W/&_B;I=]>ZC"UM;22J$P2HK'\1Z-J,R>'Q'9RMY:_/@?=ZU[Y_9<
MOJM']ER^JUG%0BDK[.YI>IIILK'B_C+2[ZX\,Z9%#:R.Z2990.E276F7S?#V
M.W%M(9@_W,<U[)_9<OJM']ER^JTY<DHSC?XG<4.>+AI\)\^0Z'K0\%WL<<4T
M<A?B/')ZUSEQIEW<:>T(\.3"X"X,NWJ?7K7U-_9<OJM']E2>JT24)2<K[CBZ
MD4ER['SL=#U/_A%;*'[%+YBCE<<BO3?A]9SVWA:.&XB:-\G*M7>?V7+ZK1_9
M<N.&6M%4@N;7>WX&<J<Y)*VU_P 3YU^+.D-8ZRMY;-L(3M^%=S\+=(-EI33R
M#YI@&S5[QG\-M;\2:HDD5S"+4+AE;KV]Z[71_#DNFZ9!;97=&@4XK/"2C3IR
MN]W^!IB8SGR)+U,7Q5;R7.A74<2EF,9  [UXOX0U+6O"5VS'0;F<8(X'_P!>
MOI#^S)?[RT?V5)ZK1%QC-SC+<5I.'(XWZGDNKZYJ/B?PM*IT>>WD+8",.?YU
M2\):7?6_AK4XY;61'<_*I'6O9_[+D]5H_LN7U6F_9VDK_$K"M4LE;9W/G[PM
MX<OWO-92XM)(UE7"EAUZ56TT:QX0U6Y@ATJXN(F0H&4<<Y%?17]ER^JT?V7)
MZK1>.EGTMZE/G;=X[NY\Z:!INJ_\)2UY<V4T<91CN8=*R=#U:\TGQ%<S6UI)
M<;9B=B=^:^F;S1)KBV>-64%@17!^%OAAJNBZU->7$\+(\I< >GYU,''VB5[)
M*URI<SA*35V[:'GFD>'M2\3^(WO[NTEM4$F\+(.M6=9T?4?#7BJ?4K.REN4<
M@;8Q7OW]ER^JT?V7+ZK57@G%P=K$/VDF^973/ GM=5\:ZY')<V$UI" .''I4
M_B?0;X>)],\BUD>.*+:64<=J]V_LN7U6C^RY?5:%[./+9[.X?O'>ZW5CP#5]
M%U*37M&D2SE*(_S$#IUK0^(>DW]W'8BWM9)-LP)VCI7M_P#9<OJM']ER^JTG
MR<L8WV=QWJ<W-;I8^?O$GAO4)- AFCM9'D5U.P#GC%=]X$UF\N[!+>YTV6V*
M83+CKBO0_P"RY?5:/[+E'=:TA4C%RUT;N9RA.48QMJCC?&7A\:[I,L8(#[<*
M:\ST/4]>\'/)8?V7<W<2C:K*.!7O_P#9DO\ >%)_9<GJM9KEC)N,K7W+M-QY
M91O8\2U'2M7\6Z;]HN$EA'WA"X[BL?3M9UW1]'GTE=%NG+/Q*!VY]Z^A?[+E
M]5H_LJ3U6BT-4GH]T-<]E>-VMCQ+1/"5W;^']2NI8V,]R-X0CD4[P+I5_:C4
M_/M9(]\>%W#K7M?]ER^JT?V7+ZK5<T+R=]U8AQJ.-FNMSPWPCI&H6_C6\FEM
M)$C:$@,1P>M1-I&H?\+$BN?LDGDA#E\<=J]W_LN7U6FOI,K(0"N2*F\5RM/X
M58J2G)ST^(^9)[VXT[Q>L\$#S.DA^1>IK3>QUCQ=KT$TUA/:K%)NRXKT&U^%
MFK0^*UU1IX3")"V._P#.O2%TJ4#JM*ER*$')ZJ^G8NKS\\N1;VU/GCQ?H.JV
MFKLQM9;ZU!&(U'%8ZZ+>W>MQ7-MH<UI&% *[>]?4']ER^JT?V7)ZK3AR1DI7
MV=R9<\H\O+TL> MHVI?\)=I,WV.7RT7YFQP*[CQS97-UX=\N"%I'\LC %>C?
MV7+ZK1_9<OJM#Y'25*^SO^-Q+VBJ^TMTL>&Z#<7F@^#+6.YT.:Z8Y4QXY' ]
MZP8M-O=8\1"6RT6;3$(Y.*^D/[+D]5H_LN3U6KYH.ISMB2FH.*6Y\_:IH&I>
M'==L]3MK66Z,:Y94'4TZY76/&NJ61N-.GM(X'YWCK_G->_\ ]ER^JT?V7)ZK
M41Y$DI.Z6Q3]H]4M;6N?/VH^&K^U\31)#:2/"DH.\#CK5_XCZ1J%Y/ ;>TDD
M *9VCZ5[E_9<OJM']ER^JT_<M%7V=P7.I<W+TL<SX9ADAT:!)4*L$4$'Z5LU
M=_LR7^\M+_9DO]X5K*M&3O<PC1G%6L4:*O?V9+_>%']F2_WA2]I#N/V4^Q1H
MJ]_9DO\ >%']F2_WA1[2'</93[%&BKW]F2_WA1_9DO\ >%'M(=P]E/L4:*O?
MV9+_ 'A1_9DO]X4>TAW#V4^Q1HJ]_9DO]X4?V9+_ 'A1[2'</93[%&BKW]F2
M_P!X4?V9+_>%'M(=P]E/L4:*O?V9+_>%']F2_P!X4>TAW#V4^Q1HJ]_9DO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "D(R,4M% $"VD22F0*-QZG%3UG
MW&MV%M,T4LX5UZBHO^$CTO\ Y^5H U:*RO\ A(]+_P"?E:/^$CTO_GY6@+FK
M165_PD>E_P#/RM'_  D>E_\ /RM 7-6BLK_A(]+_ .?E:/\ A(]+_P"?E: N
M:M%97_"1Z7_S\K1_PD>E_P#/RM 7-6BLK_A(]+_Y^5H_X2/2_P#GY6@+FK16
M5_PD>E_\_*T?\)'I?_/RM 7-6BLK_A(]+_Y^5H_X2/2_^?E: N:M%97_  D>
ME_\ /RM'_"1Z7_S\K0%S5ILD:RH489!K,_X2/2_^?E:/^$CTO_GY6@+FA#;Q
MP9V*!GT%2U#]JA^R_:=W[K&=WM6=_P )+I7_ #]+4RG&/Q,N%*<U[JN:]%9'
M_"2Z5_S]+1_PDNE?\_2U/MJ?\R+^KUOY7]QKT5D?\)+I7_/TM'_"2Z5_S]+1
M[:G_ #(/J];^5_<:]07%NLR$8YK/_P"$ETK_ )^EH_X272O^?I::KP3NI(3P
MU5JSB_N*\T+1/@CCM453SZ]I$J?\?*YK*?6+ ,0)P177#%4FM9(XJF"KQ>D'
M]QU&G_\ 'JM6JP+/Q%ID=N%:Y -6/^$ETK_GZ6N6=:GS/WD=D,-6Y5[K^XUZ
M*R/^$ETK_GZ6C_A)=*_Y^EJ?;4_YD5]7K?RO[C7HK(_X272O^?I:/^$ETK_G
MZ6CVU/\ F0?5ZW\K^XUZ*R/^$ETK_GZ6C_A)=*_Y^EH]M3_F0?5ZW\K^XUZ*
MR/\ A)=*_P"?I:/^$ETK_GZ6CVU/^9!]7K?RO[C7HK(_X272O^?I:/\ A)=*
M_P"?I:/;4_YD'U>M_*_N->BLC_A)=*_Y^EH_X272O^?I:/;4_P"9!]7K?RO[
MC7HK(_X272O^?I:/^$ETK_GZ6CVU/^9!]7K?RO[C7HK(_P"$ETK_ )^EH_X2
M72O^?I:/;4_YD'U>M_*_N->BLC_A)=*_Y^EH_P"$ETK_ )^EH]M3_F0?5ZW\
MK^XUZ*R/^$ETK_GZ6C_A)=*_Y^EH]M3_ )D'U>M_*_N->BLC_A)=*_Y^EH_X
M272O^?I:/;4_YD'U>M_*_N->BLC_ (272O\ GZ6C_A)=*_Y^EH]M3_F0?5ZW
M\K^XUZ*R/^$ETK_GZ6C_ (272O\ GZ6CVU/^9!]7K?RO[C7HK(_X272O^?I:
M/^$ETK_GZ6CVU/\ F0?5ZW\K^XUZ*R/^$ETK_GZ6C_A)=*_Y^EH]M3_F0?5Z
MW\K^XUZ*R/\ A)=*_P"?I:/^$ETK_GZ6CVU/^9!]7K?RO[C7HK(_X272O^?I
M:/\ A)=*_P"?I:/;4_YD'U>M_*_N->BLC_A)=*_Y^EH_X272O^?I:/;4_P"9
M!]7K?RO[C7HK(_X272O^?I:/^$ETK_GZ6CVU/^9!]7K?RO[C7HK(_P"$ETK_
M )^EH_X272O^?I:/;4_YD'U>M_*_N->BLC_A)=*_Y^EH_P"$ETK_ )^EH]M3
M_F0?5ZW\K^XUZ*R/^$ETK_GZ6C_A)=*_Y^EH]M3_ )D'U>M_*_N->BLC_A)=
M*_Y^EH_X272O^?I:/;4_YD'U>M_*_N->BLC_ (272O\ GZ6C_A)=*_Y^EH]M
M3_F0?5ZW\K^XUZ*R/^$ETK_GZ6C_ (272O\ GZ6CVU/^9!]7K?RO[C7HK(_X
M272O^?I:/^$ETK_GZ6CVU/\ F0?5ZW\K^XUZ*R/^$ETK_GZ6C_A)=*_Y^EH]
MM3_F0?5ZW\K^XUZ*R/\ A)=*_P"?I:/^$ETK_GZ6CVU/^9!]7K?RO[C7HK(_
MX272O^?I:/\ A)=*_P"?I:/;4_YD'U>M_*_N->BLC_A)=*_Y^EH_X272O^?I
M:/;4_P"9!]7K?RO[C7HK(_X272O^?I:/^$ETK_GZ6CVU/^9!]7K?RO[C7HK(
M_P"$ETK_ )^EH_X272O^?I:/;4_YD'U>M_*_N->BLC_A)=*_Y^EH_P"$ETK_
M )^EH]M3_F0?5ZW\K^XUZ*R/^$ETK_GZ6C_A)=*_Y^EH]M3_ )D'U>M_*_N-
M>BJ,NKV4,$<TDP$<GW3ZU!_PD>E_\_*UHM=C%Z.S-6BLK_A(]+_Y^5H_X2/2
M_P#GY6@+FK165_PD>E_\_*T?\)'I?_/RM 7-6BLK_A(]+_Y^5H_X2/2_^?E:
M N:M%97_  D>E_\ /RM'_"1Z7_S\K0%S5HK*_P"$CTO_ )^5H_X2/2_^?E:
MN:M%97_"1Z7_ ,_*T?\ "1Z7_P _*T!<U:*RO^$CTO\ Y^5H_P"$CTO_ )^5
MH"YJT5E?\)'I?_/RM'_"1Z7_ ,_*T!<U:*RO^$CTO_GY6C_A(]+_ .?E: N:
MM%97_"1Z7_S\K1_PD>E_\_*T!<U:*RO^$CTO_GY6C_A(]+_Y^5H"YJT5E?\
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MW_/JE:%% &?_ &)IW_/JE']B:=_SZI6A10!G_P!B:=_SZI1_8FG?\^J5H44
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M_8FG?\^J5H459F9_]B:=_P ^J4?V)IW_ #ZI6A10!G_V)IW_ #ZI1_8FG?\
M/JE:%% &?_8FG?\ /JE']B:=_P ^J5H44 9_]B:=_P ^J4?V)IW_ #ZI6A10
M!G_V)IW_ #ZI1_8FG?\ /JE:%% &?_8FG?\ /JE']B:=_P ^J5H44 9_]B:=
M_P ^J4?V)IW_ #ZI6A10!G_V)IW_ #ZI1_8FG?\ /JE:%% &?_8FG?\ /JE'
M]B:=_P ^J5H44 9_]B:=_P ^J4?V)IW_ #ZI6A10!G_V)IW_ #ZI1_8FG?\
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M44 %%%% !1110 5D>)?^0%<?2M>LCQ+_ ,@*X^E ,A/_ "*!_P"N/]:\OKU
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M3<Z1=6LR12*-SG KH?#NERVMS*9U4Y6MB[M(]0GMYUZ1G)Q45I,K>(+F,'Y
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<__ ![R?[I_E4E1S_\
M'O)_NG^5 &%X2_X]+G_KL?YFNAKGO"7_ !Z7/_78_P S70T,2V"BBB@84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXVA8.#\_'>G#51:5[A4]UM7Z'JEO.EQ$LB$$$9XJ6O/=5N=6T&)'BGQ;A1D
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M% _]<?ZUY?7J!_Y% _\ 7'^M>7UY&9?'$^AR7^'+U"BBBO./:"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@#MI?\ CPT;_>KMAT%<3+_QX:-_O5VPZ"OI:?\
M#CZ'Q%?^++U%HHHJS,**** "BBB@ HHHH **** .4\8J62+"D\=A6EX>@C_L
M6#=$N['=:UI(8Y?]8BM]13E147:B@ =A1'2+7<4E>2?8X/Q'#)8:S_:!3,7
MX%0ZKK4>O6JV-HC[F4#YEKOY8(IAB6-7'N*C2QM8VW);QJ?4+1'1)/H-WO=;
MG':C9O;65FA4[@G.*IZA&[16 "G[_I7H30QOC>BMCID4TVT!QF)#CIQTIIZW
M?>_X"MI9=K?C<\^N&?1/$#7LR$Q%0.!FGW]^/$EY'%:HVPK@[EQS7>R6L$W^
MLA1_J*2.SMHCF."-3ZA:(O:_036[74Y'Q'I\D.EP2HIWPQ]JPM(T^2[M+FZE
M5MX3<,BO3WB21=KH&7T(IJ6T**52)%4\$ 4EM)=QM;>1YGX7M)M0U1UG5MFW
MO^-=9)X*TZ9P[/-GV8UT$=M!"V8XD4^H%2U4I7M82C9L\]\2:;_9UY;3QAFB
MB7GN:J:GK*ZG%:1P(^8S\V5KTF2"*88DC5Q[BHA86B]+:(?\!J5M9]&4][KM
M8\QUI_*L[9F!^60$_I5_4M=BU32TL84?S..J\5I^)M#N[VYB^S0;HQ("0/3-
M=-9Z;;10)NMHPX49^6J5I1N^[9+3C)6[%;P[9M9Z>H;JP!K8I  HP!@4M$I<
MSN$8\JL%%%%24%%%% !1110 4444 %1S_P#'O)_NG^525'/_ ,>\G^Z?Y4 8
M7A+_ (]+G_KL?YFNAKGO"7_'I<_]=C_,UT-#$M@HHHH&%%%% !1110 4444
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M3^5A]9H_S+[S%HK:_P"$5U?_ )]C1_PBNK_\^QH]C4_E8?6:/\R^\Q:*VO\
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M/\R^\Q:*VO\ A%=7_P"?8T?\(KJ__/L:/8U/Y6'UFC_,OO,6BMK_ (175_\
MGV-'_"*ZO_S[&CV-3^5A]9H_S+[S)AF>"0.AY%;2^+=050O[LX&.14?_  BN
MK_\ /L:/^$5U?_GV-:16(BK13,JD\+4UFTRC?:E/J#!IB..F*IUM?\(KJ_\
MS[&C_A%=7_Y]C6;HU7JXLN-?#Q5HR1BTH)'0D5L_\(KJ_P#S[&C_ (175_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%0W9(M9"/2@"4.I. P)]C2UR7AV61];N59V("\ FNMH!!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !2!U/1@?H:BNB1;MBN8\.RR/?W09V(#\9- '6T444 %%%% !1110
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M=J]S:S/9WHBC#<K2B[QEY!+11.GB\8M)?SVWV8#RFQG/6J<_CJZ2]DMX-/\
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MHH ;L3^ZOY4;$_NK^5.HH ;L3^ZOY4;$_NK^5.HH ;L3^ZOY4;$_NK^5.HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
M6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&:
M %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1
MF@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,
MT9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BBB@ HHHH
M **** "BCI5*XN"S>7'Q_M4 2RW '"\U6"DL68YSZ]J4+CZTM !0>E%(>AH
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MCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH
MT?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H
M\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[
M[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6
MC[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/
M6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1
M\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS
M*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM
M(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/
MM(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]:
M -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S
M*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K
M.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TC
MUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^T
MCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH
MT?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H
M\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[
M[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6
MC[2/6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/
M6@#1\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1
M\RCS*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS
M*SOM(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM
M(]:/M(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/
MM(]: -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]:
M -'S*/,K.^TCUH^TCUH T?,H\RL[[2/6C[2/6@#1\RCS*SOM(]:/M(]: -'S
M*/,%9WVD>M'VD>M &EY@I=]9HN?>I%GSWH T U.!JJDF:F5LT 2T4@I: "BB
MB@"@]RTO"9 ]Z15"CBEP!10 4444 %%%-=M@!]Z +L2!%X[T\C(P:$.4!]J6
M@"A-&8W)/*GIBDCE,#<_ZOTJ^P##!%4G4*2O>@"Z"&&12U1M9MC^4Y^8GBKU
M "&H';%3-5:4\4 1IB28*>E6#9PGJ*I6S?Z8HK4H J_8(#_#2?V=;_W35NB@
M"I_9UO\ W:/[.M_[M6Z* *G]G6_]VC^SK?\ NU;HH J?V=;_ -VC^SK?^[5N
MB@"I_9UO_=H_LZW_ +M6Z* *G]G6_P#=H_LZW_NU;HH J?V=;_W:/[.M_P"[
M5NB@"I_9UO\ W:/[.M_[M6Z* *G]G6_]VC^SK?\ NU;HH J?V=;_ -VC^SK?
M^[5NB@"I_9UO_=H_LZW_ +M6Z* *G]G6_P#=H_LZW_NU;HH J?V=;_W:/[.M
M_P"[5NB@"I_9UO\ W:/[.M_[M6Z* *G]G6_]VC^SK?\ NU;HH J?V=;_ -VC
M^SK?^[5NB@"I_9UO_=H_LZW_ +M6Z* *G]G6_P#=H_LZW_NU;HH J?V=;_W:
M/[.M_P"[5NB@"I_9UO\ W:/[.M_[M6Z* *G]G6_]VC^SK?\ NU;HH J?V=;_
M -VC^SK?^[5NB@"I_9UO_=H_LZW_ +M6Z* *G]G6_P#=H_LZW_NU;HH J?V=
M;_W:/[.M_P"[5NB@"I_9UO\ W:/[.M_[M6Z* *G]G6_]VC^SK?\ NU;HH J?
MV=;_ -VC^SK?^[5NB@"I_9UO_=H_LZW_ +M6Z* *G]G6_P#=H_LZW_NU;HH
MJ?V=;_W:/[.M_P"[5NB@"I_9UO\ W:/[.M_[M6Z* *G]G6_]VC^SK?\ NU;H
MH J?V=;_ -VC^SK?^[5NB@"I_9UO_=H_LZW_ +M6Z* *G]G6_P#=H_LZW_NU
M;HH J?V=;_W:/[.M_P"[5NB@"I_9UO\ W:/[.M_[M6Z* *G]G6_]VC^SK?\
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MLZW_ +M6Z* *G]G6_P#=H_LZW_NU;HH J?V=;_W:/[.M_P"[5NB@"I_9UO\
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M2H:* )O//I1YY]*AHH F\\^E'GGTJ&B@";SSZ4>>?2H:* )O//I1YY]*AHH
MF\\^E'GGTJ&B@";SSZ4>>?2H:* )O//I1YY]*AHH F\\^E'GGTJ&B@";SSZ4
M>>?2H:* )O//I1YY]*AHH F\\^E'GGTJ&B@";SSZ4>>?2H:* )O//I1YY]*A
MHH F\\^E'GGTJ&B@";SSZ4>>?2H:* )O//I1YY]*AHH F\\^E'GGTJ&B@";S
MSZ4>>?2H:* )O//I1YY]*AHH F\\^E'GGTJ&B@";SSZ4>>?2H:* )O//I1YY
M]*AHH F\\^E'GGTJ&B@";SSZ4>>?2H:* )O//I1YY]*AHH F\\^E'GGTJ&B@
M";SSZ4>>?2H:* )O//I1YY]*AHH F\\^E'GGTJ&B@";SSZ4>>?2H:* )O//I
M1YY]*AHH F\\^E'GGTJ&B@";SSZ4>>?2H:* )O//I1YY]*AHH F\\^E'GGTJ
M&B@";SSZ4>>?2H:* )O//I1YY]*AHH F\\^E'GGTJ&B@";SSZ4>>?2H:* )O
M//I1YY]*AHH F\\^E'GGTJ&B@";SSZ4>>?2H:* )O//I1YY]*AHH F\\^E'G
MGTJ&B@";SSZ4>>?2H:* )O//I1YY]*AHH F\\^E'GGTJ&B@";SSZ4>>?2H:*
M )O//I1YY]*AHH F\\^E'GGTJ&B@";SSZ4>>?2H:* )O//I1YY]*AHH F\\^
ME'GGTJ&B@";SSZ4>>?2H:* )UF)8#%354C^^*MT 4M2_U ^M06_05/J?_'N/
MK5>WZ"@#03I4HZ5"E3#I0 4444 4**** "HU<*Y![U)59O\ 6CZT 6:; 3]N
MQ[4ZI((OWOF4 6Z*** "BBB@!",C%4)$\F3D?>K0IDJ!T*^M % 2")L_WJ?,
M05R#43H!E/2H%D\O,9/ &: '6G_'^M;-<_87"RZBH3I704 0S]!4%3S]!4%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH =']\5;JI']\5;H I:G_Q[CZU7
MM^E6-3_X]Q]:KV_2@"^E3#I4*5,.E !1110!0HHHH *(^8IOI13[4;O,'K0!
M! ,1J#6BBA5P*S;G,;H!_>K37[H^E "T444 %%%% !1110!!.X1.>]9,W0U;
MU-BOEX[FJDWW: (=/_Y":5T=<YI__(32NCH AGZ"H*GGZ"H* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBD) ZD"@!:*;YB?WU_.E!!Z$&@!:*3<N<9&?K2T %%)N7^\/S
MI/,3^^OYT .HI RGH0?H:6@ HHHH **** "BBFEU'5@/QH =12!@>A!^AI:
M"BF[USC<,_6G4 %%(6 ZD#\:7- !12!E/0@_C02!U(% "T49STHH **** "B
M@D#J: 0>AS0 4444 %%%(2!U(% "T4WS$_OK^=.R#T- !1110 4444 %%%%
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M,@G (H 6B@D#J<4@8'H0?I0 M%%% !1110 4444 %%%-WI_>7\Z '449'K2
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M$FA);AOG:/%9[T^7JG8T_P"7BEW0FDO<W$MY.TK["F5YJCI^G7&JW3AKZ9,
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MTU8/.-P/+]:6UU_3KV4107 =ST%<MK^GFVN1Y5L6MQCY1TK9T4:4=ABACBG
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M.C9QSMK+\077VUQ8P?-OX)':MK1[+[%I\41^\!@T1=X-OY!)6DK?,BUZ.1[
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M^*3G]:VT]LEW,DFZ3.YHID9R@-/K,I.ZN%%%% PHHHH **** "BBB@ HHHH
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MN*4/=ES!)<T>4R?$*,]B0JDGGH*S-!L!<:$\4\9'S$X(KJB >H!^M 55&%4
M>PJ4M&NXWJT^QQ.BRSZ5>R6[1N49R1@5!-9S^(+N<2HP6)ODW"N\\M,YV+GZ
M4!$7HJC/H*IN[N]Q6M>W4Y#0)9M.OGLGC<QH,*0.*ZV8;K=_=3_*G;$SG8N?
M7%*1D$>M$GS*S!*ST.(T _9]8:%N"SD_K2>(4DU/5[: QN8]V&XXK3N=%N!K
MT5W;@>6HYKHDC&U2R+N]<4:-1;Z [J4K=3G1X,TG[*<VW[S'6LO3()--U.>T
M6)A$(SC XZ&NZINQ,YV+GUQ2N[OS#E7+8X[PK%(EU(7C909#U'O5OQ7&\ACV
M(S<=A73!$7[JJ/H*4JK?>4'ZBG)WMY#6C;[G/^6__",!=IW>6>,54\+Q2)I#
M!T93M;@CVKJ]JXQ@8],4!%48"@#V%%_B\Q6T2['&>'H9$U5BT; ;CR1[UVE-
M"*#D*!]!3J&[I+L%M6^YR^N^($BAFM1:S,Q&T%5.*QO#6L?8ML4EI/D\9VFN
M^,4;'+1H?JM((8ATB3_OD40?+?S":YE9&-XDN -'+=,D<4SPK$8[1V(^\<T:
M]IEWJ)$48'E<&M>RMA:VL<8'(7!HAI%ON$M7%=A;V+S[.6/^\N*\U>RO5UD6
MJHWDHPQ\O%>I4WRX\YV+GUQ2C[L^8<M8V,;4],-QHX@C ! !KG]+UY]&62"Y
MMII#NX*J:[NF&&(]8D/_  $4)M-^8K*R78PHM;35K"X$=O+&57^)3S5'PQ%)
M'J$Q=&4;>XKK!&B_=11GT% 15.0H'T%--)MKJA--JS[F#K.O06<C6\MI-+QU
M53C^58&CPM>:[%=00O%$IY#BN\:*-CED4GW%*L:+]U%'T%$/==^HY^\K'!ZS
M%<:;JT-R$9UW9(49JKJVIW.K2V^V"8*'S@J:]&:-&^\BGZBD\F+_ )YI_P!\
MBE'1)/H-[W1S7]LQZ=8+'-:S2?[JFL2V7^TO$$5Q:V\D* <[UKT Q1GK&I^H
MI5BC4Y5%'T%4G[_.R>7W>5"1*5B53U K$UO74LHGB-M+(6& 54FMZFM&C?>1
M3]14/4I:(\YT76?L>IF9[.<J_'W373:YK$T.G%[>*3>0", UO>1#_P \D_[Y
M%.,:$8**1[BJE[R2["CHVSS_ $O7+>T=I9K"X:4G.0I_PKLM-U1=23<L+Q\?
MQ"KGD0_\\D_[Y%.5%7[J@?04W),2BTQ2,J1ZUYSXML9TU99((V(QV&:]'IK1
MHQRR*?J*BWO)EWTL<]:Z=_Q(&C9>74$BN0T[3[B37 KQN(XWXRM>HX&,8&/2
MD$<8.0B@^N*M2M4YR.7]WR&+X@TYKNP58NJ'=6'I?B1M+MS;W-K/(P/55.*[
MC /45'Y,1ZQ)_P!\BIC=7\RFDTO(PS>KXATN9(X9(B>/G&*PM-U:709IHKBW
MFD7.%V*:[M411A54?04AAB)R8T/U44T[-M=1-75F8VG^(8]4,D:6TT9"]74B
MN=DT\W?B=Q)$Q39P<<5WBQQK]U%'T%&Q,YVKGUQ1IS7\@UY6CB=/FN=$U$6[
MH[1.<_*M/U;Q#:WD<D#6%P7Z [3_ (5V9C0G)12?7%-\B+_GDG_?(I/WK<P)
M6=T<SX2M)8E,K JC#A2.170WP)M9 !GY35@*JC"@#Z"EZ]:*GOJP07*<?X1B
MDC:?>C+^]/4>YKJKJ'S[=X_[PJ0(J_=4#Z"G4YOF5@BK-LX".:?P]JD[M%))
M&YP BDTKO<>(]0!6-XX@0P#KCI7>-%&WWD4_44+&B_=11]!1%VLWT!K>W4P=
M2UF'3$2VEM99?D'*+GM7.V,9U#6HKBV@DA16^8.*] :.-SED4_44+'&OW44?
M041=GS/<)*\>5'":XDUCJ<=P8WD7?D[1FNOTS4%U&V658GCSV85<:-&^\BGZ
MBE554850!["A.T>5@U[UT4=74M8.%!)]JP_"ENVRZ65& +]Q75D C!&:0*J_
M=4#Z"DM+^8Y:I>1YEX@TJXM=4\R&-BLC<[1FM]]+DNO#4" 8=#NP1]*ZTQHW
MWD4_44NT 8 &/3%'V.4/^7G.<)8^()M.LVM9;:=I,D!@IQ5WP[I\\MRUY,,?
M-D CFNK\F(]8D_[Y%/"JOW0!]!5<VKEU)<=.5;"US?BZ-Y+.,(A8[NPKI*0J
MK?>4'ZBH:N6G9F)X81DTG#J5.>A%8^JPRMXIMG$;%0.H'':NS"A1@  >PI"B
M$Y*J3ZXJW*]3G(BK0Y#E/$&F?NH;N%#OC&>!3)-6N?[$A7RI/,D^4_*:Z\JI
M&" 1[BD\J/&-BX'M4]''H5U3['GDFASVMFMZJGSR_.!SBNTT>\:[LU+(RE0
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M-Y'O1Y'O0!#14WD>]'D>] $-%3>1[T>1[T 0T5-Y'O1Y'O0!#14WD>]'D>]
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M]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4
M:]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]
MJ/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :
M]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J
M/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]
M%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/
MMMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%
M9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/M
MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9
M'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MM
MS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'
MVVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS
M[4 :]%9'VVY]J/MMS[4 :]%9'VVY]J/MMS[4 :]%90O+GVJ1;J<]<4 6+T;H
MA]:BA7 I=[RC#5*BXH E6GTT4Z@ HHHH BMV9X5+#!J6D  &!2T %%%% !11
M10 4444 %(S!5)-+6=>&:>7R$4JHYWB@"-W^U3;LY4<$5,!@8%"0%%P%^M.\
MMO[IH ;32*D\MO[IH\MO[IH @*9JI<6Y_P!8@^8=!6I'&=_(XJ5[<-TXH SK
M1UG7:?\ 6+]X>E6?(]J>EDL;[E.">OO5C;0!3\@>E0S6"2CD8/K6EMHVT 9T
M%J4&TC@=*F\CVJWMHVT 5/(]J/(]JM[:-M %3R/:LYX1]L?BMS;5!H7^UNVT
MXH J>2/2CR1Z5=\EO[M'DM_=H I>2/2CR1Z5=\EO[M'DM_=H I>2/2CR1Z5=
M\EO[M'DM_=H SIX1Y+<=JL6\/^@#CM4LT#F)@%/2K%O$19A2,'% &=9VX8<B
MKWD#TIMM$Z7!!4[<=:O;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1
M[5;VT;: ,F95+E,=*C\D>E67A<WKMM.W%2>2W]V@"EY(]*/)'I5WR6_NT>2W
M]V@"EY(]*=#'F?9CC%6_);^[4T$.!N*X- $7D#TI?(]JM[:-M %,VX(QBJ;V
MH1L5L;:CEAW+P.: ,2:W(&]%RXZ5=MMLL8'\0ZBI?);^[4<:26\X C)#GD^E
M $WD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&
MV@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;
M1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;
MVT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U
M6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'
MM5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>
M1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U
M'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'
MM1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>
M1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *
MGD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@
M"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1M
MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT
M;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]
MM&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5
MO;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[
M5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D
M>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1
MY'M5O;1MH J>1[4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[
M4>1[5;VT;: *GD>U'D>U6]M&V@"IY'M1Y'M5O;1MH J>1[4>1[5;VT;: *GD
I>U'D>U6]M&V@"IY/M3UB [59VT;: (E2I *=BEH 04M%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gr4bxuv5eowy000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gr4bxuv5eowy000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #% FX# 2(  A$! Q$!_\0
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M;K^_4Z:I<_WZS$J=*EHJ[-1-2N?[]6$U"X/\=9B58CI-%7--;^?^]4Z7L_\
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MJV/%-C[T"-VBL+_A*+'WI?\ A*+'U- &Y16)_P )/8^]20>(;2XE6-,[FZ4
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MV7:?\\Z /+_LUU_=:MKP]93->([@@*:[;^R[3_GG4L-G! ?W:8H GHI:0G%
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MLM*C:YCEE+)R,G_Z]'AU&?5YKC)(9?6DTN@7?4ZPU2?4X4=U+#*]>:NFO/\
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MQ1S;!RF?HFM07]DK^8H;IBJGB/6X8;*2WB<-+(N% ZUAW/A/5;*<C2)$BB[
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ML?<5N  # [444"%HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3%+BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ Q1110 4444 %%%% !1110 F*6BB@
M HHHH *3 HHH 6BBB@ HHHH **** $Q2T44 %%%% !1110 4444 &*,444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>33
<FILENAME>eigr-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-08T23:16:18.7044828+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 867300f52dd744cb97ec68c0fc090a12 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:eigr="http://www.eigerbio.com/20201231" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eigerbio.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.eigerbio.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eigr-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eigr-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eigr-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eigr-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness" id="Role_DisclosureDescriptionOfBusiness">
        <link:definition>100080 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100110 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreements" id="Role_DisclosureLicenseCollaborationAndProductDevelopmentAgreements">
        <link:definition>100120 - Disclosure - License, Collaboration, and Product Development Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreements" id="Role_DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreements">
        <link:definition>100130 - Disclosure - Asset Purchase Agreements and Related License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100140 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100150 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans" id="Role_DisclosureEquityIncentivePlans">
        <link:definition>100160 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLegalMatters" id="Role_DisclosureLegalMatters">
        <link:definition>100180 - Disclosure - Legal Matters</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100190 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100200 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100210 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100230 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100240 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100250 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>100260 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100270 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables" id="Role_DisclosureEquityIncentivePlansTables">
        <link:definition>100280 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100290 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100300 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail" id="Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>100310 - Disclosure - Description of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100320 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail">
        <link:definition>100330 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
        <link:definition>100340 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100350 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail">
        <link:definition>100360 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail" id="Role_DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail">
        <link:definition>100370 - Disclosure - Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
        <link:definition>100380 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100400 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail">
        <link:definition>100410 - Disclosure - Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail" id="Role_DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail">
        <link:definition>100420 - Disclosure - License, Collaboration, and Product Development Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Asset Purchase Agreements and Related License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" id="Role_DisclosureDebtAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Debt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail" id="Role_DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail">
        <link:definition>100450 - Disclosure - Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail" id="Role_DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail">
        <link:definition>100460 - Disclosure - Debt - Schedule of Future Minimum Payments of Principal, Exit Fee and Interest Expense under Oxford Term Loan (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Stockholders&apos; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail" id="Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail">
        <link:definition>100480 - Disclosure - Stockholders&apos; Equity - Summary of Common Stock Reserved for Issuance (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" id="Role_DisclosureEquityIncentivePlansAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Equity Incentive Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail" id="Role_DisclosureEquityIncentivePlansStockOptionActivityDetail">
        <link:definition>100500 - Disclosure - Equity Incentive Plans - Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail" id="Role_DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail">
        <link:definition>100510 - Disclosure - Equity Incentive Plans - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail" id="Role_DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail">
        <link:definition>100520 - Disclosure - Equity Incentive Plans - Summary of Non-cash Stock Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100530 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail">
        <link:definition>100540 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" id="Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail">
        <link:definition>100550 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail" id="Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail">
        <link:definition>100560 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail" id="Role_DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail">
        <link:definition>100580 - Disclosure - Commitments and Contingencies - Maturity of Operating Leases Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail2" id="Role_DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail2">
        <link:definition>100590 - Disclosure - Commitments and Contingencies - Maturity of Operating Leases Liabilities (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100600 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement" name="StockIssuedDuringPeriodSharesProductDevelopmentAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" name="StockIssuedDuringPeriodValueProductDevelopmentAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_OperatingLeaseRightOfUseAssetAmortization" name="OperatingLeaseRightOfUseAssetAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_PaymentsOfDeferredOfferingCosts" name="PaymentsOfDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" name="RepaymentOfAccruedExitFeeAndSecondAmendmentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_POMember" name="POMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_CollaborationAndLicenseAgreementsAbstract" name="CollaborationAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock" name="AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" name="AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" name="AccruedResearchAndDevelopmentCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" name="EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_CommonStockReservedForFutureIssuancesTableTextBlock" name="CommonStockReservedForFutureIssuancesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_EmployeesAndNonEmployeesStockOptionMember" name="EmployeesAndNonEmployeesStockOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_DescriptionOfBusinessAbstract" name="DescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_NumberOfSupplyChainsForEachProductCandidate" name="NumberOfSupplyChainsForEachProductCandidate" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_NumberOfProductCandidates" name="NumberOfProductCandidates" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" name="PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_LabEquipmentMember" name="LabEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" name="OptionsGrantedToEmployeesAndNonEmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_FairValueTransfersBetweenLevelsTransfersAmount" name="FairValueTransfersBetweenLevelsTransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_DebtInstrumentFairValueCarryingValueAbstract" name="DebtInstrumentFairValueCarryingValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_USGovernmentBondsMember" name="USGovernmentBondsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_CashEquivalentsAmortizedCost" name="CashEquivalentsAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" name="CashEquivalentsAndInvestmentSecuritiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_CashEquivalentsAndInvestmentSecuritiesTable" name="CashEquivalentsAndInvestmentSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity" name="AvailableForSaleOfDebtSecuritiesContractualMaturity" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_PrepaidContractManufacturingCosts" name="PrepaidContractManufacturingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_PrepaidResearchCosts" name="PrepaidResearchCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" name="OtherPrepaidExpenseAndOtherAssetsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_AccruedContractedResearchCostsCurrent" name="AccruedContractedResearchCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_ContractManufacturingCostsCurrent" name="ContractManufacturingCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_LicenseMaintenanceFee" name="LicenseMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_MilestoneObligations" name="MilestoneObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_NonRefundableIssueFee" name="NonRefundableIssueFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_UPennCHOPAgreementMember" name="UPennCHOPAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_CommercialSalesMember" name="CommercialSalesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_ProductDevelopmentAgreementMember" name="ProductDevelopmentAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_PRFCollaborationAgreementMember" name="PRFCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_BmsTransactionMember" name="BmsTransactionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_DevelopmentAndRegulatoryMilestonesMember" name="DevelopmentAndRegulatoryMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_DevelopmentPhaseTwoMember" name="DevelopmentPhaseTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_DevelopmentPhaseThreeMember" name="DevelopmentPhaseThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_PurchaseAgreementMember" name="PurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_MerckTransactionMember" name="MerckTransactionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_ProductDevelopmentFees" name="ProductDevelopmentFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_ExpertConsultantFeesAndPassThroughCosts" name="ExpertConsultantFeesAndPassThroughCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_IncentiveBasedRegulatoryMilestoneFees" name="IncentiveBasedRegulatoryMilestoneFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_ProductAgreementTerminationNoticePeriod" name="ProductAgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_CollaborationAgreementInitialTerm" name="CollaborationAgreementInitialTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_CollaborativeArrangementRenewalTerm" name="CollaborativeArrangementRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_UpfrontCashPayments" name="UpfrontCashPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_IncreaseInMilestoneObligations" name="IncreaseInMilestoneObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_DevelopmentMilestoneObligations" name="DevelopmentMilestoneObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_RoyaltiesExpirationDescription" name="RoyaltiesExpirationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_AssetPurchaseDescription" name="AssetPurchaseDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" name="OneTimePaymentToBeMadeOnAssetPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" name="AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" name="AssetPurchaseAgreementAndRelatedLicenseAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AssetPurchaseAgreementMember" name="AssetPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_EIGTransactionMember" name="EIGTransactionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_ProductOneMember" name="ProductOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AvexitidePurchaseAgreementMember" name="AvexitidePurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_MilestoneVestedOptionsMember" name="MilestoneVestedOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AbbvieAssetPurchaseAgreementMember" name="AbbvieAssetPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_OptionsToPurchaseOfCommonStock" name="OptionsToPurchaseOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" name="VestingPeriodOfOptionsIssuedForCommonStockPurchase" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_VestingOfOptionsToPurchaseCommonStock" name="VestingOfOptionsToPurchaseCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_LicenseAgreementPotentialMilestonePayments" name="LicenseAgreementPotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_LicenseAgreementMilestonePaymentsPaid" name="LicenseAgreementMilestonePaymentsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_PaymentForAssetPurchaseAgreement" name="PaymentForAssetPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_OxfordLoanMember" name="OxfordLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_OxfordLoanAmendmentMember" name="OxfordLoanAmendmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_TrancheAMember" name="TrancheAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_TrancheBMember" name="TrancheBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_TrancheCMember" name="TrancheCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AmendedOxfordLoanMember" name="AmendedOxfordLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AmendedTrancheAMember" name="AmendedTrancheAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AmendedTrancheBMember" name="AmendedTrancheBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_FoodAndDrugAdministrationMember" name="FoodAndDrugAdministrationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_LoanPrepaidDuringFirstTwelveMonthsMember" name="LoanPrepaidDuringFirstTwelveMonthsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember" name="LoanPrepaidDuringThirteenToTwentyFourMonthsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_OxfordLoanFifthAmendmentMember" name="OxfordLoanFifthAmendmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" name="DebtInstrumentPrincipalAndInterestPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_DebtInstrumentExitFeePayablePercentage" name="DebtInstrumentExitFeePayablePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="eigr_DebtInstrumentUnamortizedExitFees" name="DebtInstrumentUnamortizedExitFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod" name="DebtInstrumentExtendedInterestOnlyPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_DebtInstrumentSuccessFeesPayablePercentage" name="DebtInstrumentSuccessFeesPayablePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" name="DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" name="DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_DebtInstrumentUnamortizedAdditionalExitFees" name="DebtInstrumentUnamortizedAdditionalExitFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_RepaymentsOfLoanAgreementExitFee" name="RepaymentsOfLoanAgreementExitFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_DebtInstrumentCovenantNoncompliancePenalty" name="DebtInstrumentCovenantNoncompliancePenalty" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_DebtInstrumentPrepaymentFeePercentage" name="DebtInstrumentPrepaymentFeePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_PrepaymentOfLoanFeeDescription" name="PrepaymentOfLoanFeeDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_DebtInstrumentUnamortizedInterest" name="DebtInstrumentUnamortizedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_DebtInstrumentInterestPaymentPeriod" name="DebtInstrumentInterestPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_DividendsDeclared" name="DividendsDeclared" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" name="NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" name="EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" name="MaximumEquityDebtWarrantsIssuedDuringThePeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_AmountOfCommonStockAvailableForSale" name="AmountOfCommonStockAvailableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_UnderwritingAgreementMember" name="UnderwritingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_OptionsIssuedAndOutstanding" name="OptionsIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" name="HoldersOfTenPercentOrMoreOfVotingPowerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember" name="RestatedTwoThousandThirteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" name="TwoThousandThirteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_ClosingPriceOfCommonStock" name="ClosingPriceOfCommonStock" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="eigr_NonEmployeeStockOptionMember" name="NonEmployeeStockOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_DeferredTaxAssetDepreciationAndAmortization" name="DeferredTaxAssetDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="eigr_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_IncreaseInDeferredTaxAssetsValuationAllowance" name="IncreaseInDeferredTaxAssetsValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" name="LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_LeaseCommencedDate" name="LeaseCommencedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_PatheonIncMember" name="PatheonIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_MasterManufacturingServicesAgreementMember" name="MasterManufacturingServicesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" name="PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_PercentageOfPurchasePrice" name="PercentageOfPurchasePrice" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_ProductAgreementDateOfExpiration" name="ProductAgreementDateOfExpiration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_ProductAgreementRenewalTerm" name="ProductAgreementRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="eigr_AmendmendFeesPayment" name="AmendmendFeesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>34
<FILENAME>eigr-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-08T23:16:18.7044828+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 867300f52dd744cb97ec68c0fc090a12 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="eigr-20201231.xsd#TemplateLink" roleURI="http://www.eigerbio.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="eigr_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="locator" xlink:label="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="eigr_OperatingLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSecuredDebt" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" xlink:type="locator" xlink:label="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PaymentsOfDeferredOfferingCosts" xlink:type="locator" xlink:label="eigr_PaymentsOfDeferredOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="eigr_PaymentsOfDeferredOfferingCosts" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eigr_OperatingLeaseRightOfUseAssetAmortization" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="eigr_IncreaseDecreaseInOperatingLeaseLiabilities" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10270.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11250.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11270.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PrepaidResearchCosts" xlink:type="locator" xlink:label="eigr_PrepaidResearchCosts" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PrepaidContractManufacturingCosts" xlink:type="locator" xlink:label="eigr_PrepaidContractManufacturingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eigr_PrepaidContractManufacturingCosts" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eigr_PrepaidResearchCosts" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ContractManufacturingCostsCurrent" xlink:type="locator" xlink:label="eigr_ContractManufacturingCostsCurrent" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AccruedContractedResearchCostsCurrent" xlink:type="locator" xlink:label="eigr_AccruedContractedResearchCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="eigr_AccruedContractedResearchCostsCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="eigr_ContractManufacturingCostsCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedExitFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="eigr_DebtInstrumentUnamortizedExitFees" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="10030.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedExitFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedInterest" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="eigr_DebtInstrumentUnamortizedInterest" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="eigr_DebtInstrumentUnamortizedExitFees" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OptionsIssuedAndOutstanding" xlink:type="locator" xlink:label="eigr_OptionsIssuedAndOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="eigr_OptionsIssuedAndOutstanding" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator" xlink:label="eigr_DeferredTaxAssetsLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DeferredTaxAssetDepreciationAndAmortization" xlink:type="locator" xlink:label="eigr_DeferredTaxAssetDepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="eigr_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="eigr_DeferredTaxLiabilitiesRightOfUseAssets" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="eigr_DeferredTaxAssetDepreciationAndAmortization" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="eigr_DeferredTaxAssetsLeaseLiabilities" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail2" xlink:href="eigr-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>35
<FILENAME>eigr-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-08T23:16:18.7044828+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 867300f52dd744cb97ec68c0fc090a12 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="eigr-20201231.xsd#TemplateLink" roleURI="http://www.eigerbio.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement" xlink:type="locator" xlink:label="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" xlink:type="locator" xlink:label="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSecuredDebt" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" xlink:type="locator" xlink:label="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PaymentsOfDeferredOfferingCosts" xlink:type="locator" xlink:label="eigr_PaymentsOfDeferredOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="eigr_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="locator" xlink:label="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="eigr_OperatingLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_POMember" xlink:type="locator" xlink:label="eigr_POMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10280.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eigr_POMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="eigr_OperatingLeaseRightOfUseAssetAmortization" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="eigr_IncreaseDecreaseInOperatingLeaseLiabilities" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="eigr_PaymentsOfDeferredOfferingCosts" order="12250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12910.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables" xlink:href="eigr-20201231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EmployeesAndNonEmployeesStockOptionMember" xlink:type="locator" xlink:label="eigr_EmployeesAndNonEmployeesStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eigr_EmployeesAndNonEmployeesStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10340.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NumberOfProductCandidates" xlink:type="locator" xlink:label="eigr_NumberOfProductCandidates" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NumberOfSupplyChainsForEachProductCandidate" xlink:type="locator" xlink:label="eigr_NumberOfSupplyChainsForEachProductCandidate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskSupplier" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskSupplier" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="eigr_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="eigr_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="eigr_SignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskSupplier" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="eigr_NumberOfSupplyChainsForEachProductCandidate" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="eigr_NumberOfProductCandidates" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" order="10280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="eigr_ComputerEquipmentAndSoftwareMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LabEquipmentMember" xlink:type="locator" xlink:label="eigr_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eigr_LabEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eigr_ComputerEquipmentAndSoftwareMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" xlink:type="locator" xlink:label="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity" xlink:type="locator" xlink:label="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_FairValueTransfersBetweenLevelsTransfersAmount" xlink:type="locator" xlink:label="eigr_FairValueTransfersBetweenLevelsTransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="eigr_FairValueTransfersBetweenLevelsTransfersAmount" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" order="10570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_USGovernmentBondsMember" xlink:type="locator" xlink:label="eigr_USGovernmentBondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="eigr_USGovernmentBondsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10800.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CashEquivalentsAmortizedCost" xlink:type="locator" xlink:label="eigr_CashEquivalentsAmortizedCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_USGovernmentBondsMember" xlink:type="locator" xlink:label="eigr_USGovernmentBondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:type="locator" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesTable" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:type="locator" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="eigr_CashEquivalentsAndInvestmentSecuritiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="eigr_USGovernmentBondsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="eigr_CashEquivalentsAmortizedCost" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11980.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="eigr_ComputerEquipmentAndSoftwareMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LabEquipmentMember" xlink:type="locator" xlink:label="eigr_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eigr_LabEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eigr_ComputerEquipmentAndSoftwareMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RoyaltiesExpirationDescription" xlink:type="locator" xlink:label="eigr_RoyaltiesExpirationDescription" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MilestonePayments" xlink:type="locator" xlink:label="eigr_MilestonePayments" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentMilestoneObligations" xlink:type="locator" xlink:label="eigr_DevelopmentMilestoneObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseInMilestoneObligations" xlink:type="locator" xlink:label="eigr_IncreaseInMilestoneObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UpfrontCashPayments" xlink:type="locator" xlink:label="eigr_UpfrontCashPayments" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CollaborativeArrangementRenewalTerm" xlink:type="locator" xlink:label="eigr_CollaborativeArrangementRenewalTerm" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CollaborationAgreementInitialTerm" xlink:type="locator" xlink:label="eigr_CollaborationAgreementInitialTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="eigr_ProductAgreementTerminationNoticePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncentiveBasedRegulatoryMilestoneFees" xlink:type="locator" xlink:label="eigr_IncentiveBasedRegulatoryMilestoneFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ExpertConsultantFeesAndPassThroughCosts" xlink:type="locator" xlink:label="eigr_ExpertConsultantFeesAndPassThroughCosts" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductDevelopmentFees" xlink:type="locator" xlink:label="eigr_ProductDevelopmentFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MilestoneObligations" xlink:type="locator" xlink:label="eigr_MilestoneObligations" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LicenseMaintenanceFee" xlink:type="locator" xlink:label="eigr_LicenseMaintenanceFee" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NonRefundableIssueFee" xlink:type="locator" xlink:label="eigr_NonRefundableIssueFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MerckTransactionMember" xlink:type="locator" xlink:label="eigr_MerckTransactionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_PurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentPhaseThreeMember" xlink:type="locator" xlink:label="eigr_DevelopmentPhaseThreeMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentPhaseTwoMember" xlink:type="locator" xlink:label="eigr_DevelopmentPhaseTwoMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentAndRegulatoryMilestonesMember" xlink:type="locator" xlink:label="eigr_DevelopmentAndRegulatoryMilestonesMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_BmsTransactionMember" xlink:type="locator" xlink:label="eigr_BmsTransactionMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PRFCollaborationAgreementMember" xlink:type="locator" xlink:label="eigr_PRFCollaborationAgreementMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductDevelopmentAgreementMember" xlink:type="locator" xlink:label="eigr_ProductDevelopmentAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CommercialSalesMember" xlink:type="locator" xlink:label="eigr_CommercialSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UPennCHOPAgreementMember" xlink:type="locator" xlink:label="eigr_UPennCHOPAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_UPennCHOPAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eigr_CommercialSalesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_ProductDevelopmentAgreementMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_PRFCollaborationAgreementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_BmsTransactionMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eigr_DevelopmentAndRegulatoryMilestonesMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eigr_DevelopmentPhaseTwoMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eigr_DevelopmentPhaseThreeMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eigr_PurchaseAgreementMember" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_MerckTransactionMember" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_NonRefundableIssueFee" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_LicenseMaintenanceFee" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_MilestoneObligations" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_ProductDevelopmentFees" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_ExpertConsultantFeesAndPassThroughCosts" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_IncentiveBasedRegulatoryMilestoneFees" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_ProductAgreementTerminationNoticePeriod" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_CollaborationAgreementInitialTerm" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_CollaborativeArrangementRenewalTerm" order="12580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_UpfrontCashPayments" order="12630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockValue" order="12670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_IncreaseInMilestoneObligations" order="12750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_DevelopmentMilestoneObligations" order="12880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_MilestonePayments" order="12920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_RoyaltiesExpirationDescription" order="12960.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PaymentForAssetPurchaseAgreement" xlink:type="locator" xlink:label="eigr_PaymentForAssetPurchaseAgreement" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LicenseAgreementMilestonePaymentsPaid" xlink:type="locator" xlink:label="eigr_LicenseAgreementMilestonePaymentsPaid" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LicenseAgreementPotentialMilestonePayments" xlink:type="locator" xlink:label="eigr_LicenseAgreementPotentialMilestonePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_VestingOfOptionsToPurchaseCommonStock" xlink:type="locator" xlink:label="eigr_VestingOfOptionsToPurchaseCommonStock" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" xlink:type="locator" xlink:label="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OptionsToPurchaseOfCommonStock" xlink:type="locator" xlink:label="eigr_OptionsToPurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RoyaltiesExpirationDescription" xlink:type="locator" xlink:label="eigr_RoyaltiesExpirationDescription" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" xlink:type="locator" xlink:label="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseDescription" xlink:type="locator" xlink:label="eigr_AssetPurchaseDescription" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UpfrontCashPayments" xlink:type="locator" xlink:label="eigr_UpfrontCashPayments" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PRFCollaborationAgreementMember" xlink:type="locator" xlink:label="eigr_PRFCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AbbvieAssetPurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_AbbvieAssetPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MilestoneVestedOptionsMember" xlink:type="locator" xlink:label="eigr_MilestoneVestedOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AvexitidePurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_AvexitidePurchaseAgreementMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductOneMember" xlink:type="locator" xlink:label="eigr_ProductOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EIGTransactionMember" xlink:type="locator" xlink:label="eigr_EIGTransactionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eigr_AssetPurchaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="eigr_EIGTransactionMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="srt_ProductOrServiceAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eigr_ProductOneMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eigr_AvexitidePurchaseAgreementMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="us-gaap_VestingAxis" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="eigr_MilestoneVestedOptionsMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="srt_RangeAxis" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eigr_AbbvieAssetPurchaseAgreementMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_PRFCollaborationAgreementMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_UpfrontCashPayments" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_AssetPurchaseDescription" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_RoyaltiesExpirationDescription" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_OptionsToPurchaseOfCommonStock" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_VestingOfOptionsToPurchaseCommonStock" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_LicenseAgreementPotentialMilestonePayments" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_LicenseAgreementMilestonePaymentsPaid" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_PaymentForAssetPurchaseAgreement" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" order="11700.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureDebtAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentInterestPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentInterestPaymentPeriod" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PrepaymentOfLoanFeeDescription" xlink:type="locator" xlink:label="eigr_PrepaymentOfLoanFeeDescription" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentPrepaymentFeePercentage" xlink:type="locator" xlink:label="eigr_DebtInstrumentPrepaymentFeePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantDescription" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentCovenantNoncompliancePenalty" xlink:type="locator" xlink:label="eigr_DebtInstrumentCovenantNoncompliancePenalty" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" xlink:type="locator" xlink:label="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" xlink:type="locator" xlink:label="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentSuccessFeesPayablePercentage" xlink:type="locator" xlink:label="eigr_DebtInstrumentSuccessFeesPayablePercentage" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RepaymentsOfLoanAgreementExitFee" xlink:type="locator" xlink:label="eigr_RepaymentsOfLoanAgreementExitFee" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedAdditionalExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedAdditionalExitFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedExitFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentExitFeePayablePercentage" xlink:type="locator" xlink:label="eigr_DebtInstrumentExitFeePayablePercentage" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanFifthAmendmentMember" xlink:type="locator" xlink:label="eigr_OxfordLoanFifthAmendmentMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember" xlink:type="locator" xlink:label="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LoanPrepaidDuringFirstTwelveMonthsMember" xlink:type="locator" xlink:label="eigr_LoanPrepaidDuringFirstTwelveMonthsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_FoodAndDrugAdministrationMember" xlink:type="locator" xlink:label="eigr_FoodAndDrugAdministrationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:type="locator" xlink:label="us-gaap_RegulatoryAgencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:type="locator" xlink:label="us-gaap_RegulatoryAgencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegulatoryAgencyAxis" xlink:type="locator" xlink:label="us-gaap_RegulatoryAgencyAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedTrancheBMember" xlink:type="locator" xlink:label="eigr_AmendedTrancheBMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedTrancheAMember" xlink:type="locator" xlink:label="eigr_AmendedTrancheAMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedOxfordLoanMember" xlink:type="locator" xlink:label="eigr_AmendedOxfordLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheCMember" xlink:type="locator" xlink:label="eigr_TrancheCMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheBMember" xlink:type="locator" xlink:label="eigr_TrancheBMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheAMember" xlink:type="locator" xlink:label="eigr_TrancheAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanAmendmentMember" xlink:type="locator" xlink:label="eigr_OxfordLoanAmendmentMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanMember" xlink:type="locator" xlink:label="eigr_OxfordLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_OxfordLoanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_OxfordLoanAmendmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_TrancheAMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_TrancheBMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_TrancheCMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_AmendedOxfordLoanMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_AmendedTrancheAMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_AmendedTrancheBMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RegulatoryAgencyAxis" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain_2" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="eigr_FoodAndDrugAdministrationMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_2" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eigr_LoanPrepaidDuringFirstTwelveMonthsMember" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_OxfordLoanFifthAmendmentMember" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentExitFeePayablePercentage" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentUnamortizedExitFees" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="12400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod" order="12690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentUnamortizedAdditionalExitFees" order="12810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_RepaymentsOfLoanAgreementExitFee" order="12850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentSuccessFeesPayablePercentage" order="12930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" order="12970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" order="13010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentCovenantNoncompliancePenalty" order="13080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" order="13100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" order="13120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentPrepaymentFeePercentage" order="13170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_PrepaymentOfLoanFeeDescription" order="13210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentInterestPaymentPeriod" order="13260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedExitFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedInterest" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedTrancheAMember" xlink:type="locator" xlink:label="eigr_AmendedTrancheAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanMember" xlink:type="locator" xlink:label="eigr_OxfordLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10080.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_OxfordLoanMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_AmendedTrancheAMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentUnamortizedInterest" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentUnamortizedExitFees" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10390.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmountOfCommonStockAvailableForSale" xlink:type="locator" xlink:label="eigr_AmountOfCommonStockAvailableForSale" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" xlink:type="locator" xlink:label="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" xlink:type="locator" xlink:label="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" xlink:type="locator" xlink:label="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DividendsDeclared" xlink:type="locator" xlink:label="eigr_DividendsDeclared" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="eigr_AtTheMarketOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UnderwritingAgreementMember" xlink:type="locator" xlink:label="eigr_UnderwritingAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_UnderwritingAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eigr_AtTheMarketOfferingMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_DividendsDeclared" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_AmountOfCommonStockAvailableForSale" order="11660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ClosingPriceOfCommonStock" xlink:type="locator" xlink:label="eigr_ClosingPriceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" xlink:type="locator" xlink:label="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_ClosingPriceOfCommonStock" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EmployeesAndNonEmployeesStockOptionMember" xlink:type="locator" xlink:label="eigr_EmployeesAndNonEmployeesStockOptionMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NonEmployeeStockOptionMember" xlink:type="locator" xlink:label="eigr_NonEmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eigr_NonEmployeeStockOptionMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eigr_EmployeesAndNonEmployeesStockOptionMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10960.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="eigr_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="eigr_IncreaseInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncomeTaxesTable" xlink:type="locator" xlink:label="eigr_IncomeTaxesTable" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncomeTaxesLineItems" xlink:type="locator" xlink:label="eigr_IncomeTaxesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="eigr_IncomeTaxesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="eigr_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="eigr_IncreaseInDeferredTaxAssetsValuationAllowance" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="eigr_OperatingLossCarryforwardsExpirationYear" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10610.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductAgreementRenewalTerm" xlink:type="locator" xlink:label="eigr_ProductAgreementRenewalTerm" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductAgreementDateOfExpiration" xlink:type="locator" xlink:label="eigr_ProductAgreementDateOfExpiration" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PercentageOfPurchasePrice" xlink:type="locator" xlink:label="eigr_PercentageOfPurchasePrice" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" xlink:type="locator" xlink:label="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" xlink:type="locator" xlink:label="us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:type="locator" xlink:label="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LeaseCommencedDate" xlink:type="locator" xlink:label="eigr_LeaseCommencedDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MasterManufacturingServicesAgreementMember" xlink:type="locator" xlink:label="eigr_MasterManufacturingServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PatheonIncMember" xlink:type="locator" xlink:label="eigr_PatheonIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="eigr_PatheonIncMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_MasterManufacturingServicesAgreementMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_LeaseCommencedDate" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_VariableLeaseCost" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_PercentageOfPurchasePrice" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_ProductAgreementDateOfExpiration" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_ProductAgreementRenewalTerm" order="11150.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendmendFeesPayment" xlink:type="locator" xlink:label="eigr_AmendmendFeesPayment" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentInterestPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentInterestPaymentPeriod" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanFifthAmendmentMember" xlink:type="locator" xlink:label="eigr_OxfordLoanFifthAmendmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheBMember" xlink:type="locator" xlink:label="eigr_TrancheBMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_TrancheBMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_OxfordLoanFifthAmendmentMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eigr_DebtInstrumentInterestPaymentPeriod" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eigr_AmendmendFeesPayment" order="10520.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>36
<FILENAME>eigr-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-08T23:16:18.7054820+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 867300f52dd744cb97ec68c0fc090a12 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, available-for-sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 12)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2020 and 2019; 33,878,486 and 24,523,381 shares issued and outstanding as of December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) gain:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on available-for-sale debt securities, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement" xlink:type="locator" xlink:label="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement" />
    <link:label xml:lang="en-US" xlink:label="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares product development agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement" xlink:to="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" xlink:type="locator" xlink:label="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" />
    <link:label xml:lang="en-US" xlink:label="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value product development agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" xlink:to="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon public offering, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon public offering, net of issuance costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon ESPP purchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon ESPP purchase, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon stock option exercise</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon stock option exercises, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Product Development Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Product Development Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Product Development Agreement, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Product Development Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon public offering, issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="eigr_OperatingLeaseRightOfUseAssetAmortization" />
    <link:label xml:lang="en-US" xlink:label="eigr_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease right of use asset amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_OperatingLeaseRightOfUseAssetAmortization" xlink:to="eigr_OperatingLeaseRightOfUseAssetAmortization_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="locator" xlink:label="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="eigr_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="eigr_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PaymentsOfDeferredOfferingCosts" xlink:type="locator" xlink:label="eigr_PaymentsOfDeferredOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="eigr_PaymentsOfDeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of deferred offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PaymentsOfDeferredOfferingCosts" xlink:to="eigr_PaymentsOfDeferredOfferingCosts_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" xlink:type="locator" xlink:label="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" />
    <link:label xml:lang="en-US" xlink:label="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayment of accrued exit fee and second amendment fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" xlink:to="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_POMember" xlink:type="locator" xlink:label="eigr_POMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_POMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock by a private company to the public.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_POMember" xlink:to="eigr_POMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_POMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_POMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of debt securities premiums and discounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Financing Costs And Discounts</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued under Product Development Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of debt securities available-for-sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of debt securities available-for-sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock upon public offering,net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon stock option exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon ESPP purchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PaymentsOfDeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PaymentsOfDeferredOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from borrowings in connection with term loan, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Debt Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of accrued exit fee and second amendment fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayment Of Accrued Exit Fee And Second Amendment Fee</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSecuredDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSecuredDebt" xlink:to="us-gaap_RepaymentsOfSecuredDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfSecuredDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="eigr_CollaborationAndLicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="eigr_CollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_CollaborationAndLicenseAgreementsAbstract" xlink:to="eigr_CollaborationAndLicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_CollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Collaboration, and Product Development Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for asset purchase agreement and related license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock" xlink:to="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset purchase agreements and related license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:to="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Agreements And Related License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Purchase Agreements and Related License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Agreement And Related License Agreements [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="locator" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Matters</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Matters And Contingencies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:type="locator" xlink:label="eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:to="eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting pronouncements not yet adopted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Pronouncements Not Yet Adopted Policy [Text Block]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated useful life of property and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" xlink:to="eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Useful Life Of Property And Equipment Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assets and Liabilities Measured at Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The tabular disclosure of prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Long-Term Debt and Unamortized Discount Balances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Payments of Principal, Exit Fee and Interest Expense under Oxford Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Long Term Debt Table [Text Block]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CommonStockReservedForFutureIssuancesTableTextBlock" xlink:type="locator" xlink:label="eigr_CommonStockReservedForFutureIssuancesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="eigr_CommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of gross number of shares which are to be issued during the future period as a result of any equity-based compensation plan or conversion of outstanding convertible instruments. Shares reserved for issuance could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and upon the conversion of outstanding convertible instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_CommonStockReservedForFutureIssuancesTableTextBlock" xlink:to="eigr_CommonStockReservedForFutureIssuancesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_CommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Stock Reserved for Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_CommonStockReservedForFutureIssuancesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Reserved For Future Issuances Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EmployeesAndNonEmployeesStockOptionMember" xlink:type="locator" xlink:label="eigr_EmployeesAndNonEmployeesStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_EmployeesAndNonEmployeesStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and non employees stock option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_EmployeesAndNonEmployeesStockOptionMember" xlink:to="eigr_EmployeesAndNonEmployeesStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_EmployeesAndNonEmployeesStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees and Non Employees Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_EmployeesAndNonEmployeesStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employees And Non Employees Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Non-cash Stock Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Effective Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity of Operating Leases Liabilities and Future Minimum Lease Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DescriptionOfBusinessAbstract" xlink:type="locator" xlink:label="eigr_DescriptionOfBusinessAbstract" />
    <link:label xml:lang="en-US" xlink:label="eigr_DescriptionOfBusinessAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DescriptionOfBusinessAbstract" xlink:to="eigr_DescriptionOfBusinessAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_DescriptionOfBusinessAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity incorporation, date of incorporation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, and Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NumberOfSupplyChainsForEachProductCandidate" xlink:type="locator" xlink:label="eigr_NumberOfSupplyChainsForEachProductCandidate" />
    <link:label xml:lang="en-US" xlink:label="eigr_NumberOfSupplyChainsForEachProductCandidate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of supply chains for each product candidate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_NumberOfSupplyChainsForEachProductCandidate" xlink:to="eigr_NumberOfSupplyChainsForEachProductCandidate_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NumberOfProductCandidates" xlink:type="locator" xlink:label="eigr_NumberOfProductCandidates" />
    <link:label xml:lang="en-US" xlink:label="eigr_NumberOfProductCandidates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of product candidates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_NumberOfProductCandidates" xlink:to="eigr_NumberOfProductCandidates_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="eigr_SignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="eigr_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="eigr_SignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="eigr_SignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="eigr_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_SignificantAccountingPoliciesTable" xlink:to="eigr_SignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplier Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplier Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskSupplier" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskSupplier" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskSupplier_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, supplier</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskSupplier" xlink:to="us-gaap_ConcentrationRiskSupplier_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskSupplier_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Supplier</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_NumberOfSupplyChainsForEachProductCandidate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of supply chains for each product candidate</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_NumberOfSupplyChainsForEachProductCandidate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Supply Chains For Each Product Candidate</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_NumberOfProductCandidates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of product candidates.</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_NumberOfProductCandidates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Product Candidates</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" xlink:type="locator" xlink:label="eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" />
    <link:label xml:lang="en-US" xlink:label="eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property Plant And Equipment Capitalized Interest Costs [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" xlink:to="eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Capitalized Interest Costs [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LabEquipmentMember" xlink:type="locator" xlink:label="eigr_LabEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_LabEquipmentMember" xlink:to="eigr_LabEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="eigr_ComputerEquipmentAndSoftwareMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ComputerEquipmentAndSoftwareMember" xlink:to="eigr_ComputerEquipmentAndSoftwareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest charged in relation to unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Interest On Income Taxes Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Penalties charged in relation to unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" xlink:type="locator" xlink:label="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options granted to employees and non employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" xlink:to="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options Granted to Employees and Non Employees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options Granted To Employees And Non Employees [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units, Unvested [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_FairValueTransfersBetweenLevelsTransfersAmount" xlink:type="locator" xlink:label="eigr_FairValueTransfersBetweenLevelsTransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="eigr_FairValueTransfersBetweenLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value transfers between levels transfers amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_FairValueTransfersBetweenLevelsTransfersAmount" xlink:to="eigr_FairValueTransfersBetweenLevelsTransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_FairValueTransfersBetweenLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers in or out of level 3</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_FairValueTransfersBetweenLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Transfers Between Levels Transfers Amount</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentFairValueCarryingValueAbstract" xlink:type="locator" xlink:label="eigr_DebtInstrumentFairValueCarryingValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentFairValueCarryingValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument Fair Value Carrying Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentFairValueCarryingValueAbstract" xlink:to="eigr_DebtInstrumentFairValueCarryingValueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentFairValueCarryingValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fair Value Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_USGovernmentBondsMember" xlink:type="locator" xlink:label="eigr_USGovernmentBondsMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_USGovernmentBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. government bonds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_USGovernmentBondsMember" xlink:to="eigr_USGovernmentBondsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_USGovernmentBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_USGovernmentBondsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Bonds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasury Bill Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Assets, Fair Value</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CashEquivalentsAmortizedCost" xlink:type="locator" xlink:label="eigr_CashEquivalentsAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="eigr_CashEquivalentsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents amortized cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_CashEquivalentsAmortizedCost" xlink:to="eigr_CashEquivalentsAmortizedCost_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:type="locator" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and investment securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:type="locator" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and investment securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:to="eigr_CashEquivalentsAndInvestmentSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents And Investment Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Investment Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Investment Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Investment Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_CashEquivalentsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents, Amortized cost</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_CashEquivalentsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents, Estimated Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt securities, Amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, Unrealized gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt securities, Unrealized loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities, Estimated Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity" xlink:type="locator" xlink:label="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity" />
    <link:label xml:lang="en-US" xlink:label="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale of debt securities contractual maturity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity" xlink:to="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available- for-sale of debt securities contractual maturity</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Of Debt Securities Contractual Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other-than-temporary impairment losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment, accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAbstract" xlink:type="locator" xlink:label="us-gaap_DepreciationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAbstract" xlink:to="us-gaap_DepreciationAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PrepaidContractManufacturingCosts" xlink:type="locator" xlink:label="eigr_PrepaidContractManufacturingCosts" />
    <link:label xml:lang="en-US" xlink:label="eigr_PrepaidContractManufacturingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid contract manufacturing costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PrepaidContractManufacturingCosts" xlink:to="eigr_PrepaidContractManufacturingCosts_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PrepaidResearchCosts" xlink:type="locator" xlink:label="eigr_PrepaidResearchCosts" />
    <link:label xml:lang="en-US" xlink:label="eigr_PrepaidResearchCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of consideration paid in advance for research that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PrepaidResearchCosts" xlink:to="eigr_PrepaidResearchCosts_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of other prepaid expense and other assets current classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" xlink:to="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_PrepaidContractManufacturingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid contract manufacturing costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PrepaidContractManufacturingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Contract Manufacturing Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PrepaidResearchCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PrepaidResearchCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AccruedContractedResearchCostsCurrent" xlink:type="locator" xlink:label="eigr_AccruedContractedResearchCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="eigr_AccruedContractedResearchCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contracted research costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AccruedContractedResearchCostsCurrent" xlink:to="eigr_AccruedContractedResearchCostsCurrent_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ContractManufacturingCostsCurrent" xlink:type="locator" xlink:label="eigr_ContractManufacturingCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="eigr_ContractManufacturingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract manufacturing costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ContractManufacturingCostsCurrent" xlink:to="eigr_ContractManufacturingCostsCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AccruedContractedResearchCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract research costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AccruedContractedResearchCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contracted Research Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ContractManufacturingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract manufacturing costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ContractManufacturingCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract Manufacturing Costs Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation and related benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LicenseMaintenanceFee" xlink:type="locator" xlink:label="eigr_LicenseMaintenanceFee" />
    <link:label xml:lang="en-US" xlink:label="eigr_LicenseMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fee annual.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_LicenseMaintenanceFee" xlink:to="eigr_LicenseMaintenanceFee_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MilestoneObligations" xlink:type="locator" xlink:label="eigr_MilestoneObligations" />
    <link:label xml:lang="en-US" xlink:label="eigr_MilestoneObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_MilestoneObligations" xlink:to="eigr_MilestoneObligations_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NonRefundableIssueFee" xlink:type="locator" xlink:label="eigr_NonRefundableIssueFee" />
    <link:label xml:lang="en-US" xlink:label="eigr_NonRefundableIssueFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable issue fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_NonRefundableIssueFee" xlink:to="eigr_NonRefundableIssueFee_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UPennCHOPAgreementMember" xlink:type="locator" xlink:label="eigr_UPennCHOPAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_UPennCHOPAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_UPennCHOPAgreementMember" xlink:to="eigr_UPennCHOPAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_UPennCHOPAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UPenn/CHOP Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_UPennCHOPAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U Penn C H O P Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CommercialSalesMember" xlink:type="locator" xlink:label="eigr_CommercialSalesMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_CommercialSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_CommercialSalesMember" xlink:to="eigr_CommercialSalesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_CommercialSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Sales [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_CommercialSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Sales [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductDevelopmentAgreementMember" xlink:type="locator" xlink:label="eigr_ProductDevelopmentAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_ProductDevelopmentAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product development agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ProductDevelopmentAgreementMember" xlink:to="eigr_ProductDevelopmentAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_ProductDevelopmentAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ProductDevelopmentAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Development Agreement [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PRFCollaborationAgreementMember" xlink:type="locator" xlink:label="eigr_PRFCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_PRFCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">PRF collaboration agreement .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PRFCollaborationAgreementMember" xlink:to="eigr_PRFCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_PRFCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Progeria Research Foundation (PRF) Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PRFCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">P R F Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_BmsTransactionMember" xlink:type="locator" xlink:label="eigr_BmsTransactionMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_BmsTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">BMS transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_BmsTransactionMember" xlink:to="eigr_BmsTransactionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_BmsTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BMS Transaction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_BmsTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bms Transaction [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentAndRegulatoryMilestonesMember" xlink:type="locator" xlink:label="eigr_DevelopmentAndRegulatoryMilestonesMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DevelopmentAndRegulatoryMilestonesMember" xlink:to="eigr_DevelopmentAndRegulatoryMilestonesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentPhaseTwoMember" xlink:type="locator" xlink:label="eigr_DevelopmentPhaseTwoMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentPhaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development phase two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DevelopmentPhaseTwoMember" xlink:to="eigr_DevelopmentPhaseTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentPhaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Phase 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentPhaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Phase Two [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentPhaseThreeMember" xlink:type="locator" xlink:label="eigr_DevelopmentPhaseThreeMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentPhaseThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development phase three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DevelopmentPhaseThreeMember" xlink:to="eigr_DevelopmentPhaseThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentPhaseThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Phase 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentPhaseThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Phase Three [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_PurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PurchaseAgreementMember" xlink:to="eigr_PurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BMS Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MerckTransactionMember" xlink:type="locator" xlink:label="eigr_MerckTransactionMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_MerckTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Merck transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_MerckTransactionMember" xlink:to="eigr_MerckTransactionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_MerckTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merck Transaction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_MerckTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Merck Transaction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_NonRefundableIssueFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Refundable Issue Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_NonRefundableIssueFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Issue Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LicenseMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License maintenance fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LicenseMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_MilestoneObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_MilestoneObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Obligations</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductDevelopmentFees" xlink:type="locator" xlink:label="eigr_ProductDevelopmentFees" />
    <link:label xml:lang="en-US" xlink:label="eigr_ProductDevelopmentFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product development fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ProductDevelopmentFees" xlink:to="eigr_ProductDevelopmentFees_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ExpertConsultantFeesAndPassThroughCosts" xlink:type="locator" xlink:label="eigr_ExpertConsultantFeesAndPassThroughCosts" />
    <link:label xml:lang="en-US" xlink:label="eigr_ExpertConsultantFeesAndPassThroughCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expert consultant fees and pass through costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ExpertConsultantFeesAndPassThroughCosts" xlink:to="eigr_ExpertConsultantFeesAndPassThroughCosts_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncentiveBasedRegulatoryMilestoneFees" xlink:type="locator" xlink:label="eigr_IncentiveBasedRegulatoryMilestoneFees" />
    <link:label xml:lang="en-US" xlink:label="eigr_IncentiveBasedRegulatoryMilestoneFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive-based regulatory milestone fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_IncentiveBasedRegulatoryMilestoneFees" xlink:to="eigr_IncentiveBasedRegulatoryMilestoneFees_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="eigr_ProductAgreementTerminationNoticePeriod" />
    <link:label xml:lang="en-US" xlink:label="eigr_ProductAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product agreement termination notice period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ProductAgreementTerminationNoticePeriod" xlink:to="eigr_ProductAgreementTerminationNoticePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_ProductDevelopmentFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product development fees</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ProductDevelopmentFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Development Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ExpertConsultantFeesAndPassThroughCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expert consultant fees and pass through costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ExpertConsultantFeesAndPassThroughCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expert Consultant Fees And Pass Through Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncentiveBasedRegulatoryMilestoneFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive-based regulatory milestone fees</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncentiveBasedRegulatoryMilestoneFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Based Regulatory Milestone Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock issued subject to quarterly vesting requirements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ProductAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product agreement termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ProductAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Agreement Termination Notice Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognised compensation expense related to unvested restricted shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period for recognition (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CollaborationAgreementInitialTerm" xlink:type="locator" xlink:label="eigr_CollaborationAgreementInitialTerm" />
    <link:label xml:lang="en-US" xlink:label="eigr_CollaborationAgreementInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement initial term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_CollaborationAgreementInitialTerm" xlink:to="eigr_CollaborationAgreementInitialTerm_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CollaborativeArrangementRenewalTerm" xlink:type="locator" xlink:label="eigr_CollaborativeArrangementRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="eigr_CollaborativeArrangementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the renewal term of the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_CollaborativeArrangementRenewalTerm" xlink:to="eigr_CollaborativeArrangementRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_CollaborationAgreementInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement initial term</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_CollaborationAgreementInitialTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Initial Term</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_CollaborativeArrangementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement subsequent renewal terms</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_CollaborativeArrangementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Renewal Term</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UpfrontCashPayments" xlink:type="locator" xlink:label="eigr_UpfrontCashPayments" />
    <link:label xml:lang="en-US" xlink:label="eigr_UpfrontCashPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_UpfrontCashPayments" xlink:to="eigr_UpfrontCashPayments_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseInMilestoneObligations" xlink:type="locator" xlink:label="eigr_IncreaseInMilestoneObligations" />
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseInMilestoneObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in milestone obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_IncreaseInMilestoneObligations" xlink:to="eigr_IncreaseInMilestoneObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_UpfrontCashPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_UpfrontCashPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Sale of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate fair value of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseInMilestoneObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in milestone payment obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseInMilestoneObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Milestone Obligations</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentMilestoneObligations" xlink:type="locator" xlink:label="eigr_DevelopmentMilestoneObligations" />
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentMilestoneObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DevelopmentMilestoneObligations" xlink:to="eigr_DevelopmentMilestoneObligations_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MilestonePayments" xlink:type="locator" xlink:label="eigr_MilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="eigr_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_MilestonePayments" xlink:to="eigr_MilestonePayments_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RoyaltiesExpirationDescription" xlink:type="locator" xlink:label="eigr_RoyaltiesExpirationDescription" />
    <link:label xml:lang="en-US" xlink:label="eigr_RoyaltiesExpirationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties expiration description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_RoyaltiesExpirationDescription" xlink:to="eigr_RoyaltiesExpirationDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentMilestoneObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone payment obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DevelopmentMilestoneObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_RoyaltiesExpirationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties expiration description</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_RoyaltiesExpirationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Expiration Description</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseDescription" xlink:type="locator" xlink:label="eigr_AssetPurchaseDescription" />
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset purchase description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AssetPurchaseDescription" xlink:to="eigr_AssetPurchaseDescription_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" xlink:type="locator" xlink:label="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" />
    <link:label xml:lang="en-US" xlink:label="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">One time payment to be made on asset purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" xlink:to="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" />
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset purchase agreement and related license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" />
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset Purchase Agreement And Related License Agreement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Purchase Agreement And Related License Agreement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Agreement And Related License Agreement [Table]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AssetPurchaseAgreementMember" xlink:to="eigr_AssetPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EIGTransactionMember" xlink:type="locator" xlink:label="eigr_EIGTransactionMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_EIGTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">EIG Transaction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_EIGTransactionMember" xlink:to="eigr_EIGTransactionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_EIGTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EIG Transaction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_EIGTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">E I G Transaction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductOneMember" xlink:type="locator" xlink:label="eigr_ProductOneMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_ProductOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ProductOneMember" xlink:to="eigr_ProductOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_ProductOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Farnesyl Transferase Inhibitors and Related Intellectual Property [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ProductOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product One [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AvexitidePurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_AvexitidePurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_AvexitidePurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Avexitide purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AvexitidePurchaseAgreementMember" xlink:to="eigr_AvexitidePurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AvexitidePurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Avexitide Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AvexitidePurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Avexitide Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MilestoneVestedOptionsMember" xlink:type="locator" xlink:label="eigr_MilestoneVestedOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_MilestoneVestedOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Vested Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_MilestoneVestedOptionsMember" xlink:to="eigr_MilestoneVestedOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_MilestoneVestedOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Vested Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_MilestoneVestedOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Vested Options [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AbbvieAssetPurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_AbbvieAssetPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_AbbvieAssetPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Abbvie asset purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AbbvieAssetPurchaseAgreementMember" xlink:to="eigr_AbbvieAssetPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AbbvieAssetPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AbbVie Asset Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AbbvieAssetPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Abbvie Asset Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Purchase Agreement And Related License Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Agreement And Related License Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset purchase description</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AssetPurchaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Description</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time payment</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">One Time Payment To Be Made On Asset Purchase Agreement</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OptionsToPurchaseOfCommonStock" xlink:type="locator" xlink:label="eigr_OptionsToPurchaseOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="eigr_OptionsToPurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_OptionsToPurchaseOfCommonStock" xlink:to="eigr_OptionsToPurchaseOfCommonStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for purchased assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Purchase Of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Purchase Of Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OptionsToPurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OptionsToPurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase of common stock exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" xlink:type="locator" xlink:label="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" />
    <link:label xml:lang="en-US" xlink:label="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting period of options issued for common stock purchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" xlink:to="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_VestingOfOptionsToPurchaseCommonStock" xlink:type="locator" xlink:label="eigr_VestingOfOptionsToPurchaseCommonStock" />
    <link:label xml:lang="en-US" xlink:label="eigr_VestingOfOptionsToPurchaseCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of options to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_VestingOfOptionsToPurchaseCommonStock" xlink:to="eigr_VestingOfOptionsToPurchaseCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase common stock vesting period</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Period Of Options Issued For Common Stock Purchase</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_VestingOfOptionsToPurchaseCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of options to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_VestingOfOptionsToPurchaseCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Options To Purchase Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation expense related to the time-vested/milestone vested options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LicenseAgreementPotentialMilestonePayments" xlink:type="locator" xlink:label="eigr_LicenseAgreementPotentialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="eigr_LicenseAgreementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement potential milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_LicenseAgreementPotentialMilestonePayments" xlink:to="eigr_LicenseAgreementPotentialMilestonePayments_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LicenseAgreementMilestonePaymentsPaid" xlink:type="locator" xlink:label="eigr_LicenseAgreementMilestonePaymentsPaid" />
    <link:label xml:lang="en-US" xlink:label="eigr_LicenseAgreementMilestonePaymentsPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_LicenseAgreementMilestonePaymentsPaid" xlink:to="eigr_LicenseAgreementMilestonePaymentsPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_LicenseAgreementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate potential milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LicenseAgreementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Potential Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LicenseAgreementMilestonePaymentsPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement milestone payments paid</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LicenseAgreementMilestonePaymentsPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Paid</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PaymentForAssetPurchaseAgreement" xlink:type="locator" xlink:label="eigr_PaymentForAssetPurchaseAgreement" />
    <link:label xml:lang="en-US" xlink:label="eigr_PaymentForAssetPurchaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for asset purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PaymentForAssetPurchaseAgreement" xlink:to="eigr_PaymentForAssetPurchaseAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_PaymentForAssetPurchaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for asset purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PaymentForAssetPurchaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Asset Purchase Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sales Of Business Affiliate And Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanMember" xlink:type="locator" xlink:label="eigr_OxfordLoanMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_OxfordLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Oxford loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_OxfordLoanMember" xlink:to="eigr_OxfordLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_OxfordLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oxford Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OxfordLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Oxford Loan [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanAmendmentMember" xlink:type="locator" xlink:label="eigr_OxfordLoanAmendmentMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_OxfordLoanAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Oxford loan amendment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_OxfordLoanAmendmentMember" xlink:to="eigr_OxfordLoanAmendmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_OxfordLoanAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OxfordLoanAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Oxford Loan Amendment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheAMember" xlink:type="locator" xlink:label="eigr_TrancheAMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_TrancheAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche A.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_TrancheAMember" xlink:to="eigr_TrancheAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_TrancheAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_TrancheAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche A [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheBMember" xlink:type="locator" xlink:label="eigr_TrancheBMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_TrancheBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche B.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_TrancheBMember" xlink:to="eigr_TrancheBMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_TrancheBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_TrancheBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche B [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheCMember" xlink:type="locator" xlink:label="eigr_TrancheCMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_TrancheCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche C.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_TrancheCMember" xlink:to="eigr_TrancheCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_TrancheCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_TrancheCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tranche C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIBOR [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">London Interbank Offered Rate L I B O R [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedOxfordLoanMember" xlink:type="locator" xlink:label="eigr_AmendedOxfordLoanMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_AmendedOxfordLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended Oxford loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AmendedOxfordLoanMember" xlink:to="eigr_AmendedOxfordLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AmendedOxfordLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Oxford Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AmendedOxfordLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended Oxford Loan [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedTrancheAMember" xlink:type="locator" xlink:label="eigr_AmendedTrancheAMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_AmendedTrancheAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended tranche A.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AmendedTrancheAMember" xlink:to="eigr_AmendedTrancheAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AmendedTrancheAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Tranche A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AmendedTrancheAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended Tranche A [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedTrancheBMember" xlink:type="locator" xlink:label="eigr_AmendedTrancheBMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_AmendedTrancheBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended tranche B.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AmendedTrancheBMember" xlink:to="eigr_AmendedTrancheBMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AmendedTrancheBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Tranche B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AmendedTrancheBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended Tranche B [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegulatoryAgencyAxis" xlink:type="locator" xlink:label="us-gaap_RegulatoryAgencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RegulatoryAgencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Agency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RegulatoryAgencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Agency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:type="locator" xlink:label="us-gaap_RegulatoryAgencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RegulatoryAgencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Agency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="us-gaap_RegulatoryAgencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RegulatoryAgencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Agency [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_FoodAndDrugAdministrationMember" xlink:type="locator" xlink:label="eigr_FoodAndDrugAdministrationMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_FoodAndDrugAdministrationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Food and drug administration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_FoodAndDrugAdministrationMember" xlink:to="eigr_FoodAndDrugAdministrationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_FoodAndDrugAdministrationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Food and Drug Administration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_FoodAndDrugAdministrationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Food And Drug Administration [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LoanPrepaidDuringFirstTwelveMonthsMember" xlink:type="locator" xlink:label="eigr_LoanPrepaidDuringFirstTwelveMonthsMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_LoanPrepaidDuringFirstTwelveMonthsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan prepaid during first twelve months.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_LoanPrepaidDuringFirstTwelveMonthsMember" xlink:to="eigr_LoanPrepaidDuringFirstTwelveMonthsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_LoanPrepaidDuringFirstTwelveMonthsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Prepaid During First 12 Months [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LoanPrepaidDuringFirstTwelveMonthsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Prepaid During First Twelve Months [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember" xlink:type="locator" xlink:label="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan prepaid during thirteen to twenty four months.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember" xlink:to="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Prepaid During 13 to 24 Months [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Prepaid During Thirteen To Twenty Four Months [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanFifthAmendmentMember" xlink:type="locator" xlink:label="eigr_OxfordLoanFifthAmendmentMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_OxfordLoanFifthAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Oxford loan fifth amendment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_OxfordLoanFifthAmendmentMember" xlink:to="eigr_OxfordLoanFifthAmendmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_OxfordLoanFifthAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fifth Amended Oxford Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OxfordLoanFifthAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Oxford Loan Fifth Amendment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement, aggregate borrowing capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Face value of term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument principal and interest payment period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:to="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentExitFeePayablePercentage" xlink:type="locator" xlink:label="eigr_DebtInstrumentExitFeePayablePercentage" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentExitFeePayablePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument exit fee payable percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentExitFeePayablePercentage" xlink:to="eigr_DebtInstrumentExitFeePayablePercentage_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedExitFees" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentUnamortizedExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument unamortized exit fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentUnamortizedExitFees" xlink:to="eigr_DebtInstrumentUnamortizedExitFees_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement, floating rate terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Description Of Variable Rate Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement, percentage to be added to the interest rate under condition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement, interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal and interest payment period</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Principal And Interest Payment Period</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentExitFeePayablePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of exit fee on principal balance</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentExitFeePayablePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Exit Fee Payable Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentUnamortizedExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loan final repayment exit fees payable</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentUnamortizedExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Exit Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loan origination fees and debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Finance Costs Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan, maturity period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings from loan agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Lines Of Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement, remaining borrowing capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Remaining Borrowing Capacity</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument extended interest only payment period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod" xlink:to="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentSuccessFeesPayablePercentage" xlink:type="locator" xlink:label="eigr_DebtInstrumentSuccessFeesPayablePercentage" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentSuccessFeesPayablePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument success fees payable percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentSuccessFeesPayablePercentage" xlink:to="eigr_DebtInstrumentSuccessFeesPayablePercentage_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" xlink:type="locator" xlink:label="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument success fees payable maximum period after approval.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" xlink:to="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" xlink:type="locator" xlink:label="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument fee enforceable maximum period from funding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" xlink:to="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedAdditionalExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedAdditionalExitFees" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentUnamortizedAdditionalExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument unamortized additional exit fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentUnamortizedAdditionalExitFees" xlink:to="eigr_DebtInstrumentUnamortizedAdditionalExitFees_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RepaymentsOfLoanAgreementExitFee" xlink:type="locator" xlink:label="eigr_RepaymentsOfLoanAgreementExitFee" />
    <link:label xml:lang="en-US" xlink:label="eigr_RepaymentsOfLoanAgreementExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments of loan agreement exit fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_RepaymentsOfLoanAgreementExitFee" xlink:to="eigr_RepaymentsOfLoanAgreementExitFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended term of interest only payment period</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Extended Interest Only Payment Period</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentUnamortizedAdditionalExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan final repayment additional exit fees payable</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentUnamortizedAdditionalExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Additional Exit Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_RepaymentsOfLoanAgreementExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of loan agreement exit fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_RepaymentsOfLoanAgreementExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Loan Agreement Exit Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentSuccessFeesPayablePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of success fee</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentSuccessFeesPayablePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Success Fees Payable Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success fees payable maximum period after approval</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Success Fees Payable Maximum Period After Approval</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fee payable maximum period from funding</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fee Enforceable Maximum Period From Funding</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentCovenantNoncompliancePenalty" xlink:type="locator" xlink:label="eigr_DebtInstrumentCovenantNoncompliancePenalty" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentCovenantNoncompliancePenalty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument covenant noncompliance penalty.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentCovenantNoncompliancePenalty" xlink:to="eigr_DebtInstrumentCovenantNoncompliancePenalty_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentCovenantNoncompliancePenalty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement, covenant noncompliance penalty</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentCovenantNoncompliancePenalty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Covenant Noncompliance Penalty</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement, covenant description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantDescription" xlink:to="us-gaap_DebtInstrumentCovenantDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Covenant Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement, covenant compliance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantCompliance" xlink:to="us-gaap_DebtInstrumentCovenantCompliance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Covenant Compliance</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentPrepaymentFeePercentage" xlink:type="locator" xlink:label="eigr_DebtInstrumentPrepaymentFeePercentage" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentPrepaymentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment fee percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentPrepaymentFeePercentage" xlink:to="eigr_DebtInstrumentPrepaymentFeePercentage_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PrepaymentOfLoanFeeDescription" xlink:type="locator" xlink:label="eigr_PrepaymentOfLoanFeeDescription" />
    <link:label xml:lang="en-US" xlink:label="eigr_PrepaymentOfLoanFeeDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment of loan fee description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PrepaymentOfLoanFeeDescription" xlink:to="eigr_PrepaymentOfLoanFeeDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentPrepaymentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument prepayment fee percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentPrepaymentFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PrepaymentOfLoanFeeDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment of loan fee, description</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PrepaymentOfLoanFeeDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Of Loan Fee Description</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Face value of long term debt</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentUnamortizedExitFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exit fee</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long term debt, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedInterest" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedInterest" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentUnamortizedInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument unamortized interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentUnamortizedInterest" xlink:to="eigr_DebtInstrumentUnamortizedInterest_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentUnamortizedInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unamortized interest</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentUnamortizedInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Interest</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Face value of term loan</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentInterestPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentInterestPaymentPeriod" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentInterestPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest payment period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DebtInstrumentInterestPaymentPeriod" xlink:to="eigr_DebtInstrumentInterestPaymentPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentInterestPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest payment period</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DebtInstrumentInterestPaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Payment Period</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DividendsDeclared" xlink:type="locator" xlink:label="eigr_DividendsDeclared" />
    <link:label xml:lang="en-US" xlink:label="eigr_DividendsDeclared_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dividends declared.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DividendsDeclared" xlink:to="eigr_DividendsDeclared_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" xlink:type="locator" xlink:label="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" />
    <link:label xml:lang="en-US" xlink:label="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional shares issued to underwriters as purchase option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" xlink:to="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" xlink:type="locator" xlink:label="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" />
    <link:label xml:lang="en-US" xlink:label="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity, debt, warrants and units, aggregate offering amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" xlink:to="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" xlink:type="locator" xlink:label="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" />
    <link:label xml:lang="en-US" xlink:label="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum equity debt warrants issued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" xlink:to="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmountOfCommonStockAvailableForSale" xlink:type="locator" xlink:label="eigr_AmountOfCommonStockAvailableForSale" />
    <link:label xml:lang="en-US" xlink:label="eigr_AmountOfCommonStockAvailableForSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of common stock available for sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AmountOfCommonStockAvailableForSale" xlink:to="eigr_AmountOfCommonStockAvailableForSale_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UnderwritingAgreementMember" xlink:type="locator" xlink:label="eigr_UnderwritingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_UnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_UnderwritingAgreementMember" xlink:to="eigr_UnderwritingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_UnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_UnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Agreement [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="eigr_AtTheMarketOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AtTheMarketOfferingMember" xlink:to="eigr_AtTheMarketOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AtTheMarketOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DividendsDeclared_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DividendsDeclared_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Declared</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Shares Issued To Underwriters As Purchase Option</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, offering price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity, debt, warrants and units, maximum aggregate offering amount</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Debt Warrants And Units Maximum Aggregate Offering Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity, debt, warrants and units, maximum issued and sale</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Equity Debt Warrants Issued During The Period</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AmountOfCommonStockAvailableForSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of common stock available for sale</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AmountOfCommonStockAvailableForSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Common Stock Available For Sale</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OptionsIssuedAndOutstanding" xlink:type="locator" xlink:label="eigr_OptionsIssuedAndOutstanding" />
    <link:label xml:lang="en-US" xlink:label="eigr_OptionsIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_OptionsIssuedAndOutstanding" xlink:to="eigr_OptionsIssuedAndOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_OptionsIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OptionsIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued And Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options available for future grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award threshold shareholder ownership percentage for pre-determined Exercise Price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" xlink:type="locator" xlink:label="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Holders Of Ten Percent Or More Of Voting Power [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" xlink:to="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Holders Of Ten Percent Or More Of Voting Power</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Holders Of Ten Percent Or More Of Voting Power [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restated 2013 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember" xlink:to="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restated 2013 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restated Two Thousand Thirteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2013 Employee Stock Purchase Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" xlink:to="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Thirteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold ownership percentage of shareholder for grant of options at pre determined exercise price</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Threshold Shareholder Ownership Percentage For Pre Determined Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual terms of options granted under the Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" />
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" />
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of restricted stock units granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" />
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled" />
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant forfeited or cancelled.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options outstanding, weighted average exercise price, and additional disclosures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Exercise Price And Additional Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Available for Grant, Outstanding, Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Available for Grant, Additional options authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Available for Grant, Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Available for Grant, Restricted stock units granted</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Restricted Stock Units Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, Forfeited or cancelled</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited Or Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Available for Grant, Outstanding, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Number of Options, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited or cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Per Option, Outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Option, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Option, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Option, Forfeited or cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Per Option, Outstanding, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Option, Vested and exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Remaining Contractual Life, Vested and exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ClosingPriceOfCommonStock" xlink:type="locator" xlink:label="eigr_ClosingPriceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="eigr_ClosingPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing price of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ClosingPriceOfCommonStock" xlink:to="eigr_ClosingPriceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_ClosingPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing price of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ClosingPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Closing Price Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of employee option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value of employee options vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NonEmployeeStockOptionMember" xlink:type="locator" xlink:label="eigr_NonEmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_NonEmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non employee stock option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_NonEmployeeStockOptionMember" xlink:to="eigr_NonEmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_NonEmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Employees Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_NonEmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contractual term (in years)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved for Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage increase in number of shares of common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average period expected to recognized compensation expense (in years)</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncomeTaxesLineItems" xlink:type="locator" xlink:label="eigr_IncomeTaxesLineItems" />
    <link:label xml:lang="en-US" xlink:label="eigr_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="eigr_IncomeTaxesLineItems_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncomeTaxesTable" xlink:type="locator" xlink:label="eigr_IncomeTaxesTable" />
    <link:label xml:lang="en-US" xlink:label="eigr_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_IncomeTaxesTable" xlink:to="eigr_IncomeTaxesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision (benefit) for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DeferredTaxAssetDepreciationAndAmortization" xlink:type="locator" xlink:label="eigr_DeferredTaxAssetDepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="eigr_DeferredTaxAssetDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Asset Depreciation And Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DeferredTaxAssetDepreciationAndAmortization" xlink:to="eigr_DeferredTaxAssetDepreciationAndAmortization_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator" xlink:label="eigr_DeferredTaxAssetsLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="eigr_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Lease Liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DeferredTaxAssetsLeaseLiabilities" xlink:to="eigr_DeferredTaxAssetsLeaseLiabilities_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="eigr_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="eigr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Liabilities Right Of Use Assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="eigr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DeferredTaxAssetDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DeferredTaxAssetDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="eigr_IncreaseInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase In Deferred Tax Assets Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:to="eigr_IncreaseInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_IncreaseInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="eigr_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="eigr_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_OperatingLossCarryforwardsExpirationYear" xlink:to="eigr_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to prior year</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to current year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reductions based on tax positions related to prior year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions based on tax positions related to current year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits impact on effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties associated with uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:type="locator" xlink:label="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee leasing arrangements operating leases term of contract month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:to="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LeaseCommencedDate" xlink:type="locator" xlink:label="eigr_LeaseCommencedDate" />
    <link:label xml:lang="en-US" xlink:label="eigr_LeaseCommencedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commenced date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_LeaseCommencedDate" xlink:to="eigr_LeaseCommencedDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Palo Alto, California [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PatheonIncMember" xlink:type="locator" xlink:label="eigr_PatheonIncMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_PatheonIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patheon, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PatheonIncMember" xlink:to="eigr_PatheonIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_PatheonIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patheon, Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PatheonIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patheon Inc [Member]</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MasterManufacturingServicesAgreementMember" xlink:type="locator" xlink:label="eigr_MasterManufacturingServicesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="eigr_MasterManufacturingServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Master manufacturing services agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_MasterManufacturingServicesAgreementMember" xlink:to="eigr_MasterManufacturingServicesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_MasterManufacturingServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Master Manufacturing Services Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_MasterManufacturingServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Master Manufacturing Services Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total leased space</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandSubjectToGroundLeases" xlink:to="us-gaap_LandSubjectToGroundLeases_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Land Subject To Ground Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LeaseCommencedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LeaseCommencedDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commenced Date</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease expiry period month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Term Of Contract Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" xlink:type="locator" xlink:label="us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit of collateral for lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" xlink:to="us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pledged Assets Separately Reported Securities Pledged As Collateral At Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases minimum payments, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases minimum payments, 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases minimum payments, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases minimum payments, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of future lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense recognized for company&apos;s operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease payments for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash outflows for operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" xlink:type="locator" xlink:label="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" />
    <link:label xml:lang="en-US" xlink:label="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of product manufactured on the basics of annual forecasts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" xlink:to="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PercentageOfPurchasePrice" xlink:type="locator" xlink:label="eigr_PercentageOfPurchasePrice" />
    <link:label xml:lang="en-US" xlink:label="eigr_PercentageOfPurchasePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of purchase price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_PercentageOfPurchasePrice" xlink:to="eigr_PercentageOfPurchasePrice_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductAgreementDateOfExpiration" xlink:type="locator" xlink:label="eigr_ProductAgreementDateOfExpiration" />
    <link:label xml:lang="en-US" xlink:label="eigr_ProductAgreementDateOfExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product agreement date of expiration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ProductAgreementDateOfExpiration" xlink:to="eigr_ProductAgreementDateOfExpiration_lbl" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductAgreementRenewalTerm" xlink:type="locator" xlink:label="eigr_ProductAgreementRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="eigr_ProductAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product agreement renewal term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_ProductAgreementRenewalTerm" xlink:to="eigr_ProductAgreementRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of product manufactured on the basics of annual forecasts</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Product Manufactured On The Basics Of Annual Forecasts</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PercentageOfPurchasePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of purchase price</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_PercentageOfPurchasePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Purchase Price</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ProductAgreementDateOfExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product agreement date of expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ProductAgreementDateOfExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Agreement Date Of Expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ProductAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product agreement renewal term</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_ProductAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Agreement Renewal Term</link:label>
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendmendFeesPayment" xlink:type="locator" xlink:label="eigr_AmendmendFeesPayment" />
    <link:label xml:lang="en-US" xlink:label="eigr_AmendmendFeesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amendmend fess payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eigr_AmendmendFeesPayment" xlink:to="eigr_AmendmendFeesPayment_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AmendmendFeesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendmend fees Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="eigr_AmendmendFeesPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendmend Fees Payment</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>37
<FILENAME>eigr-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-08T23:16:18.7054820+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 867300f52dd744cb97ec68c0fc090a12 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/role/TemplateLink" xlink:href="eigr-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eigr-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement" xlink:type="locator" xlink:label="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" xlink:type="locator" xlink:label="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="eigr-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSecuredDebt" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" xlink:type="locator" xlink:label="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PaymentsOfDeferredOfferingCosts" xlink:type="locator" xlink:label="eigr_PaymentsOfDeferredOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="eigr_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="locator" xlink:label="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OperatingLeaseRightOfUseAssetAmortization" xlink:type="locator" xlink:label="eigr_OperatingLeaseRightOfUseAssetAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_POMember" xlink:type="locator" xlink:label="eigr_POMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eigr_POMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="eigr_OperatingLeaseRightOfUseAssetAmortization" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="eigr_IncreaseDecreaseInOperatingLeaseLiabilities" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="eigr_PaymentsOfDeferredOfferingCosts" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfSecuredDebt" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness" xlink:href="eigr-20201231.xsd#Role_DisclosureDescriptionOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="eigr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="eigr-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="eigr-20201231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreements" xlink:href="eigr-20201231.xsd#Role_DisclosureLicenseCollaborationAndProductDevelopmentAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="eigr_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreements" xlink:href="eigr-20201231.xsd#Role_DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreements">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:to="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebt" xlink:href="eigr-20201231.xsd#Role_DisclosureDebt" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebt">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="eigr-20201231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans" xlink:href="eigr-20201231.xsd#Role_DisclosureEquityIncentivePlans" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="eigr-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLegalMatters" xlink:href="eigr-20201231.xsd#Role_DisclosureLegalMatters" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLegalMatters">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="locator" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="eigr-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="eigr-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="eigr-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eigr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" xlink:type="locator" xlink:label="eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="eigr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="eigr-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="eigr-20201231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtTables" xlink:href="eigr-20201231.xsd#Role_DisclosureDebtTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="eigr-20201231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CommonStockReservedForFutureIssuancesTableTextBlock" xlink:type="locator" xlink:label="eigr_CommonStockReservedForFutureIssuancesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eigr_CommonStockReservedForFutureIssuancesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables" xlink:href="eigr-20201231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EmployeesAndNonEmployeesStockOptionMember" xlink:type="locator" xlink:label="eigr_EmployeesAndNonEmployeesStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eigr_EmployeesAndNonEmployeesStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="eigr-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="eigr-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DescriptionOfBusinessAbstract" xlink:type="locator" xlink:label="eigr_DescriptionOfBusinessAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_DescriptionOfBusinessAbstract" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_DescriptionOfBusinessAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_DescriptionOfBusinessAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_DescriptionOfBusinessAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_DescriptionOfBusinessAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_DescriptionOfBusinessAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NumberOfProductCandidates" xlink:type="locator" xlink:label="eigr_NumberOfProductCandidates" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NumberOfSupplyChainsForEachProductCandidate" xlink:type="locator" xlink:label="eigr_NumberOfSupplyChainsForEachProductCandidate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskSupplier" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskSupplier" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="eigr_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="eigr_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="eigr_SignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SignificantAccountingPoliciesTable" xlink:to="eigr_SignificantAccountingPoliciesLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskSupplier" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="eigr_NumberOfSupplyChainsForEachProductCandidate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="eigr_NumberOfProductCandidates" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="eigr_ComputerEquipmentAndSoftwareMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LabEquipmentMember" xlink:type="locator" xlink:label="eigr_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" xlink:type="locator" xlink:label="eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eigr_LabEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eigr_ComputerEquipmentAndSoftwareMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" xlink:type="locator" xlink:label="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="eigr_OptionsGrantedToEmployeesAndNonEmployeesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity" xlink:type="locator" xlink:label="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_FairValueTransfersBetweenLevelsTransfersAmount" xlink:type="locator" xlink:label="eigr_FairValueTransfersBetweenLevelsTransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="eigr_FairValueTransfersBetweenLevelsTransfersAmount" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_USGovernmentBondsMember" xlink:type="locator" xlink:label="eigr_USGovernmentBondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentFairValueCarryingValueAbstract" xlink:type="locator" xlink:label="eigr_DebtInstrumentFairValueCarryingValueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_DebtInstrumentFairValueCarryingValueAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="eigr_USGovernmentBondsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CashEquivalentsAmortizedCost" xlink:type="locator" xlink:label="eigr_CashEquivalentsAmortizedCost" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:type="locator" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_USGovernmentBondsMember" xlink:type="locator" xlink:label="eigr_USGovernmentBondsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:type="locator" xlink:label="eigr_CashEquivalentsAndInvestmentSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="eigr_CashEquivalentsAndInvestmentSecuritiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="eigr_USGovernmentBondsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesTable" xlink:to="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="eigr_CashEquivalentsAmortizedCost" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_CashEquivalentsAndInvestmentSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="eigr_ComputerEquipmentAndSoftwareMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LabEquipmentMember" xlink:type="locator" xlink:label="eigr_LabEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eigr_LabEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eigr_ComputerEquipmentAndSoftwareMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAbstract" xlink:type="locator" xlink:label="us-gaap_DepreciationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepreciationAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PrepaidResearchCosts" xlink:type="locator" xlink:label="eigr_PrepaidResearchCosts" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PrepaidContractManufacturingCosts" xlink:type="locator" xlink:label="eigr_PrepaidContractManufacturingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="eigr_PrepaidContractManufacturingCosts" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="eigr_PrepaidResearchCosts" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="eigr_OtherPrepaidExpenseAndOtherAssetsCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ContractManufacturingCostsCurrent" xlink:type="locator" xlink:label="eigr_ContractManufacturingCostsCurrent" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AccruedContractedResearchCostsCurrent" xlink:type="locator" xlink:label="eigr_AccruedContractedResearchCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="eigr_AccruedContractedResearchCostsCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="eigr_ContractManufacturingCostsCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RoyaltiesExpirationDescription" xlink:type="locator" xlink:label="eigr_RoyaltiesExpirationDescription" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MilestonePayments" xlink:type="locator" xlink:label="eigr_MilestonePayments" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentMilestoneObligations" xlink:type="locator" xlink:label="eigr_DevelopmentMilestoneObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseInMilestoneObligations" xlink:type="locator" xlink:label="eigr_IncreaseInMilestoneObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UpfrontCashPayments" xlink:type="locator" xlink:label="eigr_UpfrontCashPayments" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CollaborativeArrangementRenewalTerm" xlink:type="locator" xlink:label="eigr_CollaborativeArrangementRenewalTerm" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CollaborationAgreementInitialTerm" xlink:type="locator" xlink:label="eigr_CollaborationAgreementInitialTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="eigr_ProductAgreementTerminationNoticePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncentiveBasedRegulatoryMilestoneFees" xlink:type="locator" xlink:label="eigr_IncentiveBasedRegulatoryMilestoneFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ExpertConsultantFeesAndPassThroughCosts" xlink:type="locator" xlink:label="eigr_ExpertConsultantFeesAndPassThroughCosts" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductDevelopmentFees" xlink:type="locator" xlink:label="eigr_ProductDevelopmentFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MilestoneObligations" xlink:type="locator" xlink:label="eigr_MilestoneObligations" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LicenseMaintenanceFee" xlink:type="locator" xlink:label="eigr_LicenseMaintenanceFee" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NonRefundableIssueFee" xlink:type="locator" xlink:label="eigr_NonRefundableIssueFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MerckTransactionMember" xlink:type="locator" xlink:label="eigr_MerckTransactionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_PurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentPhaseThreeMember" xlink:type="locator" xlink:label="eigr_DevelopmentPhaseThreeMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentPhaseTwoMember" xlink:type="locator" xlink:label="eigr_DevelopmentPhaseTwoMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DevelopmentAndRegulatoryMilestonesMember" xlink:type="locator" xlink:label="eigr_DevelopmentAndRegulatoryMilestonesMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_BmsTransactionMember" xlink:type="locator" xlink:label="eigr_BmsTransactionMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PRFCollaborationAgreementMember" xlink:type="locator" xlink:label="eigr_PRFCollaborationAgreementMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductDevelopmentAgreementMember" xlink:type="locator" xlink:label="eigr_ProductDevelopmentAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_CommercialSalesMember" xlink:type="locator" xlink:label="eigr_CommercialSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UPennCHOPAgreementMember" xlink:type="locator" xlink:label="eigr_UPennCHOPAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_UPennCHOPAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eigr_CommercialSalesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_ProductDevelopmentAgreementMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_PRFCollaborationAgreementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_BmsTransactionMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eigr_DevelopmentAndRegulatoryMilestonesMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eigr_DevelopmentPhaseTwoMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="eigr_DevelopmentPhaseThreeMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eigr_PurchaseAgreementMember" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_MerckTransactionMember" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_NonRefundableIssueFee" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_LicenseMaintenanceFee" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_MilestoneObligations" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_ProductDevelopmentFees" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_ExpertConsultantFeesAndPassThroughCosts" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_IncentiveBasedRegulatoryMilestoneFees" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_ProductAgreementTerminationNoticePeriod" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_CollaborationAgreementInitialTerm" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_CollaborativeArrangementRenewalTerm" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_UpfrontCashPayments" order="12620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockValue" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_IncreaseInMilestoneObligations" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_DevelopmentMilestoneObligations" order="12870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_MilestonePayments" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="eigr_RoyaltiesExpirationDescription" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PaymentForAssetPurchaseAgreement" xlink:type="locator" xlink:label="eigr_PaymentForAssetPurchaseAgreement" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LicenseAgreementMilestonePaymentsPaid" xlink:type="locator" xlink:label="eigr_LicenseAgreementMilestonePaymentsPaid" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LicenseAgreementPotentialMilestonePayments" xlink:type="locator" xlink:label="eigr_LicenseAgreementPotentialMilestonePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_VestingOfOptionsToPurchaseCommonStock" xlink:type="locator" xlink:label="eigr_VestingOfOptionsToPurchaseCommonStock" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" xlink:type="locator" xlink:label="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OptionsToPurchaseOfCommonStock" xlink:type="locator" xlink:label="eigr_OptionsToPurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RoyaltiesExpirationDescription" xlink:type="locator" xlink:label="eigr_RoyaltiesExpirationDescription" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" xlink:type="locator" xlink:label="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseDescription" xlink:type="locator" xlink:label="eigr_AssetPurchaseDescription" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UpfrontCashPayments" xlink:type="locator" xlink:label="eigr_UpfrontCashPayments" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PRFCollaborationAgreementMember" xlink:type="locator" xlink:label="eigr_PRFCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AbbvieAssetPurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_AbbvieAssetPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MilestoneVestedOptionsMember" xlink:type="locator" xlink:label="eigr_MilestoneVestedOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AvexitidePurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_AvexitidePurchaseAgreementMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductOneMember" xlink:type="locator" xlink:label="eigr_ProductOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EIGTransactionMember" xlink:type="locator" xlink:label="eigr_EIGTransactionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementMember" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:type="locator" xlink:label="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract" xlink:to="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eigr_AssetPurchaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="eigr_EIGTransactionMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="eigr_ProductOneMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eigr_AvexitidePurchaseAgreementMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="us-gaap_VestingAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="eigr_MilestoneVestedOptionsMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="eigr_AbbvieAssetPurchaseAgreementMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_PRFCollaborationAgreementMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable" xlink:to="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_UpfrontCashPayments" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_AssetPurchaseDescription" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_RoyaltiesExpirationDescription" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_OptionsToPurchaseOfCommonStock" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_VestingOfOptionsToPurchaseCommonStock" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_LicenseAgreementPotentialMilestonePayments" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_LicenseAgreementMilestonePaymentsPaid" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="eigr_PaymentForAssetPurchaseAgreement" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureDebtAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentInterestPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentInterestPaymentPeriod" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PrepaymentOfLoanFeeDescription" xlink:type="locator" xlink:label="eigr_PrepaymentOfLoanFeeDescription" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentPrepaymentFeePercentage" xlink:type="locator" xlink:label="eigr_DebtInstrumentPrepaymentFeePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantCompliance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantDescription" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentCovenantNoncompliancePenalty" xlink:type="locator" xlink:label="eigr_DebtInstrumentCovenantNoncompliancePenalty" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" xlink:type="locator" xlink:label="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" xlink:type="locator" xlink:label="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentSuccessFeesPayablePercentage" xlink:type="locator" xlink:label="eigr_DebtInstrumentSuccessFeesPayablePercentage" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RepaymentsOfLoanAgreementExitFee" xlink:type="locator" xlink:label="eigr_RepaymentsOfLoanAgreementExitFee" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedAdditionalExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedAdditionalExitFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedExitFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentExitFeePayablePercentage" xlink:type="locator" xlink:label="eigr_DebtInstrumentExitFeePayablePercentage" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanFifthAmendmentMember" xlink:type="locator" xlink:label="eigr_OxfordLoanFifthAmendmentMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember" xlink:type="locator" xlink:label="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LoanPrepaidDuringFirstTwelveMonthsMember" xlink:type="locator" xlink:label="eigr_LoanPrepaidDuringFirstTwelveMonthsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_FoodAndDrugAdministrationMember" xlink:type="locator" xlink:label="eigr_FoodAndDrugAdministrationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegulatoryAgencyDomain" xlink:type="locator" xlink:label="us-gaap_RegulatoryAgencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegulatoryAgencyAxis" xlink:type="locator" xlink:label="us-gaap_RegulatoryAgencyAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedTrancheBMember" xlink:type="locator" xlink:label="eigr_AmendedTrancheBMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedTrancheAMember" xlink:type="locator" xlink:label="eigr_AmendedTrancheAMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedOxfordLoanMember" xlink:type="locator" xlink:label="eigr_AmendedOxfordLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheCMember" xlink:type="locator" xlink:label="eigr_TrancheCMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheBMember" xlink:type="locator" xlink:label="eigr_TrancheBMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheAMember" xlink:type="locator" xlink:label="eigr_TrancheAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanAmendmentMember" xlink:type="locator" xlink:label="eigr_OxfordLoanAmendmentMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanMember" xlink:type="locator" xlink:label="eigr_OxfordLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_OxfordLoanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_OxfordLoanAmendmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_TrancheAMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_TrancheBMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_TrancheCMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_AmendedOxfordLoanMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_AmendedTrancheAMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_AmendedTrancheBMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RegulatoryAgencyAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAgencyAxis" xlink:to="us-gaap_RegulatoryAgencyDomain" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAgencyDomain" xlink:to="eigr_FoodAndDrugAdministrationMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eigr_LoanPrepaidDuringFirstTwelveMonthsMember" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_OxfordLoanFifthAmendmentMember" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentExitFeePayablePercentage" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentUnamortizedExitFees" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod" order="12680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentUnamortizedAdditionalExitFees" order="12800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_RepaymentsOfLoanAgreementExitFee" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentSuccessFeesPayablePercentage" order="12920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval" order="12960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding" order="13000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentCovenantNoncompliancePenalty" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" order="13090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentPrepaymentFeePercentage" order="13160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_PrepaymentOfLoanFeeDescription" order="13200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentInterestPaymentPeriod" order="13250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:type="locator" xlink:label="us-gaap_LongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedExitFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="eigr_DebtInstrumentUnamortizedExitFees" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedExitFees" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedExitFees" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentUnamortizedInterest" xlink:type="locator" xlink:label="eigr_DebtInstrumentUnamortizedInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendedTrancheAMember" xlink:type="locator" xlink:label="eigr_AmendedTrancheAMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanMember" xlink:type="locator" xlink:label="eigr_OxfordLoanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_OxfordLoanMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="10100.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_AmendedTrancheAMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentUnamortizedInterest" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="eigr_DebtInstrumentUnamortizedExitFees" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmountOfCommonStockAvailableForSale" xlink:type="locator" xlink:label="eigr_AmountOfCommonStockAvailableForSale" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" xlink:type="locator" xlink:label="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" xlink:type="locator" xlink:label="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" xlink:type="locator" xlink:label="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DividendsDeclared" xlink:type="locator" xlink:label="eigr_DividendsDeclared" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AtTheMarketOfferingMember" xlink:type="locator" xlink:label="eigr_AtTheMarketOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UnderwritingAgreementMember" xlink:type="locator" xlink:label="eigr_UnderwritingAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_UnderwritingAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eigr_AtTheMarketOfferingMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_DividendsDeclared" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_AmountOfCommonStockAvailableForSale" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OptionsIssuedAndOutstanding" xlink:type="locator" xlink:label="eigr_OptionsIssuedAndOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eigr_OptionsIssuedAndOutstanding" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ClosingPriceOfCommonStock" xlink:type="locator" xlink:label="eigr_ClosingPriceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" xlink:type="locator" xlink:label="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="eigr_ClosingPriceOfCommonStock" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_li0l2" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureEquityIncentivePlansStockOptionActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_li0l2" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:type="locator" xlink:label="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_li0l2" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted_li0l2" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="13010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_EmployeesAndNonEmployeesStockOptionMember" xlink:type="locator" xlink:label="eigr_EmployeesAndNonEmployeesStockOptionMember" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_NonEmployeeStockOptionMember" xlink:type="locator" xlink:label="eigr_NonEmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eigr_NonEmployeeStockOptionMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eigr_EmployeesAndNonEmployeesStockOptionMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="eigr_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="eigr_IncreaseInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncomeTaxesLineItems" xlink:type="locator" xlink:label="eigr_IncomeTaxesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_IncomeTaxesTable" xlink:type="locator" xlink:label="eigr_IncomeTaxesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eigr_IncomeTaxesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_IncomeTaxesTable" xlink:to="eigr_IncomeTaxesLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="eigr_IncreaseInDeferredTaxAssetsValuationAllowance" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="eigr_OperatingLossCarryforwardsExpirationYear" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eigr_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator" xlink:label="eigr_DeferredTaxLiabilitiesRightOfUseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DeferredTaxAssetsLeaseLiabilities" xlink:type="locator" xlink:label="eigr_DeferredTaxAssetsLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DeferredTaxAssetDepreciationAndAmortization" xlink:type="locator" xlink:label="eigr_DeferredTaxAssetDepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="eigr_DeferredTaxAssetDepreciationAndAmortization" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="eigr_DeferredTaxAssetsLeaseLiabilities" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="eigr_DeferredTaxLiabilitiesRightOfUseAssets" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductAgreementRenewalTerm" xlink:type="locator" xlink:label="eigr_ProductAgreementRenewalTerm" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_ProductAgreementDateOfExpiration" xlink:type="locator" xlink:label="eigr_ProductAgreementDateOfExpiration" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PercentageOfPurchasePrice" xlink:type="locator" xlink:label="eigr_PercentageOfPurchasePrice" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" xlink:type="locator" xlink:label="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" xlink:type="locator" xlink:label="us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:type="locator" xlink:label="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_LeaseCommencedDate" xlink:type="locator" xlink:label="eigr_LeaseCommencedDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_MasterManufacturingServicesAgreementMember" xlink:type="locator" xlink:label="eigr_MasterManufacturingServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_PatheonIncMember" xlink:type="locator" xlink:label="eigr_PatheonIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="eigr_PatheonIncMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eigr_MasterManufacturingServicesAgreementMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_LeaseCommencedDate" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_VariableLeaseCost" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_PercentageOfPurchasePrice" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_ProductAgreementDateOfExpiration" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="eigr_ProductAgreementRenewalTerm" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="eigr-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="eigr-20201231.xsd#eigr_AmendmendFeesPayment" xlink:type="locator" xlink:label="eigr_AmendmendFeesPayment" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentInterestPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentInterestPaymentPeriod" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" xlink:type="locator" xlink:label="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_OxfordLoanFifthAmendmentMember" xlink:type="locator" xlink:label="eigr_OxfordLoanFifthAmendmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="eigr-20201231.xsd#eigr_TrancheBMember" xlink:type="locator" xlink:label="eigr_TrancheBMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="eigr_TrancheBMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eigr_OxfordLoanFifthAmendmentMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eigr_DebtInstrumentInterestPaymentPeriod" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eigr_AmendmendFeesPayment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>eigr-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:eigr="http://www.eigerbio.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="eigr-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001305253_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_20210305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2021-03-05</instant>
        </period>
    </context>
    <context id="C_0001305253_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001305253_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrPOMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:POMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrPOMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:POMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:EmployeesAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapConcentrationRiskByTypeAxis_us-gaapSupplierConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">eigr:OptionsGrantedToEmployeesAndNonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eigr:USGovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eigr:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapIncomeStatementLocationAxis_eigrCommercialSalesMember_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:CommercialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UPennCHOPAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-11</startDate>
            <endDate>2018-08-11</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20180216_20180315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:PRFCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-16</startDate>
            <endDate>2018-03-15</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-19</startDate>
            <endDate>2016-04-20</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_eigrPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-19</startDate>
            <endDate>2016-04-20</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_eigrPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-20</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentAndRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-19</startDate>
            <endDate>2016-04-20</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrCommercialSalesMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:CommercialSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-19</startDate>
            <endDate>2016-04-20</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentPhaseTwoMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentPhaseTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-19</startDate>
            <endDate>2016-04-20</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentPhaseThreeMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">eigr:DevelopmentPhaseThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:BmsTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-19</startDate>
            <endDate>2016-04-20</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20100930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-09-30</instant>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20100901_20100930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-09-01</startDate>
            <endDate>2010-09-30</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20150501_20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MerckTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20101201_20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-12-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_srtProductOrServiceAxis_eigrProductOneMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">eigr:ProductOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eigr:EIGTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-02</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20160321_20160322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-21</startDate>
            <endDate>2016-03-22</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20160322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-22</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">eigr:MilestoneVestedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">eigr:MilestoneVestedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">eigr:MilestoneVestedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AvexitidePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-02</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAbbvieAssetPurchaseAgreementMember_20201119_20201120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AbbvieAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-20</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAbbvieAssetPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20201119_20201120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eigr:AbbvieAssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:PRFCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-20</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:TrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanAmendmentMember_20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheCMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanAmendmentMember_20180803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-03</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-05</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305_20190305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-05</startDate>
            <endDate>2019-03-05</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-05</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheBMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-05</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheBMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapRegulatoryAgencyAxis_eigrFoodAndDrugAdministrationMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">eigr:FoodAndDrugAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapRegulatoryAgencyAxis_eigrFoodAndDrugAdministrationMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAgencyAxis">eigr:FoodAndDrugAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapDebtInstrumentRedemptionPeriodAxis_eigrLoanPrepaidDuringFirstTwelveMonthsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eigr:LoanPrepaidDuringFirstTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapDebtInstrumentRedemptionPeriodAxis_eigrLoanPrepaidDuringThirteenToTwentyFourMonthsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:AmendedOxfordLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">eigr:LoanPrepaidDuringThirteenToTwentyFourMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:AmendedTrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417_20190417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-17</startDate>
            <endDate>2019-04-17</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-17</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417_20190417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-17</startDate>
            <endDate>2019-04-17</endDate>
        </period>
    </context>
    <context id="C_0001305253_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_20191201_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20191201_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20200830_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eigr:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-30</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_eigrHoldersOfTenPercentOrMoreOfVotingPowerMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eigr:HoldersOfTenPercentOrMoreOfVotingPowerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:RestatedTwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:EmployeesAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eigr:EmployeesAndNonEmployeesStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eigr:TwoThousandThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtStatementGeographicalAxis_stprCA_20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_0001305253_srtStatementGeographicalAxis_stprCA_20171001_20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eigr:PatheonIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MasterManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eigr:PatheonIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MasterManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eigr:PatheonIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eigr:MasterManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanFifthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-23</startDate>
            <endDate>2021-02-23</endDate>
        </period>
    </context>
    <context id="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001305253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">eigr:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eigr:OxfordLoanFifthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-23</startDate>
            <endDate>2021-02-23</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_eigrSegment">
        <measure>eigr:Segment</measure>
    </unit>
    <unit id="U_eigrSupplyChain">
        <measure>eigr:SupplyChain</measure>
    </unit>
    <unit id="U_eigrProductCandidate">
        <measure>eigr:ProductCandidate</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001305253_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001305253_20200101_20201231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001305253_20200101_20201231" id="F_000007">0001305253</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001305253_20200101_20201231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20200101_20201231"
      id="F_000526">P30M</eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod>
    <eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheBMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231"
      id="F_000540">P24M</eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod>
    <eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231"
      id="F_000541">P36M</eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod>
    <eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223"
      id="F_000779">P19M</eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod>
    <eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223"
      id="F_000781">P13M</eigr:DebtInstrumentPrincipalAndInterestPaymentPeriod>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001305253_srtStatementGeographicalAxis_stprCA_20171031"
      id="F_000754">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <eigr:ProductAgreementRenewalTerm
      contextRef="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20201231"
      id="F_000778">P2Y</eigr:ProductAgreementRenewalTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001305253_20190101_20191231" id="F_000616">P7Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001305253_20200101_20201231" id="F_000617">P7Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001305253_20200101_20201231" id="F_000618">P6Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000632">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      id="F_000633">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      id="F_000634">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20180101_20181231"
      id="F_000638">P9Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000642"
      unitRef="U_xbrlipure">0.7300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000643"
      unitRef="U_xbrlipure">0.7314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20180101_20181231"
      decimals="INF"
      id="F_000644"
      unitRef="U_xbrlipure">0.8400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000648"
      unitRef="U_xbrlipure">0.0039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000649"
      unitRef="U_xbrlipure">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20180101_20181231"
      decimals="INF"
      id="F_000650"
      unitRef="U_xbrlipure">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000635">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      id="F_000636">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      id="F_000637">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20180101_20181231"
      id="F_000639">P9Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20200101_20201231"
      id="F_000640">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrNonEmployeeStockOptionMember_20190101_20191231"
      id="F_000641">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000645"
      unitRef="U_xbrlipure">0.7700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000646"
      unitRef="U_xbrlipure">0.8319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20180101_20181231"
      decimals="INF"
      id="F_000647"
      unitRef="U_xbrlipure">0.9500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000651"
      unitRef="U_xbrlipure">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000652"
      unitRef="U_xbrlipure">0.0257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20180101_20181231"
      decimals="INF"
      id="F_000653"
      unitRef="U_xbrlipure">0.0268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001305253_20201231"
      id="F_000064"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001305253_20191231"
      id="F_000065"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_0001305253_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001305253_20200101_20201231" id="F_000028">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001305253_20200101_20201231" id="F_000002">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001305253_20200101_20201231" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001305253_20200101_20201231" id="F_000029">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001305253_20200101_20201231" id="F_000019">001-36183</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001305253_20200101_20201231" id="F_000006">Eiger BioPharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001305253_20200101_20201231" id="F_000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001305253_20200101_20201231" id="F_000021">33-0971591</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001305253_20200101_20201231" id="F_000022">2155 Park Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001305253_20200101_20201231" id="F_000023">Palo Alto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001305253_20200101_20201231" id="F_000024">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001305253_20200101_20201231" id="F_000025">94306</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001305253_20200101_20201231" id="F_000026">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001305253_20200101_20201231" id="F_000027">272 6138</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001305253_20200101_20201231" id="F_000017">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001305253_20200101_20201231" id="F_000005">EIGR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001305253_20200101_20201231" id="F_000018">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001305253_20200101_20201231" id="F_000009">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001305253_20200101_20201231" id="F_000011">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001305253_20200101_20201231" id="F_000010">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001305253_20200101_20201231" id="F_000016">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001305253_20200101_20201231" id="F_000012">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001305253_20200101_20201231" id="F_000014">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001305253_20200101_20201231" id="F_000015">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001305253_20200101_20201231" id="F_000030">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001305253_20200101_20201231" id="F_000013">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001305253_20200630"
      decimals="0"
      id="F_000033"
      unitRef="U_iso4217USD">257943696</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001305253_20210305"
      decimals="INF"
      id="F_000032"
      unitRef="U_xbrlishares">33901386</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000031">Part III incorporates certain information by reference from the registrant&#x2019;s proxy statement for the 2021 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant&#x2019;s fiscal year ended December 31, 2020.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">28864000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">39373000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">99976000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">55621000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">8966000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">5390000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">137806000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">100384000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">709000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">590000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">1176000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">1654000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">3903000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">2511000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">143594000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">105139000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">4640000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">6414000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">11405000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">10001000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">582000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">534000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">16627000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">16949000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">31194000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">30390000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">738000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">1320000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">48559000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">48659000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000078"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000079"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000081"
      unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000082"
      unitRef="U_xbrlishares">33878486</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000084"
      unitRef="U_xbrlishares">33878486</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000083"
      unitRef="U_xbrlishares">24523381</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000085"
      unitRef="U_xbrlishares">24523381</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">34000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">24000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">401509000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">297863000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">-8000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">42000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">-306500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">-241449000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">95035000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">56480000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">143594000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">105139000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">41590000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">51791000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">37091000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">20559000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">17113000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">13956000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">62149000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">68904000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">51047000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">-62149000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">-68904000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">-51047000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">3594000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">3406000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">2329000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">704000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">2073000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">997000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">-12000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">-15000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">-12000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">-65051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">-70252000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">-52391000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001305253_20200101_20201231"
      decimals="2"
      id="F_000110"
      unitRef="U_iso4217USD_xbrlishares">-2.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001305253_20190101_20191231"
      decimals="2"
      id="F_000111"
      unitRef="U_iso4217USD_xbrlishares">-3.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001305253_20180101_20181231"
      decimals="2"
      id="F_000112"
      unitRef="U_iso4217USD_xbrlishares">-3.84</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000113"
      unitRef="U_xbrlishares">28143391</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001305253_20190101_20191231"
      decimals="INF"
      id="F_000114"
      unitRef="U_xbrlishares">22785611</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001305253_20180101_20181231"
      decimals="INF"
      id="F_000115"
      unitRef="U_xbrlishares">13634152</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">-65051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">-70252000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">-52391000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">67000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">-22000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">-65101000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">-70185000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-52413000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="INF"
      id="F_000125"
      unitRef="U_xbrlishares">10526599</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">141320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-118806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_20171231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">22522000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">5357000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000131"
      unitRef="U_xbrlishares">8510918</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">90634000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">90642000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000135"
      unitRef="U_xbrlishares">17508</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">96000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">96000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000138"
      unitRef="U_xbrlishares">41208</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">310000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">310000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <eigr:StockIssuedDuringPeriodSharesProductDevelopmentAgreement
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000141"
      unitRef="U_xbrlishares">115526</eigr:StockIssuedDuringPeriodSharesProductDevelopmentAgreement>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">428000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">428000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">5007000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">5007000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">-22000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-22000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-52391000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">-52391000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000150"
      unitRef="U_xbrlishares">19211759</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">237795000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">-25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-171197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_20181231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">66592000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">3731000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000156"
      unitRef="U_xbrlishares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">53189000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">53194000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000160"
      unitRef="U_xbrlishares">15701</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">130000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">130000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000163"
      unitRef="U_xbrlishares">120921</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">844000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">844000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">226000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">226000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">5679000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">5679000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">67000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">67000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-70252000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-70252000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000174"
      unitRef="U_xbrlishares">24523381</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">297863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-241449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">56480000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">3231000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000180"
      unitRef="U_xbrlishares">9267760</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">96750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">96760000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000184"
      unitRef="U_xbrlishares">25645</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">186000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">186000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000187"
      unitRef="U_xbrlishares">61700</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">520000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">520000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">217000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">217000</eigr:StockIssuedDuringPeriodValueProductDevelopmentAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">5973000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">5973000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">-65051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-65051000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000198"
      unitRef="U_xbrlishares">33878486</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">401509000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">-8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">-306500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">95035000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">-65051000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">-70252000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">-52391000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">167000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">68000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">54000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">-124000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">467000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">426000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">5973000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">5679000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">5007000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">804000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">723000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">592000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <eigr:OperatingLeaseRightOfUseAssetAmortization
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">478000</eigr:OperatingLeaseRightOfUseAssetAmortization>
    <eigr:OperatingLeaseRightOfUseAssetAmortization
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">418000</eigr:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">217000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">226000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">428000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">3563000</eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">3698000</eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">780000</eigr:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">1392000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">2075000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">124000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">-1899000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">584000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">2647000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">1491000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">5610000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">2110000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <eigr:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">-534000</eigr:IncreaseDecreaseInOperatingLeaseLiabilities>
    <eigr:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">-430000</eigr:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">212000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">-63185000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">-63614000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">-42671000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">128295000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">96267000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">57193000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">83766000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">80271000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">28250000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">258000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">475000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">142000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">-44787000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">-16471000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">-29085000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">96779000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">520000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">844000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">310000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">186000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">130000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">96000</us-gaap:ProceedsFromStockPlans>
    <eigr:PaymentsOfDeferredOfferingCosts
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">22000</eigr:PaymentsOfDeferredOfferingCosts>
    <eigr:PaymentsOfDeferredOfferingCosts
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">19000</eigr:PaymentsOfDeferredOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrPOMember_20190101_20191231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">53194000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrPOMember_20180101_20181231"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">90642000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">6627000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">9935000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <eigr:RepaymentOfAccruedExitFeeAndSecondAmendmentFee
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">913000</eigr:RepaymentOfAccruedExitFeeAndSecondAmendmentFee>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">1667000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">97463000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">58196000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">100983000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">-10509000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">-21889000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">29227000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">39373000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001305253_20181231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">61262000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001305253_20171231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">32035000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">28864000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">39373000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001305253_20181231"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">61262000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">2791000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">2638000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">1652000</us-gaap:InterestPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000287">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Description of Business&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Eiger BioPharmaceuticals, Inc. (the Company or Eiger) was incorporated in the State of Delaware on November&#160;6, 2008. Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV), the most severe form of human viral hepatitis, for which there is currently no FDA-approved therapy. Eiger has reported positive proof-of-concept clinical results across all of our programs and have received Breakthrough Therapy designation for three programs in clinical development. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Eiger&#x2019;s lead clinical programs are complementary treatments for HDV. Lonafarnib is a first-in-class oral farnesylation inhibitor in a global Phase 3 trial, and the only oral therapy in development for HDV. Peginterferon lambda is a first-in-class, well characterized, well-tolerated type III interferon entering Phase 3.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The FDA approved the Company&#x2019;s first commercial product, Zokinvy (lonafarnib) for treatment of Progeria and processing-deficient progeroid laminopathies, ultra-rare and rapidly fatal genetic conditions of accelerated aging in children, November 20, 2020. Eiger&#x2019;s Marketing Authorization Application (MAA) is under review with the European Medicines Agency (EMA), with a decision expected in the second half of 2021.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also developing avexitide, a well-characterized peptide, as a treatment for PBH, a debilitating and potentially life-threatening condition for which there is currently no approved therapy, and as a treatment CHI, an ultra-rare pediatric metabolic disorder.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s principal operations are based in Palo Alto, California and it operates in one segment.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had $128.9 million of cash, cash equivalents and investments, comprised of $28.9 million of cash and cash equivalents and $100.0 million of debt securities available-for-sale.&#160;The Company had an accumulated deficit of $306.5 million and negative cash flows from operating activities as of December 31, 2020. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, the Company will need to continue to raise additional capital&lt;/span&gt;. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management believes that the currently available resources will be sufficient to fund its operations for at least the next 12 months following the issuance date of these consolidated financial statements. However, if the Company&#x2019;s anticipated operating results are not achieved in future periods, the Company believes that planned expenditures may need to be reduced or it would be required to raise funding in order to fund the operations. Additionally, the Company&#x2019;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="C_0001305253_20200101_20201231" id="F_000335">2008-11-06</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000336"
      unitRef="U_eigrSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001305253_20201231"
      decimals="-5"
      id="F_000337"
      unitRef="U_iso4217USD">128900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001305253_20201231"
      decimals="-5"
      id="F_000338"
      unitRef="U_iso4217USD">28900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001305253_20201231"
      decimals="-5"
      id="F_000339"
      unitRef="U_iso4217USD">100000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001305253_20201231"
      decimals="-5"
      id="F_000340"
      unitRef="U_iso4217USD">-306500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000288">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Summary of Significant Accounting Policies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation and Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, (U.S. GAAP) and following the requirements of the Securities and Exchange Commission (the SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;period. On an ongoing basis, the Company evaluates its estimates, including those related to clinical trial accrued liabilities, stock-based compensation&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; operating lease liabilities&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and income taxes.&#160;The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentrations of Risk&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consists of cash, cash equivalents and investments. The Company&#x2019;s cash is held by a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.&lt;/p&gt;&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each product candidate, the Company relies on one supply chain for each of the four product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#x2019;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents include all cash balances and highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consists primarily of amounts invested in money market funds held at financial institutions and corporate debt securities. The recorded carrying amount of cash equivalents approximates their fair value.&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Debt Securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. All short-term securities are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The cost of available-for-sale securities sold is based on the specific-identification method&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;. &lt;/span&gt;Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other expense, net on the accompanying consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. Depreciation begins at the time the asset is placed into service. Maintenance and repairs are charged to operations as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The useful lives of the property and equipment are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through December&#160;31, 2020, the Company has not impaired any long-lived assets.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Research and Development Costs&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the consolidated balance sheets and within research and development expenses in the consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842, &#x201c;Leases&#x201d; (&#x201c;ASC 842&#x201d;) on January 1, 2019. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception. Material leases with a term greater than one year are recognized in right-of-use (&#x201c;ROU&#x201d;) assets and current and noncurrent lease liabilities, as applicable, in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of its right-of-use assets (ROU assets) and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease ROU assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the consolidated statements of operations. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in general and administrative expenses when incurred.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred Financing Costs&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing costs incurred with securing a term debt are recorded in the Company&#x2019;s consolidated balance sheets as an offset to the term debt and amortized to interest expense in the Company&#x2019;s consolidated statements of operations over the contractual life of the loan using the effective interest method. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred and consist of payroll expenses, stock-based compensation expense, lab supplies and allocated facility costs, as well as fees paid to third parties that conduct certain research and development and manufacturing activities on the Company&#x2019;s behalf. Amounts incurred in connection with license and asset purchase agreements are also included in research and development expenses. Manufacturing costs related to products undergoing regulatory approval are expensed as research and development costs until receipt of such approval. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based awards to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight line-basis over the &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;employee&#x2019;s or director&#x2019;s requisite service period (generally the vesting period). &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;S&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;tock&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-based awards to non-employees are recorded at their fair value as of the grant date&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, using the Black-Scholes option pricing model and recognized as expense over the period in which the related services are received. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Black-Scholes option pricing model inputs&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;accounts for &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;forfeitures &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;of s&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;tock&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-based awards &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;when they occur. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Internal Revenue Code Section 382 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In the event that the Company experiences a change of ownership, utilization of the net operating loss and tax credit carryforwards may be restricted.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss represents all changes in stockholders' equity except those resulting from and distributions to stockholders. The Company&#x2019;s unrealized gains and losses on debt securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,697,075&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,996,211&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units (unvested)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,734,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,996,211&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, &lt;span style="font-style:italic;"&gt;Fair Value Measurement (Topic 820)&lt;/span&gt;. The standard eliminates, modifies and adds disclosure requirements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for fair value measurements. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance on January 1, 2020. &lt;/span&gt;&lt;span style="color:#000000;"&gt;The adoption did not have a material impact on the Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&#160;2018, the FASB issued&#160;ASU No.&#160;2018-15,&#160;&lt;span style="font-style:italic;"&gt;Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract&lt;/span&gt; &lt;span style="font-style:italic;"&gt;(Subtopic 350-40)&lt;/span&gt;. The standard&#160;adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The pronouncement is effective for fiscal years beginning after December&#160;15, 2019, and interim periods within those fiscal years, with early adoption permitted. The amendments in ASU No, 2018-15&#160;should be applied either using a retrospective or prospective approach. &lt;span style="color:#000000;"&gt;The Company adopted&#160;this guidance&#160;on January 1, 2020 using the prospective approach. The adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Pronouncements Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&#160;&lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326)&lt;/span&gt;. The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, &lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,&lt;/span&gt; which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, &lt;span style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), &lt;/span&gt;which provides an option &lt;span style="color:#000000;"&gt;to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost&lt;/span&gt;. &lt;span style="color:#000000;"&gt;In November 2019, the FASB issued ASU No. 2019-10, &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&lt;/span&gt;, which&lt;span style="font-style:italic;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;defers the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of the guidance on its consolidated financial statements. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;span style="font-style:italic;"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;. The standard provides optional expedients for facilitating the effects of the reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for contract modifications permitted for contracts that are modified because of the reference rate reform and meet the scope guidance. The modifications of contracts within the scope of ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as separate contracts. &lt;span style="color:#000000;"&gt;The pronouncement is effective for all entities as of March 12, 2020 through December 31, 2022. The Company plans to adopt upon the occurrence of such contract modification, but not later than December 31, 2022. The Company engaged in early-stage discussions with its lender and will assess the impact of the adoption once the contract is modified.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000301">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation and Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, (U.S. GAAP) and following the requirements of the Securities and Exchange Commission (the SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001305253_20200101_20201231" id="F_000302">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;period. On an ongoing basis, the Company evaluates its estimates, including those related to clinical trial accrued liabilities, stock-based compensation&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; operating lease liabilities&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and income taxes.&#160;The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001305253_20200101_20201231" id="F_000303">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentrations of Risk&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consists of cash, cash equivalents and investments. The Company&#x2019;s cash is held by a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.&lt;/p&gt;&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For each product candidate, the Company relies on one supply chain for each of the four product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#x2019;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskSupplier
      contextRef="C_0001305253_us-gaapConcentrationRiskByTypeAxis_us-gaapSupplierConcentrationRiskMember_20200101_20201231"
      id="F_000341">For each product candidate, the Company relies on one supply chain for each of the four product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#x2019;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.</us-gaap:ConcentrationRiskSupplier>
    <eigr:NumberOfSupplyChainsForEachProductCandidate
      contextRef="C_0001305253_us-gaapConcentrationRiskByTypeAxis_us-gaapSupplierConcentrationRiskMember_20200101_20201231"
      decimals="INF"
      id="F_000342"
      unitRef="U_eigrSupplyChain">1</eigr:NumberOfSupplyChainsForEachProductCandidate>
    <eigr:NumberOfProductCandidates
      contextRef="C_0001305253_us-gaapConcentrationRiskByTypeAxis_us-gaapSupplierConcentrationRiskMember_20200101_20201231"
      decimals="INF"
      id="F_000343"
      unitRef="U_eigrProductCandidate">4</eigr:NumberOfProductCandidates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000304">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents include all cash balances and highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consists primarily of amounts invested in money market funds held at financial institutions and corporate debt securities. The recorded carrying amount of cash equivalents approximates their fair value.&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001305253_20200101_20201231" id="F_000305">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Debt Securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. All short-term securities are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The cost of available-for-sale securities sold is based on the specific-identification method&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;. &lt;/span&gt;Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other expense, net on the accompanying consolidated statements of operations.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000306">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. Depreciation begins at the time the asset is placed into service. Maintenance and repairs are charged to operations as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The useful lives of the property and equipment are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <eigr:EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000318">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The useful lives of the property and equipment are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</eigr:EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20200101_20201231"
      id="F_000344">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231"
      id="F_000345">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20200101_20201231"
      id="F_000346">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000307">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through December&#160;31, 2020, the Company has not impaired any long-lived assets.&lt;/p&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000347"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <eigr:AccruedResearchAndDevelopmentCostsPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000308">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Research and Development Costs&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the consolidated balance sheets and within research and development expenses in the consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.&lt;/p&gt;</eigr:AccruedResearchAndDevelopmentCostsPolicyTextBlock>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000309">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 842, &#x201c;Leases&#x201d; (&#x201c;ASC 842&#x201d;) on January 1, 2019. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception. Material leases with a term greater than one year are recognized in right-of-use (&#x201c;ROU&#x201d;) assets and current and noncurrent lease liabilities, as applicable, in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of its right-of-use assets (ROU assets) and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease ROU assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the consolidated statements of operations. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in general and administrative expenses when incurred.&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000310">
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred Financing Costs&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing costs incurred with securing a term debt are recorded in the Company&#x2019;s consolidated balance sheets as an offset to the term debt and amortized to interest expense in the Company&#x2019;s consolidated statements of operations over the contractual life of the loan using the effective interest method. &lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001305253_20200101_20201231" id="F_000311">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred and consist of payroll expenses, stock-based compensation expense, lab supplies and allocated facility costs, as well as fees paid to third parties that conduct certain research and development and manufacturing activities on the Company&#x2019;s behalf. Amounts incurred in connection with license and asset purchase agreements are also included in research and development expenses. Manufacturing costs related to products undergoing regulatory approval are expensed as research and development costs until receipt of such approval. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000312">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based awards to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight line-basis over the &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;employee&#x2019;s or director&#x2019;s requisite service period (generally the vesting period). &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;S&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;tock&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-based awards to non-employees are recorded at their fair value as of the grant date&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, using the Black-Scholes option pricing model and recognized as expense over the period in which the related services are received. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Black-Scholes option pricing model inputs&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;accounts for &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;forfeitures &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;of s&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;tock&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-based awards &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;when they occur. &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000313">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Internal Revenue Code Section 382 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In the event that the Company experiences a change of ownership, utilization of the net operating loss and tax credit carryforwards may be restricted.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000348"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000349"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000314">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss represents all changes in stockholders' equity except those resulting from and distributions to stockholders. The Company&#x2019;s unrealized gains and losses on debt securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000315">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,697,075&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,996,211&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units (unvested)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,734,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,996,211&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000319">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,697,075&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,996,211&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units (unvested)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,734,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,996,211&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20200101_20201231"
      decimals="INF"
      id="F_000350"
      unitRef="U_xbrlishares">3697075</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20190101_20191231"
      decimals="INF"
      id="F_000351"
      unitRef="U_xbrlishares">2767617</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_eigrOptionsGrantedToEmployeesAndNonEmployeesMember_20180101_20181231"
      decimals="INF"
      id="F_000352"
      unitRef="U_xbrlishares">1996211</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001305253_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="INF"
      id="F_000353"
      unitRef="U_xbrlishares">37500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000354"
      unitRef="U_xbrlishares">3734575</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001305253_20190101_20191231"
      decimals="INF"
      id="F_000355"
      unitRef="U_xbrlishares">2767617</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001305253_20180101_20181231"
      decimals="INF"
      id="F_000356"
      unitRef="U_xbrlishares">1996211</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000316">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, &lt;span style="font-style:italic;"&gt;Fair Value Measurement (Topic 820)&lt;/span&gt;. The standard eliminates, modifies and adds disclosure requirements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;for fair value measurements. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance on January 1, 2020. &lt;/span&gt;&lt;span style="color:#000000;"&gt;The adoption did not have a material impact on the Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&#160;2018, the FASB issued&#160;ASU No.&#160;2018-15,&#160;&lt;span style="font-style:italic;"&gt;Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract&lt;/span&gt; &lt;span style="font-style:italic;"&gt;(Subtopic 350-40)&lt;/span&gt;. The standard&#160;adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The pronouncement is effective for fiscal years beginning after December&#160;15, 2019, and interim periods within those fiscal years, with early adoption permitted. The amendments in ASU No, 2018-15&#160;should be applied either using a retrospective or prospective approach. &lt;span style="color:#000000;"&gt;The Company adopted&#160;this guidance&#160;on January 1, 2020 using the prospective approach. The adoption did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <eigr:AccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000317">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Pronouncements Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&#160;&lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326)&lt;/span&gt;. The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, &lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,&lt;/span&gt; which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, &lt;span style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), &lt;/span&gt;which provides an option &lt;span style="color:#000000;"&gt;to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost&lt;/span&gt;. &lt;span style="color:#000000;"&gt;In November 2019, the FASB issued ASU No. 2019-10, &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&lt;/span&gt;, which&lt;span style="font-style:italic;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;defers the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of the guidance on its consolidated financial statements. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;span style="font-style:italic;"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;. The standard provides optional expedients for facilitating the effects of the reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for contract modifications permitted for contracts that are modified because of the reference rate reform and meet the scope guidance. The modifications of contracts within the scope of ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as separate contracts. &lt;span style="color:#000000;"&gt;The pronouncement is effective for all entities as of March 12, 2020 through December 31, 2022. The Company plans to adopt upon the occurrence of such contract modification, but not later than December 31, 2022. The Company engaged in early-stage discussions with its lender and will assess the impact of the adoption once the contract is modified.&lt;/span&gt;&lt;/p&gt;</eigr:AccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000289">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). At December 31, 2020 and 2019, the carrying amount of prepaid expenses and other current assets, accounts payable and accrued liabilities approximated their estimate fair value due to their relatively short maturities. Management believes the terms of its long term debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company&#x2019;s debt approximated its fair value.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;span style="font-style:normal;"&gt;: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;span style="font-style:normal;"&gt;: Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;span style="font-style:normal;"&gt;: Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s money market funds are classified as Level 1 because they are valued using quoted market prices. The Company&#x2019;s debt securities consist of available-for-sale securities and are classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. There were no assets or liabilities classified as Level&#160;3 as of December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no transfers in or out of Level 3 of the fair value hierarchy during the periods presented.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,995&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,995&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,976&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,621&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,475&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no financial liabilities as of December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the estimated value of the Company&#x2019;s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;span style="font-family:Calibri;"&gt;&#160;&lt;/span&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,992&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,995&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,976&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;span style="font-family:Calibri;"&gt;&#160;&lt;/span&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,633&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,579&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,621&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020 and 2019, the contractual maturity of the available-for-sale debt securities is less than one year. &lt;span style="Background-color:#FFFFFF;"&gt;The Company periodically reviews the available-for-sale investments for&#160;&lt;/span&gt;other-than-temporary&lt;span style="Background-color:#FFFFFF;"&gt;&#160;impairment loss. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, it also considers whether (i)&#160;it is more likely&#160;&lt;/span&gt;than&#160;n&lt;span style="Background-color:#FFFFFF;"&gt;ot that the Company will be required to sell the debt securities before recovery of &lt;/span&gt;&lt;span style="color:#000000;"&gt;their&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. As of December 31, 2020, the Company did not recognize any&#160;&lt;/span&gt;other-than-temporary&lt;span style="Background-color:#FFFFFF;"&gt;&#160;impairment losses. All debt securities with unrealized losses have been in a loss position for &lt;/span&gt;less&#160;than&lt;span style="Background-color:#FFFFFF;"&gt;&#160;12 months.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231"
      decimals="0"
      id="F_000357"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231"
      decimals="0"
      id="F_000359"
      unitRef="U_iso4217USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231"
      decimals="0"
      id="F_000358"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231"
      decimals="0"
      id="F_000360"
      unitRef="U_iso4217USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <eigr:FairValueTransfersBetweenLevelsTransfersAmount
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20200101_20201231"
      decimals="INF"
      id="F_000361"
      unitRef="U_iso4217USD">0</eigr:FairValueTransfersBetweenLevelsTransfersAmount>
    <eigr:FairValueTransfersBetweenLevelsTransfersAmount
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20190101_20191231"
      decimals="INF"
      id="F_000362"
      unitRef="U_iso4217USD">0</eigr:FairValueTransfersBetweenLevelsTransfersAmount>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000320">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,995&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,995&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,976&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,621&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,475&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">20846000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">20846000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">33941000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">33941000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000367"
      unitRef="U_iso4217USD">21980000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20201231"
      decimals="-3"
      id="F_000368"
      unitRef="U_iso4217USD">21980000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">39995000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">39995000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">4060000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">4060000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">20846000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">99976000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">120822000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">35854000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">35854000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">16644000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000379"
      unitRef="U_iso4217USD">16644000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">7457000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20191231"
      decimals="-3"
      id="F_000381"
      unitRef="U_iso4217USD">7457000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">31520000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">31520000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">35854000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">55621000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000386"
      unitRef="U_iso4217USD">91475000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000387"
      unitRef="U_iso4217USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000388"
      unitRef="U_iso4217USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000321">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the estimated value of the Company&#x2019;s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;span style="font-family:Calibri;"&gt;&#160;&lt;/span&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,846&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,992&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,995&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;99,976&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gain&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;span style="font-family:Calibri;"&gt;&#160;&lt;/span&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Debt securities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,633&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,579&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,621&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <eigr:CashEquivalentsAmortizedCost
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000389"
      unitRef="U_iso4217USD">20846000</eigr:CashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">20846000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <eigr:CashEquivalentsAmortizedCost
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000390"
      unitRef="U_iso4217USD">20846000</eigr:CashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">20846000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">33952000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">33941000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20201231"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">21980000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20201231"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">21980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231"
      decimals="-3"
      id="F_000397"
      unitRef="U_iso4217USD">39992000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <eigr:CashEquivalentsAmortizedCost
      contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231"
      decimals="-3"
      id="F_000391"
      unitRef="U_iso4217USD">39992000</eigr:CashEquivalentsAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">39995000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">39995000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">4060000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20201231"
      decimals="-3"
      id="F_000408"
      unitRef="U_iso4217USD">4060000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">99984000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">99976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <eigr:CashEquivalentsAmortizedCost
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000410"
      unitRef="U_iso4217USD">35854000</eigr:CashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">35854000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <eigr:CashEquivalentsAmortizedCost
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000411"
      unitRef="U_iso4217USD">35854000</eigr:CashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000413"
      unitRef="U_iso4217USD">35854000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">16633000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">16644000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20191231"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">7457000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001305253_us-gaapCashAndCashEquivalentsAxis_us-gaapCommercialPaperMember_20191231"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">7457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">31489000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001305253_us-gaapFinancialInstrumentAxis_eigrUSGovernmentBondsMember_20191231"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">31520000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">55579000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">55621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <eigr:AvailableForSaleOfDebtSecuritiesContractualMaturity
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_20200101_20201231"
      id="F_000425">P1Y</eigr:AvailableForSaleOfDebtSecuritiesContractualMaturity>
    <eigr:AvailableForSaleOfDebtSecuritiesContractualMaturity
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_20190101_20191231"
      id="F_000426">P1Y</eigr:AvailableForSaleOfDebtSecuritiesContractualMaturity>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000427"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000290">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Balance Sheet Components&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment, Net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;436&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;804&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(342&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(214&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;709&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense for the years ended December&#160;31, 2020, 2019 and 2018 was approximately $167,000, $68,000 and $54,000, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Prepaid Expenses and Other Current Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid contract manufacturing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,126&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,374&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid research costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,177&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;448&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,968&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,966&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,390&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Liabilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract research costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,062&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract manufacturing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,510&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation and related benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,169&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,707&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,405&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000322">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;436&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;804&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(342&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(214&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;709&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;590&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20201231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">520000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrComputerEquipmentAndSoftwareMember_20191231"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">160000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">111000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">111000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">80000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">61000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20201231"
      decimals="-3"
      id="F_000434"
      unitRef="U_iso4217USD">271000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20191231"
      decimals="-3"
      id="F_000435"
      unitRef="U_iso4217USD">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">69000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231"
      decimals="-3"
      id="F_000437"
      unitRef="U_iso4217USD">436000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000438"
      unitRef="U_iso4217USD">1051000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000439"
      unitRef="U_iso4217USD">804000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000440"
      unitRef="U_iso4217USD">342000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000441"
      unitRef="U_iso4217USD">214000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">709000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">590000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">167000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000445"
      unitRef="U_iso4217USD">68000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000446"
      unitRef="U_iso4217USD">54000</us-gaap:Depreciation>
    <eigr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000323">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid contract manufacturing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,126&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,374&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid research costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,177&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;448&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,968&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,966&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,390&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</eigr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <eigr:PrepaidContractManufacturingCosts
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000447"
      unitRef="U_iso4217USD">6126000</eigr:PrepaidContractManufacturingCosts>
    <eigr:PrepaidContractManufacturingCosts
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000448"
      unitRef="U_iso4217USD">1374000</eigr:PrepaidContractManufacturingCosts>
    <eigr:PrepaidResearchCosts
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000449"
      unitRef="U_iso4217USD">1177000</eigr:PrepaidResearchCosts>
    <eigr:PrepaidResearchCosts
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000450"
      unitRef="U_iso4217USD">1627000</eigr:PrepaidResearchCosts>
    <us-gaap:PrepaidInsurance
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">448000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">421000</us-gaap:PrepaidInsurance>
    <eigr:OtherPrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">1215000</eigr:OtherPrepaidExpenseAndOtherAssetsCurrent>
    <eigr:OtherPrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">1968000</eigr:OtherPrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">8966000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000456"
      unitRef="U_iso4217USD">5390000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000324">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract research costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,062&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract manufacturing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,510&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation and related benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,169&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,707&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,405&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <eigr:AccruedContractedResearchCostsCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">6062000</eigr:AccruedContractedResearchCostsCurrent>
    <eigr:AccruedContractedResearchCostsCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">5288000</eigr:AccruedContractedResearchCostsCurrent>
    <eigr:ContractManufacturingCostsCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">1167000</eigr:ContractManufacturingCostsCurrent>
    <eigr:ContractManufacturingCostsCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">2510000</eigr:ContractManufacturingCostsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">3169000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">1707000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">1007000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">496000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">11405000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">10001000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000291">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;License, Collaboration, and Product Development Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;License Agreement with the Trustees of the University of Pennsylvania and the Children&#x2019;s Hospital of Philadelphia&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2019, the Company entered into a license agreement (the UPenn/CHOP Agreement) with the Trustees of the University of Pennsylvania (UPenn) and the Children&#x2019;s Hospital of Philadelphia (CHOP), under which the Company obtained an exclusive, royalty-bearing, worldwide license to develop, manufacture and sell certain Glucagon Like Peptide-1 (GLP-1) receptor antagonist(s) products to treat all human and animal conditions. The Company also obtained an exclusive, royalty-bearing, sublicenseable, worldwide license to certain data developed by CHOP. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;The Company is responsible for the development and commercialization of the licensed products at its sole cost and expense.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the consideration for the rights granted to the Company under the UPenn/CHOP Agreement, the Company paid UPenn a one-time, non-refundable issue fee of $1.0 million, which is recorded in research and development expenses for the year ended December 31, 2019. In addition, the Company is obligated to pay UPenn a specified annual license maintenance fee, up to $2.5 million in certain regulatory milestones, and up to $18.0 million in commercial milestones. The Company will also be required to pay UPenn a flat royalty in the low-single digits on net sales of all licensed products by the Company, subject to specified reductions and offsets, and specified minimum annual royalty payments. The Company&#x2019;s obligation to pay royalties expires on a product-by-product and country-by-country basis, on the later of: (i) the expiration of the last valid claim in the licensed patents in any country, or (ii) the tenth anniversary of the first commercial sale of the product in such country. No milestones have been achieved as of December 31, 2020. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may terminate the UPenn/CHOP Agreement in its entirety for any reason by providing prior written notice to UPenn and CHOP. UPenn or CHOP may terminate the UPenn/CHOP Agreement, upon a written notice, for the Company&#x2019;s failure to achieve the specified diligence milestones within the specified periods, subject to the Company&#x2019;s extension rights.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Product Development Agreement&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&#160;11, 2018, the Company entered into a Product Development Agreement and a First Project Agreement (the Product Agreements) with RDD International, LLC., pursuant to which the Company will receive development program support services for its hepatitis Delta virus (HDV) program. The services are to be provided from July&#160;1, 2018 through the completion of the Phase 3 Clinical Study Reports and the subsequent new drug application (NDA) filing. As consideration, the Company has committed to pay fees of approximately $10.0 million in cash and stock over four years, including approximately $0.8 million for expert consultant fees and pass through costs to vendors, plus certain incentive-based regulatory milestone fees up to $1.0 million. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;As part of the aggregate payment, the Company issued 115,526 shares of common stock subject to quarterly vesting requirements related to performance of the services and achievement of budget timeline set forth in the Product Agreements. &lt;/span&gt;The Product Agreements can be terminated by either party due to material breach or by the Company without cause with 90 days prior written notice. For the years ended December 31, 2020, 2019 and 2018, the Company recognized research and development expense of $0.2 million, $0.2 million and $0.4 million, respectively, related to vesting of the shares issued under the &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Product Agreements&lt;/span&gt;. Additionally, as of December&#160;31, 2020, the total unrecognized compensation expense related to unvested restricted shares was $0.2 million, which the Company expects to recognize over an estimated weighted-average period of 1.3 years. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Progeria Research Foundation (PRF) Collaboration Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 15, 2018, the Company entered into a Collaboration and Supply Agreement (the PRF Collaboration Agreement) with PRF. Under the PRF Collaboration Agreement, the parties agreed to collaborate with respect to the development and pursuit of regulatory approval of lonafarnib for the treatment of progeria and progeroid laminopathies in humans. PRF granted the Company a non-exclusive, world-wide, royalty-free, sub-licensable license pertaining to all intellectual property and data controlled by PRF to prepare and file any NDA for a product containing lonafarnib for progeria and progeroid laminopathies. The Company is obligated to: (i) exclusively supply lonafarnib to PRF for use in clinical trials and non-clinical research in progeria and progeroid laminopathies at the Company&#x2019;s expense, (ii) prepare and be the sponsor of any NDA submission for lonafarnib for the treatment of progeria and progeroid laminopathies to the FDA, (iii) use commercially reasonable efforts to file a NDA for progeria and progeroid laminopathies by a specified date, (iv) submit a rare pediatric disease designation and a request for expedited approval in connection with a NDA filing, (v) establish a patient support program in progeria and progeroid laminopathies, and (vi) use commercially reasonable efforts to develop a pediatric formulation of lonafarnib for use in progeria and progeroid laminopathies.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the PRF Collaboration Agreement, the Company is solely responsible for any additional studies necessary for obtaining an NDA for progeria and progeroid laminopathies and is also responsible for any additional costs for such studies up to $2.0 million. The PRF Collaboration Agreement continues for an initial term of ten years and automatically renews for subsequent renewal terms of two years each unless either party terminates earlier.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Clinigen Master Service Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 26, 2018, the Company entered into a master service agreement with Clinigen Healthcare Ltd. (Clinigen) in anticipation of its obligations under the PRF Collaboration Agreement to establish an Expanded Access Program (EAP) for children with progeria and progeroid laminopathies. On May 23, 2018, the Company entered into the first statement of work (SOW) under the agreement. Pursuant to the SOW, Clinigen became an authorized non-exclusive worldwide distributor of lonafarnib, the unlicensed pharmaceutical product (the Product). The Company is responsible for supply of the Product to Clinigen, and Clinigen is responsible for providing the Product to patients as part of the patient support program. Clinigen is also obligated to set up, manage and close-out the patient support program. The agreement will continue on a country-by-country basis until the Product is commercially available in that country. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Bristol-Meyers Squibb License Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April&#160;20, 2016, the Company and Bristol-Myers Squibb Company (BMS) entered into a License Agreement (the BMS License Agreement) and a Common Stock Purchase Agreement (the BMS Purchase Agreement).&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the BMS License Agreement, BMS granted the Company an exclusive, worldwide, license to research, develop, manufacture, and sell products containing PEG-interferon Lambda-1a (the&#160;Licensed Product) for all therapeutic and diagnostic uses in humans and animals. The Company is responsible for the development and &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;commercialization of the Licensed Product at its sole cost and expense. The Company paid BMS $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million and issued &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;157,587&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of its common stock at an aggregate fair value of $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.2&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million in April 2016. The BMS License Agreement also includes development and regulatory milestone payments totaling $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61.0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million and commercial sales milestones of up to $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128.0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million. The Company is obligated to pay BMS annual net sales royalties in the range of mid-single to mid-teens, depending on net sales levels. In fourth quarter 2020, the Company recorded &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;in research and development&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; expense&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;a $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million milestone, triggered on successful demonstration of proof of concept, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;as defined by the BMS License Agreement, in a Phase 2 clinical trial. The next milestone is $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million triggered on the initiation of a Phase 3 clinical trial.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Merck License Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2010, the Company entered into an exclusive license agreement with Schering Corporation, subsequently acquired by Merck&#160;&amp;amp; Co., Inc. (Merck), which provides the Company with the exclusive right to develop, manufacture, and sell products containing the compounds lonafarnib for the treatment of all human viruses except certain specified viruses such as hepatitis B and hepatitis C alone. As part of consideration, the Company issued 27,350 shares of common stock with a fair value of $0.5 million. The Company is obligated to pay Merck up to an aggregate of $27.0 million in development milestones and will be required to pay tiered royalties based on aggregate annual net sales of all licensed products ranging from mid-single to low double-digit royalties on net sales. In May 2015, the first regulatory milestone was achieved and the Company paid the related milestone payment of $1.0 million to Merck. No additional milestones have been achieved as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 15, 2018, the Company entered into an amendment to the exclusive license agreement with Merck, which provides for expansion of the existing exclusively licensed field of use under the license agreement with Merck to include all uses of lonafarnib related to the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) in humans at no cost to the Company. On November 3, 2020, the Company entered into an amendment to the exclusive license agreement with Merck which expanded the definition of progeria to also include progeroid laminopathies. The Company has the sole responsibility and the continuing obligation for the manufacture and supply of lonafarnib to the PRF. Merck will not receive milestone payments in relation to lonafarnib for the treatment of progeria and progeroid laminopathies or any royalty payments for sales of a specified quantity of lonafarnib to treat the currently estimated progeria and progeroid laminopathies patient population worldwide.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <eigr:NonRefundableIssueFee
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20190101_20191231"
      decimals="-5"
      id="F_000467"
      unitRef="U_iso4217USD">1000000.0</eigr:NonRefundableIssueFee>
    <eigr:LicenseMaintenanceFee
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000468"
      unitRef="U_iso4217USD">2500000</eigr:LicenseMaintenanceFee>
    <eigr:MilestoneObligations
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapIncomeStatementLocationAxis_eigrCommercialSalesMember_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000469"
      unitRef="U_iso4217USD">18000000.0</eigr:MilestoneObligations>
    <eigr:MilestoneObligations
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20200101_20201231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">0</eigr:MilestoneObligations>
    <eigr:ProductDevelopmentFees
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811"
      decimals="-5"
      id="F_000471"
      unitRef="U_iso4217USD">10000000.0</eigr:ProductDevelopmentFees>
    <eigr:ExpertConsultantFeesAndPassThroughCosts
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811"
      decimals="-5"
      id="F_000472"
      unitRef="U_iso4217USD">800000</eigr:ExpertConsultantFeesAndPassThroughCosts>
    <eigr:IncentiveBasedRegulatoryMilestoneFees
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811"
      decimals="-5"
      id="F_000473"
      unitRef="U_iso4217USD">1000000.0</eigr:IncentiveBasedRegulatoryMilestoneFees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811"
      decimals="INF"
      id="F_000474"
      unitRef="U_xbrlishares">115526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <eigr:ProductAgreementTerminationNoticePeriod
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180811_20180811"
      id="F_000475">P90D</eigr:ProductAgreementTerminationNoticePeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000476"
      unitRef="U_iso4217USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20190101_20191231"
      decimals="-5"
      id="F_000477"
      unitRef="U_iso4217USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20180101_20181231"
      decimals="-5"
      id="F_000478"
      unitRef="U_iso4217USD">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20201231"
      decimals="-5"
      id="F_000479"
      unitRef="U_iso4217USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrProductDevelopmentAgreementMember_20200101_20201231"
      id="F_000480">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20180216_20180315"
      decimals="-5"
      id="F_000481"
      unitRef="U_iso4217USD">2000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <eigr:CollaborationAgreementInitialTerm
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20180216_20180315"
      id="F_000482">P10Y</eigr:CollaborationAgreementInitialTerm>
    <eigr:CollaborativeArrangementRenewalTerm
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20180216_20180315"
      id="F_000483">P2Y</eigr:CollaborativeArrangementRenewalTerm>
    <eigr:UpfrontCashPayments
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420"
      decimals="-5"
      id="F_000484"
      unitRef="U_iso4217USD">2000000.0</eigr:UpfrontCashPayments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_eigrPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420"
      decimals="INF"
      id="F_000485"
      unitRef="U_xbrlishares">157587</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockValue
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_eigrPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160420"
      decimals="-5"
      id="F_000486"
      unitRef="U_iso4217USD">3200000</us-gaap:CommonStockValue>
    <eigr:MilestoneObligations
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentAndRegulatoryMilestonesMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420"
      decimals="-5"
      id="F_000487"
      unitRef="U_iso4217USD">61000000.0</eigr:MilestoneObligations>
    <eigr:MilestoneObligations
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrCommercialSalesMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420"
      decimals="-5"
      id="F_000488"
      unitRef="U_iso4217USD">128000000.0</eigr:MilestoneObligations>
    <eigr:MilestoneObligations
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentPhaseTwoMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420"
      decimals="-5"
      id="F_000489"
      unitRef="U_iso4217USD">3000000.0</eigr:MilestoneObligations>
    <eigr:IncreaseInMilestoneObligations
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_eigrDevelopmentPhaseThreeMember_us-gaapTypeOfArrangementAxis_eigrBmsTransactionMember_20160419_20160420"
      decimals="-5"
      id="F_000490"
      unitRef="U_iso4217USD">5000000.0</eigr:IncreaseInMilestoneObligations>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20100930"
      decimals="INF"
      id="F_000492"
      unitRef="U_xbrlishares">27350</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20100930"
      decimals="-5"
      id="F_000491"
      unitRef="U_iso4217USD">500000</us-gaap:CommonStockValue>
    <eigr:RoyaltiesExpirationDescription
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20200101_20201231"
      id="F_000496">The Company is obligated to pay Merck up to an aggregate of $27.0 million in development milestones and will be required to pay tiered royalties based on aggregate annual net sales of all licensed products ranging from mid-single to low double-digit royalties on net sales.</eigr:RoyaltiesExpirationDescription>
    <eigr:DevelopmentMilestoneObligations
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20100901_20100930"
      decimals="-5"
      id="F_000493"
      unitRef="U_iso4217USD">27000000.0</eigr:DevelopmentMilestoneObligations>
    <eigr:MilestonePayments
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20150501_20150531"
      decimals="-5"
      id="F_000494"
      unitRef="U_iso4217USD">1000000.0</eigr:MilestonePayments>
    <eigr:MilestonePayments
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_us-gaapTypeOfArrangementAxis_eigrMerckTransactionMember_20200101_20201231"
      decimals="-6"
      id="F_000495"
      unitRef="U_iso4217USD">0</eigr:MilestonePayments>
    <eigr:AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000292">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Asset Purchase Agreements and Related License Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;EGI Asset Purchase Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2010, the Company entered into an asset purchase agreement with Eiger Group International, Inc. (EGI). Dr. Jeffrey Glenn, a founder and director of the Company, is the sole owner of EGI. Pursuant to the agreement, the Company purchased all of the assets including the intellectual property rights related to the use of farnesyl transferase inhibitors as anti-viral agents and methods to treat viral infections with those inhibitors and inhibitors of prenylation, prenyl cysteine methyltranferase and a protease as anti-viral agents and methods to treat viral infection with those inhibitors. The Company paid EGI an upfront payment of $0.4 million when the agreement was executed in December 2010. Additionally, the Company will pay EGI a low single-digit royalty based on aggregate annual net sales of products developed using the intellectual property. Within the first ten years after commercialization, the Company may make a one-time payment of $0.5 million for each contract for the three types of product related to such intellectual property that would reduce the payment term for the three products to the tenth anniversary of the first commercial sale. The obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either when the product is no longer sold in any country or the earliest of the tenth anniversary of the first commercial sale of the product. As of December 31, 2020, the product has not achieved regulatory approval.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Avexitide Purchase Agreement and Related Stanford License Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2015, the Company entered into an asset purchase agreement with two individuals, Dr. Tracey McLaughlin and Dr. Colleen Craig, (the Sellers), whereby the Company purchased all of the assets related to the compound avexitide (formerly known as exendin 9-39) including any related intellectual property from the Sellers (the Exendin APA). The Company also entered into a consulting agreement with the Sellers as part of the agreement. The Company issued 15,378 shares of common stock that were valued at $0.2 million and with the option to purchase 46,134 shares of common stock with an exercise price of $2.06 per share when the agreement was executed in September 2015.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Of the 46,134 options to purchase common stock, 15,378 shares vest monthly over four years as services are provided by the Sellers and 30,756 vest upon the earlier of the first commercial sale of the product or the approval of new drug application by the U.S. Food and Drug Administration (the milestone-vested options).&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 22, 2016, immediately following the closing of the merger, the Company issued additional top-up options to the Sellers to purchase an aggregate of 48,544 shares of common stock, pursuant to the terms of the Exendin APA, with an exercise price of $17.25 per share. The top-up options consist of both time-vested and milestone-vested options.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the time-vested options is recognized as stock-based compensation expense as the awards vest over time. The fair value of the milestone-vested options will be recognized as research and development expense when it is probable that the earliest milestone will be achieved at their fair value as of the ASU 2018-07 adoption date. During the years ended December 31, 2020, 2019 and 2018, the Company recognized $0.1 million, $0.1 million and $0.1 million of compensation expense related to the time-vested options, respectively. No expense was recognized for the milestone vested options during the years ended December 31, 2020, 2019 and 2018.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also obligated to pay development milestone payments in an aggregate amount of up to $1.0 million to each Seller. Additionally, the Company is obligated to pay each Seller royalties of low single-digits based on aggregate annual net sales of all products developed based on avexitide, subject to certain reductions and exceptions. The Company&#x2019;s obligation to pay royalties expires on the expiration of the last to expire patent assigned to the Company under the agreement. Additionally, the Company has assumed the license agreement the Sellers had previously entered into with the Board of Trustees of the Leland Stanford Junior University (Stanford). The Company is obligated to pay a royalty to Stanford in the low single-digits on annual net sales after the first commercial sale of any products developed based on avexitide. As of December 31, 2020, the Company has paid a total of $0.1 million in milestone payments to each of the Sellers related to the successful completion of the Phase 2 trials.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Asset Purchase Agreement with AbbVie Inc.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 20, 2020, the Company entered into an asset purchase agreement (AbbVie APA) with AbbVie Inc. (AbbVie) to sell its Rare Pediatric Disease Priority Review Voucher, which was awarded the PRV on November 20, 2020 upon approval by the FDA of the NDA for Zokinvy in Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies (the PRV) to AbbVie. The AbbVie Agreement contains customary representations, warranties, covenants, and indemnification provisions subject to certain limitations. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In consideration for the PRV, AbbVie agreed to pay the Company $95.0 million. The transaction closed in January 2021. Such consideration was shared equally with The Progeria Research Foundation (&#x201c;PRF&#x201d;) in accordance with the terms of the PRF Collaboration Agreement, pursuant to which the Company and PRF will equally share any proceeds from the sale of a priority review voucher that the Company may receive as the sponsor of a rare pediatric disease product application. The Company retained approximately $47.4 million of the proceeds from the sale of the PRV.&lt;/p&gt;</eigr:AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock>
    <eigr:UpfrontCashPayments
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20101201_20101231"
      decimals="-5"
      id="F_000497"
      unitRef="U_iso4217USD">400000</eigr:UpfrontCashPayments>
    <eigr:AssetPurchaseDescription
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20200101_20201231"
      id="F_000498">Within the first ten years after commercialization, the Company may make a one-time payment of $0.5 million for each contract for the three types of product related to such intellectual property that would reduce the payment term for the three products to the tenth anniversary of the first commercial sale.</eigr:AssetPurchaseDescription>
    <eigr:OneTimePaymentToBeMadeOnAssetPurchaseAgreement
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20101231"
      decimals="-5"
      id="F_000499"
      unitRef="U_iso4217USD">500000</eigr:OneTimePaymentToBeMadeOnAssetPurchaseAgreement>
    <eigr:RoyaltiesExpirationDescription
      contextRef="C_0001305253_srtProductOrServiceAxis_eigrProductOneMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAssetPurchaseAgreementMember_us-gaapRelatedPartyTransactionAxis_eigrEIGTransactionMember_20200101_20201231"
      id="F_000500">The obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either when the product is no longer sold in any country or the earliest of the tenth anniversary of the first commercial sale of the product.</eigr:RoyaltiesExpirationDescription>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930"
      decimals="INF"
      id="F_000501"
      unitRef="U_xbrlishares">15378</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930"
      decimals="-5"
      id="F_000502"
      unitRef="U_iso4217USD">200000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <eigr:OptionsToPurchaseOfCommonStock
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930"
      decimals="INF"
      id="F_000503"
      unitRef="U_xbrlishares">46134</eigr:OptionsToPurchaseOfCommonStock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150930"
      decimals="2"
      id="F_000504"
      unitRef="U_iso4217USD_xbrlishares">2.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <eigr:VestingPeriodOfOptionsIssuedForCommonStockPurchase
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930"
      id="F_000505">P4Y</eigr:VestingPeriodOfOptionsIssuedForCommonStockPurchase>
    <eigr:VestingOfOptionsToPurchaseCommonStock
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930"
      decimals="INF"
      id="F_000506"
      unitRef="U_xbrlishares">30756</eigr:VestingOfOptionsToPurchaseCommonStock>
    <eigr:OptionsToPurchaseOfCommonStock
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20160321_20160322"
      decimals="INF"
      id="F_000507"
      unitRef="U_xbrlishares">48544</eigr:OptionsToPurchaseOfCommonStock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20160322"
      decimals="2"
      id="F_000508"
      unitRef="U_iso4217USD_xbrlishares">17.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000509"
      unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20190101_20191231"
      decimals="-5"
      id="F_000510"
      unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20180101_20181231"
      decimals="1"
      id="F_000511"
      unitRef="U_iso4217USD">0.1</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20200101_20201231"
      decimals="INF"
      id="F_000512"
      unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20190101_20191231"
      decimals="INF"
      id="F_000513"
      unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20180101_20181231"
      decimals="INF"
      id="F_000514"
      unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <eigr:LicenseAgreementPotentialMilestonePayments
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20150902_20150930"
      decimals="-5"
      id="F_000515"
      unitRef="U_iso4217USD">1000000.0</eigr:LicenseAgreementPotentialMilestonePayments>
    <eigr:LicenseAgreementMilestonePaymentsPaid
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAvexitidePurchaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000516"
      unitRef="U_iso4217USD">100000</eigr:LicenseAgreementMilestonePaymentsPaid>
    <eigr:PaymentForAssetPurchaseAgreement
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAbbvieAssetPurchaseAgreementMember_20201119_20201120"
      decimals="-5"
      id="F_000517"
      unitRef="U_iso4217USD">95000000.0</eigr:PaymentForAssetPurchaseAgreement>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="C_0001305253_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_eigrAbbvieAssetPurchaseAgreementMember_us-gaapTypeOfArrangementAxis_eigrPRFCollaborationAgreementMember_20201119_20201120"
      decimals="-5"
      id="F_000518"
      unitRef="U_iso4217USD">47400000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000293">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Debt&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2016, the Company entered into an aggregate $25.0 million loan with Oxford Finance LLC (the Oxford Loan). The Company borrowed $15.0 million in December 2016 (Tranche A). In May 2018, the Company entered into an amendment to the Oxford Loan&lt;span style="color:#000000;"&gt; and borrowed &lt;/span&gt;$5.0 million (Tranche B). &lt;span style="Background-color:#FFFFFF;"&gt;On August 3, 2018, the Company &lt;/span&gt;borrowed the remaining $5.0 million (Tranche C) under the Oxford Loan.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Oxford Loan bears interest at a floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.41% or 6.95%. The interest only period for borrowed funds is until February 1, 2019, followed by 30 equal monthly payments of principal plus accrued interest.&#160;At the time of final payment, the Company is required to pay an exit fee of 7.5% of the original principal balance of borrowed funds, or $1.9 million. In addition,&#160;at the time of final payment of Tranche B, the Company is required to pay an additional exit fee of $0.1 million.&#160;The Company recorded as a liability and debt discount the exit fee at the origination of the &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;term loan. In addition, the Company incurred loan origination fees and debt issuance costs of $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million which were recorded as a&#160;direct deduction from the carrying amount of the related debt liability as a debt discount. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 5, 2019, the Company entered into the third amendment to the Oxford Loan (the Amended Oxford Loan) to refinance the Oxford Loan. The Amended Oxford Loan increased the aggregate amount available to be borrowed to $35.0 million and extended the maturity date to March 1, 2024. On March 5, 2019, prior to entering into the Amended Oxford Loan, the outstanding balance of the Oxford Loan was $23.3 million. At the time of entering into the Amended Oxford Loan, the Company borrowed an additional $6.7 million in principal under the Amended Oxford Loan, which increased the total amount borrowed to $30.0 million (Amended Tranche A). The remaining $5.0 million (Amended Tranche B) is available to the Company provided that certain milestones are achieved by February 2021. The Company does not currently expect to draw down Amended Tranche B.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Amended Oxford Loan bears interest at a floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.64% or 9.15%. The Amended Oxford Loan has an interest only period until April 1, 2021, followed by 36 equal monthly payments of principal and interest. Upon the receipt of Amended Tranche B, the interest only period for borrowed funds will be extended by one year&lt;span style="color:#000000;"&gt; until April 1, 2022, followed by 24 equal monthly payments of principal plus accrued interest.&lt;/span&gt; At the time of final payment, the Company is required to pay an exit fee of 7.5% of the original principal balance of borrowed funds, or $2.3 million. In addition, &lt;span style="color:#000000;"&gt;the Company is required to pay an additional exit fee of $1.0 million&lt;/span&gt;. The Company recorded as a liability and debt discount the exit fee for the Amended Oxford Loan. At the date of the Amended Oxford Loan, the Company paid $0.9 million for the accrued portion of the Oxford Loan exit fee and the Tranche B additional exit fee. The loan discount balance at the time of the Amended Oxford Loan was $0.2 million, which is being amortized over the remaining term of the Amended Oxford Loan. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is also required to pay a 5.0% success fee &lt;span style="color:#000000;"&gt;of the total amount drawn under the Amended Oxford Loan &lt;/span&gt;within 30 days following the FDA&#x2019;s approval of the Company&#x2019;s first product, excluding lonafarnib in Progeria and Progeroid Laminopathies. This fee is enforceable within 10 years from the funding of Amended Tranche A. The Company determined that the success fee met the scope exemption from derivative accounting and should be accounted for under the guidance for contingencies. Accordingly, the Company will record a liability for the success fee upon receipt of approval from the FDA. &lt;span style="color:#000000;"&gt;The Amended Oxford Loan includes contingent interest features and mandatory prepayment features upon an event of default that meet the definition of a derivative but were not bifurcated from the debt instrument as their fair value was deemed to be insignificant&lt;/span&gt;&lt;span style="color:#548235;"&gt;. &lt;/span&gt;In connection with the execution of the Oxford Loan, the Company agreed to certain customary representations and warranties.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The refinancing of the term loan did not have a material impact on terms, conditions, representations, warranties, covenants or agreements set forth in the Oxford Loan. &lt;span style="color:#000000;"&gt;The loan is secured by the perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company&#x2019;s intellectual property. The loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency.&lt;/span&gt; If the Company is unable to comply with these covenants or if the Company defaults on any portion of the outstanding borrowings, the lenders can also impose a 5.0% penalty, restrict access to additional borrowings under the loan and security agreement, and accelerate the maturity of the debt. &lt;span style="color:#000000;"&gt;As of December 31, 2020, the Company was in compliance with all covenants.&#160;&#160;  &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is permitted to make voluntary prepayments of the Amended Oxford Loan with a prepayment fee, calculated as of the loan origination date, equal to (i) 2.0% of the loan prepaid during the first 12 months and (ii) 1.0% of the loan prepaid in months 13-24. The Company is required to make mandatory prepayments of the outstanding loan upon the acceleration by lender following the occurrence of an event of default, along with a payment of the final payment, the prepayment fee and any other obligations that are due and payable at the time of prepayment.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for the&#160;amortization of the&#160;debt discount utilizing the effective interest method. Long-term debt and unamortized discount balances are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Face value of long term debt&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exit fee&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized debt discount associated with exit fee, debt issuance costs and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; loan origination fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total long term debt, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,390&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, future minimum payments of principal, exit fee and interest expense under the Oxford Loan were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,662&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: unamortized interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,986&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: exit fee&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Face value of term loan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 23, 2021, the Company entered into the fifth amendment to the Oxford Loan (Note 14). As the Company refinanced the short-term portion of the Oxford Loan on a long-term basis prior to the issuance of the financial statements, the current portion of long-term debt as of December 31, 2020 was reclassified as long-term at the balance sheet date.&#160;&#160; &lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20161231"
      decimals="-5"
      id="F_000519"
      unitRef="U_iso4217USD">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20161231"
      decimals="-5"
      id="F_000520"
      unitRef="U_iso4217USD">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanAmendmentMember_20180531"
      decimals="-5"
      id="F_000521"
      unitRef="U_iso4217USD">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheCMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanAmendmentMember_20180803"
      decimals="-5"
      id="F_000522"
      unitRef="U_iso4217USD">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20200101_20201231"
      id="F_000523">floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.41% or 6.95%.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20200101_20201231"
      decimals="INF"
      id="F_000524"
      unitRef="U_xbrlipure">0.0641</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="4"
      id="F_000525"
      unitRef="U_xbrlipure">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <eigr:DebtInstrumentExitFeePayablePercentage
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="3"
      id="F_000527"
      unitRef="U_xbrlipure">0.075</eigr:DebtInstrumentExitFeePayablePercentage>
    <eigr:DebtInstrumentUnamortizedExitFees
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="-5"
      id="F_000528"
      unitRef="U_iso4217USD">1900000</eigr:DebtInstrumentUnamortizedExitFees>
    <eigr:DebtInstrumentUnamortizedExitFees
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="-5"
      id="F_000529"
      unitRef="U_iso4217USD">100000</eigr:DebtInstrumentUnamortizedExitFees>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20161231"
      decimals="-5"
      id="F_000530"
      unitRef="U_iso4217USD">400000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305"
      decimals="-5"
      id="F_000531"
      unitRef="U_iso4217USD">35000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231"
      id="F_000532">2024-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCredit
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305"
      decimals="-5"
      id="F_000533"
      unitRef="U_iso4217USD">23300000</us-gaap:LineOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305_20190305"
      decimals="-5"
      id="F_000534"
      unitRef="U_iso4217USD">6700000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305"
      decimals="-5"
      id="F_000535"
      unitRef="U_iso4217USD">30000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheBMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20190305"
      decimals="-5"
      id="F_000536"
      unitRef="U_iso4217USD">5000000.0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231"
      id="F_000537">floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.64% or 9.15%.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapVariableRateAxis_us-gaapLondonInterbankOfferedRateLIBORMember_20200101_20201231"
      decimals="4"
      id="F_000538"
      unitRef="U_xbrlipure">0.0664</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231"
      decimals="INF"
      id="F_000539"
      unitRef="U_xbrlipure">0.0915</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <eigr:DebtInstrumentExtendedInterestOnlyPaymentPeriod
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheBMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231"
      id="F_000542">P1Y</eigr:DebtInstrumentExtendedInterestOnlyPaymentPeriod>
    <eigr:DebtInstrumentExitFeePayablePercentage
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231"
      decimals="3"
      id="F_000543"
      unitRef="U_xbrlipure">0.075</eigr:DebtInstrumentExitFeePayablePercentage>
    <eigr:DebtInstrumentUnamortizedExitFees
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231"
      decimals="-5"
      id="F_000544"
      unitRef="U_iso4217USD">2300000</eigr:DebtInstrumentUnamortizedExitFees>
    <eigr:DebtInstrumentUnamortizedAdditionalExitFees
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231"
      decimals="-5"
      id="F_000545"
      unitRef="U_iso4217USD">1000000.0</eigr:DebtInstrumentUnamortizedAdditionalExitFees>
    <eigr:RepaymentsOfLoanAgreementExitFee
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20190101_20191231"
      decimals="-5"
      id="F_000546"
      unitRef="U_iso4217USD">900000</eigr:RepaymentsOfLoanAgreementExitFee>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20201231"
      decimals="-5"
      id="F_000547"
      unitRef="U_iso4217USD">200000</us-gaap:DeferredFinanceCostsGross>
    <eigr:DebtInstrumentSuccessFeesPayablePercentage
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapRegulatoryAgencyAxis_eigrFoodAndDrugAdministrationMember_20200101_20201231"
      decimals="3"
      id="F_000548"
      unitRef="U_xbrlipure">0.050</eigr:DebtInstrumentSuccessFeesPayablePercentage>
    <eigr:DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapRegulatoryAgencyAxis_eigrFoodAndDrugAdministrationMember_20200101_20201231"
      id="F_000549">P30D</eigr:DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval>
    <eigr:DebtInstrumentFeeEnforceableMaximumPeriodFromFunding
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapRegulatoryAgencyAxis_eigrFoodAndDrugAdministrationMember_20200101_20201231"
      id="F_000550">P10Y</eigr:DebtInstrumentFeeEnforceableMaximumPeriodFromFunding>
    <us-gaap:DebtInstrumentCovenantDescription contextRef="C_0001305253_20200101_20201231" id="F_000552">The loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency.</us-gaap:DebtInstrumentCovenantDescription>
    <eigr:DebtInstrumentCovenantNoncompliancePenalty
      contextRef="C_0001305253_20200101_20201231"
      decimals="3"
      id="F_000551"
      unitRef="U_xbrlipure">0.050</eigr:DebtInstrumentCovenantNoncompliancePenalty>
    <us-gaap:DebtInstrumentCovenantCompliance contextRef="C_0001305253_20200101_20201231" id="F_000553">and accelerate the maturity of the debt.</us-gaap:DebtInstrumentCovenantCompliance>
    <eigr:PrepaymentOfLoanFeeDescription
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_20200101_20201231"
      id="F_000556">calculated as of the loan origination date, equal to (i) 2.0% of the loan prepaid during the first 12 months and (ii) 1.0% of the loan prepaid in months 13-24.</eigr:PrepaymentOfLoanFeeDescription>
    <eigr:DebtInstrumentPrepaymentFeePercentage
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapDebtInstrumentRedemptionPeriodAxis_eigrLoanPrepaidDuringFirstTwelveMonthsMember_20200101_20201231"
      decimals="3"
      id="F_000554"
      unitRef="U_xbrlipure">0.020</eigr:DebtInstrumentPrepaymentFeePercentage>
    <eigr:DebtInstrumentPrepaymentFeePercentage
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrAmendedOxfordLoanMember_us-gaapDebtInstrumentRedemptionPeriodAxis_eigrLoanPrepaidDuringThirteenToTwentyFourMonthsMember_20200101_20201231"
      decimals="3"
      id="F_000555"
      unitRef="U_xbrlipure">0.010</eigr:DebtInstrumentPrepaymentFeePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000325">Long-term debt and unamortized discount balances are as follows (in thousands):
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Face value of long term debt&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exit fee&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized debt discount associated with exit fee, debt issuance costs and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; loan origination fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total long term debt, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,390&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000557"
      unitRef="U_iso4217USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000558"
      unitRef="U_iso4217USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <eigr:DebtInstrumentUnamortizedExitFees
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000559"
      unitRef="U_iso4217USD">-3277000</eigr:DebtInstrumentUnamortizedExitFees>
    <eigr:DebtInstrumentUnamortizedExitFees
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000560"
      unitRef="U_iso4217USD">-3277000</eigr:DebtInstrumentUnamortizedExitFees>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000561"
      unitRef="U_iso4217USD">2083000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000562"
      unitRef="U_iso4217USD">2887000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000563"
      unitRef="U_iso4217USD">31194000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000564"
      unitRef="U_iso4217USD">30390000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000326">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, future minimum payments of principal, exit fee and interest expense under the Oxford Loan were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,662&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,816&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: unamortized interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,986&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: exit fee&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,083&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Face value of term loan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,194&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="-3"
      id="F_000565"
      unitRef="U_iso4217USD">10051000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="-3"
      id="F_000566"
      unitRef="U_iso4217USD">11662000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="-3"
      id="F_000567"
      unitRef="U_iso4217USD">10734000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="-3"
      id="F_000568"
      unitRef="U_iso4217USD">5816000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="-3"
      id="F_000569"
      unitRef="U_iso4217USD">38263000</us-gaap:DebtInstrumentCarryingAmount>
    <eigr:DebtInstrumentUnamortizedInterest
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="-3"
      id="F_000570"
      unitRef="U_iso4217USD">4986000</eigr:DebtInstrumentUnamortizedInterest>
    <eigr:DebtInstrumentUnamortizedExitFees
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="-3"
      id="F_000571"
      unitRef="U_iso4217USD">2083000</eigr:DebtInstrumentUnamortizedExitFees>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231"
      decimals="-3"
      id="F_000572"
      unitRef="U_iso4217USD">31194000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000294">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stockholders&#x2019; Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of the Company&#x2019;s common stock have one vote for each share of common stock. Common stockholders are entitled to dividends when, as, and if declared by the Board of Directors, subject to the prior rights of the convertible preferred stockholders. As of December&#160;31, 2020, no dividends had been declared by the Board of Directors.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 17, 2019, the Company completed an underwritten public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters&#x2019; option to purchase additional shares of common stock, at a price of $11.00 per share. The offering was made under the Company&#x2019;s effective shelf registration statement and resulted in net proceeds to the Company of $53.2 million, after deducting underwriting discounts and commissions and offering expenses.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Company filed a shelf registration statement on Form S-3 (File No. 333-235655) with the Securities and Exchange Commission, which permits the offering, issuance and sale of up to a maximum aggregate offering price of $150.0 million of the company&#x2019;s common stock, preferred stock, debt securities and warrants. Up to a maximum of $50.0 million of the maximum aggregate offering price of $150.0 million may be issued and sold pursuant to an at-the-market (ATM) financing facility (2019 ATM Facility) under a sales agreement with Jefferies LLC (Jefferies). In August 2020, the Company entered into a new sales agreement with Jefferies for up to $50.0 million of the remaining amount on the shelf registration statement which may be sold pursuant to an ATM financing facility (2020 ATM Facility). &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As of December 31, 2020&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;, &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;the Company&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;has &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;completed&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; both&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; the 2019 ATM Facility and the&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; 2020 ATM Facility&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; for a total of &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;9,267,760&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; shares resulting in $&lt;/span&gt;97.3&lt;span style="Background-color:#FFFFFF;"&gt; million in net proceeds, after deducting commissions&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In December 2020, the Company filed a new shelf registration statement on Form S-3 (File No. 333-251497) with the Securities and Exchange Commission, which permits the offering, issuance and sale by the Company up to a maximum aggregate offering price of $200.0 million &lt;/span&gt;&lt;span style="color:#000000;"&gt;of our common stock, preferred stock, debt securities and warrants. Up to a maximum of $50.0 million of the maximum aggregate offering price of $200.0 million may be issued and sold pursuant to a new ATM financing facility under a sales agreement with Jefferies.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had reserved shares of common stock for issuance as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,697,075&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options available for future grants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,021,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;823,598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,718,184&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,591,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <eigr:DividendsDeclared
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000573"
      unitRef="U_iso4217USD">0</eigr:DividendsDeclared>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417_20190417"
      decimals="INF"
      id="F_000574"
      unitRef="U_xbrlishares">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <eigr:NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417_20190417"
      decimals="INF"
      id="F_000575"
      unitRef="U_xbrlishares">675000</eigr:NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001305253_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417"
      decimals="2"
      id="F_000576"
      unitRef="U_iso4217USD_xbrlishares">11.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001305253_us-gaapTypeOfArrangementAxis_eigrUnderwritingAgreementMember_20190417_20190417"
      decimals="-5"
      id="F_000577"
      unitRef="U_iso4217USD">53200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount
      contextRef="C_0001305253_20191201_20191231"
      decimals="-5"
      id="F_000579"
      unitRef="U_iso4217USD">150000000.0</eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount>
    <eigr:MaximumEquityDebtWarrantsIssuedDuringThePeriod
      contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20191201_20191231"
      decimals="-5"
      id="F_000581"
      unitRef="U_iso4217USD">50000000.0</eigr:MaximumEquityDebtWarrantsIssuedDuringThePeriod>
    <eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount
      contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20191201_20191231"
      decimals="-5"
      id="F_000583"
      unitRef="U_iso4217USD">150000000.0</eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount>
    <eigr:AmountOfCommonStockAvailableForSale
      contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20200830_20200831"
      decimals="-5"
      id="F_000586"
      unitRef="U_iso4217USD">50000000.0</eigr:AmountOfCommonStockAvailableForSale>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20200101_20201231"
      decimals="INF"
      id="F_000584"
      unitRef="U_xbrlishares">9267760</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20200101_20201231"
      decimals="-5"
      id="F_000585"
      unitRef="U_iso4217USD">97300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount
      contextRef="C_0001305253_20201201_20201231"
      decimals="-5"
      id="F_000578"
      unitRef="U_iso4217USD">200000000.0</eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount>
    <eigr:MaximumEquityDebtWarrantsIssuedDuringThePeriod
      contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20201201_20201231"
      decimals="-5"
      id="F_000580"
      unitRef="U_iso4217USD">50000000.0</eigr:MaximumEquityDebtWarrantsIssuedDuringThePeriod>
    <eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount
      contextRef="C_0001305253_us-gaapSubsidiarySaleOfStockAxis_eigrAtTheMarketOfferingMember_20201201_20201231"
      decimals="-5"
      id="F_000582"
      unitRef="U_iso4217USD">200000000.0</eigr:EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount>
    <eigr:CommonStockReservedForFutureIssuancesTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000327">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had reserved shares of common stock for issuance as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,697,075&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options available for future grants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,021,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;823,598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,718,184&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,591,215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</eigr:CommonStockReservedForFutureIssuancesTableTextBlock>
    <eigr:OptionsIssuedAndOutstanding
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000587"
      unitRef="U_xbrlishares">3697075</eigr:OptionsIssuedAndOutstanding>
    <eigr:OptionsIssuedAndOutstanding
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000588"
      unitRef="U_xbrlishares">2767617</eigr:OptionsIssuedAndOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000589"
      unitRef="U_xbrlishares">1021109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000590"
      unitRef="U_xbrlishares">823598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000591"
      unitRef="U_xbrlishares">4718184</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000592"
      unitRef="U_xbrlishares">3591215</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000295">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Equity Incentive Plans&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restated 2013 Equity Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the Company&#x2019;s Board of Directors adopted and in August 2016 the Company&#x2019;s stockholders approved the Amended and Restated 2013 Equity Incentive Plan (the Restated 2013&#160;Plan). Under the terms of the Restated 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Under the terms of the &lt;/span&gt;Restated 2013&#160;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and non-statutory stock options may not be less than 110% of fair market value, as determined by the Board of Directors. The terms of options granted under the Rested 2013 Plan may not exceed ten years. The vesting schedule of newly issued option grants is generally four years.&lt;/span&gt; As of December 31, 2020, the Company is authorized to issue up to 4,705,442 shares under the Restated 2013&#160;Plan.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity under both the Company&#x2019;s stock-based compensation plans during the year ended December 31, 2020 (in thousands, except share and per share data):&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per&lt;span style="font-family:Calibri;"&gt;&#160;&lt;/span&gt;Option&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;823,598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000616"&gt;7.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,218&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additional options authorized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,226,169&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,149,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,149,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(61,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited or cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;158,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(158,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,021,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,697,075&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000617"&gt;7.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,048&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable as of December&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,041,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000618"&gt;6.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock of $12.29 as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of stock options exercised in 2020, 2019 and 2018 was $0.3 million, $0.6 million and $0.2 million, respectively.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2020, 2019 and 2018, the&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; weighted-average grant date fair value of options granted was $4.78, $8.98 and $7.50 per share, respectively. &lt;/span&gt;The total grant date fair value of options that vested during the years ended December&#160;31, 2020, 2019 and 2018 was $5.6 million, $5.7 million and $4.7 million, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records stock-based compensation on stock options by estimating the fair value of stock-based awards using the Black-Scholes option pricing model and amortizing the fair value of the stock-based awards granted over the applicable vesting period of the awards on a straight-line basis. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of stock options was estimated using the following weighted-average assumptions:&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000632"&gt;5.00 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000633"&gt;5.27 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000634"&gt;5.27 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000638"&gt;9.67 - 9.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000642"&gt;73.00%&#160;&#160;- 77.00%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000643"&gt;73.14%&#160;&#160;- 83.19%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000644"&gt;84.00%&#160;&#160;- 95.00%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000648"&gt;0.39% - 1.37%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000649"&gt;1.42% - 2.57%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000650"&gt;1.67% - 2.68%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Term&lt;span style="font-style:normal;"&gt;: The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term for employee options). The Company uses the contractual term to determine the non-employee award fair value at the grant date. &lt;/span&gt;&lt;span style="color:#000000;font-style:normal;"&gt;The contractual term of options granted under the Restated 2013 Plan is ten years.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Volatility&lt;span style="font-style:normal;"&gt;: Since the Company does not have a long trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, or stage in the life cycle. Beginning in the third quarter of 2019, as the Company had been publicly traded for four and a half years, the Company began to layer in its historical volatility in the calculation of expected volatility.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-Free Interest Rate&lt;span style="font-style:normal;"&gt;: The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Dividend&lt;span style="font-style:normal;"&gt;: The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2013 Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2013, the Company&#x2019;s board of directors adopted and in 2016, upon the merger with Celladon, the Company amended and approved the 2013 Employee Stock Purchase Plan (2013 ESPP). The 2013 ESPP is intended to qualify as an employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code and is administered by the Company&#x2019;s board of directors.&lt;/p&gt;&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The number of shares of common stock initially reserved for issuance under the 2013 ESPP was 100,000 shares with an automatic annual increase to the shares issuable under the 2013 ESPP to the lower of (i) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, and (ii) 165,000 shares of common stock, unless a lower number determined by the board of directors. As of December 31, 2020, a total of 618,831 shares are reserved for issuance and 543,791 shares available for future issuance under the 2013 ESPP. During the years ended December 31, 2020 and December 31, 2019, employees purchased 25,645 shares for $0.2 million and 15,701 shares for $0.1 million, respectively, under the 2013 ESPP.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the first quarter of 2020,&#160;the Company revised its non-employee director compensation policy to approve the granting of restricted stock units (RSUs) in accordance with the Restated 2013 Equity Incentive Plan (the Restated 2013 Plan). Each eligible director who has served for less than six months during the prior calendar year and continues to serve as a non-employee member of the board is granted RSUs, which are pro-rated for the period served during the prior calendar year.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The RSUs granted to non-employee directors will vest on the one-year anniversary of the grant date, subject to the eligible director&#x2019;s continuous services through the vesting date, and will vest in full upon a change in control, as defined under the Restated 2013 Plan. RSUs granted to employees during the year ended December 31, 2020, commence vesting on the one-year anniversary through the two-year anniversary of the grant date. The fair value of all RSUs is measured at the grant date based on the closing market price of the Company&#x2019;s common stock and is recognized as stock-based compensation expense on a straight-line basis over the vesting period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2020, the Company granted 37,500 RSUs with a weighted-average grant date fair value of&#160;$6.95 per share. The Company recognized $0.2 million in stock-based compensation expense for the year ended December 31, 2020, which is included in general and administrative expenses. As of December 31, 2020, the total unrecognized compensation expense related to unvested RSUs was $0.1 million, which the Company expects to recognize over an estimated weighted-average period of 0.4 years.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation Expense&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense recognized was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,494&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,550&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,479&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,973&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the total unrecognized compensation expense related to unvested options was $10.2  million, which the Company expects to recognize over an estimated weighted average period of 2.5 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice
      contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000593"
      unitRef="U_xbrlipure">0.10</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001305253_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_eigrHoldersOfTenPercentOrMoreOfVotingPowerMember_20200101_20201231"
      decimals="INF"
      id="F_000594"
      unitRef="U_xbrlipure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231"
      id="F_000595">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20200101_20201231"
      id="F_000596">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrRestatedTwoThousandThirteenEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000597"
      unitRef="U_xbrlishares">4705442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000328">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity under both the Company&#x2019;s stock-based compensation plans during the year ended December 31, 2020 (in thousands, except share and per share data):&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per&lt;span style="font-family:Calibri;"&gt;&#160;&lt;/span&gt;Option&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;823,598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,767,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000616"&gt;7.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,218&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additional options authorized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,226,169&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,149,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,149,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(61,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited or cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;158,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(158,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,021,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,697,075&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000617"&gt;7.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,048&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable as of December&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,041,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000618"&gt;6.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000598"
      unitRef="U_xbrlishares">823598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000604"
      unitRef="U_xbrlishares">2767617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001305253_20191231"
      decimals="2"
      id="F_000610"
      unitRef="U_iso4217USD_xbrlishares">12.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000619"
      unitRef="U_iso4217USD">8218000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000599"
      unitRef="U_xbrlishares">1226169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000600"
      unitRef="U_xbrlishares">1149750</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000605"
      unitRef="U_xbrlishares">1149750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001305253_20200101_20201231"
      decimals="2"
      id="F_000611"
      unitRef="U_iso4217USD_xbrlishares">7.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000601"
      unitRef="U_xbrlishares">37500</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000606"
      unitRef="U_xbrlishares">61700</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001305253_20200101_20201231"
      decimals="2"
      id="F_000612"
      unitRef="U_iso4217USD_xbrlishares">8.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000602"
      unitRef="U_xbrlishares">158592</eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000607"
      unitRef="U_xbrlishares">158592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001305253_20200101_20201231"
      decimals="2"
      id="F_000613"
      unitRef="U_iso4217USD_xbrlishares">10.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000603"
      unitRef="U_xbrlishares">1021109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000608"
      unitRef="U_xbrlishares">3697075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001305253_20201231"
      decimals="2"
      id="F_000614"
      unitRef="U_iso4217USD_xbrlishares">10.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000620"
      unitRef="U_iso4217USD">9048000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000609"
      unitRef="U_xbrlishares">2041834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001305253_20201231"
      decimals="2"
      id="F_000615"
      unitRef="U_iso4217USD_xbrlishares">11.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000621"
      unitRef="U_iso4217USD">4125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <eigr:ClosingPriceOfCommonStock
      contextRef="C_0001305253_20201231"
      decimals="2"
      id="F_000622"
      unitRef="U_iso4217USD_xbrlishares">12.29</eigr:ClosingPriceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001305253_20200101_20201231"
      decimals="-5"
      id="F_000623"
      unitRef="U_iso4217USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001305253_20190101_20191231"
      decimals="-5"
      id="F_000624"
      unitRef="U_iso4217USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001305253_20180101_20181231"
      decimals="-5"
      id="F_000625"
      unitRef="U_iso4217USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="2"
      id="F_000626"
      unitRef="U_iso4217USD_xbrlishares">4.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="2"
      id="F_000627"
      unitRef="U_iso4217USD_xbrlishares">8.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="2"
      id="F_000628"
      unitRef="U_iso4217USD_xbrlishares">7.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="-5"
      id="F_000629"
      unitRef="U_xbrlishares">5600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="-5"
      id="F_000630"
      unitRef="U_xbrlishares">5700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="-5"
      id="F_000631"
      unitRef="U_xbrlishares">4700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0001305253_us-gaapAwardTypeAxis_eigrEmployeesAndNonEmployeesStockOptionMember_20200101_20201231"
      id="F_000329">The fair value of stock options was estimated using the following weighted-average assumptions:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000632"&gt;5.00 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000633"&gt;5.27 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000634"&gt;5.27 - 6.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000638"&gt;9.67 - 9.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000642"&gt;73.00%&#160;&#160;- 77.00%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000643"&gt;73.14%&#160;&#160;- 83.19%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000644"&gt;84.00%&#160;&#160;- 95.00%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000648"&gt;0.39% - 1.37%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000649"&gt;1.42% - 2.57%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000650"&gt;1.67% - 2.68%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001305253_20200101_20201231"
      decimals="2"
      id="F_000654"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231"
      id="F_000664">The number of shares of common stock initially reserved for issuance under the 2013 ESPP was 100,000 shares with an automatic annual increase to the shares issuable under the 2013 ESPP to the lower of (i) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, and (ii) 165,000 shares of common stock, unless a lower number determined by the board of directors. As of December 31, 2020, a total of 618,831 shares are reserved for issuance and 543,791 shares available for future issuance under the 2013 ESPP. During the years ended December 31, 2020 and December 31, 2019, employees purchased 25,645 shares for $0.2 million and 15,701 shares for $0.1 million, respectively, under the 2013 ESPP.
</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20131231"
      decimals="INF"
      id="F_000655"
      unitRef="U_xbrlishares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000656"
      unitRef="U_xbrlipure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000657"
      unitRef="U_xbrlishares">165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000658"
      unitRef="U_xbrlishares">618831</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000659"
      unitRef="U_xbrlishares">543791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000660"
      unitRef="U_xbrlishares">25645</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000662"
      unitRef="U_iso4217USD">200000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000661"
      unitRef="U_xbrlishares">15701</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001305253_us-gaapPlanNameAxis_eigrTwoThousandThirteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="-5"
      id="F_000663"
      unitRef="U_iso4217USD">100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="INF"
      id="F_000665"
      unitRef="U_xbrlishares">37500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="2"
      id="F_000666"
      unitRef="U_iso4217USD_xbrlishares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      decimals="-5"
      id="F_000669"
      unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="-5"
      id="F_000667"
      unitRef="U_iso4217USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001305253_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20201231"
      id="F_000668">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000330">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense recognized was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,494&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,550&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,479&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,973&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000670"
      unitRef="U_iso4217USD">1494000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000671"
      unitRef="U_iso4217USD">1550000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231"
      decimals="-3"
      id="F_000672"
      unitRef="U_iso4217USD">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000673"
      unitRef="U_iso4217USD">4479000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000674"
      unitRef="U_iso4217USD">4129000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231"
      decimals="-3"
      id="F_000675"
      unitRef="U_iso4217USD">3507000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000676"
      unitRef="U_iso4217USD">5973000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000677"
      unitRef="U_iso4217USD">5679000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000678"
      unitRef="U_iso4217USD">5007000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001305253_20201231"
      decimals="-5"
      id="F_000679"
      unitRef="U_iso4217USD">10200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001305253_20200101_20201231" id="F_000680">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000296">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;No provision for income taxes was recorded for the years ended December&#160;31, 2020, 2019 and 2018. The Company has incurred net operating losses (NOL) for all the periods presented. The Company has not reflected any benefit of such NOL carryforwards in the accompanying consolidated financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27.42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.02&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.01&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision (benefit) for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of the deferred tax assets and liabilities are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,523&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,761&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,157&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,067&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,452&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,912&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;389&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,994&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(60,747&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to the Company&#x2019;s lack of earnings history, the deferred tax assets have been fully offset by a valuation allowance as of December 31, 2020 and 2019. The net change in the valuation allowance for the years ended December&#160;31, 2020 and 2019 increased by $7.0 million and $7.6 million, respectively.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the Company had approximately $251.7 million and $25.2 million, respectively, of federal and state NOL carryforwards available to reduce future taxable income that will begin to expire in 2030 and 2028, respectively, for federal and state tax purposes.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the Company also had research and development tax credit carryforwards of&#160;$1.8 million for state purposes, available to offset future taxable income tax. If not utilized, the state credits can be carried forward indefinitely. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if the Company has experienced an ownership change under Section 382 of the Internal Revenue Code (the Code) of 1986, as amended. &lt;span style="letter-spacing:-0.1pt;"&gt;The Company&#x2019;s merger with Celladon resulted in such an ownership change and, accordingly, Celladon&#x2019;s NOL carryforwards and certain other tax attributes will be subject to further limitations on their use. The Company assessed whether it had an ownership change, as defined by Section&#160;382 of the Code from its formation through December 31, 2020. Based upon this assessment, the Company experienced ownership changes on April 20, 2016, October 18, 2018 and December 31, 2020. Due to these ownership changes, reductions were made to the Company&#x2019;s NOL and tax credit carryforwards under these rules&lt;/span&gt;. &lt;span style="letter-spacing:-0.1pt;"&gt;Additional ownership changes in the future could result in additional limitations on the Company&#x2019;s NOL and tax credit carryforwards.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefits for the years ended December&#160;31, 2020, 2019 and 2018 is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,218&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions based on tax positions related to prior&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(61&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions based on tax positions related to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,443&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,477&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions based on tax positions related to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,907&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions based on tax positions related to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;451&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the $0.5 million of unrecognized tax benefits is recognized, there would not be an effect on the effective tax rate. The Company does not expect the unrecognized tax benefits to change significantly over the next 12 months. As of December 31, 2020, the unrecognized tax benefits for uncertain tax positions were offset against deferred tax assets and would not affect the income tax rate if recognized due to the Company being in a full valuation allowance position.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s policy is to account for interest and penalties in tax expense on the consolidated statements of operations. The Company files income tax returns in the U.S. federal and state jurisdictions. All periods since inception are subject to examination by U.S. federal and state jurisdictions. There were no such interest or penalties during the years ended December 31, 2020, 2019 and 2018.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000681"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001305253_20190101_20191231"
      decimals="INF"
      id="F_000682"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001305253_20180101_20181231"
      decimals="INF"
      id="F_000683"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000331">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27.42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26.02&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.01&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision (benefit) for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001305253_20200101_20201231"
      decimals="INF"
      id="F_000684"
      unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001305253_20190101_20191231"
      decimals="INF"
      id="F_000685"
      unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001305253_20180101_20181231"
      decimals="INF"
      id="F_000686"
      unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001305253_20200101_20201231"
      decimals="4"
      id="F_000687"
      unitRef="U_xbrlipure">-0.2675</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001305253_20190101_20191231"
      decimals="4"
      id="F_000688"
      unitRef="U_xbrlipure">-0.2742</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001305253_20180101_20181231"
      decimals="4"
      id="F_000689"
      unitRef="U_xbrlipure">-0.2602</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001305253_20200101_20201231"
      decimals="4"
      id="F_000690"
      unitRef="U_xbrlipure">0.0643</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001305253_20190101_20191231"
      decimals="4"
      id="F_000691"
      unitRef="U_xbrlipure">0.0727</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001305253_20180101_20181231"
      decimals="4"
      id="F_000692"
      unitRef="U_xbrlipure">0.0552</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001305253_20200101_20201231"
      decimals="4"
      id="F_000693"
      unitRef="U_xbrlipure">0.0033</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001305253_20190101_20191231"
      decimals="4"
      id="F_000694"
      unitRef="U_xbrlipure">0.0025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001305253_20180101_20181231"
      decimals="4"
      id="F_000695"
      unitRef="U_xbrlipure">0.0027</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001305253_20200101_20201231"
      decimals="4"
      id="F_000696"
      unitRef="U_xbrlipure">-0.0100</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001305253_20190101_20191231"
      decimals="4"
      id="F_000697"
      unitRef="U_xbrlipure">-0.0089</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001305253_20180101_20181231"
      decimals="4"
      id="F_000698"
      unitRef="U_xbrlipure">-0.0077</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001305253_20200101_20201231"
      decimals="4"
      id="F_000699"
      unitRef="U_xbrlipure">-0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001305253_20190101_20191231"
      decimals="4"
      id="F_000700"
      unitRef="U_xbrlipure">-0.0021</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001305253_20200101_20201231"
      decimals="2"
      id="F_000701"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001305253_20190101_20191231"
      decimals="2"
      id="F_000702"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001305253_20180101_20181231"
      decimals="2"
      id="F_000703"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000332">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of the deferred tax assets and liabilities are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,523&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,761&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,157&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,067&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,452&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,912&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;606&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;389&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,994&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(60,747&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(247&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000704"
      unitRef="U_iso4217USD">54523000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000705"
      unitRef="U_iso4217USD">42761000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000706"
      unitRef="U_iso4217USD">1068000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000707"
      unitRef="U_iso4217USD">7157000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <eigr:DeferredTaxAssetDepreciationAndAmortization
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000708"
      unitRef="U_iso4217USD">2067000</eigr:DeferredTaxAssetDepreciationAndAmortization>
    <eigr:DeferredTaxAssetDepreciationAndAmortization
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000709"
      unitRef="U_iso4217USD">1602000</eigr:DeferredTaxAssetDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000710"
      unitRef="U_iso4217USD">2452000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000711"
      unitRef="U_iso4217USD">1912000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000712"
      unitRef="U_iso4217USD">606000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000713"
      unitRef="U_iso4217USD">319000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <eigr:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000714"
      unitRef="U_iso4217USD">278000</eigr:DeferredTaxAssetsLeaseLiabilities>
    <eigr:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000715"
      unitRef="U_iso4217USD">389000</eigr:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000716"
      unitRef="U_iso4217USD">60994000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000717"
      unitRef="U_iso4217USD">54140000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000718"
      unitRef="U_iso4217USD">60747000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000719"
      unitRef="U_iso4217USD">53793000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000720"
      unitRef="U_iso4217USD">247000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000721"
      unitRef="U_iso4217USD">347000</us-gaap:DeferredTaxAssetsNet>
    <eigr:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000722"
      unitRef="U_iso4217USD">247000</eigr:DeferredTaxLiabilitiesRightOfUseAssets>
    <eigr:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000723"
      unitRef="U_iso4217USD">347000</eigr:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000724"
      unitRef="U_iso4217USD">247000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000725"
      unitRef="U_iso4217USD">347000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000726"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000727"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <eigr:IncreaseInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001305253_20200101_20201231"
      decimals="-5"
      id="F_000728"
      unitRef="U_iso4217USD">7000000.0</eigr:IncreaseInDeferredTaxAssetsValuationAllowance>
    <eigr:IncreaseInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001305253_20190101_20191231"
      decimals="-5"
      id="F_000729"
      unitRef="U_iso4217USD">7600000</eigr:IncreaseInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000730"
      unitRef="U_iso4217USD">251700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_000731"
      unitRef="U_iso4217USD">25200000</us-gaap:OperatingLossCarryforwards>
    <eigr:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000732">2030</eigr:OperatingLossCarryforwardsExpirationYear>
    <eigr:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231"
      id="F_000733">2028</eigr:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001305253_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_000734"
      unitRef="U_iso4217USD">1800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000333">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefits for the years ended December&#160;31, 2020, 2019 and 2018 is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,218&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions based on tax positions related to prior&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(61&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions based on tax positions related to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,443&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,477&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions based on tax positions related to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; prior year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,907&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions based on tax positions related to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;451&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000735"
      unitRef="U_iso4217USD">3277000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001305253_20181231"
      decimals="-3"
      id="F_000736"
      unitRef="U_iso4217USD">4634000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001305253_20171231"
      decimals="-3"
      id="F_000737"
      unitRef="U_iso4217USD">3218000</us-gaap:UnrecognizedTaxBenefits>
    <eigr:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000738"
      unitRef="U_iso4217USD">-61000</eigr:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000739"
      unitRef="U_iso4217USD">81000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000740"
      unitRef="U_iso4217USD">2443000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001305253_20180101_20181231"
      decimals="-3"
      id="F_000741"
      unitRef="U_iso4217USD">1477000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001305253_20200101_20201231"
      decimals="-3"
      id="F_000742"
      unitRef="U_iso4217USD">2907000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001305253_20190101_20191231"
      decimals="-3"
      id="F_000743"
      unitRef="U_iso4217USD">3800000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000744"
      unitRef="U_iso4217USD">451000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001305253_20191231"
      decimals="-3"
      id="F_000745"
      unitRef="U_iso4217USD">3277000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001305253_20181231"
      decimals="-3"
      id="F_000746"
      unitRef="U_iso4217USD">4634000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_0001305253_20201231"
      decimals="-5"
      id="F_000747"
      unitRef="U_iso4217USD">500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001305253_20201231"
      decimals="INF"
      id="F_000748"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001305253_20191231"
      decimals="INF"
      id="F_000749"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001305253_20181231"
      decimals="INF"
      id="F_000750"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000297">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Legal Matters&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time in the ordinary course of business the Company becomes involved in various lawsuits, claims and proceedings, including those pertaining to the defense and enforcement of the Company&#x2019;s patent or other intellectual property rights and contractual rights. These proceedings are costly and time consuming. Additionally, successful challenges to the Company&#x2019;s patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and may allow third parties to use the Company&#x2019;s proprietary technologies without a license from the Company or its collaborators. The outcome of such matters, which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred.&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000298">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Commitments and Contingencies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Lease Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2017, the Company entered into a non-cancelable operating facility lease agreement for 8,029 square feet of office space located at 2155 Park Blvd. in Palo Alto, California 94306. The lease commenced on March 1, 2018 and expires in February 2023. The lease has a &lt;span style="-sec-ix-hidden:F_000754"&gt;three-year&lt;/span&gt; renewal option prior to expiration; however, the Company is not reasonably assured to exercise this option. The lease includes rent escalation clauses throughout the lease term. In October 2017, the Company provided a security deposit of $0.3 million.&#160;The Company also has additional operating leases that are included in its lease accounting but are not considered significant for disclosure.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of December 31, 2020 were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.1%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;662&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of future lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense recognized for the Company&#x2019;s operating leases was $0.6 million, $0.6 million, and $0.8 million for the years ended December 31, 2020, 2019, and 2018, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for the operating leases were &lt;span&gt;$0.1&lt;/span&gt; million for each of the years ended December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The operating cash outflows for the operating lease liabilities were $0.7 million and $0.6 million for the year ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the weighted-average remaining lease term and weighted-average discount rate were 2.1 years and 9.15%, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Other Commitments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is obligated to make future payments to third parties under asset purchase and license agreements, including royalties and payments that become due and payable on the achievement of certain development and commercialization milestones. However, the amount and timing of these payments are not known. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Manufacturing Service Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the first quarter of 2020, the Company entered into a Master Manufacturing Services Agreement (MMSA) and Product Agreement with Patheon, Inc. (Patheon) for the manufacturing of lonafarnib capsules and packaging of bottles for commercial sale. Under the terms of the agreements, the Company is required to provide Patheon with annual volume forecasts of capsules and Patheon will manufacture 80% of such annual forecasts. If the Company order less than 80% of such annual forecasts, it is required to pay 70% of purchase price for the shortfall. The initial terms of the MMSA and Product Agreement end on December 31, 2025 with automatic renewal for successive &lt;span style="-sec-ix-hidden:F_000778"&gt;two-year&lt;/span&gt; terms, unless earlier terminated pursuant to the terms of each agreement, or upon either party&#x2019;s notice of termination to the other.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="C_0001305253_srtStatementGeographicalAxis_stprCA_20171031"
      decimals="0"
      id="F_000751"
      unitRef="U_utrsqft">8029</us-gaap:LandSubjectToGroundLeases>
    <eigr:LeaseCommencedDate
      contextRef="C_0001305253_srtStatementGeographicalAxis_stprCA_20171001_20171031"
      id="F_000752">2018-03-01</eigr:LeaseCommencedDate>
    <eigr:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear
      contextRef="C_0001305253_srtStatementGeographicalAxis_stprCA_20171001_20171031"
      id="F_000753">2023-02</eigr:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear>
    <us-gaap:PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue
      contextRef="C_0001305253_srtStatementGeographicalAxis_stprCA_20171031"
      decimals="-5"
      id="F_000755"
      unitRef="U_iso4217USD">300000</us-gaap:PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000334">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of December 31, 2020 were as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.1%; border-bottom:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;662&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of future lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000756"
      unitRef="U_iso4217USD">673000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000757"
      unitRef="U_iso4217USD">662000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000758"
      unitRef="U_iso4217USD">113000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000759"
      unitRef="U_iso4217USD">1000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000760"
      unitRef="U_iso4217USD">1449000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000761"
      unitRef="U_iso4217USD">129000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000762"
      unitRef="U_iso4217USD">1320000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000763"
      unitRef="U_iso4217USD">582000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001305253_20201231"
      decimals="-3"
      id="F_000764"
      unitRef="U_iso4217USD">738000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001305253_20200101_20201231"
      decimals="-5"
      id="F_000765"
      unitRef="U_iso4217USD">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001305253_20190101_20191231"
      decimals="-5"
      id="F_000766"
      unitRef="U_iso4217USD">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001305253_20180101_20181231"
      decimals="-5"
      id="F_000767"
      unitRef="U_iso4217USD">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001305253_20200101_20201231"
      decimals="-5"
      id="F_000768"
      unitRef="U_iso4217USD">100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001305253_20190101_20191231"
      decimals="-5"
      id="F_000769"
      unitRef="U_iso4217USD">100000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001305253_20200101_20201231"
      decimals="-5"
      id="F_000770"
      unitRef="U_iso4217USD">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001305253_20190101_20191231"
      decimals="-5"
      id="F_000771"
      unitRef="U_iso4217USD">600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001305253_20201231" id="F_000772">P2Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001305253_20201231"
      decimals="4"
      id="F_000773"
      unitRef="U_xbrlipure">0.0915</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts
      contextRef="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20200331"
      decimals="2"
      id="F_000774"
      unitRef="U_xbrlipure">0.80</eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts>
    <eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts
      contextRef="C_0001305253_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20200331"
      decimals="2"
      id="F_000775"
      unitRef="U_xbrlipure">0.80</eigr:PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts>
    <eigr:PercentageOfPurchasePrice
      contextRef="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20200331"
      decimals="2"
      id="F_000776"
      unitRef="U_xbrlipure">0.70</eigr:PercentageOfPurchasePrice>
    <eigr:ProductAgreementDateOfExpiration
      contextRef="C_0001305253_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_eigrPatheonIncMember_us-gaapTypeOfArrangementAxis_eigrMasterManufacturingServicesAgreementMember_20200101_20201231"
      id="F_000777">2025-12-31</eigr:ProductAgreementDateOfExpiration>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000299">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Related Party Transactions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As disclosed in Note 6, the Company entered into license agreements with EGI, which is owned by the founder of the Company.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001305253_20200101_20201231" id="F_000300">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Subsequent Events&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;February&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, 2021, the Company entered into the fifth amendment to the Oxford Loan. The amendment extended the interest only period by &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17 months&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; until September 1, 2022, follow&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ed&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; by &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19 equal monthly&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; payments of principal and interest. Upon the receipt of Amended Tranche B, the interest only period for borrowed funds will be extended by &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;six months&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; until March 1, 2023, follow&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ed&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; by &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13 equal monthly&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; payments of principal plus accrued interest. In addition, the Company paid the amendment fees of $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.2&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million to the lenders on the effective date of the fifth amendment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <eigr:DebtInstrumentInterestPaymentPeriod
      contextRef="C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223"
      id="F_000780">P17M</eigr:DebtInstrumentInterestPaymentPeriod>
    <eigr:DebtInstrumentInterestPaymentPeriod
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223"
      id="F_000782">P6M</eigr:DebtInstrumentInterestPaymentPeriod>
    <eigr:AmendmendFeesPayment
      contextRef="C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223"
      decimals="-5"
      id="F_000783"
      unitRef="U_iso4217USD">200000</eigr:AmendmendFeesPayment>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685638441608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EIGR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eiger BioPharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001305253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0971591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2155 Park Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Palo Alto<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">272 6138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Part III incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2021 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120 days after the close of the registrant&#8217;s fiscal year ended December 31, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,901,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,943,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685637768184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,864<span></span>
</td>
<td class="nump">$ 39,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, available-for-sale</a></td>
<td class="nump">99,976<span></span>
</td>
<td class="nump">55,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,966<span></span>
</td>
<td class="nump">5,390<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">137,806<span></span>
</td>
<td class="nump">100,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,903<span></span>
</td>
<td class="nump">2,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">143,594<span></span>
</td>
<td class="nump">105,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,640<span></span>
</td>
<td class="nump">6,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">11,405<span></span>
</td>
<td class="nump">10,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,627<span></span>
</td>
<td class="nump">16,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt, net</a></td>
<td class="nump">31,194<span></span>
</td>
<td class="nump">30,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">1,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">48,559<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2020 and 2019; 33,878,486 and 24,523,381 shares issued and outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">401,509<span></span>
</td>
<td class="nump">297,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(306,500)<span></span>
</td>
<td class="num">(241,449)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">95,035<span></span>
</td>
<td class="nump">56,480<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 143,594<span></span>
</td>
<td class="nump">$ 105,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685638057464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">33,878,486<span></span>
</td>
<td class="nump">24,523,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">33,878,486<span></span>
</td>
<td class="nump">24,523,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685647458712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 41,590<span></span>
</td>
<td class="nump">$ 51,791<span></span>
</td>
<td class="nump">$ 37,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,559<span></span>
</td>
<td class="nump">17,113<span></span>
</td>
<td class="nump">13,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">62,149<span></span>
</td>
<td class="nump">68,904<span></span>
</td>
<td class="nump">51,047<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(62,149)<span></span>
</td>
<td class="num">(68,904)<span></span>
</td>
<td class="num">(51,047)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,594)<span></span>
</td>
<td class="num">(3,406)<span></span>
</td>
<td class="num">(2,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">2,073<span></span>
</td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (65,051)<span></span>
</td>
<td class="num">$ (70,252)<span></span>
</td>
<td class="num">$ (52,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted</a></td>
<td class="num">$ (2.31)<span></span>
</td>
<td class="num">$ (3.08)<span></span>
</td>
<td class="num">$ (3.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted</a></td>
<td class="nump">28,143,391<span></span>
</td>
<td class="nump">22,785,611<span></span>
</td>
<td class="nump">13,634,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685557945880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (65,051)<span></span>
</td>
<td class="num">$ (70,252)<span></span>
</td>
<td class="num">$ (52,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale debt securities, net</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (65,101)<span></span>
</td>
<td class="num">$ (70,185)<span></span>
</td>
<td class="num">$ (52,413)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685561082600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 22,522<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 141,320<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (118,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,526,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="nump">90,642<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">90,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,510,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon stock option exercise</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon stock option exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement', window );">Issuance of common stock under Product Development Agreement</a></td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement', window );">Issuance of common stock under Product Development Agreement, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale debt securities, net</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(52,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,391)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="nump">66,592<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">237,795<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(171,197)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,211,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="nump">53,194<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">53,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon stock option exercise</a></td>
<td class="nump">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon stock option exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement', window );">Issuance of common stock under Product Development Agreement</a></td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale debt securities, net</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(70,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,252)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 56,480<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">297,863<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(241,449)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">24,523,381<span></span>
</td>
<td class="nump">24,523,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="nump">$ 96,760<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">96,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,267,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase</a></td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon stock option exercise</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon stock option exercises, Shares</a></td>
<td class="nump">61,700<span></span>
</td>
<td class="nump">61,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement', window );">Issuance of common stock under Product Development Agreement</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale debt securities, net</a></td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(65,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,051)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 95,035<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 401,509<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">$ (306,500)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">33,878,486<span></span>
</td>
<td class="nump">33,878,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares product development agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value product development agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685562740152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock upon public offering, issuance costs</a></td>
<td class="nump">$ 3,231<span></span>
</td>
<td class="nump">$ 3,731<span></span>
</td>
<td class="nump">$ 5,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685637707640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (65,051)<span></span>
</td>
<td class="num">$ (70,252)<span></span>
</td>
<td class="num">$ (52,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of debt securities premiums and discounts</a></td>
<td class="nump">124<span></span>
</td>
<td class="num">(467)<span></span>
</td>
<td class="num">(426)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,973<span></span>
</td>
<td class="nump">5,679<span></span>
</td>
<td class="nump">5,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Non-cash interest expense</a></td>
<td class="nump">804<span></span>
</td>
<td class="nump">723<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_OperatingLeaseRightOfUseAssetAmortization', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued under Product Development Agreement</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,563)<span></span>
</td>
<td class="num">(3,698)<span></span>
</td>
<td class="num">(780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(1,392)<span></span>
</td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,899)<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="nump">2,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">5,610<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(534)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(63,185)<span></span>
</td>
<td class="num">(63,614)<span></span>
</td>
<td class="num">(42,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of debt securities available-for-sale</a></td>
<td class="num">(128,295)<span></span>
</td>
<td class="num">(96,267)<span></span>
</td>
<td class="num">(57,193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of debt securities available-for-sale</a></td>
<td class="nump">83,766<span></span>
</td>
<td class="nump">80,271<span></span>
</td>
<td class="nump">28,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(258)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(44,787)<span></span>
</td>
<td class="num">(16,471)<span></span>
</td>
<td class="num">(29,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering,net of issuance costs</a></td>
<td class="nump">96,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon stock option exercises</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock upon ESPP purchase</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_PaymentsOfDeferredOfferingCosts', window );">Payment of deferred offering costs</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from borrowings in connection with term loan, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,627<span></span>
</td>
<td class="nump">9,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee', window );">Repayment of accrued exit fee and second amendment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">97,463<span></span>
</td>
<td class="nump">58,196<span></span>
</td>
<td class="nump">100,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(10,509)<span></span>
</td>
<td class="num">(21,889)<span></span>
</td>
<td class="nump">29,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">39,373<span></span>
</td>
<td class="nump">61,262<span></span>
</td>
<td class="nump">32,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">28,864<span></span>
</td>
<td class="nump">39,373<span></span>
</td>
<td class="nump">61,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 2,791<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eigr_POMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon public offering,net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,194<span></span>
</td>
<td class="nump">$ 90,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PaymentsOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PaymentsOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of accrued exit fee and second amendment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eigr_POMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eigr_POMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559515064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description of Business</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger BioPharmaceuticals, Inc. (the Company or Eiger) was incorporated in the State of Delaware on November&#160;6, 2008. Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV), the most severe form of human viral hepatitis, for which there is currently no FDA-approved therapy. Eiger has reported positive proof-of-concept clinical results across all of our programs and have received Breakthrough Therapy designation for three programs in clinical development. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eiger&#8217;s lead clinical programs are complementary treatments for HDV. Lonafarnib is a first-in-class oral farnesylation inhibitor in a global Phase 3 trial, and the only oral therapy in development for HDV. Peginterferon lambda is a first-in-class, well characterized, well-tolerated type III interferon entering Phase 3.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA approved the Company&#8217;s first commercial product, Zokinvy (lonafarnib) for treatment of Progeria and processing-deficient progeroid laminopathies, ultra-rare and rapidly fatal genetic conditions of accelerated aging in children, November 20, 2020. Eiger&#8217;s Marketing Authorization Application (MAA) is under review with the European Medicines Agency (EMA), with a decision expected in the second half of 2021.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also developing avexitide, a well-characterized peptide, as a treatment for PBH, a debilitating and potentially life-threatening condition for which there is currently no approved therapy, and as a treatment CHI, an ultra-rare pediatric metabolic disorder.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s principal operations are based in Palo Alto, California and it operates in one segment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had $128.9 million of cash, cash equivalents and investments, comprised of $28.9 million of cash and cash equivalents and $100.0 million of debt securities available-for-sale.&#160;The Company had an accumulated deficit of $306.5 million and negative cash flows from operating activities as of December 31, 2020. <span style="Background-color:#FFFFFF;color:#000000;">As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, the Company will need to continue to raise additional capital</span>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management believes that the currently available resources will be sufficient to fund its operations for at least the next 12 months following the issuance date of these consolidated financial statements. However, if the Company&#8217;s anticipated operating results are not achieved in future periods, the Company believes that planned expenditures may need to be reduced or it would be required to raise funding in order to fund the operations. Additionally, the Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559308664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation and Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, (U.S. GAAP) and following the requirements of the Securities and Exchange Commission (the SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period. On an ongoing basis, the Company evaluates its estimates, including those related to clinical trial accrued liabilities, stock-based compensation</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operating lease liabilities</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and income taxes.&#160;The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consists of cash, cash equivalents and investments. The Company&#8217;s cash is held by a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.</p><p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each product candidate, the Company relies on one supply chain for each of the four product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents include all cash balances and highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consists primarily of amounts invested in money market funds held at financial institutions and corporate debt securities. The recorded carrying amount of cash equivalents approximates their fair value.&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Debt Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. All short-term securities are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The cost of available-for-sale securities sold is based on the specific-identification method<span style="Background-color:#FFFFFF;color:#000000;">. </span>Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other expense, net on the accompanying consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. Depreciation begins at the time the asset is placed into service. Maintenance and repairs are charged to operations as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The useful lives of the property and equipment are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through December&#160;31, 2020, the Company has not impaired any long-lived assets.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the consolidated balance sheets and within research and development expenses in the consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, &#8220;Leases&#8221; (&#8220;ASC 842&#8221;) on January 1, 2019. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception. Material leases with a term greater than one year are recognized in right-of-use (&#8220;ROU&#8221;) assets and current and noncurrent lease liabilities, as applicable, in the Company&#8217;s consolidated balance sheets.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of its right-of-use assets (ROU assets) and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease ROU assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the consolidated statements of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in general and administrative expenses when incurred.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Financing Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing costs incurred with securing a term debt are recorded in the Company&#8217;s consolidated balance sheets as an offset to the term debt and amortized to interest expense in the Company&#8217;s consolidated statements of operations over the contractual life of the loan using the effective interest method. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist of payroll expenses, stock-based compensation expense, lab supplies and allocated facility costs, as well as fees paid to third parties that conduct certain research and development and manufacturing activities on the Company&#8217;s behalf. Amounts incurred in connection with license and asset purchase agreements are also included in research and development expenses. Manufacturing costs related to products undergoing regulatory approval are expensed as research and development costs until receipt of such approval. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based awards to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight line-basis over the </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employee&#8217;s or director&#8217;s requisite service period (generally the vesting period). </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-based awards to non-employees are recorded at their fair value as of the grant date</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, using the Black-Scholes option pricing model and recognized as expense over the period in which the related services are received. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for Black-Scholes option pricing model inputs</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accounts for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forfeitures </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-based awards </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when they occur. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal Revenue Code Section 382 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In the event that the Company experiences a change of ownership, utilization of the net operating loss and tax credit carryforwards may be restricted.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss represents all changes in stockholders' equity except those resulting from and distributions to stockholders. The Company&#8217;s unrealized gains and losses on debt securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,697,075</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996,211</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units (unvested)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,734,575</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996,211</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820)</span>. The standard eliminates, modifies and adds disclosure requirements </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for fair value measurements. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance on January 1, 2020. </span><span style="color:#000000;">The adoption did not have a material impact on the Company&#8217;s</span><span style="color:#000000;"> </span><span style="color:#000000;">consolidated financial statements.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, the FASB issued&#160;ASU No.&#160;2018-15,&#160;<span style="font-style:italic;">Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</span> <span style="font-style:italic;">(Subtopic 350-40)</span>. The standard&#160;adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The pronouncement is effective for fiscal years beginning after December&#160;15, 2019, and interim periods within those fiscal years, with early adoption permitted. The amendments in ASU No, 2018-15&#160;should be applied either using a retrospective or prospective approach. <span style="color:#000000;">The Company adopted&#160;this guidance&#160;on January 1, 2020 using the prospective approach. The adoption did not have a material impact on the Company&#8217;s consolidated financial statements.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Pronouncements Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13,&#160;<span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326)</span>. The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,</span> which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, <span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), </span>which provides an option <span style="color:#000000;">to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost</span>. <span style="color:#000000;">In November 2019, the FASB issued ASU No. 2019-10, </span><span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)</span>, which<span style="font-style:italic;"> </span><span style="color:#000000;">defers the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of the guidance on its consolidated financial statements. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU No. 2020-04, <span style="font-style:italic;">Reference Rate Reform (Topic 848)</span>. The standard provides optional expedients for facilitating the effects of the reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for contract modifications permitted for contracts that are modified because of the reference rate reform and meet the scope guidance. The modifications of contracts within the scope of ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as separate contracts. <span style="color:#000000;">The pronouncement is effective for all entities as of March 12, 2020 through December 31, 2022. The Company plans to adopt upon the occurrence of such contract modification, but not later than December 31, 2022. The Company engaged in early-stage discussions with its lender and will assess the impact of the adoption once the contract is modified.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559259896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). At December 31, 2020 and 2019, the carrying amount of prepaid expenses and other current assets, accounts payable and accrued liabilities approximated their estimate fair value due to their relatively short maturities. Management believes the terms of its long term debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company&#8217;s debt approximated its fair value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;">: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;">: Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;">: Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s money market funds are classified as Level 1 because they are valued using quoted market prices. The Company&#8217;s debt securities consist of available-for-sale securities and are classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. There were no assets or liabilities classified as Level&#160;3 as of December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no transfers in or out of Level 3 of the fair value hierarchy during the periods presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,941</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,941</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,980</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,980</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury bills</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,995</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,995</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,060</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,060</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,976</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,822</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,457</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,457</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,621</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,475</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no financial liabilities as of December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the estimated value of the Company&#8217;s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated<span style="font-family:Calibri;">&#160;</span>Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,941</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,980</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,980</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury bills</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,992</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,995</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,060</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,060</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,984</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,976</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated<span style="font-family:Calibri;">&#160;</span>Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,633</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,457</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,457</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,489</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,579</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,621</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the contractual maturity of the available-for-sale debt securities is less than one year. <span style="Background-color:#FFFFFF;">The Company periodically reviews the available-for-sale investments for&#160;</span>other-than-temporary<span style="Background-color:#FFFFFF;">&#160;impairment loss. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, it also considers whether (i)&#160;it is more likely&#160;</span>than&#160;n<span style="Background-color:#FFFFFF;">ot that the Company will be required to sell the debt securities before recovery of </span><span style="color:#000000;">their</span><span style="Background-color:#FFFFFF;"> amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. As of December 31, 2020, the Company did not recognize any&#160;</span>other-than-temporary<span style="Background-color:#FFFFFF;">&#160;impairment losses. All debt securities with unrealized losses have been in a loss position for </span>less&#160;than<span style="Background-color:#FFFFFF;">&#160;12 months.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685557787832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Components</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,051</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(342</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(214</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December&#160;31, 2020, 2019 and 2018 was approximately $167,000, $68,000 and $54,000, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid Expenses and Other Current Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consist of the following (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid contract manufacturing costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,126</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,374</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,177</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,627</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,215</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,968</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,966</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,390</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract research costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,062</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract manufacturing costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,510</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation and related benefits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,169</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,707</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,405</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,001</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685560029496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Product Development Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration, and Product Development Agreements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License, Collaboration, and Product Development Agreements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreement with the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into a license agreement (the UPenn/CHOP Agreement) with the Trustees of the University of Pennsylvania (UPenn) and the Children&#8217;s Hospital of Philadelphia (CHOP), under which the Company obtained an exclusive, royalty-bearing, worldwide license to develop, manufacture and sell certain Glucagon Like Peptide-1 (GLP-1) receptor antagonist(s) products to treat all human and animal conditions. The Company also obtained an exclusive, royalty-bearing, sublicenseable, worldwide license to certain data developed by CHOP. <span style="Background-color:#FFFFFF;color:#000000;">The Company is responsible for the development and commercialization of the licensed products at its sole cost and expense.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the consideration for the rights granted to the Company under the UPenn/CHOP Agreement, the Company paid UPenn a one-time, non-refundable issue fee of $1.0 million, which is recorded in research and development expenses for the year ended December 31, 2019. In addition, the Company is obligated to pay UPenn a specified annual license maintenance fee, up to $2.5 million in certain regulatory milestones, and up to $18.0 million in commercial milestones. The Company will also be required to pay UPenn a flat royalty in the low-single digits on net sales of all licensed products by the Company, subject to specified reductions and offsets, and specified minimum annual royalty payments. The Company&#8217;s obligation to pay royalties expires on a product-by-product and country-by-country basis, on the later of: (i) the expiration of the last valid claim in the licensed patents in any country, or (ii) the tenth anniversary of the first commercial sale of the product in such country. No milestones have been achieved as of December 31, 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the UPenn/CHOP Agreement in its entirety for any reason by providing prior written notice to UPenn and CHOP. UPenn or CHOP may terminate the UPenn/CHOP Agreement, upon a written notice, for the Company&#8217;s failure to achieve the specified diligence milestones within the specified periods, subject to the Company&#8217;s extension rights.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product Development Agreement</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;11, 2018, the Company entered into a Product Development Agreement and a First Project Agreement (the Product Agreements) with RDD International, LLC., pursuant to which the Company will receive development program support services for its hepatitis Delta virus (HDV) program. The services are to be provided from July&#160;1, 2018 through the completion of the Phase 3 Clinical Study Reports and the subsequent new drug application (NDA) filing. As consideration, the Company has committed to pay fees of approximately $10.0 million in cash and stock over four years, including approximately $0.8 million for expert consultant fees and pass through costs to vendors, plus certain incentive-based regulatory milestone fees up to $1.0 million. <span style="Background-color:#FFFFFF;color:#000000;">As part of the aggregate payment, the Company issued 115,526 shares of common stock subject to quarterly vesting requirements related to performance of the services and achievement of budget timeline set forth in the Product Agreements. </span>The Product Agreements can be terminated by either party due to material breach or by the Company without cause with 90 days prior written notice. For the years ended December 31, 2020, 2019 and 2018, the Company recognized research and development expense of $0.2 million, $0.2 million and $0.4 million, respectively, related to vesting of the shares issued under the <span style="Background-color:#FFFFFF;color:#000000;">Product Agreements</span>. Additionally, as of December&#160;31, 2020, the total unrecognized compensation expense related to unvested restricted shares was $0.2 million, which the Company expects to recognize over an estimated weighted-average period of 1.3 years. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Progeria Research Foundation (PRF) Collaboration Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 15, 2018, the Company entered into a Collaboration and Supply Agreement (the PRF Collaboration Agreement) with PRF. Under the PRF Collaboration Agreement, the parties agreed to collaborate with respect to the development and pursuit of regulatory approval of lonafarnib for the treatment of progeria and progeroid laminopathies in humans. PRF granted the Company a non-exclusive, world-wide, royalty-free, sub-licensable license pertaining to all intellectual property and data controlled by PRF to prepare and file any NDA for a product containing lonafarnib for progeria and progeroid laminopathies. The Company is obligated to: (i) exclusively supply lonafarnib to PRF for use in clinical trials and non-clinical research in progeria and progeroid laminopathies at the Company&#8217;s expense, (ii) prepare and be the sponsor of any NDA submission for lonafarnib for the treatment of progeria and progeroid laminopathies to the FDA, (iii) use commercially reasonable efforts to file a NDA for progeria and progeroid laminopathies by a specified date, (iv) submit a rare pediatric disease designation and a request for expedited approval in connection with a NDA filing, (v) establish a patient support program in progeria and progeroid laminopathies, and (vi) use commercially reasonable efforts to develop a pediatric formulation of lonafarnib for use in progeria and progeroid laminopathies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the PRF Collaboration Agreement, the Company is solely responsible for any additional studies necessary for obtaining an NDA for progeria and progeroid laminopathies and is also responsible for any additional costs for such studies up to $2.0 million. The PRF Collaboration Agreement continues for an initial term of ten years and automatically renews for subsequent renewal terms of two years each unless either party terminates earlier.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinigen Master Service Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 26, 2018, the Company entered into a master service agreement with Clinigen Healthcare Ltd. (Clinigen) in anticipation of its obligations under the PRF Collaboration Agreement to establish an Expanded Access Program (EAP) for children with progeria and progeroid laminopathies. On May 23, 2018, the Company entered into the first statement of work (SOW) under the agreement. Pursuant to the SOW, Clinigen became an authorized non-exclusive worldwide distributor of lonafarnib, the unlicensed pharmaceutical product (the Product). The Company is responsible for supply of the Product to Clinigen, and Clinigen is responsible for providing the Product to patients as part of the patient support program. Clinigen is also obligated to set up, manage and close-out the patient support program. The agreement will continue on a country-by-country basis until the Product is commercially available in that country. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Bristol-Meyers Squibb License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;20, 2016, the Company and Bristol-Myers Squibb Company (BMS) entered into a License Agreement (the BMS License Agreement) and a Common Stock Purchase Agreement (the BMS Purchase Agreement).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BMS License Agreement, BMS granted the Company an exclusive, worldwide, license to research, develop, manufacture, and sell products containing PEG-interferon Lambda-1a (the&#160;Licensed Product) for all therapeutic and diagnostic uses in humans and animals. The Company is responsible for the development and </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialization of the Licensed Product at its sole cost and expense. The Company paid BMS $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and issued </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,587</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of its common stock at an aggregate fair value of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in April 2016. The BMS License Agreement also includes development and regulatory milestone payments totaling $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and commercial sales milestones of up to $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million. The Company is obligated to pay BMS annual net sales royalties in the range of mid-single to mid-teens, depending on net sales levels. In fourth quarter 2020, the Company recorded </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in research and development</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> expense</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million milestone, triggered on successful demonstration of proof of concept, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as defined by the BMS License Agreement, in a Phase 2 clinical trial. The next milestone is $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million triggered on the initiation of a Phase 3 clinical trial.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merck License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2010, the Company entered into an exclusive license agreement with Schering Corporation, subsequently acquired by Merck&#160;&amp; Co., Inc. (Merck), which provides the Company with the exclusive right to develop, manufacture, and sell products containing the compounds lonafarnib for the treatment of all human viruses except certain specified viruses such as hepatitis B and hepatitis C alone. As part of consideration, the Company issued 27,350 shares of common stock with a fair value of $0.5 million. The Company is obligated to pay Merck up to an aggregate of $27.0 million in development milestones and will be required to pay tiered royalties based on aggregate annual net sales of all licensed products ranging from mid-single to low double-digit royalties on net sales. In May 2015, the first regulatory milestone was achieved and the Company paid the related milestone payment of $1.0 million to Merck. No additional milestones have been achieved as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 15, 2018, the Company entered into an amendment to the exclusive license agreement with Merck, which provides for expansion of the existing exclusively licensed field of use under the license agreement with Merck to include all uses of lonafarnib related to the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) in humans at no cost to the Company. On November 3, 2020, the Company entered into an amendment to the exclusive license agreement with Merck which expanded the definition of progeria to also include progeroid laminopathies. The Company has the sole responsibility and the continuing obligation for the manufacture and supply of lonafarnib to the PRF. Merck will not receive milestone payments in relation to lonafarnib for the treatment of progeria and progeroid laminopathies or any royalty payments for sales of a specified quantity of lonafarnib to treat the currently estimated progeria and progeroid laminopathies patient population worldwide.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685557746648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Purchase Agreements and Related License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract', window );"><strong>Asset Purchase Agreements And Related License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock', window );">Asset Purchase Agreements and Related License Agreements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Asset Purchase Agreements and Related License Agreements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">EGI Asset Purchase Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2010, the Company entered into an asset purchase agreement with Eiger Group International, Inc. (EGI). Dr. Jeffrey Glenn, a founder and director of the Company, is the sole owner of EGI. Pursuant to the agreement, the Company purchased all of the assets including the intellectual property rights related to the use of farnesyl transferase inhibitors as anti-viral agents and methods to treat viral infections with those inhibitors and inhibitors of prenylation, prenyl cysteine methyltranferase and a protease as anti-viral agents and methods to treat viral infection with those inhibitors. The Company paid EGI an upfront payment of $0.4 million when the agreement was executed in December 2010. Additionally, the Company will pay EGI a low single-digit royalty based on aggregate annual net sales of products developed using the intellectual property. Within the first ten years after commercialization, the Company may make a one-time payment of $0.5 million for each contract for the three types of product related to such intellectual property that would reduce the payment term for the three products to the tenth anniversary of the first commercial sale. The obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either when the product is no longer sold in any country or the earliest of the tenth anniversary of the first commercial sale of the product. As of December 31, 2020, the product has not achieved regulatory approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Avexitide Purchase Agreement and Related Stanford License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2015, the Company entered into an asset purchase agreement with two individuals, Dr. Tracey McLaughlin and Dr. Colleen Craig, (the Sellers), whereby the Company purchased all of the assets related to the compound avexitide (formerly known as exendin 9-39) including any related intellectual property from the Sellers (the Exendin APA). The Company also entered into a consulting agreement with the Sellers as part of the agreement. The Company issued 15,378 shares of common stock that were valued at $0.2 million and with the option to purchase 46,134 shares of common stock with an exercise price of $2.06 per share when the agreement was executed in September 2015.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the 46,134 options to purchase common stock, 15,378 shares vest monthly over four years as services are provided by the Sellers and 30,756 vest upon the earlier of the first commercial sale of the product or the approval of new drug application by the U.S. Food and Drug Administration (the milestone-vested options).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 22, 2016, immediately following the closing of the merger, the Company issued additional top-up options to the Sellers to purchase an aggregate of 48,544 shares of common stock, pursuant to the terms of the Exendin APA, with an exercise price of $17.25 per share. The top-up options consist of both time-vested and milestone-vested options.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the time-vested options is recognized as stock-based compensation expense as the awards vest over time. The fair value of the milestone-vested options will be recognized as research and development expense when it is probable that the earliest milestone will be achieved at their fair value as of the ASU 2018-07 adoption date. During the years ended December 31, 2020, 2019 and 2018, the Company recognized $0.1 million, $0.1 million and $0.1 million of compensation expense related to the time-vested options, respectively. No expense was recognized for the milestone vested options during the years ended December 31, 2020, 2019 and 2018.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also obligated to pay development milestone payments in an aggregate amount of up to $1.0 million to each Seller. Additionally, the Company is obligated to pay each Seller royalties of low single-digits based on aggregate annual net sales of all products developed based on avexitide, subject to certain reductions and exceptions. The Company&#8217;s obligation to pay royalties expires on the expiration of the last to expire patent assigned to the Company under the agreement. Additionally, the Company has assumed the license agreement the Sellers had previously entered into with the Board of Trustees of the Leland Stanford Junior University (Stanford). The Company is obligated to pay a royalty to Stanford in the low single-digits on annual net sales after the first commercial sale of any products developed based on avexitide. As of December 31, 2020, the Company has paid a total of $0.1 million in milestone payments to each of the Sellers related to the successful completion of the Phase 2 trials.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Asset Purchase Agreement with AbbVie Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 20, 2020, the Company entered into an asset purchase agreement (AbbVie APA) with AbbVie Inc. (AbbVie) to sell its Rare Pediatric Disease Priority Review Voucher, which was awarded the PRV on November 20, 2020 upon approval by the FDA of the NDA for Zokinvy in Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies (the PRV) to AbbVie. The AbbVie Agreement contains customary representations, warranties, covenants, and indemnification provisions subject to certain limitations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the PRV, AbbVie agreed to pay the Company $95.0 million. The transaction closed in January 2021. Such consideration was shared equally with The Progeria Research Foundation (&#8220;PRF&#8221;) in accordance with the terms of the PRF Collaboration Agreement, pursuant to which the Company and PRF will equally share any proceeds from the sale of a priority review voucher that the Company may receive as the sponsor of a rare pediatric disease product application. The Company retained approximately $47.4 million of the proceeds from the sale of the PRV.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset purchase agreement and related license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset purchase agreements and related license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559529256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Debt</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into an aggregate $25.0 million loan with Oxford Finance LLC (the Oxford Loan). The Company borrowed $15.0 million in December 2016 (Tranche A). In May 2018, the Company entered into an amendment to the Oxford Loan<span style="color:#000000;"> and borrowed </span>$5.0 million (Tranche B). <span style="Background-color:#FFFFFF;">On August 3, 2018, the Company </span>borrowed the remaining $5.0 million (Tranche C) under the Oxford Loan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Oxford Loan bears interest at a floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.41% or 6.95%. The interest only period for borrowed funds is until February 1, 2019, followed by 30 equal monthly payments of principal plus accrued interest.&#160;At the time of final payment, the Company is required to pay an exit fee of 7.5% of the original principal balance of borrowed funds, or $1.9 million. In addition,&#160;at the time of final payment of Tranche B, the Company is required to pay an additional exit fee of $0.1 million.&#160;The Company recorded as a liability and debt discount the exit fee at the origination of the </p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term loan. In addition, the Company incurred loan origination fees and debt issuance costs of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million which were recorded as a&#160;direct deduction from the carrying amount of the related debt liability as a debt discount. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 5, 2019, the Company entered into the third amendment to the Oxford Loan (the Amended Oxford Loan) to refinance the Oxford Loan. The Amended Oxford Loan increased the aggregate amount available to be borrowed to $35.0 million and extended the maturity date to March 1, 2024. On March 5, 2019, prior to entering into the Amended Oxford Loan, the outstanding balance of the Oxford Loan was $23.3 million. At the time of entering into the Amended Oxford Loan, the Company borrowed an additional $6.7 million in principal under the Amended Oxford Loan, which increased the total amount borrowed to $30.0 million (Amended Tranche A). The remaining $5.0 million (Amended Tranche B) is available to the Company provided that certain milestones are achieved by February 2021. The Company does not currently expect to draw down Amended Tranche B.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Amended Oxford Loan bears interest at a floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.64% or 9.15%. The Amended Oxford Loan has an interest only period until April 1, 2021, followed by 36 equal monthly payments of principal and interest. Upon the receipt of Amended Tranche B, the interest only period for borrowed funds will be extended by one year<span style="color:#000000;"> until April 1, 2022, followed by 24 equal monthly payments of principal plus accrued interest.</span> At the time of final payment, the Company is required to pay an exit fee of 7.5% of the original principal balance of borrowed funds, or $2.3 million. In addition, <span style="color:#000000;">the Company is required to pay an additional exit fee of $1.0 million</span>. The Company recorded as a liability and debt discount the exit fee for the Amended Oxford Loan. At the date of the Amended Oxford Loan, the Company paid $0.9 million for the accrued portion of the Oxford Loan exit fee and the Tranche B additional exit fee. The loan discount balance at the time of the Amended Oxford Loan was $0.2 million, which is being amortized over the remaining term of the Amended Oxford Loan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also required to pay a 5.0% success fee <span style="color:#000000;">of the total amount drawn under the Amended Oxford Loan </span>within 30 days following the FDA&#8217;s approval of the Company&#8217;s first product, excluding lonafarnib in Progeria and Progeroid Laminopathies. This fee is enforceable within 10 years from the funding of Amended Tranche A. The Company determined that the success fee met the scope exemption from derivative accounting and should be accounted for under the guidance for contingencies. Accordingly, the Company will record a liability for the success fee upon receipt of approval from the FDA. <span style="color:#000000;">The Amended Oxford Loan includes contingent interest features and mandatory prepayment features upon an event of default that meet the definition of a derivative but were not bifurcated from the debt instrument as their fair value was deemed to be insignificant</span><span style="color:#548235;">. </span>In connection with the execution of the Oxford Loan, the Company agreed to certain customary representations and warranties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The refinancing of the term loan did not have a material impact on terms, conditions, representations, warranties, covenants or agreements set forth in the Oxford Loan. <span style="color:#000000;">The loan is secured by the perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company&#8217;s intellectual property. The loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency.</span> If the Company is unable to comply with these covenants or if the Company defaults on any portion of the outstanding borrowings, the lenders can also impose a 5.0% penalty, restrict access to additional borrowings under the loan and security agreement, and accelerate the maturity of the debt. <span style="color:#000000;">As of December 31, 2020, the Company was in compliance with all covenants.&#160;&#160;  </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is permitted to make voluntary prepayments of the Amended Oxford Loan with a prepayment fee, calculated as of the loan origination date, equal to (i) 2.0% of the loan prepaid during the first 12 months and (ii) 1.0% of the loan prepaid in months 13-24. The Company is required to make mandatory prepayments of the outstanding loan upon the acceleration by lender following the occurrence of an event of default, along with a payment of the final payment, the prepayment fee and any other obligations that are due and payable at the time of prepayment.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for the&#160;amortization of the&#160;debt discount utilizing the effective interest method. Long-term debt and unamortized discount balances are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Face value of long term debt</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exit fee</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount associated with exit fee, debt issuance costs and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; loan origination fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,083</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,887</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long term debt, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,194</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,390</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, future minimum payments of principal, exit fee and interest expense under the Oxford Loan were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,051</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,662</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,734</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,816</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,263</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: unamortized interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,986</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: exit fee</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,083</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Face value of term loan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,194</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 23, 2021, the Company entered into the fifth amendment to the Oxford Loan (Note 14). As the Company refinanced the short-term portion of the Oxford Loan on a long-term basis prior to the issuance of the financial statements, the current portion of long-term debt as of December 31, 2020 was reclassified as long-term at the balance sheet date.&#160;&#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685562189816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Company&#8217;s common stock have one vote for each share of common stock. Common stockholders are entitled to dividends when, as, and if declared by the Board of Directors, subject to the prior rights of the convertible preferred stockholders. As of December&#160;31, 2020, no dividends had been declared by the Board of Directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 17, 2019, the Company completed an underwritten public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters&#8217; option to purchase additional shares of common stock, at a price of $11.00 per share. The offering was made under the Company&#8217;s effective shelf registration statement and resulted in net proceeds to the Company of $53.2 million, after deducting underwriting discounts and commissions and offering expenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company filed a shelf registration statement on Form S-3 (File No. 333-235655) with the Securities and Exchange Commission, which permits the offering, issuance and sale of up to a maximum aggregate offering price of $150.0 million of the company&#8217;s common stock, preferred stock, debt securities and warrants. Up to a maximum of $50.0 million of the maximum aggregate offering price of $150.0 million may be issued and sold pursuant to an at-the-market (ATM) financing facility (2019 ATM Facility) under a sales agreement with Jefferies LLC (Jefferies). In August 2020, the Company entered into a new sales agreement with Jefferies for up to $50.0 million of the remaining amount on the shelf registration statement which may be sold pursuant to an ATM financing facility (2020 ATM Facility). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2020</span><span style="Background-color:#FFFFFF;">, </span><span style="Background-color:#FFFFFF;">the Company</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">has </span><span style="Background-color:#FFFFFF;">completed</span><span style="Background-color:#FFFFFF;"> both</span><span style="Background-color:#FFFFFF;"> the 2019 ATM Facility and the</span><span style="Background-color:#FFFFFF;"> 2020 ATM Facility</span><span style="Background-color:#FFFFFF;"> for a total of </span><span style="Background-color:#FFFFFF;">9,267,760</span><span style="Background-color:#FFFFFF;"> shares resulting in $</span>97.3<span style="Background-color:#FFFFFF;"> million in net proceeds, after deducting commissions</span><span style="Background-color:#FFFFFF;">.</span><span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2020, the Company filed a new shelf registration statement on Form S-3 (File No. 333-251497) with the Securities and Exchange Commission, which permits the offering, issuance and sale by the Company up to a maximum aggregate offering price of $200.0 million </span><span style="color:#000000;">of our common stock, preferred stock, debt securities and warrants. Up to a maximum of $50.0 million of the maximum aggregate offering price of $200.0 million may be issued and sold pursuant to a new ATM financing facility under a sales agreement with Jefferies.</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved shares of common stock for issuance as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,697,075</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options available for future grants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,021,109</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">823,598</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,718,184</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,591,215</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559480296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Equity Incentive Plans</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restated 2013 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Company&#8217;s Board of Directors adopted and in August 2016 the Company&#8217;s stockholders approved the Amended and Restated 2013 Equity Incentive Plan (the Restated 2013&#160;Plan). Under the terms of the Restated 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. <span style="Background-color:#FFFFFF;color:#000000;">Under the terms of the </span>Restated 2013&#160;<span style="Background-color:#FFFFFF;color:#000000;">Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and non-statutory stock options may not be less than 110% of fair market value, as determined by the Board of Directors. The terms of options granted under the Rested 2013 Plan may not exceed ten years. The vesting schedule of newly issued option grants is generally four years.</span> As of December 31, 2020, the Company is authorized to issue up to 4,705,442 shares under the Restated 2013&#160;Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under both the Company&#8217;s stock-based compensation plans during the year ended December 31, 2020 (in thousands, except share and per share data):</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per<span style="font-family:Calibri;">&#160;</span>Option</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">823,598</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000616">7.94</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,218</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional options authorized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,226,169</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,149,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,149,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.43</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or cancelled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,592</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(158,592</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,021,109</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,697,075</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.81</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000617">7.55</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,048</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable as of December</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,041,834</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000618">6.71</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,125</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock of $12.29 as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options exercised in 2020, 2019 and 2018 was $0.3 million, $0.6 million and $0.2 million, respectively.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020, 2019 and 2018, the<span style="Background-color:#FFFFFF;color:#000000;"> weighted-average grant date fair value of options granted was $4.78, $8.98 and $7.50 per share, respectively. </span>The total grant date fair value of options that vested during the years ended December&#160;31, 2020, 2019 and 2018 was $5.6 million, $5.7 million and $4.7 million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records stock-based compensation on stock options by estimating the fair value of stock-based awards using the Black-Scholes option pricing model and amortizing the fair value of the stock-based awards granted over the applicable vesting period of the awards on a straight-line basis. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of stock options was estimated using the following weighted-average assumptions:&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000632">5.00 - 6.08</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000633">5.27 - 6.08</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000634">5.27 - 6.08</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000638">9.67 - 9.84</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000642">73.00%&#160;&#160;- 77.00%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000643">73.14%&#160;&#160;- 83.19%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">84.00%&#160;&#160;- 95.00%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000648">0.39% - 1.37%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000649">1.42% - 2.57%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000650">1.67% - 2.68%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term<span style="font-style:normal;">: The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term for employee options). The Company uses the contractual term to determine the non-employee award fair value at the grant date. </span><span style="color:#000000;font-style:normal;">The contractual term of options granted under the Restated 2013 Plan is ten years.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Volatility<span style="font-style:normal;">: Since the Company does not have a long trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, or stage in the life cycle. Beginning in the third quarter of 2019, as the Company had been publicly traded for four and a half years, the Company began to layer in its historical volatility in the calculation of expected volatility.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate<span style="font-style:normal;">: The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend<span style="font-style:normal;">: The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2013 Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2013, the Company&#8217;s board of directors adopted and in 2016, upon the merger with Celladon, the Company amended and approved the 2013 Employee Stock Purchase Plan (2013 ESPP). The 2013 ESPP is intended to qualify as an employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code and is administered by the Company&#8217;s board of directors.</p><p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock initially reserved for issuance under the 2013 ESPP was 100,000 shares with an automatic annual increase to the shares issuable under the 2013 ESPP to the lower of (i) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, and (ii) 165,000 shares of common stock, unless a lower number determined by the board of directors. As of December 31, 2020, a total of 618,831 shares are reserved for issuance and 543,791 shares available for future issuance under the 2013 ESPP. During the years ended December 31, 2020 and December 31, 2019, employees purchased 25,645 shares for $0.2 million and 15,701 shares for $0.1 million, respectively, under the 2013 ESPP.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2020,&#160;the Company revised its non-employee director compensation policy to approve the granting of restricted stock units (RSUs) in accordance with the Restated 2013 Equity Incentive Plan (the Restated 2013 Plan). Each eligible director who has served for less than six months during the prior calendar year and continues to serve as a non-employee member of the board is granted RSUs, which are pro-rated for the period served during the prior calendar year.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RSUs granted to non-employee directors will vest on the one-year anniversary of the grant date, subject to the eligible director&#8217;s continuous services through the vesting date, and will vest in full upon a change in control, as defined under the Restated 2013 Plan. RSUs granted to employees during the year ended December 31, 2020, commence vesting on the one-year anniversary through the two-year anniversary of the grant date. The fair value of all RSUs is measured at the grant date based on the closing market price of the Company&#8217;s common stock and is recognized as stock-based compensation expense on a straight-line basis over the vesting period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company granted 37,500 RSUs with a weighted-average grant date fair value of&#160;$6.95 per share. The Company recognized $0.2 million in stock-based compensation expense for the year ended December 31, 2020, which is included in general and administrative expenses. As of December 31, 2020, the total unrecognized compensation expense related to unvested RSUs was $0.1 million, which the Company expects to recognize over an estimated weighted-average period of 0.4 years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,494</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,550</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,479</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,507</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,973</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,679</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the total unrecognized compensation expense related to unvested options was $10.2  million, which the Company expects to recognize over an estimated weighted average period of 2.5 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685562373928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No provision for income taxes was recorded for the years ended December&#160;31, 2020, 2019 and 2018. The Company has incurred net operating losses (NOL) for all the periods presented. The Company has not reflected any benefit of such NOL carryforwards in the accompanying consolidated financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.42</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.02</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.43</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.27</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.52</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.89</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.01</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision (benefit) for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the deferred tax assets and liabilities are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,523</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,761</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,157</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,067</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,602</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,452</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,912</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">319</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,994</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,747</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,793</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the Company&#8217;s lack of earnings history, the deferred tax assets have been fully offset by a valuation allowance as of December 31, 2020 and 2019. The net change in the valuation allowance for the years ended December&#160;31, 2020 and 2019 increased by $7.0 million and $7.6 million, respectively.  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had approximately $251.7 million and $25.2 million, respectively, of federal and state NOL carryforwards available to reduce future taxable income that will begin to expire in 2030 and 2028, respectively, for federal and state tax purposes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company also had research and development tax credit carryforwards of&#160;$1.8 million for state purposes, available to offset future taxable income tax. If not utilized, the state credits can be carried forward indefinitely. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if the Company has experienced an ownership change under Section 382 of the Internal Revenue Code (the Code) of 1986, as amended. <span style="letter-spacing:-0.1pt;">The Company&#8217;s merger with Celladon resulted in such an ownership change and, accordingly, Celladon&#8217;s NOL carryforwards and certain other tax attributes will be subject to further limitations on their use. The Company assessed whether it had an ownership change, as defined by Section&#160;382 of the Code from its formation through December 31, 2020. Based upon this assessment, the Company experienced ownership changes on April 20, 2016, October 18, 2018 and December 31, 2020. Due to these ownership changes, reductions were made to the Company&#8217;s NOL and tax credit carryforwards under these rules</span>. <span style="letter-spacing:-0.1pt;">Additional ownership changes in the future could result in additional limitations on the Company&#8217;s NOL and tax credit carryforwards.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon effective settlement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Uncertain Tax Positions</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s unrecognized tax benefits for the years ended December&#160;31, 2020, 2019 and 2018 is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,634</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,218</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to prior</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,443</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,477</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions based on tax positions related to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; prior year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,907</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions based on tax positions related to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">451</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,634</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the $0.5 million of unrecognized tax benefits is recognized, there would not be an effect on the effective tax rate. The Company does not expect the unrecognized tax benefits to change significantly over the next 12 months. As of December 31, 2020, the unrecognized tax benefits for uncertain tax positions were offset against deferred tax assets and would not affect the income tax rate if recognized due to the Company being in a full valuation allowance position.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to account for interest and penalties in tax expense on the consolidated statements of operations. The Company files income tax returns in the U.S. federal and state jurisdictions. All periods since inception are subject to examination by U.S. federal and state jurisdictions. There were no such interest or penalties during the years ended December 31, 2020, 2019 and 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559296120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Matters</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Legal Matters</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time in the ordinary course of business the Company becomes involved in various lawsuits, claims and proceedings, including those pertaining to the defense and enforcement of the Company&#8217;s patent or other intellectual property rights and contractual rights. These proceedings are costly and time consuming. Additionally, successful challenges to the Company&#8217;s patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and may allow third parties to use the Company&#8217;s proprietary technologies without a license from the Company or its collaborators. The outcome of such matters, which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559510552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, the Company entered into a non-cancelable operating facility lease agreement for 8,029 square feet of office space located at 2155 Park Blvd. in Palo Alto, California 94306. The lease commenced on March 1, 2018 and expires in February 2023. The lease has a <span style="-sec-ix-hidden:F_000754">three-year</span> renewal option prior to expiration; however, the Company is not reasonably assured to exercise this option. The lease includes rent escalation clauses throughout the lease term. In October 2017, the Company provided a security deposit of $0.3 million.&#160;The Company also has additional operating leases that are included in its lease accounting but are not considered significant for disclosure.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Undiscounted lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.1%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,449</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,320</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(582</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense recognized for the Company&#8217;s operating leases was $0.6 million, $0.6 million, and $0.8 million for the years ended December 31, 2020, 2019, and 2018, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for the operating leases were <span>$0.1</span> million for each of the years ended December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The operating cash outflows for the operating lease liabilities were $0.7 million and $0.6 million for the year ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the weighted-average remaining lease term and weighted-average discount rate were 2.1 years and 9.15%, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is obligated to make future payments to third parties under asset purchase and license agreements, including royalties and payments that become due and payable on the achievement of certain development and commercialization milestones. However, the amount and timing of these payments are not known. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing Service Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2020, the Company entered into a Master Manufacturing Services Agreement (MMSA) and Product Agreement with Patheon, Inc. (Patheon) for the manufacturing of lonafarnib capsules and packaging of bottles for commercial sale. Under the terms of the agreements, the Company is required to provide Patheon with annual volume forecasts of capsules and Patheon will manufacture 80% of such annual forecasts. If the Company order less than 80% of such annual forecasts, it is required to pay 70% of purchase price for the shortfall. The initial terms of the MMSA and Product Agreement end on December 31, 2025 with automatic renewal for successive <span style="-sec-ix-hidden:F_000778">two-year</span> terms, unless earlier terminated pursuant to the terms of each agreement, or upon either party&#8217;s notice of termination to the other.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685562585576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Related Party Transactions</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As disclosed in Note 6, the Company entered into license agreements with EGI, which is owned by the founder of the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559510552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Subsequent Events</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021, the Company entered into the fifth amendment to the Oxford Loan. The amendment extended the interest only period by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17 months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> until September 1, 2022, follow</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19 equal monthly</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payments of principal and interest. Upon the receipt of Amended Tranche B, the interest only period for borrowed funds will be extended by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">six months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> until March 1, 2023, follow</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13 equal monthly</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payments of principal plus accrued interest. In addition, the Company paid the amendment fees of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million to the lenders on the effective date of the fifth amendment.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685637787176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation and Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, (U.S. GAAP) and following the requirements of the Securities and Exchange Commission (the SEC) for annual reporting. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period. On an ongoing basis, the Company evaluates its estimates, including those related to clinical trial accrued liabilities, stock-based compensation</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operating lease liabilities</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and income taxes.&#160;The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consists of cash, cash equivalents and investments. The Company&#8217;s cash is held by a financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution.</p><p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each product candidate, the Company relies on one supply chain for each of the four product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents include all cash balances and highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consists primarily of amounts invested in money market funds held at financial institutions and corporate debt securities. The recorded carrying amount of cash equivalents approximates their fair value.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Debt Securities</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Debt Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. All short-term securities are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The cost of available-for-sale securities sold is based on the specific-identification method<span style="Background-color:#FFFFFF;color:#000000;">. </span>Realized gains and losses on the sale of debt securities are determined using the specific-identification method and recorded in other expense, net on the accompanying consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. Depreciation begins at the time the asset is placed into service. Maintenance and repairs are charged to operations as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The useful lives of the property and equipment are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through December&#160;31, 2020, the Company has not impaired any long-lived assets.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock', window );">Accrued Research and Development Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the consolidated balance sheets and within research and development expenses in the consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) Topic 842, &#8220;Leases&#8221; (&#8220;ASC 842&#8221;) on January 1, 2019. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception. Material leases with a term greater than one year are recognized in right-of-use (&#8220;ROU&#8221;) assets and current and noncurrent lease liabilities, as applicable, in the Company&#8217;s consolidated balance sheets.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of its right-of-use assets (ROU assets) and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease ROU assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the consolidated statements of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in general and administrative expenses when incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Deferred Financing Costs</a></td>
<td class="text">
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Financing Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing costs incurred with securing a term debt are recorded in the Company&#8217;s consolidated balance sheets as an offset to the term debt and amortized to interest expense in the Company&#8217;s consolidated statements of operations over the contractual life of the loan using the effective interest method. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist of payroll expenses, stock-based compensation expense, lab supplies and allocated facility costs, as well as fees paid to third parties that conduct certain research and development and manufacturing activities on the Company&#8217;s behalf. Amounts incurred in connection with license and asset purchase agreements are also included in research and development expenses. Manufacturing costs related to products undergoing regulatory approval are expensed as research and development costs until receipt of such approval. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based awards to employees and directors, including stock options, are recorded at fair value as of the grant date using the Black-Scholes option pricing model and recognized as expense on a straight line-basis over the </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employee&#8217;s or director&#8217;s requisite service period (generally the vesting period). </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-based awards to non-employees are recorded at their fair value as of the grant date</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, using the Black-Scholes option pricing model and recognized as expense over the period in which the related services are received. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for Black-Scholes option pricing model inputs</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accounts for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forfeitures </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-based awards </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when they occur. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal Revenue Code Section 382 limits the use of net operating loss and tax credit carryforwards in certain situations where changes occur in the stock ownership of a company. In the event that the Company experiences a change of ownership, utilization of the net operating loss and tax credit carryforwards may be restricted.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss represents all changes in stockholders' equity except those resulting from and distributions to stockholders. The Company&#8217;s unrealized gains and losses on debt securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,697,075</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996,211</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units (unvested)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,734,575</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996,211</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820)</span>. The standard eliminates, modifies and adds disclosure requirements </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for fair value measurements. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance on January 1, 2020. </span><span style="color:#000000;">The adoption did not have a material impact on the Company&#8217;s</span><span style="color:#000000;"> </span><span style="color:#000000;">consolidated financial statements.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2018, the FASB issued&#160;ASU No.&#160;2018-15,&#160;<span style="font-style:italic;">Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</span> <span style="font-style:italic;">(Subtopic 350-40)</span>. The standard&#160;adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The pronouncement is effective for fiscal years beginning after December&#160;15, 2019, and interim periods within those fiscal years, with early adoption permitted. The amendments in ASU No, 2018-15&#160;should be applied either using a retrospective or prospective approach. <span style="color:#000000;">The Company adopted&#160;this guidance&#160;on January 1, 2020 using the prospective approach. The adoption did not have a material impact on the Company&#8217;s consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Pronouncements Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13,&#160;<span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326)</span>. The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,</span> which clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, <span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), </span>which provides an option <span style="color:#000000;">to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost</span>. <span style="color:#000000;">In November 2019, the FASB issued ASU No. 2019-10, </span><span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)</span>, which<span style="font-style:italic;"> </span><span style="color:#000000;">defers the effective date for ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of the guidance on its consolidated financial statements. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued ASU No. 2020-04, <span style="font-style:italic;">Reference Rate Reform (Topic 848)</span>. The standard provides optional expedients for facilitating the effects of the reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for contract modifications permitted for contracts that are modified because of the reference rate reform and meet the scope guidance. The modifications of contracts within the scope of ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as separate contracts. <span style="color:#000000;">The pronouncement is effective for all entities as of March 12, 2020 through December 31, 2022. The Company plans to adopt upon the occurrence of such contract modification, but not later than December 31, 2022. The Company engaged in early-stage discussions with its lender and will assess the impact of the adoption once the contract is modified.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685562789768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The useful lives of the property and equipment are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,697,075</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996,211</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units (unvested)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.32%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,734,575</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,996,211</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated useful life of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685637659368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,941</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,941</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,980</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,980</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury bills</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,995</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,995</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,060</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,060</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,976</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,822</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,457</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,457</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,621</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,475</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the estimated value of the Company&#8217;s cash equivalents and debt securities and the gross unrealized holding gains and losses (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated<span style="font-family:Calibri;">&#160;</span>Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,846</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,941</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,980</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,980</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. treasury bills</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,992</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,995</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,060</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,060</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,984</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,976</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated<span style="font-family:Calibri;">&#160;</span>Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,854</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt securities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,633</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.18%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,457</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,457</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,489</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,579</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,621</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685637955640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,051</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">804</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(342</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(214</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consist of the following (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid contract manufacturing costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,126</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,374</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,177</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,627</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,215</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,968</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,966</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,390</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Components of Accrued Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract research costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,062</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract manufacturing costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,510</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation and related benefits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,169</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,707</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">496</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,405</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,001</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685560054536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long-Term Debt and Unamortized Discount Balances</a></td>
<td class="text">Long-term debt and unamortized discount balances are as follows (in thousands):
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Face value of long term debt</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exit fee</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount associated with exit fee, debt issuance costs and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; loan origination fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,083</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,887</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long term debt, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,194</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,390</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Payments of Principal, Exit Fee and Interest Expense under Oxford Term Loan</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, future minimum payments of principal, exit fee and interest expense under the Oxford Loan were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,051</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,662</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,734</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,816</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,263</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: unamortized interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,986</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: exit fee</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,083</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Face value of term loan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,194</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559601880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CommonStockReservedForFutureIssuancesTableTextBlock', window );">Summary of Common Stock Reserved for Issuance</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved shares of common stock for issuance as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,697,075</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options available for future grants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,021,109</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">823,598</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,718,184</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,591,215</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CommonStockReservedForFutureIssuancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gross number of shares which are to be issued during the future period as a result of any equity-based compensation plan or conversion of outstanding convertible instruments. Shares reserved for issuance could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and upon the conversion of outstanding convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CommonStockReservedForFutureIssuancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559600632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under both the Company&#8217;s stock-based compensation plans during the year ended December 31, 2020 (in thousands, except share and per share data):</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per<span style="font-family:Calibri;">&#160;</span>Option</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">823,598</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,767,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.14</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000616">7.94</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,218</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional options authorized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,226,169</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,149,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,149,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.43</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited or cancelled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,592</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(158,592</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.56%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,021,109</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,697,075</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.81</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000617">7.55</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,048</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.78%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable as of December</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,041,834</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000618">6.71</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,125</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Non-cash Stock Based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,494</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,550</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,479</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,507</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,973</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,679</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eigr_EmployeesAndNonEmployeesStockOptionMember', window );">Employees and Non Employees Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted</a></td>
<td class="text">The fair value of stock options was estimated using the following weighted-average assumptions:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000632">5.00 - 6.08</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000633">5.27 - 6.08</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000634">5.27 - 6.08</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000638">9.67 - 9.84</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000642">73.00%&#160;&#160;- 77.00%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000643">73.14%&#160;&#160;- 83.19%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">84.00%&#160;&#160;- 95.00%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000648">0.39% - 1.37%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000649">1.42% - 2.57%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000650">1.67% - 2.68%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.98%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eigr_EmployeesAndNonEmployeesStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eigr_EmployeesAndNonEmployeesStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559574888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Effective Income Tax Rate</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.42</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.02</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.43</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.27</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.52</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.14%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.89</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.01</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.14%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision (benefit) for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the deferred tax assets and liabilities are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,523</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,761</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,068</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,157</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,067</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,602</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,452</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,912</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">606</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">319</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,994</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,747</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,793</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.74%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.74%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s unrecognized tax benefits for the years ended December&#160;31, 2020, 2019 and 2018 is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,634</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,218</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to prior</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,443</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,477</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions based on tax positions related to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; prior year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,907</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,800</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions based on tax positions related to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.16%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">451</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,634</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685562808008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Operating Leases Liabilities and Future Minimum Lease Payments</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2020 were as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Undiscounted lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.1%; border-bottom:solid 0.75pt #000000;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">673</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,449</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,320</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(582</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">738</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685562738120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DescriptionOfBusinessAbstract', window );"><strong>Description Of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity incorporation, date of incorporation</a></td>
<td class="text">Nov.  06,  2008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Investments</a></td>
<td class="nump">$ 128,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">28,864<span></span>
</td>
<td class="nump">$ 39,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities, available-for-sale</a></td>
<td class="nump">99,976<span></span>
</td>
<td class="nump">55,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (306,500)<span></span>
</td>
<td class="num">$ (241,449)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DescriptionOfBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DescriptionOfBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685558065896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>SupplyChain </div>
<div>ProductCandidate</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Interest charged in relation to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Penalties charged in relation to unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskSupplier', window );">Concentration risk, supplier</a></td>
<td class="text">For each product candidate, the Company relies on one supply chain for each of the four product candidates. If any of the single source suppliers in any of the supply chains fail to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect its operating results.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_NumberOfSupplyChainsForEachProductCandidate', window );">Number of supply chains for each product candidate | SupplyChain</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_NumberOfProductCandidates', window );">Number of product candidates. | ProductCandidate</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of product candidates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_NumberOfSupplyChainsForEachProductCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of supply chains for each product candidate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_NumberOfSupplyChainsForEachProductCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskSupplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of risks that arise due to the volume of business transacted with a particular supplier or reliance placed on that supplier. At a minimum, the description informs financial statement users of the general nature of the risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99380358&amp;loc=d3e7102-108593<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskSupplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685558014888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685671983976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">3,734,575<span></span>
</td>
<td class="nump">2,767,617<span></span>
</td>
<td class="nump">1,996,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eigr_OptionsGrantedToEmployeesAndNonEmployeesMember', window );">Options Granted to Employees and Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">3,697,075<span></span>
</td>
<td class="nump">2,767,617<span></span>
</td>
<td class="nump">1,996,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units, Unvested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eigr_OptionsGrantedToEmployeesAndNonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eigr_OptionsGrantedToEmployeesAndNonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685560644472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 120,822,000<span></span>
</td>
<td class="nump">$ 91,475,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Other-than-temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity', window );">Available- for-sale of debt securities contractual maturity</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_FairValueTransfersBetweenLevelsTransfersAmount', window );">Transfers in or out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale of debt securities contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_FairValueTransfersBetweenLevelsTransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value transfers between levels transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_FairValueTransfersBetweenLevelsTransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685560320744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">$ 120,822,000<span></span>
</td>
<td class="nump">$ 91,475,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US Treasury Bill Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">39,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">33,941,000<span></span>
</td>
<td class="nump">16,644,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember', window );">US Government Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">4,060,000<span></span>
</td>
<td class="nump">31,520,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">20,846,000<span></span>
</td>
<td class="nump">35,854,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">21,980,000<span></span>
</td>
<td class="nump">7,457,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">20,846,000<span></span>
</td>
<td class="nump">35,854,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">20,846,000<span></span>
</td>
<td class="nump">35,854,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">99,976,000<span></span>
</td>
<td class="nump">55,621,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | US Treasury Bill Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">39,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">33,941,000<span></span>
</td>
<td class="nump">16,644,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | US Government Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">4,060,000<span></span>
</td>
<td class="nump">31,520,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">21,980,000<span></span>
</td>
<td class="nump">7,457,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685561041160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CashEquivalentsAmortizedCost', window );">Cash equivalents, Amortized cost</a></td>
<td class="nump">$ 20,846<span></span>
</td>
<td class="nump">$ 35,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">20,846<span></span>
</td>
<td class="nump">35,854<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized cost</a></td>
<td class="nump">99,984<span></span>
</td>
<td class="nump">55,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized gain</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, Unrealized loss</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">99,976<span></span>
</td>
<td class="nump">55,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US Treasury Bill Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CashEquivalentsAmortizedCost', window );">Cash equivalents, Amortized cost</a></td>
<td class="nump">39,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">39,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized cost</a></td>
<td class="nump">39,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized gain</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">39,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized cost</a></td>
<td class="nump">33,952<span></span>
</td>
<td class="nump">16,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, Unrealized loss</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">33,941<span></span>
</td>
<td class="nump">16,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember', window );">US Government Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized cost</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">31,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">31,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CashEquivalentsAmortizedCost', window );">Cash equivalents, Amortized cost</a></td>
<td class="nump">20,846<span></span>
</td>
<td class="nump">35,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">20,846<span></span>
</td>
<td class="nump">35,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems', window );"><strong>Cash Equivalents and Investment Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, Amortized cost</a></td>
<td class="nump">21,980<span></span>
</td>
<td class="nump">7,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, Estimated Fair Value</a></td>
<td class="nump">$ 21,980<span></span>
</td>
<td class="nump">$ 7,457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CashEquivalentsAndInvestmentSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and investment securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CashEquivalentsAndInvestmentSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=eigr_USGovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685638615208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,051<span></span>
</td>
<td class="nump">$ 804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="num">(342)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eigr_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685557750392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685557828216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_PrepaidContractManufacturingCosts', window );">Prepaid contract manufacturing costs</a></td>
<td class="nump">$ 6,126<span></span>
</td>
<td class="nump">$ 1,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_PrepaidResearchCosts', window );">Prepaid research costs</a></td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 8,966<span></span>
</td>
<td class="nump">$ 5,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OtherPrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other prepaid expense and other assets current classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OtherPrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PrepaidContractManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid contract manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PrepaidContractManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PrepaidResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for research that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PrepaidResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685558115992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AccruedContractedResearchCostsCurrent', window );">Contract research costs</a></td>
<td class="nump">$ 6,062<span></span>
</td>
<td class="nump">$ 5,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ContractManufacturingCostsCurrent', window );">Contract manufacturing costs</a></td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">2,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">3,169<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 11,405<span></span>
</td>
<td class="nump">$ 10,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AccruedContractedResearchCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued contracted research costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AccruedContractedResearchCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ContractManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract manufacturing costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ContractManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685555161000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration, and Product Development Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2018</div></th>
<th class="th"><div>Apr. 20, 2016</div></th>
<th class="th"><div>Mar. 15, 2018</div></th>
<th class="th"><div>May 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2010</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,590<span></span>
</td>
<td class="nump">$ 51,791<span></span>
</td>
<td class="nump">$ 37,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Aggregate fair value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,878,486<span></span>
</td>
<td class="nump">24,523,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,267,760<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="nump">8,510,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_UPennCHOPAgreementMember', window );">UPenn/CHOP Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_NonRefundableIssueFee', window );">Non-Refundable Issue Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_MilestoneObligations', window );">Milestone payment obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_UPennCHOPAgreementMember', window );">UPenn/CHOP Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_LicenseMaintenanceFee', window );">License maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_UPennCHOPAgreementMember', window );">UPenn/CHOP Agreement [Member] | Commercial Sales [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_MilestoneObligations', window );">Milestone payment obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ProductDevelopmentFees', window );">Product development fees</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ExpertConsultantFeesAndPassThroughCosts', window );">Expert consultant fees and pass through costs</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_IncentiveBasedRegulatoryMilestoneFees', window );">Incentive-based regulatory milestone fees</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of common stock issued subject to quarterly vesting requirements</a></td>
<td class="nump">115,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ProductAgreementTerminationNoticePeriod', window );">Product agreement termination notice period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognised compensation expense related to unvested restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_PRFCollaborationAgreementMember', window );">Progeria Research Foundation (PRF) Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CollaborationAgreementInitialTerm', window );">Collaboration agreement initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_CollaborativeArrangementRenewalTerm', window );">Collaboration agreement subsequent renewal terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_BmsTransactionMember', window );">BMS Transaction [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_UpfrontCashPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_BmsTransactionMember', window );">BMS Transaction [Member] | Common Stock [Member] | BMS Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Aggregate fair value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_BmsTransactionMember', window );">BMS Transaction [Member] | Commercial Sales [Member] | Maximum [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_MilestoneObligations', window );">Milestone payment obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_BmsTransactionMember', window );">BMS Transaction [Member] | Development and Regulatory Milestones [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_MilestoneObligations', window );">Milestone payment obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_BmsTransactionMember', window );">BMS Transaction [Member] | Development Phase 2 [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_MilestoneObligations', window );">Milestone payment obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_BmsTransactionMember', window );">BMS Transaction [Member] | Development Phase 3 [Member] | Maximum [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_IncreaseInMilestoneObligations', window );">Increase in milestone payment obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_MerckTransactionMember', window );">Merck Transaction [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Aggregate fair value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_RoyaltiesExpirationDescription', window );">Royalties expiration description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company is obligated to pay Merck up to an aggregate of $27.0 million in development milestones and will be required to pay tiered royalties based on aggregate annual net sales of all licensed products ranging from mid-single to low double-digit royalties on net sales.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_MerckTransactionMember', window );">Merck Transaction [Member] | Development [Member] | Maximum [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DevelopmentMilestoneObligations', window );">Development milestone payment obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CollaborationAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement initial term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CollaborationAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_CollaborativeArrangementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the renewal term of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_CollaborativeArrangementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DevelopmentMilestoneObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestone obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DevelopmentMilestoneObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ExpertConsultantFeesAndPassThroughCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expert consultant fees and pass through costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ExpertConsultantFeesAndPassThroughCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncentiveBasedRegulatoryMilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive-based regulatory milestone fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncentiveBasedRegulatoryMilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncreaseInMilestoneObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in milestone obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncreaseInMilestoneObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License maintenance fee annual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_MilestoneObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_MilestoneObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_NonRefundableIssueFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable issue fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_NonRefundableIssueFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProductAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProductAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProductDevelopmentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product development fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProductDevelopmentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_RoyaltiesExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties expiration description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_RoyaltiesExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_UpfrontCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_UpfrontCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_UPennCHOPAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_UPennCHOPAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=eigr_CommercialSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=eigr_CommercialSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_ProductDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_ProductDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_PRFCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_PRFCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_BmsTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_BmsTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eigr_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eigr_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentPhaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentPhaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentPhaseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=eigr_DevelopmentPhaseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_MerckTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_MerckTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685561536152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Purchase Agreements and Related License Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 20, 2020</div></th>
<th class="th"><div>Mar. 22, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to the time-vested/milestone vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,973,000<span></span>
</td>
<td class="nump">$ 5,679,000<span></span>
</td>
<td class="nump">$ 5,007,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=eigr_MilestoneVestedOptionsMember', window );">Milestone Vested Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to the time-vested/milestone vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement [Member] | EIG Transaction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_UpfrontCashPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseDescription', window );">Asset purchase description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Within the first ten years after commercialization, the Company may make a one-time payment of $0.5 million for each contract for the three types of product related to such intellectual property that would reduce the payment term for the three products to the tenth anniversary of the first commercial sale.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement', window );">One-time payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement [Member] | EIG Transaction [Member] | Farnesyl Transferase Inhibitors and Related Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_RoyaltiesExpirationDescription', window );">Royalties expiration description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The obligation to pay royalties expires on a country-by-country and product-by-product basis on the later of either when the product is no longer sold in any country or the earliest of the tenth anniversary of the first commercial sale of the product.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember', window );">Avexitide Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued for purchased assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_OptionsToPurchaseOfCommonStock', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,544<span></span>
</td>
<td class="nump">46,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options to purchase of common stock exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.25<span></span>
</td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase', window );">Options to purchase common stock vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_VestingOfOptionsToPurchaseCommonStock', window );">Vesting of options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to the time-vested/milestone vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_LicenseAgreementMilestonePaymentsPaid', window );">License agreement milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember', window );">Avexitide Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_LicenseAgreementPotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AbbvieAssetPurchaseAgreementMember', window );">AbbVie Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_PaymentForAssetPurchaseAgreement', window );">Payment for asset purchase agreement</a></td>
<td class="nump">$ 95,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AbbvieAssetPurchaseAgreementMember', window );">AbbVie Asset Purchase Agreement [Member] | Progeria Research Foundation (PRF) Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems', window );"><strong>Asset Purchase Agreement And Related License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sale</a></td>
<td class="nump">$ 47,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset purchase agreement and related license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AssetPurchaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset purchase description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AssetPurchaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LicenseAgreementMilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payments paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LicenseAgreementMilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LicenseAgreementPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LicenseAgreementPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One time payment to be made on asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OptionsToPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OptionsToPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PaymentForAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PaymentForAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_RoyaltiesExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties expiration description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_RoyaltiesExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_UpfrontCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_UpfrontCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_VestingOfOptionsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting of options to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_VestingOfOptionsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting period of options issued for common stock purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=eigr_MilestoneVestedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=eigr_MilestoneVestedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eigr_EIGTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eigr_EIGTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=eigr_ProductOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=eigr_ProductOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AvexitidePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AbbvieAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eigr_AbbvieAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_PRFCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_PRFCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685554217496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2021</div></th>
<th class="th"><div>Mar. 05, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 03, 2018</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Loan final repayment exit fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,277)<span></span>
</td>
<td class="num">(3,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentCovenantNoncompliancePenalty', window );">Loan agreement, covenant noncompliance penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Loan agreement, covenant description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Loan agreement, covenant compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">and accelerate the maturity of the debt.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember', window );">Oxford Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan agreement, aggregate borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Loan agreement, floating rate terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.41% or 6.95%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod', window );">Principal and interest payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentExitFeePayablePercentage', window );">Percentage of exit fee on principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Loan final repayment exit fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Loan origination fees and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_RepaymentsOfLoanAgreementExitFee', window );">Repayments of loan agreement exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember', window );">Oxford Loan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Loan agreement, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember', window );">Oxford Loan [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Loan agreement, percentage to be added to the interest rate under condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember', window );">Oxford Loan [Member] | Tranche A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember', window );">Oxford Loan [Member] | Tranche B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Loan final repayment exit fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember', window );">Oxford Loan [Member] | Amended Tranche A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Loan final repayment exit fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanAmendmentMember', window );">Amendment [Member] | Tranche B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanAmendmentMember', window );">Amendment [Member] | Tranche C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan agreement, aggregate borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Loan agreement, floating rate terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.64% or 9.15%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod', window );">Principal and interest payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentExitFeePayablePercentage', window );">Percentage of exit fee on principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Loan final repayment exit fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Loan origination fees and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Loan outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings from loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedAdditionalExitFees', window );">Loan final repayment additional exit fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_PrepaymentOfLoanFeeDescription', window );">Prepayment of loan fee, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">calculated as of the loan origination date, equal to (i) 2.0% of the loan prepaid during the first 12 months and (ii) 1.0% of the loan prepaid in months 13-24.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan [Member] | Loan Prepaid During First 12 Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentPrepaymentFeePercentage', window );">Debt instrument prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan [Member] | Loan Prepaid During 13 to 24 Months [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentPrepaymentFeePercentage', window );">Debt instrument prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan [Member] | Food and Drug Administration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentSuccessFeesPayablePercentage', window );">Percentage of success fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval', window );">Success fees payable maximum period after approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Loan agreement, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan [Member] | LIBOR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Loan agreement, percentage to be added to the interest rate under condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan [Member] | Amended Tranche A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan agreement, aggregate borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan [Member] | Amended Tranche A [Member] | Food and Drug Administration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding', window );">Fee payable maximum period from funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember', window );">Amended Oxford Loan [Member] | Amended Tranche B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod', window );">Principal and interest payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Loan agreement, remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod', window );">Extended term of interest only payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanFifthAmendmentMember', window );">Fifth Amended Oxford Loan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod', window );">Principal and interest payment period</a></td>
<td class="text">19 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentInterestPaymentPeriod', window );">Interest payment period</a></td>
<td class="text">17 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanFifthAmendmentMember', window );">Fifth Amended Oxford Loan [Member] | Tranche B [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod', window );">Principal and interest payment period</a></td>
<td class="text">13 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentInterestPaymentPeriod', window );">Interest payment period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentCovenantNoncompliancePenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument covenant noncompliance penalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentCovenantNoncompliancePenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentExitFeePayablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit fee payable percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentExitFeePayablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument extended interest only payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument fee enforceable maximum period from funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentInterestPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentInterestPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment fee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument principal and interest payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument success fees payable maximum period after approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentSuccessFeesPayablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument success fees payable percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentSuccessFeesPayablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentUnamortizedAdditionalExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized additional exit fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentUnamortizedAdditionalExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentUnamortizedExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized exit fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentUnamortizedExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PrepaymentOfLoanFeeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment of loan fee description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PrepaymentOfLoanFeeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_RepaymentsOfLoanAgreementExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of loan agreement exit fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_RepaymentsOfLoanAgreementExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_TrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_TrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_AmendedTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_AmendedTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_OxfordLoanAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_TrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_TrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_AmendedOxfordLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=eigr_LoanPrepaidDuringFirstTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=eigr_LoanPrepaidDuringFirstTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAgencyAxis=eigr_FoodAndDrugAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAgencyAxis=eigr_FoodAndDrugAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_AmendedTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_AmendedTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanFifthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_OxfordLoanFifthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685670996728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of long term debt</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Exit fee</a></td>
<td class="nump">3,277<span></span>
</td>
<td class="nump">3,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees</a></td>
<td class="num">(2,083)<span></span>
</td>
<td class="num">(2,887)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long term debt, net</a></td>
<td class="nump">$ 31,194<span></span>
</td>
<td class="nump">$ 30,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentUnamortizedExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized exit fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentUnamortizedExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685637691592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Future Minimum Payments of Principal, Exit Fee and Interest Expense under Oxford Term Loan (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Exit fee</a></td>
<td class="nump">$ 3,277<span></span>
</td>
<td class="nump">$ 3,277<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember', window );">Oxford Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Exit fee</a></td>
<td class="num">(1,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember', window );">Oxford Loan [Member] | Amended Tranche A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">10,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">11,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">10,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">5,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total future payments</a></td>
<td class="nump">38,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedInterest', window );">Less: unamortized interest</a></td>
<td class="num">(4,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentUnamortizedExitFees', window );">Exit fee</a></td>
<td class="num">(2,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of term loan</a></td>
<td class="nump">$ 31,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentUnamortizedExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized exit fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentUnamortizedExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentUnamortizedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentUnamortizedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_OxfordLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_AmendedTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_AmendedTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685555147864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Apr. 17, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DividendsDeclared', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount', window );">Equity, debt, warrants and units, maximum aggregate offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eigr_AtTheMarketOfferingMember', window );">At-The-Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,267,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount', window );">Equity, debt, warrants and units, maximum aggregate offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod', window );">Equity, debt, warrants and units, maximum issued and sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AmountOfCommonStockAvailableForSale', window );">Amount of common stock available for sale</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,267,760<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="nump">8,510,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eigr_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption', window );">Number of additional common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock, offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AmountOfCommonStockAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AmountOfCommonStockAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DividendsDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividends declared.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DividendsDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity, debt, warrants and units, aggregate offering amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum equity debt warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares issued to underwriters as purchase option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eigr_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eigr_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685560642856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Common Stock Reserved for Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_OptionsIssuedAndOutstanding', window );">Options issued and outstanding</a></td>
<td class="nump">3,697,075<span></span>
</td>
<td class="nump">2,767,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grants</a></td>
<td class="nump">1,021,109<span></span>
</td>
<td class="nump">823,598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">4,718,184<span></span>
</td>
<td class="nump">3,591,215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OptionsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OptionsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685560964264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ClosingPriceOfCommonStock', window );">Closing price of common stock</a></td>
<td class="nump">$ 12.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock Reserved for Issuance</a></td>
<td class="nump">4,718,184<span></span>
</td>
<td class="nump">3,591,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">1,226,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grants</a></td>
<td class="nump">1,021,109<span></span>
</td>
<td class="nump">823,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">1,149,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (in years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to the time-vested/milestone vested options</a></td>
<td class="nump">$ 5,973<span></span>
</td>
<td class="nump">$ 5,679<span></span>
</td>
<td class="nump">$ 5,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period expected to recognized compensation expense (in years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employees Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee option grants</a></td>
<td class="nump">$ 4.78<span></span>
</td>
<td class="nump">$ 8.98<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Grant date fair value of employee options vested</a></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units, Unvested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee option grants</a></td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition (in years)</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to the time-vested/milestone vested options</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period expected to recognized compensation expense (in years)</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember', window );">Restated 2013 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Issuance of common stock authorized</a></td>
<td class="nump">4,705,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember', window );">2013 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock Reserved for Issuance</a></td>
<td class="nump">618,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage increase in number of shares of common stock reserved for issuance</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grants</a></td>
<td class="nump">543,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase, Shares</a></td>
<td class="nump">25,645<span></span>
</td>
<td class="nump">15,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based compensation arrangement by share-based payment award, description</a></td>
<td class="text">The number of shares of common stock initially reserved for issuance under the 2013 ESPP was 100,000 shares with an automatic annual increase to the shares issuable under the 2013 ESPP to the lower of (i) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, and (ii) 165,000 shares of common stock, unless a lower number determined by the board of directors. As of December 31, 2020, a total of 618,831 shares are reserved for issuance and 543,791 shares available for future issuance under the 2013 ESPP. During the years ended December 31, 2020 and December 31, 2019, employees purchased 25,645 shares for $0.2 million and 15,701 shares for $0.1 million, respectively, under the 2013 ESPP.
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Restated 2013 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice', window );">Threshold ownership percentage of shareholder for grant of options at pre determined exercise price</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Holders Of Ten Percent Or More Of Voting Power | Restated 2013 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Restated 2013 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual terms of options granted under the Plan</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award threshold shareholder ownership percentage for pre-determined Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685566335368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract', window );"><strong>Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Exercise Price And Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Outstanding, Beginning balance</a></td>
<td class="nump">823,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares Available for Grant, Additional options authorized</a></td>
<td class="nump">1,226,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted', window );">Shares Available for Grant, Granted</a></td>
<td class="num">(1,149,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted', window );">Shares Available for Grant, Restricted stock units granted</a></td>
<td class="num">(37,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled', window );">Shares Available for Grant, Forfeited or cancelled</a></td>
<td class="nump">158,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Outstanding, Ending balance</a></td>
<td class="nump">1,021,109<span></span>
</td>
<td class="nump">823,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning balance</a></td>
<td class="nump">2,767,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">1,149,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(61,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited or cancelled</a></td>
<td class="num">(158,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending balance</a></td>
<td class="nump">3,697,075<span></span>
</td>
<td class="nump">2,767,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Vested and exercisable</a></td>
<td class="nump">2,041,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Option, Outstanding, Beginning balance</a></td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Option, Granted</a></td>
<td class="nump">$ 7.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted', window );">Restricted stock units granted</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Option, Exercised</a></td>
<td class="nump">$ 8.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Option, Forfeited or cancelled</a></td>
<td class="nump">10.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Option, Outstanding, Ending balance</a></td>
<td class="nump">10.81<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Option, Vested and exercisable</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Ending balance</a></td>
<td class="text">7 years 6 months 18 days<span></span>
</td>
<td class="text">7 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Vested and exercisable</a></td>
<td class="text">6 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 9,048<span></span>
</td>
<td class="nump">$ 8,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">$ 4,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of restricted stock units granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant forfeited or cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options outstanding, weighted average exercise price, and additional disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685637925832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term (in years)</a></td>
<td class="text">7 years 6 months 18 days<span></span>
</td>
<td class="text">7 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employees Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employees Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eigr_NonEmployeeStockOptionMember', window );">Non-Employees Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eigr_NonEmployeeStockOptionMember', window );">Non-Employees Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eigr_NonEmployeeStockOptionMember', window );">Non-Employees Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eigr_EmployeesAndNonEmployeesStockOptionMember', window );">Employees and Non Employees Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">73.14%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">83.19%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">0.39%<span></span>
</td>
<td class="nump">1.42%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">2.57%<span></span>
</td>
<td class="nump">2.68%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eigr_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eigr_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eigr_EmployeesAndNonEmployeesStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eigr_EmployeesAndNonEmployeesStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685560908152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Non-cash Stock Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,973<span></span>
</td>
<td class="nump">$ 5,679<span></span>
</td>
<td class="nump">$ 5,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,494<span></span>
</td>
<td class="nump">1,550<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,479<span></span>
</td>
<td class="nump">$ 4,129<span></span>
</td>
<td class="nump">$ 3,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685638283768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_IncreaseInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits impact on effective tax rate</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties associated with uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 251,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 25,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_IncreaseInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase In Deferred Tax Assets Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_IncreaseInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685562345224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Effective Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(26.75%)<span></span>
</td>
<td class="num">(27.42%)<span></span>
</td>
<td class="num">(26.02%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">6.43%<span></span>
</td>
<td class="nump">7.27%<span></span>
</td>
<td class="nump">5.52%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">0.33%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.89%)<span></span>
</td>
<td class="num">(0.77%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(0.01%)<span></span>
</td>
<td class="num">(0.21%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685556752696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 54,523<span></span>
</td>
<td class="nump">$ 42,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">7,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DeferredTaxAssetDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,067<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,452<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">60,994<span></span>
</td>
<td class="nump">54,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(60,747)<span></span>
</td>
<td class="num">(53,793)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(247)<span></span>
</td>
<td class="num">(347)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(247)<span></span>
</td>
<td class="num">(347)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DeferredTaxAssetDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DeferredTaxAssetDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Right Of Use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685562513976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 3,277<span></span>
</td>
<td class="nump">$ 4,634<span></span>
</td>
<td class="nump">$ 3,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to prior year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions based on tax positions related to prior year</a></td>
<td class="num">(2,907)<span></span>
</td>
<td class="num">(3,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 3,277<span></span>
</td>
<td class="nump">$ 4,634<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685562651208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense recognized for company's operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease payments for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eigr_PatheonIncMember', window );">Patheon, Inc. [Member] | Master Manufacturing Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts', window );">Percentage of product manufactured on the basics of annual forecasts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_PercentageOfPurchasePrice', window );">Percentage of purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ProductAgreementDateOfExpiration', window );">Product agreement date of expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_ProductAgreementRenewalTerm', window );">Product agreement renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Patheon, Inc. [Member] | Master Manufacturing Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts', window );">Percentage of product manufactured on the basics of annual forecasts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Palo Alto, California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Total leased space | ft&#178;</a></td>
<td class="nump">8,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_LeaseCommencedDate', window );">Lease commencement date</a></td>
<td class="text">Mar.  01,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear', window );">Long-term operating lease expiry period month and year</a></td>
<td class="text">2023-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue', window );">Security deposit of collateral for lease</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LeaseCommencedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commenced date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LeaseCommencedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee leasing arrangements operating leases term of contract month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of product manufactured on the basics of annual forecasts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_PercentageOfPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_PercentageOfPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProductAgreementDateOfExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product agreement date of expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProductAgreementDateOfExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_ProductAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product agreement renewal term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_ProductAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the fair values, as of the date of each statement of financial position presented, of securities that are restricted as collateral for the payment of related debt obligations, primarily secured borrowings and repurchase agreements, and that are reclassified and separately reported in the statement of financial position because the transferee has the right by contract or custom to sell or re-pledge them.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66007379&amp;loc=d3e113888-111728<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eigr_PatheonIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eigr_PatheonIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eigr_MasterManufacturingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eigr_MasterManufacturingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685638378296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturity of Operating Leases Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating leases minimum payments, 2021</a></td>
<td class="nump">$ 673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating leases minimum payments, 2022</a></td>
<td class="nump">662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Operating leases minimum payments, 2023</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Operating leases minimum payments, 2024</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted payments</a></td>
<td class="nump">1,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future lease payments</a></td>
<td class="nump">1,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of operating lease liabilities</a></td>
<td class="num">(582)<span></span>
</td>
<td class="num">$ (534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 738<span></span>
</td>
<td class="nump">$ 1,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139685559499912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - Fifth Amended Oxford Loan [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 23, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod', window );">Principal and interest payment period</a></td>
<td class="text">19 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentInterestPaymentPeriod', window );">Interest payment period</a></td>
<td class="text">17 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Tranche B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod', window );">Principal and interest payment period</a></td>
<td class="text">13 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_DebtInstrumentInterestPaymentPeriod', window );">Interest payment period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eigr_AmendmendFeesPayment', window );">Amendmend fees Payment</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_AmendmendFeesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amendmend fess payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_AmendmendFeesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentInterestPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentInterestPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument principal and interest payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eigr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eigr_OxfordLoanFifthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eigr_OxfordLoanFifthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=eigr_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=eigr_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>99
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^V[JC4R ?>-+Q+?JX#<Q75D*\60N9L%EQS&,>,Q];2 8_'OF$Q['!@EX_%.
M=LHV3>#A[SWZK>T\=&;)%)^(^&L4Z/"R<]8A 5^Q+-8/8OL;+SHT,'B^B)7]
M2[;YN_U^A_B9TB(I@H%!$J7Y?_92).(@X,PY$D"+ /I#@'NL!:\(\-H&](N
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M#,C\TT)^H<7&'K8OA=8BL3]#SF#RF!?@^4H(O;\P#90?>*[^!5!+ P04
M"  3@FE2X6V]DV$%   S%   &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;*58;6_;-A#^*X17#"U@QR3U8BEU#+0)A@[82]"TVV=:HB.BDJB2E-/LU^\H
M.Y(C4;*'?4A,27?'YX[D/7=</TGU36><&_2CR$M],\N,J:Z72YUDO&#Z2E:\
MA"\[J0IFX%$]+G6E.$L;I2)?4HS#9<%$.=NLFW?W:K.6M<E%R>\5TG51,/7\
MD>?RZ69&9B\O/HO'S-@7R\VZ8H_\@9NOU;V"IV5K)14%+[60)5)\=S/[0*YO
M:6@5&HF_!'_2)V-D7=E*^<T^_)K>S+!%Q'.>&&N"P<^>W_(\MY8 Q_>CT5D[
MIU4\';]8_Z5Q'IS9,LUO9?ZW2$UV,XMF*.4[5N?FLWSZQ(\.!=9>(G/=_$=/
M1UD\0TFMC2R.RH"@$.7AE_TX!N)$@?@C"O2H0"]5\(X*7N/H 5GCUATS;+-6
M\@DI*PW6[*")3:,-WHC2+N.#4?!5@)[9W,I2RURDS/ 4?60Y*Q..'JPYC1;H
MZ\,=>OOF'7J#1(F^9++6K$SU>FE@9JN_3(ZS?#S,0D=FN>/)%?+('%%,L4/]
M]F)U$K]67X*_K=.T=9HV]KPQIVNE>&D0TQK\O)ZPZ+46O<:B/V:1Z0Q!;%!B
M!_Q[+?8LARF<L3J8"AM3]ICM-S2*0G^]W)^&9"CEQ=[*:Z5>X?1;G/XDSCN^
M-4CSI%;""*[GB.V9R-DVYPM("0L-H%V(#T:#$RQQ'*_"'N*A5!"$E+@1!RWB
M8!+QO>(5$RGB/R!S::Z;*$N3<07'XW097;B# :(H#ONPAT*!%V,WZK!%'4ZB
M_B(-RR\ & [F)MXJPGV(#C&,O<AW@URU(%=G0@MLH,QS$U*[9RO(SV:.2FY<
M6%<#$"L<]X .98*Q4$8MRF@2Y9^ D1E1/J*<0[Y&RB;FA=PM:G@8CVPT#!D9
M[%B'4!B,1#5N\<;3>)N].0XL'LP)N\WK 1L*T8",G"2"NUR/+]B5X]".ZJ_B
MX7M!W$]-+CD<$"\> 7A"1N2BQ)P+MA5YDZ*FLC/I$CZADYY_2!)90SI&%7NV
MV<[I/1UXY8<^[OL^E I],K)G2,<?9)I  *"J@8)//'=B]!S;VL=!'Z1##&,\
MMH$Z]B#3]/&R/I5431$F=TCVCN<Y!QPD$=$^?(>0-Q;BCDC(-).\SLGG< Y9
M@80A7?61NL1B?^P@=/1!IOGC-PD!-5P54))NQU,R&1*#1\CPO#K$\"C'D8X_
MR#2!]%/SN9@Z&,2+^EB'0L2C8U [$B'3+')8_', AWS@1T'0)SFG6!B,+7I'
M'&2:.6YE40AC.?A0Y22RM,'E90)XT=L_I.&(T'=.Y).6;2]XK2N6\)L9-'N:
MJSV?;9"S$/__AEZ7Y!TY43R9^Q^,3+YE,D^YTC__%%&R>M\4)>9YB@)HQRV4
MG(TNI"QMIYFC-_@*\B'0@4)0J=?<]A9XC@]_2&=,V5*S-IE4XA_(RTS;9 >-
M""^V0.\OO4RS3K8K>8\\;QZMHCGLA,-+?QY0;^Y%Y,6:T-IF^*9^K8TV,+!'
MYYSE.73+NN)-NYL_NQ;_Z/BKX]U/ 0X9.I)1Z4D;=895TU18'H"396OT!32)
M":L$G#0G3 >_8A(,:DB''(U743C2^M".8^E9CJV+.F]:W6,'(0O8QIF]E=AS
M]#:76K^#5A=>.RL$.J3513]_.61\.H*\XUTZS;NGR%.^$XEPT@$=\N;"PV&
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MF<,["I=& +]OA-"G&S- _]:S_!]02P,$%     @ $X)I4F\S67_@ @  W@<
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M<OL9*CVQY4LEU^Y+MJ5M@A[3M3:RJ, X+Y@H__2UBL,>(.P= 405(&H"ND<
MG0K0>2^@6P&Z+C*E%!>'*35TV%=R2Y2U1C8[<,%T:)3/A$W[S"C<98@SPXD4
M6G*640,9F1G\84Z-)G)!)K+ FY3;%&^ ?)%:DTOR/)N2LP_GY -A@GS+Y5I3
MD>F^;_ LEM%/*[_CTF]TQ&\8D7LI3*[)1Y%!=DC@HXA:2;13,HY.,DXAO2*=
M\()$012T'&CR;GAXTP*?OA]^?4)-I\Y+Q_%UCO#5J2 /"W(G4ED &8FLD91J
MX^=HKHW")_3KA.=N[;GK/'>/>/Z*M89CLMMR6B)[#FD+RF9XV8N#..S[F_U(
MMY@E011'AV;3%K,XZMR\L1V</Z[/'Y^,W(/)09'T($YG5M Y66(9O#T1HE[M
MHG<R1,\"*RQG?_')[#$36\8VE'$ZYW")%?E24PY8A.:&:$C7BAD&^H((,&VQ
M+5W&!]$(&H']WZ:7-(+:0A-%[1%-:KG)2;F'=^[8W4C:[D88-.]&BUF"3R9N
MR&@QBZ-NV&DH\?<J7P%JZ3J(QNROA2E+1[U:-ZF1J\V-]3$VK[+7O-&4G>^>
MJB43FG!8(&5PE6!L5=E-RHF1*U=?Y])@M7;#'!LP*&N ^PLIS6YB'=0M??@/
M4$L#!!0    ( !.":5)\K\:=NP8  "0C   8    >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&ULM9I=;]LV%(;_"F$,6 O$M4B*^B@2 XV=8 76S6C:[6+8A2S1
MME!)=$4Y:??K1\J*99$4E=C)32/9YQR]/*3XO%)]^<#*;WQ#:05^Y%G!KT:;
MJMJ^GTQXO*%YQ-^Q+2W$-RM6YE$E3LOUA&]+&B5U4IY-D.-XDSQ*B]'TLOYL
M44XOV:[*TH(N2L!W>1Z5/Z]IQAZN1G#T^,'G=+VIY >3Z>4V6M,[6GW=+DIQ
M-CE42=*<%CQE!2CIZFKT ;Z_=1V94$?\E=('?G0,Y%"6C'V3)Q^3JY$C%=&,
MQI4L$8D_]W1&LTQ6$CJ^-T5'AVO*Q./CQ^JW]>#%8)81IS.6_9TFU>9J%(Q
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M-\;+*5* 2+"ACW77Z;55(?=*"?<R=5M=7&#G)-(#2R%*[6-YGS4436[OL1;
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MHLKE]$X:##_1DXPT:^>(R!#%'O)YX ]/ 6CYP#4IR^C8?6@JVYA5_C@7N51
M)!JV3X(-/0:!P;Q.@WEI-0C$G.&/ROL6 RX&K6ZFPZ+GGMX/QG"O'&9@/\S
M4W%C=XPCR%*^V-,D .%"P1(./!WF&E0,8T,?A5@XRI;CA9KDE"V>@?T4KT9+
M8W"(JSJ72!SS76A3.#+&#J1BW8[#M[.M+M(R\MFE72E0#&+7Q&+=&X"-L\4
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M7?2R"0($Z2O#>*^?Y(RG@DV6<$B8(9CSGEM\GR;F7#@KTR95;$_!@+X"-Z"
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M>#YS0+[A VV0?L[]YG\ 4$L#!!0    ( !.":5)<@/@@G @  /P8   9
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M-@2;\^=:220($6!]:9%_U8 $-'_PN/T/4$L#!!0    ( !.":5(LRG@)YP,
M  $)   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*U62X_B.!"^^U=8
MB$./%)$XA 1:@$1WSVA7FMEM=>_CL-J#20JPQK$SMC,T_W[+#@1FMQN--'O
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MM5QBDO*"I-&$):%+,=;N9/IPS?'66X."C4#T&-$SU"F2HD]<@O-L=NHI_M]
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MU03I0AF$:V9?A$'N@/UJRY4/SJA+@!F.NRU"Q^.SE@X9G$JG]2PFFD4Z39:
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M(X4P&KLQD81">19U";B!SW!'' X5GJ2#H#6VT,J. ] #Q$?Y=-3J78<ZOX7
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MVT'8-O&/\($O>]P.%KZ&#F&:#!\]O@\E)3EISZ4H@X_K#/F!SO/"V*J]!.X
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M2POP^]P8WWPA!NW;H*_^"U!+ P04    "  3@FE2_\3LI!H*  ""&P  &0
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M'AUMMDC$PVR%D\K8@;1ZA5N1; F&F26W#?Z:E9ORI7,U)".!)Q>7S,VY#:V
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MJ%V3R4D\269)<HR2[@J/>PUI34RAX?/R%E.EUGZ]EFB ?26P13$+)96,ZZ4
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M6."U$@P9X/=<XZ&U'= "W47UXB]02P,$%     @ $X)I4K8HF%:L#   FB,
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M96$PG+[TPF 4T5T$>*.[R=3>368OO?=4:2)XQ$ZKM$7U_?^-4CZ14*^Z3MU
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MM #?"V-<]X,VZ/\+N?T_4$L#!!0    ( !.":5)4?\,3\ ,  (0(   9
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MS+L$RBSO55*K9?!["F(--'G)J69OD#-.BO(Q!>P:^*75K[Q5EAY42ASB<IH
M*1M3/;C?%O?%"^[S!3UXEYI(/[N*J^< 4W Y$5H<"=TN7D6\9SVAB_F8%K/%
M[!6\BU."%QGOX@6\.]^V)J&-4J2UJ^@.=(W;LM.&(]V;J*V/?6#Z:[V)*:!+
M_GXEZN4IZF6.>OE?97W=?4YSFGSW#(3>!=]2PD!0\N5I'*6&R8?*. P4:=^'
MB.^:-GT$8HQY'PITRAUHP]JWR-FXG;<[KL1_IX+Q?22K]K$W*8Y)6V7:2 I2
M=<%K9H!OL6Z<MKV\ ],C2L<A8>;S@L]Q, L85LZN['!>:!;9A<\9C1^^OU[,
MW_P4J5,I[P;RV X(D#";&-8>22.T!#A0D*DJ=#0J)_61_;(\H=\:%BY?B))"
M*;6/R1ZR4Q8*GCATL#VA=549.0Z4M8<QCB*M(5/=6](-EAB-$8_Y_"_"J0F^
MWS8"]!5!5,E6.,\BS@TI@2(T8!25!M>AK $GUTXAX#]],+$RPRF&G%J%W"R.
M4]B9@#JID$SAW2/8-[F#7C"<I$T2Z\9YZ[?BLS<H9Y^$A=&Y?'7NL[.^0<+H
M#/"V5FU\4,F'HCS!45I*N$/)!L1RJXYIWQC=?-5\UO".L:=JV)22V*1R4D*"
M;.YVJ ,2%A#&6G(^4:-VZ"G!YF!@H:H=2YMS74-[@KNPJS$"&.F,X$J)QX/(
M65NI3@X6)1]K/O4&5H<)O?=[\ ICJGH^5AYZ/Y6>ZYTN?9X%-@YUEQY B0K=
M9R-R[,TA:BET9< S%%5U'[([?^Y G8]= #772/8H0)1^C]$C&[$IXB"C;1%+
M&EP (%,%.QE,@:TFWSJVIF<W0\MAF^^_3,VE<DF<5D]7[+K<+%_,R_W\H,+6
M0#[+-5QGDS=7H]*QQX_DNWS/;'S"K95?&_Q-X" &V*^]3\</"7#ZX['Z%U!+
M P04    "  3@FE2J_>;%/8%  !!#@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6RM5U%O&CD0?M]?87&]4R)18!=(()=$(NE5C=2H4=/V'D[W8'8-
M6/':6]L+I;_^OO&R&R !]>&DB.S:GL_?S'PS]EZNC'UR"R$\^Y$K[:Y:"^^+
MBV[7I0N1<]<QA="8F1F;<X]7.^^ZP@J>!:-<=9->[ZR;<ZE;UY=A[,%>7YK2
M*ZG%@V6NS'-NUS="F=55*V[5 Y_E?.%IH'M]6?"Y>!3^:_%@\=9M4#*9"^VD
MT<R*V55K$E_<#&A]6/!-BI7;>F;DR=28)WJYRZY:/2(DE$@](7#\6XI;H10!
M@<;W#6:KV9(,MY]K]/?!=_@RY4[<&O6WS/SBJC5JL4S,>*G\9[/Z(#;^# DO
M-<J%7[:JU@Z3%DM+YTV^,0:#7.KJ/_^QB<.6P:AWP"#9&"2!=[518/F.>WY]
M:<V*65H--'H(K@9KD).:DO+H+68E[/SUK<ESZ1%E[QC7&;LUVDL]%SJ5PEUV
M/;:@A=UT W=3P24'X.*$W0-AX=A?.A/9+D 7W!J"24WP)CF*^$ZD'=:/VRSI
M);TC>/W&X7[ Z_^"PY-]A]D[Z5)E7&D%^V<R==Y"-?\>V770[#H(NP[^KS ?
MA:-*O7 %3\55"Z7HA%V*%L6^$QW=B'T4$#";S*T0M(3=:?8I]68J+,(;G[>9
M7PB8Y 77:X8%PHJ,2>T-XTP;_3;E.A6*3Y5@: N6$S2;\50JZ==,!73>H*-E
ML%&[EXQ1:R5'2&?49<P,?S.9"A8\8,JDW&,;[ED2#X?L@=LG=J.660<[XTT9
M-E'>M-DM5Q*06G(V'O1[9QWV!6RK35.X#1\!@TJ_YS9=L""9>!2B('X4$G$B
MP/=B:D%F37KJ;T,L."*& (#]V[7@-DRA[$M+OH'U5FS^^&V4Q.=_NJTH5"!*
M\BD%@X(-/%A!OR*G -<:9BM$E29G1J$E.G8"5GYA2@>F[O0B^JHSJ-"4FJ)2
MP19\'5(:O4"+\!-';Z*S\SX])M'964(/_2B.P\@@BJ,OQG/%RFW<!C%N#P;C
MZ*-P[H+)O"A]E7%P=#XZB9-Q=!H]D,:0T"57I2"G9J6G$MDC%[?[(%1!I:6U
M9%(8&[HO9?UPK**3X2C!1I^.+'D3G?='T6<"13IQ+ @<"JF9:_D3E$EKOY @
MQU:(_)M>YPS-5"DP:^^]D5PP,JI'&F32A$-1H*V]3&K0VKBR)M6UP<T5(APY
M:MUAR*FH8!#9W-5RVJL8MUN $AI2S@0H@V.0RH[8I,)Z'+=(AY6A%G?S  S4
M$M6;-AZY3%69A:0&\!QKD;M0H#LLZEB#[;<#P'4H7@:5)(VHQ:%HGJ=3[A8,
M5X%9$/H!\YVBJ9'.F_AO$G+V:D(.Y:-.Q'@_$9/7B[(*_"J<X2)[RY=@.">!
MT;WFF2DE+T"_6%F7%H-GHO(B03@JT9#%N!,/?]]G\PF[6K;=L[_LYM],E9R'
M]H@>G/,G49?><[(-J$M+%6U#!,L@->X<>FU1HA,&B8&!0L_5>W*KU$$.6K/F
MJNI;.MO3TA1UEL/'4M23U1%0*8JG"RF6C:)J=6884Z8(PV056K1-);KX3QYZ
M A**)F.T<!WVP:RPWE9YX'D()5EYF1.[2JG;6JSU_:3-2G?0\W6)@XBZ-98_
MXD2D$V;GI"/DF;3.,SJ-D$I"?4[^@6/OGCM:^BJ^V]K@Y/[^<7(:.#]8DY6I
MWYI<2;_ 489MJ,7<:5QI3C:OIXV>\YTMP$T9S6<<!]X4A52X4C7)29_X?+-H
M:KRGB= 8FA SQY4XV':.-!PKOI?25GHKK%G*3-3$*R^XUB7PET:5>6A' D7N
M _0.R6<CI;9<$VS4^YT6NS)MP!J4#KO;.6>9L>0 ,(,2]5%CJ-F_<(&OV7EE
MT]1"84D:==3= B?4C"M5W050[9[BMQ,O2NV!S*+_4!WL-Y3A)E@E[N\0.^YT
M0HM5Q9;80SL./8#YE:DN&Z_=,;M;UWKD=1X^7AP+?::ZX3>CS??1I/HL>%Y>
M?5SA2@3!.$1R!E.TUV&+V>J#I7KQI@@?"20GDX?'!;[QA*4%F)\9X^L7VJ#Y
M:KS^#U!+ P04    "  3@FE2.HH[NRP"  #<!   &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6RME$MOVS ,@._[%83/0>S8:5<428 D[;8>.@3I'H=A
M!\6F8Z&RY$G,W/S[4;+C9< :8, NMBB1'Q\B-6N-?785(L%+K;2;1Q51<QO'
M+J^P%FYL&M1\4AI;"V+1[F/76!1%,*I5G";)=5P+J:/%+.QM[&)F#J2DQHT%
M=ZAK88\K5*:=1Y/HM+&5^XK\1KR8-6*/3TB?FXUE*1XHA:Q1.VDT6"SGT7)R
MNYIZ_:#P16+KSM;@,]D9\^R%AV(>)3X@5)B3)PC^_<0U*N5!',:/GAD-+KWA
M^?I$?Q=RYUQVPN':J*^RH&H>W4108"D.BK:F_8!]/E>>EQOEPA?:3C=CY?S@
MR-2],4=02]W]Q4M?AS.#F^05@[0W2$/<G:,0Y9T@L9A9TX+UVDSSBY!JL.;@
MI/:7\D263R7;T6*+2A 6L!&6CO#)"NU$J)>;Q<1\KQ7G/6O5L=)76),4'HVF
MRL&]+K#X$Q!S8$-TZ2FZ57J1>(?Y&++)"-(D32[PLB';+/"R?\X6OBUWCBQ+
MWR_XF0Y^IL'/]+]4]3)K AF,WRP=%-+ERCC&2@T?#2%<CX JA+6I&Z&/@)K0
MAF,RH&3.HX,@]A:1IX@<=Q95</_^801M)?,*I /3:C;8'0.G- >^-PNF/,>.
M_U:/^*SC:K3[,%<.<B90UWS#[C"ZRZYC?ZMW<_\H[%[R!2@LV309O[V*P':S
MU EDFM"_.T,\#6%9\?.#UBOP>6FX%KW@'0P/VN(74$L#!!0    ( !.":5+]
M]O/$WP(  (8&   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;*55R6[;
M,!"]]RL&0H^!9<M.L\ V8&=! S1($"?MH>B!DD86$2X*2<7VWW=(R;)3)$:
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M?,9Q#CZNU0*K*\!%%U$=(3;'IRY1Y*L91@LB\1R=$Q-OV%_ZX.E$Y^CPL:)
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M+W=O<FMS:&5E=',O<VAE970R.2YX;6R-5FUOVS80_LY?07C-D "*+,IZ;9,
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MU5U<2*[>$N4GQW,0,2>%*2E;H6DIE($0J(LF24+T-L[0#:V.BS8ZGX/$)+M
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M7%F:G?QC3N,M:F= [Q=*V>W"!6@&YO%_4$L#!!0    ( !.":5),\V%Q-00
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M\R3-/(EUG@]K\*<LW_0SN.%) M9L>Y+5#OC[CJ4;)O^QX B;84)GB*-&,W*
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M4F:,/>K-33BP'(T(8@BD#D'4WPI&$,<ZDL+QE >UBIS:L;K>1K\VQ:MB9D3
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MM [F?"V$WAOV@GY(I_\ 4$L#!!0    ( !.":5(4R1'4L@(  %,'   9
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;(V5WV_:,!#'_Q4KZD,K;<TO2* "
M) J;MH=IJ+3;P[0'DQS$JF-GME.Z_WYG$R(*H>.%V,E]O_>YX^*,ME(]ZP+
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MR9I)X3QQ"$2]QD6MF-C@;6TZ6[MS39RK?:5?)DD8)2/_Y;"!IT%AG/;:H#?
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MAF:\ V? !>B&J00"P13/*Q;?#8ZQ7(9[XK(O, W9>':RN9K-GBCL^M!P:W-
MPRS>^)0OFAJZ\.UT,=7'',7T>/M@6)>-Z86H5ML.PSBPQ<%ONK]O[\W'Q@%J
M! X$,%12#!X3T,_AB'<#,V6DW^Q.'VX^P$$S2?",Z7'Z3='T&PKP3_K:L/7>
MT-[SP1\A(9% <\[28BPVQFZW*_>'QG<+O=:;>O7;T#WF"PK\EI Y0)WN$%H=
M+W]N*;](EA<O[V=,2I86ES'!$>%* )[/&92[_J)^#ZA_]+K\%U!+ P04
M"  3@FE2"BOSAV,)  #O-   &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6S%F]UOXS82P)_;OX(PNL ND+5%?=I%-D 2;YH<-FBPV;T^%'V@)=K151)=
M2LH'<'_\#6G98\<2)3LK7!^ZEL,9CH;#WPQ'\NF3D'_G#YP7Y#E-LOS3X*$H
MEK^.1GGXP%.6#\629_"7N9 I*^!2+D;Y4G(6::$T&=F6Y8]2%F>#LU/]W9T\
M.Q5ED<09OY,D+].4R9<+GHBG3P,Z6'_Q-5X\%.J+T=GIDBWX/2^^+^\D7(TV
M6J(XY5D>BXQ(/O\T.*>_7H]]):!'_#OF3_G69Z)N92;$W^KB)OHTL)1%/.%A
MH50P^.>17_(D49K CG\JI8/-G$IP^_-:^Y6^>;B9&<OYI4C^B*/BX=-@/" 1
MG[,R*;Z*IVM>W9"G](4BR?7_R5,UUAJ0L,P+D5;"8$$:9ZM_V7/EB"T!ZC8(
MV)6 W57 J02<5P*-)KF5@-MU!J\2\+H*^)6 _UK :1 (*H&@ZPSC2F"L5W>U
M''HMIZQ@9Z=2/!&I1H,V]4$'A):&)8PS%;OWA82_QB!7G$WYK" ?R7D4Q2J6
M6$)NLM6.4)'U?LH+%B<?8,3W^REY_\L'\@N),_+M090YRZ+\=%2 $4K5**PF
MO%A-:#=,>,5G0V([)\2V;%HC?FD6OV5R2"Q/B=-)C?C4+#[EX9 X5,]NU8A_
M[BQ>._N56?R\7(#Q^M[IN$;\M[9[?UE/7B=]W=UV?U=\!$&SB1Q[$SFVUN>8
M(N<FRPM9 LL*\N<7&$!N"I[F?QG4.QOUCE;O-L4)"SEY9$G)B9B3@LN4)()E
M=4N^4N1K18K5CV>.!?^=CAZW5[9MU(Z5[L9*UVCE%S")S&.U;R1?LA?M"?X<
M%V3.>4[@&S9+>)W1[IXY'QT["%X9O1KE-8[:,=K;&.VU&\T6DG-E[@D)Q2//
M&!B>B2P4Z3*)60;.A_3(DN*ESGBS?F]H6>\,(>!O[/2/LS/B>2CCI4)4G75F
MK=\>N(XDX%B8E*"JPBQD;L)A@B)7 5>EOY-J5)PMR!Q(6$I."J'6E;!4E&IP
M5/(3,H.Z <H*+;HV,R= 2/+$I(2+F.<GP&V(XQABA46/7.:<\/D<<G@U+=P@
MEX#;C(12Y/G:A)6:_Y31(EV-4I=QEHL$I,*7H<'1P<;1P7&.QFBH\[-9J3*3
MA2%4*1)NFQ3@=KC_4L;%B][1<!T!0DSVCS?VCXU3_?X,*2LB^C;^O.7IC$L3
M@B8;M9,^"$<MS+W607YG"_B\4-Z:"0G:5-2%;,G"N'8;7E?JMR%B>XU,HULU
M 3W(KCGLET(9LUI)8'%=XI^V:-W5LN02(CDK4\+_*6%+P*Y2(0&3JDVB(H3'
M\(74WSK6QPBVW/?A_9!,19(P2;[<7/S^54%7R(*K#:$'_L&2A,"DJNK_ERBE
M O,R*7/B#UWZC@@)'R;>.U/044R U#;>T)T$.,1+M9_UE@2[>5Z0=1J .XQ%
M5.LHLU['(JG(BH?<9"7F46I.I'=<AF .'$2T4ZO<1*"Z6V[LG[&D:9.W: ^&
MGI'U%#,I[2N5TOU<2B>-NP"S).V0)H6,%V"3KH:U'6JI%;=(G.>ESI.AR(NZ
M_7!=Z=_.WFZC69@4J3E_?5T[1R>;9&>K;OQ56]KZ>VYJ]A*F#FK&?!U[R7_)
M;9S%*6SN#CBFB'DZ[@7("'PZ.0A\FSVMD%4;>F9]&C:F6AM3A6U.%0UN7E&P
M@Y-MA+]-^W"RO75N,./MM9.7""A( C,.U5$$1*\2PLX2D#*+("6$(EL=5^N6
MI&5VG0A,]X%@M<WH:UB2;U#N02E(SCLM"^+1=GM9%L2=;<9=]P/7=:5I![C-
M=8>-:+/-:&OQZ$4GCR*Y[* 7CR*N;'-9>GQ&JQ3O.+C1O4@WVTRC!O>>@UUJ
MPQT4N Z2R[%ZZ1,@L!QS77E(IX#N962'THE;[UD'D>9T0-I1*UTIWBGAK;'3
M8-!6\\3,)KVF*W<?N8\<))/3"YD<))/SH\CTF[-/IF8P.0@FQPPFHSLO.[D3
ML>3T@B4'L>28L=3=G5?./H<,[D00.680K8ESX+G=1>:XO3#'1>:XAYV0#SRY
M7U;J=[J1S9YU$43N8;55QY-[B];_\\G==_7)?3*DYI.[BWAT6\[$QY[<6_0Z
M?OO)W=WJ+9M/Q&\\N;=H;SNYN\AGM\-!^;@F^#ZN;:=Q%R"NW0Z-XS><W*?N
M_E'9;C0+R>ZVMUE/L EJB#*S'OT,C)[\_--/MF6[IB7$G.!V*%5%6>0%> EV
M>BVSQGO%D^TTKQ9F ]><#2[6Q,S)7(KT54NCUI+)GB5^T&2(AUG#Z]".?1W'
M#)^,=@II;[\G2QO![F'"\<P)YPXM6G=]P)*3MD<A+5I#EH1EPA2&6;[NRB>O
M=T\$ TX0]N_C#\0>6N]VQB^5?3%L,(AM2!3J^WDL@:G4KI"H]]_[&(1IDS"D
M@FHL=3[:KHGU'J9$SYR\3,6&ZJ"HZ[O*@.G*^JNUY;<K:SK4)A[F'L_IHS;Q
M,&UX9K#K"6*<8(FAH]('MEMJ \:LVVYYM.=M/8,T)XTCEH4Z*OQL]Y!EP9SA
M^;TL"]+?,U/[;<MBUDW;E@43@6=.!"W+<B5$I#?R5)8+<AZE<1;#':TXT64]
M,"MXO3Q\\Y'VOIGVN]557H8AS_.&WOFT15?K$V_DO&\F\CW:L4DSZGT?W4Q?
M50R$S56=S99+*> 85VNN>1+' J:_F(I4'_'JOPFO!SP'\!&A?B\(]1&A?H=G
M48<\!VC1IX\N)LL0F_[;L-GU>8"_]1)&+V#T$8S^86\?_.#G 2VSZ^.EZ3X0
MG?Z;T'E4F]5'7OJ]\#) 7@:]OJQP6:G?Z;TVOX 5(#$#,\R.=OL/2&<!8C+H
MY6VY )D8M+POIVJ(^GRA3U7SLNE@-VW13"WRPIDTI8L R1J827C@:G5J50=(
MS\#K9140EH&Y\W!T8ZE%+Q2]K8VE8.MUK\.(*[EZRUUMX(Y;.3B@+1P@0 ,S
M0#\_%ZO5USUI*,HV_A-9\M+%B6;]5,>QR8-(V\#<L[B*Y\4#:0GF^W*6PZE9
MV?SY<?OA@>F5-^3QN)<>]QC!.FYK.1P7RQ<M>NFD/9;'"-:QN?Z\.< NLR8:
M=+ +>3QNX7&7"-G'W+%A@P >]_*T;HR,'9LKU./#QJP73O_MRX.@'IN!>DC8
MF#696OZCK1]FJ)\"W3*YB+.<)'P.NJRA2E=R]>N:U44AEOJW&C-1%"+5'Q\X
M@QI7#8"_SX4HUA?JYQ^;WSB=_0]02P,$%     @ $X)I4@]E+NZF @  QP8
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M.:2I*+_8*F\DWQ:?)#UP":U0<;EA%(Q6 O#[(^>RNE$3U-_-7?P?4$L#!!0
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MZ4#V  ;.H .KU@YH%H^/7@9FBKD OBAWB\F# \GKPR[J6F*@66/.H3:EM-_
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MT%CT;:F2UE/;49G@N$C0.Y*@Z\$=HS(1<$-CC-\3V$IM)=G;2QY[)QE#C*[
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M>HI-,U'E%7(=H+XO&)/[CIZ@*MB&?P%02P,$%     @ $X)I4AL'MY.$ P
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M0WG>%E<:KJ[_G.<P/#[0H2>2;LLK#==7S ;)-&"3TAZA_I,(T6%;@.*=CJD
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M-$BV[:'H@9'&-E&)=$DZCA?[XW=(R9+CRK1[R%ZL#W/>O!ERWE <K*3ZIN<
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M971S+W-H965T-C N>&ULM95+3]M $,>_RLCB %(;/P()08XE D6-!&I$2GM
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M"  3@FE2:4X'OL,$   '*   #P   'AL+W=O<FMB;V]K+GAM;,6:VV[;.!!
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MY^;KY2_+KYUXOV@O."?X=^?Q+U!+ P04    "  3@FE2=-+&8MX!  !:(P
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M6?]+S>P-4$L! A0#%     @ $X)I4@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  3@FE2\2:O?.X
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ $X)I4K5<'2=K @
MDP8  !@              ("!4Q0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( !.":5*R9@URSP,   $-   8              " @?06
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  3@FE2;S-9
M?^ "  #>!P  &               @('Y&@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ $X)I4GROQIV[!@  )",  !@
M ("!#QX  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( !."
M:5+;0N)O>P(  /<%   8              " @0 E  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    "  3@FE2Y]N\*=4'  #E(   &
M        @(&Q)P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( !.":5(L?1N_10X  !DJ   9              "
M@2M:  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ $X)I
M4O_$[*0:"@  @AL  !D              ("!IV@  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    "  3@FE2!K%A=V0)  !1&0  &0
M        @('X<@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( !.":5*74* -BP4  +0.   9              " @9-\  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ $X)I4K8HF%:L#   FB,
M !D              ("!58(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    "  3@FE2VQ&\=6$)   7&0  &0              @($XCP
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( !.":5)4?\,3
M\ ,  (0(   9              " @="8  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ $X)I4JOWFQ3V!0  00X  !D
M ("!]YP  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  3
M@FE2.HH[NRP"  #<!   &0              @($DHP  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !.":5+]]O/$WP(  (8&   9
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M970R-BYX;6Q02P$"% ,4    "  3@FE2-;$/0VH#  #>!P  &0
M    @(&*RP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M !.":5+C%#3NC0(  #\%   9              " @2O/  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ $X)I4LP6_4,M!0  S0L  !D
M             ("![]$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    "  3@FE2XA\%=/ $  !@#   &0              @(%3UP  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( !.":5*F!B* V (
M #D&   9              " @7K<  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ $X)I4KUK:GX= P  1@@  !D              ("!
MB=\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  3@FE2
M!I#2+[4#   !"@  &0              @('=X@  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( !.":5+0ZBWXD@(  !0(   9
M      " @<GF  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ $X)I4@L38K<) P  J@D  !D              ("!DND  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  3@FE21X<5A5H#   \"P
M&0              @('2[   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( !.":5),\V%Q-00  &,6   9              " @6/P  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ $X)I4J(LU7>'
M!   OA8  !D              ("!S_0  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    "  3@FE2&DO)C5H#  !H#0  &0
M@(&-^0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( !."
M:5)36]S(4 (  + %   9              " @1[]  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ $X)I4A3)$=2R @  4P<  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( !.":5(/92[NI@(  ,<&   9
M  " @1,> 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M$X)I4DN[X\-8 P  #@L  !D              ("!\" ! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    "  3@FE2&D]?MF($   4$P  &0
M            @(%_) $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( !.":5((!E]P: (  -4%   9              " @1@I 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ $X)I4K@NN8BX"
M0R<  !D              ("!MRL! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    "  3@FE2@_)?J_H$  !\%   &0              @(&F
M- $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( !.":5)G
MXE&';00  )D5   9              " @=<Y 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ $X)I4B6<P:43 P  O D  !D
M     ("!>SX! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
M"  3@FE2&P>WDX0#   7#   &0              @('%00$ >&PO=V]R:W-H
M965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( !.":5)CH3_(4 ,  .H+   9
M              " @8!% 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L!
M A0#%     @ $X)I4HSE6E1X P  ] L  !D              ("!!TD! 'AL
M+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  3@FE2WEEAN04#
M  #H"   &0              @(&V3 $ >&PO=V]R:W-H965T<R]S:&5E=#4W
M+GAM;%!+ 0(4 Q0    ( !.":5(IA;_C!04  #D3   9              "
M@?)/ 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ $X)I
M4DUN8?3[ @  0PD  !D              ("!+E4! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    "  3@FE2BW=T0GT"  !'!P  &0
M        @(%@6 $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( !.":5*A)Z\>4@(  %P,   -              "  11; 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ $X)I4I>*NQS     $P(   L
M ( !D5T! %]R96QS+RYR96QS4$L! A0#%     @ $X)I4FE.![[#!   !R@
M  \              ( !>EX! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M !.":5*8&UJ>^P$  ,LC   :              "  6IC 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !.":5)TTL9BW@$  %HC   3
M              "  9UE 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !$
- $0 DQ(  *QG 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>200</ContextCount>
  <ElementCount>413</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - License, Collaboration, and Product Development Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreements</Role>
      <ShortName>License, Collaboration, and Product Development Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Asset Purchase Agreements and Related License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreements</Role>
      <ShortName>Asset Purchase Agreements and Related License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Legal Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLegalMatters</Role>
      <ShortName>Legal Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail</Role>
      <ShortName>Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - License, Collaboration, and Product Development Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail</Role>
      <ShortName>License, Collaboration, and Product Development Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Asset Purchase Agreements and Related License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Asset Purchase Agreements and Related License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail</Role>
      <ShortName>Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail</Role>
      <ShortName>Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Debt - Schedule of Future Minimum Payments of Principal, Exit Fee and Interest Expense under Oxford Term Loan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail</Role>
      <ShortName>Debt - Schedule of Future Minimum Payments of Principal, Exit Fee and Interest Expense under Oxford Term Loan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Common Stock Reserved for Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Equity Incentive Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Equity Incentive Plans - Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail</Role>
      <ShortName>Equity Incentive Plans - Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Equity Incentive Plans - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail</Role>
      <ShortName>Equity Incentive Plans - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Equity Incentive Plans - Summary of Non-cash Stock Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail</Role>
      <ShortName>Equity Incentive Plans - Summary of Non-cash Stock Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Effective Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Commitments and Contingencies - Maturity of Operating Leases Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail</Role>
      <ShortName>Commitments and Contingencies - Maturity of Operating Leases Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="eigr-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="eigr-10k_20201231.htm">eigr-10k_20201231.htm</File>
    <File>eigr-20201231.xsd</File>
    <File>eigr-20201231_cal.xml</File>
    <File>eigr-20201231_def.xml</File>
    <File>eigr-20201231_lab.xml</File>
    <File>eigr-20201231_pre.xml</File>
    <File>eigr-ex1010_1144.htm</File>
    <File>eigr-ex1012_1143.htm</File>
    <File>eigr-ex1017_1142.htm</File>
    <File>eigr-ex1018_1141.htm</File>
    <File>eigr-ex1031_1140.htm</File>
    <File>eigr-ex1032_1138.htm</File>
    <File>eigr-ex1033_1139.htm</File>
    <File>eigr-ex109_1145.htm</File>
    <File>eigr-ex211_583.htm</File>
    <File>eigr-ex231_912.htm</File>
    <File>eigr-ex311_581.htm</File>
    <File>eigr-ex312_580.htm</File>
    <File>eigr-ex321_579.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gzbwht3f4aft000001.jpg</File>
    <File>gzbwht3f4aft000002.jpg</File>
    <File>gzbwht3f4aft000003.jpg</File>
    <File>gzbwht3f4aft000004.jpg</File>
    <File>gzbwht3f4aft000005.jpg</File>
    <File>gzbwht3f4aft000006.jpg</File>
    <File>gzbwht3f4aft000007.jpg</File>
    <File>gzbwht3f4aft000008.jpg</File>
    <File>gzbwht3f4aft000009.jpg</File>
    <File>gzbwht3f4aft000010.jpg</File>
    <File>gzbwht3f4aft000011.jpg</File>
    <File>gzbwht3f4aft000012.jpg</File>
    <File>gzbwht3f4aft000013.jpg</File>
    <File>gzbwht3f4aft000014.jpg</File>
    <File>gzbwht3f4aft000015.jpg</File>
    <File>gzbwht3f4aft000016.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>105
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "eigr-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "contextCount": 200,
   "dts": {
    "calculationLink": {
     "local": [
      "eigr-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "eigr-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "eigr-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eigr-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eigr-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "eigr-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 547,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 28,
    "http://www.eigerbio.com/20201231": 6,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 38
   },
   "keyCustom": 83,
   "keyStandard": 330,
   "memberCustom": 42,
   "memberStandard": 27,
   "nsprefix": "eigr",
   "nsuri": "http://www.eigerbio.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value Measurements",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Balance Sheet Components",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - License, Collaboration, and Product Development Agreements",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreements",
     "shortName": "License, Collaboration, and Product Development Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Asset Purchase Agreements and Related License Agreements",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreements",
     "shortName": "Asset Purchase Agreements and Related License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Debt",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stockholders' Equity",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Equity Incentive Plans",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Income Taxes",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Legal Matters",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLegalMatters",
     "shortName": "Legal Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Commitments and Contingencies",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Related Party Transactions",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Subsequent Events",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Debt (Tables)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:CommonStockReservedForFutureIssuancesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:CommonStockReservedForFutureIssuancesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Description of Business - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
     "shortName": "Description of Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eigr:EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eigr:EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_us-gaapPropertyPlantAndEquipmentByTypeAxis_eigrLabEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_us-gaapInvestmentTypeAxis_us-gaapUSTreasuryBillSecuritiesMember_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eigr:CashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
     "shortName": "Fair Value Measurements - Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eigr:CashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eigr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eigr:PrepaidContractManufacturingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eigr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eigr:PrepaidContractManufacturingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eigr:AccruedContractedResearchCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Components of Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eigr:AccruedContractedResearchCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - License, Collaboration, and Product Development Agreements - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
     "shortName": "License, Collaboration, and Product Development Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_us-gaapTypeOfArrangementAxis_eigrUPennCHOPAgreementMember_20190101_20191231",
      "decimals": "-5",
      "lang": null,
      "name": "eigr:NonRefundableIssueFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Asset Purchase Agreements and Related License Agreements - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Asset Purchase Agreements and Related License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_us-gaapVestingAxis_eigrMilestoneVestedOptionsMember_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Debt - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
     "shortName": "Debt - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "3",
      "lang": null,
      "name": "eigr:DebtInstrumentCovenantNoncompliancePenalty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail",
     "shortName": "Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "eigr:DebtInstrumentUnamortizedExitFees",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Debt - Schedule of Future Minimum Payments of Principal, Exit Fee and Interest Expense under Oxford Term Loan (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail",
     "shortName": "Debt - Schedule of Future Minimum Payments of Principal, Exit Fee and Interest Expense under Oxford Term Loan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_us-gaapCreditFacilityAxis_eigrAmendedTrancheAMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanMember_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "eigr:DividendsDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "eigr:DividendsDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eigr:CommonStockReservedForFutureIssuancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "eigr:OptionsIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Issuance (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail",
     "shortName": "Stockholders' Equity - Summary of Common Stock Reserved for Issuance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eigr:CommonStockReservedForFutureIssuancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "eigr:OptionsIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "eigr:ClosingPriceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Equity Incentive Plans - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
     "shortName": "Equity Incentive Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "eigr:ClosingPriceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "eigr:CommonStockReservedForFutureIssuancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Equity Incentive Plans - Stock Option Activity (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail",
     "shortName": "Equity Incentive Plans - Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "eigr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Equity Incentive Plans - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail",
     "shortName": "Equity Incentive Plans - Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Equity Incentive Plans - Summary of Non-cash Stock Based Compensation Expense (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail",
     "shortName": "Equity Incentive Plans - Summary of Non-cash Stock Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Income Tax Rate (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail",
     "shortName": "Income Taxes - Schedule of Reconciliation of Effective Income Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20171231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Commitments and Contingencies - Maturity of Operating Leases Liabilities (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail",
     "shortName": "Commitments and Contingencies - Maturity of Operating Leases Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eigr:DebtInstrumentInterestPaymentPeriod",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_us-gaapCreditFacilityAxis_eigrTrancheBMember_us-gaapDebtInstrumentAxis_eigrOxfordLoanFifthAmendmentMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210223_20210223",
      "decimals": "-5",
      "lang": null,
      "name": "eigr:AmendmendFeesPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Description of Business",
     "role": "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "eigr-10k_20201231.htm",
      "contextRef": "C_0001305253_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 70,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation Date Of Incorporation",
        "terseLabel": "Entity incorporation, date of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "eigr_AbbvieAssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abbvie asset purchase agreement.",
        "label": "Abbvie Asset Purchase Agreement [Member]",
        "terseLabel": "AbbVie Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AbbvieAssetPurchaseAgreementMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting pronouncements not yet adopted.",
        "label": "Accounting Pronouncements Not Yet Adopted Policy [Text Block]",
        "terseLabel": "Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "AccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_AccruedContractedResearchCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contracted research costs current.",
        "label": "Accrued Contracted Research Costs Current",
        "terseLabel": "Contract research costs"
       }
      }
     },
     "localname": "AccruedContractedResearchCostsCurrent",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_AccruedResearchAndDevelopmentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs.",
        "label": "Accrued Research And Development Costs Policy [Text Block]",
        "terseLabel": "Accrued Research and Development Costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsPolicyTextBlock",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_AmendedOxfordLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Oxford loan.",
        "label": "Amended Oxford Loan [Member]",
        "terseLabel": "Amended Oxford Loan [Member]"
       }
      }
     },
     "localname": "AmendedOxfordLoanMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AmendedTrancheAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended tranche A.",
        "label": "Amended Tranche A [Member]",
        "terseLabel": "Amended Tranche A [Member]"
       }
      }
     },
     "localname": "AmendedTrancheAMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AmendedTrancheBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended tranche B.",
        "label": "Amended Tranche B [Member]",
        "terseLabel": "Amended Tranche B [Member]"
       }
      }
     },
     "localname": "AmendedTrancheBMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AmendmendFeesPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendmend fess payment.",
        "label": "Amendmend Fees Payment",
        "terseLabel": "Amendmend fees Payment"
       }
      }
     },
     "localname": "AmendmendFeesPayment",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_AmountOfCommonStockAvailableForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock available for sale.",
        "label": "Amount Of Common Stock Available For Sale",
        "terseLabel": "Amount of common stock available for sale"
       }
      }
     },
     "localname": "AmountOfCommonStockAvailableForSale",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase agreement and related license agreement.",
        "label": "Asset Purchase Agreement And Related License Agreement [Line Items]",
        "terseLabel": "Asset Purchase Agreement And Related License Agreement [Line Items]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementAndRelatedLicenseAgreementLineItems",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement And Related License Agreement [Table]",
        "label": "Asset Purchase Agreement And Related License Agreement [Table]",
        "terseLabel": "Asset Purchase Agreement And Related License Agreement [Table]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementAndRelatedLicenseAgreementTable",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset purchase agreement and related license agreements.",
        "label": "Asset Purchase Agreement And Related License Agreements [Text Block]",
        "terseLabel": "Asset Purchase Agreements and Related License Agreements"
       }
      }
     },
     "localname": "AssetPurchaseAgreementAndRelatedLicenseAgreementsTextBlock",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement [Member]",
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase agreements and related license agreements.",
        "label": "Asset Purchase Agreements And Related License Agreements [Abstract]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementsAndRelatedLicenseAgreementsAbstract",
     "nsuri": "http://www.eigerbio.com/20201231",
     "xbrltype": "stringItemType"
    },
    "eigr_AssetPurchaseDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset purchase description.",
        "label": "Asset Purchase Description",
        "terseLabel": "Asset purchase description"
       }
      }
     },
     "localname": "AssetPurchaseDescription",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-The-Market Offering [Member]"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_AvailableForSaleOfDebtSecuritiesContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale of debt securities contractual maturity.",
        "label": "Available For Sale Of Debt Securities Contractual Maturity",
        "terseLabel": "Available- for-sale of debt securities contractual maturity"
       }
      }
     },
     "localname": "AvailableForSaleOfDebtSecuritiesContractualMaturity",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_AvexitidePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avexitide purchase agreement.",
        "label": "Avexitide Purchase Agreement [Member]",
        "terseLabel": "Avexitide Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AvexitidePurchaseAgreementMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_BmsTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS transaction.",
        "label": "Bms Transaction [Member]",
        "terseLabel": "BMS Transaction [Member]"
       }
      }
     },
     "localname": "BmsTransactionMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_CashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents amortized cost.",
        "label": "Cash Equivalents Amortized Cost",
        "terseLabel": "Cash equivalents, Amortized cost"
       }
      }
     },
     "localname": "CashEquivalentsAmortizedCost",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_CashEquivalentsAndInvestmentSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and investment securities.",
        "label": "Cash Equivalents And Investment Securities [Line Items]",
        "terseLabel": "Cash Equivalents and Investment Securities [Line Items]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentSecuritiesLineItems",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_CashEquivalentsAndInvestmentSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and investment securities.",
        "label": "Cash Equivalents And Investment Securities [Table]",
        "terseLabel": "Cash Equivalents And Investment Securities [Table]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentSecuritiesTable",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_ClosingPriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing price of common stock.",
        "label": "Closing Price Of Common Stock",
        "terseLabel": "Closing price of common stock"
       }
      }
     },
     "localname": "ClosingPriceOfCommonStock",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "eigr_CollaborationAgreementInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement initial term.",
        "label": "Collaboration Agreement Initial Term",
        "terseLabel": "Collaboration agreement initial term"
       }
      }
     },
     "localname": "CollaborationAgreementInitialTerm",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.eigerbio.com/20201231",
     "xbrltype": "stringItemType"
    },
    "eigr_CollaborativeArrangementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the renewal term of the agreement.",
        "label": "Collaborative Arrangement Renewal Term",
        "terseLabel": "Collaboration agreement subsequent renewal terms"
       }
      }
     },
     "localname": "CollaborativeArrangementRenewalTerm",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_CommercialSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial sales.",
        "label": "Commercial Sales [Member]",
        "terseLabel": "Commercial Sales [Member]"
       }
      }
     },
     "localname": "CommercialSalesMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_CommonStockReservedForFutureIssuancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gross number of shares which are to be issued during the future period as a result of any equity-based compensation plan or conversion of outstanding convertible instruments. Shares reserved for issuance could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and upon the conversion of outstanding convertible instruments.",
        "label": "Common Stock Reserved For Future Issuances Table [Text Block]",
        "terseLabel": "Summary of Common Stock Reserved for Issuance"
       }
      }
     },
     "localname": "CommonStockReservedForFutureIssuancesTableTextBlock",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_ContractManufacturingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract manufacturing costs current.",
        "label": "Contract Manufacturing Costs Current",
        "terseLabel": "Contract manufacturing costs"
       }
      }
     },
     "localname": "ContractManufacturingCostsCurrent",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DebtInstrumentCovenantNoncompliancePenalty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument covenant noncompliance penalty.",
        "label": "Debt Instrument Covenant Noncompliance Penalty",
        "terseLabel": "Loan agreement, covenant noncompliance penalty"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNoncompliancePenalty",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eigr_DebtInstrumentExitFeePayablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument exit fee payable percentage.",
        "label": "Debt Instrument Exit Fee Payable Percentage",
        "terseLabel": "Percentage of exit fee on principal balance"
       }
      }
     },
     "localname": "DebtInstrumentExitFeePayablePercentage",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eigr_DebtInstrumentExtendedInterestOnlyPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument extended interest only payment period.",
        "label": "Debt Instrument Extended Interest Only Payment Period",
        "terseLabel": "Extended term of interest only payment period"
       }
      }
     },
     "localname": "DebtInstrumentExtendedInterestOnlyPaymentPeriod",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_DebtInstrumentFairValueCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Fair Value Carrying Value [Abstract]",
        "label": "Debt Instrument Fair Value Carrying Value [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentFairValueCarryingValueAbstract",
     "nsuri": "http://www.eigerbio.com/20201231",
     "xbrltype": "stringItemType"
    },
    "eigr_DebtInstrumentFeeEnforceableMaximumPeriodFromFunding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument fee enforceable maximum period from funding.",
        "label": "Debt Instrument Fee Enforceable Maximum Period From Funding",
        "terseLabel": "Fee payable maximum period from funding"
       }
      }
     },
     "localname": "DebtInstrumentFeeEnforceableMaximumPeriodFromFunding",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_DebtInstrumentInterestPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest payment period.",
        "label": "Debt Instrument Interest Payment Period",
        "terseLabel": "Interest payment period"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentPeriod",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_DebtInstrumentPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment fee percentage.",
        "label": "Debt Instrument Prepayment Fee Percentage",
        "terseLabel": "Debt instrument prepayment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eigr_DebtInstrumentPrincipalAndInterestPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument principal and interest payment period.",
        "label": "Debt Instrument Principal And Interest Payment Period",
        "terseLabel": "Principal and interest payment period"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalAndInterestPaymentPeriod",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument success fees payable maximum period after approval.",
        "label": "Debt Instrument Success Fees Payable Maximum Period After Approval",
        "terseLabel": "Success fees payable maximum period after approval"
       }
      }
     },
     "localname": "DebtInstrumentSuccessFeesPayableMaximumPeriodAfterApproval",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_DebtInstrumentSuccessFeesPayablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument success fees payable percentage.",
        "label": "Debt Instrument Success Fees Payable Percentage",
        "terseLabel": "Percentage of success fee"
       }
      }
     },
     "localname": "DebtInstrumentSuccessFeesPayablePercentage",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eigr_DebtInstrumentUnamortizedAdditionalExitFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument unamortized additional exit fees.",
        "label": "Debt Instrument Unamortized Additional Exit Fees",
        "terseLabel": "Loan final repayment additional exit fees payable"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedAdditionalExitFees",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DebtInstrumentUnamortizedExitFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": -1.0
      },
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument unamortized exit fees.",
        "label": "Debt Instrument Unamortized Exit Fees",
        "negatedLabel": "Exit fee",
        "verboseLabel": "Loan final repayment exit fees payable"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedExitFees",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DebtInstrumentUnamortizedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument unamortized interest.",
        "label": "Debt Instrument Unamortized Interest",
        "negatedLabel": "Less: unamortized interest"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedInterest",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DeferredTaxAssetDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset Depreciation And Amortization",
        "label": "Deferred Tax Asset Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetDepreciationAndAmortization",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Lease Liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities Right Of Use Assets.",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DescriptionOfBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business.",
        "label": "Description Of Business [Abstract]"
       }
      }
     },
     "localname": "DescriptionOfBusinessAbstract",
     "nsuri": "http://www.eigerbio.com/20201231",
     "xbrltype": "stringItemType"
    },
    "eigr_DevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and regulatory milestones.",
        "label": "Development And Regulatory Milestones [Member]",
        "terseLabel": "Development and Regulatory Milestones [Member]"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_DevelopmentMilestoneObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone obligations.",
        "label": "Development Milestone Obligations",
        "terseLabel": "Development milestone payment obligations"
       }
      }
     },
     "localname": "DevelopmentMilestoneObligations",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_DevelopmentPhaseThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development phase three.",
        "label": "Development Phase Three [Member]",
        "terseLabel": "Development Phase 3 [Member]"
       }
      }
     },
     "localname": "DevelopmentPhaseThreeMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_DevelopmentPhaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development phase two.",
        "label": "Development Phase Two [Member]",
        "terseLabel": "Development Phase 2 [Member]"
       }
      }
     },
     "localname": "DevelopmentPhaseTwoMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_DividendsDeclared": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends declared.",
        "label": "Dividends Declared",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsDeclared",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_EIGTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EIG Transaction [Member]",
        "label": "E I G Transaction [Member]",
        "terseLabel": "EIG Transaction [Member]"
       }
      }
     },
     "localname": "EIGTransactionMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_EmployeesAndNonEmployeesStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and non employees stock option.",
        "label": "Employees And Non Employees Stock Option [Member]",
        "terseLabel": "Employees and Non Employees Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeesAndNonEmployeesStockOptionMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, debt, warrants and units, aggregate offering amount.",
        "label": "Equity Debt Warrants And Units Maximum Aggregate Offering Amount",
        "terseLabel": "Equity, debt, warrants and units, maximum aggregate offering amount"
       }
      }
     },
     "localname": "EquityDebtWarrantsAndUnitsMaximumAggregateOfferingAmount",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated useful life of property and equipment.",
        "label": "Estimated Useful Life Of Property And Equipment Table [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "EstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_ExpertConsultantFeesAndPassThroughCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expert consultant fees and pass through costs.",
        "label": "Expert Consultant Fees And Pass Through Costs",
        "terseLabel": "Expert consultant fees and pass through costs"
       }
      }
     },
     "localname": "ExpertConsultantFeesAndPassThroughCosts",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_FairValueTransfersBetweenLevelsTransfersAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value transfers between levels transfers amount.",
        "label": "Fair Value Transfers Between Levels Transfers Amount",
        "terseLabel": "Transfers in or out of level 3"
       }
      }
     },
     "localname": "FairValueTransfersBetweenLevelsTransfersAmount",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_FoodAndDrugAdministrationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Food and drug administration.",
        "label": "Food And Drug Administration [Member]",
        "terseLabel": "Food and Drug Administration [Member]"
       }
      }
     },
     "localname": "FoodAndDrugAdministrationMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_HoldersOfTenPercentOrMoreOfVotingPowerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Holders Of Ten Percent Or More Of Voting Power [Member]",
        "label": "Holders Of Ten Percent Or More Of Voting Power [Member]",
        "terseLabel": "Holders Of Ten Percent Or More Of Voting Power"
       }
      }
     },
     "localname": "HoldersOfTenPercentOrMoreOfVotingPowerMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_IncentiveBasedRegulatoryMilestoneFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive-based regulatory milestone fees.",
        "label": "Incentive Based Regulatory Milestone Fees",
        "terseLabel": "Incentive-based regulatory milestone fees"
       }
      }
     },
     "localname": "IncentiveBasedRegulatoryMilestoneFees",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in prepaid expenses and other current assets.",
        "label": "Increase Decrease In Prepaid Expenses And Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_IncreaseInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Deferred Tax Assets Valuation Allowance",
        "label": "Increase In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "IncreaseInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_IncreaseInMilestoneObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in milestone obligations.",
        "label": "Increase In Milestone Obligations",
        "terseLabel": "Increase in milestone payment obligations"
       }
      }
     },
     "localname": "IncreaseInMilestoneObligations",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment [Member]"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_LeaseCommencedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commenced date.",
        "label": "Lease Commenced Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencedDate",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "eigr_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee leasing arrangements operating leases term of contract month and year.",
        "label": "Lessee Leasing Arrangements Operating Leases Term Of Contract Month And Year",
        "terseLabel": "Long-term operating lease expiry period month and year"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "eigr_LicenseAgreementMilestonePaymentsPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone payments paid.",
        "label": "License Agreement Milestone Payments Paid",
        "terseLabel": "License agreement milestone payments paid"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsPaid",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_LicenseAgreementPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement potential milestone payments.",
        "label": "License Agreement Potential Milestone Payments",
        "terseLabel": "Aggregate potential milestone payments"
       }
      }
     },
     "localname": "LicenseAgreementPotentialMilestonePayments",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_LicenseMaintenanceFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fee annual.",
        "label": "License Maintenance Fee",
        "terseLabel": "License maintenance fee"
       }
      }
     },
     "localname": "LicenseMaintenanceFee",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_LoanPrepaidDuringFirstTwelveMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan prepaid during first twelve months.",
        "label": "Loan Prepaid During First Twelve Months [Member]",
        "terseLabel": "Loan Prepaid During First 12 Months [Member]"
       }
      }
     },
     "localname": "LoanPrepaidDuringFirstTwelveMonthsMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_LoanPrepaidDuringThirteenToTwentyFourMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan prepaid during thirteen to twenty four months.",
        "label": "Loan Prepaid During Thirteen To Twenty Four Months [Member]",
        "terseLabel": "Loan Prepaid During 13 to 24 Months [Member]"
       }
      }
     },
     "localname": "LoanPrepaidDuringThirteenToTwentyFourMonthsMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_MasterManufacturingServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master manufacturing services agreement.",
        "label": "Master Manufacturing Services Agreement [Member]",
        "terseLabel": "Master Manufacturing Services Agreement [Member]"
       }
      }
     },
     "localname": "MasterManufacturingServicesAgreementMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_MaximumEquityDebtWarrantsIssuedDuringThePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum equity debt warrants issued during the period.",
        "label": "Maximum Equity Debt Warrants Issued During The Period",
        "terseLabel": "Equity, debt, warrants and units, maximum issued and sale"
       }
      }
     },
     "localname": "MaximumEquityDebtWarrantsIssuedDuringThePeriod",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_MerckTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck transaction.",
        "label": "Merck Transaction [Member]",
        "terseLabel": "Merck Transaction [Member]"
       }
      }
     },
     "localname": "MerckTransactionMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_MilestoneObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone obligations.",
        "label": "Milestone Obligations",
        "terseLabel": "Milestone payment obligations"
       }
      }
     },
     "localname": "MilestoneObligations",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_MilestoneVestedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Vested Options [Member]",
        "label": "Milestone Vested Options [Member]",
        "terseLabel": "Milestone Vested Options [Member]"
       }
      }
     },
     "localname": "MilestoneVestedOptionsMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee stock option.",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Non-Employees Stock Option [Member]"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_NonRefundableIssueFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable issue fee.",
        "label": "Non Refundable Issue Fee",
        "terseLabel": "Non-Refundable Issue Fee"
       }
      }
     },
     "localname": "NonRefundableIssueFee",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares issued to underwriters as purchase option.",
        "label": "Number Of Additional Shares Issued To Underwriters As Purchase Option",
        "terseLabel": "Number of additional common stock issued"
       }
      }
     },
     "localname": "NumberOfAdditionalSharesIssuedToUnderwritersAsPurchaseOption",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of product candidates.",
        "label": "Number Of Product Candidates",
        "terseLabel": "Number of product candidates."
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "eigr_NumberOfSupplyChainsForEachProductCandidate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of supply chains for each product candidate.",
        "label": "Number Of Supply Chains For Each Product Candidate",
        "terseLabel": "Number of supply chains for each product candidate"
       }
      }
     },
     "localname": "NumberOfSupplyChainsForEachProductCandidate",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "eigr_OneTimePaymentToBeMadeOnAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One time payment to be made on asset purchase agreement.",
        "label": "One Time Payment To Be Made On Asset Purchase Agreement",
        "terseLabel": "One-time payment"
       }
      }
     },
     "localname": "OneTimePaymentToBeMadeOnAssetPurchaseAgreement",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use asset amortization.",
        "label": "Operating Lease Right Of Use Asset Amortization",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "eigr_OptionsGrantedToEmployeesAndNonEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options granted to employees and non employees.",
        "label": "Options Granted To Employees And Non Employees [Member]",
        "verboseLabel": "Options Granted to Employees and Non Employees [Member]"
       }
      }
     },
     "localname": "OptionsGrantedToEmployeesAndNonEmployeesMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_OptionsIssuedAndOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued and outstanding.",
        "label": "Options Issued And Outstanding",
        "terseLabel": "Options issued and outstanding"
       }
      }
     },
     "localname": "OptionsIssuedAndOutstanding",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_OptionsToPurchaseOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase of common stock.",
        "label": "Options To Purchase Of Common Stock",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "OptionsToPurchaseOfCommonStock",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_OtherPrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other prepaid expense and other assets current classified as other.",
        "label": "Other Prepaid Expense And Other Assets Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_OxfordLoanAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford loan amendment.",
        "label": "Oxford Loan Amendment [Member]",
        "terseLabel": "Amendment [Member]"
       }
      }
     },
     "localname": "OxfordLoanAmendmentMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_OxfordLoanFifthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford loan fifth amendment.",
        "label": "Oxford Loan Fifth Amendment [Member]",
        "terseLabel": "Fifth Amended Oxford Loan [Member]"
       }
      }
     },
     "localname": "OxfordLoanFifthAmendmentMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_OxfordLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford loan.",
        "label": "Oxford Loan [Member]",
        "terseLabel": "Oxford Loan [Member]"
       }
      }
     },
     "localname": "OxfordLoanMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_POMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock by a private company to the public.",
        "label": "P O [Member]",
        "terseLabel": "Public Offering [Member]"
       }
      }
     },
     "localname": "POMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_PRFCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PRF collaboration agreement .",
        "label": "P R F Collaboration Agreement [Member]",
        "terseLabel": "Progeria Research Foundation (PRF) Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "PRFCollaborationAgreementMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_PatheonIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patheon, Inc.",
        "label": "Patheon Inc [Member]",
        "terseLabel": "Patheon, Inc. [Member]"
       }
      }
     },
     "localname": "PatheonIncMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_PaymentForAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for asset purchase agreement.",
        "label": "Payment For Asset Purchase Agreement",
        "terseLabel": "Payment for asset purchase agreement"
       }
      }
     },
     "localname": "PaymentForAssetPurchaseAgreement",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_PaymentsOfDeferredOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of deferred offering costs.",
        "label": "Payments Of Deferred Offering Costs",
        "negatedLabel": "Payment of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfDeferredOfferingCosts",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of product manufactured on the basics of annual forecasts.",
        "label": "Percentage Of Product Manufactured On The Basics Of Annual Forecasts",
        "terseLabel": "Percentage of product manufactured on the basics of annual forecasts"
       }
      }
     },
     "localname": "PercentageOfProductManufacturedOnTheBasicsOfAnnualForecasts",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eigr_PercentageOfPurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of purchase price.",
        "label": "Percentage Of Purchase Price",
        "terseLabel": "Percentage of purchase price"
       }
      }
     },
     "localname": "PercentageOfPurchasePrice",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eigr_PrepaidContractManufacturingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid contract manufacturing costs.",
        "label": "Prepaid Contract Manufacturing Costs",
        "terseLabel": "Prepaid contract manufacturing costs"
       }
      }
     },
     "localname": "PrepaidContractManufacturingCosts",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_PrepaidResearchCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration paid in advance for research that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Research Costs",
        "terseLabel": "Prepaid research costs"
       }
      }
     },
     "localname": "PrepaidResearchCosts",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_PrepaymentOfLoanFeeDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment of loan fee description.",
        "label": "Prepayment Of Loan Fee Description",
        "terseLabel": "Prepayment of loan fee, description"
       }
      }
     },
     "localname": "PrepaymentOfLoanFeeDescription",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_ProductAgreementDateOfExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product agreement date of expiration.",
        "label": "Product Agreement Date Of Expiration",
        "terseLabel": "Product agreement date of expiration"
       }
      }
     },
     "localname": "ProductAgreementDateOfExpiration",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "eigr_ProductAgreementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product agreement renewal term.",
        "label": "Product Agreement Renewal Term",
        "terseLabel": "Product agreement renewal term"
       }
      }
     },
     "localname": "ProductAgreementRenewalTerm",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_ProductAgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product agreement termination notice period.",
        "label": "Product Agreement Termination Notice Period",
        "terseLabel": "Product agreement termination notice period"
       }
      }
     },
     "localname": "ProductAgreementTerminationNoticePeriod",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "eigr_ProductDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product development agreement.",
        "label": "Product Development Agreement [Member]",
        "terseLabel": "Product Development Agreement [Member]"
       }
      }
     },
     "localname": "ProductDevelopmentAgreementMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_ProductDevelopmentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product development fees.",
        "label": "Product Development Fees",
        "terseLabel": "Product development fees"
       }
      }
     },
     "localname": "ProductDevelopmentFees",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_ProductOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product One [Member]",
        "label": "Product One [Member]",
        "terseLabel": "Farnesyl Transferase Inhibitors and Related Intellectual Property [Member]"
       }
      }
     },
     "localname": "ProductOneMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property Plant And Equipment Capitalized Interest Costs [Abstract]",
        "label": "Property Plant And Equipment Capitalized Interest Costs [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentCapitalizedInterestCostsAbstract",
     "nsuri": "http://www.eigerbio.com/20201231",
     "xbrltype": "stringItemType"
    },
    "eigr_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement.",
        "label": "Purchase Agreement [Member]",
        "terseLabel": "BMS Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_RepaymentOfAccruedExitFeeAndSecondAmendmentFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of accrued exit fee and second amendment fee.",
        "label": "Repayment Of Accrued Exit Fee And Second Amendment Fee",
        "negatedLabel": "Repayment of accrued exit fee and second amendment fee"
       }
      }
     },
     "localname": "RepaymentOfAccruedExitFeeAndSecondAmendmentFee",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_RepaymentsOfLoanAgreementExitFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of loan agreement exit fee.",
        "label": "Repayments Of Loan Agreement Exit Fee",
        "terseLabel": "Repayments of loan agreement exit fee"
       }
      }
     },
     "localname": "RepaymentsOfLoanAgreementExitFee",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_RestatedTwoThousandThirteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restated 2013 Equity Incentive Plan [Member]",
        "label": "Restated Two Thousand Thirteen Equity Incentive Plan [Member]",
        "terseLabel": "Restated 2013 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "RestatedTwoThousandThirteenEquityIncentivePlanMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_RoyaltiesExpirationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties expiration description.",
        "label": "Royalties Expiration Description",
        "terseLabel": "Royalties expiration description"
       }
      }
     },
     "localname": "RoyaltiesExpirationDescription",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of prepaid expenses and other current assets.",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of restricted stock units granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Restricted Stock Units Granted",
        "negatedLabel": "Shares Available for Grant, Restricted stock units granted",
        "terseLabel": "Restricted stock units granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfRestrictedStockUnitsGranted",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised",
        "terseLabel": "Shares Available for Grant, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant forfeited or cancelled.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited Or Cancelled",
        "terseLabel": "Shares Available for Grant, Forfeited or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedOrCancelled",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant options granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Granted",
        "negatedLabel": "Shares Available for Grant, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award threshold shareholder ownership percentage for pre-determined Exercise Price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Shareholder Ownership Percentage For Pre Determined Exercise Price",
        "terseLabel": "Threshold ownership percentage of shareholder for grant of options at pre determined exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdShareholderOwnershipPercentageForPreDeterminedExercisePrice",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "eigr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options outstanding, weighted average exercise price, and additional disclosures.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Exercise Price And Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract",
     "nsuri": "http://www.eigerbio.com/20201231",
     "xbrltype": "stringItemType"
    },
    "eigr_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "eigr_StockIssuedDuringPeriodSharesProductDevelopmentAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares product development agreement.",
        "label": "Stock Issued During Period Shares Product Development Agreement",
        "terseLabel": "Issuance of common stock under Product Development Agreement, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesProductDevelopmentAgreement",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_StockIssuedDuringPeriodValueProductDevelopmentAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value product development agreement.",
        "label": "Stock Issued During Period Value Product Development Agreement",
        "terseLabel": "Issuance of common stock under Product Development Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueProductDevelopmentAgreement",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_TrancheAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche A.",
        "label": "Tranche A [Member]",
        "terseLabel": "Tranche A [Member]"
       }
      }
     },
     "localname": "TrancheAMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_TrancheBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche B.",
        "label": "Tranche B [Member]",
        "terseLabel": "Tranche B [Member]"
       }
      }
     },
     "localname": "TrancheBMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_TrancheCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche C.",
        "label": "Tranche C [Member]",
        "terseLabel": "Tranche C [Member]"
       }
      }
     },
     "localname": "TrancheCMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_TwoThousandThirteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2013 Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Thirteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2013 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandThirteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_UPennCHOPAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "U Penn C H O P Agreement [Member]",
        "terseLabel": "UPenn/CHOP Agreement [Member]"
       }
      }
     },
     "localname": "UPennCHOPAgreementMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_USGovernmentBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. government bonds.",
        "label": "U S Government Bonds [Member]",
        "terseLabel": "US Government Bonds [Member]"
       }
      }
     },
     "localname": "USGovernmentBondsMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_UnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting agreement.",
        "label": "Underwriting Agreement [Member]",
        "terseLabel": "Underwriting Agreement [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementMember",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "eigr_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_UpfrontCashPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payments.",
        "label": "Upfront Cash Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontCashPayments",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eigr_VestingOfOptionsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of options to purchase common stock.",
        "label": "Vesting Of Options To Purchase Common Stock",
        "terseLabel": "Vesting of options to purchase common stock"
       }
      }
     },
     "localname": "VestingOfOptionsToPurchaseCommonStock",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "eigr_VestingPeriodOfOptionsIssuedForCommonStockPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period of options issued for common stock purchase.",
        "label": "Vesting Period Of Options Issued For Common Stock Purchase",
        "terseLabel": "Options to purchase common stock vesting period"
       }
      }
     },
     "localname": "VestingPeriodOfOptionsIssuedForCommonStockPurchase",
     "nsuri": "http://www.eigerbio.com/20201231",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r220",
      "r221",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r388",
      "r432",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r220",
      "r221",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r388",
      "r432",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r146",
      "r207",
      "r208",
      "r389",
      "r431",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r146",
      "r207",
      "r208",
      "r389",
      "r431",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r210",
      "r220",
      "r221",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r388",
      "r432",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r210",
      "r220",
      "r221",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r388",
      "r432",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r147",
      "r148",
      "r207",
      "r209",
      "r434",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r207",
      "r209",
      "r434",
      "r459",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Palo Alto, California [Member]"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Amortization of debt securities premiums and discounts"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r35"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits Current",
        "terseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r184"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r47",
      "r48",
      "r49",
      "r423",
      "r440",
      "r441"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r46",
      "r49",
      "r50",
      "r94",
      "r95",
      "r96",
      "r309",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r222",
      "r224",
      "r259",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r200",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance of common stock upon public offering, issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r224",
      "r249",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Compensation expense related to the time-vested/milestone vested options",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r78",
      "r334"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization Of Financing Costs And Discounts",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r88",
      "r138",
      "r140",
      "r144",
      "r161",
      "r305",
      "r310",
      "r322",
      "r404",
      "r421"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r43",
      "r88",
      "r161",
      "r305",
      "r310",
      "r322"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Financial assets",
        "verboseLabel": "Assets, Fair Value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail": {
       "order": 11250.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Debt securities, Unrealized gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail": {
       "order": 11260.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Debt securities, Unrealized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r155",
      "r168"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Debt securities, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r151",
      "r156",
      "r168",
      "r408"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail": {
       "order": 11270.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Debt securities, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r153",
      "r168"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Debt securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r225",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r93",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r27",
      "r80"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Cash equivalents, Estimated Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r81",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash Cash Equivalents And Short Term Investments",
        "terseLabel": "Cash, Cash Equivalents, and Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r80",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r323"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r86",
      "r88",
      "r106",
      "r107",
      "r108",
      "r110",
      "r112",
      "r116",
      "r117",
      "r118",
      "r161",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r300",
      "r301",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Collaboration, and Product Development Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r192",
      "r409",
      "r427"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common Stock Reserved for Issuance",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2020 and 2019; 33,878,486 and 24,523,381 shares issued and outstanding as of December 31, 2020 and 2019, respectively",
        "verboseLabel": "Aggregate fair value of shares issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r52",
      "r54",
      "r55",
      "r59",
      "r411",
      "r429"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r126",
      "r127",
      "r149",
      "r320",
      "r321",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r121",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskSupplier": {
     "auth_ref": [
      "r124",
      "r125",
      "r127",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of risks that arise due to the volume of business transacted with a particular supplier or reliance placed on that supplier. At a minimum, the description informs financial statement users of the general nature of the risk.",
        "label": "Concentration Risk Supplier",
        "terseLabel": "Concentration risk, supplier"
       }
      }
     },
     "localname": "ConcentrationRiskSupplier",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r126",
      "r127",
      "r149",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r211",
      "r219",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r405",
      "r406",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument Basis Spread On Variable Rate1",
        "terseLabel": "Loan agreement, percentage to be added to the interest rate under condition"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r196",
      "r406",
      "r420"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DebtInstrumentFaceAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount",
        "totalLabel": "Total future payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCovenantCompliance": {
     "auth_ref": [
      "r15",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.",
        "label": "Debt Instrument Covenant Compliance",
        "terseLabel": "Loan agreement, covenant compliance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCompliance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "auth_ref": [
      "r15",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.",
        "label": "Debt Instrument Covenant Description",
        "terseLabel": "Loan agreement, covenant description"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument Description Of Variable Rate Basis",
        "terseLabel": "Loan agreement, floating rate terms"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r333",
      "r335"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Face value of term loan",
        "totalLabel": "Face value of term loan",
        "verboseLabel": "Face value of long term debt"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Loan agreement, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r38",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Loan, maturity period"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument Redemption Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r39",
      "r90",
      "r201",
      "r202",
      "r203",
      "r204",
      "r332",
      "r333",
      "r335",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r197",
      "r334"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net",
        "negatedLabel": "Unamortized debt discount associated with exit fee, debt issuance costs and loan origination fees"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt Policy [Text Block]",
        "terseLabel": "Deferred Financing Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Deferred Finance Costs Gross",
        "verboseLabel": "Loan origination fees and debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "negatedTotalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r284",
      "r285",
      "r286"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r280"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r266",
      "r281"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r78",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation [Abstract]"
       }
      }
     },
     "localname": "DepreciationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r78",
      "r136"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per common share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Provision (benefit) for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r268",
      "r293"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r268",
      "r293"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r268",
      "r293"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r268",
      "r293"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r268",
      "r293"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r268",
      "r293"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted-average period for recognition (in years)",
        "verboseLabel": "Weighted average period expected to recognized compensation expense (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognised compensation expense related to unvested restricted shares"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employees Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r115",
      "r162",
      "r200",
      "r205",
      "r253",
      "r254",
      "r255",
      "r289",
      "r290",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r315",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r211",
      "r212",
      "r217",
      "r219",
      "r315",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r211",
      "r212",
      "r217",
      "r219",
      "r315",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r315",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r178",
      "r179",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r175",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Impairment Of Investments",
        "terseLabel": "Other-than-temporary impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r78",
      "r181",
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment Of Long Lived Assets Held For Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r180",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r269",
      "r277",
      "r283",
      "r291",
      "r294",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r89",
      "r104",
      "r105",
      "r137",
      "r267",
      "r292",
      "r295",
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r85",
      "r264",
      "r265",
      "r277",
      "r278",
      "r282",
      "r287",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase Decrease In Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase Decrease In Other Noncurrent Liabilities",
        "terseLabel": "Other long term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r57",
      "r135",
      "r331",
      "r334",
      "r412"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r72",
      "r75",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r62",
      "r134"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance Of Stock And Warrants For Services Or Claims",
        "terseLabel": "Common stock issued under Product Development Agreement"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject To Ground Leases",
        "terseLabel": "Total leased space"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases Of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters And Contingencies [Text Block]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLegalMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Maturity of Operating Leases Liabilities and Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total undiscounted payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "Operating leases minimum payments, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "Operating leases minimum payments, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "Operating leases minimum payments, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "Operating leases minimum payments, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r88",
      "r141",
      "r161",
      "r306",
      "r310",
      "r311",
      "r322"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r88",
      "r161",
      "r322",
      "r407",
      "r425"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r88",
      "r161",
      "r306",
      "r310",
      "r311",
      "r322"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r15",
      "r406",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line Of Credit",
        "terseLabel": "Loan outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line Of Credit Facility Maximum Borrowing Capacity",
        "terseLabel": "Loan agreement, aggregate borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line Of Credit Facility Remaining Borrowing Capacity",
        "terseLabel": "Loan agreement, remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate L I B O R [Member]",
        "terseLabel": "LIBOR [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r198",
      "r406",
      "r422"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt",
        "totalLabel": "Total long term debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfLongTermDebtAndUnamortizedDiscountBalancesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r92",
      "r195"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r92",
      "r195"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r92",
      "r195"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r92",
      "r195"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtScheduleOfFutureMinimumPaymentsOfPrincipalExitFeeAndInterestExpenseUnderOxfordTermLoanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Noncurrent",
        "terseLabel": "Long term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r51",
      "r53",
      "r58",
      "r79",
      "r88",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r104",
      "r105",
      "r109",
      "r138",
      "r139",
      "r142",
      "r143",
      "r145",
      "r161",
      "r322",
      "r410",
      "r428"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r138",
      "r139",
      "r142",
      "r143",
      "r145"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Rent expense recognized for company's operating leases"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "totalLabel": "Present value of future lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "negatedLabel": "Less: current portion of operating lease liabilities",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeasesLiabilitiesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r340",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash outflows for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r345",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r344",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r35"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive (loss) gain:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r45",
      "r47"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized (loss) gain on available-for-sale debt securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r64",
      "r67",
      "r152"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments To Acquire Available For Sale Securities Debt",
        "negatedLabel": "Purchase of debt securities available-for-sale"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r225",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the fair values, as of the date of each statement of financial position presented, of securities that are restricted as collateral for the payment of related debt obligations, primarily secured borrowings and repurchase agreements, and that are reclassified and separately reported in the statement of financial position because the transferee has the right by contract or custom to sell or re-pledge them.",
        "label": "Pledged Assets Separately Reported Securities Pledged As Collateral At Fair Value",
        "terseLabel": "Security deposit of collateral for lease"
       }
      }
     },
     "localname": "PledgedAssetsSeparatelyReportedSecuritiesPledgedAsCollateralAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense And Other Assets Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r3",
      "r5",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds From Debt Net Of Issuance Costs",
        "terseLabel": "Proceeds from borrowings in connection with term loan, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock upon public offering,net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r70",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds From Lines Of Credit",
        "terseLabel": "Borrowings from loan agreement"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r64",
      "r65",
      "r152"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Sale And Maturity Of Available For Sale Securities",
        "terseLabel": "Proceeds from maturities of debt securities available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds From Sales Of Business Affiliate And Productive Assets",
        "terseLabel": "Proceeds from sale"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r252"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds From Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock upon ESPP purchase"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r51",
      "r53",
      "r73",
      "r88",
      "r97",
      "r104",
      "r105",
      "r138",
      "r139",
      "r142",
      "r143",
      "r145",
      "r161",
      "r304",
      "r307",
      "r308",
      "r312",
      "r313",
      "r322",
      "r413"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r183"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r185",
      "r426"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r85",
      "r185",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RegulatoryAgencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of regulatory agency.",
        "label": "Regulatory Agency [Axis]",
        "terseLabel": "Regulatory Agency"
       }
      }
     },
     "localname": "RegulatoryAgencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RegulatoryAgencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization that establishes and ensures compliance with rules or regulations.",
        "label": "Regulatory Agency [Domain]",
        "terseLabel": "Regulatory Agency"
       }
      }
     },
     "localname": "RegulatoryAgencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r218",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r218",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r218",
      "r350",
      "r352",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r348",
      "r349",
      "r351",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments Of Secured Debt",
        "negatedLabel": "Repayment of term loan"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r262",
      "r472"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Development [Member]",
        "verboseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r85",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units, Unvested [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r205",
      "r256",
      "r424",
      "r439",
      "r441"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r162",
      "r253",
      "r254",
      "r255",
      "r289",
      "r290",
      "r436",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Components of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]",
        "terseLabel": "Summary of Estimated Value of Cash Equivalents and Debt Securities and Gross Unrealized Holding Gains and Losses"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule Of Debt Table [Text Block]",
        "terseLabel": "Schedule of Long-Term Debt and Unamortized Discount Balances"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r224",
      "r248",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Non-cash Stock Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
        "terseLabel": "Schedule of Future Minimum Payments of Principal, Exit Fee and Interest Expense under Oxford Term Loan"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r225",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r232",
      "r238",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Weighted-average assumptions used in Black-Scholes Model to estimate fair value of stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r276",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r223",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Description",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfNonCashStockBasedCompensationExpenseDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized",
        "verboseLabel": "Shares Available for Grant, Additional options authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Issuance of common stock authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r251"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "periodEndLabel": "Shares Available for Grant, Outstanding, Ending balance",
        "periodStartLabel": "Shares Available for Grant, Outstanding, Beginning balance",
        "terseLabel": "Options available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCommonStockReservedForIssuanceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Options, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Option, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Options, Forfeited or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "positiveLabel": "Number of Options, Granted",
        "terseLabel": "Stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of employee option grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r234",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options, Outstanding, Ending balance",
        "periodStartLabel": "Number of Options, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Option, Outstanding, Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price Per Option, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Percentage increase in number of shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period",
        "terseLabel": "Number of common stock issued subject to quarterly vesting requirements"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r223",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Option, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Option, Forfeited or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Option, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Contractual terms of options granted under the Plan"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r245",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "verboseLabel": "Weighted Average Remaining Contractual Life, Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Life, Ending balance",
        "verboseLabel": "Contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedInBlackScholesModelToEstimateFairValueOfStockOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
        "terseLabel": "Grant date fair value of employee options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1",
        "terseLabel": "Options to purchase of common stock exercise price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Common stock, offering price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r86",
      "r88",
      "r106",
      "r107",
      "r108",
      "r110",
      "r112",
      "r116",
      "r117",
      "r118",
      "r161",
      "r200",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r42",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r115",
      "r162",
      "r200",
      "r205",
      "r253",
      "r254",
      "r255",
      "r289",
      "r290",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r115",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r200",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock upon ESPP purchase, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r200",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "positiveLabel": "Sale of common stock",
        "terseLabel": "Issuance of common stock upon public offering, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period Shares Purchase Of Assets",
        "terseLabel": "Shares issued for purchased assets"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r200",
      "r205",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Issuance of common stock upon stock option exercises, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockOptionActivityDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r200",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock upon ESPP purchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r200",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock upon public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period Value Purchase Of Assets",
        "terseLabel": "Common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r200",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon stock option exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r88",
      "r150",
      "r161",
      "r322"
     ],
     "calculation": {
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r355",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndProductDevelopmentAgreementsAdditionalInformationDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "U S Treasury Bill Securities [Member]",
        "terseLabel": "US Treasury Bill Securities [Member]"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsEstimatedValueOfCashEquivalentsAndDebtSecuritiesAndGrossUnrealizedHoldingGainsAndLossesDetail",
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r263",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions",
        "terseLabel": "Reductions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions",
        "negatedLabel": "Reductions based on tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Accrued interest and penalties associated with uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties Expense",
        "terseLabel": "Penalties charged in relation to unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits Interest On Income Taxes Expense",
        "terseLabel": "Interest charged in relation to unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits impact on effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r119",
      "r120",
      "r122",
      "r123",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r342",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease payments for operating leases"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/DisclosureAssetPurchaseAgreementsAndRelatedLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.eigerbio.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99380358&loc=d3e7102-108593"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r473": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r474": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r475": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r476": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r477": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r478": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r479": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r480": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r481": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0001564590-21-011758-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-011758-xbrl.zip
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MH>=/PC,LG_=LL>1"&RLN=/_/PZO&WHH+W6FN;:$7W/)^YW8H6KX?CO2JQ\*
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M7<Y"*#B2KHAPI2NV.*[8W&@3N=5!?\8CN\BN*1I.Y\ QFQ.3.1=.N_5J"!O
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M\&U#A $&?/H5UG:,VB;KIEOG3]P(")C,[3,O B+C/O/'PL S.I-9#K,"GQD
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M=NOR_JQUUUI!Q'9U_=B+J/8GMI LY6 I!TLYF)/]*^4@RL&#4@Z6<C!3#AZ
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M!NX+$0V'^E+TZ03BU-A-XJ/R.[3/6/^65'?Y*J 6&&D2[4!_X-@="K9$D&&
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M:)'O!#08CU<]TF03_JP^1RI%1$;9GE8+,%%:,S!.3B_4+X:6#70!VB8@V#7
M:-0#@FG6*TAI=:FD7%&B-;[0"H.AZVDEMX51R(;\>^NJU2)^*EUUGD K(1;=
M49>5*U1(T)/%6C!+ V!]?M7:EIS]42CO,N"]*0S+EW)!]UQUB6;M/JY%LH$B
MHR9I?[HDJX6=5+%1/$H;O61U^ @R[1'DV%SU2"E9L!/ >*(*5G/T)>1YL8I'
M%550@Y*$,4>%(H%,M655R*,?UY#%>]2\(4/#C93;&NO"KF( #BI*Y).3LX7O
M)I@9>1NO@":_LRY(W[&6GSN'G]B9.P02.G6],6 :/K(MA4&C3HN(AAMGB7L:
M^,3#KJ1V]6J"<?/=OT*KUV-;)U==/=(^^:65OF];,%@X=ATYH<C9CA^#=]1O
MI;1*H=CXV/RXDP $4&(E$9NOBQED*+:HTH.@&8%Z882V\*77&+@!S,&TP/A
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M^QX5#)H0KFF_!27_H+\KHF6,!!I3N4:J@A14QQ[&UF+D49*W(7'T9VRB*9:
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MC3O<M#SM5AY93\2>*0X"W=NXS3*R9<"VKJ[N[K;9(TI4'49$I(-\'(,CB+&
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MFY4]L%^\[(%<;/9+3&+=>_N+-1HPWS-^_3#X=^]Q&.ST=V%'R4'0K/UK//C
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M5*"490&E,:!R5C)TDRGK0)7/4]1(I++AY<>."AI(GW>XSGIJWE2PD-TQH,K
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M!J'?5^$\O8MJ+(I06._Z<CRNF%_5S/K'$R*\27A5(B,X@$G$.)A*D%F<ZS9
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M?7CK4]<R'6F!08D2Y_9W)5PXR^V1M+S R?H.B]"GUDNNXE*E#T=,=-V6?:M
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M1LFV(L:[G'HM':)E<;H&,5V(>%4^CUQV,0YR10Q?F^TZ&;^_;$AK3M],AKD
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ML0$7:NT3F;B#C'[>'NU8*OI+LEP<:WE#FJ3M-"ICF$$^Y:<<.WTT.WCQ'BT
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M1R<\!&&8[@B#, ]YN,FE"_#%- \Y-PS7Z;IFSIXJ'M?7!K+OR'OI"=L3_&.
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MYT@F<:B"ST2!QHV6ESB1'L4_$P77DKF+'!Q%56J8T:FJ 6FHPO79)^O<Z?\
MCO13/\1G5=<@#;CEI1)1K+@;/13A_R](PMHQC":SQ'>C"P&WL(!/VLV#[ILI
M&S_[<D,:F2TIJ$& C!>9XRV\RN;[FHXSS]:U1T'8R+S9>Y[;>[J?N;U/?F$_
ME5S?S\6$"ST*2'H"P20X.00+>]FMC'AAL%(-222#P>K,-*=/<5<#R7'U_$UT
M?BE:KD[7T0SZRYC"J)>'-E!1E(6#@O SQ2ZR<OUQ^XO2=SS$=+,X/V9#"8OH
MD%0Q DTA*:%RA<LOUD[2P1UK(Y!#>."+9FV0CD70N27J\]"8@@.\8I!OBOF5
M<%;ERX+:)BR4Q)<".IR.39JI)69CBJ3!/K$'X&>:1IK#B"9F0.IL!PNT $]Y
MUTA[<>O.#2E7@2'7;M,@_.WS3+O$GF"1S[5Q):IB(N3ZABM@%\8Y!JUA>,O8
MXJQ7;-"<M]3A/AA$TGVH\G4O9,;0-6A=P ']MS@M4 "HY#HZ.JRV' F77F+U
MR'<"7BX=,TTV=-/NH9C?K<1RSRTW<:Y/>M/7W15U420;5"[BKA !"'XC8"FY
MI4LUV8K%(/#J6;5L C1:"2HK?U!GD6$-+9OSD,[T@#JZU&ET>=$ ,Y?-<-,[
M,LW"#0Y'/QQS_+1NF"*IT\!7L%.;M4#M'LA=#@><)G;5=&M*L*;UJ<U-'09Y
M5:Y%T!(0;&5\'P4]^*JH@,H?; OC]<K5"C1-U/^+#N5L55"\F,!ND^L&^)6P
MW2H<5&(D3X\WU,<']Q2W,@@@BK2V,V(%I)9H6AY;$AGEZ:G@0IJ+*E*R<I<R
M7KYD7V3;1]L2]\-:97 >'F_UW0JGSJ%GV7=N@YW(O*,N83F $76/2@\$JVFT
MB-$;,(+_*NSVO+MY4#T4Y>#:47*HW=.$:Y]\*7Q3/KS1KRZ&GSA<E8N;(.OW
M.U'W:I<5/V4.1)-]A\1'("MVQIW2 '<5\%0]5;S/R1K(D@'>(0=[NVO!/5+#
M&6LNZ5BZ\78?<CLHJY.(;9:_B8$5!Z#J?<.$%+=IY@^LJ6I,CM*07\Z%/6[L
MM]D,UC\[6E>F+5P_';<-%G]C\&J*N\2M3L..6AMF\?[KIJ+01;OUWW9M3A79
M'NRV@DA>AQ_34:SZZC+?Q#*F<80UBR!9!Q["FFH$;ZT)K4P+G$#2HGC:J*S"
M>ER6RPTW!2$@7+3\>#.2O .%J-BS'\F^NVG=*.T8(2N5R[Z7A3*5R3Y&>,,O
MX3AU"YUN['%4:)L.V^$NKW ")+X' ]5Z1^.TXL0S\"GVX"!['5_-?.&SS<1E
M':6!@K2R;#A..>0C<)1:-X719DSTE)_DOPV[CUUFB)8WM8<G-/C[0:SB /3[
M+9I?+K$'E EPC7F7Z):JJ5;)3#E<N<2S1<:X%"5V>B'I;(K---*BWAA_H^2R
M#'H9KM?-E$\Y63^YHXVA122S6%)(EW"PD>Z1BWR5HV?%DEOT+,KNLFDY"XC[
M'LY^([=?R&R5K)$SN(36$X_'I8@FX O93(LI>M2/R7O#;>DW6LI*HBX;CE;.
M&8T-O[\JM#N-H ,8%%I84S&KO>Q),E>:LX+4ZA4QV SW/)LEGA;7MDS>50T3
M4\(,7R\2EYNO;M]*L2R$5GS-O2HAXS)BW;W79K_L-P#1QSJ3N,@D-C&!MFG4
MQG]-(@@C(+&S!T3ZCRJ<M-[\:/:S](-N6I@GA(Y&?6-:11-;#F8.0#UOJBH(
MH39'&1/\&/GR$)$,$+/H?T>'TTZCDMU\D3ZA?E5:R,-@DWEIO;)CDU%D"Z:Z
M+Y;:(M2>-NBHJ(5&6'"MYL%GI3J<_ZGW'XRSKC>FR-8J^-*\DDQR+TT"((Z3
M)A]^::UJ+=.X%QJD2]6X2 Y&JSLF4'#RHE]INE#;';+>-0W2+TP'"UE&<1]6
MP:,N$Q($AZD9%!;NJO22)BF^E%!@F,,T@PUIRL9MUTW+G;"F3=S$!#0_MYET
M<-&B;MJ,VVO.I;>-7D!_L]*:T:2RC10FVO"U,T<$KY8?9UQ>_)3 I+8=&<Q\
MSESD(O<FIG1&=72N4B)]\(I2GM([.H*GNN:02@JH?4!!JKP*JX?\L:F ])&Q
M0),OLO^6_2WR#2H"@;N&,(D1)2F+G6-6%J^>4!QAT9X1IYCP25MQ+J%)KAN6
M9,VZK ?T7PR*(J%2E7Q9JXH6D\-!X@XDD:>7\Z("+^SW93&_(H*T35&R[_)#
MTP;7^[;9ENR1]U5'VP0L"J7*X*KQAK(+)L%W^J%L$-;V^\[%#EF4-HX3/+<N
M(_+D>%04$ZW?DNH,T EP4D!XZ!Q+WL+V)?+2D:]CXU..\UCL]-W+O_[I[.7S
M-QDY)7.2F8LRORBPCG41-FM1<.,6O/)^)P(?'N]?(O 6(?HOE)J?"L5K.._
MA4-K!7G4E-35M'#W0)(R\NMMMT3AGJ*"KTL*,Z2= 7;*"LY[B6G'STTIRBW:
M,&".VX#M"U&CS+,'T5VV)%E9UT'E<!P+00.PXB0B5B!CA5J_&EV'^@;WCWK
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MC2PW92N$KI[ZK<<P"%_'0<#VJLM/G?SSZWM*_OD'U IXK/Y;:?HG#^J_1"R
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ME&?2IM#M1UT'-$N2 CY-=BQN"G:*'B_ +WKRQ<<Y$5=%(!B3@!_9"FPN&??
M[5D2<=1@7XCGP4N(G$2X>M#>B%YV:-T+,H60J%U#WM .IOI^#ULE6&/6\ =+
M'W&0 @\M]H>@J>Z_J4L=/PG(MP?W60S5U1;-4%KG 29@(:1LFRY,P*0RNZ2H
M5FKJ A9NX!,^F.DOC0MN">N5KPE^0+=;UF0*+R+--_KH-3SASM<[E0W&UW$?
M<-/)>@W&G3_UF@X39["?\)# >RP(?OTRX+USF^V]8'M[U15IC4TN/>/6P4B5
M=&Z888HN5U%4MD51EF;O5ASSUV?7O\ 6AEF $;4._SB<2[,B'US"3<8GEQK?
MQL.SJT4&@,\GG78_$  PY(2KOS:^0..S! 8)7%WZ3.'PXPT?H*L"C^(4]T]-
MPZ?'GPTKF+W 7G .9V:&4P@/G GW$7BH% @>/>%KAPYLNZW0OV W=A$]S.@K
MZ+/7U<KA3&!S0=/*L("+!E@"VY=<'QY6^,N.:))X']/PZY)2PGFS)#"PR];#
M'A^,1IR>D  #[#&\>X.,=%U3H/<&T&47#,5TU)("]-C2%S &9M_=3BS''L.<
M(A3Q$2132714S(!O@OWCDQ&/X JC6T53H6]&+Y$ \OX_,/$E2@J9&'7*?$?H
M; 4C<!3N"HV8-1JA]&)#HG(-ERHXG8"?!X.%/V9">0#.Q"EY8J7*0(^;.QR,
MI7OC#</D>:O4TNMR%QVS8I'Y*7R0,9>D'M6^;PX!"5_]H.<T@!(.>,N/@]XN
MVISW-\F1Y-G__MO/C[^F  @'G\L,UM=+](\OODO+]\GK]9J"D6]A&K 2C#V\
M'U]^]_KM @]<8V-GBQ!O'RA4Q5,KX =#C[",V[23^GP^W7Q4/<%5=(^-(1GA
M;V"$R^3_= 4%J+_F+?ITF[MU\OP#[")BII3M(1[@O\-X9.#EO? VY5.8''0]
MKCK (]I0#UX\O7JHB"X+%\D[S!2A!]B5*PJ\IPR2\"6:*(IM5<E^FR+*=?Q'
M K^UN03_<WGDI YNKC6:9(][*$=/?OGN,GGA,L+?MP!I];7#-8'6\._P$(1=
MGBSVJH"U4C(IYUL_WV_) GA*(=C6H= B3+ISG#'5W])NKG.,0\/3P%FUD9L'
M QR/A+SUM@>EC!JP0H5.  .V^"_Z5H:G1CUX9_^D[R3R_!JL]!)7ADX*7$#W
M1?+N]0L<;LH@X<K[8%<W#!\< S4L&K1SX?8=&+=I)-.V *=V]9X_^S,&V3M
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MXXIEU8H>6FJC@TLV6*!D."*C"#XK&QX-OIV,*B\H2N7Q$T17ADW.&ZFAE,_
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MIK^/ONUDX_4_]2F>]K<T'E"X:8N!F$A?2P3MMV/DMRCC<I3;Y@A/9**)3='
MIFW6J=>6,/* XXV]-U1@W@<'^.E(E#/*($R,NN1O;" 3Q]]**/=*LP8'%P&V
M%&N%*%[:>&/6T 11U%IML4BZ_2K(*JU'JQ#\O<;U"8D^S49XGU^S:Z$L%1H0
M,87 >"RS3Q&=U^.9?-6N(@THD=8.%-XS:??,1/%/?:F9B>*.,U& L3=B:/NS
MB27>?+X4R\8^Y'B-S=&D2\ PO<ZO*ZE#N\[;NN+D#5:$Y.FFK"0>%#.KP37;
MW)>.B!.:#N!-$37H<' ]$!O3,TWNC'XS^LWH]U'H%WQ]\.966S(XD?V6DX@E
M%1CN&1,P,B(50IZ #(F^TQH39/4F+27*UB0/GKY]W3P<QEPEWB<1++H>X!PG
M5:0YS(A7PEM)54WI-I4"9200%%-NL%Q0R*/B4TP^Q R7,US.<#G#Y4?"I8VM
MBW;<RQ*,O+:3](CT-7U7I766/'CY]KN'1BFY31!MQW!IAJ49EF98FF'I+%@R
MTJ)[S%^%5@5T$)GT@A!F>9P(K2X2"N1;GHQ2Y%3S32J0YHF_'[S\Z1F1?2/T
MP?Q)[IK%, V1!N8MP9+,T)J<@6T&MAG89F#[:/>4RI70X)*>*Y?YL@J*Q/D:
MBZRN]GO.6;>4PY^HJ[!BGQ]383,CVHQH,Z+-B/91IMKRV&_RD=H_"EKYQ$)$
MQ4%5HME6B#1ZSF.DX,(R?)AF\/6:6$2//4,S:LVH-:/6C%I_P,'$=QGVFVK]
M]PIND#&?D:H9OWAVA3/T^.N_-\GW3]]$6+60/G@M_1GA]M]T>4;%KC-XS> U
M@]<,7N>!5RCYI;B6M.\ZKCM+FZ9:Y=1'Z04_)W2.9MR9<6?&G1EW;HL[+#HD
MT:MQI4VB"P'K)E#A:I<AQ<TIB%4KG3+^A"%X*\G>5G#7&9YF>)KA:8:G\R78
ML--CM-1TLE]MAIH9:F:HF:'F+*CQ-#E,75 Q>T&?-F>L\YUK0X>2<$2S"*^Z
M,)J15=V(^8264L<4KUH$D?J^_!&PPT93[!,OQVD@\9X4C:_*324VF39-6:X>
MU>WI8>8LDCO#Y@R;,VS^DXKSIU7$E>V$.DS7E14R=TR-X<E?_M$AA45[FFQ)
MZ=A&*)K.E<>]3PWQR"<0=8V%5M70HNK&NU,#+<<HDP%3-82CSIY:R*2 =V.>
M<F%4F"**$(*(R^1IG"66)<7W(9II81MF 2;B*6Z44G3 ?2;L*DA6PN=CZU91
M4T:*NDF>=:9BQE-Y?Z;ZH0O[RP7-5E%#.2!;H<JJ\E..OZD,XI2DJ/O )H;2
M XW,DI!T*-7$&+V;O-6 (Z)/AAO47.\QV=[K:3(89G!"$J8F9P5N9/,.Q/&U
M,(E[04PG]0HDT#9.>,<\5R.;8&&8NF(N%>39E-)4+W13I$M7B!6HN\9VR7O3
M$SOJB=1U1<BE E]#Q0EN=R^'M![WB&8 Y]+(.0QY5U!_B4B5A+B0"7&JKDF1
M_8Y:^[G)U5 7R>E!O/HX,;#-X!DNMFX'$\BR?KWDBLAH@16=B0#,)FW:&E4)
MB#P98>G8M&Z'G(MDHS;)@Q(76XK$$@ ('W+X5Y:G=;UU*3W"=;6C,L"'R*Z%
M P8O2JPM\)R;CMEGZ[39WB!N>.,(X>'VP_=OWM$%W_P81HP+:YBABC?&\Z??
M S3QX$LU-;(/,.',X(^\5P+1OC!:$9\#CM@.KIX2S(F<1N/\)+"PP(08CSDL
ME)2A0>VKX6X=;%1+/R\4<3DI<K%^@/H] \]I>91K=0U;"F9(1XF)M<H)&9Q[
MOAY3*XOJR' ^\D8XBSW%WG^)/-V-:_F'[WZE#_[P]-?3R[FW?!N\*')([*J,
MCU58A!E88FZ1[(^R.&7=,1'*[I@6&](U^?'G9%VD=4QNQLN'8(H\WNM\4]4H
M/(+&UC5 *^I_[+J2=Q,Q&Y'FA?-B)2S!@S,EY&Q97F.[Y-;!BU74FPXKYU(U
MLL97RR?.5_3%_>0K&C]3_L*!O#/JW6> V\<"60 KCV0$1)?)+Q-6SV* H@P!
M0TKH41PD;D[Y*)*G@9&[8ING[R[LJU;X;"/IE--NV12'>X^5$>]W&T]T>(@1
MEI&_:2 ?@-<>F88D5?3]_*L@%6EX93+B<%YZ,E3+"L!9*S-J<"C*%%"2C^9G
MOU[>-9EY/+_NV"-Y;:X[]ERW-$F__")Y\]T/\:']^;<H\'K608YG>%[^+LXJ
MEEN#(]H123\<IM[>S/SY?N>6UA\W^_X\9+QC0W-GE_B0__L6!'9WWKR*"8YQ
M@Z&_'"GM39Y,7F]WS.L6(D%=;HWH=>%!Z77=)D,0Y(B1["UIW6F :1&.G)XZ
MWGA<P,;?;'L8NG,SD=R<K9FS-7.V9LI&'F^L)_Q"^S6KTX/12:1TBT&JN:YF
MAIP9<F;(^;,@Q]<1!^_@@$XUJ<:5P>N><6?&G1EW9MPY"W>$[WWI OD9)L-(
M-#U)D[>8R7H.X]P%RL97N1())>^(&7YS3!Z\??[JW4,JI>NE_(7#.TUVSHO_
M41<H<GH4S+M&LC2D(:2V5.01KHEZMP''>TF4;"RVHGPA:4]R')^!OK)U:=%N
M5Q@Q0E,-1:LYL/LO/@[B"NG>"*)-R'*/\9$936<TG=%T1M-ST=1+]#2=)K4=
M*>MH2SS7($F4RR#97%L\@\X,.C/HG-\4WQ%%4,>BT:R-3G+9GWKEKE<"D]P@
M0Z]6)7;2BX+EUNY:>CUV:5XJVZ^4JTKIM7(*#),=(36BI8H+463$V\6\Y2,:
M9*/%I3T5LGM<:_I<Q@;S/=/5T!/]-"2K2>G,VN'46,YX36-.-%S?YYK.EY-I
M-:\0>RU"E4<O]'3[H1F(L(?F $J3:XW& FR/U?MT0_]LX#+I!HO?,.'>2D8=
MGF17L6Q>@X4F],L:82J[>._<GGXV[+3[JFDO0DHP4F>EWO>F4?%.4A-;Q"+R
M4H>#%_%+)R]Q/%-^")/'@\\F:X?5? 5?ON5J>3,.(@WY2TF9OG>M+P6/&=98
M9C:MITB+8MVR^YOO?35H(8F:2H37*8%?Y%(:A,LQB@M4I&M3=8VV1W!&!&FA
MO$KMS0,9+U<[JZYLN&&!ZB&('A1%HN&V=57T'EG:#U8NZVI*^);,9E5YU<CO
MJRI+7D5?>(,5ISDFB!^LOG_UYJ$^'NLSTQO47*J92153_R7B!X@@*;EJ*'Q!
ML*;BGUYA(^[@&=G6JAI4*'<S"\;1-J;GXR@%=BW0V.>!F@O?A3[.I(+$04$*
MS[N\Y56^P\+MG)M#?H+9 D!^=75UK]?S57D<.VR"5K<4*=@RN@F!7#,+5!B@
M)<X,(+Y%0<KOX%]408/7Y6#7N-:U7)SQD&7Y1##1B()7:U,Y(=I1?(P:C"*5
M*%/_P+J.?;CE4OR-W5!OMJCC^D6_?$41N;YVL Y362^[JL16'Y%T'*H]3HEZ
MDW:A+FB+%\I<*8K16LN%/7!AQ\GE*'975P =NT8;-Q8Z7N?ARWT':ES82 ]3
MN$W>%!)YS3+ )3R5F;A=Y@<.U*Y7[8*[W&B3RV396E26A_1=4W*V<D<W"?]F
MH4=-PJ(!<$@%FPK_ZWQ#C1_#$J I>R\YI(V8B:9@+>7^QX(*\[-PD7W:;@\I
M:Z_[L$KO..*.<"LQV=L3/6Y5_M8Z[],>BG!]'RI(<SCIRNGKBY!TG1AB1=\X
M2+%L9>SOSQ&KU7,Y 5<!#P?R4Q<D_O)^%OC?^8&]*Y63+]=$QAX0>@.VR1&S
M.2O4%6_(6\_9GNS*]R4V$^DAP):-1Y&%[*9FI#6M*['M9I7O"4"H9A;M1MR5
M-5<$LL1C?&G<@&+L@AG+9,SF>,L;:[)E"U: ;*AOVUS!N$A^_])G?2F\#2MP
MH?YP1*@V<H=%_H@0<$BOC 62MOZAJ$_;'O"!)B/&$OLF% >APFIZ0$+P@_,B
MS]:0'U=NCLWUL1G%5@2TOU?<TAXL_1T".,NY>1[L<M/\:UP_.T>SYVCV',V>
MH]E_^S<R:+7 *>&'G4LJ9R29D61&DC.1A,VI57Z=4S_5JLYWY*_N'?P_!@EF
M6)EA98:5&5;.@I6F:P! *)CKFT%&HM SMLS8,F/+C"T?A2TI5[=0E'VBFWO&
MEQE?9GR9\>7,+K-UQQ14DM)&7RB3A%-AF;V:#GYAFB,T QY]3M0LN%N_FR%I
MAJ09DF9(^J@H33_I1::/*9<-":]545$5Q'1MU;"0C7LKJGH&IQF<9G":P>GV
M]I*TWOM4>NW !RL^Y<Z*EX&K'.N_7;.J\SV5H&'=F:^8Y+('+&HL"\]O.ZB4
M)#B?D)*-B9^)#]?7^7&I -464!WR2L@5I<9 2 \.6LT=2GCADMM\F;?:5NRK
M,\B?7J\OZ&94OLDUD"G7%(+#3746.=9:=DPS3NR^<#X1+2166_I7]M<9EH]:
M9BIL^J/JDLODA^J 52DPHMMCDZ]@S!LNC>!"L)PH)1U:XU@^P;W21?)[EVV8
M)U8F NY5N V5@*;7:5[0<>0YV*EX+7K',*I9Y1JA*J;1XC%<.GC)G+YFG\P_
MU&I;Y=P8XSEK R5RN*Z>WM$Y['6"H_YL7U2K8]:?%RE>R4T-WGVNQ,):S@W6
M.I54&).7UUBD*_WS6!E4P(3"FH)9T#5,E*6'Y* EC^X#5H!K12TC4D=N&?ZE
MC'J06!%"2.W!1%JI:J&P#X?&)2\PH.54^VY9".<P/G2_GE$*A&[J/:'VLZ@G
MBLO2Z1[X$S7U]S4 K+# )*%_((A$0@):*%WCZ^S%6J1'XXXK/X#]N[OL'C=<
M_8;&,KP*;:.\SA+4!R&*_E 0&^DO^2:<2"-D6B=!9<$9@QM77V._!!6-<;M=
M?-NL(EB)-!GT$EJRK8MGLJ1,:"B$U))U4,Y1XUB<:C[KE3N??/E(&\+T<B^;
M-M7B>VSR.[V$[GH#VF^.#S=82,@<VNV%VH.X,T(GBF/$P=I,_$3 KLI+T 2!
MFJ=O7]LUN/#=!-*U X?Y>$!;Q;FHBR L;2;+YS6V)J9CM^H4-0?<IN8FO.BX
M8XB,$]]^P,V6X8 ALX+;!?C>NS1@9:[]^G%/$LKW:&Q>;YXW^M:B #!N[6AA
MI8J]+O@L7YA%*WT9I-R#"(I=;666UIE8*]SK*YT_<I#2P)OC':;TF@X(><IH
MT\FKB5^,K[V@#T5S&^Y%UPX&V36<-C3W@[XPVN.P.^Q[HH&V2/H-5D3^4N &
MLUY]N^4H@%QS>?RXM@]N/"A.<6I;+E>#(%H42PO69U]ZPT+#485QN*&"]N8!
MX&)@/J[T0,Y4&6^PR,7:S% W"G9M22L!;Z3GX@MN[+K]<%E^,38I/'0'MC$O
M$<'"/HRK&H*)>A:*0$X.^PD&'5>D=) <JXYWT(EU13U$.^=4<2,^),C'@ L(
M&&E?'"Z6M-<*IN7'4C0^VH-(-\L<ZFW!9,CN7L,KQBV)9C4,C]3)TFG;%8AD
MXA/6%+_F3>MD9)IJ\!50D6=$ %&-@ (.('2B!A.I#$W>/I)N,KPIB_OT:]1]
M1PZV6S;WVR!_N;93"EN(AWR;[Z6H/S[F:-'U3SE:,MJ_/F*X4&<.7 @S)W6-
MVN&F,3LMX(\E4Q;3Y4@S!NWV@KI+2Y2GK-&N:K#5V]@N!:Z"M(&Y]$)Q %O6
M7_=[2Q]J7^>TU\7J&:P7?O]KEB4A#,:!H4VYZAJ8/6T5)@^YJTMT9:BO#/Y0
MP;.2>17:S>BH*XIJY1T<>)S$P8JOCHYE9N3,ZNLF&,=@($&'V#R8%CGWAM;G
M"L;\B/1BZL1*E!@[:[.NE6U2@;>S"0DO0AWO:64NS02B3R,QO+<T=NJ:R#S_
M]<C"H+O0%:5%&2VN8<.^/;H^\0ZPKSZI#K"_<"3O2LM7,+4N Q21/B'LX*H
MJ-G"O1!?N,441?],]U9,'SB.#VO8:"5)R?D^:C8FK'B?;2^ZGP>5!7924R0T
M$>0@/_3:H8(4G17P ?7> "8!;_)FR_;E*MV;2(L- IP6 M4^=:'V&,5!ZAFF
M8@'L\]9/]7N+F1E$!6,"H[_@9)&NWJLE+"$K-6BGG]V<X2.O@0LB/&T4  #O
M*BW8,9,C(D0=)^16R9K5T8V"+Z?$64D3,?:WV.943LP]O.LVI62F=.B%*U+]
M18Y7X[X]5$E#:H/2X3F7UC0>_.*3\0SM91YUED?,.Y6D0^_.QASQ_/)Z"66W
M6[J:B3KU$7WTG\+T\'X;\.&"I N;$^$=E)Z![\%"J*X_O^/O=.IL]=(2UL R
MXUAY:J@4F[C9P<_RIN[VNDAYK",EW3/'EAYP$9-%@7>7X]M+GL0N15B)E\E5
M@4MQL\7W8B<0K1C9[F&0EFZ31\N:V\J[LL!8U0&#^>SZ'R2ZDUH98!J(XP3%
M5=2T3L%YO/2"-ID-+GOI3VK@I1@1;LU<(_HG;B'NV\@B"3*&ND3H60 9#8=/
M;U9&:2@6D4"IO(^F?J;V@1&RPO80%JX:C2).K878G?JS%&;O^NGTVXC)&JMP
M8E"/#B[T&K&#&HD>T(HO:6#Q3+#]R:]@3[SGJ"\O(PJ_Y#0UO25?.I>QY_/D
MT>.OZ![\T*ZF@%2T7J0#FTDS.(Z[XH@)_4J?05[!8K#Z#54M>32_/HF[LZ=P
M]L.S7Y-]?EVUAF1%8YUO8#3PF^-+$+8X_ ?'AYR8,'9Q-B3YC^H]#-]1!PAA
MFL_+C$?P>;ZA&A,*?1;PVZ>O7O.3-\CGLG-1_"[8$2C%4T<$(3V8(AZFM<1V
M+I-7'LG].% Z1]6;^F0SS&I&"M7V<?GI,#BBCT6H%;ERQ%J$W$;+M%UM3^"N
M24_@=>F6%'R2PT$8H#%Z0L[6I$#Z3>MD\ #RCG_$$F)S12( 2[ (.-B%BF!%
M@?#B"!Y%)]3PY9#B-[A+1@I6%@?J\M9RLC4"/\;0<'YI/GW]Z\MG%X^_36@-
M[O*5O]0A;]QBZEW'$#)VBA?)#<49+^A_?^_77-#2FU8+[^NBAS?"P[0OQA)@
M6AR"3R#Q)Y 1DX:Y@6EJ\X)]P\KF7FB8Q$P2^RI?2RPHOI!&NR759D]&D^'V
M*X.4G/D;Y^T^3Y4AK#J4(*9H6.KI.G%;*SU<@<C5,+\'4;M-V&PAG0>SO<<5
MZI<J48-F6%S!^+O.Z1;W/,<WZC&..(SIBD/+N(OR<EVCLG<GJZ6V/ABA"NG%
MG5Q5NIINZTU:3K*_R!_DA(4?*-U)X"&2%(&>4*V>80FV_067ID>F.#$<T\\W
MFGS%AR#KY18[>O*=>^\9N2;WV@#].;#WX)BH:. )RL7;#=L(,2/XC9:/U":>
M-.O&/JU\-22#*8"):YI;)4YDS"S3W3DI/%JXNM$EZSTT@"5Q RM0JMZ4TLV1
M6QHJSS2),#*$=!U8@:6Z_'T2RE[6*$[>,;=3VA!5)1X-!+FW<+4]W]S$K$J6
ML6<VA@M[HYVF2%A"&[7W<2Z]:1MP1LK9IHJ<Q .5N6*12QZWGR1C_>KJJN\@
MX*_7'8.5G7@;RM"2R.5H.G.0NXL+K<0['[4[.<_ A*+,\2<?;%I>0G(TA,J)
M:R?^NN!M=7(6:&\QMW8"!RD<S:WK\[<N_"\H)>SM:W$O7!:22FK.ZQ"GMV:6
M]840VN'$3H%!"HU6W2[0@W;].LE;W^S=<%2$N,@")C"9&,UN2 HZCI^M<]QQ
M)B@5[ZGP:*<F5S2VQ^OF3I8_D<>BL#,9P_A4CH6 AD=X6_$HO;5IR*3%8,8"
MBB.&S"E$)V9*T^H6-^?G(*1P*D0ID:Z.@EE->\NSARU41:RIVLG><UWGO2TZ
MAJ%7#=&VL1JN7Y^XQTT$U5=AQCGGZ]R6&7_JE)1??U()R;LSL'<E/SFHEXCK
MZ::2.N!Q5PW9F6JIK:NBJ YDQX42&Y(QF\D-YWZRN9]L[B<;])/]YCGANW*0
MMHSQIBIMJ(MJO4),>.ZTG\%G!I\9?,X"G]>]]&:,-SL<D!B9)"&%;\T=@V-1
M3D-,K>4H:!Q)6/\8'/R@^I+%E9 :)NUE.RG)JT(0,^#-@#<#W@QX9P'>T_%0
MY5B]/O66.0G/3PA,47AL#R. (?,9D&9 F@%I!J2S+3#) $VD47S;CG;A >R@
MWDC&$?RCM'A2GVI(JH]EZGSYH:8[B!C 6F"FSFZDP*???BW&'0M%2EU4CFFR
MI0*G5C/-T#A#XPR-,S2>!8T];=)Z5.\64#&OLGQ%>D\EW'[ELHEZC*&4)^O#
M>DHAZM*DQF3)]4]*:G)=Y;#"[0;)4-^Y;RLT*!_92[%/>.3*8C=29=&XP3/X
MN\WH.Z/OC+XS^GY,7@(1JCJ4"S4V":W0$-RF6-;"Y:'@_1:.*QN8&0T#>SAD
M3!1<'IDR[=H9W6&IRYN./@ZZ?&S1VK1\+_-ZPH\SX,V -P/>#'A_3BY$&@5J
MYGHRW [*&X4N.9F"9)%US:?,!_I<"*_$[L3ZEJC/<K22/_![<G_(Z>I\8[>?
MQ5XDD8W1+JOI<LZ@P!P1$1"-R;[./7?6H$]+6XYZG"N'$X1\&L>!#U#-K2BT
M*\/UR ,280L7XQ7P+-+H#:_%7$*!A,_A0VN;FZDXMU%J+D6$3R9P\11YRI0B
M#(=WX:\;6F/V78LU!CC-U$N%'E?7<%=KX(X,0ZAOX*E.P6_+[SEEY\]C_:-*
MR>I[]HCT#2OH/TB'+T76FJA?&MNT8"TH[V:ZQP8Q8;)AVD++@.9BD?8U5GZF
MY./&3].ZU;;,_]%IWXB82>)6-MB@&562K)-E#OBW <<Y=!RN87&#!PSS25Q%
M68XULAW)XIEY91)@7,_PM[2FQD)J),'GZ)BO$X^CC)DWM5_7M"A2!>NR<273
MR.)#I@2FU$K*O:E>EEF9$:*G(8PU5^3MBM<]YJ[ '/&@SCR,*E)A^.)8TS4^
M5HLNFW,A+=I(_5?75;VP;9;KL6KU!<9I#P[9[YJ!O\[AA<!=G"5KEV&/_T)#
M$F76!SJF4'O1U1AZV%4UM^WXL2MEYZN,=J","RWX)\K9QVQM6X1.M>U3?XXJ
MV['7I:BT"1B.6]ADCEJ9.51#@XYQY[8R_$W*3PM;ZNA#V&913%/'4>5]F%'M
M>27-6.6RP@U2G5'@3TT[Y/FL5ET=E_)?)E>^M+,X+GKY00W8TR[/:87'HQ8M
MXTQ[-*6!#%X:E@;V3'!A5RC09@+@)=,L "#SM'5EPT[*OL*90"QRY75>5^7.
M'PW#YSNX6AC)=*?+4<RGB'W"1=3Y.\IM..33,BQ:BWYS@G9]3@R\.=<B4D;)
M07AVNM]=!0B4 =QGS$SL62ALD_.0A"*^8.C"L\:+F ^&*&)@ROA^&6T-:'!9
M5JN<J!II6+3S):(UY;LJN2G3@G"?%6.GL'>&C4)/M.CQ_)%M@RNKA--OT%??
MVM)C(H-N7&RP]K\2FK[N<2?T2V5JX8X6:KGORM#=,]5DB<'>'1)NUTP[93A3
MX'K$J! Q^OD:)>TUY[;K$'9=)/@'@JF=-/0%DW>4 \42@Q!5=K=>N_HR^<ZM
MTDX6F>P*V.A['^/UH$VO?.(EE9%^Q]0!\)6NF295]L6G?B?2>;U2V0-KS,B]
M*1C$7<-;&CIME^9]3\R5=75HM_>\>7I=K;JXE=Q:9V!AE\A85HCA[]GQF3\F
ME10I(&N=7M1R6"., %!_G^.B(;#"63*42GX6#EN1'R"K4+[IB9-H I#=4\P5
M>$98QALB-!HN'C$2<W3$?:,3+Q2$?^2,B#K-/*&"0+S,.R!-C=13%"<[CB\_
MIO. 7__N5,H'C,]*>D/->P*D(P>7><LFO&=D3HE40.-:^\60"/&#$PV98?5!
M*Z5TL$+EQ72FA,Y^JH<+AGB9-J1OP;L6@6(MA"TZB&K AE&E)U@ZF%^P\?)K
MY3I)$UQCCLU0:6KO&_^&]1EV$EJ@U$RH$TJR%/ZD]?U\,"<NK5?;A51G4J:>
MP[9+#-=2<FK5>FMR02>)Y;%<;9&@E!Y!WX.Z1!$;5HX+.QV FIKP\;@S,\[(
M$L9+(V$H$W'2TQ350:%7^<7@N8C;.\5C:3'6,ENDNV66+CYU'LQO[F?;V3B0
M_X4#>5?:S) .*A^:BEN'&Z2%OWR7@/'>X<F^=N)H<_<O?HLH!\@2;  *? U/
M[7S?..XUN$?,'A>LF93;1"GLP]ETLI(PND7A."2^K['HFBGPX=S>@ $+E@)<
MD\)W-3EAN&O+ROK(RN ],-?1C8IL"SDP,"C6!*+.R^3'_+UC;J$(J<,WTHES
MC,CX#?W^M/6C9(6F: HM((!]7]M^RV.@S @O(U1;.K"BG3H& -_%,3A244L/
MW'^3LB  C405=WB/JJ*,4L4-M"DNDU=5[2J2%,K7%C,![1U,<S/9"RZ$+)Z3
M#"_-/U1YEOR(CC@X7#!KCH4YE&M(UQ3R++%(3;BI]>5H0&]S=5XS=&+JA+$M
M>2OZUKOMHOQ&E .<+T6G#/TNUP:JVCK=YQE'\C@TAXWB?!!K^SAS5(HW[;>=
M7*>2V(.V;...A4NJD4A;'L:T2&L4XJB=CR6R[8"_<;3F<H8+,G(\ 0%1]HXM
MSDGFW=CS[PNWW*B]<I]]!;1_EGGEYY)]H#V&S&$%=!RJ@2?M,!(H;J@L"Y&U
MH85QS3-ORIYXC:1]@:>1-4,QLYC4+SVD'/;"!\80OON0-RJ+9I?*+M6'<*>P
ML&>H*<>H78]DZ(NC^DM)^_E=Z^F-A#LJ!-."];LC<CKY4W_D6)Z- Y-(UI(6
ML,:F/D-WBB?#_^TR>8>PK7'@^ HGOA=3U49#I?'J[_/"I?"V*XH"PI,2F>4"
MUM]J"X/U R /ON?5]XOD"JS> K?-F^@!FN27=XOD9;FZ7"3_I]J6#7SB?_Z/
MS[_YN_X$%Z/#'^/1_+%71_CG50V^]A9OWKO>(OD)$!^3#_!Q,_+T$/_ATH*
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M^%/&0.YS2@$/"D3?M*D8A/3[G-10G8O[NT.- (E9_)(H&LODC)SCDVH!G/'
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M<<F'ZC$N/B&%">\>&FWQD#74=OB@OA.RAAH%!Q-4*B;HQ.!^L['[^RH4CCK
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MGB=#ZXB#JA%,/M:-!:7ARUM9!;V:EA/':=-+ZD8+99"7%"*%VYHF2IIR'D_
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MAC/^;+%'%=5\B3[L<@G !<UX'U!(D7QT8GP!A*FDD#!B(;6R0U*U>6^-55E
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MLQPOCL<!<M8H/) .'4[)<B=G_B=>O/CR?A8O[O@9-BYE_!Y/X7F3&-0%WK.
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M^$9-H\?>1G/"" QX4NP(H$94,$!+8(C)8]83[\4\(1'AY)Y7J?VXJ-9L"BP
MVO6UQ%7LH R".C>[^#-W6P3:!,_]%:"%S),CS!XYUQ,V95<5^4J@S70I\:U6
MH?LZ!%6,R[:<^+JIJN:"QT>DR>VEE O&S^YX"$IX5EI X+5UGS/J+QU]4;+E
M40]J/DPP C%[(7?U[/"W7DHP!>T1YZ,I?;@<.4D36*17D!00!<A*$NDX_B9[
M)ZYFBV'KVG3%E%W%.HZX95L%LH"M$TC W4NF0Q;F&^EP4:J8R'(C 3WD)C?;
MG4=M1_!BN8M+%KF57, T;#4E\@C13-A%H@5G3''#;\4:EV!2D4^(CO"U5"BO
M^X1YV5E D^*86@(,94.<D4-TQPFWZ\&=C=348].D<$<S&VS9<5. D@/7N76:
MAB G<#<.TD:[,2OU(*WO7N0V9-$NP];FI?)?K]GN)6L5F9JR[@L50E?LU4Y9
MB)*_!H"WM9EE87K<)>,JFDI/L>L5HMF$15?/:DY-.,8>,IE;K(63JQ36 K;A
M7ALJ%0_>L"3JB?7U*:^B6WB"WO4J*I=)UZ@>24)WN3N[@1LEZ7?NQF&VL7#"
MF:E)N#7]N14V-Z)TFO!21=<<-66@#D'N_7([V)Y&GB478L@F=" 8?[- )1O;
M(W SB\$*M:PS6I#8Q]"WC5(F$<S?EIMDNS<)ZZ%D&I0\5]HTP8=D/)[GR&>0
M\QB:8R3-8+>7/AEK8\M@$6^Z0?586+KAA1M%:[99?KC'R='8[C9FH MT2-,T
MM@/J5,\&+0-ZT3;UJ929>J5LC?RM>Y?GD-(N(9*-W+S7W\'<U0'?JQ$A,$M.
MN.+5C,9W/=*C693W\&S4S"+,891#..OK@@&!3C$A;TB2TP,^1/@U*:X\]*%Y
MC]XSU6+^\36OW1=HHQ<C%7 4TJ$7Y1)[4L+ZP!P105)7 CLV3]<M3.EPGUZ9
MVKW==^;J39,.-]>0=\(*8+@L@UL"*--^P*KJ-U%L<!PP^^1F?7FWMEK(R"19
MZ8%Q8,R./#;4RH.K,^U6(V9U]+^1G21)&;,&Z-ITK@P89#0F98I?W>:,D@V\
M%X'Q0Q^>ZR ,XH2O>?4L D;5=CA\JS19%(MP$ZW.HU;)%//C7D5?/'F=D7MX
MG:_*O9WFL.H@7..RWOL#:50+CE((US2<<A (PD^L8-J3U970E[MNV5^H5EW(
M&EBN,BZR$(+6DV 7SH,XL-C4"$6 )%WAK#PIM<W?Y4L-EG0=I7&G0:S>;:\P
MFW7Y<@NF\A^PPY8;-^94&FPB%C,%PTYR*$-51+7W <%[3<LD.^ZI3.*Z6'%>
MBVN#.TY%[E."/%P,<Z[&\Y$@\NBKJ89A0"$$?;# +39&<#@$AAP\P&\G\+_0
M247SAY-SBJ%(JF4MGE04!_P33 C2G]!Z\:I)*GN2 ^^,PT?0\?FT/+'UW8>[
M2W^^J/6$*F'R#H/DR@WXM)W9B,)#7(X+A/0.54+7VTB\&X BGWII[D_WM#1W
MUP?VKO09O3)&$J&)X)U<U%HMH+WHU1YI\R"[+G3ZNLV5&22>+-?9>K.VB3%3
MLA%.8:OX#7.E:M]BL,R9>)W+OLI;E,B#%GP@;7<?52O.Z5(V+XF 6T!B#926
MLFNI^+V%2QY'CB"/84SC(K-5J=?(04NY<]).J%A($K?;B<$>L;H/+)UDQ;39
M:PQBP[A3,%<%#WXH#*/3H_I[P#._<>D45QUS&GG73&D$^G-M9I=D6V_FPS)/
MX"ZA*U8>/LFN:U^#M#VDM+GF==NMMOTN&3.T 2,#1A\_*5PA+%?D7!!U1K\S
MBRT;F&6?2&"\(/=O:.>%P!WY":0*,<A3",,*WG+$))G05FD6W2JFL=QM[#Y:
M\<P".;,Q%X9S,*@_@3]Z5:P,PY_Y0S#)OF^*''T'*&RG5.P# FF_.*[<_CF7
MY)P+&2KY0:/*,V\F2K-1W"-RZX32Q/1= _G:N)/AWZNA> M3_K%V^RTMMF[Q
M-O+_8_"?6BWF=0#__R9AS._%UZ"YA.O47%P-I BLC&_(NG "@W?$\5E9K!?/
M66<*+MYKUA]I9;<TQO:4Z04R)<FDCS*Q!N\?6I^5\+6$\/\^!XF*>#RC"P:&
M/^UM>):?ES1D3:M;_49#J8%5(PP)%Z)44+3GD'F1X&*8'9'.7^;@\\=:PUDC
MNC*DL=I#?@Y#JQ9P3V+*2U(9 B8 -B=#0'$F%8[:.E-A \JJLBY4RW> SF?9
M]F5P863J^0P=S/=>139IFBD%;J\=BO'DB9E.+X88Q+^0%_6))  OK2ZR1*6"
M*W2RL74'6!&%WB\F!W-I"66NL;7-Y\1B791&/<O2-)?FA92=]36Y.B$KW>1Z
M0F=)8]3:)\ $K;(+.%BFF>G;FA'AS!FE(3N>:R\1H^P^-PON!DV=L!\Q+Y+V
M[9X5:<?6!B%E;8)"@Q0T)\42=RQZO6M)E<8D.*++KJ1MF=/8?\#,H!=KD$AP
MD!:>'ZG*7<_7MK_)"&-C[B!WJB4MTS!OO&+]0$U9)7:FZ4SU=O$F7PP=E[:+
M.;%A>YA^MNTH+@-MXV(5,N*GK9*C^!IRYH<CVS<>8<,[TNAIWDCW2F[(954?
M1$"8"5/<[Y2F*!.JLKNJ2+&!='JAOA4FZ0[06$(S1YSY#=5987Q-HQ#M)Y ;
M!._A/A]P1[P:GQ44\ '&_]GC;/'DT9-'VF"S6CSYBMO9#AC4Z8 ;^-Z-9/.V
M56YZK9&+,B#!'>*^D5ETH'[)Q*-LG,71SBN/'Q<4/=I)LQC>99&A*Y-PV8>K
M@4I28#(NW<]&5U>21E5<'8"K+'VH3%,7  >2(XR!5HZ.W-!%OLHO:04<K'+I
M*3HO _DQO7VS&]*]N\MBJ*T0H<"D+C 0QVOM.R@\/;Z\G<3UV!N=,ZUQ 4_S
M]%X4^8=:M)S+R,>>TS3VIK@5)P7(/"@+H0JC=C%@GJ"1U^[Z6@F1[._.81"+
M2X8^=NL*TY*<5A24J=/A5J T="B'K@Y."O%*(J-\"TODJ=QC1E<G._*Z#5GV
M=ZI,"!,,V6:6A>@4U)JPSKGE.\46^W(]A$4QNO"*J</'S10U^LK,K"W51!'"
MDW.0,_PV)*/>0DE;2!LC(*RXZ()3MKT#H]HL[&\>+$%)+:_K@6WA-%FXF"2.
M**T4KH[6JC;^,:)C4R+T;/[%+W<BW>.89V)D6:%'GE,&^%//4G]U3[/4=]L'
MN1L-)"^BF^U;Q$+'6Q-[GU%B$X-[:II97B)QVU(\OV1\"LO&!SWU$%WRQTX1
MO-1L!WS&V#IA'WBWR?A@EF34*Z8L:L%81&9A#>,A8(%:)$ >9O($+! 107EB
M@JLR<#AG9L<,428HN1*(6Y0*Z:/,BB^^^GIZ>$1S, ]T#\&>2M34Q51I4D$S
M;]_RIE4)5D5Q!U1=,E\9Z6U,;L865>>WYPJ$BP<R'W@"J^-P++:3WO>VF;=A
MQ3%>$ZM+B=PYN=PM"M/[C<7A3"K#6<+1'!=?%V&YW!%*HP[F1.D9:%:@:[8]
MD$TO?>7?P5WUB63]RT3+VH\)8Q .A+)&>'8\9-/FT"^4D4"FAYL)!+2*"[.[
M%I/CVHPS 1&4G$66O@9"T*M&Q ;32MF3KZJ\E9-_DTY<Y2(:#41J"4+.)@L:
ML+P%=*^>%;25S_@[#ZT^K5R>[$H#.34]%6F+*N(SZ0$*A0;'U1*RXLQ&WTFQ
M@=W%086%23IZ\B/8'M31@8FQX3(:C"U#@9;*H=&L :#KMZ'D$?<PD'\=_"R5
M5%ZM LR!+T?+3OH<W!*7) )K*6%!R-#XT"1V]8S;%8S<RY:.$&W!S8D^I]@L
M)]L1WRQ3,^4!A4IPF"FVK-R9]H8FDVI!Y8I,5BT9HT%KOP*B.3?%^DT0=!XG
M(EBU 9MDM$5T>'A(,I_&&+ROZ4EY2NTHMXB-QHO4"P6A1YCQC6=*IMZ-,TO\
M[6C0O3F^]O[2F['W>&#XN19?JR905^#\8S1[H(=4!FRL^S!+;9)L2)L1?!!X
MG\O[+R?;\4)N<@\\:& UDA0R?XK7 ;Q:VI8@'PQL6/BZ6D\S4AZT:09//L;6
M=?0$TM<JT6!B:]6VOC,V9<L,OM!+O.?R^3':U3M>AD?+W<-,S*X<9Z/SA?=,
M[!T(V\7N*YA_>HL#<]^B*0F69MR?$*2&TR1 ())SOUDG.V"0V=7P4(@>T;DC
M='S%:FIL09C2MO!"Q^P=#^($AK::1 V!OQ/H0IQVX&!;\(D3.27<43)UJ*?F
M-M(+V:3_5=[B96U*&6]00+"^2+H0JKU]'7YUM.0,P..OO_YR\>"O+]\<'3UD
M\L^-#(IVRH6KQK%Y[]J$:(2>TQIK-EH%.;8WU._I39X\>O0U;O+^^?%?'T*G
MT#@+M:$"V3$-FE.NYPL7ZWOHL0>PF"MN#<4G4NWK5</;X,^N&(#\LZACE)PF
MF%X N<I"*9I-86XJ'J]</.@5W.UDN'@,[[6!>W&%=Y9=YT9A'I__L/A6X":+
M9[C&FW@-YTP_^/;9F[>Z\'=@#M3N&AKS5[19GCQZ_)46:R7+Z\RD?ZCBM.PJ
MO7D .@9K<3M3$W7;%::JYG 2O"BH3Z9369C[D!*A6!"4]D9$NG1'JBY/(>#\
M3K"6P:.KE=MPA>H.B-&$FU:)V5-CHKO#>A[0 (4G8O*#.$W\=(-()HLJ2*KT
MS9"MDYS<5&.4''F$;O"R]-2:")7<Z(P_[-UTWI7=@.!L-/.Z!ZU;19Q]??W,
M@]BDU*67%\<Y-D"HN\O.UM228"(?/S! SLB )'>40@ZR@;')%EHARM<4]:&F
M[G*OS04JDMC*$6(6_&E)-IOGS&'%U!@'K,_S'OB>O(ZGR1$Y1(L'SY_3J:1A
MRH@$E39'MQMQH*HLLW3O!T!6\C@,B QQ%0"1(MNS9$[UTSYO5PGIB/]R&XJK
M@YD4BS?TLU(0]-]I':U P$8/_XZ,Z+^*MN+]JL9$J],VBH*B?%T'<R2$A9?^
M,7/C"AB ZJ-(6*-L55=,@0P_C4M'!VU1#UA9=?B>_W# ZE-OU#EY1R%;M;)W
MZ;K)O[($$AJBD+G8D,7J=IXL*7UH\@MHQJPV<2Q)]N)P\=?FHC@W-,HQJ+'Q
M][_UG6<#I[,'OIV1D03@W_Y'EYHZ@_Q7-/_LYO(APEW7J\4_>QA1#N!/<-H%
M[.-X0NBL(9<XEX+WE>-%!C"'YF26KOOH:0>J?S!9KFB.Z6\2KP('=UPA%D,J
M+^<5)JU>)X5T>T48QV"6;?5VR7Q/;JR +0Q;ZG#Q3A:F/35/=P@5AB<]%H3W
M%^.K<<Y I\C:@U>12F7_*GIAJTB@*0%8>-/W]7MMZJ45]G/%W.,KYV6DLI<'
MOF*&#A='C/#L.#FV"QSH:Z3)#*1Y+O[GS5?/+7:;9@"O>4;7A G5"4>)RDYP
M@,]8.J'X9<MIZ^"NX''-KNX_YZY?=M%!<VAOEY$ ZVL7^E)89WVU4'U#?G(-
M):YY7^<Z3)KF3%%NTPG*-MKHP"T?S(]XH9UM%6>$O*K%OGD%,FM3P#$LNXW0
MM//NOFY]?^)%P*_O:1%P>F#GWI2_L"&PVM =>::Q&;AC#SAI,N_:,TY8\#OV
MB(P#0Q$U<RW;$<YBQ\B59]S$F7C=@1= >8*:;0MFKLI4+*ZRYFT9.R&)<Q6>
MKJGZD,%D_ C+&UCME]EFA:R%2P@1HB7%:DD4!C]S^ES#P0JD,@[%G\DK4\]'
MVU:NB?_]JR+GZBH.UP8>^V._;!@ST6AY-RYD?)(2SM[" TY[N='__J\OOO[&
M%9<26,] ;??X[6MDX*5 (C49&DTE5S+>!;_N+>ARN<HKAUX>1DH$GN@K5/8%
MFI>F4[PV='PO8.9]7E215X>+3T!%Z"B4#+E3:1#QNYQ="&2YXS$WSG35%V 5
M<,;E,54Z*C#JS2W;AESJ$RG%\7B'#>^#<9XIWC(QEX=2F>3R%]I2L;Q,8;@C
MF$8LXH:JZXH<6L<@&6IRO+@"T"+EGDC,*JW=IOWS?SWB_Y-<+BV!'/?(%D_;
M_%]E%8,O&QH\T+Z$[7?YQ>+!=T5)'VA9LES^^+__Z\EGC[^A_WWRIV_0?T[?
M6S7=X@T]44.A$T;[NV_?/'M(WZ4+?-\<+AY_EOWIT==_1%HWB#Z:6H$6QE2U
MTZ<,]V2,8K:D\T;2YU^Y[!2* KPG6S/QB<N.W-6GH+$5I57Q1IDOU"JDGY-+
MHZ,A':BUTFW&415DDI.:EW;3(MR*3S0^C108M5[T6_-53/2>RS^@&*\P?]B@
MO$@^_^^(2>:^P0MLX;RN$:^%;I,'BOA\J#;2;45)3 M'Q71B6_([_*!G?+39
MB:G=#*+X$0MD58CO!_G;! <1.A#U1IFS!6*\T9=:,I0<Z%$'$+?PKG,41FX1
M!RD@?N1XK#S_09/ZFB6(C^).D[:O[G]Y/59K:?S^UM>%%H..T=;2M'69)Z;+
M_?K8"MT65Z/R^.#X^,U1L#D7C%^N [H6*^9O.:VW]G*A?02R8O M;D?J_!VL
M7Z[3M@UZAL@6DDLSHS_(R:(7D5QI7V($J'3X(3O?&C]I^;JSO VD+U;%#I6A
MQ$9RQ@I*;E<D9 #DIKW@WEC=&ZTN,?8QM0ZAV[S+O,N8!P2DJ*4 5AXE9ARZ
MP<Q( @7WZ(<!LZ \5I"PLU%WADS\]702/\M$?FBP0&Q=O)4Y"X5ILDT/M*GP
M^,W;(^TH? @.QP;+7]7@Y0@^+_3!Z)/2TY0IB$MV*E0EP6B(Q1.P%W*V.3=3
M?$_-"?DY68'W;*7LA!WZGI2>T#L0F_R7<M-O]LX-[DL+J58M%WT$"0. (W_\
M99;6MO:-E/,%CB 481Y]%=FFK$D<5P!DCEPC=T*'C+\,G1P2B,%"5__.)IFQ
M S2H ;E8NG9]5X^+T-U,VRPB!:M,362;DUT^?1])Q>;M 2\\ZQ:57*+WPQ63
M.>6%IW7:;8.047\(4+=I"H30$\&-_X[53K"^+BL;GELAR; ]X/45F(D3 1^P
MO\K#XEX,2K!S8A+K$LB3TGUIN#L]F^+3QP&.Y^6($'E_I?TB@(;43DV96+?]
M<7*#G'3+57RGWR+83+SL6M7,Q_"G )&*6 $V01S_;T'2L,J&3CI#B,;OF-U@
M:(:"33?6U[GS9_,>O#YGLJ_W32;1LT.ZD-\&H1^L8A;!^EVN&8T]8/U]R'R'
MA?\H!+Q3UMS2QX2C1"N)0(@5(XRLXL22W>E.V@ ,7;$PPEG#3D$A#:#))L/D
M]%VF]%JA$%)=3B<^>L7U!JR4\&^XXO:QHZ>T(HR& ZO)G)CN/'&1I*]:CC:_
M?J:!1LS@S@[#*L'K(C+P@9[K @DH#XX*^-:1$MS1;ZZ9JZ3BLIOM?"\'(N:;
M]M9!4 3Q])5A/<1E.UXU/$9&)]QN!D'[\<#?G]PK3DPQ/D@6SB874\36OZF'
M2Y*$?.9DVC+'\FXY-Z-M%)A_!3)8#D?7PQYYC4S[01KY'!)3F)%5[$@Z!3HR
M;(62PAI(\SY;Q:/:2L$="Z_N\')& !5E6*\Z%5SS+]:YA3]-FW2KJGFYQZWO
M=H#$UMQ8RXQX4CFYN34E4H:UFA'3';ZA!8UV6(^LF\(C)H%'I@*)#!Q8!HU+
MIW/ 73EF],D.Y@"J(,X2CO;8%\XNX$J>0.;:95VKRX"#3\#)PQO>YQ[\UX-6
MU5]$;C093PR76@T5('4X;:/\:0Q#+AU18E\%E]UB" 5I%?IP=0CW+)T'+]\_
MM#43^Y]R$&PYU(:F:1."I<C@-I5U90C6R_=A.8;V(APIYWV%Y*G5CYB^23X@
M/%VBMLF2>X4\@%KK[!.OVW_YZ'[6[:?WWERV_TNTM4M:_&!ZW9ZQ_TI.?\_U
M 369%$X6%7(GF[[VZC=UL1->=#D(V#>%PX3.F;-^ W/!>S"DBAPTF SM)45]
M!W3"YLL/CI-AVUP(%Z$$G/8L# NJ#UB$B4E>$U^<PN@M)-OMB1*$\ G=X*#?
MNE/&2VE8/R1=<]7$'BO8#1S], DA=*2C(#4/V[/+CF-T5&80 +<-C=!"MD19
M=\+(U./8.2];X)7N6/D<8['>77C#%[J;<8%FPW_36;IC#R^^A9;[3&CWO C\
MIX'LXM?Y!**SH-=G/L:(5F0AMI0AGIE.SHV,PQ[&];TX_I\)69)P5#H7(R'Z
MN?>UK7>*S);*;]K7&YT[0^9BL,&-P@,J&<1:7.@,B.,H&F(F0T-DAE#LU8 8
MD<E.)_(GNKNB:0K97*TA-<"=Q%XBN6*7>1H]//VIMG,G;DPJZ:.>#:;>N2F6
M>7_@NG; W(T@F+UD]G]T1&%.'UJSE#1QMG%M35S:^T:O?0(#FT&-HQ0& Z0]
M^$:LZI!.82R1V#V&V@LN<@K?I2D3K>17X2!1TS,6A9/F:)81.="@F,O_=(JA
MVW[I>JL%I,-G!UWFM&WZ;1 22<GD\@77+-N\/M6^8T'P7C?F2M;'.6HZBAK0
MNSP,F6%ZX*Y()%6$&@PM0I;EDJ?*C WQC%X:0)>.%J=1(JKX<3= U]*$:9=7
M%AOT!QVK39NVN:/#0+*LO"R1VR_-XD@&SF5)0VGYC[Q.VU;YU[4D!'A5O1/H
MBO35;83:M;HT+HHD"37=K;7VD^''2C4-0(0U82H&C+?3UL29W)4H"&::A3)P
MD.K:> Q02C;B83@\'B%ULQH/2?1F!OI$5W+=2U]V<E<>+M'>"I P!Z,8-CWZ
M 74MK=%030W]0S,U"7VF&YB1&;3,9Y:LP:/)P7?9.T=MS<L$+]D)RT(0)PMD
M$[&9C"\@+I_59'W]/K'7\9UO,$0AA9LNQ/::TLHP(3?:+B%#V!;D^H5O;;9%
M99J/+E_J*AS87K)GKV@=5Q2:UK( C-\)\>IH#:9E+R"1UI<:G?-G:R6"Q+2=
MH B"U1\TFB+-1'K+6"&2^N-^*@]KM4J@%IF.G'!JN&RF<MVT8>LH3,2TA%)<
MIRD][-GO4XM.J"&V3;WRG8C598K9[.BSW9I-P*52<3/,PT*'0<=Z2#<[]] 1
MET&>HFB'2\2R%$GV-+%^<0SB"HI)1?ZKY^Q0;-"E*R [O<**6^I:\..Y%U_M
MVSG.6NCV$*J0H3A+5\3QC@]##^G:/'6_ZN[5<SA)-$.<=:F4HW C5D4E&E6Z
M:R\C[2_/G6;O=U#X8$$HM91Q(<GVDP(QZQM2<$BG[ F242<-ROTQ;MR9\&F%
M]]3QVC0T34RKQXDC:>:7%]FKMF6WEX*.,<SO]VUCW<N;>IOV?;?);G6>'"Y^
M/,.+6&TGZ8X<IEXQ2G3$&0%75&1*WT&<ILEL74C4U:C=[)(^X' 7*6J162ZY
M6J,Y/:3:[1.>29\W) BR-.*_SU'/,TU1T'O1SN0(IG4#XVP:P 7+<AMZW,GJ
MN=]8<.NW[" O+IUINMMJ5BY0_H@H11=5 4:3??T<"X#'GI>S':OFHNY<F2\P
M\]A7'@2I1_$VV)D_$*GA4 !]>+AX%^?;0H88*,20!2=A9PW^?-06/#SRYY"2
M4H<TB7LF&"FS4"X-R>T0ZZ61TA51C+?N6R&Z3)(/:L5&=;Q])Y^AHJ/AERO8
MD4"_8%O'Q5Z>]?5N[',ZEH1]H;"0 ZBPA9$#B*9(-GW>)^>[-LV>:Q%F+\9W
MZIRZUUL:@)8X.<%!#UT0NHK;0J6N]0"R-% I"4[A-BT9.AKE%)OP%T&K<7Z*
M,9(:#=67\IVXK]GGD-4;5'SWV0 ^;3R%Q#J%RB:<6E%!+NC25THQ&--@%P."
M05L=O99,''&B9#*DG))'^GH[M/<,VR?.C?KEX_M97KGC1>J[P8V:TF2G^6+L
M9'<<F]\;U-RS("N>>86<E*_X:M+G^\_;&>"3^RC+HU.C#77-LI\H1\=,1J&,
MG!$7R('+N27/]NI!!$+;\4!+0&$R.$-  M1.5+A1L@L<_J!NOC"EG'X[YHV^
MR8+(;KLB%F^-YHPE(?)-LO88>CE!@1UHS=T4!)&4A/,>(R@E0$=VK[M IV:@
M%A913^#!"Y,2'J^95.+@PPSIA(W$\IC!0M'6OC C.>UV]-)!:HI;R/1Q^"&A
MXD77N916_JL&,Z5NNEZ/ !_WJ%>X@0,6P7&*63C5&F6&^;-NY55Y;IM9#L**
M?$#:+O0GT6&1]K?_^<.C/RR6%"&2&5C2U\//6[R8_JS7D6\<< 9PVQ5_MG]\
M@\SX[HRV-UD"N4/+_[OB_M;3F@[D9ALN(Q_^XO#)Y__]#86[N^( ]\;6OVCS
M[1_V'>3\_%<>:%_>U+IH]QS%6LVD=5)#]G\&ENS_W-PL507@80<ZJ'^6 W/O
M@7.U&5P5RT:22G+#I_GRPRG+L!WX%_F]7FI?X?>&MX<?\=63)U]^XTZB_^N/
MN]7$ OH/KXQ?,RZW<J22L=LSNY,K87KTA[VA7LV'PW [=;P]VA1TBJXDE&?.
M6?XT1*Q0@TZX<!6N.BQN^ZQ<8J0'-I&;H(>33?_3XG]@F>B_9+QF&S;;L-F&
MS39,;-B$V@L2"V@SEJP_NGLV^+63_8Y^(_=LBH.J)6?N-[[2=YOMU&RG9CLU
MVZE;^UI[5"&#@+8H'J+88X%APN\KV8?9^LS69[8^L_6YO?6Y(O0*@CYGS053
MG7#Q'Y5"Q'#,JA3:Z(5KDS^@#$ST.9!QM RA=.0.W"JHS:K23=C7(G=I?EI?
M1WEBX[((@I@AN3J;O-GDS29O-GFW,GDF%F7T5U8&2TF68:K:@D$*>SRTYJ1K
MJD+JU<PHKXKF]/W9+LUV:;9+LUVZE5V:,#$708_9_#!#[@P;6 *M1BZ@ZP#F
M+'Y95CTS5PC3QFR:9M,TFZ;9--W*- FM'*(OQ1N,;)40";%JU6+5!YI:A48L
MND8\*E&:#U\7HP8>/0KX!+E@/1E>!E=MX&RZ9M,UFZ[9=-W*=.VS55H79*KT
MBCMU3HJ(PY.$>T1;+?[9Y]:5B@:>VA2%\5U [ADSA[]45:!LGTW5;*IF4S6;
MJM_(5(G%*5@*"OI^0@C R7>$=Q01QE9J=MB*%9<'E6I'6\*33JG\LFD30/<5
M=NI>-M6\9!VUR,&GW2#-<MFW0?'YA'7BEH*,S4]H6!4W[=%N!N<-_B_[M4UP
M<85!;@)T\F\"70?2<N61/)_D?XE$YJ/F,>D;\FQ$TN.K3>5"9.NI8O[]31OI
MAKC%LKG%BA#=Z24:P /I+^O%X9MIX^A'#*K1O *M?Z.QNU&KQ$>/RV^^G28%
M[J5#E$>+Q4%52#>$;]@)#J'NA[VD*Y51UQ#?0KOD69PD[F=D3I*H5L(ZT ";
M/GGT^)$8NS?:73Z0F3S"KEWQ/CS&U8ZX.WR?B#E_!%][3IM-X/5O"["EEU4I
M/[)HP-'QT</%!6BGE2!:=F)*.R^QL) ,7F QR2WXG2";S-T-\@0T\6>.W5A;
M,XV(6'KY6N7'2*DDA0Q(VL29:GF+RBSY:/V.3;\2R5Q:!Y\PHG>+GWLZ&JP'
M]+BI3]N"]3=Q6IS1XQ<F/EV#'![$.=Q4VUEW'^Y'HY!P#YN!U"%]W_:;;4+P
M+E(9W%M;:9<M"V 817F>TK[3]0^E7TP:S^TQF?";>[IY])G^HBW.E)Y7+Y]H
M?Y<[_HX)0\2>4R5O#ZH*4^^H*0NTJVSHSTP&$ABD:;Y;+D@G"@./O\Y4+&6G
MY!Q&06H7#1*ND:=!V3<D]Y&W[66D"[%>2R89 Z.!25>''OS04F2O0O<XT NN
M%NNB8)7@Q;-B*8+ICS_/3$5]\9ZV52>KYUFI2EDBH?NW?G5:L&Z(TV#%D$ :
MH@;M,$5$O9Y0@'-#^H+6?PLJ2Z.,P'>4A6C\LL9%=,'CBYF3'1'FFC=9&YHY
MW^>_+(Y[[?'Y6W/B9!H>_^D:O:.!1)0?C:]LUL(^"AK"1UL\520W^@)FHFR7
M/00:MF=HY\&O!R-'8R9SQ(.6&UW7:*[QWJ.1E'-D(UH6W'"&HQB\@]:Y,[B;
M$E^TM-6*P'3&S!&\W36JG5C:;(M$A-1VLA#K\QB\Z[>@+-&;T)R3S]2*/%1;
MG)?%A;PB_I##I<FMJZ[<Z0JIBKP5K8T\"BB;7 <(M X7+W>ADTW=4/L>Y$EX
M[T4F=OFN8T#CEU#*Q1O*7@V)1T3APWAS.C30\8#1<(-DF YQF@D5Q:J878MI
M6:+?/5"(R>S!XOXS]9!\18^?+VW1[V@QTSN=T>E\P*)?2IF$ (4FJFDC91"[
MBG@<)A50OUXH1?@R].O]C_0XTT[!\/C\B-Z\8+WDOQQ>$:2\>*'C=P.UN+O?
M_MDUT6M11?,SOGX!!HCD*.Z6+6W,^C)JHS$.?'#0TF&]3#4_R!Y6IG:C+"XB
MN-+M1)R">62$F''5]J<J#5"BGZ9<=DI=$>Y^QA82SJ6DIKJ"Z=GUJ09G>%FS
MWE01N"=!7KA2@10Y!,=2&%X"P]&W3.O7G'"&GYG>><S)2)L C(4J.B29&@LU
M2,J>=%9N:=AW%QAY&SLAS*A[\"7QDC3&H!AAB6ED3]VI07SBK?Q/[F<K_\R4
MO.<Y+'?0%N7FI*> <M!-9XI- 1OI8I^;I)&RO?[W3;[-1#S@RJPN;_1QVM)"
M/)/;.?>TZ@O:T_4N''3-HF(>9M@YWNZ%1<NB--'O#IKUP;99HL"H!#9KM8KL
M/MT,UL6QXTT^2D][0T"&"@AYP55^B<1.&:#,J,^B%%==G#8<WW*#XX7$O^:C
MFPEVP6ZT='09N-+GR /YFW5Q-(5UI1-+:YJ5I:>K=V/,8@/[QSDNMFU>L@L>
ME,$.[YH8]\B#FUKJ(<(Z01"S"V)0O+/698=#^Q)NYI.IMQOG=E_P_]'=R9^*
M8EOYXG\]_NR+PT=T;HMZ)5.A"C$.M):WK&[L$QYQ375%\4$[T72.W/9PZRA9
M73+SZ43RUV0VV6PD?)KA,G:81M)+OI9XGLQ<52[-!0DLV-B!=VSV[]QR? TA
MRNI2SL,GGTL4P"/Y#NEZB3 _\\'!9&HDK^NFYXR0N7:BFX%%P^6\1,XH+)40
M9F(Y=:D GUU(/= ]&R2L2!8_-_HD>=(7SXZ\@5\SMS 2 @A<XNO96_L8Y'OR
MS_B/GSVR/PHQ&Y[XM"]7O$O61E+*CW[2EY6XJ5U_ A4JD0>7 1(R=5:,Y(.!
M>:".\SI?Y8>+%Q2BGB&;3A\,=WX2[GS'EDQ(,SPKD-W8*+V[9B%9E8_93MZI
MW C7!N[8._SUK^_NV!-E=^QY9+LP+W?N^&QC(I&+>!1'GD268&-TD2.=SP75
M<L1J'P2=([^ 174T>6"*GF^0/GN6&4'<J@19K_#4&ON;7A8YN[I80\$K!^,X
M4LY]S<AV)>7SCX2T3>"L)G^ARB\D=\3F@1,.2Q9XADT! Y!_V\E7I,"N$BHC
M39AM&W(B<="1=2H&BK+#JP6GJOQ%,IZ+O&7>=5$7"['FOE<=19^2,9VP)<>O
MWM&[=R)')&20Y<:;QF" ,<=O3+)2K'ZPNJ]P[+[(SSG+\[TLC('!3RM\='HO
M7G'FIRUD4I^B?BNOYT= 5$1H+1Z8P6? L'K31@U[403'D3T^L/0)7I@<OV8C
M>@JH>$F58@EFK)9SWGO33&F*^<E7_LA+*D;#_&6)<6;[77NQ3QMD9:IG*GT*
M3B2+Q:R3/_>UEGJ4YW"<$#>=A'2.+._H<I0A:?H4TS4\G3GQR&(P[*Y)'7#
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MN.5J2=^#)HUIBTNRI6[.0YXG?A4OGV_+N-B&U1Q96KD6^;I".(HD%33&OMP
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M<3^4YOV=Y;Q))*Z4&O9P 2)+5EWC<,V&2$C^8*]'L:KD.]S06;PZ6D*R3!(
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M>&%#OP[[4.+;$(BSC)TX[D['3GP>!$G> T0P<D4@^.4=7Y5V//+@B5>D%@-
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M?O_\IW='+YZ__W]^>O;RW?%WK]_]\#8]]#X_7+RBR5R\R]<%K;)GL0GI'I^
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M+[7F:]3O#ML<]@/IBD4]1KI%D:[!2+=[6WIQI)M*]1^VEJ]77]D>:&T(L-B
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M(F.GP&.V$X4 H<!=Q.+PA;O('L)0<"G44QWAX?O>H^N:#*(PO1N@M>'+$4K
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M?@F[V!9?[C)3#=48NMQ%JET)\1];PR8:?U4/MBQP8V,E)<LD[63XKAIZ21C
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MQIR5C?'ICPJOY.!JQO,3@\''7IRHG+3G/V9Q4QXCOE&"/8QCYPI1&XW_V?.
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MSM^.ZD>& _)$KQ*^GO^L_%7Z.?. I9<*'J)OCV+Q)OO'6R/+L]75IM:I8CX
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M!?WILQV[]G\*XC)5/P'-0WT)EMD.?E#"2)36:)XB4JI]EA)1X5@U:Z!K=;>
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MX#VA\^.D1VM2?(29CZ?\FC$HX#N4:=OSAQ6F2>RYL!HBNO><\KL!.>/41[
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M;QA%E8U#'[[EP+S.Z:V3"6AK'(M0Y6@(SA*!.(6/R-HD+6Q9BI]$6LVS,9_
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M@*B84;?$J%/'%"[/J&OD"AIFR]K<683,J/N00-CF&0%NF/9\831JU2%7>3Z
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M&%@J"+@!HF\H"HBEP U<8&"I(. &B+ZA*"!NV"'/UMYSG@W9L:,6*#0=/3
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M1/HV2JQ8.&E$&BOBFA4(=(,\M*;P6'33[14+%%"P@I-V7&!@J2#@!HB^H2B
M&\ -7&!@J2#@!HB^H2A@WPS<P 4&E@H";H#H&XH"]LU^>[7]QEGO\<;957(G
M(KD?%HD[$<3>O;@,G' B9HGW?X6^1.!WVPL^AG%\%=P4B?;SR(OI3^7V'I]%
M<C7^:O^LJL+=<=))ZM,GW55/NG'K7"6P]?*F6ZN%)B',9/HU/P# L9!Z,U%
M_(7XBPL,+!4$W #1-Q0%Q%^[Q%]]!O$7(J63D+[7SR]+?&Z9Z%P-HC4*(U=$
M^=K&H>^YEOZ@I=YH:D>TB*<+"*F>*E(\5-%NR24Q'@NFQ?[-]=#DZV:2&6.*
ME"Y+J02L4W:!#GRL;R.M*AL\:!;8R#0DP$9'CQ38"&QT]-B C8 $V.@$D-+;
M@F CL-$18P,V A)@HQ- 2F]$@HW 1D>,#=@(2("-3@ IQ$;[*IT9/"Z=^2P2
M72LCRV(J.F_P122V%PCWO1T%A&^\]>&"S9I]M6KM89--MR]P\SX.)("63][8
M@Y:/!2D$B?NBY>&NM Q.!:<:U%&SO(:CT'>?!\:N*__6]NW $9:=6.^$HYQ;
MJ]VL65('^15TXW3-0:KH<Y,EUQ0.#4^8YBN"=D?JE+V9-<[,SU'D>[%L"!Z7
MO9ENX[$W<Q%.)F%PDX3.=]4_/+Y*DSBQ XE*13F'TBU*Z8;''M'EYP_K/*'?
MFL-:J]FL];M#G-1A)H=,30CH%?0*F$"O>Z#7Y;F";O,QNRK2NZ-H2$2QIL@7
MY52592@R"$TP)S<18VH=P)Q@3L"TR08XF+,:YFR]&'.>NT_-E-]YQE6KW:_U
MAUVP+#-Q9&I)P+)@6<"TR7XV6+::S>QN^^5H=JO&MIMV:0*W<A-"]+.%O0:M
M'@M,"%[W0JN=%Z/5-?7;SR\Q:_:;M>:PNBG-X%AP[#&N-U/C#8X]"I@0NNXC
M0=Q]%L4^*ZW;Z]6Z0_0'YB9#B^I_F";!+UYIS06 RSA.5;%U.";-D_4(])*D
ME%9*CJLU34>^YTAX3O3UM?SI_Z4E& O9I+QF!2*1"_*7;4U<J[%@XL[=_Z1Q
M(D."^&NX8M]*F4&)A'!S/"[".'GB8,HP/Y@RW-DJMFO]]N)Q%/GJ7BX7CGP0
M=D>EX+L>YB2AV=S$ @7,(M^E9GYAIF#)YI9'4^CZ>7IT]:>J3NPOK?1;;;^?
M*J/OUIK];HV>A<U)0M@,UC8#= G1-Q0%T.4.B9J%"5 KV/+?MI^* Y/E?'U\
M=<4%L LG;1= B1!]0U' Q-P=*'&AL]M+4N*3]>X5Y *[[5IS4-WI,MB0D[8A
MH$^(OJ$H8*CPH?MT0T%8*PBX :)O* H(K< -7&!@J2#@!HB^H2@@;M@A[;;0
MN?FY:;?JDF7##I)ES.2KJG+BHVO<S 6 ]>7$[V^NKZUI&CEW=BSXE=[#-<%Y
M!S-10)',#C6EO84^S&MK2M]/IG[X((3ZT'5F!*]]>C:>1:;-;JW?J&Y6!2S(
M25L0D"=$WU 40)[/S?E"04Y:0< -$'U#4<!^X/8YW][R#OPK<KXKPRH>I9>E
MQDSMZH[KP6J<M-4 84+T#44!FZ0(IKC P%)!P T0?4-10# %;N " TL% 3=
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M_Q<QG37#L!TG2H5KB9]>8HV%L.S M6)!BNE:I,Z!JSY(?^"WQP,/!3MKIJ(
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MUMI]E%L<A0RB/!)0@'9/!"G0[GYH=V'$V!YI=_>L1*]9:_5:H-UCD$'0+J
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M&2*IB/1>3]Q3!+?V;>X[1?X#F1WZ6:&6$IQR(17VTH[[0BV\1%:YQUH4EA!
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M0S$8X-3>S"4 5@RP>IE$#V#8GE%.>MP+5QQ@MHX#IZHH!DH&SC$5!G .#QS
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M35Q+5DZFF0]NY3@=Y^>!$*SAD6 ":WCTN+[/-_C^(9',7[A\NPMZ\5'DE61
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M>1UX1KI:;.=AO R4<,/F]I6'>]Q7?I9/-1S6AH,.F^JZ54[52C(PRJ8<EA_
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M&H/;.^&HDD"-7[M9LXCBAP<OYGL)LN4!@,']6XX+%E -9V@*JFEQ8)IF9Z?
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MBB1U2H!*R /3#G3F16Y  VV22;W<!\NE17#/NO5.MW1[1NX7A/CO36\&6PA
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MA-TLL@#L)92/0NA_"3C3\).QLL$: KH=CXJ',Y_CB%HF*_&GGDP;^16J9KA
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MSSIY&)9_M,'1-'9&Y:NE,$:96JYP&@O@6X)F']B/')H1A2.QW4YVWEF<UJA
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MOD*N:GGM) 23D70N=5L'%X0$WA@B[DH1MWK@-Q4H&5$EGDPC;&>!MPS@+Y\
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MJ8'/E,30H@"J,SRR$AOX@TT^TU@!<&^DZL.)H;>G^I"T^P;IMR>#?K=->OK
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M_TD=!6*O+![B97\HLY7G$VS,B3^SLG!Q?&WLLAILSJ=M1RJO+W]Y.3<O4(=
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M?N#,(EQ'_;9HHQE*>,:6.PL@Z -?W!VNC9:7\%<P]LC9]V_>P_R:M3!/?:5
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M=X&]9*Y7 1P(IIYIF+J[NM=Q'!$U0G& WH='?='=[\0/>9*P)P4I7XCPAY'
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MA)&F"2#FA)S<!Q'\6C2+:*X7"H<D/6J4\\DT#(N<Q$VY8,TY"\=%GAJEX])
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MX'HN84\,/DAU$((-$O8JP%ZF;7Z=L+<]X!S#WJ SJ"_,+/7\T#.M9'GUD3B
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M>[)T06-8TP]LQ* _.:YO_D5?$"XD)=T1&0EL,!ND.U+%'8FFF<,BW(PODC2
MU[9QG3!_ASJ":W $K\\?D5I_V5HO,4]*?X/9(#&O"N9-#H)Y>YS!U=:PJTG,
M$TVR9,Y; ";<^\[L>WNJ>\2@'1.)[>UU_);9@ L+0S?>*(G!!NF*5'!%U,P
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MS.#+9V9/RH3@.BVDB-9?>FG5D+/<95_MG<R"RRZ+4EH)P%(V"1V//?<G\"@
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MJU/O,O8(>L80P,QFMX/OSG3YPX-/(S5X[]KVA5#Q#VC#/<! 3VW7^%$L=,G
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M#NIZQ"S\77S-K2P<RW2@W'8S7!^=#[R)$PJ-S!!,N"<P^TS1\PH,]$D)D<\
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MU3(JDZ7Z!\SA9PL#A)0 '<!O 15C,KX%@BNM^+Y<?2[W[,YFYA.8CGPOI\?
M]P'VV9-[>(L'"[<G7@L8EEQXAG9<@-'Z3G!!+>^?U ZWL[:6;^;-M^^*-_/*
M8E<VO:D!3W"%/"4.:DI?<P8@6T MH>J*&,A=>/1^(C4N-F'PAGXH+D0905<+
MF(*RD=J<XZK>3 S[A=Y#3@J&P6'F:\X&UEYL:&E8B)S; $,OGN&8/K&3/JRH
M'R?<1_U"[1<Z =3Z7"PY8/U99K;K9X+G&=^MH+.4HZBKU;G3%$)79Q7SE47[
MW%JXI@%?T@]H36PK"+^W^Z&CB!IY\:V9U0LNO" C!A+HXMUOL5U(<9L;PSL^
M^<AC06[H _3ZG[X4KEFW'5$4[O8FKK48UA<:!N[7#=SLW26[-6OEFK[:0?*M
MIQ+-.4UYN46M57*+UA7Y[PZ"!>(+X(B0Z#&=<#MNMXE?>KDF6;&,U9GQULF^
M,#BT-?_^ 5R-';??TO7RBG4S<E,_LW;'_B^I.?V_)*ST#NF3[Y$6*0?A5R^H
ML+O*)3.(DYM??;@I[[ B-.D*R@BT.5RB+STS\K;UK#<Z,*(.@^R./[I6W@J+
MU"F/3.AK[I3'4N?\+C+&ST-V Z-Z>&'V,^-!U,UJ(32:*[>AWYUZ.*K5OT7K
MY:W]Y<-E BP<7;HC><HXV<EIUB/7/KOG@3! E'U1S+Y8D'._FGV!6[(/+^YF
M9D5#WXY9H1:V?&;%6P=%#I<)(N- Q3SV!=*44W/ /%!FQ3IFQ5QB>2&S K.D
M-C(L-$W%*^02(8GB%2MOYA]'@2A8336U>2\#)V3TJE6;B_W@4W;[1?6XV)XI
M,U>XHH@I<^&&RQ+75[!DY B0J-X<*FK2*+?J<O/AP0VH#4LZE:2X:7JBBJ<<
MD"^O<DCV@$DJD>0MS)C&7,6J5<V8-<R7E>J':J5:;?Y<IERRJ*(T*DHC!V=P
MM7XAUF@<!N)H-Z_3IN(V,O!&QGB BMOL!Y]4W&8UWGTL;O',UZ189O&DC[9U
M?V)!L,X(/VT6O5E0>4+%;Z03KD\J=+-K%MR!.8-U*+!Z-J\E-PB#T&-;.F2J
MHC@'%"!049P]8)**XKQ)%$>?M6ERK)FW"]I4\82R"MI()$4J:",K9T30)B[X
MBK6IHB8N2\K"J)".#)R3,52@0CK[P2<5TGFSD$YU1?/G3*C<C6(W]98DAY-4
M[$;^V,TRP^<MFL[*']"YW;Z)LQTF+31Q5&-@65PWU17X. K!J); VX\.S55R
MS3&/;ES'V(*%U*RVY @%J>:_JOEO--O[N+4.=C%*-6[%0M<K%.CUR0OUURA1
MWI@K49Y=>ETQHF)EDO.KBC=RJXJ7UAG\7)&IXH/7VM'@Y]MO%AD\=A=88P)S
M52S6F$ KGL!\2_29"<QKO:1!<RQF*_3)+"6-,GF/JK%HQ&Q/RN0[W"8>@]7V
M_;BV]$R;#G^N%P O'X^/PEKOJ/AP-'&;9+Y4\,OLCNJTG#Q6B4^7E,>'C^#:
MT,MT<,M:\S#:?^8\.";%_ KC[7!Y^X,U6#UWLCA^?]0ZPW\-TU9<9,5'-G=0
MJ-C("JR@18>"YKX0_272@LFH,8S9N%1 8\EL[WV_ZJGP&=0?8J^Z :^IGB.<
MF?KL7$Z+2VAS+M,ZJXSBU.IM84$S7QNMITV;<XE3:TQ@*WB04:>O"NNL&EW:
M75[(&3-/Z#/,[0EMA5'4R7+:Z$1TB9^],LX3$_WAT\V]Y[O@-%_9L/TC>GA'
M//L^'@3_$7OA:"M9Z+/MH,W00Y)]^*9/=472P4<L?9S:$M'XV?=L:PRZ/R,9
MK\1?9V9S'A'J'NATQSRCN+]12R3E1/_PK5W6ZG.R\LL,VY=IK,7=UQ9IK%VT
M)[OE#453+=GVN$'90]8R<?LV=JX4C8E&] >+T[NF9H@[T\<TY$80Q0X_!.30
M&-*HJVS<HC1M"$W[TGKN).I:SIO79JP<T?N6]_B,?A0=T82M ^"(S4EC6R>V
MFTSXSG;'_&O1@'8TPL9*( C_$3U9@+[,#X 8?JJ1*'\B3R"-.]#BZ 3XIJVD
MV/+Z 6ZH4R;[*[W7U D'V/R4]XKO,>\9^ZD=2+,]Y.; \OR 8-<X;%T+G)R"
M24[GO6OJXZ4+*>-/24,^7E_W.I^XG-QYKAD:0>I'WOGUCL)KT#^Z=(PR^1A]
M_)3@XRCS"AB;[3IT0#W'ZH/A,_9#.UD0Q@_Z%%V$U,8?N)N0B#7Q0>'F.B%+
MW ^/_1E:4?.QJ =8/' Q"^HXV!KWV;4!BO"M#(PRT9DW,\CI3;:=FAHKCE>U
M3 ^Z"(, F6X'$:&GO&'FK0-:ZY3ZEN'?#CI\K!?Q&)?@5@2%]PS[BYEW(!Z3
M!Y0K,4;_=)+^A;</P\%$<P1^7G/S)'[,PV0,HTLUR$ON$-*4$:98EA)IB9Z5
ML1\KU2RFZAE,;<UG<_V2M'*.&)9PJDPN,VV."(^V@<'$FXQ3ISB#ZN_ (-\#
M"P2H*5JW>?#(G]8H'&7I?@SL YP,YA8JG13G6B.?:Q%2WX&EN2S>LM]4;^90
M/;%3QCC]1#O[0]<+!M2V1?M%,/ #U+,9O8H0D(, X/<L;2':;&;9(1Z0W(]-
M1&\'W:2?Y!YS9<[96=B_=-;CJ\]Y0 *-0C U@")&TH,3^04+!\_^@"^Q0DO/
M9NO#M^#%S33TY%PMP1KB6A%^L"W$4?C6<K@%#$+BA]A[,>HSGX@!#\\D^%K"
M%O7A&!C/+.X8H&$\C5N#S8@BAM(3/1I7;O1(%V_(\X3R]S36-[FRNPPS30N7
M])^?"YGEB=YVF\]'S>P.JW>\:AV_J,6G5)WCJU*-9H,^]I*UL<^EYU0:Q50C
M]4*X?B%I!;-JL_O3O/2^H@ZM-&D&'3_N "SV?6[<@)'&$L=V/@ C +7[ZV6)
M@,("%,.0SXL#-_0GPG=V13@GVR5U8;OAW#ZUE;FX>B_L^V#*P@BZSSB,;4 #
MB9"+F9U@^F;1:E<?U*M&OUT[J=7;U9-:OUD]:=?-VHE6&;0:K59EH-/V86)+
M3NQ)@8M$ZKPFU6@V )="PB83NDSU$1$*:1FH'%.;]=;>MEDOKOOW,<(]+^$[
MRAEW2*X2V\V(+EC?"ZDWD6Q8LI%)S_=L=C,@'OC1EABQ8D=G@'$@,&%-'FB+
MOK[]"8\WR95+'1&PFUX! Q!9" &/XXDB7,1U[ D9@Q9WN<$K&2ERXX:M2B9N
M>,[ZP:7C@Q6,4[V,)A<E>]SQV;T>.LP^) GX"9(B12^0YIV8H-F X8P]C_%#
M_H3%/T\#A%I%UZO)'PNS(7B,$*"H.1<+Y+_XDO&,A !&-NFQ<2!"F2*2J9=@
M;K;MOD@V7&9*-B )EZ'6)B"\U!8"9TN'*$E& NYC>)9C6&,8+.Y(Q'JN3+Z/
MHUP)CQG,&O,\";Z602-B,,6 GTY+^<H1 ^S@R'KN"V9DAX[IBSW>/IMJ5ODX
MEZ] ]>TKT#- *"NXH ;/KDT4:$3=TZS"E%7;OL#K?=R*\:V?B8*="?/(Q>-(
MX5Y3SQA&RK:JE.W^*MOJ/BK;L1WZA!J&%[*TUKUT",8# WY (FW0CJEE1HEF
ML8$Z8(P_]"^2S;AP$G*KFM&ML0XS+V""D4H]1&6:GR6]J!B!5"Q.DK8C-\I&
M//?\.+V2#08B1Y?@GGV\$S#C@F6CAK/[R!M'AG80".4B??G0O7YL/Y[]UKGY
MM=M[O+QY/+_L=7Z][W:ONS</O<<_+A]^>^R<G7WXAE>*N%2[3,Z&F#GAXZ8,
MVF'GEC^[Y=(Q>((UY:K$B3]B>A_><&$Y(.B8:C+=/M_C/,P;^.V-\F/?50XZ
MCV>W-P_WMU>]Q[O[V[/N^??[;B_#^@[P'I[BN;8?YP09#.PJMBPEO$ <>!<;
M A_I)]+%ZIXT+H(U%<J\V2Y+YI==6O]@/+=[]C@>GN\(HH,FYI0 1IH XX0
M)4)]P(2!Y8B]V7N>(ZM5Z8E6_\A$RK!6-Z-/89*RV_UI<-T!&@$,B/-7W\.'
MFOG-%3E'TRM,YEM/CD@:9 Y_&$^J%\Z>< *0L>GDPCY+;2V#E1CZ\<%"CV$U
MM"@O_P5Q !/Q,?VJ/[*"G)F(W$4#=T+-DAB;[^.??C@"4<!SON)0I7@ZO!.5
M9/3& -@?^:$^P?,BUL":'G3L=<^2U"HO243&6?DKT2\Z.%GB;W3#@-@6S(,*
MFRWOICR2OB,YP=H,1Z%(BHA/-X!M9L1G-=P01=:A3U%.VO2@!?XR-5W93V:$
M'-W=P< R\.0&"E'FFD$"1]$U7+KI&"@"%Z%1@%GSZ'%Q9MD3;@WYF)T!$WRB
MGCC@$1-DNGKV^I3B*45NHD;,D#J11C;5F1\YYB,;^2$9I&I24'!S;GR*G_.Z
M6D*^)7P 042U%&FE'%DK;6.$9$B?^9BB0\I<VE<<,3^F-[5!4=+$>1\<JH7[
MDG%RYMC%W)9E9P=Y0JZP7Z/ EN$^,R].=^%:"M=C.6.:9Q-^4GLX^VK2?/O8
M_X2'6V8E]IY/'D6:Q\ <8&"$[P3)E#)+Q96PJO<9Z&\SZU9@5!;SP8NG?=OR
MA[%AGC8"J(F1BB"*F"*QC#2QIHO BXF%PLGS^_D152MC(&3T>VI9?AQ\*D_9
M\>H;$!EB@)W"U'1I^^$8\[7]^)#Q<L6T/H L!8_4,2./4=]U>&H5]4$/P*6
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M1Y+.K63!'N\^:3B%A0H+Y<!"79H6+OLH@WN,E#6MV:QF^KM4B^+DP@8NMP/
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M9H S7<&9@K,-X$P'."O<BGDYG(DM7 O^4G"V)TI*P9F"L]UKYJJNO#,%9YO
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M=_1LY5C!TOG+.>'<<W8KF4J[#,GNP ::7TJ1 ?1>T+,C=W'5HTGO0P0Q#2N
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MRE68L47,4%N,A\[RO:F.G"YUNA>E3S6M(>C==\T))_4P&-GPQ_\#4$L#!!0
M   ( !.":5*_!7+!H1@  /48 0 1    96EG<BTR,#(P,3(S,2YX<V3M75EO
M(SF2?E]@_P/7#XMN;,E7W9ZN'LA7M0&[+-AR]\Q3@\JDI$2E2#63*=OSZS?(
MO$\F);E,S62]E)4,!B,8'\E@\/KE[T\+'ZT(#SQ&O^P=[1_N(4(=YGIT]F4O
M# 8X<#QO[^^__O=__?(_@P$ZO[SZAH:.\%;DW L<GP4A)S_=W_R,_G%Z=XWN
MG3E98'3.G'!!J$ #-!=B>7)P\/CXN.]./1HP/Q105+#OL,4!&@P2QF><8)F
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M(U.D9J G\?C?/D\]6'*V)%QX )7<-%<QF',R_;(G)Z*#Q(Q_@H;[8+>$I%)
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MPDZ^NW/L\0_\?T]0YD__!U!+ P04    "  3@FE2:WT/]&TU  #ZIP, %0
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MF1.C _:?KP?'A\='KP_?O3[\?'_\[NO1QZ]'G]]\.GS__O/QY_][>/CU\+!
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M(HPG]\Z+C-C]\: #P9'WKR2*V82[QR//8_/="6X<W[L,3YVY'SO!W=0AB)H
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MH3.4_C_\'21TESA_@>-'^(AN8=V=3R9(;LKHYDP'VK"$*:-@BCWYH.-.%C_
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MXQ+]/X3<YJI]#I?NM-8D*;>0:-6NX1FUAJNS6I)I6FV=VE.CGR]/-'&2(*[
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M;%'*>QI*2&CK\ DJDYI9P?\DQ(\\WU5+(F@DI4,>,!-IH5_WE*H,LI"7HH*
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M\A@>X:NZ*M]]]CG]']K(_+_^/U!+ P04    "  3@FE275/7?7B&  #<# @
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M7W!*G0FF&T/K[24SXCU.-UD/F^:*&7] I;(#O_^,"P@^?/Q#&#:O@QLV4&3
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MC_&)A'"/XW8P,WE">:YP0\2Y)C_:'78IWW9PFE)2\WJ22[D QB80N^_!HNU
MJZ&E\/1^?+2KK?*9>];P>U B>%8(NSF#3TF:\M<;1*[-0$6"8,KI:HSD1-37
MG:/[5,>MZV?XE?W&,!AI$1S9(6F(@8=2&(0NQ8DV#-XH%:O!84]^W!\>4;(A
MO]O"C#TR2V%!_S*1W]K@/)S#>Q/(F]VN]#2_"'C+R$AAY"P;292\R0AARW\=
MB'/R0.'2.X\H.L>OP2%,_Y35YX/VTR[TAQVU%8-E(#WLJJ(Z?6B^RB+(Y6Z/
M\"N$O'$2&?MSE,-;HF%7$VL/ S^1N)/AU(Y]>7][2[R;"Q"TWVI:@N9\.P#
M(E'7G8^E&+(OF! $4$G"\'H>C#K5Y6[*[F/A*;)WLYS5]X?W3P'$ &V[T)W,
MA\!8J UH3_=]H2"D%0#[W7K/RN!>?H/9)LG-2KM8$/<S![0RF]KS^8^820&@
MD")HS]>P LV9OP> Q2&N.^/S/Q R@%*(,!R<AR)?'MY+W5-X#]?'\P5-\V.]
M?1"+Y:&O/:\;.[S&X.=_^Z5G_&D,,R!DJ;6X*:59N!ITH_X\.ICHB:LK6] +
MB.'K0SLT6%J%ISS-_SCP"MWY ^Y(MF-B/Y)-":O-!=.<O?R\@W\_)'E2P'N8
MO20;R,=X!S?X*654F N8I7KZEF5,'J)?V7QD*! [/&7BL.)44IZPVCU,9G]X
M:BS?NJW)!+U*6/" 04\6;24R4&4&I=! 2"W#I2(WGT\7D.MQF<KV*I>R2.?R
MTCRZ!C%3AH>6/U13OUR+G-,+4>?S3R<?S_[>P7?V:^@0\T.<&(SIA-$+T)*-
MPSS0JRO@TIS.^^U#KY!+V2#LAE9*O*/%DM?;+SE<Y3DL5CN<%<D_>%T2#;\W
MI6A9K$6;@Y?R+%5+-<2*2V:4/_7M _E'1$4 D2)#"/58S$'&=JJVJB74+"-Z
MG=YF<$]<H&RTG8H'$H<LH[M,REMK'AI%WM(X[=AYL=2R$&HL"Z$F9+[ATI0]
M1EG5>\PK[G*)N!'G(1CN2-/ #C!Q9-)U1[I)HL<$L5J-(^RXAZ8SX^WD,9W%
MXD; 19408=KH,-;=ACF@;RMKO(U>V2ICO;V 9)69P7@M5IO:*WH].I96-T#7
MBZ5)GG3BC@77<A'.E]XA&)<N=-A$E59&=$<"YBLO;K7:;#*R$KW\EA17D'88
MN(=D'/&*_#:F?T$^U+8I4[*6)F;&QHO%E2)0DXNX$&063@JPA9#-PCD3A*P>
MA23T%R$8H27T>(3N)R[>=Q[ESU<(?\U'UNQKH>.D5-\177\5^B@KP'B%7)BO
M&[#V>GP="IS$S Z/>1(G4?9Z'R$H2@,:%R_K)C+"P+J(>K@[H>7QL:C_&(@U
M#>*"M545+ ;2PTLN@"$A*W'.4Z%,&>EG,MFMMP]9E.;$*<D\:5ZN3(?:"'P&
MJ7\?SJ(/&3977OCP( 69TGDH1U8MON)I7OVL:\^VUB]]T?B"[2YL[;*<0K.F
MM3!I?O'Q^ HBL,^2%S(_LZOT*'T%!0;%,Q3W(2$L>X\@P*V:"D+=:OBXY3=*
M<N.G64-D>IF%3]V"]5PU-C[#@BX,;S/\DL0P/GO]DL-8.8-9$9]^X>U?+/8%
M-M1'M>(SY.:A<5MY4E=Q"V/^&H$T'J_CY:$J?).V0V$;0BD .'L%5 1Z.]F&
M]GRMUHB$VZ2H]7G7\%'U6_8H553FZ($YI1^U:!EWZR$<C<JYAI%E)>OF3+FA
M>5CI)D&PUC_U 7N<C/SP=Y2%X4@>'S5&JQ0-LC[-I)RL5@3U2OHI_7E#@^2!
M!L;:A554RAA(TU*O9MB5X.,4WK=H<NT)0:6(K"N9VO.4_'(AL_(%W!.G2=@N
MD/R,(/UA14_\S3*+S.C9VX@.??=A1N7*;H+4!*(P H<1D-A&H4L #;7@57)D
MC>976LCYJFZ<\:$K,JRW%TF^P0?:^B*-;S.X2PZ[_#I]@2+2&"TB+#F,JI%K
MP7$DV#]QL%/X1&NQRJ6 (@!/&JCU^J5Y54P,YK^QE"\,YQUI&=@-'@NS@J.R
MR9GP<M40UEM02L'\7\H!%$&FOEZA3PK.FB]9C*Y4.BB,.*=OI3C=&ZTP_'
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M67PIA""LT#<3!6P)GY!#C3;^G3%'3_O+PGHH"GWXD4+\\8\31*%I!MP3CJ0
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M]F5F*2V7XK-*[64+QJ>71S:];-1I*%*FH<=7?DPN_JYLG<RFH4(.C?\-'QO
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M']8[N%D!SJ!]I/]]IN(8=6^Z8&6Y$3Z>M9?];RX62KE<*%($4]OP>'Y,<3]
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M^K0I^&V?X.H'%)Y_TP_E1_1?]&T=_^M_4$L#!!0    ( !.":5*Q#)BL45
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M%BW\9$/=(>)BYXK^3/C@5Q!HG5VV_QLPF_N\15832(#'O.3C%MB<T&&<&!.
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M VDW.<F4,UL9YV9Z&I,* $5L!E-SG0"1HSM;;CNZU?14'CF<1"*9.7)FJ[U
MY*!A[CPER&Q!!X-1)"&"(S>*N.J$F RI%AZ93-%&ZI.A.(H:')I]2-Z[BP%?
MH-"UK:QK0\-,OD*:_4[KVV99;_Z.5(-5,3J:,Y$2#N)"K$ZC26Q(=,+_) H7
M],S_L^$<\F0TSX/NYBF)-[T3J\!WB,0\2<ZGG-P8%]:[)R>A=3.]]X5"$/</
ML^F-,I2#MY'FIG?24 Y<8:T-+=TV.E)-LQ\&TUGJLJ;_*J^65M/KG4I:PJZ&
M2_:OB$4#(6?R3$>=I_6WIK-X&^9VX9D5N#8UG2Y<+PIA^I'L"#I4C(T'8G-!
M-IAF+2D=\[E%(7=#0;C?^5!;"MPM/1F;%ZJ$@30V%,)\'24=L[GVGU$0OW<D
M@\?UKNE/(/,HIZ%G!LEH$@NP]ZG6-$2Y'5_XN5:^4[3DN.8?Z^#Y._+IN!X5
M9Q-GZ?IQ)R-6REUBK]22TE/@)T!4K6-9$!?H&7DXCAJ6F$T-H4[VDXQM7$%$
MC^QA9S#3@F1F4$JB<ZN@;G)%T1K[R\!MJ*]&VU#UVQD+'S^>^74\8B8L@#EJ
MGT?4*BY>GA]W:O3#FXS\RBM5'"?UDNM <=I3F'E.UT=E&'U+,/+1G+D8#A*E
M,GN(9RR9+=@A1Z_&".:0F2W5 9#M.#UX)LXHST6=6APSL[52 &:R_DZ>R*3N
M"NBSFW\K>"[OO6GF[2\EVVNG_S[7>@('=L,798K_5I+1YDDNX.*G3Y#EL;?;
MOV"/G;GOENLS<*<^+]8P(6Y _^F"_M6?)YW<94!HCX<N$<Q'LR9\T9\3EDER
M@9+_2CF;%(PVOJ:4!LLD0\=9%WL0-XR;$2/=^6TM"X: ;GAL>B!W8^14G.ZA
M!(PHE+L"*]#\+AI*K3$%QZ!2*^(X:LCZ[8&N7]X&I)FR7]=>I*?:?@';AD2>
M_^FYQ][I8?:6T<G[(:F6HWG5O!/-WZ/$D1T\XI+TR_@H/=&;/;YHZ!QC 76/
MZ-8,W! ](/+LVBCA_A[9>.['5, E=MOGI1K1?5'/?I(<QR1>.+].B8"Y(]B)
M[##WQ#N9$Q1+4Y&I-QQ Y7R2</SVIE-/7YMD+L,Z_L=IK-T$EZ^(V&X B[24
MH=[AK.,E:6O25<0[7^E+JGSA-4KXNXN(O: BA=5J!-UXTD-TO>:EO*E:]XH!
M.E_[6_02_Y.ZI<Y1['IE54YNEV GF8\'FX-ZF/TE,UN0VI_HFOX1N)'VO^ZB
M*^8/E/1J%^>\C$)/NE_")P0@VF''2XEY51/2+*/@_!=\K"6=*)8A;!-@GY[/
M"[RDVQV41%1,0*M,VN$AF+RZ<N*IF)#6N3RRXJ=2S*=?:GZZ4]4J58A@G[SL
MT#(XVZO$GXO41V[U\EEB>U\7(5-\^ ;WC%DIS'"MX.5XF1TT67UQ%6>J;R[6
MH22F"&-4HSSQ='ZSA94X7N)*-,=.0XSD(6!79E%QH,P67( ;,6<M<W3,%ED5
M?@;!HH+')\H#<%:)3R^T2'A8. E6:5$?&G.PB FZ/'F"V$"T4AG0]IS@'+6!
M5*.2WFH5[R0\[\[T,K.-MU[54UN;+>F,@;'JK78H'<84[,-:!(=\B32+#>$I
M:$.^4AJ&"PVE(9G846X_W&PXS3!$\&X_]O_DPWA%E>8'M5$^_O# *8^MSG#Z
MU))?X=+O3:6+YEZ%/=34:X?%J/4R9411QP*)00XLF41[3P.A2YXK5.Q_60>&
M<QR$H-""9N.,;_E]?,MOMJ9:Z]GW0"J>6\'BRL,OJHIE[)+KM:3CW&HLA\LV
M(E7V(&=V[U,MDB=:T35C2%G>!JAK?X;)TI)NF"%*4DL\(&6 _3^3*,^6QW;$
M/<68N#;=)>P?)KZS_8/<;X)B!YL,I#.'\# 0.0 LBC/LZ=^]R(DK/MH+RY^C
M>RJ)+F<S!#M$NCG3E+W*&+TC^-FE4O]L_3.@-[.?]KSPYQ,[=)_39KGB2$&H
MZHEW7UGKC9+-?"2L/>$3:/%+24CE%&;4IK.T8_WEJQM>(5:=@%+'OC.A_^JP
MWZ _%.%3BJP.[.DFL!%R@BNJ9,9MOYD;2MIN$*$FM2)WV>I>I*KEE!Y#YCT3
MYE&,CF[,DT<^:*I>&85.N&^2;2E 3/><-MLUKA7'&_7*S:F$6+_N#AF5589Z
MA[-.*MRJOC$+J6K9KZD8HX:\3948PEX;5XB$:R8'0GJ=,-5F)9KG+D-5NZ2A
M>AKEX(<5LB>4-;U!GRW78[&(5YBP?^2/*]+R!S)$)ZM<SA!47P*3[M?952BQ
M*JEW..NLPKM2B55(55/CD1W3:E-'F^XS$K_=9)VC82X@"%TIW;-@B V*-^SO
M0,[A-+M9G]1$4;8N1?0ZFQF.F-%OK:%IBP+$>G&:)D& 8*:;,$E%9^B.4&O8
M=;*6('Z:DP+EOQ'YCM9J<]335Q?)+DS"5+7,,C-T8A.'XOU7BQ"J-@9,H4@"
MBX(I.?<L%U:$ 4A8:G=NR]Y[5E9^.J,79KQ-)DM,0O>?L2=>>$,"*&JI5Y ;
M,6N9F_H\XM+X02+$0&_$PC2UO,JD71.V0]M CS E%#35S" H?NK9 C7#D.))
M!=K2C98![]4"6RW)$73,_@*M"++=F"7Z9R_ADWE#82</1D][/4(644F/B(>V
M0MH>L:">+G-+M#.^)MM_YH;0HIWYK_IENRFT6#M?&]U5E<K>!*;B]6IV/M""
MDN5ME)9;:TG_^$BUEH N$I-*X((U(M3T1#\\!:[C6F2=XPA<N::<R%BUIB+2
M+8O+:1C@5D"G3W%MY=,4*4US.I#,N/)$_/+3Q5-9S6[G5R^E,$RT#B9S6OS2
MPGNWZN 2I>5J87P8TZ?D=-LV^]OV"<$&5@4NMH6&TL95#7+M6,U#Z0O;JL\#
M0[T\0^F;J@MU63]B&TU7^]EW6]=*E/FK,Z2_FBWKM>UXX7<.COPHX9L@#WU!
MRW#_9G:A1UT['OCDRN$W^XI5HUQ"'NZS=/1CLZMP2H1(X(:1'[R8B3I9W4]]
M1 Y<<%A0!NBI.B$\#$#W(L@XE&8+U!: W(LPY,5T1A$J+$(K8E%Y_1VSK8N6
MI68)IF;;#6H4*$AD.Z^"I-XRV&O_?*@^]\H,"(Z@V7=1@]R3O,\=FE:3P?M%
MG3CMI]:D"&#9?"T.]"!E;--]7)$)F"'[U73%7PVVD%Q2CJUZZ6O,_569<YPA
M^,UL_;]!MG>)>"U)7=\ >JJ^4],S(D_89$AK*FJ?&MZHJ"5 =TKCGQK>:Z89
MBF)54#(L3TU_K56_)\OJWF28?ABD!@K9G]!"21FT'P>J@@*W:VFU+ ZD.AEJ
M,I"02FH9MI_4:Z*'I\OKKM:7H?]9O=]Z8.CGP51^E1UL"S8EU4PS8+\HMP0.
MM&J_<&E<#IW9ZC^T_/#6J]1.N>0,LV\:'O/:+^K-0O$\'%!UY@(%-G%72<C>
M6130'<83B2LK>0O2Z+)\=QV+&G(2-V/E&*#B[<P*7*I1WN40>*0S/O. !11E
MJ.O(Q)R2N>6G48>\='K"79ZM+$J4%=3?5%672=E4-&#G,DLM<+C93C&LDP&7
M!@_1<FF1-37IW+GOSER;/=4DL46LRQ0%W<X5\1*4@C"B_1"+@CSKR-VN8D!*
M-HI2U%2U9H<!J1HE%50ZEUP"4\3PQ3%6!%U9+HF[!?Z@!CG]^U:9(D&)4TFC
M'P*FF$4-)RX;F/,B)T9J".F0'D4LR,B/:CJ=2Q"A:6+AE3%6=)Q9'GLL>5@@
M%+*$-NQ+R(YJ(OT0'B4\:NY<E.>BJ3"!T=4A6_)<W".//3PTE#*B%#N7-\"I
ME[C:ZI?16$%TX]HL<>@<>W0+8,+MU-)6U% IU6"$?H@PF0GHZ$W%^7E&$Y:Q
M.(\'YXQ+B3<06:E*=KM IOAR]" 2"TJQ,XDE.74LN3+&"JPX ^\N(O;"V@*.
MO3?%\G\/4Z"\DA^@'^)*@G^94UP\3,4H(&G4> @IR02'#BRJF@S1K>Q2  Y6
ML+#&"K9\4QOA1[O=/CA="Y^8(RU%M)^:*CJE)/04 <\/+F.BE5'HW"2KF1H6
M6 %CS_A^#W/H U4I@7Z<_P+^M!0-WAWU%H>HH7P $-4A,4I:W@M,9/?+SB5$
MR52P%/;&RHIDWM<^5868P;?5-5506E21Z(>\*.10Q_V;<1 G?&4%Y5(%-$YB
MX"7GL@11*3VCZ5!:]!%1)I_R3$KI+0U'ZEQZ*8(**]PAQLK I-3;H_4*CN0I
M^+(?$B_/F)Y^;,EP#;6A:CJ:.LOM<B#92JZ<3.?"16226'15C!4+-VAN>3^L
MD'$!?8TJ^+0?@F&+,PWG*3_>Q*>W3!R_A7SI8#U!@CID!<OA=\.-?W*+DV;2
M TBX<WDB!P0&+ZJQHJ8"0*#D$:#4#T%4Q6A?SJ[DTS:,\BBI#DE205?76)&5
MFHUW%@G7N89&4'E51Z8?PJJ42PUGMVSLAF(*1%:'C"IC2$8LU=/J7!()3Q=+
MKIFQDH<UHD/_B.@XE\\2D3=EG_=#TNQQIZG_:'Y,R8#E4B*Z>JCFAY?JYEE*
MHW-I43L]++02!LL$D?3$5O,U#SEO4RQ_LRR>C9,CE(?(MY-PJEL<_@V%$X?N
M*'IGL1'6$M%Y4L3U]"E_*6,NX4=BRO*TM00'6,2G_+!20?%#48,)UI+29!73
MH[A ?N ^IR\FC5=.G*;6UXP&,RJGH6N-BEXJ&RZ1$$D]5D^ J!K *AGE<CS2
M1CL)1S##1X"<KM##!FM4^+D.ON/N',%T=H." #4-[A(@)A=!GA1P+%YLV>,A
M2UF+'%NN+)?$U2L)A7&% \NCL&)_?D/%K)/T2VHBXZ3HZYAY:9'X!K,5IZEC
MAC\L\@N%K,4 [RT %WQ55+3<4TDUNMVBB@UN*3&">N[@.'(NR2>[=X-?Y]0H
M=$/V)]B]6T%&QSQ^!F@ZNPQ"=TGO_ #"^NZ7>O*MXXI+.\9:$]U4E.)8YZ:#
M.C>BBZ/5A7,PZ.T>4([2AQ$E,0G,(?LT0@:]ACEX7T;PA)0RCMBW$3$)U3S#
M[V2\!YH:<AS+\;:0=P1P%,<+!.0#XL"-ET>-"Y!#-=X:0*]O!MWI>&%(/ 9P
M^,8[0N1QB.,UW@8RSX,<O_%2 +P;<]C&"Z))/$&&XX?QMF@4BL*!U'!O]"_D
MZI%9_^T$7&V3/J1PJY1S'6&1]@(YD8>FLPGEP'&]B!5 X-Z8RU?6WPLYK,DB
MNYNB3=.(74$K%Q/:PNA2#^8;S[#S,T"SR+MQ9XCULDA\+7DW2[PR\&=S:?KC
M4XMN*2Z]5./#2V&P<0M'7.OC3>>M'*1N2 %*_;@0JQC5>_\]6Z['QKW"Y,'*
MOTC<L^ZWMNNY25<C\ V@;BPMB1(9E]G2)%[QN%"P]41Y8XRFR^5,_7O&/.MC
M';]0JX!'R<!C.PUE$A_:3D/Q2@[E8I6'65:>&'N1%O?[D+I)14CUXRJMY%3O
M79H\#N;.NI);LY:JE.W'![@C:&6Y3OHNPJ35-%P@<DYE$T4R$6&2!F"S03H-
M)%8;0CPVI>E_4QJ1Q1O*I0Q'4<%Y'TIT8H.^28!;06O@HNY:_5(ZS?Z'_=!@
M<GQIU5=^6&&J+R>Q8(^(+#->&FHMHK3UVO:J9M?53,;.!;7+,)0;6@8OT4-I
MK(&\7]I>[B&VADP_KI52+F7,15;@#?LQ21961YZ1<X7)512RJLI!$#&%1M9*
ME*(]MGU0U/9!?@F,+9M3U!A!2E#4$^J'J*C@4ZM^=DEAP&N$'N@.=)F%M*F[
MGX]'G7CQV8N?2YFC=^Z[_T3.':*;+PE2;:C<*6="KXZ[UZQ@\F(1)S[:T_@T
M!LS;GDR"GNQE\C,56K&:D;M"*[^Z>9XG-CT2F\M3&4+0T;2@0H5-_!)-Q0VZ
MIG\$)8,7?2T7E92>/^8TNL5^]M<<3#_0\@D1804#0%$+SL42A3>5#<[6Q6<I
M_I]'.EW6 ID*Z5MKB2[PTG)]T$JU,KZ6F*UL_%<7M#EW/M1ZFN*C+'62TB_'
M'D2]*CJIO@?1[H)SQ?K4:!]&R1'!I>=V*"\$Q7(.MRW".;R?C8:WU0L8PY4.
MCOM7LW&O/>]%2B1/;C5\5Y:KWX7>7'EC8BB9U?*(-C%@AY+B"457N5_%V!RR
M7)M"*;=CZ??]\#;NLZ?5Y?/3)]G&HDR<(1_-W#"@&'I7F,07O )7#WP4W4_A
MR7&@O!5%*:MY)0<-H7?^E[,98M<CWXWW5)RI3WJ0&6?LZ-E-1\]FJS:4R -I
M4('R8"C&OC2>\"O&V)C BOYS4AJ4,+U^:%3U[&JI$<]*>4U7B!72].=QA:_-
M\5ZGH4<-7M&DR(]=)#4*,@7];B66V-@HE L4V,1=);;P6110*SL()H[C)I.Y
M]F>8+&,6+E!HN1XX&EJ.?#\D'IA[+4U+Z$@^<C8Y_!/;CI91$M]/;V;;!39K
MK*>FY<VU-,N2A8[ROZ6I':!762CI[EH63,)SBY U78@X5Q4DQL4(ZIK;+A^^
M\[# )&2QP-?^,PH2 0Z=H"A5+2W((O:L,IUE%\D#FH,G54&D?@[!9A(!LM_-
M\?-[![D)__0/NVS3'_UY2>_*.  /DQ5."I%?T),^G6W]2(1_"#6I\)QBR0M0
M;T2H=*;+ *:(86";[AZ (2=PS$RW_^4 @PA;TWL7R",H<!^;WKM #CRPRF9Z
M0P,Y&$64>ZVM#/I7(E.=I:MLO'Z8OLVGHZ.I6+%OFA?&1I2SI!)>7"$ HIK#
M:6MIHU;&%3UL]$J>^KEG;Y63KB*ON0GE;D>1OR"/I9']A,U4D*"4\;)1-^\(
M=B*;7OF^XSJB;>_J*#3BZ"%:K;SU^8)>"P&=XJ5E+W:' /,H1+.35HDQ9ZY8
M"H< $;D*2%7B\P:2 @,BIR7,(45F#S+QQ!EA4IWL'Q:""T]\J233R3S.UC+9
M+)5DU)\%X00685)C?6?=]9U%5L7TM!/H3J]J$9D_<:8[JB#2JPJSO+0=2JJ)
MR,V% ;>MZ:DB$F<4I'UQI\KQ0/';UVRKSBS7L4WOK"F)'-S@,KVMI@H@"ZQK
MT_MH-CRY@EX3GIPTRK\"%*6\;*8G?+6%::F[5FN3O_Z]?.32$':[\CRSTGU%
M;7E:?!AISLXAO9LTF&V7Y<IYVR:(=T.(7*=EV$%^6 @U+8U2(N*[K(0>Y>'*
M?65_"N >V"HJ4LZ^I.$4(ADL+( $S\(7>@, *RN)D)+BD8KHC":0IZ)/NVTE
M(.6L%B+7Z;SDG-="Y/3F@I9##2[=)$Q3ZE24$CVW5FYH>4S%VNBJ<;8\."ZS
MP0C=ZJ?-H2G,L:M;1M-]YM*'1:2QQA"=Z!!I*M2<9(!.=<A-BRNT M.=Z4WP
M$M'L3'>F2^(GHKASZ,9[ WQO%+[G?#0:1X"!+()@WK[7ZECOL[>M8:MF+2XX
MI3P>IE].#00Z(I":,3I9,@A P4IJ!M02G=6,52FWH+HQ=2!T3PU5XMHA2@H0
M_O19:9>'GW#_80TA*4=$6@[Q.Z%G%3F/N*S8*=!U!R7;W4Z5J[Q>3^L SM[9
MNI@ N"9[FVSH=2 VG$H#-Z.:D<=X7(WQN&TMXO!<D4J/'=8DF8;BZ-1QR]2N
MV1"KVPLK+%A2ZVK1;?I,[49\F% *JMM#\9GV7DH7.A'-OCF5&]WJ5F/C>] :
M'*W3&7EEN22N+/(#6>SO29E$934.9,GWPP4(YEYS7KMD8;12$E(^E]W2*TG_
MZUS)%>S'MD9D>9M:F<*.%RG:4K/(EOJ1JAL!/;[!&0I?$/)OT#/R@NRGXMY/
M*;):PO]<W_)MU_)R1:XS/OGF!\4"BI+48M''V04-9U1!1,L:;08NJDB>2B-G
MZM^SDT#HA96HQ&3SUS,K<&&U EH:6 *K@(0YG.C?=C&B/_KSA^N[RV@I[L<M
M^*@UWJQ7"=ZV/VJ+MWO62@S&V=8GK?(EZJG=^4#K>;SVJ;(8Q-+[@T3,=!49
MK?/(:S39#__B(D+5]L4:_H0 )*QUKF?K?49BZ*%/ Z(4#^6& #OX%0ZJ%2-^
M?4MY]ZOI=&X_"TT3M[**0W'NJS]M1>M1(U:&XJ('"NXB),5NH:&XWN5N_2)<
MB_26H80KMR(#=G39[2-^:AR6Q;H^+K T3*\(4&:-X4)[D*-AYCU;A\:VY<[1
M,#NZ6H_6H<;3P]=D('>I4L\<%O(\:BU 83+&POYJWLO9S.I2K2,N]0K"41\U
M2GG4I1[/,N@_F:EH:!,QI8^L'&$-%V7GH019%DT5SI.0"U]E40;-1NYQ (+D
MQ,:7UV9SD H+KR=V*&\%^\+N(%Z3P5C]?'@D,6/K,]?S^&T)?^RKHZ2E"T9V
M\["<\',K1'-ZU_PS%E[P&8E0TS\KZ"M>T==2,4,_'[[C9T3\N$P&]AUH6EGI
M]WIJ_B=- -&V4@C?%#6$=,R%&Q"^\X#(LVM3X3&=95;>M4^E;11?GFS)@^)_
M@C]ZJQU7:^P7'Q_\"%Y&0E=3<T38Z'?6"A&9W5I(0 ?O/["/UC\L\@N%5Q%(
M6M11T)OW6]RHL/BG3=*"9<;IL!,SM%E*!94QHJG9/$[5S..TZWF<J)G'R1AA
M-D:8C1%F@FW$GT*NV&3<;#7AE>@J#B':=<]8"0#&X+*N?=%C<-D87-8QH"J#
MRTX&&URF$L73/10-S^[6%.AH>#YVJ_=1E=UK>O0CP(-06+E!QB/"-ZW9UY 2
M_Q2N][5Q/,V^D%3C6>)X-3W,5X^.7^:2WQ:H'\U%M^99(X>5VC>;H40BM_+"
MMB4=*A\1AQ)<W!;,U<_-'%VSK[1697!15,&V^/UL++ 5\1BE"!5'C_#(7[--
M+$!<3KYE94U$$4?/[-OH(/-B/IN]H[O+B^&O$1SK@?BPN\Q!^O)-1Y7-S@/8
MLW:K\;],9[M.&]_95EGI#[X3' 2LO7#2WNTOV',HZM]9]W6V5/0?4: NSET+
M@ST.AV]W_CHBSG?R=#BKVXR# L^%:6J)J=_A9F=!;#M:1AY;PIV%82MQAF:8
M55M];3)]R0'[C W;K5JQV1FP!]@L,0D99ZQO9GRG*82A@'9WL84-,VH 1.4:
M-^](W#QVPC$RU424\.4[W.SB2[VO"$%9K:4[YJV,>2MCWLJ8MS+FK8QY*V/>
MRIBW,LR\E49:FG @.9SF6(E4>R52^"*9'@LN?12D0NO,PZ_3T#K#([RUA]89
M'NNM.[3.T*!O%2)3,'+.W%#D[B/G3LR.5>A+Y)SAX=\=1\X9&@RN0L36!\:9
M&Y?<0F"<H06@-07&&1JFW>2<RCUI98A^';QRN?^ 6(;J]ILFA]#,VL)-(91X
MOMY >F*HET,5I/#@APS9%@IAX]#R!H*L:'1-!O>G<2.W ?=.H%<&]Y=/RN#^
MEL#MHSD;WU3 RP,+,TR_:6A6H#-,^,SRJ.&('A8(A:QY./89F+RQ_!W!*T3"
M-867@;UBZ$J%^S8?J!]ANPWFH>%I;C/Z'64RS+-PBT!/<]5TM(1+<G%W@>@"
MVV[:FYRN?BQB?">]VN.?ES(,"J-4-J8.A$J'CZ\'):N=4NIT-OL2O,F,;O0&
M,I[CV!]GL^URS3;,G(HJJ?BN*CHZ9G*#K  ML.=<+U<$/R?I"O")5)+1$KP0
M$=\-6::5[URYK^Q/$M.HHB(7.$*ODHBJ ME&9:Y?/ M?J!($C&@4(27%(U52
M,II GHH^[52J,(<</-90B%RG\SI;RT3C"I'3,:]]/6H?:F@53G&:G:Z<3 25
M +'.G>#B$\8R:\9?7\STADN?# P\WAQ(=6Z#/@()$9TB&.9%_U""?B#7*JY0
M 4R/ZFF"EX@:-Y0BCD#\1+3TH83L2$)7::<-)0Y'$KMJ8]WT,)M6%9:;HA[-
M [T[*I\VZEQZ'#TSW^N;H:?.$9SA_-'4Q[B6]FG\T,#14UZ?9_^AOOMGMXGC
MN,ELKOT9)LMTTRE[;1.@W^='MBKV-7AN\I( XJ39_DZ'CRD_HHQ;J?C[SB5,
MY;1P&>#<)E=^TW5=XZO^+1JM+->Y?%TA/XB+14W#!2+G$6%0)W716GK,AP[<
M9[DC-2\MKN0\-QMF$BY2EF#.9 %R4@]',2%%W ()ZG'IQXQ<^W0+L>TC 7KN
M6RF$4S+W]*A0>;I@L8[B)8"*/V["![6 8^G\P_*C&?UOQ"HU2C%514GCVE9M
M,KF'&P#9SB]>&1"P^#H.Y^6A,8P[9Y0CI]X^,@"Y<B'+G7!FAB2KV'+BERQ'
M4T-T[.&A"5*PVG3,]=#EP75K_K/I;&+;)$+Y0M"MF"F0(0_#0!&:D9[HW9VQ
M)0R2"B(Z5+_D=*J82!TE3?'4;/A+NG_Q&J$SY*.9*V4GUE&2C'\LTP^AMJ$
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MM>NA'LH[JL##?VN'C&-L=L.6>HPE9#Q_S5*? ]]ICD^"UK7/NH:XS^C.L_Q
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M+>_K/@Q!7NE@++5$.$IF2G,AE&1,4-,SZT#;J\K+P($R,_!7?(>)^Y=X%M:
M3Z60YY G/PWC!JQ$2M:-S$$TN,]10Q#%GB,R)#]KV(X=/<_QM^A["I1ONYX;
MCSV=93LK^VVVOYJ^W#4;KW>/>I+3T5')JW!\EG#J^A&]MM+["_L@?QN$JI9Z
M987\[*Q%N$!DXOP]"L(XI*+Y?.OH]V7FMYCM^HC^&K6T4F.A."CA' >P:F\M
MC-X7U+8,]=Q95XU/^3A]02)3UI3//4^Y+[,]7["P'V5/H:T-W1>\)N$5<EA<
M']O($05@O?7+JC&J'6Y\<]'[YJ)T\;C'V.P,_1:P!0F/%H,.3<<Y?V=Q&,WT
M@[4(8[G:P]W79GHN6@05JFMS/Z[9I6M:@'K?W.-@CG=7+9C%OH(V?>0XM+P^
MN-K8*<0^VS+3V=Y=W=2O!B#>.R>:".\Z8@%WA[YQK2=62\I%P2T"Z?>UI+3$
M-G(F<L-+3F.+@E1T73&Q>Y:E.YW]#% "E'#,G2@Y'4B7;. <7S)&(H2JYOV4
M@-OT4'1Q$E1X='KCI=ECY#O!@>P)WZ+0](2G4H^%8 !ECRBE3O!END_ZLU3)
M9JG!Y#E^/XS?#2VO&?Z"(_1D]EMID[ZS>5Y5\\;0SOA*=O8%HJJ2[6[&G2PQ
M"=U_QG^5WN.5-+M:[_U8C<;;NY!D)_-3DY0%(MNA-I(PIU 1V24X^M^[L;,%
MEV<H2?VP[8\E#S+W59H9JJ8>S3+1SY$TNX\#&$FXEL"A-#OM0NFF;*Y2FAX]
MK@/V0BN' VMVQI4:T5!@) ^E-8NZG9GZ/SAPZB^EO?<((X"K##;XJ.X^^I:@
MZ*,Y*['4%QR!*GNQ*Y1'[JN_1_JTZ=38-X5^< [A(&^,JA>'@FNC\N&$9S^H
M$X']/+QR8-8]DG'\VA)^CP=\J&M?2'G+'G7"L Z^SG-P2M*5[K'G724&L[K\
M&^A8O0L;D)A*=_7E(-[)$A)_>NZQ=]IIE;P+E*15!]1<BSSF&KNB0N \(DPZ
MW"%Z0MEOW^' !6<6J1JQ=^C<,;FE$9O2\3I$9I..KV_?@$>4>A>L&7RS0*KV
M@_HQ.]P3"A9Y?'/J2GTK71">QZ$\L'@5[]^'T"+A@2F]ZL_MF"X#V9;@RV#,
MDH' "]1#VLB=Z:=CH4UX17;OF$<C ._&K&HQ)2:YN2Y]IS-OPSE>+MTD7V7B
M.TD.QASYMJNR0'^S0?KA7Y"<@XSQ<$<PR]B:S F*FTW<TPWYDC2"%S8&*FE(
MF32[%"^H0)W.>$TK:=;V"<GQAPAK6&K-*;&[B-@+*VWJ)<Y8.87F'"63_F'Y
MT8R*(;JAG*G_N&"1 ZX=3&<3WX\LYI1"MA4 LAT:C:&WP#V[JG::K['CQ2I\
ML?RO="80RPE.N_,9WR-6!G3SC^PXGBB;<2%M_3-.^^%(-C#8IJ"#^S\LXK**
MH_'0T%CT@H_U(R[1YKB$@ [>[SSDS.FFC5]W'A!5Y^@)]=;W:(4):XZ$[(C$
MSSW9+YYCSZ._PSJ%A5FK<\ALE0VI Y\;1-E$VPL$5 &$24G=:PE51HS2S/<D
MVQXH8$-,9TQ58IKW#_I?UB@/U*Q%Q5"2<XS/\Y(.9B/G0K!L3>FG6O:-Y3L/
MT=/?D1T^XN^$WGU. @YHQY03T2+76 Y]3M6^D6ED7D%$:B_\H-H2(ERMHKON
M 9%GJA@&F1(KWB $3%('[OFC10_.+35F^$\>Z9\"*RY)'L ;H8!):VEW11FG
M"C%G!-I?I(2 G)U@T0V+_6O?!NZB_0_U]*AG-Z-S9Q&9QC)%7^OF.K_KSM;Y
M?X%N PA5B5D&),S-D/YM=W;T1W_^H#K_,EJ*[YV"CUKCS7J5X&W[H[9XNV='
M%\;9UB>M\B6Z$7<^J.<IV# 5(/O='#^_#\(5H4R=?(W_]);]*<\0_=F?YQ,A
M5C:_VA8P#VC.).UWA.?$6BU<V_+$Y4\-@=9XWC1#S@\*6=P* ETH9,+]KVH(
M:,IW+7/9-GNQ!Q+N_#U$#@A<NXBF=]$2.P2X]J":WDQ+3-#A6B%L>B,ML4L,
MYZ[2H?3+$CIA.3UG^T2=&H=+L1Z("[10T_/-RS1U7&@KF-X.K Z-;:MN*!GT
MM=)#QES?%C$?C05/PC%2@NC>-6YXM8$*1Q@N]=#Q:"(SY37X3)9X4K>/WV=C
M<:KV1.,&?G2>9&WF7=CT[0)+O,6TF?[?)TR%3V_%6QM/N1X65C=5?><JWE=-
M[\\'PJOT)9VC9':" P2EYC$2'%6SVU; SFI=] S/Y#>[60((-66Q5AQ=,[VF
M4NB6Q.VU45/BX+$JB,WDQ2-&G:0V^#8#Z^MX !M$8',81XVE0>A^!N.W\;)5
MD/O!X1QOC-KTGPU8)X8^3$J 59O$E6%V,BQ'ISAFA;;$R8D&S:0G&:8_+.9N
M"]?3V8ZIFJOYI3KA%#YF[_-/ 5/2GIJT86%]BWT[R4P'18_5$].?;I6Q<:YL
M0N<]F(V":727()6Q\--W4NV1E9"VZ:].ENQOD-E)#M#YW#>FVP4L.TZ<9I]F
MR!R75S@"Y:+ :?=MQH]TX%86-T>\=W-^P:W-F)'NTWQOJ=KP^(*\9Q0[Z&&Y
M>])CC-'8AQ2-+;_.0ZD.I@WB3(;PVE5F>Z?T(IO<1T,INJ85VT2]X=":'7.@
M#=H\I.IE;)_JNK<+:;F5Q:-+U4G:?E8);)ZV56:E<PS52U2C]FB=NZ:-BHK#
MVHQY5QY'4X-ZJM,'_A ]!>@?$1WG\CE&4%EI10G*_?!G0QB7*:HQH5O58?]_
MA5"07M B5F7%QY(=HI_":Y\>BX@1N:;W&04Y3&DF15J%V1*BI8#+.^+2@[VR
M/'K257(L0%>')V)GZ^T_V DX'<II2.$_?:5[WKG!EG_ESL+%9O]!RPK5D='3
M33N_Y+?6$L&+Q)33T#\#:$F8HJ^E]@1+7; 7Z RX!W8_T^+;B_OW7EEV?*7#
MU[OX>_V<0]>ZZ.L.)!B\*%<)@0YX9_E/\ U30:2C.4"W3BF)+OB'%G4I_KX#
MSO<;\,&Y#WKT-E [/5RW"$.IR5*YA2M0RLZ9Z4591&55-59#*<TB?CN5X[67
M)&IXT1;1(UBD)9E>P$5 ORQ%:+^.@MD1M)76 RXQ:TRO] (]9$5FYU!*F%08
M[*4(Y9T*0ZG)4>N:P8)^) [8>/BJO8%#*<)1ZU/%LAYACN"@]'11!&M1,SNP
M0QBUXB<=7O= 0]A6^8MC^B_L?YZL /W'_P=02P,$%     @ $X)I4L>_&59-
MP   !^0( !0   !E:6=R+65X,3 Q,%\Q,30T+FAT;>R]^7,;5Y(_^/M$?/^'
M^GIV)LA=D!*IRQ;='4%1E,UNB=)0=/?T;FQL/* >@+(*57 =I#!__>;UKCI
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MY9GDBR7.._J0Y;<9+MI[5:A2%0]>@THY5466C*,]8//HZ=-'CYXR]=OG@4"
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M1QT8B&&&VI3S%*^T*IH[UHYY?GZ"R>^%(#/I0V? >(K!=],D%B7:)UN+RK.
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M\=IN/KIX\7; / P\=/>R/#M\LJ<'_W?/:<1MLZ-7"5:)D )^ UL-;'7O6.W
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MPY/[$T.7 QQ$$[$BBH1720&JRZ6>Y6 '<FMU)I:=6,H]M8]^&[VL4.  %=^
MS(P;FN3>>)_-U0G_NXE.6H(N!J. L]5(+N_!(R=I%THHVU,#2B.RA1D,Y<-[
MDZKC7,8C',1^6T.%0[[<&>[ W;I@88(61N76&"56%I/  QT]F< BCA/X/"WR
M!4JE6*.M VQ#-UNU'C9!!:<>JTV9K#PI3LK;-GI^/9D']^!#X"@U8BWO5M#-
M#H\]/<XWH *Z/#(J_"_OV5YYHWZ%69S7*(M!G)[!S@(A:K!FIFAPP6^+O$ _
MBWR/]Y^6B8(A3I)I,@&3C%GA;VJILGUS3M.GP'88=6@(R=0;,\R65H!6G.R.
M6W22PB][2)3'#T_NKU3YF68DF>@)1R?[A[C-]!JT*V_("&V,BSG*,S!#$Y3U
M%?B9O#0XVCR:Y7D<315N:N:$8LG;;!^/-E?P*&_O[;OP(H]]^S:=SKA.(@U(
M*J3!S=>Q.P\V6%&>%FI;28[F/IB<V83VDS<_1DO%4V$G&J9>TD_>-I$0A/,Z
MH:O8ZQBK%5U7:'(&17MXSR>1@DF4:I."XWA:4?R(:T6^_8)X1W'3 7]?B7-6
ML+M +>A>K$MB"X\*:)MA3R@88%C;&\IA]+)F1C7+P-^/@A'0"\R+=>,5=&?7
M_D3DC366/R@_L'YEGI%KQ/EEX*)I G8&7B-?TPK8B_&^*:IJELSLT:!8?_,N
M-;Y>39NHT>53%Q(?23+8[XKZH(C_@GDJ#OP39C&:E-Z_4LE4Z(3&37]Z#B7F
M93B<%TLT>D786([A.W$0S=,8Q)"]R@_C-,]A<\#[7\%9S^_E,P$WK=/[4QA%
M:DJ*E$=;<O\8^ ;5KM@]*79J,C <FE<T)]&5^3RRLT\\O009B#AB1X[RR7X'
M8V,HP:[.K2(1E%3EEY#K(PY). FNDI1$<9/F:"#V,HV\1=?IC\@$%/KX(@.B
M3R LF,:!RDCH+BNC&?IB%T@)1@_#;TJ^6@0&G"%H 43U$B49R0E42S+^FKC:
M'%G=TD@&TR7HLN;1"V0_+=B3Y4TZT)/<:T6'\@^XYN&)"WX+Y,\.#=' .U9A
MXX/Q;K10<-2<6&X<1?/\%NBR&'EB"TZBJ1%@H83:$9:-NUC6KH35&<Z U&$1
M>3^B/3"^8CTEYQG*N 2T3Y*"R$:>7[3LU+W1Y^XVKM=FZM&B6TKC$DPQ3XT;
MM7C0JD+M:9%R$,QMA H5&(#X-J,6AY/7O^$)+-KA-$]3\OL^)SD7O#.\+>$O
M0]ZEQWN+D: 4PGPB6((E,"MY;^BA)RSJON0+6+5SQ[%]H5TPQR<G)@!LQ_")
MK^MX]F'T"MWE=;',K1&=H"D^X0W95$($RQ**@V@!EE;HQ54+M*]*0Q-DS#F[
MH8.HA::]E<>9$^&2]A,N@0YE* GP50_1W\^,!/4K@X,J9E7.303X@)Q%_N_&
MQ3# (@98Q "+Z(%%?/^GAD6L8>FMV89 M&_-J-($!($H!?7R ,X"&*21LAR\
M3U*,DV3:?MVO;@;:@GN,U;[+I2:O'OD-R!1!"Y(.(+P5OI_4J3)Z27#&@>YQ
MM"\'W78N9;35H^/3LZQH3Z<U^D\P*J!50<[*&'1=UU!V"IQ&:N;>\;#FG['F
M&(K.T9AE_0O6\]&PGI\^.A(O*BD,H.A&I;4V80PP61(,A)1EW5!P&S8^V.-&
MT*#&/@'].A9M%%_@^4!,\,5*)/Q]G"NPS>$#8USR(O#I[0][_'FC,_@XI^F3
M^OEX6--/'YW?*[Q]G%NW%C "G C+G&2_N[ 1,!8K;:LGO-W;\>SP&'0M(V^,
M;6YA); OY!L%4^V.C8MK'8;<MWK:V[\I+01Q5PS/'BL"56J'V=U!XP!S]W+]
M;?4";??V60RH>*Y^K;, "N%MD*"[;)\ QK%2-!!]N;'& *,FD+3HQ$U]@K"T
M)3E)T!-2)!A0)(.E$UO8A2MT,8&.55WG^&MW.=CB73$!BE&WI .U+9^8.!#C
M6R@ZY;FEF].EY#4O,@PB$?Y-RGECCP03E0:?X1A#1Z&$B]22H(#X^JX82Q
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ML]-V>#3EDN[1\$FR6HX8\PE+>^3.#>N8X*XH1$]T_=-JZA]_FS7U+TCX'X&
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M:HID7+,I/4>_5%IR3!66]^.JH3L=F+[4AH"*H!LR/!],YKE&TQQGL<AC+>G
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M L]PHU@/-"GS- Y[2#>[F4J#TP SUCH'1 J1T&N-!A_AY!&UA1,1T]G\UK8
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M7"4KPCS<J5=2;C;64[*Q$;[N*OZ8'ATH.%JQ'-?GP\A;$J:^)&NREY,DY"E
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M0-M*AMSVE;C=4Z6OLPPPCP'F,< \^F >1[L*\]B:?=A.;('7XD5R0#EO4K)
M]S?3M>I4FVKI1E6V*+\P' WG4(TU=.3Z\X^3N4)0)E8AAZ,<A=L>9?<%&ME6
MPS2V.S^O= NNS6(K:YW KMKB2?LG0W60SQL=E=-(V+#!NI)Y)6>WFI %PQU
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MW_"O]?3,I.F"K(%@,:>M>AY<J^AGTPJ[=<2Z$QEB@)]]!+3@=2/'N14-D^\
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MR%EZ=8LQ''%S%Q.]C:@0VVAZK)<[FU7=0"L@L:-PJIZ2F?+I;W! W<G*QGX
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M+ M^__?^R9'Z!+\!5Q!>K[YY!BMU>M;O7>R?_:&753T4/JFVZ^P01_1'9T[
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M]1G<ONHPNWM&HA5%89-"020"$*\9ZA)XW$B\T2[3= 2$T\65)EDOD:M#CBJ
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M6.)5V^;I$&Q"T/W4M3;C..O;%--/QMZAS?Y?J'XX!\G;@&_KVMZ5\Y34!3Z
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M,.IAT+LL#G6W8K3'M1S_[]7N[LMO68^=Q[4>WPJ/8%:DCVE!OF] <@VO.UP
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M2(W)Z1G?DO1J;PR<5;ZC\YKI? HDBL<!J?,C'-XDAZ<A@\-5S5O>0<2]7?O
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M>M5YO9_C^]__\3_>G[U#\;<%;F0MJB)K)-84><^,216F08EL4$B48A\#D'Q
MK7# QB#Q!UH#GY]$!1L\+).C @46+. 8!1:91/ *G>$+D<!1#GA7:1GC+:A3
M3('ZQ?F,7OUA&:-<G)8#(&'X#HY,$(-"%/8>87C\#O)@0[C_S9RW&"OF=G7-
M%4REWGG/]PPG%_7Z_<=^]1720]N=QU_G[OO4K^[;*N'[XH\7OK!'M[20E3>(
M8)U&49 ;=[$11L1E<+-!WX.EJJX+T7H&^\U8#T@ 'X[Z()9!;\,8&-YDI:0C
ME$7 NL*N16 :2MPFFGFY%IKQ[J:TL0$4)<@7S!Z3>8"/9L(9@9C@2*C0$X@D
M0RXKDH.K$R$'\YG,@ SS M;6FZH9V0"&-?EUSL5&G2B0H%#!E2#-0G3=A:".
MC2/X+O3**8SQ0Y2!D7((QC-8*"@%SU'%<X9";R:]KIK95I'KJ_60ZX<(?A_=
M@5A![=;3@M1NAQ"-*4]/KU/P#?2Y59O^>@V;_NG<^RN&EW])KVZY[>9VX1E5
MIE ]I<=''?C0]:K9&+EU=I%CCJ.I%#O'K ^5IPF0Q@Q$9*#S7(%Q.<38 H5;
M<23[K]_EWA$PESB=6A]%Q5NB?];"BBUQ<KC^*5!BD_2L_^9#I$$S%\]E7@T=
M1NE8L@N?GKM75?->L$Q;1?!OUD/P7SC#XHRR*6Y)]3M*/&KD-*,'<JA?TC<<
M%2\W ; HJ:5CW=$9I$$R?D?S?LGQ^][.0,:,@AI3IW*JO\W9/Q\E)0^W\1%H
M9P_3^Y!8,PU$NZ._BTO="V(5<<AQT2U@")F#&_$)GV%Z!.J[8 -C[6V4H*[@
MG RT6UM.QBX>P2H4,;_./!H<UC2+V/G4[D;'DVL]Q_1$\:K+-J9M3\_9U33(
MQ9D+!.#7G;CX)+FO]0GL,^/8R7*OLT1&,VMS_YJ9PN8&SN::1T=Y7I+(9:UL
M+K7"?0=Y(@8PJ9W0>1)>&XUP?TMT$^&N$N>Z\7$20X!A ><W,1C/6:/:9-G8
MX: *)W'0-8=I.C5Y(1<@"V!+=^Z/%WPYO$#UU8YB55; >9IP'ISU@J5 AZ8Y
M2;!XL 6:_MK3WX&I)N:GO(17DU<=%&#0H0LA+,P#BX8X)KP--ALF!4*%EFF%
MA<=MY(S*&KNCLQJ36ZK:^4$*9XSU=V 'J>R7IG=51[S:NX4T2S$<VN<%XHTY
M F9VMJL"07HI%(!NL)0A O!1PBQD 2AP 78%!CAQ+'F!23_P7NM7:U4<8!)P
ML?,3+ ,ZUUH<T^9-<Q)]98'>L@=A2D[ EF6F^>-$%BZ!7Q]EAH&P<1KB!25'
MC]($DU;Y;AQP*C$]E3A<KV5B#6;VJ!9YF[2FG]:@-94Y_):#GJUFJR<49-[]
MC61@1A+>8B3&(P?WNJ?B7 &1P7>8YI[0;ZQHT)\FVR&HO!4#E7P#I2X-3.)2
M2RT LCC%0;!_:CI;Z2".1DH4G8_JBJ+*Z,;?*N+=?_;'4^^ABD%95IGW7US1
M<0?_AL1/D>^ 8A*EH3 D3#7%-%8=E/1C8%XY@>>.,94@%#WLD\J",:_!\WVI
MS_C/,M'RU3/YZEQ/"ST9H(G+WY-X/ (NZWRYOUVDLX;,.$LZ_]#JMG2C%; /
MF-G>#)XA9,/L) F$*/X39!W(3I[?OI1?&8K9[DU?0^[<(?R$151@<D2W=MVC
M !F7&-4.S./RH@QG[/Z<UJJU4/W?.F_G_AIR:$"_'(@%9MQ\MU8BYD(I9-J(
M3I]7N5@8.D$\  8[\Q1+#SC;H-=26HRCB;3Z$'N<31OJ&&X$!?M2@T(2HW&H
MPM_*2UC7G U1_3V(IA%71I QAT;&CYG5<M!EM719+5U6RSV2S\T,L(KF@N4R
ML 6Q<PPM%T[I(T,"-=9SLUNOT(G,H=TF0ZOXF;B]A)MQ'"A(1PF94DY<$<L)
MDA:.VI+_=[#O'7XX@W^>]9[O#'9W7N]NE[!=0\[,7 QNO9X#=SBK5T6(U$=2
MX^1P=L!+<KA]-/"QRF]%&:Q<;RI1B<#4,V8ZF@S*+)>L:LFAR!U/N9."Z[R5
M2Q?0/YAZN9K4DV7A(9.4_ZRR:O%3!(H$N^[0C:=C"L//:S#;=2+6D!%TZ-+)
MF?&0DC,3]N>6H4C_07=M__7&[)F-5]R\0&T5\IH76827_CZE.C04)UPCWI8?
MGPY^8V^/;PXA.0=AQREV*L^B72_4-U"23 3++5O$;"K0:ZH!4 B$-")\![Y7
M).0@2O<:EB%L0PE'F<Q&NB,CBL$E%4:2IV6&99/_[?V']S^B<-6][S2; .^.
MHUQJK&Z8F63>PUI0*(KXFG6"!2K+9L1-R@+'=7/RA</!T'\[6M-:A!H+<[@(
M2TQNC]Z?1T"]BD(<(TI$0]B&T)D6QKODAC@:\NNP_$7N8R;L3=."-6[BQ<.H
M]LU (:ME#=S4,<%$$RR"NE2<&D6E[NH;A_1DUTIXO<8:"A7,?&#Z0XWA7@S.
M$$9)R>Z#J48 GBJ,:$HUX)6Q&NB8Y( )*HDB3GYT=$?$H%,G7!(W-<DO>1K3
MX;@81UEHB^IE<WB^5*_K.[%L7A8.S\.0LD@7&!%R@UAT,;_#MY7]<?0-1CA.
M.8SE2CZ37,AICNR!M;\"+90<1XJ2RS2&N?:\&UAL57H6:HQND2&$!.I]4K_!
M)G^BB6&B$BP[C#_?&\SV%OR$.QKE-J[5E*:^X'^@^@J,#&3_E+S_1/(T:Z0O
MG# ?!B!^&%DP5@F0((=!(Q3PF1Y2 1FF6]"/=A> 6HLRG\ML,OX(L[KN\'?R
M79G ; >FL.NLW*]P]O! QT#3A0E!VA"S?^/*2G(RSX]8JE.?AZK)M" P':SX
M)CZ+J \#H/MB5J5[KL1*4 <2#N5@ >5@8Z04?QECWI8<(1KJD(\Q,.:<DW4F
M:1(5YMWV%\J6@/_N<7"=MMEW8J-8ZBZH'CEF]B0XL5SK;\QH*=.U&AF]APM-
MT>2UC)='@'N,"@/348VSKKP@OK&[S4!K YR @&*2G$C>@>7V/!386 II.7R4
MZ_-9R57A)9E3=IF: K,N5QK3>UC=<I.TE,$#:2D8__[#=)2*<JH*A)J5DU4,
M8(JUOX0=QC.S@M8,>[OLBC6D;A]6,MUZC6]IX9+FM%T;MH:TZ\5HGK=S2X#B
M -,--5:O9^2V!2Z-"3DH%/#IH#)AK:TJE&\3MLDO@"HB@2GYDH@I&:!C/2&=
M&SB)J4O"PC-Q\")B@@[&2?0[Y;95I4B@$E)N&V; Z1')I !T]A08!V7!<D8;
MJXBN5WK'21&,ZPYKDI_FO8).@;!]-O?;O$"DF,T0K337F=&%HHPX6QD7&#79
M95W%>KBM!YHQ+?E.X<N"?T%?M3%01LF!IQD8M]H6'\F3G>L%RM*%K*(-@K=_
M4B82_-SW#I[MOZQ#:MX#^1VM7,VVBXKH2&5A+$:#P8IHS4=$[4N""14"A%V.
M>?>>8RTX/Z+ *9.(TVQJ^R ^8-DP?"/O#.6>H;%UE6&P JR@4::FXRA@CS+J
MT1FH? &=B9YY^Z+3Z""BH/ U!4Z<M(?O=ZLGMHMGKB%SOTH87;<?F;%L5AT%
MP:LD%F*+\$PU*M1%NL":)[A'EU\"UQI%J'(Q$.0<@DP,)S0V:6>L!LHS+-?T
M=E)[9NO8E+L5MJ&RE:ID&PWLI^%U(\W;>*6\S>'%=!01B-$@Q?R@(>KG78BZ
M"U%W(>H_-$1M-JA&6W[-&8G,QU&5:X1GG1AU!B:&=HV'78FW#+<\&!MW&4.(
M25:[J@,P-AZQ7?K"&G+6'<_9+<TJ N$RR7OD\#,?0D[(<EQS;HC6QANXGM7J
MKF'#EP>2=1(1X!M+UAHAJE8X);>6JDB_1[BA(_A6(B7TR?'"XWE(*<>"2A,S
M7<U'/#UHR.6%*2*9&V&AQ$.+5YD@<T#Y]]6EUL2DL==^<!_8"(S;](]\EA=Z
M4K_O=U O\+4JS\N,W(XX'/.MP=NKW8+><*P^XLU2\8R\MK7D2]P>Q]+$]:B0
M]J=I7NP9- -Q],H] _3&NK&PJ@*R/4SO)@>LE  @)64TELJJ1D,H*LA,?RIN
M=OK0\WZU*B7AW\-Z#OQ[U'7E#-TV83[U=#*2B)IS'+>*]1VLH>#!#1I\B=4M
MW4HMD'%M02[R^0A-"[OC*ESD&!.JYX>#-E69&VPW03,*@ 9EEN%0;=$$)<J;
M\%5QE7H[!^)4K] @\9J<K!E3\#@D5!$$EL!P5[]O\"9 @\-Q9;N(44SGB7&*
M%3#@R41EUG]QU,[0V8&.4=N2SK0-5K6BYX$]Y@;<JG!AC76/M8-LDI.?W_ +
M>!<H*B-=( Z+\D88%1TJW FSH!PDM?[W1@@)P_S,-K[IV:(Y$<R4A>/ "]VX
MJI5+-79I7C\7M.)2!G&##;G>@2/I&*@W#-@9B7 Y%YJ5T@*QT8% N@*OI*T!
M@IBFD2FNITI)COQCV Z-RQ'E.TN00VSKP$GS9MUK/JOZZ=SN#<56I;TUK-^\
M=90^3=*]45K%50*0QVA*M-[7\RYHBQESNWD>%Y?'8JRX*& !85RX)-1ZY]Y1
M _B!!TNSA9[7AS6=VH/"A0R8;) "6ZTA$?%/%,HF?%<&%,+]06<9'$6%N0Y$
MMT0"0XH;ZWQ+HT4':ZAI.C*Y@>DM*YK:!$/ 205^T\R1JH@*.:61T^-4^0([
MA\.L,]*P#*ZG/)=S-% A)]4KQP/#Z1<[2$;&&J.32BZL-+,^+"MTG.+Q12XL
M<H)AAJ0 T\A*$0I7E(^1)4^!$('KA MJ>(@7R4\1!T<2NCQ05*\]4HE$[N&W
M$2KGB6  ("LC7-V=A=O"A$:X_4'[YNK>\O!-/5#<-?;=B%E[YB.)20"Q<&BV
M(O#831'V*QBKG+-(G5G<=;B]I<?K-Y=\ .0R1"\FKW$&V^>F%#6)J EP)F11
MH5%C0E A8GB.C 2.[&;WITO]>1KKV :1",FA:"^;YS3B:3R;PZN-U95X(30+
M?,Z>KT[Q(IK=0;L%G5Z$5$3:""? 3%*$4VE) ";(]2!6;&HJSV$5[$-N57GL
M(:VJCEQH@RF#QF, AH"B&U$W6F@T8'@9*Q1R.+>.&[IR%].!EVM <>*4G8S2
M6B(=NAK+@'09%YZ<SMA,&LI5'IY&ER98+WBJQDI=WPAO@EIPH MH<>LK-%&S
MJB\&.][I2<(Q&!:!LO$L.[%9A37SDC1,0CW.:OC(38+>K?2.N8TQ\4AGW7+$
M6L^; ,\VOE#+R4(^U.3RE25+DXT2\[$E8R^_7DUV9[%= G\-]:Q'8#3=HGKY
M7J-F_WJ'HGM@@.B)9S,QL%IHK>_(=A'1&DIGCS_=%@&7S)P29258/I]TB$XP
MC:D3N)F^5UE/* HMCV:XL2+=KHU=0YG6\=?[V%<XC)1TGI,LG1!@ ;6E0*$(
MNA7EF*/SA/H&P"*23D0)SL;$KBA@*[=^#?5('U;/ W+[/B%0+[9[8F@2#(GT
MPPDJ-H7I+'N[L_W8(_\ONLA_%_G_,2+_&\LPK^^+O38F_FJQK_:A>3FB%-\E
M?QA8LIJ29T7\"&J4I!A/1=<=U1P1G(UQB4<32@.NQS2PE(USB'VO0+Q.DQIK
M(K;B@H/CI%7.W7_2#+-I^1JNB]LNN;^&]/-6_/T'[RMEW412OG:ALPRKKV:^
MH,/CH,CM@:Z#DMT^E*X]F;JM#<1)+,S9=B&[R<T@P,)]IY%"^WU-SY3O&4^&
MTW+#]*4"*5-Y6*P#T3=C;6V)9=Z\E?Z/-60._]SO?[DE9ZSW-JW"$]SG0-OR
M0DGO2()H2LA,M<H[\N5N6\O3-61\_>Q&4^QQNP-^VZ2,BVB/ \D8)*G^JL=-
M? Z:@(Z*Y0K15'(.+Y$>\&\BD9E3^H(M%#F$D9<#@\3N&^O(7C9(0^SZF$XT
MR>$TLW#<]I(J@N3F?;.4311[JNOPV[684_7NVD!"S-<H6.]6XJ<9P+-4Z:/V
MG:!?/,6:=.US<I*T+<6)!A'/.,.B0O1<)UQ&Q./E$,!V@>\\7T,*T,GIT:T)
MWSM)+I'B1D+NM#!LWU=@W^3KH4:\5<MPZO'<TK=*(BQM6/(U</C<#7O9Q)&"
MK3879_P>0> /+_JW 7YOC$Y_UZRDW//8_K[ZV"2UIKZ#$W:[5F%JX"IP9G6V
M78[SYVM(MSBA)*#;5W>Z=4/S>1=UK%+6I$,NB;-=EU"OGL((:M7<_'6(R?)&
M4:X_:[L(8PUAN3OV7;+%8'S>[4?'GU:OTJ6_3;ZXJ=EWRWZ]'1-69S@78L/
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MV/O0.^MYS_</>@?[).W(XC391-7KI$^ZO5UB/VT]0<H"HTA<FM_;KB;H+]:
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M\S?G;G1LA?U6(P1;<P(N[<RC,G=0@3A,)Q.=!7#&8>O/M,K3A-;P>#BD,6%
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MS(#;2!;FD 1J2A54M$CS:6WR$']^O=S>[@G5/B9[5#C)&6P<CN& ;=Q"38M
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M]&F\T%D649M0T^M[OB_D3I0$<4F0!P3_X73)QK(Y7!3L-4I?V :YS<?L6N
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MD?-\\%FR7>GUQK4I$W2(I==,RM8-EB"!#-WJ=Z2'$NX2S%_ [\AGFL-CA4H
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MV3A,K2H%S=O)(E,VI83O/(O)2LG#BNPI^!;:#30G#K7IQYJ?"EUD7(SS9]B
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M/F5[70!N^U@0Q_M& 7MDO8(3EJ%M0?SLE?!%!L3G 8=5"CD]A&RGZMHEC,
M?HFL5"-L$G_&[514#TNI4+CZZ%<<A3<\R@*[XI+,V_Q(#$L@E#)WZ&C<*S>&
MY:)W$1:&"SGV7+;FX(7K!<?(,N@6"NUNB,/3-5$CZ@X,B)BL5ZK9#QL5^Z6!
M?S<E_++>?B6_%/(?>)@E#V]Q)Y<&G6G=$T4VB:FH& F]D!J%;=\'Y0"?04)G
M)A^O(! K;1ONRM=9U65<:HQ=D#K\"YHL,\O0YKV;LOOG-$&D!=(*9W6IX(+B
M\">/5FUZ U C![(Q7K?&&]>JLCDPBV=CD??(@G+ ]XP]O^3U?+*<QB0_K^5F
MHXK2B1_G1(2&R#Q)S=%I[(B6>X\-!X(_ @,'A,LWA#EP+K+SDRLLRD5M44[7
M6A2GQ86@6\N$SQ>RMN;+1. 7J5()N;PUI9RL*]?+C^D7#E9NT(4W7/G"P[9J
M%W/$)H&=>ZE%5[1W314N14\Q9>JS91I#=LR)"[EC86!-^9&;]7*_+\3/KE%;
MJ<HD)<EJ43,;I##MQU;EUUY?AX4F_B)5)^3Q2_#1N2:XZ2"J32.2"T:SZ%'I
MP%]ZMPX-H?E8SZ!HK-*#!H2O<M /E6]06.DQETG(U(C4?RS=8S7+P%5L#LF'
M-,LY72LK60BN=;"R,"Z5.[Z4;Q"ZS9"<B:(2-YE/D"L#!KB,MJ#5:$BZA,(_
M9-4MN>#=6]FZDU]@(]?81V_AGW+%G;"OB9[Z2^W>@+SL6N'16$%NDI_GABX&
M>W'=\$B<QI**XP/-3# L@QJ%1-/,/I2+F= \ZS(/MZNB\(E38(\FXWI45:%O
MQRPI+-RRS&9[D7/K^K\S82#"44MJ)OW8J:BJ Z.9[DNZG%URRGJ!AE.XP!:B
M!)&TC&K][V[=AK;53+5N:-]PVRT+<?B%1&UE1&I8/;)29UFNDX;XU6LF%!QZ
M RHF=B#1FWLA/D%,MR\P%^/ N1K7N!$_4&GITD-1CU)*!4%'U9TT@G1"Q/*5
MT5%]_\UG,E_L,IF[3.;WD<G<7"-E$]L\49L;2WA5]=M#W!MQ<D$RQ6VLV-=U
MH;;A2&@H4ZMCC<45$GZ&/,9$ARQ\38M##>]RP8@, @_R)PE>@LOGVB0'T+["
M!$UEI5CO<N!#\VOS0@69NA;:);223N605BXM.EPX\]* !].;\CFQL]:(YCN>
M)"@\C8)F<0K@N6SB!^^\%+4U_6)!BZ@;C[SJZY0JRK99G!AD9<<K-GY"C,5V
M7/2U03.WR^-YM;K'\T>]B91DE!J[$'*=N\1\1#'XQ.#L&&3QM->C_X;_0N#]
MD%'WZ3">]"JF9NL1.[V0=--W.3C7\@[B;-)(IY/5I2+;DKZE%;6$LNZ5O^J)
M;,H*A3+@ST(3X+0,=QT%[K&BL=;3/:25X)BEB!JGN/@(NL;G(,U5$\ Y+_;=
MYC_-7B5J?M8B+A+YYZ%53@FKP5!R"0MJ"LUG81;E C(2[!W*EUTZ9L?7L^M-
MR#^\$ZP*6O_D6S64;Q>2]5@["!ES4Y\T*VZXQL8T69<1J\MJ/D$,H'_!-XDU
M?JP\ 65BT(>8Z:'&7.&HY1;&!-C>^P2&'W&ZA:FG=2X&F!!^B^HP4O[L*=A=
M*-3X-8UQ4@[%__#*^I<WQT9J;!@=UR&&-0"%RU88\G9(W8&^)K9*W*E675:1
M,1?80HN,8TQ$+Y.@OY73ANL>\YER 9A0-+/%<GX3_9X:M(;C0H!25^:X6%ZH
M7PS)RC8<[C52%?]TNG70OF"V)D*QG%=NMWI4QZD"EQ'8GD1%9<)#/EPH) "O
M*!DZE9Y ;R81\0,)K*N,+=C3/!#)JF@YJ0TP]2MMV3),%R-T832'[Y>ZR*@J
MTTQB5HJZ:'A#+ZW.[?'7,'=2Z43$2-OW:(@XP=-4UGI:G3\9X$2RG8@AC- 5
MVY&V3/*KT:QE]@LQQ6!0T]NP!@AL%5BX1 +88G2*)A0[ GRU?)XT\1/HCUBF
MGR8M-"8X8];13CWA,CFAZ&#[=>K=C%MGG+2E33K=">T>0PQ>JL(Q?%A\PB(0
M<-P..%X$\N4'(!MFKWO-JT6.A2ST?(*YXQ?\2MBVVO:)-H/)YB>?$(BNRA8V
MPLMW/_KF010S!FEDAVZN<AV\@1<D?:-M'V1<&:ZAI4-O-.'Y!\AKYQ"3'%:$
M,<^2E XI94X=[-@NP.X.W-BQ(5XI,6!15?11L!)E(MXVN(ON #A*0X,"BQ:F
MP]P?"RZ2XKDVX/T98G 4Y3);%0,*28O%%3LV7WTH6W?XVD*TK8?OBC/S6AM]
MQY92FJ/(%J7)<C?)M22?;( %.PRU2KFHQX*MB>:&!SM9^?B'VYB[>G7P^DOM
MET4'6FF[" _]3A T83N*$1FJ]IR[H81&6IKS6DZLP+3 864",5<GC@+0,>_5
MN!VTEUP]')Y22:A(>&FC$C? C?RZ M3RD_,^Z/B.:>0@KQ>4T5J;!L))$OI-
M]L;I<PIL:F&R0).*5%I+WQ(^JM%M1-5FYG*C.V%6C#Y6C!/JB 0]H77+46G&
M!+@Z7&I#_X28Q%EQ'];JA=P*+BMMSE%V$J2%%$K*V,LF==^#6%9NL:8\GGLU
MT)_DLIV&GT\@86BSR9TMW1H(^%MY(]7AK/C@A]$(I*TO^HC^[%U2:I%2*B5$
M2O+^@+-K07MH"1HVJV\,V6QOIP2[7N8P\4KH=7-(KK[3;-?+7;9KE^WZ/K)=
M&V+#K-.W9Z\H5'T")ZZ*BJ';"42:5)0$A!RJ=4FM3 O8>(D3+KO=9HYN[_Y<
MN*5FYT_KE4RU!J#)WXKRFQ1W,ID,BSCE@+($1DSVK+C/V64[*HB9(G.#D2W)
M.C\:9#,%>DV[-*7U5($'6-=]K5*NH 8QVITZ>TQ4V&94_!"6#:4*.1C.#OE=
M9\GH-D^QQ8R3#"5B_%<)Y@\X'B=@:MW";),P-E.JYRBCCCG+2L!VA4&N"_$-
MD[G"PD^2V6U!YH0$^]P \-*#)]E0:V9(J-N5HV[J% %#P"!;Q?8N_5J8SL38
MHIX'90IF.=;Y"G6U8WC:RI\.^_;G@^"*0?1Y)#9RI(73MFK?#*BT2"$2]T6R
M*<PHP 4JL5]L%V8ZX6?,/R%IGGII+BPK&H6HTEQ_R/^0<BK )LZS1!4B\AX(
M$$B35 '6% N]F64:%,(SW@(>2YYDDJ592;+WMTY!_KRJ@KQN<ME)??!]SCDJ
M.LEH).U5X!%^N.J=$<N [0>-"PI1TB]M[(S*!EIR-%''C6=<Q"'S]E76C&JJ
MT%:5V?7D/<ZP4BTKR/:,>#V4?0/CJ+;-P+)@E!]E+G*,0HX)%)G$>4MJE$0-
M4$X+T@ X?_Q;5MP4)A&R[T<;./R.W:4,[^)D"M2^=*X2U24W^;Y;DM%(+.WQ
M40 M8+ZJ?]M?DA/6='!A$Z-FKYV-YN0??"=/9NY>&S8L![GZJR W;^!Q>_,8
M>X1;;' +W!272<]%>,V#[%7@/80215H\&R81W;RBX5 QSJ06A_2YDQ/HA*D\
M?'WP:C\P73,V]ZW)0!Z9;>E#;%FZA/:B?71[B.#5JW%::B,)3*UC(F'Z>[9"
M#L3ME?)?Z+^'UZMIB9G\B_8F.E##+7F#_5J0"'?I\^9I$B:=U1S4%:QZAQT*
M\5@)^#?F,@909!+G0%8D*;;'Y 92LH(TC6TIVH-\6#Q);3W%UU[KL>>;V>IX
MF:^9X8/:O;V+Q.7-LS(4>^19#OJBO^1FZ[0I-.@@8J6E];]+D*72(>W '!.V
MV@S#F7,\ $T#L<,^W9/2@UJ^US*]\MYTKDQW44B;9/A'8U]J=Z+Z>B*1660V
MDW8VY*5T:Y2D'L*OA6#20:=.J:,&8M<*\;FSW, [ZY<G\*&I$@O+=&Z2G/R@
M> 7UTS3G8M\C_K$FEYY3#%Y@<H?7TQ(?4BY'QQVI.[A;9Z$</E]UN\_<%+P;
M;">S/#;]PPZ5+BGOU2H<&LF(K=N(E?LW;1 "+\7B/G$("RBRG%>FKDK:LN4\
M(6=S5(YNP]5B3?C8=M>I#9>\O:_/;:37%D-KBMJBE"JAZHS9;=,J)4-Z^^1A
MY6+H'KF;U:Q&0<Y5+:Z5UF%]V-HO$Z(COP&#>G%2[R)KCS=9?<#A:6G -$%#
M94RF3%QN&,,;@W9B:,WQ^^_HD(AO/IOW:I?-VV7SOH]LWN:JV,WM77NY9O/:
M8,: *91** JI=,([-[:Q4Z,Y\=3,,BE>::M.)\AQ)*2-R3T4C!@N8U*(E:J#
MZ1;&[Q6F: A1>V?TH4+7;CBMS:"0-L@CHMJ^6W_E0L>!P[K$:2.++91RMK'>
MWH P1%E;[6,;UQ^UD,PT'$?56GX03B/8]VD3R$LP)</5<F(W.=L#+CB2X:*R
M<4_;XR*/=X"'TGH&L@6FO77>;4V"9"^GLRK)QNP:WG*F ,R7J:(E@9@37?0J
MC5F(@^X"\G?LBQO*+TW?1&U5#05ULRNJP_'50E5Z4Y0U.QM,85=5</=0U='L
MY><L_%%39;76F.&%22!0"#TE%N&>L3?E0S@!E*IAHLAB,K!ZBQDOPCYAI\ZY
MV6S)HBS-(WL&YK0 V7-+>9>LT"I%%Q7(8P?O!@A0Z'O W5GY)+^)$#O4!POK
M/LZ=7EJM$!EGZ"1X$Z&":".X0L/<M<M#)WLM:Z-.@IF#CL:2V^G)59(X8IC2
M;D 4%_HW9[GJR(#ZN&6[*<P$556,4@HQD839M/:R[_+(MN]Z6;DN^ZS \VB[
MFI9X?/56#6ZP\B][+W;TI:[]76!Y<S%VV@3O*3!V;'0 E?-;%\OJ:>%WS'M<
M;M$FI,Z++2.T?;TZ[MP.9N/+PFQLV6WV>G6XB$=T9#*<-V>?"0QYSH%N:1ZL
MMT"&ZW1P$IVNP9C[=OLY_8ELG?BMW!#\V!ZW-9K7;.L- 0(W2Z\VK;MMZZ1E
MY<#.U\VS;OD9?C)_Z/5Z_I"%;/UB\<^'Z94VS4=HZ]YXM(_0]U!<?6-^7<\@
M6?*LS[#W5R!AVK03\]-ZYO[?;'1]OI7UG>:87^]RS+L<\S>68V[7EANB&A]6
MAW^7O[:UQMU/J\<'ED&YE0D#9#FW&6SD75K,:2^CU/3C&9C[;5OGE1WA+^O:
M;+&DK^Q<7M^:GI=&;^4*H5,-U;8 RK\X./2-K%0[%9P )VPVW%MR;I[-I]M%
MO-/6?+FF?W/%=%F/I1FX7IKB,'O$/,,/( MJ4W8[^++_I\_L&/E&][NM^V_=
M_9Z7=^E=E*VSQP3:HS#:3M&6)M;QB<F2@'1#,,(Z/"T7=#F/YJ &-HO?)FD9
MP&.I2 'Q)I%7TJ E-5[]#XMT2?VX-ORQ'ZI^J8(W!S\'>US$#D,*]EY*6],B
MB4JWF<[!"CJ*,O@I*H,_X3-.9-.7^'N4=!,KM:_DQ_^"]6RUW[RN_08N@\/F
MKUY)N8N+TZGLJ2%AR)$[;+G9J#Z(8%_;HKOU@<$;WH1VY0Z=?[^H?Q13]7OI
MV T)/P5S2/,UKUM>LU+&M#&[EXC.5?_5SV%[X.U-\Z.'SYT%><6PI?KCZ^U2
M06W-7.MBV4?YQW(^G8T6:RHAK42D4CYMFG?JHR*Q YGGB7CND^&L4*&[IL[T
MPT,]T1\.K@[@CHGA_#\=*)Z^Y!$8>%V7IPW_#A/"'U%(8<K>>K+Z\J?7>^#_
MX74NXT#R;+7/T/E@.PS^)5-&=9IAC=X\HJ:[:2)XJ# FAKX;4W!"<-T/@GY$
MS:]44EG9A[LIF3;/1]HR,M7 \%TI%^;(AXZ7*;V<8DVJVZ)_PP 94+Y]:71&
M[=^EYE2=5PN(ZQI+NET'OK6?;\U#<5: Y68(7F$I+W';X"BO0_%H@JG",-",
M?R!*@8\W"+8%9UG$Q\-@6QDI1*!ODK1%:[TFLOH7UC!XG/8Z\4UI.*K0Q$W-
M4H=GW?%9V=)0I]6>L\_*S.$F8^"!J%Z3=CCD.OQ\#77>=ZT]U6"],UB!T+NP
M[45*5:"@.CY:_'<'JT><!IQ;/I\,A4F2A%TJ_?&K^S#=272#R!&V^ZL4\1*T
M-$Z*17=1FE'<BU?/3XP)+SO6_LX6OH/IMC@4XS'*!!5*,^:RK(.,0E#_<2"\
M9D((H00,'G=[#9G]%>$%P&DD;:4/I!9E?!Y:LU/\]DQLH0:DA%#@XN *)RRB
MOR<\>XDX61''U(4"C[K?:H.M<#7?OT>$W/ ?/_R?7G]P_N$DJF:7:)B727P!
M \?"N8_TEQ<O?OA/S Y\3^F.GW;ICEVZ8X/2'>M+'@[EQ:N53]K?;XIL8H-=
M[_)Z<'32!]6]:EKWB8S$S=F6X\'5Q8?K?G#9OSH_^7 ].#_;!K/X56O5PII6
M\652%=E<:\ZODARMN?ZG9#1'-?4XV[@%BHNC7:@28=@O0]]E5NLEK:;S&;9.
MS>Y1V;K&:6N3?\T29M,:3+<Y?XIJ\L92?:$>8 BV!IN[I3%UQ?KUTCC&P'7!
M0664D<66JKCX*1'@+JSZ,)=%DXVZ:9*W!)&J .-5!R]"_M^7- &.*87>FK!M
M.$Y+-*O@6II,*11Q@^VRXXB6"!-]L+]W"9M69H4709[<%' O*O0ZK=P\$^?(
MV8%)E<#76YO O$>FE3@6]#I*Z$:Y7KH99GG3RB/6#AO=,R&.JT:R+;:W8Q.&
MS-C$[6;R<OB4 >F7_BD/;TMHWTNWXTU6+(EYS.8(.,OGKI''"<ZQ69J_LKMC
M#QY#F+E\,(9(@#Z;Z+%""QZ^53JU_IJ4(K(SE)4XH3XRY!8 'X..)6B0B'#)
M4.2*26,#XB1+;BA(B:9V$L6VM:]MMMM4AM?.PKBFKNR5PW16KIF=VJ)".ECD
MU0OIUKLN'KXA7+QD/-YE2NWCZ,_7=*XE*#+:"KWC$8A!3%$%NE[\\/LKS UX
MY\W)\\M#T&5()>1C)26(8O"U$<!:4%_^V6-F$*/W\1?:J(K9QC*Y37+$P0P<
M@0LN#93P!298XGF9"-"K34GO&8QED3J)1M(KZ0$2?'QX>_:Y@^>O>7S#_&G"
M]>%.[#XJ8Z?:ER9H63#*&49?<37^FL-FQ!)0X5+Y\:X9\GM#V</3OW)MTG5-
MELQI CL$<^I2-AY,(P2_)KO)RY$R,#9!;8&%Y5!+)L$4'>MHE, =A^Q50X21
M2*KJ'VU7.!Q,O>#1"+4#"OD2=N.(%7.0(I,KOYV))$F%Z3>+TK3%S>X+_OHS
M_B(VO)A/5?XS(U11I?L!?["<*THI7%BD^8S"8 @3X1Y)>JJ^BI/6-EF%(*;<
M(0_/1J)$&CREL.93.=OU,82MOW7J*7@P5JMQ@HP!)/SEM%^RYI^64]A\L08N
M)Y-Y;M@DW&_V\YLLK6ZWJA *C]7*I6C7=7E@'&Z&M!",2EWEG&LSJQ:OQ$:>
M"=V ]+R&@MD30^AL5>A%HYJ@-0H?,5YP<9^W0:21-,!^E'FRJ/0V'"?Z%PJ*
M(^_P;52:+E5GIBW?6)B;%V40;E/Z6TTN2S"8RYA0W>2A8#!@XM;D+IQ/;YW<
MK5R )\9<%Q<(0<7DX*E.J&"$Y(F@,M1Z,-Q6H$FRZ#Z$[[)SJ-GTG#2KJX;P
MFQHNE;<*2TA( DI&"W%Y@5LKV2UOZS7;PR!0Z%^I[ZEDO? ="NVJ%FT_791B
MQF)G0^.+JI7FR#U269J,U7YB/]@/>/!XL2>RK"CK1B#94EI0P5<4+["&C',,
M%N\]'H<*W/8YI]LRD^'<JJJT=A[;M:D$_YKGG+V\I$U;(_A5YY@S.5^3LG42
MC@W3HEF?30G)U [(\#E3;I"V7P2+<,)];4AG2TQPD E..Z! >X9X=_W2ZX,W
M7M+2.\C179&"K04RB930.!"TMS!ODE)2A<&.4"*KX'_G!5>$)552WOD,LXQ)
M;E"F]"CXP3:-FW&-'%;QXDDPP31;*_:XI.#+[R\I^/,N*;A+"NZ2@KNDH"0%
M7V]M4O!T<'74/SGIG?7//UQM@Q'4#EJT;FD^YBND FP-^V<@A5@Y$] 5UDEK
MP5>UCF:*A729UDZF^1V()+D&\UPP6@V0GGV0%RRJ4KK8P6"ZH_\5<VB).RNF
M2*&OHQ0+@QD(]Z4S9 E6>I6__*A)]!%3,TZZB+$'.>DF*)H,B-(Z*6<^PA3&
MGR.OV/D8+BD7T=T*:FE!!A1F9]G1F<#+6F(^]Q@;IK/-#!5^BT"=@8XHG\V(
MC%M&1"GQ-KD2[0!,:]>:8E9PG>PY%AQ++M$XPT7IU-KQ$;F!;<^;=7=>E S=
M6*5>=(J4L_1.4Q"WQ"E4$MMU3BX'.@MI4DIF'6T<ZM]09%A)F,,!R0BW"^S[
M&Y3@A#I%X8F<A0;'M:HP07NC^0[T9L'PX@IK_'JH<&"4+IW.%/56\8#B&.MI
M\:?**7PE4G.%WQ_=(A9GS$R)M&)5P0OS95'J6$X_3RR?T-C'\*]@R_WCBT:D
M-F;&G"E_FQ877H@?)&Z0CPZ^9(YE8Y;@Y>OGP5$T&99I# >PAUQY5W-D#X4_
M;,4"7$19$?2R61$&1[W@EU<OG_^T%?/N8622>PN/;C'N8VJT@G,N)MEE4C\3
M5G9C]OH/M@='Q10C;NLJ]V]3OH^*(DL6P<G)Q59,]^7ASZ^#]U%.C(U7L^VX
MO)JZ^]56S-O1W;]E8+Y?1;-B*R9^4\%,@_]W1&?[8%1,ML@P?WMZM1V:^VT)
MSEZ1/3M=8$'K%?BNPR'5L47Y8BL6X.+@_"!X6WP*7L% MF+&EP6FFU\\%VC+
M?XLFTU^Q+/$NQ?+)DS1/8!Q1O!5K<5'BI&=8,H;O_"<< K!CGK]Y_>KELZT1
M".>&^QT#,A=E4E&2+0S>2OV=2\ZY%=? -EKQN[M@=Q?L[H+=7=!Z%[@"TB/:
M+:P^^HVXU#/0$O.\2K+V"\/A\DOSFZVX/GK*)ZPYCAK<C$WH2&DA)3*U">T@
MZ#FT5%$<A]0=AA56F)*A#(K2UE6,RB&I%]-=QN_%=*>6JE!19,08#D1R1Z7C
MM8X].RZI!O71//2I+1TW+4!8L"?KAD:^T:3C$]0OOB-.T]/HKV1>)NO4+K;C
MEV)WK- (PIY&"^T<F)>&2K -BF7,5=X&D:5RL&)2J:EN/J]2"! JH<+"JD4A
MC$4.NQ_7R69NE>!W"F7^9E?&MROCVZ ROL_0NANB8Q_6A$S(, Y^*^"V'*<E
MPCDEH!-O_W<>?<0?$!7JH_279-$0%2.7+2/=F7SY/BH)E*LLP!6:A,$HO4N1
M\ PQI1C>:8;U1[GI.<NQY1SK, 1=SK81/"$@H'<U: _HJC?$_J\/D'?SEJ0P
M^G34_OY&1_S*+P]MW5-$3:Z)<L?",R?36<9%(&,&VJIA3L$^C>>EA76-E3V\
MY7&63O;(936^M+=/G[EE;1$\M9=,"D57D*NK0$[8_)E'/YZ3-00*!B_%Q(%*
M,VU&#'O/[2NV< >569K/_9O64 [/9Q.DM$4AC&;P#*SXPL7UAH,-(CQ*, K_
MP)HP_FM:@E9$$WQ$'TJKI U=0B$0DAJR!(KMI(B1:#WR./RXPZQ9Z=?>3U"4
M3 <V+?4=8!$RPD%4EIC<)G/3Z7K81O""=IJM=<$+B)=X/9Z@+<(N>'W0#J?3
MNC "U!&:'C*J3#(^CO2/A<'>)VE79E+HT"!T4$>+<DU7U&Y8,D4ZF\\.6FF[
M)4W0RPO+YBGTX:P[]A;>:]V7A6U(.N3/&>9KI;">*#1/EG72@C:P]$,=F<OR
MO><T]:#VP=//2(=T&^+-.%R(G4_P@TEY@T/%=2RH0E> (XD*D#3FD(('K**=
M <+($[Z'B8FI:,?')JB(I'HL6]^N<F:C3_'*& 26K:YY3M8ZC*H%+.&\T0%T
M'+Z6S/.$]LA\*(*LP/-621>S<Z2=6?+!1/M5YV ;2)F3N$=LG<SH2U7O^7P,
MMNZ<&7KXU2[T2@-C7[K\.Q:Q#>!S$^Q-6K3V;7-:-@E (<;F7U0H1/+&@1%T
M] A]9KQT^>D?D6FC!]-HB =2*_F[;"G"<M4J;VO84LW!5O6HXW%?G:_6)WB%
MIX-M2WQ[K;7T8':7!G]L"(;U&.D-QBS1N%,"]8,'Q;&;%8C %NX;*1)@ A*%
M2B#&NXYE<)<6F8/C[(S71NCR><:A"/)&\!_WMP5J!^DY"54_P#L2S^9($@7J
M62:>@AXQHG8$E'(YQ/=P0JJ"@<T4[@1='GX,#A%_TL>0IG!]+,:)&Q7PT7\E
M(;7VRY+//"P :J0Q'ULRT*V3^95Q&9J@?43!SB)HS='*])<3&K.N:]6B>%#"
M$L&IGL*FBL'78HGBF_".' J2?B4J[B\$C<D$WIJZS5!D)=IL[%':;H>L?BPH
MCM'(N)OUCY"[3S@1EL9'H:9I[DS)4.?)]*UJYCIK03L4F#Y>NJ[U*NPGZOYO
M<Y7HB<I@_>VMU#9>-NL0*S^: Z -&Y4[ -M]-#(QOZB_)7:>N=/V^69II>W0
M2T*M4[H]R%"1L8TE1D?&$C6,CMT+=#\P\BOW@/VB^15A@_%D"X85LM*][UPS
MU!!')JZ!!YLEH]L<).AFH:PA)E/IQ@X]47= ;8Q+3WVK0]D9=_45M\4,%D=8
M.0M!W] 8II GV/U5.B7XO?'CA43!#)RP/BDYKJ0H#&<&!CRFVAEG0SG5\(%W
MW,)GP=7J_9_XC1;*,QC$5K.=M5.IKQM\EQ!TKZKF)<5;UT%5=IANS-T0%ZR6
M.2@<, $:?$Z#W92,8,O,P*KQH6 (6M;JDJEW61<L;4VH?9NCB/(;*0$K,Z,-
M?5F2:I4?S27A_TYSLK_L<K*[G.PN)_M5<[+U:YE0WT!%!5%\EU9DE+I)HU%4
MHAX25+>44>#(PAVA,"!X)!>N.$1;+6 1\*0$@RJ4C4,M2YDZU^17.#LG/F@L
MANVZ('_Z_ ORCPCO(;Y73MVDXKK\H%)-)#:SF&,(]('%AEHGMY0_JD$@)U:D
MQ_$6!?<T8IN\=?BG_C!_<@',^"<+L,&X(BN^PY*3VL?5 #O$F:M1F.*4-;L<
MN9\CIX Y.O5/B&$G[PR]U"XB-F3@*W"."LY(/'$<$V?I>-D*[_W=;+P&%<5R
MA@F^0QW" J-7=$%8#@7C+6S767L"JN6CVR)EP3^)[M<Z7^W;R+4KM#^AXM;$
M;@G#T+!RM..LXV9FT;UQ&!GQV%*Q(3XK'>(9^2]CN+C9NX0O.4@]VR4(3\#!
M_$\'"W(-.7"BZ!V0E@@->5<@1"GJF>$DG576AP9?G)#M/21*"F$G6.8B,H#P
MD>RCC).8JL,)S-+&MBR-1_TV9^V6SD+#2VR@)0V&IL-0[-($-)554>H?3(I<
MLC4>\!+'[CQ?S5T$G,<\-X#+%,0C12NTTPSGQ"D@/@T+R1V91:% 73?/\H.S
MH,"''7[5-O[ P>Y\>/'YB&O4,I<P!"(!B0^Z\@K$ZMCB-0A+,,V0N<3 X+IY
M"H8T)1_3YBZZEV4(!Q_!C9J/, Z&]Q&,%14Y+'J:,"'K?+)=:N4)>)4OR+5:
M#SSN [81"#E..U.[3=6G5367S@7J5E#;!#D]0,08ZLP!@VY/GTI";<+W%&?6
ML4ZO\LA6N]/0Z]9>3:=@-J6?@M>?%?F1 \)+X)I[[D)8+4<[P<>9YBW.+BD*
M/J*.B]Z=PU]9?ZP$J-U@<Y)3R1^0&0X3JIB5RDM^,L9;0^X<$%PQ52=@;VQ(
MP8!.PS/K33Y3,RZR#^BI<'D2D4?9R+80P1(>-)&^X 4 @CF:EQS&A6N4&GA"
M%%AGF<@GMD" SG[[/3@:)AYIRQ6<@B=<0;D!UEU!>\89PQ$;C% 8\7]9Y.L2
M7:\\0;!$3I'76L=^A.6T5;WIOTQBO27D+1]OA+V#/;)>Z&)Q=E"S\VD.&@3#
M4!U%&_L>WG8+&N.#)^>M$FRT,-";Z\W(D3-$*XT2A_,#=4J00C*'.0:B37%U
M RP)43#YTU[S(4TA;ZLWQB"?6Q$<I^!>X@(DMO@:21TF<.<9/B8=%!<7-6<X
M0^AP0[)NULH=G3F()B+(:36_-!]&,EITQ.1%_MMR2=($KD$ EF*YL+0B$=V<
M%IQ.T0,UT'3A4*+[JF"2:D<-3$O4TB.'99HRCE[!MTD\H75>C6Z3>)X1.1Q=
M(H;,D;\.EUT9%3@^C/)[#VH!LS<+859!4M6HG^B:=5>#;3AW+4"<<1 S,?(?
M'.G#8/I(,D)7Q1R)VL$L3<& 8HIN))M)D Z%%&JEU:LMH\(ST,;.WBG4"ZR5
ML)8)/\88GCR*1+UDZ2-@P%@KEC0-^J0MHG%V&B-&6BP F^.<FS$WI\C)8+TA
MK!C&3?(&AME>.%59I(9#2A/ 4]$<,QGM5!AH;YOZ,$=1SK??,]DJ#N&XK8:J
M]B)=1'-&X5N1%![NBG2?"-YN<]R,P^=/P5O+Y7'5;3JMQ00?9V-CBAX]P#A!
M6QT%D6LT1C-";F[AH4?2#ZKIL.DMU,LIW764>XA-]I_/J V$585PQ]*O4J)O
MH=(L.%E::42%#WE28NGM#1_<DFN",# P@W-=5NW=NUR<"D<<-%\IMW**Z0]4
MG*05\1[T^&K P.(NA.\S>8OHJ+OD[2YY^\TD;[N'LB%Z_&'U.B+&GEJ6J J(
M7QK4U!C5-I>E40%Q-$E: @0!&W]8;=WXDQAKJJ=#6[X2J,Z>101D;HHEG4*M
M[0KM'3X!-\3[)"*:QC4N6/T*'?!1-&41P)[4,8=P.-J*<;I< L41U9I3Z&1>
MV;H]*EV$VVP6M0<)MVP[GX"DH ^Z'M;:K.#CLX'6B.$F[(2?;(]C&V%S9-)"
M;91@S2ZB:HY8-4DL20,J6JV$011=1(>MG3@(B'4LG^DO;&F;I"-@;;0\M_(<
M<!@0Z*(MDZ<GP)]!!"<\H["_U:]!'PN#RR)/1TA4B&4%ZZ0$:@*F)--<O1AS
M$RN][1F]SJ:2<>NTMQXD+*U1.-Y&IJ# ?%K-F8.@IX64(V<J#>0E+%L&*QH<
M[BQL2W+/BIN$JRG=/GZU\K'B69MFZ/6VLO(@N(*A13.F]FY$"6DSU:8"VQ[I
M-' E!"9B6I3<(J_S"=B&$[@' R=Q,(W'\KM]2HI2 D^3"8G=MDD"[[..#,6X
M'"(_78/@IHRFMQ31BH-IBOX26733:1*547L*IA:IJ6W:]'914?Q0*E07ADLH
M A5@YX><LI3-T)%4NGQ;=GB? ![@PJF*&CJ-Y8_TIDWC5F4!-^IU?%J^W-+_
M_E"+*/Q(B5NWJ<6OT[?]=VW?WY0.TZ+ANC,+%97F([F5(G#5"]<P7>]U/8BR
MJY6C@6),2O/-Q#8L."_>LK/R! 7]_4^H:]<Z&1S2\=*X"3V%062>\0]8K (G
M!WN^R#'2G\)Z8#ATDBQQ-(M"2?CAQS$ CQDK4R7('P =.\VXTP^#K5/).S!<
M(/[VAH 8NTY,HR>5(LB6C%AF(PAM& G_K)*L;P^BY? )"F$'GH^SPVGI6.C5
M@5KZS8K1 %8E+^ZS)+[QRX_DGO*$WL2R- ]I\D?2A 9?-Q!)YC>.MS,1;9]*
M(:[KI+CUK!,WRR*>"S_0LC=+NEZL1[E4QV3X1*XKYL6B7:Q$+B[+;^9(WG:O
M55_.+"5<C+>:&05[=!QVUB1L?479G$U+'2)8TE3E"2]%Y:6-ARC9[3G.MN)H
M[ PGBW,^H;"!MJ.#SL&\:X1VLU/G37/ I[==G?<\&'Q57$;CF=37M0_$+ZT6
M"(O),+V94_D%I<+A<V&S=],O_+ >06.T(97'4?<=L7N/)=5FC2.O'ISC^12O
M%\>%QU/,*SO0+6O&!36P,M(+9C_C!(Y*VH)5)CD;5[K@@J0:18U/@+C,,3-*
M'DXVQYI('&+M0?0&15DC'#;M](6)T:9*FC-4><?\JX&;H#95^4K)0DPR.XFJ
MT1SOC# 8)UC[( YDGLPQ6D(#X00O2GFE[J \4#R]L/;K2KU"?)+W)WBE_JWN
M^'(2:UQD67%O$[_3VQ+KSN0A31P9>9H=HOUHEC5>Y;K1-0<1_5%M"K#.XJSV
M5'I2YSMAX?U7XD.=/VH[O'Y(6A*<QI\,G$Z"V(BI-5)T-.WQ]IW E<%7/O Z
MN@="#H.SN&&P%RER&=;)F1,KF8(R0>@2='\D\A_9"*&-HM@*2!,H\(ZXKYDK
M?FHI161<^+'B8^'+S5(UZI#!&[2:@RZAQ[!];66(NVO@MWN5K:9G"F*$&!V9
M/ F/1EMN*O>9S,?J(3#:TE69;R&50FF^#TL[=):VL9)HKZ^[3/2=UC7X3G/(
MA[L<\BZ'_ WED+^'!N DCQ"P@AR2),I8E1H=NS=J56JBR$2W73#%0;N)X=I=
M_$%3)MT.W 4OC>6EL[K-Q>^MFUSLSK087*;7U'R#,+SHB1B\D7J\=,*QH?8)
MT*Q;L@7H=,$MP:DX 4.6R!-9G^B[C<BJ;3I>>XDN*T4D95DK9UVE]PM60P@;
MZ#Z2/@>J"VU83NCMT&V598O AD\?F%7+BW F]DU-/X[7>&_L[!(:Z-;*PP)O
MW0["TB-O.W=)-IQ*+<)>47?;-W;_1ZO%_]3'<<[$_!G_Q#D6U%CT<?/9[;,6
M5X8M:S2;JD(W802^21H"3A&1:"0]8B.YEFR7:(O3+\[VJ"RJZIF1=6Y559EK
M[=/F^@4KLN3QL'/.85%CN?I-V:WHV&)2Z?NH(Q+[=+$O/NJ0E/4-CS4-K0?D
MAF7CQ2IULH^5F_\G@/_;L&E_A>/R_UVUI*3PT3\?O"9S8/#;6>_ZPV5?!*/K
M7'G?N>C]MM;GWYV?G)S_<>5]Y?_?RBKL;]YQ>;%S7':.RS?DN*S3UK QA&V#
ML^"/P?59_^HJ^.-]_[)__LYO<*-@)@E#S)(D+8:^&>!6.7& -2T#)U40SS'[
MP:7[_T(K9 PF-38"?&W-O-K%_X54<YS>!:2Y_N,'ZF= >>;BIR%A0?W'#\]_
M /,ORT2#F)^G41SKS[)2_ U<I2R:5LD_]!^_!GQ@7LEYF97X7S$!U^"+)VD<
M9\D/@3Y'CM>+=4^7_)@EXQG][&\ _J*VZ([>QB]YA^S??YS%_C#YQ8UA?J%1
MKG;TUIM!^T*_^7G3I_ C2XR(#8@5""-,Y^4/9F8PLOJTX&@73SZO^F ;U_/7
M,FS[@]_ZE\';P?G%^][E:>^H_^%Z<-0[N0J#P=G10<O:Z2+<\F!)_G]813R^
MR#H^N8@;H7CQP[<_'U_>-T+&_R86[,4_UM'%W_MRV(O[J58$1RG7MOSF"G&K
M@^<'/X/O&JBQ(I?]][*./U8_!L?178IH%>5B8P[>%[OW=Z=EMR*X(GNF*V)_
M8X1^@Y;G+)HDN_MF=X*6K,@&WAH;M#K7Z2S;G:#="5JV(A=E4E& F(*U1_WS
M]7S5-N?_._'S-BZN\7>IV%GRCZ W+=,L./PE#%X\/_QI)R.;*B-_1^SK[>7@
MZOK\Y-GIG_W+J^#JOS\,WKX-CLY/+WIG?^XB7]_T?':FU"[RM8M\?=G(UV]E
M=!M-@LN#X&T9_2O%ANL-.7^[ -B&'YIO?45V ;!= &QW@CYG13;W\MB@1=K%
MP78'Z:$5^1V+TDTP+ S>*NZ[@[B_"WML:MCC[P^-O7C>$1K[D<KWX'=Q>K=]
M%>;^9-X\.)DU=K.C!/>;KVE_N:MIW]6T;U!-^]=_XQ>4]8TIJE\13<NAV#K\
M^LURW]YJ(=7 142H4I?$7KR9'89?(2MSU>\'O>OKWM'[_O'VS9XH=G8]?5_
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ME^VS+9 M]TX"W%_??7;O)-G&Q(2$N.@^ 9*XE[W;W6>?W9/834<C2(BB$/Z
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MHVWZ*!G(*/_F'8\ :+OT?H?>]X,4D*(XRLOL/78/W\B^]<F)<-0X^ 5^QVI
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M1+G>::J6R+*,;&%/4?F^V5F0(/;%"30P]G"8@K@.:#9JL8IR^T%2%'R6"'Z
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MLHI0V<733*+:TR2X2:T@2DEK6)9-KIQ#OD%1X^+Q>,_@ [',V&F(RRUM;0)
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MI2Y%Z;*JU 3SAQ(5G;,Z*JJ5>XV;B#+=RU2@23$//%7$C72K7RJ)LM'A:9B
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MXXB<BBMR!:;J=#34UZMW;QI03=MWSN?%]2T/J^7,NJ81HQ;8 %$DGP,>Q!5
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M&.Y;4>D](\DWE%KCO&?4[&H6C-@U.355FXXFT*)[N9<=X<NF$\ID)2?'RA9
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MG)B5:]Q>C<#KB>UUE+\9BIM2NO JS&U#/Z:';QO035I_IT&"H:F*'':IIUU
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MA8,K-IKHNZ.#4="Z!S5H (:RAW^9W76=H;"_84YJ\>1"S6+L-C*JM$'1&2]
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MMN P0W(=D47..WV%@7$)4ED_NM"@7KQL$PGQ\6I/9ZIDGUR$('+HWSQ,<ZK
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M1*+9'=Q$QT&/XZ"5S0?!CDEE7D6=N]-GG0XU>5[66=G$CW,U5+GJ "M]QNF
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M870=8(PH5@6B(97782D_3:H\NH:M"(9Y-I8[>RX/%/!/+RBU<8^_A 0$@QQ
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MIG?.T F.U$>@9_82*7SN_&"7=DCS):41<<;UMTE)W9Z34%3M6B1R8'10/O7
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M#7<]C6PW7C0C 1PIMK #2>LLA?7DS.-4>H'[-[>SY][]^ZS*ZRS&=7-9P6>
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MS_Q:>FCT#\J-=,2)_F[BYF\4DK\QZYQS#YR:<T*</*:Z7R04"BWW+O]LUK@
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MS6A["'6C#XPX.,MNG>PQ6\ 9NBUT.1= 6MIB= M4^22F] #I=,$QZN JR^+
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MUN\<)H5G(3X>V/=P2T$*@RMGINYJTY7H#2,!JM41)@V@2M( 8\B:\9W\*.Q
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M3"R>C0=QJ#']&:>M+2,-'WZM1HP)Q>GYG(!,F7.4<8$>-VZR:AXC"<G<UYE
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MS ,RM&@6U BDYY1OV +RX![X5C=@K%L/-TJ"Y!2\'ZO6UB':8P5'JY,X*:%
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M\D:.&B)XV5TF7@37  *3)\M?H/B9.RY@MH[DCT9I^$L%D$ZL^N'EC\Z+6*X
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M %V((:WQ,;WIG1;:6B=C5# 9<T+LY762RW"7L!#NTP[Q);4ET+8?3G7*HE&
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MS.G>.@.SRP@X,->\K '[-)FY%%2XK$@M9FOSQ1W07CTJN2RE.943;C9S:Z3
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MT[;"N.GB/!P2\ !#"F,X@&OG8!@E(Q\(PKT&EN-^&00$[O6);,,FJG6VP+'
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MD2Y)BS!:^46)8%GPP=89?4DI=X5^*8(U'6-NB% 7/-K9IZ0$HHF<RB59"XG
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MX.CR(C@_^O3K)3[Z@-^,3Z-Q')W C7\$!X=X5W * X27GP?'_4_<R^:PW_\
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MFGZ;TJ=5VZ+H_:[&8UW[TN;VY\!82Q8[N[_0L0YSO'.;"C-=L(EHVV_2V'1
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M?W-W]^V;_>U-_W^O-W=?FP\LW6;MQ _JQ&SF'"W8E_X!O'9T$OQ^='G2O[A
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M6N:MQ5-BC*IIY\8KC)E1!D?H(B,3QA_QLXF!35=)']:)/+BED:9A%^&JYM$
M92=O[&H[Q5H$Y1OA R+'4-ZS]64[.#7H*OK' +M&;^@QB6XX:?)MP"F4RU:X
M:CM3U!789B+0%L/XAA7'"M6LD/:9?)"Y)!)!V['U=5O?$P.T_NQ=]M/UK)>J
M;E(WOH>IG<HH=I^20=TNR7@BL0>?7!$$\20)QC.H3W&<X%Y\6V1UWH;3J_;M
M>;-U<]PYOVK#U1>K?CC0 Q) )$7(%([ 6-Y%ZW%LKO 3-]Z&2**74L9CR*+$
MNXC!+#8<SN>1:L20>6P(%JC/.8-4#HLTZ0;(74)Z5'[..3ETXR!0$7%Q+DZO
M(^)YD^L)ZG&3@C$;B11M3#X<P(AYVL?U'Q=+>P=I7CP8)G=&*^0FG<2BL0E&
M/M.T8&YM4!Q)$N5>9N6E#(7#%K+Q@0RT6-YH =6X,A02F!K.,A[SX%RYHX^\
MJZ(#8Q,,\KQM@6>%.?(2)#%B,:(3Q9:?;AXR7;R6Q#<\(>Y=7XH!]PII-5Y%
MI3*2EI$^^FNCOU5GG['F7]CD4?N9T#7&+-U#TBR.;E&F27N,VX1,S4.,+]*\
M&(K#=V2_S>7 <KU8W=N$69Z18$:":U*)9"2X)A+L8.P7AWHFA?*FE(BI*QQC
M2.@BOYV;E-8$BYAV>A05PMC1Q)22VH3+0\["^%RG>VHLQ:@O,%AR;:0G#/CW
M;+?\'8%YDG_, #]O([0AYN3,&NI:8M*(G22@)>D**!]S:@@IX7 VT*[/N!*\
M\)4%.  /)HW@=LP]#/6IM4E<*AAFJZ@K%Q'!#(VJ8A;&;]*DSE:P][:"5;(5
M;$TK6.O>I9&.-ZPTKD!FNVFRLV'XTR41TPCEG[A0H1ZA0KUTO-+9'5JSA36W
MYQL3KT^&--Y/008VJV.?#<U>G#"%8=PRM5GW@X&W*8G8%(K)&#ACX#6I5,T8
M>$T,?!XS(1T:^A0]C$/'R(ZNX(HI3;D[GGF.$7.P?2(VS[OV^<FL2(I@\T\U
MCVF[+X94\HR-M\E!,S9^;VQ<R]AX[?$PO8\D52H83Y^=QILX<5R<T&O,I_$C
M0N[%V^$_4"](&IHGU/B_-\"VB) ;[S=0>T!A.;:=/TPSOYF3LN;F[.6<M^'[
M>:?=NKV%[V>MF];5E_S,XWB;)=![Z@[,MMB/BU)W;,29!&]@##'0OI V%Y'4
M6 >EB'ETK5+'1!:< )E_@OVL(UFKL[)=*9^S.";3.3X0E7OV4HD">!?LJ)J;
M71=F%X9ZTNPQVDC.9#T)6'ICT5S/(F@*TA[V<*QM!>]\^;&VL^!NI[Y?J=7K
M.\G1M84G9Q8LK'//DHJ5O9\&X;)GWY8+%Y9TD=I><;?RIKUDX6&P%&:E>'(]
M%HS.A5MS</T,^Z\4',[Y\'8-MS;/61L^WD<H8L-'O&W^6ZS/$]2&CWCS7'@5
M;DO"F<EHE0B8!TYQMXY!M&7<B$@<UGHT?)V8]F3<6(5.7Q6A-?KL(KT>\JEU
M6-W:S3Z5<%_H!RM8O:1*<"N9)"'<C/'6*U+^6_2";/HOMQJ]1=N_4P8XH?Q_
MYF0(='PA.9591K!IPTT[IAG1S_/*+&784@??RI1ARWP\RRD6KBUM$M(LJWC5
MF.)5[)YE%-GD7W7R9SG%VS%]ED]L^G"W,-;*\HDLGWCK/I[E$XM_B<7\A%&6
M4+R_@.+49[0'7Q@GW&4D@*M>C[DS<4666V1$D"47[X$+;O]SG9QA.J/$,^<C
M3YKV^B(/ES<76:ZQ:</=PC@LRS6R7..M^WB6:RQ<9LS)^BS5>'_AQ?0G#>UO
M*%:<+,?(""!+,3(.F%DUG_@2V_J_>O7"K\T]QU62'P,_+"4_//Y_4$L#!!0
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M43\^9H"9[^S,O7-@!=^XZP,71[[%SEN_>-UP=*K_?7_4/'S#=C46<VA+0;&
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M$=AX&2/PF.U>@DJY%ML/\9@;>;>WA/WG.#JH4?(4F7WE9E]O[6;?I>P5 L-
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MU AW!F#T'[$\URU4U_-PX-]%_1T_>/F#H=-#039)0R>XW1D2*XJ"LN3S477
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MQ:;S2"SLYU;:5SMIAKV!DF=E)\:+*BL/ZU+XLHTV.ZI58'<,F@6VAAXCE?2
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MT"W JQ>:M2O\,>>=/=[Q5M-0"N5XZKD6-NH(_QKT@,QC@HY[8.Q73"B%ST$
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MW/&K^J:.?&;I8Q&NYJS:,]5BR _)RV,P^*F\SU0%^=QX5!=94EXWS&6N ,R
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MDBFWLQ04$>[Z&"09&^Q%4AI>'-Y]B+T><[Z-O@L&CFT'8SO,<+CP1L^4WV-
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MW:BP"5H"H:!U1%8:R3!/5PQ7=8405HU4[>P&/1M@,:VK7;ZH33R4R^DZ-''
M<#6-MN;2J?DF0I?(<HO^9OP=':/>(".G5V+4:=DV51TYZG1_L_PI39NN*^<O
M%_N#NRKR>9?-$"]+%PF9S'$'C,\!-\$D,:WHK8$CI[/1<D B: X,G\-UL#R[
MP7%=F!SV*PS2MJ)>)F3UR^[^C@D5@,Q%@1O.4UF4HZV$F6F^>R0,5*>[E T>
MM.V'QN7?Z!+OXAW&S=VQ0#Q=?KTT<65.:5'E^/B;_>$KYW.CC:,:O3)SD0YC
M^2T\,@L-8-H+8?L$>+S >TS-&931A!&M5MJ1"XX./&8"A#P+%Q(*=\!CU"#'
M8;&+'_LT;BB%[UH\:/0$6%4GU2*5R<U,U<;W)F1=>C;Y'(\Q]3,E!KRXLRG<
MBPKXW'L8)S#K$(LFC$#XG2:D8Q,"Z:P0SC <:-<%W39RWYQD6"F.[YU=!9?]
MB\O^H']V14DI8?!'[_(2OC_I#\*@=W8<'/4OKWHG9\'1^>_],_CA4<O UF>!
M?,*4RD54 U2!WA+A&*9W;X-YBUL>#ZAEB%]8._B]YQ]?S34HEW">\4^UU*8X
MUX0)QJM,D5_ZU,":0K,-RR'0+S92F'7""H[M"Z'8-VY8M^_RXM8-G(\#(KCK
MDB'NR1R32KQQN7#24(<=+Z\Y.XC=@9X_ORL>2 - 5P8(W*HTU?>S1C#+Z7"<
M:'"C!8&.FIBPS[.UKC;S8(%#;_-(L;F7(RR)\4VI1D6BB%E#:*/6CM!&^ML8
M-I2LQ,^]$&NKK,=CA+4F$=:VG5K64*N.1ZX.I<%7I9MH\A&&*S#9P@_=-_*\
MMB0P3P+7E"<F3F_+:QJ!L&9Y#P;#N/-J&38C8GCWN$ZP8C/C!M+7C'-@DF>V
MFW'/9AC9VH0+*.=. _-@^-\MZG$%;:+W,X(VLB,WUD-%\"(<HOX7,&3&?J!4
M1=MXQ35VX!8+W-4GF9KD27.=+=66*MYFH_&W!K/@N*C'0<\+AK)709HYLS3P
MNIS,@6L:R/--)P<#V;$L63#>:6#M)L.PHZ0 *PX-(]P[EK3(4!6W%B:8^2BJ
M06)W=%_K]KQAG'KD H5^#\1$@FTLUSE]#X9.0$-F0-?4"P=)JS$TKYF-H*1T
M-80+L&M?3=Q_DI2I5M(%4$K#.24@;AKD=P0:MO&?;?SGQX[_O/BAXS_?H>^A
MX29=FU$-SD]/CD[8"<(@BA\N>F=_!OT/%Z?G?_81_>;1/=IKLQ@=4@^%4TNL
MF%ZFA'*-[4WQE#%_OM/#2Q;T(B=F,R,,+7[BV(6."NHR5N; 1?$/"5F0W,..
M'?E,:R_%/)0^C#6'@C!/>S*M.)V;OEQPGS$'<VI>JX-K3BA$382O)@_%PC2^
M#<"&.CD[[G\X.WE[<K0I96PG,*9)9F%1FK&95:"BF/X3>9SD?,*\2$^@RB3C
M:FCEN+6+PTS!A=1IY(5$"2269'P5;=WQ(?!.WDAD'2J] MB3>=U.:%*.,9B!
MGOZJX2X!C8A@XTPG7@I#QVH"$KHTO:?H.PPK4;"J%)M HD"-KMA^1BC05Y'I
M62DL!EM@E5ZBGKT=5LNU,-Q9.79[2A-8'01+5F7&R/JXMY&X%+"M8LG./M/.
ML#3=!N>SC9^J57?VBNXFD,P5FW8X^-<,+"?)^Y9<^GEB"5N)CFAFH\7%/;F:
M98/8)(P[O65Z3$!&S+_1,8.*](18<ZL@R1Z1GCTBK)D/=P3D@>,[#9^;B6C:
M=J.(!\I- )F[<P8%Y_)2$P=; >D:/7+#LLZ2S@5UEW.>;\\KU(F=T:P)T%09
MT:J4(8MS;C?+8$25EJ[+!"S=U+XU:3.UQ743/EJ'">;^O'NP04'^3@G (+VK
M!?U7D0!WTC;UUJ6T%2H$SA$ DS)5L-F=QD?2)Z/AF"BREI:X@HA7,<'_K>*$
MI_68LH19L>.L'4=CGG&UA_687,N2@_1G=GM[:!D7CL;Z&9HQB!:6J@U+)@8J
MRH0EF]4XW64K?R-'$26HFYWLXR)R/Z4-8BS48SE>,@VP)YO!C8:HIS>C.5'#
MG?;R/^1T6CZG9>-75PD\*K.;*VS/)BJ* ]4G&@)3X^EY*8Q"\'.42"D_QMMI
M*YF]OI)-#23P"J\;)YRCIA%V;6<PM7!^704AH+&X7'0XMUING@3Z6GG7>/.3
MZBVGH0*;92<P93EUKTIGTE.7@A'K$?6+DD,YMW0,C<65W[(45#+#A; E:9<\
MO<2M'RZ.C8MPG%'2B9+*ED?)B[E"'8YIJ5-3/)??PF"O\YSX*1)O);E ,IO#
M;]>SR\TS+_Q$1U(<31H2;%$M*52&D2^UUEUK >L HKJYQ/;5Z%T&!EFENIOP
MK=^$R^T[?"5F,'/$&=+#N?"OSKSL->I,K-,8DQA(!2'.3H,02#?L5&ZSJSPT
M-W@5993M!@-N[V9.E#<O3+<0J'U>+XMW.S\Y("O"_AXI&%)S<X (.U>H6U*M
MODSNI.T&)XV?<!(F(^7!A* <0D"@ACDV3T!Y5\T?,UXCH]>81",>LQ'26578
MELA_U?'8]#0FA[WTWV!):_:P73&Z</U9[4!\V.[!Z8F?^*BFG&T)/"%LF%P>
M 5!,O=!4L^R#:+(K3O1@?[T9;-TNEPG?.%6!*[Y5DF(I)OKK!(:Y54<JTSSQ
MAT*:2P-!@G,C;<DOI04"*S;T37JEQV*]-50=*\@T2@<%K,A$"R/QED.XP%W*
MDB="8;+843"+6PI:YR%CH%?0#8$FDL@@ZFP[&&_#@-LPX,MM&'"]MF4]PX!7
M_<L/E/:,?YR<281C4ZQ1C.HMA[C2R->U-47:MNBRH$(<&&P"_GZS9@3HJGF
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MI8B2.LX &>E,L,#D4\CEA4F&Q<QIR*@8H6E+@&7.](>!SF#<<=,TQH/7""T
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M;0.Z@0ZV)/K"FT)S[.F9=@FQLHA3(LW8VGR \X -_A-C%FB<7$+):&55QVW
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M/ V#=4K+8E[8[9M0?C0 A+124LBX=&&P R1#8V$]Q<):H'P_M'*Y(&?+!,^
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M6Z)Y'AJ76:UYCW(5M]!][R)]W<"/M*Z0LJ]6W+,5[Z[X<.@/'=:TV@%QUK1
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M0/:P*8NV+9@-.XJ<Q/*5@RYG3\1R1-!T(A'Y4E43=6/G@LLPK=*9YA._EVC
M\6;N/DNHR1 _26[KS6H#85Q8\H3J6FO4X85DMHFTZ1K-P DLD6X\9GGWU<]"
M2_N@H+*'O*J@I])DJE3_-&7\!>I.7E(7?"^KZR>:>A0GO:RZ.CNV54% \[VI
MB [B6;5.E*]J1KQ5B5Y8S+>3/(Y/@XWWB\K2IF9I56B;,>Y  T27S1 CN4%G
M1I5[2Y',7OI>0-%<C[(ECXC$Q1^5/T]T. +W=L/4=(=UM@O;5+'#N,7'Z=$
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M"92V[J&%16> I_Z7V3#')OM"HDXA>'O;0"[7TVR4LR(^47+@B4?R/>2/;#0
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MWQ+V*$?R[6E!$#&);GD5L=T]_=9 13'#BL!#4OGKWA7Y^4K./NY\L:_S6I3
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M]!K%2V?)?%.'@@C:%&J7PNT%!FE[8*$%',D\5)@)NM#X$>\A1@I4TY_]&Z%
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MT]$_6)?3J2%,<<;,"<'Z^;8BNK0Z1'TF[' ^S!]KSQ<D_8+Z)8 F_+#-XS,
M"^F]7N-[ZX>I&76O3-A35_7EW<O-^N@'%&+<C2.4)0B^I!E<^)9IR_,XB5EU
M/(7YDKH5RME' KJC&MIK=RDLY8VR_%7#.0GR?;$+583P^]<$FY=6Z\$X+FR2
M+TXSTYU=^-6AL85VM,\C/A S,G?\ (?KNC7NOE=5UM8;:W,TL6RA?!MX<T:0
MZ#T?^O+:I<ZR<2<7FI^6OV$'BE.1!^9'5"MY#B:N8;/E!)\=MM1HA-($NVOU
M"W\<O^>A<0L(YAH;YPIB$V'."2U_YZ&9(<]%KLB?H:"#G3V<5_Z*1 ?G*I!5
M>#/+T_<3^ AT1#2NF9P>['K?V^VT^.$0K71YHJ8+1MJ!3+'L_EB!B?-\9X;?
M!H_=-=*%!F^RVI,O#:1GX8/K,$Q]"B'4>4[W2:VNI4J$8\F$#:8,F=:45\B\
MC3!_6+U2;8MB><+M0U$M4V0BQ=H<K:MQPP@;68SK-:3+4_\>+63%/!25QZ8O
M#Y)E2W*'C50Z9LCGK=\O%Y!.2W1]I3Q\@%]3/EKAG]-2,8O7G60CVN=026+Z
M+?69&TSQT+?@;E.)6LQ+4KEZ^AF;G4AAU].I^E>C4:!UAX6=K7%Q2C4_<L\6
M[O%F]#&5J7>O4%*8PP+M%RH%'DO!K)QYIY7,;P&B!?RIGV!].#+EI94)P(@P
M)&9/>QW[C4GP=3Z,OU##'849QR-W;0IR:O.Z7%G%Y_A+'A4WMD4?&$.>Z?R[
M:,>Z7F-HG9100S;+QT>E-F2E(<<7&@$E"^3<:,-#M@M)!5Z].&.E@LH/H_-[
M*[ORFPNUO+[< C;51#WW;:TV0)X26;4ZA,[G\'X@,'=[?FX9M;U)T]D73T_G
M3&5L^4U0@K(?1@@.O'KWR<:%[P3K&&GN,M,C(E1HBV.6E0]N166\4L #&KV?
M"7RZV7.GC<@FM/G-MX">LVC08_$\-S&KX$_4&H?\'RF."VS]A\G6*KY-OWZR
M\O!#\9(5CD*J7,E>X9CAI%(\>^3 6,':I'I][,8L#GX[#6MU^H"A3:PC)&8I
M[M/GBC3"8U?S5+=N?0UY,?&\20E;>G>M=N&O14KCF5ZO1PMMBS+#)C(_<GNU
M[1K86'[;V9ML-2;(JC\BL?@ZI$OT"X, N.^$(O%?<I'(+V7^'N+Y@V&)_UFN
MPIL_5>N9S;Z-K8X__TVQ^?*_%)S-D)U_V8;N"*>G,J)ZW0TH_IU%M/[N\6NU
M6MWRMQ!ZY&(/QMT_'O0H\RN 4M7HE_\#!/Q!/_I?%!00;GU7,.(/1H2B]-#^
M*<LY^"&\9'T+J!C=D#N5@E<]$Q@8.2Z3S[O _(^030KW?<4;07!#^6('U!/G
M__"?-:,;E/Y6+V--\-X8%5O),^'I(OI:Q< 7Z,[NGV\!#K""/0XF+XL33Z*/
M2A%"EJ.JPV\?BVAYC'8?4JQF5]PIH ,"9Y^;E7-:!;J1KC:+]K:C)M9!)"&F
M* ;>BXFCB;IE[[AE%3B$28[\&RI@92$]3Y4>^3)/RDU+M[,=6C=*2Y,K !/K
M]MN#K0OO3\:3%_B/-3#IV;B!,R3%GA&IM2=E#>:IA[@*,6CM8\>%6P\K/J7R
M\+>Q:A747A1(=IB/I!4V1UM"@W^S/?:L/2?.^M)IDEQ;57BHK[:6N]$O&SL-
M$W/FI(A1\M!8H0'!-L!/,<04^!.PJ;X:16^ :L,\$A#L1AJ3,/J<!V-' >FX
M:+.5@G/XF)404UH\"$\HYV7YZCJI=).::<)0S=Y.CKE-V8"-!C?I^Y/<_)CT
MF JV:/M$^^ENVI25:$>/U/ZX1#5I0EO5<_C=QY","+J,D$SFM+?BJ@0_8XJ[
M!F^[=A@@R^I=<\?(C5-BXF7'(=1S%VNCQKERD@T,D0C9X0J7X3PAE;>AHDV1
MYT2\UF]^#_O0#W_O!#H6>COKEDP GGZ!*F05)@3,V$LZ:"N>*'3@"(A!!1SG
MQ;6$K8XRY;:6Y#)/ _A5&V'I-YL^ZL:,P]V*$=Y#D\G+#*=HRWKF]IJ7LNP[
ME<M2)S&&,[;=4'>9ZZ9SY5\G10A\?W52\P5)7(]=Y8_'I$Y3QE*H^-KYJ"']
M3[?_UMU>QRN%QB/I'A0TW#6KDPUE#]0(,P/23EJ/.+U+A+ 52WQK&"<:9_"1
MT*8>#PXAFKE>MMVL91@C_(?2/4IK17$I1/O(Y9/+]-#@ZR&11W>=[II5MPQW
M(-SLIQ( T?]WQQI95 KO:1^[RD6T$)B9* )WPE)BD,2W@]9\F14K&-+R3A"=
M21'COGMZ:>Q!\G(B)2#GKK,U8ES !\2?6=PUI]Y=B/+=P,@XB$X9B'9+;\2%
M2"(N\BOZ7:?P_^?&H@F[X+*.M>U.9KVREB1H9$Y@'/:=H8SE=QNF6::,!:C\
M7WK9_XW&6O$R<HA:CZ3V0[<Y9O]@ \=F'7W/X&K;'M\.R9#Y^ ZM3^6,B@ 6
M2"=Z_N?AT:Y_TQXA"+_Z#3SX$GJN?)WUY!1A= Q^V:)??Z)TWW";L;%F+I9R
M4MG7N9&Y_%<7J5\F"_ _W?Y_[N9N_^:&"8N?V&ID?"<\R]UJ?Z$.YWS[CP@&
M((OQ;2.[?FA(B :87GI=5T9?JYVM?[7^#/6X&*89&2;MY<N_H3_ZJ.P1OC-]
MW=2\2QX&:*4K\33L'.40BD-^EN>TJ5@FMNB4 2KF5[+QRCW*X,P[Y%!\Y"5:
M!G_KABL(%PZ2=]_)V$=1J7+A/JQ[<T30)?^B=SDYB&%D1'T< U=.-4I]F5ZG
M>F1GI\AGB#,K$^UIJDX9>Q"7]N(/NBF.1:+",AF=@PRVMRRE==#J?IEL)8NO
MXG>14TB,0HQ?C[Z:_(*4[&M#M!?U, >V)?,F@BV2K/" (W)Z@<105M/I*;=B
MZD'?)3X0@HL!1WV>T@@'4&,\H+O$R3() C/J%O"TT&X(G  'TBQFJ8>6JX=9
M50B50QZ6=VM=\=<T5$52V&/D[/,@UU(&NI3^L!CN<FRV&> :GR7G7-]F:?W4
M?: *-5.^).YB#7U37TAPF2+GN'?AS<@ZXBIG]SYP>J4>]?*UW"8V_X,OZE[?
MT"T' ML,2"K*N+G[@%Z(MY7YIIZY9J*+F$K;@4DM)DDE;IR<L4UV?[:W=Q^G
M99L5YO1([G[=NZ5.19V%K0;R-K>0N2G"KH!V3(Q-+^NHOOE$+DG;!"4.G*K\
M246_HUI]VMF-* 7TIG.MX<Q)%0=OZ]=P2V[=C,A]M);+T(<_S)\ ^9_U:Y1=
M$9/')'2&75#1FIJ@UGNVX4ZQ^S_2-6VE%I!S+D8OK;*R6G+F/>\X+&A1<TC*
M8/MH#,H=#@[;VA7TG0_VE&'-_/:.FM_4GV#0S;=%!]P8"-TI>JH(DVX$4GP=
MES(W?Q+D](D4"2*)5.38AN!A/TI %UY2]^D X>VE"LH&'=!; (II!G?^D>SN
M2.=XW0OHC"Y/<I[MNY3'D_DX'^,IS6261HQ%%I\^+SI4X8.K7>3>J(<N]HE9
MR0O+O;(&,O *Z^ G##G'?DS//K[130K+V&M8Z%#0;?(D^]2! M:$WY#J6]8X
MC=M/Y^)6<%^,I[6V;\Y?9S=KQ0EWJA=C/X#-8<Y*]QS:=BYNJJTL;C_VQ7PE
MB>'3E[5OL(K<B+Y*N*!]3)1VSWR5MPAH,!0OT6!E5BVS]_*  OBCO3++[7,R
M_W&6]N-E4DF^8H[]\4":P6-N:3FB_<BJI9'\Z%6]*:'@$SM[KYKRQL@.%1(=
M<7V&9Y/B<M*@7Z%\($#,I#/WNU^TX?F?+E"\NY.S_&\!2T;#=^6-$31!-U6O
M[29+> ;_PM1P0_5Z2+'H1=4?5;#_R5"'WWO\SK"V?T;$_K\CL0A8=R#V!T4)
MG'_/>J@AW%D;EMA:%9(:_XT+-2U7,7<:5B; K2#"D*4AQ%3.K5FMZ?+M+E9)
M]='?BUBZ'TR:8>9)\%V_G;L?."@\;QE0H64.SXB5.FV\=EYICQCI8@)R9# \
M<7*YZ&CE<\;4\)L<T2G \HHE#-Y'7I0+Z1"D!*D\#^1J5U74B55@XIK.45$8
M]R0_GFL5$/A4D1UT#YRT@W(+*%8_5OSDL/&HC:@<]]SJ/60!!*M/DMHV]2"H
M;%TDC(MS7._B[@^9A5T*0T)MK??D<F@[.W@M#_/!/.@5<_;,43)T@T?85@M6
M&V/TH]:$=%,PDW+WD]U$UP:+S"QT2>SR$8<\ILQ4\=J]@=:"<!P=3N2I?K1J
M(2"F]O[KR89"=@.A*KMY8&IF]D+2^>Q"R+119X5 3WB0RH#%-^\0+, +[0;:
M_<*4IQ450=!6'[&?N+/5XF-1.3\Z]JL6590]7"H[=ZZ$]^GE'\N'=6W%.8FV
M;XP@WM7OS:@?0:"2<)JKA(,-<04E%5<CXJH"FF&:,RCX26\"&2;5S3.^&^<.
MM_C6TC/(>9$^AJD)V(B$V3O)UJ&^L'#<_B[4J^ IF"HKDS. [N[SW:^(KP?R
M.:H61(%9MF>&-Y+DPC<UD.]_%@.FUF,$'2@R_E\53CC8CYENUG+&B:?_7%]3
MM]U5:1Y=C<#+Y1#)G-0-!<;E%O%ZB96^_5Z>%*Z4<P5,&RX/!DO.]4NB?UU<
MX=(K&J??..%DS/4?K25[L,@P^"Q'L.1K3V>^D$P;57AZ0?E,-9'NI[*;L\*I
MYQY<#PQT.U-03M6>+1ZG63:M%8&5E1(+[,?<.J[05>D:*B%H\7V2&!QVS>'/
M6(:T:GR#K(MW0M#%(EY$6:D7O5&LYS39:$Y.(.BRR&89XNWNS'SX<QA[IFI3
MT.3F'A-6 F3!2PJJ#[TB''MBD7C6[P;=IMJA*E?U=7]<P2?@SUO0\5G%!42*
MKV9ECWG=I=P0PH0]6L7[HATG>U[:%*8FN?"H-B07K6A>;$:WNKF/^&7O7;DW
M^NKW"B06':/^#QQ1DFB'2HZP$*W_ LF4AB.WYQG*-!Q8$%* >D$"</Z76D@J
M*DD9@.<@\I"\-FX_P6A#0/+?-,%XXJ?KP\?X$[]2T]]1_4%!\Y>HF?*7TFGN
M/ZBJP0_YC]A*QMQ9MXS+ ^IK7?PA9YL.3$'3RV=?'^06ZH;C3NG.)4I*LCWD
M )J1>@ ?+G(Z53E_^[.=Y-3D'9').(?RCEB8NC@=O+L(&@)_;>P6BZK]CF(E
M[=*L\NI*XA;@#0&D0 8:1[^6B&P?^KTX2$AIWF??)EQX)E8I8J%3\&%HHNS/
M[]CXFT^]'D@) &>"4/,% <^>QK+T9]:+]!6@*;E 7<0T2O\;#?9_ZTP!#4J(
M\!*.\&5YM=8L+40&EA?%R=+FAER65V(W_9,3JJD0J'!@!ER)?6HFI9,9'T^H
M$=6ZI4X>C(QCN>G%E";V1M7=E,?DS%]KG]LO'#<.773R>8F4SFR&<NSE1#?F
M%ZX-^UN Y;=**W>H[5OWH)Z"Y]^%DRTW$@IF)_*J(S,^I=9EIYJ[DKW48Y^'
MM]H94EY[R+]50[,KZQRX@*BLU;61;ER%U'H*>(:*(9FX"D:F-LBEX*SJD-A%
M86M<L'.+$;CUD%0:%35A=CP8:NCONY)"?.G7I155\1H-26)3Y#ZJFXJZ4UD?
MCX.]7U^2OY37.&NCA7^D/2 ;<8$,"6UGR%,IN824(&8,1WNZS;M&6EM2D5;#
M2<=LRK)2^WUSV9Z]C$T&O$W.P'Q%=<A)FN)":;B[]M$WJG#KRQ&..>U9?8+Z
MVC@J8F;NDC5ADI%*W1D>K2\O.V@_]<"X>5>YD$J]V3:]$G3UT01JG 8LV3UY
MRALITJP<Z>IO 4B3;-#*[0A1H""576%'0K <7%=K!$-.L#LP-;;/1DN/;K2^
M.1L"3K1%(_?5<0U@9:.JGZ%ER4A)S[-B]<0["I:KX;O6;(D[T6DKKTHQ+G*G
M"Y/:5#8<L+W?-;Q2$VL4LM<4YIOL-+F<=.CFUP>G-T6+0I/M'^,,A(T8'&X%
M+.M=]VK8>TA]KNZ8==EZJ[6AI+U1TF;D2#N$&Z5?"U^OB+*\*&^* HD%WA!R
ME1BYDPT7FK2L/ YO#$N%"K3$\>!N5(;L<= ($U/*P@4V)X*\V-H$)DCD7ZT_
MZJ,*Y9NI6@F>885AYIH%N!L"JW9--,JO7^[T:(+%)GGB!<'*ZJ9@<<.ZCS)6
MM!@9H,[<8#!]Y88>7#ZG'/;B1\[(KLBA'IJ-2TF!#,J: 548[TKD2)&/"WWA
MY#H/=TWV'!.DP'M+;7(F="2%.NR5_P_D,)&"#[+*E;K1P'+@D?3.=E(7F#1E
MD8M5]"W&CU;T)LS.O VZ:N6)/]M!_I_S!O*18XP_)N;53(=H@_!L7# RJHLH
M6U]2@[2:D+Z3X0F,Q:QW9Q:&Y(^&,AY*&SXZ^]3=CNERCO0S##: M?DB.+;"
M1GV -F&5=7NE+HF9R5B1MUA\\(CQZ$R\"IMJB5)V"TKBE'?@S/OLH$"G^&7G
M- *8#@B)_,'XX=^.S+<869]_/LQ^AY^$K&BY5">Q0"=AY>F")DBBB.OV49)D
M%G7)]U$1)TME]$_DWO9:NS,?6Q]/"A\@0<^.N*/AJS&;-_4 \JG^A_(>_-Q+
MJAO +WNG@?!9KA0[XL].0@6Y *3W6@MT#Q2G>9K;,XUVOR&N'"7SKS&2J%^U
MJK);?KDQ).Q_R#K4)%?N1TB:*OTJ_?D/V,YJW5^Z+4O*OV0#/V\!GP<B-X7/
MGWCU(R:SZ+#K5VS&8;O$TLA5)$U^Y!6+A%+UMYOVJ'8+&SJ7Z"CB4)W]0C ;
MM%P71 ,U'!:DL:?6G=:;_:*&Y2^4F^7SZF1$W0=HFS8P-S?]\JMYJ&A$9)N-
MMEN.1L -INZ922BQ&\WP07Z-?YV]6] B!K??,V$2Q<<WNUHP9N'ESS=B^1P:
MX6\G,I,G-Z*X=YV%<?U,2V&A\QL/CJ[RR5^TN88[@8_O22^A\!+TR^7.S!1'
MG[17J.THZMB\@Z10 86^QQ!<KGQJVZ@74Y2[(.U:\+:YV'DUO+T8B?M-!@$C
MU6MW\0Q_3+9G<UYJ\YH5@B49G3938=J&Q7J?!X\+@^?*-UC)#@3$B!OVMV4L
MH\1M^BH/^!,5'V]\FZ/526+">]8OE;.L#^&?U@U$6[8?J]O!P9&RYW20*Z(-
M#:]1O 7HU*/"N2I+0WD"U/5LCO.C]%),VQI,@O8)*CY51I$FB[FM=LQH\-XX
M,_B]RI16_[& TV22 G14N6F.Z;0A0>'&F14<YYIOCW16J5@Z)QV869<-USKW
M"M2U2N:!T)H.3X%HEH6P[5SXQ:;7=KU.7P2AI* D^?+O>&DB;N_*!<FBH-#\
M5+U*;XTAI[WM92S^L-?8 5M&Z:<U]N4J6!S3PU<F@&C=.%>=:1(RX1]CZPSC
MMX!1^5&G&/B6'QLFP=+%&,MD<O>ZTE0;4 3%^Z*2S2IKQD<2I%UPXONEW&K!
MVX!<14!> 7UA9H#R)C_LL.T",@/C'LIP]!^X!>17ET->C4-[9J\+@,FSR4#)
M-H)RW\_F. K A._+/7WK%PD5%,"1]J]CDR$RQ)@IPM?J^ W/1@V66JRP;%KG
M'6\!&_G\:U,+YAV4K&Q^D,D$/ Y7M8XYF8LP3?\;PZ#B3+>B"]T?K,=$<&[1
MR=3<LT1EGO2YUT%TQAQ(13YGE&?2.\UV\NHD7MOYN9Z+EM*7J^643X 'I'7N
M\6DCZS<L5:T]><Q2U$[(>=-NJ3JU":]*_/BH)MU?IL:^[9G/O!0<IB\JJR+^
MON$K6S9?V\GRU:)(6T,D<->;$<0Y9TH[>=E^IJ%M-NHJ"_!>?>IM!;?J]^*B
M[BHD%&V*N 7P'UE67ST_PO?A\_#'5]:.^X6-3%,/N'VG+(_I[K;TT/W3]!Q4
M-/>+E I0N;"HQ?]>@T<9>/DG23A&9PAT0L$]I[._.%:/)?S=?2(\Y [C6#DB
MX<B">8^R!Y]CTS%E9B*3R*K*_)9)@Q03 XL!Q-PM,BL]ATTZ<T>@@["9,CFQ
M9$&;"MDIL'>_$!'^W8D',G*(3G 5N H2CHZLZEC4;\NZ*'=A'=+&=[J-"/;=
M:N]O:[X1OTC9+T"%\NC/T9,6VI\PM2_67-7'O;_)-=D2OZDWBP+_.3D>!7!7
M"0% /WI$&>N0L./OZ^@RSGU?0WQ3WPP?"NWP)N&U@&&[K&S0CU!POUJ$;$'!
M8[,S)@![U2'-OJQ/RV,+;SR4WZ\Q6>0QOL81E43[>I5G\?7>]R/\-QYJFD^4
M)K/74RTRR^O\3M@YT!XVP%!;)RABWE!\17BSZ3;KQ&5PP:8('ICBPT$&"OPK
MK*&R0>SD $W)3EXK>UC4,^B=!^29T'U6_'>_#9WU7PHMD139L,@_G#J')K=Z
M,Z*\4-Z_7Q^3__&TJ<WBAZ&$-R".IFD[X;#/IWUE=G]69.K!N4RVQ61OC==F
M%W!-WN5:73:5D_S'ZK5]>S'M:.0&_@]:K8C:1P#B_+C)V/JVG!2R-UB5Y?8W
MU/N8>GQ^J.=(E]^/BRR=LO@<,HJR+(;#7Y OX.!^Z1&U:94:'.>QM65=;D[W
MDR,SQ]?5E??D#7NFG5"/(S:8/CS_<)'C6=<]IV(QE0 2LI+I@_D'"ZM]K!_$
M!C.&TS6=*5SXN*HE"%:Z%12VCA<)"$SO DQ%_TAP#$%T_J;2^F: ,+>G1@%V
MMQ34SH!IN(AP.9LTQ* ::M'\(CFSUYZ #IU/0F\3UJ>#+2LTE"*EES!83#]\
M_,":C6 D":6SSX,[OJ E5Q=M6O [QW>7@N) I]E$8J,2YORR:3@M4I2]7OPG
MKU<TJ)@NJQG*"^R//FI45KYQG-8D*6"=:4?5_CQ6Y27,TR@44J+58.A ^JF
M;F2FY['^>."58$5G67]CW0;,S;-ETSI8</.RF4\%F U >L?8:LQ7WVE-I,?
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M]SN/ 5/>K?-(:M&Z%,PVX:;+*Q1!91#N0$$+L))Q[";%_K9]0(M62<# M&9
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M'Z91;H)CD)>%=R/V_*"]1>^QDYV^,:B=ZO8=7;KSS_F^2SS.RH>C#X]D"81
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M4@,#U:GC]+'H.4GTLF;C"BQ\V*]?%>#?/7N:85B:3,4HW0&'Q&.;P)89GQ*
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M@YDK -(5P )D,Q$ ];K#=3HBG'-L<P60+;<'.]]^N3UO!1ZK%G9,K?6R.N7
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MX]VL@;'6WRBXFE-7[W?V-H.I)!.=GZZHM7IQ]K-Q?-O9Q]O$Y^)RJ)P8/US
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MX%F)^#2?)H=< IVJUN.1^...9F3-2@KC<)Q4M[Q,E!$&2^:ZI47+L_7>9(:
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M]K+D"C#),6?+2\@N%2*[F,(ADO@XKFK43V71/Z1@]GISP9G]Z=]R25)1TI;
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M:3KLHM&<8SZ')^W"ILTI2KQ82!YANDN*C_Q.NS3FT,5K"IZ_-1!>H1@BO79
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MZC>#*6F.K)]K<;Q<'JN0+'U_!U!+ P04    "  3@FE2BJ4>;H_6   ?_P
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MH8;,G6:UK;K$[VY:][USO%^K(:NO702$.=8?B/2'LM2M:7^$A,<8/QQG10/
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M;*8SAR95W;=C)!1^P'Z_T8:K.*2_*BQ^^T.C=S S.3_.$E50F]=8>.61RQ,
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MSC7X;6;GV5)5=%$PY:,OFC_Q^T(_,>3+XYV;IADB_]3GP'7-DT'CYP;OX!/
M0_,1_PD0QSOW,/ $&(\VA2NI[6S-7BUG*+AF,O\K307=L=V]L1&EC]7RWM*W
MC#T,KDT:/=2V:(@I:%N!N B5?*?@D!T54QA#^-\>>1\P7)8_ 3!4*OJ NY.L
MK#N?WYWC0*,H*,SB]'V-4IVGP/9'37^K$S=+[L96MML25S)E33PW0JK&$]2;
MI@JC4XW9!RU[\/T2K<1/T<@>RH8I+!ED>F1&XD5P39#K%=3=;E"WB.27FN=
M97$[BHUBW9>(G3"6G4V]?8* E<".VW_E,UC.!2YM1Y SWB0FJ+!D5,9&?'O&
M;5K2(SN?XPHYA-/&Z%_B%^L;UH2HB])8>)-9L[[5>$62&ZGN\)D_CI8#"L6^
M5S7EX*-E1MD38$AZZ@EPD'S)8_0GOHS1Z;"RY=#JZ/1-#EFI=XM=R_Q46M_&
ME!*?3JK=U5D*KRQJ5LK#K<:AL)K(\D-;W0+/3,WHMYI!CUV5(A@5V[C5+)3&
M6Q;;$=5>U7M6-'EC>)$9Z3+B- <V9U)L0(QUK*N1N>RHI!*T'/E&6QG!F/[P
M6%CO65E8K3S$'#<] 0@\2JGQAW$<[*=:L].9X205 >DXF3,[9:R%U7"A?R=T
M@9"USV_"S;&3*%\-795_FX9_Y.-QB4F'V$Q%1//9R"_>CX[)SIC.<L^?F*B7
M/FBF'XGTF2C"=<@2^Q+;XQR=$+R8T;6WIL4>6.>'U\0+0G\KMZJMZ].#'C9>
MW3.SS3VOC;!6V0C$>HZU<9/==B^&C"E_IA(2\Q%>N#L5GUAQ>-$^8);CD8MK
M[PF);DV:([B,'E5FYA6C%.F;'@?MSG'5??GLZ9 92KJG>8_O<'6D<*Z7)'6>
M$7&CV 7J1TPWMX)6\ETBK1F<!CP2JP#+ET!CG8(1$=[ZP]@*4XJ/+?=*APD0
MUCH18OEI^FE(JEZY1=W7>4R:S;N+_%G7,L,W8T?$']+3F6+*;7T%3CY41\->
MQ3/G9>R1#E*<WNH X6-91I/OW7JM$O:NRY*B^:>A?ZZ$3H$[LKBC,"^'G4T;
MAJACT(??N\3?B;K.N?J?Q>?E3RB-'\9:EV-W.!7\7FF^W[?,V_3P7QT$E60
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M/#SW!1'!%^6KNH'02TWBVME%I]$XM6.%_OE0A]4FAV#%HB@-,U[]^<2K&I"
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M^3P5;P9"C>;Z:]WL6YZ%F#TH/N,3;\[W<<T$.V7%&E3[__;E]/^_HO3])PS
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M@!*'[ENH&*J'_3EG@WE>&T^W W=ZCI39&Z71J>R__SP(I)W?H<Y4R,03)=#
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M%9-"'W%>>W;DFAQP:N+^;&K*/NM"H>/18NC9A<**2C&W08]D8U']KTPQ9/J
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MVK)P >W>: 9^]> R[DWE[L6KKO3Y_7N50[>:X#2*MZJ^MV=CHS?QW=^LN*_
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MN#Q*$D!R#WYEBL7O'IA@5[N #,+,R+"O4%-5KR3V$]D"6;N?['K?QB-7A[H
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M3=ET\-\R WP_+;/HVLDW8G.UN!!WKW[QCL:7GF7R%E@J$I6C'V'9E:?Q7"E
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M!(B<5]?V3>9GU-0[E]+?>5L\H?50HQ%_#W-XL)UP&-A#XTKV[?1%E:0%_OB
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M3^>A?BU#J=@XV@YT\R/CTA_G]YA%K!O5+V^HV?#" 80!6)W;AT]9+H*+L9,
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M?>1J>.I"HS?L)PLKT#8WYM%J)7:E*;E9\L+T)#MWV\AT533QR0O6]AQTO]<
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M1XP,60QCQ^I+%?:Y/Z;'ET8*Q>L;C'.Y<)C+Y^[PP\Q58J_U9JHO>EA\SEV
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M7WJ&\FX94_JOAA@5Z5W_$ADW6AM[GQ+-=D]<?FY,J$0"D8:06?,ULP#P;LJ
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MP K!RJF=8I[Q51=S[<FK0J7M3Z.)R^@(!3D1-V%F58L+N'><\GH"IDZ2WW"
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M\U1*:T(D8#K#[N.,&^0'_OJQGF.[I>,H3*F\ BZQ?]B=]+$(@ZG7]1H0.HI
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M[A50\;?9D] TU3S2YMY6%&[/N#=ZJ>AJYN@R +5<3K*#&Y67A0E,,"7RDFH
M=X'OE[]?1#SN=OL=%=_\IQNH-M+O(Y4*+I!U_== CM6FY=\ES<[)_U278+9K
M%<DZB'$-3/;<O&DZC8\:FE=LYCS X0V,[B \&<=#_M=M6H4R='WDW>^X/G73
M-P)"_U$9\_^D;?""*2R$>*^!*1/=OO! _8$JEW[^1-#,;'ISI)6%4&5B=:$4
M^/7CQ 75A-=CGOA3%RJW9UBB2B'3YHFX[N#'8427/3^ 76\(MS2\(*[,@$)
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M\'TG?6$8->55QTAZ)^$J2/ZD]V;V9*)X:3</09/$X<\=F#2G/C=KB!T?83?
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M7(V#_$0^(<H&R0T_<.KBY$AUMS=Y(J@?(4Z4>@(*6:"B8%\/5PMU4[U\YB,
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M3-Q3F$<:B>7(R[H"'&F/40V\Q(?<I5M2ZB-[NJJ5ASI4"6_/-8H?V1%_OP$
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M>+.0>V,]O,/^YD7Y1.F>QJ?N""%FV\H<4BYT-,IS+1!',E%0H>W]]*ZT2?$
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MGEJ<W2M\\-N[676,]E-*DC,<)E2=U<1/'4" ONY);I:<O4EXB^%?'<S+<J#
MH#.*(1Q:$>X87Y:_0+AFP438%/VG_LTB9V+U?N[L:$"0U%%K%BO*)J;/%W7.
MWU8UYCPTHK"Y1L;MSG/Z=GP\I>6$"=_:AX.C(H\]F 1.O7MY8F?ZN34B^/:^
MI</RQ;LN5TH&F+&YYNE88PB:/&?=Z86VS=>A8 ZS]?C*7=<B7#[T8H@'CTG
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MB^R,)^!QT]DY-C;\>0]/C>HVV9VZ1MWLR[A)_Q/4^QN.:?A;S?M_#:G^P\'
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M;$%F8X]Q8,U)WJ=5"J$@C997G)[#=%31#PQHP.J:H9$I)\M"9GJ:)\E(_//
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M$$2K&5P$RYTUW-O_WE$ =1DB6LT.6\F%!7@Q@Q1?E 9<HR57WH4?+$\B5/!
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M)/:1# +;P7Y !\Y6,+5<N=?)F<U"75 <FLE"MR@(*]T(+-T&G&Z?+H[@L"'
M)@QM_D+EX%S/'&%VTYI.RE5BX <[RY/($'-2W"/1Y+U5L()SB*T1!<(AD)&/
M9"&.A5MU(QW4;Z!8=["SB6)UX2#7!?G8SLH@#'$*"4Z^.)%D["%=,C(0;0W6
MQ-!#J&F+"DPK6!?I]E/:I4EDG[B"U_DMW#YDQN -",$, \,Q#7SPC5["P00M
MPA_LGX3@X38/23<XRHZV!QH;6"2T%1Q [IL;F9.P21*,51](2E(D' ODP39Z
M"<<PM(W9N(>BT+U%-=)$6-/-1:EM<*(<3L%"06JH!ATN5041M&@#$)&3,090
M8>KYH#]51X3@Q -7=H*P!W1$]6!&M$M=8@YL$B38- B1TSQ%)E4'803HAM*8
M(&S+(,$Y\,9%E;!@HW'TD_X]F*YX&&$1-A(R&]<&@NR7L/$0DENEVA9.N7R0
M699,F912_/F0KL3*![;Q?@6&T$,+@\0ISX9-1M[5=25IU'2Y_&T,[=UX(5TB
M<ICC>#RPN/C/FF@6:+6RGZT9.#]0DG^!OI3_MJ' ^4>13$",D022TJSC_<H$
M$^I\@EGN\H5W2P<O]GFOE6OK7) X(:CF!D*6JC\T+*A<TX'0&%HJ'4OP8$AX
M_**RP#/S]3B\BKZBK<X*VG@P_UY2]AW:3N^U0$$^<1?]-_-3MTZ;O,R9HFZ[
M#:R:_U$3,QX?__Z2CO3K>7?!\%)^N^EO\<(< H%EFZ_.'3-QY* Y77 -:TXR
M\(>9LY0O7J?H.M-X-L9XE3>XO[!&;H9I;G![[8%P(E^EKGY9A]"=Y$F)*K.P
M5T3?^M1U,XK&TI3%$L^^%$ZXL2Y=P7;Q#UY3+G!IK3L;W:1#HM]P*FI>@?I&
M_H#]3AY%[;WF.MJ:OKFA'<52"=VO,1-.#$O4P7$^QU\?-D6/]!-,+65D>3A3
MF?_(!^<6%9.GTJ#P86&Q^:A&@^(Z _F&Z?6Y=%:DE#O+&D:N(#NH1L+^O6*@
M+(OI*=AI8U]T// EK69]=Z]51\6?ZOG\X'3E2YLH+XG5]E1CXZ_U'1RL./H)
M;0.%'(O=O0@\D)LD$NG]S$3M:,B_8GK-RVC89RO2<W9L;4OGRVQ"@&_(+>Z4
MDY>TX+?G^![&-L*H';$,GW'+TTWJ@?*N!0L6\:(:W&?BHOU]>$CZ_G!0"NQ:
MW0='-<-GM6UL[J*>,3Q7194#6%+Z4&3(^NY6@](Y;//';^1OA13GPAR6S4EJ
M?S_/3(K)TMQ.KZ?%0 , Z9 MFROCDAX+E@<%N0YVV<S,UAQE558.'P]7[_LY
M; S03RX-JUN,>HI&2!;2*0589%RYS.9FW)%"<?]W9MMZV<U2EENRR+?E#'PT
M;FQ&--3)?*R80:*A/H,'[Y<V7>FWI13N#&ZLFU16*GD\7R](,GVCYQO!%%'1
ML620D?V4UYB9N>7W%RCH%;2K:HK[;07X^*5''%_$37T6>SN2A%;00,F--"=T
M&5)+JK\NI6FS(J&)#&P D%?D /< ^D9TS+*72ZNH-W7(LJ[5/:K10B[?3D6M
MQ/=,3Z_=ZQW2%8END)8H[INNK:P<$'&4H%EW?CT31^SZF&O&,DEJD:3O[Z[\
MK%O"ZH!))*V4V"6Z.2>G$R^956^<_!/G!/3^7C.&E$OE69^WM,I#IDX=9WT+
MJ=?\=K=-4HE/A5V,Z+7O5 C@]8<&+B\[GW]N/JH>I?KH?DFWL<IP:I2-Z+I$
MW(S#:6$SG_JI\'X?P3\T,E'\E),9YY,>I?RP8<:.\MNR559#[O5S,[?FR%Z)
M*KD[M@!V?7^4[;Z(OIUR[]JPE\JFA'G<E- >-.!\=/Y2_-J[R@%!SLIGE^]V
M?,$)$Z7^H:6UAHU\M]UP2X$QHTKU,!^FV;W?4CPQ)OKQGLL>N1VQUX)#?0J%
MHZ9FY+3^:8,)X=H;O-&0"?((A06=DG_Z0GN]ZTOCZ9% YO91HXCSJJA'!][T
MW,T?"B%!:>IO$C1?V U8#;>%8*Z,8IQC&6*AIH-YIELV6:TR4F32S310EEPK
M1*VNVLA:J1WUMZ_MU@V'(K51'UY>QHF.?Y:_NE"9<K+(>_'@;M_O;R4\=(UM
MB3$XK6@<:>"Q$ETV.GPF-@(K=77EP<2I7A&R4A#945MYR&=ZWR=[-2O+]'FH
MQ\'_X#XCCAE%ALH8W4T6C>0QOZE^;E/QCJR???DD--'60K8%"DKLX";S^1$0
MU(6+O))>GW2=83,GL?V#TRDJ*#IX^HOUN5+DJLXS!A<Q$!+;GHO@"!18X*YL
MO;RAUYKP#JU[!UV4(9ME&6/X%6D1)1/%MRR_$0TDWPO9V5_E6T_V:LF@^3!S
M19X)EU;I@KS)/7VT_#F-A$A)R!!"=)HZJLWV=-;5AI23-:=D.&;9KV>F9_Z>
M]@$S0CQ(V]Q9/)"W>9(W"%D>N.,!#ZRR694^4U=:<TASVGQM;LPVW:Z36>+P
M[<N1'+WK;$,E,9L%B[-W"0\;]KHJ-1_8OA;PSUP>OI51=O<"E[S8*7E8@/TF
M4MR$!1A'JI2+/9?D-8,]35&ISXM;5.0RVRX(_+@M=9:25+YL@+_8R-?9SSWI
MZ2V,LOGO[X\SH\Y.?UI\LA3+4.A@#Q-OLLXYO-W1<>+DR<O^>NOEQOF+:^F6
M!KQU_AH#:P+4S@W,SUJ;7TK,EF&,I7)+46:!, 17<;EV0?SP9O\CJ9IEHM$I
MZI[R\T4;&*%I59HN*[MIBO'+PNVF-!WT?E<M'KBIN2R$9P+.?54=-.)>PVI:
M2RI9:7SV[WD:<P"J1RJ_&[^3I-/M)(V[%9!-+&33TC"DLWO*U;[QQ1B(@=?7
MF?,+F=%/8;1+I[XV2#XI<:&X8$'$X9MT]6 XYF.ZKE75N=98E^2+KIT,!N_M
M7X;;RS![GS=O:UII_/)U5P"ZD731[HA\'YI33HL):O0<#\SX?0"A&CU*9#?1
M+FVY*O/%DOJED\CTX#FY:VI?]SV )[P5@4QK"$4CF<C65 T%&=+K,E3_@A$D
M"4D+.\^+IACD^[':\9TNZ[*2EYA^L17?@?A/2'B@76O6!!>*M4.TZ**U8J]G
M3$=/IY0J-_=$'CJZ 8:,L&+0R=#IWDUT>IQ75%J<>OBE9^+>(L\ AC?WP42;
M).[*T :G;/2)OD;ZN@H9<Y)W?UM]5OL8I]FHKCDWR;ML=1EVU:R5^9F66/?U
MRE2K.I.;+<;'+?HO!4N4V0^B]C62_5E*7*39X[MM"OJBS!RX(NAE8R2/+:J6
MNGL9H8V;G'&,_=T!)?W=S)$9XP)"40ZC/J)_ZS_Q8DS^Z>X, P7F)N$[I'-:
M%F1''FX+$\W"3V(H4E;@5-9C6J6,L2<"Q+KV$#/KA5F\.6@+F)L'(B9DW;GB
MD*_GB(.8EHS*%8^9;(3<0M-<U.ZROH3!H&.U59U92=G7N4HIU4\9+P^I]:5C
M,T?-1ZU%&=3)IIX_DL%T0._]WOLY;RCZ!8Q+1ZHLENY2^VAFXRBM^+K<"?(.
MM@,MTP?QN_[&T_PB>841K[ZQL:DP,SD^]#(G\4$)@!":S#8Y<\7>DE$+#SRJ
MN+EI-[NEH=%..1<F^M;+0RM;MY.[+.0A&0W'0RKKER-G&'W^O_;>.RBJ]LOW
M;41! <DY*PA(EAR:))(E2):,2&R:')J,($&B@( 2FIPD0Y.#9) <&VR@@29G
MFM@2C^],S53-F;?JU*TZMWY3][Y_?/[:M?-ZGN>[]MIK+5K0KGU=%O&.46];
MK7,<?$NQ.GQOZ6F(ZX?IV?< /3P< /6]_^RS_I^T7H[=J@7^T>-F)'> )V:A
MA@D0!P0?E0DD4O-Y8QK%QS[7*JPE>+#XQYAY?Y>$M0'CS!?W;1E44UD#[V6A
M8*(R9, GY/ZMI%+='WZ)2&R>/&WF(X68+?6\D5VRAPZ>_[KH]'&.%Y#1$GC(
MO$H?JC[NSYLF-3S;('HAD7F=9]_<C-_*=R&K!:#WU<*Y^3_E48**#!&0D][+
MA;3AYSY%]K4!:7"DW)?'P6I6LQO]*P9 NA_R:*_:E8\)B#[B!LKB119M+$ZI
MFNDQ %$5)+U7PG&)>^-T-!CZ%J]XX%JN!$;*=\N^VS#N#S]ZF7)KL66,IWS-
M;X?=\M_'C9+U*^Y^/!R5; +\&\%7X]>");@-X5R*L<AW'?YKH;-+==;77&I?
MCA@J$7JS'C4PN<O(Z,2L\ 4#R2*37YA#G=N9V3,_0X]T>^6ZJ<==V6YB2^SB
MN_-BRZYFF;:NME+--^%VS\("M2Q=!J4:L_'_+KW.%2D^4T'P!N+]FN>FH+@2
M:?[;FC+01D;KX25<M--/H>KHH, NYBWS-%NL&J,R85=A]5%_#&S$7'?FP4:$
MM]1J8HT)ZWQN//9#?ME^FLNTO"._*ZO!F=MQQ\#^\]\7ORVOQP2''5>!X-W#
M/\)=]6]6,D)\5 I,Z.9IMZ9]#\F.]]-'ST;QBNGB-QN88HTG_-^NS(/2I0B1
MD\?=7#5SBT9?$U];6!J>"6NB M//H\%TNG[NPNWIONR9LF,#<B:K[8]P2C&[
M.E/"-X*J59.\3UK:&YMC]Z]#&_OX ZWBFW&4C "G#L^K0ZJ?-FAETWK^]QY#
M8U%&#)(H_=CONY(&JLI&8C9)-R:";F[]V;_=! _55KSB=3 )I3L(+BZ[$3PE
MUNJL1'M%'[-^^LU=A7D$7^]SXQ[>W'&C_>HK)>)-9FBKT]6B@R2-15"TZQW
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M02F8Q>P%B'LOI?2+R<Z86BP6CJUEUTML?6G2[>-=Y).9=N:=+=5P*\H WXP
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MGM8;ZH9A0UL)OV43!JT&A<'F#5EF9][[797"]&T=PP"$Y%[;9E_3>!HB_1^
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MB[0$%"4)?0([VS+KZBERXK^G3PKVT]<O_X[<:<>9G'_S'C04X(5OGXF#+=#
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M30L;0. [ -YWCOK*%.8&U]OS=9E16!F0<\2R.//=^Z;VZ=47"ZU6ZWK,*V3
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MM[P&[!:Y49PQ+__5QO /__!_ :*[7_\+4$L#!!0    ( !.":5)G=[E&-+0
M 'OK   6    9WIB=VAT,V8T869T,# P,# T+FIP9^R\!U23[[8G'*2)BO3>
ME"(" B*]JT@7D ZAJ8"4"$@/-2!->A-0NK300N]5NH#40)#00^\)-4" X7^^
M^>:>.U^9N7?NK+/FKO-D_=9Z5YYWOWOO/+MF9>?ZS_4B@%Q-254)@(>'!WA[
M\P)<SP 4 +>)B(B)"&\3$Q.3D-R^<X^:]-[=N_<8**G(J%D8V5A9&)F9'W *
M<#]@?\+!S/Q8G.?)4R$1$1$V;DE9B6<R L(BS_YZ"!X)"<F]N_?H24GIGSUD
M?OCLW[RN?P(H;M]J(53"QV,'W*+ PZ? N^X&L $ >(1X?UN _[KP;N$3$!(1
MWR:Y<_?FAEIRP"T\?/Q;!/B$A 0$-[M^-_L  @I"RH="+XBHM-\1LSM3/PN,
M_W&;XV5E!XW.&)I3^+W+9Y([M'3T#(Q<C[@?\_"*B(J)2TA**;Q25%)64573
MU=,W,#0R!EI:67^PL;6S=W5S]_ $>WD'!8>$AGT)CTA(_)J4G/+M>VI.;EY^
M ;2PJ+BJNJ:VKKZAL:FSJ[NGM^]7_\ X?&(2,?5G&KF$6EY975O?V-S"'!P>
M'9^<8L_._](+#X"/]W^O_U>]*&[TND5 @$] _)=>>+<\_[J!@H#PH1 1Y0MM
MXG?.5.S/ F]3OXS_4=E!PB&L@Z9Y[S)VAY939(D+\Y=J?]/L?TZQS_\NS?Z;
M8O^B%Q)P#Q_OYO#P*0#R@-/SQSD!=_Z)_PTH$T3)ASYQS[IO83$ [_&T W'T
M/'E6%5]#BP]8A@$\OAJ.0&Z)W+6@F%ZP!];4&SY#SA9WEW^Z4 :L!VU;O,0+
M#'Q.2*W]KV'8VE8+_[C2W)+QX+-02OP,X$ZEN2@&JIN\#$3OA]$,S,S-?O@D
M_\7*\BP5L*V+&@F)J7;*EZF/FS.M^A*,* VL^G1?R\E[MX/@EA1C3P.Z+*QP
MQ-++JZ!+="A;ER"/_$U,!I]3]L_L6Q&/_QN(U)]\>GGX>IO9-C_CS^)C%E71
MR!QPURL,M;C.IN?G16 "YQW)Y5%/F(92+[^61E/EMXJ(M4?A \=XH??EI9:O
MV'S%JM$4;6 !JP:?@JW+E(IL(BT,I-.C*<'NE,I<T>W@=J=L"7[")[Z6+6$+
M&9QKJ$0;)UBOC['H4TA$E,UI3EN(19/<5T"-MB* VI !@]_9Y%'Y8V%A<%W9
MB[":?C7"0.<I"3-^Q 'D\SQK#>8U$'K24F](1(P,GI7H6['%WVA:]U5?-N/H
M?&>B?Z'&(;#_3()AXMYR@I1AE*]2Y:0_#8B6L2ZPV,PO8O7DVZ-$\*PDW\A'
MP])H)7@OV[V"B?QZ Y-(!OH2025]R3[48WS=SBO^<=]W;T^;9*I4;\EUFC\+
MDX]V-(R]&KX&''#.0:;ZL%,5;_ 4J?][N&T_)Z1)GW\PIK.\LU_RY\E97[+C
M&_'5=,3G"NM[>32RMV5M\6QS*GTUEB[8R.UT7GA7^488LTHRJ*6[+XX23=(<
M<G=&WV?Q[/7._%X\.S?;\;&47+0KYL5V1[DNPI]VIUZ<E7ZRW&T&>Q;[+.6E
M7]>' %GVB /!, NJ?2?1:5]N5+!1K9%1CCK\-T?EZ36 \1@)>)P3 7A<SHNQ
MB3Z.YD,-QV:;J.3TKK.^C^]?%MVJ 6@K4O^GAX%@Y#5@10/1OMWK= E 3+['
MME^]F@-=M7RX!HR2 KP,=V:N >QKE=< "\MKP'.:W6,46[43+C*U[](O]A)@
M6&NJ10.K2:&24,G5^=U708TW@%/"%(.YNQS A57F:O/Z+3;-K.LS$>N^XHNM
M"MWG-&V5*#_'<Y.9PNYPYF=>H-L<#]XY)QX/?9*G$SW"^(?E@DZ$5"_36&;C
MG!RC]"O(1@- \SAQ&4,Y1KA-&*O)3*Z E"4UWIJ44Z1H+ %.*;)3:G5[87/J
MA6+^[VSBUPD 3DM,"81Q<;+45_)1*Q14;[#)H!)=3'C;Q?_$.?UPVQ3:L\&F
MBZW.MCN!8$[FC08RE;1H9G ..EDD>_I-I7%!9Z-$AB$X690@(Q9?X\*QW16*
M%.%DGR&W2EF3%Q8B6-_P,=#JF@,!T>4]3+&WMH!1J2&-OT)F5XIFVB5ECE"M
M'$L07*+&W:L&MDN2DD&Z*\WR*P+(46: ]#4@,I,7X2NXU&#RJMZSL>F;XEJ>
M]6\%@I7[WY>9SQ&TT,6++.P+2PRG-R+?"<9?9=K<SP.H!"3QC+H?P6(CY,GE
MEZ@<Y%_7UH2N:[>]9:>Z5WQOV7-=>]N<LB6EXW0JDWVR3-")=K8]A>E;KL)F
M2*\R(D#05P##M1[M>RM%ZFOPG*.M59+27<OH6<]R-FS8HH\?5>_Y_2Q6*$1J
MKC\TP4[]F8O<YJYY](7<-:!?6O[XX!HP7-$F".G70&==NK/]?D/L\P.L)(AO
M=QZ:#_(KW'HFVK9$VIU_]D83<#KD/'\G2 ^;+"K=3FFZ)8;I$XJ9I^\/>>,\
M&D7IWUBN,R5: B$#.Z[K-Q+T.9'XY9:02Y'!O/8_.[J/?*D3MD\Q#'H]?B^$
MH[KZ3>E57@4#BP\C8!BM_$74["XJ?_^S0"V#Z%UJ I.6AB=9 E>M6E#1,5^+
MNDE^'+<7;!,Y-YGU!\50'R4P_>RG5;J-S/D4<?8FV@Y2DX[PF+=)HI<XY!18
MV'+METD]&KDQ]0.UXX7SE:QS(5O\WSCA FQ[CSPQ*PINW$C),? V0HQIW0&W
M]V'%,OUMQ*;;)5W/ 8Y3:Y?TPZ'6Q"[M2_*/3D)*8GN<5/!1!/0GY(S+0/YX
M'G)Y;PJ$LCBCK64[7YS 6V8CZ8N0,5X:_'6_5A36GNX[F*TPL+!3MA,@?^<S
MQOT:$")/+M) 9=0T(0)34C2D$VS(]#I_2S'>1#:]?*7(MW!^)FJR[(F+NB*_
M!I3GXA !LM+=3;(G[7E/@/Z5S@5J>A5@?<T#9;PJ,C:U0Z= S_.DN?4O[!-.
M^4T))+]]\MY[DTN4OZ^_!L0:06;9!EHL%K5PH;Z&-]Y;!=G0PXO%H"6Q04OO
M*&XI,.YR9\LYT<QL0^X=1YM";-NC1(4*<_9B) ;R>/V>$JF<3]%@%J[4Y(.O
M 7-:ERP6+P1GB9$!,BE+AMVD6CJ3^RW<*#%*^^37%S8 TB7-VQ++GY7X$-OK
M(R39;9<YM<:E@4;O['P1^)\5[EU]: O*OA=+ _E55'P-F"JY!O"BVP/GN<;=
MJ!%$^6X/!1\9KG++7!@V@4NN%#4,KUHMS@RCKD80M)[QVTI;XR0#@WUI]!]=
M]Y^3XY3:F['E-X?.%O9D/6$ J;'O@?GZ.I.DOP]@6$'*SD^\M'-N933C!/V5
M%[/^KA]W:#(*G$&6S8#90_PXGN<>%7M? W"1WM!+;_5K0#8C -T>)&5>#\/*
M;0V/Z#@\ZQN^7!D-L'8=P7\0( _TZY]JH\:]&M^5KW-T)^73^5@U*[8FT>N?
MGCDYYO\ON0[AV;M_QBK#<IQX#7@)!!S+,X ,S=G0&5=0:X>3R"\<3^(7T[,Z
M6RXZV^A;,%/!AD93H@XZI)KO9YCEDU:/.NX\O7T>L=/&#FX3),1J.JCN)J\I
MO:-V%I_[(-GKUU J3V+G#8W"R=J5@IK2\O.17G%_IK-XM,F>&W^:QMGBRR\N
M1(I&FV\;C]:" CV0(#*!Q<"&SRH=??!C*!;>#3?W?05O>>#./7YT]OZ9J6:#
M0=QA",$1,7[^6U_2$'Z<$VK#<KC[-I&FUKSC\1_P8$<;,S:R<-!>$+A@! \P
M2'B@\$ FP*]Q^SF#.1_:(#_73F@."P*VBUWY*J$F?ED=&GH?0!/D\:,,-9;W
M&<F(P(J"- KSP[1\;HY[RA!$2[EV)>8:T,D5J6VFMY7ZLH&RZ/V%H43''+Q>
MK1'3NUD+(0';&-]&(6Q468C1R3H3>).;_N0./HIA.E,M&F[G^=WJ[-_6*4H)
MHA9Y%YE]UDIPHI@"J&"DNQ;1-IV\0VI_UJ_FY35%"<F^"8/8L"MFL)8^^B3+
M-WZ!0K9)M?>'^">R#S _LI_S%.CZ<-IUS<"<R8*0G\],9:+ZXQMPW1=OB"W-
M7V":@0B8H2I<Y,]>3^MOZ"ZI(U1 XLQ%DNW2^_@<YL>?U,)FUV:K\[C-X6#Y
M[M&(-V!%=ZD\I.SH,2I1?8:CDVGHF?RW4B779LEAT/#5;=!Y K89B#Z:$C8U
M?CEL><CD_+(\!IKYN7E7H4=JY$NR"1F)W;#E)TNIC)_3E,X3^(=4V/=Y6#\T
M:JJ#S]7ME&A?M[D_TQ6>F$!<9XO?6%C6OCSN=+ZV,)#_+Y<!<OY8[FL EZ#9
MN?QA^8^2]:S/D .=XX7<:X#4.6. G!7VYW:.KTU%:^V;&(Y0CYG>M?G9J\^M
M6JBPR./R^^"7G7ZT\\I-K0]?%Z;]-L5/]UEKF>FI6T81]_GX:$C>JS#^@FJ(
M<VG6#K?,^E&N@DU93D:'M*7E_3%6]"PT2XJA^7JK:!@/MX$O;H)^C<9*@$[.
M3W+O5](T-'E9I80Z-$<D7>3"\S_Z\F-D%V)D[G+8"RS8FXVJ\J)-)#OH]R/*
M2\":!^L=AO7S')..@H*$N;\XHG]K]WHD$-'A5>X;6U3WX<+%(<>8*Q&\]38^
MM$;;=XRE\AB53GNR=-0'+ZY'BLLRC*<6]\#L9+=%A[H9DW^ A[,\MG06+<=;
M!OMPOG[H/;^;4/>B_--$^>)XS4SD1?+,O=MF(Q799#<..5R-$>QF[-S>A]B\
ML__YPH%<2%!R9*B#.W#^>YY]$_2S''_'$NWDH_9QQUPRQM\*(M;A^)FM)0H=
M2$0C1L!G\%<9G<J895QAS!S=[V\7Z<Y8UN,A>Z1B7>3%"]ODN@(#!0)-H#%0
MB;/:\[V6/>#\SM^U#_\IT:C%9(3-U8<7P&O8=E8^K]'&&#M:O>V2) !0QR1-
MCCUGY5^T /B^0#/3/34RLTU4^'0Q;15_=2*4OG,"LZ"R9:/"J>8-%:3-T8Z3
MA$[+%+$YLYE]I]GZ^H8X"PQ:JA'+NC?5Z;V>)&<\E\FN0ACS@F!Q+6?,5W39
MB>0/*;=J.WS?#8L-*6=(6F9-YQE9-X]6!'SR9\2"/[:HBH<?SW1 2@?'ZI;8
M62/DSR=&PML8,.)1(F%C;NT[?TJM>/>?'#0D?I+LO14?V]M\_A@_'"T0C[IQ
M#EL[QC@XU\43+@=6'HNUCXEA9TK$LDJ@"*<P<TEY2LB2B+&(?N-<%L=P7)G8
MQUX/;\/:&S6=,%1+K2/1B_!R5$,$W+@*WZY?*'$B:EEBQ%>O[HH&DUR=)Y>&
MBG99V-E),_YH2(A=Y@]0]&:YJ6'9R%K(4",$*DC(24@44CS55(#L&P2SL&WL
M+XPFCI'11_G(FG&-P=HZIP-EICY>9"6TQD0 UJS'W,DHP"^W53#L0$61#<LY
MVYTMHJ=,<9+;/<[FE&BV&-R#!+LF_WIH-$^>0.EFFR+NSC)ZR'N.&F_Y%'*G
MY044/,]&!888A:KG_E[#)B8HW9>0L3PH2^OSIHMH45^R&=V)2:7=XC+Y7A#_
M-92 [2LA![.ANR+ :Z'+XAZVO*-)3XKK&G!BBO1U'%GKX3L+<NY?+"0^+(OM
M.6DZOHKE3PZMDUY_&<LU$=4L/ NX#_J1$R!3O13[N<5L\>V)H5:^J=VA:NLT
ME]_V=F!]UG Q^.*GOQ@FIM'&B[I)L8:6K&WN=9FJ''3UA-FP7/LY\Y]K0'"M
MC%AE'J/A2043GK#\5R*Y$X]UN3]E;$O[@3(VBT/V!R@OM[1(D\W7B<6_EKXF
M)B@/FC?>B)O2319:;RZ!"4WS.1FI D[/4*P]'O1*JWK*]^)HX8NEUM60^B5_
M[LSJ96TDB<?1\%S#R++9+C5>/Y;M9[+<W>IORGRS"Z9U%VE%DC9.!Z#2FT9Q
MU=?.&A6MJYFF-:J4'F_ZRC+!Y#O]TU]] !Z:3E\Y+&0YZY;IR.I0KNG,;,6S
M$K7%&"^.E7+KG  *SX]FBT1]$INI/S'N=>U^N1K6V9$/N3I%7&3A5;LZ3YT#
M7$#9-Y]2^Q+D,\YXT2A+J\5/P$_.<'Z(N;S5^XC)"[<5%NN+OZQ%#XX9U(XP
M8Y_GETW;&;!V,:*\;[*ZW>-]28W7#4[K.)V70"N?F#<@3I !SNRM);3/NZ!O
M9/WXV#JOR#%KB?D*/^9 R4*;G\J3HQV_?^4N4(MB\YV"WEBP^M(U(+2-$^T9
MN2]8(ZLV5C,SGF/=R)7W4_)(#MIJT8RF^Y+81S?//7X,=H!^?:RBPL5)#PBC
M/S^?RK^A]BO"6O:8\]>927<;BM$B'5?M<JL_>*012TA_M8Q'-IF!.KW-FY="
M1P5^7 ,4#I)%^O20  *VSOK'V62/QEHHEJ\!M[O=+HG-*],T2+_21:@7GIQI
M>-P44#T]F=GGO=4^)[O 5]-KA,AX07?MF?HI&OC8<T(OFQ[!6^#FWM20%F\#
MJ!U1"N6MMTG3ZJJ)"9_N*VO6;KF](0Z$=I%%Q.?D@,L(%>GO".0#R"[6ZG \
MB_)?FBS"/^Z+0B@572V9J)Z\7%-Z\M2'(J9V1^0-GE$F!^N#A,&!4<O*9Q*\
MNYX< K/G;YD1-[ZS>$6+-<'@=V8^3#&JGA#Q3'W[JG /^U93"VWHY9R+/076
M@=0OS?LT0U_4(KOI?'TH<VGF;^QW/;B%*@\LUK\$S_E=E0$WE1=\>"KKO&O$
M1B7'K+JL7]U<T6QBIC94357GD<X<%0\G:KT3 3AL=KH#[C,<6WB-$6MTY(\R
M-S;AZI*G9_B(?R6JNS02Z*NUZ-/X<?Z\UXQF1;#6=8U-<P'1*G=#1Q;.1BK*
M1@U*EEH+]R,M^V$O=(%ZF:7P4RZI,7]#[G%[16,-QJ/(SIT _0UYU_8YL>SI
M6\:=C;^2XTA7.1.8=V]MYB6B%%*UYO<GPV5YEC3/OV87LF30+AB^XZN1M^T\
M6-Q3/R0>$,S)C,O&#]P=;_6. !05\!_8C9;E85H7+>9K%%:YD; Q10"U]C_Q
M3_Q;8-I64HQ-[C4)?PAW,!\6,%#R5^DKL-^$NWHHZ9?P:J_9M2NZ%N8T9'!W
M9W(A.*A,[)(=[N^6SOSB.!3U5,(H3NY_$1 9W'@7G"TM9O/$]?@(9AU:Q+0+
M_1XL- $=!%W,F+%HT/P"9_52V::F&R2C%1\I60EF"F\&F1@B&^K0RUOQ(9R*
M:^SU+_UXS4CRZ9PBWR,$$K^B,BMG)W,:(RUHOJ)_3M;2QS-\"XZ1P<UGV$>Q
M<F'X=YO-@+9H)O_LQ@?Q1R.BZJ3:"X,:O\!;O(CFIK:(<Q88S3#8J4<=UL]5
M@SZC<S[6[-LTF7KVS>'#5X#:P[=D%:50S3<I3^K%\X$T[W8?[(7;EOETIE[V
MMCNY<V*4&4(U I0SE62W$.WE,QMBGU7QO$Q1$GVZ>AM#>B<>$]]0=DWFR*O-
M<D5G=90\M6S6#)U2T YV1+>9[?5:+4X69>0^8\QDDR)CX2^/+LYD=8X55Y "
M(_4YL\O2D%M3XH5EQ!J8RZ'>$I;6R5(>_/[5_=<KS)<@UQ[SAUDO/X^K@W,2
M1^**%C*)I-^G5]1RB!+5O@^5"RX:*/;F'XZ(*#Y]S_]T7C7P2TNG_+TIECSP
MUM:%T6?D&I(>MO:>]D6<\TA140C)D#A-I;NS6Y&:4!K"A&6.)@G%HJ/!II)\
MP*GLML&6_W;S_!H042NMUU@W7HJDE1'_'KLV\3(8RNK'OT4CY+8Y<>(@=CIF
MNK-1:N8$3%$<;9OF5''4I%:><;Y*REJ"T)B"#%-HZ^,4"2H#]!XI^7FGTI T
M2$5:4?:,1^LKMGMEZ-,,@:N[/:4 =1<B0BK6G&S"\J,(LZE(]UW^=VG:X[OC
M\Z;D8Y7<;!EZ3VNY:;BF?D=\VQ)96>;;;$MC&:+Y#0[J$2S80'B>:"L+(NGO
MJ69*C-BG=;9Q.OC/6\B)1* X0O6'A; 3+;**9'8.=XT&!,HKM71_Y#1&\W5/
MB5]QM,&M0KEB%OP1IBN[$NNI6F38U'7#B;+=@E!.%?_-URN77@7H8TJ'HZE]
M:N>O>>-:'E.S[M2&)':H71_=EH8P+3C,ZD!+^EM0['!-BRRJT5U6R4SJ?/IM
MTVOT]XX^8-&2O:+8.846FU)>@N&48D&8KB)-G_T\[\1NBY);VEUIK_1EIV\J
MG,MRM4F\.H6[5-['2R]Y=;=V/$0,&<@BCYG,WO.1?NA\?"\,T*O:MP4JG-@W
MU(3;-+^]'>[Y]A0J)1RD>OPG%5SLSL$C6-UZ3KM1QMTU+]8X*6J[L\^_%&)E
M^N.YBY9C0;VO<OFC0&CX@%/\,(6?AE[%,8>H!LQ8!%-CHXK0FE,:HOD%!%UQ
MQ,/RLU2#@;\7':,2?E)-,13Y:J! <VS:-375=:&&#?BL'[P3 Z3@YS6SC?IM
M!^9B"4&%>PD'?IK%$6L[^[YZI\XP1(H=,P%NI\HJ\!K@IT^JW)-:ZL_IQZU5
M59_4<'>-DF19KB&OXC"Q"M2VG"R6;CG$.3E79V.CZ"RXS*+[ND6E%B;Z,#I&
MO%OUT@54'6J[]U UY^U8PVR>)XWHX^&,M.E4[6YX*3)F.W<L-J?1B1J<N:_8
M7%]?4Q]JD'+E;7/.^,,=M>NDDDQ5O!FG?"\LB(D2DF'ZJ98ST<SWM[WE!CPQ
MJKS@W#8&%;'FJX[RJO$3&]X;IU^Y4+>DM F,.BF$'<O3::Q*CG_LU@IJ4,5Q
MM\_?R.J\-B8H9EKY=6).) U4Y>1:DM.X3PXND"57OM6S;JXB$>WC!Y(!^3\Y
M(+@&_$%<&:\SQ>P/BBB322JG65U4:C&I/?LT6=N:Z"'-R/>]'<,UEQ4"U[MX
MH#H8+*1V^U;">O<4.5B.Y:T"1:I&.[>T%\[6R*N];4&HQ9K+IS7I2EE+T865
M#A.,G+P FG50:QJZ^>"M3\'LP+D6#G<&Q$-%$E"&R"_3';C"9-:<HAWD!$=4
M+J] E?^6N&V989<_3Q/"8=\<-?\8.:>*)SQ,[)LZ F\Q1/&;K=$R.N1%4KU=
M_7+UH62K5@!>EVGEYQ^I;;^?YB#-,DDSTE92,@WV/K@&:%=_YONBI$U1!<W$
M39+=Q0Z8V9_!!!8C>.[LO?S>@1O2FEQ#K=2JU$?E01E=Q@9!N>4YC3/MY+,F
MV+H%%:/W3W\5JZ?O,11[IT0Z$34@-1-M6+HWN[R" S,O>RBZ)I)@R&O @V2Q
MK[K-TS-K[A,&K&%%6RDI5!U%?_BK>[-#7^\Z]=:X2]=5PFT:%>^-_7C+]*-T
M5:/();6WQIK,;K1>T951,+Q,E(UL;DOX!6.+9&?!)XC4;SA.'V6F,[GG(-*L
MRJX0*OU%/AED43R!.('_7@>?BT4:^@YL_=HK++-XCODTL<_8>;*P,Q6$]<8_
MF]10Z/&N D=H_,U@ORYY)I!<.K_LTEMSWBV<EXIE3_74F'&$VBB^VQ3W?YAZ
MZ B%SKQPJL%AVC0APJ8[%N0"D#K%TI,*_L:400'A^&'A*6IE4DFQ7!NGIYE2
M22+I>^4%A?N%I614VW#;9')3$V7F-M#NV6&4/PWA21%*1%LV.0/$7QEN-;\?
M=.H"'GIMJZ8JMSI"<[N_SV#*VF\X-6+)K9P:FVBLRCKXNCK>\FV9>GP0-K79
M%95V84$^;><R\_S>0*AN/Z_*RGW[>=H<WR:+B6')$ 9%+1-9,1L311?OT_!:
M%GFSH-<5M9_M'N'?Q)U^^6@SN !.E7^K(!=JHN 4E!+S.@XB%?923688>99<
M^2E)6>,1TF-Z9E]\HPS4Y<_9@*CEV[;[$4ZYP*1FPYT@N58%:S$KMY>*[BG(
M@B+5WEF>?HL1C@7FAQ1Y-%-BCKPLN3R'W&IV//4,N$+VZD],BFK5'S\0Z@4*
M,=DXX\L<@++^LD<-@WGU2%F!<95E"<N&H+,/7S\=)NT@,BTSQ=(_IGKZ/=G_
M,3=F6A>"6BZTJ,N".)V *D==\$[6FA)_#BFJN12<63DHM? II]Y[7/;0UQ@V
MOTTG)N68Y2#XM8_ISTU4KO_HSJ+)IQX9[8*\JQ?N2<9?'7^6VKBT3@AKNWQM
MM\PSX;^[.X^T6W/0-M5C?8*HM<N3DDNACGO8NZG*<*FHE8?MM'.WV)DSF'0H
M(^E,&A;&PL' <'G!EF_+&ZKYGC;5U?7S[A.&#TNQN;JU&,9-1K\\*NG ^M^<
ME,Y9P&!PEV[%)'L-P@V;;7P?7TGUJ@9!FZM:UK1'V3<6E6YVY-%:TUZ$'%-T
M;DJ)J#5J>874S+)Q$B9KO@F5E\[&NOF\,6/BY5]"J-//-SST#.F<EDF59H"1
MFH@G'"'Y#_ 9N(M^[ME;D(.+KP$:B!_P'8>W2?G:L4\S526.87(ENM^5VPK8
M+')_K9?%S( @"C>NN2MWV'U@WIN"M"XUZ).>X^QG]K.OJT:=U$P0913,^!5O
M2\BJQ0[DOUM;'63QMVXQD^C*-#03U;P&.$]JFP9M9_+6W^7JC29.]C[[:+2\
MF9K8G<G;- :IQJ79_IDM>L(U; B%(HK>%:SDE.ZOJ??I1#&ONCMN'DLU\:5C
MZ"+D*W/J5=Y1SFG*Z<D2*EC"MJ\!CI_Y%=2B'WY;E'F5[N<EDLSJ*-,C8\TE
M;P.[%&N<&#/] $.Q4=F1][O*??]0-_"'K"6Q?SG WH'#!"-0D'R*KU%#ZY)I
M138L'-1KUR)RYK4'VWK9I^MZXN%Y=&/PGS#@:K/V28&=HUTYA$5UM8TK^:?[
MLO;SD:B9-)CIIG=&SLQL5G.UQ,BRIA$PW*+^F\+37!ZNLK(9.X@N+*=*1K4T
M@TP5E*?H=9= T3$XZQJ@_P$,ZA&7^ETO-B6&Z7(E'\A9L=E.#7GI>#_G#\*H
M6+NXL'Y?N#BG(5JWN^W1V-+AWM&@R)<ZO'FM _NQ\6,MRGG5>RF,#J4>,<_,
M+-+]A/70<.VUIOJB=.>)5;E7&9<,<&W3OE"<NC/,7AP![Z(&.67D"X](K#\J
MF<=VKIEIEXJ8<#7%WV=(D\@_MD\?%OL#,<_=F53?.#*[6B[/:2B2L2C>](SO
M@=E5=C&E.WY)/%^9W*<"YVBP#B-\)'*_:?T23+=$0V](^SW_6)CG#O*(.YH=
M3>U)>?/=[6)]('4<U,_^Q+7WTT:K;#$+?K<X8QT,8O=$B-V$HJ;,Q36S/4GA
MA^@0I+HQSUDO+QN.K9.2>IQ3)?4/^UZSNG;_#,_\&C#UZ$H_5Z\6;-4P+O C
M7%T%4Z'/,LR[B;,=+G9,3]AQ;;]_#5C!Y[YT*VW]1,J!(LS8DU/]PDE6@)Q'
M&V1X%MCNDZ[P4X<<4,?#T<57$F-EQ](@X]('SV85N=%QMYFO < ]?8[C(K.-
MO5A>/>CQ;9'6C>F9LC"A$F!_.8AQ<HP9^%"QKSB.>#/5?:_H)!9@A*2[W/SV
M +]L<OE\2F-)EG)K2KU5*DK14>!;LH&D[/9WN Q'<4^Y":PG-^UQ?K]+%SUN
M.T?4K@XU'U?;MASAQL<)I6^>:/(W]/-_=25<>T$4F6/\V8.]PLD_::/N2_QT
M9WP ^8.?-+&H#,!VDWT?$V$FQ[?^S:-2:?41>J-I_F_CP?E$D]\J1@[+E"^V
MA%1+"O;]Q&5O+]S]DIYN$JF&,)SY8:*I'XM*WZ:]Y7N&#YTMV[L&7+V8LCCN
MN0;$EX$ZYQD;JUI2]":,F!I=0Z[V0-!FI80!\*AUJM@;V5^%W<//BIBDISD=
M/D,EQA(3ZH4=YZ$LZ)DK&7>V\SWY)&U,Y:&,/K2'YW*TEWA5-;L/Y42F[$PM
MQ99>U=_._X#^$J1L-.;.1K$99S[XL2XUZHDSK6M\EL5 4UJ4LT"N_<C(K\/Q
MKVBUB,@U('*D<3J.P IP:SF[7 )=WK],^H+]Q@-KS]U.8!2%X,$="^NK =8/
M8F>KH1#>,71]:-[8;D'F:M#<L-Q'C]+W28RN.G8+E9,Z6E3 M&"@]N2<R<HG
MI&:"NX:T@=#Z2#V[RJ_S]&L ;W.Y?:X>>C[N-\2/>H@Y:!;/C.RSB,_E,Y^3
MUCK;9!VQO0?KB9M&WOO!HD*EXG_X4TV4(4_?1O'(>D\!820&=JVU%A[05/3D
MNQ"=*+/57 OI D=LUQNQ>=JZNI<$*;Q?)#>>DKX%?QY ="F."_ 71*AF<WCG
M?O8ZB]T&-M6%%(*D=J/$:6/JR%\5CCO2RUB=CM1:M*)I8Q"Z=TT\54\RPGY;
MCJ! C.X\X]H:9\U>IU(E;\J_)"G3;UHE'<V8B>P)=Z=$%H*9=M5CY]D38_I:
MK; @?0QA6_P] ^!KW9F@[B@L]S$4N,G8C[9&?!?]^EG?MSL_[#<9=ZL[*VUU
M(QPG>X].B'[--"%X8N -5+7'>,M,0K_<7)1E>6\;:K);+-E.:QJM90%W*V)Y
M_USAM?K;>]> 4%[8T:CMO'1]<UT2*T, )<VGY]Q!<&29,1;H9]E-5Y\ZEYMW
M3S5:?5D^/A]#%^B0"^].%2VYS#?R;7LGR18.>RBE[5RPH.X%6K/426:WUY_P
MGG/RDRE5QK!4I?H(2KY7M-Y"9N:6I+%PO_G,1S\\5\4<U\5L4-:>M\U8D)@7
M:/VP(?+2?L6W'68/+G^1I3L*:QNAW6[^U* ]@<:CUBW2I @V:]K^PS=68N!N
M0[UKN[G0] SG:ILLQS2^FRMIM(K/T3[@54BC%5H+>W:)1YL2Q_Z+^+T>!%A?
MMIG:6[+D\(SCP]H>CSSX.P/@%M[V$6Q.65$J)22GRGW&F9FG_C(9H,=;&<7!
M(#U7<PWX/:['I5.Z]5+,3K$\16MTS5?L!6:XX@4!FS@!I%7YL_R*;)&_/"(/
M[1A4_,>^GHX.4<Y8\_K'MZ $YWT#'$^N/2UC#V[*8(C9Q<:24K($)@&TD_LR
M0J:9ZY:'FFI]Y&K.TC ).U9?SD/"NJ.[0M^*'</8[OSF]S61VJI420UNQ(MY
M>E^V</QCBW*VO:&KR<;:HIIS\B=B",1[;+R&W_ -ANVDK?QV #<?J]?)IB'P
MD^^4_9!C9H&1MSY=M:K:EHEHCMG0"%;]2+[&B\V1]<-EFH>XZ3(+7Q1BM2D6
M19[0^U#T9\<K;@ N::-].IGI]#)TQL.U><!T?2K?&8A(*>U:9MLU89&9[6W@
M.P20#<8"5SL'4M-6=TXAZ#Y_.9HYB4/0OF"(=#[VN^<471$*I-Y. 6P!9<63
M?R9>-IF7G=#[@S3J7L <=-3;X-M> XXGU7?%N^6XV^LOW".F7U#TGU7KS&$=
MUPTQ.G[%"$7XP^<1ZI>+$LO$,@C<Q-D/'M$]:,[,KY456+\.-=S>P1[1YGD@
M[*M,("73I+$:/-H\4ZCT>#$]RC)VN"F+?!._AY%9T(%W']_WHS?S<;%4>Z!(
M1_XPTKWDLE# DO6=I%QZ:LQ/<)86^CCOC7&L&)VU;9JCL42??(9"N@W]0'KK
MROF& Z,.5"JNA,Q#U<&S+E/)(27</994@R:YTA%X/S#VC>R7;?7E\%0-']7,
M:<_&5[83I](--&+Y4'!8CR'MF(41_U<A,75'XG)@6@_P4=YYS'>Y+-LI/OO(
M='))W=1Q@=0B!FD>D)_;TW20%-7G-6<-X+:%L*5:&X9S:B,U]#LU[;ITABFE
MQ/F41/N!GN'ETC4@&W&968DR=ER.67YA],,R%"(LP9;Q?@MH7@]:YIY\4K/L
M$OFY_2D UW!<6F2LICIM)IN%H\II=H$2L]H!59NAD'XF5GF5F:ZHWT2K<0YR
M6%%01^GN4J39V>);F_'&BSGY[DSNS,=.N\D#DR;.ID&XDH:JFIC>83XC)8[P
ME[&=E<43CWD]FUN'4^_H.^N4)6K7UHZOXV/P,MPC::,])5;(=/7<32[VR>UI
M@0909B!8M\O%-=W@&A!9XZ#P9G+G0TV=G644;H6B1VN9GVA9MZ(N<X!]ZA-%
MYR*EQ/ZNF4AQIU!!1GE9:PRS$FLI%*AVT@0_2SG^,X0-N5T_YM:@M\(11U8^
M")32N :$_T$J"Z10(G>UUYP89F):[;/"W88L#-%[R256:UN/Y#[ZA"K3'Y<8
MI-9'O%=YX$3V6/%.2$O'J'-F+=.8]EBK)P2M(6I4I''(.>%@O3JE9-5W%8\1
MO^0@K6U[L["'&&Y%\3NII!IJ/*.KUDRH=K^TRV1'3\X-'0%[OW5*=P.J;(KZ
M[$<FV7I2VU(_VHQUAEZ,$S%?,10T\DJHJW-]2/NC<U)#HR)@->,@4@[1T2+?
MBBT%$PJRBD9G6@^4:X9F3T!64I"7.K!Y6\8 -#/0[=-W@># "![6HXLYIC<I
M/VG/O4V$FG0:8SDXJ)=Y[12YH>*+KS<1B5_S,N;DYEXST-0X+UU:T_/*O&/&
M^\,*>0K2W-)&:3%V4#+/(+-=E%\'-E\#8$#Q5-*A]4#^G=<2+2%XMYWC7FQJ
MH)4"W?,[7&5W'DF'R[TI?2$!Y:U8<6UO*4N9?_QNJS@^W\D9J;52:^&5L7@-
M.(N%S*@-HO,1M8ZG6=,&JBYW<1=I-]D\%ST<#?G@'ELS(^+O!1'D])W>- :R
MM(?[RG/]"E,4#C>1M,$_GVSL:0HWGI^I%M5TUDO3,5B;MF_'ST9PM67]3!DI
M_%EA^E4Z7O,Y4RA?7,2 .O]=C:E=Y?T'<:5!F<J61_1EG9NUT3:=R&!QH-/T
M7H9''V6%=&.1""FK(CKEQ!W'Q=!%]-+//RF8M_B-9WU/U:YE,8S8O+CVBH7)
M3!>^]G;0D^4T]FCF6XR.BG:(O#EZK^0=K!]FNV.6GFQ-/W!^O*LOHD4*HC7G
MKD_P\1 ;%2-HI$?* ^=;VC'Z!3^D9C;[/1U-3C7BGO*IJB?;Z=J5N&]9:C(?
MY6WWJC9:O-K+J">[BZT\]@FK; D;:'X1'Q.]C47T?8&LX'M= TR'7*_HT)<X
M8#>R-R^')TLBRB?*4!7V@FLXUOT>+U#Y)8VRJVFM7VI9H]CH?E?3>&<[J*UN
MWS&,9@ER1BDJ7P1C"V,[(,RZ:H)$<X>YF;V<Z:Q'>-*N\:P,][R7+)TC\=7^
M8=0/(@IO]['QD5@^+BM.+BQ6XK>?T@W]G,2@G9ZSDW/^%)%DB4VQM010ODGW
M1A5;#/J0=9-D=A*F+E+5TB^R@CQ?HN=PR'Y$;0+!XBK'D:CZ&[A[LP7]8+&Q
M'<SE^P#NY\WAO<R3;!3(R'7BD/IJ+^&C3%LNO5&KW@C?\ 3.=2>2 GOXDYX?
M#%1(Q_H?_]QL>C[9V\@8.]]WV!?32(#!3KGFV7OOSNVG%-IN@XC&?7^>K56W
M/,RSL$.6Y?//-2LRYWWDC$U+[:0Z47-Z=31]EJ%OQ[OWU1TTWPPR:Z48VFJJ
MG&CAL*&&7K(C(0+/_4K&Z*X4)Z\!Y5J7"0T6E&!E[:LI+Y$9CV2DQWU]E<[,
M2U K^2\1;:*%^;M^:7XGJ*C710T*\<=.H^#'^OJ\O)%621=_5JX8KP%]F;G7
M +.4,\:B<DB_2M4U( #".X462/++!\[#=IM?CJO=^:S,P3II8316>S>6&6BA
M\''D8YJGRNV?/TO68Q$?]O.S5JQWH,>,VM5-H,,/3A&K#6%]!L^0W5P9+^F7
MN?%B\]V0<M!R,XO;M2R\TK9BB6M\ZYESV_(&XX)[,L[0!47'(0<&C8-;3X7,
MHBV!>7[I'%9'%S'IHB07]HD.^4/U2I]8;UT#XDXJC]A^(P2"G(M-L*&7-26O
M&KY6$QE\?/NA*?:V'=VY1V71D*?CF+* F!#'V@I"+LT2Q4]FW-)4/_8;9?#
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MF<YX?Q[#"YD?XG["%K*^\G%@=6/T</VOZDD%X&N\BW'*Y_*%17)<FO."63W
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M#)AQ[G_PAK!D/YPQ_S3<\<B"Q#:R2/8[G[-,>9VHT^OU;0,900SC^AO,35S
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M\A;.O@7L,J*$-1Z.A&0>^625;EXT.$A[8MD+SN<DZOZH)UJY++82 VBS19>
M+?E4%O6V^S6V]XX:40W0B-I0&,A<RUJI3KFK'G5O+A) /]/5!B$.%*V$/O'*
M$OQ\64>.@L=Q]2G&ZW7Q5D/S:0-%$0$D*N=M"H+O0Y.U'VY2CP!*BT?*GGDF
MCC[RA<4]H)HG_)<+Y/Q&[!<;O$](?-Z7;4H/U@Y[=2%*DE"632-3\[P/(-;T
M6KSOMN1GMI^ Q2U5;:T>[8W.\IS5BTXB-4K.SZ@43:X$H/>'+=4%2E8$0^MI
M='DECRM[/Z,>/YH9?NA*HR C"FFW-G?ZZ\.6K-QNYFZZ25:2QHA 6B/ZHLN
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M5_+MQ?'^A.AT6D-;8 4%<Y S 2@H^16+@8\4JI^48/IZ@V8XT;>Z3@+4: ^
M][\ OA\1$_' !>/O 4?<#>;X'4'OWK$3=7M6VWN,=%Y6DV[45S>\NAG6DK,A
M/B^[Q793B=O8=A>H>05QDYYAJ>*"(ZM=?<F[(9.1[/$H+!6_>S^ ;/6<X47@
MCI3368W,+ T'X7K[B&L?@LWJ=$XF]?6PL5WK1$5%_XBEIBK#OX"ZOW1#=?*T
MA/73[SWV9=DL^S[#B7G/J7ZF?&BA GWI"%7KX4&(**5>2PY\BV+C X/33[)4
M7/L[J[K#VBCND9=@!-_SA<+!;P*KWB) I\&L^!* Q#:V6V]W-.Z,.<2ZV&*L
MNFKB=XW2&[C2D[.R[SQ:QP,^&V0K;P0=@SOG;J/U_9'CVU)1F"&KSML$E4"M
M\KBJ(>T#^4GJQMJT\?<&CNG5!R3ZW?K82^[V"G;G)V^O(D*K):['P)B,7H*!
M6)^9O;2YZK,+-:T\] J[/]ON[1,YOY AI4S0+S--F=]5$/FC0AOT9] G(P.(
MM7M"._IXD@]DIP6NNN#,5:8:X")[I*,?ZD._Y2')DQ=\[7TD].Z]0^9-AK[E
M!FL3$R*#=)YN(V1?;WA X%4;@5B2Y2*W;GU!ML!&"&@MOVP(VQ;A5.LJ-M."
M7V4UD,^/M]=W^\0C7.;2PKU$MZP(L=-;]WWE.?KP$YV76WNZZ^'P9O;.\PYR
MT2FC,\<!ODEH-9\64#NE-D.9&<<VI:0UZ5US0F19FF4BU([V;69'-M8C#<;L
M^@M!E9KV?Z(FH;'<T2A.4;]8TNJT"\CNJR\#*5^JPTNV2&268Z?ZEL7GU'P(
MYL9 )'%1@\-.66*A.L=!E]8(A5=,8G#*(ZP !NHWWWLWXO2\5\A5NQR6(H7T
MZDQCIPV8XZIN;NZLML)6F\#+Y'S=']CH6+$196/,%Q0KS4[C73>P0@=0A]ZK
M7"1(V+$-R0QU$MH(4/*7GXS'L_YR$)7=F'\$BUR]!ZC"DZ6AG%8EAQE^IR//
M]A-9)W3Y.^7N@G_NZ6J,;8HQ,\,*F'2E5K*"2HBT^GMC,UYYR7Y#'G3N/VFN
MX*&^#$!XGHZMZ%] ACR:"3)JHH]I]$L&KF;62HIOE7T27X4C3^G3893X:Y3;
MI:J;N:"",?DY]C7)ZT:DZT6ZRKDO_D-:3@IWNI8!BB,I+_/8;[L3Q!8::*Y!
M96-*.[A7H'GVXH*FC$5W:C=5A*IOZ1%F^?AJ2H#FH7X4[5B9ST29O"N13A6%
MH5#;>G-8V"MZ4'/2/,/7 (W&FY$88%./+TV_+9_+PO<-T833UB]..\WL';P:
ML-(/[:[//0J%OUQJM(WOHHW, G/U7"_.3S2V2Q#>Q7)=\)_I/8J@!]9,T._R
M]\N?PF+E9I.[E<)-#[E9.=>^SO63N*V()])TH$M[*8AMES@W8"_PJ4FW!TTW
MV??%L.FM.M,O^%814@%/:)[Q0Q+48B?4'!M8:\NB57N\E$Q$@Q$83B$(,8/T
M(QO6FBC\N!/V8XCS!*GR99$SY6P9Q*]:M67AG.)N9Y*$^Q,F=:P@GJ!RA:3-
M,SZ/E93R4B'KT8P2EL5KG2#HTJZ+[*-$K:]6_L<UZ[9%!WIBB.A+*?8C*_C-
MTSAM0F)T_O.TN7K6:UB5*BH'^CR-^&*CE"73Y*HK=XG\+)OJH&*F%^5** ^K
MGD $7^(+X#KSQH:Z#K+8"@QO3IV&5FM1NR$FV68U)2/(ZX61U?-5YO< ;X*6
M'.Y,-**/@%/\-8VCZD 2LLKFTP>*-X@<(._M =\#!*FV&]Q-YCD?K:2LG\YA
MB,%!5JJDSB=-YU<U)[U*_<VMGVR7JETIN*(LA O/$Z8;E92CF!,\G?8NGQ_^
MKCE8.A*FU)YBXX8XRC;ZO3=##JJ)F>OV2["FLTR(DD%2W PUH$=LFO46SYPT
M1(J\))83IYR=I]XX,WVVZ?I$K?;X6<3YK8*%FUDG[R))A=OKF+58T-*;*'?3
MXB(-O *3>GSS80*P)X4J@HB;V(=N1__P&T\_>$__39N=O+5V_>?:DL-R[2A#
MOAFTCKOH(;(KSV[/EQ(O>==#GYXQ,RUJ?YZK<+DV"M/7'&.QMFVSPBQQ7;P'
MA*Z1G&>AQR#849=T$S5?5PY\XXJ.5__EL,AWA(PIM(">8(LIH"W"88]">PFV
MK/%M(\=RC/+5R%2*J;&HBZ,-PS(^0VKR;IYXZR4I[7-5I[W9=IE[=;P]7RAV
M=$ _OJ2]UD+N9GGR8>*5U8QM9KS</6!S7/1YE,"<[AI!2N&DCH(N8WW1N? !
MXBL]XJ+C"-UIP;?6@XQ@>%'BK'B1LLH6^U:VX=<D<1G%N<AYK<KQZJ,^AD/J
M9M88,&D\F0.GX$=E>71F3)RO44!MB+F#YM!HT]6^G<:V+]Q.EXS,.][Q2ET_
MI$,74WM"6,&:V(C",!X7T<<_LJ874^%J,_O'=)0"V@=_[!R-&"V>E9W+"]I<
M9.-;F%]M(;<X!KLY+<WWUAQ\_#8OY]N$RW)-,@0]P>WV)I$E^II('7J&: 8
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MTUND&/.2]ST1WF:%6_X_[7UU6-3=MO @*(H@!B -2DCW( V"M#0,,(!(,XR
M=#,H2@PEK737,'2GTB%=,G1W=PT?ON>\=>Z]SSWW7M_SW>]YOC_6\^S9O]EK
MK]^.%;^]UMIG).[X,[N[5X-6?,4N _=_CAW F(]&UOEXX7/R;DY6D)OQI \:
ML=QPM1NNB3>MJ-BF:XC-CDQ4OU7#/XY!4RM/GV_?MRS@OB<P"5Z]3?"%LS-/
M_9V':R]V-G>*QZ)&3W8:5TLF[JI(1H4H_M<?(>ZI.1.KW+J6/G:X*M+,U,J
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M'I8[$<I7@O/.?R:',Z(E7^6NWEJ^E:DA'\36LKDH&!"@E18C]-I1-_)K6S/
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M630>ED[1LFBZM;:6#N1PELR\@>&\IS+/PB)?L*HLT\'%X"+.1<=JRC'?MHM
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M%4FX#>6:,2+9N;%KGS:IG9PCC04)&-J(\QI:0(E*Y9_1>RVYGFD@K 3BFDN
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M2E7&0)) #9#R\:/@H*?M$DG2+?.,+7VPLBT#AOG/]=#^9^'GWQOX,X!+2-Z
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M0QM-WKXR+R:_ZS*%&&H;Z<T 3E#"=39&\Y^3..[_PS\"YN7H_P%02P,$%
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MJ7?N"S9]?S)Z>%H63>Q*F:O&;"^/:BM<_M*9T]_2A0Z8@\X>M!\/.\=BV?M
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M ;$^\Y"=:E_C'*MO>C],GO<U?^%WX%AI4GY^X&Q+0=76&:1KFO9FF+2X0HS
M*V$.6#M-W1@C9:LS+ J9*U(>KM. 8F-E.,8"K^Y'QXEDYPQ13Q]G!MR.J+1<
M9Z+;1\7Z.P_]7L$'GC(TE!E)!T)?F;-NSZP0(X ,3G#PH WFB&&$4D%$*LOO
M:"7)/EVA#0\UN=\&;209T]L+Q6C2W-;_<O23!%]B J6[%U;6UZ.IHL-3Y!-D
MCZ5D-G\9>EE*SE@@';$_)0X\/">QJ-JHPK*=TJ\_RA@FHE6ABY;>H:T>M^F&
M6$9, VV]6*G/6"H2S>2.OI[+?Z5L+2C7U(NONVR_$IBG?VT@Q?FXM_3ZX:EM
MQW2;71JX@7K6;<3:M,6/BTZ^DFN5?]193[&OH#*'K+%AP]<Y;C(>W%*FJ-]U
MYWZWNJAO*#RXF,"([X'T<"A?(OJ!6]_(9G#_@O7EH@SDZ+&B"LV>/.[%X+!%
MVU+Y;A^*R7C&+N2R @^2L>%5>^_$L"3=G='@-K"MM]MKB <TNK<0$JIJ.%[=
M3J8P/-E52=HXGCV.IF=0U!7231:E'WEQDVYB^D-V1BYH%;%.%*\YYES+"8'9
M 6WP;HZP_,#ED*3\>BI*N(B_(NN)5\Q<3\UJ_0\7_J;P$2#<,92J! PD?=8P
M7,WXY;:*XWYX#]=/(QEWCI17$?/]#\6T2$'O3C,;0:#-PW2!78M@"4YO[UMQ
MP&;DCA_U!J8]DE[:V8X !5]T'#+95IHR]DTP7#Q?F^G\:'3.C%*!V]K8774F
MG^&1')6*?+:[ _=,W&J.PTSJQK 41C5>C8QP-!>FX5'7]6A,-:"^%M>0:R]3
MS;'(XYC@+ CK@$9!&=?FR*;V9Y/I5F= AHT(L9L8(?UVRUZ<;IVJ<+".Q%J@
MLJNN_+6#OI4]J4L!^67UCEW?Y]KG<@>*/O7)*UF6I[DK0/G1X^SS)&^K>R47
M)U=#76$3QI77+GB;/ OS7NF2J5W5>WKYGJ:FX<MHJ(7^ ?63>FQR^LTCX0F?
MDE<EO=G<3@B\>$\4)]_[OJRGL'T[VNH$#S;#S/=I'7NPWU%,!\$ ,;-B-_+<
M]J32376GCVV'SBZ\0\ZO$1KNG#7LVA1L'=<.1ZDWXY84&9R^.T_C)X16Y$[M
MC.4[EH%_+(B=2:W! %5?Q"Z81FYL:OBB6>21Z@T([C0K7O6V$#Y0J^X)EGMZ
MZ^I>BR,<N*YD9K)-<C.CQO8TJ+$N5DZ[OD;X_L"XH)5DWVK2)I#'>R6[VV8
MZ8RH(J$.6_$%TXM:&WIGZA+5-M,EOJO\7,9,EN"9:"R%IT[WMU8JF0MN_&$
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M.'YU6S05<DCJ+1@3VDR[W>VB /4:12+IMK+0UHDZJ4]7+3_:[ITB!J**OV9
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MLT#TF*EI^86U.2"U?7=LU3E=YD6&?:Z,[P=&[,*V*&SMX>JW&OOHC;,O3A1
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MT!/+[)EXMNQZFT*^KC6X6L:>?J(Y3;SDR_RIU[A>:F\\3V5L_F+;%/MH!)$
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MW26U@D@NGON2 W/C3QZ3*:R#Z.JCV9%5?:[E_D [X$6GJTNQ*5/K_NA:2S'
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M-3=CN/ ^0>+%"YW8J@I[H\PGVPD/?B2M0(K74'S.:AED,[5E#\N RQ6_TW/
M/L,REG@>SIG7&)G7V:&[52/HY4.NLIQ(AGWBM)JJ&ZM5?;$>V.@%B45/R<V\
M^Q;YXT9Y6?+IHL&3::5GFO@+P2*5PQI-CU(>#N%YT['LH+CK%_C'ZJ?_]9G2
M96+=-R'<;3N)$ ;]LMAJ)( NJNIJ=;%G4FY9P1,2=HO_("^28WMX^*^#8?;Y
MRBQW7YQ/WT(3Z%.DDC*436-YW;SD55CSWH?\N9.>]@"QIV"U^U)_E*I>MG^&
M!^>'-S8(2WS8\V*R9B$3MB%0 S3:@36O)/A/"TO"R?2#AR[$>-J<N0B[7,GT
MO1AS4_Z>3*:B7%O'7U(^DYTJE<S7*:H]\*IK?'J2@H&)R8--_NM1_\N\S$AK
M3WER6Q&29B3@?A"*'ZG!2^UDI?9E+^XLBF0I#/<[D=E@9>C^YX'-9XU=BW[C
M-"23T?Z(@5O^:'?EB3?>%A2"C#.1SEU<Q%L,/@76GNQ]+V6+)M/^N10ML# G
M_!1[QU7B82+Y)DA%*[(E3;.8K5G>I#^OUN5$]59,,&'YGJXD)94NP=8YH:'D
MS(<G'[X*)"U/CE,6"EP:393+.QC:/[H*+6D,>3R:(".MPB,A73+]S39]OL.J
M'.U+X9Y%D/&V_L?R_L&^79M1>1+;O^KC,#8C1 +BR]61@,JV$3B7DX\J0@$J
MCFA" N0,X0BJ5O(ZRHO#4_.T[7_%^WTT<+WZ]QY3_6_*L:.RRD[2P[5R'=O
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M;3^I_*PYP,4';WCZYMR-/_/^"L1W.0\_+:>A0 +>X=9?YU]JC8AE>N6[EYF
MKT 3T)84'*&35=OZ&Q3<HGL+631?9Z^/;%NU'/N<?SD91_&N2>#9"4X!PO)]
M[&N45'SG0;N/M7IC&74/5J3QJ)]#Z@'U)4DI:#F&G5J*;HJM4?\=OF 4049G
MT./8'PS8E.Y)C-Y(P..$>R8_LVH*A)H*:#D//QN&%W%H:$]J!7!/6;3!%6L#
ME:"XP$Y/7#Y_($+PBU3R!NF4SD*&*>ZKQ^2R%MMH'QSPY>H.8])@HP29 4<)
MJ^?K]:7ONNA#&;1"M5YI%&AMC#CP;2'86WWV:#;HK!G08FNY.K+9?E*YFN+7
M=*+;]5H<$YR67]%A=IY?4H>?%EV4,8_!P&J63)=Z'W]X'^@JYZ_(/U@"D?AQ
MT)$,FQKV6A2"Q"8KO;LI+H/]+.L#3/GF?&2+S&(U)_>89\3;L(QDV<,4@^_@
M4J.7AE>9*08)1+T=TBO4V#"U.?TV,]W/3X5A!EO79KP*JG$I&LPJ=RN2?F[;
M-$QA^O%36)?0924E&&V*V("(=1.H9;XE/&[2D^WTG9&?1I&L/!NK5=HN1R/^
M$WS_9:""_>NOI'EW4=_%>]<1-,/J&13:YEHN26:TK<M\D;+OJK!4O:@E3\+T
MWU/YY>^V9Y*U,I>(JT_0!9+A3U\<[L>[>-$KNW"+FJ[L1UM3#!5<.MEX#=J/
MG<74[:9L</Y4IEU4,#\/8TN>F@77B<W>I@+K8L@;E-^YM66] (N!QF"/ZH?6
MNE9=]"39GI:[K274<$,QR*Z5Q#N&4=/J9/XI*;_J,.?FE:?+U3KDA,@DU,L,
M-V)C#*:4ISW&][!,++&N\:?YM^O8@7NPJ?R;6%'=&@QJY2^5A;59+ JUKZ\-
M&5/6;>88%#EJ@1:'B"I;X/**1K9(_@O#-!^J*=GE&+$=8Z'4*P\U5R+%UQ_M
M, 4%'5A8"[G$4Y^^R7_0^^T(^ G\LSJY8K.NU(*TL(A4*/;EUUB5]&;F^+SI
M+5+A*3 #>3[&.U%R@9U3,>G7*^/./HTI3V>EF_C3HSJDC[A M*<]$*->%>VU
M7U=J;BYHOA$M[*OJRVKFRZXO^*YHY5*R-1M:T?*P(P%?)6&("[TWPKJ^H2$^
M>*%GX$YZ/2OPD#JA^EO:QZ",<FU5_WZRBI71VM,$<@+#->R)\T$6K:.C^LG3
MN@6K&.*-H018(JRJS=IJ'B0D)OUV+T77EZOP,M]TFNZG?@"(.?7L*Y$<7=.1
M#CA<7"\HZ?.3^=OF@OWKZ8UC$HU.9>+/''7*&03O&>Z.%<VM/5 ^L8&K9+*/
MAP#7S2/)P4Y+6S0B4L/NO%:O^6K0+G5YEC:A+1HT.6P\V,%?7K\.X>,H2J%6
M&-:*G%4;US2,MM0SNW]:=E4'61*#S9^W% [?'NM0C+F-[N>@8%@[B80 L;Z
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MDK)"PXZ<\A0#['T%.Y$Y#3G3P@Q*[P,4O1_T'27+OW<4YJ99Y^;6*)5Z7NS
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MN.Q'8"E Y6'E0KB:RA$C,GJ\(93V81L8;$ *@QR$[CD63-=;B)A&12+PEV?
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MZ'=!=(PIOTL9#6 6 ZH7;C^Y+@5(_(FQ1DWQV)$\XJDKOL('=^K8)SSS/:S
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M*NI>+-A.^=PVN5O4L#,S[Z)?8&?;.R:LQEJOX2(,;278%5K;%<])UB'9/NU
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M4ZO'X +3UOTG2P%K_G&HP#?05DR<#[5G)AS$+#Y55V=YWS . Q+K8".N5FQ
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MI'0(4X#S)X>P%6FX)4!<Y6ZSCS;GE!L^6C]Y4Q:(02Z@>P/H.7,YOD:X=-T
M#E8=;K==XMGP'4E>Z"&88T9.!&B:F80Z.AN_)JN9()E$ZMF/3Q,M"KE,368L
MT65@03Z3GK_>PY^=;@D'4?3EH5R'/G'YCW^#J]X =,<%\2R.9Y\4)T$FQ?#C
M)RKZ8C;9@T;@#&/BAH4*[FW<O- N^RL66?/$*1@J8'7&8# 6F("VGVG&!/\9
M,3O_$PS?L;IO/V+ORIX:%M4%BZQI%/YN%F,.TS$LED38K#$%? YB)K.H!5S'
M=6CN1^;GH<2\5$:O$C$?;J^7E[E5E=2\K*R=9 B QD<M2IV1EK4$GTW.,@E6
MKC_0VRQ;VLA61I#2D25^[Q+9,;S7X /) PFM#VHGU>-.>Q^RX4B=L>C0W,J1
M><K+D#/,+[=K@GE$=!Z>A1DQF[O?S#53^50J7M:*-"1_[)%U@6*,UJI*YCIZ
M[@'D,BP:#,FSV1#MC$(]<4!].&,X"P+?I<(H(@UR*T*06;[?H@'Y17\CCB0I
M@QMOZFAK1[2R[Z\J]+%!L#"<BC<3-Z5<6.G4EC4]=:YE11,O;@"C?IQ&-HF-
M)$$4!PG NE_%'KQ?6^]<JDE4U)-JE/#T1+W).UCBK:J.PRUUWG4PZ;0'VI+@
MO8F]RN;Q]UK/H]VT\O0P3C@7"_=!=$ZT>)BUGG6J(UHFW)KZ,YA0[+I+X.*(
MS%@-SS?AD58:+3CA+JG"9N]M; ?X7[3$[-5<20/[9[(^#WWB^6&/O&J9?Y$Z
MIUC.QT#\AO?;4G6S6,G,K+4PJ0>S3]<*+G9P^WG:P'4DA*K=*XC(XA'$)T#C
MIY!NUOYL1VPTO9[JDK=9F"S]F+U@F@TK%_TX?3#NLRYU0D.+Z'K@*]+GY J:
M[)'C EOLGHSCKF7/VWQ1$V_1;7/V)RZ1T'"BHQM Z> HV$GVCNVMM!KTSPL5
M_S<L![9.$I&ZOWGI"A?^Q8#P?\CR_$^""G'EJ5MBX=UGVE=O/!/A&;<[-NHP
MOXZHEND?Y8K*/SKO<K_\PPW+_Y]%5_YI=;6QA<]?PW,/!-OL>:GZAV356L;*
M3AX[T"]Z*&S ZN0 SZ.?N"_=I:$EZT;(F.0#06TR]BD>E9;K#25QZG=)1^V,
M-8!+&:T:?BX&Y:%TRE$D^G+TN]ID#/OPI2P?92]+O70B$&G.PY[\)!@?89NH
MY@N:/K. :)R/[/JVBE8(H<'61@8R8@FB()VJJJ"V[W8+AI7E,NHVHA+IA9D&
MG?7ES_#QC+/]>!;WTQ-Q2VA#D\I5!E7LB@/5BWDPI5FM,W&3F\4*U K#UX-/
MVRG7$'JRK)I\!!K*<@"3@445+M#+="UVPEA$3PG,/=PJKUJPZL%7'B53VV=A
M7"0LW;G(SJ*6S*+KZ.6[U7*H>-M")9P9IK70.FX)/*-L/_KZ.NC:I++7/3,W
M9#LRNW)LY_B"UQ9]B2Z=X-.M%,O+)<Z>-_-R-"E9#ZHZ25^Z<4Z5D$SGXTH7
MY=PQ&?^KM'*48DVXAL^JVGRK%@Q\G6)7)%_DV!2OR[->_VOAO-XNPL:VJYA^
M5-81/^MNA_EF.*U+1Y"YGD'9C<( [,(:P]MN\CH-X1RB/"*">7( TVE/XY>(
M9 O=<+[CF8[)O($:#_<J8%]#9->ONRO8*'?';\BR9IQ:P1]LG43J=Y^,[IB-
M3ZN_NKI@U?R^HUP(JD7&*5/U[;Y^2GDKI*/'KR7:@JUKQ_)_C*_@3KYK>32:
M9]?%1&F&UD/<)(=F^BDMCD1H"<<5*P A:Y6G_VV(8YB)6BOAZ99.8286G#.[
MR3\K&8/![5XE9)%@U.6Z[//QG!/P6)V$?5H/B 2"T\G:NB-,J_+V$Q(Y2M>8
M[D(5\:7+D"SH>;5I=B#KR8HN$J$[#[=@T#'%FJHJ'\6<#B[G/C7]5CG FPPL
MD%SUJB1_JH-(68J/9]D;71/UPAP_-OU_T-/19R".6D655U]4,['U?V=6$[_'
M&JC?BW@-LBE]#;)&UU#-#W/[C]=@^J/J=JM8_,&'H@4,W;;Y<ITE&<^H@'G^
MX?Q5W#^M,M3_1N7OVE#=%D;')]<;P/DV)%ZP/J_R'TQGOV6;4/A[M@DFK%N-
M\MY_2GD2#3FB?Y=:^X=,$$V,F@E^+%%_\$842XW^9F=A_+N=)>C=@?0##>6
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M?O0&L+Y[NRI7T-O7R_IM5<Q^T6=]2Y_T"0ND32[O!C T TFC^=N#=:Z[[6X
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M13/6UY3I**0<]+E%.T\/^1L\EU,8N"PX1."^G=TH$\D%7P[E(WZ=:\8SX_V
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M5.]A TZ=@Y&3P4Z=OZL/,"4\1/_ HAY\*(P$/AF^)]G*%%>'9^9BZU6HYN"
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M;DSM]%R'16I6&T!&H8+F;Z+5_1]Z\ \E75FYNF:,8@C&FY:U[RO0/]+9P Q
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M!6*LR%^V,PKG%/GO&)V!/A?+O;#;(3(^Y\ZZ+FKEVFS(]3F(*@6C;2I2)\_
M2SI"IVPG?*Z^RR,[\H04,?#UAKY'@*;.J*A>OL:G+.2Z,A4T%RJ?9,.^4WB0
M_7%+.=F&FZSX;L%'-&!?2Y;6W[SG[D1#1$LJSK!KKI4.8]'=C?6:D<72RM=)
M9*6B,5)!Y5\+Y.-E?3(+I2-''8\A=&=WW%Z"!=A+.-=>-2LL1S'(59< .+E?
M/$*P6=^.4*^8#Q5IM!*/CI=G\']^IB0+=3EP4]>N$%E8(G1S/@(QH<C0@"X
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MJ1K[M';: )GIYQ+(3A4G:&(,_-H>-)APLY[2[7D?/QS(X[,6VZO$VF5 *1>
MVQ9M]0 T4[6J9T#V3458]L,P83/U3'7 ](-4"_M<^47]IIC(PHJ:3L_--]5T
MZ4>)Q&0?\S6HSQ#PQ?7/UX]T^XSOJ;;=H@Z-+:X_C61D=>U!E=4H/12CZ3JF
M,95L^?I^YVJF!@2U#+5[UYSPYCZO6L_96ZW29,PJNY\"9\$._]/&K,%NANT0
M!9RO[)YL;4\U60S,&VVT+V!V@V/B.S"(%/"? 4#^2S8MWE- M<W'$[AKV9DW
M\VE=9>C-YQS)7[ /38XAD^V'ACV+V3IU:<:V73+P"N-,1=]3$S/UI!E!A.Q6
M\$Y3%\-;OZ#X^WR1E,'.C,GJ#6HOY]_G=?G"^XM[-@HXKW%_NT^S<GAVE_Q(
M0O093?'#9'!N&NM3R\91-:$5ST<[\7?)Q.O*;M9I=2<EWI=]:MT58,R8F+;]
M&.OV3'XBI5IL4$E%_+;+@-[+*EE>!ON;MF$*9<D90U;Y'DX+IV"K%(](N24Y
M8*>^%?F#H8<3K_5/-!2"9M:->QO5<TDWLT$:A75!L5[U]R3)950]3;7DC:>A
M+8MP<X^#_:^B Q=,2$8.8RIILB:H[.OP -[).1^GZSFO#+H>PI?(ZP3R*TCJ
MT0 ?_/8!OI&29>^*PG@+>)M+)M%;[<E;<'7OPL@1Y0RRXO>3=WU2/[.BE"[I
M)U=<;DYT-!C@U5-*'3]/</ 3YV%7<-'X-N\35"@8#4I+]4KTS>IR^!BQKN[C
MMTEQ*OKA!)(90.^G>+!;=5T<.7">LV3]=#SGF$JB2E>]GA7TX)"W(#!2J+S1
MYMGF^].#=9$:-J-/!I'=(W/-^>QYK]LF?8SUN=JH%E*4?!\-XH3C[+Q<IZ?)
MEB6BXK3(O=FD5/50H&]MUH#RP>B*U![?Z-*9BF58AX74\Z:BO74F'V6E=V%)
MGO4C\IU?.<#]^-N1$I9[('SV9(RE>(@&X"Z&TI=:94^S+S+8!1&O6'\NT#J6
M/YD@6I#! 3HM*B6B%EL<H[H$$2S5K%[W#"UB*$-E!+.#6=M-]0M)4R+>E]VW
M1!1.QS7%/Z+E4?'>5J]]N=GWP&?[AO"W_@,@AQ?)M@M9B-RBU78]0R9Q*O<!
MZ;'M*-5+@AO:U(X&9J]4EW6%)^5JJT75T^65A.1';A<8C33J00Z$3(S=KBA5
M/_=A([X6='J)V_ZQEI+%##0PL)O-)X/$$PNR@3 I&>1@?@,H\F[FSZEO@CAZ
M\N+"L_&<NH3W!!??SMKFOQ)()IVUO1_Z+-@O\2@_0J]DRN<:7 (E9J_R)-PR
M90K;\])4.N-K.Y+HIQ:A8%6W\=WRF7#(&"69^',U'AYJGG<^JQE;9^*/"ASJ
MYR%W/[E2! T5)8Z%L+.]'R U<LX QJ\(,J:P]8* 83W_O=;J,J_!&,;&Y,?<
M/)\%<V::+A*X$HN_R W:SL&S0Z2ZW=%]3.NHZT9+WIM*P-,:C2VQREJOO<NM
MM-,>2:-Z.RCD=53%Z290V\KN$T_5.\%A7I5^;TV3[-8B1A>;V>O<\M"<*^L5
MG^R>0$;-5"=CDNWN/!-%ABF&?-G5AWQL/K7=:M[T'(A5))X9*5*^[%NKZZ#?
M/H<& .+F:]NW1:S9L56WS4(2!"+O5I5*/#</I",;GEI\6ADV\IJ50[-G,BYN
M#V*67P%U9VB)N7(GJA,$G5%DKSHL5II\>BW<4[VXQM\5&D<*>3+$$0?6NWVK
M1<9)&!)X7W/<4VW9<?_3"COM5(.;NT"?[FU['MZ7BHXS5(K0)J3#V!"";*R#
MJS:L .0<+<[;OVZQHV/*$;3%>D#+^:FV0IO85,:D:1MN)? I3M'Y8\J[&S(@
MCCO^?^GM/3W*O)!T.@?90KC@L#E<K@'5:SW]L#DJ^XMO*8?GFI3V9R]MT8!Q
M4D,T("<GH.'1Q4TR.$O^;A?^0+\GOQDJ(ZXWEVT*#TD4U(.Q\4$;O_M)V-\"
MMOQD%YNUN7C.=;@>G90A..T,*C!Y5]CF@)74>,2[XX3:LY?(USO0L56P/F'-
MBQ#X9;66F$I^D.]4>QVB444QD1@YICT>5R6X2$_UVE&)O3G!AFFMS\?U'OAQ
MK.9KIK NH!13=:W!40UM7$Z@HJ)I^>-OG\0(%=QC_29"NB/;4\24X8OVHNJ$
MT0%:&DG69$'B_8;>:, MI)3X?"^OI<I-BR#/_935F.9/X=4:58G-H&>14XU5
MVGL>=K;A0OD,MI]5)132,[SU:J.U%,54Y,G@LW<^')RMI)*S.B$:1L$+8M9P
M^*A9>5F(V=)JF%J?)Z%([J\S31T=@@;,T1&=#B[N+_W945E R 6O>"8;&N!F
M=/_[U.W]/7X8'@(V.RTQ"1ST2+T0,\9L1NEC+4:J8R=V$T&A_*0+DJ51!GD;
M$J54"OY!O(<:/O$)"5W4C]F\M+OP#WCVE(0*S(7<'^&&9P*'EE&C/B7](.!X
MD1SY@I;$N><B54,+D^SKWJ?XSP@F\Y)N,>E$-0+CLH&]"HA;(&OGIZQ/V6I*
M]F7R$_Q1\U^:6ZP1P0-%1S'$']9;9T5=\SQ$Y7HF:YK#K\\WL=64EJ!./E03
M^TE)<+#,W([G'['FRM$XS"^#"%.U5TB4?924,SC'RLVD&WWUS13IQ NUY?P8
M;:B*H^P("7V;M$YK'RZ\2*K6(*47LS:<^3+;S*RG%J'D5'DQ8$X0UG.*VDWC
MR-';Q(9%"39_RG>L-@P9F_Q*4:-DKI+?R;\S_ES+\@M%)C5(D*' QXXK9S!6
M/E=';V#D<^P2]%V^G,$XP"-;%'1SG.J1T+7.$+:D,\86L+O.'5=J[E4-^S/)
MPZ*'DY"I>PO) QFI;1/[G GXX]O>I47"5UW:J9BEG+V$V\-V-@0O7-6;L!X%
MEH5]>C+ /C,_?#E*;DWB#<J\ )$ +GJ*UX09JOY(<3EW?%+V4S.AO3T>:$DO
M9@G@.J,!^JOA)0FV^620(#G<K<3]ON994C@OY?!MM?NR"!#NU2;]OO&EIJ:T
MOB!Z9XEZU*6-[;?F!H'E3RNQ\MI.GA=;]C"-VS7S^Z,!>)3IK;%4FJ%B40@T
MH,Z S!UFT5Q[:T*W/U>96UZ,[,(<N#28+<!,L)Q117E0^A;JFY4G_WXQ=M&L
MY(-'J(@'CR9DB$F@W;F[S4,?E8D9!/4XTJGSB[V:=%:6TO4GP91[8U:&*W5'
MV<^#320\!.Z&XFZ[J)PR59RN+G/E4VIUB^6@(G)+HSFW:2^XP3(EFA9"KA4E
MG_I/"HKU$H#I T4>47SWW#9$S:-5J]Y#2Y?P"&IOX2*<>Z!*US/*$K49J-=3
M9O6L-F<K=YZSC#3J.Q*#_3YWJW/E*"8>]*&.$SAV4JWAVD2?12 6<//RD$,;
MFW9:W G!O-5.UXU\,M6X^R,S);+P61<"?KB<IUFV0KI0<]3!@&HR)"ZHPMZL
MT+E^7D\V<F/.+$B *Q'$@4)DCHZH !'M+5T2@4BCPAK%8$[Y)R40(31 0V0
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MCUJ6?!X-0.4E'8'X58[W/:$>*IK-9YXUXIX7QOO>926*6K1B@TBETGX&:_\
M=C1@I4!M:YHCDUU #<>CW\,=7!1F'CL1)G!=R8LYX#K? -T:?.GCW-QQ*/N#
M](<)MW(>($^H^, @UR31?WFL<O-%[$-)"OXX]V== SE!^HFOE*W9UOH@UWA8
MK9$OF(9)K#M9V46 Y*X.*7#6:[]W1/A_ VR(S9,<I*;]SQ,T F[+%/BFZ#>$
MDD JQ. 7S8#8BE,]ZL1XHN5=W_ZY+^7X$V3<YSM1 .2U#=ZD'TR]NTC:S^:I
M>L5T*_JTGE_C:^@TXADU]S$(Q'230LUY^;&,112L2A8#NFP:H94P-LG6T'(8
MVQ6+8]OS?MFHJ0G^U H)3(%^YB'1O-RU*18TP"UN+G0#E:A^&K"3UF:Q(3 O
M2?%9\F*>%@/60*DSIC1MX&M'R5L7W\M43OF+#XR794>:TP$F;V C:>'T\V&?
MPG3[9.B5&C0AY9#+.$)IHYS<$8,4$,CDX[7># ):J-6C5^XY/1UA0O<R8TOY
M;\'*!RK"E.,G2PF+O'I+5=05S]/)#RDC3A6X-LKF97G(BY*>C''5,(V(+<-*
M4BY6?3621KEAKK5L0N^\* Y8K1]D;$RU^\9T\\.4 EI>W5[67*B1U[+.[H(J
M#,+<6"!V\_+*]^?-_-/3TG.X_ZXHPC2$/CA^[U*2)I+H:"ON?!2 ,,F3]G%G
MK#1QNA;;5R"^Y7X63#ZU,?2Q_ZD4B%3MUO_I*$C3:RR]"/EL*F40WK)]O^NE
MX]Y' EW?=+*/_JGT(>6YR,:CF^E#QWOYG3$:9F\ K@P]7PE $(.'K5-/#;YT
M+C%<'DQ,O?NC5Y@-Q4<":,T;:^^8O[&M>55(A%@H*_=3=75W2V2\LK+2Y;D%
M^'J0AF98O5"%2#%4!0T(U<S55&C2U'N"!S3I5@$?#U'W+UC8/J@ <P#)$Q-3
M=U._%PZ,1'>\M<RJWMNG2Z#U] SM"KR_\*A$P_![-E1,3'81],'YKBX;U_>L
M['>JE ZAL#]GT&M.W1(%#_PENYB9=;94?-U4$03Z);O;/^#KHA/ PYB2\DOV
MV?**A/"]^AB27O O6='OK9(9_]&!/SKP#W1 ;8#ZWA//@7!#&;^B#69>B3)K
M5#R5NSF_-2/57<R6J>RZC3# Z&5-6QVFX1?[P&"+C;@>PVUK.$N^=,F_RD \
M5I4!<9!BX49T68G""T%83^_<H,DR/0!BRLCJER38+GOO_9+O-I;I-E;KE22V
M.2"U00-,-4I4+^L1?4P?]6%38+DD2J?P(#8<#H#+E66,YMS3H)XIZ)5/>1\[
MG&*C<9!VT4T;Z0N_%[#.H'H*V$M=P^XKZ)5EHT.&26.R$1@H84F-Q$6&26JS
M"#7J!S_@9-U3C7S[?KP,,R@Q=_Z>J[*_:K[BWU3@=#6UY#;H0&5K*/D2D73L
MCNT#]FS7U:_0*K=)MZ'D(T_V#RX]95[5'6@ \ $#5,-9.6J;+YR:A8*?T<)Z
M%#;V;6RA"""B(5^2#Y<7R 8FO<GCRM>=I, +\X2[I1:,6,&V=SK$_<JGB'0#
M54@F'MXJG5RHBANVZ;AVR)UZS=58B^^]1ABW;6MC)-\FB=5)O)^(.V/H4W:C
MV]<B#&$9>H&A-V4=S<O+'K\LRW V,*\,3[AKSQJCSW49S,Z2[7YUHK-A8)P[
M'BYPS>)N]8:!N0??JY<=)@_&;R9:<;A6)/?0ZYB*.]K)B_:@0B:PQ+1BEJHP
MEG3W(T]B$-&LX>.3O"+]0+W YM</*":)%**ZC2[:*X@;W898FJ-,^A+\.SPS
M]FFT?5V3<B=K(I/BR/ *A"+40RYF9G1<F9\7L'S<ST7I5DU8R4S$EVLR.XHF
MLC$DT?N P>&+<JO50KE*.3I\0U32N/3PT?'4HX!%0Z54:]Z)*_UWGL;%)[0]
M6]6-':[R\_(PK0AG43CKP\QL[&')RB.JTLR4U[C)N$M6T,2MP7B'.M.0XPUI
MHADQ]N1T1@OC)BVM&^^$XR&R;W5@G_+%C?M1T0U@ Z4,8,G$@L41U&\@SS6M
M,"R#Y-@D7XGA02?==>LP*V&W9%?6NJ:JVDC-@!G#L!DJ]G:Y_*OO'_E4J8OR
M6A%VQ62!?)A:1ASD]V:JO9IU(6]3#$I&.3]U.ZP'O/7XDL?0'Q%T8%X8_"W>
MG</C43=YJ(%YU8<&+#M3P=7]@B=&<,^'4+(34V>R8X=Q=^#.U@ 79$Z.9M;D
MJ\.S1L^A^AKL>G<!;H/NO&?1,5U-^6WRK3)<ILZHV,7WJ!WQMZ4)G+9]ID):
M%, [MZ_%ONXD$9$+YWU/\-PZ86^#RO*;YP#+KD(+H[CVA/_\@M,;C[P9)V<I
MH560FPP;6\M,_'C","9 >T00+A(K()!]MLSR\>F&O?IQ;T6-RJ(\","YL"^1
M0!4W<.'R7O72WT+@&"BLKZV9QJBPL3<W-\!N&:V4N8W:W*^4'%Y$ P8-"S"^
M?PNM?;J'1 !_%0U]@W"N05MVQ86JUUX^=+(JT TB?+?6N2-RHNNP7H+8?H/?
MHA^)".NJ>7@RE(ZH ^)V4@>=KQQO3([:>C62GP2GA%WO;%L]ZDVMSX5.,I#1
MC0H0-UUQ0BSK/DQ+2R6K6<A_O)S.VBH&#'VZC;/X)B5!)J10U&.NRAU11;%!
M^%[)HZTX\OB+':^AV*SFYQYSOZO[>&/<<PF#*HVC42FEGB3U[FPE;W=O3'@.
M-*6 ^_6J?+$/E)7%^"HV/GO"NC71@,_9WOMH0&+JQ4E!XGX5H9Y\O\T^=XY^
M\>,C[JAOZOL$/L9[+,C& 4[2:'P3PD8MI/P#5%>'0C1_WN'P"4''EU9?,6>E
MW?X+SX+S?4.K-$,TH [T;=E_8G?4YL[CG&<TT)>HR7:YCBAQUO**2*&==O=,
M->^(^7?9_8O!_0,G])T TUHZ714QV&(6IBNY]?MT)$8&'@^:'B7TJ0G=WK&&
M7?6PUT"Y1 UD#-J]C[3AW! &=VQR\+VI(/&+\$H<8"3L_7I"*=H;;T]Q,O36
M0ZM!@)*I'$49//;I7@,%D<W@U+7)J=5)]BB7\HBUK<X>VJLYK][/ VESIH7M
M\+66CQ*3"JS5EBLU&SLL%A_=XS4$IWF@ <WBM\LM]\8\Z*AWOX=<<ML!M#15
M:$"^3+7T%\^NBHQ)[KZ2*20U\1'DACN"I;6*P3HR*YNAP#<3>62]VM '2O 4
MG,%H>+QU [K$I-U!V&;.;HV%#BK?FT*L<;]81__*%WPO9_WK,2:Y4%VS^>E!
M3I.=ZP!"5$FDGA"[-Y-CNDO:Y$9SC]_C/>]S0FEGESME80TOG;+I.0Q%OG4#
M]?5&K=^-=_7QE\#8A>;V\A#"8K)-L<$#]>#$JPUF=:F.39;QR!+7OFE*MZHX
M9$)(O^SV1J;/+'%Z:W'+[1WAH52\@2PF,!K@H]4U2>X'E:#@$0TR ']^^BR[
MQ'+? *9747S16QY\+=V=W27E9C4]:?ZZ4TZ_@E/D6M@>RWN!B7=TJ:IF!(=I
MV"O0+WL(=]6M@K>&35[9=O16#Q9DEK60P4]/&\59XA3+*L(G!5ONI%I[GXWG
M4(Y'RS=^=C<-M=M]<5ITR2>V(MAPMV%[I2<C\1TRF4[(?*&Z\ABI<AD:]M)+
M;. 1T7[P*J1:'C$E/V-PK]GY+D/8%39$L[6"M=I+ X. M7%[WR&QC$GW4U'S
MZ4$S^@6JJH%$3S2@^Q>A_#R25 ?2!ERJ/.R95/@_N96A4E ?!\Y$G*$.KB(!
MNVGXFG$O'N9Z/<B+LZ0A*_E<6K'FV1VTA\ W!J[-:[\31'AQ/*0Z(K-D& _B
M$2J(/[.W.70G-HC+M)W7HECNJW&>1@,"TOKY6N:AR^;CV,:A"I7D\::+O6$Z
M+%GE^\(^4.U V?[YBIB6JQ4%_*'-ONPH.U-;_%MI989.DTF15M[:";-]I:RW
M>:@'0_U+"[E>K\\-"_ X.:**TA)TE*:F^1*R^P.1X\$J^$<1J@,,IYQ9EPRP
MH@CZ*FO%)!9ST( IS::C1<V ^DIPA1^I3OS:.*[H4.+P$F5^1<JX=7NN@<S*
MF0RBV=,.V>_6)U*DR1'G54/DMBO8=2%>,O7K!FMTH2.=$G^;/=*QN2"U@\L<
MV]R+0!K=$%MP9?_00%!N:U<R?KX07HG\JMZWXX9J[O%UFA6WQ!!FD;Q>OBTA
M;21FF0H9<*4H@:T3A$[<\3FM$(/5(459<U:$5>#1BA45469/]#@'9OF9HEU=
M6/L=U7;&#V_RA!01G:Z\X$D,Q]ZSWB*("U;1W-8:-OF<R!?UD ?1E\38E#G-
M1:Q7=]@_SE"T?CSZGHW5:4(O[FFZ?&[:1N_F:S/#(JQ]Z\MMGG)$O;GMU4KV
M)MZUME7;EU%4:( _$;!A>72Y3U0U3&=E9VIL_;1K8KG./:G8NB-:97Q1);T[
MN:--N 5W,)==KW*@KR>!I6EG]GFG(?N,R+DR&M  >=!CJ'3K@P7^8.]*I=+!
MB^FRI%.%9PSAHF>=AU !M;V:U%ZC?0YUI";AR%(B;>7@?/^LSQ.9Z,O>8T3
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MCL@[/C'LB7]_EG\NGV?O0A44I-@KA6_>>75OQ\TEQ>N2NNB\JC1LDG4&^54
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M.CFBT [^_#6HU!(KM]#Z%<,%H/F>&JUB=K$KH.;A^TA952N3L6N5M"^I#$>
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MS"W+K6\(R+Q 9%JKMD?.)MZBZ0$B;G2..3>_&4QUWKOQQJH+XSD.ZBN,W#P
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M 83;'!4<7S&TY=X R!8VU+;.%=$/\P-D_&\EQ&]MH?OM $V<E\LZ;U3?C@!
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MEBE1$9*$/ _3S^?_3WM7'M3DM<4_H 1,142)+ %$P*(@+I1%1""((6(02$*
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MM^[6[E;==^I434WW=+^GW^<\SWFZJ]%SZ#7@F9J2JA* @8$!O'WX .A%0 '
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M%A.=_1W;I_] ^QO-D%-P.*]54FPNK>@IE 39?;*H7C/.,EL;KEA>13)9:D?
M]17I4;P,QH<K5E06<4>1]3A28:S] .9A![(,AKHDP* 85E-!I5>_1.D>/4E[
MNINQK0*!V/Z[MYY!R''LSNF_I/&N%4%T<LF0OH)0.'XRSZ.)/SEK26_G4&4;
MIN;8QJUN=H6.@NK-.Q^^;9[B;4;>K':W4T^B!-\ZU[:\"6)^L;F(TH@M#!3Y
M[P9%,5^!O=#M#[UCYG^Z]S&$-T!X,DQ. =P(CY7LX@%JRC4[G:RU(%GZ&J@3
MSNLID[\F@^ZU<0E$PK\=0#3<'J[D\TA_H1\;:7!7]A85&87@:9N%-I5 GVC8
M\ C!Q_M)3U]2PH4@FS@S:N#&,5)21_8QZ?\(^N9J]SR"&HWMV3)OB'\PT'\)
M9$NQSS4;XE22-@\LSN^H2:[O]\+*5HRG/CDF,%OULT#(%-Z$G(\[&+S#/;0!
M<1$D)&;G5$+UD0IVA/DCZRTEGY?EL*WMD8_;;L9Q"B)L[-BK.3SV<TXY+M97
M<5PO?#NH#IB,LE1YD[Y^VJD<EQ6>0;U%N!2LTV&.'FOX5ZL+,KG/$8SCY.N8
M-72W.1[TR.!,>4A.I4>,IX(BR*;',11)M?\%;,V."I&P=[P&D^H9B<D* U"I
ML(WDZ';&ADE0526Y0P$QR21&;?8'P_)G1#IIUSMPVPSR#FHI$#-_J= I3GS0
M5>Q?;9SQXL4-@SY1P&&&E@%QS' ;?/TFZ3\5?SVSS@\866 X3N$5?O9H03D?
M*5A/#:$1'J;78.R7TR<B_29A6AL[];(P&PV +CNNKB%]0:4.FVN6I@RW'SHV
M+-EVLVAJT$!(!QK O>C;*Y\\_L.Y4PQUGY$A #ON_WE=]75^R9F%.:[2UR.'
M2#'6:,M\HKGYIF1$IOWMB5?TQ3$V$@W<$R_>PIJJC8>?5H+-O,C.]U^!9_J5
M@'&LXO\045QC*&.$/!'>V$MS!U$2I>^8BA^P;@QS#,D0!BL<*(P EA@C@E<#
M1X*RY*TX&V ICY^JQ:8+TM4_0Z4K.VMB+V9@<0%C#*<L6FC DN^.RPZ.!J+J
M^'!W/RX[E),KQW/L',C2)RC:@/6TT_5/1F(..X>K>\K[EX),A?[7FRZ*;,0.
MWVV=M)PW&J#_A 9:U$P%<A%,_6.HKT1W'O=U!PL05/ :&OAH&)]]C<MP<W#G
M!*M% ]<XG?=K4"9NY$]_<M\3/>X)1;*_#"+>L)X.@J@6V^G#J:N$:!G).),S
M0M8C9R[=T'T2_82F&R]H_A%C[/;R>I(M[=O(D['GNWSY^Z>]#5<?O#AN)I.5
M21W4OJ4WZ&K1K?:66YA8*,=E/5,Y%R^SP)YA&C]?5ML;(/PM=R37ZXXMH$3D
MB/E*/C"SZ!L7J)S+:'$_[A/^7N&TZ\_&I)1O2B,^Q]W9A(2"FK>?!V^O0PVE
M0]PLB$X0,Q>?5SJ:PD/=+99IG4@=(U^5OGKL0!VKTE7 @N.27S8JY8X&7H2C
M@8/L"Z@R5 PQA@IE>J@ZD-E&=X8U^BSU^_,VRD4G08]UO,CH9C&FO2P'*3+?
M2V?+0;:(T-4#4POB<*WUV_#PVS_*9Y7B5+5MEHRH<7&HC&7SI;[.7X6K^]6G
MM^E98JUG=6)K.'>Z\8JO%O AV-Y?K99' S*LJXZVG?4,^%"ZO\CFD2G$KNOV
MUE@T;[ NX!D07\XZOQ#0)7@\=W9_6_2_>B#JUIW?V:?4B?=-##L6,>;77B<R
M=@F9D#;0Z_?@L'O%V]6;'0OSPH<28@*[;^$[@^H@B%!15QT7HZTM_XT%:HI#
MY-YY2)Y:7CEFPQ3F'^+[4BOMB9-*Y,?1G-LT#[< ME\S1QXLONQ;]I<7%LDQ
M/K$9WM^:ID)RJ6?$67@M13QE/EN>S8".<Y4S*5 76K>[AC_0@ TR[AZ\%/ 9
M\N]?/ 8O]K//#K/B+LWYKE%Q_YSEH8&L$C3@_P2BDV!AW:P<?D70[0:;;7LY
M8?YAW5BPE9$PV\Q0B;ZUM&&$AA;<RLS.O"',=<E:JK<GXD5AO6W4H"+M$Z#O
M&;GKIKNT$;V% VZAM.#4UR+2+,V5M0BT;@010@8^$55XM7,_,'W<?UO7"7:Z
M5XCW=^KO@[1V;_K3&]]OZ.U<T__+-E7[C4=__+DA1@7%:4%6P,-EV&5B4WIK
M+YKX<?TJC7QVR(Z%LS[S\-2]*$ZG)%P3?^Y\';8A2V'MSLR^^;;ZBW*!3"0[
M%E=/QRF/(^BBLR,9S/8;<DWGX0J]$#X.8$$#"4X/]JN2$%6VG1UBPC+; &_3
MY#+7/="RM59?;)_T%L(XQ^EA>&9L'T T;9MEC^K&PZ.R2I'Y#J5"XN2:+R'K
M=WJP6=7MNXN9;20[]PXL(E=Q/M3A)V>;SEP0OLX=,/Y) $KVNK%(MLTW*L@,
M:9;#?$J,_1@ [QP^Q"XCS_/[]D4T(%M&3S+;:@A9RY09ZKIDSZ,<\/T1CB4N
M!2P[=AR^^*_[R4'ED=:8**E)64IZG?OW@5)]J_"P:#^>#=S:. IF7>9H@#\'
M"Z?H9=NNQ/?NG2TFX;4.AGRY\EV!QQ@+:YC+ _"V;DV,VK*/2\&4(X#W1^2/
M8C"TSW5]E5 EI4NZL_*=[#P7; ND5@)?)0>OKF_6IYH4;%(G?YW\P/+":-0M
MP\W@1=V)<B#*5'CKZ^3*@: @0W4^YN\&,[=CLZL^?T/3&3\^)YZ5E$OR+#?.
MQ*!M._I^4HS#%8;9' 1VA'/)HMV?S$\"DE>5%(:(V9)29 _2IEM);"L<2W@H
ML-,'$7S$9;I.@4K48+N;10/C,=Z6T:WB<%=,\+;K<_M7JF[.@M[?G@DTB3,S
MN-ACU2 T5GLLG^RF4AP4+^X_"5<GQBQ*/8Z]6$&:ZJ?JG_06YGY6_H[ CM_
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M9.'4$:5>TS!EJO6%+'(Y/O<-Y5HT]19D71]IZ_R-W2J+0C.QEW4>=%RNC<.
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M);S]*%B;8"J# ZN\(.:I6/2.HUH?,?^'*]HLGVO174+\2\8&7F^E<^P0D]C
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M\DJYDTL 9A_4%/6!^YF!:N3<O&#.I:OT"..[]\<<3WZ3R !'"\)72OV(UWP
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M_ #HG.  K@2D?V1] "R-/0#><(7YUULTSMTCC)<%;GV7KA\ 8/CAJ&?'T /
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M3>\L@YHJE?VG5#3=6C>0ME3KN%=B&^HT-%:_,%YHDIZM]SP'LZR;G*?%Z\)
MSRX^UM"F5V-^^?.;EO\!@W!1UKT8=OM3P\ZL-O-G9-LZ4-ZS22]/^IA_^KS(
MUM#<@867]GY-Q 3:/8T?8MU$F(O_6UZ%-KMW3\^9TG7RJ C/E&T2XHBA1T&
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MS9K F;#A&J>SF_=#T]=XIA0_/+[1(<, NI=K\ONGB$0Q\Q[.N-?A6UM@4M*
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M7Y342^URT'G#D$Q<I73S1YEZF>_3OZ<O!*Z-(7ON;H'<SW9\;Q^M.,6BL>.
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MY_D$YI ?]0&&'6[X6WX#28,UQ@31ISYR-,BP?<*Z97\ _ 1UW-G?9Y7QOGL
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MV$&_JT]Q)V8O\ULF@M(]0<VGO4:IGF^W.*S"=9\8[:*8%\F4T_97(FQ5>!E
M4M(,G,6A-.[V6[DTH?LJC.\_2MWV"Y+Y&5WBW1B.5D ]5 CD#S37LW,'\K0(
MLBQ33S.'#_B;<@5M^[%*K36/VVA^*.,MI$VAU7<\V^2;;V0;A)=K ]O>:$<W
MLR:Z.!1RMCDNF(]G3GNHM<^Z!FT7\D)@B$P?FMA^NG9]/LC ^Y]];)USZC]
M61PP$(:$Q86C$;<A2G]&OA:XN_. ]\D#@/2M]MG$M9*U4Y83Z!Q11?Y;P^3\
MM."1G)!S'N&"H[DR?\=9CD)7E>=WPP.YXM9X5AHVJZZ#1_S]?ORB>;-XJ-/+
M>37A0[O]M>W3$N62GMC'7&XN+A.H6MV7V=+5@PU=3L/.<-+Q9N/XI1FB&<NY
M 5Q_SJEN,RO7)'4].(I%M/+AWOKWQSP[Y/1ONDJR$ 1U7BZ=C?UI^=.\_![Y
M%LE0S%6SU"*JP%PF-8X!+6^'3\&;+ KRPNYF@[=GM;5_6,?_:5O*+W86S2]#
M4D%'E<JZ/TU/Y9ZIG ].?RZ>:2UIK\<5 >2:_.?'P_1FA/85L&^#FNT$8@?3
M=<?[+0J'1JE,C 299339\J>@K3'B05'K-\+TR"+XY!/"Q$+9&>/,:1U!3>V5
M=>414[_BR0(9[6MUCCZHBRZ$) O"74Z2("VJ-;A3H^7^E@S$I1AC@Y>V;3'7
MY9!GJZ(.=;@";:JJ&-7N,$;]*P+=HPB%<ZY0ZDLVV..B_CS]_%\<IOQ90)/%
M;=K89/-B[?$1X#FN.<_/^3Y>VB[B2+=<9[']HJ(FXBV^P3?"(ULQL(3QR"K(
M4D;IQDSH4?^C7)?^/49&B\R7L6[/W("2/LCV2I5;Z\)K]QS<9]-RD$AWK:J"
M0GRV;&5D[YZ,)]N0XCPY)(Q[FMWZ'^X0P$W)Z\@5"ZQQ;?UUL[NZZ@Y$E1Q#
M "VQ*\)R2B4(^;8H$I.KUKUXIO\7V8D5Q?J7XW<*R5J37^N^&V5/S.QVQ%$,
MN0-6IR-@8"684^)E"(CG:.U7FQ.DG102C"Y[85O4C1]B5/M)",WG)5^;S3WU
M80A/'J*O&&ON26+8,O]9O^D]4^,@[BZ(-FF>_W6EMF5S#4P$-,%'<IWAC_]K
MB:RL=;M&\G9 *KV*46"9OL<.>_\YE(,+K;X!,=>^0V6V;5/ "HR!OQIVB/]8
M?)FG]GV.T_6/-C[*U#^[%ON?#6 ?K['NN99F+W(/9Z\'8LM^X+)2YL;BYS'M
MU=)50+V-OJFK!--,QE#W$6G'ZX2I36<_'%(,=-P3X^E_#O_PX R9==A12WI:
MO;*Z7WC<^YIC@UB[,=C ,<:=A_6C^1<P?8)K?9"Q3#3UX5&%Y*5Y]CQF_V1A
MW%!PJ7NAU6BK#&_?MZ3&OL33\^$9CBE54_XS_I1LOJNH@)<E[VQ:792F$:%K
M&92S7>L983&"@V-M#X ?COZ22#\LXK#N#X04"2%))XQ8M@5S[(MG+OA'8&FK
MWG>AB<Q6]$]?<H'&G+3E'**FZ>E%UTH^>@9#SP;:(-3KJ>2!AG/%=!(1J\'0
M2GK<U6T9-A4Q P='[.81*H/V>FE!K?(WK3&.''B7QTLAJ] -XGM$*[1\1T%.
MHG^Y92):%9BO1@LW*!T)>CH11V7#2A^Z*M?&,4E]\H8$PJUHK6HTE$_P$7C7
M9&G,-^X6Q0@MC\5SQ)MD;5<B]:]TXX]HB'8IKICH0#[,)_RNRN*D;=Y#D-B(
M(1 0/R<GD\(9W2^NMT8X&V\1^ZN7KZZDO93G==&%+)R#*UGU%6&,_B3*_-@#
M8%5KI,'W2O&TE/T 4\OLI8"'EKQ&S0:(O\WV>$%2L[&@T;C/W-+P8K(]4KKV
M!VH=8[E]!_N,)!TSF@\K)\5;RE&4D:$SU_;1".XL4\J?2V,UA#'/)<GPB>S(
M:EF_=Y2T@60PAC6^-D>[E*R'1-2HBO(+/O,=55"NER&C5*@2''&F/,F+'J V
MUB_$7@^*V'Z,/2G^<'3(%.Q0+!&UQ"=?:].G@DGH\44O',G:ZQX S2[6#6-#
MDQ[[E%4W$SE/O+T'5<MB%$KM"4ZX]RF.0W%'_FAQ<^D8^ ]U6QF9^2HQI4RM
M<:RLST$1V<( O:\[R,)#MW?"$P,T**EW*],Y3F9]L+I8M88( <0L&H-NTV1#
M=%&^"0=X(OJ\G'&-N/"CDD,R27E9M?J**2I=9U<JNLN_Q]V>R 96L,)O'079
MB$(,,.)(=H:WB1+4F"D>G7[IN]T64 -I94E.ELV*U8)Z^M9\AS<&8C^>-6K8
MO.DG]R2_CJTZ89A/>4\"-V6EGV[4<0&RD.9Z 'SNTEB.QRB+J)/1C^82TE O
M'!RP?Z&%2?E*0MU>>\&<J1YKBUV1(OI]J$&H+R6:S\>1G2Y^_XL_NPKWGPX1
MN6UE?\%M=$:<)ZOWE,,S4F-4_ZV]MXR+<TGZAH=  B1HPF#!@@097$+P ,&#
M^PR2X!+<+4B"#18@N,O@#,$=@D/PP3VXN_M#SMG=<_9]][EWG_WMWKL?SH?Z
M,')U55=W5?^KJ[HO!2''5=N40@/U/.<$2>*LQ#:)W0PBY:O-;DU-DGP,UA_0
M\QX+;$-EV;B3:B,F/;K\*QF;NSC+)CG@9TJJT:#!TQ>>H5O_) [MI)TA*2O)
MPLX2;O5"*B5.<EVU8'>YY'% <U24XU?+3ZIZME+'A4F29? B SOQX*&H)/B.
M/=BWE3M0'S99'?/=/8:JB&1$%[>OT#6Z.&5FBKFM8U73\?0QN*]4W'H3$4=5
M5L)1W/TDPK2ODE/7Z?R9<HNMK"#T%N VO7;%0UI?T&@:/:]N&S5U#)34\M3;
M$+1G+K4DZH?I#\I,@>EIS+$WQA)AM/87I#I)1:_TJMF;<WJP!,[@.IHHD9S>
MUNA]]%^4DDQEJ2^ ,M@/E6S#E#6Y D;N78=CH8(S7&R9LP[QV0C;61GJ@>RY
M]"#V#'$<)\G909J@2\$=U(1N4U[RYBP.R'J-6"NFO7&TWHLB!3:M&6 Z?-A"
MG_Z=2N:4*[>;*RE_OD6.2;3U=9KB(C+%-0,?*$CC;17"$M:CA---0=2$? LH
MTEK&NRDNXBHG&"$ !47'-&9,;W 6"LF7-4H9UF,(GS_@C3=0L[MS!^HDE?=Y
M/+D9O@4_7,E;AL,$X->9; ;TT5O8L)>C?H'YU#NO]T:8EV".(^5/E+_(YFJ]
M7*_S/A^11J>.<(T')<OMK!I0=0/)FL3PE.CH5?#?9N2^Q(M".,N(<Y\VFD1Y
MVI'SGW+!&"PSAW%#7 ?39(=C1.%[%5'72;!\W@7-#T8GA9.HR'CJP\H^V4#@
MP)GTB*%:1B[3N*(8T$CX/QDV:C0\VSMNJ#011C)6_&(M)#V9GO?D"TTO:6>N
M')?>/)=]/_> PU01U@:JS BR"\\W_:G9>GR>QR:CDN/L7SLIB^O$YL>Y:D6_
M07S)J6X!(;;)Y&/PLD>',#/O3R[-Q=O:I9]L<%?]6RLE8N0R]Y15\FJ;MBY=
M. ;7LCHH98AK6 W??1;CK<+6^D_CD;]-<1Q 'W%2D0@A!J0U0>BR.WWNC.[,
M+*QE![=X:AL,S@[8.LI]K>3O@M:'1SRI\CR[L]R8DTUE66:RTN"]HB;8J-$P
MKPWT:HY3E-D_!YA\PXT8Y7JK63J&O(-08> V\-M745%)C(I##!&KB"#7Y JP
MNXX)L838YTP ;+^/=P.L.31N6(9?50_!*6,#-/R^)V?$5[W+IJ?K J^HV@RG
MH=+5CN^LP=WD]HU2G&Q(<XPT'^Y!ZF5RS]);9*M>],ETAXJ<Y)P >:HM<HM&
M<P[L#D%/08SOVU2'OVX@K<O#G[2 ([KA9NK/U5@!&L9?OQ5:G<G:S[U\AH57
MP?W9YBIOU2\^AE&U)U<_5YH$X3B2Q(0WOJ2IKRX:=1<]CO0Y_MU5TUJ0=> -
M^]-+^W/"FSVLV>,YY>>!M('IX:)4&#CF&&+WP20%&TT+,+^\K ;CP$%( ]4
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M\Z'S,&6[D1#[W([\M/\6H!.V?0L@N/LD?[GXL_V0<L\:(8871:<2RQ*C:;<
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MM6Y+O9ZFZ>ED-C1MA&SD_?8/K7?RS';3"JCF=R:%3&V#]V;)@*[7V-.BY1;
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M0=G*  L6P^*J2#D<:C<]NZJW9.P\^;RRR<D#&[;KD[+3C*/PAO<(-J9M'SK
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M81>OI1]DC?YBQ_TVM+./G$:3*Y)6PG':S NG@'75/A5])W;T:ZO.-SN*JO>
MR&+3N\,[%YME491Q9P%37\;5>T"SO[[9;29#+5QQ1F6^Z5GJT TSVGOV41D/
M)V[G&8@:!G#]CG3HC-)-=>Q5P-YB&2&UH'7GO@IH^NUEEBQ^;YA#(@A9GZ2-
MZVQF\-;M+KLD2PV2F'QN%,<&CBYC.L9N>N >V;=[X=1C"@)L=Q57O'XK/<&9
M&JQ2%; XV^86+O#4P5?^'D ./Y*\DW#^\7/G%@0?>\T'UU/RZU-U+QUF-1A
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M!E9&RCXE%9 K@>-*]+_FN^1X%%E"\U)9)STG[OCX%+LA!!>YC=O*S2T6OWO
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M.<S4[PI34&W8D%@Q!L$+,/%H_G-_SZ9>;_2_1O/ P1*EYF-46N89J1=BM 7
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M4-.1.V\JEZXATPJ&^E0+[RB#1V7\BRLJ;NNKUB,A(K/E80\ZF1=R1=I(GVX
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MH5[4=XH\Y\(;WP] #I46>/L6EL,O"D='UC?TZ]H>M&.5&6O"#8D<A,D!(!;
MT4A\;^N(/780YL)*P4?='3$6<33CTV:0TIP@U>Z[_+[WM93G'R.XR3Q<+]]M
M3^\V*;N+)F,'1Q2CCI?(LH<@VDGNYUA%O<G*%PP],ZOTH-0*6\4&:8IM,Z*&
MN7W<&@9M-MG6:Y?%E#/)\3 !QGQU/<) M6,]1QT+KSQNZJ"%CQ;SZ;H%7G&K
M:OC$M-V>@-WK>9D-Z\P(G93_7XKVE;\TR*_3O7[V;<H%8)?^![#,F;+#3Z9O
ME#N^2E4^F?ROW+9#?I;<*?"&#*WWB^P4:M<T#O=-N,XI_2>:I%"12?>B#^#O
MHGONHL.!";KX(6#& D]U!\XR+#FJ+PU[MC,G7-VN;Q$9W^>&:JI7$NC3!EI3
M.QH+XE^)E2"[_NPU;8M'GYKP+UB25(ERC@$-3M/!.W@-8#M&;HX'+$J(!?PP
MA1])ZPFCC7IDU.^D5^Z ['UPY>^3=)YQ"YG=.<4RML[F+SH%!W2_K@Q4*KR$
ML7E\+G.T=D-]E5PK#3)1UD9#-_8([K5,-6^I-Y9152]MQ:-133('KMY_H]W1
MZ.MNS;TI;[RI7;):X<@W]+.&[+6+TU6A^7HV>L\];\I#U#L.;C.^ "/.5@Y\
MMBOM@68H\<.QK"T9?WLW[7<_199:))"8*4)LO5QVZ'PC;<GX5O!])YYFG9BG
MWY"FYZ245X2=YJU;3Y/T11R(SEX82+[-3F>P)JE3<[84K7#")8P5)=9NL/.F
M.)H^NM"_H!D^_ !<*Z$0''>J*3-(,E,E(\*D2Q?!\8PR9.55X%FTAXB70G5J
M$(CNYI6$JKU3K25]OK2)-L6%?EAT9A@)4Z7C?J".;MK-G,UGJ) 5KC0N<IGN
M %_3W/:=:_T&)2=O\,]>40U8T+0>[U#_L,=.C/F^AK% ^LVO2@X#7G:"'_TY
M_!K[X*]S]8V-P2K$W11E0FM!+BKFJP7JLGC7)>Y&L4/;]W-3_*,5^PZO!>$?
M4!(NK6K;Y)VVU!ZB[N*<N*?34HS'VSL[7.L.YBC*W70S7[ZCM+XL#K QXA@1
MJ+1.2G)9_/FS8,I^JEM)D!>.VWKW3#DKV]H$09NA3QEMOBEA_LH[*M0KSN$D
M^($X'+E_2,0\8H^J@7 3LS"+MO:K]G&_FA\PO8/8I*N+/Y2)P:*..%"EMBE9
MT&7%6&Y:H:#"L,59BZ+O.(?? GZ)=7%O3CM/7QY@<QJ/54!)B4'Y25<E7]JK
ML9)CIB?TH4P-6[R,]1/L1ZNCN-^$E[JO!HV'B@,O>_=-EF7YL!<O]F-9YX6S
MJEM]BVX@?;SX*(R;.0V1)@JFD8_%O.GA"1#901@N+6PIV\4/=;S3EGR7*]HX
M084?4R20"IK 0N94Q2*G2;)J;^^<+0X'IDN^HUU_G:XVPP7./KH-M$PGQWK4
MJZ1ZKPYE][F V6?<!4QE;F>N:>!/GG")01^TS03>!W#.CB8VSESC*3GU%EU*
MNE\Z1P'#&^XX[7>X'KX/;>CY[_(/[Q<IG.@ZBLH9AVDH&KN*I\J5&1UX0%UR
MTD<BA18(Z*I7;*N=-SXTA>.Z5(^X>%?HJ?O7IA@I4A#'=]=4LE0Y6/,:IO<_
M\%P89;>KJL%+<*>/*_?<;8T4+QZWR&@#=1T*@Z;F2+\K%-Y9\%#J?- 0<QYT
M;91Y:>^ LEIAH>:/U826;^+RU-^N/!E5Z\P'=B=9U0\U<AJ>OBH]98@_(5-?
M)K>D1Y,':$J3FU/"?5]2EFAU FHM:I1QX0)S^V^D80-/!M#!=SS@4\>=[^]-
M0=;8F&/.ZL8R8A<U[[_5(K8#?Y:J&^/(-;T')*7;<4F/6ABNB,U_G!ID7?:4
M0$C,A?2Z\Q.]DG&('VQ0_M3H<VD,.,F8TQGGR"@!%QCQ[%7_L'W;)@DN__7-
MC3G18;-^9[K*K=4:UI(]%M(W^_.AJ&S_Z/K(>F:D!X_8.QUJ(8Q*B?(;F#(E
M65<^3%'??*=HCR9QK<-")!NWYZ$CY4%\B,A]GHQG>+G&PM9-"[\L6-\>Y0)'
M/W&13BGB;0_0)0<VA-$D,;3P]UCI;\1A?K<2'!"^J?A]_/:$@WIW5:BM\]VK
MCKF\Z01-MWAVC\3B<[:;(K@'T^B!(\<>P@HBG&\E]YX2O,5/-9>-!N/@CW6E
M]\M!9W:<@XIKGMA(#%*/<VN?Z$B*O[9J=RR6I6WZ1A\OC7%*^#[2D"N.2T8
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M'$^B@<@_#Z"R :S-XC7Q=CP_5&V:C)ZRU6K8=>)0AS+X;&,KZ]I*H%@N).S
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MXMM'G\5&-0#(]SKW^EWAF335R-?I'3;.QX#8^E&"+!AQ#E>7M,<MQ<EL#Q?
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MU (A2J%\:[9ZU%$[^8,.A??V-XJD58P[+KT^$-WXC&PA/3?Q!%#^E[Z(EL+
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M0!KZ@]3ROR1319BSUQIH(E\O46A]M-H<"76#)!.7YKJ;\*YH?*VBS-GE2([
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MH>@U?H G+0&X$2.4*LB6B(/6O6O4A4^K31WP"\DO*??/$;W$] 49["_?8J7
M;*4K1*FY@<J(TZK'(X)[9KCMM;)(F:F(4,R2X(WA2R&08B\5PJHD9VT1&/)T
M0I/CIV\Z44-@VSU:#WJ,,RL@5QO*VT5RC%"AS/"4R0B1\O'DSPAY,69#&!A3
MZ^^$,[ GW>KOT-XH3OF]JOQ*HRBF9R.>@MVW9O@MY=4RUI13JE$VL^K"L,:
MUA36I^UR#:>*_2LGX<T'4Q<!\D)KDS]UZSM'>M]G294U7!E)=HR/A8FTC=&/
M1,_(9 A\RF:59EN,&@MDYS\1#73/00$CH%-@UI_5*!C2/BC'\VR3I+?1N5WP
MO<?*^YZ5K:>/6:7N#.2[">9#QD\I-K:^4_(JW[;%"7++U;X'W^2T\-+5#KY^
M1^2\OT>%K(- :]79.9W$X:M_B$!T*%#WS)C\%P=6R0]W^2OUQ+6EYN!V<C6Z
MC12Q[925JS%HXR75DQ?H23J->;,E>P?,OA.0U^Z/)8HB*\(ZA7'_6UH9G&]Y
M$Y )@-J>L<<LKUG$;Q"_?VGLJG>A<%)A@U;=:?;8MLQN-XHLRF40B84U!=9[
MJ&[LH1;"%0EPV_:-=>FUGG)C8X2KI>/3V#7LFN2:E]KP!!Q;4M!3/?4)7[_Y
M+=4O*![^<#P,.KK'5;&V=[,@>6GV\>[S<(]:B0E8#+'>M=JE0.GMF1W-6-;S
M):JZRJN31S3*._AIK_:!%H;W4#*M211O>X_U[ O;ZDO,O1/D@=3,N22A_P/L
M1D-LA+MH\@("X]:^>Y?;H$TCMGQKS%OZ.TDGA4Y;E/3;8^J)3$A2@\33'5W\
MZ(JBQC]W7*KZDO79[L,>J0$-ST9@%;I;W&?X@'^:B!8GCDI?&.<\;.O,C+_A
M6FR[=&_&8[>I]M.1Z6#34&>NTL'[H% ! HVV77-F.QD(<V;R _KK3(!M9=+/
M'A\ZGYL8./E%CW,!OL%DMX<R[-I#_I<I^QEX#]4]2%&V%H ]*9PU53W^8.MB
MTII<H2DQ0*?\0#>@EP/S;&@941%FT[+W9^?__)M$?6%"J.3DE[?7QYH?F*?\
MJ'C(ON&AS0)'OO<V;YG_QVA.X:F]%?H[,\2HIR>;7A*BN9=;^^VWR;B*T>(N
M\L&[WPR_U(CNJ>LJA^HI:!=81SD:IAU2*A1\!8[;91E$3AC(F84NV*PO*W F
M+J%+BPJT+P(0.WBM1XX:Y>$,(HW#]*)8&8Q \;^ !J&;P]4/5(G!]LP_^_<,
M\29F.CT"&7F=O=BRMRG/=7U% A-U3-Y!%XXBOD'CGEMT$U6&Q[1YEV \/N%.
MUR_V=E/Q*9,T41P\;LA(]6I$?SR4Y5_4+<P(O/&B'#%\957?'LC=O )A632<
MUV:.@_[TLQN R8Y.VA$UL96A0>U?Z[-O82^AO<9OSDCAAD\.O;-$2"06&&-'
M+M_$ [=\[1I"TG63WG9'#R+'%OU'JJ)YXK[?'P1T+3L+C=,M1T59]V]LR8)+
M"ZJ22E\T?AVB)G:+RZ2J.++7A@%/(4\*0?3UHF"CMJTY5R-'S3P:6Z?2JG4#
M0T[@*K+LE_2N)SNRA^3L)J-.4SPNN[RXTY:LW9.RJXT)G>A>[!A@$$OXF<U1
M^[A?E@]:L(E>4JY,%OVU4J_-'\W(SITUK;QAT-[6P24ZE)-"0S/LY' >I_@U
MO4QUH'N+7NP>Z-<N+-SN*2YCUZ6N*LUEQG'31(E^'9\AF\@S3,\&=(=[5U;2
M:4PU/I9"?WHCRT^IR[1^-E6^$E3"OY7+^D4]FXAYJ)$/E<IUG8]9_P2>22!]
M\N;\Q*60/6B$M0]<R)HQ+?H,::#0/P+D;FYDY5YR-;PKZ]#N,)^ $Q6B:\/4
MWL(%QA-$,J\+4G4[GCS_N#S7D N8:]^!H^KS0-!U\9TI 1/_IU ^WLV:R>!>
M,A,;J  \^BNWQ+"+W931C.;PBP?R>UDPLB$H/_;K5GEY\_V)R/2C$BG"JUM#
MPT6&GAP\$Q#9@#*_L>LA79_NG4")@("M*H-=ADNY$U2HA>SM8_I4M/+ 5H=Z
M:U#JLWT"L1MZ*<*=\VH=<M>)N?X?[O"=+X[G?@H"%7\!W*[.SN_0Q4RE LJ&
M@PRE-YX3#=MMBNJ<U/\U +[]UP XYJC);&"EPM'L7VO)WVS.)?ZM!&S\<+^?
MZJTS,B_4H%!:7YNWF6X2E]5ZI]'A1U*"5CDO XMH$?*2,T-TFIET$4V89W>*
M'_ \Q+^73S<<B"LI.5L_!0IX!$92Z((R_F_E]#.$6#3$S1E*:2IE\1TUH$*)
MJL3:RSU*Q0OH)>K'Z?UZ[K^-M% <#5.&F W?YS-H8^'QV4C-B;'+M*WXFV =
M!6+/F$SN?N4M /$3QOVLYA1*,&\.)8-519PRC78J_]-N[\LJ@XNQ\;RU>$&Z
M(C<NOF3_E^6+A0+<'^V?DD[=&30!J]H(8#0'JF;>P.]#%$EGV:N>J,;#WCG8
MZHQ_6V/#(KU:<W94Y6)_JBE;.*6F-[Z-W!@S&S(A>A_HG5Q9FQSU0IF$LB!!
M#K!4-B0-G<B[80,^DN;R9/&_I>&O-_LBQ)CC'K6>_EZJMO,\&^L[:\<[/^PM
ME8'WN&0+Z<[WC=CQE]!R5%&5S)S"5BX/Q97X@7Y5EKW45SLL5VL#&_C[5$<.
M]8L>M:**QH-6A:F+TOEWF^I\LV_;;]^R;K\)CQE%+%OPG;VX"2"%N"_U[K@H
MGZA[)124*6 -JR?MV],V[X[HT>+NMWS'$2T6*V]4??$*(9+8HW7[*I4-H3BW
MO%!N"DT5!)1M 1C;9JJ18,[<;T*V>0&$#M;I]SUN$!J@Y$1'#3G^2S=\86'D
M9]XV5GY\AU[\@'G5-\RO"SGM<[*4&-'BTQ_RF5FELKY;4_QRL?ZS9YYVZFGV
M& VWB&0PU.BG[=?!6[EHJ=)&;_OPLZGVRK_?7BT1!IGV_I:3!P3,5"PX67NI
M;#,264N\RGB.$C;U EB@"LN$XSK4W,!K" '1E!N(M*,E38)B9+S*"J72<_Y!
M>GPWU8%S,%7"0%.=&N=CX[#@Y"L%*$M7VEK&YMIGO,@6X[2>FK,GA))T7OP_
MI+\#5^LN*>A+]*BI5JDY0W6MV.UKB?H%P8+QMMJI,3&=CVKMK$R)WU"L>5R=
MJN.8^)AU3Q0NO6).WTKDU *BT3&S-BS+=;9(W@)1.8GIE*\((3YEE4)#I#8?
MB5#X#_L8J]YAMB0,U]DUH%E*#RK@93-S6S%)^\U+>24"KG^$5O3KRW[:[]\%
MGS;)WL9;(@_".3-NFLFK-\X +4>>??_^O7@ Y=(Y@!993U-=#-O2]M1^]@_>
M<XJ[GW["%H5I__8:,:3]+L6%OL 3?O^00N6D1Q>8I^''3X[4;RW3()['YOFB
M&S/6U$I.I5GH/E.F&FJF_<Z_<(KR^%B1_(BT#G\@/I]"Z)6] _O;KWACS7MZ
M)D6]*<V=TL %L==?51YE'7;6BVK[?YUP8086 -Y419@JZKMY?V="(TM;W%0&
M',/G&_1<HHP6(-M&4E91R5\LU;@$M:YU[\26&'"D@?7OTBL-:HE&Q==S(9P<
M_&)D+\5ICO0'*6Q!;([?&1CS"V6]38C'XSY::CBE);\,2:P/3UPI>H;E,62#
MI>TXVIKVHW&%O%%Y1]CLG7&*M3TG(T38R!6">BE:.0SY:-"HBBLWXFE 626U
M43N:"O]B:60)?63]QX*VO[AG*WKUR'XMX:J@07[^&03W ^![JN<B&OR,[<62
M6N<^D;&>R2?L2*E$_7S_PU^'].Z9$TG$1:_A@SNT#[;$(JCYNL9X KL4&B0K
MLWI_<\RV>'OC#:O=ZNU,5HO?T3L1Y]H]8VDC>$NUKS(8;6$MD"!*/DQ,.Y_-
MBJ$1-AK1]T HEAE#-Z?O0(U<>AY.X@Y#J*TII73#U]V&)NQG(,IHG^/?>_I]
ML+LNDX"IXDCGJ\+"[JST6*^?KJ!QBM#P9JNR04LIG3AX4(T_CM&?5N42&QWQ
MHB7U3\S#XZW3GD)'% [%E7F>C;[9BA6B@JS_I#/@$ETB68,->?P;EG(-*9^1
M@;%M 3^Q$Z.O/3QCM,]>]@]D&F+X"AN:K,%'K^9^ %,()J6)V(NLX^6UQ+O.
M9\H?OWL4Y_[2CH<87P[X_JV0)G5"6V@G(+@!-9ORI+#6 ER1B#NG?(%QZ:I4
MBOC$2IS;:D,W"BDU80-J40;O5)J UE _A^.53  XU85\*$2JQWTM6YMBSOW7
M%.'"R2<HHF] >*GT?F'AO;%:0XU R4VD"8\O%X#00.B!2C$)G3[J-W!9.)G-
M\ACHO]Z^TL'=L\8VL?S]AS7J''R8>\KDP[G^?Y#?__3OD-_O(-KX#&J"&J9C
M>U#83&O\U\87BG <<F!T-M1I;;29O62<+QN:Z?X[<1>QPM[3 &-0[ V(-J4;
M_CIY6%%U>"(*&T2HN*1PY%:8[/E$&7NRU@SD2#LAG9:-NZGY6^7)9OC<E/P3
MM;WS).,':"U3LD*U>;ZL2=&-HN@AJME<AA'D_'9 "4\4ILD$_1(U@(-XWGZL
M$-=\64G_L9KW**^I'47+.V>14.QV#^WEE30E@$E1U[*"17Y/>?T#]2MO36EY
MC\W&/V%AF7H)LP4H]O:*HMV=,1@KB<]=T:@5J#6(U$7^SPU@5P7,@_SNT.7"
M:]@^G"=$RUEH651*]:4$PP[' WWY8[V9:=21M>!8.T@7-IA50=\AAW+^Y"LD
MXD2ABXL397HLI#QP_\-FUFCFMJ=NL,V)]*SY".3[RM=) *))-Q">CQT6 IP?
MKRB$:U]%,<@.E'=M[.G\3M)MK(\1!BD,!%#V*CTY&TQQ9(G*=?#Z(SL:)8=0
M%X?3[30T(6=US5DVE1&B0_,,=!I%'60J0A.U>J)!.\\-[X9%M?X"5$1Z-@4M
MZE^LTI$WWB[E%[6=ME-K\6U/?4H^HPF-B0)5>T7&TR-2149^X"0\KH LDT"H
M#D^7Q9OPM_2TY*Z+E[39QT%OZP9B<GVC5NE8LE(6G,Y(Q_<]1EU@=+VX28'6
MU>I!,Q*PI8A^PRHWVE1?5LH11](5ARODV;P91JC (WX>,.,LT5O-.#!BT71.
M'^7QY4\ V<1>Z*X.!D;.1MK,I^RSG:-1<JD@W;Q,-9J<U5P%)GH_DE?*.3]C
M2$,&-(S%_E,8*':G^"D^V*A74Q-Y2)QLTM'Q)8&/\K$I=RUME<^YV;?)(I!5
MBHN-G*_%KUO#.Q",)4DTU:-)UD-EV!0)(]'^J+'9:S):S%$J5ER5)VX\(RQM
MB1+7*3#S>65T579U]<NDKQ'";C6!G<I&MUL\ _OACT2JD4J;)'N:+A]-;^>^
M3L(RA)0RT/GNIB1@T'?I!?.$^I&Q#C<46#$=>1A/I^+'C7(*7NPWI3Q>)=D<
MS>T+9?CRXL)I+A6\'Y7"MN6+W8 ;V)14FB:4[WD<]A<JEPL1X5[8M5UE%@_>
M,8G[U(<#UP3QE>=8,15'[",%,LHZ?6XDDZB%Z!\3HXYY]+O)]43?PY40!Y9%
M"7G+#7>LCTB%)JVW\=F50'0^B7C]RT--/#+V(X#RUI"H8V<R-?":"TT80(OD
MP'0+&5NB4I+:ZLHAE+1EXO_3  %=,#]5@RWI%O2\+Q/B>G'FOPGW*D?>*E([
MU1D_(M!.92V/;V%"4U_=@5<TR!>[# 6P639H+TL0FNJ^<<CQ^QHWJ=H/*H5"
M7W)$%J86IIVS8!;PI76J3AW57?&*GT>J?,)86,V)B>)6QGBU:(*#7HZ5+=MS
MTKH/V0#AEC4S%LA@N%3BBX\,_+:;$^A\?WXB*BH2@E%OH4\XE1%*IDGANIC*
MOP#;A7Z>8R::\5]TN"-K!]K3PAGTW >Q#JLK%%;22R72!Z15X060H_%"::T5
M?LTFF#*"]=O,*V_-.$_)UZ/+4L9J.=!QQP_L2UJE9,=OJYFS/&>ZN(0?%S5_
M3!N[[PR<#5C8Y)8B75".&DXEE-MR:*M3"_F.GQN\_\!(-^BAE&**%6KBLS#6
M,<7:@IBU(D7/Q4\'.W4[1&A;LN:_'^LV=&KC;&R$4D=Y=RGW1=Y.]?)K&):S
MS9# >#.;=-70(@E/-BBWJ9'N)RTH$X(3MK!\L=N9JQJ;ILG\!C+1=&[L6A+L
M;*BS%+?05<6$:6YD] O/&UV*O(ROD1P6"V#%B0+EU<^"  ;C_#<X <%I)0.$
M7#3X#$CA..+( O9N>?/7_&NJ+EQ-]<OL4RC'%J#R<^ES!=.%%R)*_L$U V-[
M"8?&^MM(FAZCR5<P.*\K#PD;YE[U"1YB0V[:1"7%HYH[I%(K9%1]<5)H4)J3
MS-4N,\?8]!?*!>-PC*O+.WPQZ&NG/_0Q\FSPZK*2JJZI?0JA\:G6YYGEFQ/M
MQIHFM#^'P5SE.3]E)./.@O?OS2;@:'NIV&Y^(?W/U!R\\KQ]5AU(<6J0VE@2
M/)CBCM<(M)%(R:*CAJ<W-^RXO&CJG"QTQ"*^2Z+M^...0F_/6&.SORJ=E3.^
M(6,[/B>6S@[5Q"4]FWW <<Q N-T*\1B&AOD>T8B?F/[3,IE"]N+L$B.2?/N'
MQ'J<"X\V Z#^C,^NNRY'"[F4FNP(^Z;:1?V]OSX :JM\@>5>%(EB4UXMO"Y%
MQBT?@^#=V!=5X>J(2S[-CH5(]&,?_GVGM%]VR"OJP1!'N:BW'AUQ$!?ME&]O
MNO/=?1)!L0Z67.X$)"N>7_HF6O]PZT]>+O/10YK,&ZH!7QS7%S:7"CZS;,L%
MPS)=2F%@?'VT^D@^=SW<0)R+6R92;-<K8"0I!$IQ[6\$Y*?G$XP9:D@RC(RY
MB1 LL:IRXS<\DE)RKUUM$U1MJ\%R"6L4.B%?,.L?,U\LV7!4"\WT*H>5S)<G
MV5DL#;@<VY'BQLO[K(I2\I9IV%I*J/'+S_4S;']9)W#@>?7<28_V\9*6..6[
MH2SE^]Z!E7?+RX&A>E>35JW8/]P:^YL)&=843IW^290J6FVF<[T*'T!1(X!B
M")O'O."**D'.#0USF^'1255>+92UA9@QYB@(V1NH^U/>Q.Y!Y8O.G0'IPV[6
M79.7K/I(PS1[K'%@K]E0NS7%W3=QQ,M*DWR!N)$GJW1Y9&IL3_.WC.@WF1K,
M0 5Q&>6QBWV(K3PFF]*SS0V'BJUFBS F#VU9<+V[9+HU.D;EVB-@"MK(":K\
MWM)LX=G@57&X66FUX; _J,SUO/[)UFH3>_WHEF'XD+5%-Y[N 5A!+5M:\DBT
M3LO6A1+;ZW:&LDL#]_"CJ$3*ZDZC^+ PD1 GZG P-1TB@[;^EQR;X9>3S(#I
MK']-!_X";,X>QB^BHR5X?0BNG3Z?[BA5=08?^1<[-.@J 2C^34'Y/\%Y<[G9
MT9_TLINN37\!U9;WPS"%#<'RT\R^B/9O#0-LN\JRZMVSK'=,+2S$SS(K87Y:
MV-)+H5J/*=,W'#AC]91M=QCE*MGOC=KC*]@JB8A;IPJNQOH1S.*I"224W"!M
M[G*-#RV'GJ!@ZJROF*>)F34[DZCCY=>K6+W<Z:+4UK9\1O:0O1)X1?I2<;SC
MUH7>:T-6MY-ADX]P=_@49(>(5;U%]UJEDAJVE''@(78$2U&VQHFIY2G%H<^3
M<Y]]5-KGSDI&R$/Q%T!:H-&O<\B&M%;*NB36VQA9D7-S3]1J2,_<K'U^.^U0
MY)3UZR90;E=30FSE15.I]..\!9 6!N0>K]1F3ZB>/2WE&44<75+P*8.D[80X
M!4>7W]=N0SJ2_EARF62$=-[$;R=)*1GC2V\9M>HF)W09(V(6^9J(O:/!YRSI
M:6AV<[X&O[E\X7 #1C2+GG%PHMID?P@RF.7VG1"%,*$&8"$"IC6^\$D7K-K#
M)SNFTRX0]<H+H_1\"I]'LD6RG;)(4]S*.:Q'2$H*VMI:T"A9/NVDL>N"?%^;
M?H/CPSA,E:*T"J7I_D<*9OVQ&><F\@%J'FK>L5M#0P.393;.*7*#O-94.HW2
M]MM,!W+.DXLR_?VW$S<.+:/JA>XLI9\>X\MZK2-P$BGOZP3GLJ=N](RY]&.,
MA7F%'P\D)WVB+JER6<<N<R1__3Z4Q"6%\3Z5E)D_RT/V(S%:)-G@Q-8Y'9]U
M F7Z"4.5V]^2\!=0[P+\V)V\.YWK<E03UP*4"!AWC&',9V6*JNBQ@FWRL5DW
M7TL9-+;&>&J:)'Q?!&$8Z&U8MR]*8!4Q+5G10]K:ZC-!+]<<&?=SX!LHTZ%(
MSK$*W@%UN\^E=P,!^L0V"EN'R]EO-AY5]0&?]557VO^<0Q".J6W5,$K209?W
MG^R_X<S@'L:Q8<A9"-1U=='GEXHHL<R$>VK5RCB;BY+08KB_"SN*]0QEVZV=
MP5,NBP,=).<3^D-=3/W3Z%4P2NW.:^GIQO$BDWR<AFU+ X]9H32;!L;D5/J,
MI5MXH!!U']MR1"+,G2';XF;VPTK#W)%EM#6_9-_S\![VREH$;W=<@4WIH6/'
M].;,6+)#TX<UE0E4FX_<1F5B->/,K$XL,CBY\WQD,9Y1FU4:F$F6ZN0_RQW%
MBM=@AWWT LEZS@3R+86RT*E%/$V\27<S:2,WLM@ _@@#XH51)?GCN_>Z0<%J
M2G-8LC[XX#A,\.F&*#W(&C^F6O #33V@^<BPNEJ-^'FGY<%"#GR)QNH&)UYE
M>!?X3XUQCX]8/PE@3O^](59@\E9>D5DTO5]\<UH-S79N-*_#[4NP@I05?^$/
MINJ_0YL6998MQ'P<E>PU: M-X4AWM74[%ZP]&_@5.BPSXKO"9AWFP:__0^B3
MT&%?\7,Z>L>ULE:%BO'\)84=5QU'KT^<*NPQ3=?E C,*[!O*S R;=],W\Y&8
M3X9AI)@CM6(/&Y35,^0X#66LJC_.=6&=R9IQXKR!J%6 /F)(0\BU>>W-B9[C
M,]XI(A?F0<^)E,G)%M&OD;R*[7#:C*VC&,3 /A>KP^B*;F_@M$^8:N[KF]PY
MXN@.!5<L,J4.]=<NGBM9J;PQ=5NBA^TYJF]M+BE"S?CH=&X8^371]:H%_J'B
MK(6"?H]7L^]G@J,".PBXA. F,56"O<30"E5C:=4CP_5TD5!F>3='59$>;E99
MMFLAD)8(I4BG8S&.S7510>)2XTH.DZ,_/\O10;@!V '&%_'&[4C3:5^LO%I@
M^4^RP.(AJ$_Z@(GVA!=RB(@\^PL(K5]H-%IC]Z1)(,M/U$31% (?[]3F\2VH
MLBR,)X?4S:R!^K7^Z3-0"]-X=QZ=8=4#@=-[^<QV78W$DH9.$.](LU#>%R<H
MA@QPC<>VL?.V[;ES5<&GL81J^&U,VDV@]CP&NQ0\UG969;B9P<7BIE)2]IJ'
MX"6V#XW;_ %8W%Q?=>#V4J@!\\)O3O'U@)L:#4?5DM0G&K_9W!WA=+H,_S>&
M0!-_O ;K)1Z&^A.7O#P-2)+TL=5OI-(7!>1;BQW*[>F5@R;Z"RC>:]7-P%E<
M,R_#E,^B%)62N/\; JJ17U8B14!V./42Q:V-N9O^0?+N_V)8\?\E8OZU>(W,
M:_E/0=0/,C)M_US/_U.@\D,D>).&FI5VDN9T_[4;X'5 ,]24F&-5D%T^TT$;
MQ+/QN3L^BOM)%29>+<O2L.L8K)QRT2:?L,2&O+FD;_)=1V!Y/]ULR%;_"Z@P
M%F?)"UN9V+R)HK4UV[%0[B7I\)\Y]J4^JAY.N?#UL+@I"3;<?&"IQ,A>A=],
MSAV"6I2MY(13@D^A?4-G6<<)ASK:.'01H^^#MLUE!\UR:$BTJPO9&EJQY4],
M.^:?VRM&2QKT+GYB5@_K,N,;F'F[U+1@SGL.)P&'D9"@6]-/7*;53"N4<R>]
M.D3VU6P[,BT]1+*_3E53H+2/@=V8];N2E'Q%'"S$KB"JI>B S'1!*.$M[B09
M+<,J7;=JY<R?!PQ.)9Y( @D8Y*S6PF0@4%9NPW>2QEQI#CQD#9KSBP<Q"<<\
MMDHJ%3B_+_V\5C[3I$?W;/#G\.A,R=)P"3V&;$?OSY!*WL[V54G[(J;2],;8
M(0>NRKS5-Q$Y[!+&\RJZX%R (]Y?#B-_@=*.%OZTHC:.%)O*:G%$NZY+.DFZ
M+IG0VNO6%FQPE*J]KQATZ;\>ARCON#U]S'J6=_3N+^#CH?FTYO!79&.]:43B
MR 2VFW;+D>G]]IF8YH?$MT%D5I(M1\-0J,">;GD6&&KGY4*; 9P..FC5;/Q5
M#"TR8<;FI"E5.W)*":2A>O:NV<\(2RC]KF=8ZRO%MP3_5%%22)2L=T'?>9%C
MP/"%?H5#36=BIF*:Y5&B#L;CFG-8]"T;P;7]H/V>@FO(;Q9-%,':U.1F_/K*
M[1,S8G6A<-3[J52?_B(:R^5,4H9T3AGT8$B!5)'<#U\W?/7QI;&!;PYJXZHC
MJW_VG&;UTNL8K;DX$5*7SJW*/?67%7='RD[%W!S/WPQ89Z<HC' '9AAG>'K?
MM$[?- PK]L;?!A62>"A)BK#;-H\VF7>-^1\Q#&86#S]0;&LJ.T5IF"'7^F5
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MA_=5:NPHKL(V*#9C1,6Q*[5%C3BY]_O9VXC<&E?O>SPOBN7:-#Q_3VO7),^
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MM]>8<EPO8-!0@1A5\[!_7\Q0TB>V!S;&%,U#$V-G!$=('M,76B^\@;I+1;*
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MT+_/=LJ=9G<>*! S/O8U==;F<[/G"6 Y9]PF8PWH7.]&-BPRAEAQ?8,P('$
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MS3$@UC?/1\>M+A9XD$ZJ-5H]F\[G\+VP1$!E.73\[MGN&=U[R!!DS%<SC8\
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MM[HT0LPS%2M2FLXG<HY5P:TQ6R*W,M C.MXU\&-%7%8*]V>T6%1"K)R=QXM
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M%54 ISVCZ?"3<U'3Z\W%@4;0^V^A6T:]X:KO]IQ^G]R6&-!VR4LP7[*O;N9
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MX:;,^>!'Y60[1HNW[&H+#C<H6^/?"QW$/./DEES70&:1R ;8+O-/8CV2@JK
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M?/#!XO'Q-:^52HGJ!/>H4P%4@/G?13DS)-:65'4&&\M'#FF$W&B'O>(XBO>
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M/MA)[=*@.._O!!FH\/RW_'^9^G_8'J!@-:GMOY8P"/T_7L(@VT(,N&W1C;?
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M"D3G-?7%_[D_>SZ$>9.$-C2GF[C.D8)7_<50ZN.VR 95%LQ_#77P^T"B)<:
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M"7\0+B/V44JIWDL5 ^/XL@Q^V!.LNE.20)*);4$R4P,E153PQG)!K"2[YB2
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MPQQOG9AJ4O\][IW I4Q^$O9L^=1[-*[^BIC#!U Y1B+N L:)2^L6UZ<EM/Q
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M2W3+3L> >_UP6J #8JDUL7;JQ3T7+2S.8R_X'O0'$(@6^:,$N]SSM8"J_P\
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M$%$VK\+10HV?CV%"<5"J*FR^WV7F3;Q#A:R401S] <9+7G<@,0=QZ[&(8?M
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M= TG"S*)0D%2OA?]#_8!#;.26CR?;DZ?N3AP4Y=/K 'P<.)+_CU$[+&(QJ&
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M_(Y?&V= ZU@:((++)Z0LLPEC7$@HU]LUTMR9RJ=&2R?O%+*45D@ M@+"%])
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M4<F)'R M\W$[>%<PIZS&.6&7<##B,W6*D*:P*[&U8FTI7(6( ^]^1E'T^P8
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MQ6-![Y+G/\7<,:# 2]E%[1;"_T5'TQ957R=0MS>PA<RS5H]3WKR'(<-F$S_
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M!EJ0[S\>.T JCA)UT==?HMQ+7AVAOI6 6OG18[]ZB:?;-HQMV]NTK('XIS_
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M]S2F;?LFRF(PW,J[22O_^_Y9,D96\B_,%D\<CH9;:YM-5Y?2&!E%F"C9V#8
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M'6"TO6?$\RHN.5IUXD'W1]?DQSULITS_R]]LV^NNN;_Z(3I8ZV!E?\^JW7?
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MC%R&VP0%$^-*W_=4DPZ8C"7</0@N1CX  _F9&+1$/X61[*M:*2:W#[MG+K#
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M/!;BKC :R+>)]U6.II8VML =V+GD-,VB^8A* ;T354=M&>-U'S\VW1X@CBG
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M@3GH<!.-3B]0<AJ72H'=S,>@+/(W<&*!P[<Y<E,P+50V5:LU=M<%3T1B][O
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MG$EM2;-/V(:H)DA LJ:KG9-EL827;6W+]FA;4G*NQPRI5 6^ 7;3UM\=WS?
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M.Q9*R* 8:V1P"]%L_*VYLK1R&#MLH7H ^DD$<M_H\BT^[B2./I!MNB+Q;DO
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MPWY4GB8"^GJ7*6+S.#LO&UEKZ=:7P=8AA4-[DD/ECJ.;!MNWF?WW#P AC@>
MMJZ?X8I@F%H+-2-AK_#'E08)# .*A8SSK*HF;)CF6".^86IM=-EI-! D\G$_
M(Z?;!(!TX=LQ2J6N<H3]?MGHM2" JU$:E!Z;[SH5>>ZW,+Q@;4H-GG7Q=;">
M,C )U/:GD:MO59P&AG$2QV*P8YS!]&:[35\UPF]T* @&'-,=5;MK;A_E *W_
M ^"NZ@$P%JGAA7HO;]"Z4_IH1(D=?L>-$O Q>)Z5LU9UL_*D1:RW)"VL95(?
M!=?4\\#C&6L:-2_(UH1@>*<E1A>1!V[S?K8>'CS#:YSSG>O?S\ND\)DG[E\C
M53\V&JZ%_^8BIU^Z=QLA,E:R/<)E"_MANQ;5.4!PY@)8<@+GD/DXV"G9K/IZ
MIT.<(;E*W5H7N?1I)C%IZ@AQ)>= -'VC%R$83M1OLQ)]IF+Q+VMFI2UK#8:Z
M9J/")I>XIM-RO1(T)N'$-?6CG!]7695297Z3[?7';AIW)W[1N,SP0) %LMHJ
M?[GO>Z6GF4\JN/F2N71&8F@S+-VVF[]@-@&.G%W_8!?8;@$%H:4^MB-N-0ZP
M>C2\;MB.)'N:*J*L^A(:MUHGY[*O2.>*?\=64BYTE'P;Z^-XYQKY )"UTY'(
ML)U-0O)6F"[B*&_G>H)SKC+CC&%?5OK._'TVU7UM5A5K[2WI$[[$@$O*^0_5
M;V.2'P!*4J>L_<'"_>FS(#H_$]MV.'/7GX6"D-+5G6@QX\Q>0^!A!V/[;,P*
M6UG39!(5KHDR@%XW=.B-.D94Q,EJ :Q\U=^AKXZ7/A@O]\DS 4?YR8PFFM(M
M4A%2$F=)E)W:B4.IX0:[]UMU75UVT,"4#EER0S6[W+$34!\L5/K]BBVLB<ZY
MK+F!/<ZA\UTZI9Y\<I2?;%&[5=7H:BKWK,IKX9%\V=P'0!]GRW7?;9?&8588
MURF44Y'#32QRS5:%G([CDY/PLGJ^5C:6:C=+]5[YK0A!EXY#?#I23<A#'[%O
M'9AC:K;P.\7])5>E&F51[)23R*/?\>W*<_Y4F2D0]/;JH%L$]3V!VB:[+&Z-
MSHW8G5<J\HZVN#3=!-V6DO9D';,\5II6FONO;"'X6K <A$FL7MDZ-GLAJ0?D
MX)C&<47$\M O=>+-9SDMOY]JO+BLH2%-#LCA_'.V4J]E:RV+#Q9]5/4E'F;'
MRH4/ .?64]:-Y8K4Q0X/BC.87$U598N$T >:P;A+A!OW:5Y!ZO2Y6?;Z9+=^
M5'&?&$R7L?%";)'0*\D><[^?#+J::$S)8PX4>=+ [?+C.N+$D6Q1H9CJZ3'=
ML;*0/RY08=,TOM4Y -)GE!HL+ :&WI^,MB,@RF?$^Q#HB0+7"@VQ>BXX*=7/
M8ZPWH:2*CS NB2ZVOP%'9FW&%D&JG!VEF8SINZ2?Z??&([++@X"5U#+HF>;4
MS[TNL\DF4(FQ;3)WWW)DKY;BC!&0(QC-_092U7XBDYY3NZB=8E'/JA>M9%^3
M::IR(B@NMF(+SZ ]/P>Y14/#V[.%A8VG.9*CS^:5/H Y2$2FQ1V9#5:E[DNL
M@P+7]*:EELRNT:668Z\SU._^//86=N-N6Q/G\>O-J171HF?;-\].X(,9"QDX
M.$P]/'.+D3C*8[O[Y#7%4IZ2H>(1\1==R234[*J,OC9=C97!R4S"[Q$G*Q4M
M#-*4K@8FM,'?][4ZBE'1M,7!]O1(P82R3W)!Q/1TDU%?KC;"-'.%R(WZ]4VC
M6%><^2>7ASR?9MS !D]%-E1\O9F^+=-I[?I_&G*])SJB0H3)3\8C>[ U7Q 5
MT\?[ZN+A[Y1R?5JN U);;K-[4<4>!=(99>),M%8U"3B4\= OM@06;UV;U_O'
M!Y.R<( JKQP\68]+(Z)>W4W"[GU)Q:5+)*-SC,UZ*'K'[-LKEM8_W</[Y5=-
M?,!<-3TY=+/8&_)S"E1@UQZI8Z9%_\<V:W2Z;H^FFWN+FESPR;@AH]@O\S=J
M@4:+./+*L;RQ?*U++JO.O"%,<9/KL1SWGM:.RXL$;2M8(A\4![5E[RMY71'9
M&!,1F^SWM$J<94D7),[YC4H_&RKZ3S[9]7QRLRTKX^3:9)4<_P'\L;E.OE$O
MP:4H6I-5YOTN9:\WB5ML*3VVOSJ8@O*,< :T[DKQO<RL,F\ZWM-Q&'G/?-I*
ML,-KXR-FVD6@W#8E4[&:6IMG)IB?9[0@BF;[C4=S5!^]R.X!@&S%)1W\."?-
M*\_HD^XF!7&GD-_>6D"K;0R( SGT%.]*B6X4RR9!H >N!GNYD>>0V=;Z_I38
MLLMK>S']S/&%<1;SX)JJ*LJ$A485E<2FJI -J7I6#)JP<L&Q:H7)V]=E9LI8
MQF]G<YF*9_INA^7=I/#<:> VC&,C(W;K"C>%<7?@MZH4=AG+32999]L6G[OT
M(!]*FAEA3?#9?='M7T?J8;&A9=GQPDF&^?XE94[<HJF+Y9)3>.>/O8X*B.<$
M-+-4MRU\E78B3#P24D@^?#QC-SSG;JA=:!=(E*JRX7!IW7D,GO9\>[Y%-4A%
MI^7401D C_-=Q7NQ->I]X4,A2[+7^#W=JMB YE*AA6[ +@#D6\ JP3U7OM-E
M?_O8A\:]"T2T!]*9F ZG@YF/%WCAL5*S>DDD6JYV&@V^=M*%EUF=^AL+<J.)
ML\H=%R5J@IL))OZ#L<1EXW+9:W+L);[?1/7TO[:NZ4X\ ':2SP3@D^\0#-X*
MF6/193["!B,S+,JJ-<GV_"+EF%Z9ZB\B(9EH(8J*R\]%,'9TFI16;=U4S78U
M9A5X2T(\K$3(]PQ-J6D>%04^%_O+K\D^,*\'@&V@^J9!0SH>=!&,3%W+;_S<
MJOJ;Y@?L<GG+UPIY\3%KP5N !SY-+B_E+Y@UH.>3?YY-51 K^8.[]UN*_AV,
M5TJ2+;/JR'ZJ)YC+/86#5AOUJQRVTUS0R*;!Q75/VN'PC&? ,9!D;^1"_1)%
M?W^WI>T0FDV';:[@(%;UY0Y,-AJEI654#UIS&R'5RDLKV$T4:7$T%Y,BO8S4
M^#)2/1IO$]Z]SD1^NV.^:M9:>5B=FK'^N<,-6MM+OPI#@>FWW]--\@^1@69M
MA(0JPLF;?@]8,-5B!F:X2;+5QQ_\@CJSXSC2!Y'G!!2YCAZREHPKEX32*M\]
M )921CN5=1BTD4(,+Y%(I@LB>W'0BMB.>QU\5,L ]$HTX4ML-]S13S:P\%+_
M1FV_S;QQ\>>OSB77J'O=H4MP9T-,1G8'V''YIK1WLH(0",*)5[>4&JYILA6;
MNWQM'4\2O&8SD^M0I&XAM\6@*_U?=_UDDFC5\5@C<ETT6TKE[E>!/9UQ?<O.
M90NTG0 1>0E%88"_G106&(&\=1V12'<"%<^^9!&Q6&A:82ML"54>=[ 4G&:=
MX?2A3#@)5#X74S'X"+6HJ7T3!ZS38.7ASP9R@/1.CX%UE/+&;Q-:&XG*-Y"W
M86=L?TZ'1,%]FO.TQA#I/IC@0?=U5YZ**V.(.=PUV/8Y&L+;V+&30^L9O^/N
M;4A=1A 2;U[#-74 ,Y>E2'AAX_)"BVA><21IH'(JXVEH61MLJ]3[2:4K?*RA
MF*J4J8N:0Y3H" 1ZDS#'F^QN[E1ZZ8\CO^S5NDQYZ)?L.:,ZDUZ\_?0IQN3J
M6=E+7Y'R4QS'3OW<"P1^93O>83F55/*R47NT%)CQ+,+#]&,[C+4JFPS*.+48
M;[;A$4 ^_0'A%N3-KD+H'96FL^8<\1NFO;QY&[%ZW]AZ"H/55^!KEC)#89[O
M-EE&O^8W2LL3Z3$I:LH3 ?YOH(<7>6:V6XXWN.W,OM@0N^U[;PC=_A"GP-P9
M5QHT$V*WU0=4@KM9&Q%D")$U"DVN25+;FEF.Y[7$.3-,^-7?+ST "%-GCH!%
M_!E/5IP"?3H&8N]6[ZG [W5U98I0%-Y@*"M$,YA4TM:=OD\==Z_?OE&BH_!R
MM P]YY_/J+U38UN>3C*O2-.&J-U\J7A^_V?G^@' NB- )8/#V0YJ3)JEM)!<
M.T==@+*6,.MHE(@"N-%EW:WM_5]$;#_;B*)J^Z !]+?5*2F9VDQJ4\#]HZ%3
MO-_*%W=XGN%:.C>T(B&OGD$;9TO^)S(&[S+ O;]+(,J4I'5B_YW4+)Z3("HY
MQZ3G[<N3<E,Y@S%-(M:B7P G=.ZVYPF#/$"SFUD@V&N5@Q$YH>)ML%Z<="+/
MP.'>:'?1<H"H4)>-L.%_^0S&MTG_C(SZQVJ^BZ38."="HV:Z+-?Z^&C#GIQ5
M9XWF,8'\Y2V4&PNUD70E+20"13>,Y_"L["Z\L',IBP$C]?.FP%+4]1'$>*D7
MGU)S_;0UXF#%YG:HF[OC9:2[U-L/^J[G(/_9IK"JG9\Z<$?\9UW=Z?:!?&1+
MVVIYUJ9^<XUL(-/=$_\7-)=&I.F!E%-;1&W8,K*OHE$SRXBL3PJGW7=\]3*@
MEA8?.6E^ S6;]V=O^D5';H,< W<>533KLB3-EB!%=/.JJ9&"B()&/D)XI?G5
M)^"S7O[?*S&OY)QS4!%V*R49GIA:G[=5/]*6F@I85K:$<JRJ?'>+Q8)#RVQ)
MD7B))5\H/>_8F("'\H-(U:8'P"RI8('E";;FEZ"L3H\NSV-YRA_/Z110"]:'
MQ %/ ;^(-;N4B:[>-^_/$'._* 4A=::,^NP=ZX[K.-8.8V-^1&_8FB< >CO0
M(74BMX$0LZ-%2;;QP'GU.VS$CR9\Q;9,>BLJ+&9ZK2:>Q^_\5J9?B^CULHPO
M)I%3;&0/ "MD8C'02,A]3;KX =#+>G!?UWHLT'G+>Y,:.A4(]<'0_/(VACEG
M))F"T6=/@\] II:#1;MFT^2MD(277FM'8.=Q(.9.4BINA3_'G^2/$1H?C=/W
MASRO]<-/[[SFY*T8YRE]TP;?.E]-5U37,#$NT*K?/,F@?-&I%$,O\[@>F_+9
MUI3?7,/U]_=.D)];LAG"U^"K=-*.]\F30926TB.K!M0L/Y-E)SEW1VDJYKE3
MI:2C'@#L<:8-<0HD?G5C? B[57XE;*W5P6@:*B%F >=N9%6Q/8TLBV7Z;YNQ
MC2DS,Y/! YS/XD*%3[C]@N]UNR_-[I5)'CL&^\#3UZ81  " &^,-2RFVXOHT
MO[Z$ 7-?F859<I9ZV';QUXUSGUN:\.@5O!<9Z'LSNVNISWFI)B[!D4=JC>"5
MKS7P"7:K^"5)S\2KBMC&GJN59@F(B4=E"$8%>0']BTY72LWL,]TG)=%>VM7U
M_NL;0"8LO>;E$9N6I#OE5([T) J.C+*Z$]HH-HOINE@ROIU,CJJQ]Q]9W_&@
M"G/T27WJ\A'@ZXL<.O&K/I%JKK8^*<XWFYETIT"8-4W@!Y]70XAVJV^29</K
M#M$[9D4#'4Q4CH]>?JG.[#C0L_Z*,GEJ#^HXSH#I^QGN^M[_"(!O02BDB3X:
MTLI;3)9\4K6I2'!R3FH$];:M5T_)B_IP:!LU%IZ((SH:;EOP;4_G]<8MH_J:
M7HAHC]XI/&EHIND*AVX7(,?[WSN\J,CH%MGE>0 @8)\5S9/O/MA<;M5+YRN.
M\WR5U_R32RP GBCV%KX9&6P@,YJT1]>>-S6Z-C[)"C4[IIQLW<FZ'](+8 HL
MF6A="-PR69$E^O!]59ZI6!>57XG(Y6__"9=<CY]OPUM+7U2>_XS%&6HURQC&
MZ$EY 'P%*][^XRCN!\VEOI$C1A!NX,$7DXDNR@CB5:#F*.^7" KF!8EHBL3[
M+4JM&#:(/,C:>02PSAJ;MJ+DWX/QPVM6:<*-346DJR>-X'U-][-M_YVJZH;:
M:3=XYJONYZ-1PFT]RLF['JTG>WAW-\2\)3G!\IBY/U"?5)5JI2_RZV85UU!'
MVX&3\A*40." PO#Y-"BGO:S<&X\^WF+J1G6:+.(=I$#$5H, ]/L.Y3NA1L\[
M5SWD HG_'K;E Z!)QRH/RD-6;D\$=;C_V(/QZ;IZG1-\:JI\(9[<CEPO""HS
M4_%A0"[]>%8O,F\:E.N5JXYPH/\\^):*U/F$$)4FP^ZEBKF2X!&!3_SG?V4.
M1(.YW#1#;WV@O.CPN_)OM^SA='^!VUYWKBOT^4<'D3XV!ZK>%QU[K!U:,7?E
M]G3IW7T_ZX;Y&@6VK./^RN>5?^:SIEICL(BT>P7TD:J,B"VK'0N+9GUM.%[C
M@SKC@**LV)@GK:A%DER34\FO>EZ]BCWO\E'E>1].60F,Z"G&1.$OGEZ+RKD?
MU>OP54Y<RZA7%VBD.0R[W+-ZHS6\M!8T 7:G"2KTJJ.Y5"\3?@!D2ET3^\A]
MZV)YJAC7^Q@Z73C8:LM(?BLJLD=".NIF8&"$PV,,+:'=&EJ5+@T3#IM9?TGA
M;RT)IU+7+XHE7QN**[TOE8;$T^)_]]@O/!58$.=1E([G=Q$ET7!6/LJ+A(\9
M^I-]T.D@'N@K[ C,&"A-OE$'>Q[-KEM$'C[-?#_F<+"&,=A _R2P@>^V3R!E
M*7*LX#(0U.1X]8$H%H8K9:R?Q\K*K/N/6LGR>8$8*(W]'E023,:?'[&QN6%&
M:/9I]9.3SA7#(=-%2V&*EUD'*<5\&3+V/.H\ZICX*<_%3>9JL^R*/>9FA[Z>
M_HX_QP1I;[QT?^52T.2CGC<M"8N#3<KKGFH&*=%K]C=^D'=&8/,9L?O=%?+-
M5D3VL_A2R]WM7Q]LN0Z)N[O4UAI)3 :Z&*#B=4[WQ)P&.>=T%,MDM=9B-07U
M:=]C$,\(-+$3\?-\:W4CIO1G6==-+ 7H'$I3ZK";<3&Q7CK8'=\'V@X?C#BD
M\9M?JNO>3Q_>-<%<^2T&$N9B'@!A,&T9FB-71Z\##A]*YQZ"O6ABC)PHC=?A
M'WB?C8ILMP$#1<,0FJZ5EZVHALN6 NJI1FV+D_XN-/AMDA2Q,<EL63?KI>4%
M3;:T>W'$B+$0>4M@855JEH6?/)>]LLX!.)WZRZH_D]KH'OLF*?5')?ACNNV<
M%?NY>E/G+K.I]*)Z:_63>V)3OCN##?PKXUZ',$8!+62^Y$#(;DL#'55U=.FH
M'/V'U4OT(*1 5SUX4M:AFM,66]DEP?1H[()_"@7?GU_.QE*AUG5IW11VQBP$
MH%CZSR(HTCNF#0"-)Y\ ?]"YI9\E#.*_<KV5?C3'[<@O+M&H^>"XKM1R.V]9
M@$T8>>\A/M%9J_G;3SYB_]V"#I#)/I<)@ OQ-#G*V3[GM47*E^U?H%J(<0GO
M X@7)9H(:K9>1\].)1+*2&,K\'2&!<YHL-Q99>0.O:R#K37A?-C(U>IW.%!U
MOTIWAX4S1B[AR(AT<S*&Y\5)#R\($VO_,I+,",P=$IA/UU:L^D:.H,?&/)B1
M9=$#?)G$5XS[IPMTQ'72Z1MJ?5/96S#S&,99IS^H6J-4^,I%:Y'(I.F\ X"'
MW-(&LE!W2 4OSBL%JIL<-1%49#Z(H@E3_F_F<OK447S:P%9:Y_@&J^]17/!$
M:XP!YEWOD3 _C06&&A,NA>I,:;HGN_H),0N+1HU06P7@I?NY8%N<B9&,5).Z
MP)P"MF9@:3BAU+P&BPF)/'*;7%VC@[;Z>CR6_?U+^H-MBS-RE4Q=!F\ED#W!
MJ3#H5>"R5E_/;57" P!(T;B49G#@1S(]P6D!6=.C[FYH(S*78J?]NE6-*\6J
M(Q?MD<-:GA.%F;+BG4N?M+^1>&A<%976G-OO!;W5UQ,:W2(%Q(&=NOEBLB-.
MSZ]<+Q%5)@^ GO0'P-E0*T3D1_"<6&=41RXQVF2B?N>-@PG'^_?<4GJN%^5#
MEP9+DN2!)9-2"V8[)G>\PKF1DL8V*3OP-T.25>7ZR$E7.,S^:_:9#RODP&*D
MR3%_ 036N]Y+5WVEFG\>M6<I3K@7I5MS&6MY+IZ?MW% "508R()ZS -QY,]!
M3K-?\:T1[Z!ZM 2?HQ47%JSP,+2(&43YUC<657;6G"6?C96_U*Q#.*[:(.T7
M#-Y_5J%,ZLG7.AR5.JPXPY6*<=PTC7O[HK.2G(0?U^>G9H+JREQZ&JC4AY"R
M7EY;,Q"K\81&%_Y\HV9B,Q.)*M[[-4_V,C;?,*>>L*K^3Y]@J@)!*F[S"@D!
MN#9D^O<QQ[O56-E'5A]RN$M6/X1%NTKDUTR&"]6(6-,5J'X<YRU]#*3BI<^B
MT^/E+'_NJ0=D4S,)B Z8=S@/]+SV8%#+(O!(L5=0?IQT?Q?%&HTTXD>Y\IBX
M2N%.O!+.MT0R'0(J;IZ)&+#*/[.1Z'(I@O:M,RTAPB[("-&I_2C!H34- 0J2
MA!CZ>!Q6&1<3^B?UVL9HEX%:@ ]IAH&GJ*;>2XN$6]<XD$']S^;CBN1^U2-D
MUXBB;\]>17V9I C]5YH3E0+YYT5*"VS#VB<S;*8+V?BS5-))([(?"WS:VUH$
M__?U;S)&0EIU'W$OSTN3LO _CG?I[4\[NY6@L@:%2(TW?HBF,ZG(*;EF_E7P
M$N0R&X5/N*VAZV^>%O%UU:UF,K9X*EI!*WUWX=KF]D(8#\<6T; 9OFC6]*D+
ML\(-S<*Y&T"C;B0N7;AX&=A%,WO.73TJYN#TU$FQ W77'SP& +S#QGR&]BXJ
M(M X64J@&@Y=X]K]?<.IYNASBS@1OS$ZZLXJ_B,DZ-SF5$O(.)\/Q%@U6L3+
M3J+!%4I[R;B5DNS4#41W:[6L'0X8(?'WP$S+?[O3,7,C#$0NNFR]9V7=AAO.
MY]N7N=X+H5U*/@"HXQX ?[I@H YJGHEJ>W1[QAC/#).T9[D8DE?EBI;Z6K#L
MQ#.T#Q21NQX=^=52%[]R,KQ838>=6VKGV-[;*3= U?0\:A#;WONQUOXKL<0X
M=MM/0Z9)L>M7A6]^^%RG?NF\>*0VN9#_GMJV?@&X 0 /HI[:SWKS]#R-/I6?
M[:;Y%AN-C*9YDXSF.76Y?--2:J?2SY)CW")O?MN_)I7\,(CO"03TW8)3IO<<
M_7A65J'2J"I@MF1ZMZN60\F,G;&DZ7DRWC:"GW]DL"/B$GDA[YY)2!._*,=T
M::++U;.M,JI3AOR *-WTS?/7"&]>AEK2V]5XZ/,9"SWAY4:YCIJFB2Y\<=FH
M5I]BJ/LN_#=*;P</;3,+QU)T+3U/J4])D-PW69;!..":I^73DDS:#)$3H%0X
M\4_W4FWG8FT0+*/%ZFG6JCV35DO$,(KS1K]38RX@4'3]E@COEC'YUN.1F&3*
M@2"PV[L^-.6.[&<HA>P\=,F*8P9GK]\PYNM_M6!N%X.M#V#IY2V+QJMV+3I>
M,J'G?'D 8,EJ72O=L;;&L#.,PX%3'(EAY70V!:@%BFVWUW?R/LP1/*^_ 8-&
M]+#Z;FU-^>,\>B,&_G30%IOO::HAC3I5N#9R6?V0-4C_&%0%C'MB]PN,>Z-
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MR* 3&!Z.B?[OO<!-),W-.:LTMHP4N]QGOELQH!1KBG[!MJ_\HZ+O+_Q:5M3
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M%\9/F*S\=2%Z;)1CC;C9!@1L_;>.*_[6JI?URU#6X7N#CPX>WJ,PP1:#+ZF
MLPB6:'Z55]%Y;_;&5+"SVN.]Y4B.!W6_ X,CBOJ$R5<^T><TF>E?%J[.FDC
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M6SJNYC,&8<L;'<)J6P7(L,=2)=?!GM&H1PV1;[3OMXNANZY79M;^,A;P4(U
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MB03TB!0@ 9.?@ \RGD+RS[9V:E*ZHP^]=9=[4(Z82  ?@A_X9^.Y_.":="0
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MK]6?.,K9NM)1):2&&,V"1?%(?&Y[P).A8F],2PZUSXRH)5Q*A;C.?MS/2.'
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MP"IH]X'E<?DM'9]:?'WKS\]:P"<NNUHB DM =J_I[,XNCI+NA'YO5WLF\$K
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M>W80##8NDH9C) #74KO0-"I6<85=7*S5"0G@:YAJ"#30!.4J=<48ZHZW6.(
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MAIX,A8PBDT/1JZ3@%NID8_ZD@J29^5AM\6^20P)?=7;_PO__1XW7_R?3/ZW
MK2P(8G0C7%IM2QQ]076UR<?*%G">+MUAMI+E+<H_0.QO+.N>8*LN 1U_).D?
M(86J6;8J(R,W?"8E6I6TFKXYCM)='<_T_=G[R]:7 ,@EX/0 \H_?"';4"M%>
MQ(?\ J><W\R2O 1DLW.=70*N))^/I]%E@XS&Q%W\\;@]53^F>13R"C_8?:2H
M_=>B/["_^6-4UOL'\'\\'V[/VN>?W:^$V%CY 7G_H6SC'S@ZW*E]=I'[4J7Z
M;EO<O\VM /YG.=<,B\5 Q#\4J:"(L$7GN.E+P.(E -_F!V* V!M2_XH6L^[M
M^&L1%^8#&([W?PO9^X,?B[;Z2)5:(=(C#>8JM.5?B^)P:HH.EP!E:97C/YYA
M%K/J7$C&X#-N\FFLV#^4:?Z#\&"@O+@=LJ[_(]C_J&"-/,2NX?*H&1R,CA&(
M$A<GZ6/Q[S<&QML^I I'4.@*1]-)/O_>BP%L.=K&0GF'3E,H8-1/'[N:Y&7V
MUU@[E9LXN'UGVMTQ1NOJM4%&J\IGH\PM%BV:VZH^W*"S,;A87LYA7,+?PH(0
M1<L:4R)SN1_T0!TS!HJ! ?BZ XV0LJZ*C>3FI"9V?M5>PF/3QG-*.\/@(H:S
M])^]I>.?_1CP8VB7OTLJ[-S^3#.BXX_!P'-AH4@APJ_]S$A%G;]W!//''13V
M6)F_RZH'+]6B3F!-O@/D^_NDP$'ZXVK!Z7^3#^H2P#:?%U05<A1'_[=Y<*ZR
MK/F7BIS'5%]V_ZFQ_#_7TV"?(VP5D-^[^/>AIL:-_:D>TUH]IKOM_U.>!<A9
M+/_$I.2?JT'L,!!'B_V92>4_U>/D%7GM_V?='9#BK6B"%+_\Y@T"<7CMW[@1
M<U*1_$^FROSM$EQCW\7P PB5:<%I?RYQAAMGL8UBU1%AHDG2:@>S,MM6H$RZ
M;NMXA94Q-#[/WNYUJ9K<H*SBU2HO)APOAT$]A61APA7<C0U)WCSQ]08A+RN,
M4(LA?!B7CR('Z5'O%5%(8]; #6%?:L>MXK\I'X.!-W%E_<GQY+,"&G&%#P*3
MA_9"LU82-'Y9DV5PN5OD0ES< _*'B:';,V;#0+I5&O'HTR"P5/?YVTM O" <
MW^UU"4"T,7$=TEX"FE62 #Y9=:A%A@U?WMT23ZP@[H$3^>/%#5KW]S_=)[)4
MV#:4676A\SBVH6/+9K^HX3PXB2>@W.8\9XEJ#B\5C!5T4%1'4Y)WUI>[^@@T
M3Y!= HBN0RJH5X3&\R)E;SUZK1??GVN@J4JJIDH[OV#J<%1M;F&F[N+",OQ-
MB-@ N(+@2UT>)7=BSAOJ,:U-6XUE4NK3#I @@9"M*O,*3)Q;+<V3[&5*;^T4
M9BF/)Q':*\]E_RC ->5NNOJK-+:'CI/[097R$Q O/W%S.Q,"(@'YV. ^)IJ*
M3-1RF515UF^Q'>+PZNK9K"+NACHOB^LUF,.*D(X>^E:D1S73<YLW!&&D[$V<
M0C%8%',]D*"E,8*RKS_7<;Q*+>$14?".10G'L^[TVS'/2-6?O5?E6(]XJZA?
MLM#EE+=5?VH0EVSBE\^<?N<MIK3H#TA)$*D)5BP,SU/T46I>Q]//KT7?W<7C
M-6WSLB*-ROSM-L*7B+>2G*(@S>>-+T5RS6ID(%9;NH7O\*3C8H>+].;@?9,&
M)P=1[M^2VT;;#%P++NX7.@"G[6:5:,_,UQY56")YT12VXI#<!KH1H5=TICS$
MK(/G0F)7,SG\<,9?MP*GVTL_X.-9N./1^G!VC=N:%=AX$R\%Q\'ZI"T8QME^
MKYPD-LV WF:T_@9&YE7B.<&OSY[$Z4T=5L6X&"?^:%0;9\0SG-]3Y>RZ]3<(
MR;1U/MQ[E$* \L(IR&U29%?M;A6_*$'7+=<,&\\^#^;_CF[P^9SZIV2)_[7F
MCPB]44]7X?AO/$,<OT@)-'RIK;95@=E.)=.+#L/%)@MJ(NEW7.5E[[R?6$=6
MIJ!5@K,P)F+A;Z,+=KA4AK./V_>VS73?5TCNT./IS\B[.S!QTQ9-TQH&>NMN
M[W$$Q@MW$#R3>*"E=";F9.?@3;"_3#5+_G1;P8WC#C$3P#9> '< ?O#X@P+Y
M(+U!\J.9U_$R;^@>O3G8,9$)Y!\[UUK:,0P0ZG5Z4ZD> 5N.B9N)6)>5'469
MB<7&(95)P;[H5\#7B.#O5LG]2D[UN&"BN_["4T3BFBS2#S,C27Q]]4B.8A2E
M\<Q5C=D&IH.&DYQU-^Y^,$!2?W&'*SDF9RYWD#LB@RJKID3XFOG)6=XZ*T=E
M4:,L;)?)T^,Q<9TF_G=;?RX&Q,KE&MU8)Z"YK9A%HON[3/D.O%4+MG''R@ZS
M?*:,)M6L;XK=G6-Y_ G<0Z@*A 9 -]- JW6%.[_T=-TXNJLYG*^W?%G/Z61=
M*]X,E,0L-!1+A::7(^?F!?B'-%:6*^X==U!,$6,)=76,^A< 59/6^T3?T6A%
MS( ]C^OL;>CY$[AP;<OB=4<FILI9,_4R]6NU LPKK]QD=_H VFA()).O6-P!
ME%=*R*-2__:67SY/?R=EOBS>8":;T5X[]VOM:6&S0W7 <!@HMRW4AQ_9"&$U
M[5QD:65B8QF,MQ-+XI+AO' R15.''%(^5P*>:=35-:4\;MK'=RDSR?7+^]K!
M)0G&[;/XQOPU.1+L3Z.97]_;#Q\5.B2--ZHCGZZ=EU\[=0^'HATL-_+YFKA(
M<'':DYYELYH_T]6Q1.)B2.A*-(G-*-%=5)@*U R7_)N_)R @_\=>M;0X[DV0
M.)[CY<(B[O:98<+FSJ&2KY9SX$^292JWDB _@0W!]GR4"Z.#+VCD8K2W9>+#
M E_2]+1Z)Z%RW22801!'KG8CIL,JJN@LK\DETMO=$;X))*UR$Y6*Z#$#;25O
MN/6>N9[J$2R!6_71NJ'M >OASB(PV!L)4PN?ZS_B23I/P%S2U.O&[2+CY_HH
M%4H+)_ISC?;$;Y;S?4<" U_60\S6$6V&/Q#L[ (B(A,\=S6J\F([*<CV+1FS
M<4_:^3:!3''K\ /8P84J5?3<6WT\)#*(DZ\$;>^13;(APY;85;K-&S-YG%RX
M;'!_!: A8TU8Z(!SLFR%UT'H-T[7\IR7QOR;#$]?D/7+1"NS RBBIQZ@Q2A>
MXA+87=UY1UJ/JGWJCZ6KWR;S;2;QT)X$6SA!"C9_._HFQSE)S2.27@?.HLE/
M"A9%)B(E/CD#J'IN4LGKD5HM-4P<SFYW,%KJN%)F(D]\/:/DKG\B[(UNDY$Q
M.V*\?_0&L]BOS61X>[37$$I? :;O&U0)OQGH29*]K$MK:HKS>SY1>R&A1&^<
M+'LS=A:<-B?+)]&;67Z=,Z@ E_<8G-CIPG4ZNM.8PETQ;N2]J0I,,</#EN,H
M[(TTIIXCH*\:+=N8T-\[])H&ELV)?>I&(X1ML, R!Q2,.-/Q]QVOQ7F!6,E]
M>4;1"UU.I6+"=GB= J?%-S')[49G:/;N-WH2+GSS0!MV+T1RY^&T^7:]JUEP
MW:=VK^S[FH18J;4%HHY6>*L4ENTE-+!+JGQ?F[/X5??\D7CG ,<KC^7(;64V
ML+MF(JHB<VW&="Y]XTF#F+!5='3O.L^^*D.KMP_;^0.,\+9;WMPH=RHABFS)
M/>M+G^>I98RB#-11I&@3.0+M&U\_?C27X=D?>(Q*6VJ_9>_KCY?  *./EL]4
M1NQ;/X&G =T7LF66]+7#(J)[7<TA(>724[1.>J9"]]]#O#I7P3N_(P%;4G0J
M**O-!W@ZHWJ^26Q^^&_1N[JC+8K6F\C:0QB]?3MG#)?1!'2'\**+VW_D@##1
MS/!*I>==[U$YHDHYJ7.O;T!"1_LL&18&4-8P'0?!V0?-X)^F_?*OY/:F;@<I
M68SV(OER"T9*C;<,]V?N%Q8F2__HE)/CU%PU\KBX#S> HSJJ,OGK4KTU!3VL
M+$ H'6I32+A)5KX/*NX7"'@)T+T[9WJ";=82105_5*1K:?%%6(;ZJ^)O8"#1
MDMHIEX!'/VU=[=G+"E)_CZZ?;Q!._&I]4. HW>!MV(#YYF(GI.XJZE7NG,-$
ME"4[6,KF'7LN4N9XK7O K#9M(T/8JJKQC+[K7&A(4;-P'N>.@GP\4'/AV2NQ
M+$CY&89\\^:DGDF1(H,J0$B[S\0[PG./6C3;&K-^IKQ&JEGW/_9.7QL]4JAC
M6GUVWHS46I$/);0Y@Y7W+<6I7[;C[[UP(/^XYXD_EW1429];%$RUVN>IFH5?
M;#ZV3/GVQVTN)G_N_*T-()*=N=G>,LDG2&[4^MB1.K*9+]4)S46R98AP?>!U
MVGNWI3_76W3)AQ!V)4^WJMU6@UQCW0#**SN&*/D6Y6!\_8E?OQ'LN>M/PSX?
MT=3\S=.&@0XZI8MFLX!DQ(W76G)Z9R^<!^ZK\@-3<Z@?CBGJY.%BY;@T)W):
M:#EDHW^WIY+&&^PI.J&@BN;I;:^17-5/;GX1ES/J]UIFO?JD0DR_+E@#MYW3
MGLYVWY/\CN&N;)!>IQV%ZFE@DGZ7"5-FR;D!MF[UL-1,"^3%Q/N9Q& ^(P-X
MKW,M2'Y[N%%,T19U%@5A9+G5^'XE2N?E[X:R#][.HRS ^3*+_3Y?JFRE%9FT
MPE8Z8T&I[L'I:7:%P((EC% XEN=9%Q;6)?XPBL/!2;Y4H/-97>.UTDVD>F@)
M=M_";]LF^U>]JS;=H$0NCG7 C4 E$^"=G"6)F3]*42YT@9HH99#2#=G,UL!O
M_KXWBRCZ2Y<SKKK<H><#D[.D<* []VN,U1;X?JU+]#SZ]3U1UT;8 [Q43OTG
MAT4N-),KSPW/_'O?XX-*?W$!/BE@! A+)_V]40%T.U I3F<$>XBL_3&3K3)*
M;6#9!-%<D1WP]1)@CUQXH)0UCO< -;V3_ZTD% 2A,S9S2H,VA)S3>*:^SDPX
MW;B^K)&("UT_ZZ]69E'LP(3CT*0-9X)]?AY,4^]N4^0.79-=9D$'*1'[>Z*\
MDOMY$= G*4OL-D2[[YZ2LBSS3S$6%FR;.+>\/9:W19KU<(3RVXQ2R >G[>\%
M SG'C3J9Y*-FU$56AVOC)(M9WQO>4N7/86'IDWG8%-:E0N^O53AW-TJG(VBK
M?@5#\.RLCZODE QPH !R>MHZZ7PP[%>;</3]3F.$^Y=CCU%GQY7J 2)=X6IA
MUQSA'^L$JEM:%:0HI8P:>V18A',*L\G.[#S'430=30#@AR"LOZ7LR[F(E>TU
MQ?B%Q0&*L7R0A)AYJB)%M@E@2]C?#V6N_8R)R7<GHT'X73$7>UP.?S".;:(#
M43LOL89 GOX6X&T1OFDDNUAKVW1$VN:C&7&P1[.=Q2*O4]3C4CD,A#NY<JXV
MWJW^I,;R]J@$S^VP_@RAS#'M.+9W[\FF1WH[=A:(BM]3!09_Q<WVF/07>%RH
MF-0VMG!R:ZYVS/]:#'7$PZZT&\K4EDD7J]I@V44A:_Z?5 470J.! IN&\C9
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MC[&8_M(;/9;U0+"!Z(/NIE;> ECCV+@FZ@G.VY5B3340SA?'0>Z"'[,>!<[
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M/=Q?;O#:<K, Q4]' #[Y_\E"_WLL5->WF4'M!<OCTUGB;S7I28I,KL<B%E$
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MSW!5.+W"Z,^Y^:9>:KQIFT#6RHV>;9<V6'*$$:U470.0[[>Z.%K]R8WC7]L
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MK8>!68?=[27VOC[&%V<['P<J*'B/9/9^@T%$'&N=2+>;HDN^-KZFLB"A?&J
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M!]P<)E8G4HQZ;>'H,^T9/QKW,A-LU.F.YDQMQR"=13'#.R%+8!T !_8/H";
MFHL%$U8YLU]Y(JY&IC9(8U-;JV>;(>1OZ/F#S?,C_9#VCI_^I'KL(P"CDIK
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MH/A8')$DELB(+6+R\/$WU$-^GX1Y6ZJ%EUT@(0SA1Y'T_ICCWVX[#1[5:L(
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M,L=&:YR1&:RDB)Y-RK)7*["?M:<N3;32&?R4063AS1X%Z,&^?>GW=/SUPVM
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M7CUR<RTRGDOU^B4[="]1@[DE!8!J403B^ ^ :2X0?GE9]'U-+/A*M3\6NH.
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M6=8^N.6 /T& =9OI<"'886D3<J:9L@U^Y9XF&Q4:>#\S4^D36Y*BNA52!]5
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ML($#TI,JBC9K5 V1UG7>SR<2=>]EG^=EY0M_N7/<&%^\62&;U3"JK5[(6E0
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M[KR22AG3(H17N!>!!?E#<8#^% Z0%8:BR$Q]E?<H/7PGZ3[?(#GY(]GNPLG
M*-!5O(D$S:4R[%CMES.C(]4Y_<3$&RNT2^OY;*)3C[\B2;NF-J2]NH9=RLJ,
M@>S;$26  \C!B]]R CW=$4JI++G]HN5U'WQ,'6W6,)*+?8@[OI(3I7P[KVJ^
MO7&PGWS%EH\,2[6A4>CPN4[=_3!L-XBDT(=+["LC[.GRV-P--.=YV^RUT</"
MB#P'OE+XQMTL I;ZDD<(NT%"[;8+=SXRS+TAAY6*QCJMZ2_<\P+?3J,?,Q2:
M''3<0D>WS#+S;R!3TN(L'_A/V0S^[$W]O*7'1';(A2!!/P0/EV*:JF2*F/KL
MVQ(>%MML':MO&C*.<J=/K>E#X-;?YLV"K@)><ZU-!!NBC+>'X$\#Z&9M[#(6
MDK0=ISDI"O($ P$FJ#,C_;@0WZU&6+%G5MM99Y6'V^M%5H;D.'D"V9^9IH'R
M/DQO*FU+R3P?OOA3=TB><CN[$H_;+1C;Q/*]N0C,'1\_LM#;RJ-"$;7(!9Z?
MRU:SA [IY*.JA)9OV. 1;8W\9></8(Y9K0R'*TWO8\;NTG&*NM-02;])5'0,
M%/.<<""F=>B)_,G&[G0<ML2:"J;9-8#&-[UWQ$CGRY9 )7E_LKH&<2E/J5)U
M?>\?7:W5::3?%&4BY,8\=)'@W]3:-B<F73_Q*IIG4I55O8:_)(X#KK<LH(7)
M;EB)1:7X.$HX.N859\<\;Y.<OM@^G]!%*<@-E\#!\_7YKN?N7U3'[H5OA+MP
MFC\?/Z)9A*' H5@6SZXV!5!#]/.*<!9H]8V[D=O9IG&MI$?#Z-W6I(1:\\P9
M:SY@M-(G[V<FJ.?&/?W7X-&;0#,Z=1Q+L9>0EKF>@#"VSIN[O@JA;-O>7)!9
MXVDN ;<39<AG=? %^W(L,HCK5[KZ^,2/K*BW,\JFSD?K'4)MV\3F(GWO4WI7
MZ%DC9ZJZ:RM]M'ACRB\&VX\03S <7_5]P6Y*7MR^DK>)">L%NINC55.;H("I
M9U- N$3 @B/1W&?6D>5*T9.$S0ZYXNZ;/[9OI@V4^]]#BRON'5<M^#2PW+:D
M1R:#[E?^X9O#'"DR&WC<[YXJO)>3GV^#!+^#2TN0;]$:F^O\%%Q!T+FI*ZC@
M@!1C6__;J-+PTDJHK&9LZ[3.;!?+#\@3]CQ2W;XT^ S_5< [Q;.DPCK'"BLZ
MOBOAD3%MM%%3SE$^^JSR*R3G45F@/[C81_-U4H&OG!??MOU.I7@]7:A;J-?G
M^"QH16#?T+MK3"& "PZXK:T2O<#[,4D.ZY[*9]].X16R7VOG[%5H*"B[*/W.
M\,Y>RFB44"VS3WU>_+O;]B^K5,2=SD:J D)/EA8</B_8BWGFUE;51EFS?=A^
M&:1D>K!8+6&ZP*.. ]2&,$_3P03> _'Q<FE2^MUMQ-E1*;\.&EML9/VEEI^%
M"TK]++<MXFSY%>Y7VOGF/.FV;\ G?>ZWV15]Y.,S][XZB;?4.F]V_=@]R*.\
M_'WV0;9#2.N^# T.>% IC+B!GNCP\);$%CY(<SPF0EM B"SO7WF;Z.XR]JT9
M?W1\-]R7JTCZ_8Z$YD)AA-GH?/!4OZ,K6:*$5S=!U%-*O$ZK<@C$5VG(<B\W
M["B%MW5>0BQ24+>'DL#^/B05C[ A:5'M:F4%>0PM=5<)H>VG(4M4_T#A;5L1
M;\F$U QX>Y!"@O;CQRV/ 4N&P@)F@7A6YDAR&2:I2WMH4+@>T@_ID&(8=VMX
MON\AY>JNKD0)2J46>$QS7)+;C'P]YLNT2/)0>X1W>=C>P5!93%*=6EL#J4CC
M^#-M34_,,LS7<CZTMFQOV=L"EM4GJ$S@X2SD_/3;<HD"@38$)K](!R5%">.
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M%U8H-J &'9I(,+52;V-7T?).\:/J#FAM&PE8&][=-T)E8:D9O^  J<2 6!P
M=;[XA6"$ Y Z1FL*1O+.3/\UEA4." G+P0$(V-QRT]+_@A,R#DAA^#\-^!?D
M$RP$Z^IVJ'T/!Q"1*>. -*6FGH#.:+2.MR/FS "K=&GM_HEUE'#G=&AB2#\,
MPRTIBO7CQ0'W<0"M](+Q1M/!AL<I'WKH/Z&M_D>X?Q_AG Q9<$!,M.KE KV#
MV1(HWDRT]BN8,7A>E"\4,BJJ>J,@_E!H1!5T+"52H9[_H+YBS/4W&(GKWEJ$
MX=*+$&L<H/_R].;Z/?H_825F?]G@1$KJ+ZG3U*TH?XO@_VVIQSSJ>I)NML[2
MTP0/.T 2E#MQ!\7U;.QHEZ2',/H>*.&)Q]68-Q^H.IN;W"I&5C=&5:]976=E
M7J;EZH5;&@=D8>A'7XWQ1HYXH2KZ5[_.YFALDLTLH17PJP05X4-"NS3"EW;=
M]Z:]Z*F-$5"^U_W^6J>@+QY.3:4JHWA;E-J?-P(H:3=/7@@J92L1PCC;>>P?
M6GRKGKZA?KI0CQ_(#_9&#DJ 2K=FF4=?1?6V,O"I-/KHFGL$".@30P-?7^\>
M\%Z+^H@WJ69HCP(=5HUAF.NF,C?L_?B0<I'/R%=$!*-]M1R^%*<1;S#RC5>R
MP[ZT51?2)WGKW]F?1)TC^#S$!=&60GA;KMKD+HL!%#K(#92^-=)I3-CK6&<J
M&U'--E4;61SE'E7OO9KY#<7T+FA+CVJ9^I8M_P8.L*NN?9/-#[I['\SDI?/J
MY#"==#_\P/Y.^QDV?IZ$PF>Y<E281+'%,;>@>R$EQ5G/PNX0GRU\_&U'4FI\
MD;YUX\/JBLCBR,0A_1\5E*[1=*.AR_P#W@<R#"E47>MU..#=+K?QA# 1@\B<
M?-+T= @H&4'IX\'A(%*MD/-(]VWG+.M;N6J4Y&R<21WQ+J,Q2'^Z@ZY,TZ5S
M9)3BVIH,PQF"J(\-Q"D4L^1-2%#B;>:>S_5N;PC1CKA[RU/:K.OBC'*7*??X
M.Q(<0JWU-+]W6%] Y&;+K3Y_.PU_5SSDD*%7-KI\5P4-]LKK+G3*MWIW7)$=
MO)#];F>MB?4:JA 9$.ZV@B*$FA=MC/-/V3[J'N]$:EF&Q(CN^$;2E^8&Z $[
M-D*I=]EBA>)I%;M)"YKC$7]$C778-/),"$FJ3.[N5+[)17@F-,II<T^P,U07
MIO)[=<K06Q:;I#ALM36RHAKS"6X(J1K^^!)OMV+,*5N^].V:$-ZF:W (02S
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MT1X.3K\^+*'1R_%LY*L, /LW 'G]N]$?:N'LZ?B47ZPR TDJ[2\9(D/5X>S
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MQB3(DV6/FIGIL/!R+B_-KUZX=AIZ]E9D3.O*[1]]#8I]TQ^FFS6BN_:V['F
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M>4%ER[)&8!$D[;6:?HH[8DB"QRF'"[-IH3U@0F+*/59!%RD#?^.(6$*]#B:
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M>ED\U];U[J>$IY*L-_J;P\_2F_)-CH<A=9G!P-3?4?&E8K=Z%X5(_EOQ0<K
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M+D'0(S6[L)-'-RV@GWFV)(6ME]FB:&GB)%7:5(ZZ*4WX".C]%$B_DX\(LGF
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MF9')T)=+&9E&8VH5@DA7JH*( ?_89@QV!M-,3<024PIV5"Q/1(8.1$8\XOJ
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MP6L78BW.FMZ5TQF9!T";::YY5/MV>=0#P'M (6&88-Z#IRBGT>?O_:A$;!X
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M-YG=J:#^!\9_$^8:;MCQ?]0JT!A%$?$\N7FZL7Y[:EB:9RB6G;=@T ^P5'=
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M8<&M$<.Y%:-"??0R"144U-'3C<AT-W4/Y&1J5V#O-!G*US2"+F*4L7UH?D9
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M+#K7O+CS9$Z?\;B/X=U0J/_@E ](EJ.FH*.DKT#!@VCE?7,\JN^7%[4HGC7
M8>S!;C[4D3_:O=5L6=D=N(4,F3#UJ5L;)(SR& :D^8*81WKV_G)D&4E8LR'3
M_V+ HQ:X4Z%*L2M!J?*.+N"EYI>G;W&H$\Z+6;Y1]F8Z%2L62KM1+4ME;WRE
M39%<?:ZVO+Q@B5!;-OQ0N=#9G!<WBBVJ"-#.R88W!5[,<;#GZQ@[)+KL@&DU
MC@M#SA36S8KW21'U]-+D>29I+T+\^8O*6AFZ/<5:R'=UO_)[8>@-"O8PW3(V
M,2/$J_'S,2]"'"Y\5H  A;)=TNNM- 2_(EUP/_MF'=;%M4:I@D49C![^]3.S
MRDL""8PGLGY%<[NN^Z+GG9+/!2)Y,G!>!):QEO;2:),PT-VHH!65+=#XR4]5
M'%I;5R S]A;NG.4\E&&6_\]JJS0.RVSLXM3VE@43M=_B-W;0X&G_)\KL-6ZZ
M]N7_"@-;H&[^6V%8D-,#X$6-7X-?HH*J_@.@KVSED'93"L/8G>S^72O_7>\#
M8&S866/DZI](%S$^<X4KAS-L6)%.>;8Q,+=*(]$U'O-]#4@R>V3>70?&%#ZC
MGI[$AVFL&J2<T#E&FF[<$$_.M+FFVB'6"+MF1GMV9;6XJSKK =OLO0DRR5A!
M:MDY]_\VKTU,*ZZ+%?(7.M8JRL(FH]1WH\QOO1$D0"7&B<97?MRHQ<M7MJS-
MNW:D6W(%<5*'AC\TEXA14BRSY^9GY2WK/0?OJU)+:76'[3 6Y.U>M22KU;[[
M#+S?WA]VKE7!T+@()5FM,TO,R5B2ZF.)C!7O+]B]1M<D.S'$6I8W!7 9(^ [
M64]ML\"I.O0Z'SZLHTR90GY$=-J0S#4:J-EQM1W/"I8G00"][4=G_#7LG1^.
M%ID!/].5D6J6\R2M 4E2P[P3414,YPP3<(LL?+=[0BKC-U@.+ M< _[.XE%V
M7=AZG57OLE5E ,37S*B!NP[EY?/1IUO<!PO10I_3,:"Q5L^70E\5J.29%/Q5
M6YE*&F$;9P2BYY9UOUE2IJF"%%HBPVS,9?FY!ZC-'=\IH6;"[%0E7OC@IZ/I
M+\M[D2PZ49 716&1#W10SR@C*^!1@L$#CMG]8?UO%X1--0= 3*\D;]]8H(E_
M'#]PL:@;R1.*B0>)P$P45J?=3^RV/%1"HK[;/[TH+X  ABKAK3[  _C+R&T6
M"H_^ YFH'.E<;7B9TDB9/%L7=#+'GYNW@F!^EY]G%(?44LF#UME3L_5_?**8
M7.O*YT+B=U^1]_#)F7\DI@>1,@Y7FR<BZNNRMU]AXDOWB9LN>YF4XANO+.]_
MGU6P5JACW3*Z-ZRL5^9 6/,V_BM_]$=#=CWU '#7FKHG?P#$677=-_KI_OG,
M>5Y\?U11?,OUB!"G0^\<[^';ZVT#>V;M%HA'CJ.B*O_!T8$:MV>1=<[[]^VH
M8CAB4U:0+O&*C(XRH]2*D/?:^YAIV91.!8,SV%N:KQ4)FLX/-HFM#?J<%I,8
M=I^8F'^UO'7921E=\ZH,_ K6786.:R]%_:5Q!<.]7G'<F]"AT)!"[6)9)R!H
M4#B<K?N3"U"A\^0N%TD*?ZMIQ'V(K(L+Y.[UY[.YM5E_1+GX'*V6V3JI].3>
M(K]H0HO(88,KM'JZ5_@$A&'5,UAAQN+=M[?MV46W;.)K8Y:YM*?X1IOZP.G$
MZ=$.'VPO=]S.D?4#(CH*86DQ]]\29"V6Y>Z-+62\\P51%DG\A-O.SVN:3+U;
M3%:@.^W(O[P&<^0#(/3VN]BXCXL-M>M1!AI-KJ!XE*G[8*^G8?;1'YCUAV0R
M(@F4J&>WWPV==F,\AX]]H3.^6$<:BW'ZHNEE5K9XS20NN! 4\BU_(;U,<O?,
MKDM7]C6:UR/"5,4B=4G+3O21ZZ)O!<K->Y-U;[P_CF4L+\]6!405\3RC42!H
M[:.>GAZ[IS5HK;_] /<J^/+D)7B.L>-2_UC-_="B=B5<C*3ENY!.G[7*SX\'
M1FF?GB]  +O !P#IGB=>8E1Q)<3']KR*&GNCSU]&WMIU-/^C&.<Q?FCIK-Y5
M@F)-(.)\R)*]9?-G)<7&)TW.[@#SDCTQVND\,KM\T!9C]7P-0_%G@*"A@U+=
MF B:B]\7DRF@PD#]8?B+$WFI3(<$"& '&$-NQ>V>>8/659<TXZ;:MZ7TY5M6
MI#E-P':^.@).0#JZ"G/A=!X4X*!7S,K;*)7Y>/C)8<I!&U'#]+6-<R\96LRE
ML\?U'+V9N[%_M=XV<=:*<BDSW/M->5\!Q2LNB?&$2O_NXM[)E:,L?"]D<%_8
M P!)^74 ;(5X7TWL)Y#,'HW!M:\%)'CFOJ\T63!5..X\;D<VU,_QO6ZE8!DN
M_2.#(9  %9A8FE#<F4"(92C-+"J+U->K2RQV?[^OCG#Q4;/Y8J\#RTYZ]]%.
MF>U%9C# )9,07G0^&NP*K963TJ=!.O3OB>?KBK$=NR8B%PPT??#'+,=S,%%=
M3U%-DA9B)/41!>2WJ&.=]"8U 8LGT^/[&7P3%2( :UADM:&R+3L"C8*@H7PY
MW2'C#,5H#7CFF6;XO#7B3O\4BTSL1M'E!=.QS7ET/3C;(NF-6_$'_LI$R$OZ
M$2P&T1X',;::I%&IHP]$Q40,=,8[]G#S/E=2Z351^&'-Q4[MKHTF2<:$5F1I
MH/RB5IVH!5K^I+=!F>Y5#@U!MRLI8D*_UW!9P4,A9)M<$(UZQI+_.EQ\";AU
M_2)H-6&-5>>7'9!J<*?- JI7F**5Z2A1(9=Z]R[S$ HXJ4"_6I<<8P,*T\@<
M?VZ@3.\Z8'1F[_DH1C?9 CK.?=\X:?[\75('>8Q!;Q-!J)!8BE>NE;K!+B)A
M\*[4D7\0NZH7N0@9G"JSL?;EWR6<F^^RHX"K:3)W!KK1O@?PWKC;^@KMO1&1
M9XEP14X1COM8C78O4>*1(A:ZYS_=L"^2<3'\\<:4^O%,5BDQY:[*),?;=HH#
MB/65BQ<7C=\IN%2,YQC=4%!!&=^"2]'^54.TSA:S!HEJ@#B_4DK6$P2'>(V(
MP^,^)?D3; ,70&!]PP=@RXFGP&+")^7]+ O=/9>E&*>9".6CLY^*W"<Z]2Y3
MDXFA@H5-EX!05BD?OEB_V'*]'[JI5Z?=1_OUS[A?9]IL?,H0&9L;W;! F[:&
M(29Z<5P 3]<UUF>UXJW</ TR^P;#@3HVN4&_5$_M958:?,"S^P-,575M=UD<
M#,UU$/?['MI!%@Q:^^LQE'P6JTPR\5IO$?$U=6KL9"(9+JI*)CJ3H/G&3,)=
MLN1V0OB!] <.()Y :IC4B;:_0-^Z0? WR]48"$;OTR'/+Y7BKEFWI9R,J\[4
MV'XAO;Y<[D$,=,7W"A*$5YE&0=U^>+7[.PJV-SY-<F5OI4,Z^J^##,S#7%S&
MO0E>3>(F ,(E]AM#QJ^A)WZ4NZ=7TKH&+/."^ G%*R#[E%<M=>K]H];QX,+C
MF7D129\L=]W.[8&4'U!-U@9F%0I'L1Q_+EYV(3]TJWORZ5=X9!=E8#N?EC-O
M4L;M'=9%2=SL4"ENUI^/ZTY NG+E*&\'W =7F=_L("'],MTWS]S7FMLQ]L47
MEI]/GJ-FOY [&D@[H(N[8T9S_6]^@0(#+QEB8P<LG!0IC :-4(1U?2Y7*),E
MK2&%?OY\@ALZBMJ@S;O=W(+@^$2[RU==%K;\(UYV'3)1.Y7P\5@T^&?EXN>N
M@%OVH#B-S[9N&D^6?L[K\0[EU\4T"4&W.(&L7YL3M73@D1A(BC^T^=8[;@1.
M-O1)AZPY3__D"J(FACI^$V-5KNNQ\S &9B7?Z?7_"+DME?TXC9R8>-MO!I4.
M6U,?I/PQ5><>T4UZ4=?.RV?3I*.5)1JZ]0;ZO26ASZHND-2Y7A-5S5Y0E$M"
M?X=W6&WM6D:^=@[VEALW$M^/9;*,"D_ISB6W8(_K1]GXG[A:TQ.>Z/-6.0N6
M_Y7!4*(+V;X7_?( L'\ L#SCP?G1?O)JM_V0_SX$G%/N]H]4:?%QC9!15TR6
MAH',N?.!&+A>:I]HHT@$"M=YP?07>+BY;WP J*I86,G<F[Y?_?06D_@Z$)-P
MMG<[*_+Y'RW^PK[B_=A13Z#\P;=F1H>>2.^\:$=FM-*<1LX#\,J5C!W6]XAF
M2^^*MRX"=%^RVY+5)\\:@.K%B@S/&U<%YF(>MRW^"/20(2J]B9D1@5%AWPAG
MTLA Z#Q_2>Z0/.IK%14YD^RP5Z=FI'^_1[?/$- >ZYZ%9\"CFZK>8$*2>_==
M4)5#1@!6LM;";SON[NL5#I1?C6 T-<&:S/CVZGQ(:]ZKHWA97YH-236$ P]%
M2M# 2(;VU%86KT+PQ)8O%-R7^5S?1!Y#OI3>Y>)=I!O;%0WA!M?W.R0$G&7A
M%\+-ADM%-,EF.,&,GZ=,,1BVUXO*!CWL>'\3P2)G)@U ;)]B^&G?C,)E75QX
MK\W#U71PV&2MT&X9'J%OD%(+V0778C!KBSD&;.:YB5DQ4PCB@D;-8LA*7XJK
M!NUHV 5J?>!4L*#T /"4FXZ9@@!&6F<VZMK!<LYSASI:C+DHMWL;E!G[6!R'
ML.5I%;,D*:P^I,YETY?\N_Q7F]_&RS=[R<^WJN VNGN775KCRN31[HR$_639
M_:_]@:&0J2=)"ECK\"_83&Q\:1FB^UFR.H0&^!HADN=E>(8"*QT[C&@6P4^O
MUVJ=Q?^@:#\ 9DCN/Z)D@QQ5_"RM/+<*GTYM!SY]18_NWK_JT+^K<88L7=F]
MY)8O5:;2.\16IQ4W;%'!!(,<.<N6,C$CZM+ZWJ:]FXC.LNT &C U)NO5U%7-
ME'-D.Z7(S;M&^C"CP4W@\F?E#MZ:!\^5>%-C:DJ?F2TWK)Z LQ/"4G?U14OV
MB=RM3 -L[G_J?EA-OQH8A0-<M'1;^*YUC8*Y938EL/U:).[AI!6P* X]]R2$
M0KBY35&1Q#;%;^WZYQWB@=EOWVC(FT@1Z(=0E'INWT9"F>[<Q*^QLG#>NL<I
M3N@MSPU^F:"FCPTDOR=IP)<!.2US:_M5IN<)N%CW^LT?Z&F^2\5Q]/RCD-FO
M@G[VWQNG@:6C=;GYTGL%6/W,69(6M/W.1!)E,-.U[]PTZ0W"3>9:8-7K2S$5
MP#FEA,0[1(W#R(L57W_:]R5O'#M8AUJNQ0K;H. 9SVB+L-J)%9N8V97K&L*'
MEG6T&=FT ITFZACLL*-41<3ODLITOLJ<Q2QCB%ZOY<[KN+&/-_]RA)*%%LR
MQB&F,;^.4_!7E>RQ[A/1FT3BW%T7M+F+HSV645X(/I$0O ,W'XU\F^<HK=#A
M8GQ5D\C4E&CMFS@Z3)MZM"T;4W"GI'$[;>DELUDPCS?QGO)WQ5;T>\@952XR
M!F?)S\S ,O#>;,TCC[KX 6".D1?1.>]2$7[(NTM/).EB,:$KDB[]Z1-!]^3%
M8)6XEAM\5"BGE4#JR"7MGJK5*[;@6C;.YM+%B#E]MBSU@&-%X8@F[9+4(76_
M<;:L4/BKE^.;DBK;?J6O\<T'3IAR$^5 F(PPJ[5'-37NM%_UP,7O:K]!99[!
M6R?(;AN57_^NR?W5O4NL^(:U^/FUWYF0]VA*MB/'NYMJ=K!LX]COX'R$2!?E
M0%_VKL[T7M-T5$'N\7O$\C4]>^/D5'6FZ>NBW;$K/9V6!(D@I9,-NC*M[W=(
MAL9MFA(2.Q>^*+/02Z@R+$8@)Z\AHK\QGFW;A*1HW^G;_YNY5/\0N:"(0A[0
MG-,>8$S"AK=O+YCY?5UX=672G^0E5>ET)IW4"/>2A3 5B^LV@P"2>(FUI KF
MQ$^3^IM)7]$R&WU0T]/6U9F#Y;>V..@5_8B2(2;(UWYT;&&WP!Q=K)ZV9)MG
MF6*VLS]6,AI+]RUMDR(L*K/J-689T/Q%6:R8T5Z,=C;A9[I<E"J^GJ XS>1B
M $PO22M43=NTC?J!288$1P;(7L+&)4B2E6L4.*M@M9\7J+RSVCG$$M]W=5&^
M2+8WKYHXL-D4-13X 82! .I3SNGB6D']4VS(QC#J7XF.;RYT?0K2;=E_':P'
M$HXSZ&/7@ !?YG<H08F_DI/F?5JTN,V]B[Y_&2TN(,#="3Q1Z,B?CT@1NVW3
M7ER)LAJ7(/:KJEVI[#.Y8/8=)%N,L/O9+JE2$<IK-O7D>K>N\Q<N5B#>#Q^P
M&@10ZE:H8_1]>*G6B3QZ8[EQW@<D=-([HU(/]NIGR"#=B^;^*\#$X[Q"L$LI
MS&,Y[]):;%O B ;,DV# S'[4<X6E"=B8JL\2W3ZW,2X1 \5DZDZ16Y&[UT"2
M<P,>7C[N6M;C^TF41W,G"]='NA.* 7.XB)*6JVW\_@"@K@JTV@Q)-,[OV=36
M!=G17IKH8S>"  PL3=QOGVA_"EK4$.67FZQUSV 7&J'2WK YK.) $8.[0@ L
MA1<&,1=Q4X\S6\ ^X#GX4[4+K0<!-)HFK2N^!()+M?/C,9:>"VUD]W*_>3G)
M]JDU_H)5.W[+J)W9**6MX"^=/+IB-/*J=C:?TV0ZIN3^BJ*]W!7RW*.UTQ,
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M#Q%M1S6,6*#VD/06=O_&%9V7LHLS<9M-B.?CN@#.EK)FN0BJ<3_]_;]*@(@
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MU=)([:M^EV?C5Z9\EF4L0;YKD+_X!?QFS:CEN#JF6RO.G4F_[L@@I#[/RL'
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MU1FXR28G 3Q1$Y(T!W#>EC$3 *F2#E$W__LGA@$6$G2TZ')^$49A$'J@O5=
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MTT^^9BFG[*+X/>=QVHJ$'[9?>G$1:N5.96)4A!WY?072Y_:2).7M JHG??F
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MXVGO5(Q5$Y^FD:="*-O(PYEDGE[.*'5M6DSK=EV)PMO.>D Q)82#(S6_[L/
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ML2':H:2NR@1GD!&;T5BR82FL]Q*31ZAF$'^:J=D9?M/Y'=(<:E#8KV:LXCE
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M+,FWS1@!8Y#!]XG9V>G1G2Q+F6[N&9$23)F[^$)>3J%Y*OF^^%7,_'SQ';O
MI[7'W.O-#IWN4U7;YXFC\8TBP@E;%WN'DZ>,J1%?2\VHM,'8KO1#XE.=(V_4
MS1*0/S5^*H;.W;99Z,YUQGVC8>^:GO3:XX'G'><?)TL?K<OS&^)DV"$R&O$I
MN>02M%UGHV5N7,^<O>09+$0E4F,'I8=J<0LLSZ+*!!WNW1EBDI]VT& GIHD
MY&3=]0]?%+P0UA3_^G9,W7SA%(IMO?V9]<M""?H([A+A\B;E<WEYS^(DXT%V
M+\:^O6<^3WA0A4N-!QBR6BKQM[GQZ5)FYO@M-QX_C:![O%>\'=81))K/M;9\
MF)"J(VL[T0QKPAPZ,=L6 &OE(GO)FB6< JP_"\R\8GQ!,Y+QV XLI0H=%F;W
MZ<?LNFJ5.N;:8AN,RW+4'_0(.[&):#N^]?$:J(A%13K?(#XD6N"71QW[3SWJ
MCO]6CYIF5?;@2.C#Q;S/&]T#7<*C6#G7\G%P<=WJC2\=>/5D(/**:)@2O):J
MY?O5YVRG>*)B+PV[ZD.M,$(0+C:W(.U<TX2W$^9R+M='OQ#U?JN7L7;+RFT?
M&R55ZLJR357W'C4M /;+.-NJY1EPS:LPTA.R2&+?FL54$*[964)O\_A)DF?@
M7_'VASIQ"*,#!;',@%Q\=ML*X]3'L?U"3SN27H\T\-N>DI -:(F_'%$_QL=1
MPD5/C>D,KNJ/DD],[F1BC,W$:8>:;5 Q'#+VE9]5GO$20\@71]Z^F3&;/O"$
M]XZ]!'89\.R^80\\P>*[3=I?\TI00-]]/8^9/)ZP[C9=,==PPV;O@":%=7J)
M/'_)L*V),6^'T!VG%'"X]=XSM($XK$-< UV#0J:/.@G8S90*C#DRE2A]#]()
MYC+E!%G;C#BINMGME\OS4IQF:+TB0I;?W"I;XD8[\0;9$G^V<;,+U^"\7S7"
M&2<O1?X<Y_WJA0V5>YC?L#9TG\Y;?+)I@G1PDFM'7I:+ :%]]@92,Y7B01X7
M'OY)L.1?;0:S_'DS>(-?[%^EK^,:-Q:+0E,GIOY>J"Q",I2U95% P665\]@X
MSJ!C/G[@RDFP$98&O]4KYPA5RGXE58 AJEZ4A1F9_X7[_64*O-_J/.!76&;"
M$'*FLVI[3CC)(+^/W&YNB38?5R07M*J33H 6;H#PHNS=8LV=S)(;\X,H\0FJ
M_2QC'SQ?65I97WR6^"5<;'CZ/C%OB:/2+?:28G4EU4/14@^]^YO</,,>L/P.
MBB'R]P!?60H]6EP7^6$S>Y;YHFQ51@#EO0^-NK&%F[69)I,PH]JW=K#02;KB
MDFJEN^HEB!8R[?G+PL(NA[J"0U?4!P\O*L7JCU R#^G5&I.Y<;\.0O<PH!A:
MH*FID<H(=8SZXG>7:],!GC@J_^EC]<]G^8T2&-^)\B$YO@Q?+.#N3D6UG^JD
M#2CPI B3/4D0745D)WGSET5I/Y+Y1C>TJI7N, [3*$[=?KH/Y_-\F_P=M]&K
M^/L%+*/P7M#Y(ET$>: /I$8">-,V4>HD1V/F914_'QO-?/%FE_.G//LX,U.6
M!K5B8_B86@K]K;PY6$+/+E'5?.Y"NTR8^+3]2[M7[B;O(!$I_EHYB_VII,I3
MY0YAO]+/POC'SXC/[OIA+]@E3^@B%&G5@M4<C0T2#/R%)/C#@,)""V?^U[C8
M@56B9 VQ"?R/A>09+1+EBUERX)LVA(*5/+8-(R#^FXK>A,M6^N^O[S,::^Y+
M<_"2M]Z]ZX-9"$/(8TXJ07]ZL=_;3UX;1!NV4A8AJ&%^VJ51^U,X&TK1+>1<
MOY+@6$(P"5;0TNA)*>_ X46?*+^!#T0OJ!I&N'BZQT_F[)!(CPM*AZ3*5=6W
M!IU#C3V2.;Y)NY=+XC L$J!E?C!W-ZV[%ZY2%?8-K1_G!?Q"/C\JPVKWJ9;&
M.<*S\KOE&0':.N1Y^,K!@WE%(YA1@4[OI,S3US_#*3XK#O^ S_@UOW!!S)X]
MF-_"JZC(M]#E;5U9VT#G^C(N0@X.:*;C3EV!.>BUJ&F%_PB5H(B/WF:LR0D#
M\@NW'I.J]-<^KFQ_9K^/CTQ.N_&=#D[GA51FYY>U\@[C</JV8H=OU$YO"6%)
M+=5ZX"4V(A 2+&&G,FM1"S$IJJVJ_1,,+,. H9K#I6@3#ZYOM9E88'RSS[&B
M0Z9E&ENU[E;V4F;6,7E1.IW?C::F/]"C\R^+3NQQ:9[Q,N5$7?B<?4([X9DY
M+BZ<9"JWR6I)^4*Y?H>1(/C#VQE"ZS!@=)I3G@,223-5NMJ@RJ>TFEVZ3+B%
MK^O*?2(]D:NQI-%<WV="0CBN+$)\132.W]5*\6EB;&/@]>,SOM&S,@L:F1S7
M/*7^KR7H"Z1.!&@I@J"\\L0+_<H030%K<UOG>'5\A4_1"J3N6EG5#SZ^XC>:
M*%,6(=2?M-JSDHC@WDS,>O@4/<I]^H'-S="SDR=L3;IMP??9%_V$]$N.+V,X
MF5J5%MLMKW2P85\4<%HZCWO?G%1G9L[*L9XZ.>U R2%SI/;&+JA#)(+2N;KA
MSI5=S[KN)B25Q.Y(E,<6?M$==8-!R<%$P'UCW8JH][^&J4T(9_+9(N:!?-*^
M0JKB1BRJ!"0RGD^)$RP)7Y$YP@M3X^N*R-S2(21 (VRIYD[<NM-LR!MCH.IX
MJR@:9^O!>7HM'FX-^?#,QH8@_,;(8.?GMT3F.==6,BF]:E(FR@DK<<FQJ)L+
M;+F<3K-?G,<29S1[,>):AGFC#PJ&R==!6Z?S&H@4?8V]J^<;)"@H74<&5>JK
M3TV))U!=G07!D:Z/1FG>A)/_(,WG?WJJ<-)VW]5;8/C1DK/!"3IJ9_ROY[?"
MAPEKL>;<@RT :*2IZ!K 6+=5NP9<?U $5@3#8IVK2F[Q]7_@:;U5G?XYL2I9
M9AOW:;G6]C<1+&PKR'(?#P6V(F=B;\8(.R27L>L*YZULBU:#\0GMFX3V7FRI
M(Q[E8\&78[F&,A0^+&?3+S#RW7QZ-MYQ^1?! LEX+\+6*YY/6NUV3(85Q0DN
MLJH3\O;NNJOY5 <Q]:;??>_@$"&IIGA$VIA!V?=( 6.B>>/N:-9Y(GM> U67
M2I^]ILB"W$:$V@%2<D90 43:8I8G:MZ4%TMRJ2A+@+%WCPQRC-"8?>RI/V.!
M$*C,W^1)2>LN85&]N\^[I7W*KY-_.2A!KM]@G:6ZQ%,?-[*T+.L73@M-HFFS
M7.LIEIU:G0HOS'U9?A94W^2"_B0Y!3[)=8I3.>A<9Z0-3MY>Q+PBM+ZOO.C9
M.Q]U-DX #^1C-/>0"D:!G]5TY@XTTOBJIQ^Y&]<?KJ<S69&0?GTH-3:#9L S
MF*^PBX-;!CEZGNM@AYC7LF WBOI*.&K-#RY\:S.7Y_H^_]FN":T7VC]=6BDZ
MW/GU3770?T=$#>$JZ-%7(CT\SN3[[:Z^E_(>7*XSW4$OCLAD#*9>@=Z71[#V
M'9NQ<""ATZ3JWD2^^HEW:XP/6P*GVQ(XW4X9.PC?PXJEZT>@AO/J&$%W:V!Q
M.1GK)$C7#(LOSH*?9LN<(3A)-CD:EQE8:6F?\*<FL]*?:8=5\ZL[I.65#A7*
MLKE('U&%7$3/"8+IETCI>_&/2<HE/<[H:;1AE-/<U2PL7"4)QLX^7!]!I,80
MPNXNAX3H+R5#*?96%Y;R8O<)Y3L#28H>[X;R\E+L&#3S1S0O.)SE*6(7V?T\
MBCC1_& U,Q>KL91L=D(8U?[2<A<2VM8413_=BKP=+6:YHOE%E#ABUV!K1TN8
M:@*&B(/)$-#:%0OQ/B^H;DGG'F>!+#2L,NL*L;ZNG3#RZL'8TN:J+:.U=TO^
MX+Z4;5>T[:##:TA1Y7M.F9!)OEMX.\U=G=C2/N!1XFJX]&DD7?>]=D$5F &\
M!=1Y1:LC>J=Z'\O7LVQ'#[05)_EL@=P&U!55,V,Q\PDR0!Z3B%-('790,,=G
M]U"-Z/TD\O>3$+-V\",=E/RTV3M#*1(#9-BYY2G;KZ75*"(AEU7]1GWZCH'_
MP3801+^1P"C^7[]([K^M_*=^X<827JU;-2,LZQ0TTH+Q%\O6BW0QKD POKBW
MC7O"-4UD2<41)8O,C+6<E#3M,-!RGH/TS57G!JK:O;E3RI?*_TZ%L>^>LO;W
M2,[\UHF(-.L0LTS9[4K5@S+X/ER:+!=+=0A*1#2X'YUZ1J&A^4D*;Z$KBI%A
MXFI]Y8JG87%M(P8*YP(%EVPT]?KY\94&'7)D7P/J4@C-#]);&<]5U&?S:";5
M<7GKVW5]S\KY?WR[L1\A!-&"]!7BBIB$.OE:A-2''WQ&:7XHDPH6<O')LFIR
MV_,_;G@>3M80_OE=U/TBXQF:Q@8+:]$3[;7*L_*OKAPCJT.7]#8 [YHD+CQ?
MR3\^2=V)Z544SV,>=*:B+\59-9\P\$38O4K*]3!DJ"@5%47!,!3/-[SDZ&_J
MQ=2N26/#X\V@\YSRW3 !=(6CJ_<XJ8@FSL@Z#FU_C4O&LJI)VA#?(A^&C2OZ
M]G'SQ\_:-K[ZT.AHF.<K4WISE^9+@H5,?POI^#V\X^W"N-4-SI[\1YC]EY0;
MRQ.;&=(H?1;BPZ$[I"NUFHQ:#DLA]7$#+N4=#5IY-D>T]=I;E.TG%>*T/0OJ
MRCBU >DRJ-:S2"E"+R4TS89:&V):9?\!0W*U'I&:YW-D?BI?U*6B74\4PN7:
MH&D?\M+"3K3VG!$#40O<0A)>]U=\<"3*)4ZBW[N#,Q<\0>:S?H^]>DQV)UW,
MM.W8(ZRB>+JB"08'/*62%6^GM)76Y)=E)F&,,N+@YL,JWE(^'^DE/B_N"_3[
MV=^W_<*#T".M*FWAX/,H5X V4W:H(4>\SJLK1J?)1SU/YHG -,7ER:[*BM+1
MWQ2O@8"'PR.#=&(<%JW!KZ$#3KSF-KL;=W#&,[*FEDTGU_C8&,&&@O=IY3-?
M6#H>ICY9I_GQYERZ+M0KRG!DD"]/-8@ZZSO7@OD544B Q3/=!@'WR3).5OH(
M25'*Z7$-C<$\[#S,<5$:DIFT*+F.[>(C,X@J0$\'>$FX7[H1!239] S#O(BO
M 3;=)JT5X6>;45BLG9<:RA*$(_^>(6%,@PLZ9)LGW5I:^9:7VFS+FCQTAIX/
MW7+/+Z\T3$JTMPE$8M0+!_TY(%5#^,61?&'@KHK%=%X*^#X!/?N(3/M*J:L'
M.!4R>6?JW!XBTUP<.?6VS]L<'1+6,],,SD7:H4U9)Y!'A"0ET7QQGSQEQ;?0
MI:D].9W/CW$1$S&YB)I"JY#0AV9PC'L*L7=XV [SD1QGZ^QC%%,$ZDUP-6';
MCVG/:C-59F112DTY9V'_M>,,U8V!:41V<W).F-JR'.2OOW)X8;CGE[J&=8G%
M3;.^SEKHIXDVM/X1VCX,0)5%^$C^0M;2<IF_$"=EXT!0@=?U@?>98EO^']^L
MD'6W4K_M<C=<>LU#E/#D%84<6_NE/& UKLFS1%TUP3E;?B:COE"_(K@6OXGA
M7IB-G']U=/O QLQVB#^-N$ GPMMW#$-"PGC'FW8")839FFU?-/J=AKSIID_A
M8D>ZL2O/;#YJFTR=$+R%1G>5 ;!Q[<N^B&HH[,WNHQ%$EY6%\]6>UEB="%0<
M#+>JEN>6^]GWE("D$^N3!_V^.;I86!^\YMN$(UX)$RX3B/'EG'V1&QUE9S63
M#<T4$_/!D]$$0<-7_;N2$H#&GT*)"S]LW\_?BE]JW-=X5TGY:TGY^7#_8^,U
M$%SJ9"P?[O0PAK7 PFG1?JBKT6B;:%WT%CD^J34H ;!05M;2EG*QP/ZLR?8Y
M_*FQ_M>(L,3?L,+335JUJ4O5.JW#4U8JJ=):7T+JM+)-ZDED^;(JRU:(G4/D
M<5&1:5-M72)]00;OVKM8TD^ %H7=CO8U$($RP'A;6F9M%M+_:?@;(&"7 FP5
M%8A3)Q*O45"(>SM>_),8L8^>;U;,FSDL;A_W&I_D:[1?Q(#*_A*F^N^%0J[]
M9;G\X1K ;K\9K62*PL._;E%?.#*-9&E![)3<,U:->_5$LQ&<KHE\T'OA5:4%
M@:X3O]G/>0R 7_.9R"4T6=JK;@1:.Y&54);>87;S03VE>@C:-(V_NK $(1XB
M_:X!<<[,[Y/*N[FH_@H;T)J/WS9Q ?N)KLDU<"^X&_>").\::$V)1KX2IO89
M&Z:[/)U*OQFR_+A_O+HE@;9]YQ5\T[VH@O^F=Z 5C$NL"9]E>9D;8I?H:V#3
MQ.?G5K''O;\2;#X?I$$]C?[8=SFNZ_7[2S<>0(! WS5PRMYVTX3'KR:(ZC*/
M0>VG$C42NPQZ].Z8)SY(<93/37^9?O7WAMCG#^)?G A%^*3C[N!?22$I8]=8
MLPHNWX,:&4=\$+A_X^_7^W]CQXAJ0W1O Q5]*/3BB=HNXZ@P&\#)B.4SVG\E
MF?4[(VJLK12N7>H:*U-.'7:DW%]I%T2XRNC%\%7L)=4^*.21JU(6EFOX]///
M7-47'A,:YM1&=$&Q7JWE,,0)!<II1SO4_!?-5RJFOH_#7H^G ) 7')+F:.9Y
MPR19=W+B.6\>-^?VHH.(/(5!7Z@^SY28-I_T7F%.UXP^A&PWFJQH#=SV4/OH
M@A[?WP,3S6?6$\_$)^%E4?-27J ',+T9A]H0#X^N@4NLJAO>I5!/07^!2IL)
MU;K8^<DO >>&B7'HZMV(,_IW='C_!1TM[WS2,?ZDN>'JWE!%)<;A-@3>'WKX
MB]Z"_ZHWW5[0R-OYT1]47]W)(+T^ =ZJRQ][;J"A4[J9P3?.&1XIZ8,G.R[2
ME,Q(GF&G)L@%7=7#GQUP@JZ0C./5QNQ[,;26-OP/]MXZ+JYGV1==0!(<@@:7
M0-  P0E."![</4#0"1!\T"$0W-V">_#@'H(3".X6W-T&&(8WV>>W]>Q[[CWO
M?=X^]]UW_FCXK-55_:WJ[E5=U=/BWI@0#"X<^M%WZ/'K:SAU$XOY1^TLHLU[
MX#@8? _  W7%C@KR$6TJ^:?>U7\/>/,J5T6=Y=RUW ,Q<-2\:WE/#$F[PLH*
M_K\GHOX;_MR9WNL1;U-(WSV ,O:P">*L\8/$:')3[&])X'C4P=3GW'*_><7,
MJ#?_K7_A8MX#_2;3D"6Q0>TR[<]@C@ZRNHA5U@AMC5:%$ 8#[K>'9AD%K>0\
M)34;N=O"/.^RKA-J34?E4KEU*)%__Q/'E&*P&@+8"%-R>8 :-8OPD8?<$Z,2
M>XA8:4.,N(UN=PF[L:9F+$?\M/PR\?5"P[K9GE&9;FI]4(VWBZJ+H2!F91#+
M,X-57^X6S%5FF.J*OJ'2)@'A&&ZR&<5FD[S?SY_SRK4*^K)J)'0D.B-O,3)\
M,89.'N7>Q649VZ# #5<YKK42+*#^2H+M04<UQQ_LGC)GE@'NN)^$9?)TK88]
MV</X<EU/A0P66EY'HPL ,7V]^1[M 1>*C-JC:GO2KQ4L3#%8WL\M0LM1OHOR
MCK6(K) ZIYNJVT.LWAG3QF\J*7%^C 1!5FP#ABJ"&!L:/V;=&BY4]Y*[H U%
M0^C$G\"L5\,BD%E9#447E(ML\)/?&H0S]SA" %#&!.\]0 )5I)G@G2VSY[GZ
M\$R'!FT49=?120TF$^C-KS\BC(B4E$&%"TF->!>OYZ0A7"Q1$3#M FCU*T-<
MB61CPZ7*\"_,5#ITQ7V43"CDJT&70\LA7F(.MFYV=6<U]E9E./+XVK%.P[Q[
M<Z\]XO4\V$L<"*_>PH8)/0GA1)MMHK6)V#(=E82F(S6R,Y1H+*Q35BA\9Z_&
M*NP#+C;B"0:+*WF*R%$J/,[$4&<AW2M31S5]"3S@Z!ZX%K(]K8.O&-DX-&0M
MSJ1( A&/1U6U]MW=G3&S8L IMJ*F:EJ(BJ%"RK51LJ.U3 4-<9N.>/ZR2WDQ
M1^*D8M@U,[R>Z98&$T\C-]W+\P+T5$B^Y'+]LBPD8@PZR#J^![J'C-_4#N@;
MS'9S=>$.E.J&?#L8*P++Z-4>BU:4[I#!<D;)7#-0S>D%'/4K17-J6BA.P5&]
M<^TA;3]_F*T_JZW)>_M2^B7=,0_2)'A<JVFDA?S+;J*4U%#-(]FK<FE'P="U
MG!/42!<.7&R/0;WY>7K/0=S'%O%(/W' Y5&K]K X0PB\5?F,J'>[_3%/FG%0
MX,#*'*44VP!;-?/S]4C.CZ' 'L\]0+ ,C>IPV/6@9[$GA15H]Q!][*3R?EGN
M<]4MRGQ<5UB8;G/3<S-V:,^4WR)!)LH]S%#E56;?28W^=NYTKK7[*OUYS(?1
M7GK?>X!.QX@Q3+*Q86Q><@+AX(Q]N,*Y%D)%-.@VBGHO'MA/.5R/MKZM3NZ=
M^/N4[+X0-V<['[//TX:KMLHZHZ4U3+4,7UM:4R\%-I+VU^PPUS90LWL]?IR,
MP(>@$2N&CD><.R,]53\X'P0(A6Q135KVS@64USX)XG#>\1E]?_-)Z)V4@("/
MQ\BCWE O,R?;51)AWIP6N>*^YB4Y7V;\-9K/%\.\QK(G6M4FJY[>N,:I4P?E
M/30-=2JY;L)O"6:TN==:B<DA(:,@P9JO'?D&WZI(<^'(N>U;>FW47X]?9]!7
MI2E.YK>UAIR1O/51]Q]F84(V66TGV#7BF/82*:#'F*K^B/VC!Z,G38(F<HNA
M NS6Y7&P""]>.5"2?:)3*VZ68G9-3A/M"M?4_H[6N>H6EER,82>-3NDC571>
MXW#2J^-85C-?@"-P&X_T \9?=R()+C2X%<VU2K/3/] O.VLY?#D_3#2Y ,WM
M\N@-O<!FE&JHKM)'Q[*]C,>QH+MM"7<IC4+9K6NC/ND-+KVPY(M=6'CB[Y&Y
MA+Q%TJUSXMWKSS!A7W#K,%Z[IXL10JM&[WKSZV8$-=^:RUBAX-5-^"O6KV+@
M+#_N3)M587L"&Q^!XZ7$WA?\*=P5Q6]>E$=].]M](OJX,DV#W6Y6Z?1.F?$!
MG*3<K7N\+*HK"FM1KNM]G$RF(T"(- GU4Z2:Z[>[\-3,8%+2?N&>KUS94<'W
ML>8('Z8R[H*-SU/G-TSE8'Z:*IF1IH2^9Q13!LU5.-Z/QE:"/'T9HAGM)RT^
M;&)D7[9L[<, ]<]66$GN[IY01[>S?ZJ&7"A,\>M&Y5% 0NI>)JF+] 2^4##/
M^NFO2(GHYGB*7[>APHIF]CE>TJ-V/-M3LT=FB2\?F &P!E24/95AI]].3;=^
MNH*F/8?2A&E?IC6MKK@!A<>9EMX--;F7S'C^.%+#N'.71>PZ,F$U!V"9D>/[
M@K$^ YM [WAPRE&QQ-"89U16Y6"^4>E@$17#<UK*UNU)F+ 4P>) ]/:-*D8&
M*(!@X)$DU@4)O0]1U1JEWN;F(2ZV-;O4P?+-SA.XCLS=VD4/:^JT\Q"NU(E2
MC'E95^;,BQDB"1;B<(5V$50O"U\1 LU02O7.I$K]?HJ8'R@]I9_PQBE+/D/5
M'9SX_86;B_E;:R?J=B&SDKZLK"N#!3^^I2;T834YV[+.EWQ ]IOMK;7RHG?B
M\-_\7(QL^VI5:CC[?2BPXR7!7D69RAY!8>'VGKO?CXZJ00041L5P(OIQE5)P
M6+_Y:WM]6_QK[!I3;G*"Y;C4YA-)U8GGSVN&JPV&099L'?K]OP3>15EOG76[
MW]UL1ZTN8]>%05R*,NND+5).-94\*#X. 1Y\[:L1:O8$%8$PD8W\[:C!1&MU
MQQ[.F%ZO4+]KF'P;V13;Q0K6EV@+H60-&D>/B-8J7;=ZZQ7E, *;IL+#FCTH
MH#L02_AE#96JH,[%F&AGB6[D(LR6+16\4H^]522D\SD<ZRQ&G*(^P%[XO2C%
M3CV9H+ZD/>@]LLQSD[E?.+^V-NZ!/:W#YM7K<CAAA#L;[=F[!R2%$D_]N'"I
M5?7%<":35B*#2]&>]KW#NRA_HA*I#%7IX.,[XE+B'%[V /8NADG:@E;*R/M"
MR%7: VGQ 2*-Z$:!<](=76YH?9?1DY;JI*XG=?R)VESNEONC 9S4/DH@CMXY
M]:$LJ()Z[,N(LCR\O$WV+Z0:EL<Y(D(KA[F\+0KERB[,']3P<1GAUUDX[3(G
M?+F,D1>4N*JG74)>>UPE?F:_G':=4LOA+]JI."9-J8PO^1+LAAQ.S<,.L%Y
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ME#LC11VW]_!?3=E:NEFZ<'HV#L\9O0D@CWQRO&-4M%\4OO_A"Y?B!V-T79D
M=HU*[+M<EQ[W>T '5'3"^1EL=P_L7Y]YY=936J&DMD"S"SJ=Z%VUM/FKI.!U
M.A.^[85B ;J3,'.0RR_]=&,Y[2:M5VDJ!U;#=(SCA,,!7_4Y.@^>L])$2WLM
MN?]<FVH40Z$W4SJ92-R5*JDZ'39UK7. CB##J!MJ,A:>C(J-D[D;+#<\;-SE
M#I\N!+DEU9%Y&NC,IC6JQ^%7JG7N@I*A"O? 4T'(]&#[SZ8A=:VOHZ5&IW"7
MP >DSR>00K+ 1W+3).*#4V[9CL=*&&LG JC'Y5F/I27Z1- JZ*9,FZ$I]&P%
MVPJV=H37'NES9^$7KW#/B'92&3+YDO+T9X==G@W&E&-]I8@3)VF:_E3NLOAA
MP6#W2L5ZCP1O?JYOM-+.48Y21G[3B]C>.2KXILW_+I_W(MS!O2KD<_-K-R0_
M11<?CI,W1M0ULCE4=MF.KOK?"V.](3BU,AU43P0%%VW<QF38:XNHN5;%/0CF
M=[H!5Y>^W?;'SJUT>BUCY73Q"_I?N+X@][Q:HP$>\K&*44;(Z2D<T,]>IYAC
MW-;= \^G7UK9:J]M( R<V1-JLR@3L8OASRJHZBL5E#MPNI;4+JEG^>?"M2VM
M#C.1+POVVD0J1R]P]Z%O$R_/O;=SJ-UV'4(W><>Q,LEX,JM^+3XW;F>]&RJK
M%XLP@#J/% 9[:; /8,ONHKH>M=;;P..1QL&6/8+VH?B:M6R4@XSX'32T\7 1
M$/5WCX*X1RFE2S-AK=$&;RSD"I;/6"G6(A])F>O=)<"%GE1UL)K3-+..0W[4
MBP580,7@4AS$]\#TT#+\TP12@RC[#K=.MQO(W$78'.6-IM+3X;:7,!9E2G #
M=6 ]648T0ZQ0LZ-I0_@!YSU0NS=7#J;JF:(.:/+H169*[/7RQ6WI]DC=*---
MN_2<((Q]-=-'Z.'5XRO8C@S-V=(?_Q6ZIIS!(!MH$?.5.K(6TLNMT['BGJEZ
M!A_:E";OBS/;^M#+:_;=KK"3#(R%?JJ=?4D4=J(/?\U:<7/P!![(A-R3O7K'
M\;V)+^I91_S<$G\"1?A\BH^:H[>'EB-,9U3MXFE+X.K4G/$%/SYM)YQDM7&9
MO).H)^B7CH7X2>TFJ;+D;;7^/8!?6E9><X0K)<Q,;UO42<Z*@_'K1)Q@'J8Z
M]FR2MC81,_AM@VWT@B!E^6P/9Y3>Q'2+?0'434U!:/*#H=LCU<Q.E-1.:!J6
M*M13%NWC:X^ +^5"V&NA0R=BO\\U]N]LMYK?^+7EIMS@($Y)%7%"H#3IHG.^
M4[99G6%_@:P"<3]?S2R'28P[8\OMLYLF;*+)?WJ0*!((E-H'<V!E,!RGZG]-
M&Z[WXYQUK=6()$Q;*WVJ@5WW79IT7\((822I'Y_7')\+UDXXZ5__[*=L9F;O
MHG#NELSWDANOJ&4JY6 KK$R%7(A^$(#TDA"EK'*5G%B*\W_"5,5JYG=>K('H
M1:T]F=T<XVGHH5I?Q*5A[O\I#9$']IR'B>9VC>@F>%0)>ATLW)^#'7KISK)A
MVA89K(8 ,[<[&W=_,\9'AP[87OS)4[DL\*W$U#BZO2OQSY6H-GVQ?/,=A[J*
ME2,2:(ZL?.V"&ENSV]P7C;73+)S0H]6,).R)'[;63BX@E/W435XAC2W4>H'+
MLKUEXIVZ-H*XK@_M<\]5'Z2H^TG0^%""AKQPS5:;VQ]T$R<5616;/?WZ5<![
ME@X[TZ,=LI(6A>5%-L5S6WRP:?'V'FCX^0V3 X4'J9Z_.QV?5$TZ<&W_N3BH
M-<@FL^!EH8&7UFA. I6 W;,J>E;#3[0:F>_5O73-0-0=S=NQA#HKE6QD'[]G
MVB095-;XKTA*$*+%8-*LB*^Y#FZ=9>&$J9\@+,UV6(FAP<-:%VQ2E&=GXRAE
M;ZV-\6OF[^27!G:G/(D;5Q<+4/%]!-9.REE[_+2.MWPO19JPPQ(;'O3@=/<X
M'.EE/#UV"V]1M;=_E/UE.T<@_PPO%S?:NPBE[ 0WRKD=V^;8^NJ[XOBKL5P:
MML\49H"&'FH7)K:]MJ"ZOK(U6*6?PM'_MAOE)2I50H2W.5;[$V?90SJY-V2@
MK[&"+TSZ2HR8J+2[*K 5J <V23OH&E9]7S;"G(KFO;1;@W46^]_7G635X3M$
MZV_UMI]7Z'UMY'=56>!1Q(MQ(S0;F,[P>[)6.VL*"#I3^I09Q:+1T?B)%*%$
MC+/S%$ #OLB@-]]ZX"X%IG'>C8XZ=*M1$_,T:CG753=D[)*^B\@65T:3913H
MM<G-O@?ZS:;;%^Z!62G&CENP%K:C"5D(%?SM4*0L/B_@ND1VPAL5RC-<-Y,(
M<,KA!6*\V,56@X8X\!9V+CJN+FF'6AWHY&9WJ.^#4%>V3V$*JU;3GVX-@JAN
M2RQ7+6%QQH\AT[DJR. G6J'VJ#-R+A#R-^J;7/+\/B]YAV$B$X?V+2ZKP?G-
ML>"GLQO%W@/MW,ZERX]@G*.URIBZ1HKTJW)/Z)$Y56#LM?4C7IJKT#6S]?F>
MLL3SA^W??7G::-LJ*J!^V)A2S;$SLS*7/T*>>IDK2>.([)4>$]>X#*/K+LC?
MEFNZ#NV2$$P?5_ >;[:6R57L"5Y$!2*^,7N#;HI1V_F-+1I'*6NO%^UME2>1
M5;E&.W$[>ZZ*"ZJ*X44 NX!H#5+9\4_XX9GQR6LW?JZ!& .:",,0C)<[1C%&
MAL<E<.D_&=P!R/[D+L]_ZOCW?W625.D?*^!]T,J$(KA^8O3DA!\N77'[MGVJ
M=6 KNP(;FG(/T&G?51KO&8+%5C_K!AW[6&JN& ?I:56L_!#:6>R*DVFL9#6#
M$XF&W%V+L<Q (0B_0 G!9"!SQCNNH5&FJI@WD!^4]RLM2A+APP<HYT!\E >B
MH!HWC%?KL)*VG,+YB4/K"QNQ@0]BQ\7GRD?]UXCP R/S-1R6F> VH7JPZX9;
MH@I7_Z>\4?;J#=YZ4:>?<6$LW@2WISX:D.^%HV+MC!N&%X2>'NF=NQ.0^%^0
M%?7MS.6XT]P_"WE4E(L I=;*A16B_ 6+^@]T;6\IJJ7"#S>UU!L"U'] %?T%
MO'F7Z?)"*&@2\8;YVSWP!YK,'_":RZHR]<4+HF4RUTJH?T83^P.^_"94I%5I
MY?^OJFI3GV!VI$(":YKUP_A,QP95UEU[0/,E0SY<]T ?JO(]4!'W>\_]5(#U
M0(YBLJF5>@0S3P@, [*:4'D/.-\#W(:?*1\Z^#RZ!V+T>N_&84.N'YR) HPC
M;M(U($'4KPWE8W/E8ZMY_K3845IE5].7YN)18BBP:@DUSZWM^JJGP)OGF#XF
M14Y9ZGFU6LO>0EY@ +6\1<6J2YL<IH^50&T?:V)A0F'?>U7;='QF51'S?C3X
M'@"<-,M;GN4O05W9\#<YN*9H3RW]<"OV]&M44'':,9W%6-\//1]C18Y]R6A%
M6?59DYH:;%ZKL(RIF_\YB=CUM.\9"PZ>JR]ZK_RY#1-*]+@HQ7:3:S'1M79#
M+.X%LA:]U/EFC;#D"C9'EP4S^RJKP^,N)UK:>*T[0J1!*Y]'8S4*R_5,GF'?
M,$K'8F6I.@7*R"&X<_-@OS.=5UZW1<1/*"OS8F![>J' P&@-IB&.PE4=XQT7
M1/3-Y7ND.^9+,MZVS*)=[2K\=^TN[A*4$V^U$@B1!G2@J/+C+K.\0M*Q8IQA
M-33I^5'T%Q?EQ0F&&)4#,7[,5EDX#'LKD6&\$['?QO5EF =CI'M!/BW:DI8K
M!T+*H]1RU;Z2-GTJ'X\FILH(D5*RMA.7J,<?!A1X96U<7_"Z;HYAUJ [X/=E
MK3^BT)A005'C"4&6#@T5?$B"G"Y%B-0#CEOI25LU_&!3ST\@(R#NRR$1ZA-R
M?#/^>B*W-1*^J24970X6*W,E5$$RTBX"\]^ZK?;D.WA;"E3SG;AKT]$\PIRY
M TTR9>$X=;9AC+7P"T_S;8\9#G4.TSX+/B_BK4"RUNN^;B<_J""!C;]6TM\;
M<M%0><08U,): +8A)>ZAD&->?%XJ9RD6(54(EE$>=[Z]%:@G;'6G>B7C1I^Y
M9?B0$$E2<2QKG$>6ITCNA21N;-Z-&9%:;R>9=U*04J#Z4/4[IMWE+O2R+TPH
M:<=;?OO"O-QRUO2E.*ZL!)]0*S=K:A>)EXW'EI6;AN/W2QWVG?00Z#BY*T+8
M\I3LS%^?*,8-?L(UP+NSF:K(G@?AS>9WT.C]K"X0:VEE54,TXC0/IJ''&*9G
M["M)KC<-%Y(Q!AQA,$[VYA-&Z;/]@B0EC.^Z&H]+3C^_B_(XOV%"21CU>IAO
M->?;3G[(KOW)74Y(]/-4*-2FWTN%]R2S-CB5XST%).#]J#C)S3T0Z+R,K_]<
M^_B0>4" GDATIC2=;F4S)G^YUYLV]G"3XT*94XQQQ))H^O<N0KKCQ:B0\TXS
MKT(+-U:<+]Y2RKG;=1[L4<1)());GK>^A6T>4Q&$2%T+7ERC2X>Z9?2IHQ;T
M_12O#TP]KE;KJ+_K61]WI6*P/BOU?;0>^T'BZ+QLEPF%7W74MI8#=SA77K8^
ME0#3K)QYVN/UDU3:L3S&OA?!U8@H.X 0*<)EQ9O]'N@\WIZ.1C\PC5"5_""-
MBGI>JL 1V&18-L@EY^ @*.Y$\7[]X1VH)L>7R[CS,FJ5W/O=NH$$TD<9V[RM
M&[5E*[ZFP"KS8GGE=*O2JJBKJLP-/<2WRET!I7LS?8%6B^[6Z4;2FT:Z7I%O
MKS/;73C3:8WCU9!DL[X56B4%F.F#;0:FNY[H#5@>\-/A7IO=J*[< ]BS4%?6
MX /TI^X96L,E^,IG9:E,*'3RQQ<%,=Z>;DBBY@N!<MR[2C8]M?D2Y5;3'N8_
M7_-S)B]3!5:,BA/6I'-A4[\)[%D6U9#$3.VK/;;(M';ZLO!ZD%K-,(["=0L&
MRLOQY3Y7I)J6&+,]WY/J>I&EVJM76 0U&E<]P8ZL.>QWLN K'[T*=/+7CU=Y
MQ!"T$L:&? C?G!8Z,A!.N2"]!\CF_X.Q_7]V7]R_(M$6/=M13_4SBD=*<1J9
M#H2]05CP$O@,QT6%8^,VJ-.' =(W>0^\?W(S;80++20V@5&G[!GCW@/K<N-B
M>\%PBR:;31]JQ!@15P"9QH,-.4\.:Z]9*E*O](X@-/07+S4FVN/( MN=J8:*
MG+X.>GO5T0.RJ7:9=>ZK20FLHG>8E16NYW+>"E=!_0S66^N!/ZVKGUP]P4FF
MB^GP-*9)Q%R&EHQ>1$#>C-A&].2[1DN+N(LEZ1TC(LCMQ'L ]X)-2..XKN8D
M'S: W52/E1?YV7DS\P2'O,QLU2[-FE6O:VR>([%>OXX@;D><:C87ZJ\P728Z
M7FB8-^H1B;MN\PG^\GBCK;))(S4>\MX4$$=?OSVO8!EK82T"JQD_-L36ZUH0
M^12>6&?^M1#EP3O-Y4!BT<>9'<>[9!-\ML68=6?/TH0ZDZZM4"9Y*PBLX%2^
MBL5+O<@9_L6P(%Z&F(J=U(/DYO'R,7#P3QD#;\'I: G[0IM[@)1CY81'M0F-
M4+>7?]'\89,/D9@_V\%S.-O>Y0W3O&G5BW?*#2V1#P$/BO;'7IS8.8NBQ20A
MF6\%7OYT&#\N&RW6Y<N\/'$BK65N'US@#+=H@QSS!YV7*7>T<;6V?@WU3*:'
ML,A0%#XX496A+SY&7G3CFD^7^I3G:LP/8T*I@$:M_= ?8NB">FJ;T#3/,H>$
M?G8P"BF&YLH=7WSBMID.0WN'&BTGYEN!=S*5M (2PP+;&+((.;?$C*;$'0FL
M/9@V7/.<!T416 N^\: ,.(!-K;V?_EA7-*R$#7B(IJPJ,NJ,+]WTG#RKET@T
MF?%F%?&"K"3)SKH(],4L$@*.\MZ'K/W"C^%&[:N>X+:^Z+OT,\H,KZQ7KL.\
MN<>>W_5$"T&>Q<9Z]%?(*Y.DO8N=5/%(>WHR(3QEKE.@=,%M1<+G6I)^&#'3
M_M)!JR*L71^&^!*<V>D"8(UH:B^6/D\'[Z66W@,X7MJK"K)I*.I!@S52V_F9
MA>NL$SXDVV(S1IC5^-],FAN,^7[A_=S/W D%MEK<R_=VUA3Y7X]Q9-<\0>MJ
M"=9QB)(\,A0+/#]ZO//H<,UXZL ^"^]0%>M-,V>L7+](B3\TQ-2%.I2,M[(E
M<=S9_G8[&.NEL=[1\QJZG&V]G'2;(]5E6T9^K$+[ 8^W*@\B3@B^]]O:?G#1
M@35G7LB@9A[#0*[>2@/SRORG"SUUV6[N:0W=7F<K4;@[VF(/:H>40"1Y;6&B
M!NM>/ZX\-%N-7OG@@%79#1,[\JD\/>UL@&UAS[6B6FS)SL+.FYJ,-TFA<6C)
MY4?ITFBPO?$*8?5<'9NR D-C&:*YGF><]=3,PV+YX*C(\V7LG9OA3](11"U.
M-2,\?NREF SH)3XOH]XDK5U\TNM-?*\WQ4F3=)A!3@JS0IDY5R;<7GJJBY/D
M$7=MB87ZP.=1R1X5W_&EOQ-E6VY1+R'";K)=K^6[9Z38FIB<I.I#<')D[*)7
M=VBW"T7N ?G"X\WA3KTN4=JF$Y8.!Q?*3F+/C"+_ES!!%=1"<+L^'EC04$9Q
MTO;@(Y/6QD23KW+69E[E"6]DYLH!E;>^6DA>FSA=,K-F]!KC#G0Z(%<.X167
M=)7@F15BGEP:>"^V6>] 36M]:)D@@<:XDX&:Z4A4N599N%;C,).LW=2\)MN,
M;(HDU;OUG6N/:;Q[ #-)09GB1_X05WER:.<!.>XRR=IT.8BQB^Q10HZ7RK'.
M^/.<6GSYM"XS\D9>.6<V(A]1 SU#7?'GBM7]&Y77;B9*$"XKE(6#K<C-I9<K
MMJ-]V1,W_GW%+ +X3 =KL@ >BZ^O,TJMW+]M>G"OZ#&^!G;N@8M3R#F!4<*_
M'<(J"+GSRKQ[, 6U_[=C5PG Y' I$/65\AGO;,>(-NDO^VNB4LBBV."T):J$
MJO::3T'\O_.7_W=-_V17ZK\ZH=F@>VAL9B7E Q8&Y[PK[01BZP@36X=Y!UHH
M]R [7@[)/.6%S#^$UT[[PYF[DR&HFQ[3G?? -;[S\,VJ6$IY:F-FT#UP2K^3
M>=$%X3;D=9J$SH[+0!W.$0IFC;#4W@74%5I<UL>@FT!:"DI'Q2E:DSJ7L7:N
M8A8["G$%155:PCM\?%/;RZ#JTB=/$EV$>%-R;R-B\WR>UEEE88E0?R=C"*#K
M-[&L^FQK^M.8[H2AF+&S K,7<CDQ_FIHTST%GX_?\F6/PU03PF=!U3VV"ZCX
M&;?+]U1.Q<10IQAEEZ4G;"6=KO.XGSC-JK(TB-U13BQDL[8(4;+8=T&&!!-/
M<\MW5?I+L9;B74?#]T!YXOQWO6<%?G/T?$P\EQ9FZ/3A<7'ZSBJHSYYT*F-(
MX84X5U6N!<9$OG#DC.LVGA(FS0:-=_+EFF_V8QQ(XPR(P[#M5<4I#E-^V>-:
MG2I="GITC1?+X9RZ(7/N:9\;X^YD4->#>7Z8/+#;F$%6DGLI E(*!4Z5@S.H
M&D[$HLX5\ H&;/'\AUP?'Z"@AM^!IDPE*&3]<XH($0XFBL&QD?\J:]&ABQ"'
MH%4'VLJL+"R"/>'7W1.I)\@]LR,&C$E,UKI?VT.N?KNC&.,=<T2)_J(A]J;%
MA</PKY2]FS (AB=8X34$MS>[-I12D//3I[C>M>E66X2\>6(XPJQ E$6RF-O3
MOH \4TGFOEU0X(GRIW+>]DAB_B>"SM76#+-:<H"0!%)SU/?6V%"@<U28+@?L
M*O=N_/DG+H6KF2I3"('&!6Y0!LG$T;OFQG&)5.,VU5E)'V :X2"9*JY0XGBC
MWN(K$ JZTR1_I(M!V'@PM\1$S1ZVZ&'WN[I*FGE:LU.ST&6$TULA+)2_2Y:>
MF.MD0[7;YX^R#OND:6C<X8'3[)64&A =N_*(6'Q#>1OD$PI$DJ@MH:T$FPI,
ML(2?(^?]^=JV?XRXS[^<&8>WGR*-WP-[Z_? -D-])X2( MK^JR_MV_(IJ\X]
MT 1)*?^)X]<PC +I*S.#[\ MF@4$,4+;R2]X<F$"-T]W-1+(-!)2LOY7+CS\
MKTK_>\RT*8P5_FFFC>OOI]:,-O[>,RYOH3Y1>MX)%>.>:OL[UW<0)H:@8400
MEM-=I^Z49%3T_$P5ZXS*TK*K+:I+>3N-EAU,\_8.)-]X#Y @.S,# O21$#R5
M,(O\NWD]:W7#HA\R5,<LR1/E^6,'AV\_<??]>D&/A76F*UB>4BR3;2![\[F"
M).@9S@N90OG XY@56R%4N!'=/3!2/,/NRO!:DWQ1(U,]-+_8YO+&]/N8UQ+(
MEL1$QZ.[M'T.Y.0">K81E B\O@<2W^$HJDZ7E;*?+W)M$BV4OD+V..B5?_Y$
MR#F!ZL7NKC;I3RM=,Z=/+F;[3@9UA7:)JCH[B9\ZB'X415<X[*CNZGGY4*>.
M;7;,8@Y4-46M]J/PZ+"_+\@7 J=Z"P><JA$Z]+Y\.7Q:)IW(*V#]F/K5]\9Z
MQPS.-H<.?1Z$I%1%/$,XE,;RBJ].+6-779:HA0O'PA[^K*?!BN7<>T/P7>E!
M5=Q.@S;Q7'HG6$V,3_O:[H'2W:(C.+]FW/EVR&=*411[ZJ3 PN1*TBRJ%P'L
M0IS$[[B\(,5#2ZO<,$MQIBT\<V5[]L2MP+U<4*B1C9?-\=W+=TK<\YLE>NQA
MV)OIH&(Y[KMRB=9\U,^C;QO'!^ &2O? (ND7,O8\%]9'#=$/NLHS8[H-&DAJ
MHBT%)(<<*A.-41:)Z/&<H71WNTCI%6FDMCFO%W>:XF4#ZH+4EGS/#(@VTR\-
MD8<U0MT?SB*EOCEUTCZLN1BK.&\.?N;T?.R+?"^TXR*GPZF<Z^F64U&O02K1
M:*!F?)0***:AEBPHG+XN4?IQ\FF?(!7S5+#SHIG:N(FC;4#=A3J,WC_U^1/!
MJN?O?.E?*2LG.TDJD'WF"<;-MEF%T18\^YE.!!L3^H%[TX((@HA ;T96IIP1
MP][2X*DRLX#7:3*]@Y3?EI;A(ZX![G'&,F9S [NWW.,,#2:7)<LXU[.QNJ7E
M..2-4G80">V"5OC<Y',\;<YNZCEZXZL@ZB*$M,769I*!+NJ'#DK/L]Y5 E=#
M'SX,W14ZN;--I;B!7P>8<?J^]NE,C;V[>'#L%U:;R*SE,F,<^+L]7+_K_+#%
M9Q;U'2L-[@IPH7<!IC&_["S/ULUY+]:<TI\1ZE)0R;Y'@>W"$C%SH6%*MSP5
M\.AN\^&37P1#Q)CI^K(A5XO:NPX*C?*'6'PW6Z&K[.S8\'9/HLF H?T7HEV1
MM-&"5#:+L4M2V38[PMR=&#U> <EO/_ZIJBKXA#]N,BA+-&CJ#RF1LZ;IT-.Y
M=,:C?B '_U1TY+_1TX%:+*OA-R]^),7G7$>)9/E9:&9;M+"M3="#N=!?I^Q0
M@RA$B.CM $:TQ+9$?I&M;4YU7>02T3P9%M-Y<3'6?]OE_Q/MLB:EMJ*AVN"\
M<. +V9<HO!ZA_J_*-E*7K,=FDUB^,GS_YOQ%W8ISJ&!^EG3F.1=KX/PT*F^%
M%&"V;%5MJ/0N3"7VX3NTOL>/Q6]&^8-L\\;HQB=G'YBM1^-(7)2%,F&2C&V+
M657)LK,OR:GZT\^+LTAQX>)2U\J('.PG^6@O:*D L!+'4'96TN59SG136_$^
MN41:O#<?@&'HE!OLZ<&3%,JZ?![B0T<3##2JV?*/>5+F6BY8BT@BUK.D/58-
M.AM>$B9$&7'6UECO:>7BJXOZC1IY#:GT]6_?C7.0K;^D,@W^IB+2=V3H_T5@
M9D6'JB>%LK6U[8V##)5'@@KSPG/+CFQ)HHV-3ED#0RPNO&^;7SI6"OS?@XH4
M+C6%)6N0HMY<E-V !%D2+51RBQD_RJ^8D+T823[SU;9]QQ&4:TAFR'^ I27W
M)N#RE,LI=!:+Q%R6YHJP!JN_<22W<71U/'RPA 00H/BL,=VD9]2:RU/:;A$M
M\.UVI@R#"9/"9>A34@97M(S0M^^B]*J?'?2U! E=01^&A12%=S4W3/RC"M?T
M,@Q,!M,(Q5Q[>9K';W]<CS>46F[?O+*Z =?(Z4G!3TB^H'X_((UA<R$M.UA_
MR<GB)R:X[119\_'CML0-F39EJ.N<>6OYYRE5+.D!2:HM$46-T1:Q1^%C7^7'
M:OQ)349<B<IU</)PB[.X,CY19V=AR7F)KA[J[A^MUY[I.WW)HLGLR6\>@<_G
MLX5/*W6],&,8C8NRF?XI+45*58/1HY6=PY - J&\Z6.;E:6Q%'* $_$N)=9[
M!.3/1I?H<[[-\MX/U[QA(HUPRW*O+W.S=KVL%EMFR:[W<1'V4(\079T"U2?_
MS'\3($X7)3^6$Q80_F.1E,-98US/0E/%'TP!JZ5<"JSG<XU^]J/KLI"SCY#@
MLUD^:%1<)W"*T6].("]^8/>%03AQ<1$B OL'$]3*TC*]Q@'S18P%-]=B-^AE
MQ\O=,J(<4"Z&8WY8Z)388>8FJ-H_JYS[[RU43D7/G2+3/8 C&MR4\$PZX9F%
MU7_UW?7_V6NY_M7I\03^>?&0!(<\,/@/LZ2-_Q"'5J#"U,->P'$'+RK^/M(4
M^[M)U*V2D^J"J..U;82&$G\[)" -VX*&206K42CS6)]&N?;QZBUK*A@3&<NX
M.6K1M+-4_:*8N+&Y%GTQH3IC9X47M&F37Y90>Q3.^[ QX!V2(]+-.'VJH29[
MB[8Y95D_V"MQJ63\)1%_R+O&])7QTO5WJ2K#C<IT]KQ:GJP@#I(9MAI6LAH<
M6<IK(LI2;<&E>C>(O7#B#NEI=+@+!1DP=7RW7Z_'K/N5T9]35)G^XU0QV,TU
MW[Q8TOG@*6G=2M1[35L1^M$622=+X3*:IBB/JL->^LE,5$CQ!&1O[4;E82;Z
MXEVN/"=^]TI,?*SW3Y;+PB_8O&:BK^.X/S^4[STVK8_SIGW .G0*)RUND8,\
MJ[FL],[=KQQ0VHLZ7-N343U_K@\.9&VPXYOO2WI<OH:)UTR4OK+\>''90!'K
M\BO_T0L*O$]4%\K2[R"$RALVN%X%"[B\5;O@U3*HT>;2SS.5KPT)=(V@J$0^
MX0PFHI]!&JZ*+ <3T3\P'\O8L:+*UU<WU-6Z3EAR?V4E6EZJ=[&_1EF"3#^!
M:PYO7QF118X-<\^5_>Q&W7RY&/IX:?WJJ\'NW/5X=B/8]I?B:?)/DK-P36^]
M.0ANGO:QD8$<60.^#-W6TW3A_FSP%X4T7ZVI [[KPL,22^%QWCOI><- -F[%
M> /A4LP:2]HG;=;!F3K12S8>&A:KLK09#*XS,_MH9>0@DM*L1K#=1G+R\++W
MS&HUKSZ:Q90S2"$>7[I2@.;J&U$U59REF>V'YP=3?#%H0G);H9)TQ_L5_$&E
M[V+"A*1B>XN+G'7SDM0G)Q=3U,PQT'=.IUP_5NC.[#C,& \DUA-W_F"F[>!U
MZA3:]'X%S=8Y-,>F\O3E%"<__\<30?YO36R1_](P6]''1[HMO$X]H(DX%E7_
MZ^26OGQL:DS[E:+<!N*/A15?J%LBP@OG<;>_&Q?'SDG__99*_QYP'D&Q*OS]
M4N9/V< <\]+OMZ._\X'_9OH_C.FWCZGP.Y>EYS9HP&/DX;\['/V_WK0O.E=@
M_;,5-V5>?^]?)AUC!0L3%2#OXL8+9CH9<J11P\Z5;[>UB'SXG%7A%-ZHHV_.
MS.Z!C)![P!M#>.8>V,J!++^JYJ66XAZ*@GLPWITS_34?\"8<YA.[WLZ\&LG]
M<R[2N?I?V*+^R,S":B[C,CZ8]Y9>P$FSZ.\=0"7Z\GNW%)/9Q,?^O'^"EQS
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MYO5:A#219@,1(XQ^;OGNP:'84=- 3JNHSJ6PD;L;+V2%80KQK3$Z(+[_T7L
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MRN[H)2J[V=L%EL$QZ\9'=PLH-=A:>'CUPA?-Q&R\K_Z#XF-/J;1A1=L A7L
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M?RN7M=Y--YB4-[-I'M/69#3I$_'7J]V=FTZN*NN@2X7V5"I89$6-2IDWVB:
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MM-VC?F6].2R7XLGK8%/>F@!HJ$.@<$MK^#KCE!G"/J,DU7-,)WQXL(0J%3S
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MDC'NMX 8893#NMY$7$!MMDA^;U?F-GPPN:AE<[LZQD@VQ3YB37OGZ!8P<PO
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M88O\3*.<-F+E-'ATR0%3'Y6 %%CBPV>',S?EEO4B77"@#GZH_0<)OB*8=_X
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M37Q5VV'%&MX@=D DF/RJZQ<Q++)/J)!JLZ/N42KZ3\U$<6:=2/O[)4$H4^D
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M%YX)IO5"/(!K**61#UVF;[%5:Q+E'B/^(@4)OU%Q_RXP5"OVR#2O)_[5G_1
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M6JQ]>.SBH69&H5*&$5?IB _Q4=#$X9Q+^&[PS]D [9Y!OT_@)\C4M[> KEL
M$:B,?$.VDOA25GK9=%5P>XE0BM8&2SW.PSSFFL^39=-:%O\!AS /P3FR:4*
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M\<]"^C19QY=O+Z$0&AFQH[90%^$B0^-^6^[N"5\<]G'U-W2NJZ!O<#"LA.J
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MK6LWC270ZN:KXNF5^-%E"^[?N16+C$B698/320O]_::*^H(X'\_=+2M;AZQ
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MY%0+.-=I H;HE34<,X9N]N"G8 7'/)9:S#O%J+9S#O>NP=3GFY6N%1JQ&[#
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MEM:ZNJM!OO=:DEQ<7#QOIRD<[6=O<UQ);^0A\]=R#JM^5S5+B7U@5\LMDM3
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MT5-&<(>;5*![&;VW!R6\990U<5D6!^WLT>83NH@B^\_^,DI!E"^+';JK@Z'
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MSE.C)73JZ!&2Y_/'FH?V^_4P')B [+-'XV.&&3OE5'L$K7>$2\1=_M)4V*L
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M@W^".GM"K=3Y3QY"/@5;[)"6)CP;WGJ_[#P3/AV29S#[Z?"P#%9NL_G"E#;
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M,!5XL6OY@]TABWY\<+I-&D\%]GQC9^WI$7^-S_9?59 1@4*TVFIAT4L+Z)P
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MPK_-C!"7?O+7<BN67R=X+:JGX:TSKI1%;/D";HVQ@@J4B-+4<L3Z>2BF:#%
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M\59?\8MWK?R#C^JL4HJ^E&JP&9[\Q=[&9O )^'36$FYS ]>'&OKEX@WPMS&
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MW'X8_@A(U_J5P31VOY\ ;L8#]4H_GK/F]W-F5:IFXR#-^/,-I:!JAZE+)I"
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MN#^B;[PCR,$W!^:6WQ( S,R[]OMMNPG11,VO]A+Z#2C_>S'?/T[_N=F!::=
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MN6.@O4=98FF$)H)4L)BM5#.#9$3FU:!JRM10I^NS=N(L7:[@]3N[X0Z&3OS
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M11C3N%3YCR=(%]X2 $O]SUIH::+KQ7=$F"RX).VG J><"0 &:79KE]>7\HZ
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MZPAHV847[P)?OQ5O6T@\69QX!L*TJ%'@I2S'^7$MYAU:*+:9039O8FF;G[W
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M*( L.11N@0]K])<>"@$/ICGHF[5HWXV8I^XHYD)CYG>CZ<\(>2/K0>6Q/K*
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MH&QWKJ8H>-Y=OWF#G01G\$(FA(>/TN@>V1S>;SY. 3*<O?KBK64,H2D"CE;
M24TV8W:6>&43WQ VAPDB.!:M84D35R:UO7R_B6J]%-$^L>E!@_<X-X, MC=X
MYX7YQ^>L0:%5EN#P]\RNF;ZUO31\W71D"]LA NMU?GH_F(D&OU/6S.6[/9K-
MJW<1* T\9P_G!;?-3"WY>4:YVB?& PRLA&#I=T-1T\J>S\/55V!K0TRSP9$=
M#,F.-WF!!ZWA[A?YV$"G9T.?953B8?DB<2M+9ZR3F1E%>8TY8+C:+Q.\YX2H
M6 ,Q1R=$!2?1&5.P-N!*>WD&)26I1/VP3] 9T2MXH,\8$7K#2A[?;Y;>J<P9
M7/"M_-7CS0$'4OFCHS]37B9!\K7'WT2%A >06(L4&G'15S)(/Q$<S,B)F:-*
MC:X4RHJQ7-"-:#2<8I78,.[G'BEQ"S0>:Z,@2']M(J?KU5<WVT!"8X*J()5=
M3^Y"I_=\&^9?S$AL1+^&VYY>P#:"A0@#XI-5.3/H?> !98TS6T2;4+-6#77W
MK6"FA?/**P!I,P-)WI=+U32Q8E5Q<^ [_7@>O;15!$&O329;P(=$(.J6CQ5E
M$+!P(X#%8D/:HV]YCSQ^?$7Y09-,QO)8P>I)K(H!]--"6S0S-"ZOR^4%@Q'3
MV;BG)J,#XXY6)F^,Y^??Y3BN'\QN<44QFT!JFW<I>F\'[ A"$RAD$)CM0V(L
M#9&F(R*F^U(YN;-7R#:AOXY$D745F+N7WW$P#>/2]^9D?,O$A0++"^CEB\!6
M=#A?I,+/:=OP7X:N9Q[>/;U_&]9-( ];%%+P%5LY07]1A!1FF7=@Z!'BOYHA
M PB,/'OEBBN_H/"SBJ\TT,-09-P!7YNOXWCT)=)C3:"UT)\M_#U&7)0,H2NU
M:@;I&I#]TRU"IRY0<M/3"[$4Y(AC=_65<'8JDE7X$'+D%6R<GRX4GQI3D#O@
ME8)QIT1C6:*3$P7;1!:M'N%IM>4=PX6 W6SYMR);_*DZYDAUD2[1/I+VYD_]
MW+A*63&M%BDUHX4"HJ4LUB' T=B,8FU]=6$RFG*CB<2#D\Z_BW[8AD42$(LU
MI""(Y^NY2B3XIP63IPH75 @U&UP'K:_G5<AND>D(I?%&LCR-Z"WI\T&R<G_M
MHS9;<]SFQ,5[!HC@[3!EV>4JD]Y-GZ*[.WGJ9U2P\5DE5AW.-$3[M<,3-8H^
M)<')[<FMKQU4\_?1\M[%+/Q"0\993MKG:+O538Q\0M224M#D%> 3NC!(ROE8
MA-+4?/$6)P S&$)7[?JD,ZT\%ONHYP!=PO68U27L"R-JR[U)1U3Q%]DJ4CYG
MHGBPC=;O"M!NY=,D.]<5(-+.V?9'\+:,7<Y@PUQ,(UTY/"/625-:ZX,\1&8^
ME$4E?(>)6WM/X\UC)?X1Z"AY/UM[T[%)EYSKM;TYDT8<=./K\DGK^/OM=N;'
MY^[ ]^#%AAFS"AZL'D7SWX]6ZB_"M61<XZ\ %2.-&CN^8WK/T\ (WL1XX&.>
M2ADYW2CV!Y:TCS^ L/ZWZ0*]T5GZ2S%#U?*1"G76)Z@J+$<4BR6.&$SK%L$C
M\'$W8XM O;>JTS+,U3@N%/;S_CS[^+K-2*[65+^OOTDM#M@2*\\ZK4+O8V)M
MHC\E6O:%*A-#[1%P8A9C6=\AD2:+_M*V8(*'70;1'J$I<2^S*-/1 ZYNG[F@
M[]!4QLFE.T+/<9*P[O0V4/[:$(76"MZWJRIG&KV/%L'_#&W<F1W691%7_XWY
M J?Q$ E'#IT84HTTVV&%UMMP]B640;5\*O(K[T40=79E1D+O5G8J_-I(!!61
MPBO+Z>G6CPD@*NSE!YLVQ 7#Q4LMYD.1R#0KN[WP-#6FQ9MC*M2'Z&T."ATC
M+TZJM%27VLX#7]\+DLC\@?"EG;:%!(GA9C7:A9W<8H:. ON2LXS2O;[>67RI
M Y>R'M49AM$4*\+(33&/.$*'27,H#:RSBF^3K,%:-1[KY&U> 2C\OR:7+&@<
MAN[I/L<!>ZM_BSP<%*/N"AIV;WJ!N^E8FN:1,]CRKVN)/\WB?53B;&V%<$CD
M[OVOXPL-]4Q/[V.$K=@<I'U7/$=$U4?/C+Y6C6QO?^])^XAZ@O5MHL]:.!4R
MZLD2G2<VF8KL!IG,<XY,*R3V<-LV-T$FI#CH7*"OFF8^$LKDNAPH)#<,F],B
MJKI&"W73*'<F>/9"LL^*H[=MR3333Q,*@V6(_(UQ/1?CQ/O U;F[BLQ34NB_
M:%H&&DJZ*\#= "%C\;*4%(CJ:SH+SE7A7 N9+NTKP!Z"[=,5P$3"<L &7J<E
M7_O6@^ABOC 2 ^S,RG#,A:W!&=[T)0#_NG>+!EP"#_LNA@_1*=0H;VT3&C(M
M\MB$PD#*9)R?;J D0Q]7"F7@2LMS2QE]L10?Q:"[ST92\I6H=/.:NS>Q1SD?
M*R?_1FNQ.LJBGV@UKY=[=S#%RK%_ J[J9"ZP.W.-%9L!'_8S^,)%ND '?MB(
M1YXE;R#!>S&ZTF<4R=\6LO#*XXNM7-?Z>S3V_EI_25:AR0LY46?0F/PG3GTR
M G%S9H?^#UD%WOLIUNF+=\O]7$NP+ED-%9Y5/]0/U9Q'*@LXUZ5?ET:'K'?Q
M+0,^4,X6^H!;73\6E[@.@"MCQ;*@ZH#JC?;\:M.#8L3.%:!:4==+V*L!!SV9
M!U%]A1M/<8IJ")UBAJ1?M.:C"H)-ERYKCMBS2.M&D8O$C'&AJ0&,.3._8U60
M5!+DY[^>EX6:9:OCDJX /K_H'[?NL'#HF>60O")R]K),/8U)'7@=2B,R< 5
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M%&X1M_UNKV7HQL\P!#1IGD4Q3B=:.=-"6IEPW8\4HJH%D>:7YJ!B$61\\A@
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M-=[[89 %I7=<5E;4*0:1SZWC_,P5UIF;&MR37$>=WA1WWRGL_[']J5 >R%^
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M*K+W$ G=02@,9R^R@+%QG>*4P-,T#7"!YC'VE%14K7!VH+ JF7IAEMN63K
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M;!F)>2=LW2CT0Y Q'NBSSBB&KJ CR2"O3_&Q1)%"?6QL8<B,\>MRG/&4\'R
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M8HZ_.H&S1-_%G*X6*$H]G"#OB<Z2UQ;( V?>G!UF"=C-O;?_UW-]B75U(AE
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MT0>?M/O5'6P_%K^=N.9(U3FU17TT7H&T(\RO*+%#\VB6;!=MA^36''),+>L
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M3Z@!0G+YSAUG[,\]OKW''>>>_?O=LX=_K#'>E&=EKI6UYGR>]:ZY7MI]&Z^
M@--[\?5) 3_['IWT@K-],$]1KOD9,W&=?3OU;^N@_@G"$EEE3KE&K07?(\G"
M D1R\SQ>UI6B^(=V%@*V\]EB?L"D+==T##>_4536?.-'VCJQ[I!M0X[:RL=*
MX[)#T^U&#0KUBP>=>#1EWY3%>#A-"!F7H(2>EM<.[1SI,M[ZV9UMWFX/-E%U
MA]Y$WY!<3P6)/>ABBK24J3@O H/=/7IE,MWR\-=']Y8=H 3"^3M<.K5A9V,O
M:+T_+I&W>SR^=!NU2Q>#%^!A#,&2GH>*IX3QDWO=<*<(NX15YB%2(#I[I;LN
M[6FF]ZYXCBI(5]5R;L,^1"9O5!3J2BL-\W.:GG@V-F746I(<DM_V?D[7R.+
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MI;);X,C(]82Z4,&VW@4-ZD?A=G@;>EBFZE'>"H588$!W[5M%HSKPH SM)JP
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MHVK$UB%D]*S-6579I+KW]4;M6&9ZG4R**TL=?PN9M+QV=4W"KG."*V&D0(_
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M^'E2^/RT<+365]HR_\E(-CMOQJN$; TA3Z).)RX5M@X;5TC!VS#[#O.N3?#
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M',*(M,I]4IXI>>V'.Z2EU:<OAK>J@-MJ&RZ*TA[L+WQ@BXF3!LLB;%K[[T%
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M0(73ZQ-4IP%2 J<'"$R!8<CC'"@#Y9WW\7I"!ZG!*94R.%E'HT.ZW>ZCA3-
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M1,T8O;.J5&=H$PE6[R6_2V"7X?9V" -O5M%2).Z;'L>:KL<,%]P:C\CH08>
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MXN^A5(GM7_;Y04VY&4=Q7)CW)JQ P?S".LZOTX>EL+$]V7LX?5 H8C!^3(8
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MZ.9:@Z5&Z;JYT\JUY>T!9V./4#>'NRIK1WLF@6-W<\=\94KL.BB.1J:)#P=
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M)G.B[)GW?ZHYBYLOHCX;?D:ZU62\5_C9BWY#FU"&,6\N'EX:>1SLRRSB-M^
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M/70[EJ'KP-O&I&L1W291KMW',T?2.;3A65 6G&\!DMPLXT&K^G]E"/^?V?4
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M=!BU!<7^-$0-U>!MWODA <WE9]G#<(-A[WY)ZYI$(V-O32%DVS2=.^5:A96
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M/XX,61&YXK6\(OFW\A<9Y.9PVD: 6^*0HMA@U:Y[P9+WQ@XCAV'3].C%YC5
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M%8(*J17+H(:U3-Y/^&0M>U\-**Q2;Q X&^GXV70DF./08F\FU1*V8W VDAH
MUWP9F(.S+I;]K8P#89M :6\:O6'D/4^[1;E#(94S,2U"(/RF1#1/^(#Y6W'
ME\-7<8)B"P6>>. ?L8T;=\*EC,#OH1X""_=YKP&5]0.3Q!KW+R &/W20I,X4
M'Q(EY][9U&SU8O6"G*I3DTZ]F,#+3.)">\A$:!K>BP--IIP>8"_=*.=+_9F=
M":[ZCZ(%@@Z7.E<$9(XYH_0'@1J^U/> :\Z5:9^5W2<;5$$\TI3@R#MNUN2%
MHG*M:6^0A8?#%)$V\ARJBG,T$UK1+0]=/AX)XFR^VNIXF1BN<ZY=4;":Q,2E
M_.1-/;YE9IJ0D9.W/>-&9!/GOJ@50YC$OE#5P'+L8IAXXWJ39M !)*9IUZDX
MIVK"".*>P%\;&39>"$DC:H%9'F!?*AHH.9"]DF;O93^FF4AMI5;<QL$Z\U58
MD5:Y^SEZPJ:89=!#62 ^=ZS-F:&5Y8Z('?=61Y;QKE%XGJ5\8@HBYPF6[-@>
M*@_8]$3 ;-E-BZ<OV&F&3^"W]S F61^R.*.*)_ N9"/P+&^S8YF[U%9^=*Y7
MH2<V(KMIDGY>5<8ZP5&X(:(YK[6[%9"<&]4S8TLV^TC#!?IJA ]RR]833%PG
M,$70.!<VNE1[-(+:#GWCR-O1<Z!W_\S6J'SNG.Y-AD'KVP/NC^7A:JP+E++*
M)Z5X.F ZY00ULR_,1TQ$P4^?=_W&B/K^=B,&.F,0MU)'1246>0*IDV>!L,K>
M4S!JQ$;7\A%H0K[:S*)K=J1E6F?[5<,P$F>0<SH60U17R_V\O:+4/5#K+=W7
M?HSZ&872$0^I8LO5D^VXW5XXHV@9R^#-1MANW4T:B<OR\4-H+]/N*6K!F+A.
MF"8@>X9OR6=2I> 1H1W/]P(PFYWG3^*F*<%BYI$**P4/X9S2A*&IJ=8AYGY:
MQ8JYC8J@"R73 I$! $YDV=;9:!WHU'CWB7&L:VKB?@=Y2V?!T?,<#!SN^W0C
M% ?*_$CUO=#>T9&J'1PN^<'T6ZG^7WU;4?Y!4(>:97"F<C.3: .KD_Y.#<CA
M4)14?22CM#SN=6?/AY2Z?'S\#=H)?1&!S6#:+SP?7(A7]M'>&G6[3<?UB4FG
M0]G[U5M],NHT3^+E=XUB(52]^*G)G1GT]BJ(6O>U,_\+F%7>)C:OBDT9'>V+
M[P/[';0SCL8G8<!V@U:2,\.(R354_0FA.2=Y8.BH.PC!P<&7BU2OB4.UI<MJ
M%-1%"699?3C*<K2-?=TR0C5*K7\&$AON"V*(+ ]Y9(CT,=(8NC>".UJ)U]MR
M5SL@E(.A<M"Y=<+ 6Y_5/??)CC"EMK.W19D_V*E]NRYH)4NEK'WEP5.!P7(C
MG?S)=6=G(6I8Q8+DN\KN"*$#[9R@D^9&IM+/T&F+HEMLF::H?&1L7>7GICIO
M8&K22W"Z5$ DT7D)44COL6?W2="B3IPE(7"RGQ%6^)/2QRF=<=-^2Z_*W&1H
M:*7@AN&9!.NX.%U!>H%80E&0 +1]@:$E/P_],+R;*H3@BVG('BAT*W\:]=/Z
M&N#X Z,(W&%BLE/3K[!@(+N'!=;^+M]*W;L&$JYM#]FTR>=6=@WM"S9/1\^H
M^".>U7UC",_KM4:W& +9W$3A']\EQ;U? -" /?VLIKJJ&G<JHMG!C3P!FGLX
MM>\)\J2?'XA"\HI9=Z<JXN(79'W('UE[';OM&7VS?>8_M;1.]"ZY\&NF8EV2
M,:*Y?K"C1?[#&4F;B841W=5X;4U UZN'=1P2&T&+O'7LJFV]CKEB7W?SY0?;
MOYK?4V%M^H38'T)JRR_WK&^+M'0L*( $>E$+[N#ICCS777^46;AS]ERBTU&?
M $ZJ+]^"SHD:"N69K6S]KHDJ@FY!+ $&OA%FWE!2 QXN[1=EYW&68..=JFE\
MU8Y=T1=EQ=.OQ;+CZ<B+\+5'WXV*2.6,C2M*OWW$0CQF3!+\,B*OA=4Q+QHN
M.),V^WR#@?C2L,3\DV,LYL5]S?W[G70T%4M>E$-\G ]U02#E//EO[R)-R<XS
M^60](.YOOJE:\1::*R0^X;3!=+,;5DG7WUIU*TE\.B&=:W"SN@'E@T]2Y$:0
M0=36J&F$<"=?S?3)DP21Z/X*\ 9%40[,T.*SE=WQEKVU_DO\X[SQU7AWK(V\
M59VSUCB47T4]@1R;G6_-B0-,D_6ISW9!Y.1\_= 5ZJ"EMC+!&IKH^-9DG&Q-
M%:XLU2[4,)2$]$$ ^+^2]S+D#_= E8V/:M84NQ9^LX$L85N'3G%EW0W8LC4H
M YAKU\;)%7'CB,-&L'^U[AM\<A$[97[11QJC<&R8OI4"0I(\UG:B)(MINT8.
M@LO^_J1FVL5;7V@J,_I+\WO/:N)B0_,6/\>!91WA+TH_CXKZX(F*VM(2E17_
MI1HDO]K_<RNBN ;(-<3/W\M:GR@W8+;J'].Q5_B8/.^7&5-W!\$AVF?:3D-%
MT9C4..XTU<I#KMX'B1IE<[R44AI>JBY-Z"W,Z0FD(E%[!AP%\X>8WJ%55# X
MH.ZG'V%S!*F->T9+1(T_B> RD>@%KU,X%4/FL8&K#J=,4H @Y1Q*R-#M7#(L
MS#G96^OWM#8Y]TN7H%G&%HD-;7.#J<>4V1RO3!=% <M5'DRFN3_SNKWMS8^?
M/[B<E)&U#=??ZBK (<9<9P;<^O",.;@DL\@,'31M ".<)U.K#WE^NWJF9 /E
M'; EDJ3)V@&$5RY)L#7I'[J]Q#&]0\Q?L;6$)O9L]/Z\Y)0(.H;-8ROE\GZ&
M'_JUR"^548[8&L5Z@H\;N"$:W@A9'3X+UN(I-3&?N.3"A2Z&S)IP'GB:T>X6
M#!&3*(UD/B60S[P58E*@BU;5;-SM7=1QVB+N5@S+G]HSRM52^*FF.A1_9RAT
MQ_,:T"FTMNXJ-J6^B50-;@FG[GQ^T#>$.:>O7Q5P1,<12/B(Q5]CB)@,.](H
MN-0^)4.L.NO[88ZGYD$U+*N^T,992/0<W; =-Q7"B.*=VA8:;<)<<XX3\LJ@
M[L&E5! N\YVDV'PFRF(CRL).U[WTID'?*^WC4MS5PZ;ZBE'35 Q))*/NP84N
MU2NN[-PX@K6"N0Y2)3^>E.J3Y\6ZWZESQVKZ!M,,U9>&+WQ[#H)W\"PK'ZZA
M0NN-/$=SA1=DVNVUBC.1]3*%X#+^<-Z'+T[?F>!;'M$T@&_GKG[UO,=[U&1N
M:Z#DJONI?;E3%@\QACE47XEH41^JP(:G22?N*]"_4Q# >9WZG&^#U^]5<NS=
ML_ELU$R-\;N.N%4A\4#VQ"N9"OY>%G,M,\PJQ0)7:-YZW.!X]]Q:U)&N=;4V
MP'%Q5J?HM9O&>\,5B_XBEIWJ( KB9 0%7P-\4U_:D!"2FJ94#Z66<GML:@V+
MNJS5,9/%S.+?$?/>4&>PV$_FJ,J8,43/-V\SD\.&9-@6OLXBM(J/5_R.A*OG
MALQJPYS>R6E@/! L5OW>KRB9KZ+HX]FFJ*U]=.'(LKZSAJ8!9:\F=J^=94R.
M"RG9@&+QJV%Q0YSA+=T0VO(JE!81V7E8Q>1K-ZQG7"&:<:6VAQ>W^#.SQN;Z
M(F\^-];V=,?FUG$L]I?SHT+A+:!!>?40QY;#*0/$KBW&I$'S#ED;&8U/$C2A
MN^\:D'8:%:6^=%7K';FBC >;GWKWL^APC9W=RMAV6F*J'5?=$V^G11\^Q!B!
M\H/[^E23B;HC\_RT?N/^/:W&7<QU%JN2D\F#4&'%4>NM(^P$-J^>*,EN*@99
M%3=[D( OFS4;[_.YFL".QW=8(=^^WP'@: RK($M@GCW01VOLA:ME^M]:%KDO
M96SS\EQ">=,VC3?U0IJ<^SK;Q6+7'))(!5$\&T%)[)KCL9YU&3U\M/=G)BR$
M/.$/X66%(?NFE9"A]X,991_)WL3QW76?S_DN*D-LV-?K.AD#,^T7T?P*DB@N
M*H6\A3ZRT DT/1MU!X*47HW>7<NB%D/P"E=]L(,,!=Y]'3*LS\=5!L"0?4[,
M=:)5]U[S)*6?8=#14U5I#Z/R_>$:QSPD/.G-'4PH<19^P)'P&!^UROIH1DW-
MDZA'(SJ@=+0C;U+WZ0GP,M^8AR;9I,KFYGN [;(0".++Y3.CE62^N(:<56TC
MY6\)=$[<$UOD=!MZQRCV[8JB"4.9S-X<&<H[="2=4&O@: E7"(X:L<YV+JV$
MRDDT]*P:9C%.8_66KPG3<%("+X%]J;X(I'>?C'Y('ZUX#=!6ZI4]IL-MK0NQ
M+5E\U\"<7S6MYI4>GZ-H ',><W_OZMJP1R6$>4PV^,Z5#N2C)GO_S(N/$JVD
M%M]<^]Y_-'0J_^ !52IDY+C('FZ.)*HF:V>I/-G(F:6.ESE+U349Y9/S1TQ(
M0)[6BQ3>(O;65C97;:3Q2KG,>&NJA15$"KZ3"AEH9A;$PAQ0T])]\T%<7<%'
MY/Q'(M^AV\A9,$K!S'JCXHU]JCVBEI9,S]#8XDH+_DYN)AEK%0!X#1"+@2M-
M*SC=7YVL2W7B598[-Y"*W^PMPS:)HMU.'ITA!0L@IY\,K51]S QC$!YS6JY[
MCZ]XHUYF7IT+!Z$,NMK< S.C?F1(!;!\/-6)!R/TXV).2 XL-$&&/*5Z2CAV
M+K-(F(;5OTQ85JL"SZ[&N.>J 2BCK.R?#IPP_7M.YFJ>O<XQK]W47TUM*FK7
MM$/<0%L=H6S6\Q\3[P;ZVPY0(5+S9GM)=>O.M1;QAKU=WSZMQ<%79*&/T=C4
M=)L\4!*_]0.Z@.%8\46OP"/D+=_JT/<R S+O3T6LAOB*S&XMD<%@>[K>]]Y5
M(@SLO3%"AE4V79M[M1$8NLMYNA9"2^VQN;R591*\?=N/:OHMCTSRW7+%U64!
MJ_<H=QI;&FN=:Q9-AC6BI:_Z?%O*V9NS:;1?VT'22P>7Q?$UVJ_$675-,'''
M0A*W?7[C_9RNT9,!!D04;]C"3XD6@'SG!8O*-KOS_7'><ZKX%G8AL-A@+HBZ
M1[53V?DLY\+WW37 *2ES+0),X>$4@<.*8XXHG&PY#G8.?C[)I=)4GPCR4YJ*
M'5^<)D(<I8@KU_@,*\:M"Z2^",L$X*TW70/NBT[U^;$-R\HL* [?[UQ)'9UP
M<9=0QFN#[1<GZ+]<&%FNM,QY-]6X)[NQ(_*5(X\A4]_#B-IEFQ1K."73TU:_
MW((B"*(/_/(R^%Z-'D@6(%PPX,3QK[)'$\.BEW. #88"J<R#')*ZM[R5X^Z3
MSTN_WA1^5[80H+,;5VS+5YG"L 2?]6S&0!UZX-^HRQF7.T?$V#)F*^B8HYFS
MTF7$%?F(B)RC=^ZZ&E]I=>!3V2E97!EJ9*!#+^N"# 7O,,];^J\?N% -(@ ,
M0!OC*!.#K*>M<I:U5DG1CG--MPMA^WZ'7"3G-XLLL( 5WZCZ<!:Q1CQ/=7IA
M(9&ZC/R?QM_\:G_: "M4.FD;"%(U);ZCJ8O@9]$/98@^W19^J^,UCK)%5KA>
M3B?-ZU4@:UU@V7X&)Q9;WZG#$7'[4N=L&[P)16:[F]Q3+ :^#]CNK[H6&?\X
MJX^&N-4[Z]"RRM_&L$[6,25(7M.KT=*K+Z]F>F%KI/<5#>;;>;B^5%QD5:F(
MN:W"TZ:UHW4FWOL(HG&:D;F'*#K>,6'GX*H)VX*!&.-AJ&GYRJ!K0)-\[)='
M_4_K)]J\B)7QYMME1CB*G 7G-2. FMK7@"#G5GWK?#%=:RVZ:.IGI+Q?A\(:
M9A8#Z">&RR[&)XQ<_-N[UI5<J:"A E6B]\R]FQTSXT#%-:K:F!\-_0J5\]<2
MIZN8^U:G>?N_BFBG^1^F<-63BH3BO&Q[P";W>#Y4PQK$)DHY7%"*4B@<D\D)
M1E9+W"+'3<4U&T</*];5//PL4N:U9OJCF$/O7>(TI6!*8RM3"(<;0>*6AWW6
M6J41E=[6FR"6R&'3QS\VI. Z/*CCBZ8>)9WND75'8P)=,%:CQ]=RSU',:"UV
MD3=9,ZK4]1KA0E(?$A9UL.?ZT8GH3%P]J<T[W7I"#@5N*2E^.:T@\4V+P':)
M&LU5"TN$*NP:@!UTHEP4=_'>>+<C,+2FWOWT2T[J>F;J%\LMII$MV.:]A>K]
MH&U,44BO@Q6OI9M8*1[WO(*BI[.6;4%W/OC8C2)ZN4THT_<R\D?V]A9QHZ^3
MAM66DQLU,@@^H?2\B#[&Z]!:NI]>\[")<.TLORJ66=LHMR/24#;M#90IS*2T
M_L6>!#8K7=CS@BN6\F'>]C@(XSX4*VVJX[M8!7L6C?7)W22/AD+K_@40*W8&
M?D(3YKV17=;+F\E^KD14[SK2/$5& ^SB?8O(&CC 2\CI?G0GX>WY3.@C T/O
M9G;BAI'(VGAK@C),/L/BN8V<^3;')F5ONL&,O;ZP@T#4ZP^'3M:X2M %:HYE
MM'[A5Z[GVDR^AT7"[8G*H971Z?>M,B2WZP*ITF)>-3(.P]BV> 6M9N47N;/U
M9!]\,]@K.8(LV6>75DO,*W2#MK6T&;!M6)!B D.P;1R)GH\JV'FS.DRFO+8N
M4<<*8Y_VZ2?EC&)ER=]5#[WSY%&J=#?)/*W"]J>CMH1:%#.<^8Q635T%%.C.
M3*SS%]A:/789>_L00MO&[6K3DN2++RIERA>Y^W,,[0$DB!QS(&HB$%] ("\7
MM/BZ>>,=F.O:9OIW^:'UJCEK7%)40ZY1,9H5JJ)"HPU,H#+$PPKXAY+UFD6=
M-,M:Y3&$:=/P5:\ST_@"+DYO%( F-F<6)CE>X;J564&"_&C7&>S7;A'0T#C'
MSK\OW!T<"'L-SK;)S:!/G!>16' G=QBG@\<4[% :"F 474A%20\^?65"O*SE
MX493$0^S0&FXD#R@\WG<\H[^3O3/PNE2.W=V7)*HH&TH6&B1Q(L87M>4C/&V
MO\>5CS]M?DM +:E+@5_>:[UT$1F_KFD$=R-Z*!O%$EI*U>1PH+UC59'34!X%
M$17K^7:JS^,S6GZ2?3$A"Y3G5+I1#MT;7MS\3[==V(>M1:J T7V0O-VI0PHK
MO]9R(_A@JXJ2F'S;:_"Q#6V@'; YX*&TF_.VY2=6##]8+A4TQJLB&?05-G'$
M"TF$CGK)N5X#'DR'@0#1K#,=J?<@DQO:_''8KFRK3][$"FX8"@["T8TT]#=F
M>.+KJ3JH8)N= -)Y: U%1> 7B?-X,^(B<WL^#V9(<B*=XY U.+,K:JRZYY60
M:WB?1)6]?PK';015_!E^R8 0S,1]<G5/!)E@68E:^&F]/PX^EI%'[24_ZGV/
MMD91*[5570-0BF7U;YR !Q,5#^RM5M!W//(WZS+1']93!1->?ZFH;&W>GG5#
MNK/EX5C1AQ 3O8U&U6^\A%>6H^/MJ?-9&5OGW)R+^EOM)R96G57M=&5*MB<0
MT6"-8%"00FVH.&=G;U*'T"O-+R<D:C:&-/? DRZ^*I7#<4<KJBS?)_KU#QY,
MKUMA.)4-;8EUJ:7Q:[68(C=4@Y4]-9M)O$ ]DA9=Q&%RS<GJ5K2Q?EG(GD-J
M@3:4=98=^^!%#;Z,/:**7KS61+P6T@7C3.PVJ "9*OM/O^#/^)[B>E3\R@2W
MG& @YS"'OH;C4])RN<B![-Y[)Z&BK_'#/ O;V=MN2!W2(/@X_+A>02+4OMH\
M,FBQGBY+#[1QEEGUD+X0T#Z7;/_* 23(R:=LKRR#32GME+OZP#+I//\:T)6V
MJ*F4T)B,N.A7$DHI&6Z<JG<5=C87+6 T)E]3N]\3]7&98^GGAI%7;0\LD\,W
M>H4R^@'MID-!8EPD!//SH3O+J**<]2W<25_M#%>]]].?IKM!0\["#0)M0DXY
MXI&4F]%EI8O#CN+$:[6&TR^C,&,<M42"%CWLH7A)^7K*.;*EJB5[9#]$ANL?
MF4'RC-<U+0DRD>14\MQR-SN+6*32%<DU@*O)V:OR GHE!\V!Q FEU"G?[9(,
M*>E7[([N$))VQB6/(=;T.9W52=V(4LJ&Z+=2&'?CM76J^-2ZXP+EH[^7*]$_
MBV=M2_Z8O)>H?!Z6/N8$CZ'5N3)>5IZ'$K"/^OFUIW"-(84?:")JV>D,*^M9
M+&E/UFL>IT*Z8:.D+=J6:3:6=_&SK-87T?8Z9:/#3YD"Z2X5"LK"4CC/'A4H
MP+;.4C83IY+U \O,::R'.E(_.!;^](!FMCDNGB9]>,Z!3]R6FWB,:VQ(+AC_
M7MK;-H"O82Z%5B[M1XF2+8YTF=DB76*L0]&9P=XUX /_Z&;M58"J<_':L1/$
MD:&9Z$WLCPVMPW[B-53F]$N[NQ&'VB*)![B@9(@3?^V[[ESB_KCRM)C1/%A%
M'.)PW+RBI S((1<SQMZA:%ONE1X[="!_B-U$#G:RK^=D?*N2C\]'>\%$(5AY
M$/>ZE8H(M[-(IX7"K&(GJ-AHFRCVDR?96W,^4C_>.I9ZI?S"N+TR8#66W.VH
M"2,D9<54K3"UYW(5.']55136^8(,XTF-L67<C'[YT"$EV-I:RMKH@;5^_2G!
MFRKDMQ"K4"@ 2PB/=;1M*GW-C9?]0>IJJY.L#JOKCER.@==+?B=/SC/JQI0%
M7 'U6I+U:<,0+[45F /Y M^"SKM3$:6LAM$46/ZVL$?J@S-D25MOK?T%W:FF
M-^:SXAW=EA&/-]G@$S$I\2\M.^]%68W1B@[#$.JNGFR!UPF8WXHP-A0;2T:W
MB]Z;P$>>V#D'6/74'WPO(&$Q+T1;'I,]YC*4['WRHOI60):BUU879+IT-=XM
MJR(E:JIK5GH,L%($8852@-6L\!G)_257$F?]\S@:P-FKBJH)!++Q5[==8<SP
M8 6O)Z>$K<54;[YK/,^OK-SQK@%&N\N!D*=CZW1[[>'TN$S)=S@ORMD/M.IH
M'ZTAC\OZB3).I#@R]X'^94.;:?,RDXS3XBRJ#\)NM(@$=4X@W^IK"2HO28^"
M89CRY<2)\F6;@8$39$_XT0*,R;GK/(:*Y\[W?"^V/3M=<(GRV_5I4YS(?N*4
M.5&FE_$_3KB5<%ZV*P@(4AT5O6:.;^EA>-$9WZ:6MCV<"*]QUU5S5@1MNRG'
M!['%2_KO+ZNE,6/:KH//G(,/>V5G7Y2YVM'6WCQ(<W:?'L$+4=#2'OR&HU/Z
M?D^?1JRT?#B]/+6=>:Z:\#'(]Z[/Y*BPT<Z[3>;LT;CCFA%CEZ:7);51*#W,
MQ)17-,J2C<^'*,:Z&"D#+LJG#G08,L8D<M'SQTJ=VK*&-BVH4&RELO@.MQA5
M*_(P/HU<N=LQFDZJ^4V3N 6"''$7ZE-CZ&B5IO*H9<$1>E..!VNO3/?:8TXD
MJ9<DGN.I8E3G\J+?CE1L$,5:S4-LPYP^QN5G61\&ZP[]Y@$7UZLBO8?;&Z[_
MOYAYJ[@HOZAM>)12)$1 &I20!FEI 6D)J0&&H6L8ANX4D)20EI;.&6KHEFYI
M&;H%9&@898#7__,<?-_A=_:]!^OD/MB_W]Y[K6M=U[W76JHE,[^.,'$EB-:2
M2<MXQ3211&K!FB&6#CL'U&5\_,?ED?S)=Y.O\@J6%=R+0.K.>1S?N//4-G;C
M>14V=10"\K?>!4;=DJK!9((4]S"/189V)[K43V5R*M!D:F0+%;6[%28^2ZJA
MV[V[SH#UUEP\"Y^*4?49]7';5<4-@L>,^($.9H3[M/J#G]H7\V.48?TKD2)B
M4Z--6*8SNJFBOSG2@_\8%A2W _*C^S^&)<-/#Q%<+F)^3_!O?Y2[XK[MLKSU
MSV!]9WC8P\I3S50KNPUNSF^-<:R$).OB$URYF1>M9H%=8SS'HPMFWW?,&##A
MI;-'R!O_:.;H(;8M1_)).-3':K2NJZ<KR<8P(V;XI=5'[NRN4!I/V.-<$;9-
M^44&7[AP'/.IU[>H?#W0&("ATUA].2&O T.HE74/8,,:S;#'>_B^(F/-_QJJ
M2:H&Q9PKZX\,=S%XY:9.8%B4:H*)E\&J,+JQ(<U=4V7\2HR62FWZV\Y<D(<O
MB:_%3"8;>FW8I AQYX6=:'2FMS]E;AUC)4#,WW09STJL?)SI7'8B'QYPSSR?
M?+1OH(O1O#.";7DOKS^3L*C,;6UN S^<IGX]XIPCW[0B,XC*3LU* ,L^,ZBX
MZPHY\ H2FD:C<9DUPN,I:C<Z4]WU3RDCOE3NC3P1>T>0;&I6!H*ZH8S_I-%Z
M5G _K,OO$2G,?]L:^1FV-:<VIH/?[227S]WV8K>N3=CR5.PJ+[[*JB&C/9DN
M/4&:M,/[FLA@7HE!/F_'U)LWM3B][U  2OOJUS8/!3 ?'#R8G8=FVM'E]J=8
MR-L=.#XROI"Z[I41C)@6G_YKD-@7*]"6..Y%T(=R_EG81L[];L])[A<TX>1Y
M>BE8.9"MCTSUI=?$QLQNU;BLQHT#U."U.R&+L.$OZB:'<DG[&_8_)*OGETV[
M?H$#Y3"8.3_#8 K01?Q0UQBL[.N03A8X2$.YO05,-ZBMFZ+($^3\KB*[2 ^L
M-%HJCONDS?''\KVK1N6KNTWR.;X.+:GY8W1#%^5P4<-^?2@S\&5,&M;!T./(
MKC<SK@VE)7)9E1?L3L4,7T/9FW+-H7GG56'.\)^%;^A4I7VJH+\\S?!6%9@=
MGH%!M0/#3.QGY:6E7,>8=%V#HWL $5^5\Z4674>,Z3"N/_#CMA5SVHE#$.4<
MCY'S^(@6WX"2VR#UN$YG#<QY\'?! <AR*-+#CB!1QR>R]WACL&'V'H"T;K?/
M<U'-DR9PX+RIH/K!=BS.ALC+G\:D]P%MU<%\O4_<72AJ6=!A>EG=J )Y)Z!^
ML]@+IZ7=G):_!@$+IF:Q'K?R.UZ*PF0?M=Y"RT^E.^$^GV52O>E=N;:37W'"
M\/@0]X"7[+Z@XO2Q<HMRA\%>L>%@\D'I&E1UK--Z=LQ>)PTF_FSW+TA]'XR=
M^3I*?\+YE[&RS!0B,=YQL0I]V^^-/W134HOLNQN=%NZ X..J*22NO4)(:#35
MJY^^4E^N6Q'#.'BLD8O<9%&O-]4EI@[_&<E-_>GC .$3YO9ELYQ09KWE'A>1
M]VP#@_2=+/44R*Z/31,WS/Y0'=WE_= I@6NL!<J2C:^JK4+/7LTUW# P**-L
M'OR'0 4S4AJE#B'MY?)UL:E60Y1#HQ1^D7V1$7\4!KZ4*P9EC&ML5O+R:PB-
M_H.6Q9"((0RN'KL]ITQQ@^\;1,3O.]%I\];7OEE7V52ZW94+,LPS<.1.)V3V
M?V EXZ0SN7ARO5:J1I&U^C&$(5*R!AKE!9&2='=4A7KDBB3,T%1"RMT\9\YK
M!;Q-5D1NM30_#_Q]E\Y-F@EPBM?"1WI*!_6JA5@W9P0%M[;L=*;V87I5:VM/
M/KDM+2DE<852DSBDYJZH#SQW60.<LKJF ']I<JAGG/V[B>)^?S;V.;/3VM7]
M((Z9!@/KF+?QA6R&YS%PSRT-KOGM;NLUY$:&UL/:@ ]61?OEGM*5C_AQ9;F4
M!P*Y$Z: QGGO<_)G'%\ILWLDW6[HY%R""1N:#OSZ[E[.K,\8W);JXCP5PSDT
M&M[*>8E^+BM&./C@O*=:PM^_Z"3E%-S^'NY/_83.FN,"\;DO4S&\].-Z$IW]
MO*)U;\BD<6GQFGIUWP>@@S3X'O!P+ZK=TC% T0;Z!.<)^2[9:I.SE%D)Y%>>
M_1?NU[@/_1:>2+V>K/ )W(FC[CSJBV\(UI^!.V']+8AJN=_1!,F_D=(NF"O<
M_2?PHX<#3-7/)28Q[X5KS9N4S"F_5B!\7V59;#$(WBG%F5F53<Q+9>X&:-QF
MV50M+2XN\J1S*?!(RL@ESM?D'87U-P8[(AL:E_5@D<W7Q72J^_,;W/UFM3]^
M8H81[0K^4"%+$:+R^+FV;Z:]SE!?X>N0+2"-K>-6S,Y%I;H91K4AH"_CX7O7
M(T/!42Y[L:BB*!3ZQ?8'AB00LDN28J']QNQ"FO%_THNOJ>T<^X/A];D5Y;Y6
MKZ^65.0<SVYG,O<\Q^E4(WM*5+Z%&^E1NHB/N[D,>$IVD0[ZM<V5FBMX4Y>D
M[HRTW25@H[O:)G?NE OW[_AG1.BZZEFS6&4]!&[6U$28J/9;/0>3CG??'"(O
M$.K]:08H[RBD*#+\Y2N7QQ]BXQKDM]0[D7.OVFOCI^_$"/R&EC("?2C%6K46
M3ABJCO8QN3DE!XVM\*X<*'/KQ0O&5+:CR\X\IYGED=IOZ$'*80S)W?0&GT4,
MTRN+E^=/^0 BP$T6H65#4!N9$[KX]O&*OL@Q:^M/;6^-SG0Q7BEH,=CD4?LD
MOS1- G[S,1WTV+T:M5]KHD[$UND55Z,"-Z/=-X:51KR;_]%/7P&TXN@Y-#GX
MGB[#,46[R<9S%#%TV,]1S%G-_M<$UMS3^>N2X=DR"*(]P.K[9F+/,3/P"FY5
M^A):^75ST/;-N'$<);.^-@#G(_>XE,(&V,;3=I8"OH-PLTS9.Z-0 WZ1,V9_
ME\L)=O#E<83MH8;>9@>N3;3$07LS&U/MV)9;>\,G*'Q+DU&M_$30*T$U'J7L
MJ^2R;5\;O7GOS]:!5OW/)03)=[;&7=%5'*[720FF^33VRXV*#+0W>C^P+_D*
M_86&67?>60RSVL6PU\U[W+Z =L&\O@2,TU@U,:G]Q(1#=WP<1*)=Z9VR299G
M_X[WF9U\;$/K$)F3V*=<I,SO%Y'%UWX^],_!CRXCUE6+V/:T"+NL0.7%"!]Q
M_5XR&<)M4\";-(:O1ZW*$GVG-T^S,EFMM'(./!4PV'Q]4/L2$%->O7K&+PCI
M6CF7&52DBA?VM;0]#ZV[!SQPT@!/MZN6'O1@,P#6!T7G)B^G?V=MOFVZ$;8D
M(SGZNB5>YLEQ#ZAO!WJD<;#@K^KHXTOJN?/I\^W?X2'_9/N#3B5!"700T6N-
M!RFBO1$N/I1._$\75_>3P2 5&C*_,)/2<(]QOKT>YLU=CER[3\CXK>SU!>EB
M$]ZF</01?'*<!?#U[TP*>(>D:^];P0RRU0P[,?G];W3CE-WL)5TH64[GC0M
M)&O3C!9DLCB0IH-T<Y9"'VK[5"S];K6-L^Z#MR,"UC25?,L#($7[-?9>SQ1P
M5=9C!>.U1C4-G&[YTK<)K\XA76/0@W2K?@EK&?<_SD[A$7Z9%S%GY2J,_-.J
M;^X!2O$=[U4B"TDG\GZ:R8[E-9PIE/U_F;O[?ZUQ/]_KE] O/JE/LR4GCZ=B
M.2^$AQ6/1U,%..:MXAH\C]PHNP#=+*5D+"_76%*3<'LR6+\]D-/]$:.<]F8
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M2;D7:?%9+\O0#D*:=& YB$L&%L&U-K\NAO&TDGHM'?C,*%JQ51V15 ;;T9'
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M@&TP:;29-NO]++GNS&9;K 4K^'M[H@@-&FYU,L0^'NJ!&UQ'*G)X95!N8\.
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M>2O9?Q> FWMW@R>QHJY@\CWKQP^NQC7_$D1JA3/Z6T1]9+->&<)"2=5@$O<
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M#9+$D]'M,.2=9YLB*="+K620J31 MK9NUKS+_W.T7=0V#1L/EP:H>][[VO:
M9J\I-8)NY$N9;*IGBO9E#2^)M^9)8$2.A71=!D.I#@*]:)7GQW(2'NNG"UD?
MWA$ZEA431\3$,'Y#OI;=H*B[T4_Y$SB?^ =R[C7A  ;V>F4VW#8L[UQW/S*A
M)T05Y%Q9.)^)@\UZGOO%3:(L,_U]$W0IPMW_Z,/IOHO2OM-YT&F78H$R6-;:
M ^-1I/TWQ]V.W/5D=\"H:-'3XXLXV[_=TE]NMDJ3OFOZX=@YZFA8XGY.GSE3
MD.EE@(] CS$]]3&=,7LTC4P<R?/<@A49J& \S7>LFUM:T_3-Y7Q5^[U2=$S_
M*W':;M!ZN+AF<EM"LQ>J>QWK1CFY8VQ,$ $3IK!ZG*1J=BP5UYPWT/@KW[XJ
MI!*M/7=1YADGHRY^[>OTVBM;3\C>8,8^3-UR544CQ[??84H-9>CMK54[/KX^
M+A'(S"O=WET+(.NUB) ^R,U9IY,$]3<WM[0T6]^$&JD_^+-@H:@#DTRV@=(C
MFM8_2QO_!O/,](BY_W<(.ONY^#,7PT6IK#G;7RPREI.@Y05)!@9T"[K<2C_@
M2!![0YB[$GK"F_Y,$TIXO7&;T[\TCC<^]N3E:)%;*L$)Y>('A;F5T"G#'?X+
M*(RTMQH/7J]9>KSM9'5LZNU;NK\@RI%67M;06[?Y/)VK_2^P23!"ITJ0](.^
M[ONZ>"T!7DO@W8FI_4KCH#\W2]8TEHW@RNGK-:AO/NHM8+-6RD2WSZ^X))6X
M*JO04?B3"_=TF]X3.Z=D&@.*9XQ5!,)+[>BKCCOK?K>!47_#"H_/D N;F=VW
ME@+A%AB@&%5OI7"K ;2M-!SD$EW"%LQU9%^\\#78+F77TQD/\O=+7"&$=SO.
MJ_+=D@^6,]/[$\^%CQ,?SJATKU)O0'7SQ5'F >01KOF%L <$_ZIE1X;IQ&?.
MKB-3%0U;\MD4)PS[ _2UV0B4&7T/I90_;>X5RD[&S+=K*Y($E,T)+># 5947
M=TB:WH2=;(Z--QVE!]NQOY)]LW4&STH@--2<5R8JF.K]1D ?$@_UBX$@\47K
M-Y; UDM9H?> %I=#Y%:B1M-)?VIGP768J[>!SN,M_,9?14B"\OZ5 *GZM*.B
MB(,#ZN6=0E45LY'6.*'W3=-5TZA%EQC)2Q&W&/*Z&FGP8D@UQG@&O,B:P*K[
M<N1_HE!+[<0S][.0F2K/-3G'^LA.;<+[!:#*6XM006+"4XS<8<NN=TUU3( =
M4:)QJ[*CG)U%3P]B"7AR65)-_UAT_:6G)\IU2!Q.#>-=MYR2C]+2*81K:$ H
MTK7&&):S_@3$@JW^1=WHVYGTVV$\KT8)^NF#3J:&.<;'K_B_$HR&Q2P6I&/?
M!/<RZCMO!!\%4QW(;><21V4QBG%G'B&="0WWGZI$6:?N4'LG-I%CYJ=!O?1Q
MS$H51W,?MV>1O,R%.^9^PT,[CMC'I4:3;H>L8^D M%) M4QH>4*D:+#]/2"A
MK:L>/9F^1Q^DO_1!^2NUF"E%30M('S72V(U+Z/ICMV@N0 Q2:8I:'C,+;/[C
M\A->P='9]">\:VBPZ^02D1]HY\D9>#7('69D7!T"XZ\F7A9:!HUTXY\5<3UB
M4CNT+[98[O_Q;X5O?=\?'K.X3;(XL9]6MI:DPRJ-11I&=K1<9_51G*.KR^H:
M\7PS&SLI5&IG*V"-9_1%;FJ&04KP0\;'M;.E5&2JO,B5,?[Z?Q GK'V)DSW=
MSF15(L<5D63$1@UAA0V>5[8:A,&*(=56CYUY,[YN;Y^Y&\]J7[8&RMF[[:_'
MB0L/_Y9+'LU87-K=>U6U[*,YLHD:P>=O_%'^7JS8>4KS-Y&_&:DQ"DI<_C)8
M/(2 /1ZBVWM5CF#0HSJ/]S\=ATZI-WTQ[/_<ZY4(K3L8,9O\LHU=ULZEJ0,;
M[V(C['+D:]A9<%"-987%'S?M,)ZVUT26;6WQ5.+V\Y8$,G/(5<H9S<3;G)H_
M5ICZ<[L%D19%!AX&)Y?1D_G^'*(%;S<>1QK*$E8B(,3YX1*HB#.G[+60SI0F
M>IXR%>V&6@CE:?A\[G<V27^;*4XXF\G_"2ZL:OQKF.?\'N '7$F8:#5^--13
MU#%G'_?/#8T+V&.P(/L:5&LQ\MO0[S<LB::I%)8<.B*_"A\6QDRO$MC%4"@Y
M%9$T2(L4Z6E+VXS90B48<IN@VRN<ET3M9)@%?JI>T(?7Y\[5ID_=GDZH(- Q
MZLH>Q"N&NY?.^/NHDASB9.?X-Q%45I9UP(V<^+=)?_]\"7Z<O=E6P7'HLF\9
M7I)@9U,:&,&1/CSPB 7N=OV/;>WD%#6TM8:Y#NM]+<.&>UUH7WK_5[7<0=Z3
M&13'GEUB5,*2GMK$-%]EA+&<F-1K[9+?54_R#EUV$P"EZ'8V4<8'OS])RRM>
M X/?T@7LL;.74F_"]R6(&Q.%S]Z"A */!D4J%=E*M\6J=S_,>53"+(>/G-(Y
M>FD8E*=;*F4CY[VN(3Q-0"%66$J\JOH##.WO?RD"'7)0-0$$GDC'%TI,$B6#
MU/"%GOS>.JFD!7[B\1B%?!%.4A5,]66%C0_U[+9R<1ASX\P.3U\\@7&_AU*K
M^SJV:6IJZ#2<.&4YEVK81-KO'"8G<1<61"(V:ON7_F%,S)%UVL&!X9<=*U]5
MLQ'$(2-A[6R14:$O;%>?D)9JJ7M_NM6/PR\2E+WZ>?V&]T5[UDZF'34_"_H-
MU@&=^LUX_]7O;M MVVBGIB_<CW/90/S0^=%/T'#0EN^-E5- 4X!E?3[&MU0!
MPM:4XS(EB4\X31[K![119"M9FXNP/O##*RDO#@QU634$?PO[)WYS[P'AKC8\
MO)3C*\O1L5P9T0_;_/Z[*JNO72=*><&E/0['@E$"M:DG2M('(*9'1D9KRMZ=
M1JPJL6:2>R\6%!4E8U"&6\Z=3(O+IE(G)LO=K.(>\3K?[AXBE<,N=J8TO^9C
M&U_4V^V^N49$Q(!Y) _=7QW*-;;^6%)S6U4GHF>$"IYWHSSG\XCKD+5(=C>5
MA(C)^=9,#K^#)XK6;BBQ4)CP:%?#L/ U.<F#-/F?V,/R@AA8(S>>0>YWU.9C
M9A]=QSQ_'+A107%E_-[3('HCWY]4WI;+V7\LK1)&&H_;>4M-]]7-ASX\#:C*
M?BW3 A_A1%<Q.+FB@C_R'#D_\T4[V9U-?+!.J6$*071SZ!'B Z@?IL7 5@S_
MS\*N/;/M;U^;H_]NW6/]?4^[S?Q7+'NY3VK+Y?SU>HOT][W<;A=]6W2KJ_Z/
MQ+U^[D$7'ES2T7^7^Z"Z?3[KA3\W?X7/SY*JFU^\W%MV599NJ9J34^JIYB_K
M\Q0,#DJRK5HV,V5296>V0,WS@KA,U77[K[87S_IPO.7QAD_Y:G>?_<S^-/ER
MUZ7K>W33UXE.<IND.7WQL=O^SZ.OA'I^MO7L>NHNO_P/L)FW+_K8O$>1AZ:>
MF31M1=X_Z1LQ6<+W=,]>\3?.R]<+VG,]UU5QSKW6AQ(EWI.-8N]Z^6>FZF@O
M 06<RB0NC443#M%QF23__YL 4$L#!!0    ( !.":5)GRNE8!(<! *7% 0 6
M    9WIB=VAT,V8T869T,# P,#$S+FIP9^RW951<?=?F66@!00+!"B<4@:#!
M"P\A>'!W#^[N!(*[)[B[!'=W#PZ%4[@7! O6W,_3W3/O6C/3W3,?>LU:[[_6
MKB_GK#IU[7WV;U_[>?%Y _!:6EQ*'(" @  P>/D GI<!H@ T5%0@*@H:$ A$
M1T?#P,3'PGSU"A.$]P8'GYR$DH*<A(R,"LQ"1_66B8:,C)[G/=,'-DY.3DHZ
M7D$(NP +!R?[/S^"@(Z.COD*DQ@+BYB=FHR:_7_Y/'<!<-$0NU!&D!#> A!Q
M$9!P$9[[ )0   (*PK\.X+\>!$0D9!14(!HZQJN7&^I? Q 1D) 0D9%04)"1
M7Z[ZO%P'(..BX%&SB:"^430$OG7 9_\6EX-&\ZFZFT!IZAS,8>08@(Y!2$0,
M(J%]1T?_GH&3BYL'PLLG^EE,7$)22EI9155-74-3R]C$]*N9N86ED[.+JYN[
MAV?@]Z#@D-"P\/B$Q*3DE!\_4W/S\@L*BXI+2FMJZ^H;&IN:6WIZ^_H'!H>&
M1Z9G9N?F%Q:7H)M;L.V=W;W]@T/XQ>6?J^N;V[N__^A" " A_+?S?ZD+]T47
M(C(R$C+P'UT(B&[_W("+C$+-AHHGH@@T='CSEOT;&OZGN)SJ;G0:#J5S B/'
M*0Q",.<F+?P?:?]2]C\G+.#_E;+_+NS_T 4%8"(AO!0/"1<@#+CY2Y_KC_&?
M\;\IJM*%P+>_;A/Z',%*-!8-3%-:24B[^^0WB&ZHC-T3W$$;9'M:G!F:&KVX
MNHI1-T(QN6TX&WW5$C"/[_%O!1K8P88_$$_:29%F-Z4&LX62SA+5"HYW1O@(
MVNMX3PQ*W: -:05W?E"2H(*BGQE9YC^-5R/-0#20H8?#'7?Y@0R12@%U"Z-&
M=#!W0TZD3(!QW&+R!"]R<>3&=??9L'A671:]$<,]@ZU9PY(E-U\Z,U?03ON*
M]#)H(\E$81$( E:B/1R..PICUEW//" 4EB<?8,X$9US#6$!AXF 76FZ7;0#0
M6EU7D3,Q5:Q'3E$V2-3%S<;8^H8G!5>[Z\<JTP2N.AT2^)R72F5N=QUTI5_C
MKK4L)W4MXV/_2J)6R$22W6.0V ETB+.9ZKPYR86KFE4;F&+<4K/ &27MA!)<
M8NKR07<7PH*[R/)Q N$@7IBO4T_T7%C>D**Z1+#%QICL]82]-@W3(?^W,9-K
M 4^'H]G#[D^V]"H,?(FST!7ZW/"QV9<OP'^,MN4M_3XLT5ZBAK]ZR7%,E]J<
M-;),7@VHM I%D!6,:OYOE&Y5;RM?.Z4P?3E4B8)<RAA/FU<J;\[GE!P^X00J
MS=D]+0F.U;!GT1I?S&E_74\$>"@YQ6P-6AX>FE*H32FF<*JD*.2&O\?'5Q0#
M_!,$6'.K]5&U*VLZ8G:(QLZU$#&==,R$KNUOM[-S>\*@*]2&\^^$#BMON5:G
MR^/(;..Y4*(1]A"^>] LNNT>#&9*"XX=3L9CZT:OC>I,<[T?(R0I2)K-<?NQ
MT21AT(P$ 19*/AP^>N!T/0I^]QS(OSZHC[07X^VVCJPM/@6R)2S"#P:KE,M0
MT)MR%(H/E96M['-_<DYI=X,OA^)$25(\R -*BT'@A-\(^JRWG7TS[D5]')8<
MWM5F(PVRWZ0_HS-@HX\Z2FU?R$&Z",0C2N]Q0_L8WO/KUA[R,0X\H8[BK1Q5
M@U[+OOTX"C)L3OKB'RN(8#I\0U%_G,1E<<_;E")>51^095]*U+(;5SA!U3G'
M5&'*V"8AV$-#, SJ%F3'V5$_VJ,,UPK4OWT&*%":2^4TH"-K?_@$R*[9=L/6
MY]TFBUXLS9&!CB9&RMH98YOXX%JYV?A8IW"[X>I\O%MF8B'7!@*1[3V0?0FX
M3&[UY6T8>UI4(Y,/[#BYJ\NGWGT 0U_]V8A? M^ 4^?+,ZIRVFSG<Q16=9<U
ME@7'=_K4SM_QR'!\5QWN&A; EB3@\F@<\%$_SB1LF(GWB5_709PZGOR)AYGI
M,$ VX!EX^[4TG7<W5TSS'L+KRE_&["0Y6_1!PS)971EES3A@DSQ@&W.#XB?-
M9=G5MC#2GVO<(Y*$Y<)YMF[,/90:]HF\)K(!>>/!(GP!,[BZ3N."W9^3=Y+E
M)R<LF$;*  N-0M5O*YJNR</$@ T<!ZTV?A<RZM_=1O'YI?(E)W4JA [R6%%M
MZNJ4%DV2<Z99!O)L_CL-T:CR$'(.Y07>>7SUB4PN>$,>#$OWN-PD\>"K/ ,4
MBK5^(/P!.M:$\B,V_STE*P!S.UX^B()5VQQ,8NW(V=K8T\AV&@%$<M5 RLRS
M$+H]T+7"C)=SK)\@BK2550ZTH!2;TE,VKK 40KJ5LO(0<(LIT=&Y4Q0I9B0(
M1/9OE5)3N=@:0FKUI&!Z^  7:M^J4%=KFKTB\-)VUDT.LPTOG6:C"D9RQ:<F
M!N^YT44[.IOD[DR1EG_62>1KEY?-#6=\8Y\;3@\H+VZ3W[P/RPLF=_L2KTG\
M]JWN@ P;! #P $^[YRG\4\N*/V[H+[6LX63O>*GE)Y]3=&9_A$-)@DW*5\[7
MG?#';_=\LEB_/';6 UZC4&L#FQQ_#%)M7(_;2<>GT[Z[YBU3MR\AIFW^8X.O
MJ$%.+8:O@"#FW0\[>@:<X) ?J:.R,MH,?X]:FDQ&]MCG.Y[@-R.;JWKSP+\@
MP&R4TACP*D+-IHJVC ,MQN9.T=\3:4: #(]C\5?IR$6M&=+ R,5.T/3E,\#?
MAT[,_:8["U=_15_/W$UYW,$V><M<8)C'@QJCL']H8AKD/H&Z!GS7'MQ\...\
M,S)1RJ6J\3[[)0<<"O_DX"40$F0)VMAE.</(%$O<W P(5!REZ+(1B[5N0SYW
M-,M8R1K+-V5<UM!7QBW]8K='&-YX<ZL&[,=2OV?M<NNFNRAL9;0B&F[UA5U6
M?4(UQAE^X.WW6.BV$2R"JZY>:N?'0J%)> WHT1(&1*!MO%R1N&6:3OZ><.<,
MB=^[);H#=1:TS:>SZO'>GV^3RLRA5Q-A>7<*'FR#NSH"(NF\O0\_:5U/&'AU
M]MRJJSZ=)RXTZN%-G]:_FJQ?U5DN/^-)K-[S&T,EBD9XE7D[Z1FFE&B4_S?U
M4YT9#\KOI?^J<+?-;FO1FS:[_?>']H=.VH*V2#_W)1"$[$3!T=,5A!($Z1]>
M>O.>OM*L>GI*[\WY?2^/+R<<LX-F?I7E>.O'W9K?F"TM]$.K.$ 510Z'&.$C
M#>3&<KJ"2_9B;=?9LJ5ZMS[EX\N3: S^G<L+RO ._HZ:6>%-RFD6BL6!XAMU
M7 ZFM)BQUQ0?V.KB<7@'B:D.Y-)*6%1,M<HM1%,EJA3U(5+G>\HQ73);7YVI
MD[X2A@8M'Y]$2L7%K3N0I\2+(*N[G$<,D 27<:V%E:S(.L,EKD/I$D\-6OU=
MOM+1)2M!A/LG$,/GG?$B$DV]B&?Z&KG0!Q86K[08]X3?B#X#T.3[[NBJ&U,A
MS*?&+<%<0@K.!J X-&+T^(,N&D!@.LE?]MH2F3@ZKY7I*#OS'<+RF1>_4,/S
MO]^P_*]&H2RGVKF4P 588:!@3<*@M!15"OP'H #$A<OWX]UZ]5K9F7+T^OD.
M0+8_B8I'!!QCHTU2>P9>;E,F-[$&^6)'Z),4/)Y>U;^6,B85[^*^>UT6-XFB
MV%H"]/4+;L["/7+K@,#MTL.2,\7J:[Z7YJ#IA,Y>1O4U@M--,@,!SH0=V+=I
MQM;)\\8*C=\X&NA=.%\&;#K".R X]4\2%X9.HU3M4)*94B-?A(6-,=%F_VI[
M5A\YB57(8K!:F!SZ708(W^%P# C3&X33#;QQ5Q8-LY;V,U^K!3,=2D9]O,LB
M[J9A  @N"_B+G'N!<$*\E:UH'^2PT[RC!!0W?Q"O$"*EO[F(6Z"X6GJP1'IZ
M(R.Z?L\G_ ABYJN;/1*_UU"Q',FD4%M[!OQ,RW$WZQ/&LZOD0C^[86)G<EQ9
M)8)@RA!$(C3N#/,C*/!@^R\PEBT] TPM%Z[?R7,<I^")[MHLMQH3O* )U.\E
M$2B@7NCNMLE<,#ZW6MWT72?TY$N70"6MT6N$A'0^DXV-#W3A%\\ @,76,V!0
MB_E7RLB2_3N@K=,.TCN^FZ7(ZPF/TB(E]31/L)B60AW>O-+*'WE*][Y;^2_U
MY]%!'!&A-C3AVK54K'@H4'SC_.\ J:XNJFA)QL%]/^SZ+/Q;U[,^W)4\6<9:
M[4%&6Z\&3-'XI3LY$21!2=ZNNRB_<.)G0%!<&6R>[!FP_N-HSAANFA7BBV_A
MUK.[)E-=^#GY]UWXE_C24MRHKMAR\6,R?QS/D=,DR(7M^ G)G-D)19P ;#,F
MPLXY"V_QP$FO\5IU^0X5Q,.7U^!JC70:?XQP[(;GB<@IQ&7I9P&GC4Z->560
MT7&]Z'@$#DFR=;]312,&[DXZ:&1A.FMRV9%JC,S'<&4DW%U":-7> 7X,\Y*=
MO?JV#HQ$4A'P\GO,@[5;PD8N&E9^<)^N9M&C7<YTC,$:',:MABG+=9W%R2[^
M%F2I>88$LAB?R_<0S>\V-,?MN#:;DV+(<* E@,BH$4@%SJ5 &^H9G[GL0E/G
M^M?*2GNMK.S"3)M:'!NN2\?*ZCDN2@0,\'AL>'F'*Y>WM*#=Y[VB-?4=P5<V
M+,P;E[D&HD:KH0)O(DO4D 2)/1=P-SK1%F];I"KR%][(MXM3Z.!@=*:CT6W?
M=8-M>(DW#/8R.0I&1QFJQ-=VZYN;86*,^0WME2;MXY/! B+VSKK&7MI#BJS,
M4JI)HDA# NS;F(%)D"?J "_6"#WZ65MO,;?-G:3<&9L^[4UD(W4HI0,,<M<%
ME0)]]/P#/7?[+D!JL47_EN3F^K3X1W/@<6@/<4"L* >U81.!L,>Y&T)C7 :6
MF_3Y8#^G5?L;#=&RY2XEJOY8]@!BNZC@DV9O.\5N6S=C?+Y?+F^L;!O(S%54
M"O"/UV6>@*1%WK2S5QE(<K-_'N7E8G7%3>)YOB*RBF%FG]KF!*-.H^U5N&2]
M?I"E"^0DY^F!,ITFI(E%51)G<=.K6"NA 6QM*BZQQ6?\T9$]BD)<M)\!F.XU
M!#6MJ>;3<.-,0<&V_E95HWR&/PE4#2O/ '?<P''=VYR86TV2#D'#R<>[Z(KN
MB5)E-^V?I7%!J =E@C^=>O6Q7&((#VJM9+V0WSOLULES$'GL8 5HDR/8=%6/
MFOC,I,\?)UCZH0N K^F&4]3F;,ES4D&:F]\(% BA75AWMD(Z%#QOZIC=G@@7
MG"/L$,UK5BSGV0;)RPFG^5>R57]\SA^0$N#F79YOJX6!?Z^XMPRX@Z6,$KZ$
M37\V&!DQB0U .\2I,$4?J9"3LK932C=7NHZ];?W[HT&(+$5[QI;KT:J/<%YD
M7@0S]7OTC&Z;9:>;0$ODR<@I5:0-5]YYGDIG([P^.HM@>]C4:?=N_KXFVKO&
MJ3';.O>"MVO (4[N=QM"OI4ON:YFFZZ-27'>"=LDQM>59 :>+!Y_27ZI 7$(
M.>.4+]F^$.',TYQ#KIYL\9IHFE7:O+K&\)T,@_WK2@4>E%!D[S[<M#(U!O;H
M9P!SY+YB6KIIX\2-P.A6_>P-Y>LS6*KLL&V<&!H4=9:M#!;=R5&]-Y]6[,ZO
M)X\@LD5ZM.C;B_%Y?OY;S##9=Y:-;!LE^>1!LH8MC5.R3;^AJ:WUNTN^^F?
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M7>R(0"JAX!3,K*NZLT)(R$.4PEJSML:=K-[-KRHNU;5]SJ]R->(M.?L,J'E
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M@YC]]0?-8 V;]X%7Q!MO#M>!5:=G;80'+OQCS+:I:&XNDCW4K[)$FF""0'(
M09^WQ2P)K-\UF=$^7M3*$CW,_HLC/][2(%42;CK%HN#=']8@+<_%6\3AIXGS
M<><+>9;'KF8F56U@-GU)I+TXCO=,Q;MSN.,*O9@$ 2UYW+<R]_7!^=3QJ_JL
MH(<C#5MP-,BO=L]FGSC(.KA[J'NHU.\\RUOB&9 C\PQXWTCYH*HSUV8'.Y+]
M^A<ZV?/D4LZ#)X'9N739\ ?S4X.HP;;!MJKPK7P'S3/@=\$S('$YYHDA"$N(
MX"9<E<OWH0-6><X:*B!5R9TM()+O9Q;ZV5?B+V><W<3)NG<Z[-7,?%O,5KXC
M79^N;":/6)RA"5,^4/^]N$3Q$ U-$TV]Y]XW;Y$M68=ZA"TLFGN!3S07PE/Y
M$;YNMO?;>\1ZF?5^FC7G1>'4J<QR,J3U,Z!,(Q;7^BJ@Z[4:BL2((_K@Z*0<
M1Y"\J6I#!\PRL;T=!?_J$F*'YZTY74^),FYCAIFGU-EH;A(T\Q[5OB)Y:$*E
M6HGCMPEV4M"YRC.@W\Q5^)#B&?"7G:\,-OQ :4AT+1]47K&=M 1N;M<4V $@
M?A(?TT;>QE.(]L?S0&JZ%=[,*3*7KU@1BZ@0#8U@?0\0,*;";7I8P4-#L])T
M_!184W__0S2SD-J)_^*:ES)*_X(7ZK<H*/S').EH#6?P@9H/F\_/3/L9L%]?
MA0#__ PX3_*6:+O'#9(].=3JIDMKX1Y83+I!F&H(WJ!H/SK0, R'HFT$@,.)
M9\$.N4$J"A\ 2-E(]::A-Q8]K$[6K.UJ^?.]^[GAV_P!X?39B/]_BE\/ZCFK
MMS&?;;@75'T@TK")N+=K)C' ][.OT0?L/9#(T2M&WA?.M.#GYI=/"I['] QY
MLU85EK$47<^'<VLD#+$=?X6YBJ8_% 2C/3%=5WW*#2^94':+XSP82/<P*(]A
MF//%? 986A'=[.E?/"TX@)_T%R\;O0@'W"XC85QS[C-=R11LC5$93Z-^A,AN
MEFG18]MYF%&]"='N=#0EP++<DOEBJ-MB4$AA@MJZTPC3$YI6WR5IN^DITJ<C
MO(K.E)I/'RI]G6+;7>'Q0,@03QO;>=83;B>>YN$S8-G/_)[-:<<GY>O)T/""
MQ[^VL@-.9??P&EF>9K:>J0A9YFCE@4R47_"H.M/M>^8'".YJN5?TRD4Y.P]V
MT[;!!5^L>]XY$RP&U]_GV._>U L%/T<OGR!W4(#K_6BJC#).+\6;Z0=:@^L6
M1UX+;>?:,9%XN29D?U0 ! #@R\Q/&+P-V;@JK*[4.>1.+5MB'@69!F5?^KE+
M,76=$B.GP]+)8)$(!XE*49H#.L.'*OLSZ1XDO[?JY$/46MP"77"P]-?:=]J/
M=XW!%MLU9._81AU?Q@XP!]EE9^>6%)0J2A2J:<0DS;AT:JISCH[-[K".M,^X
M8%X:Y1EG4]3,WJL4+U413=,MC,W\0.G#=3=;T-82SQT2VN?PG59^=9B_IMTI
MDB+CZ&?"ALE7"TPA*I/OU1=SQS?L509R\(3H6TH1O58QC/;/*PES@;U*#HI6
MGSV> 4&^^!:9%)VRGTX/ZDF;TISY<]')S"*Y5])_46WLD46S(Y0]<=YZ&,+0
MC5NM2BI8MR(_QQ>O!;F988: !K2):<Z<TA%THPA8RE>:JTJD@[BP9<P]\/V0
M7LN"4OJ8IE!)YYBN:UD\ "D0R%E@C*CN8*0W@2&,$6+<DFK.PMR8YI''"]5P
M!,EC-F-X4:8$L#M-3\FIEDH5KO5$4R0:;25'PI\!MXIFE!=LE\\ />''FE:?
M5]T.MUX]/"VTT07VM;IER:TT6&05Q++[J&B 8BJ3N"-=67RY=JDRJ?!,BB0>
M][QQ =[S<.97?=R>^= :O8+:E->"/P -T_C;S=W(P4#RCQ6=Y.YOGMZ(%F6=
M4%8_QHR]+-T47Q_O_:#$ ^OSK1CT+H4[$VMY&IZ6V.CF$U[=F?@QW7]I+."K
M[3-2'++@R&_B6X NL@U#":<)W\"PSEMJ"ZX_TXM'K%:6)S\VO/PX!P1Y[$"@
M@[AT8_"54)48;@5D>%A00P9'3O$E_8:W,KUQM^J]OP\L&+[L3US(_0H=*]=(
MCTL8(E7G%:"O^)D3OHM.E0E.!JGDQ[4$JRM]$ $&H)W(Y];:-+I:$1>7T8RP
M/J%!)_TX&_A&M9;YOT(HEL?98F27!\0]3<R(AP6E=1Y>USLW$$)G>H;1-)=.
M;NYJ3.)A>Z025"CDB-%2PT+58C97J>T3?J6*"ZL0F9@0I?&-5ZP8A0UPYK83
MIH1RX)OW9C9!/']0N@\]/OHF"^"</[&BKNA-+)1X<?6\!0<OBD\5@W\!'3:C
M5Z*%]BLGPF.LA-1)]\<)2"REU>8H[+9B@BC/X]WC+]6?H/<\4%??H^/6ZQ,Q
MO=8!WU-/=4V/34%6A?,Z"HK6J-VZ /SP]\0Q;!@L<_8.O<8='QS%/TA6C-"[
M?)V6/<:(XER6\9E\&[)A;:0QMD9M%OEAK<2L_J?3$')S]Z W94Z1W@-VL%=9
M2,."T#AR] !]QY#^J)(<D4,"'5)D9E.5=F[5$9?7ST>YD(LG0YW.*._W;EO+
MQ$RY\R\[LAJS@ PVG!=FZVM@WT1'CDYUA=@2SD@\W+]*.L+@L.-%)A$@1"ZZ
M<734.M!Y;WWY^:WXQ1=?K3TFMJ; >**#QI4%.S'\/5[92TF%[Q:#R8RB(W4Q
M@<)+GNU!=PL/ZS4Z$D*3U2?KU8'&_!,<X6OPK%XK'$)="2_\9X!!)S'>6+7=
M&WIBTA2:73+#VIG 3+;E*;6C64>ECN)QPQ+ZIF5QC\^4R,Q*TP?OYO6TPP@^
MXT7XE*%COL)K?3+ZV+6-$.\!&5@(Z"#UZZ&LE"GQL_*I&FLP%^BL]7 ?933C
MC[GQ-&YWJU-.\HR7Y6F2P)+&DF94>6GY2"%"J'N>)E\^2>#BBF2V#A)1:LUK
M@!+J9MV&P36$#"G>8>.6VC*Y44JH[F+R;7%CK+:-AJ2!1M+Z)1XJD HS(< A
M1B,W*+0XA<&0B>N]U/"@FKT>QJW-RS[NV\A2\%AQW<F^E'WQ-+X#8ZI(/Q5>
M/8B^$NT3!E9P13GN*=;-Z0W;:HPR,0/3[GNDO@+MN\![9"^D,<#YDIO26#(^
MZ2.R>0!QU!:-^/U$#CU8PYX5X/'SO&FX2?@9&489/]QC3-9(E2V4$4I3]<X7
M)=UA2R1+_]?+>C1RC?%^H%VR86:%-K@ G*"-&4Q<D1V-]E8R)^J3! F]JAC2
M"[\!_&KR86T<1;=5TB2^>7M,5@PC,:].3 SCXF(E/DE075UU5Z0R@J%NXN/O
MRB<I*1$G>.'$=-#!9T"#NLBF?!")64@]\BS+:9IB:UB$: M57 X,JQ&<C$Q&
M!HL;^,BUCZ]6TZ<:7_L5]V4,[2I"<(B]F>O@XK6/):C9USQX]$2 _MWR[P#\
M;TTV$&+!:"!@C_U69K.@*(1ZSJBU15:,"PVEE;+V[DM<QO+L!R/[)5 WI;.7
M<4MN2D,6*^V?]PJ%19,V\F]3_@UW:I/0ZL4JL^: /7])AW_!76GE?]CLZO.6
M-S2'SL*)O>?KP5N_O=]C!PJ4^& PE1[# 36,K6PH4@*&U6<ZM,^ ;E+-L]WD
M04TO;77K0:3ENV"V@U;WH<DOD3#0I/+A'Q7QNJWEB)7FWT6<>;35.T3ZR,PF
M,H96Y6VHD$]CDW:=XPG@E'N8^38@+UMQF)=KW5U9Y!GPW:S7M44"ZCMS[41]
MZ=V>UL@O_"7=V)7ONB+U8AWD+007#O46+5[5/&PX*%HME[GVJ#0%E-)W,>!'
M E>Z/*L%I<J4D_1='7^'R''Z_'5H%5COK[*K\A;I)&&2''9Q_=7SQJB\AHS:
M0&0YQ+OA^+*5KL+KYKNW(&6P )=%8;$H>^5]B([W1:;&'A*5,W+D"<"UTJN+
M$MOHO,'NBC!X3\VZM,V#K:M=Z(N_#.[<+[X-A_C5$U7/$:E/_&\_S))IEP@N
MJO/ [-"? 3W&>=U%CXW'F:I=66,7;6.;F@Z1,6>^2=.*.O"$B!:^ @+:D6O(
M&>(M_BUS/=)CP76W*PULZ.+:>O5I:L+--TEB0!_3"*[7Q 6YPJ\VQAA\6U'L
M1(/H:^2&F4Y *4:P/J56)BN?^?=G"_Z*8$8=KQ4ELI;H!O4F_W)(<R-TLS#2
M0S:!.O8#"$(5MT %BQ7I=W!\P(H<IX[H8ZHFI"5X&?>5[L@A(,C9MS\$1W7*
M_[(.3?(XTA;OF?\_6@<NO5Q;J<.^\]ET%:TI"K]-_7\:HFI&H;7%1OSTW2KV
M?H $Z*4AZ)C0(+R#-)'^EGM1+RWL/K"U=JPGF'0LLP-R]0B';\<6.'X0 0?@
M.*7#HZ?#LVR$;+T.U7\5#0_;X-#5W5);D8[87A4UJ07-<VG;L5I_-]1YV*/V
M/(&!,=--2)^(;N5?.+,>QG3E=])9Y_.C^:)CM-9UV^2H#79F5F3Y)Y4A\VW>
MBQ/$_9<3C!&&^_6,RN-;T:D$*GB1AJF\\C>Z5/L$P/BXPIV.23&(Y.\HFX7V
MP!?2J^;97S#W@I&@CB*\_K<>[YCHL=&&C#QPEHG[7?^HW%M<7.A_2L*P]+Z>
MO7COBSKP-;9WBU R B_\VNNGN@"B:&2Z6]=?C'VN]6!NZ&2(LRP+(]SB70HH
M4CJY*[_5?ZV?_</8""FOH)Q3^H*7F'*?B@WW-5[/M%1^HT XZ[?JL#P.]V^9
M5%TM!9GSII-4Y'M \G/?X'9&D=_.SP"L [8#J+,VM9QF#"N-FZO@\. ^H N@
MED' 4<%[\([/^?V,6\ O]0F2$980N*N%"[JB4:"&3#,Y>[>Q!:'B $=L.3O@
M*/UK1TPYN56W+R6<X&+ML('2O$FR3_K).2P(.?9#.5"-2X6AF&>\E@Y7;#9\
M9Y4_[G:R%^^V\;,LMZ#4L?JDIHGIIRTQP$.^+0A$]:BBYO;MB;)_8SEB"7K%
M^K7I\^?8930H%W(RX%2 ;3EN<)5@7A,J4K2XO*0UN+.\/%#]^2>=97$72. /
M@:!$77S,6T\2/@4G59+92S]\;_H7*B3TI:1V7B\L=<S4WNB;KC=:,ERM<=PX
M3;<^<@\(<LC4S6R:F5<82BJF!_2K?@IPB'8OXU1DB(]7M/O\N@!-:H11#5]1
M3"1;/8:NJZ*8Z F/K6OPP?U? X&$4=K%3'[SJRI]3]5 I<?$MW,OL9EWEU=2
MZZIQVO31F3JBR+B)R,F\P!*H2+=6,YQG@*8W%513ER1<SZJ2"]C1(QZB&F'[
MO1>T[30T,<W84FEYU"5$W#ZGK]PZ(S3E!@Y0]RB*Z\6=8=!&MD==,48B'B20
M+N*\*SW\7 +I38Z*Z_4&GZM42W;0SF:[3ZS?II0XHF.B66#\?6W?++"=[C.C
MURY&P,7 %[]K.I5?(B*&@J^HF1J$K_@1Y3_C/^-_$%CQGX/IDM55HO!K^<E0
MD$KH?I7&6OXUG1W%ZLBS8*JX4>*=^P'/! @E37A_GM,;_1P^ G*5<;\U0#+I
M:VM VW!4>.T93$.1:?IFU)0KZ?@KD;W8&-6VOY*X8I/#@T-F2)'G:>_&8X70
MUY/%"X>?";WSUY8\T@L7@M?APZUP[CAC&S,')[>=?@_*GPALO&M-0 @2S1EV
MTY%R;X7%#0G'(5Q.JQ]/PL*[@5@%S+8<":^[WJMW:))BK,\Y8*A;:59)FO(-
M'YGQELJWO)&U,7;;'2LV8=QI><CVEZ=RH[DLOL(A,&_1O=1<TPL])1!E1UMM
MV"N4#D XBVZBNL%_3+QK]M#M/SEP=+ID=.L('B>(*[K-DIBC<*YIY1# O8L.
M(,)4GQ,!V=UB>\8H?JF!?PTK7NLWL_ TR53ZQ!H/@R!G2F_88PF;*NN[[%.L
M)6=>+-BH=03/F<AO^5 LJSZ-)1\D7XY)MG723H[=0MF)*/MX)X">,L\ _/T6
MW64MW74&.7_"CY'++TSX;>\P@0.ANB&8U-.Z_0H;P%V5+5F7*&D[ETQ^TE3%
M^KZ83WS!\2U63EQ>#JJ4Y_,UHZ(@Y2HGR%N>.8E7_$9J]1F@E3%.L)<)@4LQ
MDT<G%(^2TK3HH@72H"HUW?W"45AWOEQKD<>\#1A4KJFOC3XI; ^?(S$861H"
ML#&)HP]?Y6I8QA66<C6)DHN[9.!?Z:7^)>3L?+/_=VYRZ<]]8;(^TVA=ST$0
M,N;#"'_<H-9")5WWM1!IPUQ&G8_2Z>&&=DW+ER92-Q;M4U9>I$ZG?IO5VU:1
MZF8KCROBA[DA0Y*Z;Y+@UR]91R:+S@VO\WG2LGB8SQ%]XZES54"P_^?=;)M$
M_OX-HYV?V_;($!EK\LG%=N0Y3DZ%U@4.Z6&#UD"5G8LA))6R%AF,B$:]'H"-
M)HA#DP/,(3@B:FR NB0VICB&9H>Y\6>N^V\G_$88%L HG26 B)2MQ@7WM\Q9
MBBTG<]?>#^]7.K1Y;-;+[BE8>VE+R^\T<OT68W+Z'-]W!+;-B?N]_4$03;#?
MD,$II*_<9:9"KJ@;_$@^.*<^>TS30EBCKTW;3?V9F2%D>)\M?7M;M?1BW.I)
M.MWOZL;F(;Z^5U'59,:+,?UV1:9W@%WZQH*B2,S44H]FVMDKJ;&S]<+4!)MH
MU/7.4=P=^'N6R/?#;VO;PH:F3D0-N075L'7@# ,:W<%Z^+A2\77$?51!:![A
M;&%2VU2S&#<O32HXF4X]:I:])3T8F -L*D>"Q6 #G9^FD?,(P*+4R('1V"NX
MIQ#./#DGU_!FY3*YU+;ME#(^$L;W#U+Y@_F]I8)3VKSI^8[$6<D@&/'D>>9J
M*<A;/[L;I6U:WS\%8YR"QE$2B!R+*D$5[;D!*^"2SH.RGM)NT5?LMIXV<.^7
M/ZKKS#A_#KMZ%8>6%)Z].*9-[JX@!ZR2DR@N55MC^\UR1ET7HH!JD69MF.N"
M? UB])<721CN.K1@<++Z26<XTDX_&C=,!_V;5J?F6U9Q  4[2!7KA'ZNJ >(
M&\G[XK^)\4V/451Y"Z\*,4TR)DDWUZ9S+A[*0Q*H!0#E=H.D;9S QWA5TNP[
MB?$^E793JG97I((LBROZ.A+(HA 67W@W!*D$ OPVW&^<1>YNS>)7)R=\M*;_
M]"YT.GUN*PU]H4 6ZB@SET% (*\\9UWG)5RO/T$=8J_@F@S.] >@"[5A^V<&
MU(1$>T-TB>XEL8[Q"8,_HLKQTMH#FS?<<CGW:-T+?\NUTPMI2M$=.G.JJ/-P
M7]MSWBCW(S-\M*"U+V6WYQ7*_W8[3W*[UVNKX&>!LM8MXFZBP'$HO8'CU'7V
MV6)"&JY.=J0<*.TH_;CD) NG2"C7J6\/6L]@R''LT*X:C>48HLBMMQH5(GD&
M#/4[/ /THIX!.06>&3;A>21<O&^=3&]_;IG?2YUMJS;/'C/EXZ[J:XM0DP:,
M,I30+"#?JU N0WD>4<J%SVF%!]INMM0?(M6> 5?[G7])%\2> 1@+XL^ K+1G
MP/UMUH.LU94G6Q%H0EXYZ^C'S_D,/@7YE%9^$D9*!;A:1(%>&O_H%-FF* %N
MJP'%3P8TX'+E2R_PR\.%(DI7?#(GGGC2;HT-%-,"?!6Z;#?P'-+=*N5-A?2L
M^"E"&@O&A\>JH']39]5LB[:P&,5-M>]GPY:)(Q$G ]/)2]&1=@1@9*H0;]-L
M'9F=?E_-  [84$)NB9'O63;G'$.4KMCR;Z4^I<AF4W!6*4]I0TZQUH&KDIZ>
MI'%CI/_8ZP;VCV0 >27&\7IY0BD'V"L/@SDZDB\< Q]C'-_+I_AN )B'!)W6
MR:U^S9[]D?7KN7&4\F.PZ)ZC3053)P8KH6)D[DC(7=7]J@UA3)VZ?FKDS8DI
M4I55MH1WG'FY_+GDXFS7&]1LC/="CZR6H$L>4TS9[8+<^4\B.ZF7I9S_@6)'
M;!Z5I3%_\G"^:EH%UU+3$G_7 >"3^:P-EI2%]/_%6*I8F@4$;;.]OUBG]4>&
M1VX@\@[P4M2G[X_^+'[1-9_YCBQL-EYN85W^UM@Q/*?@R-.U+KXCR_$=[@=U
M4NFD23DT('"A"/A[ADOXM846/X/^VB!^5  -H'9C#VBY_>TBTR&:44C*R7%9
MV<Y*/B'KIW:GJ'3X7DBT $24\H3Z(A;MPQ#ZA"=66S3OX)?(*]!2=4?#;#FL
MM2YA+.#+B4V^&7)@]UXQYXZ<@WJ\N4*5=%X=..W"-+S*S<?,D&38RP6ESGJ9
MH#"6BCG 'OW,WX\A1',6-E47D?%)L>G33]5M6R/[LEAL=DG0(&C<0[ @LP3F
MXZM)H8)W@@4NKZBAOP$0V..44$N!>LGVWC7DA%R'3<A-Z<I9ZW$LCG!N4EB,
MFGCFP%'#\YC++38\TQ*? 20^IXV%!]>OUW5TL^M_?",K?E6V;8+;R(N,N=ND
M?JOO7#TT7-Y+$T2+6R&-Z(6X/ 'LP)FNO(4N';=A%4!'5(8QX\3[Y43><@,I
M5M3"H]#EV+Y7N1HSJ3'@%_'%2H\<:6<41%TU%)B1K^9GFN"96=G00, 4.((B
M902C[FI_EV7/"0I65S)U<,]6EJ4&3 T@9%=O&YU7U48U&JPBT-OVDT8(%T<O
M#<@<@<65GG7IIHS,;^HG1@A@2J]WK7[FGSP# ,UBIA8=--,N$<F-OUHO"U18
MU$==[AQ1/9!F%4O=8Z2FS,)?W5?CUY28*I*^U",C&[8L:._P>_:>]])Q::5>
M+R&$+[[1:]]R2E/++HPS0^^@HIPE<H8!A'$GUZ3P\? CN62>R@LA<B?QB6Z,
MWILJC>1R.T7_Y!<9;'@!<T[>TF1:\L3F20GDWT:E@B#(!D:.>G%!*LG:*\MA
M\]'(!?FO226JE\F%/5]J9\D1B6L,6O+3*03)9XZ7:<7?/B\A,G+#(=/<>3>+
M46Z39+: "#+,V;+2+F;0#1-$W-TB=;<;E>$(G?(.XS6R!Z["4MM+CU)M0^.$
M<ARI\:I52$$1QE48Z%U7!T-7^'S*\DG]*S1ZB;G;^:FZMN:*&O]/L\#RNJC"
M LKIT)'C^"L,7854AG!0#T!'\02;#Y&VU*G@#ZB2ZA^7TG3I"/K+\(I_U.M>
M\K3"5-,@T59"[QFPX=.J<H7%>3S^1E87M/Y_XET6=GV!C@YM&TE&8FV'JWA"
M&8>!R0920M>[MKP>/O*&SC(9*^=+L 5"+'$HD#K1#3A?[A[2=<-'^/-ZH"W\
MXO7RU\>%I%HP"H3)$1URM.*P0)'XR]E8^.N>V;Y[W279EP,O4UE(%<>">:5$
ME];50$61O)7[&=-UT,>DD#5QH*V<AX%JC<,,N9RLKAV9NX/NPKTD7J1*4O G
M;$$TG9=YS#7(0("_@M>J&R--W,)>0%(I1;<NFI-;<I!:D5QM=EV&WO?[E%YN
M.A]W]O5'FH6XWX&_PPN*W<O$IL]21R[^2-B7@A+%3^K^A>(.OHW %35+/+LD
M9EE3M73CR??@UI6EW)KR-JG\P]>ZDU;.)M%3/!-KRE%E 4Y#>Z>9/XN5^_^^
M@LHZ-\*&@Y)T?JR0-=@#!N1%9P312Z]5A9,>^QZ-HA+VM.[R;,,G2=;2G;_.
M/4VCA"H-*.4[0PXB$^+\V>(]U8S=+WLMTR:R%Z\;$K-&;<U52OFAK/)4R6\C
M;<;!50W%^_NEC211&97IT.^-:,R$PASC0'L&3]SH9ACQ45SXP,LJ?M;KY>9G
M3N:WT-;\T# =Q3NZ*1OM<J#LFAY_928AIBYSSVN=>LW?1#$GRI9A@@+0.>5O
M<0C,^D(RZ$=ZZP)VY@NE)2YAQ/R.]^^,OHQCUB!NWODB6;U_INEO155F+AG&
M54[+#W*=QM1IX_8*@/P N6,#3(KZ: &WS099V(O-6Y;&V6GD%$_<ADKMOU<O
M0$[/3[J>??GGU^H-T*A$]>3X,)L=W:$-W*QB@0"^UQ[ 0$V\VX7>7T-#+I"5
M8J"SY,7[H4G,[,!;$AHY1]?PICVM=+S$_'A?TY(7O[I\F/<E^<QFTT6$,GEO
MU]K C/B4?[["@_GDI"$/3C%_,:V:C&Y;\9/,;9/?!9D"32#@@]5\F;48@91(
M9>D>"PX!PT5Q1@61J6T?#X_KO&(82^7; ';7X*2> !]V+[BJ<.,?N[^O-/PV
MI/VBG)X!>)W;NHW/@*KZ9\!OBN9'_F[7EI3 @>*4"CM7Q76.#Z]9YFEV850&
M+I/D]@[ATYD4:?FELO5NQ@R+(T>O]Z?#7=7G,G_:N-AY($Y:"2CW+"V#Y4!R
MV-AHL.*W!55LMU8ND'D6Z[[Q:]=&BR^ZC<&*K8L;L/7(/P300PJ&*>?6W=JV
M=MP5AF 3W%:;R2])R$CKY/8BIXP,BQ;*I0>#RM;<W 3F##,W/IJU+XCT?4%D
M6IC!KU:\4;Q@$[8:,C,0J?]D!Y^)67'^K(!\[H$ZI5E;9]2[)_I9(M,-RA_T
M_.Y4D3#!,E8S(5MM_@PA:!:=,/L+**T4=<[A@R$8MB2Q]_T.V\.9;,NV#I-Z
M(<#?\T%KS44:![\MB7A(F<V6=X:KHT]Z[3<P_^"O,D2XMWN':80S<Q?678I'
M$<B1JXW I/G2E6UKT29,%GMW=+9AH&,O%2V]YB(K(;MKG\&,'6._H='(/?*/
M?[@$XFM=%ZNL9.N:D]:@9_NB!2^KX'RE[V31*F?-W5?=0J(O]%1FNXHKT7SS
M[0Y".-7GJPWE)WF'*6[JB*M)TZ9=R\V.ZPX>0^3WF8P^WO)Y0CFT_NV*#B#[
MPZ$1(@/:FCYC -*$E]J<.=1&A)]E?Z]WRTY6NCS/]:\@EB<CASP<.ZE4U(&K
M8*O.]9#$S-F\!RE3R@"R\:2:^1_?9Z[4/,56^LZFI2WS_/S=\H>IJ2F5S3FF
M2LZL$\DB'+,=D'<7#@:0EUR$F)=XB(9XW*PJDI.H+G7?$NE?.$C_;S@00'QQ
MZ5[O5,J4HQ+SDQ[&1Q@I9OH]"?9_])=\(GQ=,-8<"I #,J%Z4#FLQ"@J0F\'
M1=I;@J%8'T%?;8I)Z!3D#>,!R->3RH-:OB.%'4<S0UGEBC/K6B>ELRNYV>WM
M#3/E!6VMB6+(,LTKUP_ %\.-+;6A1OH?J6(AGKY;A;^XIY7!8S',JN;LK/KJ
MQ$INIMRHO;E%M2'Q'X\0_%_8>\N@.*.H3; )%H(% L$:"33:D. T'DB0AN#N
MP0(-P=T#! C06!/<@D/P((V[:W#7QMU=-M_4S-9L37T[55NU,[55^^/Y^=ZZ
M=<ZYYWG.J??>TPLRM11YR9.<^R[\G/P-,EGA/4:MIN4)%>*],)0.+U("B()
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M*^[N[%\W"&&J-M4^[(B[_80U3RG2-<_2EH(=@0"4_ G^TB^.[+.X36[V3T\
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M/ZQQI_+EZX=-K(5^16RZ=^^AHM"A[]<ICJ8(#U[\^#4C-D&IV3<IMONTBRM
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M15&6;1*A@O_#6=O:[.%"JX?-'X2,K!*Q]6?*Y=:Y^"MR/HX';MSLBYSSB*S
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MB.UE;\+[B&A^,H&\"\?N3 K,CO.&9H"3M!:^.Q'5]_$@U]ZZ/<+2L<F_->A
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M$D5(:ZGOM+-$MTIQT8,]>H$HHH&A:\D2!$:#;,&@$YZ?:,"/"T6.!0J6Y,N
M*+^,:7]:?L56&).8* F+Y97!6>N5(O?1*M-EFM$?NB9P1 .+S]% X)]/@/W(
MW[T7JMS3>]S</LKK8;ZE<))*'!2ZT5SMX@-:_AZ;G++%-;2E?%U;B'O;2X)7
M5?8L#@W<!C8Y"DGVBBQ0@;700S9H6]1?_O<5V?P_O2MV]'8R(;UKOQ3O+G&+
MMRVJ_R%*<XZNPR-NO6[Z94$&SX>N7\6D,1L#A-B<T>?RTH>IQ/'_@@L;L %G
M<G4Y0*<)#7SR'KIVM%\%]S9;'%P .TRG)RF71!X#Y\B ?>A.+)3%6.4*!.W!
MTT4#)9EH8-@2>\KR/U8/^+_GQP#QVD1I9HBYF+% 7MJ[MQ&![#CTI"H8K@8O
M15W>(KE::F[S%0_E2O@C)PJAZT.-,9J?T$ 3'9(#.S>]%OIGUO]S L50?7C0
M]S3KQU.J1*OG?%1)9-,,J[R*O1OCM"5H@("DG>F$C.F\'1IHNN4Q_[W8ZY55
M(?M=><&*)^\5[LV>7X8"([_IYT"'^?310(L "F/OV\>:-ZF*H(LT:(!VIZKD
M7&%-?@*UB<S%COZ?*KHE1%XG[KS<\HPWE(FC]USVO(13E7Y'_&7TLDA=G3^\
M8DUQY4MGZ<6 K_S\-G6RY[*O!!-"U\/M^L9I"1(;M** Y):20/EYP%!8*?!B
M;7M:<))0=IZ9NZ"(2'0AD;UHF"6CN4?X<;B.ZN*>SJNO6A/.MOJ08HL?'-J:
M4>9:GQGE58L $(J2\3O&Y36"T0 PA!CYS:N7&,8:5Z(!7PLDN'BZ>8XICD[G
M*N,HE5CA_Z(PB0 <&G%RM4?!TQF9<PO\$>6^%\IG8@C+)O:O,0DST&AEZVDQ
MR UA=NTM(H53M2&8X (F5XN_.[B+I@X/AC)5V\+)W?\OB^FPS N3)2N$D38)
M0@U/0\YQX8\L]3_+ X[ZD97Y[2L%&;G&VV?Z:G6A'+04C"\5U8.D-X1T$1EZ
MRITPW P6 P:UJ; 77E^%8U-**-ZBSMLN(PN/#2'9.F/S[[X7AEO0P:C;/1S&
M*'"]:*Z+>4%+]YS>\DI/G+'0='\-MY#^(O58AG ,J5>879:]K4/[(<9@F[8B
MGLFLNR>4.C_ZP+C=6.[=/%'YY$H#!BN$K%8$K>VG55@.DLGWLH,TMHQRD-PF
M!-!A%>A! ,8BCH\85O\U ]K6>5A]C0-#(4!+,@PJPJJGJJBM8E,4)5]@\^:#
MYG,,_K@-1CX[K(WP'8>Q,BUB2A$A7-# _;GNZP^\T),WQ56U)$']K(<%?:F[
M,6=+P]'A>9\^@4O^1\P/KA*]D[QI',5(70%A $+3X==T.\%3BHJ'=_UI* "-
M%'6-$1D*[I-&T$M>&QL>6^45:/3M[%WG03PI:[,JOP=6,?B3VE>#=W!!&J\P
M!3=*R^M</,,4'YA=%;&^^8C<=E'+IY !G ',RYL0-- -.D518*Q7'NB;RR[%
M"AJ@1P,PA ZJ*1/E,(Q7^H?/-9PO6V9X C,)5AQSGJA/7!0H<[\!8&$W3V:@
MQN$6UP2'T-\.(P)P(=?AN\Y;'KJDPFA+"\8ET((J)?70P!,D$X*L>46&08X"
MXZJL(>6H0 0(8_F[HO94*:'#S7@HG!+$,)ZZG..&%OPUC313-=/92?.*TG71
M<H/%U8T%QF9K$W@J<7;HVF#1<AE,IAK3R7.R_G^01P/3R=QH(,V'!'G+!)YQ
MI=&9<L+7^C?O*8@UKL,&7K9U>Z5G/H:4C#4HC*"M-^:,C3)]]0?- B_!>O#"
M[882IG@T /[,OR$J1HYE?V70"3WAEL-0VE(XJPY% YNZ86@ >[3.F@,[$34)
M-[DF((4N>JAC6M1\27D?PYV3XJ108!U:V:"#:4"'"8+Q<\H,X\-!T!)-L'2*
M_?.MG9\-]N3:2==516#( :N.0]:(LJ_QG.*2EL#PJ2#6!!2,*!#%= !S^DOO
M1@X4#*[M@ ;P^\4P$CTI$0U0KXLU^JHM4AXAZW)L7F;/<LY";923VPV*T#OL
MG&N%G1C)S ^>5\-@ZD;W/GWJR?)?]7RMA@?]2^TR_M(B(R%RK'Y,8R$EJ,"/
MS8=2'/_9(!T5.< )-#W/A6'J6SXDR?,-+ZM\\%!JOLFF^HQ!Y3A=ED&E(\@C
M)_52)U.'"?Z8U1ZO-N2I^&R+EE*7ZI<:<JS)#B="BPDYZ5K%2A E-P=>\**H
M&FAE#=J5\J<B =L<Q29_R OZ%Z%@'-FQ_<=)M^KISNB/G6Q%60VQRGC3TY0V
MT8/D_AXZ3_^DU3LIN*=C#$EY=1B7N4=U6W_)P\-E2X;>."\7:LFS-^NFXYIG
MFF4P8$I=XU 997A\S%1L=9F=YLV;D6L]X.)8/9EP5B9+G>B_][:6#JMUT%L"
MIN>9;KQ]U^"GRV*CM'RU6O2ZV9*"+"PUQW!+/&*^,"D315SFV<'9]E3\U/C#
M\;AK*C&*_X6UZBLLP6U,!/A7%58XRPD#;9H$H($;.DC+O[GOOZCPR-^SA"L1
M>O'P$W3J@?TU'87(']R9XX09U,'MSZIR3"DRU7])U>7WT9=9R.^AME*)\_]%
M]UW=/E\X(JE% \4JR AWD3\&NDKT_AFF CR)_GW-$;_);VN<,\:&!C31P'X2
ML(9BA/84@G:V,>9)0<K%I0L):J@,:Y=@K0VD-C(TTVL![1C7I>P1\%T@J]%
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M5W8+$H;N<5 Y<; SB3 ]WYF@N'.?0PL;P/+EP++\NW,T5ALP;I9%(10#O\Y
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MFQBW>*12+FPJY3XS)@GK2Q:L5.:CW1$>";Q%,9-[.TT>ZX3^-G#)WM),>G)
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M_>T*)BK-6R<JV!GJDJ:77[WE\M^XY/6IX?5G7KH@-W"Q*_LRFA77_6+E*8W
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M<#TJ?G8LW9**?Z5^:>C&Y=L5ZH@N'80+X ;]QLL@%:  E #=O!^U@?B[9 _
MU_LTS\M@*GX\\A+2!\ +\[Q"]S_M;,/R2T3Q1'>A-X"V;7I%+Q6EV7^+TX&$
M W!?.C0LE@&\Y8):68J]</H;ZKGW7'@/^]K9)K5#RJ$;E(.N5\'JZ!?'@U6:
M2%0IO7=O3UI@$3UP_QR34NUDWK)B3/F]G%M(O!,+3A=<M+GA)V@-^BR\H86D
M=JJS6[XGE")[*0%7KF//;:/5.\_B4-#B%]W43E%^>72*X(C03][_;76N?(A#
M%42)3B+5 ,LX6H:3:;[*Y&M^<WWR",F\='S*C_P@E>51%);X=*-80Z83AV1'
MF^)/;'XEEA&JM5-(6OQ/-]?>QE@.+9)P#E*LM[U;[R_SS[OC!%>=+Z35M[R.
MQ;>&6> PTQE?"FN?"E+*8OGU,$6+Z#E:<"_"!HQ"H+K/",N61C%KY&.6+0]G
M 1P.1-C'H#ADP#\L=WYI%A:H5#O%="MS0%0CX\QW"C>/"N)V$/F6H*S"6 66
M"[.\E0L]5V@'B8Y]-4&\OD+$5_PR=>2<>AW_;FCC0M3.,$CD;#TBPEWTK0U9
M?;*#@X/;KY0OG4*-J"+8=U&_3XZRURGE^N:S8^HH&15?TOVPKJB@5R>==1'8
M7Z".]:DC0.CW(NX-8)PI:*=Z/D[^1EN*1"$2]'OTX/[X+<[HSW,L#/5:6$W5
MWD_=P7HMO)PH=0%3 D3#"!G RS'R_)C(+D#0[G8%>]%HUR,IT<YV#DU"A!.Q
MTN?,L&8M^E#V 9#7<1?EOA6R,,W#=%.;K"_)05'$5WDFPXP:VP_6)$72&GL
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MR(\@A1P,JK^@&U<XUA1;Y1UGT4+O 5-];=3+O$122A(:5.9.JOP*QR0"?'G
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ML,^06<]CG[X:.MT(GBGV,3JP>WS<'KLJ)1Y5H0&FV<-+"P^AE.>WWT(D^X7
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M)+Z2V2A&2'*J%4.TU^P*S,JD22E![7M>?BNJ;]?\  3Q(EP51IE"1,F'_**
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M _!<'/T!F-5Z *R'5*#%<>4B#%:UV;6V7#&2MM]^4K_;>8$X*/88 PP>6SP
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MFZE@G><WFB'IR_P-)%9N'U?MI*WL1PY&?831A2_T$8GOJ<581KV'O]O+AGG
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MW1B0#O(SCL06BQ]6[E"42VH:&+MVKEG,-]G=06<[7>G9VA")VBH(WUA7KXO
MJ+>E0>"=T]F!,6,+MM3[VH^2W!9IIY&H*D^^.Y7Q'<F53LW*/[\TH_[0SL;J
M)UY/K?#R(OO(YIB4:IX>WRR'[N,G[%%DOR/6IZ:K:'PIV2J5579?#..&>@V5
MJ5!/773WI['2!0BBRINJ\^>-#:Q&YY2>D+(/I.K+\#<@HG*'D^D]PEQ8BGV)
M,!S^M@G ?W5DE%BUS!DSC5>6BO9=@XNJ%VT7YD0S#-=8Q08=HDTD(.Y+78N
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M(IP4C=_!#O  GQAZ(7[@&]CVN1)BI=2N<441-[2AV":$89%>K%6UX+>COWA
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M"^K E7NCQ>IF9J'UHNBP%-6/G<0W-5.D=''U+=4AGB&J 8!R$85L4,4# GI
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MJ5'5=>4TX?FXT!#+1I"H5:5*3(K,MUN;;6O$4<0[O!LN'S3 IP43V\::_I\
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M'73]1*QK(5;&9!,EAU!)-SHNH34<SY]4ES[:&Q]P<2W%>K?5O1+_*ISS'Z2
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MNG=R2SC5?4NU^V?5$;GT/ZEC&VF44E8KU</"I??[2O1G]LC8++4.!ZU895^
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M$X",82^A+PNN !H9YF%Y\"CRI,_Q#%BX I9JKE?&!GH1-7P%R#! SI'9%\:
MMQ 5U* _1HIS@_KNB?;$+G=I +ZES?NHK$S&Z2D$29\2FSZ%7!UG!ZE/S2H+
MB@GPEJ=:D5Y8HFO?P'2\EIN35T!D[KGWBO E8'\%[,]#$*X8.U/_&=1+"\'U
ML)_)9D+'>[$@HAJ")B7"IX]C39C])=LB$%R\5!<F4Z\_MM2,E^;5I\HIP-@Q
M0F''TG\S-\RYPG*ZWR?(\CNN.22O/K98_XXPY#=4_273(A ALVC^STEB5!6
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M6]<#Y$:T^TE89X^9+D[LX1[N0 Y>X:^'WQ(U2G"!*CPK_N3D@%CD:0##)ZG
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M3A@&K+[<\!MS7P.P2M+=Q6=+=+/!PAU-^9DPKE@R< 1:?/B9]K<L$_></O$
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M\\L]]ZJ83(R?_J)"".+<1\$K1#@Z3V/RK!@$C)XT'-* ;V:7V>77A4D!8-_
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M]%-T SOV:^:%V%)RL$#7)/M]WI :CZ<4EL]F^,CH][B#3\%TKT28!B6W'2*
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MO OWU=2S#B$C&[XFORKW/JT=,'?#(HNJ>E72=LS:2Q&2!-<1?7R"J<6[+W?
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M=R1*W]Q[>>N;8[N[D(/B6W'#OJF?6L=A=%'_%GJ/R3Q(G*BHL6\9^<><>;(
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MB\6U<TJZP7@A0+%)%C+PX<SX7#7@B.41:+!IGVS#*MDCR2*\NB:,91;\_D,
MGU^M;5W\^.")6Z-(9]XWW%?N+-\\ I:W2LL'8'?8_&TSQ&\W[DT,HY*JPXIQ
M1&E(WW2A$H[\:4 P>,/1B%_;F,B8(/8K6TRY>=>GK;+!2V(D/_&+ZHQ' ++
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MW71T1D6D6M-B ?>V$ZSL,RPHE,_R+)FD?RU\!-J>Q<3!QX3/^*H#JE3+I21
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MLZH*+0<I[OPN3^I^/?=84Q>+LN8@/54:-20OWB?JCJ_$7N^L+-A>B:C4ROO
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M@E_JP_+G:$='5*I@P6!^Y#)H+75^]4=?KHF>M>5]I#]IR@]O"KAWIPO*9UK
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M0N+RM"@RUZ+)W_P1'!&$2?"_.A/JZZUQ^P1."/@#14+4D\0GE&/,Q3.<B/V
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M)5(M'F=$=)O9*S&B':L!*L0DPO&YPCTCADFWRK$ZJW,YSH@%Z;<$8GGX9$?
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M-N$V^+:Y,4ZZONF9CJ[D6N6GVE%>##*R-;87[:/TA<%X842S?(4J91%L%<@
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M#-"WP9^3]F D 2Q:LA:C,\K+L56M82O9^H+?V8TZH34W="NTC\!WS;F'*&L
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M*#E8+,@6I:X-/R$\,$89+D.!;1@S>TR'KA<Z=%(U=T[%X[6V1R[[1@1)&N:
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MR#"F;/GQDN8<S_+[HUME/)EVPE&2NPL\R \6KZ\NTKV%IYP07D0=E3&CQ+
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ML\D#F*U/*Q8(=JO2F2BGLO8A[Q'R82)]<KD*.<O@*T"IZ([SOZGE[P9'\RC
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MB&KR$>?$R/#;,C5J91<E"*0%!1V.*Y6+L=55RKW& NW:V1L@*\DTWW'#._M
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MQZV 7<DK$W0,6;,=,,A,%BDG/-3:B<;VMVI$MPM$!Q<NL"R%2<I*%Q$-;Z[
M1./:1#-.V\+!:'*K]PVL(WP$VG6VT+I6\(M.M^ D\V",?*S%06RF^,:M]D]C
M$O.;WN5YH1IF18E+]4^.1QEM>127[1>CAP>U0KA&;SF;+GWU/"L@9T_5?3E(
MEO[LDYBE*_$5V,2[DU-W^ ]5KE5<1<7FL(CW\1GGMKY8+7,.CM#H7RF^"V*&
M]GF*0ZL=]2ZANY7B&%LBC[>H:W2M"D$:Z;E+@3?[,P<*\NBN!EJ%BF+CP%/P
M"$G_D:5D^G/J3^PR+NJEP^C9OL(],\97'?4[S2\%=RDO,7.']7B.](1EK1B7
M?V&J\]F:3]1F+OZ2&>:J7%452%!I/$M$2'<(,Z;X>./^ X7*B,2VQ? L;74J
M!<E <+/_=/'C^=)*MO8BCS"MRJ&-3:;Z"KA:&?DC/@&M C\:0^V\WI@($_XF
M."^10ET M9I!N\4_LPZ/:.!%5Q5Q5+C:S4]><MJ4= Y<0[7)(CY3&@8%8GR.
M4T+MQ 5R=24JOJI=*%J4X%#^#H]N'9W  Y6X%E&*@X=Q'CY%'OS/:L,4ODQ7
M%[D8G8DP1+E&1+?&Q\9..(<EI7Q[&G9<@Q_Z)C\->_@Z M1R8<]0\GCV@<K=
MX^&<"0ZS+BFZB)[Z I.6F:LU UA& \CMCO1]&\V,Y_?N,)E$M/F*3G"_&BA7
M89R:T#6:<6L^]U#WNJ\NA\BR+:1>]8&OLK*((%"N_5%OS8<;E5Q7R,RH_59Q
MR&G5IP^T=3;0G-DQ^76"#8KAF"+(HS@#2@J=%'5NUBV''.HIC6N@\?E228<7
MJ ][V<PSWVDV'A%RL]O,C!6J*[_$=3[F)) I42N[#@;Q: \M@@O,K[>43EKQ
M;=E^??X@W^/&.5^)<R'SXNS%Z[?="M20Q8WBKMIW423!?",/W$NC(VHEN.O^
M[.WF[UF"_\G;S>P_[>V&1>TG>+#[$SQ0K_@!#QKQ\ !>A9^ WRTMGWJ!EHVR
M(#B I00'5(-C+"4B>Z01IN5J,B^<_IY=.(OBS]O$Q05_F>2YC17CH 0@4 NH
M/2)5389FRNWJ?W; Z==K";'IOYHVW^:@8!HC/M0XH%-D$(LO<QK#QGKH7^S,
MP3_LS&%1,(RN1]E>[L;KD!N%@7_4856:SUXRZ) &"H@B">-E:(%ARO0#XOOK
MVX:G;E4M"G'-4#IQ"428[%U1]=9%>((#90U^SB*C8$+C@!8/TF3F\B%!-,.)
MQEM^TKP.Z*,ZY#+B7 X,$A_X"L%-M[$/48-?X[M3CP.RK*WDOHANCJ8@2.IE
MNQ1X<("['><$P(TV%VI"*V^!:3'.P^+261DXX,7DY!&OY*WKSUY)L4S_5(U7
M64FC *8H2$PM.G(>(E99E: FHC4^R,,WX(=%TYU:$!:DYQJMZ]DF9=W-<7:G
M=GE4A]G\=M;38Y3O(XJB6;1^T25VXA55-[90Z7(;:$4'L"#,^T%5_^FCT7\3
MOJ"(@TQ&V 0>G#&\,7=@9Z(_K*'<]/Y)S,>>%1:Z\"_B)ZVZ?!3(?1(]82/0
MD!W!K'5^.SK:3\])[>NVPY-K,87VAS[$TM&6#MH#!N;[A8HP4JO8&DFY#QEI
MH8MC60-/LCN<6/NN*VP['38I")*M1G$;C;4QO*>C>O]1SB <*KJ=75Y5K5[V
M()PB?Y1WUE^P._RYEN]Q6DYO\J+GS?9Y,T]C1EV%UJ\J%PZ.\I=P0 @/;V%H
M?U>9O,\:><UAL<_V%V'[UZ.[US,^)9,YQETIT^U]5AW<SKI&)D17[[_V)&3X
M6[^7E-/Z*NGZ!W/K&N8G8ZGM]J3O"CNO?1@WO>L&8\W+H%5.?<AIMD%[+^>&
M0;QSHF:5A++2HS;^1M>+IP::(G"E+.G$J<#V0UG(JPC9X>+;E:.R?8?YBT94
M(\;;4J6G.D]VY KX)WHVPJ.,&58+L$5FT'Q$GL)"\8 N*,^C"/1JF_$C7[K:
M"D&/T=O/HSA@9V)-&KO)@B 9?6':(#2L?ZKW,$6S1SVE9:)PSL]!%;1E;V@M
M23&XT+;O#IX1<@!36*J=N=)[.W);3M"3N"SWT/P#E>[;V]>CHU0\1/KH,=P9
M*.) TU)'^Q<!F^,[OJ9%%FC'YC,257'=<6N1R3/?81_UOC]ZGUBC[$)!8>7*
M1<^K0]C!WVK\]DM\ K1PYYWG74B_A_JHST!"/N6]7 S)U2]1>Q1/8USXS^H2
MG'S+LDMK=:967S;+OV5(*N]U,[,5!_#HXH!9ZY&./9N[_#7FER3KK$ZIB[M4
M0U9,K+"@BN&BRG0>C1M'S'(K$$YI9&2(B61Z?JLRU>T.R?VQ 96/$TU.B.FN
M.RO'3K/K/ C)$XBDW7E+#6BW"%Z-?AHO6KMI&-;$[^0@X,;  :ZI,\4/+T?=
M7337*7BXFRE%(V0[-Z>WP^EIWZV$9H]"(-I*'S0EDO]BXGAX*2V9;>L\3#_[
M$[?WDL8^C=' .^1ZAGB14-@CH8FJ,H(AQOQ(]@]E5#J)41YCK@@0*?M$Q4A4
MP >'#E&AEX7AG^B^R;^TKV+Z7LPK$<I)+_,MR3A(7/GY33.OQ9R'[P\.A"9)
M*2/[Q]CF^TC/'QC-IO*/7).H[W$>>;_I39YO,-6 Q"M@A7]JAQS!$-=2_VS3
MRSCO"%]T<YW. V[6]2B.W@N'!2#2_5GJ5>R-BGZXW,OH+[GCIY7CX7FS-'UN
M"?/8"C/$S?+."FY].Y+9-;"M:\SG9M>^=</9 (P(U!-U9;FEK._RJM8[[P@E
MRL2E>]]])>[^6%D61]=!B!J;D[3DGSUTSWR3:4;'YTK>4)%7Z&;H93PG)L&^
MS3+"?,W%254!<,IKN.KF<]B"):\=+-^EJXEYE_=NWNVIDG"+T96:40S]N3BR
MC=BX2H1PB,Z'B"1BZ0T+PDA4]BM0\RF1ET*:P?3;;MV,72W=;X-/>NF>(KF'
M"Y=/-,/JOQ@V6%NA]SIZ7@K'T[[UTB>KC$&(>9(HW;FIKIL\H;XM.=/"\K'X
M-0XPK!W$&*9;V.M)C6J75N\*8U#O#4YG53R [UBR18OC?CNXD,(G"F,XI%?(
MGO, ^O8##LC#L^(H4(X19&"HN8$/V=!8H#*?NV&[=ZJ V>;[_B"07BPRO/S$
M+G 0%!0?&^;Y$I9O157QM8HP]4-BJ.=%( 6QC8E:W[9G =_6E3Q'Q=]J:*""
M+5F],M[GD\2E.$N&GFTYT/,)@O'Z,YA294P9W+]IR7FAWZ02HM'"0C?&*ZYO
MB3 F]8Y7&!S7ZX.\G-1ZR$SN+0.8RU\'EY\U,KZ?E2*P&C^*6H)%V/(5]OD5
M;[+ZLWFGJH3&=K3=H; >@K//%^F!**TD.5 7?*VT+:[*/[7II#9))#2L -QH
M0YQP0"@E6ON)M[':4(JROKDP-[UAZ^W>>WLPQ7]A\^0>.(3EZ@@<G&TY:'DY
M4\# T/VQKO29VP;&F.M@RG9,BS4.V!XOCE@0QO@)@H]Q@/&2+N]AF.N#1]3I
M1QKUAW*\EIV*#R(PUXTI&U?8S'& 3RL(&?EC128U+.7TA,8EQ&?RI&#KSD'4
MECJ^3=XBA$_/_B0R TO%'SR[1UF& QJ?%P_(56+73OPF%&L4?_T^ BW?P ;M
ME^W#GH;4R;#\D$1AR;?$_ZO7X/EK/V#5?4;PR0'7)K6GW1:L6B*S+G&O8.'F
MLOMB7=4=,5N35YU%0BCB%DW5#+7RSW2@.AJ/$(FJ0^TI]KN5-Z%-,OAJ>GT7
M>KCQPT4P;8O=\?EO>'U6JFV1,0EU]F[^P[)NC);W^<MSC>+/8O*0VRTSUT;$
M%: Y$%>UQZS!M\[[/AW+&8OTPN.KJ(!"/+BD@1D6WKYY<Z4H773U[H(+'NHX
M_D3E6&10\9J!.$ F<K="\?(K ^&#TZ#"E,,>;UKW[&]6C#YC$.I)GZW]7BX8
MADV/_Y20MW%['*9"]H%+<)C'_</7XF0^*T=/D"0.L!OW^&%Q-7#:^&R=\W37
M^#ZT22@=!_3?F<3G51;Y/3A?9S5VG)#S\'D5=M2XRQ[/D/?$RI:W-T\H=,';
M\>"J#0F\HFZ C(&TD 8.=X3\=37\3B(53DOG8$?(MUA,R,KQDO'10:_*QD8=
MU@?+&07]JQ2-JGZ)"ZX4I\$!DI30V4BY,2X<T%?)OX'Y5_X&^G;DBCG%J+!C
M9TJQN]@G*9,'+)^@LT*E^?JKNVMQ=R;U4P.FWC-Z:D//P>9:J]X8M?%V^8*F
MPJN+UD;SSL:';:.9JKTDSQ1FT2NT3<\LO_\'4]?Q=H!A3LRU#WP,<0 8>KGS
M+]5C@9TMV8_&'L'TL>-(;0Q:!C]\9$"3+!=Q0,KYQNV.C/48Z/(DQ=\M;#UY
MSESGLGQ4$V_O%[DM.;U5\#SC '2%WN;',#07;WN"O2=HI\CQ951I*&GS6\HO
M[3K$.6:=//%$_>3C>1"O-PD..#_Z%@=(==N='. IBS\$GY%4LRK\\$TY^(35
M,'NGJGSX@OC/!D0X8(_-,$O:!D*42$($5Z16/%23!?(*.O+XW&M<)88+"_&]
M4>H/,R'*LZJ5":S*Z33)G92SMV/](D>/R=^4L[\S.:DHYE":YA@A)2#%\F(6
MP%RR]?I"-*[<H%-]KQ@_(/J=9LE75TVR)MKMSARH=1YRUL HAB7ON(VZ*VU%
M9^D61PL-5%1&F5XO,Z?C%!IUHVC%"HY@;.PST;$3@P.\F]T?,@P+%Q?..CC<
M(!SY80FZ@+UAI;YJ3%&A,/>NG4UN*8A9UJU83JYQ>')^^ )D7H<#B:[$ ?*Z
MWV\*PKTV:)F.QZ +A@1PE7E>Z4>R)#P#*3S)"77:S-ENG]8?(_U]0/4#%12;
MU4_O=C/H"SQLIR.&/E8E%BOJRYBU9#D[6&Y\:Z5L>KG[X]M;[<A*[_5<]( =
M4>.K9XWR,2]*Z@+FS$".WS<-3K=]*PR)/Q\3C=27U@SOU66XVI/*77_MKGF,
MYXFT$ &,]) U')RQ*NIO(X[J=&8?*7M8RI68K*(AQ9*6;2 T$V/I@ ,\=#3[
MAD.J5"<^\]I<K=*(>7.&<(^F;\;*Z&;XUL.*_OE8P$=.&*"2?$\P^#=^BNN<
M1\2-=(B1& *%9E Y[$QUQ*_<D/SVD.I_&<S617D8ZFNT"<R,:UC7N-5#+I?$
M*^DFLL3,,[[A3]A<,*44MEO TTUM.])+DZGR&4_4^@E"8D-LE:+/W_AI%_T?
M[H&YDA'/CU_/E%\T9S[QMM=>257BK/Y7SAH@P]B:9I&57BH(,D6#8?,KL;0V
MEF29-KYG#MF012K$EF-&!.A<+,UKK'X]Q\'PE&S473T.YOH EFM(BA#!".H9
MJYFS(^F5D.T9 STQ\L898#2G&7K.ZHK'TN$;<9G\UER(LKC?DN3\I2V*M!^K
M&']>6,VWR=)M*(Q/>,"PR;8S*HWAWM3^;?G^^TL2+&:H!.S]>- I%+93&'O2
M5M$@ .T0D,;SRGVL9M2LVY@YIB;HZP(,=4&&^@G=?]JJO.PW4B\T,.& S@>C
MT/60L>*_FM0R:% PF2/F81]\V;@_#/]L;AV59V&J-IQW)D4&V!=_#3T'47'D
MYBUI%KF&)]7^W/IX=?G,J%W& R)8](V%L>/6YLP&J@_]H*+QZ( :VD13A-?]
M)3"3](A-O>EWC2,881>W9<Q5O5G,R47P_$4\_UJ>J \/ 5= 7.YC8?-U9>W0
M/[V=W,_\BWBK ]$;V)&B;\3'C8%;?4P_IRKW9SG_S&?V$J1+&7F:'??DO+J4
M @8RFIM9;"#+Y1:86,L22$*H<CX^>R9]0(;FJ\L?ZG+A1Y 3Y[:WN\Y_:/H@
M:$66ZU'(8A<OQZW0+LI*BH/2]G4I%MG9B\XD4-)UAC-6R-/$J;?U_*[G:'N5
M?2I,/F/)4=H8CIR69.YAUB@W&VP?Z<N2HZ"\5GL/4* M1E\RPQF&GEA0&EZH
M<?(4X+AX0YQ%Y=$>B,"-@X("'0!C0SG5%M ]\DZ:8C)OU /VNOZ;FPO_3H&P
MPX=.D2-OH?$*1#0P?=8Z?+Z(:B A()2%$11P?WZ%MGF6N7AO6EC-LPYRXEI=
M&USY4"41WUF*GJ-WE=#>>6Y1:VM@ZH;H/+MO#N\2SSU;WS;D;'IK3+A:Z]]O
M4?MEQ/E-!O_U'8<3.56)7,+1/\PI&L%W8_K&1<8T_,#$HWZN+CLX1'%!O<SB
M6#2MF;&?^IA)F]3)!@K>H=+;NTK$=;NN<ID9&KR:6VQ^PFB$1P]1 Z=A,&B_
M@J4G7N&(WBX=4C/H.[A;CP?J[!E_B;&1@5GA<1K6%OA35 MLVUCCRO7RG_Y!
MPBQ$\Q4'F$!F]ZCTP*45V\<7>%FZP+VOVY5D','C$X>G9V,C-FP\L:\5Y3Y%
M[*;^(0E$GS :_R+(N9$<NI@& >^W0L8@;3[4S?9V"X9:8A_%.V.)IF;@8V5:
M]RJLWKBS549\_@'(&?[PT?O/!!EG^,1C-IN(I<K1O7MSP^7?:(PXM4\R+\T^
M HZBFQN8D5IYCOG@$(RTN&C7=,=U$KX1[N3S$NN##2QN=I^/58)G%IIKIZKB
MLL]I7%:JMNGH;#4Q6FV\8"3A@%7D>&]9+#G8U4ZZX<$OGCBR': -I=C>+WCC
M)9*ME+-F27E.I+-;UB-2BJ7^3RO'8TZA9M^>>$2' ,[4 ;Z&+;X9B=%J[8YG
M>RIO+KCL:9_M/UNN)O._^I(1&O43C=(A2I;C-6YGQX [=^]8$/H/>UU%MJVK
M5R<?3WR>5KAJJ?CH/N^L^)C(O*(QB84Q@U%[<ZD,C^L5'E?95KA?F]2!8"VL
M&098313UI@D'3YM6O^OH*IL[X\V=B23VPS#.U\M:"NHOPALCR0TSI^;%^HG3
M_]ZJTG_3/(+PZV^F^Q9;\!VL\XS;4!.E6U/;Z(1B7-4.^ZXTI[I]R&+CO!+G
M*3%?H^B&?UZM?6C6BV)'S9R;CU;Z%DZZCP;:#^-VBRC0&@KX(=H-ZXWX^2DI
M%\^*YLPWKINC3I<P*S\BCP9A;N+GWM2EL66YGY]D?HK'TB0+!<T8]X:#X8U)
M%M"F>)5C<D,?IY\?]")VL03_C\B*8P.[0T4;<<!%2_"*B//1P"]/5N ^-'%)
MI/Y\'^8]KSFVNLACT]Z' @VE]=_G?CO2$+OT72H(:K7)S?0PX^9)\5K'6@XM
MW3>\1M*Y\C_J+/2_VI\A6E21"&M12Q1KZ\J9"KV8G%Z;L#'JJ!)ZI%:V,$8H
M2+#3M5K;^I72C>2$"B'V44@V=FLCK26O[K5**DP>61_6FX,*U#^Q$2K<.^4:
MVK"Y;7#A@WVK_1A6#/TF]W/M:6P:36R<LY?U_!DA,7+[3C:A"33Y2=LE+YD$
M!911&5,6[^-W3?E W+VC0&!5BJ7QAT,O@;/J7Z54[RAL&A&CI%L8(M[,*X;=
MU0 %6=M%78E1)FNIV=S@'H7;94'T9@.SA\K%JGEM.:X:*92%)7UN+W('MT@(
MM]2"?)U.1;_//O!3"5QC5_GTD9!V0WG;:(]@%*,PS,?2WNQ!!-]Y4%O8R;01
M]MKD<T>/*NHP4'"6T$)+#P<$94!($L0^Q&J%]6V_2[ST30@4OC!<Q -G@UEU
MVR4PQIS<KR U><CFUR?DB6@KRX'X4%8,"D[FPFR=&3_ <^=>+ENP1DFMW" <
MXMDBFGY/RW6+76K.6];*HR!'/T'ISNCX?@B[-/KBYP9TT'R1Z(ZB8L$W=8M>
M>IGR,+]]DA!@[6\VC@SC,4K(S.+2+$Q6XB;AQJ=],))A0?(G7 8^/OFW5<$&
M<1%PMDRW,@5_B+:#WJ1N3<)7N<GPVSW.%8N-3)S5=17]XA)G>T@]DG;:!6ZV
M:?G><J8(A)()%C!")K>I5(@JQHX_ZFD$'6LK(8>:C$@^C>2,BO,7*>2*JWTP
M9>PDJ4L.6M6=$4<R*H#\]A3%;O+MK8M4*K=_<N4H<#-6\/L"9BYVDA!V6!V+
ME;1X"W9N[+4@G/P)F!5SMJ=<8D4FI]PJ"[/=OSZA1SG(?IVL9X4+!P2+ZPA2
M$)$YZ'AU)@ONS!LC7/"MF),.'S6F<ZMK[LF:<8M3*<'V-GZ\:F*E[UUCFU#6
MZB%_U9=UD>5^*E$Z?!.NBTCR-!KA]>(W?W8@(03/XX#SGGP3RT=DEZ&C&=%G
M<$ +K4L@8QT]PPS$8/>[GR_Q<#^QMXS[>^QM5+B?3<[:#.M0X;DX5R[955O]
M'C^HTC=$!5P:T:./I8*HD+M934SHKSX]>?QI^O)2._WJ4&(_L9V,_<QEE%86
MM&B-!316],Q/LTSMJL6%G<70/>YD2.D_Q#S_Q:M?_C<$1Q8.5'N0N/"MTE&8
M>&SRG0<QO4]0AA+N?2VG)E]JKTVJ()B9A<2^2>I<)8EC.U8E3BYOI+@L,[KW
MP4OM1EE#C'G%@T;4.JM(1Q$XX(J'X5B8:6,U2FR=H=!EZ:JZY(9)O2'2# <T
M1]!:V60U^C\?<@:$K]/>[(Y0,TK(<I-NGF">KQO<2X#HOZXCC2PFE[A!:/MC
M02!_UK)2+_$,XXE.\7,M4JHGI 3,9'KIOE>3!V?61HK,7XL\-9LP<>Z*7 WI
M&<+<G#_E6#%8/99(*I][JD M1:F/'UD*KU9N6J2>*V%4(<QRPP'_A.O#?Y=
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M+\T)044>_.'BE#8+^MPZ[+6>NKS?J7A*BW7"U_>$RH_9_6LI!S)?Z;6T+G[
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M3.W;L_B-&JP""+E.*7@CG.\VG*)?IGL$MHNB/8=0NM!^\ALURRS"";<_"ZZ
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M6,^%RRC:U\PY^$LD64O089C4'D44E##\5Y1;5T6]97N4YOC!AU+-AC&@)5"
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MG-2;]S3W%2L)^5+.KI]A=G"V6#;>+$ATMZ_UD"A8FY0F_4@77/_ 1VY')%C
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M21RD7L1Q\O+*&SF'I'L>$75=7AM&/MCQH>K/Z^0HF:0S$'NG8&&Z]^80)P'
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MA"?9P;\\A7=/!0O*#$M=.Q;QQYO$"W9$*H8]P44V1*F?;C:U/Y=1R,X6DN&
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M8/GR)(%3T"Q3'VQ%(!LZ\P@:QH"(-C?:I1Z$(6Z!6ZJX49I'6B<XST]!6PV
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M=]?TM#D*GI:7!SWU9;X8F(DEN?&H#R\,3?M2_66+!+?BHT66U&<:<9&/^0[
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M_#X3MA9T+%AV"KI'OG6RIZ+\;I6"@]K39E4&!U2<.3:(@7[Q@QN/H0$]>(U
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M [J!&[3>4BNM=2"[^5F\D"]XF*L]E= +4-2)^PFDXAW:"1D6GNXBL)3Y),>
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M<*<?%.>:\P[CA.?K06ZL%GY&O( Z^Z?<;F[]S;;_7\SX;R@GJ "MB_QMQ<
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M^_-%J27Z$":,0CY*.RMUB4=#,8RQV/)"F;/55;G>9Q./ G,YZX*:\>O8)GG
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M?4*"IVN,]Y?"]+D(\#.?*NLZN?,!C>[T^0./0MH.KIO,=KRX:KLW&.0D?:\
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MU."!'C7*0-$W#+Q943=CHZY <=DMC=R][P//)G.]?/K: I>7SY49D=:QY%<
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M6ZN1H=$$/O*GI _?/ \/#X\-4^EPS@5C:=+JQXRQY[ B</1A*0XP&S'9+<\
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M_U9:5OZ]HK*JNKFEM:V]XT?GSX'!H>&1T;'Q"2P./_][87%I>86PO;.[MW]
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MZA;I?51MK$;!J#[NDX:<KIRF7#/+L?%O-\N[RPI?:?3(G*_=DE^="5"J-BU
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M,&M?,C R,#$R,S$N:'1M4$L! A0#%     @ $X)I4K\%<L&A&   ]1@! !$
M             ( !S&8# &5I9W(M,C R,#$R,S$N>'-D4$L! A0#%     @
M$X)I4J4J;/R/$   _?@  !4              ( !G'\# &5I9W(M,C R,#$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( !.":5)K?0_T;34  /JG P 5
M      "  5Z0 P!E:6=R+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  3
M@FE275/7?7B&  #<# @ %0              @ '^Q0, 96EG<BTR,#(P,3(S
M,5]L86(N>&UL4$L! A0#%     @ $X)I4K$,F*Q14   X#$& !4
M     ( !J4P$ &5I9W(M,C R,#$R,S%?<')E+GAM;%!+ 0(4 Q0    ( !."
M:5+'OQE63<    ?D"  4              "  2V=! !E:6=R+65X,3 Q,%\Q
M,30T+FAT;5!+ 0(4 Q0    ( !.":5(IW_Z^A_(  +YO!P 4
M  "  :Q=!0!E:6=R+65X,3 Q,E\Q,30S+FAT;5!+ 0(4 Q0    ( !.":5()
MW,N% 2   %?P   4              "  650!@!E:6=R+65X,3 Q-U\Q,30R
M+FAT;5!+ 0(4 Q0    ( !.":5(_H4">P6<  ,0# P 4              "
M 9AP!@!E:6=R+65X,3 Q.%\Q,30Q+FAT;5!+ 0(4 Q0    ( !.":5(VQ[2.
M<7<  $L>!  4              "  8O8!@!E:6=R+65X,3 S,5\Q,30P+FAT
M;5!+ 0(4 Q0    ( !.":5+=!KA<=@@  .E<   4              "  2Y0
M!P!E:6=R+65X,3 S,E\Q,3,X+FAT;5!+ 0(4 Q0    ( !.":5(:P>E4T2,
M  T[ @ 4              "  =98!P!E:6=R+65X,3 S,U\Q,3,Y+FAT;5!+
M 0(4 Q0    ( !.":5)]J^$(8X,  '$X!  3              "  =E\!P!E
M:6=R+65X,3 Y7S$Q-#4N:'1M4$L! A0#%     @ $X)I4I2!)/$* P  &1P
M !(              ( !;0 ( &5I9W(M97@R,3%?-3@S+FAT;5!+ 0(4 Q0
M   ( !.":5)5,U$QPP,  *\3   2              "  :<#" !E:6=R+65X
M,C,Q7SDQ,BYH=&U02P$"% ,4    "  3@FE2\MR@ZV8(  #^1   $@
M        @ &:!P@ 96EG<BUE>#,Q,5\U.#$N:'1M4$L! A0#%     @ $X)I
M4B!+ %-L"   +44  !(              ( !,! ( &5I9W(M97@S,3)?-3@P
M+FAT;5!+ 0(4 Q0    ( !.":5+A)05Q7 8  /\H   2              "
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M+FIP9U!+ 0(4 Q0    ( !.":5(C=O*B]%\" $:M @ 6              "
M </M#0!G>F)W:'0S9C1A9G0P,# P,#@N:G!G4$L! A0#%     @ $X)I4@A9
M9WF"*0$ 7VT! !8              ( !ZTT0 &=Z8G=H=#-F-&%F=# P,# P
M.2YJ<&=02P$"% ,4    "  3@FE25WY9D9$' 0 R1 $ %@
M@ &A=Q$ 9WIB=VAT,V8T869T,# P,#$P+FIP9U!+ 0(4 Q0    ( !.":5+Z
MW?$!N#\! /2_ 0 6              "  69_$@!G>F)W:'0S9C1A9G0P,# P
M,3$N:G!G4$L! A0#%     @ $X)I4DQD"2=QS0$ /[4" !8
M ( !4K\3 &=Z8G=H=#-F-&%F=# P,# Q,BYJ<&=02P$"% ,4    "  3@FE2
M9\KI6 2' 0"EQ0$ %@              @ 'WC!4 9WIB=VAT,V8T869T,# P
M,#$S+FIP9U!+ 0(4 Q0    ( !.":5)1"-.U\AP! !]I 0 6
M  "  2\4%P!G>F)W:'0S9C1A9G0P,# P,30N:G!G4$L! A0#%     @ $X)I
M4CD.[P*/! $ "T@! !8              ( !53$8 &=Z8G=H=#-F-&%F=# P
M,# Q-2YJ<&=02P$"% ,4    "  3@FE2/4ZMV;X7  ! &0  %@
M    @ $8-AD 9WIB=VAT,V8T869T,# P,#$V+FIP9U!+!08     (P C !T)
(   *3AD    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
